FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Ksiazek, TG
   Erdman, D
   Goldsmith, CS
   Zaki, SR
   Peret, T
   Emery, S
   Tong, SX
   Urbani, C
   Comer, JA
   Lim, W
   Rollin, PE
   Dowell, SF
   Ling, AE
   Humphrey, CD
   Shieh, WJ
   Guarner, J
   Paddock, CD
   Rota, P
   Fields, B
   DeRisi, J
   Yang, JY
   Cox, N
   Hughes, JM
   LeDuc, JW
   Bellini, WJ
   Anderson, LJ
AF Ksiazek, TG
   Erdman, D
   Goldsmith, CS
   Zaki, SR
   Peret, T
   Emery, S
   Tong, SX
   Urbani, C
   Comer, JA
   Lim, W
   Rollin, PE
   Dowell, SF
   Ling, AE
   Humphrey, CD
   Shieh, WJ
   Guarner, J
   Paddock, CD
   Rota, P
   Fields, B
   DeRisi, J
   Yang, JY
   Cox, N
   Hughes, JM
   LeDuc, JW
   Bellini, WJ
   Anderson, LJ
CA SARS Working Grp
TI A novel coronavirus associated with severe acute respiratory syndrome
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PORCINE EPIDEMIC DIARRHEA; ANTIGENIC RELATIONSHIPS; VIRUS-INFECTION;
   NIPAH VIRUS; PATHOGENESIS; PROPAGATION; ADAPTATION; DIAGNOSIS; GROWTH;
   FEVER
AB BACKGROUND
   A worldwide outbreak of severe acute respiratory syndrome (SARS) has been associated with exposures originating from a single ill health care worker from Guangdong Province, China. We conducted studies to identify the etiologic agent of this outbreak.
   METHODS
   We received clinical specimens from patients in seven countries and tested them, using virus-isolation techniques, electron-microscopical and histologic studies, and molecular and serologic assays, in an attempt to identify a wide range of potential pathogens.
   RESULTS
   None of the previously described respiratory pathogens were consistently identified. However, a novel coronavirus was isolated from patients who met the case definition of SARS. Cytopathological features were noted in Vero E6 cells inoculated with a throat-swab specimen. Electron-microscopical examination revealed ultrastructural features characteristic of coronaviruses. Immunohistochemical and immunofluorescence staining revealed reactivity with group I coronavirus polyclonal antibodies. Consensus coronavirus primers designed to amplify a fragment of the polymerase gene by reverse transcription-polymerase chain reaction (RT-PCR) were used to obtain a sequence that clearly identified the isolate as a unique coronavirus only distantly related to previously sequenced coronaviruses. With specific diagnostic RT-PCR primers we identified several identical nucleotide sequences in 12 patients from several locations, a finding consistent with a point-source outbreak. Indirect fluorescence antibody tests and enzyme-linked immunosorbent assays made with the new isolate have been used to demonstrate a virus-specific serologic response. This virus may never before have circulated in the U.S. population.
   CONCLUSIONS
   A novel coronavirus is associated with this outbreak, and the evidence indicates that this virus has an etiologic role in SARS. Because of the death of Dr. Carlo Urbani, we propose that our first isolate be named the Urbani strain of SARS-associated coronavirus.
C1 Ctr Dis Control & Prevent, Special Pathogens Branch, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.
   Ctr Dis Control & Prevent, Resp & Enter Virus Brach, Natl Ctr Infect Dis, Atlanta, GA USA.
   Ctr Dis Control & Prevent, Infect Dis Pathol Act, Natl Ctr Infect Dis, Atlanta, GA USA.
   Ctr Dis Control & Prevent, Influenza Branch, Natl Ctr Infect Dis, Atlanta, GA USA.
   Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA.
   Ctr Dis Control & Prevent, Off Director, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA USA.
   WHO, Hanoi, Vietnam.
   Queen Mary Hosp, Govt Virus Unit, Hong Kong, Hong Kong, Peoples R China.
   Int Emerging Infect Dis Program, Bangkok, Thailand.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Singapore Gen Hosp, Dept Pathol, Singapore, Singapore.
   Ctr Dis Control, Dept Hlth, Taipei, Taiwan.
RP Ksiazek, TG (reprint author), Ctr Dis Control & Prevent, Special Pathogens Branch, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.
RI Guarner, Jeannette/B-8273-2013
OI Guarner, Jeannette/0000-0001-5610-3541
CR Becker W B, 1967, J Virol, V1, P1019
   BOHLANDER SK, 1992, GENOMICS, V13, P1322, DOI 10.1016/0888-7543(92)90057-Y
   BRADBURNE AF, 1970, ARCH GES VIRUSFORSCH, V31, P352, DOI 10.1007/BF01253769
   BRADBURNE AF, 1972, J HYG-CAMB, V70, P235, DOI 10.1017/S0022172400022294
   BRUCKOVA M, 1970, P SOC EXP BIOL MED, V135, P431
   Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432
   Falsey AR, 2003, J INFECT DIS, V187, P785, DOI 10.1086/367901
   Guarner J, 2000, AM J CLIN PATHOL, V114, P227
   Hazelton PR, 2003, EMERG INFECT DIS, V9, P294, DOI 10.3201/eid0903.020327
   HOFMANN M, 1988, J CLIN MICROBIOL, V26, P2235, DOI 10.1128/JCM.26.11.2235-2239.1988
   JACOBSEGEELS HEL, 1983, J GEN VIROL, V64, P1859, DOI 10.1099/0022-1317-64-9-1859
   JOHNSON KM, 1977, LANCET, V1, P569
   Jonassen CM, 1998, J GEN VIROL, V79, P715, DOI 10.1099/0022-1317-79-4-715
   Ksiazek TG, 1999, J INFECT DIS, V179, pS192, DOI 10.1086/514313
   KUSANAGI K, 1992, J VET MED SCI, V54, P313, DOI 10.1292/jvms.54.313
   Lavi E, 1996, VIROLOGY, V221, P325, DOI 10.1006/viro.1996.0382
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Luby JP, 1999, J CLIN VIROL, V12, P43, DOI 10.1016/S0928-0197(98)00067-1
   MCINTOSH K, 1969, J IMMUNOL, V102, P1109
   MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348
   OSHIRO LS, 1971, J GEN VIROL, V12, P161, DOI 10.1099/0022-1317-12-2-161
   PATTERSON S, 1982, J GEN VIROL, V60, P307, DOI 10.1099/0022-1317-60-2-307
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Smolinski Mark, 2003, MICROBIAL THREATS HL
   Swofford DL, 1999, PAUP 4 0 PHYLOGENETI
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699
   *WHO, 2003, AC RESP SYNDR CHIN U
   Wong KT, 2002, AM J PATHOL, V161, P2153, DOI 10.1016/S0002-9440(10)64493-8
   WULFF H, 1975, B WORLD HEALTH ORGAN, V52, P429
   ZAKI SR, 1995, AM J PATHOL, V146, P552
   2003, MMWR MORB MORTAL WKL, V52, P241
NR 33
TC 1871
Z9 2214
U1 163
U2 499
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 15
PY 2003
VL 348
IS 20
BP 1953
EP 1966
DI 10.1056/NEJMoa030781
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 677TJ
UT WOS:000182823400004
PM 12690092
OA Bronze
DA 2020-04-03
ER

PT J
AU Drosten, C
   Gunther, S
   Preiser, W
   van der Werf, S
   Brodt, HR
   Becker, S
   Rabenau, H
   Panning, M
   Kolesnikova, L
   Fouchier, RAM
   Berger, A
   Burguiere, AM
   Cinatl, J
   Eickmann, M
   Escriou, N
   Grywna, K
   Kramme, S
   Manuguerra, JC
   Muller, S
   Rickerts, V
   Sturmer, M
   Vieth, S
   Klenk, HD
   Osterhaus, ADME
   Schmitz, H
   Doerr, HW
AF Drosten, C
   Gunther, S
   Preiser, W
   van der Werf, S
   Brodt, HR
   Becker, S
   Rabenau, H
   Panning, M
   Kolesnikova, L
   Fouchier, RAM
   Berger, A
   Burguiere, AM
   Cinatl, J
   Eickmann, M
   Escriou, N
   Grywna, K
   Kramme, S
   Manuguerra, JC
   Muller, S
   Rickerts, V
   Sturmer, M
   Vieth, S
   Klenk, HD
   Osterhaus, ADME
   Schmitz, H
   Doerr, HW
TI Identification of a novel coronavirus in patients with severe acute
   respiratory syndrome
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID LASSA VIRUS; FEVER
AB BACKGROUND
   The severe acute respiratory syndrome (SARS) has recently been identified as a new clinical entity. SARS is thought to be caused by an unknown infectious agent.
   METHODS
   Clinical specimens from patients with SARS were searched for unknown viruses with the use of cell cultures and molecular techniques.
   RESULTS
   A novel coronavirus was identified in patients with SARS. The virus was isolated in cell culture, and a sequence 300 nucleotides in length was obtained by a polymerase-chain-reaction (PCR)-based random-amplification procedure. Genetic characterization indicated that the virus is only distantly related to known coronaviruses (identical in 50 to 60 percent of the nucleotide sequence). On the basis of the obtained sequence, conventional and real-time PCR assays for specific and sensitive detection of the novel virus were established. Virus was detected in a variety of clinical specimens from patients with SARS but not in controls. High concentrations of viral RNA of up to 100 million molecules per milliliter were found in sputum. Viral RNA was also detected at extremely low concentrations in plasma during the acute phase and in feces during the late convalescent phase. Infected patients showed seroconversion on the Vero cells in which the virus was isolated.
   CONCLUSIONS
   The novel coronavirus might have a role in causing SARS.
C1 Bernhard Nocht Inst Trop Med, Dept Virol, Natl Reference Ctr Trop Infect Dis, D-20359 Hamburg, Germany.
   Univ Frankfurt, Inst Med Virol, D-6000 Frankfurt, Germany.
   Univ Frankfurt, Med Clin 3, D-6000 Frankfurt, Germany.
   Univ Marburg, Inst Virol, D-3550 Marburg, Germany.
   Inst Pasteur, Natl Influenza Ctr No France, Paris, France.
   Erasmus Univ, Inst Virol, Rotterdam, Netherlands.
RP Drosten, C (reprint author), Bernhard Nocht Inst Trop Med, Dept Virol, Natl Reference Ctr Trop Infect Dis, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.
RI Preiser, Wolfgang/J-4875-2016; Escriou, Nicolas/A-2392-2016; Panning,
   Marcus/I-7889-2016; Fouchier, Ron/Y-3755-2019; Fouchier, Ron
   A/A-1911-2014; Becker, Stephan/A-1065-2010
OI Preiser, Wolfgang/0000-0002-0254-7910; Escriou,
   Nicolas/0000-0002-1224-6839; Fouchier, Ron/0000-0001-8095-2869;
   Fouchier, Ron A/0000-0001-8095-2869; Becker,
   Stephan/0000-0002-2794-5659; Osterhaus, Albert/0000-0002-6074-1172;
   Gunther, Stephan/0000-0002-6562-0230; Sturmer,
   Martin/0000-0003-4300-9315; van der WERF, Sylvie/0000-0002-1148-4456; ,
   Simon/0000-0002-2765-1589
CR Cho KO, 2001, AM J VET RES, V62, P1436, DOI 10.2460/ajvr.2001.62.1436
   Cossart Y, 1998, LANCET, V352, P164, DOI 10.1016/S0140-6736(05)77802-8
   Drosten C, 2002, J CLIN MICROBIOL, V40, P2323, DOI 10.1128/JCM.40.7.2323-2330.2002
   Felsenstein J., 2000, PHYLIP PHYLOGENY INF
   Gunther S, 2000, EMERG INFECT DIS, V6, P466, DOI 10.3201/eid0605.000504
   KEW MC, 1996, LANCET S2, V348, P10
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   POUTANEN SM, 2003, NEW ENGL J MED, V348, P1993
   Severe acute respiratory syndrome (SARS), 2003, WKLY EPIDEMIOL REC, V78, P81
   Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9
   TSANG KW, 2003, NEW ENGL J MED, V348, P1975
   *WHO, 2003, CUM NUMB REP CAS SEV
   2003, WKLY EPIDEMIOL REC, V78, P73
NR 13
TC 1779
Z9 2044
U1 84
U2 210
PU MASSACHUSETTS MEDICAL SOC/NEJM
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 15
PY 2003
VL 348
IS 20
BP 1967
EP 1976
DI 10.1056/NEJMoa030747
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 677TJ
UT WOS:000182823400005
PM 12690091
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Rota, PA
   Oberste, MS
   Monroe, SS
   Nix, WA
   Campagnoli, R
   Icenogle, JP
   Penaranda, S
   Bankamp, B
   Maher, K
   Chen, MH
   Tong, SX
   Tamin, A
   Lowe, L
   Frace, M
   DeRisi, JL
   Chen, Q
   Wang, D
   Erdman, DD
   Peret, TCT
   Burns, C
   Ksiazek, TG
   Rollin, PE
   Sanchez, A
   Liffick, S
   Holloway, B
   Limor, J
   McCaustland, K
   Olsen-Rasmussen, M
   Fouchier, R
   Gunther, S
   Osterhaus, ADME
   Drosten, C
   Pallansch, MA
   Anderson, LJ
   Bellini, WJ
AF Rota, PA
   Oberste, MS
   Monroe, SS
   Nix, WA
   Campagnoli, R
   Icenogle, JP
   Penaranda, S
   Bankamp, B
   Maher, K
   Chen, MH
   Tong, SX
   Tamin, A
   Lowe, L
   Frace, M
   DeRisi, JL
   Chen, Q
   Wang, D
   Erdman, DD
   Peret, TCT
   Burns, C
   Ksiazek, TG
   Rollin, PE
   Sanchez, A
   Liffick, S
   Holloway, B
   Limor, J
   McCaustland, K
   Olsen-Rasmussen, M
   Fouchier, R
   Gunther, S
   Osterhaus, ADME
   Drosten, C
   Pallansch, MA
   Anderson, LJ
   Bellini, WJ
TI Characterization of a novel coronavirus associated with severe acute
   respiratory syndrome
SO SCIENCE
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS; TARGETED RECOMBINATION; SPIKE
   GENE; VIRUS; DETERMINANT; ENTRY
AB In March 2003, a novel coronavirus (SARS-CoV) was discovered in association with cases of severe acute respiratory syndrome (SARS). The sequence of the complete genome of SARS-CoV was determined, and the initial characterization of the viral genome is presented in this report. The genome of SARS-CoV is 29,727 nucleotides in length and has 11 open reading frames, and its genome organization is similar to that of other coronaviruses. Phylogenetic analyses and sequence comparisons showed that SARS-CoV is not closely related to any of the previously characterized coronaviruses.
C1 Ctr Dis Control, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.
   Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Biophys, San Francisco, CA 94143 USA.
   Erasmus Univ, Dept Virol, NL-3000 DR Rotterdam, Netherlands.
   Bernhard Nocht Inst Trop Med, Dept Virol, D-20359 Hamburg, Germany.
RP Rota, PA (reprint author), Ctr Dis Control, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.
EM prota@cdc.gov
RI Fouchier, Ron A/A-1911-2014; Fouchier, Ron/Y-3755-2019
OI Fouchier, Ron A/0000-0001-8095-2869; Fouchier, Ron/0000-0001-8095-2869;
   Osterhaus, Albert/0000-0002-6074-1172; Monroe,
   Stephan/0000-0002-5424-716X; Guan, Yi/0000-0001-6057-9243; Gunther,
   Stephan/0000-0002-6562-0230; Campagnoli, Ray/0000-0003-0531-3893
CR Centers for Disease Control and Prevention (CDC), 2003, MMWR-MORBID MORTAL W, V52, P357
   de Haan CAM, 2002, VIRUS RES, V82, P77
   de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998
   DROSTEN C, 2003, N ENGL J MED    0417
   Enjuanes LBD, 2000, VIRUS TAXONOMY CLASS, P835
   Escors D, 2001, J VIROL, V75, P1312, DOI 10.1128/JVI.75.3.1312-1324.2001
   Garoff H, 1998, MICROBIOL MOL BIOL R, V62, P1171, DOI 10.1128/MMBR.62.4.1171-1190.1998
   HOLMES KV, 2001, FIELDS VIROLOGY, pCH36
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   LAI MMC, 2001, FIELDS VIROLOGY, pCH35
   LEE N, 2003, N ENGL J MED    0417
   Leparc-Goffart I, 1998, J VIROL, V72, P9628, DOI 10.1128/JVI.72.12.9628-9636.1998
   LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   POUTANEN SM, 2003, N ENGL J MED    0417
   Sanchez CM, 1999, J VIROL, V73, P7607
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   Siddell SG, 1995, CORONAVIRIDAE
   THIEL V, 1994, J GEN VIROL, V75, P3041, DOI 10.1099/0022-1317-75-11-3041
   TSANG KW, 2003, N ENGL J MED    0417
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 23
TC 1506
Z9 1765
U1 51
U2 153
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAY 30
PY 2003
VL 300
IS 5624
BP 1394
EP 1399
DI 10.1126/science.1085952
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 683ZW
UT WOS:000183181800035
PM 12730500
OA Bronze
DA 2020-04-03
ER

PT J
AU Peiris, JSM
   Lai, ST
   Poon, LLM
   Guan, Y
   Yam, LYC
   Lim, W
   Nicholls, J
   Yee, WKS
   Yan, WW
   Cheung, MT
   Cheng, VCC
   Chan, KH
   Tsang, DNC
   Yung, RWH
   Ng, TK
   Yuen, KY
AF Peiris, JSM
   Lai, ST
   Poon, LLM
   Guan, Y
   Yam, LYC
   Lim, W
   Nicholls, J
   Yee, WKS
   Yan, WW
   Cheung, MT
   Cheng, VCC
   Chan, KH
   Tsang, DNC
   Yung, RWH
   Ng, TK
   Yuen, KY
CA SARS Study Grp
TI Coronavirus as a possible cause of severe acute respiratory syndrome
SO LANCET
LA English
DT Article
ID HUMAN-DISEASE; VIRUS; INFECTIONS; DIAGNOSIS
AB Background An outbreak of severe acute respiratory syndrome (SARS) has been reported in Hong Kong. We investigated the viral cause and clinical presentation among 50 patients.
   Methods We analysed case notes and microbiological findings for 50 patients with SARS, representing more than five separate epidemiologically linked transmission clusters. We defined the clinical presentation and risk factors associated with severe disease and investigated the causal agents by chest radiography and laboratory testing of nasopharyngeal aspirates and sera samples. We compared the laboratory findings with those submitted for microbiological investigation of other diseases from patients whose identity was masked.
   Findings Patients, age ranged from 23 to 74 years. Fever, chills, myalgia, and cough were the most frequent complaints. When compared with chest radiographic changes, respiratory symptoms and auscultatory findings were disproportionally mild. Patients who were household contacts of other infected people and had older age, lymphopenia, and liver dysfunction were associated with severe disease. A virus belonging to the family Coronaviridae was isolated from two patients. By use of serological and reverse-transcriptase PCR specific for this virus, 45 of 50 patients with SARS, but no controls, had evidence of infection with this virus.
   Interpretation A coronavirus was isolated from patients with SARS that might be the primary agent associated with this disease. Serological and molecular tests specific for the virus permitted a definitive laboratory diagnosis to be made and allowed further investigation to define whether other cofactors play a part in disease progression.
C1 Univ Hong Kong, Queen Mary Hosp, Dept Pathol & Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Princess Margaret Hosp, Dept Med Intens Care & Pathol, Hong Kong, Hong Kong, Peoples R China.
   Dept Hlth, Govt Virus Unit, Hong Kong, Hong Kong, Peoples R China.
   Pamela Youde Nethersole Eastern Hosp, Dept Pathol & Med, Hong Kong, Hong Kong, Peoples R China.
   Kwong Wah Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
   Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China.
RP Peiris, JSM (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
RI Poon, Leo/C-4382-2009; Yuen, Kwok Yung/C-4465-2009; Peiris, Joseph
   Sriyal Malik/C-4380-2009; Nicholls, John Malcolm/C-4375-2009
OI Poon, Leo/0000-0002-9101-7953; Peiris, Joseph Sriyal
   Malik/0000-0001-8217-5995; Nicholls, John Malcolm/0000-0001-7217-7444;
   Yuen, Kwok-yung/0000-0002-2083-1552
FU PHS HHSUnited States Public Health Service [A195357]
CR CAUL EO, 1977, ARCH VIROL, V54, P107, DOI 10.1007/BF01314383
   Chan KH, 2002, J CLIN MICROBIOL, V40, P1675, DOI 10.1128/JCM.40.5.1675-1680.2002
   Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7
   El-Sahly HM, 2000, CLIN INFECT DIS, V31, P96, DOI 10.1086/313937
   FOTZ RJ, 1999, CHEST, V115, P901
   Fouchier RAM, 2000, J CLIN MICROBIOL, V38, P4096, DOI 10.1128/JCM.38.11.4096-4101.2000
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   McIntosh K., 1974, Current Topics in Microbiology and Immunology, V63, P85
   MCINTOSH K, 1970, AM J EPIDEMIOL, V91, P585, DOI 10.1093/oxfordjournals.aje.a121171
   TALBOT PJ, IN PRESS ADV EXP MED
   WENZEL RP, 1974, AM REV RESPIR DIS, V109, P621
   *WHO, 2003, WKLY EPIDEMIOL REC, V78, P81
   Wiedbrauk DL, 1993, MANUAL CLIN VIROLOGY
   World Health Organization, 2003, WKLY EPIDEMIOL REC, V78, P86
   Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9
NR 15
TC 1465
Z9 1695
U1 91
U2 274
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 19
PY 2003
VL 361
IS 9366
BP 1319
EP 1325
DI 10.1016/S0140-6736(03)13077-2
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 669HP
UT WOS:000182346100007
PM 12711465
OA Bronze
DA 2020-04-03
ER

PT J
AU JOHNSTON, SL
   PATTEMORE, PK
   SANDERSON, G
   SMITH, S
   LAMPE, F
   JOSEPHS, L
   SYMINGTON, P
   OTOOLE, S
   MYINT, SH
   TYRRELL, DAJ
   HOLGATE, ST
AF JOHNSTON, SL
   PATTEMORE, PK
   SANDERSON, G
   SMITH, S
   LAMPE, F
   JOSEPHS, L
   SYMINGTON, P
   OTOOLE, S
   MYINT, SH
   TYRRELL, DAJ
   HOLGATE, ST
TI COMMUNITY STUDY OF ROLE OF VIRAL-INFECTIONS IN EXACERBATIONS OF ASTHMA
   IN 9-11 YEAR-OLD CHILDREN
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID WHEEZY BRONCHITIS; RESPIRATORY-INFECTIONS; VIRUSES; SYMPTOMS; ADULTS;
   PRECIPITANTS; ASSOCIATION; CORONAVIRUS; CHILDHOOD
AB Objective-To study the association between upper and lower respiratory viral infections and acute exacerbations of asthma in schoolchildren in the community.
   Design-Community based 13 month longitudinal study using diary card respiratory symptom and peak expiratory flow monitoring to allow early sampling for viruses.
   Subjects-1O8 Children aged 9-11 years who had reported wheeze or cough, or both, in a questionnaire.
   Setting-Southampton and surrounding community.
   Main outcome measures-Upper and lower respiratory viral infections detected by polymerase chain reaction or conventional methods, reported exacerbations of asthma, computer identified episodes of respiratory tract symptoms or peak flow reductions.
   Results-Viruses were detected in 80% of reported episodes of reduced peak expiratory flow, 80% of reported episodes of wheeze, and in 85% of reported episodes of upper respiratory symptoms, cough, wheeze, and a fall in peak expiratory flow. The median duration of reported falls in peak expiratory flow was 14 days, and the median maximum fall in peak expiratory flow was 81 1/min. The most commonly identified virus type was rhinovirus.
   Conclusions-This study supports the hypothesis that upper respiratory viral infections are associated with 80-85% of asthma exacerbations in school age children.
C1 UNIV SOUTHAMPTON,DEPT MED STAT & COMP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.
   UNIV LEICESTER,DEPT MICROBIOL,LEICESTER LE1 9HN,LEICS,ENGLAND.
   MRC,COMMON COLD UNIT,SALISBURY,WILTS,ENGLAND.
RP JOHNSTON, SL (reprint author), UNIV MED SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.
RI Lampe, Fiona/I-5826-2019; Johnston, Sebastian Lennox/I-2423-2012;
   Fahimifar, Sepideh/M-5303-2019
OI Lampe, Fiona/0000-0001-6851-5471; Johnston, Sebastian
   Lennox/0000-0003-3009-9200; Pattemore, Philip/0000-0002-4968-1287;
   Josephs, Lynn/0000-0002-7157-2992
CR BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679
   CARLSEN KH, 1984, ARCH DIS CHILD, V59, P310, DOI 10.1136/adc.59.4.310
   CLOUGH JB, 1994, AM J RESP CRIT CARE, V150, P48, DOI 10.1164/ajrccm.150.1.8025771
   CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755
   GWALTNEY JM, 1979, PRINCIPLES PRACTICE, P429
   Hamparian W, 1979, DIAGNOSTIC PROCEDURE, P562
   HENDERSON FW, 1979, J PEDIATR-US, V95, P183
   HORN MEC, 1975, J HYG-CAMBRIDGE, V74, P157, DOI 10.1017/S0022172400024220
   HORN MEC, 1979, THORAX, V34, P23, DOI 10.1136/thx.34.1.23
   HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587
   HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393
   JENNINGS LC, 1987, NEW ZEAL MED J, V100, P488
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993
   JOHNSTON SL, 1993, THESIS U SOUTHAMPTON, P99
   KRAAIJEVELD CA, 1980, J CLIN MICROBIOL, V12, P493, DOI 10.1128/JCM.12.4.493-497.1980
   LARSON HE, 1980, J MED VIROL, V5, P221, DOI 10.1002/jmv.1890050306
   MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7
   MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124
   MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292
   MITCHELL I, 1976, ARCH DIS CHILD, V51, P707
   MITCHELL I, 1978, ARCH DIS CHILD, V53, P106, DOI 10.1136/adc.53.2.106
   MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x
   PHILLPOTTS RJ, 1983, J VIROL METHODS, V6, P267, DOI 10.1016/0166-0934(83)90041-1
   PICADO C, 1992, THORAX, V47, P197, DOI 10.1136/thx.47.3.197
   POTTER PC, 1984, S AFR MED J, V66, P397
   ROLDAAN AC, 1982, EUR J RESPIR DIS, V63, P140
   SCHMIDT NJ, 1979, DIAGNOSTIC PROCEDURE, P67
   STORR J, 1989, ARCH DIS CHILD, V64, P103, DOI 10.1136/adc.64.1.103
   WILSON NM, 1989, ARCH DIS CHILD, V64, P1194, DOI 10.1136/adc.64.8.1194
NR 31
TC 1340
Z9 1387
U1 21
U2 76
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0959-8138
J9 BRIT MED J
JI Br. Med. J.
PD MAY 13
PY 1995
VL 310
IS 6989
BP 1225
EP 1229
DI 10.1136/bmj.310.6989.1225
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA QY877
UT WOS:A1995QY87700015
PM 7767192
OA Green Published
DA 2020-04-03
ER

PT J
AU Zaki, AM
   van Boheemen, S
   Bestebroer, TM
   Osterhaus, ADME
   Fouchier, RAM
AF Zaki, Ali Moh
   van Boheemen, Sander
   Bestebroer, Theo M.
   Osterhaus, Albert D. M. E.
   Fouchier, Ron A. M.
TI Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi
   Arabia
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; PCR ASSAYS; IDENTIFICATION; DISEASE;
   INFLUENZA; GENOMES
AB A previously unknown coronavirus was isolated from the sputum of a 60-year-old man who presented with acute pneumonia and subsequent renal failure with a fatal outcome in Saudi Arabia. The virus (called HCoV-EMC) replicated readily in cell culture, producing cytopathic effects of rounding, detachment, and syncytium formation. The virus represents a novel betacoronavirus species. The closest known relatives are bat coronaviruses HKU4 and HKU5. Here, the clinical data, virus isolation, and molecular identification are presented. The clinical picture was remarkably similar to that of the severe acute respiratory syndrome (SARS) outbreak in 2003 and reminds us that animal coronaviruses can cause severe disease in humans.
C1 [Fouchier, Ron A. M.] Erasmus MC, Dept Virosci, Virosci Lab, NL-3015 GE Rotterdam, Netherlands.
   [Zaki, Ali Moh] Dr Soliman Fakeeh Hosp, Jeddah, Saudi Arabia.
RP Fouchier, RAM (reprint author), Erasmus MC, Dept Virosci, Virosci Lab, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.
EM r.fouchier@erasmusmc.nl
RI Jha, Babal/AAC-8337-2020; Fouchier, Ron A/A-1911-2014; Fouchier,
   Ron/Y-3755-2019
OI Jha, Babal/0000-0002-7660-5255; Fouchier, Ron A/0000-0001-8095-2869;
   Fouchier, Ron/0000-0001-8095-2869; Osterhaus, Albert/0000-0002-6074-1172
FU European CommissionEuropean Commission Joint Research Centre
FX Supported in part by the European Commission Seventh Framework Program
   for Research and Technological Development Project EMPERIE.
CR Corman VM, 2012, EURO SURVEILL, V17
   Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Fraaij PLA, 2011, VACCINE, V29, P7524, DOI 10.1016/j.vaccine.2011.08.010
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Jothikumar N, 2005, APPL ENVIRON MICROB, V71, P3131, DOI 10.1128/AEM.71.6.3131-3136.2005
   Kaw G. J. L., 2003, SMJ Singapore Medical Journal, V44, P201
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   The International Committee on Taxonomy of Viruses, 2012, VIRUS TAXONOMY CLASS
   Tong S, 2008, J CLIN MICROBIOL, V46, P2652, DOI 10.1128/JCM.00192-08
   van Boheemen S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034961
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Verstrepen WA, 2001, J CLIN MICROBIOL, V39, P4093, DOI 10.1128/JCM.39.11.4093-4096.2001
   Vijgen Leen, 2008, V454, P3, DOI 10.1007/978-1-59745-181-9_1
   WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   World Health Organization, 2012, NOV COR INF UPD REV
NR 25
TC 1333
Z9 1412
U1 85
U2 211
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 8
PY 2012
VL 367
IS 19
BP 1814
EP 1820
DI 10.1056/NEJMoa1211721
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 033DG
UT WOS:000310773200008
PM 23075143
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Marra, MA
   Jones, SJM
   Astell, CR
   Holt, RA
   Brooks-Wilson, A
   Butterfield, YSN
   Khattra, J
   Asano, JK
   Barber, SA
   Chan, SY
   Cloutier, A
   Coughlin, SM
   Freeman, D
   Girn, N
   Griffith, OL
   Leach, SR
   Mayo, M
   McDonald, H
   Montgomery, SB
   Pandoh, PK
   Petrescu, AS
   Robertson, AG
   Schein, JE
   Siddiqui, A
   Smailus, DE
   Stott, JE
   Yang, GS
   Plummer, F
   Andonov, A
   Artsob, H
   Bastien, N
   Bernard, K
   Booth, TF
   Bowness, D
   Czub, M
   Drebot, M
   Fernando, L
   Flick, R
   Garbutt, M
   Gray, M
   Grolla, A
   Jones, S
   Feldmann, H
   Meyers, A
   Kabani, A
   Li, Y
   Normand, S
   Stroher, U
   Tipples, GA
   Tyler, S
   Vogrig, R
   Ward, D
   Watson, B
   Brunham, RC
   Krajden, M
   Petric, M
   Skowronski, DM
   Upton, C
   Roper, RL
AF Marra, MA
   Jones, SJM
   Astell, CR
   Holt, RA
   Brooks-Wilson, A
   Butterfield, YSN
   Khattra, J
   Asano, JK
   Barber, SA
   Chan, SY
   Cloutier, A
   Coughlin, SM
   Freeman, D
   Girn, N
   Griffith, OL
   Leach, SR
   Mayo, M
   McDonald, H
   Montgomery, SB
   Pandoh, PK
   Petrescu, AS
   Robertson, AG
   Schein, JE
   Siddiqui, A
   Smailus, DE
   Stott, JE
   Yang, GS
   Plummer, F
   Andonov, A
   Artsob, H
   Bastien, N
   Bernard, K
   Booth, TF
   Bowness, D
   Czub, M
   Drebot, M
   Fernando, L
   Flick, R
   Garbutt, M
   Gray, M
   Grolla, A
   Jones, S
   Feldmann, H
   Meyers, A
   Kabani, A
   Li, Y
   Normand, S
   Stroher, U
   Tipples, GA
   Tyler, S
   Vogrig, R
   Ward, D
   Watson, B
   Brunham, RC
   Krajden, M
   Petric, M
   Skowronski, DM
   Upton, C
   Roper, RL
TI The genome sequence of the SARS-associated coronavirus
SO SCIENCE
LA English
DT Article
ID PROTEIN FAMILIES; RNA-SYNTHESIS; VIRUS; TRANSCRIPTION; DATABASE;
   GENERATION; INTERPRO; SITES
AB We sequenced the 29,751-base genome of the severe acute respiratory syndrome (SARS)-associated coronavirus known as the Tor2 isolate. The genome sequence reveals that this coronavirus is only moderately related to other known coronaviruses, including two human coronaviruses, HCoV-OC43 and HCoV-229E. Phylogenetic analysis of the predicted viral proteins indicates that the virus does not closely resemble any of the three previously known groups of coronaviruses. The genome sequence will aid in the diagnosis of SARS virus infection in humans and potential animal hosts (using polymerase chain reaction and immunological tests), in the development of antivirals (including neutralizing antibodies), and in the identification of putative epitopes for vaccine development.
C1 British Columbia Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada.
   Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada.
   British Columbia Ctr Dis Control, Vancouver, BC V5Z 4R4, Canada.
   Univ British Columbia, Ctr Dis Control, Vancouver, BC V5Z 4R4, Canada.
   Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada.
RP Marra, MA (reprint author), British Columbia Canc Agcy, Genome Sci Ctr, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.
EM mmarra@bccgsc.ca
RI Brooks-Wilson, Angela/E-9399-2012; Roper, Rachel/A-7935-2013; Holt,
   Robert A/C-3303-2009; Marra, Marco A/B-5987-2008; Jones, Steven
   J/C-3621-2009; Upton, Chris/A-4670-2008; Schein, Jacquie E/G-3674-2015;
   Griffith, Obi/P-1286-2014
OI Brooks-Wilson, Angela/0000-0003-1009-6408; Roper,
   Rachel/0000-0001-6971-7745; Holt, Robert A/0000-0002-7259-1247; Marra,
   Marco A/0000-0001-7146-7175; Jones, Steven J/0000-0003-3394-2208;
   Griffith, Obi/0000-0002-0843-4271; Upton, Chris/0000-0002-9019-8967
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37
   Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276
   DONNELLY CA, 2003, LANCET          0507
   Enjuanes LBD, 2000, VIRUS TAXONOMY CLASS, P835
   Felsenstein J., 1993, PHYLIP PHYLOGENY INF
   Fields BN, 2001, FIELDS VIROLOGY
   HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V347, P166
   Jonassen CM, 1998, J GEN VIROL, V79, P715, DOI 10.1099/0022-1317-79-4-715
   Krishnan R, 1996, VIROLOGY, V218, P400, DOI 10.1006/viro.1996.0210
   KSIAZEK TG, 2003, N ENGL J MED    0410
   KUO L, 2002, ANN M AM SOC VIR LEX
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LAPPS W, 1987, VIROLOGY, V157, P47, DOI 10.1016/0042-6822(87)90312-6
   Munch R, 2003, MICROBES INFECT, V5, P69, DOI 10.1016/S1286-4579(02)00053-9
   MYINT SH, 1995, CORONAVIRIDAE, P389
   Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1
   Ortego J, 2002, J VIROL, V76, P11518, DOI 10.1128/JVI.76.22.11518-11529.2002
   PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444
   PEIRIS JSM, 2003, LANCET          0408
   POUTANEN SM, 2003, N ENGL J MED    0331
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SAWICKI DL, 2001, J GEN VIROL, V82, P386
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   SCHAAD MC, 1994, J VIROL, V68, P8169, DOI 10.1128/JVI.68.12.8169-8179.1994
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Tsai JC, 2003, J VIROL, V77, P841, DOI 10.1128/JVI.77.2.841-850.2003
   Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 32
TC 1288
Z9 1550
U1 47
U2 142
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAY 30
PY 2003
VL 300
IS 5624
BP 1399
EP 1404
DI 10.1126/science.1085953
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 683ZW
UT WOS:000183181800036
PM 12730501
OA Bronze
DA 2020-04-03
ER

PT J
AU Allander, T
   Tammi, MT
   Eriksson, M
   Bjerkner, A
   Tiveljung-Lindell, A
   Andersson, B
AF Allander, T
   Tammi, MT
   Eriksson, M
   Bjerkner, A
   Tiveljung-Lindell, A
   Andersson, B
TI Cloning of a human parvovirus by molecular screening of respiratory
   tract samples
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE bioinformatics; nucleotide sequencing; respiratory tract infection;
   virus
ID MINUTE VIRUS; BOVINE PARVOVIRUS; SYNCYTIAL VIRUS; CANINES MVC; SEQUENCE;
   IDENTIFICATION; CHILDREN; CORONAVIRUS; HOSPITALIZATIONS; PATHOGENICITY
AB The identification of new virus species is a key issue for the study of infectious disease but is technically very difficult. We developed a system for large-scale molecular virus screening of clinical samples based on host DNA depletion, random PCR amplification, large-scale sequencing, and bioinformatics. The technology was applied to pooled human respiratory tract samples. The first experiments detected seven human virus species without the use of any specific reagent. Among the detected viruses were one coronavirus and one parvovirus, both of which were at that time uncharacterized. The parvovirus, provisionally named human bocavirus, was in a retrospective clinical study detected in 17 additional patients and associated with lower respiratory tract infections in children. The molecular virus screening procedure provides a general culture-independent solution to the problem of detecting unknown virus species in single or pooled samples. We suggest that a systematic exploration of the viruses that infect humans, "the human virome," can be initiated.
C1 Karolinska Univ Hosp, Dept Clin Microbiol, SE-17176 Stockholm, Sweden.
   Karolinska Univ Hosp, Ctr Mol Med, SE-17176 Stockholm, Sweden.
   Karolinska Inst, Dept Woman & Child Hlth, Astrid Lindgren Childrens Hosp, SE-17177 Stockholm, Sweden.
   Karolinska Inst, Ctr Genom & Bioinformat, SE-17177 Stockholm, Sweden.
   Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore.
   Natl Univ Singapore, Dept Biochem, Singapore 117543, Singapore.
RP Allander, T (reprint author), Karolinska Univ Hosp, Dept Clin Microbiol, L2-02, SE-17176 Stockholm, Sweden.
EM tobias.allander@karolinska.se
RI Andersson, Bjorn/G-9832-2013; Tammi, Martti/C-1115-2008
OI Andersson, Bjorn/0000-0002-4624-0259; 
CR Allander T, 2001, P NATL ACAD SCI USA, V98, P11609, DOI 10.1073/pnas.211424698
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Bloom M. E., 2001, FIELDS VIROLOGY, P2361
   CARMICHAEL LE, 1991, CORNELL VET, V81, P151
   CARMICHAEL LE, 1994, J VET DIAGN INVEST, V6, P165, DOI 10.1177/104063879400600206
   CHEN KC, 1986, J VIROL, V60, P1085, DOI 10.1128/JVI.60.3.1085-1097.1986
   DURHAM PJK, 1985, RES VET SCI, V38, P209, DOI 10.1016/S0034-5288(18)31828-9
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Fredricks DN, 1996, CLIN MICROBIOL REV, V9, P18, DOI 10.1128/CMR.9.1.18
   FROUSSARD P, 1992, NUCLEIC ACIDS RES, V20, P2900, DOI 10.1093/nar/20.11.2900
   Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758
   Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   Kellam P, 1998, TRENDS MICROBIOL, V6, P160, DOI 10.1016/S0966-842X(98)01239-6
   KIRKBRIDE CA, 1992, J VET DIAGN INVEST, V4, P374, DOI 10.1177/104063879200400402
   Ohshima T, 2004, VIRUS GENES, V29, P291, DOI 10.1007/s11262-004-7430-3
   Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7
   Relman DA, 1999, SCIENCE, V284, P1308, DOI 10.1126/science.284.5418.1308
   Schwartz D, 2002, VIROLOGY, V302, P219, DOI 10.1006/viro.2002.1674
   Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440
   Simmonds P, 2002, J MED MICROBIOL, V51, P455, DOI 10.1099/0022-1317-51-6-455
   Tammi MT, 2003, NUCLEIC ACIDS RES, V31, P4663, DOI 10.1093/nar/gkg653;
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Young NS, 2004, NEW ENGL J MED, V350, P586, DOI 10.1056/NEJMra030840
NR 26
TC 1037
Z9 1213
U1 21
U2 50
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 6
PY 2005
VL 102
IS 36
BP 12891
EP 12896
DI 10.1073/pnas.0504666102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 962FP
UT WOS:000231716700045
PM 16118271
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU COHEN, S
   TYRRELL, DAJ
   SMITH, AP
AF COHEN, S
   TYRRELL, DAJ
   SMITH, AP
TI PSYCHOLOGICAL STRESS AND SUSCEPTIBILITY TO THE COMMON COLD
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID VOLUNTEERS; INFECTION
AB Background. It is not known whether psychological stress suppresses host resistance to infection. To investigate this issue, we prospectively studied the relation between psychological stress and the frequency of documented clinical colds among subjects intentionally exposed to respiratory viruses.
   Methods. After completing questionnaires assessing degrees of psychological stress, 394 healthy subjects were given nasal drops containing one of five respiratory viruses (rhinovirus type 2, 9, or 14, respiratory syncytial virus, or coronavirus type 229E), and an additional 26 were given saline nasal drops. The subjects were then quarantined and monitored for the development of evidence of infection and symptoms. Clinical colds were defined as clinical symptoms in the presence of an infection verified by the isolation of virus or by an increase in the virus-specific antibody titer.
   Results. The rates of both respiratory infection (P < 0.005) and clinical colds (P < 0.02) increased in a dose-response manner with increases in the degree of psychological stress. Infection rates ranged from approximately 74 percent to approximately 90 percent, according to levels of psychological stress, and the incidence of clinical colds ranged from approximately 27 percent to 47 percent. These effects were not altered when we controlled for age, sex, education, allergic status, weight, the season, the number of subjects housed together, the infectious status of subjects sharing the same housing, and virus-specific antibody status at base line (before challenge). Moreover, the associations observed were similar for all five challenge viruses. Several potential stress-illness mediators, including smoking, alcohol consumption, exercise, diet, quality of sleep, white-cell counts, and total immunoglobulin levels, did not explain the association between stress and illness. Similarly, controls for personality variables (self-esteem, personal control, and introversion-extraversion) failed to alter our findings.
   Conclusions. Psychological stress was associated in a dose-response manner with an increased risk of acute infectious respiratory illness, and this risk was attributable to increased rates of infection rather than to an increased frequency of symptoms after infection.
C1 UNIV WALES COLL CARDIFF,HLTH PSYCHOL RES UNIT,CARDIFF CF1 1XL,S GLAM,WALES.
   MRC,COMMON COLD UNIT,SALISBURY,ENGLAND.
RP COHEN, S (reprint author), CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213, USA.
RI Smith, Andrew P/B-2192-2010; Winwood, Peter/A-6363-2008
OI Cohen, Sheldon/0000-0003-2248-4600; Smith, Andrew/0000-0001-8805-8028
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI23072]; NIMH NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [MH00721]
CR ADER R, 1981, PSYCHONEUROIMMUNOLOG
   AFIFI AA, 1984, COMPUTER AIDED MULTI
   ALEXANDER R W, 1956, Stud Med, V4, P61
   BARCLAY WS, 1987, J VIROL METHODS, V15, P53, DOI 10.1016/0166-0934(87)90048-6
   BEARE AS, 1977, CHEMOPROPHYLAXIS VIR, V2, P27
   BOYCE WT, 1977, PEDIATRICS, V60, P609
   BROADBENT DE, 1984, J PSYCHOSOM RES, V28, P511, DOI 10.1016/0022-3999(84)90085-0
   CALABRESE JR, 1987, AM J PSYCHIAT, V144, P1123
   CALLOW KA, 1985, J HYG-CAMBRIDGE, V95, P173, DOI 10.1017/S0022172400062410
   CLUFF LE, 1966, ARCH INTERN MED, V117, P159, DOI 10.1001/archinte.117.2.159
   COHEN S, 1991, PSYCHOL BULL, V109, P5, DOI 10.1037/0033-2909.109.1.5
   COHEN S, 1988, SOCIAL PSYCHOL HLTH, P31
   CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297
   EYSENCK HJ, 1964, MANUAL EYSENCK PERSO
   FELTEN DL, 1985, J IMMUNOL, V135, pS755
   FELTEN SY, 1987, J NEUROSCI RES, V18, P37, DOI 10.1002/jnr.490180108
   FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x
   FLEMING JS, 1980, J PERS SOC PSYCHOL, V39, P921, DOI 10.1037/0022-3514.39.5.921
   GRAHAM NMH, 1986, AM J EPIDEMIOL, V124, P389, DOI 10.1093/oxfordjournals.aje.a114409
   HENDERSON S, 1981, NEUROSIS SOCIAL ENV
   Hosmer D. W., 1989, APPLIED LOGISTIC REG
   JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435
   KIECOLT-GLASER J K, 1988, Brain Behavior and Immunity, V2, P67, DOI 10.1016/0889-1591(88)90007-4
   Kiecolt-Glaser JK, 1991, PSYCHONEUROIMMUNOLOG, P849
   Laudenslager ML, 1987, VIRUSES IMMUNITY MEN, P391
   Lazarus R. S., 1984, STRESS APPRAISAL COP
   MEYER RJ, 1962, PEDIATRICS, V29, P539
   MORAHAN PS, 1989, NAT IMMUN, P557
   PAULHUS D, 1983, J PERS SOC PSYCHOL, V44, P1253, DOI 10.1037/0022-3514.44.6.1253
   RABIN BS, 1989, CRIT REV IMMUNOL, V9, P279
   SHAVIT Y, 1984, SCIENCE, V223, P188, DOI 10.1126/science.6691146
   TOTMAN R, 1980, J PSYCHOSOM RES, V24, P155, DOI 10.1016/0022-3999(80)90037-9
   Tyrrell DAJ, 1988, LAB DIAGNOSIS INFECT, V2, P723
   ZEVON MA, 1982, J PERS SOC PSYCHOL, V43, P111, DOI 10.1037/0022-3514.43.1.111
NR 34
TC 1010
Z9 1024
U1 23
U2 151
PU MASS MEDICAL SOC
PI BOSTON
PA 10 SHATTUCK, BOSTON, MA 02115
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD AUG 29
PY 1991
VL 325
IS 9
BP 606
EP 612
DI 10.1056/NEJM199108293250903
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA GC328
UT WOS:A1991GC32800003
PM 1713648
DA 2020-04-03
ER

PT J
AU Li, WH
   Moore, MJ
   Vasilieva, N
   Sui, JH
   Wong, SK
   Berne, MA
   Somasundaran, M
   Sullivan, JL
   Luzuriaga, K
   Greenough, TC
   Choe, H
   Farzan, M
AF Li, WH
   Moore, MJ
   Vasilieva, N
   Sui, JH
   Wong, SK
   Berne, MA
   Somasundaran, M
   Sullivan, JL
   Luzuriaga, K
   Greenough, TC
   Choe, H
   Farzan, M
TI Angiotensin-converting enzyme 2 is a functional receptor for the SARS
   coronavirus
SO NATURE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; MESSENGER-RNA EXPRESSION; AMINOPEPTIDASE-N;
   CARBOXYPEPTIDASE; VIRUS; SITE; LOCALIZATION; INHIBITORS; INFECTION;
   CLONING
AB Spike (S) proteins of coronaviruses, including the coronavirus that causes severe acute respiratory syndrome (SARS), associate with cellular receptors to mediate infection of their target cells(1,2). Here we identify a metallopeptidase, angiotensin-converting enzyme 2 (ACE2)(3,4), isolated from SARS coronavirus (SARS-CoV)permissive Vero E6 cells, that efficiently binds the S1 domain of the SARS-CoV S protein. We found that a soluble form of ACE2, but not of the related enzyme ACE1, blocked association of the S1 domain with Vero E6 cells. 293T cells transfected with ACE2, but not those transfected with human immunodeficiency virus-1 receptors, formed multinucleated syncytia with cells expressing S protein. Furthermore, SARS-CoV replicated efficiently on ACE2-transfected but not mock-transfected 293T cells. Finally, anti-ACE2 but not anti-ACE1 antibody blocked viral replication on Vero E6 cells. Together our data indicate that ACE2 is a functional receptor for SARS-CoV.
C1 Harvard Univ, Sch Med, Childrens Hosp, Perlmutter Lab,Pulm Div,Dept Pediat, Boston, MA 02115 USA.
   Harvard Univ, Dept Med Microbiol & Mol Genet, Brigham & Womens Hosp, Partners AIDS Res Ctr,Sch Med, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.
   Tufts Univ, Sch Med, Tufts Univ Core Facil, Boston, MA 02111 USA.
   Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.
RP Choe, H (reprint author), Harvard Univ, Sch Med, Childrens Hosp, Perlmutter Lab,Pulm Div,Dept Pediat, Boston, MA 02115 USA.
OI SUI, JIANHUA/0000-0002-1272-9662; Farzan, Michael/0000-0002-2990-5319;
   Li, Wenhui/0000-0003-1305-7404
CR BONAVIA Z, 2003, J VIROL, V77, P2530
   Breslin JJ, 2003, J VIROL, V77, P4435, DOI 10.1128/JVI.77.7.4435-4438.2003
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Dales NA, 2002, J AM CHEM SOC, V124, P11852, DOI 10.1021/ja0277226
   DELMAS B, 1994, J VIROL, V68, P5216, DOI 10.1128/JVI.68.8.5216-5224.1994
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   DONOGHUE M, 2000, CIRC RES, V87, P1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   DVEKSLER GS, 1993, J VIROL, V67, P1
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   Holmes KV, 2003, NEW ENGL J MED, V348, P1948, DOI 10.1056/NEJMp030078
   HOLMES KV, 1993, ADV EXP MED BIOL, V342, P261
   Huang LL, 2003, J BIOL CHEM, V278, P15532, DOI 10.1074/jbc.M212934200
   Jackwood MW, 2001, AVIAN DIS, V45, P366, DOI 10.2307/1592976
   Komatsu T, 2002, DNA SEQUENCE, V13, P217, DOI 10.1080/1042517021000021608
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   Sturman L S, 1984, Adv Exp Med Biol, V173, P25
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Tresnan DB, 1998, ADV EXP MED BIOL, V440, P69
   Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
NR 30
TC 999
Z9 1133
U1 67
U2 145
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD NOV 27
PY 2003
VL 426
IS 6965
BP 450
EP 454
DI 10.1038/nature02145
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 747JE
UT WOS:000186800800040
PM 14647384
OA Bronze
DA 2020-04-03
ER

PT J
AU Guan, Y
   Zheng, BJ
   He, YQ
   Liu, XL
   Zhuang, ZX
   Cheung, CL
   Luo, SW
   Li, PH
   Zhang, LJ
   Guan, YJ
   Butt, KM
   Wong, KL
   Chan, KW
   Lim, W
   Shortridge, KF
   Yuen, KY
   Peiris, JSM
   Poon, LLM
AF Guan, Y
   Zheng, BJ
   He, YQ
   Liu, XL
   Zhuang, ZX
   Cheung, CL
   Luo, SW
   Li, PH
   Zhang, LJ
   Guan, YJ
   Butt, KM
   Wong, KL
   Chan, KW
   Lim, W
   Shortridge, KF
   Yuen, KY
   Peiris, JSM
   Poon, LLM
TI Isolation and characterization of viruses related to the SARS
   coronavirus from animals in Southern China
SO SCIENCE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME
AB A novel coronavirus (SCoV) is the etiological agent of severe acute respiratory syndrome (SARS). SCoV-like viruses were isolated from Himalayan palm civets found in a live-animal market in Guangdong, China. Evidence of virus infection was also detected in other animals ( including a raccoon dog, Nyctereutes procyonoides) and in humans working at the same market. All the animal isolates retain a 29-nucleotide sequence that is not found in most human isolates. The detection of SCoV-like viruses in small, live wild mammals in a retail market indicates a route of interspecies transmission, although the natural reservoir is not known.
C1 Univ Hong Kong, Dept Microbiol, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
   Ctr Dis Control & Prevent, Shenzhen, Guangdong Prov, Peoples R China.
   Univ Hong Kong, Dept Pathol, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
   Dept Hlth, Govt Virus Unit, Hong Kong, Hong Kong, Peoples R China.
RP Guan, Y (reprint author), Univ Hong Kong, Dept Microbiol, Queen Mary Hosp, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.
RI Poon, Leo/C-4382-2009; Yuen, Kwok Yung/C-4465-2009
OI Poon, Leo/0000-0002-9101-7953; 
CR Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   HOLMES KR, UNPUB
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   ZHONG NS, IN PRESS LANCET
NR 8
TC 911
Z9 1011
U1 45
U2 208
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD OCT 10
PY 2003
VL 302
IS 5643
BP 276
EP 278
DI 10.1126/science.1087139
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 730HT
UT WOS:000185825900039
PM 12958366
OA Bronze
DA 2020-04-03
ER

PT J
AU Li, WD
   Shi, ZL
   Yu, M
   Ren, WZ
   Smith, C
   Epstein, JH
   Wang, HZ
   Crameri, G
   Hu, ZH
   Zhang, HJ
   Zhang, JH
   McEachern, J
   Field, H
   Daszak, P
   Eaton, BT
   Zhang, SY
   Wang, LF
AF Li, WD
   Shi, ZL
   Yu, M
   Ren, WZ
   Smith, C
   Epstein, JH
   Wang, HZ
   Crameri, G
   Hu, ZH
   Zhang, HJ
   Zhang, JH
   McEachern, J
   Field, H
   Daszak, P
   Eaton, BT
   Zhang, SY
   Wang, LF
TI Bats are natural reservoirs of SARS-like coronaviruses
SO SCIENCE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; NIPAH VIRUS; ANTIBODIES; IDENTIFICATION;
   BANGLADESH; EVOLUTION; PROTEIN; CIVETS; CHINA; COV
AB Severe acute respiratory syndrome (SARS) emerged in 2002 to 2003 in southern China. The origin of its etiological agent, the SARS coronavirus (SARS-CoV), remains elusive. Here we report that species of bats are a natural host of coronaviruses closely related to those responsible for the SARS, outbreak. These viruses, termed SARS-like coronaviruses (SL-CoVs), display greater genetic variation than SARS-CoV isolated from humans or from civets. The human and civet isolates of SARS-CoV nestle phylogenetically within the spectrum of SL-CoVs, indicating that the virus responsible for the SARS outbreak Was a member of this coronavirus group.
C1 CAS, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Peoples R China.
   Chinese Acad Sci, Inst Zool, Beijing, Peoples R China.
   CSIRO Livestock Ind, Australian Anim Hlth Lab, Geelong, Vic, Australia.
   Dept Primary Ind & Fisheries, Moorooka, Qld, Australia.
   Consortium Conservat Med, New York, NY USA.
   Guangzhou Inst Biomed & Hlth, Guangzhou, Peoples R China.
RP Shi, ZL (reprint author), CAS, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Peoples R China.
EM zlshi@wh.iov.cn; zhangsy@ioz.ac.cn; linfa.wang@csiro.au
RI Shi, Zhengli/A-1013-2013; Barr, Jennifer/H-9254-2013; Crameri,
   Gary/H-8441-2013; Ren, Wuze/D-2926-2011; daszak, peter/U-4588-2017;
   Zhang, Shuyi/B-5117-2011
OI Shi, Zhengli/0000-0001-8089-163X; daszak, peter/0000-0002-2046-5695;
   Barr, Jennifer/0000-0001-5266-9142; Hu, Zhihong/0000-0002-1560-0928
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [R01-TW05869]
CR AbuBakar S, 2004, EMERG INFECT DIS, V10, P2228, DOI 10.3201/eid1012.040452
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432
   Fenton M. B., 2003, BAT ECOLOGY
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Harcourt BH, 2005, EMERG INFECT DIS, V11, P1594, DOI 10.3201/eid1110.050513
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   Hsu VP, 2004, EMERG INFECT DIS, V10, P2082, DOI 10.3201/eid1012.040701
   Hudson P. J., 2002, ECOLOGY WILDLIFE DIS
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   LAI MC, 2001, FIELDS VIROLOGY, V2, pCH35
   Lio P, 2004, TRENDS MICROBIOL, V12, P106, DOI 10.1016/j.tim.2004.01.005
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mickleburgh SP, 2002, ORYX, V36, P18, DOI 10.1017/S0030605301000011
   MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   POON LLM, 2005, J VIROL, V79, P2110
   Reynes JM, 2005, EMERG INFECT DIS, V11, P1042, DOI 10.3201/eid1107.041350
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   SULKIN SE, 1974, MONOGR VIROL, V8, P170
   Tripp RA, 2005, J VIROL METHODS, V128, P21, DOI 10.1016/j.jviromet.2005.03.021
   Tu CC, 2004, EMERG INFECT DIS, V10, P2244, DOI 10.3201/eid1012.040520
   WANG LF, 2001, INFECT DIS REV, V3, P52
   Wang Lin-Fa, 2003, Current Genomics, V4, P263, DOI 10.2174/1389202033490385
   Wu DL, 2005, J VIROL, V79, P2620, DOI 10.1128/JVI.79.4.2620-2625.2005
NR 27
TC 873
Z9 958
U1 65
U2 295
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD OCT 28
PY 2005
VL 310
IS 5748
BP 676
EP 679
DI 10.1126/science.1118391
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 980ET
UT WOS:000232997700042
PM 16195424
DA 2020-04-03
ER

PT J
AU Peiris, JSM
   Chu, CM
   Cheng, VCC
   Chan, KS
   Hung, IFN
   Poon, LLM
   Law, KI
   Tang, BSF
   Hon, TYW
   Chan, CS
   Chan, KH
   Ng, JSC
   Zheng, BJ
   Ng, WL
   Lai, RWM
   Guan, Y
   Yuen, KY
AF Peiris, JSM
   Chu, CM
   Cheng, VCC
   Chan, KS
   Hung, IFN
   Poon, LLM
   Law, KI
   Tang, BSF
   Hon, TYW
   Chan, CS
   Chan, KH
   Ng, JSC
   Zheng, BJ
   Ng, WL
   Lai, RWM
   Guan, Y
   Yuen, KY
CA HKU UCH SARS Study Grp
TI Clinical progression and viral load in a community outbreak of
   coronavirus-associated SARS pneumonia: a prospective study
SO LANCET
LA English
DT Article
ID VIRUS
AB Background We investigated the temporal progression of the clinical, radiological, and virological changes in a community outbreak of severe acute respiratory syndrome (SARS).
   Methods We followed up 75 patients for 3 weeks managed with a standard treatment protocol of ribavirin and corticosteroids, and assessed the, pattern of clinical disease, viral load, risk factors for poor clinical outcome, and the usefulness of virological diagnostic methods.
   Findings Fever and pneumonia initially improved but 64 (85%) patients developed recurrent fever after a mean of 8-9 (SD 3.1) days, 55 (73%) had watery diarrhoea after 7.5 (2.3) days, 60 (80%) had radiological worsening after 7.4 (2.2) days, and respiratory symptoms worsened in 34 (45%) after 8.6 (3.0) days. In 34 (45%) patients, improvement of initial pulmonary lesions was associated with appearance of new radiological lesions at other sites. Nine (12%) patients developed spontaneous pneumomediastinum and 15 (20%) developed acute respiratory distress syndrome (ARDS) in week 3. Quantitative reverse-transcriptase (RT) PCR of nasopharyngeal aspirates in 14 patients (four with ARDS) showed peak viral load at day 10, and at day 15 a load lower than at admission. Age and chronic hepatitis B virus infection treated with lamivudine were independent significant risk factors for progression to ARDS (p=0.001). SARS-associated coronavirus in faeces was seen on RT-PCR in 65 (97%) of 67 patients at day 14. The mean time to seroconversion was 20 days.
   Interpretation The consistent clinical progression, shifting radiological infiltrates, and an inverted V viral-load profile suggest that worsening in week 2 is unrelated to uncontrolled viral replication but may be related to immunopathological damage.
C1 Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
   United Christian Hosp, Dept Med Intens Care Radiol & Pathol, Hong Kong, Hong Kong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
RI Yuen, Kwok Yung/C-4465-2009; Poon, Leo/C-4382-2009; Chan, Chung
   Sing/C-4577-2009; Peiris, Joseph Sriyal Malik/C-4380-2009
OI Poon, Leo/0000-0002-9101-7953; Peiris, Joseph Sriyal
   Malik/0000-0001-8217-5995; Yuen, Kwok-yung/0000-0002-2083-1552; Hung,
   Ivan Fan Ngai/0000-0002-1556-2538; Chu, Chung Ming/0000-0002-9959-1271
FU PHS HHSUnited States Public Health Service [A195357]
CR BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   *CDCP, SARS COR SEQ
   *HA, HA GUID SEV AC RESP
   Ho W, 2003, LANCET, V361, P1313, DOI 10.1016/S0140-6736(03)13085-1
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   KSIAZEK TG, NOVEL CORONAVIRUS AS
   LEE N, MAJOR OUTBREAK SEVER
   Majeski EI, 2003, AM J RESP CELL MOL, V28, P208, DOI 10.1165/rcmb.4891
   Ning Q, 1998, J IMMUNOL, V160, P3487
   OLLIFF JFC, 1989, CLIN RADIOL, V40, P463, DOI 10.1016/S0009-9260(89)80245-4
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   POON LLM, RAPID DIAGNOSIS CORO
   POUTANEN SM, IDENTIFICATION SEVER
   *SEV AC RESP SYNDR, MULT COUNTR OUTBR
   TSANG KW, CLUSTER CASES SEVERE
   TURNER RB, 1986, J INFECT DIS, V154, P443, DOI 10.1093/infdis/154.3.443
   TUTOR JD, 1995, PEDIATR PULM, V19, P393, DOI 10.1002/ppul.1950190614
   ATYPICAL PNEUMONIA
NR 18
TC 839
Z9 922
U1 56
U2 151
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD MAY 24
PY 2003
VL 361
IS 9371
BP 1767
EP 1772
DI 10.1016/S0140-6736(03)13412-5
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 682CY
UT WOS:000183074800008
PM 12781535
OA Bronze
DA 2020-04-03
ER

PT J
AU NICHOLSON, KG
   KENT, J
   IRELAND, DC
AF NICHOLSON, KG
   KENT, J
   IRELAND, DC
TI RESPIRATORY VIRUSES AND EXACERBATIONS OF ASTHMA IN ADULTS
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID RHINOVIRUS INFECTION; PULMONARY-FUNCTION; WHEEZY BRONCHITIS; CHILDREN;
   TRACT; PRECIPITANTS; VOLUNTEERS; AIRWAYS
AB Objective-To study the role of respiratory viruses in exacerbations of asthma in adults.
   Design-Longitudinal study of 138 adults with asthma.
   Setting-Leicestershire Health Authority.
   Subjects-48 men and 90 women 19-46 years of age with a mean duration of wheeze of 19.6 years. 75% received regular treatment with bronchodilators; 89% gave a history of eczema, hay fever, allergic rhinitis, nasal polyps, or allergies; 38% had been admitted to hospital with asthma.
   Main outcome measures-Symptomatic colds and asthma exacerbations; objective exacerbations of asthma with greater-than-or-equal-to 50 l/min reduction in mean peak expiratory flow rate when morning and night time readings on days 1-7 after onset of symptoms were compared with rates during an asymptomatic control period; laboratory confirmed respiratory tract infections.
   Results-Colds were reported in 80% (223/280) of episodes with symptoms of wheeze, chest tightness, or breathlessness, and 89% (223/250) of colds were associated with asthma symptoms. 24% of 115 laboratory confirmed non-bacterial infections were associated with reductions in mean peak expiratory flow rate greater-than-or-equal-to 50 l/min through days 1-7 and 48% had mean decreases greater-than-or-equal-to 25 l/min. 44% of episodes with mean decreases in flow rate greater-than-or-equal-to 50 l/min were associated with laboratory confirmed infections. Infections with rhinoviruses, coronaviruses OC43 and 229E, influenza B, respiratory syncytial virus, parainfluenza virus, and chlamydia were all associated with objective evidence of an exacerbation of asthma.
   Conclusions-These findings show that asthma symptoms and reductions in peak flow are often associated with colds and respiratory viruses; respiratory virus infections commonly cause or are associated with exacerbations of asthma in adults.
RP NICHOLSON, KG (reprint author), UNIV LEICESTER,SCH MED,DEPT MICROBIOL,LEICESTER LE1 9HN,ENGLAND.
CR BEARE AS, 1977, CHEMOPROPHYLAXIS VIR, V2, P27
   BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679
   BLAIR HT, 1976, AM REV RESPIR DIS, V114, P95
   DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008
   FRIDY WW, 1974, ANN INTERN MED, V80, P150, DOI 10.7326/0003-4819-80-2-150
   HALL WJ, 1978, ANN INTERN MED, V88, P203, DOI 10.7326/0003-4819-88-2-203
   HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587
   HORNER GJ, 1973, AM REV RESPIR DIS, V108, P150
   HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393
   HUHTI E, 1974, ANN ALLERGY, V33, P145
   IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204
   JOHANSON WG, 1969, AM REV RESPIR DIS, V100, P141
   KRAAIJEVELD CA, 1980, J CLIN MICROBIOL, V12, P493, DOI 10.1128/JCM.12.4.493-497.1980
   LAMBERT HP, 1972, BMJ-BRIT MED J, V3, P323, DOI 10.1136/bmj.3.5822.323
   LO YMD, 1988, LANCET, V2, P679
   MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7
   MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124
   MINOR TE, 1974, J PEDIATR-US, V85, P472, DOI 10.1016/S0022-3476(74)80447-6
   MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292
   MINOR TE, 1976, AM REV RESPIR DIS, V113, P149
   NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251
   PICKEN JJ, 1972, AM J MED, V52, P738, DOI 10.1016/0002-9343(72)90079-4
   WISELKA MJ, 1992, LANCET, V339, P367
   WISELKA MJ, 1991, THORAX, V46, P706, DOI 10.1136/thx.46.10.706
   1962, AM REV RESPIR DIS, V85, P762
NR 25
TC 802
Z9 823
U1 4
U2 25
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0959-8138
J9 BRIT MED J
JI Br. Med. J.
PD OCT 16
PY 1993
VL 307
IS 6910
BP 982
EP 986
DI 10.1136/bmj.307.6910.982
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MC441
UT WOS:A1993MC44100020
PM 8241910
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU van der Hoek, L
   Pyrc, K
   Jebbink, MF
   Vermeulen-Oost, W
   Berkhout, RJM
   Wolthers, KC
   Wertheim-van Dillen, PME
   Kaandorp, J
   Spaargaren, J
   Berkhout, B
AF van der Hoek, L
   Pyrc, K
   Jebbink, MF
   Vermeulen-Oost, W
   Berkhout, RJM
   Wolthers, KC
   Wertheim-van Dillen, PME
   Kaandorp, J
   Spaargaren, J
   Berkhout, B
TI Identification of a new human coronavirus
SO NATURE MEDICINE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; RECEPTOR-BINDING; SARS-CORONAVIRUS; ORGAN
   CULTURES; SPIKE PROTEIN; S-GENE; VIRUS; DISEASE; GENOME; OC43
AB Three human coronaviruses are known to exist: human coronavirus 229E (HCoV-229E), HCoV-OC43 and severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). Here we report the identification of a fourth human coronavirus, HCoV-NL63, using a new method of virus discovery. The virus was isolated from a 7-month-old child suffering from bronchiolitis and conjunctivitis. The complete genome sequence indicates that this virus is not a recombinant, but rather a new group 1 coronavirus. The in vitro host cell range of HCoV-NL63 is notable because it replicates on tertiary monkey kidney cells and the monkey kidney LLC-MK2 cell line. The viral genome contains distinctive features, including a unique N-terminal fragment within the spike protein. Screening of clinical specimens from individuals suffering from respiratory illness identified seven additional HCoV-NL63-infected individuals, indicating that the virus was widely spread within the human population.
C1 Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands.
   Municipal Hlth Serv, Publ Hlth Lab, NL-1018 WT Amsterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol Clin Virol, NL-1105 AZ Amsterdam, Netherlands.
   Slotervaart Hosp, Dept Pediat, NL-1066 EC Amsterdam, Netherlands.
RP Berkhout, B (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.
EM b.berkhout@amc.uva.nl
RI Wolthers, Katja C./E-5140-2018; van der Hoek, Lia/Y-6412-2019
OI Wolthers, Katja C./0000-0003-1617-7049; Pyrc,
   Krzysztof/0000-0002-3867-7688; Spaargaren, Joke/0000-0001-8728-316X
CR Almeida J D, 1967, J Gen Virol, V1, P175, DOI 10.1099/0022-1317-1-2-175
   Bachem CWB, 1996, PLANT J, V9, P745, DOI 10.1046/j.1365-313X.1996.9050745.x
   Boivin G, 2003, EMERG INFECT DIS, V9, P634
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   BRADBURNE AF, 1967, BMJ-BRIT MED J, V3, P767, DOI 10.1136/bmj.3.5568.767
   Chen LL, 2003, BIOCHEM BIOPH RES CO, V307, P382, DOI 10.1016/S0006-291X(03)01192-6
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   DUARTE M, 1994, VIROLOGY, V198, P466, DOI 10.1006/viro.1994.1058
   GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Guy JS, 2000, J CLIN MICROBIOL, V38, P4523, DOI 10.1128/JCM.38.12.4523-4526.2000
   Hamparian W, 1979, DIAGNOSTIC PROCEDURE, P562
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   HENDLEY JO, 1972, AM REV RESPIR DIS, V105, P805
   Holmes KV, 1996, FIELDS VIROLOGY, P1075
   Jubelt B, 2001, NEUROLOGY, V57, P945, DOI 10.1212/WNL.57.6.945
   Krempl C, 2000, J GEN VIROL, V81, P489, DOI 10.1099/0022-1317-81-2-489
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUNKEL F, 1993, VIROLOGY, V195, P195, DOI 10.1006/viro.1993.1360
   Lai MMC, 2003, J BIOMED SCI, V10, P664, DOI 10.1007/BF02256318
   Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   MOUNIR S, 1993, ADV EXP MED BIOL, V342, P61
   MOUNIR S, 1993, VIROLOGY, V192, P355, DOI 10.1006/viro.1993.1043
   MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sawicki S G, 1995, Adv Exp Med Biol, V380, P499
   Shingadia D, 2002, LANCET INFECT DIS, V2, P310, DOI 10.1016/S1473-3099(02)00265-7
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9
   Stohlman SA, 2001, BRAIN PATHOL, V11, P92
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   TYRRELL DAJ, 1965, BMJ-BRIT MED J, V1, P1467, DOI 10.1136/bmj.1.5448.1467
   van Marle G, 1999, P NATL ACAD SCI USA, V96, P12056, DOI 10.1073/pnas.96.21.12056
   VAUGHN EM, 1995, J VIROL, V69, P3176, DOI 10.1128/JVI.69.5.3176-3184.1995
NR 41
TC 768
Z9 818
U1 14
U2 44
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD APR
PY 2004
VL 10
IS 4
BP 368
EP 373
DI 10.1038/nm1024
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 808RU
UT WOS:000220587000027
PM 15034574
OA Bronze
DA 2020-04-03
ER

PT J
AU Snijder, EJ
   Bredenbeek, PJ
   Dobbe, JC
   Thiel, V
   Ziebuhr, J
   Poon, LLM
   Guan, Y
   Rozanov, M
   Spaan, WJM
   Gorbalenya, AE
AF Snijder, EJ
   Bredenbeek, PJ
   Dobbe, JC
   Thiel, V
   Ziebuhr, J
   Poon, LLM
   Guan, Y
   Rozanov, M
   Spaan, WJM
   Gorbalenya, AE
TI Unique and conserved features of genome and proteome of
   SARS-coronavirus, an early split-off from the coronavirus group 2
   lineage
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE nidovirus; genome organization; subgenomic mRNA synthesis; replicase;
   RNA processing
ID ACUTE RESPIRATORY SYNDROME; MOUSE HEPATITIS-VIRUS;
   INFECTIOUS-BRONCHITIS-VIRUS; MULTIPLE SEQUENCE ALIGNMENT; MESSENGER-RNA
   SYNTHESIS; CYSTEINE PROTEINASE; BOVINE CORONAVIRUS; CRYSTAL-STRUCTURE;
   ESCHERICHIA-COLI; ACTIVE-SITE
AB The genome organization and expression strategy of the newly identified severe acute respiratory syndrome coronavirus (SARS-CoV) were predicted using recently published genome sequences. Fourteen putative open reading frames were identified, 12 of which were predicted to be expressed from a nested set of eight subgenomic mRNAs. The synthesis of these mRNAs in SARS-CoV-infected cells was confirmed experimentally. The 4382- and 7073 amino acid residue SARS-CoV replicase poly-proteins are predicted to be cleaved into 16 subunits by two viral proteinases (bringing the total number of SARS-CoV proteins to 28). A phylogenetic analysis of the replicase gene, using a distantly related torovirus as an outgroup, demonstrated that, despite a number of unique features, SARS-CoV is most closely related to group 2 coronaviruses. Distant homologs of cellular RNA processing enzymes were identified in group 2 coronaviruses, with four of them being conserved in SARS-CoV. These newly recognized viral enzymes place the mechanism of coronavirus RNA synthesis in a completely new perspective. Furthermore, together with previously described viral enzymes, they will be important targets for the design of antiviral strategies aimed at controlling the further spread of SARS-CoV. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, NL-2300 RC Leiden, Netherlands.
   Univ Wurzburg, Inst Immunol & Virol, Wurzburg, Germany.
   Univ Hong Kong, Queen Mary Hosp, Dept Microbiol & Pathol, Hong Kong, Hong Kong, Peoples R China.
   Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.
RP Snijder, EJ (reprint author), Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, Room L4-34,Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.
RI Gorbalenya, Alexander E/J-4818-2012; Jha, Babal/AAC-8337-2020; Ziebuhr,
   John/G-7669-2015; Snijder, Eric J./E-6073-2018; Thiel,
   Volker/AAI-2391-2019; Poon, Leo/C-4382-2009
OI Gorbalenya, Alexander E/0000-0002-4967-7341; Jha,
   Babal/0000-0002-7660-5255; Snijder, Eric J./0000-0003-3297-2309; Poon,
   Leo/0000-0002-9101-7953; Thiel, Volker/0000-0002-5783-0887; Ziebuhr,
   John/0000-0002-5741-8825; Guan, Yi/0000-0001-6057-9243
CR Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685
   Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48
   BAKER SC, 1993, J VIROL, V67, P6056, DOI 10.1128/JVI.67.10.6056-6063.1993
   Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260
   BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   Brautigam CA, 1999, BIOCHEMISTRY-US, V38, P696, DOI 10.1021/bi981537g
   BREDENBEEK PJ, 1990, VIROLOGY, V175, P303, DOI 10.1016/0042-6822(90)90212-A
   Breyer WA, 2000, NAT STRUCT BIOL, V7, P1125
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   Bugl H, 2000, MOL CELL, V6, P349, DOI 10.1016/S1097-2765(00)00035-6
   Chouljenko VN, 2001, J GEN VIROL, V82, P2927, DOI 10.1099/0022-1317-82-12-2927
   Crotty S, 2000, NAT MED, V6, P1375
   CULVER GM, 1994, J BIOL CHEM, V269, P24928
   DEHAAN CA, 2002, VIROLOGY, V269, P177
   DENBOON JA, 1991, VIROLOGY, V182, P655, DOI 10.1016/0042-6822(91)90606-C
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X
   Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757
   Enjuanes L, 2000, VIRUS TAXONOMY CLASS, P827
   Feder M, 2003, GENE, V302, P129, DOI 10.1016/S0378-1119(02)01097-1
   Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4
   GONZALES JM, 2003, IN PRESS ARCH VIROL
   GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6
   Gorbalenya AE, 2001, ADV EXP MED BIOL, V494, P1
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Hegyi A, 2002, J GEN VIROL, V83, P581, DOI 10.1099/0022-1317-83-3-581
   HENIKOFF S, 1994, J MOL BIOL, V243, P574, DOI 10.1016/0022-2836(94)90032-9
   Herold J, 1999, J BIOL CHEM, V274, P14918, DOI 10.1074/jbc.274.21.14918
   HOFMANN MA, 1993, VIROLOGY, V196, P163, DOI 10.1006/viro.1993.1464
   Kanjanahaluethai A, 2000, J VIROL, V74, P7911, DOI 10.1128/JVI.74.17.7911-7921.2000
   Kimura M, 1983, NEUTRAL THEORY MOL E
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lai M.M.C., 2001, FIELDS VIROLOGY, P1163
   Laneve P, 2003, J BIOL CHEM, V278, P13026, DOI 10.1074/jbc.M211937200
   Lim KP, 2000, J VIROL, V74, P1674, DOI 10.1128/JVI.74.4.1674-1685.2000
   LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992
   Marchler-Bauer A, 2002, NUCLEIC ACIDS RES, V30, P281, DOI 10.1093/nar/30.1.281
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153
   Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211
   Nagy PD, 1997, VIROLOGY, V235, P1, DOI 10.1006/viro.1997.8681
   Nasr F, 2000, NUCLEIC ACIDS RES, V28, P1676, DOI 10.1093/nar/28.8.1676
   Nicholas KB, 1997, EMBNET NEWS, V4, P1
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   Pasternak AO, 2001, EMBO J, V20, P7220, DOI 10.1093/emboj/20.24.7220
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Ponting CP, 2000, ADV PROTEIN CHEM, V54, P185, DOI 10.1016/S0065-3233(00)54007-8
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   SANCHEZ CM, 1990, VIROLOGY, V174, P410, DOI 10.1016/0042-6822(90)90094-8
   Sasseville AMJ, 2002, J GEN VIROL, V83, P2411, DOI 10.1099/0022-1317-83-10-2411
   Sawicki S G, 1995, Adv Exp Med Biol, V380, P499
   Senanayake SD, 1997, VIRUS RES, V48, P101, DOI 10.1016/S0168-1702(96)01423-2
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728
   SIDDELL SG, 1995, VIRUSES
   SNIJDER EJ, 1993, J GEN VIROL, V74, P2305, DOI 10.1099/0022-1317-74-11-2305
   SNIJDER EJ, 1990, NUCLEIC ACIDS RES, V18, P4535, DOI 10.1093/nar/18.15.4535
   SNIJDER EJ, 1991, VIROLOGY, V180, P448, DOI 10.1016/0042-6822(91)90056-H
   SNIJDER EJ, 1990, VIROLOGY, V178, P355, DOI 10.1016/0042-6822(90)90332-L
   SNIJDER EJ, 2001, FIELDS VIROLOGY, P1205
   Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tijms MA, 2001, P NATL ACAD SCI USA, V98, P1889, DOI 10.1073/pnas.041390398
   van der Meer Y, 1999, J VIROL, V73, P7641, DOI 10.1128/JVI.73.9.7641-7657.1999
   van Dinten LC, 2000, J VIROL, V74, P5213, DOI 10.1128/JVI.74.11.5213-5223.2000
   Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317
   ZHANG XM, 1994, J MED VIROL, V44, P152, DOI 10.1002/jmv.1890440207
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
   Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017
NR 78
TC 688
Z9 743
U1 21
U2 69
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD AUG 29
PY 2003
VL 331
IS 5
BP 991
EP 1004
DI 10.1016/S0022-2836(03)00865-9
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 716NZ
UT WOS:000185036400004
PM 12927536
OA Bronze
DA 2020-04-03
ER

PT J
AU Poutanen, SM
   Low, DE
   Henry, B
   Finkelstein, S
   Rose, D
   Green, K
   Tellier, R
   Draker, R
   Adachi, D
   Ayers, M
   Chan, AK
   Skowronski, DM
   Salit, I
   Simor, AE
   Slutsky, AS
   Doyle, PW
   Krajden, M
   Petric, M
   Brunham, RC
   McGeer, AJ
AF Poutanen, SM
   Low, DE
   Henry, B
   Finkelstein, S
   Rose, D
   Green, K
   Tellier, R
   Draker, R
   Adachi, D
   Ayers, M
   Chan, AK
   Skowronski, DM
   Salit, I
   Simor, AE
   Slutsky, AS
   Doyle, PW
   Krajden, M
   Petric, M
   Brunham, RC
   McGeer, AJ
CA Natl Microbiology Lab Canada
   Canadian Severe Acute Respiratory
TI Identification of severe acute respiratory syndrome in Canada
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID HUMAN METAPNEUMOVIRUS; MECHANICAL VENTILATION; CORONAVIRUS; INFECTIONS;
   RIBAVIRIN; CHILDREN; TRIAL
AB BACKGROUND
   Severe acute respiratory syndrome (SARS) is a condition of unknown cause that has recently been recognized in patients in Asia, North America, and Europe. This report summarizes the initial epidemiologic findings, clinical description, and diagnostic findings that followed the identification of SARS in Canada.
   METHODS
   SARS was first identified in Canada in early March 2003. We collected epidemiologic, clinical, and diagnostic data from each of the first 10 cases prospectively as they were identified. Specimens from all cases were sent to local, provincial, national, and international laboratories for studies to identify an etiologic agent.
   RESULTS
   The patients ranged from 24 to 78 years old; 60 percent were men. Transmission occurred only after close contact. The most common presenting symptoms were fever (in 100 percent of cases) and malaise (in 70 percent), followed by nonproductive cough (in 100 percent) and dyspnea (in 80 percent) associated with infiltrates on chest radiography (in 100 percent). Lymphopenia (in 89 percent of those for whom data were available), elevated lactate dehydrogenase levels (in 80 percent), elevated aspartate aminotransferase levels (in 78 percent), and elevated creatinine kinase levels (in 56 percent) were common. Empirical therapy most commonly included antibiotics, oseltamivir, and intravenous ribavirin. Mechanical ventilation was required in five patients. Three patients died, and five have had clinical improvement. The results of laboratory investigations were negative or not clinically significant except for the amplification of human metapneumovirus from respiratory specimens from five of nine patients and the isolation and amplification of a novel coronavirus from five of nine patients. In four cases both pathogens were isolated.
   CONCLUSIONS
   SARS is a condition associated with substantial morbidity and mortality. It appears to be of viral origin, with patterns suggesting droplet or contact transmission. The role of human metapneumovirus, a novel coronavirus, or both requires further investigation.
C1 Toronto Med Labs, Toronto, ON M5G 1X5, Canada.
   Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada.
   Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   Univ Toronto, Dept Med, Div Infect Dis, Toronto, ON, Canada.
   Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada.
   City Toronto Publ Hlth Dept, Toronto, ON, Canada.
   Scarborough Gen Hosp, Toronto, ON, Canada.
   Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
   British Columbia Ctr Dis Control, Epidemiol Serv, Vancouver, BC, Canada.
   British Columbia Ctr Dis Control, Lab Serv, Vancouver, BC, Canada.
   Univ Hlth Network, Toronto, ON, Canada.
   Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada.
   St Michaels Hosp, Toronto, ON M5B 1W8, Canada.
   Vancouver Hosp & Hlth Sci Ctr, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.
   Univ British Columbia, Ctr Dis Control, Vancouver, BC V5Z 1M9, Canada.
RP McGeer, AJ (reprint author), Toronto Med Labs, 600 Univ Ave,Rm 1460, Toronto, ON M5G 1X5, Canada.
RI mcgeer, allison/H-7747-2014; Poutanen, Susan M./N-8066-2019; Low,
   Donald/B-1726-2012; Slutsky, Arthur S/A-6013-2008; McGeer,
   Allison/AAB-6885-2020; Slutsky, Arthur/M-3325-2019; Poutanen, Susan
   M/F-9640-2012
OI mcgeer, allison/0000-0001-5647-6137; Poutanen, Susan
   M./0000-0003-4747-2550; Slutsky, Arthur S/0000-0002-6063-3876; McGeer,
   Allison/0000-0001-5647-6137; Poutanen, Susan M/0000-0003-4747-2550
CR BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Boivin G, 2002, J INFECT DIS, V186, P1330, DOI 10.1086/344319
   Borio L, 2002, JAMA-J AM MED ASSOC, V287, P2391, DOI 10.1001/jama.287.18.2391
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Crotty S, 2001, NAT MED, V7, P255
   Falsey AR, 1997, J AM GERIATR SOC, V45, P706, DOI 10.1111/j.1532-5415.1997.tb01474.x
   Farr BM, 2000, RESP MED, V94, P954, DOI 10.1053/rmed.2000.0865
   Greensill J, 2003, EMERG INFECT DIS, V9, P372, DOI 10.3201/eid0903.020289
   Heymann D L, 2001, Lancet Infect Dis, V1, P345, DOI 10.1016/S1473-3099(01)00148-7
   Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104
   Nissen MD, 2002, MED J AUSTRALIA, V176, P188, DOI 10.5694/j.1326-5377.2002.tb04354.x
   Peret TCT, 2002, J INFECT DIS, V185, P1660, DOI 10.1086/340518
   Severe acute respiratory syndrome (SARS), 2003, WKLY EPIDEMIOL REC, V78, P81
   SIDWELL RW, 1987, ANTIMICROB AGENTS CH, V31, P1130, DOI 10.1128/AAC.31.7.1130
   Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092
   SMITH DW, 1991, NEW ENGL J MED, V325, P24, DOI 10.1056/NEJM199107043250105
   Stockton J, 2002, EMERG INFECT DIS, V8, P897, DOI 10.3201/eid0809.020084
   TRUYEN U, 1995, VET MICROBIOL, V43, P103, DOI 10.1016/0378-1135(95)92531-F
   Vabret A, 1998, PRESSE MED, V27, P1813
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WEISS RC, 1989, VET MICROBIOL, V20, P255, DOI 10.1016/0378-1135(89)90049-7
   2003, MMWR MORB MORTAL WKL, V52, P241
NR 23
TC 668
Z9 787
U1 14
U2 37
PU MASSACHUSETTS MEDICAL SOC/NEJM
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 15
PY 2003
VL 348
IS 20
BP 1995
EP 2005
DI 10.1056/NEJMoa030634
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 677TJ
UT WOS:000182823400008
PM 12671061
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Lau, SKP
   Woo, PCY
   Li, KSM
   Huang, Y
   Tsoi, HW
   Wong, BHL
   Wong, SSY
   Leung, SY
   Chan, KH
   Yuen, KY
AF Lau, SKP
   Woo, PCY
   Li, KSM
   Huang, Y
   Tsoi, HW
   Wong, BHL
   Wong, SSY
   Leung, SY
   Chan, KH
   Yuen, KY
TI Severe acute respiratory syndrome coronavirus-like virus in Chinese
   horseshoe bats
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID SARS-CORONAVIRUS; PROTEIN FAMILIES; GENOME SEQUENCE; IDENTIFICATION;
   RECEPTOR
AB Although the finding of severe acute respiratory syndrome coronavirus (SARS-CoV) in caged palm civets from live animal markets in China has provided evidence for interspecies transmission in the genesis of the SARS epidemic, subsequent studies suggested that the civet may have served only as an amplification host for SARS-CoV. In a surveillance study for CoV in noncaged animals from the wild areas of the Hong Kong Special Administration Region, we identified a CoV closely related to SARS-CoV (bat-SARS-CoV) from 23 (39%) of 59 anal swabs of wild Chinese horseshoe bats (Rhinolophus sinicus) by using RT-PCR. Sequencing and analysis of three bat-SARS-CoV genomes from samples collected at different dates showed that bat-SARS-CoV is closely related to SARS-CoV from humans and civets. Phylogenetic analysis showed that bat-SARS-CoV formed a distinct cluster with SARS-CoV as group 2b CoV, distantly related to known group 2 CoV. Most differences between the bat-SARS-CoV and SARS-CoV genomes were observed in the spike genes, ORF 3 and ORF 8, which are the regions where most variations also were observed between human and civet SARS-CoV genomes. In addition, the presence of a 29-bp insertion in ORF 8 of bat-SARS-CoV genome, not in most human SARS-CoV genomes, suggests that it has a common ancestor with civet SARS-CoV. Antibody against recombinant bat-SARSCoV nucleocapsid protein was detected in 84% of Chinese horseshoe bats by using an enzyme immunoassay. Neutralizing antibody to human SARS-CoV also was detected in bats with lower viral loads. Precautions should be exercised in the handling of these animals.
C1 Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Queen Mary Hosp, Res Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Queen Mary Hosp, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
EM kyyuen@hkucc.hku.hk
RI Tsoi, Hoi Wah/C-4428-2009; Wong, Samson/C-4446-2009; Lau,
   Susanna/C-4321-2009; Yuen, Kwok Yung/C-4465-2009; Woo,
   Patrick/C-4449-2009; Leung, Suet Yi/C-4340-2009; Leung, Suet
   Yi/T-9620-2019
OI Yuen, Kwok-yung/0000-0002-2083-1552; Leung, Suet Yi/0000-0001-8614-4619
CR Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37
   Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276
   Che XY, 2005, J INFECT DIS, V191, P2033, DOI 10.1086/430355
   Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Fujita M., 1988, Bats (Austin), V6, P4
   Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hung IFN, 2004, EMERG INFECT DIS, V10, P1550, DOI 10.3201/eid1009.040058
   Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lyon GM, 2004, AM J TROP MED HYG, V70, P438, DOI 10.4269/ajtmh.2004.70.438
   Mackenzie JS, 2004, ARCH VIROL, P97
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   NEUWEILER G, 2000, BIOL BATS, P266
   Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1
   NOWAK RM, 1983, WALKERS MAMMALS WORL, P230
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175
   Stoffel W., 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143
   Tu CC, 2004, EMERG INFECT DIS, V10, P2244, DOI 10.3201/eid1012.040520
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vijgen L, 2005, J VIROL, V79, P1595, DOI 10.1128/JVI.79.3.1595-1604.2005
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   WOO PC, 2005, IN PRESS J INFECT DI
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2004, J CLIN MICROBIOL, V42, P5885, DOI 10.1128/JCM.42.12.5885-5888.2004
   Woo PCY, 2004, LANCET, V363, P841, DOI 10.1016/S0140-6736(04)15729-2
   Wu XD, 2004, CELL RES, V14, P400, DOI 10.1038/sj.cr.7290240
   Wu Yi, 2004, Acta Theriologica Sinica, V24, P30
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
NR 41
TC 660
Z9 735
U1 28
U2 148
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 27
PY 2005
VL 102
IS 39
BP 14040
EP 14045
DI 10.1073/pnas.0506735102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 969KB
UT WOS:000232231900059
PM 16169905
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Woo, PCY
   Lau, SKP
   Chu, CM
   Chan, KH
   Tsoi, HW
   Huang, Y
   Wong, BHL
   Wong, HL
   Poon, RWS
   Cai, JJ
   Luk, WK
   Poon, LLM
   Wong, SSY
   Guan, Y
   Peiris, JSM
   Yuen, KY
AF Woo, PCY
   Lau, SKP
   Chu, CM
   Chan, KH
   Tsoi, HW
   Huang, Y
   Wong, BHL
   Wong, HL
   Poon, RWS
   Cai, JJ
   Luk, WK
   Poon, LLM
   Wong, SSY
   Guan, Y
   Peiris, JSM
   Yuen, KY
TI Characterization and complete genome sequence of a novel coronavirus,
   coronavirus HKU1, from patients with pneumonia
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; MOUSE HEPATITIS-VIRUS; INTERNAL RIBOSOME
   ENTRY; SARS-CORONAVIRUS; HEMAGGLUTININ-ESTERASE; BOVINE CORONAVIRUS;
   PROTEIN FAMILIES; TRACT INFECTIONS; MESSENGER-RNAS; LEADER RNA
AB Despite extensive laboratory investigations in patients with respiratory tract infections, no microbiological cause can be identified in a significant proportion of patients. In the past 3 years, several novel respiratory viruses, including human metapneumovirus, severe acute respiratory syndrome (SARS) coronavirus (SARSCoV), and human coronavirus NL63, were discovered. Here we report the discovery of another novel coronavirus, coronavirus HKU1 (CoV-HKU1), from a 71-year-old man with pneumonia who had just returned from Shenzhen, China. Quantitative reverse transcription-PCR showed that the amount of CoV-HKU1 RNA was 8.5 to 9.6 X 10(6) copies per ml in his nasopharyngeal aspirates (NPAs) during the first week of the illness and dropped progressively to undetectable levels in subsequent weeks. He developed increasing serum levels of specific antibodies against the recombinant nucleocapsid protein of CoV-HKU1, with immunoglobulin M (IgM) titers of 1:20, 1:40, and 1:80 and IgG titers of <1:1,000, 1:2,000, and 1:8,000 in the first, second and fourth weeks of the illness, respectively. Isolation of the virus by using various cell lines, mixed neuron-glia culture, and intracerebral inoculation of suckling mice was unsuccessful. The complete genome sequence of CoV-HKUI is a 29,926-nucleotide, polyadenylated RNA, with G+C content of 32%, the lowest among all known coronaviruses with available genome sequence. Phylogenetic analysis reveals that CoV-HKU1 is a new group 2 coronavirus. Screening of 400 NPAs, negative for SARS-CoV, from patients with respiratory illness during the SARS period identified the presence of CoV-HKUI RNA in an additional specimen, with a viral load of 1.13 X 10(6) copies per ml, from a 35-year-old woman with pneumonia. Our data support the existence of a novel group 2 coronavirus associated with pneumonia in humans.
C1 Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China.
   Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.
   United Christian Hosp, Dept Med, Div Resp Med, Hong Kong, Peoples R China.
   Tseung Kwan O Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, Dept Microbiol, Univ Pathol Bldg,, Hong Kong, Peoples R China.
EM hkumicro@hkucc.hku.hk
RI Tsoi, Hoi Wah/C-4428-2009; Lau, Susanna/C-4321-2009; Poon,
   Leo/C-4382-2009; Wong, Samson/C-4446-2009; Yuen, Kwok Yung/C-4465-2009;
   Cai, James/C-4928-2008; Peiris, Joseph Sriyal Malik/C-4380-2009; Woo,
   Patrick Chiu Yat/C-4449-2009
OI Poon, Leo/0000-0002-9101-7953; Cai, James/0000-0002-8081-6725; Peiris,
   Joseph Sriyal Malik/0000-0001-8217-5995; Woo, Patrick Chiu
   Yat/0000-0001-9401-1832; Chu, Chung Ming/0000-0002-9959-1271; Yuen,
   Kwok-yung/0000-0002-2083-1552
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01AI95357]
CR Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37
   Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276
   Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6
   Eickmann M, 2003, SCIENCE, V302, P1504
   Fischer F, 1997, J VIROL, V71, P996, DOI 10.1128/JVI.71.2.996-1003.1997
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Gattiker Alexandre, 2002, Appl Bioinformatics, V1, P107
   Goebel SJ, 2004, J VIROL, V78, P669, DOI 10.1128/JVI.78.2.669-682.2004
   GUAN Y, 2003, CHINA SCIENCE, V302, P276
   Herold J, 1999, J BIOL CHEM, V274, P14918, DOI 10.1074/jbc.274.21.14918
   HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V347, P166
   Jendrach M, 1999, ARCH VIROL, V144, P921, DOI 10.1007/s007050050556
   Kanjanahaluethai A, 2003, J VIROL, V77, P7376, DOI 10.1128/JVI.77.13.7376-7382.2003
   Klausegger A, 1999, J VIROL, V73, P3737, DOI 10.1128/JVI.73.5.3737-3743.1999
   Krempl C, 1995, Adv Exp Med Biol, V380, P371
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L
   MAKINO S, 1986, P NATL ACAD SCI USA, V83, P4204, DOI 10.1073/pnas.83.12.4204
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1
   NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Popova R, 2002, VIROLOGY, V294, P222, DOI 10.1006/viro.2001.1307
   RISKI H, 1980, J MED VIROL, V6, P259, DOI 10.1002/jmv.1890060309
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruiz M, 1999, AM J RESP CRIT CARE, V160, P397, DOI 10.1164/ajrccm.160.2.9808045
   SCHWARZ B, 1990, J VIROL, V64, P4784, DOI 10.1128/JVI.64.10.4784-4791.1990
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175
   Suzuki H, 1996, J VIROL, V70, P2632, DOI 10.1128/JVI.70.4.2632-2636.1996
   THIEL V, 1994, J GEN VIROL, V75, P3041, DOI 10.1099/0022-1317-75-11-3041
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526
   VLASAK R, 1988, J VIROL, V62, P4686, DOI 10.1128/JVI.62.12.4686-4690.1988
   WENZEL RP, 1974, AM REV RESPIR DIS, V109, P621
   Wessner DR, 1998, J VIROL, V72, P1941, DOI 10.1128/JVI.72.3.1941-1948.1998
   Williams GD, 1999, J VIROL, V73, P8349, DOI 10.1128/JVI.73.10.8349-8355.1999
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   Woo PCY, 2004, J CLIN MICROBIOL, V42, P2306, DOI 10.1128/JCM.42.5.2306-2309.2004
   Woo PCY, 2004, LANCET, V363, P841, DOI 10.1016/S0140-6736(04)15729-2
   Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997
   Yang HJ, 2000, MOL BIOCHEM PARASIT, V111, P213, DOI 10.1016/S0166-6851(00)00298-X
   Yeh SH, 2004, P NATL ACAD SCI USA, V101, P2542, DOI 10.1073/pnas.0307904100
   Yokomori K, 1995, J NEUROVIROL, V1, P330, DOI 10.3109/13550289509111022
   YOKOMORI K, 1991, VIROLOGY, V183, P647, DOI 10.1016/0042-6822(91)90994-M
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 51
TC 657
Z9 739
U1 23
U2 102
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JAN
PY 2005
VL 79
IS 2
BP 884
EP 895
DI 10.1128/JVI.79.2.884-895.2005
PG 12
WC Virology
SC Virology
GA 885IG
UT WOS:000226149700024
PM 15613317
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU MEULENBERG, JJM
   HULST, MM
   DEMEIJER, EJ
   MOONEN, PLJM
   DENBESTEN, A
   DEKLUYVER, EP
   WENSVOORT, G
   MOORMANN, RJM
AF MEULENBERG, JJM
   HULST, MM
   DEMEIJER, EJ
   MOONEN, PLJM
   DENBESTEN, A
   DEKLUYVER, EP
   WENSVOORT, G
   MOORMANN, RJM
TI LELYSTAD VIRUS, THE CAUSATIVE AGENT OF PORCINE EPIDEMIC ABORTION AND
   RESPIRATORY SYNDROME (PEARS), IS RELATED TO LDV AND EAV
SO VIROLOGY
LA English
DT Article
ID EQUINE ARTERITIS VIRUS; DEHYDROGENASE-ELEVATING VIRUS; HOG-CHOLERA
   VIRUS; MESSENGER-RNAS; CYSTEINE PROTEASES; SERINE PROTEASES; CORONAVIRUS
   IBV; NESTED SET; SEQUENCE; POLYMERASE
C1 CENT VET INST,DEPT VIROL,HOUTRIBWEG 39,8221 RA LELYSTAD,NETHERLANDS.
OI Wensvoort, Gert/0000-0003-2699-6558
CR ABRAHAMS JP, 1990, NUCLEIC ACIDS RES, V18, P3035, DOI 10.1093/nar/18.10.3035
   BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872
   BOURSNELL MEG, 1984, VIRUS RES, V1, P303, DOI 10.1016/0168-1702(84)90019-4
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   BRINTONDARNELL M, 1975, J VIROL, V16, P420, DOI 10.1128/JVI.16.2.420-433.1975
   DENBOON JA, 1991, VIROLOGY, V182, P655, DOI 10.1016/0042-6822(91)90606-C
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   DEVRIES AAF, 1990, NUCLEIC ACIDS RES, V18, P3241, DOI 10.1093/nar/18.11.3241
   Favaloro J, 1980, Methods Enzymol, V65, P718
   GODENY EK, 1990, VIROLOGY, V177, P768, DOI 10.1016/0042-6822(90)90546-4
   GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7
   GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5
   HANAHAN D, 1983, J MOL BIOL, V166, P577
   HILL H, 1990, 1990 P MYST SWIN DIS
   HYLLSETH B, 1973, ARCH GES VIRUSFORSCH, V40, P177, DOI 10.1007/BF01242536
   KUO L, 1992, VIRUS RES, V23, P55
   KUO LL, 1991, J VIROL, V65, P5118, DOI 10.1128/JVI.65.9.5118-5123.1991
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   LOULA T, 1990, 1990 P MYST SWIN DIS
   MCCOLLUM WH, 1971, RES VET SCI, V12, P459
   MOORMANN RJM, 1988, VIRUS RES, V11, P281, DOI 10.1016/0168-1702(88)90002-0
   MOORMANN RJM, 1990, VIROLOGY, V177, P184, DOI 10.1016/0042-6822(90)90472-4
   PATON DJ, 1991, VET REC, V128, P617, DOI 10.1136/vr.128.26.617
   PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444
   PLAGEMANN PGW, 1992, ADV VIRUS RES, V41, P99, DOI 10.1016/S0065-3527(08)60036-6
   PLANA J, 1991, 1991 P PORC REPR REP, P7
   POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x
   ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022
   Sambrook J., 1989, MOL CLONING LABORATO
   SETZER DR, 1980, CELL, V22, P361, DOI 10.1016/0092-8674(80)90346-3
   SNIJDER EJ, 1990, J VIROL, V64, P331, DOI 10.1128/JVI.64.1.331-338.1990
   SNIJDER EJ, 1990, NUCLEIC ACIDS RES, V18, P4535, DOI 10.1093/nar/18.15.4535
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   STUECKEMANN JA, 1982, J GEN VIROL, V59, P263, DOI 10.1099/0022-1317-59-2-263
   STUECKEMANN JA, 1982, J GEN VIROL, V59, P245, DOI 10.1099/0022-1317-59-2-245
   TERPSTRA C, 1991, VET QUART, V13, P131, DOI 10.1080/01652176.1991.9694297
   TIMONEY PJ, 1986, RES VET SCI, V41, P279, DOI 10.1016/S0034-5288(18)30616-7
   VANBERLO MF, 1986, VIROLOGY, V152, P492, DOI 10.1016/0042-6822(86)90154-6
   VANDERZEIJST BAM, 1975, VIROLOGY, V68, P418, DOI 10.1016/0042-6822(75)90283-4
   WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296
   WENSVOORT G, 1992, IN PRESS VET MICROBI
   WESTAWAY EG, 1985, INTERVIROLOGY, V24, P125, DOI 10.1159/000149632
NR 47
TC 609
Z9 676
U1 1
U2 27
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JAN
PY 1993
VL 192
IS 1
BP 62
EP 72
DI 10.1006/viro.1993.1008
PG 11
WC Virology
SC Virology
GA KC982
UT WOS:A1993KC98200008
PM 8517032
DA 2020-04-03
ER

PT J
AU Assiri, A
   McGeer, A
   Perl, TM
   Price, CS
   Al Rabeeah, AA
   Cummings, DAT
   Alabdullatif, ZN
   Assad, M
   Almulhim, A
   Makhdoom, H
   Madani, H
   Alhakeem, R
   Al-Tawfiq, JA
   Cotten, M
   Watson, SJ
   Kellam, P
   Zumla, AI
   Memish, ZA
AF Assiri, Abdullah
   McGeer, Allison
   Perl, Trish M.
   Price, Connie S.
   Al Rabeeah, Abdullah A.
   Cummings, Derek A. T.
   Alabdullatif, Zaki N.
   Assad, Maher
   Almulhim, Abdulmohsen
   Makhdoom, Hatem
   Madani, Hossam
   Alhakeem, Rafat
   Al-Tawfiq, Jaffar A.
   Cotten, Matthew
   Watson, Simon J.
   Kellam, Paul
   Zumla, Alimuddin I.
   Memish, Ziad A.
CA KSA MERS-CoV Invest Team
TI Hospital Outbreak of Middle East Respiratory Syndrome Coronavirus
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID INFECTIONS; SARS
AB Background
   In September 2012, the World Health Organization reported the first cases of pneumonia caused by the novel Middle East respiratory syndrome coronavirus (MERS-CoV). We describe a cluster of health care-acquired MERS-CoV infections.
   Methods
   Medical records were reviewed for clinical and demographic information and determination of potential contacts and exposures. Case patients and contacts were interviewed. The incubation period and serial interval (the time between the successive onset of symptoms in a chain of transmission) were estimated. Viral RNA was sequenced.
   Results
   Between April 1 and May 23, 2013, a total of 23 cases of MERS-CoV infection were reported in the eastern province of Saudi Arabia. Symptoms included fever in 20 patients (87%), cough in 20 (87%), shortness of breath in 11 (48%), and gastrointestinal symptoms in 8 (35%); 20 patients (87%) presented with abnormal chest radiographs. As of June 12, a total of 15 patients (65%) had died, 6 (26%) had recovered, and 2 (9%) remained hospitalized. The median incubation period was 5.2 days (95% confidence interval [CI], 1.9 to 14.7), and the serial interval was 7.6 days (95% CI, 2.5 to 23.1). A total of 21 of the 23 cases were acquired by person-to-person transmission in hemodialysis units, intensive care units, or in-patient units in three different health care facilities. Sequencing data from four isolates revealed a single monophyletic clade. Among 217 household contacts and more than 200 health care worker contacts whom we identified, MERS-CoV infection developed in 5 family members (3 with laboratory-confirmed cases) and in 2 health care workers (both with laboratory-confirmed cases).
   Conclusions
   Person-to-person transmission of MERS-CoV can occur in health care settings and may be associated with considerable morbidity. Surveillance and infection-control measures are critical to a global public health response.
C1 [Assiri, Abdullah; Al Rabeeah, Abdullah A.; Alabdullatif, Zaki N.; Assad, Maher; Almulhim, Abdulmohsen; Makhdoom, Hatem; Madani, Hossam; Alhakeem, Rafat; Zumla, Alimuddin I.; Memish, Ziad A.] Minist Hlth, Global Ctr Mass Gatherings Med, Riyadh 11176, Saudi Arabia.
   [Memish, Ziad A.] Al Faisal Univ, Riyadh, Saudi Arabia.
   [Al-Tawfiq, Jaffar A.] Saudi Aramco Med Serv Org, Dhahran, Saudi Arabia.
   [McGeer, Allison] Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
   [McGeer, Allison] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Perl, Trish M.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
   [Perl, Trish M.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA.
   [Perl, Trish M.; Cummings, Derek A. T.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA.
   [Price, Connie S.] Univ Colorado Denver, Denver, CO USA.
   [Cotten, Matthew; Watson, Simon J.; Kellam, Paul] Wellcome Trust Sanger Inst, Hinxton, England.
   [Kellam, Paul; Zumla, Alimuddin I.] UCL, London WC1E 6BT, England.
   [Zumla, Alimuddin I.] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England.
RP Memish, ZA (reprint author), Minist Hlth, Global Ctr Mass Gatherings Med, Riyadh 11176, Saudi Arabia.
EM zmemish@yahoo.com
RI mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020
OI mcgeer, allison/0000-0001-5647-6137; McGeer,
   Allison/0000-0001-5647-6137; Assiri, Abdullah/0000-0002-5605-2876;
   Kellam, Paul/0000-0003-3166-4734; Zumla, Alimuddin/0000-0002-5111-5735;
   Cotten, Matthew/0000-0002-3361-3351
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [U54 GM088491, U01 GM070708]; Wellcome
   TrustWellcome Trust [093724]
CR Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   [Anonymous], 2013, SEVERE RESP DIS UNKN
   [Anonymous], NOV COR INF UPD 12 M
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Buchholz U., 2013, Eurosurveillance, V18, P20406
   Centers for Disease Control and Prevention, 2013, COR MIDDL E RESP SYN
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   Cotten M, 2013, EMERG INFECT DIS, V19, P736, DOI 10.3201/eid1905.130057
   Drosten C, PRELIMINARY SEQUENCE
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Hijawi B, 2013, E MEDITERR HEALTH J, V19, pS12
   Kwok KO, 2007, P R SOC B, V274, P611, DOI 10.1098/rspb.2006.0026
   Lessler J, 2009, LANCET INFECT DIS, V9, P291, DOI 10.1016/S1473-3099(09)70069-6
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   McDonald LC, 2004, EMERG INFECT DIS, V10, P777, DOI 10.3201/eid1005.030791
   Memish ZA, 2013, NEW ENGL J MED, DOI [10.1056/NEJMoa1303729, DOI 10.1056/NEJM0A1303729.10.SEVERE]
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Rambaut A., NOVEL HUMAN BETACORO
   Reich NG, 2009, STAT MED, V28, P2769, DOI 10.1002/sim.3659
   Rha B, 2013, MMWR-MORBID MORTAL W, V62, P194
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Tahir M, 2013, EUROSURVEILLANCE, V18, P4
   Thompson M. G., 2010, Morbidity and Mortality Weekly Report, V59, P1057
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Wang SX, 2006, EPIDEMIOL INFECT, V134, P786, DOI 10.1017/S095026880500556X
   WHO, INT SURV REC HUM INF
   Wong SSY, 2008, J ANTIMICROB CHEMOTH, V62, P437, DOI 10.1093/jac/dkn243
   World Health Organization Regional Office for the Eastern Mediterranean, 2012, WEEKLY EPIDEMIOLOGIC, V5
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 32
TC 561
Z9 588
U1 37
U2 164
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD AUG 1
PY 2013
VL 369
IS 5
BP 407
EP 416
DI 10.1056/NEJMoa1306742
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 193GQ
UT WOS:000322547400007
PM 23782161
OA Bronze, Green Accepted
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Chen, Y
   Liang, WF
   Yang, SG
   Wu, NP
   Gao, HN
   Sheng, JF
   Yao, HP
   Wo, JN
   Fang, Q
   Cui, DW
   Li, YC
   Yao, X
   Zhang, YT
   Wu, HB
   Zheng, SF
   Diao, HY
   Xia, SC
   Zhang, YJ
   Chan, KH
   Tsoi, HW
   Teng, JLL
   Song, WJ
   Wang, P
   Lau, SY
   Zheng, M
   Chan, JFW
   To, KKW
   Chen, HL
   Li, LJ
   Yuen, KY
AF Chen, Yu
   Liang, Weifeng
   Yang, Shigui
   Wu, Nanping
   Gao, Hainv
   Sheng, Jifang
   Yao, Hangping
   Wo, Jianer
   Fang, Qiang
   Cui, Dawei
   Li, Yongcheng
   Yao, Xing
   Zhang, Yuntao
   Wu, Haibo
   Zheng, Shufa
   Diao, Hongyan
   Xia, Shichang
   Zhang, Yanjun
   Chan, Kwok-Hung
   Tsoi, Hoi-Wah
   Teng, Jade Lee-Lee
   Song, Wenjun
   Wang, Pui
   Lau, Siu-Ying
   Zheng, Min
   Chan, Jasper Fuk-Woo
   To, Kelvin Kai-Wang
   Chen, Honglin
   Li, Lanjuan
   Yuen, Kwok-Yung
TI Human infections with the emerging avian influenza A H7N9 virus from wet
   market poultry: clinical analysis and characterisation of viral genome
SO LANCET
LA English
DT Article
ID PATHOGENESIS; CORONAVIRUS; DUCKS; MICE; ASIA
AB Background Human infection with avian influenza A H7N9 virus emerged in eastern China in February, 2013, and has been associated with exposure to poultry. We report the clinical and microbiological features of patients infected with influenza A H7N9 virus and compare genomic features of the human virus with those of the virus in market poultry in Zhejiang, China.
   Methods Between March 7 and April 8, 2013, we included hospital inpatients if they had new-onset respiratory symptoms, unexplained radiographic infiltrate, and laboratory-confirmed H7N9 virus infection. We recorded histories and results of haematological, biochemical, radiological, and microbiological investigations. We took throat and sputum samples, used RT-PCR to detect M, H7, and N9 genes, and cultured samples in Madin-Darby canine kidney cells. We tested for co-infections and monitored serum concentrations of six cytokines and chemokines. We collected cloacal swabs from 86 birds from epidemiologically linked wet markets and inoculated embryonated chicken eggs with the samples. We identified and subtyped isolates by RT-PCR sequencing. RNA extraction, complementary DNA synthesis, and PCR sequencing were done for one human and one chicken isolate. We characterised and phylogenetically analysed the eight gene segments of the viruses in the patient's and the chicken's isolates, and constructed phylogenetic trees of H, N, PB2, and NS genes.
   Findings We identified four patients (mean age 56 years), all of whom had contact with poultry 3-8 days before disease onset. They presented with fever and rapidly progressive pneumonia that did not respond to antibiotics. Patients were leucopenic and lymphopenic, and had impaired liver or renal function, substantially increased serum cytokine or chemokine concentrations, and disseminated intravascular coagulation with disease progression. Two patients died. Sputum specimens were more likely to test positive for the H7N9 virus than were samples from throat swabs. The viral isolate from the patient was closely similar to that from an epidemiologically linked market chicken. All viral gene segments were of avian origin. The H7 of the isolated viruses was closest to that of the H7N3 virus from domestic ducks in Zhejiang, whereas the N9 was closest to that of the wild bird H7N9 virus in South Korea. We noted Gln226Leu and Gly186Val substitutions in human virus H7 (associated with increased affinity for alpha-2,6-linked sialic acid receptors) and the PB2 Asp701Asn mutation (associated with mammalian adaptation). Ser31Asn mutation, which is associated with adamantane resistance, was noted in viral M2.
   Interpretation Cross species poultry-to-person transmission of this new reassortant H7N9 virus is associated with severe pneumonia and multiorgan dysfunction in human beings. Monitoring of the viral evolution and further study of disease pathogenesis will improve disease management, epidemic control, and pandemic preparedness.
C1 [Chen, Yu; Liang, Weifeng; Yang, Shigui; Wu, Nanping; Gao, Hainv; Sheng, Jifang; Yao, Hangping; Wo, Jianer; Fang, Qiang; Cui, Dawei; Zhang, Yuntao; Wu, Haibo; Zheng, Shufa; Diao, Hongyan; Li, Lanjuan] Zhejiang Univ, Coll Med, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China.
   [Chen, Yu; Liang, Weifeng; Yang, Shigui; Wu, Nanping; Gao, Hainv; Sheng, Jifang; Yao, Hangping; Wo, Jianer; Wu, Haibo; Diao, Hongyan; Chen, Honglin; Li, Lanjuan; Yuen, Kwok-Yung] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.
   [Li, Yongcheng] Xiaoshan Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Yao, Xing] Huzhou Cent Hosp, Huzhou, Peoples R China.
   [Xia, Shichang; Zhang, Yanjun] Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou, Zhejiang, Peoples R China.
   [Chan, Kwok-Hung; Tsoi, Hoi-Wah; Teng, Jade Lee-Lee; Song, Wenjun; Wang, Pui; Lau, Siu-Ying; Zheng, Min; Chan, Jasper Fuk-Woo; To, Kelvin Kai-Wang; Chen, Honglin; Yuen, Kwok-Yung] Univ Hong Kong, Dept Microbiol, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
RP Li, LJ (reprint author), Zhejiang Univ, Coll Med, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM ljli@zju.edu.cn
RI Chen, Yu/Y-3292-2019; Chan, Jasper F. W./D-8007-2013; Chen,
   Honglin/C-4224-2009
OI Chan, Jasper F. W./0000-0001-6336-6657; Chen,
   Honglin/0000-0001-5108-8338; To, Kelvin/0000-0002-1921-5824; Yuen,
   Kwok-yung/0000-0002-2083-1552; gao, hainv/0000-0003-4590-9181
FU National Key Program for Infectious Diseases of China
FX Larry Chi-Kin Yung, National Key Program for Infectious Diseases of
   China.
CR Arzey GG, 2012, EMERG INFECT DIS, V18, P814, DOI 10.3201/eid1805.111852
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Chan JFW, 2012, J INFECTION, V65, P477, DOI 10.1016/j.jinf.2012.10.002
   Chen H, 2006, P NATL ACAD SCI USA, V103, P2845, DOI 10.1073/pnas.0511120103
   Chen LM, 2012, VIROLOGY, V422, P105, DOI 10.1016/j.virol.2011.10.006
   Cheng VCC, 2012, CLIN MICROBIOL REV, V25, P223, DOI 10.1128/CMR.05012-11
   Cheng VCC, 2011, J INFECTION, V62, P394, DOI 10.1016/j.jinf.2011.02.007
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   Estenssoro E, 2006, CRIT CARE, V10, DOI 10.1186/cc4941
   Feng Y, 2011, INFECT IMMUN, V79, P229, DOI 10.1128/IAI.00709-10
   Gao RB, 2013, NEW ENGL J MED, V368, P1888, DOI 10.1056/NEJMoa1304459
   Hung IEN, 2013, CHEST, V144, P464, DOI 10.1378/chest.12-2907
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Koopmans M, 2004, LANCET, V363, P587, DOI 10.1016/S0140-6736(04)15589-X
   Law AHY, 2010, CELL MOL IMMUNOL, V7, P263, DOI 10.1038/cmi.2010.25
   Li IWS, 2009, J CLIN VIROL, V46, P325, DOI 10.1016/j.jcv.2009.09.013
   Li KS, 2003, J VIROL, V77, P6988, DOI 10.1128/JVI.77.12.6988-6994.2003
   Ostrowsky B, 2012, EMERG INFECT DIS, V18, P1128, DOI 10.3201/eid1807.111913
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Steel J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000252
   Sturm-Ramirez KM, 2005, J VIROL, V79, P11269, DOI 10.1128/JVI.79.17.11269-11279.2005
   To KKW, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.24
   To KKW, 2010, CLIN INFECT DIS, V50, P850, DOI 10.1086/650581
   Tweed SA, 2004, EMERG INFECT DIS, V10, P2196, DOI 10.3201/eid1012.040961
   Wu HB, 2012, ARCH VIROL, V157, P2017, DOI 10.1007/s00705-012-1370-3
   Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang AJX, 2013, J INFECT DIS, V207, P1270, DOI 10.1093/infdis/jit031
   Zheng BJ, 2008, P NATL ACAD SCI USA, V105, P8091, DOI 10.1073/pnas.0711942105
   Zhou HB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006277
NR 30
TC 547
Z9 618
U1 49
U2 409
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUN 1
PY 2013
VL 381
IS 9881
BP 1916
EP 1925
DI 10.1016/S0140-6736(13)60903-4
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 163EV
UT WOS:000320319500032
PM 23623390
HC Y
HP N
DA 2020-04-03
ER

PT J
AU SEDGWICK, JD
   SCHWENDER, S
   IMRICH, H
   DORRIES, R
   BUTCHER, GW
   TERMEULEN, V
AF SEDGWICK, JD
   SCHWENDER, S
   IMRICH, H
   DORRIES, R
   BUTCHER, GW
   TERMEULEN, V
TI ISOLATION AND DIRECT CHARACTERIZATION OF RESIDENT MICROGLIAL CELLS FROM
   THE NORMAL AND INFLAMED CENTRAL-NERVOUS-SYSTEM
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE ENCEPHALOMYELITIS; MACROPHAGE; ANTIGEN-PRESENTING CELL; CORONAVIRUS;
   AUTOIMMUNITY
ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; BONE-MARROW CHIMERAS;
   ENDOTHELIAL-CELLS; ANTIGEN PRESENTATION; MONOCLONAL-ANTIBODY; RAT-HEART;
   T-CELLS; BRAIN; MACROPHAGES; REACTIVITY
AB In addition to the major population of infiltrating leukocytes recovered from inflamed rat central nervous system (CNS), all of which expressed high levels of leukocyte common antigen CD45, many cells were coisolated that were MRC OX42+ (complement receptor 3/CD11b) but expressed low-to-moderate levels of CD45 and major histocompatibility complex (MHC) class I molecules. Most cells from normal CNS, in contrast, lay within this latter, CD45low population. From previous in situ immunohistochemical studies, the fortuitously isolated CD45low cells were probably resident (ramified) microglia. Using irradiation chimeras, we show that resident microglia respond to inflammation by upregulating CD45, CD4, and MHC class I molecules with a minority of these cells increasing their expression of MHC class II molecules. A 3- to 4-fold increase in the number of microglia isolated from inflamed CNS provided indirect evidence that the cells had proliferated. In normal CNS, a very small population of blood-derived CD45high-expressing cells are present; most MHC class II expression is associated with these few cells and not with the resident microglia.
C1 INST ANIM PHYSIOL & GENET RES,DEPT IMMUNOL,CAMBRIDGE RES STN,CAMBRIDGE CB2 4AT,ENGLAND.
RP SEDGWICK, JD (reprint author), UNIV WURZBURG,INST VIROL & IMMUNOBIOL,VERSBACHER STR 7,W-8700 WURZBURG,GERMANY.
CR BUTCHER GW, 1987, J IMMUNOGENET, V14, P163
   CHEEVER FS, 1949, J EXP MED, V90, P181, DOI 10.1084/jem.90.3.181
   COHEN JA, 1987, CELL IMMUNOL, V108, P203, DOI 10.1016/0008-8749(87)90204-8
   DOHERTY PC, 1990, IMMUNOL TODAY, V11, P55
   EVANS RL, 1978, J EXP MED, V148, P1440, DOI 10.1084/jem.148.5.1440
   FONTANA A, 1984, NATURE, V307, P273, DOI 10.1038/307273a0
   Frei K, 1988, Ann N Y Acad Sci, V540, P218, DOI 10.1111/j.1749-6632.1988.tb27064.x
   GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q
   HART DNJ, 1981, J EXP MED, V154, P347, DOI 10.1084/jem.154.2.347
   HAYES GM, 1987, J NEUROL SCI, V80, P25, DOI 10.1016/0022-510X(87)90218-8
   HAYES GM, 1988, J NEUROIMMUNOL, V19, P177, DOI 10.1016/0165-5728(88)90001-X
   HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004
   HINRICHS DJ, 1987, J EXP MED, V166, P1906, DOI 10.1084/jem.166.6.1906
   HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73
   JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117
   LAWETZKY A, 1990, EUR J IMMUNOL, V20, P43
   LING EA, 1973, J COMP NEUROL, V149, P73, DOI 10.1002/cne.901490105
   MATSUMOTO Y, 1987, J NEUROIMMUNOL, V17, P71, DOI 10.1016/0165-5728(87)90032-4
   PATERSON DJ, 1987, MOL IMMUNOL, V24, P1281, DOI 10.1016/0161-5890(87)90122-2
   PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5
   PRYCE G, 1989, IMMUNOLOGY, V66, P207
   ROBINSON AP, 1986, IMMUNOLOGY, V57, P239
   SEDGWICK J, 1987, J EXP MED, V165, P1058, DOI 10.1084/jem.165.4.1058
   SEDGWICK JD, 1990, J IMMUNOL, V145, P2474
   SORENSEN O, 1980, ARCH NEUROL-CHICAGO, V37, P478, DOI 10.1001/archneur.1980.00500570026003
   SPENCER SC, 1990, J EXP MED, V171, P1841, DOI 10.1084/jem.171.6.1841
   STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502
   SUNDERLAND CA, 1979, EUR J IMMUNOL, V9, P155, DOI 10.1002/eji.1830090212
   TRAUGOTT U, 1985, J NEUROIMMUNOL, V8, P1, DOI 10.1016/S0165-5728(85)80043-6
   WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125
   WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9
NR 31
TC 535
Z9 540
U1 0
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG
PY 1991
VL 88
IS 16
BP 7438
EP 7442
DI 10.1073/pnas.88.16.7438
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GB701
UT WOS:A1991GB70100111
PM 1651506
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Gaynor, AM
   Nissen, MD
   Whiley, DM
   Mackay, IM
   Lambert, SB
   Wu, G
   Brennan, DC
   Storch, GA
   Sloots, TP
   Wang, D
AF Gaynor, Anne M.
   Nissen, Michael D.
   Whiley, David M.
   Mackay, Ian M.
   Lambert, Stephen B.
   Wu, Guang
   Brennan, Daniel C.
   Storch, Gregory A.
   Sloots, Theo P.
   Wang, David
TI Identification of a novel polyomavirus from patients with acute
   respiratory tract infections
SO PLOS PATHOGENS
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; BK-VIRUS; HUMAN CORONAVIRUS; CHILDREN; SV40;
   DISEASE; DNA; SIMIAN-VIRUS-40; ASSOCIATION; ANTIBODIES
AB We report the identification of a novel polyomavirus present in respiratory secretions from human patients with symptoms of acute respiratory tract infection. The virus was initially detected in a nasopharyngeal aspirate from a 3-year-old child from Australia diagnosed with pneumonia. A random library was generated from nucleic acids extracted from the nasopharyngeal aspirate and analyzed by high throughput DNA sequencing. Multiple DNA fragments were cloned that possessed limited homology to known polyomaviruses. We subsequently sequenced the entire virus genome of 5,229 bp, henceforth referred to as WU virus, and found it to have genomic features characteristic of the family Polyomaviridae. The genome was predicted to encode small T antigen, large T antigen, and three capsid proteins: VP1, VP2, and VP3. Phylogenetic analysis clearly revealed that the WU virus was divergent from all known polyomaviruses. Screening of 2,135 patients with acute respiratory tract infections in Brisbane, Queensland, Australia, and St. Louis, Missouri, United States, using WU virus-specific PCR primers resulted in the detection of 43 additional specimens that contained WU virus. The presence of multiple instances of the virus in two continents suggests that this virus is geographically widespread in the human population and raises the possibility that the WU virus may be a human pathogen.
C1 Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   Royal Childrens Hosp, Queensland Paediat Infect Dis Lab, Sir Albert Sakzewski Virus Res Ctr, Brisbane, Qld, Australia.
RP Wang, D (reprint author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
EM davewang@borcim.wustl.edu
RI Sloots, Theo P/E-6118-2011; Nissen, Michael D/M-6823-2013; Whiley,
   David/E-8955-2011; Lambert, Stephen/N-7819-2019; Lambert, Stephen
   B/B-8348-2008; Mackay, Ian M./B-2537-2010
OI Nissen, Michael D/0000-0003-1686-3313; Whiley,
   David/0000-0001-5969-3161; Lambert, Stephen/0000-0002-2709-193X;
   Lambert, Stephen B/0000-0002-2709-193X; Mackay, Ian
   M./0000-0003-3598-2350
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U54 AI057160]; NIDDK NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [K24 DK02886, K24 DK002886]
CR Agostini HT, 1997, ARCH VIROL, V142, P637, DOI 10.1007/s007050050108
   Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Allander T, 2007, J VIROL, V81, P4130, DOI 10.1128/JVI.00028-07
   ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402
   Arden KE, 2006, J MED VIROL, V78, P1232, DOI 10.1002/jmv.20689
   ARTHUR RR, 1986, NEW ENGL J MED, V315, P230, DOI 10.1056/NEJM198607243150405
   Behzad-Behbahani A, 2004, J CLIN VIROL, V29, P224, DOI 10.1016/S1386-6532(03)00155-0
   BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1
   Brennan DC, 2005, AM J TRANSPLANT, V5, P582, DOI 10.1111/j.1600-6143.2005.00742.x
   Cantalupo P, 2005, J VIROL, V79, P13094, DOI 10.1128/JVI.79.20.13094-13104.2005
   Choi EH, 2006, CLIN INFECT DIS, V43, P585, DOI 10.1086/506350
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   GARDNER SD, 1971, LANCET, V1, P1253
   GOUDSMIT J, 1982, J MED VIROL, V10, P91, DOI 10.1002/jmv.1890100203
   GREENLEE JE, 1981, INFECT IMMUN, V33, P297, DOI 10.1128/IAI.33.1.297-303.1981
   Hahn WC, 1999, NATURE, V400, P464
   Heikkinen T, 2003, LANCET, V361, P51, DOI 10.1016/S0140-6736(03)12162-9
   Jafar S, 1998, J MED VIROL, V54, P276, DOI 10.1002/(SICI)1096-9071(199804)54:4<276::AID-JMV7>3.0.CO;2-1
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lundstig A, 2005, J GEN VIROL, V86, P1703, DOI 10.1099/vir.0.80783-0
   MARKOWITZ RB, 1993, J INFECT DIS, V167, P13, DOI 10.1093/infdis/167.1.13
   Minor P, 2003, J MED VIROL, V70, P490, DOI 10.1002/jmv.10422
   Mulholland K, 2003, PEDIATR PULM, V36, P469, DOI 10.1002/ppul.10344
   PADGETT BL, 1971, LANCET, V1, P1257
   PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992
   Poulin DL, 2006, J CLIN ONCOL, V24, P4356, DOI 10.1200/JCO.2005.03.7101
   Shah KV, 2004, J INFECT DIS, V190, P2061, DOI 10.1086/425999
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Stolt A, 2003, J GEN VIROL, V84, P1499, DOI 10.1099/vir.0.18842-0
   Sumino KC, 2005, J INFECT DIS, V192, P1052, DOI 10.1086/432728
   SUNDSFJORD A, 1994, J CLIN MICROBIOL, V32, P1390, DOI 10.1128/JCM.32.5.1390-1394.1994
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Wang D, 2003, PLOS BIOL, V1, P257, DOI 10.1371/journal.pbio.0000002
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
NR 35
TC 495
Z9 533
U1 6
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAY
PY 2007
VL 3
IS 5
BP 595
EP 604
AR e64
DI 10.1371/journal.ppat.0030064
PG 10
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 196VU
UT WOS:000248511100004
PM 17480120
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Kuiken, T
   Fouchier, RAM
   Schutten, M
   Rimmelzwaan, GF
   van Amerongen, G
   van Riel, D
   Laman, JD
   de Jong, T
   van Doornum, G
   Lim, W
   Ling, AE
   Chan, PKS
   Tam, JS
   Zambon, MC
   Gopal, R
   Drosten, C
   van der Werf, S
   Escriou, N
   Manuguerra, JC
   Stohr, K
   Peiris, JSM
   Osterhaus, ADME
AF Kuiken, T
   Fouchier, RAM
   Schutten, M
   Rimmelzwaan, GF
   van Amerongen, G
   van Riel, D
   Laman, JD
   de Jong, T
   van Doornum, G
   Lim, W
   Ling, AE
   Chan, PKS
   Tam, JS
   Zambon, MC
   Gopal, R
   Drosten, C
   van der Werf, S
   Escriou, N
   Manuguerra, JC
   Stohr, K
   Peiris, JSM
   Osterhaus, ADME
TI Newly discovered coronavirus as the primary cause of severe acute
   respiratory syndrome
SO LANCET
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; HONG-KONG; EXPERIMENTAL-INFECTION;
   IDENTIFICATION; PATHOGENICITY; CHILDREN; OUTBREAK; DISEASE; GENE; PCR
AB Background The worldwide outbreak. of severe acute respiratory syndrome (SARS) is associated with a newly discovered coronavirus, SARS-associated coronavirus (SARS-CoV). We did clinical and experimental studies to assess the role of this virus in the cause of SARS.
   Methods We tested clinical and postmortem samples from 436 SARS patients in six countries for infection with SARS-CoV, human metapneumovirus, and other respiratory pathogens. We infected four cynomolgus macaques (Macaca fascicularis) with SARS-CoV in an attempt to replicate SARS and did necropsies on day 6 after infection.
   Findings SARS-CoV infection was diagnosed in 329 (75%) of 436 patients fitting the case definition of SARS; human metapneumovirus was diagnosed in 41 (12%) of 335, and other respiratory pathogens were diagnosed only sporadically. SARS-CoV was, therefore, the most likely causal agent of SARS. The four SARS-CoV-infected macaques excreted SARS-CoV from nose, mouth, and pharynx from 2 days after infection. Three of four macaques developed diffuse alveolar damage, similar to that in SARS patients, and characterised by epithelial necrosis, serosanguineous exudate, formation of hyaline membranes, type 2 pneumocyte hyperplasia, and the presence of syncytia. SARS-CoV was detected in pneumonic areas by virus isolation and RT-PCR, and was localised to alveolar epithelial cells and syncytia by immunohistochemistry and transmission electron microscopy.
   Interpretation Replication in SARS-CoV-infected macaques of pneumonia similar to that in human beings with SARS, combined with the high prevalence of SARS-CoV infection in SARS patients, fulfill the criteria required to prove that SARS-CoV is the primary cause of SARS.
C1 Erasmus Med Ctr, Dept Virol, NL-3000 DR Rotterdam, Netherlands.
   Erasmus Med Ctr, Dept Immunol, NL-3000 DR Rotterdam, Netherlands.
   Erasmus Med Ctr, Dept Pathol, NL-3000 DR Rotterdam, Netherlands.
   Publ Hlth Lab Ctr, Govt Virus Unit, Kowloon, Hong Kong, Peoples R China.
   Singapore Gen Hosp, Dept Pathol, Singapore 0316, Singapore.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Hlth Protect Agcy, Enter Resp & Neurol Virus Lab, London, England.
   Bernhard Nocht Inst Trop Med, Dept Virol, Hamburg, Germany.
   Inst Pasteur, Unite Genet Mol Virus Resp, Paris, France.
   WHO, SARS Aetiol Study Grp, CH-1211 Geneva, Switzerland.
   Univ Hong Kong, Queen Mary Hosp, Dept Microbiol & Med, Hong Kong, Hong Kong, Peoples R China.
RP Kuiken, T (reprint author), Erasmus Med Ctr, Dept Virol, POB 1738, NL-3000 DR Rotterdam, Netherlands.
RI Fouchier, Ron/Y-3755-2019; Escriou, Nicolas/A-2392-2016; Fouchier, Ron
   A/A-1911-2014; Chan, Paul KS/J-9360-2013
OI Fouchier, Ron/0000-0001-8095-2869; Escriou, Nicolas/0000-0002-1224-6839;
   Fouchier, Ron A/0000-0001-8095-2869; Chan, Paul KS/0000-0002-6360-4608;
   Osterhaus, Albert/0000-0002-6074-1172; van der WERF,
   Sylvie/0000-0002-1148-4456; van Riel, Debby/0000-0001-9753-3564
CR BHATT PN, 1977, ARCH VIROL, V54, P345, DOI 10.1007/BF01314779
   CHAN PKS, IN PRESS EMERG INFEC
   CLAAS HC, 1990, EUR J CLIN MICROBIOL, V9, P864, DOI 10.1007/BF01967500
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   DUNGWORTH DL, 1993, [No title captured], V2, P539
   Fouchier RAM, 2000, J CLIN MICROBIOL, V38, P4096, DOI 10.1128/JCM.38.11.4096-4101.2000
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   JABRANE A, 1994, CAN VET J, V35, P86
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   LAI MMC, 1999, FIELDS VIROLOGY, P1163
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   MAHY BWJ, 1997, DICT VIROLOGY
   Myers J.L., 1993, PULMONARY PATHOLOGY, P57
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   OTOOLE D, 1989, RES VET SCI, V47, P23, DOI 10.1016/S0034-5288(18)31226-8
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Peiris JSM, 2003, EMERG INFECT DIS, V9, P628
   Peret TCT, 2002, J INFECT DIS, V185, P1660, DOI 10.1086/340518
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Reischl U, 2003, EUR J CLIN MICROBIOL, V22, P54, DOI 10.1007/s10096-002-0858-2
   SCHNEIDERSCHAUL.S, 2002, EXPERT REV MOL MED
   Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   *WHO, 2003, WKLY EPIDEMIOL REC, V78, P81
   PCR PRIMERS SARS DEV
   PNEUMONIA CHINA GUAN
   CUMULATIVE NUMBER RE
NR 29
TC 493
Z9 534
U1 29
U2 56
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 26
PY 2003
VL 362
IS 9380
BP 263
EP 270
DI 10.1016/S0140-6736(03)13967-0
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 705UL
UT WOS:000184413400007
PM 12892955
OA Bronze
DA 2020-04-03
ER

PT J
AU Nelsen, CJ
   Murtaugh, MP
   Faaberg, KS
AF Nelsen, CJ
   Murtaugh, MP
   Faaberg, KS
TI Porcine reproductive and respiratory syndrome virus comparison:
   Divergent evolution on two continents
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID EQUINE ARTERITIS VIRUS; SUBGENOMIC MESSENGER-RNA;
   DEHYDROGENASE-ELEVATING VIRUS; HEMORRHAGIC-FEVER VIRUS; REPLICASE ORF1A
   PROTEIN; ISOLATE ATCC VR-2332; LELYSTAD-VIRUS; STRUCTURAL PROTEIN;
   CORONAVIRUS TRANSCRIPTION; SWINE INFERTILITY
AB Porcine reproductive and respiratory syndrome virus (PRRSV) is a recently described arterivirus responsible for disease in swine worldwide. Comparative sequence analysis of 3'-terminal structural genes of the single-stranded RNA viral genome revealed the presence of two genotypic classes of PRRSV, represented by the prototype North American and European strains, VR-2332 and Lelystad virus (LV), respectively. To better understand the evolution and pathogenicity of PRRSV, we obtained the 12,066-base 5'-terminal nucleotide sequence of VR-2332, encoding the viral replication activities, and compared it to those of LV and other arteriviruses. VR-2332 and LV differ markedly in the 5' leader and sections of the open reading frame (ORF) 1a region. The ORF 1b sequence was nearly colinear but varied in similarity of proteins encoded in identified regions. Furthermore, molecular and biochemical analysis of subgenomic mRNA (sgmRNA) processing revealed extensive variation in the number of sgmRNAs which may be generated during infection and in the lengths of noncoding sequence between leader-body junctions and the translation-initiating codon AUG. In addition, VR-2332 and LV select different leader-body junction sites from a pool of similar candidate sites to produce sgmRNA 7, encoding the viral nucleocapsid protein. The presence of substantial variations across the entire genome and in sgmRNA processing indicates that PRRSV has evolved independently on separate continents. The near-simultaneous global emergence of a new swine disease caused by divergently evolved viruses suggests that changes in swine husbandry and management may have contributed to the emergence of PRRS.
C1 Univ Minnesota, Dept Vet Pathobiol, St Paul, MN 55108 USA.
RP Faaberg, KS (reprint author), Univ Minnesota, Dept Vet Pathobiol, 1971 Commonwealth Ave, St Paul, MN 55108 USA.
EM kay@lenti.med.umn.edu
CR ABRAHAMS JP, 1990, NUCLEIC ACIDS RES, V18, P3035, DOI 10.1093/nar/18.10.3035
   BAARSCH MJ, 1991, J IMMUNOL METHODS, V140, P15, DOI 10.1016/0022-1759(91)90121-U
   Bautista EM, 1996, ARCH VIROL, V141, P1357, DOI 10.1007/BF01718837
   BENFIELD DA, 1992, J VET DIAGN INVEST, V4, P127, DOI 10.1177/104063879200400202
   BRINTON MA, 1986, J GEN VIROL, V67, P2673, DOI 10.1099/0022-1317-67-12-2673
   BROWN T, 1993, CURRENT PROTOCOLS MO
   CAVANAGH D, 1990, VIROLOGY, V176, P306, DOI 10.1016/0042-6822(90)90259-T
   CHEN ZY, 1994, J GEN VIROL, V75, P925, DOI 10.1099/0022-1317-75-4-925
   CHEN ZY, 1993, J GEN VIROL, V74, P643, DOI 10.1099/0022-1317-74-4-643
   COLLINS JE, 1992, J VET DIAGN INVEST, V4, P117, DOI 10.1177/104063879200400201
   CONZELMANN KK, 1993, VIROLOGY, V193, P329, DOI 10.1006/viro.1993.1129
   denBoon JA, 1996, J VIROL, V70, P4291, DOI 10.1128/JVI.70.7.4291-4298.1996
   DENBOON JA, 1995, J VIROL, V69, P4500, DOI 10.1128/JVI.69.7.4500-4505.1995
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   DEVRIES AAF, 1990, NUCLEIC ACIDS RES, V18, P3241, DOI 10.1093/nar/18.11.3241
   Faaberg KS, 1998, ADV EXP MED BIOL, V440, P275
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   Fischer F, 1997, J VIROL, V71, P5148, DOI 10.1128/JVI.71.7.5148-5160.1997
   FROHMAN MA, 1994, PCR METH APPL, V4, P40
   Godeny EK, 1998, J VIROL, V72, P862, DOI 10.1128/JVI.72.1.862-867.1998
   GODENY EK, 1993, VIROLOGY, V194, P585, DOI 10.1006/viro.1993.1298
   HABILI N, 1989, NUCLEIC ACIDS RES, V17, P9543, DOI 10.1093/nar/17.23.9543
   Hiscox J A, 1995, Adv Exp Med Biol, V380, P529
   Jeong YS, 1996, VIROLOGY, V217, P311, DOI 10.1006/viro.1996.0118
   Joo M, 1995, Adv Exp Med Biol, V380, P473
   Kapur V, 1996, J GEN VIROL, V77, P1271, DOI 10.1099/0022-1317-77-6-1271
   Keffaber KK, 1989, AM ASS SWINE PRACT N, V1, P1
   KUO L, 1992, VIRUS RES, V23, P55
   Lai M M, 1995, Adv Exp Med Biol, V380, P463
   LIAO CL, 1994, J VIROL, V68, P4727, DOI 10.1128/JVI.68.8.4727-4737.1994
   Lin YJ, 1996, J VIROL, V70, P7236, DOI 10.1128/JVI.70.10.7236-7240.1996
   Mardassi H, 1996, VIROLOGY, V221, P98, DOI 10.1006/viro.1996.0356
   Meng XJ, 1996, J GEN VIROL, V77, P1265, DOI 10.1099/0022-1317-77-6-1265
   MENG XJ, 1994, J GEN VIROL, V75, P1795, DOI 10.1099/0022-1317-75-7-1795
   Meulenberg JJM, 1996, VIROLOGY, V225, P44, DOI 10.1006/viro.1996.0573
   MEULENBERG JJM, 1995, VIROLOGY, V206, P155, DOI 10.1016/S0042-6822(95)80030-1
   MEULENBERG JJM, 1993, J GEN VIROL, V74, P1697, DOI 10.1099/0022-1317-74-8-1697
   Meulenberg JJM, 1998, J VIROL, V72, P380, DOI 10.1128/JVI.72.1.380-387.1998
   MEULENBERG JJM, 1993, VIROLOGY, V192, P62, DOI 10.1006/viro.1993.1008
   MOROZOV I, 1995, ARCH VIROL, V140, P1313, DOI 10.1007/BF01322758
   MOUNIR S, 1995, [No title captured], V80, P317
   MURTAUGH MP, 1995, ARCH VIROL, V140, P1451, DOI 10.1007/BF01322671
   Nelson E A, 1995, Adv Exp Med Biol, V380, P321
   PALMER GA, 1995, VIROLOGY, V209, P637, DOI 10.1006/viro.1995.1296
   Pirzadeh B, 1997, J GEN VIROL, V78, P1867, DOI 10.1099/0022-1317-78-8-1867
   PLAGEMANN PGW, 1992, ADV VIRUS RES, V41, P99, DOI 10.1016/S0065-3527(08)60036-6
   PLAGEMANN PGW, 1996, FIELDS VIROLOGY, P1105
   POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x
   ROSSOW KD, UNPUB PORCINE REPROD
   SAGRIPANTI JL, 1985, VIROLOGY, V145, P350, DOI 10.1016/0042-6822(85)90171-0
   SAGRIPANTI JL, 1986, VIROLOGY, V151, P146, DOI 10.1016/0042-6822(86)90113-3
   Saito A, 1996, J VET MED SCI, V58, P377, DOI 10.1292/jvms.58.377
   Sawicki S G, 1995, Adv Exp Med Biol, V380, P499
   SHIEH CK, 1987, VIROLOGY, V156, P321, DOI 10.1016/0042-6822(87)90412-0
   Smith SL, 1997, GENE, V191, P205, DOI 10.1016/S0378-1119(97)00061-9
   SNIJDER EJ, 1992, J VIROL, V66, P7040, DOI 10.1128/JVI.66.12.7040-7048.1992
   SNIJDER EJ, 1995, J BIOL CHEM, V270, P16671, DOI 10.1074/jbc.270.28.16671
   SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994
   Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961
   TRIEZENBERG SG, 1992, CURRENT PROTOCOLS MO
   van Marle G, 1995, Adv Exp Med Biol, V380, P507
   VANBERLO MF, 1982, VIROLOGY, V118, P345, DOI 10.1016/0042-6822(82)90354-3
   vanDinten LC, 1997, P NATL ACAD SCI USA, V94, P991, DOI 10.1073/pnas.94.3.991
   vanDinten LC, 1996, J VIROL, V70, P6625, DOI 10.1128/JVI.70.10.6625-6633.1996
   vanNieuwstadt AP, 1996, J VIROL, V70, P4767, DOI 10.1128/JVI.70.7.4767-4772.1996
   Wassenaar ALM, 1997, J VIROL, V71, P9313, DOI 10.1128/JVI.71.12.9313-9322.1997
   WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296
   ZENG L, 1995, VIROLOGY, V207, P543, DOI 10.1006/viro.1995.1114
   ZHANG XM, 1995, J VIROL, V69, P1637, DOI 10.1128/JVI.69.3.1637-1644.1995
   ZHANG XM, 1994, J VIROL, V68, P4738, DOI 10.1128/JVI.68.8.4738-4746.1994
NR 70
TC 488
Z9 555
U1 1
U2 56
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JAN
PY 1999
VL 73
IS 1
BP 270
EP 280
DI 10.1128/JVI.73.1.270-280.1999
PG 11
WC Virology
SC Virology
GA 146YP
UT WOS:000077461700031
PM 9847330
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Raj, VS
   Mou, HH
   Smits, SL
   Dekkers, DHW
   Muller, MA
   Dijkman, R
   Muth, D
   Demmers, JAA
   Zaki, A
   Fouchier, RAM
   Thiel, V
   Drosten, C
   Rottier, PJM
   Osterhaus, ADME
   Bosch, BJ
   Haagmans, BL
AF Raj, V. Stalin
   Mou, Huihui
   Smits, Saskia L.
   Dekkers, Dick H. W.
   Mueller, Marcel A.
   Dijkman, Ronald
   Muth, Doreen
   Demmers, Jeroen A. A.
   Zaki, Ali
   Fouchier, Ron A. M.
   Thiel, Volker
   Drosten, Christian
   Rottier, Peter J. M.
   Osterhaus, Albert D. M. E.
   Bosch, Berend Jan
   Haagmans, Bart L.
TI Dipeptidyl peptidase 4 is a functional receptor for the emerging human
   coronavirus-EMC
SO NATURE
LA English
DT Article
ID ACUTE-RESPIRATORY-SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; SARS
   CORONAVIRUS; AMINOPEPTIDASE-N; PATHOGENESIS; MECHANISMS; RESERVOIRS;
   BATS
AB Most human coronaviruses cause mild upper respiratory tract disease but may be associated with more severe pulmonary disease in immunocompromised individuals'. However, SARS coronavirus caused severe lower respiratory disease with nearly 10% mortality and evidence of systemic spread(2). Recently, another coronavirus (human coronavirus-Erasmus Medical Center (hCoV-EMC)) was identified in patients with severe and sometimes lethal lower respiratory tract infection(3,4). Viral genome analysis revealed close relatedness to coronaviruses found in bats'. Here we identify dipeptidyl peptidase 4 (DPP4; also known as CD26) as a functional receptor for hCoV-EMC. DPP4 specifically co-purified with the receptor-binding Si domain of the hCoV-EMC spike protein from lysates of susceptible Huh-7 cells. Antibodies directed against DPP4 inhibited hCoV-EMC infection of primary human bronchial epithelial cells and Huh-7 cells. Expression of human and bat (Pipistrellus pipistrellus) DPP4 in non-susceptible COS-7 cells enabled infection by hCoV-EMC. The use of the evolutionarily conserved DPP4 protein from different species as a functional receptor provides clues about the host range potential of hCoV-EMC. In addition, it will contribute critically to our understanding of the pathogenesis and epidemiology of this emerging human coronavirus, and may facilitate the development of intervention strategies.
C1 [Raj, V. Stalin; Smits, Saskia L.; Fouchier, Ron A. M.; Osterhaus, Albert D. M. E.; Haagmans, Bart L.] Erasmus MC, Dept Virosci, NL-3000 CA Rotterdam, Netherlands.
   [Mou, Huihui; Rottier, Peter J. M.; Bosch, Berend Jan] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Virol, NL-3508 TD Utrecht, Netherlands.
   [Smits, Saskia L.] Viroclin Biosci BV, NL-3029 AK Rotterdam, Netherlands.
   [Dekkers, Dick H. W.; Demmers, Jeroen A. A.] Erasmus MC, Prote Dept, NL-3000 CA Rotterdam, Netherlands.
   [Mueller, Marcel A.; Muth, Doreen; Drosten, Christian] Univ Bonn, Med Ctr, Inst Virol, D-53105 Bonn, Germany.
   [Dijkman, Ronald; Thiel, Volker] Kantonal Hosp St Gallen, Inst Immunobiol, CH-9007 St Gallen, Switzerland.
   [Zaki, Ali] Dr Soliman Fakeeh Hosp, Virol Lab, Jeddah, Saudi Arabia.
   [Thiel, Volker] Univ Zurich, Vetsuisse Fac, CH-8057 Zurich, Switzerland.
RP Bosch, BJ (reprint author), Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Virol, NL-3508 TD Utrecht, Netherlands.
EM b.j.bosch@uu.nl; b.haagmans@erasmusmc.nl
RI Mueller, Marcel/O-2425-2019; Smits, Saskia/A-2953-2014; Thiel,
   Volker/AAI-2391-2019; Demmers, Jeroen AA/F-4046-2016; Fouchier,
   Ron/Y-3755-2019; Fouchier, Ron A/A-1911-2014; Victor, Stalin
   Raj/E-9670-2016
OI Mueller, Marcel/0000-0003-2242-5117; Demmers, Jeroen
   AA/0000-0002-8757-9611; Fouchier, Ron/0000-0001-8095-2869; Fouchier, Ron
   A/0000-0001-8095-2869; Dijkman, Ronald/0000-0003-0320-2743; Thiel,
   Volker/0000-0002-5783-0887; Victor, Stalin Raj/0000-0003-2250-8481;
   Haagmans, Bart/0000-0001-6221-2015; Osterhaus,
   Albert/0000-0002-6074-1172
FU European Union FP7European Union (EU) [223498]; ANTIGONE [278976]; Swiss
   National Science FoundationSwiss National Science Foundation (SNSF)
   [31003A_132898]; 3R Research Foundation Switzerland [128-11]; German
   Research Foundation (DFG)German Research Foundation (DFG) [DR 772/3-1,
   KAl241/18-1]; German Ministry of Education and Research (BMBF SARS
   II)Federal Ministry of Education & Research (BMBF)
FX We thank E. Snijder for peoviding the anti-SARS-CoV NSP4 antibody, and
   E. Kindler, H. Jonsdottir, R. Rodriguez, T. Bestebroer, S. Pas, G.
   Arron, M. van Velzen and W. Ouwendijk for techn ical assistance. This
   work was supported by a fellowship from China Scholarship Council to
   H.M. The study was financed by the European Union FP7 project EMPERIE
   (contract number 223498), ANTIGONE (contract number 278976), the Swiss
   National Science Foundation (31003A_132898) and the 3R Research
   Foundation Switzerland (Project 128-11). C.D. was supported by the
   German Research Foundation (DFG grant DR 772/3-1, KAl241/18-1) and the
   German Ministry of Education and Research (BMBF SARS II).
CR Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Boonacker E, 2003, EUR J CELL BIOL, V82, P53, DOI 10.1078/0171-9335-00302
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   Drexler JF, 2010, J VIROL, V84, P11336, DOI 10.1128/JVI.00650-10
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Huynh J, 2012, J VIROL, V86, P12816, DOI 10.1128/JVI.00906-12
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lambeir AM, 2003, CRIT REV CL LAB SCI, V40, P209, DOI 10.1080/713609354
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Muller MA, 2012, MBIO, V3, DOI 10.1128/mBio.00515-12
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   SCHULTZE B, 1992, J GEN VIROL, V73, P901, DOI 10.1099/0022-1317-73-4-901
   Sims AC, 2008, VIRUS RES, V133, P33, DOI 10.1016/j.virusres.2007.03.013
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   World Health Organization, 2013, INT SURV REC HUM INF
   Wu KL, 2012, J BIOL CHEM, V287, P8904, DOI 10.1074/jbc.M111.325803
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 23
TC 482
Z9 517
U1 32
U2 166
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAR 14
PY 2013
VL 495
IS 7440
BP 251
EP 254
DI 10.1038/nature12005
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 113FP
UT WOS:000316652300054
PM 23486063
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Anand, K
   Ziebuhr, J
   Wadhwani, P
   Mesters, JR
   Hilgenfeld, R
AF Anand, K
   Ziebuhr, J
   Wadhwani, P
   Mesters, JR
   Hilgenfeld, R
TI Coronavirus main proteinase (3CL(pro)) structure: Basis for design of
   anti-SARS drugs
SO SCIENCE
LA English
DT Article
ID VIRUS-ENCODED PROTEINASES; 229E 3C-LIKE PROTEINASE; PROTEASES
AB A novel coronavirus has been identified as the causative agent of severe acute respiratory syndrome (SARS). The viral main proteinase (M-pro, also called 3CL(pro)), which controls the activities of the coronavirus replication complex, is an attractive target for therapy. We determined crystal structures for human coronavirus (strain 229E) M-pro and for an inhibitor complex of porcine coronavirus [ transmissible gastroenteritis virus ( TGEV)] Mpro, and we constructed a homology model for SARS coronavirus (SARS-CoV) M-pro. The structures reveal a remarkable degree of conservation of the substrate-binding sites, which is further supported by recombinant SARS-CoV M-pro-mediated cleavage of a TGEV Mpro substrate. Molecular modeling suggests that available rhinovirus 3C(pro) inhibitors may be modified to make them useful for treating SARS.
C1 Univ Lubeck, Inst Biochem, D-23538 Lubeck, Germany.
   Inst Mol Biotechnol, D-07745 Jena, Germany.
   Univ Wurzburg, Inst Virol & Immunol, D-97078 Wurzburg, Germany.
   Univ Jena, Inst Mol Biol, D-07745 Jena, Germany.
RP Hilgenfeld, R (reprint author), Univ Lubeck, Inst Biochem, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM hilgenfeld@biochem.uni-luebeck.de
RI Hilgenfeld, Rolf/C-9675-2011; Ziebuhr, John/G-7669-2015
OI Wadhwani, Parvesh/0000-0002-7290-5154; Ziebuhr, John/0000-0002-5741-8825
CR Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hegyi A, 2002, J GEN VIROL, V83, P581, DOI 10.1099/0022-1317-83-3-581
   HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419
   KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   MARRA M, 2003, SCIENCE, V30, P1399, DOI DOI 10.1126/SC2ENCE.1085953
   Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000
   MYINT SH, 1995, CORONAVIRIDAE, P389
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ryan MD, 1997, J GEN VIROL, V78, P699, DOI 10.1099/0022-1317-78-4-699
   SIDDELL SG, 1995, CORONAVIRIDAE, P1
   Thiel V, 2001, J VIROL, V75, P6676, DOI 10.1128/JVI.75.14.6676-6681.2001
   Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   ZIEBUHR J, 1995, J VIROL, V69, P4331, DOI 10.1128/JVI.69.7.4331-4338.1995
NR 18
TC 471
Z9 523
U1 21
U2 69
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD JUN 13
PY 2003
VL 300
IS 5626
BP 1763
EP 1767
DI 10.1126/science.1085658
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 688WF
UT WOS:000183459700056
PM 12746549
OA Bronze
DA 2020-04-03
ER

PT J
AU BRIERLEY, I
   DIGARD, P
   INGLIS, SC
AF BRIERLEY, I
   DIGARD, P
   INGLIS, SC
TI CHARACTERIZATION OF AN EFFICIENT CORONAVIRUS RIBOSOMAL FRAMESHIFTING
   SIGNAL - REQUIREMENT FOR AN RNA PSEUDOKNOT
SO CELL
LA English
DT Article
RP BRIERLEY, I (reprint author), UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,CAMBRIDGE CB2 1QP,ENGLAND.
RI Digard, Paul/B-7717-2008
OI Digard, Paul/0000-0002-0872-9440
CR ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   CLARE J, 1985, P NATL ACAD SCI USA, V82, P2829, DOI 10.1073/pnas.82.9.2829
   CLARE JJ, 1988, P NATL ACAD SCI USA, V85, P6816, DOI 10.1073/pnas.85.18.6816
   CLARKE BE, 1987, NUCLEIC ACIDS RES, V15, P7067, DOI 10.1093/nar/15.17.7067
   COLMAN A, 1984, TRANSCRIPTION TRANSL, P271
   CRAIGEN WJ, 1987, CELL, V50, P1, DOI 10.1016/0092-8674(87)90652-0
   DECKMAN IC, 1987, J MOL BIOL, V196, P323, DOI 10.1016/0022-2836(87)90693-0
   DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645
   DOTTO GP, 1981, VIROLOGY, V114, P463, DOI 10.1016/0042-6822(81)90226-9
   GORINGER HU, 1986, NUCLEIC ACIDS RES, V14, P7473, DOI 10.1093/nar/14.18.7473
   Hames BD, 1981, GEL ELECTROPHORESIS, P1
   HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041
   HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0
   JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298
   JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054
   JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0
   JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1
   JACOBSON AB, 1984, NUCLEIC ACIDS RES, V12, P54
   KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057
   KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488
   MADHANI HD, 1988, CONTROL OF HUMAN RETROVIRUS GENE EXPRESSION, P119
   MALY P, 1983, NUCLEIC ACIDS RES, V11, P7263, DOI 10.1093/nar/11.21.7263
   MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129
   MELLOR J, 1985, NATURE, V313, P243, DOI 10.1038/313243a0
   MILLER WA, 1988, NUCLEIC ACIDS RES, V16, P6097, DOI 10.1093/nar/16.13.6097
   MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987
   PLEIJ CWA, 1985, NATURE, V331, P283
   RICE NR, 1985, VIROLOGY, V142, P357, DOI 10.1016/0042-6822(85)90344-7
   RIETVELD K, 1983, EMBO J, V2, P1079, DOI 10.1002/j.1460-2075.1983.tb01549.x
   ROTH JR, 1981, CELL, V24, P601, DOI 10.1016/0092-8674(81)90086-6
   RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6
   SAIGO K, 1984, NATURE, V312, P659, DOI 10.1038/312659a0
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHOCHETMAN G, 1977, VIROLOGY, V77, P772, DOI 10.1016/0042-6822(77)90498-6
   SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761
   STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x
   STERN DF, 1980, J VIROL, V34, P665, DOI 10.1128/JVI.34.3.665-674.1980
   STUDNICKA GM, 1978, NUCLEIC ACIDS RES, V5, P3365, DOI 10.1093/nar/5.9.3365
   WILSON W, 1986, NUCLEIC ACIDS RES, V14, P7001, DOI 10.1093/nar/14.17.7001
   WILSON W, 1988, CELL, V55, P1159, DOI 10.1016/0092-8674(88)90260-7
   YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9
   YOUNG JF, 1983, ORIGIN PANDEMIC INFL, P129
NR 45
TC 467
Z9 477
U1 3
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138
SN 0092-8674
J9 CELL
JI Cell
PD MAY 19
PY 1989
VL 57
IS 4
BP 537
EP 547
DI 10.1016/0092-8674(89)90124-4
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA U7436
UT WOS:A1989U743600007
PM 2720781
OA Bronze
DA 2020-04-03
ER

PT J
AU Ruuskanen, O
   Lahti, E
   Jennings, LC
   Murdoch, DR
AF Ruuskanen, Olli
   Lahti, Elina
   Jennings, Lance C.
   Murdoch, David R.
TI Viral pneumonia
SO LANCET
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY-TRACT INFECTIONS; HUMAN
   METAPNEUMOVIRUS INFECTION; INFLUENZA A(H1N1) INFECTION;
   POLYMERASE-CHAIN-REACTION; SYNCYTIAL VIRUS; PANDEMIC INFLUENZA;
   REQUIRING HOSPITALIZATION; STAPHYLOCOCCUS-AUREUS; ETIOLOGIC DIAGNOSIS
AB About 200 million cases of viral community-acquired pneumonia occur every year-100 million in children and 100 million in adults. Molecular diagnostic tests have greatly increased our uwnderstanding of the role of viruses in pneumonia, and findings indicate that the incidence of viral pneumonia has been underestimated. In children, respiratory syncytial virus, rhinovirus, human metapneumovirus, human bocavirus, and parainfluenza viruses are the agents identified most frequently in both developed and developing countries. Dual viral infections are common, and a third of children have evidence of viral-bacterial co-infection. In adults, viruses are the putative causative agents in a third of cases of community-acquired pneumonia, in particular influenza viruses, rhinoviruses, and coronaviruses. Bacteria continue to have a predominant role in adults with pneumonia. Presence of viral epidemics in the community, patient's age, speed of onset of illness, symptoms, biomarkers, radiographic changes, and response to treatment can help differentiate viral from bacterial pneumonia. However, no clinical algorithm exists that will distinguish clearly the cause of pneumonia. No clear consensus has been reached about whether patients with obvious viral community-acquired pneumonia need to be treated with antibiotics. Apart from neuraminidase inhibitors for pneumonia caused by influenza viruses, there is no clear role for use of specific antivirals to treat viral community-acquired pneumonia. Influenza vaccines are the only available specific preventive measures. Further studies are needed to better understand the cause and pathogenesis of community-acquired pneumonia. Furthermore, regional differences in cause of pneumonia should be investigated, in particular to obtain more data from developing countries.
C1 [Ruuskanen, Olli; Lahti, Elina] Turku Univ Hosp, Dept Paediat, Turku 20521, Finland.
   [Jennings, Lance C.; Murdoch, David R.] Univ Otago, Microbiol Unit, Canterbury Hlth Labs, Christchurch, New Zealand.
   [Jennings, Lance C.; Murdoch, David R.] Univ Otago, Dept Pathol, Christchurch, New Zealand.
RP Ruuskanen, O (reprint author), Turku Univ Hosp, Dept Paediat, PL 52, Turku 20521, Finland.
EM olli.ruuskanen@tyks.fi
RI Murdoch, David/A-2012-2009
FU Hoffmann La-RocheHoffmann-La Roche
FX EL and DRM declare that they have no conflicts of interest. OR has been
   a consultant to Novartis Vaccines and Abbot. LCJ has received grant
   support from Hoffmann La-Roche and honoraria or travel assistance from
   Hoffmann La-Roche, GlaxoSmithKline, Sanofi Pasteur, Baxter, Novartis,
   Wyeth, and CSL for participation in advisory groups and scientific
   meetings.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Agarwal PP, 2009, AM J ROENTGENOL, V193, P1488, DOI 10.2214/AJR.09.3599
   Almirall J, 2007, RESP MED, V101, P2168, DOI 10.1016/j.rmed.2007.05.007
   Arens MQ, 2010, J CLIN MICROBIOL, V48, P2387, DOI 10.1128/JCM.00220-10
   Arnold JC, 2008, PEDIATRICS, V121, pE631, DOI 10.1542/peds.2006-3073
   AUSINA V, 1988, EUR J CLIN MICROBIOL, V7, P343, DOI 10.1007/BF01962334
   Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449
   Beigel H, 2005, NEW ENGL J MED, V353, P1374
   Berkley JA, 2010, JAMA-J AM MED ASSOC, V303, P2051, DOI 10.1001/jama.2010.675
   Birnkrant D, 2009, NEW ENGL J MED, V361, P2204, DOI 10.1056/NEJMp0910479
   Bishop JF, 2009, NEW ENGL J MED, V361, P2591, DOI 10.1056/NEJMp0910445
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Bocchini JA, 2009, PEDIATRICS, V124, P1216, DOI [10.1542/peds.2009-1806, 10.1542/peds.2009-2345]
   Boivin G, 2007, CLIN INFECT DIS, V44, P1152, DOI 10.1086/513204
   Bonney D, 2009, BRIT J HAEMATOL, V145, P667, DOI 10.1111/j.1365-2141.2009.07654.x
   Bustamante-Calvillo ME, 2001, PEDIATR INFECT DIS J, V20, P495, DOI 10.1097/00006454-200105000-00005
   Calvo C, 2008, J CLIN VIROL, V42, P268, DOI 10.1016/j.jcv.2008.03.012
   Calvo C, 2007, PEDIATR INFECT DIS J, V26, P904, DOI 10.1097/INF.0b013e31812e52e6
   Camps M, 2008, J MED VIROL, V80, P1452, DOI 10.1002/jmv.21209
   Carballal Guadalupe, 2002, BMC Pediatr, V2, P6, DOI 10.1186/1471-2431-2-6
   Cevey-Macherel M, 2009, EUR J PEDIATR, V168, P1429, DOI 10.1007/s00431-009-0943-y
   Charles PGP, 2008, CLIN INFECT DIS, V46, P1513, DOI 10.1086/586749
   Cheng VCC, 2004, J INFECTION, V49, P262, DOI 10.1016/j.jinf.2004.07.010
   Cheuk DKL, 2007, PEDIATR INFECT DIS J, V26, P995, DOI 10.1097/INF.0b013e3181586b63
   Cilla G, 2008, J MED VIROL, V80, P1843, DOI 10.1002/jmv.21271
   CLAESSON BA, 1989, PEDIATR INFECT DIS J, V8, P856, DOI 10.1097/00006454-198912000-00006
   Dare RK, 2007, J INFECT DIS, V196, P1321, DOI 10.1086/521308
   De Wals P, 2008, PEDIATR INFECT DIS J, V27, P963, DOI 10.1097/INF.0b013e31817cf76f
   Debur MD, 2010, J CLIN PATHOL, V63, P930, DOI 10.1136/jcp.2010.077867
   Diederen B, 2009, SCAND J INFECT DIS, V41, P45, DOI 10.1080/00365540802448799
   Doan ML, 2007, J HEART LUNG TRANSPL, V26, P883, DOI 10.1016/j.healun.2007.06.009
   Don M, 2005, SCAND J INFECT DIS, V37, P806, DOI 10.1080/00365540500262435
   Don M, 2010, PEDIATR PULM, V45, P120, DOI 10.1002/ppul.21151
   Donoso AF, 2008, PEDIATR INT, V50, P589, DOI 10.1111/j.1442-200X.2008.02673.x
   Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137
   DURRINGTON S, 2008, BMJ-BRIT MED J, V336, P1429
   Empey KM, 2010, CLIN INFECT DIS, V50, P1258, DOI 10.1086/651603
   Esper F, 2003, PEDIATRICS, V111, P1407, DOI 10.1542/peds.111.6.1407
   Esposito DH, 2010, J INFECT DIS, V202, P214, DOI 10.1086/653498
   Falagas ME, 2010, INT J ANTIMICROB AG, V35, P421, DOI 10.1016/j.ijantimicag.2010.01.006
   Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951
   File TM, 2010, POSTGRAD MED, V122, P130, DOI 10.3810/pgm.2010.03.2130
   File TM, 2003, LANCET, V362, P1991, DOI 10.1016/S0140-6736(03)15021-0
   Finelli L, 2008, PEDIATRICS, V122, P805, DOI 10.1542/peds.2008-1336
   Fitzpatrick M, 2002, THORAX, V57, P1, DOI 10.1136/thorax.57.1.1
   Flood RG, 2008, PEDIATR INFECT DIS J, V27, P95, DOI 10.1097/INF.0b013e318157aced
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   Frangides CY, 2004, EUR J INTERN MED, V15, P364, DOI DOI 10.1016/J.EJIM.2004.04.016
   FRIIS B, 1984, ARCH DIS CHILD, V59, P1038, DOI 10.1136/adc.59.11.1038
   Fry AM, 2007, J INFECT DIS, V195, P1038, DOI 10.1086/512163
   Gilbert DN, 2010, J CLIN MICROBIOL, V48, P2325, DOI 10.1128/JCM.00655-10
   Harter G, 2010, CLIN INFECT DIS, V50, P1249, DOI 10.1086/651604
   Hamano-Hasegawa Keiko, 2008, Journal of Infection and Chemotherapy, V14, P424, DOI 10.1007/s10156-008-0648-6
   Han LL, 1999, J INFECT DIS, V179, P25, DOI 10.1086/314567
   Harper SA, 2009, CLIN INFECT DIS, V48, P1003, DOI 10.1086/598513
   Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406
   Heikkinen T, 2002, J CLIN MICROBIOL, V40, P4337, DOI 10.1128/JCM.40.11.4337-4339.2002
   Heinonen S, 2011, LANCET INFECT DIS, V11, P23, DOI 10.1016/S1473-3099(10)70255-3
   Heiskanen-Kosma T, 1998, PEDIATR INFECT DIS J, V17, P986, DOI 10.1097/00006454-199811000-00004
   Heugel J, 2007, PEDIATR INFECT DIS J, V26, P753, DOI 10.1097/INF.0b013e318054e31b
   Hicks LA, 2006, J AM GERIATR SOC, V54, P284, DOI 10.1111/j.1532-5415.2005.00529.x
   Hohenthal U, 2008, THORAX, V63, P658
   Hohenthal U, 2008, SCAND J INFECT DIS, V40, P131, DOI 10.1080/00365540701534525
   Hopkins P, 2008, AM J RESP CRIT CARE, V178, P876, DOI 10.1164/rccm.200711-1657OC
   Imakita M, 2000, CLIN INFECT DIS, V30, P611, DOI 10.1086/313723
   Jartti T, 2002, PEDIATR INFECT DIS J, V21, P873, DOI 10.1097/00006454-200209000-00019
   Jartti T, 2008, PEDIATR INFECT DIS J, V27, P1103, DOI 10.1097/INF.0b013e31817e695d
   Jennings LC, 2008, THORAX, V63, P42, DOI 10.1136/thx.2006.075077
   Jennings LC, 2004, PEDIATR INFECT DIS J, V23, P1003, DOI 10.1097/01.inf.0000143648.04673.6c
   Johansson N, 2010, CLIN INFECT DIS, V50, P202, DOI 10.1086/648678
   Johnson AWBR, 2008, J NATL MED ASSOC, V100, P370, DOI 10.1016/S0027-9684(15)31269-4
   Johnson JE, 2007, MODERN PATHOL, V20, P108, DOI 10.1038/modpathol.3800725
   Johnstone J, 2008, CHEST, V134, P1141, DOI 10.1378/chest.08-0888
   JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977, DOI 10.1093/oxfordjournals.aje.a116770
   Juven T, 2004, EUR J PEDIATR, V163, P140, DOI 10.1007/s00431-003-1397-2
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   Korteweg C, 2008, AM J PATHOL, V172, P1155, DOI 10.2353/ajpath.2008.070791
   Kotsimbos T, 2010, AM J RESP CRIT CARE, V181, P300, DOI 10.1164/rccm.200912-1878CP
   Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496
   Lahti E, 2009, THORAX, V64, P252, DOI 10.1136/thx.2008.099051
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Lauderdale TL, 2005, RESP MED, V99, P1079, DOI 10.1016/j.rmed.2005.02.026
   Levy MM, 2005, AM J RESP CRIT CARE, V171, P518, DOI 10.1164/rccm.200405-621WS
   Lieberman D, 2010, CHEST, V138, P811, DOI 10.1378/chest.09-2717
   Lieberman D, 2009, J CLIN MICROBIOL, V47, P3439, DOI 10.1128/JCM.00886-09
   Lim WS, 2009, THORAX, V64, P1, DOI 10.1136/thx.2009.121434
   Lim WS, 2001, THORAX, V56, P296, DOI 10.1136/thorax.56.4.296
   Loens K, 2009, J CLIN MICROBIOL, V47, P21, DOI 10.1128/JCM.02037-08
   Longtin J, 2010, EMERG INFECT DIS, V16, P1463, DOI 10.3201/eid1609.100476
   Louie JK, 2007, J INFECT DIS, V196, P705, DOI 10.1086/519846
   Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583
   Louie JK, 2009, PEDIATR INFECT DIS J, V28, P337, DOI 10.1097/INF.0b013e31818ffc1b
   Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   Marcos MA, 2006, ANTIVIR THER, V11, P351
   Mauad T, 2010, AM J RESP CRIT CARE, V181, P72, DOI 10.1164/rccm.200909-1420OC
   McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05
   McIntosh K, 2002, NEW ENGL J MED, V346, P429, DOI 10.1056/NEJMra011994
   Midulla F, 2010, ARCH DIS CHILD, V95, P35, DOI 10.1136/adc.2008.153361
   Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821
   Miller EK, 2009, J ALLERGY CLIN IMMUN, V123, P98, DOI 10.1016/j.jaci.2008.10.007
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   Murdoch DR, 2010, INFECT DIS CLIN N AM, V24, P791, DOI 10.1016/j.idc.2010.04.006
   Murdoch DR, 2009, J CLIN MICROBIOL, V47, P3405, DOI 10.1128/JCM.01685-09
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nguyen-Van-Tam JS, 2010, THORAX, V65, P645, DOI 10.1136/thx.2010.135210
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Ou ZY, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-122
   Palacios G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008540
   Peltola V, 2008, J INFECT DIS, V197, P382, DOI 10.1086/525542
   Peltola V, 2009, J MED VIROL, V81, P1831, DOI 10.1002/jmv.21590
   Pierangeli A, 2007, J MED VIROL, V79, P463, DOI 10.1002/jmv.20832
   Poggensee G, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-155
   Reed C, 2009, PEDIATR INFECT DIS J, V28, P572, DOI 10.1097/INF.0b013e31819d8b71
   Renwick N, 2007, J INFECT DIS, V196, P1754, DOI 10.1086/524312
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Ruiz M, 1999, AM J RESP CRIT CARE, V160, P397, DOI 10.1164/ajrccm.160.2.9808045
   Ruohola A, 2009, EMERG INFECT DIS, V15, P344, DOI 10.3201/eid1502.081468
   Saito Atsushi, 2006, Journal of Infection and Chemotherapy, V12, P63, DOI 10.1007/s10156-005-0425-8
   Samransamruajkit R, 2008, JPN J INFECT DIS, V61, P446
   Schildgen O, 2008, CLIN MICROBIOL REV, V21, P291, DOI 10.1128/CMR.00030-07
   Schuetz P, 2010, EXPERT REV ANTI-INFE, V8, P575, DOI [10.1586/eri.10.25, 10.1586/ERI.10.25]
   Seki M, 2007, INTERNAL MED, V46, P953, DOI 10.2169/internalmedicine.46.6364
   She RC, 2010, DIAGN MICR INFEC DIS, V67, P246, DOI 10.1016/j.diagmicrobio.2010.02.020
   Shieh WJ, 2010, AM J PATHOL, V177, P166, DOI 10.2353/ajpath.2010.100115
   Shiley KT, 2010, J THORAC IMAG, V25, P68, DOI 10.1097/RTI.0b013e3181b0ba8b
   Shun-Shin M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3172
   Simpson JCG, 2000, THORAX, V55, P1040, DOI 10.1136/thorax.55.12.1040
   Soderlund-Venermo M, 2009, EMERG INFECT DIS, V15, P1423, DOI 10.3201/eid1509.090204
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Talbot HK, 2010, CLIN INFECT DIS, V50, P747, DOI 10.1086/650486
   Templeton KE, 2005, CLIN INFECT DIS, V41, P345, DOI 10.1086/431588
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Tivejung-Lindell A, 2009, J MED VIROL, V81, P167, DOI 10.1002/jmv.21368
   Toikka P, 1999, CLIN INFECT DIS, V29, P568, DOI 10.1086/598635
   Tsolia MN, 2004, CLIN INFECT DIS, V39, P681, DOI 10.1086/422996
   Tucker SN, 2008, EXPERT REV VACCINES, V7, P25, DOI 10.1586/14760584.7.1.25
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   Soto-Abraham MV, 2009, NEW ENGL J MED, V361, P2001, DOI 10.1056/NEJMc0907171
   Virkki R, 2002, THORAX, V57, P438, DOI 10.1136/thorax.57.5.438
   Vuori-Holopainen E, 2001, CLIN INFECT DIS, V32, P715, DOI 10.1086/319213
   Walsh EE, 2008, ARCH INTERN MED, V168, P2489, DOI 10.1001/archinte.168.22.2489
   Werno AM, 2004, J PAEDIATR CHILD H, V40, P549, DOI 10.1111/j.1440-1754.2004.00461.x
   *WHO, 2004, [No title captured]
   Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472
   Wolf DG, 2010, J PEDIATR-US, V156, P115, DOI 10.1016/j.jpeds.2009.07.014
   Wong SSY, 2008, RESPIROLOGY, V13, P950, DOI 10.1111/j.1440-1843.2008.01404.x
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   YIN MT, 2009, CLIN VIROLOGY, P217
   Yu HJ, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4779
NR 152
TC 460
Z9 493
U1 25
U2 79
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD APR 9
PY 2011
VL 377
IS 9773
BP 1264
EP 1275
DI 10.1016/S0140-6736(10)61459-6
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 751DI
UT WOS:000289597300033
PM 21435708
HC Y
HP N
DA 2020-04-03
ER

PT J
AU YEAGER, CL
   ASHMUN, RA
   WILLIAMS, RK
   CARDELLICHIO, CB
   SHAPIRO, LH
   LOOK, AT
   HOLMES, KV
AF YEAGER, CL
   ASHMUN, RA
   WILLIAMS, RK
   CARDELLICHIO, CB
   SHAPIRO, LH
   LOOK, AT
   HOLMES, KV
TI HUMAN AMINOPEPTIDASE-N IS A RECEPTOR FOR HUMAN CORONAVIRUS-229E
SO NATURE
LA English
DT Article
ID AMINO-ACID SEQUENCE; ENDOPEPTIDASE 24.11 ENKEPHALINASE; MEMBRANE ANTIGEN
   GP150; NEUTRAL ENDOPEPTIDASE; MOLECULAR-CLONING; LEUKEMIA ANTIGEN; GENE;
   KIDNEY; IDENTIFICATION; EXPRESSION
AB HUMAN coronaviruses (HCV) in two serogroups represented by HCV-229E and HCV-OC43 are an important cause of upper respiratory tract infections 1. Here we report that human aminopeptidase N, a cell-surface metalloprotease on intestinal, lung and kidney epithelial cells 2-5, is a receptor for human coronavirus strain HCV-229E, but not for HCV-OC43. A monoclonal antibody, RBS, blocked HCV-229E virus infection of human lung fibroblasts, immunoprecipitated aminopeptidase N and inhibited its enzymatic activity. HCV-229E-resistant murine fibroblasts became susceptible after transfection with complementary DNA encoding human aminopeptidase N. By contrast, infection of human cells with HCV-OC43 was not inhibited by antibody RBS and expression of aminopeptidase N did not enhance HCV-OC43 replication in mouse cells. A mutant aminopeptidase lacking the catalytic site of the enzyme did not bind HCV-229E or RBS and did not render murine cells susceptible to HCV-229E infection, suggesting that the virus-binding site may lie at or near the active site of the human aminopeptidase molecule.
C1 UNIFORMED SERV UNIV HLTH SCI, DEPT PATHOL, 4301 JONES BRIDGE RD, BETHESDA, MD 20814 USA.
   ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA.
   ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA.
   UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA.
CR ASHMUN RA, 1990, BLOOD, V75, P462
   ASHMUN RA, IN PRESS BLOOD
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   KENNY AJ, 1982, PHYSIOL REV, V62, P91
   LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247
   LOOK AT, 1985, J CLIN INVEST, V75, P569, DOI 10.1172/JCI111733
   LOOK AT, 1986, J CLIN INVEST, V78, P914, DOI 10.1172/JCI112680
   LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015
   LOOK AT, 1989, LEUCOCYTE TYPING, V4, P784
   MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7
   MATSAS R, 1985, BIOCHEM J, V231, P445, DOI 10.1042/bj2310445
   MCINTOSH K, 1990, VIROLOGY, P857
   NOREN O, 1989, FEBS LETT, V259, P107, DOI 10.1016/0014-5793(89)81506-6
   Noren O, 1986, MOL CELLULAR BASIS D, P335
   OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X
   RICH DH, 1984, J MED CHEM, V27, P417, DOI 10.1021/jm00370a001
   SAKAGUCHI AY, 1982, SOMAT CELL GENET, V8, P83, DOI 10.1007/BF01538652
   SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255
   SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297
   TURNER AJ, 1987, MAMMALIAN ECTOENZYME, P211
   UMEZAWA H, 1985, J ANTIBIOT, V38, P1629, DOI 10.7164/antibiotics.38.1629
   VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001
   WATT VM, 1989, J BIOL CHEM, V264, P5480
   WILKES SH, 1985, J BIOL CHEM, V260, P3154
   WILLIAMS RK, 1990, J VIROL, V64, P3817, DOI 10.1128/JVI.64.8.3817-3823.1990
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   WU Q, 1991, P NATL ACAD SCI USA, V88, P676, DOI 10.1073/pnas.88.2.676
   WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993
NR 30
TC 460
Z9 498
U1 4
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD JUN 4
PY 1992
VL 357
IS 6377
BP 420
EP 422
DI 10.1038/357420a0
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HX172
UT WOS:A1992HX17200069
PM 1350662
OA Bronze
DA 2020-04-03
ER

PT J
AU Makela, MJ
   Puhakka, T
   Ruuskanen, O
   Leinonen, M
   Saikku, P
   Kimpimaki, M
   Blomqvist, S
   Hyypia, T
   Arstila, P
AF Makela, MJ
   Puhakka, T
   Ruuskanen, O
   Leinonen, M
   Saikku, P
   Kimpimaki, M
   Blomqvist, S
   Hyypia, T
   Arstila, P
TI Viruses and bacteria in the etiology of the common cold
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID CLINICAL SPECIMENS; DOUBLE-BLIND; INFECTIONS; PNEUMONIA; DIAGNOSIS;
   ENTEROVIRUSES; CHILDREN; SEROLOGY; ANTIBODY; ILLNESS
AB Two hundred young adults with common colds were studied during a 10-month period, Virus culture, antigen detection, PCR, and serology with paired samples were used to identify the infection, Viral etiology was established for 138 of the 200 patients (69%), Rhinoviruses were detected in 105 patients, coronavirus OC43 or 229E infection was detected in 17, influenza A or B virus was detected in 12, and single infections with parainfluenza virus, respiratory syncytial virus, adenovirus, and enterovirus were found in 14 patients, Evidence for bacterial infection was found in seven patients, Four patients had a rise in antibodies against Chlamydia pneumoniae, one had a rise in antibodies against Haemophilus influenzae, one had a rise in antibodies against Streptococcus pneumoniae, and one had immunoglobulin M antibodies against Mycoplasma pneumoniae, The results show that although approximately 50% of episodes of the common cold were caused by rhinoviruses, the etiology can vary depending on the epidemiological situation with regard to circulating viruses, Bacterial infections were rare, supporting the concept that the common cold is almost exclusively a viral disease.
C1 Univ Turku, Dept Pediat, FIN-20520 Turku, Finland.
   Univ Turku, Dept Pulm Dis & Clin Allergol, FIN-20520 Turku, Finland.
   Univ Turku, Dept Virol, FIN-20520 Turku, Finland.
   Natl Publ Hlth Inst, Oulu, Finland.
   Natl Inst Publ Hlth, Dept Virol, Helsinki, Finland.
RP Makela, MJ (reprint author), Univ Turku, Dept Pediat, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.
EM mika.makela@utu.fi
CR ALNAKIB W, 1988, LAB DIAGNOSIS INFECT, P723
   Arason VA, 1996, BMJ-BRIT MED J, V313, P387
   Arola A, 1996, J CLIN MICROBIOL, V34, P313, DOI 10.1128/JCM.34.2.313-318.1996
   Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997
   ARSTILA PP, 1988, LAB DIAGNOSIS INFECT, P60
   BURMAN LA, 1994, J INFECT DIS, V170, P220, DOI 10.1093/infdis/170.1.220
   EKMAN MR, 1993, EUR J CLIN MICROBIOL, V12, P756, DOI 10.1007/BF02098463
   Englund JA, 1996, J CLIN MICROBIOL, V34, P1649, DOI 10.1128/JCM.34.7.1649-1653.1996
   GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105
   HALONEN P, 1995, J CLIN MICROBIOL, V33, P648, DOI 10.1128/JCM.33.3.648-653.1995
   HERZOG C, 1986, ANTIVIR RES, V6, P171, DOI 10.1016/0166-3542(86)90011-2
   HIETALA J, 1988, SCAND J INFECT DIS, V20, P595, DOI 10.3109/00365548809035659
   HOVI T, 1979, J MED VIROL, V3, P313, DOI 10.1002/jmv.1890030410
   HUOVINEN P, 1989, ANN INTERN MED, V110, P612, DOI 10.7326/0003-4819-110-8-612
   HYYPIA T, 1989, J GEN VIROL, V70, P3261, DOI 10.1099/0022-1317-70-12-3261
   HYYPLA T, UNPUB
   JACKSON GG, 1973, J INFECT DIS, V127, P328, DOI 10.1093/infdis/127.3.328
   JALONEN E, 1989, J INFECTION, V19, P127, DOI 10.1016/S0163-4453(89)91864-1
   Kaiser L, 1996, LANCET, V347, P1507, DOI 10.1016/S0140-6736(96)90670-4
   KOSKINEN P, 1987, EPIDEMIOL INFECT, V99, P55, DOI 10.1017/S0950268800066863
   KRAUPP TP, 1986, J MED VIROL, V19, P123
   LEHTOMAKI K, 1988, SCAND J INFECT DIS, P1
   Mainous AG, 1996, J FAM PRACTICE, V42, P357
   MONTO AS, 1994, EPIDEMIOL REV, V16, P351, DOI 10.1093/oxfordjournals.epirev.a036158
   MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43
   Mossad SB, 1996, ANN INTERN MED, V125, P81, DOI 10.7326/0003-4819-125-2-199607150-00001
   PUTTO A, 1986, AM J DIS CHILD, V140, P1159, DOI 10.1001/archpedi.1986.02140250085040
   RUUSKANEN O, 1992, EUR J CLIN MICROBIOL, V11, P217, DOI 10.1007/BF02098083
   SAIKKU P, 1988, J INFECT DIS, V158, P1095, DOI 10.1093/infdis/158.5.1095
   vanBuchem FL, 1997, LANCET, V349, P683, DOI 10.1016/S0140-6736(96)07585-X
NR 30
TC 428
Z9 442
U1 3
U2 36
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD FEB
PY 1998
VL 36
IS 2
BP 539
EP 542
PG 4
WC Microbiology
SC Microbiology
GA YR636
UT WOS:000071515100037
PM 9466772
DA 2020-04-03
ER

PT J
AU DELMAS, B
   GELFI, J
   LHARIDON, R
   VOGEL, LK
   SJOSTROM, H
   NOREN, O
   LAUDE, H
AF DELMAS, B
   GELFI, J
   LHARIDON, R
   VOGEL, LK
   SJOSTROM, H
   NOREN, O
   LAUDE, H
TI AMINOPEPTIDASE-N IS A MAJOR RECEPTOR FOR THE ENTEROPATHOGENIC
   CORONAVIRUS TGEV
SO NATURE
LA English
DT Article
ID INTESTINAL BRUSH-BORDER; TRANSMISSIBLE GASTROENTERITIS; VIRUS;
   EXPRESSION; SEQUENCE; CLONING; KIDNEY; GENE
AB CORONAVIRUSES, like many animal viruses, are characterized by a restricted host range and tissue tropism 1. Transmissible gastroenteritis virus (TGEV), a major pathogen causing a fatal diarrhoea in newborn pig, replicates selectively in the differentiated enterocytes covering the villi of the small intestine 2. To investigate the molecular determinants of the infection, we characterized the surface molecule used by the virus for binding and entry into host cells. Here we report that aminopeptidase N, an ectoenzyme abundantly expressed at the apical membrane of the enterocytes, serves as a receptor for TGEV. Monoclonal antibodies were selected for their ability to block infection by TGEV of porcine cell lines. They recognized a brush-border membrane protein of M(r) 150K, which was identified as aminopeptidase N by amino-terminal sequencing. Two lines of evidence supported the view that the peptidase itself acts as a receptor. First, virions bound specifically to aminopeptidase N that was purified to homogeneity. Second, recombinant expression of aminopeptidase N conferred infectivity by TGEV to an otherwise non-permissive cell line.
C1 INRA,UNITE VIROL & IMMUNOL MOLEC,DOMAINE VILVERT,F-78350 JOUY EN JOSAS,FRANCE.
   PANUM INST,DEPT BIOCHEM,DK-2200 COPENHAGEN N,DENMARK.
CR DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   GORVEL JP, 1989, J CELL BIOL, V108, P2193, DOI 10.1083/jcb.108.6.2193
   GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0
   HAELTERMAN EO, 1972, J AM VET MED ASSOC, V160, P534
   HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1
   JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H
   KENNY AJ, 1982, PHYSIOL REV, V62, P91
   KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0
   KRAMERS MTC, 1979, EUR J BIOCHEM, V99, P345, DOI 10.1111/j.1432-1033.1979.tb13262.x
   KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0
   LAUDE H, 1986, J GEN VIROL, V67, P119, DOI 10.1099/0022-1317-67-1-119
   LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015
   MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8
   MAROUX S, 1973, BIOCHIM BIOPHYS ACTA, V321, P282, DOI 10.1016/0005-2744(73)90083-1
   MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9
   OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7
   OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X
   PENSAERT M, 1970, ARCH GES VIRUSFORSCH, V31, P321, DOI 10.1007/BF01253767
   SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761
   SJOSTROM H, 1978, EUR J BIOCHEM, V88, P503, DOI 10.1111/j.1432-1033.1978.tb12476.x
   SJOSTROM H, 1982, EUR J BIOCHEM, V122, P245, DOI 10.1111/j.1432-1033.1982.tb05873.x
NR 21
TC 428
Z9 460
U1 5
U2 22
PU MACMILLAN MAGAZINES LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW
SN 0028-0836
J9 NATURE
JI Nature
PD JUN 4
PY 1992
VL 357
IS 6377
BP 417
EP 420
DI 10.1038/357417a0
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HX172
UT WOS:A1992HX17200068
PM 1350661
OA Bronze
DA 2020-04-03
ER

PT J
AU Nicholls, JM
   Poon, LLM
   Lee, KC
   Ng, WF
   Lai, ST
   Leung, CY
   Chu, CM
   Hui, PK
   Mak, KL
   Lim, W
   Yan, KW
   Chan, KH
   Tsang, NC
   Guan, Y
   Yuen, KY
   Peiris, JSM
AF Nicholls, JM
   Poon, LLM
   Lee, KC
   Ng, WF
   Lai, ST
   Leung, CY
   Chu, CM
   Hui, PK
   Mak, KL
   Lim, W
   Yan, KW
   Chan, KH
   Tsang, NC
   Guan, Y
   Yuen, KY
   Peiris, JSM
TI Lung pathology of fatal severe acute respiratory syndrome
SO LANCET
LA English
DT Article
ID A H5N1 VIRUS; CLINICAL-FEATURES; HUMAN MACROPHAGES; HUMAN-DISEASE;
   INFLUENZA; PNEUMONIA
AB Background Severe acute respiratory syndrome (SARS) is a novel infectious disease with global impact. A virus from the family Coronaviridae has been identified as the cause, but the pathogenesis is still unclear.
   Methods Post-mortem tissue samples from six patients who died from SARS in February and March, 2003, and an open lung biopsy from one of these patients were studied by histology and virology. Only one full autopsy was done. Evidence of infection with the SARS-associated coronavirus (SARS-CoV) and human metapneumovirus was sought by reverse-transcriptase PCR and serology. Pathological samples were examined by light and electron microscopy and immunohistochemistry.
   Findings All six patients had serological evidence of recent infection with SARS-CoV. Diffuse alveolar damage was common but not universal. Morphological changes identified were bronchial epithelial denudation, loss of cilia, and squamous metaplasia. Secondary bacterial pneumonia was present in one case. A giant-cell infiltrate was seen in four patients, with a pronounced increase in macrophages in the alveoli and the interstitium of the lung. Haemophagocytosis was present in two patients. The alveolar pneumocytes also showed cytomegaly with granular amphophilic cytoplasm. The patient for whom full autopsy was done had atrophy of the white pulp of the spleen. Electron microscopy revealed viral particles in the cytoplasm of epithelial cells corresponding to coronavirus.
   Interpretation SARS is associated with epithelial-cell proliferation and an increase in macrophages in the lung. The presence of haemophagocytosis supports the contention that cytokine dysregulation may account, at least partly, for the severity of the clinical disease. The case definition of SARS should acknowledge the range of lung pathology associated with this disease.
C1 Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   Princess Margaret Hosp, Dept Pathol & Med, Kowloon, Hong Kong, Peoples R China.
   Yan Chai Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China.
   United Christian Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China.
   United Christian Hosp, Dept Med, Kowloon, Hong Kong, Peoples R China.
   Kwong Wah Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China.
   Govt Virus Unit, Kowloon, Hong Kong, Peoples R China.
   Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China.
   Queen Elizabeth Hosp, Dept Microbiol, Kowloon, Hong Kong, Peoples R China.
RP Peiris, JSM (reprint author), Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
EM malik@hkucc.hku.hk
RI Poon, Leo/C-4382-2009; Yuen, Kwok Yung/C-4465-2009; Nicholls, John
   Malcolm/C-4375-2009
OI Poon, Leo/0000-0002-9101-7953; Nicholls, John
   Malcolm/0000-0001-7217-7444; Yuen, Kwok-yung/0000-0002-2083-1552; Chu,
   Chung Ming/0000-0002-9959-1271
FU PHS HHSUnited States Public Health Service [A195357]
CR Bellingan GJ, 2002, THORAX, V57, P540, DOI 10.1136/thorax.57.6.540
   Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7
   Collins AR, 1998, ADV EXP MED BIOL, V440, P635
   Corse E, 2002, J VIROL, V76, P1273, DOI 10.1128/JVI.76.3.1273-1284.2002
   FISMAN DN, 2000, EMERG INFECT DIS, V6, P60
   Fouchier RAM, 2000, J CLIN MICROBIOL, V38, P4096, DOI 10.1128/JCM.38.11.4096-4101.2000
   Garantziotis S, 2001, CHEST, V119, P1277, DOI 10.1378/chest.119.4.1277
   HALBUR PG, 1993, J VET DIAGN INVEST, V5, P184, DOI 10.1177/104063879300500207
   Halbur PG, 2003, VET REC, V152, P358, DOI 10.1136/vr.152.12.358
   HALBUR PG, 1995, VET PATHOL, V32, P648, DOI 10.1177/030098589503200606
   Kim EA, 2002, RADIOGRAPHICS, V22, pS137, DOI 10.1148/radiographics.22.suppl_1.g02oc15s137
   KSIAZEK TG, IN PRESS N ENGL J ME
   Lai KN, 2003, J PATHOL, V199, P496, DOI 10.1002/path.1291
   LEE N, IN PRESS N ENGL MED
   Mitchell S, 2003, J CLIN VIROL, V26, P331, DOI 10.1016/S1386-6532(02)00082-3
   MYERS JL, 1994, PULMONARY PATHOLOGY, P57
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   PENSAERT MB, 1989, VIRUS INFECTIONS POR, P154
   POUTANEN SM, IN PRESS N ENGL J ME
   To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N
   TSANG KW, IN PRESS N ENGL J ME
   *WHO, CUM NUM REP CAS SEV
   *WHO, 2003, WKLY EPIDEMIOL REC, V78, P81
   World Health Organization, CAS DEF SURV SEV AC
   Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9
NR 25
TC 412
Z9 481
U1 12
U2 42
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 24
PY 2003
VL 361
IS 9371
BP 1773
EP 1778
DI 10.1016/S0140-6736(03)13413-7
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 682CY
UT WOS:000183074800009
PM 12781536
OA Bronze
DA 2020-04-03
ER

PT J
AU Allander, T
   Jartti, T
   Gupta, S
   Niesters, HGM
   Lehtinen, P
   Osterback, R
   Vuorinen, T
   Waris, M
   Bjerkner, A
   Tiveljung-Lindell, A
   van den Hoogen, BG
   Hyypia, T
   Ruuskanen, O
AF Allander, Tobias
   Jartti, Tuomas
   Gupta, Shawon
   Niesters, Hubert G. M.
   Lehtinen, Pasi
   Osterback, Riikka
   Vuorinen, Tytti
   Waris, Matti
   Bjerkner, Annelie
   Tiveljung-Lindell, Annika
   van den Hoogen, Bernadette G.
   Hyypia, Timo
   Ruuskanen, Olli
TI Human bocavirus and acute wheezing in children
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; HUMAN METAPNEUMOVIRUS; FREQUENT DETECTION;
   CORONAVIRUS HKU1; HUMAN PARVOVIRUS; YOUNG-CHILDREN; INFECTION;
   RHINOVIRUS; DISEASE; IDENTIFICATION
AB Background. Human bocavirus is a newly discovered parvovirus. It has been detected primarily in children with acute lower respiratory tract infection, but its occurrence, clinical profile, and role as a causative agent of respiratory tract disease are not clear.
   Methods. We investigated the presence of human bocavirus by quantitative polymerase chain reaction of nasopharyngeal aspirate specimens and selected serum samples obtained from 259 children (median age, 1.6 years) who had been hospitalized for acute expiratory wheezing. The samples were analyzed for 16 respiratory viruses by polymerase chain reaction, virus culture, antigen detection, and serological assays.
   Results. At least 1 potential etiologic agent was detected in 95% of children, and 11 agent was detected in 34% of children. Human bocavirus was detected in 49 children (19%). A large proportion of the cases were mixed infections with other viruses, but human bocavirus was the only virus detected in 12 children (5%). High viral loads of human bocavirus were noted mainly in the absence of other viral agents, suggesting a causative role for acute wheezing. In addition, infections that had uncertain clinical relevance and low viral loads were prevalent. Human bocavirus DNA was frequently detected in serum specimens obtained from patients with acute wheezing, suggesting systemic infection.
   Conclusions. Human bocavirus is prevalent among children with acute wheezing and can cause systemic infection. Results suggest a model for bocavirus infection in which high viral loads are potentially associated with respiratory symptoms and low viral loads indicate asymptomatic shedding. Therefore, quantitative polymerase chain reaction analysis may be important for additional studies of human bocavirus.
C1 Karolinska Univ Hosp, Dept Clin Microbiol, SE-17176 Stockholm, Sweden.
   Karolinska Inst, Karolinska Univ Hosp, Dept Microbiol Tumor & Cell Biol, SE-17176 Stockholm, Sweden.
   Univ Turku, Dept Virol, Turku, Finland.
   Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland.
   Erasmus MC, Dept Virol, Rotterdam, Netherlands.
RP Allander, T (reprint author), Karolinska Univ Hosp, Dept Clin Microbiol, L2-02, SE-17176 Stockholm, Sweden.
EM tobias.allander@karolinska.se
RI Niesters, Hubert/AAH-6808-2019; van den Hoogen, Bernadette/J-5461-2013;
   Waris, Matti E/A-6418-2008
OI Gupta, Shawon/0000-0002-8501-6962; Waris, Matti/0000-0002-6747-0889;
   Niesters, Hubert/0000-0002-1758-0430
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Arden KE, 2006, J MED VIROL, V78, P1232, DOI 10.1002/jmv.20689
   Arnold JC, 2006, CLIN INFECT DIS, V43, P283, DOI 10.1086/505399
   Bastien N, 2006, EMERG INFECT DIS, V12, P848, DOI 10.3201/eid1205.051424
   Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368
   CARMICHAEL LE, 1994, J VET DIAGN INVEST, V6, P165, DOI 10.1177/104063879400600206
   Choi EH, 2006, CLIN INFECT DIS, V43, P585, DOI 10.1086/506350
   DURHAM PJK, 1985, RES VET SCI, V38, P209, DOI 10.1016/S0034-5288(18)31828-9
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Foulongne V, 2006, EMERG INFECT DIS, V12, P862, DOI 10.3201/eid1205.051523
   Fredricks DN, 1996, CLIN MICROBIOL REV, V9, P18, DOI 10.1128/CMR.9.1.18
   Greensill J, 2003, EMERG INFECT DIS, V9, P372, DOI 10.3201/eid0903.020289
   Heim A, 2003, J MED VIROL, V70, P228, DOI 10.1002/jmv.10382
   Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629
   Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027
   Jartti T, 2006, PEDIATR INFECT DIS J, V25, P482, DOI 10.1097/01.inf.0000215226.69696.0c
   Kesebir D, 2006, J INFECT DIS, V194, P1276, DOI 10.1086/508213
   Lefrere JJ, 2005, BLOOD, V106, P2890, DOI 10.1182/blood-2005-03-1053
   Lindblom A, 2005, CLIN INFECT DIS, V41, P1201, DOI 10.1086/444503
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9
   Ma XM, 2006, J CLIN MICROBIOL, V44, P1132, DOI 10.1128/JCM.44.3.1132-1134.2006
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC
   Semple MG, 2005, J INFECT DIS, V191, P382, DOI 10.1086/426457
   Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   van Doornum GJJ, 2003, J CLIN MICROBIOL, V41, P576, DOI 10.1128/JCM.41.2.576-580.2003
   Ward CL, 2004, J CLIN VIROL, V29, P179, DOI 10.1016/S1386-6532(03)00122-7
   Weissbrich B, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-109
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
NR 32
TC 398
Z9 454
U1 5
U2 21
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 1
PY 2007
VL 44
IS 7
BP 904
EP 910
DI 10.1086/512196
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 143KY
UT WOS:000244721600003
PM 17342639
OA Bronze
DA 2020-04-03
ER

PT J
AU Storch, MK
   Stefferl, A
   Brehm, U
   Weissert, R
   Wallstrom, E
   Kerschensteiner, M
   Olsson, T
   Linington, C
   Lassmann, H
AF Storch, MK
   Stefferl, A
   Brehm, U
   Weissert, R
   Wallstrom, E
   Kerschensteiner, M
   Olsson, T
   Linington, C
   Lassmann, H
TI Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the
   spectrum of multiple sclerosis pathology
SO BRAIN PATHOLOGY
LA English
DT Article
ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; DEMYELINATING
   ENCEPHALOMYELITIS; CELL-DEATH; LEWIS RAT; PATHOGENESIS; PATTERNS;
   ANTIBODY; CORONAVIRUS; EXPRESSION; ANTIGEN
AB Multiple sclerosis is a chronic inflammatory disease characterized by perivenous inflammation and focal destruction of myelin, Many attempts have been undertaken previously to create animal models of chronic inflammatory demyelinating diseases through autoimmunity or virus infection. Recently, however, a new model of myelin oligodendrocyte glycoprotein (MOG) induced autoimmune encephalomyelitis became available, which, in a very standardized and predictable way, leads to chronic (relapsing or progressive) disease and widespread CNS demyelination.
   In the present study we actively induced MOG-experimental autoimmune encephalomyelitis (EAE) in different inbred rat strains using different immunization protocols, The pathology found in our models closely reflects the spectrum of multiple sclerosis (MS) pathology: Classical MS as well as variants such as optic neuritis, Devic's disease and Marburg's type of acute MS are mimicked in rats immunized with MOG antigen. Furthermore we demonstrate, that by using the proper strain/sensitization regime, subforms of MS such as for instance neuromyelitis optica can be reproducibly induced, Our study further supports the notion, that incidence and expression of the disease in this model, alike the situation in multiple sclerosis, is determined by genetic and environmental factors.
C1 Univ Vienna, Inst Neurol, A-1090 Vienna, Austria.
   Max Planck Inst Neurobiol, D-82152 Martinsried, Germany.
   Karolinska Hosp, Ctr Mol Med, Neuroimmunol Unit, S-17176 Stockholm, Sweden.
RP Lassmann, H (reprint author), Univ Vienna, Inst Neurol, Schwarzspanierstr 17, A-1090 Vienna, Austria.
RI Linington, Chris/M-4883-2019; Lassmann, Hans/Z-2269-2019; Weissert,
   Robert/B-2585-2009; Weissert, Robert/AAA-4791-2019
OI Lassmann, Hans/0000-0001-8617-5052; Weissert,
   Robert/0000-0002-1295-1271; Linington, Christopher/0000-0002-0937-9526
CR Adelmann M, 1995, J NEUROIMMUNOL, V63, P17, DOI 10.1016/0165-5728(95)00124-7
   AMOR S, 1994, J IMMUNOL, V153, P4349
   Balo J, 1928, ARCH NEURO PSYCHIATR, V19, P242, DOI 10.1001/archneurpsyc.1928.02210080044002
   BaracLatas V, 1997, GLIA, V19, P1, DOI 10.1002/(SICI)1098-1136(199701)19:1<1::AID-GLIA1>3.0.CO;2-5
   BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307
   Bonetti B, 1997, ANN NEUROL, V42, P74, DOI 10.1002/ana.410420113
   Charcot J., 1848, GAZ HOP PARIS, V41, P554
   COMPSTON A, 1992, CURR OPIN NEUROL NEU, V5, P175
   DALCANTO MC, 1982, ANN NEUROL, V11, P109, DOI 10.1002/ana.410110202
   DALCANTO MC, 1995, MICROSC RES TECHNIQ, V32, P215, DOI 10.1002/jemt.1070320305
   DEROSBO NK, 1990, J NEUROCHEM, V55, P583
   Devic E, 1894, B MED PARIS, V8, P1033
   DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361
   EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603
   Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472
   FAZAKERLEY JK, 1993, ADV VIRUS RES, V42, P249, DOI 10.1016/S0065-3527(08)60087-1
   GAY D, 1991, BRAIN, V114, P557, DOI 10.1093/brain/114.1.557
   Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054
   Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469
   HEDRICH H, 1990, GENETIC MONITORING I
   JOHNS TG, 1995, J IMMUNOL, V154, P5536
   JORDAN CA, 1989, GLIA, V2, P318, DOI 10.1002/glia.440020505
   LASSMANN H, 1988, ACTA NEUROPATHOL, V75, P566, DOI 10.1007/BF00686201
   Lassmann H, 1983, Schriftenr Neurol, V25, P1
   LASSMANN H, 1998, IMMUNOPATHOLOGY MULT
   LININGTON C, 1988, AM J PATHOL, V130, P443
   Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x
   Lumsden C.E., 1970, HDB CLINICAL NEUROLO, P217
   Marburg O., 1906, JB PSYCHIAT NEUROL, V27, P211
   ORiordan JI, 1996, J NEUROL NEUROSUR PS, V60, P382, DOI 10.1136/jnnp.60.4.382
   OZAWA K, 1994, BRAIN, V117, P1311, DOI 10.1093/brain/117.6.1311
   PIDDLESDEN SJ, 1994, J IMMUNOL, V152, P5477
   PRINEAS JW, 1981, ANN NEUROL, V10, P149, DOI 10.1002/ana.410100205
   Prineas JW, 1985, HDB CLIN NEUROLOGY, P337
   RAINE CS, 1985, HDB CLIN NEUROL, V3, P429
   Rivers TM, 1933, J EXP MED, V58, P39, DOI 10.1084/jem.58.1.39
   RODRIGUEZ M, 1994, J NEUROPATH EXP NEUR, V53, P136, DOI 10.1097/00005072-199403000-00004
   Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464
   Schilder P, 1912, Z GESAMTE NEUROL PSY, V10, P1, DOI 10.1007/BF02901445
   STONE SH, 1965, ANN NY ACAD SCI, V122, P227
   Storch M, 1997, CURR OPIN NEUROL, V10, P186, DOI 10.1097/00019052-199706000-00004
   Storch MK, 1998, ANN NEUROL, V43, P465, DOI 10.1002/ana.410430409
   VASS K, 1992, ANN NEUROL, V32, P198, DOI 10.1002/ana.410320212
   VASS K, 1986, ACTA NEUROPATHOL, V70, P149, DOI 10.1007/BF00691433
NR 44
TC 396
Z9 403
U1 0
U2 8
PU INT SOC NEUROPATHOLOGY
PI PITTSBURGH
PA 200 LOTHROP ST A506, PITTSBURGH, PA 15213 USA
SN 1015-6305
J9 BRAIN PATHOL
JI Brain Pathol.
PD OCT
PY 1998
VL 8
IS 4
BP 681
EP 694
DI 10.1111/j.1750-3639.1998.tb00194.x
PG 14
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 126MP
UT WOS:000076297500009
PM 9804377
DA 2020-04-03
ER

PT J
AU Imai, Y
   Kuba, K
   Rao, S
   Huan, Y
   Guo, F
   Guan, B
   Yang, P
   Sarao, R
   Wada, T
   Leong-Poi, H
   Crackower, MA
   Fukamizu, A
   Hui, CC
   Hein, L
   Uhlig, S
   Slutsky, AS
   Jiang, CY
   Penninger, JM
AF Imai, Y
   Kuba, K
   Rao, S
   Huan, Y
   Guo, F
   Guan, B
   Yang, P
   Sarao, R
   Wada, T
   Leong-Poi, H
   Crackower, MA
   Fukamizu, A
   Hui, CC
   Hein, L
   Uhlig, S
   Slutsky, AS
   Jiang, CY
   Penninger, JM
TI Angiotensin-converting enzyme 2 protects from severe acute lung failure
SO NATURE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; DISTRESS-SYNDROME; FUNCTIONAL RECEPTOR; SARS
   CORONAVIRUS; DEFICIENT MICE; HONG-KONG; EXPRESSION; IDENTIFICATION;
   REGULATOR; CLONING
AB Acute respiratory distress syndrome (ARDS), the most severe form of acute lung injury, is a devastating clinical syndrome with a high mortality rate (30-60%) (refs 1-3). Predisposing factors for ARDS are diverse(1,3) and include sepsis, aspiration, pneumonias and infections with the severe acute respiratory syndrome (SARS) corona-virus(4,5). At present, there are no effective drugs for improving the clinical outcome of ARDS(1-3). Angiotensin-converting enzyme (ACE) and ACE2 are homologues with different key functions in the renin-angiotensin system(6-8). ACE cleaves angiotensin I to generate angiotensin II, whereas ACE2 inactivates angiotensin II and is a negative regulator of the system. ACE2 has also recently been identified as a potential SARS virus receptor and is expressed in lungs(9,10). Here we report that ACE2 and the angiotensin II type 2 receptor (AT(2)) protect mice from severe acute lung injury induced by acid aspiration or sepsis. However, other components of the renin-angiotensin system, including ACE, angiotensin II and the angiotensin II type 1a receptor (AT(1)a), promote disease pathogenesis, induce lung oedemas and impair lung function. We show that mice deficient for Ace show markedly improved disease, and also that recombinant ACE2 can protect mice from severe acute lung injury. Our data identify a critical function for ACE2 in acute lung injury, pointing to a possible therapy for a syndrome affecting millions of people worldwide every year.
C1 Austrian Acad Sci, IMBA, Inst Mol Biotechnol, A-1030 Vienna, Austria.
   Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China.
   Peking Union Med Coll, Beijing 100005, Peoples R China.
   St Michaels Hosp, Dept Cardiol, Toronto, ON M5B 1W8, Canada.
   Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Montreal, PQ H3R 4P8, Canada.
   Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.
   Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada.
   Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada.
   Univ Freiburg, Dept Pharmacol, D-79104 Freiburg, Germany.
   Res Ctr Borstel, Div Pulm Pharmacol, D-23845 Borstel, Germany.
   Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada.
   Univ Toronto, St Michaels Hosp, Interdepartmental Div Crit Care, Toronto, ON M5B 1W8, Canada.
RP Penninger, JM (reprint author), Austrian Acad Sci, IMBA, Inst Mol Biotechnol, A-1030 Vienna, Austria.
EM Josef.penninger@imba.oeaw.ac.at
RI Slutsky, Arthur S/A-6013-2008; Slutsky, Arthur/M-3325-2019; fukamizu,
   akiyoshi/J-5350-2012; Uhlig, Stefan/A-7290-2014; Penninger, Josef
   M/I-6860-2013
OI Slutsky, Arthur S/0000-0002-6063-3876; fukamizu,
   akiyoshi/0000-0002-8786-6020; Uhlig, Stefan/0000-0003-2332-1280;
   Penninger, Josef M/0000-0002-8194-3777; Guo, Feng/0000-0002-4506-7618
CR Boehm M, 2002, NEW ENGL J MED, V347, P1795, DOI 10.1056/NEJMcibr022472
   CORVOL P, 1995, METHOD ENZYMOL, V248, P283
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   GASC JM, 1994, HYPERTENSION, V24, P531, DOI 10.1161/01.HYP.24.5.531
   Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   HANSEN TN, 1985, J APPL PHYSIOL, V58, P812
   HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0
   Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419
   HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182
   Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104
   INAGAMI T, 1995, ADV EXP MED BIOL, V377, P311
   KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086
   Martin EL, 2003, AM J PHYSIOL-LUNG C, V285, pL1222, DOI 10.1152/ajplung.00141.2003
   Nagase T, 2000, NAT IMMUNOL, V1, P42
   Plante GE, 1996, CAN J PHYSIOL PHARM, V74, P824, DOI 10.1139/cjpp-74-7-824
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Roy BJ, 1996, AM J PHYSIOL-HEART C, V271, pH222
   Skeggs L T, 1980, Adv Exp Med Biol, V130, P1
   SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Vincent JL, 2003, CRIT CARE MED, V31, pS296, DOI 10.1097/01.CCM.0000057906.89552.8F
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
NR 30
TC 390
Z9 441
U1 36
U2 77
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUL 7
PY 2005
VL 436
IS 7047
BP 112
EP 116
DI 10.1038/nature03712
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 942QJ
UT WOS:000230296600049
PM 16001071
DA 2020-04-03
ER

PT J
AU Traggiai, E
   Becker, S
   Subbarao, K
   Kolesnikova, L
   Uematsu, Y
   Gismondo, MR
   Murphy, BR
   Rappuoli, R
   Lanzavecchia, A
AF Traggiai, E
   Becker, S
   Subbarao, K
   Kolesnikova, L
   Uematsu, Y
   Gismondo, MR
   Murphy, BR
   Rappuoli, R
   Lanzavecchia, A
TI An efficient method to make human monoclonal antibodies from memory B
   cells: potent neutralization of SARS coronavirus
SO NATURE MEDICINE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; SYNCYTIAL VIRUS-INFECTION; HONG-KONG; MOUSE;
   IDENTIFICATION; GENERATION; DISEASES; MYELOMA; STRAINS; MICE
AB Passive serotherapy can confer immediate protection against microbial infection, but methods to rapidly generate human neutralizing monoclonal antibodies are not yet available. We have developed an improved method for Epstein-Barr virus transformation of human B cells. We used this method to analyze the memory repertoire of a patient who recovered from severe acute respiratory syndrome coronavirus (SARS-CoV) infection and to isolate monoclonal antibodies specific for different viral proteins, including 35 antibodies with in vitro neutralizing activity ranging from 10(-8)M to 10(-11)M. One such antibody confers protection in vivo in a mouse model of SARS-CoV infection. These results show that it is possible to interrogate the memory repertoire of immune donors to rapidly and efficiently isolate neutralizing antibodies that have been selected in the course of natural infection.
C1 Inst Res Biomed, CH-6500 Belllinzona, Switzerland.
   Inst Virol, D-35037 Marburg, Germany.
   NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   Chiron Vaccines, I-53100 Siena, Italy.
   Osped L Sacco, Ist Microbiol, I-20175 Milan, Italy.
RP Lanzavecchia, A (reprint author), Inst Res Biomed, Via Vela 6, CH-6500 Belllinzona, Switzerland.
EM lanzavecchia@irb.unisi.ch
RI traggiai, elisabetta/A-2316-2009; Gismondo, Maria Rita/I-3965-2017
OI Subbarao, Kanta/0000-0003-1713-3056; Gismondo, Maria
   Rita/0000-0001-6926-8660
CR BECKER S, 1992, MED MICROBIOL IMMUN, V181, P43, DOI 10.1007/BF00193395
   BEHRING E, 1965, DEUT MED WOCHENSCHR, V90, P2183
   Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071
   Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   GEBAUER F, 1991, VIROLOGY, V183, P225, DOI 10.1016/0042-6822(91)90135-X
   GIACHINO C, 1995, J EXP MED, V181, P1245, DOI 10.1084/jem.181.3.1245
   GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207
   Green LL, 1999, J IMMUNOL METHODS, V231, P11, DOI 10.1016/S0022-1759(99)00137-4
   Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944
   Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115
   JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0
   Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   Karpas A, 2001, P NATL ACAD SCI USA, V98, P1799, DOI 10.1073/pnas.98.4.1799
   Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   KOZBOR D, 1981, J IMMUNOL, V127, P1275
   KOZBOR D, 1982, HYBRIDOMA, V1, P323, DOI 10.1089/hyb.1.1982.1.323
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0
   Perri S, 2003, J VIROL, V77, P10394, DOI 10.1128/JVI.77.19.10394-10403.2003
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Stack AM, 2000, VACCINE, V18, P1412, DOI 10.1016/S0264-410X(99)00399-0
   STEINITZ M, 1977, NATURE, V269, P420, DOI 10.1038/269420a0
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
NR 30
TC 389
Z9 418
U1 3
U2 31
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD AUG
PY 2004
VL 10
IS 8
BP 871
EP 875
DI 10.1038/nm1080
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 843DK
UT WOS:000223055700043
PM 15247913
OA Bronze
DA 2020-04-03
ER

PT J
AU Thiel, V
   Ivanov, KA
   Putics, A
   Hertzig, T
   Schelle, B
   Bayer, S
   Weissbrich, B
   Snijder, EJ
   Rabenau, H
   Doerr, HW
   Gorbalenya, AE
   Ziebuhr, J
AF Thiel, V
   Ivanov, KA
   Putics, A
   Hertzig, T
   Schelle, B
   Bayer, S
   Weissbrich, B
   Snijder, EJ
   Rabenau, H
   Doerr, HW
   Gorbalenya, AE
   Ziebuhr, J
TI Mechanisms and enzymes involved in SARS coronavirus genome expression
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; PAPAIN-LIKE PROTEINASE; 229E 3C-LIKE
   PROTEINASE; SEQUENCE-ANALYSIS; RNA-SYNTHESIS; VIRUS; IDENTIFICATION;
   POLYPROTEIN; TRANSCRIPTION; PROTEASES
AB A novel coronavirus is the causative agent of the current epidemic of severe acute respiratory syndrome (SARS). Coronaviruses are exceptionally large RNA viruses and employ complex regulatory mechanisms to express their genomes. Here, we determined the sequence of SARS coronavinus (SARS-CoV), isolate Frankfurt 1, and characterized key RNA elements and protein functions involved in viral genome expression. Important regulatory mechanisms, such as the (discontinuous) synthesis of eight subgenomic mRNAs, ribosomal frameshifting and post-translational proteolytic processing, were addressed. Activities of three SARS coronavirus enzymes, the helicase and two cysteine proteinases, which are known to be critically involved in replication, transcription and/or post-translational polyprotein processing, were characterized. The availability of recombinant forms of key replicative enzymes of SARS coronavirus should pave the way for high-throughput screening approaches to identify candidate inhibitors in compound libraries.
C1 Univ Wurzburg, Inst Immunol & Virol, D-97078 Wurzburg, Germany.
   Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, Leiden, Netherlands.
   Goethe Univ Frankfurt, Inst Med Virol, D-6000 Frankfurt, Germany.
RP Ziebuhr, J (reprint author), Univ Wurzburg, Inst Immunol & Virol, Versbacher Str 7, D-97078 Wurzburg, Germany.
EM j.ziebuhr@mail.uni-wuerzburg.de
RI Gorbalenya, Alexander E/J-4818-2012; Thiel, Volker/AAI-2391-2019;
   Snijder, Eric J./E-6073-2018; Ziebuhr, John/G-7669-2015
OI Gorbalenya, Alexander E/0000-0002-4967-7341; Snijder, Eric
   J./0000-0003-3297-2309; Ziebuhr, John/0000-0002-5741-8825; Thiel,
   Volker/0000-0002-5783-0887
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   BAKER SC, 1989, J VIROL, V63, P3693, DOI 10.1128/JVI.63.9.3693-3699.1989
   Bonilla PJ, 1997, J VIROL, V71, P900, DOI 10.1128/JVI.71.2.900-909.1997
   Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   ELEOUET JF, 1995, VIROLOGY, V206, P817, DOI 10.1006/viro.1995.1004
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713
   GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6
   Gorbalenya AE, 2001, ADV EXP MED BIOL, V494, P1
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hegyi A, 2002, J GEN VIROL, V83, P581, DOI 10.1099/0022-1317-83-3-581
   Herold J, 1998, J VIROL, V72, P910, DOI 10.1128/JVI.72.2.910-918.1998
   HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419
   Heusipp G, 1997, J VIROL, V71, P5631, DOI 10.1128/JVI.71.7.5631-5634.1997
   Kanjanahaluethai A, 2000, J VIROL, V74, P7911, DOI 10.1128/JVI.74.17.7911-7921.2000
   Kocherhans R, 2001, VIRUS GENES, V23, P137, DOI 10.1023/A:1011831902219
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lai M.M.C., 2001, FIELDS VIROLOGY, P1163
   Lim KP, 2000, J VIROL, V74, P1674, DOI 10.1128/JVI.74.4.1674-1685.2000
   Liu D X, 1995, Adv Exp Med Biol, V380, P413
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Pasternak AO, 2001, EMBO J, V20, P7220, DOI 10.1093/emboj/20.24.7220
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097
   Seybert A, 2000, J VIROL, V74, P9586, DOI 10.1128/JVI.74.20.9586-9593.2000
   Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728
   Siddell SG, 1995, CORONAVIRIDAE
   SNIJDER EJ, 2003, IN PRESS J MOL BIOL
   Thiel V, 1997, ANAL BIOCHEM, V252, P62, DOI 10.1006/abio.1997.2307
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   THIEL V, 1994, J GEN VIROL, V75, P3041, DOI 10.1099/0022-1317-75-11-3041
   van Dinten LC, 2000, J VIROL, V74, P5213, DOI 10.1128/JVI.74.11.5213-5223.2000
   van Vliet ALW, 2002, EMBO J, V21, P6571, DOI 10.1093/emboj/cdf635
   WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x
   Yao Z, 1992, PCR Methods Appl, V1, P205
   Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   ZIEBUHR J, 1995, J VIROL, V69, P4331, DOI 10.1128/JVI.69.7.4331-4338.1995
   Ziebuhr J, 1999, J VIROL, V73, P177, DOI 10.1128/JVI.73.1.177-185.1999
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
NR 50
TC 389
Z9 429
U1 10
U2 36
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD SEP
PY 2003
VL 84
BP 2305
EP 2315
DI 10.1099/vir.0.19424-0
PN 9
PG 11
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 715VM
UT WOS:000184993100003
PM 12917450
OA Bronze
DA 2020-04-03
ER

PT J
AU Chou, KC
AF Chou, Kuo-Chen
TI Impacts of Bioinformatics to Medicinal Chemistry
SO MEDICINAL CHEMISTRY
LA English
DT Article
DE PseAAC; PseKNC; Multi-label systems; Graphical rules; Wenxiang diagram;
   Drug and target-protein interaction; Distorted key theory and peptide
   drugs
ID AMINO-ACID-COMPOSITION; PROTEIN SUBCELLULAR LOCATION; CORONAVIRUS MAIN
   PROTEINASE; HIV-1 REVERSE-TRANSCRIPTASE; STRUCTURAL CLASS PREDICTION;
   TUPLE NUCLEOTIDE COMPOSITION; SEQUENCE-BASED PREDICTOR; SUPPORT VECTOR
   MACHINE; STATE ENZYME-KINETICS; S-NITROSYLATION SITES
AB Facing the explosive growth of biological sequence data, such as those of protein/peptide and DNA/RNA, generated in the post-genomic age, many bioinformatical and mathematical approaches as well as physicochemical concepts have been introduced to timely derive useful informations from these biological sequences, in order to stimulate the development of medical science and drug design. Meanwhile, because of the rapid penetrations from these disciplines, medicinal chemistry is currently undergoing an unprecedented revolution. In this minireview, we are to summarize the progresses by focusing on the following six aspects. (1) Use the pseudo amino acid composition or PseAAC to predict various attributes of protein/peptide sequences that are useful for drug development. (2) Use pseudo oligonucleotide composition or PseKNC to do the same for DNA/RNA sequences. (3) Introduce the multi-label approach to study those systems where the constituent elements bear multiple characters and functions. (4) Utilize the graphical rules and "wenxiang" diagrams to analyze complicated biomedical systems. (5) Recent development in identifying the interactions of drugs with its various types of target proteins in cellular networking. (6) Distorted key theory and its application in developing peptide drugs.
C1 [Chou, Kuo-Chen] Gordon Life Sci Inst, Boston, MA 02478 USA.
   [Chou, Kuo-Chen] King Abdulaziz Univ, CEGMR, Jeddah 21589, Saudi Arabia.
RP Chou, KC (reprint author), Gordon Life Sci Inst, Boston, MA 02478 USA.
EM kcchou@gordonlifescience.org
RI Chou, Kuo-Chen/A-8340-2009
CR ALTHAUS IW, 1994, EXPERIENTIA, V50, P23, DOI 10.1007/BF01992044
   ALTHAUS IW, 1993, J BIOL CHEM, V268, P14875
   Althaus IW, 1996, BIOCHEM PHARMACOL, V51, P743, DOI 10.1016/0006-2952(95)02390-9
   ALTHAUS IW, 1993, J BIOL CHEM, V268, P6119
   ALTHAUS IW, 1994, BIOCHEM PHARMACOL, V47, P2017, DOI 10.1016/0006-2952(94)90077-9
   ALTHAUS IW, 1993, BIOCHEMISTRY-US, V32, P6548, DOI 10.1021/bi00077a008
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Andraos J, 2008, CAN J CHEM, V86, P342, DOI 10.1139/V08-020
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028
   Berardi MJ, 2011, NATURE, V476, P109, DOI 10.1038/nature10257
   Cai L, 2011, MED CHEM, V7, P121, DOI 10.2174/157340611794859343
   Cai YD, 2004, BIOINFORMATICS, V20, P1151, DOI 10.1093/bioinformatics/bth054
   Cai YD, 1999, ANAL BIOCHEM, V268, P407, DOI 10.1006/abio.1998.2992
   Cai YD, 2002, J COMPUT CHEM, V23, P267, DOI 10.1002/jcc.10017
   Call ME, 2010, NAT IMMUNOL, V11, P1023, DOI 10.1038/ni.1943
   Cao DS, 2013, BIOINFORMATICS, V29, P960, DOI 10.1093/bioinformatics/btt072
   CARLACCI L, 1991, BIOCHEMISTRY-US, V30, P4389, DOI 10.1021/bi00232a004
   Chang TH, 2013, J COMPUT AID MOL DES, V27, P91, DOI 10.1007/s10822-012-9628-0
   Chen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035254
   Chen W, 2015, BIOINFORMATICS, V31, P119, DOI 10.1093/bioinformatics/btu602
   Chen W, 2014, ANAL BIOCHEM, V462, P76, DOI 10.1016/j.ab.2014.06.022
   Chen W, 2014, BIOMED RES INT, DOI 10.1155/2014/623149
   Chen W, 2014, ANAL BIOCHEM, V456, P53, DOI 10.1016/j.ab.2014.04.001
   Chen W, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1450
   Chen W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047843
   Chen YK, 2013, J THEOR BIOL, V318, P1, DOI 10.1016/j.jtbi.2012.10.033
   CHOU JJ, 1993, BIOPOLYMERS, V33, P1405, DOI 10.1002/bip.360330910
   CHOU JJ, 1993, J PROTEIN CHEM, V12, P291, DOI 10.1007/BF01028191
   Chou K.C., 2009, OPEN BIOINFORMATICS, V3, P31
   Chou KC, 1998, BIOCHEM BIOPH RES CO, V252, P63, DOI 10.1006/bbrc.1998.9498
   CHOU KC, 1980, EUR J BIOCHEM, V113, P195
   Chou KC, 2003, BIOCHEM BIOPH RES CO, V308, P148, DOI 10.1016/S0006-291X(03)01342-1
   CHOU KC, 1980, BIOCHEM J, V187, P829, DOI 10.1042/bj1870829
   CHOU KC, 1981, J THEOR BIOL, V89, P581, DOI 10.1016/0022-5193(81)90030-8
   CHOU KC, 1981, J THEOR BIOL, V91, P637, DOI 10.1016/0022-5193(81)90215-0
   CHOU KC, 1979, SCI SINICA, V22, P341
   Chou KC, 2006, BIOCHEM BIOPH RES CO, V339, P1015, DOI 10.1016/j.bbrc.2005.10.196
   Chou KC, 1996, J PROTEIN CHEM, V15, P59, DOI 10.1007/BF01886811
   CHOU KC, 1992, J MOL BIOL, V223, P509, DOI 10.1016/0022-2836(92)90666-8
   Chou KC, 2005, J PROTEOME RES, V4, P1681, DOI 10.1021/pr050145a
   Chou KC, 2005, J PROTEOME RES, V4, P1657, DOI 10.1021/pr050135+
   Chou KC, 2005, CURR PROTEIN PEPT SC, V6, P423, DOI 10.2174/138920305774329368
   Chou KC, 2005, J PROTEOME RES, V4, P1413, DOI 10.1021/pr050087t
   Chou KC, 2005, BIOCHEM BIOPH RES CO, V331, P56, DOI 10.1016/j.bbrc.2005.03.123
   CHOU KC, 1992, EUR J BIOCHEM, V207, P429, DOI 10.1111/j.1432-1033.1992.tb17067.x
   Chou KC, 1996, PROTEINS, V24, P51, DOI 10.1002/(SICI)1097-0134(199601)24:1&lt;51::AID-PROT4&gt;3.0.CO;2-R
   Chou KC, 2005, BIOINFORMATICS, V21, P10, DOI 10.1093/bioinformatics/bth466
   Chou KC, 2004, J PROTEOME RES, V3, P1284, DOI 10.1021/pr049849v
   Chou KC, 1997, PROTEINS, V28, P99, DOI 10.1002/(SICI)1097-0134(199705)28:1<99::AID-PROT10>3.3.CO;2-1
   Chou KC, 2004, J PROTEOME RES, V3, P856, DOI 10.1021/pr049931q
   Chou KC, 2004, J PROTEOME RES, V3, P1069, DOI 10.1021/pr049905s
   Chou KC, 1997, J PROTEIN CHEM, V16, P765, DOI 10.1023/A:1026363816730
   Chou KC, 2004, CURR MED CHEM, V11, P2105, DOI 10.2174/0929867043364667
   Chou KC, 2004, BIOCHEM BIOPH RES CO, V319, P433, DOI 10.1016/j.bbrc.2004.05.016
   Chou KC, 2004, BIOCHEM BIOPH RES CO, V316, P636, DOI 10.1016/j.bbrc.2004.02.098
   Chou KC, 1996, ANAL BIOCHEM, V233, P1, DOI 10.1006/abio.1996.0001
   Chou KC, 1997, FEBS LETT, V419, P49, DOI 10.1016/S0014-5793(97)01246-5
   CHOU KC, 1995, FEBS LETT, V363, P123, DOI 10.1016/0014-5793(95)00240-A
   Chou KC, 1999, BIOCHEM BIOPH RES CO, V259, P420, DOI 10.1006/bbrc.1999.0792
   Chou KC, 2000, FEBS LETT, V470, P249, DOI 10.1016/S0014-5793(00)01333-8
   CHOU KC, 1981, CHEM SCRIPTA, V18, P126
   CHOU KC, 1992, PROTEIN SCI, V1, P810, DOI 10.1002/pro.5560010613
   Chou KC, 2003, J PROTEOME RES, V2, P183, DOI 10.1021/pr0255710
   CHOU KC, 1993, J PROTEIN CHEM, V12, P337, DOI 10.1007/BF01028196
   Chou KC, 2002, J PROTEOME RES, V1, P429, DOI 10.1021/pr025527k
   CHOU KC, 1995, FEBS LETT, V363, P127, DOI 10.1016/0014-5793(95)00245-5
   Chou KC, 2001, PEPTIDES, V22, P1973, DOI 10.1016/S0196-9781(01)00540-X
   Chou KC, 2002, BIOCHEM BIOPH RES CO, V292, P702, DOI 10.1006/bbrc.2002.6686
   Chou KC, 1999, PROTEIN ENG, V12, P107, DOI 10.1093/protein/12.2.107
   CHOU KC, 1989, J BIOL CHEM, V264, P12074
   CHOU KC, 1990, BIOPHYS CHEM, V35, P1, DOI 10.1016/0301-4622(90)80056-D
   CHOU KC, 1995, CRIT REV BIOCHEM MOL, V30, P275, DOI 10.3109/10409239509083488
   CHOU KC, 1995, PROTEINS, V21, P319, DOI 10.1002/prot.340210406
   Chou KC, 1998, PROTEINS, V31, P97, DOI 10.1002/(SICI)1097-0134(19980401)31:1<97::AID-PROT8>3.0.CO;2-E
   Chou KC, 1998, PROTEIN ENG, V11, P523, DOI 10.1093/protein/11.7.523
   CHOU KC, 1994, J BIOL CHEM, V269, P22014
   CHOU KC, 1992, AIDS RES HUM RETROV, V8, P1967, DOI 10.1089/aid.1992.8.1967
   Chou KC, 1996, J PROTEIN CHEM, V15, P161, DOI 10.1007/BF01887396
   Chou KC, 2001, PROTEINS, V42, P136, DOI 10.1002/1097-0134(20010101)42:1<136::AID-PROT130>3.0.CO;2-F
   CHOU KC, 1993, J BIOL CHEM, V268, P16938
   Chou KC, 2001, PROTEINS, V43, P246, DOI 10.1002/prot.1035
   Chou KC, 2001, PROTEIN ENG, V14, P75, DOI 10.1093/protein/14.2.75
   Chou KC, 1999, J PROTEIN CHEM, V18, P473, DOI 10.1023/A:1020696810938
   Chou KC, 2011, NAT SCI, V3, P862, DOI [10.4236/ns.2011.310111, DOI 10.4236/NS.2011.310111).NATU-RAL]
   Chou KC, 2010, NAT SCI, V2, P1090, DOI DOI 10.4236/NS.2010.210136
   Chou KC, 2008, NAT PROTOC, V3, P153, DOI 10.1038/nprot.2007.494
   Chou KC, 2007, ANAL BIOCHEM, V370, P1, DOI 10.1016/j.ab.2007.07.006
   Chou KC, 2007, BIOCHEM BIOPH RES CO, V357, P633, DOI 10.1016/j.bbrc.2007.03.162
   Chou KC, 2007, J PROTEOME RES, V6, P1728, DOI 10.1021/pr060635i
   Chou KC, 2006, J PROTEOME RES, V5, P3420, DOI 10.1021/pr060404b
   Chou KC, 2006, CURR MED CHEM, V13, P3263, DOI 10.2174/092986706778773077
   Chou KC, 2006, J PROTEOME RES, V5, P1888, DOI 10.1021/pr060167c
   Chou KC, 2006, BIOCHEM BIOPH RES CO, V347, P150, DOI 10.1016/j.bbrc.2006.06.059
   Chou KC, 2012, MOL BIOSYST, V8, P629, DOI 10.1039/c1mb05420a
   Chou KC, 2013, MOL BIOSYST, V9, P1092, DOI 10.1039/c3mb25555g
   Chou KC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018258
   Chou KC, 2011, J THEOR BIOL, V273, P236, DOI 10.1016/j.jtbi.2010.12.024
   Chou KC, 2010, CURR DRUG METAB, V11, P369, DOI 10.2174/138920010791514261
   Chou KC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011335
   Chou KC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009931
   Chou KC, 2009, CURR PROTEOMICS, V6, P262, DOI 10.2174/157016409789973707
   CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, pCH4
   Dehzangi A, 2015, J THEOR BIOL, V364, P284, DOI 10.1016/j.jtbi.2014.09.029
   Du PF, 2014, INT J MOL SCI, V15, P3495, DOI 10.3390/ijms15033495
   Du PF, 2012, ANAL BIOCHEM, V425, P117, DOI 10.1016/j.ab.2012.03.015
   Du QH, 2005, ANAL BIOCHEM, V337, P262, DOI 10.1016/j.ab.2004.10.003
   Du QS, 2007, MED CHEM, V3, P1, DOI 10.2174/157340607779317616
   Du QS, 2006, J BIOMOL STRUCT DYN, V23, P635, DOI 10.1080/07391102.2006.10507088
   Du QS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009388
   Du QS, 2009, J THEOR BIOL, V259, P159, DOI 10.1016/j.jtbi.2009.03.003
   Du QS, 2004, PEPTIDES, V25, P1857, DOI 10.1016/j.peptides.2004.06.018
   Esmaeili M, 2010, J THEOR BIOL, V263, P203, DOI 10.1016/j.jtbi.2009.11.016
   Fan GL, 2012, AMINO ACIDS, V43, P545, DOI 10.1007/s00726-011-1143-4
   Fan GL, 2012, J THEOR BIOL, V304, P88, DOI 10.1016/j.jtbi.2012.03.017
   Fan YN, 2014, INT J MOL SCI, V15, P4915, DOI 10.3390/ijms15034915
   Feng KY, 2005, BIOCHEM BIOPH RES CO, V334, P213, DOI 10.1016/j.bbrc.2005.06.075
   Feng PM, 2013, ANAL BIOCHEM, V442, P118, DOI 10.1016/j.ab.2013.05.024
   Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149
   Gan YR, 2006, PEPTIDES, V27, P622, DOI 10.1016/j.peptides.2005.09.006
   Gao Y, 2005, AMINO ACIDS, V28, P373, DOI 10.1007/s00726-005-0206-9
   Georgiou DN, 2009, J THEOR BIOL, V257, P17, DOI 10.1016/j.jtbi.2008.11.003
   Georgiou D.N., 2013, OPEN BIOINF J, V7, P41, DOI DOI 10.2174/1875036201307010041
   Gonzalez-Diaz H, 2009, J THEOR BIOL, V261, P136, DOI 10.1016/j.jtbi.2009.07.029
   Guo SH, 2014, BIOINFORMATICS, V30, P1522, DOI 10.1093/bioinformatics/btu083
   Hajisharifi Z, 2014, J THEOR BIOL, V341, P34, DOI 10.1016/j.jtbi.2013.08.037
   Han GS, 2014, J THEOR BIOL, V344, P31, DOI 10.1016/j.jtbi.2013.11.017
   Hayat M, 2014, COMPUT METH PROG BIO, V116, P184, DOI 10.1016/j.cmpb.2014.06.007
   Hayat M, 2012, PROTEIN PEPTIDE LETT, V19, P411, DOI 10.2174/092986612799789387
   Hiss JA, 2009, BRIEF BIOINFORM, V10, P569, DOI 10.1093/bib/bbp030
   Hong-Bin Shen, 2009, Journal of Biomedical Science & Engineering, V2, P136
   Huang C, 2013, J THEOR BIOL, V335, P205, DOI 10.1016/j.jtbi.2013.06.034
   Huang C, 2013, BIOSYSTEMS, V113, P50, DOI 10.1016/j.biosystems.2013.04.005
   Huang C, 2013, J MEMBRANE BIOL, V246, P327, DOI 10.1007/s00232-013-9536-9
   Huang RB, 2008, BIOCHEM BIOPH RES CO, V377, P1243, DOI 10.1016/j.bbrc.2008.10.148
   Huang T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034460
   Jia CZ, 2014, INT J MOL SCI, V15, P10410, DOI 10.3390/ijms150610410
   Jiang Y, 2013, BIOMED RES INT, DOI 10.1155/2013/287019
   Kandaswamy KK, 2011, J THEOR BIOL, V270, P56, DOI 10.1016/j.jtbi.2010.10.037
   Kandaswamy KK, 2010, PROTEIN PEPTIDE LETT, V17, P1473
   Khosravian M, 2013, PROTEIN PEPTIDE LETT, V20, P180, DOI 10.2174/092986613804725307
   Knowles J, 2003, NAT REV DRUG DISCOV, V2, P63, DOI 10.1038/nrd986
   Kong L, 2014, J THEOR BIOL, V344, P12, DOI 10.1016/j.jtbi.2013.11.021
   Letunic I, 2006, NUCLEIC ACIDS RES, V34, pD257, DOI 10.1093/nar/gkj079
   Li BQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033393
   Li LQ, 2014, BIOCHIMIE, V104, P100, DOI 10.1016/j.biochi.2014.06.001
   Li XB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028111
   Liang GZ, 2007, BIOPOLYMERS, V88, P401, DOI 10.1002/bip.20669
   Liao B, 2011, PROTEIN PEPTIDE LETT, V18, P1086, DOI 10.2174/092986611797200931
   Liao QH, 2011, MED CHEM, V7, P24, DOI 10.2174/157340611794072698
   Lin H, 2007, J COMPUT CHEM, V28, P1463, DOI 10.1002/jcc.20554
   Lin H, 2014, NUCLEIC ACIDS RES, V42, P12961, DOI 10.1093/nar/gku1019
   Lin H, 2013, INT J BIOMATH, V6, DOI 10.1142/S1793524513500034
   Lin H, 2009, ACTA BIOTHEOR, V57, P321, DOI 10.1007/s10441-008-9067-4
   Lin S. X, 2013, J BIOMED SCI JBISE, V6, P435, DOI DOI 10.4236/JBISE.2013.64054
   Lin WZ, 2013, MOL BIOSYST, V9, P634, DOI 10.1039/c3mb25466f
   Lin WZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024756
   Lindsay MA, 2003, NAT REV DRUG DISCOV, V2, P831, DOI 10.1038/nrd1202
   Liu B., 2015, BIOINFORMATICS, DOI [10.1093/bioinformatics/btu1820, DOI 10.1093/BIOINFORMATICS/BTU1820]
   Liu B, 2013, MOL INFORM, V32, P775, DOI 10.1002/minf.201300084
   Liu H, 2005, BIOCHEM BIOPH RES CO, V338, P1005, DOI 10.1016/j.bbrc.2005.10.046
   Liu WM, 1999, PROTEIN ENG, V12, P1041, DOI 10.1093/protein/12.12.1041
   Liu Z., 2015, ANAL BIOCHEM, DOI DOI 10.1016/J.AB.2014.1012.1009
   Liu Z, 2015, ANAL BIOCHEM, V474, P69, DOI 10.1016/j.ab.2014.12.009
   Ma Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038546
   Marchler-Bauer A, 2007, NUCLEIC ACIDS RES, V35, pD237, DOI 10.1093/nar/gkl951
   Mei SY, 2012, J THEOR BIOL, V310, P80, DOI 10.1016/j.jtbi.2012.06.028
   Mei SY, 2012, J THEOR BIOL, V293, P121, DOI 10.1016/j.jtbi.2011.10.015
   Min JL, 2013, BIOMED RES INT, DOI 10.1155/2013/701317
   Mohabatkar H, 2013, MED CHEM, V9, P133, DOI 10.2174/157340613804488341
   Mohabatkar H, 2011, J THEOR BIOL, V281, P18, DOI 10.1016/j.jtbi.2011.04.017
   Mohabatkar H, 2010, PROTEIN PEPTIDE LETT, V17, P1207, DOI 10.2174/092986610792231564
   Mohammad Beigi Majid, 2011, J Struct Funct Genomics, V12, P191, DOI 10.1007/s10969-011-9120-4
   Mondal S, 2014, J THEOR BIOL, V356, P30, DOI 10.1016/j.jtbi.2014.04.006
   Munteanu CR, 2009, J THEOR BIOL, V257, P303, DOI 10.1016/j.jtbi.2008.11.017
   Murvai J, 2001, NUCLEIC ACIDS RES, V29, P58, DOI 10.1093/nar/29.1.58
   MYERS D, 1985, COMPUT APPL BIOSCI, V1, P105
   NAKASHIMA H, 1994, J MOL BIOL, V238, P54, DOI 10.1006/jmbi.1994.1267
   Nanni L, 2008, AMINO ACIDS, V34, P635, DOI 10.1007/s00726-007-0016-3
   Nanni L, 2008, AMINO ACIDS, V34, P653, DOI 10.1007/s00726-007-0018-1
   Nanni L, 2014, J THEOR BIOL, V360, P109, DOI 10.1016/j.jtbi.2014.07.003
   Nanni L, 2012, IEEE ACM T COMPUT BI, V9, P467, DOI 10.1109/TCBB.2011.117
   Nanni L, 2009, AMINO ACIDS, V36, P409, DOI 10.1007/s00726-008-0076-z
   Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3
   OuYang B, 2013, NATURE, V498, P521, DOI 10.1038/nature12283
   Oxenoid K, 2005, P NATL ACAD SCI USA, V102, P10870, DOI 10.1073/pnas.0504920102
   Pielak RM, 2011, BBA-BIOMEMBRANES, V1808, P522, DOI 10.1016/j.bbamem.2010.04.015
   Pielak RM, 2010, BIOCHEM BIOPH RES CO, V401, P58, DOI 10.1016/j.bbrc.2010.09.008
   Pielak RM, 2009, P NATL ACAD SCI USA, V106, P7379, DOI 10.1073/pnas.0902548106
   Qin YF, 2013, INT J QUANTUM CHEM, V113, P1660, DOI 10.1002/qua.24383
   Qiu WR, 2015, J BIOMOL STRUCT DYN, V33, P1731, DOI 10.1080/07391102.2014.968875
   Qiu WR, 2014, BIOMED RES INT, DOI 10.1155/2014/947416
   Qiu WR, 2014, INT J MOL SCI, V15, P1746, DOI 10.3390/ijms15021746
   Sahu SS, 2010, COMPUT BIOL CHEM, V34, P320, DOI 10.1016/j.compbiolchem.2010.09.002
   Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994
   Schnell JR, 2008, NATURE, V451, P591, DOI 10.1038/nature06531
   Shen HB, 2007, AMINO ACIDS, V33, P57, DOI 10.1007/s00726-006-0478-8
   Shen H. B., 2009, NAT SCI, V1, P63, DOI DOI 10.4236/NS.2009.12011
   Shen HB, 2005, BIOCHEM BIOPH RES CO, V334, P288, DOI 10.1016/j.bbrc.2005.06.087
   Shen HB, 2008, ANAL BIOCHEM, V375, P388, DOI 10.1016/j.ab.2008.01.012
   Shen HB, 2008, ANAL BIOCHEM, V373, P386, DOI 10.1016/j.ab.2007.10.012
   Shen HB, 2007, BIOCHEM BIOPH RES CO, V363, P297, DOI 10.1016/j.bbrc.2007.08.140
   Shen HB, 2007, BIOCHEM BIOPH RES CO, V355, P1006, DOI 10.1016/j.bbrc.2007.02.071
   Shen HB, 2007, BIOPOLYMERS, V85, P233, DOI 10.1002/bip.20640
   Shen HB, 2006, J THEOR BIOL, V240, P9, DOI 10.1016/j.jtbi.2005.08.016
   Shen HB, 2010, J BIOMOL STRUCT DYN, V28, P175, DOI 10.1080/07391102.2010.10507351
   Shen HB, 2010, J THEOR BIOL, V264, P326, DOI 10.1016/j.jtbi.2010.01.018
   Shen HB, 2009, ANAL BIOCHEM, V394, P269, DOI 10.1016/j.ab.2009.07.046
   Shen HB, 2009, PROTEIN PEPTIDE LETT, V16, P1478, DOI 10.2174/092986609789839322
   Shen YZ, 2010, MED CHEM, V6, P165, DOI 10.2174/1573406411006030165
   Sirois S, 2005, COMPUT BIOL CHEM, V29, P55, DOI 10.1016/j.compbiolchem.2004.11.003
   Sun XY, 2012, MOL BIOSYST, V8, P3178, DOI 10.1039/c2mb25280e
   Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41
   Thompson TB, 1995, J THEOR BIOL, V177, P369, DOI 10.1006/jtbi.1995.0254
   Wan SB, 2013, J THEOR BIOL, V323, P40, DOI 10.1016/j.jtbi.2013.01.012
   Wang JF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031048
   Wang JF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018414
   Wang JF, 2009, NAT STRUCT MOL BIOL, V16, P1267, DOI 10.1038/nsmb.1707
   Wang M, 2005, J THEOR BIOL, V232, P7, DOI 10.1016/j.jtbi.2004.07.023
   Wang Meng, 2005, Med Chem, V1, P39, DOI 10.2174/1573406053402505
   Wang SQ, 2009, BIOCHEM BIOPH RES CO, V386, P432, DOI 10.1016/j.bbrc.2009.06.016
   Wei H, 2009, MED CHEM, V5, P305, DOI 10.2174/157340609788681430
   WOLFRAM S, 1984, NATURE, V311, P419, DOI 10.1038/311419a0
   Wolfram S., 2002, NEW KIND SCI
   Wu ZC, 2012, PROTEIN PEPTIDE LETT, V19, P4, DOI 10.2174/092986612798472839
   Wu ZC, 2011, MOL BIOSYST, V7, P3287, DOI 10.1039/c1mb05232b
   Wu ZC, 2010, J THEOR BIOL, V267, P29, DOI 10.1016/j.jtbi.2010.08.007
   Xiao X, 2006, BIOCHEM BIOPH RES CO, V342, P605, DOI 10.1016/j.bbrc.2006.01.166
   Xiao X, 2005, AMINO ACIDS, V28, P29, DOI 10.1007/s00726-004-0154-9
   Xiao X, 2005, J THEOR BIOL, V235, P555, DOI 10.1016/j.jtbi.2005.02.008
   Xiao X., 2014, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.07392014.07998710, DOI 10.1080/07391102.07392014.07998710]
   Xiao X, 2008, J THEOR BIOL, V254, P691, DOI 10.1016/j.jtbi.2008.06.016
   Xiao X, 2013, J THEOR BIOL, V337, P71, DOI 10.1016/j.jtbi.2013.08.013
   Xiao X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072234
   Xiao X, 2013, CURR TOP MED CHEM, V13, P1707
   Xiao X, 2013, ANAL BIOCHEM, V436, P168, DOI 10.1016/j.ab.2013.01.019
   Xiao X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030869
   Xiao X, 2011, J THEOR BIOL, V284, P42, DOI 10.1016/j.jtbi.2011.06.005
   Xiao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020592
   Xiao XA, 2011, MOL BIOSYST, V7, P911, DOI 10.1039/c0mb00170h
   Xiao X, 2009, J COMPUT CHEM, V30, P1414, DOI 10.1002/jcc.21163
   Xie GS, 2011, J THEOR BIOL, V269, P123, DOI 10.1016/j.jtbi.2010.10.018
   Xie HL, 2013, PROTEIN ENG DES SEL, V26, P735, DOI 10.1093/protein/gzt042
   Xu RF, 2015, J BIOMOL STRUCT DYN, V33, P1720, DOI 10.1080/07391102.2014.968624
   Xu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105018
   Xu Y, 2014, INT J MOL SCI, V15, P7594, DOI 10.3390/ijms15057594
   Xu Y, 2013, PEERJ, V1, DOI 10.7717/peerj.171
   Xu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055844
   Yu JF, 2009, J THEOR BIOL, V261, P459, DOI 10.1016/j.jtbi.2009.08.005
   Yu LZ, 2010, J THEOR BIOL, V267, P1, DOI 10.1016/j.jtbi.2010.08.001
   Zeng YH, 2009, J THEOR BIOL, V259, P366, DOI 10.1016/j.jtbi.2009.03.028
   ZHANG CT, 1994, J MOL BIOL, V238, P1, DOI 10.1006/jmbi.1994.1263
   ZHANG CT, 1992, PROTEIN SCI, V1, P401
   ZHANG CT, 1993, J PROTEIN CHEM, V12, P329, DOI 10.1007/BF01028195
   ZHANG CT, 1994, PROTEIN ENG, V7, P65, DOI 10.1093/protein/7.1.65
   Zhang GY, 2008, J THEOR BIOL, V253, P310, DOI 10.1016/j.jtbi.2008.03.015
   Zhang J, 2014, J THEOR BIOL, V363, P412, DOI 10.1016/j.jtbi.2014.08.002
   Zhang J, 2014, INT J MOL SCI, V15, P11204, DOI 10.3390/ijms150711204
   Zhang LC, 2014, J THEOR BIOL, V355, P105, DOI 10.1016/j.jtbi.2014.04.008
   Zhang SW, 2008, AMINO ACIDS, V35, P591, DOI 10.1007/s00726-008-0086-x
   Zhang SW, 2008, AMINO ACIDS, V34, P565, DOI 10.1007/s00726-007-0010-9
   Zhong W.Z., 2009, HEALTH, V1, P249, DOI [10.4236/health.2009.14041, DOI 10.4236/HEALTH.2009.14041]
   Zhong WZ, 2014, INT J MOL SCI, V15, P20072, DOI 10.3390/ijms151120072
   Zhou GP, 2005, CURR PROTEIN PEPT SC, V6, P399, DOI 10.2174/138920305774329377
   ZHOU GP, 1984, BIOCHEM J, V222, P169, DOI 10.1042/bj2220169
   Zhou GP, 2013, CURR TOP MED CHEM, V13, P1152, DOI 10.2174/15680266113139990003
   Zhou GP, 2011, PROTEIN PEPTIDE LETT, V18, P966, DOI 10.2174/0929866511107010966
   Zhou GP, 2011, J THEOR BIOL, V284, P142, DOI 10.1016/j.jtbi.2011.06.006
   Zhou XB, 2007, J THEOR BIOL, V248, P546, DOI 10.1016/j.jtbi.2007.06.001
   Zia-ur-Rehman, 2012, PROTEIN PEPTIDE LETT, V19, P890
   Zou DS, 2011, J COMPUT CHEM, V32, P271, DOI 10.1002/jcc.21616
   Zuo YC, 2014, ANAL BIOCHEM, V458, P14, DOI 10.1016/j.ab.2014.04.032
NR 272
TC 383
Z9 384
U1 14
U2 104
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4064
EI 1875-6638
J9 MED CHEM
JI Med. Chem.
PY 2015
VL 11
IS 3
BP 218
EP 234
DI 10.2174/1573406411666141229162834
PG 17
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CF1RM
UT WOS:000352325300002
PM 25548930
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Bosch, BJ
   van der Zee, R
   de Haan, CAM
   Rottier, PJM
AF Bosch, BJ
   van der Zee, R
   de Haan, CAM
   Rottier, PJM
TI The coronavirus spike protein is a class I virus fusion protein:
   Structural and functional characterization of the fusion core complex
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; MOUSE HEPATITIS-VIRUS; TO-CELL FUSION; HIV-1
   TRANSMEMBRANE GLYCOPROTEIN; INDUCED CONFORMATIONAL-CHANGES; VIRAL
   MEMBRANE-FUSION; STRANDED COILED-COIL; ENVELOPE GLYCOPROTEIN; POTENT
   INHIBITORS; INFLUENZA-VIRUS
AB Coronavirus entry is mediated by the viral spike (S) glycoprotein. The 180-kDa oligomeric S protein of the murine coronavirus mouse hepatitis virus strain A59 is posttranslationally cleaved into an S1 receptor binding unit and an S2 membrane fusion unit. The latter is thought to contain an internal fusion peptide and has two 4,3 hydrophobic (heptad) repeat regions designated HR1 and HR2. HR2 is located close to the membrane anchor, and HR1 is some 170 amino acids (aa) upstream of it. Heptad repeat (HR) regions are found in fusion proteins of many different viruses and form an important characteristic of class I viral fusion proteins. We investigated the role of these regions in coronavirus membrane fusion. Peptides HR1 (96 aa) and HR2 (39 aa), corresponding to the HR1 and HR2 regions, were produced in Escherichia coli. When mixed together, the two peptides were found to assemble into an extremely stable oligomeric complex. Both on their own and within the complex, the peptides were highly alpha helical. Electron microscopic analysis of the complex revealed a rod-like structure similar to14.5 nm in length. Limited proteolysis in combination with mass spectrometry indicated that HR1 and HR2 occur in the complex in an antiparallel fashion. In the native protein, such a conformation would bring the proposed fusion peptide, located in the N-terminal domain of HR1, and the transmembrane anchor into close proximity. Using biological assays, the HR2 peptide was shown to be a potent inhibitor of virus entry into the cell, as well as of cell-cell fusion. Both biochemical and functional data show that the coronavirus spike protein is a class I viral fusion protein.
C1 Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Virol, NL-3584 CL Utrecht, Netherlands.
   Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Immunol, NL-3584 CL Utrecht, Netherlands.
   Univ Utrecht, Biomembranes Inst, NL-3584 CL Utrecht, Netherlands.
RP Rottier, PJM (reprint author), Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Virol, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.
RI van der Zee, Ruurd/O-5256-2015
OI van der Zee, Ruurd/0000-0002-4331-2755
CR Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X
   Bos ECW, 1995, VIROLOGY, V214, P453, DOI 10.1006/viro.1995.0056
   Buchholz UJ, 1999, J VIROL, V73, P251, DOI 10.1128/JVI.73.1.251-259.1999
   BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   CAVANAGH D, 1995, CORONAVIRUS SURFACE
   CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7
   Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205
   Chen J, 1999, P NATL ACAD SCI USA, V96, P8967, DOI 10.1073/pnas.96.16.8967
   Chen L, 2001, STRUCTURE, V9, P255, DOI 10.1016/S0969-2126(01)00581-0
   Chen X., 1994, J APPL POULTRY RES, V4, P69
   DAVIES HA, 1979, ARCH VIROL, V59, P25, DOI 10.1007/BF01317891
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777
   Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898
   Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Gallagher TM, 1997, J VIROL, V71, P3129, DOI 10.1128/JVI.71.4.3129-3137.1997
   GALLAGHER TM, 1991, J VIROL, V65, P1916, DOI 10.1128/JVI.65.4.1916-1928.1991
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   GOMBOLD JL, 1993, J VIROL, V67, P4504, DOI 10.1128/JVI.67.8.4504-4512.1993
   Hingley ST, 1998, J VIROL, V72, P1606, DOI 10.1128/JVI.72.2.1606-1609.1998
   Holmes KV, 2001, ADV EXP MED BIOL, V494, P173
   Joshi SB, 1998, VIROLOGY, V248, P20, DOI 10.1006/viro.1998.9242
   Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426
   Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368
   Kobe B, 1999, P NATL ACAD SCI USA, V96, P4319, DOI 10.1073/pnas.96.8.4319
   Krueger DK, 2001, J VIROL, V75, P2792, DOI 10.1128/JVI.75.6.2792-2802.2001
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186
   Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8
   Lewicki DN, 2002, J BIOL CHEM, V277, P19727, DOI 10.1074/jbc.M201837200
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Luo ZL, 1999, J VIROL, V73, P8152, DOI 10.1128/JVI.73.10.8152-8159.1999
   Luo ZL, 1998, VIROLOGY, V244, P483, DOI 10.1006/viro.1998.9121
   Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662
   Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134
   Malashkevich VN, 2001, P NATL ACAD SCI USA, V98, P8502, DOI 10.1073/pnas.151254798
   Matsuyama S, 2002, VIROLOGY, V295, P160, DOI 10.1006/viro.2002.1391
   Matsuyama S, 2002, J VIROL, V76, P11819, DOI 10.1128/JVI.76.23.11819-11826.2002
   Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413
   Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315
   Nash TC, 1997, VIROLOGY, V233, P1, DOI 10.1006/viro.1997.8609
   NEHETE PN, 1993, J VIROL, V67, P6841, DOI 10.1128/JVI.67.11.6841-6846.1993
   PARRY DA, 1978, J MOL BIOL, V248, P180
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x
   Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998
   RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785
   Russell CJ, 2001, EMBO J, V20, P4024, DOI 10.1093/emboj/20.15.4024
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   SIDDELL SG, 1995, CORONAVIRIDAE INTRO
   Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9
   SLEPUSHKIN VA, 1993, VIROLOGY, V194, P294, DOI 10.1006/viro.1993.1260
   STAUBER R, 1993, J GEN VIROL, V74, P183, DOI 10.1099/0022-1317-74-2-183
   STURMAN LS, 1990, J VIROL, V64, P3042, DOI 10.1128/JVI.64.6.3042-3050.1990
   TAGUCHI F, 1995, J VIROL, V69, P7260, DOI 10.1128/JVI.69.11.7260-7263.1995
   TAGUCHI F, 1993, J VIROL, V67, P1195, DOI 10.1128/JVI.67.3.1195-1202.1993
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   VENNEMA H, 1991, GENE, V108, P201, DOI 10.1016/0378-1119(91)90435-E
   VENNEMA H, 1990, ADV EXP MED BIOL, V276, P9
   Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x
   Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8
   Westenberg M, 2002, J VIROL, V76, P178, DOI 10.1128/JVI.76.1.178-184.2002
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0
   Yang EH, 2001, IEEE T INFORM THEORY, V47, P126
   Yao QZ, 1996, VIROLOGY, V223, P103, DOI 10.1006/viro.1996.0459
   YOO D, 1991, VIROLOGY, V180, P395, DOI 10.1016/0042-6822(91)90045-D
   Young JK, 1997, VIROLOGY, V238, P291, DOI 10.1006/viro.1997.8834
   Zhao X, 2000, P NATL ACAD SCI USA, V97, P14172, DOI 10.1073/pnas.260499197
NR 83
TC 379
Z9 408
U1 6
U2 31
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD AUG
PY 2003
VL 77
IS 16
BP 8801
EP 8811
DI 10.1128/JVI.77.16.8801-8811.2003
PG 11
WC Virology
SC Virology
GA 706PU
UT WOS:000184462800022
PM 12885899
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Daffis, S
   Szretter, KJ
   Schriewer, J
   Li, JQ
   Youn, S
   Errett, J
   Lin, TY
   Schneller, S
   Zust, R
   Dong, HP
   Thiel, V
   Sen, GC
   Fensterl, V
   Klimstra, WB
   Pierson, TC
   Buller, RM
   Gale, M
   Shi, PY
   Diamond, MS
AF Daffis, Stephane
   Szretter, Kristy J.
   Schriewer, Jill
   Li, Jianqing
   Youn, Soonjeon
   Errett, John
   Lin, Tsai-Yu
   Schneller, Stewart
   Zust, Roland
   Dong, Hongping
   Thiel, Volker
   Sen, Ganes C.
   Fensterl, Volker
   Klimstra, William B.
   Pierson, Theodore C.
   Buller, R. Mark
   Gale, Michael, Jr.
   Shi, Pei-Yong
   Diamond, Michael S.
TI 2 '-O methylation of the viral mRNA cap evades host restriction by IFIT
   family members
SO NATURE
LA English
DT Article
ID NILE-VIRUS-INFECTION; PROTEINS; GENES; METHYLTRANSFERASE; TRANSLATION;
   IDENTIFICATION; INITIATION; INDUCTION; PROTECTS; ALPHA
AB Cellular messenger RNA (mRNA) of higher eukaryotes and many viral RNAs are methylated at the N-7 and 2'-O positions of the 5' guanosine cap by specific nuclear and cytoplasmic methyltransferases (MTases), respectively. Whereas N-7 methylation is essential for RNA translation and stability(1), the function of 2'-O methylation has remained uncertain since its discovery 35 years ago(2-4). Here we show that a West Nile virus (WNV) mutant (E218A) that lacks 2'-O MTase activity was attenuated in wild-type primary cells and mice but was pathogenic in the absence of type I interferon (IFN) signalling. 2'-O methylation of viral RNA did not affect IFN induction in WNV-infected fibroblasts but instead modulated the antiviral effects of IFN-induced proteins with tetratricopeptide repeats (IFIT), which are interferon-stimulated genes (ISGs) implicated in regulation of protein translation. Poxvirus and coronavirus mutants that lacked 2'-O MTase activity similarly showed enhanced sensitivity to the antiviral actions of IFN and, specifically, IFIT proteins. Our results demonstrate that the 2'-O methylation of the 5' cap of viral RNA functions to subvert innate host antiviral responses through escape of IFIT-mediated suppression, and suggest an evolutionary explanation for 2'-O methylation of cellular mRNA: to distinguish self from non-self RNA. Differential methylation of cytoplasmic RNA probably serves as an example for pattern recognition and restriction of propagation of foreign viral RNA in host cells.
C1 [Daffis, Stephane; Szretter, Kristy J.; Youn, Soonjeon; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Li, Jianqing; Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Buller, R. Mark; Gale, Michael, Jr.; Shi, Pei-Yong; Diamond, Michael S.] Midw Reg Ctr Biodef & Emerging Infect Dis Res, St Louis, MO 63104 USA.
   [Schriewer, Jill; Buller, R. Mark] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA.
   [Errett, John; Gale, Michael, Jr.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA.
   [Lin, Tsai-Yu; Pierson, Theodore C.] NIH, Viral Pathogenesis Sect, Viral Dis Lab, Bethesda, MD 20892 USA.
   [Schneller, Stewart] Auburn Univ, Dept Chem & Biochem, Auburn, AL 36849 USA.
   [Zust, Roland; Thiel, Volker] Kantonal Hosp St Gallen, Inst Immunobiol, CH-9007 St Gallen, Switzerland.
   [Thiel, Volker] Univ Zurich, Vetsuisse Fac, CH-8006 Zurich, Switzerland.
   [Dong, Hongping; Shi, Pei-Yong] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12208 USA.
   [Sen, Ganes C.; Fensterl, Volker] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Klimstra, William B.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15261 USA.
   [Buller, R. Mark; Gale, Michael, Jr.; Shi, Pei-Yong; Diamond, Michael S.] Pacific NW Reg Ctr Biodef & Emerging Infect Dis R, St Louis, MO 63104 USA.
   [Buller, R. Mark; Gale, Michael, Jr.; Shi, Pei-Yong; Diamond, Michael S.] NE Reg Ctr Biodef & Emerging Infect Dis Res, St Louis, MO 63104 USA.
RP Diamond, MS (reprint author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
EM diamond@borcim.wustl.edu
RI Thiel, Volker/AAI-2391-2019; Lin, Tsai-Yu/B-8873-2016; Jha,
   Babal/AAC-8337-2020; Diamond, Michael/AAH-1733-2019
OI Lin, Tsai-Yu/0000-0002-8076-1584; Jha, Babal/0000-0002-7660-5255;
   Diamond, Michael/0000-0002-8791-3165; Szretter,
   Kristy/0000-0003-0391-2307; Thiel, Volker/0000-0002-5783-0887; Gale,
   Michael/0000-0002-6332-7436
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U54 AI081680, U19
   AI083019, R01 AI074973, R01 AI56540, U54 AI057160, U54 AI057158, R01
   CA068782]; Swiss National Science FoundationSwiss National Science
   Foundation (SNSF) [3100A0-118425/1]; Novartis FoundationNovartis
FX This work was supported by National Institutes of Health grants U54
   AI081680, U19 AI083019 and R01 AI074973 (to M.G. and M.S.D.), R01
   AI56540 (to S.S.), U54 AI057160 (to R.M.B.) and U54 AI057158 (to
   P.Y.S.), R01 CA068782 (to G.C.S.) the Swiss National Science Foundation,
   3100A0-118425/1, and the Novartis Foundation (to V.T. and R.Z.). We
   thank H. Virgin and B. Moss for reading the manuscript.
CR Coley SE, 2005, J VIROL, V79, P3097, DOI 10.1128/JVI.79.5.3097-3106.2005
   Daffis S, 2008, J VIROL, V82, P10349, DOI 10.1128/JVI.00935-08
   Daffis S, 2008, J VIROL, V82, P8465, DOI 10.1128/JVI.00918-08
   Daffis S, 2007, PLOS PATHOG, V3, P1005, DOI 10.1371/journal.ppat.0030106
   Daffis S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000607
   Decroly E, 2008, J VIROL, V82, P8071, DOI 10.1128/JVI.00407-08
   Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623
   Dong HP, 2008, ANTIVIR RES, V80, P1, DOI 10.1016/j.antiviral.2008.05.003
   Fechter P, 2005, J GEN VIROL, V86, P1239, DOI 10.1099/vir.0.80755-0
   Fensterl V, 2008, J VIROL, V82, P11045, DOI 10.1128/JVI.01593-08
   Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9
   Hui DJ, 2005, J BIOL CHEM, V280, P3433, DOI 10.1074/jbc.M406700200
   Hui DJ, 2003, J BIOL CHEM, V278, P39477, DOI 10.1074/jbc.M305038200
   LANGBERG SR, 1981, J BIOL CHEM, V256, P54
   Latner DR, 2002, VIROLOGY, V301, P64, DOI 10.1006/viro.2002.1538
   MUTHUKRISHNAN S, 1978, J BIOL CHEM, V253, P1710
   Samuel MA, 2005, J VIROL, V79, P13350, DOI 10.1128/JVI.79.21.13350-13361.2005
   Sarkar SN, 2004, PHARMACOL THERAPEUT, V103, P245, DOI 10.1016/j.pharmthera.2004.07.007
   Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005
   Terenzi F, 2006, J BIOL CHEM, V281, P34064, DOI 10.1074/jbc.M605771200
   Wacher C, 2007, J VIROL, V81, P860, DOI 10.1128/JVI.01167-06
   WEI CM, 1975, CELL, V4, P379, DOI 10.1016/0092-8674(75)90158-0
   WEI CM, 1975, P NATL ACAD SCI USA, V72, P318, DOI 10.1073/pnas.72.1.318
   Zhang YG, 2007, J VIROL, V81, P11246, DOI 10.1128/JVI.01282-07
   Zhou YS, 2007, J VIROL, V81, P3891, DOI 10.1128/JVI.02704-06
NR 25
TC 375
Z9 389
U1 14
U2 60
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD NOV 18
PY 2010
VL 468
IS 7322
BP 452
EP 456
DI 10.1038/nature09489
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 681KP
UT WOS:000284313100046
PM 21085181
OA Green Accepted
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Fraser, C
   Riley, S
   Anderson, RM
   Ferguson, NM
AF Fraser, C
   Riley, S
   Anderson, RM
   Ferguson, NM
TI Factors that make an infectious disease outbreak controllable
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE epidemiology; severe acute respiratory syndrome; HIV; smallpox;
   influenza
ID ACUTE RESPIRATORY SYNDROME; HONG-KONG; TRANSMISSION DYNAMICS; SMALLPOX;
   SARS; INFLUENZA; SPREAD; AGENT
AB The aim of this study is to identify general properties of emerging infectious agents that determine the likely success of two simple public health measures in controlling outbreaks, namely (1) isolating symptomatic individuals and (it) tracing and quarantining their contacts. Because these measures depend on the recognition of specific disease symptoms, we investigate the relative timing of infectiousness and the appearance of symptoms by using a mathematical model. We show that the success of these control measures is determined as much by the proportion of transmission occurring prior to the onset of overt clinical symptoms (or via asymptomatic infection) as the inherent transmissibility of the etiological agent (measured by the reproductive number R-0). From published studies, we estimate these quantities for two moderately transmissible viruses, severe acute respiratory syndrome coronavirus and HIV, and for two highly transmissible viruses, smallpox and pandemic influenza. We conclude that severe acute respiratory syndrome and smallpox are easier to control using these simple public health measures. Direct estimation of the proportion of asymptomatic and presymptomatic infections is achievable by contact tracing and should be a priority during an outbreak of a novel infectious agent.
C1 Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London W2 1PG, England.
RP Fraser, C (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London W2 1PG, England.
EM c.fraser@imperial.ac.uk
RI Fraser, Christophe/A-8109-2008; Ferguson, Neil/B-8578-2008
OI Fraser, Christophe/0000-0003-2399-9657; Ferguson,
   Neil/0000-0002-1154-8093; Riley, Steven/0000-0001-7904-4804; Anderson,
   Roy/0000-0002-9528-3175
CR Anderson R. M., 1991, INFECT DIS HUMANS DY
   Babiker A, 2000, LANCET, V355, P1131
   *COMM DIS SURV CTR, 1978, BRIT MED J, P587
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Eichner M, 2003, AM J EPIDEMIOL, V158, P110, DOI 10.1093/aje/kwg103
   Ferguson NM, 2003, NATURE, V425, P681, DOI 10.1038/nature02007
   Halloran ME, 2002, SCIENCE, V298, P1428, DOI 10.1126/science.1074674
   Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355
   Huerta R, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.056115
   Kaplan EH, 2002, P NATL ACAD SCI USA, V99, P10935, DOI 10.1073/pnas.162282799
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Muller J, 2000, MATH BIOSCI, V164, P39, DOI 10.1016/S0025-5564(99)00061-9
   Murray JD, 2001, MATH BIOL
   Pearson H, 2003, NATURE, V424, P121, DOI 10.1038/424121a
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478
   RVACHEV LA, 1985, MATH BIOSCI, V75, P3, DOI 10.1016/0025-5564(85)90064-1
NR 19
TC 373
Z9 384
U1 11
U2 52
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 20
PY 2004
VL 101
IS 16
BP 6146
EP 6151
DI 10.1073/pnas.0307506101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 814ME
UT WOS:000220978000084
PM 15071187
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Assiri, A
   Al-Tawfiq, JA
   Al-Rabeeah, AA
   Al-Rabiah, FA
   Al-Hajjar, S
   Al-Barrak, A
   Flemban, H
   Al-Nassir, WN
   Balkhy, HH
   Al-Hakeem, RF
   Makhdoom, HQ
   Zumla, AI
   Memish, ZA
AF Assiri, Abdullah
   Al-Tawfiq, Jaffar A.
   Al-Rabeeah, Abdullah A.
   Al-Rabiah, Fahad A.
   Al-Hajjar, Sami
   Al-Barrak, Ali
   Flemban, Hesham
   Al-Nassir, Wafa N.
   Balkhy, Hanan H.
   Al-Hakeem, Rafat F.
   Makhdoom, Hatem Q.
   Zumla, Alimuddin I.
   Memish, Ziad A.
TI Epidemiological, demographic, and clinical characteristics of 47 cases
   of Middle East respiratory syndrome coronavirus disease from Saudi
   Arabia: a descriptive study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID FEATURES; SARS; CONFIRMATION
AB Background Middle East respiratory syndrome (MERS) is a new human disease caused by a novel coronavirus (CoV). Clinical data on MERS-CoV infections are scarce. We report epidemiological, demographic, clinical, and laboratory characteristics of 47 cases of MERS-CoV infections, identify knowledge gaps, and define research priorities.
   Methods We abstracted and analysed epidemiological, demographic, clinical, and laboratory data from confirmed cases of sporadic, household, community, and health-care-associated MERS-CoV infections reported from Saudi Arabia between Sept 1, 2012, and June 15, 2013. Cases were confirmed as having MERS-CoV by real-time RT-PCR.
   Findings 47 individuals (46 adults, one child) with laboratory-confirmed MERS-CoV disease were identified; 36 (77%) were male (male:female ratio 3.3:1). 28 patients died, a 60% case-fatality rate. The case-fatality rate rose with increasing age. Only two of the 47 cases were previously healthy; most patients (45 [96%]) had underlying comorbid medical disorders, including diabetes (32 [68%]), hypertension (16 [34%]), chronic cardiac disease (13 [28%]), and chronic renal disease (23 [49%]). Common symptoms at presentation were fever (46 [98%]), fever with chills or rigors (41 [87%]), cough (39 [83%]), shortness of breath (34 [72%]), and myalgia (15 [32%]). Gastrointestinal symptoms were also frequent, including diarrhoea (12 [26%]), vomiting (ten [21%]), and abdominal pain (eight [17%]). All patients had abnormal findings on chest radiography, ranging from subtle to extensive unilateral and bilateral abnormalities. Laboratory analyses showed raised concentrations of lactate dehydrogenase (23 [49%]) and aspartate aminotransferase (seven [15%]) and thrombocytopenia (17 [36%]) and lymphopenia (16 [34%]).
   Interpretation Disease caused by MERS-CoV presents with a wide range of clinical manifestations and is associated with substantial mortality in admitted patients who have medical comorbidities. Major gaps in our knowledge of the epidemiology, community prevalence, and clinical spectrum of infection and disease need urgent definition.
C1 [Assiri, Abdullah; Al-Rabeeah, Abdullah A.; Al-Hakeem, Rafat F.; Zumla, Alimuddin I.; Memish, Ziad A.] Minist Hlth, Global Ctr Mass Gatherings Med, Riyadh 11176, Saudi Arabia.
   [Assiri, Abdullah] Minist Hlth, Infect Prevent & Control Program, Publ Hlth Directorate, Riyadh 11176, Saudi Arabia.
   [Al-Tawfiq, Jaffar A.] Saudi ARAMCO Med Serv Org, Dhahran, Saudi Arabia.
   [Al-Rabiah, Fahad A.; Al-Hajjar, Sami] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia.
   [Al-Barrak, Ali] Prince Sultan Mil Med City, Riyadh, Saudi Arabia.
   [Flemban, Hesham] Alhada Mil Hosp, Riyadh, Saudi Arabia.
   [Al-Nassir, Wafa N.] Imam Abdulrahman Bin Mohamed Hosp, Natl Guard Hlth Affairs, Dammam, Saudi Arabia.
   [Balkhy, Hanan H.] King Abdul Aziz Med City, Riyadh, Saudi Arabia.
   [Al-Hakeem, Rafat F.] Minist Hlth, Communicable Dis Program, Riyadh 11176, Saudi Arabia.
   [Makhdoom, Hatem Q.] Minist Hlth, Jeddah Reg Lab, Jeddah, Saudi Arabia.
   [Zumla, Alimuddin I.] UCL, Div Infect & Immun, London, England.
   [Zumla, Alimuddin I.] Univ Coll London Hosp NHS Fdn Trust, London, England.
   [Memish, Ziad A.] Minist Hlth, Publ Hlth Directorate, Riyadh 11176, Saudi Arabia.
   [Memish, Ziad A.] Al Faisal Univ, Riyadh, Saudi Arabia.
RP Memish, ZA (reprint author), Minist Hlth, Riyadh 11176, Saudi Arabia.
EM zmemish@yahoo.com
RI Jha, Babal/AAC-8337-2020
OI Jha, Babal/0000-0002-7660-5255; Assiri, Abdullah/0000-0002-5605-2876;
   Zumla, Alimuddin/0000-0002-5111-5735
FU National Institute of Health Research, Biomedical Research Centre, UCL
   Hospital, London, UK; European and Developing Countries Clinical Trials
   Partnership; Hague, NetherlandsNetherlands Government; EC-FW7 (European
   Commission's seventh framework programme for research), Brussels,
   Belgium
FX We thank staff of the Ministry of Health, Riyadh, Saudi Arabia, and Adam
   Zumla (UCL School of Pharmacy, London, UK) and Matthew Bates (UNZA-UCLMS
   Project, Lusaka, Zambia) for technical and administrative support. AIZ
   acknowledges support from. the National Institute of Health Research,
   Biomedical Research Centre, UCL Hospital, London, UK; the European and
   Developing Countries Clinical Trials Partnership, The Hague,
   Netherlands; and EC-FW7 (European Commission's seventh framework
   programme for research), Brussels, Belgium.
CR AlBarrak AM, 2012, SAUDI MED J, V33, P1265
   Alqurashi KA, 2011, ANN SAUDI MED, V31, P19, DOI 10.4103/0256-4947.75773
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Bauch CT, 2013, LANCET, V382, P662, DOI 10.1016/S0140-6736(13)61504-4
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Breban R, 2013, LANCET, V382, P694, DOI 10.1016/S0140-6736(13)61492-0
   Buchholz U., 2013, Eurosurveillance, V18, P20406
   Cauchemez S., 2013, Eurosurveillance, V18, P20503
   Christian MD, 2004, CLIN INFECT DIS, V38, P1420, DOI 10.1086/420743
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3
   European Centre for Disease Prevention and Control (ECDC), 2013, TABL CONF CAS MIDDL
   European Centre for Disease Prevention and Control (ECDC), 2013, EP UPD ADD CONF CAS
   European Centre for Disease Prevention and Control (ECDC), 2012, RAP RISK ASS UPD SEV
   Fan Cheng-Kuo, 2006, Journal of Microbiology Immunology and Infection, V39, P45
   Gastanaduy PA, 2013, MMWR-MORBID MORTAL W, V62, P480
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Hijawi B, 2013, E MEDITERR HEALTH J, V19, pS12
   Hui DSC, 2010, INFECT DIS CLIN N AM, V24, P619, DOI 10.1016/j.idc.2010.04.009
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Leshem Eyal, 2012, Morbidity and Mortality Weekly Report, V61, P820
   Leung GM, 2004, ANN INTERN MED, V141, P662, DOI 10.7326/0003-4819-141-9-200411020-00006
   Lin CL, 2004, CHEST, V126, P509, DOI 10.1378/chest.126.2.509
   Mailles A., 2013, Eurosurveillance, V18, P20502
   Maunder RG, 2006, EMERG INFECT DIS, V12, P1924
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Palm D, 2012, EUROSURVEILLANCE, V17, P11
   ProMED-mail, 2013, PROMED MAIL     0522
   ProMED-mail, 2013, PROMED MAIL     0602
   Rainer TH, 2007, EUR J CLIN MICROBIOL, V26, P121, DOI 10.1007/s10096-006-0246-4
   Tahir M, 2013, EUROSURVEILLANCE, V18, P4
   WHO, 2013, GLOB AL RESP GAR MID
   World Health Organization, 2013, GLOB AL RESP GAR NOV
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zumla A, 2013, LANCET RESP MED, V1, P284, DOI 10.1016/S2213-2600(13)70099-7
NR 38
TC 372
Z9 392
U1 32
U2 116
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD SEP
PY 2013
VL 13
IS 9
BP 752
EP 761
DI 10.1016/S1473-3099(13)70204-4
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA 205SU
UT WOS:000323465900020
PM 23891402
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU van Boheemen, S
   de Graaf, M
   Lauber, C
   Bestebroer, TM
   Raj, VS
   Zaki, AM
   Osterhaus, ADME
   Haagmans, BL
   Gorbalenya, AE
   Snijder, EJ
   Fouchier, RAM
AF van Boheemen, Sander
   de Graaf, Miranda
   Lauber, Chris
   Bestebroer, Theo M.
   Raj, V. Stalin
   Zaki, Ali Moh
   Osterhaus, Albert D. M. E.
   Haagmans, Bart L.
   Gorbalenya, Alexander E.
   Snijder, Eric J.
   Fouchier, Ron A. M.
TI Genomic Characterization of a Newly Discovered Coronavirus Associated
   with Acute Respiratory Distress Syndrome in Humans
SO MBIO
LA English
DT Article
ID MURINE CORONAVIRUS; VIRUS; RNA; TRANSCRIPTION; REPLICATION; SEQUENCE;
   BATS; IDENTIFICATION; NIDOVIRALES; EVOLUTION
AB A novel human coronavirus (HCoV-EMC/2012) was isolated from a man with acute pneumonia and renal failure in June 2012. This report describes the complete genome sequence, genome organization, and expression strategy of HCoV-EMC/2012 and its relation with known coronaviruses. The genome contains 30,119 nucleotides and contains at least 10 predicted open reading frames, 9 of which are predicted to be expressed from a nested set of seven subgenomic mRNAs. Phylogenetic analysis of the replicase gene of coronaviruses with completely sequenced genomes showed that HCoV-EMC/2012 is most closely related to Tylonycteris bat coronavirus HKU4 (BtCoV-HKU4) and Pipistrellus bat coronavirus HKU5 (BtCoV-HKU5), which prototype two species in lineage C of the genus Betacoronavirus. In accordance with the guidelines of the International Committee on Taxonomy of Viruses, and in view of the 75% and 77% amino acid sequence identity in 7 conserved replicase domains with BtCoV-HKU4 and BtCoV-HKU5, respectively, we propose that HCoV-EMC/2012 prototypes a novel species in the genus Betacoronavirus. HCoV-EMC/2012 may be most closely related to a coronavirus detected in Pipistrellus pipistrellus in The Netherlands, but because only a short sequence from the most conserved part of the RNA-dependent RNA polymerase-encoding region of the genome was reported for this bat virus, its genetic distance from HCoV-EMC remains uncertain. HCoV-EMC/2012 is the sixth coronavirus known to infect humans and the first human virus within betacoronavirus lineage C.
   IMPORTANCE Coronaviruses are capable of infecting humans and many animal species. Most infections caused by human coronaviruses are relatively mild. However, the outbreak of severe acute respiratory syndrome (SARS) caused by SARS-CoV in 2002 to 2003 and the fatal infection of a human by HCoV-EMC/2012 in 2012 show that coronaviruses are able to cause severe, sometimes fatal disease in humans. We have determined the complete genome of HCoV-EMC/2012 using an unbiased virus discovery approach involving next-generation sequencing techniques, which enabled subsequent state-of-the-art bioinformatics, phylogenetics, and taxonomic analyses. By establishing its complete genome sequence, HCoV-EMC/2012 was characterized as a new genotype which is closely related to bat coronaviruses that are distant from SARS-CoV. We expect that this information will be vital to rapid advancement of both clinical and vital research on this emerging pathogen.
C1 [van Boheemen, Sander; de Graaf, Miranda; Bestebroer, Theo M.; Raj, V. Stalin; Osterhaus, Albert D. M. E.; Haagmans, Bart L.; Fouchier, Ron A. M.] Erasmus MC, Virosci Lab, Rotterdam, Netherlands.
   [Lauber, Chris; Gorbalenya, Alexander E.; Snijder, Eric J.] Leiden Univ, Med Ctr, Ctr Infect Dis, Mol Virol Lab,Dept Med Microbiol, Leiden, Netherlands.
   [Zaki, Ali Moh] Dr Soliman Fakeeh Hosp, Jeddah, Saudi Arabia.
   [Gorbalenya, Alexander E.] Moscow MV Lomonosov State Univ, Fac Bioengn & Bioinformat, Moscow, Russia.
RP Fouchier, RAM (reprint author), Erasmus MC, Virosci Lab, Rotterdam, Netherlands.
EM r.fouchier@erasmusmc.nl
RI Fouchier, Ron A/A-1911-2014; de Graaf, Miranda/K-1262-2018; Fouchier,
   Ron/Y-3755-2019; Snijder, Eric J./E-6073-2018; Gorbalenya, Alexander
   E/J-4818-2012; Victor, Stalin Raj/E-9670-2016
OI Fouchier, Ron A/0000-0001-8095-2869; de Graaf,
   Miranda/0000-0002-7831-0098; Fouchier, Ron/0000-0001-8095-2869; Snijder,
   Eric J./0000-0003-3297-2309; Gorbalenya, Alexander
   E/0000-0002-4967-7341; Osterhaus, Albert/0000-0002-6074-1172; Victor,
   Stalin Raj/0000-0003-2250-8481; Haagmans, Bart/0000-0001-6221-2015
FU European Union under EMPERIE [223498]; European Union under SILVER
   [260644]
FX The research leading to these results has received funding from the
   European Union Seventh Framework Programme (FP7) under EMPERIE grant
   agreement no. 223498 and SILVER grant agreement no. 260644.
CR Adams MJ, 2012, ARCH VIROL, V157, P1411, DOI 10.1007/s00705-012-1299-6
   Bermingham A., 2012, EURO SURVEILL, V17
   Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334
   Cornman VM, 2012, EURO SURVEILL, V17
   Cruz JLG, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002090
   Darriba D, 2011, BIOINFORMATICS, V27, P1164, DOI 10.1093/bioinformatics/btr088
   de Groot RJ, 2012, VIRUS TAXONOMY, P806
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Firth AE, 2012, J GEN VIROL, V93, P1385, DOI 10.1099/vir.0.042499-0
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Gloza-Rausch F, 2008, EMERG INFECT DIS, V14, P626, DOI 10.3201/eid1404.071439
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Gorbalenya AE, 2010, ANTIVIR RES, V87, P95, DOI 10.1016/j.antiviral.2010.02.005
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hall, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Holmes KV, 1996, FIELDS VIROLOGY, P1075
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Keng CT, 2011, MICROBES INFECT, V13, P179, DOI 10.1016/j.micinf.2010.10.017
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lauber C, 2012, J VIROL, V86, P3890, DOI 10.1128/JVI.07173-11
   Leontovich AM, 2008, BAGG BLOCKS ACCEPTIN
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Mazumder R, 2002, NUCLEIC ACIDS RES, V30, P5229, DOI 10.1093/nar/gkf645
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   MCINTOSH K, 1996, FIELDS VIROLOGY, P1095
   Narayanan K, 2008, NIDOVIRUSES, P235
   Oostra M, 2007, J VIROL, V81, P13876, DOI 10.1128/JVI.01631-07
   Pasternak AO, 2006, J GEN VIROL, V87, P1403, DOI 10.1099/vir.0.81611-0
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pewe L, 2005, J VIROL, V79, P11335, DOI 10.1128/JVI.79.17.11335-11342.2005
   Pfefferle S, 2009, EMERG INFECT DIS, V15, P1377, DOI 10.3201/eid1509.090224
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Reusken CBEM, 2010, VECTOR-BORNE ZOONOT, V10, P785, DOI 10.1089/vbz.2009.0173
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sawicki SG, 2007, J VIROL, V81, P20, DOI 10.1128/JVI.01358-06
   Senanayake SD, 1997, VIRUS RES, V48, P101, DOI 10.1016/S0168-1702(96)01423-2
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   SNIJDER EJ, 1991, VIROLOGY, V180, P448, DOI 10.1016/0042-6822(91)90056-H
   Sola I, 2011, RNA BIOL, V8, P237, DOI 10.4161/rna.8.2.14991
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vijaykrishna D, 2007, J VIROL, V81, P4012, DOI 10.1128/JVI.02605-06
   WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005
   Zaki AM, 2012, N ENGL J ME IN PRESS
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Zlateva KT, 2012, ARCH VIROL IN PRESS
NR 54
TC 368
Z9 373
U1 16
U2 93
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD NOV-DEC
PY 2012
VL 3
IS 6
AR e00473-12
DI 10.1128/mBio.00473-12
PG 9
WC Microbiology
SC Microbiology
GA 064UK
UT WOS:000313100700029
PM 23170002
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Cinatl, J
   Morgenstern, B
   Bauer, G
   Chandra, P
   Rabenau, H
   Doerr, HW
AF Cinatl, J
   Morgenstern, B
   Bauer, G
   Chandra, P
   Rabenau, H
   Doerr, HW
TI Glycyrrhizin, an active component of liquorice roots, and replication of
   SARS-associated coronavirus
SO LANCET
LA English
DT Article
ID NITRIC-OXIDE
AB The outbreak of SARS warrants the search for antiviral compounds to treat the disease. At present, no specific treatment has been identified for SARS-associated coronavirus Infection. We assessed the antiviral potential of ribavirin, 6-azauridine, pyrazofurin, mycophenolic acid, and glycyrrhizin against two clinical Isolates of coronavirus (FFM-1 and FFM-2) from patients with SARS admitted to the clinical centre of Frankfurt University, Germany. Of all the compounds, glycyrrhizin was the most active in inhibiting replication of the SARS-associated virus. Our findings suggest that glycyrrhizin should be assessed for treatment of SARS.
C1 Univ Frankfurt, Sch Med, Inst Med Virol, D-60596 Frankfurt, Germany.
RP Cinatl, J (reprint author), Univ Frankfurt, Sch Med, Inst Med Virol, Paul Ehrlich Str 40, D-60596 Frankfurt, Germany.
CR BOOTH CM, 2003, JAMA-J AM MED ASSOC, V289, P1
   Crance JM, 2003, ANTIVIR RES, V58, P73, DOI 10.1016/S0166-3542(02)00185-7
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Jeong HG, 2002, FEBS LETT, V513, P208, DOI 10.1016/S0014-5793(02)02311-6
   Lin YL, 1997, J VIROL, V71, P5227, DOI 10.1128/JVI.71.7.5227-5235.1997
NR 5
TC 367
Z9 448
U1 16
U2 56
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 14
PY 2003
VL 361
IS 9374
BP 2045
EP 2046
DI 10.1016/S0140-6736(03)13615-X
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 689JT
UT WOS:000183488900013
PM 12814717
OA Bronze
DA 2020-04-03
ER

PT J
AU Meyers, LA
   Pourbohloul, B
   Newman, MEJ
   Skowronski, DM
   Brunham, RC
AF Meyers, LA
   Pourbohloul, B
   Newman, MEJ
   Skowronski, DM
   Brunham, RC
TI Network theory and SARS: predicting outbreak diversity
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
DE SARS; epidemiology; intervention; contact network; mathematical model
ID ACUTE RESPIRATORY SYNDROME; INFECTIOUS-DISEASES; MODEL; TRANSMISSION;
   SPREAD; CORONAVIRUS; EPIDEMICS
AB Many infectious diseases spread through populations via the networks formed by physical contacts among individuals. The patterns of these contacts tend to be highly heterogeneous. Traditional "compartmental" modeling in epidemiology, however, assumes that population groups are fully mixed, that is, every individual has an equal chance of spreading the disease to every other. Applications of compartmental models to Severe Acute Respiratory Syndrome (SARS) resulted in estimates of the fundamental quantity called the basic reproductive number R-0-the number of new cases of SARS resulting from a single initial case-above one, implying that, without public health intervention, most outbreaks should spark large-scale epidemics. Here we compare these predictions to the early epidemiology of SARS. We apply the methods of contact network epidemiology to illustrate that for a single value of R-0, any two outbreaks, even in the same setting, may have very different epidemiological outcomes. We offer quantitative insight into the heterogeneity of SARS outbreaks worldwide, and illustrate the utility of this approach for assessing public health strategies. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Univ Texas, Sect Integrat Biol, Austin, TX 78712 USA.
   Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA.
   Santa Fe Inst, Santa Fe, NM 87501 USA.
   Univ British Columbia, Ctr Dis Control, Vancouver, BC V5Z 4R4, Canada.
   Univ Michigan, Ctr Study Compex Syst, Randall Lab, Ann Arbor, MI 48109 USA.
RP Meyers, LA (reprint author), Univ Texas, Sect Integrat Biol, 1 Univ Stn C0930, Austin, TX 78712 USA.
EM laurenmeyers@mail.utexas.edu
OI Meyers, Lauren/0000-0002-5828-8874
CR Anderson R. M., 1991, INFECT DIS HUMANS DY
   Bailey NTJ, 1975, MATH THEORY INFECT D
   Ball F, 1997, ANN APPL PROBAB, V7, P46
   Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509
   *BC STAT, 2003, 2001 CENS PROF BRIT
   *BC STAT, 2002, LAB FORC EMPL UN REL
   BECKER N, 1977, BIOMETRICS, V33, P515, DOI 10.2307/2529366
   BOOTH CM, 2003, JAMA-J AM MED ASSOC, DOI UNSP 289.21.JOC30885
   *CDCP, 2003, SEV AC RESP SYNDR SA
   Chowell G, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.066102
   Chowell G, 2003, J THEOR BIOL, V224, P1, DOI 10.1016/S0022-5193(03)00228-5
   CHOWELL G, 2004, MODEL PARAMETERS OUT
   *CTR HLTH SERV POL, 2002, BRIT COL HLTH ATL
   Cyranoski D, 2003, NATURE, V423, P467, DOI 10.1038/423467a
   Diekmann O, 1998, J APPL PROBAB, V35, P448, DOI 10.1017/S0021900200015072
   DONNELLY CA, 2003, LANCET, V1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Durrett R, 1999, SIAM REV, V41, P677, DOI 10.1137/S0036144599354707
   Eubank S, 2004, NATURE, V429, P180, DOI 10.1038/nature02541
   Farrington CP, 2003, BIOSTATISTICS, V4, P279, DOI 10.1093/biostatistics/4.2.279
   Ferguson NM, 2000, SEX TRANSM DIS, V27, P600, DOI 10.1097/00007435-200011000-00008
   GREENHALGH D, 1986, [No title captured], V2, P339
   Hethcote HW, 2000, SIAM REV, V42, P599, DOI 10.1137/S0036144500371907
   HETHCOTE HW, 1984, GONORRHEA TRANSMISSI
   Keeling MJ, 1997, P ROY SOC B-BIOL SCI, V264, P1149, DOI 10.1098/rspb.1997.0159
   Keeling MJ, 2003, NATURE, V421, P136, DOI 10.1038/nature01343
   Kleczkowski A, 1999, PHYSICA A, V274, P355, DOI 10.1016/S0378-4371(99)00393-3
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   LEFEVRE C, 1989, MATH BIOSCI, V95, P27, DOI 10.1016/0025-5564(89)90049-7
   Leo Y. S., 2003, Morbidity and Mortality Weekly Report, V52, P405
   LIPSITCH M, 2003, TRANSMISSION DYNAMIC, DOI UNSP 1086616
   Lloyd AL, 2001, SCIENCE, V292, P1316, DOI 10.1126/science.1061076
   LONGINI IM, 1988, MATH BIOSCI, V90, P367, DOI 10.1016/0025-5564(88)90075-2
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MASLOV S, 2001, CONDMAT025379
   Meyers LA, 2003, EMERG INFECT DIS, V9, P204, DOI 10.3201/eid0902.020188
   Morris M., 1995, EPIDEMIC MODELS THEI, P302
   Muller J, 2000, J MATH BIOL, V41, P143, DOI 10.1007/s002850070003
   Newman MEJ, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.016128
   Pastor-Satorras R, 2001, PHYS REV LETT, V86, P3200, DOI 10.1103/PhysRevLett.86.3200
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   POURBOHLOUL B, IN PRESS HALTING SPR
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Renshaw E, 1991, MODELLING BIOL POPUL
   RILEY S, 2003, TRANSMISSION DYNAMIC, DOI UNSP 1086478
   RITTON T, 2002, SCAND J STAT, V29, P375
   Sander LM, 2002, MATH BIOSCI, V180, P293, DOI 10.1016/S0025-5564(02)00117-7
   SATTENSPIEL L, 1988, MATH BIOSCI, V90, P341, DOI 10.1016/0025-5564(88)90074-0
   Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6
   Van der Ploeg CPB, 1998, INTERFACES, V28, P84, DOI 10.1287/inte.28.3.84
   *VANC SCH BOARD, 2002, VANC SCH BOARD DEC 2
   *WHO, 2003, SEV ACUT RESP SYNDR
   Xu RH, 2004, EMERG INFECT DIS, V10, P1030, DOI 10.3201/eid1006.030852
   Yu ITS, 2004, NEW ENGL J MED, V350, P1731, DOI 10.1056/NEJMoa032867
   2003, SUMMARY SEVERE ACUTE
   2001, HOUSEHOLD SIZE CENSU
NR 56
TC 358
Z9 370
U1 11
U2 78
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-5193
EI 1095-8541
J9 J THEOR BIOL
JI J. Theor. Biol.
PD JAN 7
PY 2005
VL 232
IS 1
BP 71
EP 81
DI 10.1016/j.jtbi.2004.07.026
PG 11
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 873TV
UT WOS:000225304900008
PM 15498594
DA 2020-04-03
ER

PT J
AU Reusken, CBEM
   Haagmans, BL
   Muller, MA
   Gutierrez, C
   Godeke, GJ
   Meyer, B
   Muth, D
   Raj, VS
   Smits-De Vries, L
   Corman, VM
   Drexler, JF
   Smits, SL
   El Tahir, YE
   De Sousa, R
   van Beek, J
   Nowotny, N
   van Maanen, K
   Hidalgo-Hermoso, E
   Bosch, BJ
   Rottier, P
   Osterhaus, A
   Gortazar, C
   Drosten, C
   Koopmans, MPG
AF Reusken, Chantal B. E. M.
   Haagmans, Bart L.
   Mueller, Marcel A.
   Gutierrez, Carlos
   Godeke, Gert-Jan
   Meyer, Benjamin
   Muth, Doreen
   Raj, V. Stalin
   Smits-De Vries, Laura
   Corman, Victor M.
   Drexler, Jan-Felix
   Smits, Saskia L.
   El Tahir, Yasmin E.
   De Sousa, Rita
   van Beek, Janko
   Nowotny, Norbert
   van Maanen, Kees
   Hidalgo-Hermoso, Ezequiel
   Bosch, Berend-Jan
   Rottier, Peter
   Osterhaus, Albert
   Gortazar, Christian
   Drosten, Christian
   Koopmans, Marion P. G.
TI Middle East respiratory syndrome coronavirus neutralising serum
   antibodies in dromedary camels: a comparative serological study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID BOVINE CORONAVIRUS; BAT CORONAVIRUS; INFECTION; VIRUS; SEQUENCE;
   PROTEIN; RISK; 2C
AB Background A new betacoronavirus Middle East respiratory syndrome coronavirus (MERS-CoV) has been identified in patients with severe acute respiratory infection. Although related viruses infect bats, molecular clock analyses have been unable to identify direct ancestors of MERS-CoV. Anecdotal exposure histories suggest that patients had been in contact with dromedary camels or goats. We investigated possible animal reservoirs of MERSCoV by assessing specific serum antibodies in livestock.
   Methods We took sera from animals in the Middle East (Oman) and from elsewhere (Spain, Netherlands, Chile). Cattle (n=80), sheep (n=40), goats (n=40), dromedary camels (n=155), and various other camelid species (n=34) were tested for specific serum IgG by protein microarray using the receptor-binding Si subunits of spike proteins of MERS-CoV, severe acute respiratory syndrome coronavirus, and human coronavirus 0C43. Results were confirmed by virus neutralisation tests for MERS-CoV and bovine coronavirus.
   Findings 50 of 50 (100%) sera from Omani camels and 15 of 105 (14%) from Spanish camels had protein-specific antibodies against MERS-CoV spike. Sera from European sheep, goats, cattle, and other camelids had no such antibodies. MERS-CoV neutralising antibody titres varied between 1/320 and 1/2560 for the Omani camel sera and between 1/20 and 1/320 for the Spanish camel sera. There was no evidence for cross-neutralisation by bovine coronavirus antibodies.
   Interpretation MERS-CoV or a related virus has infected camel populations. Both titres and seroprevalences in sera from different locations in Oman suggest widespread infection.
C1 [Reusken, Chantal B. E. M.; Godeke, Gert-Jan; De Sousa, Rita; van Beek, Janko; Koopmans, Marion P. G.] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Res Diagnost & Screening, Div Virol, POB 1, NL-3720 BA Bilthoven, Netherlands.
   [Haagmans, Bart L.; Raj, V. Stalin; Smits, Saskia L.; Osterhaus, Albert; Koopmans, Marion P. G.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
   [Mueller, Marcel A.; Meyer, Benjamin; Muth, Doreen; Corman, Victor M.; Drexler, Jan-Felix; Drosten, Christian] Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
   [Gutierrez, Carlos] Univ Las Palmas Gran Canaria, Fac Vet, Dept Anim Med & Surg, Las Palmas Gran Canaria, Canary Islands, Spain.
   [Smits-De Vries, Laura; Bosch, Berend-Jan; Rottier, Peter] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Utrecht, Netherlands.
   [El Tahir, Yasmin E.] Sultan Qaboos Univ, Coll Agr & Marine Sci, Dept Anim & Vet Sci, Muscat, Oman.
   [Nowotny, Norbert] Sultan Qaboos Univ, Coll Med & Hlth Sci, Dept Microbiol & Immunol, Muscat, Oman.
   [De Sousa, Rita] European Ctr Dis Control, European Programme Publ Hlth Microbiol Training, Stockholm, Sweden.
   [Nowotny, Norbert] Univ Vet Med Vienna, Inst Virol, Viral Zoonoses Emerging & Vector Borne Infect Grp, Vienna, Austria.
   [van Maanen, Kees] Anim Hlth Serv, Deventer, Netherlands.
   [Hidalgo-Hermoso, Ezequiel] Parque Zool Buin Zoo, Dept Conservat & Res, Buin, Chile.
   [Gortazar, Christian] SaBio IREC CSIC UCLM JCCM, Ciudad Real, Spain.
   [Smits, Saskia L.; Osterhaus, Albert] Viroclin Biosci BV, Rotterdam, Netherlands.
RP Reusken, CBEM (reprint author), Natl Inst Publ Hlth & Environm, Ctr Infect Dis Res Diagnost & Screening, Div Virol, POB 1, NL-3720 BA Bilthoven, Netherlands.
EM Chantal.Reusken@RIVM.nl
RI Koopmans, Marion/Y-9170-2019; Meyer, Benjamin/F-3285-2018; Raj, V
   Stalin/E-9670-2016; Corman, Victor Max/K-1319-2019; Drexler, Jan
   Felix/C-1004-2014; Meyer, Bernhard/Q-9413-2016; Gutierrez,
   Carlos/E-2989-2012; Smits, Saskia/A-2953-2014; Nowotny,
   Norbert/A-5474-2019; Mueller, Marcel/O-2425-2019; Gortazar,
   Christian/E-7918-2012
OI Koopmans, Marion/0000-0002-5204-2312; Meyer,
   Benjamin/0000-0003-0601-3550; Raj, V Stalin/0000-0003-2250-8481; Corman,
   Victor Max/0000-0002-3605-0136; Gutierrez, Carlos/0000-0003-0764-7408;
   Nowotny, Norbert/0000-0002-3548-571X; Mueller,
   Marcel/0000-0003-2242-5117; Osterhaus, Albert/0000-0002-6074-1172;
   Drexler, Jan Felix/0000-0002-3509-0232; Haagmans,
   Bart/0000-0001-6221-2015; Gortazar, Christian/0000-0003-0012-4006; De
   Sousa, Rita/0000-0001-6134-6003
FU European Public Health Training Program (Euphem), ECDC, Stockholm,
   Sweden; European UnionEuropean Union (EU) [223498]; ANTIGONE [278976];
   Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG)
   [DR772/3-1]
FX We thank Prof MC Horzinek for helpful suggestions. RDS was funded by the
   European Public Health Training Program (Euphem), ECDC, Stockholm,
   Sweden. Contributions to the study were funded through the European
   Union FP7 projects EMPERIE (contract number 223498; to BLH, SLS, AO, CD)
   and ANTIGONE (contract number 278976; to CG, CD, MPGK, AO). Work in Bonn
   was also funded by Deutsche Forschungsgemeinschaft (DFG grant DR772/3-1
   to CD).
CR AlBarrak AM, 2012, SAUDI MED J, V33, P1265
   Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Assiri A, 2013, N ENGL J MED
   Breban R., 2013, LANCET
   Buchholz U, 2013, EUROSURVEILLANCE, V18, P6
   Cauchemez S., 2013, Eurosurveillance, V18, P20503
   Cernicchiaro N, 2012, J ANIM SCI, V90, P1929, DOI 10.2527/jas.2011-4599
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Cotten M, 2013, EMERG INFECT DIS, V19, P736, DOI 10.3201/eid1905.130057
   Luna LKD, 2007, J CLIN MICROBIOL, V45, P1049, DOI 10.1128/JCM.02426-06
   Drosten C, 2013, LANCET INFECT DIS
   da Siva LVRF, 2012, J INFECT DIS, V206, P384, DOI 10.1093/infdis/jis274
   GERNA G, 1981, J GEN VIROL, V54, P91, DOI 10.1099/0022-1317-54-1-91
   Gutierrez C, 2000, VET PARASITOL, V90, P155, DOI 10.1016/S0304-4017(00)00225-9
   Hufnagel L, 2004, P NATL ACAD SCI USA, V101, P15124, DOI 10.1073/pnas.0308344101
   Ithete NL, 2013, EMERG INFECT DIS
   Jin L, 2007, VIROLOGY, V365, P198, DOI 10.1016/j.virol.2007.03.035
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2013, J VIROL, V87, P8638, DOI 10.1128/JVI.01055-13
   Lau SKP, 2010, J VIROL, V84, P2808, DOI 10.1128/JVI.02219-09
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Muller MA, 2012, MBIO, V3, DOI 10.1128/mBio.00515-12
   Ohlson A, 2010, VET REC, V167, P201, DOI 10.1136/vr.c4119
   Pfefferle S, 2009, EMERG INFECT DIS, V15, P1377, DOI 10.3201/eid1509.090224
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reusken C, 2013, EUROSURVEILLANCE, V18, P2, DOI 10.2807/1560-7917.ES2013.18.14.20441
   Reusken CBEM, 2010, VECTOR-BORNE ZOONOT, V10, P785, DOI 10.1089/vbz.2009.0173
   Traven M, 1999, ACTA VET SCAND, V40, P69
   Trujillo D, 2006, FAUNA QUIROPTEROS AR
   Vijgen L, 2006, J VIROL, V80, P7270, DOI 10.1128/JVI.02675-05
   WHO, MIDDL E RESP SYNDR C
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   World Health Organization (WHO), GLOB AL RESP GAR NOV
   Wunschmann A, 2002, J VET DIAGN INVEST, V14, P441
   Yang DK, 2008, J VET MED SCI, V70, P977, DOI 10.1292/jvms.70.977
NR 37
TC 353
Z9 371
U1 18
U2 128
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD OCT
PY 2013
VL 13
IS 10
BP 859
EP 866
DI 10.1016/S1473-3099(13)70164-6
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 224PD
UT WOS:000324899700020
PM 23933067
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Hota, B
AF Hota, B
TI Contamination, disinfection, and cross-colonization: Are hospital
   surfaces reservoirs for nosocomial infection?
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; INTENSIVE-CARE-UNIT; ENVIRONMENTAL
   CONTAMINATION; ACINETOBACTER-BAUMANNII; CLOSTRIDIUM-DIFFICILE;
   ENTEROCOCCUS-FAECIUM; PSEUDOMONAS-AERUGINOSA; MOLECULAR EPIDEMIOLOGY;
   AIRBORNE TRANSMISSION; RISK-FACTORS
AB Despite documentation that the inanimate hospital environment (e. g., surfaces and medical equipment) becomes contaminated with nosocomial pathogens, the data that suggest that contaminated fomites lead to nosocomial infections do so indirectly. Pathogens for which there is more-compelling evidence of survival in environmental reservoirs include Clostridium difficile, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus, and pathogens for which there is evidence of probable survival in environmental reservoirs include norovirus, influenza virus, severe acute respiratory syndrome associated coronavirus, and Candida species. Strategies to reduce the rates of nosocomial infection with these pathogens should conform to established guidelines, with an emphasis on thorough environmental cleaning and use of Environmental Protection Agency-approved detergent-disinfectants.
C1 Rush Univ, Ctr Med, Stronger Hosp Cook Cty, Infect Dis Sect, Chicago, IL 60612 USA.
RP Hota, B (reprint author), Rush Univ, Ctr Med, Stronger Hosp Cook Cty, Infect Dis Sect, 637 S Wood St, Chicago, IL 60612 USA.
EM bhota@rush.edu
RI Hota, Bala/A-7240-2009
CR Allerberger F, 2002, AM J INFECT CONTROL, V30, P318, DOI 10.1067/mic.2002.127205
   Tuberculosis Along the US-Mexico Border Work Group Centers for Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1
   BEARDPEGLER MA, 1988, J MED MICROBIOL, V26, P251, DOI 10.1099/00222615-26-4-251
   BLOM DW, 2000, 40 INT C ANT AG CHEM, P432
   Bonilla HF, 1996, INFECT CONT HOSP EP, V17, P770
   Bonten MJM, 1996, LANCET, V348, P1615, DOI 10.1016/S0140-6736(96)02331-8
   BOYCE JM, 1992, INFECT CONT HOSP EP, V13, P725
   Boyce JM, 1997, INFECT CONT HOSP EP, V18, P622
   Bradley CR, 1996, J HOSP INFECT, V34, P191, DOI 10.1016/S0195-6701(96)90065-1
   BRADLEY SF, 1991, ANN INTERN MED, V115, P417, DOI 10.7326/0003-4819-115-6-417
   BRADY MT, 1990, AM J INFECT CONTROL, V18, P18, DOI 10.1016/0196-6553(90)90206-8
   Bridges CB, 2003, CLIN INFECT DIS, V37, P1094, DOI 10.1086/378292
   Byers KE, 1998, INFECT CONT HOSP EP, V19, P261
   CDC, 2003, MMWR-MORBID MORTAL W, V52, P1
   *CDCP, PUBL HLTH GUID COMM
   *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P1112
   Cheesbrough JS, 2000, EPIDEMIOL INFECT, V125, P93, DOI 10.1017/S095026889900432X
   CHEN YC, 2004, EMERG INFECT DIS MAY
   COOKSON B, 1989, J CLIN MICROBIOL, V27, P1471, DOI 10.1128/JCM.27.7.1471-1476.1989
   D'Agata EMC, 2000, INFECT CONT HOSP EP, V21, P588, DOI 10.1086/501808
   Das I, 2002, J HOSP INFECT, V50, P110, DOI 10.1053/jhin.2001.1127
   DUCKRO AN, 2003, 13 ANN SCI M SOC HLT, P64
   DUCKWORTH GJ, 1990, J MED MICROBIOL, V32, P195, DOI 10.1099/00222615-32-3-195
   EDMOND MB, 1995, CLIN INFECT DIS, V20, P1126, DOI 10.1093/clinids/20.5.1126
   Fawley WN, 2001, EPIDEMIOL INFECT, V126, P343, DOI 10.1017/S095026880100557X
   FEKETY R, 1981, AM J MED, V70, P906, DOI 10.1016/0002-9343(81)90553-2
   Fitzpatrick F, 2000, J HOSP INFECT, V46, P271, DOI 10.1053/jhin.2000.0838
   Fridkin SK, 1996, CLIN MICROBIOL REV, V9, P499, DOI 10.1128/CMR.9.4.499
   Garner JS, 1996, INFECT CONT HOSP EP, V17, P54, DOI 10.1017/S0195941700006123
   GOULD FK, 1993, LANCET, V342, P241, DOI 10.1016/0140-6736(93)92333-O
   Green J, 1998, J HOSP INFECT, V39, P39, DOI 10.1016/S0195-6701(98)90241-9
   HIRAI Y, 1991, J HOSP INFECT, V19, P191, DOI 10.1016/0195-6701(91)90223-U
   HOTA B, 2003, [No title captured], P369
   Jawad A, 1998, J CLIN MICROBIOL, V36, P1938, DOI 10.1128/JCM.36.7.1938-1941.1998
   Johnson IL, 2000, CAN MED ASSOC J, V162, P1127
   KIM KH, 1981, J INFECT DIS, V143, P42, DOI 10.1093/infdis/143.1.42
   Kim WJ, 1999, J INFECT DIS, V179, P163, DOI 10.1086/314564
   Mah MW, 2001, AM J INFECT CONTROL, V29, P284, DOI 10.1067/mic.2001.114232
   MAKI DG, 1982, NEW ENGL J MED, V307, P1562, DOI 10.1056/NEJM198212163072507
   Marks PJ, 2000, EPIDEMIOL INFECT, V124, P481, DOI 10.1017/S0950268899003805
   Martinez JA, 2003, ARCH INTERN MED, V163, P1905, DOI 10.1001/archinte.163.16.1905
   Montecalvo MA, 1999, ANN INTERN MED, V131, P269, DOI 10.7326/0003-4819-131-4-199908170-00006
   NDAWULA EM, 1991, LANCET, V337, P488, DOI 10.1016/0140-6736(91)93420-E
   Oie S, 1996, J HOSP INFECT, V34, P145, DOI 10.1016/S0195-6701(96)90140-1
   OLSON B, 1984, J INFECT DIS, V150, P808, DOI 10.1093/infdis/150.6.808
   Orr KE, 2002, J HOSP INFECT, V50, P133, DOI 10.1053/jhin.2001.1137
   ORSI GB, 1994, J HOSP INFECT, V27, P49, DOI 10.1016/0195-6701(94)90068-X
   POLISH LB, 1992, NEW ENGL J MED, V326, P721, DOI 10.1056/NEJM199203123261101
   Porwancher R, 1997, INFECT CONT HOSP EP, V18, P771
   Rampling A, 2001, J HOSP INFECT, V49, P109, DOI 10.1053/jhin.2001.1013
   Rogers M, 2000, AM J INFECT CONTROL, V28, P378, DOI 10.1067/mic.2000.109908
   Rutala WA, 1996, AM J INFECT CONTROL, V24, P313, DOI 10.1016/S0196-6553(96)90066-8
   Samore MH, 1996, AM J MED, V100, P32, DOI 10.1016/S0002-9343(96)90008-X
   Sampathkumar P, 2003, MAYO CLIN PROC, V78, P882, DOI 10.4065/78.7.882
   SHAY DK, 1995, J INFECT DIS, V172, P993, DOI 10.1093/infdis/172.4.993
   Simor AE, 2002, INFECT CONT HOSP EP, V23, P261, DOI 10.1086/502046
   Slaughter S, 1996, ANN INTERN MED, V125, P448, DOI 10.7326/0003-4819-125-6-199609150-00004
   Traore O, 2002, J APPL MICROBIOL, V92, P549, DOI 10.1046/j.1365-2672.2002.01560.x
   VAZQUEZ JA, 1993, J INFECT DIS, V168, P195, DOI 10.1093/infdis/168.1.195
   Vazquez JA, 1998, J CLIN MICROBIOL, V36, P421, DOI 10.1128/JCM.36.2.421-426.1998
   Weber DJ, 1997, INFECT CONT HOSP EP, V18, P306
   Webster CA, 1998, EUR J CLIN MICROBIOL, V17, P171, DOI 10.1007/s100960050042
   *WHO, 2004, 1 DAT STAB RES SARS
   Yu ITS, 2004, NEW ENGL J MED, V350, P1731, DOI 10.1056/NEJMoa032867
   ZAIDI M, 2000, PRINCIPLES PRACTICE, P3000
NR 65
TC 349
Z9 360
U1 8
U2 46
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2004
VL 39
IS 8
BP 1182
EP 1189
DI 10.1086/424667
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 904JF
UT WOS:000227491700014
PM 15486843
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU DENBOON, JA
   SNIJDER, EJ
   CHIRNSIDE, ED
   DEVRIES, AAF
   HORZINEK, MC
   SPAAN, WJM
AF DENBOON, JA
   SNIJDER, EJ
   CHIRNSIDE, ED
   DEVRIES, AAF
   HORZINEK, MC
   SPAAN, WJM
TI EQUINE ARTERITIS VIRUS IS NOT A TOGAVIRUS BUT BELONGS TO THE
   CORONAVIRUSLIKE SUPERFAMILY
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID STRAND RNA VIRUSES; BERNE VIRUS; SERINE PROTEASES; MESSENGER-RNAS;
   STRUCTURAL PROTEINS; CYSTEINE PROTEASES; SEQUENCE-ANALYSIS; POLYMERASE;
   GENOME; EXPRESSION
AB The nucleotide sequence of the genome of equine arteritis virus (EAV) was determined from a set of overlapping cDNA clones and was found to contain eight open reading frames (ORFs). ORFs 2 through 7 are expressed from six 3'-coterminal subgenomic mRNAs, which are transcribed from the 3'-terminal quarter of the viral genome. A number of these ORFs are predicted to encode structural EAV proteins. The organization and expression of the 3' part of the EAV genome are remarkably similar to those of coronaviruses and toroviruses. The 5'-terminal three-quarters of the genome contain the putative EAV polymerase gene, which also shares a number of features with the corresponding gene of corona- and toroviruses. The gene contains two large ORFs, ORF1a and ORF1b, with an overlap region of 19 nucleotides. The presence of a "shifty" heptanucleotide sequence in this region and a downstream RNA pseudoknot structure indicate that ORF1b is probably expressed by ribosomal frameshifting. The frameshift-directing potential of the ORF1a/ORF1b overlap region was demonstrated by using a reporter gene. Moreover, the predicted ORF1b product was found to contain four domains which have been identified in the same relative positions in coronavirus and torovirus ORF1b products. The sequences of the EAV and coronavirus ORF1a proteins were found to be much more diverged. The EAV ORF1a product contains a putative trypsinlike serine protease motif. Our data indicate that EAV, presently considered a togavirus, is evolutionarily related to viruses from the coronaviruslike superfamily.
C1 LEIDEN UNIV, FAC MED,INST MED MICROBIOL,DEPT VIROL,POSTBUS 320, 2300 AH LEIDEN, NETHERLANDS.
   STATE UNIV UTRECHT, FAC VET, INST INFECT DIS & IMMUNOL, DEPT VIROL, UTRECHT, NETHERLANDS.
RI Snijder, Eric J./E-6073-2018
OI Snijder, Eric J./0000-0003-3297-2309
CR BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9
   BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   DEVRIES AAF, 1990, NUCLEIC ACIDS RES, V18, P3241, DOI 10.1093/nar/18.11.3241
   DEVRIES AAF, UNPUB
   DOLL E. R., 1957, CORNELL VET, V47, P69
   DOLL E. R., 1957, CORNELL VET, V47, P3
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   GODENY EK, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P36
   GODENY EK, 1990, VIROLOGY, V177, P768, DOI 10.1016/0042-6822(90)90546-4
   GODENY EK, COMMUNICATION
   GOLDBACH R, 1988, INTERVIROLOGY, V29, P260, DOI 10.1159/000150054
   GOLNIK W, 1986, J VET MED B, V33, P413, DOI 10.1111/j.1439-0450.1986.tb00051.x
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7
   HABILI N, 1989, NUCLEIC ACIDS RES, V17, P9543, DOI 10.1093/nar/17.23.9543
   HARDY WR, 1989, J VIROL, V63, P4653, DOI 10.1128/JVI.63.11.4653-4664.1989
   HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0
   HORZINEK M, 1971, ARCH GES VIRUSFORSCH, V33, P306, DOI 10.1007/BF01254687
   HORZINEK MC, 1986, J GEN VIROL, V67, P2475, DOI 10.1099/0022-1317-67-11-2475
   HYLLSETH B, 1973, ARCH GES VIRUSFORSCH, V40, P177, DOI 10.1007/BF01242536
   JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1
   KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1
   LAIN S, 1990, NUCLEIC ACIDS RES, V18, P7003, DOI 10.1093/nar/18.23.7003
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   MURPHY FA, 1980, TOGAVIRUSES BIOL STR, P241
   PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444
   PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717
   POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x
   PORTERFIELD JS, 1978, INTERVIROLOGY, V9, P129, DOI 10.1159/000148930
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   SIDDELL S, 1982, CURR TOP MICROBIOL, V99, P131
   SNIJDER EJ, 1990, J VIROL, V64, P331, DOI 10.1128/JVI.64.1.331-338.1990
   SNIJDER EJ, 1990, NUCLEIC ACIDS RES, V18, P4535, DOI 10.1093/nar/18.15.4535
   SNIJDER EJ, 1988, J GEN VIROL, V69, P2135, DOI 10.1099/0022-1317-69-9-2135
   SNIJDER EJ, 1990, VIROLOGY, V178, P355, DOI 10.1016/0042-6822(90)90332-L
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217
   STRAUSS JH, 1988, ANNU REV MICROBIOL, V42, P657, DOI 10.1146/annurev.mi.42.100188.003301
   STURMAN L, 1985, TRENDS BIOCHEM SCI, V10, P17, DOI 10.1016/0968-0004(85)90010-6
   ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404
   TIMONEY PJ, 1986, RES VET SCI, V41, P279, DOI 10.1016/S0034-5288(18)30616-7
   VANBERLO MF, 1986, VIROLOGY, V152, P492, DOI 10.1016/0042-6822(86)90154-6
   VANBERLO MF, 1986, J GEN VIROL, V67, P1543, DOI 10.1099/0022-1317-67-8-1543
   VANBERLO MF, 1982, VIROLOGY, V118, P345, DOI 10.1016/0042-6822(82)90354-3
   VANDERZEIJST BAM, 1975, VIROLOGY, V68, P418, DOI 10.1016/0042-6822(75)90283-4
   WEISS M, 1983, J GEN VIROL, V64, P1849, DOI 10.1099/0022-1317-64-9-1849
   WESTAWAY EG, 1985, INTERVIROLOGY, V24, P125, DOI 10.1159/000149632
   ZEEGERS JJW, 1976, VIROLOGY, V73, P200, DOI 10.1016/0042-6822(76)90074-X
   Zimmern D., 1988, RNA GENETICS, V2, P211
NR 57
TC 343
Z9 362
U1 6
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUN
PY 1991
VL 65
IS 6
BP 2910
EP 2920
DI 10.1128/JVI.65.6.2910-2920.1991
PG 11
WC Virology
SC Virology
GA FM165
UT WOS:A1991FM16500018
PM 1851863
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Fouchier, RAM
   Hartwig, NG
   Bestebroer, TM
   Niemeyer, B
   de Jong, JC
   Simon, JH
   Osterhaus, ADME
AF Fouchier, RAM
   Hartwig, NG
   Bestebroer, TM
   Niemeyer, B
   de Jong, JC
   Simon, JH
   Osterhaus, ADME
TI A previously undescribed coronavirus associated with respiratory disease
   in humans
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HOSPITALIZED-PATIENTS; VIRUS-INFECTIONS; IDENTIFICATION; COMMUNITY;
   SEQUENCE; ETIOLOGY; CHILDREN; ILLNESS; GENOME; PCR
AB The etiology of acute respiratory tract illnesses is sometimes unclear due to limitations of diagnostic tests or the existence of as-yet-unidentified pathogens. Here we describe the identification and characterization of a not previously recognized coronavirus obtained from an 8-mo-old boy suffering from pneumonia. This coronavirus replicated efficiently in tertiary monkey kidney cells and Vero cells, in contrast to human coronaviruses (HCoV) 229E and OC43. The entire cDNA genome sequence of the previously undescribed coronavirus was determined, revealing that it is most closely related to porcine epidemic diarrhea virus and HCoV 229E. The maximum amino acid sequence identity between ORFs of the newly discovered coronavirus and related group 1 coronaviruses ranged from 43% to 67%. Real-time RT-PCR assays were designed to test for the prevalence of the previously undescribed coronavirus in humans. Using these tests, the virus was detected in four of 139 individuals (3%) who were suffering from respiratory illness with unknown etiology. All four patients suffered from fever, runny nose, and dry cough, and all four had underlying or additional morbidity. Our data will enable the development of diagnostic tests to study the prevalence and clinical impact of this virus in humans in more detail. Moreover, it will be important to discriminate this previously undescribed coronavirus from HCoV 229E and OC43 and the severe acute respiratory syndrome coronavirus.
C1 Erasmus Med Ctr, Dept Virol, NL-3015 GE Rotterdam, Netherlands.
   Erasmus Med Ctr, Dept Pediat, NL-3015 GE Rotterdam, Netherlands.
   CoroNovat BV, NL-3015 GE Rotterdam, Netherlands.
RP Fouchier, RAM (reprint author), Erasmus Med Ctr, Dept Virol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.
EM r.fouchier@erasmusmc.nl
RI Fouchier, Ron/Y-3755-2019; Fouchier, Ron A/A-1911-2014
OI Fouchier, Ron/0000-0001-8095-2869; Fouchier, Ron A/0000-0001-8095-2869;
   Osterhaus, Albert/0000-0002-6074-1172
CR Bertino JS, 2002, AM J MED, V112, p42S
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   DUARTE M, 1994, VIROLOGY, V198, P466, DOI 10.1006/viro.1994.1058
   El-Sahly HM, 2000, CLIN INFECT DIS, V31, P96, DOI 10.1086/313937
   Enjuanes LBD, 2000, VIRUS TAXONOMY CLASS, P835
   Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499
   HOLMES KV, 1996, FUNDAMENTAL VIROLOGY, V1, P1075
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Madeley C.R., 1988, VIRUS MORPHOLOGY
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MCINTOSH K, 1996, VIROLOGY, V1, P1095
   MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779
   MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Tobler K, 1995, Adv Exp Med Biol, V380, P541
   van den Hoogen BG, 2003, J INFECT DIS, V188, P1571, DOI 10.1086/379200
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213
NR 27
TC 340
Z9 367
U1 3
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 20
PY 2004
VL 101
IS 16
BP 6212
EP 6216
DI 10.1073/pnas.0400762101
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 814ME
UT WOS:000220978000095
PM 15073334
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Stevenson, GW
   Hoang, H
   Schwartz, KJ
   Burrough, ER
   Sun, D
   Madson, D
   Cooper, VL
   Pillatzki, A
   Gauger, P
   Schmitt, BJ
   Koster, LG
   Killian, ML
   Yoon, KJ
AF Stevenson, Gregory W.
   Hoang, Hai
   Schwartz, Kent J.
   Burrough, Eric R.
   Sun, Dong
   Madson, Darin
   Cooper, Vickie L.
   Pillatzki, Angela
   Gauger, Philip
   Schmitt, Beverly J.
   Koster, Leo G.
   Killian, Mary L.
   Yoon, Kyoungjin J.
TI Emergence of Porcine epidemic diarrhea virus in the United States:
   clinical signs, lesions, and viral genomic sequences
SO JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION
LA English
DT Article
DE Diarrhea; enteric disease; porcine; Porcine epidemic diarrhea virus
ID TISSUES
AB During the 10 days commencing April 29, 2013, the Iowa State University Veterinary Diagnostic Laboratory received the first 4 of many submissions from swine farms experiencing explosive epidemics of diarrhea and vomiting affecting all ages, with 90-95% mortality in suckling pigs. Histology revealed severe atrophy of villi in all segments of the small intestines with occasional villus-epithelial syncytial cells, but testing for rotaviruses and Transmissible gastroenteritis virus (Alphacoronavirus 1) were negative. Negative-staining electron microscopy of feces revealed coronavirus-like particles and a pan-coronavirus polymerase chain reaction (PCR) designed to amplify a conserved region of the polymerase gene for all members in the family Coronaviridae produced expected 251-bp amplicons. Subsequent sequencing and analysis revealed 99.6-100% identity among the PCR amplicons from the 4 farms and 97-99% identity to the corresponding portion of the polymerase gene of Porcine epidemic diarrhea virus (PEDV) strains, with the highest identity (99%) to strains from China in 2012. Findings were corroborated at National Veterinary Services Laboratories using 2 nested S-gene and 1 nested N-gene PCR tests where the sequenced amplicons also had the highest identity with 2012 China strains. Whole genome sequence for the virus from 2 farms in 2 different states using next-generation sequencing technique was compared to PEDV sequences available in GenBank. The 2013 U.S. PEDV had 96.6-99.5% identity with all known PEDV strains and the highest identity (>99.0%) to some of the 2011-2012 Chinese strains. The nearly simultaneous outbreaks of disease, and high degree of homology (99.6-100%) between the PEDV strains from the 4 unrelated farms, suggests a common source of virus.
C1 [Stevenson, Gregory W.; Schwartz, Kent J.; Burrough, Eric R.; Madson, Darin; Cooper, Vickie L.; Pillatzki, Angela; Gauger, Philip; Yoon, Kyoungjin J.] Iowa State Univ, Dept Vet Diagnost & Prod Anim Med, Ames, IA 50011 USA.
   [Hoang, Hai; Sun, Dong] Iowa State Univ, Dept Vet Microbiol & Prevent Med, Ames, IA 50011 USA.
   [Schmitt, Beverly J.; Koster, Leo G.; Killian, Mary L.] US Anim & Plant Hlth Inspect Serv, Diagnost Virol Lab, Natl Vet Serv Labs, USDA,Vet Serv, Ames, IA USA.
RP Stevenson, GW (reprint author), Iowa State Univ, Vet Diagnost Lab, 1600 South 16th St, Ames, IA 50011 USA.
EM stevengw@iastate.edu; kyoon@iastate.edu
RI Pillatzki, Angela/W-9005-2019
OI Pillatzki, Angela/0000-0002-1888-396X
CR Hermann JR, 2008, CAN J VET RES, V72, P367
   Kim O, 1999, J VET DIAGN INVEST, V11, P458, DOI 10.1177/104063879901100512
   Marthaler D, 2012, VIROLOGY, V433, P85, DOI 10.1016/j.virol.2012.07.006
   Moes E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-6
   Shoup DI, 1996, J VET DIAGN INVEST, V8, P161, DOI 10.1177/104063879600800204
   Song D, 2012, VIRUS GENES, V44, P167, DOI 10.1007/s11262-012-0713-1
NR 6
TC 335
Z9 371
U1 2
U2 104
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1040-6387
EI 1943-4936
J9 J VET DIAGN INVEST
JI J. Vet. Diagn. Invest.
PD SEP
PY 2013
VL 25
IS 5
BP 649
EP 654
DI 10.1177/1040638713501675
PG 6
WC Veterinary Sciences
SC Veterinary Sciences
GA 289CX
UT WOS:000329660100018
PM 23963154
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Yang, HT
   Yang, MJ
   Ding, Y
   Liu, YW
   Lou, ZY
   Zhou, Z
   Sun, L
   Mo, LJ
   Ye, S
   Pang, H
   Gao, GF
   Anand, K
   Bartlam, M
   Hilgenfeld, R
   Rao, ZH
AF Yang, HT
   Yang, MJ
   Ding, Y
   Liu, YW
   Lou, ZY
   Zhou, Z
   Sun, L
   Mo, LJ
   Ye, S
   Pang, H
   Gao, GF
   Anand, K
   Bartlam, M
   Hilgenfeld, R
   Rao, ZH
TI The crystal structures of severe acute respiratory syndrome virus main
   protease and its complex with an inhibitor
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID GENOME SEQUENCE; CORONAVIRUS; PROTEINASE
AB A newly identified severe acute respiratory syndrome coronavirus (SARS-CoV), is the etiological agent responsible for the outbreak of SARS. The SARS-CoV main protease, which is a 33.8-kDa protease (also called the 3C-like protease), plays a pivotal role in mediating viral replication and transcription functions through extensive proteolytic processing of two replicase polyproteins, pp1a (486 kDa) and pp1ab (790 kDa). Here, we report the crystal structures of the SARS-CoV main protease at different pH values and in complex with a specific inhibitor. The protease structure has a fold that can be described as an augmented serine-protease, but with a Cys-His at the active site. This series of crystal structures, which is the first, to our knowledge, of any protein from the SARS virus, reveal substantial pH-dependent conformational changes, and an unexpected mode of inhibitor binding, providing a structural basis for rational drug design.
C1 Tsing Hua Univ, Struct Biol Lab, Beijing 100084, Peoples R China.
   Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100084, Peoples R China.
   Med Univ Lubeck, Inst Biochem, D-23538 Lubeck, Germany.
RP Rao, ZH (reprint author), Tsing Hua Univ, Struct Biol Lab, Beijing 100084, Peoples R China.
RI Hilgenfeld, Rolf/C-9675-2011; Yang, Haitao/G-9116-2012; Sun,
   Lei/F-5167-2012
OI Yang, Maojun/0000-0002-6798-3094; Bartlam, Mark/0000-0001-5173-5080
CR Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Thiel V, 2001, J VIROL, V75, P6676, DOI 10.1128/JVI.75.14.6676-6681.2001
   Zhu JQ, 2003, PROTEIN ENG, V16, P373, DOI 10.1093/protein/gzg041
   Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 17
TC 335
Z9 361
U1 14
U2 45
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 11
PY 2003
VL 100
IS 23
BP 13190
EP 13195
DI 10.1073/pnas.1835675100
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 743LR
UT WOS:000186573700016
PM 14585926
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Song, D
   Park, B
AF Song, Daesub
   Park, Bongkyun
TI Porcine epidemic diarrhoea virus: a comprehensive review of molecular
   epidemiology, diagnosis, and vaccines
SO VIRUS GENES
LA English
DT Article
DE Porcine epidemic diarrhoea virus; Review; Molecular epidemiology;
   Diagnosis; Vaccine
ID TRANSMISSIBLE GASTROENTERITIS VIRUS; CORONAVIRUS SPIKE PROTEIN;
   POLYMERASE-CHAIN-REACTION; SEQUENCE-ANALYSIS; RT-PCR; PROTECTIVE
   IMMUNITY; ANTIBODY-RESPONSES; LYMPHOPROLIFERATIVE RESPONSES;
   DIFFERENTIAL DETECTION; ALPHA-INTERFERON
AB The porcine epidemic diarrhoea virus (PEDV), a member of the Coronaviridae family, causes acute diarrhoea and dehydration in pigs. Although it was first identified in Europe, it has become increasingly problematic in many Asian countries, including Korea, China, Japan, the Philippines, and Thailand. The economic impacts of the PEDV are substantial, given that it results in significant morbidity and mortality in neonatal piglets and is associated with increased costs related to vaccination and disinfection. Recently, progress has been made in understanding the molecular epidemiology of PEDV, thereby leading to the development of new vaccines. In the current review, we first describe the molecular and genetic characteristics of the PEDV. Then we discuss its molecular epidemiology and diagnosis, what vaccines are available, and how PEDV can be treated.
C1 [Park, Bongkyun] Seoul Natl Univ, Dept Vet Virol, Coll Vet Med, Seoul 151742, South Korea.
   [Park, Bongkyun] Seoul Natl Univ, Program Vet Sci BK21, Seoul 151742, South Korea.
   [Song, Daesub] Univ Sci & Technol, Taejon 305350, South Korea.
   [Song, Daesub] Korea Res Inst Biosci & Biotechnol, Viral Infect Dis Res Ctr, Taejon 305806, South Korea.
RP Park, B (reprint author), Seoul Natl Univ, Dept Vet Virol, Coll Vet Med, Seoul 151742, South Korea.
EM parkx026@snu.ac.kr
CR Bae JL, 2003, VACCINE, V21, P4052, DOI 10.1016/S0264-410X(03)00360-8
   Baquilod G. S. V., 2006, Korean Journal of Veterinary Research, V46, P355
   Baudoux P, 1998, J VIROL, V72, P8636, DOI 10.1128/JVI.72.11.8636-8643.1998
   Bernasconi C., 1995, CLIN HISTOPATHOLOGIC, P542
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   BRIDGEN A, 1993, J GEN VIROL, V74, P1795, DOI 10.1099/0022-1317-74-9-1795
   Bridgen A, 1998, ADV EXP MED BIOL, V440, P781
   Callebaut P., 1981, INT C VIR, V420
   CARVAJAL A, 1995, J VET DIAGN INVEST, V7, P60, DOI 10.1177/104063879500700109
   Chae C, 2000, VET REC, V147, P606, DOI 10.1136/vr.147.21.606
   Chang SH, 2002, MOL CELLS, V14, P295
   Chen JF, 2008, VIRUS GENES, V36, P355, DOI 10.1007/s11262-007-0196-7
   Chen JY, 2010, COMP BIOCHEM PHYS B, V155, P155, DOI 10.1016/j.cbpb.2009.10.017
   Chi Y.Z., 2003, J VET RES, V43, P219
   Cruz DJM, 2008, VIRUS RES, V132, P192, DOI 10.1016/j.virusres.2007.10.015
   Curtis KM, 2002, J VIROL, V76, P1422, DOI 10.1128/JVI.76.3.1422-1434.2002
   De Arriba M.L., 1995, P 3 C ESVV INT S, P222
   de Arriba ML, 2002, VET IMMUNOL IMMUNOP, V85, P85, DOI 10.1016/S0165-2427(01)00417-2
   de Arriba ML, 2002, J VIROL METHODS, V105, P37, DOI 10.1016/S0166-0934(02)00063-0
   de Arriba ML, 2002, VET IMMUNOL IMMUNOP, V84, P1, DOI 10.1016/S0165-2427(01)00386-5
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   DEA S, 1985, CAN VET J, V26, P108
   DEBOUCK P, 1980, AM J VET RES, V41, P219
   Dijkman R, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-106
   DUARTE M, 1994, J GEN VIROL, V75, P1195, DOI 10.1099/0022-1317-75-5-1195
   EGBERINK HF, 1988, AM J VET RES, V49, P1320
   GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994
   Ha G.W., 2010, KOREAN J VET PUBLIC, V34, P53
   Haijema BJ, 2004, J VIROL, V78, P3863, DOI 10.1128/JVI.78.8.3863-3871.2004
   HERREWEGH AAPM, 1995, VIROLOGY, V212, P622, DOI 10.1006/viro.1995.1520
   Hou XL, 2007, VACCINE, V26, P24, DOI 10.1016/j.vaccine.2007.10.065
   Hwang Eui-Kyung, 1994, RDA Journal of Agricultural Science Veterinary, V36, P587
   Ishikawa K, 1997, J VIROL METHODS, V69, P191, DOI 10.1016/S0166-0934(97)00157-2
   Jackwood MW, 2001, AVIAN DIS, V45, P366, DOI 10.2307/1592976
   Jinghui F, 2005, VIRUS GENES, V30, P69, DOI 10.1007/s11262-004-4583-z
   Jung K, 2008, VET J, V177, P231, DOI 10.1016/j.tvjl.2007.04.018
   Kang TJ, 2005, PROTEIN EXPRES PURIF, V41, P378, DOI 10.1016/j.pep.2005.02.018
   Kim O, 2002, CAN J VET RES, V66, P112
   Kim SY, 2001, J VET DIAGN INVEST, V13, P516, DOI 10.1177/104063870101300611
   Kocherhans R, 2001, VIRUS GENES, V23, P137, DOI 10.1023/A:1011831902219
   KUSANAGI K, 1992, J VET MED SCI, V54, P313, DOI 10.1292/jvms.54.313
   Kweon C.H., 1994, J VET RES, V34, P321
   Kweon CH, 1999, VACCINE, V17, P2546, DOI 10.1016/S0264-410X(99)00059-6
   Kweon CH, 2000, J VET MED SCI, V62, P961, DOI 10.1292/jvms.62.961
   Kweon CH, 1997, J VET MED SCI, V59, P231, DOI 10.1292/jvms.59.231
   LAUDE H, 1992, J VIROL, V66, P743, DOI 10.1128/JVI.66.2.743-749.1992
   Lee CS, 2008, J VIROL METHODS, V151, P30, DOI 10.1016/j.jviromet.2008.04.001
   Lee DK, 2010, VIRUS RES, V149, P175, DOI 10.1016/j.virusres.2010.01.015
   Li BX, 2007, VIROLOGY, V365, P166, DOI 10.1016/j.virol.2007.03.031
   Lissenberg A, 2005, J VIROL, V79, P15054, DOI 10.1128/JVI.79.24.15054-15063.2005
   Murphy F.A., 1999, VET VIROLOGY, P496
   Narayanan K, 2008, NIDOVIRUSES, P235
   Nguyen VP, 1997, J VIROL, V71, P9278, DOI 10.1128/JVI.71.12.9278-9284.1997
   OFFIT PA, 1985, J VIROL, V54, P58, DOI 10.1128/JVI.54.1.58-64.1985
   Oldham J., 1972, PIG FARMING S    OCT, P72
   Ortego J, 2003, VIROLOGY, V308, P13, DOI 10.1016/S0042-6822(02)00096-X
   Park JH, 2008, VIRUS GENES, V36, P71, DOI 10.1007/s11262-007-0191-z
   Park SJ, 2008, VIRUS GENES, V36, P95, DOI 10.1007/s11262-007-0164-2
   Park SJ, 2007, VIRUS GENES, V35, P321, DOI 10.1007/s11262-007-0096-x
   Park SJ, 2007, VIRUS GENES, V35, P55, DOI 10.1007/s11262-006-0036-1
   Park SJ, 2011, ARCH VIROL, V156, P577, DOI 10.1007/s00705-010-0892-9
   Pensaert M.B., 1982, INT C PIG VET SOC, V52
   PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606
   Pensaert MB, 2006, DIS SWINE, P367
   PIJPERS A, 1993, VET REC, V132, P129, DOI 10.1136/vr.132.6.129
   Puranaveja S, 2009, EMERG INFECT DIS, V15, P1112, DOI 10.3201/eid1507.081256
   Pyo HM, 2009, VACCINE, V27, P2030, DOI 10.1016/j.vaccine.2009.01.130
   Ren XF, 2011, VIRUS GENES, V42, P229, DOI 10.1007/s11262-011-0570-3
   Ren XF, 2011, BIOTECHNOL LETT, V33, P215, DOI 10.1007/s10529-010-0420-8
   Rottier P.J.M., 1995, CORONAVIRIDAE, P115
   SAIF LJ, 1972, INFECT IMMUN, V6, P600, DOI 10.1128/IAI.6.4.600-609.1972
   SAIF LJ, 1993, VET MICROBIOL, V37, P285, DOI 10.1016/0378-1135(93)90030-B
   SAIF LJ, 1999, DIS SWINE, P295
   Sato T, 2011, VIRUS GENES, V43, P72, DOI 10.1007/s11262-011-0617-5
   SCHWARZ B, 1990, J VIROL, V64, P4784, DOI 10.1128/JVI.64.10.4784-4791.1990
   Shibata I, 2001, J VET MED SCI, V63, P655, DOI 10.1292/jvms.63.655
   Song DS, 2007, RES VET SCI, V82, P134, DOI 10.1016/j.rvsc.2006.03.007
   Song DS, 2006, J VET DIAGN INVEST, V18, P278, DOI 10.1177/104063870601800309
   Song DS, 2005, J SWINE HEALTH PROD, V13, P269
   Song DS, 2003, VACCINE, V21, P1833, DOI 10.1016/S0264-410X(03)00027-6
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   Sturman L S, 1984, Adv Exp Med Biol, V173, P25
   SUEYOSHI M, 1995, J COMP PATHOL, V113, P59, DOI 10.1016/S0021-9975(05)80069-6
   Sun DB, 2008, VET MICROBIOL, V131, P73, DOI 10.1016/j.vetmic.2008.02.022
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   To TL, 1998, J GEN VIROL, V79, P2661
   Tobler K, 1996, SCHWEIZ ARCH TIERH, V138, P80
   Tobler K, 1995, Adv Exp Med Biol, V380, P541
   TURGEON DC, 1980, CAN VET J, V21, P100
   Usami Y., 1998, Journal of the Japan Veterinary Medical Association, V51, P652
   Utiger A, 1995, Adv Exp Med Biol, V380, P287
   Ward LA, 1996, CLIN DIAGN LAB IMMUN, V3, P342, DOI 10.1128/CDLI.3.3.342-350.1996
   WOOD EN, 1979, BRIT VET J, V135, P305, DOI 10.1016/S0007-1935(17)32831-2
   WOOD EN, 1977, VET REC, V100, P243, DOI 10.1136/vr.100.12.243
   Woods RD, 2001, CAN J VET RES, V65, P28
   Youn S, 2005, VIROLOGY, V332, P206, DOI 10.1016/j.virol.2004.10.045
   Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005
   Yuan LJ, 1998, J VIROL, V72, P330, DOI 10.1128/JVI.72.1.330-338.1998
NR 99
TC 333
Z9 404
U1 15
U2 189
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-8569
EI 1572-994X
J9 VIRUS GENES
JI Virus Genes
PD APR
PY 2012
VL 44
IS 2
BP 167
EP 175
DI 10.1007/s11262-012-0713-1
PG 9
WC Genetics & Heredity; Virology
SC Genetics & Heredity; Virology
GA 900RB
UT WOS:000300905100002
PM 22270324
DA 2020-04-03
ER

PT J
AU Woo, PCY
   Lau, SKP
   Lam, CSF
   Lau, CCY
   Tsang, AKL
   Lau, JHN
   Bai, R
   Teng, JLL
   Tsang, CCC
   Wang, M
   Zheng, BJ
   Chan, KH
   Yuen, KY
AF Woo, Patrick C. Y.
   Lau, Susanna K. P.
   Lam, Carol S. F.
   Lau, Candy C. Y.
   Tsang, Alan K. L.
   Lau, John H. N.
   Bai, Ru
   Teng, Jade L. L.
   Tsang, Chris C. C.
   Wang, Ming
   Zheng, Bo-Jian
   Chan, Kwok-Hung
   Yuen, Kwok-Yung
TI Discovery of Seven Novel Mammalian and Avian Coronaviruses in the Genus
   Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of
   Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene
   Source of Gammacoronavirus and Deltacoronavirus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; CHINESE HORSESHOE BATS; COMPLETE GENOME;
   SARS-CORONAVIRUS; NATURAL RECOMBINATION; DIFFERENT GENOTYPES; TURKEY
   CORONAVIRUS; MOLECULAR-BIOLOGY; PROTEIN FAMILIES; SOUTHERN CHINA
AB Recently, we reported the discovery of three novel coronaviruses, bulbul coronavirus HKU11, thrush coronavirus HKU12, and munia coronavirus HKU13, which were identified as representatives of a novel genus, Deltacoronavirus, in the subfamily Coronavirinae. In this territory-wide molecular epidemiology study involving 3,137 mammals and 3,298 birds, we discovered seven additional novel deltacoronaviruses in pigs and birds, which we named porcine coronavirus HKU15, white-eye coronavirus HKU16, sparrow coronavirus HKU17, magpie robin coronavirus HKU18, night heron coronavirus HKU19, wigeon coronavirus HKU20, and common moorhen coronavirus HKU21. Complete genome sequencing and comparative genome analysis showed that the avian and mammalian deltacoronaviruses have similar genome characteristics and structures. They all have relatively small genomes (25.421 to 26.674 kb), the smallest among all coronaviruses. They all have a single papain-like protease domain in the nsp3 gene; an accessory gene, NS6 open reading frame (ORF), located between the M and N genes; and a variable number of accessory genes (up to four) downstream of the N gene. Moreover, they all have the same putative transcription regulatory sequence of ACACCA. Molecular clock analysis showed that the most recent common ancestor of all coronaviruses was estimated at approximately 8100 BC, and those of Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus were at approximately 2400 BC, 3300 BC, 2800 BC, and 3000 BC, respectively. From our studies, it appears that bats and birds, the warm blooded flying vertebrates, are ideal hosts for the coronavirus gene source, bats for Alphacoronavirus and Betacoronavirus and birds for Gammacoronavirus and Deltacoronavirus, to fuel coronavirus evolution and dissemination.
C1 [Woo, Patrick C. Y.; Lau, Susanna K. P.; Lam, Carol S. F.; Lau, Candy C. Y.; Tsang, Alan K. L.; Lau, John H. N.; Bai, Ru; Teng, Jade L. L.; Tsang, Chris C. C.; Zheng, Bo-Jian; Chan, Kwok-Hung; Yuen, Kwok-Yung] Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   [Woo, Patrick C. Y.; Lau, Susanna K. P.; Zheng, Bo-Jian; Yuen, Kwok-Yung] Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Woo, Patrick C. Y.; Lau, Susanna K. P.; Zheng, Bo-Jian; Yuen, Kwok-Yung] Univ Hong Kong, Res Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China.
   [Woo, Patrick C. Y.; Lau, Susanna K. P.; Zheng, Bo-Jian; Yuen, Kwok-Yung] Univ Hong Kong, Carol Yu Ctr Infect, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Ming] Guangzhou Ctr Dis Control & Prevent, Guangzhou, Guangdong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
EM kyyuen@hkucc.hku.hk
RI Lau, Susanna Kar Pui/AAJ-6848-2020; Tsang, Chi-Ching/H-9170-2012
OI Lau, Susanna Kar Pui/0000-0002-1383-7374; Tsang,
   Chi-Ching/0000-0001-6705-2866; Yuen, Kwok-yung/0000-0002-2083-1552
FU Research Grant CouncilHong Kong Research Grants Council [HKU 780709 M];
   University of Hong KongUniversity of Hong Kong; Tung Wah Group of
   Hospitals Fund for Research in Infectious Diseases; HKSAR Research Fund
   for the Control of Infectious Diseases of the Health, Welfare and Food
   Bureau; Shaw Foundation
FX We are grateful to the generous support of Hui Hoy and Hui Ming in the
   genomic sequencing platform and Eunice Lam for her generous donation to
   emerging infectious disease research. This work is partly supported by
   Research Grant Council grant HKU 780709 M; University Development Fund
   and Outstanding Young Researcher Award, The University of Hong Kong; The
   Tung Wah Group of Hospitals Fund for Research in Infectious Diseases;
   the HKSAR Research Fund for the Control of Infectious Diseases of the
   Health, Welfare and Food Bureau; and the Shaw Foundation.
CR Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37
   Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Cao J, 2008, VIRUS RES, V136, P43, DOI 10.1016/j.virusres.2008.04.015
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Chu DKW, 2008, J GEN VIROL, V89, P1282, DOI 10.1099/vir.0.83605-0
   Circella E, 2007, AVIAN PATHOL, V36, P251, DOI 10.1080/03079450701344738
   Dominguez SR, 2007, EMERG INFECT DIS, V13, P1295, DOI 10.3201/eid1309.070491
   Dong BQ, 2007, J VIROL, V81, P6920, DOI 10.1128/JVI.00299-07
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Gloza-Rausch F, 2008, EMERG INFECT DIS, V14, P626, DOI 10.3201/eid1404.071439
   Gomaa MH, 2008, VIRUS RES, V135, P237, DOI 10.1016/j.virusres.2008.03.020
   Gough RE, 2006, AVIAN PATHOL, V35, P122, DOI 10.1080/03079450600597733
   Groot de RJ, 2011, VIRUS TAXONOMY, P806
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hasoksuz M, 2007, J VIROL, V81, P4981, DOI 10.1128/JVI.02361-06
   Herrewegh AAPM, 1998, J VIROL, V72, P4508, DOI 10.1128/JVI.72.5.4508-4514.1998
   Huang Y, 2008, NUCLEIC ACIDS RES, V36, pD504, DOI 10.1093/nar/gkm754
   Jonassen CM, 2005, J GEN VIROL, V86, P1597, DOI 10.1099/vir.0.80927-0
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2007, VIROLOGY, V367, P428, DOI 10.1016/j.virol.2007.06.009
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Lau SKP, 2011, J VIROL, V85, P11325, DOI 10.1128/JVI.05512-11
   Lau SKP, 2010, J VIROL, V84, P11385, DOI 10.1128/JVI.01121-10
   Lau SKP, 2010, J VIROL, V84, P2808, DOI 10.1128/JVI.02219-09
   Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Liu SW, 2005, J GEN VIROL, V86, P719, DOI 10.1099/vir.0.80546-0
   Mardani K, 2008, J VIROL, V82, P2013, DOI 10.1128/JVI.01694-07
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mihindukulasuriya KA, 2008, J VIROL, V82, P5084, DOI 10.1128/JVI.02722-07
   Muradrasoli S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013640
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Robertson MP, 2005, PLOS BIOL, V3, P86, DOI 10.1371/journal.pbio.0030005
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175
   Stoffel W., 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143
   Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872
   Tang XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Woo PCY, 2006, J VIROL, V80, P7136, DOI 10.1128/JVI.00509-06
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   Woo PCY, 2009, J VIROL, V83, P908, DOI 10.1128/JVI.01977-08
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   Woo PCY, 2004, LANCET, V363, P841, DOI 10.1016/S0140-6736(04)15729-2
   Zhang JQ, 2007, VIROLOGY, V369, P92, DOI 10.1016/j.virol.2007.06.035
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
NR 54
TC 332
Z9 378
U1 15
U2 70
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD APR
PY 2012
VL 86
IS 7
BP 3995
EP 4008
DI 10.1128/JVI.06540-11
PG 14
WC Virology
SC Virology
GA 906TV
UT WOS:000301371500055
PM 22278237
OA Green Published, Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Chou, KC
   Wei, DQ
   Zhong, WZ
AF Chou, KC
   Wei, DQ
   Zhong, WZ
TI Binding mechanism of coronavirus main proteinase with ligands and its
   implication to drug design against SARS
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE SARS; coronavirus proteinase; KZ7088; AG7088; binding pocket;
   octapeptide substrate; "distorted key" mechanism
ID PROTEASE CLEAVAGE SITES; TERTIARY STRUCTURE; PREDICTION; COMPLEX; MODEL;
   CDK5
AB In order to stimulate the development of drugs against severe acute respiratory syndrome (SARS), based on the atomic coordinates of the SARS coronavirus main proteinase determined recently [Science 13 (May) (2003) (online)], studies of docking KZ7088 (a derivative of AG7088) and the AVLQSGFR octapeptide to the enzyme were conducted. It has been observed that both the above compounds interact with the active site of the SARS enzyme through six hydrogen bonds. Also, a clear definition of the binding pocket for KZ7088 has been presented. These findings may provide a solid basis for subsite analysis and mutagenesis relative to rational design of highly selective inhibitors for therapeutic application. Meanwhile, the idea of how to develop inhibitors of the SARS enzyme based on the knowledge of its own peptide substrates (the so-called "distorted key" approach) was also briefly elucidated. (C) 2003 Elsevier Inc. All rights reserved.
C1 Gordon Life Sci Inst, Kalamazoo, MI 49009 USA.
   Tianjin Normal Univ, TIBDD, Tianjin, Peoples R China.
RP Chou, KC (reprint author), Gordon Life Sci Inst, 7088 Arbor Valley, Kalamazoo, MI 49009 USA.
RI Chou, Kuo-Chen/A-8340-2009
CR ANAND K, 2003, SCIENCE
   Chou KC, 1996, ANAL BIOCHEM, V233, P1, DOI 10.1006/abio.1996.0001
   Chou KC, 1999, BIOCHEM BIOPH RES CO, V259, P420, DOI 10.1006/bbrc.1999.0792
   Chou KC, 2000, FEBS LETT, V470, P249, DOI 10.1016/S0014-5793(00)01333-8
   Chou KC, 2002, BIOCHEM BIOPH RES CO, V292, P702, DOI 10.1006/bbrc.2002.6686
   CHOU KC, 1993, J BIOL CHEM, V268, P16938
   MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X
   Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4
   Zhang JW, 2002, PROTEINS, V48, P447, DOI 10.1002/prot.10173
NR 10
TC 330
Z9 339
U1 5
U2 22
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 15
PY 2003
VL 308
IS 1
BP 148
EP 151
DI 10.1016/S0006-291X(03)01342-1
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 709AG
UT WOS:000184602100023
PM 12890493
OA Bronze
DA 2020-04-03
ER

PT J
AU Rakes, CP
   Arruda, E
   Ingram, JM
   Hoover, GE
   Zambrano, JC
   Hayden, FG
   Platts-Mills, TAE
   Heymann, PW
AF Rakes, CP
   Arruda, E
   Ingram, JM
   Hoover, GE
   Zambrano, JC
   Hayden, FG
   Platts-Mills, TAE
   Heymann, PW
TI Rhinovirus and respiratory syncytial virus in wheezing children
   requiring emergency care - IgE and eosinophil analyses
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
ID ASTHMATIC SUBJECTS; CATIONIC PROTEIN; INFECTION; EXACERBATIONS; INFANTS;
   LYMPHOCYTES; COMMUNITY; ADULTS; RNA; PCR
AB This cross-sectional emergency department study of 70 wheezing children and 59 control subjects (2 mo to 16 yr of age) examined the prevalence of respiratory viruses and their relationship to age, atopic status, and eosinophil markers. Nasal washes were cultured for respiratory viruses, assayed for respiratory syncytial virus (RSV) antigen, and tested for coronavirus and rhinovirus RNA using reverse transcription-PCR (RT-PCR). Also evaluated were eosinophil numbers and eosinophil cationic protein (ECP) in both nasal washes and serum, along with total IgE and specific IgE antibody in serum. Respiratory viruses were detected in 82% (18 of 22) of wheezing infants younger than 2 yr of age and in 83% (40 of 48) of older wheezing children. The predominant pathogens were RSV in infants (detected in 68% of wheezing subjects) and rhinovirus in older wheezing children (71%), and both were strongly associated with wheezing (p < 0.005). RSV was largely limited to wheezing children younger than 24 mo of age, but rhinovirus was detected by KT-PCR in 41% of all infants and in 35% of nonwheezing control subjects older than 2 yr of age. After 2 yr of age the strongest odds for wheezing were observed among those who had a positive RT-PCR test for rhinovirus together with a positive serum radioallergosorbent testing (RAST), nasal eosinophilia, or elevated nasal ECP (odds ratios = 17, 21, and 25, respectively). Results from this study demonstrate that a large majority of emergent wheezing illnesses during childhood (2 to 16 yr of age) can be linked to infection with rhinovirus, and that these wheezing attacks are most likely in those who have rhinovirus together with evidence of atopy or eosinophilic airway inflammation.
C1 Univ Virginia, Hlth Sci Ctr, Dept Pediat, Charlottesville, VA 22908 USA.
   Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22908 USA.
   Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA.
RP Rakes, CP (reprint author), Univ Virginia, Hlth Sci Ctr, Dept Pediat, MR-4 Bldg,Box 29,Room 5061, Charlottesville, VA 22908 USA.
RI Arruda, Eurico/E-4101-2012
FU PHS HHSUnited States Public Health Service [1U01-A1-34607]
CR ARRUDA E, 1993, MOL CELL PROBE, V7, P373, DOI 10.1006/mcpr.1993.1055
   CALHOUN WJ, 1994, [No title captured], V94, P2220
   CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282
   DUFF AL, 1993, PEDIATRICS, V92, P535
   FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879
   FREEMAN GL, 1962, AM J DIS CHILD, V104, P44
   FRICK OL, 1986, J ALLERGY CLIN IMMUN, V78, P1013, DOI 10.1016/0091-6749(86)90295-2
   GARAFALO R, 1992, J PEDIATR, V120, P28
   Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088
   Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003
   Gern JE, 1996, J IMMUNOL, V157, P1605
   Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x
   GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301
   HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976
   INGRAM JM, 1995, J PEDIATR-US, V127, P558, DOI 10.1016/S0022-3476(95)70112-5
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Koller DY, 1997, J ALLERGY CLIN IMMUN, V99, P752, DOI 10.1016/S0091-6749(97)80007-3
   LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   OPENSHAW PJM, 1992, INT IMMUNOL, V4, P493, DOI 10.1093/intimm/4.4.493
   PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x
   Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791
   SKONER DP, 1995, CLIN EXP ALLERGY, V25, P561, DOI 10.1111/j.1365-2222.1995.tb01095.x
   SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802
   Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026
   Srikiatkhachorn A, 1997, J VIROL, V71, P678, DOI 10.1128/JVI.71.1.678-685.1997
   WINTHER B, 1994, DAN MED BULL, V41, P193
NR 28
TC 325
Z9 332
U1 0
U2 5
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAR
PY 1999
VL 159
IS 3
BP 785
EP 790
DI 10.1164/ajrccm.159.3.9801052
PG 6
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 175QQ
UT WOS:000079106600014
PM 10051251
DA 2020-04-03
ER

PT J
AU Zust, R
   Cervantes-Barragan, L
   Habjan, M
   Maier, R
   Neuman, BW
   Ziebuhr, J
   Szretter, KJ
   Baker, SC
   Barchet, W
   Diamond, MS
   Siddell, SG
   Ludewig, B
   Thiel, V
AF Zuest, Roland
   Cervantes-Barragan, Luisa
   Habjan, Matthias
   Maier, Reinhard
   Neuman, Benjamin W.
   Ziebuhr, John
   Szretter, Kristy J.
   Baker, Susan C.
   Barchet, Winfried
   Diamond, Michael S.
   Siddell, Stuart G.
   Ludewig, Burkhard
   Thiel, Volker
TI Ribose 2 '-O-methylation provides a molecular signature for the
   distinction of self and non-self mRNA dependent on the RNA sensor Mda5
SO NATURE IMMUNOLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; RIG-I; SARS-CORONAVIRUS; INNATE IMMUNITY;
   STRANDED-RNA; VACCINIA VIRUS; INTERFERON; PROTEIN; RECOGNITION;
   INFECTION
AB The 5' cap structures of higher eukaryote mRNAs have ribose 2'-O-methylation. Likewise, many viruses that replicate in the cytoplasm of eukaryotes have evolved 2'-O-methyltransferases to autonomously modify their mRNAs. However, a defined biological role for 2'-O-methylation of mRNA remains elusive. Here we show that 2'-O-methylation of viral mRNA was critically involved in subverting the induction of type I interferon. We demonstrate that human and mouse coronavirus mutants lacking 2'-O-methyltransferase activity induced higher expression of type I interferon and were highly sensitive to type I interferon. Notably, the induction of type I interferon by viruses deficient in 2'-O-methyltransferase was dependent on the cytoplasmic RNA sensor Mda5. This link between Mda5-mediated sensing of viral RNA and 2'-O-methylation of mRNA suggests that RNA modifications such as 2'-O-methylation provide a molecular signature for the discrimination of self and non-self mRNA.
C1 [Zuest, Roland; Cervantes-Barragan, Luisa; Habjan, Matthias; Maier, Reinhard; Ludewig, Burkhard; Thiel, Volker] Kantonal Hosp St Gallen, Inst Immunobiol, St Gallen, Switzerland.
   [Neuman, Benjamin W.] Univ Reading, Sch Biol Sci, Reading, Berks, England.
   [Ziebuhr, John] Queens Univ Belfast, Ctr Infect & Immun, Belfast, Antrim, North Ireland.
   [Ziebuhr, John] Univ Giessen, Inst Med Virol, Giessen, Germany.
   [Szretter, Kristy J.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, Dept Med, St Louis, MO 63110 USA.
   [Szretter, Kristy J.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
   [Baker, Susan C.] Loyola Univ, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL 60153 USA.
   [Barchet, Winfried] Univ Bonn, Univ Hosp, Inst Clin Chem & Pharmacol, D-5300 Bonn, Germany.
   [Siddell, Stuart G.] Univ Bristol, Sch Med & Vet Sci, Dept Cellular & Mol Med, Bristol, Avon, England.
   [Ludewig, Burkhard; Thiel, Volker] Univ Zurich, Vetsuisse Fac, Zurich, Switzerland.
RP Thiel, V (reprint author), Kantonal Hosp St Gallen, Inst Immunobiol, St Gallen, Switzerland.
EM volker.thiel@kssg.ch
RI Jha, Babal/AAC-8337-2020; Maier, Reinhard/AAH-5159-2020; Thiel,
   Volker/AAI-2391-2019; Diamond, Michael/AAH-1733-2019; Ziebuhr,
   John/G-7669-2015
OI Jha, Babal/0000-0002-7660-5255; Diamond, Michael/0000-0002-8791-3165;
   Habjan, Matthias/0000-0002-3623-4496; Barchet,
   Winfried/0000-0002-6745-6606; Neuman, Benjamin/0000-0003-1240-8954;
   Thiel, Volker/0000-0002-5783-0887; Siddell, Stuart/0000-0002-8702-7868;
   Szretter, Kristy/0000-0003-0391-2307; Ziebuhr, John/0000-0002-5741-8825
FU Swiss National Science FoundationSwiss National Science Foundation
   (SNSF); European Commission (TOLERAGE)European Commission Joint Research
   Centre; Novartis Foundation for Biomedical Research, Switzerland; German
   Ministry of Education and ResearchFederal Ministry of Education &
   Research (BMBF); Austrian Science FundAustrian Science Fund (FWF) [FWF
   J3044]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG);
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI060915, AI085089,
   U54 AI081680]; Medical Research CouncilMedical Research Council UK
   (MRC); Wellcome TrustWellcome Trust; Biotechnology and Biological
   Sciences Research CouncilBiotechnology and Biological Sciences Research
   Council (BBSRC) [BB/G012067/1]
FX We thank V. Lohmann (University of Heidelberg) for Huh-7 cells; G. L.
   Smith (Imperial College, London) for D980R cells; S. G. Sawicki (Medical
   University of Ohio) for 17Cl1 cells; M. Pelegrin (Institut de Genetique
   Moleculaire de Montpellier) for LL171 cells; L. Onder for assistance
   with fluorescence microscopy; and R. de Giuli, B. Schelle and N. Karl
   for technical assistance. This study was supported by the Swiss National
   Science Foundation, the European Commission (TOLERAGE), the Novartis
   Foundation for Biomedical Research, Switzerland, the German Ministry of
   Education and Research (V. T.), the Austrian Science Fund (FWF J3044 to
   M. H.), Deutsche Forschungsgemeinschaft (J.Z.), the National Institutes
   of Health (AI060915 and AI085089 to S. C. B.; U54 AI081680 (Pacific
   Northwest Regional Center of Excellence for Biodefense and Emerging
   Infectious Diseases Research to M. S. D), the Medical Research Council
   (B. W. N.) and the Wellcome Trust (S.G.S.).
CR Bocharov G, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001017
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Bryson K, 2005, NUCLEIC ACIDS RES, V33, pW36, DOI 10.1093/nar/gki410
   Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770
   Cervantes-Barragan L, 2009, J IMMUNOL, V182, P1099, DOI 10.4049/jimmunol.182.2.1099
   Chen Y, 2009, P NATL ACAD SCI USA, V106, P3484, DOI 10.1073/pnas.0808790106
   Daffis S, 2010, NATURE, V468, P452, DOI 10.1038/nature09489
   Decroly E, 2008, J VIROL, V82, P8071, DOI 10.1128/JVI.00407-08
   Eriksson Klara Kristin, 2008, V454, P237, DOI 10.1007/978-1-59745-181-9_18
   FAUMAN EB, 1999, S ADENOSYLMETHIONINE, P1, DOI DOI 10.1142/9789812813077_0001
   Feder M, 2003, GENE, V302, P129, DOI 10.1016/S0378-1119(02)01097-1
   Fensterl V, 2011, J INTERF CYTOK RES, V31, P71, DOI 10.1089/jir.2010.0101
   Ghosh A, 2010, WIRES RNA, V1, P152, DOI 10.1002/wrna.19
   Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Haller O, 2007, CURR TOP MICROBIOL, V316, P315
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505
   Hui DJ, 2005, J BIOL CHEM, V280, P3433, DOI 10.1074/jbc.M406700200
   JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1
   Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008
   Kato H, 2008, J EXP MED, V205, P1601, DOI 10.1084/jem.20080091
   Le Gall O, 2008, ARCH VIROL, V153, P715, DOI 10.1007/s00705-008-0041-x
   Loo YM, 2007, CURR TOP MICROBIOL, V316, P295
   Loo YM, 2008, J VIROL, V82, P335, DOI 10.1128/JVI.01080-07
   Morin B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001038
   Nallagatla SR, 2008, RNA, V14, P1201, DOI 10.1261/rna.1007408
   Nallagatla SR, 2008, RNA BIOL, V5, P140, DOI 10.4161/rna.5.3.6839
   NOMOTO A, 1977, NATURE, V268, P208, DOI 10.1038/268208a0
   Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998
   QI X, 2010, NATURE          1117, DOI DOI 10.1038/NATURE09605
   Reguera J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001101
   Rose KM, 2010, J VIROL, V84, P5656, DOI 10.1128/JVI.00211-10
   Roth-Cross JK, 2008, J VIROL, V82, P9829, DOI 10.1128/JVI.01199-08
   Schlee M, 2009, IMMUNITY, V31, P25, DOI 10.1016/j.immuni.2009.05.008
   SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897
   Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Takeuchi O, 2009, IMMUNOL REV, V227, P75, DOI 10.1111/j.1600-065X.2008.00737.x
   Terenzi F, 2006, J BIOL CHEM, V281, P34064, DOI 10.1074/jbc.M605771200
   Thiel V, 2008, CYTOKINE GROWTH F R, V19, P121, DOI 10.1016/j.cytogfr.2008.01.001
   UZE G, 1994, J MOL BIOL, V243, P245, DOI 10.1006/jmbi.1994.1651
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Wunschmann S, 2002, J VIROL, V76, P4350, DOI 10.1128/JVI.76.9.4350-4356.2002
   Zhou HX, 2010, MBIO, V1, DOI 10.1128/mBio.00219-10
   Zust R, 2007, PLOS PATHOG, V3, P1062, DOI 10.1371/journal.ppat.0030109
NR 46
TC 321
Z9 332
U1 5
U2 46
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
EI 1529-2916
J9 NAT IMMUNOL
JI Nat. Immunol.
PD FEB
PY 2011
VL 12
IS 2
BP 137
EP U46
DI 10.1038/ni.1979
PG 8
WC Immunology
SC Immunology
GA 708QF
UT WOS:000286378400007
PM 21217758
OA Green Accepted, Green Published
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Yang, ZY
   Kong, WP
   Huang, Y
   Roberts, A
   Murphy, BR
   Subbarao, K
   Nabel, GJ
AF Yang, ZY
   Kong, WP
   Huang, Y
   Roberts, A
   Murphy, BR
   Subbarao, K
   Nabel, GJ
TI A DNA vaccine induces SARS coronavirus neutralization and protective
   immunity in mice
SO NATURE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; HONG-KONG; VIRUS; IDENTIFICATION; CHALLENGE;
   INFECTION; PROTEINS; GENOME; PIGS
AB Public health measures have successfully identified and contained outbreaks of the severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV)(1-5), but concerns remain over the possibility of future recurrences. Finding a vaccine for this virus therefore remains a high priority. Here, we show that a DNA vaccine encoding the spike (S) glycoprotein of the SARS-CoV induces T cell and neutralizing antibody responses, as well as protective immunity, in a mouse model. Alternative forms of S were analysed by DNA immunization. These expression vectors induced robust immune responses mediated by CD4 and CD8 cells, as well as significant antibody titres, measured by enzyme-linked immunosorbent assay. Moreover, antibody responses in mice vaccinated with an expression vector encoding a form of S that includes its transmembrane domain elicited neutralizing antibodies. Viral replication was reduced by more than six orders of magnitude in the lungs of mice vaccinated with these S plasmid DNA expression vectors, and protection was mediated by a humoral but not a T-cell-dependent immune mechanism. Gene-based vaccination for the SARS-CoV elicits effective immune responses that generate protective immunity in an animal model.
C1 NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
RP Nabel, GJ (reprint author), NIAID, Vaccine Res Ctr, NIH, Bldg 40,Room 4502,MSC-3005,40 Convent Dr, Bethesda, MD 20892 USA.
EM gnabel@nih.gov
OI Subbarao, Kanta/0000-0003-1713-3056
CR Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Epstein SL, 2000, INT IMMUNOL, V12, P91, DOI 10.1093/intimm/12.1.91
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   Kong WP, 2003, J VIROL, V77, P12764, DOI 10.1128/JVI.77.23.12764-12772.2003
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lai M.M.C., 2001, FIELDS VIROLOGY, P1163
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Park SK, 1998, AM J VET RES, V59, P1002
   Perlman S, 1998, ADV EXP MED BIOL, V440, P503
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SAIF LJ, 1993, VET MICROBIOL, V37, P285, DOI 10.1016/0378-1135(93)90030-B
   Sestak K, 1999, VET IMMUNOL IMMUNOP, V70, P203, DOI 10.1016/S0165-2427(99)00074-4
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   World Health Organization, 2003, CONS DOC EP SEV AC R
   YANG ZY, IN PRESS J VIROL
NR 23
TC 321
Z9 350
U1 12
U2 31
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD APR 1
PY 2004
VL 428
IS 6982
BP 561
EP 564
DI 10.1038/nature02463
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 807ZT
UT WOS:000220540100042
PM 15024391
OA Bronze
DA 2020-04-03
ER

PT J
AU MEULENBERG, JJM
   PETERSENDENBESTEN, A
   DEKLUYVER, EP
   MOORMANN, RJM
   SCHAAPER, WMM
   WENSVOORT, G
AF MEULENBERG, JJM
   PETERSENDENBESTEN, A
   DEKLUYVER, EP
   MOORMANN, RJM
   SCHAAPER, WMM
   WENSVOORT, G
TI CHARACTERIZATION OF PROTEINS ENCODED BY ORF-2 TO ORF-7 OF LELYSTAD-VIRUS
SO VIROLOGY
LA English
DT Article
ID DEHYDROGENASE-ELEVATING VIRUS; RESPIRATORY SYNDROME VIRUS; EQUINE
   ARTERITIS VIRUS; PORCINE EPIDEMIC ABORTION; STRUCTURAL PROTEINS; SWINE
   INFERTILITY; MEMBRANE-PROTEIN; CORONAVIRUS IBV; SEQUENCE; SITES
AB The genome of Lelystad virus (LV), a positive-strand RNA virus, is 15 kb in length and contains 8 open reading frames (ORFs) that encode putative viral proteins. ORFs 2 to 7 were cloned in plasmids downstream of the Sp6 RNA polymerase promoter, and the translation of transcripts generated in vitro yielded proteins that could be immunoprecipitated with porcine anti-LV serum. Synthetic polypeptides of 15 to 17 amino acids were selected from the amino acid sequences of ORFs 2 to 7 and antipeptide sera were raised in rabbits. Antisera that immunoprecipitated the in vitro translation products of ORFs 2 to 5 and 7 were obtained. Sera containing antibodies directed against peptides from ORFs 3 to 7 reacted positively with LV-infected alveolar lung macrophages in the immunoperoxidase monolayer assay. Using these antipeptide sera and porcine anti-LV serum, we identified three structural proteins and assigned their corresponding genes. Virions were found to contain a nucleocapsid protein of 15 kDa (N), an unglycosylated membrane protein of 18 kDa (M), and a glycosylated membrane protein of 25 kDa (E). The N protein is encoded by ORF7, the M protein is encoded by ORF6, and the E protein is encoded by ORF5. The E protein in virus particles contains one or two N-glycans that are resistant to endo-beta-N-acetyl-D-glucosaminidase H. This finding indicates that the high-mannose glycans are processed into complex glycans in the Golgi compartment. The protein composition of the LV virions further confirms that LV is evolutionarily related to equine arteritis virus, simian hemorrhagic fever virus, and lactate dehydrogenase-elevating virus. (C) 1995 academic Press, Inc.
C1 DLO,INST ANIM SCI & HLTH,MOLEC IMMUNOL LAB,8200 AB LELYSTAD,NETHERLANDS.
RP MEULENBERG, JJM (reprint author), DLO,INST ANIM SCI & HLTH,DEPT VIROL,HOUTRIBWEG 39,8200 AJ LELYSTAD,NETHERLANDS.
OI Wensvoort, Gert/0000-0003-2699-6558
CR BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241
   BOURSNELL MEG, 1984, VIRUS RES, V1, P303, DOI 10.1016/0168-1702(84)90019-4
   BRINTONDARNELL M, 1975, J VIROL, V16, P420, DOI 10.1128/JVI.16.2.420-433.1975
   CAVANAGH D, 1986, VIRUS RES, V4, P145, DOI 10.1016/0168-1702(86)90038-9
   CHEN ZY, 1993, J GEN VIROL, V74, P643, DOI 10.1099/0022-1317-74-4-643
   COLLINS JE, 1992, J VET DIAGN INVEST, V4, P117, DOI 10.1177/104063879200400201
   CONZELMANN KK, 1993, VIROLOGY, V193, P329, DOI 10.1006/viro.1993.1129
   DENBOON JA, 1991, VIROLOGY, V182, P655, DOI 10.1016/0042-6822(91)90606-C
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   DEVRIES AAF, 1992, J VIROL, V66, P6294, DOI 10.1128/JVI.66.11.6294-6303.1992
   DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193
   DREW TW, 1994, UNPUB PRODUCTION CHA
   GODENY EK, 1990, VIROLOGY, V177, P768, DOI 10.1016/0042-6822(90)90546-4
   GODENY EK, 1993, VIROLOGY, V194, P585, DOI 10.1006/viro.1993.1298
   HARTY JT, 1988, J VIROL, V62, P3210, DOI 10.1128/JVI.62.9.3210-3216.1988
   HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824
   HULST MM, 1993, J VIROL, V67, P5435, DOI 10.1128/JVI.67.9.5435-5442.1993
   JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LOULA T, 1990, 1990 P MYST SWIN DIS, P29
   MEULENBERG JJM, 1993, J GEN VIROL, V74, P1697, DOI 10.1099/0022-1317-74-8-1697
   MEULENBERG JJM, 1993, VIROLOGY, V192, P62, DOI 10.1006/viro.1993.1008
   MICHAELIDES MC, 1973, VIROLOGY, V55, P211, DOI 10.1016/S0042-6822(73)81023-2
   MURTAUGH MP, 1993, 9TH INT C VIR
   NELSON EA, 1993, J CLIN MICROBIOL, V31, P3184, DOI 10.1128/JCM.31.12.3184-3189.1993
   PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013
   PLAGEMANN PGW, 1991, ADV VIRUS RES, V41, P99
   PURCHIO AF, 1984, J VIROL, V50, P666, DOI 10.1128/JVI.50.2.666-669.1984
   ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421
   ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022
   Sambrook J., 1989, MOL CLONING LABORATO
   SUTER M, 1982, J IMMUNOL METHODS, V53, P103, DOI 10.1016/0022-1759(82)90244-7
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   VANBERLO MF, 1982, VIROLOGY, V118, P345, DOI 10.1016/0042-6822(82)90354-3
   VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990
   VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683
   WENSVOORT G, 1993, VET RES, V24, P117
   WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296
   WENSVOORT G, 1992, J VET DIAGN INVEST, V4, P134, DOI 10.1177/104063879200400203
   ZEEGERS JJW, 1973, VIROLOGY, V73, P200
NR 41
TC 311
Z9 362
U1 0
U2 8
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JAN 10
PY 1995
VL 206
IS 1
BP 155
EP 163
DI 10.1016/S0042-6822(95)80030-1
PG 9
WC Virology
SC Virology
GA QD149
UT WOS:A1995QD14900018
PM 7831770
DA 2020-04-03
ER

PT J
AU van Elden, LJR
   Nijhuis, M
   Schipper, P
   Schuurman, R
   van Loon, AM
AF van Elden, LJR
   Nijhuis, M
   Schipper, P
   Schuurman, R
   van Loon, AM
TI Simultaneous detection of influenza viruses A and B using real-time
   quantitative PCR
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID NEURAMINIDASE INHIBITOR OSELTAMIVIR; REVERSE TRANSCRIPTION PCR;
   DIAGNOSING INFLUENZA; ENZYME-IMMUNOASSAY; SPECIMENS; CULTURE;
   INFECTIONS; SAMPLES
AB Since influenza viruses can cause severe illness, timely diagnosis is important for an adequate intervention. The available rapid detection methods either lack sensitivity or require complex laboratory manipulation. This study describes a rapid, sensitive detection method that can be easily applied to routine diagnosis. This method simultaneously detects influenza viruses A and B in specimens of patients with respiratory infections using a TaqMan-based real-time PCR assay. Primers and probes were selected from highly conserved regions of the matrix protein gene of influenza virus A and the hemagglutinin gene segment of influenza virus B. The applicability of this multiplex PCR was evaluated with 27 influenza virus A and 9 influenza virus B reference strains and isolates. In addition, the specificity of the assay was assessed using eight reference strains of other respiratory viruses (parainfluenza viruses 1 to 3, respiratory syncytial virus Long strain, rhinoviruses 1A and 14, and coronaviruses OC43 and 229E) and 30 combined nose and throat swabs from asymptomatic subjects. Electron microscopy-counted stocks of influenza viruses A and B were used to develop a quantitative PCR format. Thirteen copies of viral RNA were detected for influenza virus A, and 11 copies were detected for influenza virus B, equaling 0.02 and 0.006 50% tissue culture infective doses, respectively. The diagnostic efficacy of the multiplex TaqMan-based PCR was determined by testing 98 clinical samples. This real-time PCR technique was found to be more sensitive than the combination of conventional viral culturing and shell vial culturing.
C1 Univ Med Ctr Utrecht, Dept Virol, Eijkman Winkler Inst Microbiol Infect Dis & Inflam, NL-3508 GA Utrecht, Netherlands.
RP van Elden, LJR (reprint author), Univ Med Ctr Utrecht, Dept Virol, Eijkman Winkler Inst Microbiol Infect Dis & Inflam, POB 85500, NL-3508 GA Utrecht, Netherlands.
RI Schuurman, Rob/M-4687-2019
OI Schuurman, Rob/0000-0002-0060-9831; Van Elden,
   Leontine/0000-0002-3878-8927
CR Atmar RL, 1996, J CLIN MICROBIOL, V34, P2604, DOI 10.1128/JCM.34.10.2604-2606.1996
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   CLAAS ECJ, 1993, J CLIN MICROBIOL, V31, P2218, DOI 10.1128/JCM.31.8.2218-2221.1993
   DOLLER G, 1992, J CLIN MICROBIOL, V30, P866
   Ellis JS, 1997, J CLIN MICROBIOL, V35, P2076, DOI 10.1128/JCM.35.8.2076-2082.1997
   Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802
   Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240
   Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302
   Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986
   Kato T, 2000, J CLIN MICROBIOL, V38, P94
   KOK T, 1994, J VIROL METHODS, V50, P87, DOI 10.1016/0166-0934(94)90166-X
   NIJHUIS M, 1995, BIOTECHNIQUES, V19, P178
   NIJHUIS M, 1995, BIOTECHNIQUES, V19, P182
   Pongers-Willemse MJ, 1998, LEUKEMIA, V12, P2006, DOI 10.1038/sj.leu.2401246
   Schmid ML, 1998, BRIT MED J, V316, P275, DOI 10.1136/bmj.316.7127.275
   Schweiger B, 2000, J CLIN MICROBIOL, V38, P1552, DOI 10.1128/JCM.38.4.1552-1558.2000
   Silagy C, 1998, LANCET, V352, P1877
   Vet JAM, 1999, P NATL ACAD SCI USA, V96, P6394, DOI 10.1073/pnas.96.11.6394
   WISELKA M, 1994, BRIT MED J, V308, P1341, DOI 10.1136/bmj.308.6940.1341
   WRIGHT KE, 1995, J CLIN MICROBIOL, V33, P1180, DOI 10.1128/JCM.33.5.1180-1184.1995
   ZIEGLER T, 1995, J CLIN MICROBIOL, V33, P318, DOI 10.1128/JCM.33.2.318-321.1995
NR 21
TC 310
Z9 319
U1 2
U2 33
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JAN
PY 2001
VL 39
IS 1
BP 196
EP 200
DI 10.1128/JCM.39.1.196-200.2001
PG 5
WC Microbiology
SC Microbiology
GA 393KZ
UT WOS:000166468900032
PM 11136770
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Wang, D
   Urisman, A
   Liu, YT
   Springer, M
   Ksiazek, TG
   Erdman, DD
   Mardis, ER
   Hickenbotham, M
   Magrini, V
   Eldred, J
   Latreille, JP
   Wilson, RK
   Ganem, D
   DeRisi, JL
AF Wang, D
   Urisman, A
   Liu, YT
   Springer, M
   Ksiazek, TG
   Erdman, DD
   Mardis, ER
   Hickenbotham, M
   Magrini, V
   Eldred, J
   Latreille, JP
   Wilson, RK
   Ganem, D
   DeRisi, JL
TI Viral discovery and sequence recovery using DNA microarrays
SO PLOS BIOLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; IDENTIFICATION; CORONAVIRUS; VIRUSES; GENOME
AB Because of the constant threat posed by emerging infectious diseases and the limitations of existing approaches used to identify new pathogens, there is a great demand for new technological methods for viral discovery. We describe herein a DNA microarray-based platform for novel virus identification and characterization. Central to this approach was a DNA microarray designed to detect a wide range of known viruses as well as novel members of existing viral families; this microarray contained the most highly conserved 70mer sequences from every fully sequenced reference viral genome in GenBank. During an outbreak of severe acute respiratory syndrome (SARS) in March 2003, hybridization to this microarray revealed the presence of a previously uncharacterized coronavirus in a viral isolate cultivated from a SARS patient. To further characterize this new virus, approximately 1 kb of the unknown virus genome was cloned by physically recovering viral sequences hybridized to individual array elements. Sequencing of these fragments confirmed that the virus was indeed a new member of the coronavirus family. This combination of array hybridization followed by direct viral sequence recovery should prove to be a general strategy for the rapid identification and characterization of novel viruses and emerging infectious disease.
C1 Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.
   Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA.
   Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.
RP DeRisi, JL (reprint author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.
EM joe@derisilab.ucsf.edu
RI Wilson, Richard K./AAF-4139-2019; Mardis, Elaine/W-2202-2019
OI Wilson, Richard K./0000-0002-1992-1358; 
CR CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Jonassen CM, 1998, J GEN VIROL, V79, P715, DOI 10.1099/0022-1317-79-4-715
   Kellam P, 1998, TRENDS MICROBIOL, V6, P160, DOI 10.1016/S0966-842X(98)01239-6
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Muerhoff AS, 1997, J MED VIROL, V53, P96
   NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699
NR 10
TC 308
Z9 330
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1545-7885
J9 PLOS BIOL
JI PLoS. Biol.
PD NOV
PY 2003
VL 1
IS 2
BP 257
EP 260
AR e2
DI 10.1371/journal.pbio.0000002
PG 4
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA 772GZ
UT WOS:000188835200016
PM 14624234
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Li, F
   Li, WH
   Farzan, M
   Harrison, SC
AF Li, F
   Li, WH
   Farzan, M
   Harrison, SC
TI Structure of SARS coronavirus spike receptor-binding domain complexed
   with receptor
SO SCIENCE
LA English
DT Article
ID ACUTE-RESPIRATORY-SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; MOUSE
   HEPATITIS-VIRUS; POTENT NEUTRALIZING ANTIBODIES; PROTEIN FUSION CORE;
   CRYSTAL-STRUCTURE; MEMBRANE-FUSION; AMINO-ACIDS; IDENTIFICATION;
   GLYCOPROTEIN
AB The spike protein (S) of SARS coronavirus (SARS-CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The crystal structure at 2.9 angstrom resolution of the RBD bound with the peptidase domain of human ACE2 shows that the RBD presents a gently concave surface, which cradles the N-terminal lobe of the peptidase. The atomic details at the interface between the two proteins clarify the importance of residue changes that facilitate efficient cross-species infection and human-to-human transmission. The structure of the RBD suggests ways to make truncated disulfide-stabilized RBD variants for use in the design of coronavirus vaccines.
C1 Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
   Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA.
   Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, New England Primate Res Ctr, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA.
RP Harrison, SC (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 320 Longwood Ave, Boston, MA 02115 USA.
EM harrison@crystal.harvard.edu
OI Li, Wenhui/0000-0003-1305-7404; Farzan, Michael/0000-0002-2990-5319
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA13202]; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI061601]
CR Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   LAI MMC, 2001, FIELDS VIROLOGY
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sainz B, 2005, J VIROL, V79, P7195, DOI 10.1128/JVI.79.11.7195-7206.2005
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Sui JH, 2005, J VIROL, V79, P5900, DOI 10.1128/JVI.79.10.5900-5906.2005
   Supekar VM, 2004, P NATL ACAD SCI USA, V101, P17958, DOI 10.1073/pnas.0406128102
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   van den Brink EN, 2005, J VIROL, V79, P1635, DOI 10.1128/JVI.79.3.1635-1644.2005
   Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200
   Xu YH, 2004, BIOCHEMISTRY-US, V43, P14064, DOI 10.1021/bi049101q
   Xu YH, 2004, J BIOL CHEM, V279, P30514, DOI 10.1074/jbc.M403760200
NR 33
TC 307
Z9 328
U1 66
U2 111
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD SEP 16
PY 2005
VL 309
IS 5742
BP 1864
EP 1868
DI 10.1126/science.1116480
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 965ZN
UT WOS:000231989500052
PM 16166518
DA 2020-04-03
ER

PT J
AU WEGE, H
   SIDDELL, S
   TERMEULEN, V
AF WEGE, H
   SIDDELL, S
   TERMEULEN, V
TI THE BIOLOGY AND PATHOGENESIS OF CORONAVIRUSES
SO CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY
LA English
DT Article
RP WEGE, H (reprint author), INST VIROL & IMMUNOBIOL, VERSBACHER STR 7, D-8700 WUERZBURG, FED REP GER.
CR ADAMS NR, 1970, AVIAN DIS, V14, P392, DOI 10.2307/1588483
   ADAMS NR, 1971, AVIAN DIS, V15, P426, DOI 10.2307/1588719
   ADAMS NR, 1972, AVIAN DIS, V16, P817, DOI 10.2307/1588762
   AKASHI H, 1981, ARCH VIROL, V67, P367, DOI 10.1007/BF01314841
   ALEXANDER DJ, 1977, RES VET SCI, V23, P344, DOI 10.1016/S0034-5288(18)33129-1
   ALEXANDER DJ, 1978, RES VET SCI, V24, P228, DOI 10.1016/S0034-5288(18)33077-7
   ANDRIES K, 1980, AM J VET RES, V41, P215
   ANDRIES K, 1978, ZBL VET MED B, V25, P461
   ANDRIES K, 1980, AM J VET RES, V41, P1372
   ANDRIES K, 1981, BIOCH BIOL CORONAVIR, P399
   APOSTOLOV K, 1975, LANCET, V2, P1271
   APPEL MJG, 1979, CORNELL VET, V69, P123
   ARNHEITER H, 1981, BIOCH BIOL CORONAVIR, P409
   BAILEY OT, 1949, J EXP MED, V90, P195, DOI 10.1084/jem.90.3.195
   BANG FB, 1960, P NATL ACAD SCI USA, V46, P1065, DOI 10.1073/pnas.46.8.1065
   BANG FB, 1981, BIOCH BIOL CORONAVIR, P359
   BARDOS V, 1980, INTERVIROLOGY, V13, P275, DOI 10.1159/000149135
   BASS EP, 1975, LANCET, V2, P822
   Beare AS, 1977, CHEMOPROPHYLAXIS VIR, P27
   BHATT PN, 1977, ARCH VIROL, V54, P345, DOI 10.1007/BF01314779
   BHATT PN, 1972, J INFECT DIS, V126, P123, DOI 10.1093/infdis/126.2.123
   BIGGERS DC, 1964, AM J PATHOL, V45, P413
   BINN LN, 1975, 78TH P ANN M US AN H, P366
   BLACK JW, 1980, VET MED SM ANIM CLIN, V75, P811
   BRADBURNE AF, 1967, BMJ-BRIT MED J, V3, P767, DOI 10.1136/bmj.3.5568.767
   BRODERSON JR, 1976, LAB ANIM SCI, V26, P824
   BURKS, 1980, SCIENCE, V209, P933
   CARSON CA, 1972, APPL MICROBIOL, V23, P903, DOI 10.1128/AEM.23.5.903-907.1972
   CARTHEW P, 1981, RES VET SCI, V30, P270, DOI 10.1016/S0034-5288(18)32540-2
   CARTHEW P, 1977, VET REC, V101, P465
   CAUL EO, 1977, ARCH VIROL, V54, P107, DOI 10.1007/BF01314383
   CAUL EO, 1975, LANCET, V1, P1192
   CAUL EO, 1975, LANCET, V2, P953
   CHEEVER FS, 1949, J EXP MED, V90, P181, DOI 10.1084/jem.90.3.181
   CHHABRA PC, 1980, RES VET SCI, V29, P148, DOI 10.1016/S0034-5288(18)32655-9
   CLEWLEY JP, 1981, INFECT IMMUN, V32, P1227, DOI 10.1128/IAI.32.3.1227-1233.1981
   COLLINS MS, 1980, J GEN VIROL, V48, P213, DOI 10.1099/0022-1317-48-1-213
   COTTER SM, 1973, J AM VET MED ASSOC, V162, P1054
   DARBYSHIRE JH, 1980, AVIAN PATHOL, V9, P179, DOI 10.1080/03079458008418401
   DARBYSHIRE JH, 1975, J COMP PATHOL, V85, P623, DOI 10.1016/0021-9975(75)90128-0
   DARBYSHIRE JH, 1979, ARCH VIROL, V61, P227, DOI 10.1007/BF01318057
   DARBYSHIRE JH, 1981, POULTRY SCI S SERIES, V16, P205
   DAWSON PS, 1971, ARCH GES VIRUSFORSCH, V34, P32, DOI 10.1007/BF01250243
   DEA S, 1980, AM J VET RES, V41, P23
   DEA S, 1980, AM J VET RES, V41, P30
   DEBOUCK P, 1980, AM J VET RES, V41, P219
   DESHMUKH DR, 1974, AM J VET RES, V35, P1549
   DESHMUKH DR, 1976, AVIAN DIS, V20, P631, DOI 10.2307/1589442
   DICK GWA, 1956, BRIT J EXP PATHOL, V37, P90
   DOUGHRI AM, 1977, ZBL VET MED B, V24, P367
   DOUGHRI AM, 1976, EXP MOL PATHOL, V25, P355, DOI 10.1016/0014-4800(76)90045-9
   DOYLE LP, 1946, J AM VET MED ASSOC, V108, P257
   DUPUY JM, 1975, J IMMUNOL, V114, P226
   ESTOLA T, 1967, ACTA VET SCAND, V8, P86
   EVERMANN JF, 1981, VET PATHOL, V18, P256, DOI 10.1177/030098588101800214
   EVERMANN JF, 1980, J AM VET MED ASSOC, V177, P784
   FLEURY HJA, 1980, NEUROPATH APPL NEURO, V6, P165, DOI 10.1111/j.1365-2990.1980.tb00288.x
   FREDERICK GT, 1976, J IMMUNOL, V116, P1000
   FURUTA T, 1979, JPN J EXP MED, V49, P423
   GALLILY R, 1964, P NATL ACAD SCI USA, V51, P1158, DOI 10.1073/pnas.51.6.1158
   Garwes D.J., 1978, VET MICROBIOL, V3, P179
   GARWES DJ, 1981, J GEN VIROL, V52, P153, DOI 10.1099/0022-1317-52-1-153
   GERDES JC, 1981, J VIROL, V38, P231, DOI 10.1128/JVI.38.1.231-238.1981
   GERDES JC, 1981, BIOCH BIOL CORONAVIR, P29
   GERNA G, 1981, J GEN VIROL, V54, P91, DOI 10.1099/0022-1317-54-1-91
   GERNA G, 1978, B I SIEROTER MILAN, V57, P535
   GLEDHILL AW, 1951, BRIT J EXP PATHOL, V32, P559
   GOMEZ L, 1974, AVIAN DIS, V18, P346, DOI 10.2307/1589103
   GONDER E, 1976, AM J VET RES, V37, P1435
   GOTO N, 1979, JPN J EXP MED, V49, P169
   GOTO N, 1977, JPN J EXP MED, V47, P59
   GOUFFAUX M, 1975, VET PATHOL, V12, P335, DOI 10.1177/0300985875012005-00601
   GOUGH RE, 1979, RES VET SCI, V26, P329, DOI 10.1016/S0034-5288(18)32889-3
   GREIG AS, 1962, CAN J COMP MED VET S, V26, P49
   HAELTERMAN EO, 1962, 66TH P ANN M US LIV, P305
   HAJER I, 1978, AM J VET RES, V39, P441
   HARDY WD, 1971, J AM VET MED ASSOC, V158, P994
   HASONY HJ, 1981, ARCH VIROL, V69, P33, DOI 10.1007/BF01315263
   HASPEL MV, 1978, P NATL ACAD SCI USA, V75, P4033, DOI 10.1073/pnas.75.8.4033
   HAYASHI T, 1980, JPN J VET SCI, V42, P197
   HELFERBAKER C, 1980, CANINE PRACT, V7, P37
   HERNDON RM, 1975, ARCH NEUROL-CHICAGO, V32, P32, DOI 10.1001/archneur.1975.00490430054008
   HERNDON RM, 1977, SCIENCE, V195, P693, DOI 10.1126/science.190678
   HESS RG, 1977, ZBL VET MED B, V24, P753
   HIERHOLZER JC, 1979, INFECT IMMUN, V24, P508, DOI 10.1128/IAI.24.2.508-522.1979
   HIRAI K, 1979, AVIAN DIS, V23, P515, DOI 10.2307/1589582
   HIRANO N, 1979, JPN J VET SCI, V41, P31
   HIRANO N, 1981, ARCH VIROL, V70, P69, DOI 10.1007/BF01320795
   HIRANO N, 1980, MICROBIOL IMMUNOL, V24, P825, DOI 10.1111/j.1348-0421.1980.tb02887.x
   HIRANO N, 1975, JPN J EXP MED, V45, P492
   HIRANO N, 1981, BIOCH BIOL CORONAVIR, P301
   HOLMES HC, 1973, ARCH GES VIRUSFORSCH, V43, P235, DOI 10.1007/BF01250418
   HOLMES KV, 1981, BIOCH BIOL CORONAVIR, P287
   HOLZWORTH J, 1963, CORNELL VET, V53, P157
   HOPKINS SR, 1974, AVIAN DIS, V18, P231, DOI 10.2307/1589131
   HORVATH I, 1981, ARCH VIROL, V68, P103, DOI 10.1007/BF01314440
   HORZINEK MC, 1977, ZBL VET MED B, V24, P398
   HORZINEK MC, 1979, ARCH VIROL, V59, P1, DOI 10.1007/BF01317889
   HORZINEK MC, 1978, J SMALL ANIM PRACT, V19, P561
   HOSHINO Y, 1980, AM J VET RES, V41, P672
   HOSHINO Y, 1978, CORNELL VET, V68, P411
   HOSHINO Y, 1980, ARCH VIROL, V63, P147, DOI 10.1007/BF01320772
   ISHIDA T, 1978, LAB ANIM SCI, V28, P269
   ISHIDA T, 1979, JPN J EXP MED, V49, P33
   JACOBSEGEELS HEL, 1980, J IMMUNOL, V125, P1606
   JACOBY RO, 1975, VET PATHOL, V12, P196, DOI 10.1177/030098587501200305
   JONAS AM, 1969, ARCH PATHOL, V88, P613
   KAI C, 1981, MICROBIOL IMMUNOL, V25, P1011, DOI 10.1111/j.1348-0421.1981.tb00107.x
   Kapikian A Z, 1975, Dev Biol Stand, V28, P42
   KATAMI K, 1978, JPN J EXP MED, V48, P481
   KAYE HS, 1975, LANCET, V2, P509
   KAYE HS, 1977, J INFECT DIS, V135, P201, DOI 10.1093/infdis/135.2.201
   KAYE HS, 1975, AM J EPIDEMIOL, V101, P238, DOI 10.1093/oxfordjournals.aje.a112091
   KEENAN KP, 1976, AM J VET RES, V37, P247
   KERSTING G, 1956, Dtsch Z Nervenheilkd, V174, P283
   KNOBLER RL, 1981, J NEUROIMMUNOL, V1, P81, DOI 10.1016/0165-5728(81)90010-2
   KNOBLER RL, 1981, J EXP MED, V153, P832, DOI 10.1084/jem.153.4.832
   KODAMA Y, 1980, AM J VET RES, V41, P740
   KRAAIJEVELD CA, 1980, J CLIN MICROBIOL, V12, P493, DOI 10.1128/JCM.12.4.493-497.1980
   KRAAIJEVELD CA, 1980, J GEN VIROL, V49, P83, DOI 10.1099/0022-1317-49-1-83
   KRAFT LM, 1962, SCIENCE, V137, P282, DOI 10.1126/science.137.3526.282
   KRYSTYNIAK K, 1981, J GEN VIROL, V57, P53
   LABONNARDIERE C, 1981, INFECT IMMUN, V32, P28, DOI 10.1128/IAI.32.1.28-31.1981
   LAHMY C, 1981, ANN INST PASTEUR IMM, VC132, P101, DOI 10.1016/0769-2625(81)90010-6
   LAI MMC, 1981, J VIROL, V38, P661, DOI 10.1128/JVI.38.2.661-670.1981
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1981, BIOCH BIOL CORONAVIR, P69
   LAI YL, 1976, INVEST OPHTH VISUAL, V15, P538
   LAMPERT PW, 1973, ACTA NEUROPATHOL, V24, P76, DOI 10.1007/BF00691421
   LARSON DJ, 1979, AM J VET RES, V40, P477
   LARSON HE, 1980, J MED VIROL, V5, P221, DOI 10.1002/jmv.1890050306
   Leinikki P O, 1981, Adv Exp Med Biol, V142, P323
   LEPREVOST C, 1975, J IMMUNOL, V115, P640
   LEPREVOST C, 1975, J IMMUNOL, V114, P221
   LESLIE GA, 1973, J IMMUNOL, V110, P1
   LEVY GA, 1981, J EXP MED, V154, P1150, DOI 10.1084/jem.154.4.1150
   LEVYLEBLOND E, 1977, J IMMUNOL, V118, P1219
   LEVYLEBLOND E, 1979, J IMMUNOL, V122, P1359
   LEWIS LD, 1978, J AM VET MED ASSOC, V173, P636
   LOEFFLER DG, 1978, FELINE PRACT, V8, P43
   LUCAS A, 1977, CELL, V12, P553, DOI 10.1016/0092-8674(77)90131-3
   MACNAUGHTON MR, 1980, ARCH VIROL, V66, P71, DOI 10.1007/BF01315046
   MACNAUGHTON MR, 1981, INFECT IMMUN, V31, P845, DOI 10.1128/IAI.31.3.845-849.1981
   MACNAUGHTON MR, 1981, ARCH VIROL, V70, P301, DOI 10.1007/BF01320245
   MACNAUGHTON MR, 1981, BIOCH BIOL CORONAVIR, P19
   MALKOVA D, 1980, ACTA VIROL, V24, P363
   MANAKER RA, 1961, JNCI-J NATL CANCER I, V27, P29
   MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7
   MCINTOSH K, 1978, J MED VIROL, V2, P341, DOI 10.1002/jmv.1890020407
   McIntosh K., 1974, Current Topics in Microbiology and Immunology, V63, P85
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   MCINTOSH K, 1970, AM J EPIDEMIOL, V91, P585, DOI 10.1093/oxfordjournals.aje.a121171
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V58, P2268, DOI 10.1073/pnas.58.6.2268
   MCINTOSH K, 1969, J IMMUNOL, V102, P1109
   MCKEIRNAN AJ, 1981, FELINE PRACT, V11, P16
   Mebus C A, 1976, Dev Biol Stand, V33, P396
   MEBUS CA, 1973, AM J VET RES, V34, P145
   MEBUS CA, 1975, AM J VET RES, V36, P1719
   MEBUS CA, 1973, VET PATHOL, V10, P45, DOI 10.1177/030098587301000105
   MENGELING WL, 1976, J AM VET MED ASSOC, V128, P236
   MOCKETT APA, 1981, AVIAN PATHOL, V10, P1, DOI 10.1080/03079458108418453
   MONTO AS, 1974, YALE J BIOL MED, V47, P234
   MOON HW, 1978, J AM VET MED ASSOC, V172, P443
   MOORE B, 1977, LANCET, V1, P261
   MOSCOVICI O, 1980, CR ACAD SCI D NAT, V290, P869
   NAGARAJA KV, 1980, AM J VET RES, V41, P915
   NAGARAJA KV, 1978, AM J VET RES, V39, P1463
   NAGARAJA KV, 1981, AM J VET RES, V41, P1283
   NAGASHIMA K, 1978, ACTA NEUROPATHOL, V44, P63, DOI 10.1007/BF00691641
   NAGASHIMA K, 1979, ACTA NEUROPATHOL, V45, P205, DOI 10.1007/BF00702672
   Nagashima K, 1978, Adv Exp Med Biol, V100, P395
   NAGY E, 1979, ARCH VIROL, V61, P341, DOI 10.1007/BF01315022
   NAQUI SA, 1975, AM J VET RES, V36, P548
   NELSON DT, 1979, VET PATHOL, V16, P680, DOI 10.1177/030098587901600606
   NELSON IB, 1952, J EXP MED, V96, P293
   OREILLY KJ, 1979, VET REC, V104, P348, DOI 10.1136/vr.104.15.348
   Osterhaus A D, 1976, Berl Munch Tierarztl Wochenschr, V89, P135
   OSTERHAUS ADME, 1977, ZBL VET MED B, V24, P835
   OSTERHAUS ADME, 1978, ZBL VET MED B, V25, P816
   OSTERHAUS ADME, 1978, ZBL VET MED B, V25, P301
   PANIGRAHY B, 1973, AVIAN DIS, V17, P430, DOI 10.2307/1589228
   PARKER JC, 1970, ARCH GES VIRUSFORSCH, V31, P293, DOI 10.1007/BF01253764
   PEDERSEN NC, 1976, AM J VET RES, V37, P1449
   PEDERSEN NC, 1978, ARCH VIROL, V58, P45, DOI 10.1007/BF01315534
   PEDERSEN NC, 1976, AM J VET RES, V37, P567
   PEDERSEN NC, 1980, AM J VET RES, V41, P868
   PENSAERT M, 1970, ARCH GES VIRUSFORSCH, V31, P321, DOI 10.1007/BF01253767
   PENSAERT M, 1978, ANN MED VET, V122, P301
   PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606
   PENSAERT MB, 1981, ARCH VIROL, V68, P45, DOI 10.1007/BF01315166
   PHILLIPS RW, 1980, AM J VET RES, V41, P1039
   Piazza M, 1969, EXPT VIRAL HEPATITIS
   PICKEL K, 1981, INFECT IMMUN, V34, P375
   POMEROY BS, 1975, AM J VET RES, V36, P553
   POWELL HC, 1975, LAB INVEST, V33, P440
   PURCELL DA, 1972, RES VET SCI, V13, P116, DOI 10.1016/S0034-5288(18)34055-4
   REYNOLDS DJ, 1977, ARCH VIROL, V55, P77, DOI 10.1007/BF01314481
   REYNOLDS DJ, 1979, ARCH VIROL, V60, P161, DOI 10.1007/BF01348032
   REYNOLDS DJ, 1980, VET MICROBIOL, V5, P283, DOI 10.1016/0378-1135(80)90027-9
   RISKI H, 1980, J MED VIROL, V6, P259, DOI 10.1002/jmv.1890060309
   RITCHIE AE, 1973, AVIAN DIS, V17, P546, DOI 10.2307/1589153
   ROBB JA, 1979, VIROLOGY, V94, P385, DOI 10.1016/0042-6822(79)90469-0
   ROBB JA, 1979, COMPREHENSIVE VIROLO, V14, P193
   ROBISON RL, 1971, J AM VET MED ASSOC, V158, P981
   ROE C. K., 1958, CANADIAN JOUR COMP MED AND VET SCI, V22, P305
   ROSENBERGER JK, 1978, AVIAN DIS, V22, P95, DOI 10.2307/1589512
   ROWE WP, 1963, P SOC EXP BIOL MED, V112, P161, DOI 10.3181/00379727-112-27980
   SABESIN SM, 1972, AM J GASTROENTEROL, V58, P259
   SAIF LJ, 1979, AM J VET RES, V40, P115
   SATO K, 1977, VET MICROBIOL, V2, P73, DOI 10.1016/0378-1135(77)90034-7
   SATO K, 1976, VIRUS, V26, P97
   SCHALK A. F., 1931, Journal of the American Veterinary Medical Association, V78, P413
   SCHINDLER L, 1981, INFECT IMMUN, V32, P1128, DOI 10.1128/IAI.32.3.1128-1131.1981
   SCHMIDT OW, 1981, INFECT IMMUN, V32, P1000, DOI 10.1128/IAI.32.3.1000-1006.1981
   SCHNAGL RD, 1978, MED J AUSTRALIA, V1, P307, DOI 10.5694/j.1326-5377.1978.tb107864.x
   SEBESTENY A, 1974, Laboratory Animals (London), V8, P317, DOI 10.1258/002367774780943733
   SHARPEE RL, 1976, AM J VET RES, V37, P1031
   SHEETS P, 1978, P SOC EXP BIOL MED, V159, P34
   SHEPHERD RW, 1979, GASTROENTEROLOGY, V76, P20
   SHEPHERD RW, 1979, GASTROENTEROLOGY, V76, P770
   SHIF I, 1970, J EXP MED, V131, P843, DOI 10.1084/jem.131.4.843
   SHIF I, 1970, J EXP MED, V131, P851, DOI 10.1084/jem.131.4.851
   SHIMIZU M, 1979, AM J VET RES, V40, P208
   SORENSEN O, 1980, ARCH NEUROL-CHICAGO, V37, P478, DOI 10.1001/archneur.1980.00500570026003
   SORENSEN O, 1981, BIOCH BIOL CORONAVIR, P271
   STAIR EL, 1972, AM J VET RES, V33, P1147
   STOHLMAN SA, 1981, NEUROLOGY, V31, P38, DOI 10.1212/WNL.31.1.38
   STOHLMAN SA, 1979, LIFE SCI, V24, P1029, DOI 10.1016/0024-3205(79)90323-0
   STOHLMAN SA, 1979, VIROLOGY, V98, P448, DOI 10.1016/0042-6822(79)90567-1
   STOHLMAN SA, 1980, J IMMUNOL, V124, P1733
   STOHLMAN SA, 1978, IMMUNOGENETICS, V6, P277, DOI 10.1007/BF01563919
   STOHLMAN SA, 1981, BIOCH BIOL CORONAVIR, P387
   STONE SS, 1977, AM J VET RES, V38, P1285
   STORZ J, 1980, DEUT TIERARZTL WOCH, V87, P252
   STORZ J, 1981, MED MICROBIOL IMMUN, V169, P169, DOI 10.1007/BF02123590
   STORZ J, 1981, INFECT IMMUN, V31, P1214, DOI 10.1128/IAI.31.3.1214-1222.1981
   SUGIYAMA K, 1980, ARCH VIROL, V66, P95, DOI 10.1007/BF01314978
   TAGUCHI F, 1976, JPN J MICROBIOL, V20, P293, DOI 10.1111/j.1348-0421.1976.tb00991.x
   TAGUCHI F, 1979, ARCH VIROL, V59, P275, DOI 10.1007/BF01317424
   TAGUCHI F, 1977, JPN J EXP MED, V47, P109
   TAGUCHI F, 1980, INFECT IMMUN, V29, P42, DOI 10.1128/IAI.29.1.42-49.1980
   TAGUCHI F, 1979, MICROBIOL IMMUNOL, V23, P249, DOI 10.1111/j.1348-0421.1979.tb00461.x
   TAGUCHI F, 1979, ARCH VIROL, V62, P333, DOI 10.1007/BF01318107
   TAKAHASHI K, 1980, JPN J VET SCI, V42, P311
   TAKEUCHI A, 1976, LAB INVEST, V34, P539
   TAMURA T, 1980, MICROBIOL IMMUNOL, V24, P243, DOI 10.1111/j.1348-0421.1980.tb00584.x
   TAMURA T, 1976, JPN J EXP MED, V46, P19
   TAMURA T, 1979, MICROBIOL IMMUNOL, V23, P965, DOI 10.1111/j.1348-0421.1979.tb00527.x
   TAMURA T, 1977, MICROBIOL IMMUNOL, V21, P683, DOI 10.1111/j.1348-0421.1977.tb00337.x
   TAMURA T, 1979, MICROBIOL IMMUNOL, V23, P177, DOI 10.1111/j.1348-0421.1979.tb00454.x
   TAMURA T, 1978, MICROBIOL IMMUNOL, V22, P557, DOI 10.1111/j.1348-0421.1978.tb00403.x
   TARDIEU M, 1980, J IMMUNOL, V124, P418
   TAYLOR CE, 1981, J EXP MED, V153, P732, DOI 10.1084/jem.153.3.732
   TIMMS LM, 1980, BRIT VET J, V136, P349
   TRAAVIK T, 1977, ARCH VIROL, V55, P25, DOI 10.1007/BF01314476
   TYRRELL DAJ, 1978, INTERVIROLOGY, V10, P321, DOI 10.1159/000148996
   TYRRELL DAJ, 1965, BMJ-BRIT MED J, V1, P1467, DOI 10.1136/bmj.1.5448.1467
   TYRRELL DAJ, 1975, INTERVIROLOGY, V5, P76, DOI 10.1159/000149883
   TYRRELL DAJ, 1968, NATURE, V220, P650
   UNDERDAHL NR, 1975, AM J VET RES, V36, P1473
   UNDERDAHL NR, 1974, AM J VET RES, V35, P1209
   VIRELIZIER JL, 1976, J IMMUNOL, V117, P748
   VIRELIZIER JL, 1978, J IMMUNOL, V120, P1616
   VIRELIZIER JL, 1976, ARCH VIROL, V50, P279, DOI 10.1007/BF01317953
   VIRELIZIER JL, 1975, INFECT IMMUN, V12, P1127, DOI 10.1128/IAI.12.5.1127-1140.1975
   VIRELIZIER JL, 1979, TRANSPLANTATION, V27, P353, DOI 10.1097/00007890-197905000-00014
   VIRELIZIER JL, 1981, CURR TOP MICROBIOL I, V92, P51
   WARD JM, 1974, AM J VET RES, V35, P1271
   WARD JM, 1970, VIROLOGY, V41, P191, DOI 10.1016/0042-6822(70)90070-X
   WARD JM, 1977, LAB ANIM SCI, V27, P372
   WATANABE H, 1975, J IMMUNOL, V115, P998
   WATT RG, 1978, RES VET SCI, V24, P147, DOI 10.1016/S0034-5288(18)33066-2
   WEGE H, 1981, J GEN VIROL, V54, P67, DOI 10.1099/0022-1317-54-1-67
   WEGE H, 1981, BIOCH BIOL CORONAVIR, P327
   WEINER LP, 1973, ARCH NEUROL-CHICAGO, V28, P293
   WEISBROTH SH, 1977, LAB ANIM SCI, V27, P466
   WEISER W, 1976, P SOC EXP BIOL MED, V152, P499
   WEISER W, 1976, J EXP MED, V143, P690, DOI 10.1084/jem.143.3.690
   WEISER WY, 1977, J EXP MED, V146, P1467, DOI 10.1084/jem.146.5.1467
   WEISS RC, 1980, AM J VET RES, V41, P663
   WEISS SR, 1981, BIOCH BIOL CORONAVIR, P245
   WERDIN RE, 1976, J AM VET MED ASSOC, V168, P240
   WITTE KH, 1977, BERL MUNCH TIERARZTL, V80, P396
   WOLFE LG, 1966, PATHOL VET, V3, P255, DOI 10.1177/030098586600300309
   WOODS RD, 1981, AM J VET RES, V42, P1163
   YAMADA A, 1979, JPN J EXP MED, V49, P413
   YASEEN SA, 1981, CAN J MICROBIOL, V27, P334, DOI 10.1139/m81-051
NR 287
TC 306
Z9 310
U1 4
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0070-217X
J9 CURR TOP MICROBIOL
JI Curr.Top.Microbiol.Immunol.
PY 1982
VL 99
BP 165
EP 200
PG 36
WC Immunology; Microbiology
SC Immunology; Microbiology
GA NQ198
UT WOS:A1982NQ19800005
PM 6178564
DA 2020-04-03
ER

PT J
AU Knoops, K
   Kikkert, M
   van den Worm, SHE
   Zevenhoven-Dobbe, JC
   van der Meer, Y
   Koster, AJ
   Mommaas, AM
   Snijder, EJ
AF Knoops, Kevin
   Kikkert, Marjolein
   van den Worm, Sjoerd H. E.
   Zevenhoven-Dobbe, Jessika C.
   van der Meer, Yvonne
   Koster, Abraham J.
   Mommaas, A. Mieke
   Snijder, Eric J.
TI SARS-coronavirus replication is supported by a reticulovesicular network
   of modified endoplasmic reticulum
SO PLOS BIOLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; ACUTE RESPIRATORY SYNDROME; DOUBLE-STRANDED-RNA;
   DOUBLE-MEMBRANE-VESICLES; VIRAL REPLICATION; NONSTRUCTURAL PROTEIN-3;
   INFECTED CELLS; ELECTRON TOMOGRAPHY; INTERFERON RESPONSE; CELLULAR
   AUTOPHAGY
AB Positive-strand RNA viruses, a large group including human pathogens such as SARS-coronavirus (SARS-CoV), replicate in the cytoplasm of infected host cells. Their replication complexes are commonly associated with modified host cell membranes. Membrane structures supporting viral RNA synthesis range from distinct spherular membrane invaginations to more elaborate webs of packed membranes and vesicles. Generally, their ultrastructure, morphogenesis, and exact role in viral replication remain to be defined. Poorly characterized double-membrane vesicles (DMVs) were previously implicated in SARS-CoV RNA synthesis. We have now applied electron tomography of cryofixed infected cells for the three-dimensional imaging of coronavirus-induced membrane alterations at high resolution. Our analysis defines a unique reticulovesicular network of modified endoplasmic reticulum that integrates convoluted membranes, numerous interconnected DMVs ( diameter 200-300 nm), and "vesicle packets'' apparently arising from DMV merger. The convoluted membranes were most abundantly immunolabeled for viral replicase subunits. However, double-stranded RNA, presumably revealing the site of viral RNA synthesis, mainly localized to the DMV interior. Since we could not discern a connection between DMV interior and cytosol, our analysis raises several questions about the mechanism of DMV formation and the actual site of SARS-CoV RNA synthesis. Our data document the extensive virus-induced reorganization of host cell membranes into a network that is used to organize viral replication and possibly hide replicating RNA from antiviral defense mechanisms. Together with biochemical studies of the viral enzyme complex, our ultrastructural description of this "replication network'' will aid to further dissect the early stages of the coronavirus life cycle and its virus-host interactions.
C1 [Knoops, Kevin; Kikkert, Marjolein; van den Worm, Sjoerd H. E.; Zevenhoven-Dobbe, Jessika C.; van der Meer, Yvonne; Snijder, Eric J.] Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, Leiden, Netherlands.
   [Knoops, Kevin; Koster, Abraham J.; Mommaas, A. Mieke] Leiden Univ, Med Ctr, Dept Mol Cell Biol, Sect Electron Microscopy, Leiden, Netherlands.
RP Snijder, EJ (reprint author), Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, Leiden, Netherlands.
EM e.j.snijder@lumc.nl
RI Knoops, Kevin/F-6247-2012; Snijder, Eric J./E-6073-2018; Koster,
   Abraham/I-7665-2017; Jha, Babal/AAC-8337-2020
OI Snijder, Eric J./0000-0003-3297-2309; Koster,
   Abraham/0000-0003-1717-2549; Jha, Babal/0000-0002-7660-5255
FU Euro-Asian SARS-DTV Network [SP22-CT-2004-511064]; Netherlands
   Organization for Scientific Research NWO-CWNetherlands Organization for
   Scientific Research (NWO) [700.52.306, 700.55.002]
FX This work was supported (in part) by the European Commission under the
   context Euro-Asian SARS-DTV Network (SP22-CT-2004-511064) and by grants
   from the Council for Chemical Sciences of the Netherlands Organization
   for Scientific Research (NWO-CW grants 700.52.306 and 700.55.002).
CR Ahlquist P, 2006, NAT REV MICROBIOL, V4, P371, DOI 10.1038/nrmicro1389
   BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992
   BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8
   Bost AG, 2001, VIROLOGY, V285, P21, DOI 10.1006/viro.2001.0932
   Clementz MA, 2008, VIROLOGY, V375, P118, DOI 10.1016/j.virol.2008.01.018
   DAVIDFERREIRA JF, 1965, J CELL BIOL, V24, P57, DOI 10.1083/jcb.24.1.57
   Egger D, 2005, J GEN VIROL, V86, P707, DOI 10.1099/vir.0.80442-0
   Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667
   Frangakis AS, 2001, J STRUCT BIOL, V135, P239, DOI 10.1006/jsbi.2001.4406
   Frey TG, 2006, ANNU REV BIOPH BIOM, V35, P199, DOI 10.1146/annurev.biophys.35.040405.102039
   FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075
   Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Haller O, 2006, VIROLOGY, V344, P119, DOI 10.1016/j.virol.2005.09.024
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505
   Imbert I, 2006, EMBO J, V25, P4933, DOI 10.1038/sj.emboj.7601368
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Kanjanahaluethai A, 2007, VIROLOGY, V361, P391, DOI 10.1016/j.virol.2006.12.009
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Kirkegaard K, 2005, AUTOPHAGY, V1, P182, DOI 10.4161/auto.1.3.2065
   Kopek BG, 2007, PLOS BIOL, V5, P2022, DOI 10.1371/journal.pbio.0050220
   Koster AJ, 1997, J STRUCT BIOL, V120, P276, DOI 10.1006/jsbi.1997.3933
   Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013
   KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55
   Kutik S, 2007, J CELL BIOL, V179, P585, DOI 10.1083/jcb.200708199
   Mackenzie J, 2005, TRAFFIC, V6, P967, DOI 10.1111/j.1600-0854.2005.00339.x
   Mackenzie JM, 1999, J VIROL, V73, P9555, DOI 10.1128/JVI.73.11.9555-9567.1999
   Martone ME, 2008, J STRUCT BIOL, V161, P220, DOI 10.1016/j.jsb.2007.10.003
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Miller S, 2008, NAT REV MICROBIOL, V6, P363, DOI 10.1038/nrmicro1890
   Miyanari Y, 2007, NAT CELL BIOL, V9, P1089, DOI 10.1038/ncb1631
   Netherton C, 2007, ADV VIRUS RES, V70, P101, DOI 10.1016/S0065-3527(07)70004-0
   Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07
   Novoa RR, 2005, BIOL CELL, V97, P147, DOI 10.1042/BC20040058
   Oostra M, 2007, J VIROL, V81, P13876, DOI 10.1128/JVI.01631-07
   Pasternak AO, 2006, J GEN VIROL, V87, P1403, DOI 10.1099/vir.0.81611-0
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Posthuma CC, 2008, J VIROL, V82, P4480, DOI 10.1128/JVI.02756-07
   Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Pyrc K, 2007, J VIROL, V81, P3051, DOI 10.1128/JVI.01466-06
   Quinkert D, 2005, J VIROL, V79, P13594, DOI 10.1128/JVI.79.21.13594-13605.2005
   Roth-Cross JK, 2007, J VIROL, V81, P7189, DOI 10.1128/JVI.00013-07
   Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001
   Salonen A, 2005, CURR TOP MICROBIOL, V285, P139
   Sawicki DL, 2001, J GEN VIROL, V82, P385, DOI 10.1099/0022-1317-82-2-385
   Sawicki SG, 2007, J VIROL, V81, P20, DOI 10.1128/JVI.01358-06
   Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996
   SCHONBORN J, 1991, NUCLEIC ACIDS RES, V19, P2993, DOI 10.1093/nar/19.11.2993
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Snijder EJ, 2001, J GEN VIROL, V82, P985, DOI 10.1099/0022-1317-82-5-985
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Sparks JS, 2007, J VIROL, V81, P12554, DOI 10.1128/JVI.01257-07
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   STOLLAR BD, 1970, VIROLOGY, V42, P276, DOI 10.1016/0042-6822(70)90270-9
   TARGETTADAMS P, 2007, J VIROL, V81
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Uchil PD, 2003, J BIOL CHEM, V278, P24388, DOI 10.1074/jbc.M301717200
   van der Meer Y, 1998, J VIROL, V72, P6689, DOI 10.1128/JVI.72.8.6689-6698.1998
   van der Meer Y, 1999, J VIROL, V73, P7641, DOI 10.1128/JVI.73.9.7641-7657.1999
   van Hemert MJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000054
   Verheije MH, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000088
   Versteeg GA, 2007, VIROLOGY, V361, P18, DOI 10.1016/j.virol.2007.01.020
   Versteeg GA, 2008, NIDOVIRUSES, P245
   Walther P, 2002, J MICROSC-OXFORD, V208, P3, DOI 10.1046/j.1365-2818.2002.01064.x
   Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006
   Westaway EG, 1999, VIROLOGY, V258, P108, DOI 10.1006/viro.1999.9683
   Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997
   Wileman T, 2006, SCIENCE, V312, P875, DOI 10.1126/science.1126766
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhou HX, 2007, J VIROL, V81, P568, DOI 10.1128/JVI.01512-06
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 79
TC 303
Z9 306
U1 1
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1545-7885
J9 PLOS BIOL
JI PLoS. Biol.
PD SEP
PY 2008
VL 6
IS 9
BP 1957
EP 1974
AR e226
DI 10.1371/journal.pbio.0060226
PG 18
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA 356MZ
UT WOS:000259783600018
PM 18798692
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Simmons, G
   Gosalia, DN
   Rennekamp, AJ
   Reeves, JD
   Diamond, SL
   Bates, P
AF Simmons, G
   Gosalia, DN
   Rennekamp, AJ
   Reeves, JD
   Diamond, SL
   Bates, P
TI Inhibitors of cathepsin L prevent severe acute respiratory syndrome
   coronavirus entry
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE SARS; viral entry; proteolysis; membrane fusion; viral envelope
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; SPIKE
   GLYCOPROTEIN; SARS CORONAVIRUS; MEMBRANE-FUSION; AVIAN-SARCOMA;
   SUBGROUP-A; LOW PH; RECEPTOR; INFECTION
AB Severe acute respiratory syndrome (SARS) is caused by an emergent coronavirus (SARS-CoV), for which there is currently no effective treatment. SARS-CoV mediates receptor binding and entry by its spike (S) glycoprotein, and infection is sensitive to lysosomotropic agents that perturb endosomal pH. We demonstrate here that the lysosomotropic-agent-mediated block to SARS-CoV infection is overcome by protease treatment of target-cell-associated virus. In addition, SARS-CoV infection was blocked by specific inhibitors of the pH-sensitive endosomal protease cathepsin L. A cell-free membrane-fusion system demonstrates that engagement of receptor followed by proteolysis is required for SARS-CoV membrane fusion and indicates that cathepsin L is sufficient to activate membrane fusion by SARS-CoV S. These results suggest that SARS-CoV infection results from a unique, three-step process: receptor binding and induced conformational changes in S glycoprotein followed by cathepsin L proteolysis within endosomes. The requirement for cathepsin L proteolysis identifies a previously uncharacterized class of inhibitor for SARS-CoV infection.
C1 Univ Penn, Dept Microbiol, Sch Med, Philadelphia, PA 19104 USA.
   Univ Penn, Inst Med & Engn, Dept Bioengn, Philadelphia, PA 19104 USA.
   Univ Penn, Inst Med & Engn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA.
RP Simmons, G (reprint author), Univ Penn, Dept Microbiol, Sch Med, 225 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.
EM gsimmons@mail.med.upenn.edu; pbates@mail.med.upenn.edu
RI Bates, Paul/F-8823-2011; Simmons, Graham/G-3523-2012; Reeves,
   Jacqueline/I-5379-2012
OI Simmons, Graham/0000-0002-9615-7023; Rennekamp,
   Andrew/0000-0001-6174-7253; Bates, Paul/0000-0002-3918-5976
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI043455, R21 AI058701, R21 AI 058701,
   R21 AI059172, R01 AI43455, U54 AI057168]
CR Barnard Dale L., 2004, Antiviral Chemistry & Chemotherapy, V15, P15
   Bosch BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/pnas.0400576101
   BOYCOTT R, 1994, VIROLOGY, V203, P313, DOI 10.1006/viro.1994.1489
   Brana C, 1999, EUR J NEUROSCI, V11, P2375, DOI 10.1046/j.1460-9568.1999.00653.x
   Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656
   CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016
   Earp LJ, 2003, J VIROL, V77, P3058, DOI 10.1128/JVI.77.5.3058-3066.2003
   GILBERT JM, 1994, J VIROL, V68, P5623, DOI 10.1128/JVI.68.9.5623-5628.1994
   Gosalia DN, 2003, P NATL ACAD SCI USA, V100, P8721, DOI 10.1073/pnas.1530261100
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hanisch FG, 2003, EUR J IMMUNOL, V33, P3242, DOI 10.1002/eji.200324189
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   LUBISCH W, 2002, BIOORG MED CHEM LETT, V12, P1385
   Melikyan GB, 2004, J VIROL, V78, P3753, DOI 10.1128/JVI.78.7.3753-3762.2004
   Montaser M, 2002, BIOL CHEM, V383, P1305, DOI 10.1515/BC.2002.147
   Mothes W, 2000, CELL, V103, P679, DOI 10.1016/S0092-8674(00)00170-7
   Netter RC, 2004, J VIROL, V78, P13430, DOI 10.1128/JVI.78.24.13430-13439.2004
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531
   Sparacio S, 2000, VIROLOGY, V271, P248, DOI 10.1006/viro.2000.0294
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Zhou J, 2001, J VIROL, V75, P5851, DOI 10.1128/JVI.75.13.5851-5859.2001
NR 24
TC 303
Z9 328
U1 5
U2 20
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 16
PY 2005
VL 102
IS 33
BP 11876
EP 11881
DI 10.1073/pnas.0505577102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 956RH
UT WOS:000231317000055
PM 16081529
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU BOURSNELL, MEG
   BROWN, TDK
   FOULDS, IJ
   GREEN, PF
   TOMLEY, FM
   BINNS, MM
AF BOURSNELL, MEG
   BROWN, TDK
   FOULDS, IJ
   GREEN, PF
   TOMLEY, FM
   BINNS, MM
TI COMPLETION OF THE SEQUENCE OF THE GENOME OF THE CORONAVIRUS AVIAN
   INFECTIOUS-BRONCHITIS VIRUS
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
RP BOURSNELL, MEG (reprint author), HOUGHTON POULTRY RES STN,HUNTINGDON PE17 2DA,CAMBS,ENGLAND.
OI Tomley, Fiona/0000-0003-2188-8013; Boursnell, Mike/0000-0002-2554-8190
CR AMBARTSUMYAN NS, 1980, FEBS LETT, V114, P265, DOI 10.1016/0014-5793(80)81130-6
   ATKINS JF, 1972, P NATL ACAD SCI USA, V69, P1192, DOI 10.1073/pnas.69.5.1192
   BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1
   BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   BARIC RS, 1985, VIRUS RES, V3, P19, DOI 10.1016/0168-1702(85)90038-3
   BEAUDETTE F. R., 1937, Journal of the American Veterinary Medical Association, V90, P51
   BIGGIN M, 1984, EMBO J, V3, P1083, DOI 10.1002/j.1460-2075.1984.tb01933.x
   BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963
   BINNS MM, 1985, J VIROL METHODS, V11, P265, DOI 10.1016/0166-0934(85)90116-8
   BINNS MM, 1985, J GEN VIROL, V66, P719, DOI 10.1099/0022-1317-66-4-719
   BOURSNELL MEG, 1984, VIRUS RES, V1, P303, DOI 10.1016/0168-1702(84)90019-4
   BOURSNELL MEG, 1984, GENE, V29, P87, DOI 10.1016/0378-1119(84)90169-0
   BOURSNELL MEG, 1985, J GEN VIROL, V66, P573, DOI 10.1099/0022-1317-66-3-573
   BOURSNELL MEG, 1985, J GEN VIROL, V66, P2253, DOI 10.1099/0022-1317-66-10-2253
   BRAYTON PR, 1982, J VIROL, V42, P847, DOI 10.1128/JVI.42.3.847-853.1982
   BRAYTON PR, 1984, VIROLOGY, V133, P197, DOI 10.1016/0042-6822(84)90439-2
   BROWN TDK, 1984, VIRUS RES, V1, P15, DOI 10.1016/0168-1702(84)90031-5
   BROWN TDK, 1986, J GEN VIROL, V67, P221, DOI 10.1099/0022-1317-67-2-221
   CATON AJ, 1982, CELL, V31, P417, DOI 10.1016/0092-8674(82)90135-0
   CAVANAGH D, 1981, J GEN VIROL, V53, P93, DOI 10.1099/0022-1317-53-1-93
   CORNELISSEN BJC, 1983, NUCLEIC ACIDS RES, V11, P1253, DOI 10.1093/nar/11.5.1253
   DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   FOX TD, 1980, NATURE, V288, P60, DOI 10.1038/288060a0
   GEORGE DG, 1986, NUCLEIC ACIDS RES, V14, P11, DOI 10.1093/nar/14.1.11
   GERMINO J, 1982, P NATL ACAD SCI-BIOL, V79, P5475, DOI 10.1073/pnas.79.18.5475
   HERMAN RC, 1986, J VIROL, V58, P797, DOI 10.1128/JVI.58.3.797-804.1986
   HONG GF, 1981, BIOSCIENCE REP, V1, P243, DOI 10.1007/BF01114911
   JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054
   KANEHISA M, 1982, NUCLEIC ACIDS RES, V10, P183, DOI 10.1093/nar/10.1.183
   KASTELEIN RA, 1982, NATURE, V295, P35, DOI 10.1038/295035a0
   KORNELUK RG, 1985, GENE, V40, P317, DOI 10.1016/0378-1119(85)90055-1
   KOZAK M, 1983, MICROBIOL REV, V47, P1
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   LEIBOWITZ JL, 1982, J VIROL, V43, P905, DOI 10.1128/JVI.43.3.905-913.1982
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426
   LOMNICZI B, 1977, J VIROL, V24, P99, DOI 10.1128/JVI.24.1.99-107.1977
   LOMNICZI B, 1977, J GEN VIROL, V36, P531, DOI 10.1099/0022-1317-36-3-531
   MAKINO S, 1986, P NATL ACAD SCI USA, V83, P4204, DOI 10.1073/pnas.83.12.4204
   Maxam A M, 1980, Methods Enzymol, V65, P499
   MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHOCHETMAN G, 1977, VIROLOGY, V77, P772, DOI 10.1016/0042-6822(77)90498-6
   SCHUBERT M, 1984, J VIROL, V51, P505, DOI 10.1128/JVI.51.2.505-514.1984
   SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761
   SIDDELL SG, 1983, INTERVIROLOGY, V20, P181, DOI 10.1159/000149390
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   STADEN R, 1984, NUCLEIC ACIDS RES, V12, P551, DOI 10.1093/nar/12.1Part2.551
   STADEN R, 1982, NUCLEIC ACIDS RES, V10, P141, DOI 10.1093/nar/10.1.141
   STADEN R, 1984, NUCLEIC ACIDS RES, V12, P499, DOI 10.1093/nar/12.1Part2.499
   STADEN R, 1982, NUCLEIC ACIDS RES, V10, P4731, DOI 10.1093/nar/10.15.4731
   STADEN R, 1984, NUCLEIC ACIDS RES, V12, P521, DOI 10.1093/nar/12.1Part2.521
   STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951
   STEINHAUER DA, 1986, J VIROL, V57, P219, DOI 10.1128/JVI.57.1.219-228.1986
   STERN DF, 1980, J VIROL, V36, P440, DOI 10.1128/JVI.36.2.440-449.1980
   STERN DF, 1980, J VIROL, V34, P665, DOI 10.1128/JVI.34.3.665-674.1980
   STERN DF, 1984, J VIROL, V50, P22, DOI 10.1128/JVI.50.1.22-29.1984
   STRAUSS EG, 1984, VIROLOGY, V133, P92, DOI 10.1016/0042-6822(84)90428-8
   STRAUSS EG, 1983, CURR TOP MICROBIOL, V105, P1
NR 63
TC 303
Z9 365
U1 1
U2 7
PU SOC GENERAL MICROBIOLOGY
PI READING
PA HARVEST HOUSE 62 LONDON ROAD, READING, BERKS, ENGLAND RG1 5AS
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD JAN
PY 1987
VL 68
BP 57
EP 77
DI 10.1099/0022-1317-68-1-57
PN 1
PG 21
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA F6814
UT WOS:A1987F681400005
PM 3027249
OA Bronze
DA 2020-04-03
ER

PT J
AU Azhar, EI
   El-Kafrawy, SA
   Farraj, SA
   Hassan, AM
   Al-Saeed, MS
   Hashem, AM
   Madani, TA
AF Azhar, Esam I.
   El-Kafrawy, Sherif A.
   Farraj, Suha A.
   Hassan, Ahmed M.
   Al-Saeed, Muneera S.
   Hashem, Anwar M.
   Madani, Tariq A.
TI Evidence for Camel-to-Human Transmission of MERS Coronavirus
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE-EAST; DROMEDARY CAMELS
AB We describe the isolation and sequencing of Middle East respiratory syndrome coronavirus (MERS-CoV) obtained from a dromedary camel and from a patient who died of laboratory-confirmed MERS-CoV infection after close contact with camels that had rhinorrhea. Nasal swabs collected from the patient and from one of his nine camels were positive for MERS-CoV RNA. In addition, MERS-CoV was isolated from the patient and the camel. The full genome sequences of the two isolates were identical. Serologic data indicated that MERS-CoV was circulating in the camels but not in the patient before the human infection occurred. These data suggest that this fatal case of human MERS-CoV infection was transmitted through close contact with an infected camel.
C1 [Azhar, Esam I.] King Abdulaziz Univ, Dept Med Lab Technol, Fac Appl Med Sci, Jeddah 21589, Saudi Arabia.
   [Azhar, Esam I.; El-Kafrawy, Sherif A.; Farraj, Suha A.; Hassan, Ahmed M.; Al-Saeed, Muneera S.; Hashem, Anwar M.] King Abdulaziz Univ, Special Infect Agents Unit, King Fahd Med Res Ctr, Jeddah 21589, Saudi Arabia.
   [Hashem, Anwar M.] King Abdulaziz Univ, Fac Med, Dept Med Microbiol & Parasitol, Jeddah 21589, Saudi Arabia.
   [Madani, Tariq A.] King Abdulaziz Univ, Fac Med, Dept Med, Jeddah 21589, Saudi Arabia.
RP Madani, TA (reprint author), King Abdulaziz Univ, Dept Med, POB 80215, Jeddah 21589, Saudi Arabia.
EM tmadani@kau.edu.sa
RI Hashem, Anwar/E-9411-2011; Hassan, Ahmed/AAB-7241-2019; El-Kafrawy,
   Sherif A/C-8699-2012
OI El-Kafrawy, Sherif A/0000-0002-3667-7529
CR Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Guery B, 2013, LANCET, V381, P2254
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   WHO, 2013, LAB TEST MIDDL E RES
   Zaki AM, 2013, NEW ENGL J MED, V369, P394
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 16
TC 302
Z9 318
U1 18
U2 86
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 26
PY 2014
VL 370
IS 26
BP 2499
EP 2505
DI 10.1056/NEJMoa1401505
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA AJ6KY
UT WOS:000337804400007
PM 24896817
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Ge, XY
   Li, JL
   Yang, XL
   Chmura, AA
   Zhu, GJ
   Epstein, JH
   Mazet, JK
   Hu, B
   Zhang, W
   Peng, C
   Zhang, YJ
   Luo, CM
   Tan, B
   Wang, N
   Zhu, Y
   Crameri, G
   Zhang, SY
   Wang, LF
   Daszak, P
   Shi, ZL
AF Ge, Xing-Yi
   Li, Jia-Lu
   Yang, Xing-Lou
   Chmura, Aleksei A.
   Zhu, Guangjian
   Epstein, Jonathan H.
   Mazet, Jonna K.
   Hu, Ben
   Zhang, Wei
   Peng, Cheng
   Zhang, Yu-Ji
   Luo, Chu-Ming
   Tan, Bing
   Wang, Ning
   Zhu, Yan
   Crameri, Gary
   Zhang, Shu-Yi
   Wang, Lin-Fa
   Daszak, Peter
   Shi, Zheng-Li
TI Isolation and characterization of a bat SARS-like coronavirus that uses
   the ACE2 receptor
SO NATURE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; FUNCTIONAL RECEPTOR; ADAPTATION;
   DIVERSITY; ORIGIN
AB The 2002-3 pandemic caused by severe acute respiratory syndrome coronavirus (SARS-CoV) was one of the most significant public health events in recent history(1). An ongoing outbreak of Middle East respiratory syndrome coronavirus(2) suggests that this group of viruses remains a key threat and that their distribution is wider than previously recognized. Although bats have been suggested to be the natural reservoirs of both viruses(3-5), attempts to isolate the progenitor virus of SARS-CoV from bats have been unsuccessful. Diverse SARS-like coronaviruses (SL-CoVs) have now been reported from bats in China, Europe and Africa(5-8), but none is considered a direct progenitor of SARS-CoV because of their phylogenetic disparity from this virus and the inability of their spike proteins to use the SARS-CoV cellular receptor molecule, the human angiotensin converting enzyme II (ACE2)(9,10). Here we report whole-genome sequences of two novel bat coronaviruses from Chinese horseshoe bats (family: Rhinolophidae) in Yunnan, China: RsSHC014 and Rs3367. These viruses are far more closely related to SARS-CoV than any previously identified bat coronaviruses, particularly in the receptor binding domain of the spike protein. Most importantly, we report the first recorded isolation of a live SL-CoV (bat SL-CoV-WIV1) from bat faecal samples in Vero E6 cells, which has typical coronavirus morphology, 99.9% sequence identity to Rs3367 and uses ACE2 from humans, civets and Chinese horseshoe bats for cell entry. Preliminary in vitro testing indicates that WIV1 also has a broad species tropism. Our results provide the strongest evidence to date that Chinese horseshoe bats are natural reservoirs of SARS-CoV, and that intermediate hosts may not be necessary for direct human infection by some bat SL-CoVs. They also highlight the importance of pathogen-discovery programs targeting high-risk wildlife groups in emerging disease hotspots as a strategy for pandemic preparedness.
C1 [Ge, Xing-Yi; Li, Jia-Lu; Yang, Xing-Lou; Hu, Ben; Zhang, Wei; Peng, Cheng; Zhang, Yu-Ji; Luo, Chu-Ming; Tan, Bing; Wang, Ning; Zhu, Yan; Shi, Zheng-Li] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Ctr Emerging Infect Dis, Wuhan 430071, Peoples R China.
   [Chmura, Aleksei A.; Zhu, Guangjian; Epstein, Jonathan H.; Daszak, Peter] EcoHlth Alliance, New York, NY 10001 USA.
   [Mazet, Jonna K.] Univ Calif Davis, Sch Vet Med, Hlth Inst 1, Davis, CA 95616 USA.
   [Crameri, Gary; Wang, Lin-Fa] CSIRO Australian Anim Hlth Lab, Geelong, Vic 3220, Australia.
   [Zhang, Shu-Yi] E China Normal Univ, Coll Life Sci, Shanghai 200062, Peoples R China.
   [Wang, Lin-Fa] Duke NUS Grad Med Sch, Emerging Infect Dis Program, Singapore 169857, Singapore.
RP Daszak, P (reprint author), EcoHlth Alliance, New York, NY 10001 USA.
EM daszak@ecohealthalliance.org; zlshi@wh.iov.cn
RI Shi, Zhengli/A-1013-2013; Crameri, Gary/H-8441-2013; Chmura,
   Aleksei/K-9971-2018; daszak, peter/U-4588-2017
OI Shi, Zhengli/0000-0001-8089-163X; Chmura, Aleksei/0000-0001-5544-0431;
   daszak, peter/0000-0002-2046-5695; Li, Jialu/0000-0001-9772-3886; Wang,
   Lin-Fa/0000-0003-2752-0535; Yang, Xing-Lou/0000-0002-5317-8983
FU State Key Program for Basic ResearchState Key Development Program for
   Basic Research of China [2011CB504701, 2010CB530100]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [81290341, 31321001]; Scientific and technological basis special project
   [2013FY113500]; CSIRO OCE Science Leaders Award; National Institute of
   Allergy and Infectious Diseases (NIAID)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI079231]; National Institutes of Health (NIH)/National Science
   Foundation (NSF) 'Ecology and Evolution of Infectious Diseases' award
   from the NIH Fogarty International Center [R01TW005869]; NIH Fogarty
   International CenterUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC); Office of the Secretary of the Department of
   Health and Human Services [R56TW009502]; United States Agency for
   International Development (USAID) Emerging Pandemic Threats
   PREDICTUnited States Agency for International Development (USAID)
FX We acknowledge financial support from the State Key Program for Basic
   Research (2011CB504701 and 2010CB530100), National Natural Science
   Foundation of China (81290341 and 31321001), Scientific and
   technological basis special project (2013FY113500), CSIRO OCE Science
   Leaders Award, National Institute of Allergy and Infectious Diseases
   (NIAID) award number R01AI079231, a National Institutes of Health
   (NIH)/National Science Foundation (NSF) 'Ecology and Evolution of
   Infectious Diseases' award from the NIH Fogarty International Center
   (R01TW005869), an award from the NIH Fogarty International Center
   supported by International Influenza Funds from the Office of the
   Secretary of the Department of Health and Human Services (R56TW009502),
   and United States Agency for International Development (USAID) Emerging
   Pandemic Threats PREDICT. The contents are the responsibility of the
   authors and do not necessarily reflect the views of NIAID, NIH, NSF,
   USAID or the United States Government. We thank X. Che from Zhujiang
   Hospital, Southern Medical University, for providing human SARS patient
   sera.
CR Anthony SJ, 2013, J GEN VIROL, V94, P1028, DOI 10.1099/vir.0.049759-0
   Becker MM, 2008, P NATL ACAD SCI USA, V105, P19944, DOI 10.1073/pnas.0808116105
   Chan JFW, 2012, J INFECTION, V65, P477, DOI 10.1016/j.jinf.2012.10.002
   Cui J, 2007, EMERG INFECT DIS, V13, P1526, DOI 10.3201/eid1310.070448
   Luna LKD, 2007, J CLIN MICROBIOL, V45, P1049, DOI 10.1128/JCM.02426-06
   Drexler JF, 2010, J VIROL, V84, P11336, DOI 10.1128/JVI.00650-10
   Hon CC, 2008, J VIROL, V82, P1819, DOI 10.1128/JVI.01926-07
   Hou YX, 2010, ARCH VIROL, V155, P1563, DOI 10.1007/s00705-010-0729-6
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2010, J VIROL, V84, P11385, DOI 10.1128/JVI.01121-10
   Lau SKP, 2010, J VIROL, V84, P2808, DOI 10.1128/JVI.02219-09
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Li Y, 2010, J VIROL, V84, P3889, DOI 10.1128/JVI.02497-09
   Martin DP, 2010, BIOINFORMATICS, V26, P2462, DOI 10.1093/bioinformatics/btq467
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Morse SS, 2012, LANCET, V380, P1956, DOI 10.1016/S0140-6736(12)61684-5
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ren W, 2008, J VIROL, V82, P1899, DOI 10.1128/JVI.01085-07
   Ren W, 2006, J GEN VIROL, V87, P3355, DOI 10.1099/vir.0.82220-0
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Tong SX, 2009, EMERG INFECT DIS, V15, P482, DOI 10.3201/eid1503.081013
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wu KL, 2012, J BIOL CHEM, V287, P8904, DOI 10.1074/jbc.M111.325803
   Yuan JF, 2010, J GEN VIROL, V91, P1058, DOI 10.1099/vir.0.016378-0
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 29
TC 301
Z9 313
U1 69
U2 211
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD NOV 28
PY 2013
VL 503
IS 7477
BP 535
EP +
DI 10.1038/nature12711
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 258MU
UT WOS:000327464200045
PM 24172901
OA Green Accepted, Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Li, BJ
   Tang, QQ
   Cheng, D
   Qin, C
   Xie, FY
   Wei, Q
   Xu, J
   Liu, YJ
   Zheng, BJ
   Woodle, MC
   Zhong, NS
   Lu, PY
AF Li, BJ
   Tang, QQ
   Cheng, D
   Qin, C
   Xie, FY
   Wei, Q
   Xu, J
   Liu, YJ
   Zheng, BJ
   Woodle, MC
   Zhong, NS
   Lu, PY
TI Using siRNA in prophylactic and therapeutic regimens against SARS
   coronavirus in rhesus macaque
SO NATURE MEDICINE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; SMALL INTERFERING RNAS; SPIKE PROTEIN;
   GENE-TRANSFER; VIRUS; MICE; REPLICATION; INFECTION; SEQUENCE; EXPRESSION
AB Development of therapeutic agents for severe acute respiratory syndrome ( SARS) viral infection using short interfering RNA ( siRNA) inhibitors exemplifies a powerful new means to combat emerging infectious diseases. Potent siRNA inhibitors of SARS coronavirus ( SCV) in vitro were further evaluated for efficacy and safety in a rhesus macaque ( Macaca mulatta) SARS model using clinically viable delivery while comparing three dosing regimens. Observations of SARS- like symptoms, measurements of SCV RNA presence and lung histopathology and immunohistochemistry consistently showed siRNA- mediated anti- SARS efficacy by either prophylactic or therapeutic regimens. The siRNAs used provided relief from SCV infection - induced fever, diminished SCV viral levels and reduced acute diffuse alveoli damage. The 10 - 40 mg/ kg accumulated dosages of siRNA did not show any sign of siRNA- induced toxicity. These results suggest that a clinical investigation is warranted and illustrate the prospects for siRNA to enable a massive reduction in development time for new targeted therapeutic agents.
C1 Intradigm Corp, Rockville, MD 20852 USA.
   Sun Yatsen Univ, Biotechnol Res Ctr, Guangzhou, Peoples R China.
   Minist Educ State, Key Lab Gene Engn, Guangzhou, Peoples R China.
   Guangzhou Top Genom Ltd, Guangzhou, Peoples R China.
   Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing 100037, Peoples R China.
   Peking Union Med Coll, Beijing, Peoples R China.
   Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   Guangzhou Inst Resp Dis, Guangzhou, Peoples R China.
RP Lu, PY (reprint author), Intradigm Corp, 12115 K Parklawn Dr, Rockville, MD 20852 USA.
EM nanshan@vip.163.com; patricklu@intradigm.com
OI Cheng, Du/0000-0001-5105-7777
CR Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164
   Boeckle S, 2004, J GENE MED, V6, P1102, DOI 10.1002/jgm.598
   Bonnard E, 2002, PEPTIDES, V23, P1107, DOI 10.1016/S0196-9781(02)00034-7
   Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X
   Chen ZW, 2005, J VIROL, V79, P2678, DOI 10.1128/JVI.79.5.2678-2688.2005
   Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Delepine P, 2003, J GENE MED, V5, P600, DOI 10.1002/jgm.385
   Elmen J., 2004, PRECLINICA, V2, P135
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101
   Ghanayem N S, 2001, Pediatr Crit Care Med, V2, P315, DOI 10.1097/00130478-200110000-00005
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Haasnoot J, 2003, J BIOMED SCI, V10, P607, DOI 10.1007/BF02256311
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Heidel JD, 2004, NAT BIOTECHNOL, V22, P1579, DOI 10.1038/nbt1038
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004
   Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831
   Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   LU PY, 2000, Patent No. 20030148975
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Massaro D, 2004, AM J PHYSIOL-LUNG C, V287, pL1066, DOI 10.1152/ajplung.00067.2004
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Qin C, 2005, J PATHOL, V206, P251, DOI 10.1002/path.1769
   Rowe T, 2004, J VIROL, V78, P11401, DOI 10.1128/JVI.78.20.11401-11404.2004
   Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011
   Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100
   Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Thomas Neal J, 2005, Pediatr Crit Care Med, V6, P160, DOI 10.1097/01.PCC.0000154965.08432.16
   Tompkins SM, 2004, P NATL ACAD SCI USA, V101, P8682, DOI 10.1073/pnas.0402630101
   Wang Z, 2004, J VIROL, V78, P7523, DOI 10.1128/JVI.78.14.7523-7527.2004
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9
   Zhang RL, 2003, CHINESE MED J-PEKING, V116, P1262
   Zhang YJ, 2004, FEBS LETT, V560, P141, DOI 10.1016/S0014-5793(04)00087-0
   Zheng BJ, 2004, ANTIVIR THER, V9, P365
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 50
TC 298
Z9 325
U1 22
U2 79
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD SEP
PY 2005
VL 11
IS 9
BP 944
EP 951
DI 10.1038/nm1280
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 962IL
UT WOS:000231724700021
PM 16116432
OA Bronze
DA 2020-04-03
ER

PT J
AU LEE, HJ
   SHIEH, CK
   GORBALENYA, AE
   KOONIN, EV
   LAMONICA, N
   TULER, J
   BAGDZHADZHYAN, A
   LAI, MMC
AF LEE, HJ
   SHIEH, CK
   GORBALENYA, AE
   KOONIN, EV
   LAMONICA, N
   TULER, J
   BAGDZHADZHYAN, A
   LAI, MMC
TI THE COMPLETE SEQUENCE (22 KILOBASES) OF MURINE CORONAVIRUS GENE-1
   ENCODING THE PUTATIVE PROTEASES AND RNA-POLYMERASE
SO VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; AMINO-ACID SEQUENCE; NUCLEOTIDE-SEQUENCE;
   MESSENGER-RNA; GENOMIC RNA; MHV-JHM; CLEAVAGE SITE; PROTEIN;
   IDENTIFICATION; STRAIN
C1 UNIV SO CALIF, SCH MED, HOWARD HUGHES MED INST, DEPT MICROBIOL, LOS ANGELES, CA 90033 USA.
   ACAD MED SCI USSR, INST POLIOMYELITIS & VIRAL ENCEPHALITIDES, MOSCOW 142782, USSR.
   ACAD SCI USSR, INST MICROBIOL, MOSCOW 117811, USSR.
RI Gorbalenya, Alexander E/J-4818-2012; Lai, Michael M. C./I-7001-2012
OI Gorbalenya, Alexander E/0000-0002-4967-7341; 
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI19244]; NINDS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [NS181146]
CR ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0
   ARMSTRONG J, 1983, NUCLEIC ACIDS RES, V11, P883, DOI 10.1093/nar/11.3.883
   BAKER SC, 1989, J VIROL, V63, P3693, DOI 10.1128/JVI.63.9.3693-3699.1989
   BAKER SC, 1990, IN PRESS PATHOGENESI
   BARIC RS, 1990, VIROLOGY, V177, P646, DOI 10.1016/0042-6822(90)90530-5
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BRAYTON PR, 1982, J VIROL, V412, P8547
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   CAVANAGH D, 1990, VIROLOGY, V176, P306, DOI 10.1016/0042-6822(90)90259-T
   CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165
   CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881
   DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9
   DENISON M, 1987, VIROLOGY, V157, P565, DOI 10.1016/0042-6822(87)90303-5
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   DUFOUR E, 1987, BIOCHEMISTRY-US, V26, P5689, DOI 10.1021/bi00392a017
   GORBALENYA AE, 1989, J MOL EVOL, V28, P256, DOI 10.1007/BF02102483
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539
   GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5
   HIRANO N, 1974, ARCH GES VIRUSFORSCH, V44, P298, DOI 10.1007/BF01240618
   KECK JG, 1987, VIROLOGY, V156, P331, DOI 10.1016/0042-6822(87)90413-2
   KOONIN EV, 1990, IN PRESS BIOPOLIM KL
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   LAI MMC, 1988, RNA GENETICS, V1, P115
   LEIBOWITZ JL, 1982, J VIROL, V42, P1080, DOI 10.1128/JVI.42.3.1080-1087.1982
   LEONTOVICH AM, 1990, IN PRESS BIOPOLIM KL
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   MAKINO S, 1984, VIROLOGY, V139, P138, DOI 10.1016/0042-6822(84)90335-0
   Maxam A M, 1980, Methods Enzymol, V65, P499
   OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0
   PACHUK CJ, 1989, VIROLOGY, V171, P141, DOI 10.1016/0042-6822(89)90520-5
   PARKS GD, 1989, J VIROL, V63, P1054, DOI 10.1128/JVI.63.3.1054-1058.1989
   PARKS GD, 1987, J VIROL, V61, P3680, DOI 10.1128/JVI.61.12.3680-3687.1987
   PORTNOY DA, 1986, J BIOL CHEM, V261, P4697
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHMIDT I, 1987, J GEN VIROL, V68, P47, DOI 10.1099/0022-1317-68-1-47
   SHIEH CK, 1989, J VIROL, V63, P3729, DOI 10.1128/JVI.63.9.3729-3736.1989
   SHIEH CK, 1987, VIROLOGY, V156, P321, DOI 10.1016/0042-6822(87)90412-0
   SHIN SU, 1989, METHOD ENZYMOL, V178, P459
   SKINNER MA, 1983, NUCLEIC ACIDS RES, V11, P5045, DOI 10.1093/nar/11.15.5045
   SKINNER MA, 1985, J GEN VIROL, V66, P593, DOI 10.1099/0022-1317-66-3-593
   SKINNER MA, 1985, J GEN VIROL, V66, P581, DOI 10.1099/0022-1317-66-3-581
   SOE LH, 1987, J VIROL, V61, P3968, DOI 10.1128/JVI.61.12.3968-3976.1987
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   Strauss J.H., 1988, RNA GENETICS, P71
   VEIDT I, 1988, NUCLEIC ACIDS RES, V16, P9917, DOI 10.1093/nar/16.21.9917
   WEGE H, 1978, J GEN VIROL, V41, P217, DOI 10.1099/0022-1317-41-2-217
   WU SX, 1987, VIROLOGY, V161, P73, DOI 10.1016/0042-6822(87)90172-3
NR 55
TC 295
Z9 306
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD FEB
PY 1991
VL 180
IS 2
BP 567
EP 582
DI 10.1016/0042-6822(91)90071-I
PG 16
WC Virology
SC Virology
GA ET825
UT WOS:A1991ET82500012
PM 1846489
DA 2020-04-03
ER

PT J
AU Kotaniemi-Syrjanen, A
   Vainionpaa, R
   Reijonen, TM
   Waris, M
   Korhonen, K
   Korppi, M
AF Kotaniemi-Syrjanen, A
   Vainionpaa, R
   Reijonen, TM
   Waris, M
   Korhonen, K
   Korppi, M
TI Rhinovirus-induced wheezing in infancy-the first sign of childhood
   asthma?
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article; Proceedings Paper
CT 19th Annual Meeting of the
   European-Society-for-Paediatric-Infectious-Diseases
CY MAR 26-28, 2001
CL ISTANBUL, TURKEY
SP European Soc Paediat Infect Dis
DE asthma; atopy; coronavirus; polymerase chain reaction; enterovirus;
   rhinovirus; wheezing
ID RESPIRATORY SYNCYTIAL VIRUS; HOSPITALIZED CHILDREN; VIRAL-INFECTIONS;
   EASTERN FINLAND; RISK-FACTORS; DIAGNOSIS; PCR; BRONCHIOLITIS;
   EPIDEMIOLOGY; PREVALENCE
AB Background: Although known as common causes of upper respiratory infections, rhinoviruses, enteroviruses, and coronaviruses are poorly studied as inducers of wheezing in infants, and their possible role in the development of childhood asthma has not been investigated.
   Objective: The purposes of this study were to assess the occurrence of RV, enterovirus, and coronavirus infections in wheezing infants and to evaluate the association of these viral findings with early school-age asthma.
   Methods: In 1999, outcome in relation to asthma was studied in 82 of 100 initially recruited children who had been hospitalized for wheezing in infancy during the period 1992-1993. In 2000, etiologic viral studies regarding the index episode of wheezing were supplemented by rhinovirus, enterovirus, and coronavirus detection by RT-PCR from frozen nasopharyngeal aspirates in 81 of the children for whom adequate samples were available. Of these children, 66 had participated in the follow-up in 1999.
   Results: Rhinoviruses were identified in 27 (33%) of the 81 children, enteroviruses in 10 (12%), and coronaviruses in none. Rhinoviruses were present as single viral findings in 22 (81%) of the 27 rhinovirus-positive cases, and rhinovirus infections were associated with the presence of atopic dermatitis in infancy. Enteroviruses were commonly encountered in mixed infections and had no association with atopy. As single viral findings, rhinoviruses were associated with the development of asthma (P =.047; odds ratio, 4.14; 95% Cl, 1.02-16.77 versus rhinovirus-negative cases [by logistic regression adjusted for age, sex, and atopic dermatitis on entry)].
   Conclusion: Our results present rhinoviruses as important inducers of wheezing even in infancy. The association with atopy and subsequent asthma calls for reevaluation of the role of rhinoviruses in the development of asthma.
C1 Kuopio Univ Hosp, Dept Pediat, FIN-70211 Kuopio, Finland.
   Univ Kuopio, Dept Pediat, FIN-70211 Kuopio, Finland.
   Univ Turku, Dept Virol, Turku, Finland.
RP Kotaniemi-Syrjanen, A (reprint author), Kuopio Univ Hosp, Dept Pediat, POB 1777, FIN-70211 Kuopio, Finland.
RI Waris, Matti E/A-6418-2008
OI Kotaniemi-Syrjanen, Anne/0000-0002-9375-376X; Waris,
   Matti/0000-0002-6747-0889
CR CARLSEN KH, 2001, TXB PEDIAT ASTHMA IN, P211
   DUFF AL, 1993, PEDIATRICS, V92, P535
   Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514
   Gern JE, 1999, CLIN MICROBIOL REV, V12, P9, DOI 10.1128/CMR.12.1.9
   Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019
   HALONEN P, 1995, J CLIN MICROBIOL, V33, P648, DOI 10.1128/JCM.33.3.648-653.1995
   Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   ISAACS D, 1983, ARCH DIS CHILD, V58, P500, DOI 10.1136/adc.58.7.500
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   JOHNSTON SL, 1996, AM J RESP CRIT CARE, V153, pA503
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   KAMAHORA T, 1989, VIRUS RES, V12, P1
   KELLNER G, 1989, ACTA PAEDIATR SCAND, V78, P390, DOI 10.1111/j.1651-2227.1989.tb11098.x
   Lonnrot M, 1999, J MED VIROL, V59, P378, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;378::AID-JMV19&gt;3.0.CO;2-I
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301
   MCINTOSH K, 1993, CLIN INFECT DIS, V16, P151, DOI 10.1093/clinids/16.1.151
   MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052
   Nokso-Koivisto J, 2002, J MED VIROL, V66, P417, DOI 10.1002/jmv.2161
   Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052
   Reijonen TM, 1997, PEDIATR PULM, V24, P35, DOI 10.1002/(SICI)1099-0496(199707)24:1<35::AID-PPUL6>3.3.CO;2-K
   Reijonen TM, 2000, PEDIATRICS, V106, P1406, DOI 10.1542/peds.106.6.1406
   Reijonen TM, 1998, PEDIATR PULM, V26, P113, DOI 10.1002/(SICI)1099-0496(199808)26:2<113::AID-PPUL7>3.0.CO;2-N
   Remes ST, 1996, ACTA PAEDIATR, V85, P59, DOI 10.1111/j.1651-2227.1996.tb13891.x
   Ruohola A, 2000, J ALLERGY CLIN IMMUN, V106, P467, DOI 10.1067/mai.2000.108912
   Santti J, 1997, J VIROL METHODS, V66, P139, DOI 10.1016/S0166-0934(97)00049-9
   Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076
   STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2
   SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067
   TIMONEN KL, 1995, EUR RESPIR J, V8, P1155, DOI 10.1183/09031936.95.08071155
   VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689
NR 32
TC 294
Z9 310
U1 2
U2 10
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JAN
PY 2003
VL 111
IS 1
BP 66
EP 71
DI 10.1067/mai.2003.33
PG 6
WC Allergy; Immunology
SC Allergy; Immunology
GA 636PR
UT WOS:000180465500010
PM 12532098
DA 2020-04-03
ER

PT J
AU El-Manzalawy, Y
   Dobbs, D
   Honavar, V
AF El-Manzalawy, Yasser
   Dobbs, Drena
   Honavar, Vasant
TI Predicting linear B-cell epitopes using string kernels
SO JOURNAL OF MOLECULAR RECOGNITION
LA English
DT Article
DE linear B-cell epitope; epitope mapping; epitope prediction
ID ACUTE RESPIRATORY SYNDROME; SARS CORONAVIRUS; PHYSICOCHEMICAL
   PROPERTIES; NEUTRALIZING ANTIBODY; SPIKE PROTEIN; IDENTIFICATION;
   RECEPTOR; PEPTIDE; VIRUS; CLASSIFICATION
AB The identification and characterization of B-cell epitopes play an important role in vaccine design, immunodiagnostic tests, and antibody production. Therefore, computational tools for reliably predicting linear B-cell epitopes are highly desirable. We evaluated Support Vector Machine (SVM) classifiers trained utilizing five different kernel methods using fivefold cross-validation on a homology-reduced data set of 701 linear B-cell epitopes, extracted from Bcipep database, and 701 non-epitopes, randomly extracted from SwissProt sequences. Based on the results of our computational experiments, we propose BCPred, a novel method for predicting linear B-cell epitopes using the subsequence kernel. We show that the predictive performance of BCPred (AUC = 0.758) outperforms 11 SVM-based classifiers developed and evaluated in our experiments as well as our implementation of AAP (AUC = 0.7), a recently proposed method for predicting linear B-cell epitopes using amino acid pair antigenicity. Furthermore, we compared BCPred with AAP and ABCPred, a method that uses recurrent neural networks, using two data sets of unique B-cell epitopes that had been previously used to evaluate ABCPred. Analysis of the data sets used and the results of this comparison show that conclusions about the relative performance of different B-cell epitope prediction methods drawn on the basis of experiments using data sets of unique B-cell epitopes are likely to yield overly optimistic estimates of performance of evaluated methods. This argues for the use of carefully homology-reduced data sets in comparing B-cell epitope prediction methods to avoid misleading conclusions about how different methods compare to each other. Our homology-reduced data set and implementations of BCPred as well as the APP method are publicly available through our web-based server, BCPREDS, at: http://ailab.cs.iastate.edu/bcpreds/. Copyright (C) 2008 John Wiley & Sons, Ltd.
C1 [El-Manzalawy, Yasser; Honavar, Vasant] Iowa State Univ, Artificial Intelligence Lab, Ames, IA 50010 USA.
   [El-Manzalawy, Yasser; Honavar, Vasant] Iowa State Univ, Dept Comp Sci, Ames, IA 50010 USA.
   [Dobbs, Drena] Iowa State Univ, Dept Genet Dev & Cell Biol, Ames, IA 50010 USA.
   [El-Manzalawy, Yasser; Dobbs, Drena; Honavar, Vasant] Iowa State Univ, Bioinformat & Computat Biol Grad Program, Ames, IA 50010 USA.
   [El-Manzalawy, Yasser; Dobbs, Drena; Honavar, Vasant] Iowa State Univ, Ctr Computat Intelligence, Ames, IA 50010 USA.
RP El-Manzalawy, Y (reprint author), Iowa State Univ, Artificial Intelligence Lab, 226 Atanasoff Hall, Ames, IA 50010 USA.
EM yasser@iastate.edu
RI Honavar, Vasant G/K-9835-2015
OI Honavar, Vasant G/0000-0001-5399-3489; Dobbs, Drena/0000-0003-4404-9554
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R33 GM066387-04, R21 GM066387, R33 GM066387,
   R33 GM066387-03, GM066387]
CR Alix AJP, 1999, VACCINE, V18, P311, DOI 10.1016/S0264-410X(99)00329-1
   Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45
   Baldi P, 2000, BIOINFORMATICS, V16, P412, DOI 10.1093/bioinformatics/16.5.412
   BARLOW DJ, 1986, NATURE, V322, P747, DOI 10.1038/322747a0
   Beniac DR, 2006, NAT STRUCT MOL BIOL, V13, P751, DOI 10.1038/nsmb1123
   Bjorklund AK, 2005, BIOINFORMATICS, V21, P39, DOI 10.1093/bioinformatics/bth477
   Blythe MJ, 2005, PROTEIN SCI, V14, P246, DOI 10.1110/ps.041059505
   Bulashevska A, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-298
   Chen J, 2007, AMINO ACIDS, V33, P423, DOI 10.1007/s00726-006-0485-9
   CLARK A, 2006, INT C GRAMM INF ICGI
   Cui J, 2006, IMMUNOGENETICS, V58, P607, DOI 10.1007/s00251-006-0117-2
   Demsar J, 2006, J MACH LEARN RES, V7, P1
   Dimitrov DS, 2003, CELL, V115, P652, DOI 10.1016/S0092-8674(03)00976-0
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Fisher R A., 1973, STAT METHODS SCI INF
   Flower D.R., 2007, IMMUNOINFORMATICS PR
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Friedman M, 1940, ANN MATH STAT, V11, P86, DOI 10.1214/aoms/1177731944
   Greenbaum JA, 2007, J MOL RECOGNIT, V20, P75, DOI 10.1002/jmr.815
   Haussler D., 1999, UCSCRL9910
   KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P213
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Langeveld JPM, 2001, VACCINE, V19, P2352, DOI 10.1016/S0264-410X(00)00526-0
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Leslie C., 2002, P PSB, V7, P566
   Leslie CS, 2004, BIOINFORMATICS, V20, P467, DOI 10.1093/bioinformatics/btg431
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WZ, 2002, BIOINFORMATICS, V18, P77, DOI 10.1093/bioinformatics/18.1.77
   Lien SP, 2007, BIOCHEM BIOPH RES CO, V358, P716, DOI 10.1016/j.bbrc.2007.04.164
   Lodhi H, 2002, J MACH LEARN RES, V2, P419, DOI 10.1162/153244302760200687
   NETER J, 1985, APPL LINEAR STAT MOD
   Odorico M, 2003, J MOL RECOGNIT, V16, P20, DOI 10.1002/jmr.602
   PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   PELLEQUER JL, 1993, IMMUNOL LETT, V36, P83, DOI 10.1016/0165-2478(93)90072-A
   PELLEQUER JL, 1991, METHOD ENZYMOL, V203, P176
   PELLEQUER JL, 1993, J MOL GRAPH MODEL, V11, P204, DOI 10.1016/0263-7855(93)80074-2
   Pier G.B., 2004, IMMUNOLOGY INFECT IM
   Platt J, 1998, FAST TRAINING SUPPOR
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   RANGWALA H, 2006, PROTEIN STRUCTURE PR
   Saha S, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-79
   Saha S, 2004, LECT NOTES COMPUT SC, V3239, P197
   SAHA S, 2006, ABCPRED BENCHMARKING
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Saigo H, 2004, BIOINFORMATICS, V20, P1682, DOI 10.1093/bioinformatics/bth141
   Sainz B, 2005, J VIROL, V79, P7195, DOI 10.1128/JVI.79.11.7195-7206.2005
   Salomon J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-501
   SEEWALD A, 2005, TR200513
   Sollner J, 2006, J MOL RECOGNIT, V19, P200, DOI 10.1002/jmr.771
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   VAPNIK V, 2000, NATURE STAT LEARNING
   WALTER G, 1986, J IMMUNOL METHODS, V88, P149, DOI 10.1016/0022-1759(86)90001-3
   Witten I.H., 2005, DATA MINING PRACTICA
   Wu FH, 2006, IEEE IJCNN, P1612
   Wu XD, 2004, CELL RES, V14, P400, DOI 10.1038/sj.cr.7290240
   Yu CS, 2006, PROTEINS, V64, P643, DOI 10.1002/prot.21018
   Zaki Nazar M, 2005, Appl Bioinformatics, V4, P45, DOI 10.2165/00822942-200504010-00005
NR 59
TC 293
Z9 310
U1 2
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0952-3499
EI 1099-1352
J9 J MOL RECOGNIT
JI J. Mol. Recognit.
PD JUL-AUG
PY 2008
VL 21
IS 4
BP 243
EP 255
DI 10.1002/jmr.893
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 331IR
UT WOS:000258006400006
PM 18496882
OA Green Accepted, Green Published
DA 2020-04-03
ER

PT J
AU Haagmans, BL
   Al Dhahiry, SHS
   Reusken, CBEM
   Raj, VS
   Galiano, M
   Myers, R
   Godeke, GJ
   Jonges, M
   Farag, E
   Diab, A
   Ghobashy, H
   Alhajri, F
   Al-Thani, M
   Al-Marri, SA
   Al Romaihi, HE
   Al Khal, A
   Bermingham, A
   Osterhaus, ADME
   AlHajri, MM
   Koopmans, MPG
AF Haagmans, Bart L.
   Al Dhahiry, Said H. S.
   Reusken, Chantal B. E. M.
   Raj, V. Stalin
   Galiano, Monica
   Myers, Richard
   Godeke, Gert-Jan
   Jonges, Marcel
   Farag, Elmoubasher
   Diab, Ayman
   Ghobashy, Hazem
   Alhajri, Farhoud
   Al-Thani, Mohamed
   Al-Marri, Salih A.
   Al Romaihi, Hamad E.
   Al Khal, Abdullatif
   Bermingham, Alison
   Osterhaus, Albert D. M. E.
   AlHajri, Mohd M.
   Koopmans, Marion P. G.
TI Middle East respiratory syndrome coronavirus in dromedary camels: an
   outbreak investigation
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID PROTEIN; BAT
AB Background Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe lower respiratory tract infection in people. Previous studies suggested dromedary camels were a reservoir for this virus. We tested for the presence of MERS-CoV in dromedary camels from a farm in Qatar linked to two human cases of the infection in October, 2013.
   Methods We took nose swabs, rectal swabs, and blood samples from all camels on the Qatari farm. We tested swabs with RT-PCR, with amplification targeting the E gene (upE), nudeocapsid (N) gene, and open reading frame (ORF) la. PCR positive samples were tested by different MERS-CoV specific PCRs and obtained sequences were used for phylogentic analysis together with sequences from the linked human cases and other human cases. We tested serum samples from the camels for IgG immunofluorescence assay, protein microarray, and virus neutralisation assay.
   Findings We obtained samples from 14 camels on Oct 17, 2013. We detected MERS-CoV in nose swabs from three camels by three independent RT-PCRs and sequencing. The nudeotide sequence of an ORFla fragment (940 nucleotides) and a 4.2 kb concatenated fragment were very similar to the MERS-CoV from two human cases on the same farm and a MERS-CoV isolate from Hafr-Al-Batin. Eight additional camel nose swabs were positive on one or more RT-PCRs, but could not be confirmed by sequencing. All camels had MERS-CoV spike-binding antibodies that correlated well with the presence of neutralising antibodies to MERS-CoV.
   Interpretation Our study provides virological confirmation of MERS-CoV in camels and suggests a recent outbreak affecting both human beings and camels. We cannot condude whether the people on the farm were infected by the camels or vice versa, or if a third source was responsible.
C1 [Haagmans, Bart L.; Raj, V. Stalin; Osterhaus, Albert D. M. E.; Koopmans, Marion P. G.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
   [Al Dhahiry, Said H. S.] Hamad Med Corp, Dept Lab Med & Pathol, Doha, Qatar.
   [Reusken, Chantal B. E. M.; Godeke, Gert-Jan; Jonges, Marcel; Koopmans, Marion P. G.] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Res Diagnost & Screening, Div Virol, NL-3720 BA Bilthoven, Netherlands.
   [Galiano, Monica; Myers, Richard; Bermingham, Alison] Publ Hlth England, Virus Reference Dept, London, England.
   [Farag, Elmoubasher; Diab, Ayman; Ghobashy, Hazem; Alhajri, Farhoud; Al-Thani, Mohamed; Al-Marri, Salih A.; Al Romaihi, Hamad E.; Al Khal, Abdullatif; AlHajri, Mohd M.] Supreme Council Hlth, Doha, Qatar.
RP AlHajri, MM (reprint author), Supreme Council Hlth, POB 42, Doha, Qatar.
EM malhajri1@sch.gov.qa; m.koopmans@erasmusmc.nl
RI Koopmans, Marion/Y-9170-2019; Raj, V Stalin/E-9670-2016
OI Koopmans, Marion/0000-0002-5204-2312; Raj, V Stalin/0000-0003-2250-8481;
   Haagmans, Bart/0000-0001-6221-2015
FU European Union FP7 project EMPERIE [223498]; European Union FP7 project
   ANTIGONE [278976]
FX We thank WHO and the Food and Agriculture Organization of the United
   Nations for their generous help in organisation of the study, Theo
   Bestebroer for providing Middle East respiratory syndrome coronavirus
   specific primer sets, Berend Jan Bosch for providing antigens for the
   microarray, and Jeroen Cremer for technical support. Contributions to
   the study were funded through the European Union FP7 projects EMPERIE
   (contract number 223498; to BLH and ADMEO) and ANTIGONE (contract number
   278976; to MPGK and ADMEO).
CR AlBarrak AM, 2012, SAUDI MED J, V33, P1265
   Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   [Anonymous], 2013, PLOS CURR, P5, DOI DOI 10.1371/CURRENTS.OUTBREAKS.0BF719E352E7478F8AD85FA30127DDB8
   Cauchemez S., 2013, Eurosurveillance, V18, P20503
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   de Sousa R, 2014, J CLIN VIROL, V59, P4, DOI 10.1016/j.jcv.2013.10.030
   Drexler JF, 2014, ANTIVIR RES, V101, P45, DOI 10.1016/j.antiviral.2013.10.013
   Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3
   Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Lau SKP, 2013, J VIROL, V87, P8638, DOI 10.1128/JVI.01055-13
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Muller MA, 2012, MBIO, V3, DOI 10.1128/mBio.00515-12
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Reusken C, 2013, EUROSURVEILLANCE, V18, P2, DOI 10.2807/1560-7917.ES2013.18.14.20441
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   World Health Organization (WHO), GLOB AL RESP GAR NOV
NR 20
TC 292
Z9 304
U1 10
U2 82
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD FEB
PY 2014
VL 14
IS 2
BP 140
EP 145
DI 10.1016/S1473-3099(13)70690-X
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 299UE
UT WOS:000330420400027
PM 24355866
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Memish, ZA
   Mishra, N
   Olival, KJ
   Fagbo, SF
   Kapoor, V
   Epstein, JH
   AlHakeem, R
   Al Asmari, M
   Islam, A
   Kapoor, A
   Briese, T
   Daszak, P
   Al Rabeeah, AA
   Lipkin, WI
AF Memish, Ziad A.
   Mishra, Nischay
   Olival, Kevin J.
   Fagbo, Shamsudeen F.
   Kapoor, Vishal
   Epstein, Jonathan H.
   AlHakeem, Rafat
   Al Asmari, Mushabab
   Islam, Ariful
   Kapoor, Amit
   Briese, Thomas
   Daszak, Peter
   Al Rabeeah, Abdullah A.
   Lipkin, W. Ian
TI Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID VIRUSES
AB The source of human infection with Middle East respiratory syndrome coronavirus remains unknown. Molecular investigation indicated that bats in Saudi Arabia are infected with several alphacoronaviruses and betacoronaviruses. Virus from 1 bat showed 100% nucleotide identity to virus from the human index case-patient. Bats might play a role in human infection.
C1 [Memish, Ziad A.; Fagbo, Shamsudeen F.; AlHakeem, Rafat; Al Rabeeah, Abdullah A.] Minist Hlth, Riyadh, Saudi Arabia.
   [Mishra, Nischay; Kapoor, Vishal; Kapoor, Amit; Briese, Thomas; Lipkin, W. Ian] Columbia Univ, New York, NY USA.
   [Olival, Kevin J.; Epstein, Jonathan H.; Daszak, Peter] EcoHlth Alliance, New York, NY USA.
   [Al Asmari, Mushabab] Minist Hlth, Bisha, Saudi Arabia.
   [Islam, Ariful] EcoHlth Alliance, Dhaka, Bangladesh.
RP Lipkin, WI (reprint author), Columbia Univ, Ctr Infect & Immun, 722 West 168th St, New York, NY 10032 USA.
EM wil2001@columbia.edu
RI islam, ariful/V-8200-2019; daszak, peter/U-4588-2017
OI daszak, peter/0000-0002-2046-5695; Lipkin, W. Ian/0000-0002-8768-9386;
   Olival, Kevin/0000-0003-3211-1875; Fagbo, Shamsudeen/0000-0003-3448-6136
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID); US
   Agency for International Development (PREDICT)United States Agency for
   International Development (USAID); Defense Threat Reduction AgencyUnited
   States Department of DefenseDefense Threat Reduction Agency
FX Work in the Center for Infection and Immunity and EcoHealth Alliance was
   supported by the National Institute of Allergy and Infectious Diseases,
   the US Agency for International Development (PREDICT), and the Defense
   Threat Reduction Agency.
CR Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Anthony SJ, 2013, J GEN VIROL, V94, P1028, DOI 10.1099/vir.0.049759-0
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   ITHLETE NL, 2013, EMERG INFECT DIS, V19
   Khan SU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042689
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Quan PL, 2010, MBIO, V1, DOI 10.1128/mBio.00208-10
   Smith I, 2013, CURR OPIN VIROL, V3, P84, DOI 10.1016/j.coviro.2012.11.006
   Teeling EC, 2005, SCIENCE, V307, P580, DOI 10.1126/science.1105113
   Watanabe S, 2010, EMERG INFECT DIS, V16, P1217, DOI 10.3201/eid1608.100208
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 15
TC 286
Z9 306
U1 8
U2 53
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD NOV
PY 2013
VL 19
IS 11
BP 1819
EP 1823
DI 10.3201/eid1911.131172
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AA4JE
UT WOS:000331061100013
PM 24206838
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2020-04-03
ER

PT J
AU He, JF
   Peng, GW
   Min, J
   Yu, DW
   Liang, WJ
   Zhang, SY
   Xu, RH
   Zheng, HY
   Wu, XW
   Xu, J
   Wang, ZH
   Fang, L
   Zhang, X
   Li, H
   Yan, XG
   Lu, JH
   Hu, ZH
   Huang, JC
   Wan, ZY
   Hou, JL
   Lin, JY
   Song, HD
   Wang, SY
   Zhou, XJ
   Zhang, GW
   Gu, BW
   Zheng, HJ
   Zhang, XL
   He, M
   Zheng, K
   Wang, BF
   Fu, G
   Wang, XN
   Chen, SJ
   Chen, Z
   Hao, P
   Tang, H
   Ren, SX
   Zhong, Y
   Guo, ZM
   Liu, Q
   Miao, YG
   Kong, XY
   He, WZ
   Li, YX
   Wu, CI
   Zhao, GP
   Chiu, RWK
   Chim, SSC
   Tong, YK
   Chan, PKS
   Tam, JS
   Lo, YMD
AF He, JF
   Peng, GW
   Min, J
   Yu, DW
   Liang, WJ
   Zhang, SY
   Xu, RH
   Zheng, HY
   Wu, XW
   Xu, J
   Wang, ZH
   Fang, L
   Zhang, X
   Li, H
   Yan, XG
   Lu, JH
   Hu, ZH
   Huang, JC
   Wan, ZY
   Hou, JL
   Lin, JY
   Song, HD
   Wang, SY
   Zhou, XJ
   Zhang, GW
   Gu, BW
   Zheng, HJ
   Zhang, XL
   He, M
   Zheng, K
   Wang, BF
   Fu, G
   Wang, XN
   Chen, SJ
   Chen, Z
   Hao, P
   Tang, H
   Ren, SX
   Zhong, Y
   Guo, ZM
   Liu, Q
   Miao, YG
   Kong, XY
   He, WZ
   Li, YX
   Wu, CI
   Zhao, GP
   Chiu, RWK
   Chim, SSC
   Tong, YK
   Chan, PKS
   Tam, JS
   Lo, YMD
CA Chinese SARS Mol Epidemiology
TI Molecular evolution of the SARS coronavirus during the course of the
   SARS epidemic in China
SO SCIENCE
LA English
DT Article
ID ACUTE-RESPIRATORY-SYNDROME; HONG-KONG; GENOME SEQUENCE; AMOY GARDENS;
   VIRUS; OUTBREAK; IDENTIFICATION; VIRULENCE; MUTATION; RATES
AB Sixty-one SARS coronavirus genomic sequences derived from the early, middle, and late phases of the severe acute respiratory syndrome ( SARS) epidemic were analyzed together with two viral sequences from palm civets. Genotypes characteristic of each phase were discovered, and the earliest genotypes were similar to the animal SARS-like coronaviruses. Major deletions were observed in the Orf8 region of the genome, both at the start and the end of the epidemic. The neutral mutation rate of the viral genome was constant but the amino acid substitution rate of the coding sequences slowed during the course of the epidemic. The spike protein showed the strongest initial responses to positive selection pressures, followed by subsequent purifying selection and eventual stabilization.
C1 Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China.
   Shanghai Med Univ 2, Ruijin Hosp, State Key Lab Med Genom Pole Sino Francais Rech S, Shanghai 200025, Peoples R China.
   Guangdong Ctr Dis Control & Prevent, Guangzhou 510300, Guangdong, Peoples R China.
   Sun Yat Sen Univ, Affiliated Hosp 2, Guangzhou 510120, Guangdong, Peoples R China.
   Chinese Acad Sci, Inst Zool, Beijing 100080, Peoples R China.
   Guangzhou Ctr Dis Control & Prevent, Guangzhou 510080, Guangdong, Peoples R China.
   Guangzhou Inst Resp Dis, Guangzhou 510120, Guangdong, Peoples R China.
   First Med Univ, Nanfang Hosp, Dept Infect Dis & Mol Immunol, Guangzhou 510515, Guangdong, Peoples R China.
   Chinese Acad Sci, Wuhan Inst Virol, Wuhan 430071, Hubei, Peoples R China.
   Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200030, Peoples R China.
   Chinese Acad Sci, Shanghai Inst Biol Sci, Hlth Sci Ctr, Inst Plant Physiol & Eocl,Bioinformat Ctr, Shanghai 200031, Peoples R China.
   Shanghai Ctr Bioinformat Technol, Shanghai 200235, Peoples R China.
   Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA.
   Fudan Univ, Sch Life Sci, Shanghai 200433, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Shatin, Hong Kong, Peoples R China.
RP Zhao, GP (reprint author), Chinese Natl Human Genome Ctr Shanghai, 250 Bi Bo Rd,Zhang Jiang High Tech Pk, Shanghai 201203, Peoples R China.
EM gpzhao@ibs.ac.cn
RI Zhang, Shuyi/B-5117-2011; Song, Huai-Dong/G-8961-2011; Chim,
   Stephen/O-6271-2016; Lo, Yuk Ming Dennis/D-4468-2011; Chan, Paul
   KS/J-9360-2013
OI Chim, Stephen/0000-0002-2152-7050; Lo, Yuk Ming
   Dennis/0000-0001-8746-0293; Chan, Paul KS/0000-0002-6360-4608; Hu,
   Zhihong/0000-0002-1560-0928
CR Brown EG, 2001, P NATL ACAD SCI USA, V98, P6883, DOI 10.1073/pnas.111165798
   Bush RM, 2000, P NATL ACAD SCI USA, V97, P6974, DOI 10.1073/pnas.97.13.6974
   *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P241
   Chim SSC, 2003, LANCET, V362, P1807, DOI 10.1016/S0140-6736(03)14901-X
   Chiu RWK, 2003, NEW ENGL J MED, V349, P1875, DOI 10.1056/NEJM200311063491923
   Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Ewald PW, 1998, J URBAN HEALTH, V75, P480, DOI 10.1007/BF02427686
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   LAI MMC, 2001, FIELDS VIROLOGY, pCH35
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   LI WH, 1988, MOL BIOL EVOL, V5, P313
   Luo ZL, 1999, J VIROL, V73, P8152, DOI 10.1128/JVI.73.10.8152-8159.1999
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   RASSCHAERT D, 1990, J GEN VIROL, V71, P2599, DOI 10.1099/0022-1317-71-11-2599
   Rest JS, 2003, INFECT GENET EVOL, V3, P219, DOI 10.1016/j.meegid.2003.08.001
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Tsui SKW, 2003, NEW ENGL J MED, V349, P187, DOI 10.1056/NEJM200307103490216
   Vogel G, 2003, SCIENCE, V300, P1062
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 26
TC 285
Z9 306
U1 15
U2 132
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAR 12
PY 2004
VL 303
IS 5664
BP 1666
EP 1669
DI 10.1126/science.1092002
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 802GG
UT WOS:000220151400043
PM 14752165
DA 2020-04-03
ER

PT J
AU Arden, KE
   McErlean, P
   Nissen, MD
   Sloots, TP
   Mackay, IM
AF Arden, Katherine E.
   McErlean, Peter
   Nissen, Michael D.
   Sloots, Theo P.
   Mackay, Ian M.
TI Frequent detection of human rhinoviruses, paramyxoviruses,
   coronaviruses, and bocavirus during acute respiratory tract infections
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE virus; respiratory infection; epidemiology; RT-PCR; diagnostics
ID POLYMERASE-CHAIN-REACTION; TRANSCRIPTASE-PCR ASSAY; REAL-TIME PCR;
   CLINICAL SPECIMENS; SEQUENCE-ANALYSIS; SYNCYTIAL-VIRUS; RT-PCR;
   DIAGNOSIS; CHILDREN; SAMPLES
AB Viruses are the major cause of pediatric acute respiratory tract infection (ARTI) and yet many suspected cases of infection remain uncharacterized. We employed 17 PCR assays and retrospectively screened 315 specimens selected by season from a predominantly pediatric hospital-based population. Before the Brisbane respiratory virus research study commenced, one or more predominantly viral pathogens had been detected in 15.2% (n = 48) of all specimens. The Brisbane study made an additional 206 viral detections, resulting in the identification of a microbe in 67.0% of specimens. After our study, the majority of microbes detected were RNA viruses (89.9%). Overall, human rhinoviruses (HRVs) were the most frequently identified target (n=140) followed by human adenoviruses (HAdVs; n = 25), human metapneumovirus (HMPV; n=18), human bocavirus (HBoV; n = 15), human respiratory syncytial virus (HRSV; n = 12), human coronaviruses (HCoVs; n = 11), and human herpesvirus-6 (n = 11). HRVs were the sole microbe detected in 37.8% (n = 31) of patients with suspected lower respiratory tract infection (LRTI). Genotyping of the HRV VP4/VP2 region resulted in a proposed subdivision of HRV type A into sublineages A1 and A2. Most of the genotyped HAdV strains were found to be type C. This study describes the high microbial burden imposed by HRVs, HMPV, HRSV, HCoVs, and the newly identified virus, HBoV on a predominantly paediatric hospital population with suspected acute respiratory tract infections and proposes a new formulation of viral targets for future diagnostic research studies.
C1 Univ Queensland, Clin & Med Virol Ctr, St Lucia, Qld 4067, Australia.
   Queensland Hlth Pathol Serv, Div Microbiol, Brisbane, Qld, Australia.
EM ian.mackay@uq.edu.au
RI Nissen, Michael D/M-6823-2013; Sloots, Theo P/E-6118-2011; McErlean,
   Peter/O-5187-2016; Arden, Katherine/D-7970-2017; Mackay, Ian
   M./B-2537-2010
OI Nissen, Michael D/0000-0003-1686-3313; Arden,
   Katherine/0000-0003-3195-124X; Mackay, Ian M./0000-0003-3598-2350
CR Arola A, 1996, J CLIN MICROBIOL, V34, P313, DOI 10.1128/JCM.34.2.313-318.1996
   BERNET C, 1989, J CLIN MICROBIOL, V27, P2492, DOI 10.1128/JCM.27.11.2492-2496.1989
   CARRIERE C, 1993, J VIROL METHODS, V44, P221, DOI 10.1016/0166-0934(93)90057-X
   Coiras MT, 2003, J MED VIROL, V69, P132, DOI 10.1002/jmv.10255
   Corless CE, 2002, J MED VIROL, V67, P555, DOI 10.1002/jmv.10138
   Druce J, 2005, J MED VIROL, V75, P122, DOI 10.1002/jmv.20246
   Fouchier Ron Am, 2005, Curr Opin Infect Dis, V18, P141
   Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406
   Heikkinen T, 2003, LANCET, V361, P51, DOI 10.1016/S0140-6736(03)12162-9
   Heim A, 2003, J MED VIROL, V70, P228, DOI 10.1002/jmv.10382
   Hibbitts S, 2003, J VIROL METHODS, V108, P145, DOI 10.1016/S0166-0934(02)00268-9
   HORWITZ MS, 2001, [No title captured], V2, P2301
   Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204
   Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629
   Klig JE, 2005, CURR OPIN PEDIATR, V17, P111, DOI 10.1097/01.mop.0000150599.31091.f0
   KOLLS J, 1993, ANAL BIOCHEM, V208, P264, DOI 10.1006/abio.1993.1044
   Kosters K, 2002, J CLIN MICROBIOL, V40, P1719, DOI 10.1128/JCM.40.5.1719-1722.2002
   La Scola B, 2005, EMERG INFECT DIS, V11, P449, DOI 10.3201/eid1103.040538
   Ledford RM, 2004, J VIROL, V78, P3663, DOI 10.1128/JVI.78.7.3663-3674.2004
   Mackay IM, 2003, J CLIN VIROL, V28, P291, DOI 10.1016/S1386-6532(03)00072-6
   Maertzdorf J, 2004, J CLIN MICROBIOL, V42, P981, DOI 10.1128/JCM.42.3.981-986.2004
   Monto AS, 2002, CLIN THER, V24, P1987, DOI 10.1016/S0149-2918(02)80093-5
   Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Savolainen C, 2004, J GEN VIROL, V85, P2271, DOI 10.1099/vir.0.79897-0
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Syrmis MW, 2004, J MOL DIAGN, V6, P125, DOI 10.1016/S1525-1578(10)60500-4
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   van der Hoek L, 2005, PLOS MED, V2, P764, DOI 10.1371/journal.pmed.0020240
   van Elden LJR, 2004, J INFECT DIS, V189, P652, DOI 10.1086/381207
   VANDERHOEK L, 2004, NAT MED
NR 32
TC 282
Z9 294
U1 1
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2006
VL 78
IS 9
BP 1232
EP 1240
DI 10.1002/jmv.20689
PG 9
WC Virology
SC Virology
GA 068WE
UT WOS:000239404400013
PM 16847968
OA Bronze
DA 2020-04-03
ER

PT J
AU WILLIAMS, RK
   JIANG, GS
   HOLMES, KV
AF WILLIAMS, RK
   JIANG, GS
   HOLMES, KV
TI RECEPTOR FOR MOUSE HEPATITIS-VIRUS IS A MEMBER OF THE CARCINOEMBRYONIC
   ANTIGEN FAMILY OF GLYCOPROTEINS
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE CORONAVIRUS; IMMUNOGLOBULIN SUPERFAMILY; HOST RESISTANCE TO VIRUS; VIRUS
   TISSUE TROPISM; VIRUS RECEPTOR
ID MOLECULAR-CLONING; IMMUNOGLOBULIN SUPERFAMILY; GENE FAMILY; RHINOVIRUS
   RECEPTOR; ADHESION MOLECULE; SEQUENCE-ANALYSIS; PLASMA-MEMBRANE;
   ECTO-ATPASE; CDNA; PROTEINS
AB The receptor for mouse hepatitis virus (MHV), a murine coronavirus, is a 110- to 120-kDa glycoprotein on intestinal brush border membranes and hepatocyte membranes. The N-terminal 25-amino acid sequence of immunoaffinity-purified MHV receptor was identical to the predicted mature N termini of two mouse genes related to human carcinoembryonic antigen (CEA) and was strongly homologous to the N termini of members of the CEA family in humans and rats. Polyclonal antibodies to human CEA recognized the immunoaffinity-purified MHV receptor and the MHV receptor in liver membranes and intestinal brush border membranes from MHV-susceptible mouse strains. In membranes from MHV-resistant SJL/J mice, the anti-CEA antibodies recognized a homologous glycoprotein that failed to bind MHV. The MHV receptor glycoprotein was detected in membranes of BALB/c colon, small intestine, and liver, which are the principal targets for MHV replication in vivo. The MHV receptor glycoprotein resembled members of the human CEA family in molecular weight, acidic pI, extensive glycosylation, solubility in perchloric acid, and tissue distribution. Thus, the MHV receptor is, to our knowledge, the first member of the CEA family of glycoproteins to be identified as a virus receptor.
C1 UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,4301 JONES BRIDGE RD,BETHESDA,MD 20814.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 25231, 1 F32 AI07810, AI 26075]
CR BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267
   BARTHOLD SW, 1986, ARCH VIROL, V91, P247, DOI 10.1007/BF01314284
   BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221
   BEAUCHEMIN N, 1989, CARCINOEMBRYONIC ANT, P49
   BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7
   BOYLE JF, 1987, J VIROL, V61, P185, DOI 10.1128/JVI.61.1.185-189.1987
   COMPTON SR, 1988, THESIS UNIFORMED SER
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439
   GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0
   HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   KNOBLER RL, 1985, J NEUROIMMUNOL, V8, P15, DOI 10.1016/S0165-5728(85)80044-8
   KODELJA V, 1989, J BIOL CHEM, V264, P6906
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LIN SH, 1989, J BIOL CHEM, V264, P14408
   LIN SH, 1989, J BIOL CHEM, V264, P14403
   MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035
   MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9
   NEUMAIER M, 1988, J BIOL CHEM, V263, P3202
   PAXTON RJ, 1987, P NATL ACAD SCI USA, V84, P920, DOI 10.1073/pnas.84.4.920
   ROONEY BC, 1988, GENE, V71, P439, DOI 10.1016/0378-1119(88)90061-3
   SMITH AL, 1991, J INFECT DIS, V163, P879, DOI 10.1093/infdis/163.4.879
   SMITH MS, 1984, J IMMUNOL, V133, P428
   STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2
   STOHLMAN SA, 1978, IMMUNOGENETICS, V6, P277, DOI 10.1007/BF01563919
   STREYDIO C, 1988, BIOCHEM BIOPH RES CO, V154, P130, DOI 10.1016/0006-291X(88)90660-2
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   SVENBERG T, 1979, MOL IMMUNOL, V16, P245, DOI 10.1016/0161-5890(79)90063-4
   TAWARAGI Y, 1988, BIOCHEM BIOPH RES CO, V150, P89, DOI 10.1016/0006-291X(88)90490-1
   THOMPSON JA, 1987, P NATL ACAD SCI USA, V84, P2965, DOI 10.1073/pnas.84.9.2965
   TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   TURBIDE C, 1991, J BIOL CHEM, V266, P309
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WHITE JM, 1989, CELL, V56, P725, DOI 10.1016/0092-8674(89)90674-0
   WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8
   WILLIAMS RK, 1990, J VIROL, V64, P3817, DOI 10.1128/JVI.64.8.3817-3823.1990
   WILLIAMS RK, 1985, DEV BRAIN RES, V19, P253, DOI 10.1016/0165-3806(85)90197-X
   YACHI A, 1989, CARCINOEMBRYONIC ANT
NR 41
TC 282
Z9 292
U1 1
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL
PY 1991
VL 88
IS 13
BP 5533
EP 5536
DI 10.1073/pnas.88.13.5533
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FU901
UT WOS:A1991FU90100012
PM 1648219
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Wong, SK
   Li, WH
   Moore, MJ
   Choe, H
   Farzan, M
AF Wong, SK
   Li, WH
   Moore, MJ
   Choe, H
   Farzan, M
TI A 193-amino acid fragment of the SARS coronavirus S protein efficiently
   binds angiotensin-converting enzyme 2
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; SPIKE GLYCOPROTEIN; RECEPTOR; VIRUS;
   IDENTIFICATION; EXPRESSION; DOMAIN; ENTRY; SITE
AB The coronavirus spike (S) protein mediates infection of receptor-expressing host cells and is a critical target for antiviral neutralizing antibodies. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for the coronavirus (severe acute respiratory syndrome (SARS)-CoV) that causes SARS. Here we demonstrate that a 193-amino acid fragment of the S protein (residues 318-510) bound ACE2 more efficiently than did the full S1 domain (residues 12-672). Smaller S protein fragments, expressing residues 327-510 or 318-490, did not detectably bind ACE2. A point mutation at aspartic acid 454 abolished association of the full S1 domain and of the 193-residue fragment with ACE2. The 193-residue fragment blocked S protein-mediated infection with an IC50 of less than 10 nM, whereas the IC50 of the S1 domain was similar to50 nM. These data identify an independently folded receptor-binding domain of the SARS-CoV S protein.
C1 Harvard Univ, Brigham & Womens Hosp, Sch Med,Partners AIDS Res Ctr, Dept Med Microbiol & Mol Genet, Boston, MA 02115 USA.
   Harvard Univ, Childrens Hosp, Sch Med, Pulm Div,Perlmutter Lab, Boston, MA 02115 USA.
RP Farzan, M (reprint author), Partners AIDS Res Ctr, 65 Landsdowne St, Cambridge, MA 02139 USA.
EM farzan@mbcrr.harvard.edu
OI Li, Wenhui/0000-0003-1305-7404; Farzan, Michael/0000-0002-2990-5319
CR Bannert N, 2000, J VIROL, V74, P10984, DOI 10.1128/JVI.74.23.10984-10993.2000
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   Breslin JJ, 2003, J VIROL, V77, P4435, DOI 10.1128/JVI.77.7.4435-4438.2003
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   DVEKSLER GS, 1993, J VIROL, V67, P1
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Jackwood MW, 2001, AVIAN DIS, V45, P366, DOI 10.2307/1592976
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sturman L S, 1984, Adv Exp Med Biol, V173, P25
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
NR 18
TC 281
Z9 323
U1 11
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 30
PY 2004
VL 279
IS 5
BP 3197
EP 3201
DI 10.1074/jbc.C300520200
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 766MF
UT WOS:000188379600009
PM 14670965
OA Bronze
DA 2020-04-03
ER

PT J
AU DVEKSLER, GS
   PENSIERO, MN
   CARDELLICHIO, CB
   WILLIAMS, RK
   JIANG, GS
   HOLMES, KV
   DIEFFENBACH, CW
AF DVEKSLER, GS
   PENSIERO, MN
   CARDELLICHIO, CB
   WILLIAMS, RK
   JIANG, GS
   HOLMES, KV
   DIEFFENBACH, CW
TI CLONING OF THE MOUSE HEPATITIS-VIRUS (MHV) RECEPTOR - EXPRESSION IN
   HUMAN AND HAMSTER-CELL LINES CONFERS SUSCEPTIBILITY TO MHV
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN-LIKE DOMAINS; BILIARY
   GLYCOPROTEIN-I; MURINE CORONAVIRUS; MONOCLONAL-ANTIBODIES; PROTEOLYTIC
   CLEAVAGE; RHINOVIRUS RECEPTOR; VIRAL GLYCOPROTEIN; ADHESION MOLECULE;
   MESSENGER-RNAS
AB The cellular receptor for murine coronavirus mouse hepatitis virus (MHV)-A59 is a member of the carcinoembryonic antigen (CEA) family of glycoproteins in the immunoglobulin superfamily. We isolated a cDNA clone (MHVR1) encoding the MHV receptor. The sequence of this clone predicts a 424-amino-acid glycoprotein with four immunoglobulinlike domains, a transmembrane domain, and a short intracytoplasmic tail. MHVR1 is closely related to the murine CEA-related clone mmCGM1 (Mus musculus carcinoembryonic antigen gene family member). Western blot (immunoblot) analysis performed with antireceptor antibodies detected a glycoprotein of 120 kDa in BHK cells stably transfected with MHVR1. This corresponds to the size of the MHV receptor expressed in mouse intestine and liver. Human and hamster fibroblasts transfected with MHVR1 became susceptible to infection with MHV-A59. Like MHV-susceptible mouse fibroblasts, the MHVR1-transfected human and hamster cells were protected from MHV infection by pretreatment with monoclonal antireceptor antibody CC1. Thus, the 110- to 120-kDa CEA-related glycoprotein encoded by MHVR1 is a functional receptor for murine coronavirus MHV-A59.
C1 UNIFORMED SERV UNIV HLTH SCI, DEPT PATHOL, BETHESDA, MD 20814 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI26075, AI25231]
CR BANG FB, 1960, P NATL ACAD SCI USA, V46, P1065, DOI 10.1073/pnas.46.8.1065
   BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267
   Barthold S. W., 1986, Viral and mycoplasmal infections of laboratory rodents. Effects on biomedical research., P571
   BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221
   BEAUCHEMIN N, 1989, CANCER RES, V49, P2017
   BEAUCHEMIN N, 1989, CARCINOEMBRYONIC ANT, P49
   BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7
   BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279
   BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303
   BOYLE JF, 1987, J VIROL, V61, P185, DOI 10.1128/JVI.61.1.185-189.1987
   CAVANAGH D, 1990, VIROLOGY, V176, P306, DOI 10.1016/0042-6822(90)90259-T
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985
   FULLER SD, 1985, EMBO J, V4, P2475, DOI 10.1002/j.1460-2075.1985.tb03959.x
   GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0
   GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000
   HINODA Y, 1989, P NATL ACAD SCI USA, V86, P1668
   HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959
   HIRANO N, 1980, MICROBIOL IMMUNOL, V24, P825, DOI 10.1111/j.1348-0421.1980.tb02887.x
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824
   HUANG JQ, 1990, DEVELOPMENT, V110, P573
   KESSLER M, 1978, BIOCHIM BIOPHYS ACTA, V506, P136, DOI 10.1016/0005-2736(78)90440-6
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   KNOBLER RL, 1984, J GEN VIROL, V65, P1543, DOI 10.1099/0022-1317-65-9-1543
   KODELJA V, 1989, J BIOL CHEM, V264, P6906
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LENTZ TL, 1990, J GEN VIROL, V71, P751, DOI 10.1099/0022-1317-71-4-751
   LIN SH, 1989, J BIOL CHEM, V264, P14408
   LOWE T, 1990, NUCLEIC ACIDS RES, V18, P1757, DOI 10.1093/nar/18.7.1757
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8
   MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9
   RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2
   SHIVELY JE, 1985, CRC CR REV ONCOL-HEM, V2, P355, DOI 10.1016/S1040-8428(85)80008-1
   SMITH AL, 1991, J INFECT DIS, V163, P879, DOI 10.1093/infdis/163.4.879
   SMITH MS, 1984, J IMMUNOL, V133, P428
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   STAUNTON, 1990, CELL, V61, pU1155
   STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2
   STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O
   STOHLMAN SA, 1980, J IMMUNOL, V124, P1733
   STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985
   STURMAN LS, 1977, VIROLOGY, V77, P650, DOI 10.1016/0042-6822(77)90489-5
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   STURMAN LS, 1972, INFECT IMMUN, V6, P501, DOI 10.1128/IAI.6.4.501-507.1972
   THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201
   TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907
   TURBIDE C, 1991, J BIOL CHEM, V266, P309
   VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526
   WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WEISMILLER DG, 1990, J VIROL, V64, P3051, DOI 10.1128/JVI.64.6.3051-3055.1990
   WHITE JM, 1989, CELL, V56, P725, DOI 10.1016/0092-8674(89)90674-0
   WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611
   WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121
   WILLIAMS RK, 1990, J VIROL, V64, P3817, DOI 10.1128/JVI.64.8.3817-3823.1990
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   YACHI A, 1989, CARCINOEMBRYONIC GEN
NR 64
TC 278
Z9 284
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 1991
VL 65
IS 12
BP 6881
EP 6891
DI 10.1128/JVI.65.12.6881-6891.1991
PG 11
WC Virology
SC Virology
GA GP878
UT WOS:A1991GP87800059
PM 1719235
OA Bronze
DA 2020-04-03
ER

PT J
AU Kuba, K
   Imai, Y
   Rao, SA
   Gao, H
   Guo, F
   Guan, B
   Huan, Y
   Yang, P
   Zhang, YL
   Deng, W
   Bao, LL
   Zhang, BL
   Liu, G
   Wang, Z
   Chappell, M
   Liu, YX
   Zheng, DX
   Leibbrandt, A
   Wada, T
   Slutsky, AS
   Liu, DP
   Qin, CA
   Jiang, CY
   Penninger, JM
AF Kuba, K
   Imai, Y
   Rao, SA
   Gao, H
   Guo, F
   Guan, B
   Huan, Y
   Yang, P
   Zhang, YL
   Deng, W
   Bao, LL
   Zhang, BL
   Liu, G
   Wang, Z
   Chappell, M
   Liu, YX
   Zheng, DX
   Leibbrandt, A
   Wada, T
   Slutsky, AS
   Liu, DP
   Qin, CA
   Jiang, CY
   Penninger, JM
TI A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS
   coronavirus-induced lung injury
SO NATURE MEDICINE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; HONG-KONG; CARBOXYPEPTIDASE; IDENTIFICATION;
   REPLICATION; EXPRESSION; RECEPTOR; CLONING; MICE
AB During several months of 2003, a newly identified illness termed severe acute respiratory syndrome (SARS) spread rapidly through the world(1-3). A new coronavirus (SARS-CoV) was identified as the SARS pathogen(4-7) which triggered severe pneumonia and acute, often lethal, lung failure(8). Moreover, among infected individuals influenza such as the Spanish flu(9,10) and the emergence of new respiratory disease viruses(11,12) have caused high lethality resulting from acute lung failure(13). In cell lines, angiotensin-converting enzyme 2 (ACE2) has been identified as a potential SARS-CoV receptor(14). The high lethality of SARS-CoV infections, its enormous economic and social impact, fears of renewed outbreaks as well as the potential misuse of such viruses as biologic weapons make it paramount to understand the pathogenesis of SARS-CoV. Here we provide the first genetic proof that ACE2 is a crucial SARS-CoV receptor in vivo. SARS-CoV infections and the Spike protein of the SARS-CoV reduce ACE2 expression. Notably, injection of SARS-CoV Spike into mice worsens acute lung failure in vivo that can be attenuated by blocking the renin-angiotensin pathway. These results provide a molecular explanation why SARS-CoV infections cause severe and often lethal lung failure and suggest a rational therapy for SARS and possibly other respiratory disease viruses.
C1 Chinese Acad Med Sci, Natl Lab Med Mol Biol, Inst Basic Med Sci, Beijing 100005, Peoples R China.
   Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing 100005, Peoples R China.
   Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100005, Peoples R China.
   Peking Union Med Coll, Beijing 100005, Peoples R China.
   Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria.
   Wake Forest Univ, Sch Med, Hypertens & Vasc Dis Ctr, Winston Salem, NC 27157 USA.
   Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada.
   Univ Toronto, St Michaels Hosp, Interdept Div Crit Care, Toronto, ON M5B 1W8, Canada.
RP Jiang, CY (reprint author), Chinese Acad Med Sci, Natl Lab Med Mol Biol, Inst Basic Med Sci, 5 Dongdan Santiao, Beijing 100005, Peoples R China.
EM jiang@pumc.edu
RI Rao, Shuan/V-3653-2019; Liu, Geoffrey/N-4421-2016; Slutsky,
   Arthur/M-3325-2019; Slutsky, Arthur S/A-6013-2008; Penninger, Josef
   M/I-6860-2013
OI Slutsky, Arthur S/0000-0002-6063-3876; Penninger, Josef
   M/0000-0002-8194-3777; Guo, Feng/0000-0002-4506-7618
CR CORVOL P, 1995, METHOD ENZYMOL, V248, P283
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100
   Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419
   Imai Y, 2001, J APPL PHYSIOL, V91, P1836
   IMAI Y, IN PRESS NATURE
   INAGAMI T, 1995, ADV EXP MED BIOL, V377, P311
   Itoyama S, 2004, BIOCHEM BIOPH RES CO, V323, P1124, DOI 10.1016/j.bbrc.2004.08.208
   JEFFERS SA, 2004, P NATL ACAD SCI USA, V20, P20
   Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MYINT SH, 1994, REV MED VIROL, V4, P35, DOI 10.1002/rmv.1980040108
   Oxford JS, 2000, REV MED VIROL, V10, P119, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;119::AID-RMV272&gt;3.0.CO;2-O
   Pelchen-Matthews A, 1999, IMMUNOL REV, V168, P33, DOI 10.1111/j.1600-065X.1999.tb01281.x
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Roberts A, 2005, J VIROL, V79, P5833, DOI 10.1128/JVI.79.9.5833-5838.2005
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   *SARS EP WORK GROU, 2003, WHO CONS DOC EP SEV
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   *WHO, 2004, CONF HUM CAS AV INFL
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Zou Ke, 2003, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V25, P495
NR 30
TC 275
Z9 298
U1 20
U2 55
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD AUG
PY 2005
VL 11
IS 8
BP 875
EP 879
DI 10.1038/nm1267
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 951XC
UT WOS:000230964700033
PM 16007097
OA Bronze
DA 2020-04-03
ER

PT J
AU Vennema, H
   Godeke, GJ
   Rossen, JWA
   Voorhout, WF
   Horzinek, MC
   Opstelten, DJE
   Rottier, PJM
AF Vennema, H
   Godeke, GJ
   Rossen, JWA
   Voorhout, WF
   Horzinek, MC
   Opstelten, DJE
   Rottier, PJM
TI Nucleocapsid-independent assembly of coronavirus-like particles by
   co-expression of viral envelope protein genes
SO EMBO JOURNAL
LA English
DT Article
DE budding; coronavirus; envelope protein; virus assembly; virus-like
   particle
ID B SURFACE-ANTIGEN; VIRUS-LIKE PARTICLES; BACTERIOPHAGE-T7
   RNA-POLYMERASE; LETHAL JEV INFECTION; MEMBRANE-PROTEIN; STRUCTURAL
   PROTEINS; E1 GLYCOPROTEIN; VACCINIA VIRUS; MONOCLONAL-ANTIBODIES;
   ENDOPLASMIC-RETICULUM
AB Budding of enveloped viruses has been shown to be driven by interactions between a nucleocapsid and a proteolipid membrane. By contrast, we here describe the assembly of viral envelopes independent of a nucleocapsid. Membrane particles containing coronaviral envelope proteins were assembled in and released from animal cells co-expressing these proteins' genes from transfected plasmids. Of the three viral membrane proteins only two were required for particle formation, the membrane glycoprotein (M) and the small envelope protein (E). The spike (S) protein was dispensable but was incorporated when present. Importantly, the nucleocapsid protein (N) was neither required nor taken into the particles when present. The E protein, recently recognized to be a structural protein, was shown to be an integral membrane protein. The envelope vesicles were found by immunogold labelling and electron microscopy to form a homogeneous population of spherical particles indistinguishable from authentic coronavirions in size (similar to 100 nm in diameter) and shape. They were less dense than virions and sedimented slightly slower than virions in sucrose velocity gradients. The nucleocapsid-independent formation of apparently bona fide viral envelopes represents a novel mode of virus assembly.
C1 UNIV UTRECHT, FAC VET MED, DEPT FUNCT MORPHOL, UTRECHT, NETHERLANDS.
RP Vennema, H (reprint author), DEPT IMMUNOL & INFECT DIS, DIV VIROL, YALELAAN 1, 3584 CL UTRECHT, NETHERLANDS.
RI Rossen, John W/G-7564-2011
OI Rossen, John W/0000-0002-7167-8623
CR ABRAHAM S, 1990, VIROLOGY, V177, P488, DOI 10.1016/0042-6822(90)90513-Q
   ALLISON SL, 1995, J VIROL, V69, P5816, DOI 10.1128/JVI.69.9.5816-5820.1995
   Bredenbeek P J, 1987, Adv Exp Med Biol, V218, P65
   BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059
   BUDZILOWICZ CJ, 1987, VIROLOGY, V157, P509, DOI 10.1016/0042-6822(87)90293-5
   DELCHAMBRE M, 1989, EMBO J, V8, P2653, DOI 10.1002/j.1460-2075.1989.tb08405.x
   DUBOIS MF, 1980, P NATL ACAD SCI-BIOL, V77, P4549, DOI 10.1073/pnas.77.8.4549
   DUBOISDALCQ ME, 1982, VIROLOGY, V119, P317, DOI 10.1016/0042-6822(82)90092-7
   ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743, DOI 10.1073/pnas.87.17.6743
   FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97
   GAROFF H, 1994, ARCH VIROL, P329
   GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8
   GILMORE W, 1987, P SOC EXP BIOL MED, V185, P177
   GODET M, 1992, VIROLOGY, V188, P666, DOI 10.1016/0042-6822(92)90521-P
   GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195
   HOBMAN TC, 1994, VIROLOGY, V202, P574, DOI 10.1006/viro.1994.1379
   HOGUE BG, 1986, VIRUS RES, V5, P131, DOI 10.1016/0168-1702(86)90013-4
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995
   HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008
   KARACOSTAS V, 1989, P NATL ACAD SCI USA, V86, P8964, DOI 10.1073/pnas.86.22.8964
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   KONISHI E, 1992, VIROLOGY, V188, P714, DOI 10.1016/0042-6822(92)90526-U
   KRIJNSELOCKER J, 1992, J BIOL CHEM, V267, P14094
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAUB O, 1983, J VIROL, V48, P271, DOI 10.1128/JVI.48.1.271-280.1983
   LIAO CL, 1995, VIROLOGY, V208, P319, DOI 10.1006/viro.1995.1155
   LILJESTROM P, 1991, J VIROL, V65, P4107
   LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S
   LOCKER JK, 1995, J BIOL CHEM, V270, P8815, DOI 10.1074/jbc.270.15.8815
   LOCKER JK, 1994, J CELL BIOL, V124, P55
   LOEWY A, 1995, J VIROL, V69, P469, DOI 10.1128/JVI.69.1.469-475.1995
   LOPEZ S, 1994, J VIROL, V68, P1316, DOI 10.1128/JVI.68.3.1316-1323.1994
   MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944
   MACNAUGHTON MR, 1980, J GEN VIROL, V47, P365, DOI 10.1099/0022-1317-47-2-365
   MASON PW, 1991, VIROLOGY, V180, P294, DOI 10.1016/0042-6822(91)90034-9
   MOUNIR S, 1992, J GEN VIROL, V73, P2731, DOI 10.1099/0022-1317-73-10-2731
   OPSTELTEN DJE, 1995, J CELL BIOL, V131, P339, DOI 10.1083/jcb.131.2.339
   OPSTELTEN DJE, 1994, ARCH VIROL, P319
   PARENT LJ, 1995, J VIROL, V69, P5455, DOI 10.1128/JVI.69.9.5455-5460.1995
   PATZER EJ, 1986, J VIROL, V58, P884, DOI 10.1128/JVI.58.3.884-892.1986
   QIU ZY, 1994, J VIROL, V68, P4086, DOI 10.1128/JVI.68.6.4086-4091.1994
   ROLLS MM, 1994, CELL, V79, P497, DOI 10.1016/0092-8674(94)90258-5
   Rottier P.J.M., 1995, CORONAVIRIDAE, P115
   ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987
   ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981
   ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981
   SIMON K, 1988, J CELL BIOL, V107, P2163, DOI 10.1083/jcb.107.6.2163
   SLOT JW, 1985, EUR J CELL BIOL, V38, P87
   SMITH AR, 1990, J GEN VIROL, V71, P3, DOI 10.1099/0022-1317-71-1-3
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   SUBBRAMANIAN RA, 1994, J VIROL, V68, P6831, DOI 10.1128/JVI.68.11.6831-6835.1994
   SUOMALAINEN M, 1992, J VIROL, V66, P4737, DOI 10.1128/JVI.66.8.4737-4747.1992
   THIEL V, 1994, J GEN VIROL, V75, P3041, DOI 10.1099/0022-1317-75-11-3041
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475
   VANDERMOST RG, 1991, J VIROL, V65, P3219, DOI 10.1128/JVI.65.6.3219-3226.1991
   VENNEMA H, 1991, GENE, V108, P201, DOI 10.1016/0378-1119(91)90435-E
   VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990
   WILLS JW, 1994, J VIROL, V68, P6605, DOI 10.1128/JVI.68.10.6605-6618.1994
   YAMSHCHIKOV VF, 1993, VIROLOGY, V192, P38, DOI 10.1006/viro.1993.1006
   YU X, 1994, VIROLOGY, V202, P1018, DOI 10.1006/viro.1994.1430
   ZHAO HX, 1994, EMBO J, V13, P4204, DOI 10.1002/j.1460-2075.1994.tb06740.x
NR 66
TC 275
Z9 288
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD APR 15
PY 1996
VL 15
IS 8
BP 2020
EP 2028
DI 10.1002/j.1460-2075.1996.tb00553.x
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA UG748
UT WOS:A1996UG74800030
PM 8617249
DA 2020-04-03
ER

PT J
AU Sui, JH
   Li, WH
   Murakami, A
   Tamin, A
   Matthews, LJ
   Wong, SK
   Moore, MJ
   Tallarico, ASC
   Olurinde, M
   Choe, H
   Anderson, LJ
   Bellini, WJ
   Farzan, M
   Marasco, WA
AF Sui, JH
   Li, WH
   Murakami, A
   Tamin, A
   Matthews, LJ
   Wong, SK
   Moore, MJ
   Tallarico, ASC
   Olurinde, M
   Choe, H
   Anderson, LJ
   Bellini, WJ
   Farzan, M
   Marasco, WA
TI Potent neutralization of severe acute respiratory syndrome (SARS)
   coronavirus by a human mAb to S1 protein that blocks receptor
   association
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID INFECTIOUS-BRONCHITIS VIRUS; IN-VIVO; PROTECTIVE IMMUNITY; MURINE
   CORONAVIRUS; HEPATITIS-VIRUS; AMINO-ACIDS; ANTIBODIES; GLYCOPROTEIN;
   IDENTIFICATION; PREVENTION
AB Effective prophylaxis and antiviral therapies are urgently needed in the event of reemergence of the highly contagious and often fatal severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) infection. We have identified eight recombinant human single-chain variable region fragments (scFvs) against the S1 domain of spike (S) protein of the SARS-CoV from two nonimmune human antibody libraries. One scFv 80R efficiently neutralized SARS-CoV and inhibited syncytia formation between cells expressing the S protein and those expressing the SARS-CoV receptor angiotensin-converting enzyme 2 (ACE2). Mapping of the 80R epitope showed it is located within the N-terminal 261-672 amino acids of S protein and is not glycosylation-dependent. 80R scFv competed with soluble ACE2 for association with the S1 domain and bound S1 with high affinity (equilibrium dissociation constant, K-d = 32.3 nM). A human IgG1 form of 80R bound S1 with a 20-fold higher affinity of 1.59 nM comparable to that of ACE2 (K-d = 1.70 nM), and neutralized virus 20-fold more efficiently than the 80R scFv. These data suggest that the 80R human monoclonal antibody may be a useful viral entry inhibitor for the emergency prophylaxis and treatment of SARS, and that the ACE2-binding site of S1 could be an attractive target for subunit vaccine and drug development.
C1 Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
   Childrens Hosp, Dept Pediat, Div Pulm, Ina Sue Perlmutter Lab, Boston, MA 02115 USA.
   Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Dept Microbiol & Mol Genet,Partners AIDS, Boston, MA 02115 USA.
   Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.
RP Marasco, WA (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
EM wayne.marasco@dfci.harvard.edu
OI Li, Wenhui/0000-0003-1305-7404; Farzan, Michael/0000-0002-2990-5319;
   SUI, JIANHUA/0000-0002-1272-9662
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI28691, R21 AI053822, P30 AI028691, R01
   AI048436, AI28785, AI053822, AI48436]
CR Bai JR, 2003, J BIOL CHEM, V278, P1433, DOI 10.1074/jbc.M208297200
   Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891
   Casadevall A, 2002, NAT BIOTECHNOL, V20, P114, DOI 10.1038/nbt0202-114
   DANIEL C, 1994, VIROLOGY, V202, P540, DOI 10.1006/viro.1994.1376
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Harrison JL, 1996, METHOD ENZYMOL, V267, P83
   Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI200318819, 10.1172/JCI18819]
   Holmes KV, 2003, NEW ENGL J MED, V348, P1948, DOI 10.1056/NEJMp030078
   Igarashi T, 1999, NAT MED, V5, P211, DOI 10.1038/5576
   Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000
   Koo M, 1999, P NATL ACAD SCI USA, V96, P7774, DOI 10.1073/pnas.96.14.7774
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   KUIKEN T, 2003, LANCET, V352, P263
   Li G, 2003, NEW ENGL J MED, V349, P508, DOI 10.1056/NEJM200307313490520
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Moore KM, 1997, ARCH VIROL, V142, P2249, DOI 10.1007/s007050050239
   Parren PWHI, 2001, ADV IMMUNOL, V77, P195, DOI 10.1016/S0065-2776(01)77018-6
   Pearson H, 2003, NATURE, V424, P121, DOI 10.1038/424121a
   REFF ME, 1994, BLOOD, V83, P435
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SCHIER R, 1995, IMMUNOTECHNOLOGY, V1, P73, DOI 10.1016/1380-2933(95)00007-0
   Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568
   Song CS, 1998, J GEN VIROL, V79, P719, DOI 10.1099/0022-1317-79-4-719
   SPIGA O, 2003, BIOCHEM BIOPH RES CO, V3310, P78
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
NR 27
TC 273
Z9 312
U1 4
U2 22
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 24
PY 2004
VL 101
IS 8
BP 2536
EP 2541
DI 10.1073/pnas.0307140101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 802CA
UT WOS:000220140400055
PM 14983044
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Martina, BEE
   Haagmans, BL
   Kuiken, T
   Fouchier, RAM
   Rimmelzwaan, GF
   van Amerongen, G
   Peiris, JSM
   Lim, W
   Osterhaus, ADME
AF Martina, BEE
   Haagmans, BL
   Kuiken, T
   Fouchier, RAM
   Rimmelzwaan, GF
   van Amerongen, G
   Peiris, JSM
   Lim, W
   Osterhaus, ADME
TI SARS virus infection of cats and ferrets
SO NATURE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS
C1 Erasmus Med Ctr, Inst Virol, NL-3015 GE Rotterdam, Netherlands.
   Queen Mary Hosp, Dept Pathol & Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Govt Virus Unit, Kowloon, Hong Kong, Peoples R China.
RP Martina, BEE (reprint author), Erasmus Med Ctr, Inst Virol, NL-3015 GE Rotterdam, Netherlands.
RI Fouchier, Ron/Y-3755-2019; Fouchier, Ron A/A-1911-2014
OI Fouchier, Ron/0000-0001-8095-2869; Fouchier, Ron A/0000-0001-8095-2869;
   Haagmans, Bart/0000-0001-6221-2015; Osterhaus,
   Albert/0000-0002-6074-1172
CR Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
NR 5
TC 271
Z9 291
U1 51
U2 62
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD OCT 30
PY 2003
VL 425
IS 6961
BP 915
EP 915
DI 10.1038/425915a
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 737KY
UT WOS:000186230600030
PM 14586458
DA 2020-04-03
ER

PT J
AU Ruan, YJ
   Wei, CL
   Ee, LA
   Vega, VB
   Thoreau, H
   Yun, STS
   Chia, JM
   Ng, P
   Chiu, KP
   Lim, L
   Tao, Z
   Peng, CK
   Ean, LOL
   Lee, NM
   Sin, LY
   Ng, LFP
   Chee, RE
   Stanton, LW
   Long, PM
   Liu, ET
AF Ruan, YJ
   Wei, CL
   Ee, LA
   Vega, VB
   Thoreau, H
   Yun, STS
   Chia, JM
   Ng, P
   Chiu, KP
   Lim, L
   Tao, Z
   Peng, CK
   Ean, LOL
   Lee, NM
   Sin, LY
   Ng, LFP
   Chee, RE
   Stanton, LW
   Long, PM
   Liu, ET
TI Comparative full-length genome sequence analysis of 14 SARS coronavirus
   isolates and common mutations associated with putative origins of
   infection
SO LANCET
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS; MOUSE HEPATITIS-VIRUS;
   BRONCHITIS VIRUS; SPIKE PROTEIN; RECOMBINATION; DETERMINANT; EVOLUTION
AB Background The cause of severe acute respiratory syndrome (SARS) has been identified as a new coronavirus. Whole genome sequence analysis of various isolates might provide an indication of potential strain differences of this new virus. Moreover, mutation analysis will help to develop effective vaccines.
   Methods We sequenced the entire SARS viral genome of cultured isolates from the index case (SIN2500) presenting in Singapore, from three primary contacts (SIN2774, SIN2748, and SIN2677), and one secondary contact (SIN2679). These sequences were compared with the isolates from Canada (TOR2), Hong Kong (CUHK-W1 and HKU39849), Hanoi (URBANI), Guangzhou (GZ01), and Beijing (BJ01, BJ02, BJ03, BJ04).
   Findings We identified 129 sequence variations among the 14 isolates, with 16 recurrent variant sequences. Common variant sequences at four loci define two distinct genotypes of the SARS virus. One genotype was linked with infections originating in Hotel M in Hong Kong, the second contained isolates from Hong Kong, Guangzhou, and Beijing with no association with Hotel M (p<0.0001). Moreover, other common sequence variants further distinguished the geographical origins of the isolates, especially between Singapore and Beijing.
   Interpretation Despite the recent onset of the SARS epidemic, genetic signatures are emerging that partition the worldwide SARS viral isolates into groups on the basis of contact source history and geography. These signatures can be used to trace sources of infection. In addition, a common variant associated with a non-conservative aminoacid change in the S1 region of the spike protein, suggests that immunological pressures might be starting to influence the evolution of the SARS virus in human populations.
C1 Genome Inst Singapore, Singapore, Singapore.
   Singapore Gen Hosp, Dept Pathol, Virol Sect, Singapore 0316, Singapore.
   Natl Univ Singapore, Dept Microbiol, Singapore 117548, Singapore.
   Natl Univ Singapore, Electron Microscopy Unit, Singapore 117548, Singapore.
   Tan Tock Seng Hosp, Singapore, Singapore.
RP Liu, ET (reprint author), 1 Sci Pk Rd 05-01,Singapore Sci Pk 2, Singapore 117528, Singapore.
EM gisliue@nus.edu.sg
RI Chia, Jer-Ming/C-9992-2012; Liu, Edison/C-4141-2008
OI Ng, Lisa/0000-0003-4071-5222; THOREAU, HERVE/0000-0001-6643-167X
CR Bergmann CC, 1996, J GEN VIROL, V77, P315, DOI 10.1099/0022-1317-77-2-315
   Bush RM, 2000, P NATL ACAD SCI USA, V97, P6974, DOI 10.1073/pnas.97.13.6974
   CALLENBAUT P, 1998, J GEN VIROL, V77, P309
   DROSTEN C, 2003, N ENGL J MED    0410, DOI DOI 10.1026/NEJMOA030781
   *GISH W, WU BLAST 1996 2003
   Gomez N, 1998, VIROLOGY, V249, P352, DOI 10.1006/viro.1998.9315
   HOMBERGER FR, 1994, VIRUS RES, V31, P49
   Jackwood M W, 1995, Adv Exp Med Biol, V380, P213
   KSIAZEK TG, 2003, N ENGL J MED    0410, DOI DOI 10.1056/NEJMOA030747
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Lee CW, 2001, VIRUS RES, V80, P33, DOI 10.1016/S0168-1702(01)00345-8
   MARRA MA, 2003, GENOME SEQUENCE SARS
   Ndifuna A, 1998, J VIROL METHODS, V70, P37, DOI 10.1016/S0166-0934(97)00170-5
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Phillips JJ, 1999, J VIROL, V73, P7752, DOI 10.1128/JVI.73.9.7752-7760.1999
   Rowe CL, 1997, J VIROL, V71, P6183, DOI 10.1128/JVI.71.8.6183-6190.1997
   Sanchez CM, 1999, J VIROL, V73, P7607
   Swofford DL, 2003, PAUP PHYLOGENETIC AN
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   *US CDC WHO, 2003, MMWR-MORBID MORTAL W, V52, P269
   *WHO, 2003, WKLY EPIDEMIOL REC, V78, P81
   World Health Organization, CUM NUMB REP PROB CA
NR 22
TC 271
Z9 338
U1 3
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAY 24
PY 2003
VL 361
IS 9371
BP 1779
EP 1785
DI 10.1016/S0140-6736(03)13414-9
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 682CY
UT WOS:000183074800010
PM 12781537
OA Bronze
DA 2020-04-03
ER

PT J
AU GORBALENYA, AE
   KOONIN, EV
   LAI, MMC
AF GORBALENYA, AE
   KOONIN, EV
   LAI, MMC
TI PUTATIVE PAPAIN-RELATED THIOL PROTEASES OF POSITIVE-STRAND RNA VIRUSES -
   IDENTIFICATION OF RUBIVIRUS AND APHTHOVIRUS PROTEASES AND DELINEATION OF
   A NOVEL CONSERVED DOMAIN ASSOCIATED WITH PROTEASES OF RUBIVIRUS, ALPHA-
   AND CORONAVIRUSES
SO FEBS LETTERS
LA English
DT Article
DE PAPAIN-LIKE PROTEASE; RNA VIRUS; POLYPROTEIN PROCESSING; SEQUENCE MOTIF;
   CATALYTIC CENTER
ID SERINE PROTEASES; CYSTEINE PROTEASES; SINDBIS VIRUS; SEQUENCE;
   PROTEINASE; GENOME; FLAVIVIRUSES; PESTIVIRUSES; POLYPROTEIN; FAMILY
AB A computer-assisted comparative analysis of the amino acid sequences of (putative) thiol proteases encoded by the genomes of several diverse groups of positive-stranded RNA viruses and distantly related to the family of cellular papain-like proteases is presented.  A high level of similarity was detected between the leader protease of foot-and-mouth-disease virus and the protease of murine hepatitis coronavirus which cleaves the N-terminal p28 protein from the polyprotein.  Statistically significant alignment of a portion of the rubella virus polyprotein with cellular papain-like proteases was obtained, leading to tentative identification of the papain-like protease as the enzyme mediating processing of the non-structural proteins of this virus.  Specific grouping between the sequences of the proteases of alpha-viruses, and poty- and bymoviruses was revealed.  It was noted that papain-like proteases of positive-stranded RNA viruses are much more variable both in their sequences and in genomic locations than chymotrypsin-related proteases found in the same virus class.  A novel conserved domain of unknown function has also been identified which flanks the papain-like proteases of alpha-, rubi- and coronaviruses.
C1 ACAD SCI USSR,INST MOLEC,MOSCOW 117811,USSR.
   UNIV SO CALIF,SCH MED,HOWARD HUGHES MED INST,LOS ANGELES,CA 90033.
   UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033.
RP GORBALENYA, AE (reprint author), ACAD MED SCI,INST POLIOMYELITIS & VIRAL ENCEPHALITIDES,MOSCOW 142782,USSR.
RI Gorbalenya, Alexander E/J-4818-2012; Lai, Michael M. C./I-7001-2012
OI Gorbalenya, Alexander E/0000-0002-4967-7341; 
CR BAKER SC, 1990, IN PRESS PATHOGENESI
   BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9
   BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BRODSKII L I, 1991, Biopolimery i Kletka, V7, P10
   DING MX, 1989, VIROLOGY, V171, P280, DOI 10.1016/0042-6822(89)90539-4
   DOMINGUEZ G, 1990, VIROLOGY, V177, P225, DOI 10.1016/0042-6822(90)90476-8
   GORBALENYA AE, 1989, J MOL EVOL, V28, P256, DOI 10.1007/BF02102483
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7
   HARDY WR, 1989, J VIROL, V63, P4653, DOI 10.1128/JVI.63.11.4653-4664.1989
   KASHIWAZAKI S, 1991, J GEN VIROL, V72, P995, DOI 10.1099/0022-1317-72-4-995
   KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   LEONTOVICH A M, 1990, Biopolimery i Kletka, V6, P14
   OH CS, 1989, VIROLOGY, V173, P692, DOI 10.1016/0042-6822(89)90582-5
   SEBTI SM, 1989, BIOCHEMISTRY-US, V28, P6544, DOI 10.1021/bi00442a003
   STRAUSS EG, 1990, 8TH INT C VIR BERL
   STREBEL K, 1986, J VIROL, V58, P893, DOI 10.1128/JVI.58.3.893-899.1986
NR 20
TC 271
Z9 283
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
J9 FEBS LETT
JI FEBS Lett.
PD AUG 19
PY 1991
VL 288
IS 1-2
BP 201
EP 205
DI 10.1016/0014-5793(91)81034-6
PG 5
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA GD736
UT WOS:A1991GD73600047
PM 1652473
OA Bronze
DA 2020-04-03
ER

PT J
AU FLEMING, JO
   TROUSDALE, MD
   ELZAATARI, FAK
   STOHLMAN, SA
   WEINER, LP
AF FLEMING, JO
   TROUSDALE, MD
   ELZAATARI, FAK
   STOHLMAN, SA
   WEINER, LP
TI PATHOGENICITY OF ANTIGENIC VARIANTS OF MURINE CORONAVIRUS JHM SELECTED
   WITH MONOCLONAL-ANTIBODIES
SO JOURNAL OF VIROLOGY
LA English
DT Article
C1 UNIV SO CALIF,DEPT OPHTHALMOL,LOS ANGELES,CA 90033.
   UNIV SO CALIF,DEPT MICROBIOL,LOS ANGELES,CA 90033.
   ESTELLE DOHENY EYE FDN,LOS ANGELES,CA 90033.
   UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455.
RP FLEMING, JO (reprint author), UNIV SO CALIF,DEPT NEUROL,LOS ANGELES,CA 90033, USA.
FU NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [NS00795, NS07149, NS18146]
CR BAYBUTT HN, 1984, J GEN VIROL, V65, P915, DOI 10.1099/0022-1317-65-5-915
   BUCHMEIER MJ, 1984, VIROLOGY, V132, P261, DOI 10.1016/0042-6822(84)90033-3
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   DIETZSCHOLD B, 1985, J VIROL, V56, P12, DOI 10.1128/JVI.56.1.12-18.1985
   ERLICH SS, 1985, PATHOLOGY MYELINATED, P276
   EVANS DMA, 1983, NATURE, V304, P459, DOI 10.1038/304459a0
   FLEMING JO, 1983, J NEUROIMMUNOL, V4, P129, DOI 10.1016/0165-5728(83)90017-6
   FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1
   GONZALEZSCARANO F, 1985, J VIROL, V54, P757, DOI 10.1128/JVI.54.3.757-763.1985
   GREENSPAN NS, 1985, J IMMUNOL, V134, P1065
   HARMON RC, 1983, IMMUNOGENETICS, V18, P541, DOI 10.1007/BF00364395
   JACKSON DP, 1984, VIROLOGY, V137, P297, DOI 10.1016/0042-6822(84)90221-6
   KENDALL C, 1983, J IMMUNOL METHODS, V56, P329, DOI 10.1016/S0022-1759(83)80022-2
   KNOBLER RL, 1982, NATURE, V298, P279, DOI 10.1038/298279a0
   KNOBLER RL, 1981, J EXP MED, V153, P832, DOI 10.1084/jem.153.4.832
   KNOSSOW M, 1984, NATURE, V311, P678, DOI 10.1038/311678a0
   LAVER WG, 1982, VIROLOGY, V122, P450, DOI 10.1016/0042-6822(82)90244-6
   LAVER WG, 1982, MONOCLONAL HYBRIDOMA, P104
   LOVE A, 1985, J VIROL, V53, P67
   MAKINO S, 1983, MICROBIOL IMMUNOL, V27, P445, DOI 10.1111/j.1348-0421.1983.tb00603.x
   NAKAJIMA S, 1981, VIROLOGY, V113, P656, DOI 10.1016/0042-6822(81)90194-X
   PORTNER A, 1980, VIROLOGY, V104, P235, DOI 10.1016/0042-6822(80)90382-7
   PRABHAKAR BS, 1984, CONCEPTS VIRAL PATHO, P158
   SEIF I, 1985, J VIROL, V53, P926, DOI 10.1128/JVI.53.3.926-934.1985
   SIDDELL S, 1982, CURR TOP MICROBIOL, V99, P131
   SORENSEN O, 1980, ARCH NEUROL-CHICAGO, V37, P478, DOI 10.1001/archneur.1980.00500570026003
   SPRIGGS DR, 1982, NATURE, V297, P68, DOI 10.1038/297068a0
   STAHLI C, 1983, METHOD ENZYMOL, V92, P242
   STOHLMAN SA, 1981, NEUROLOGY, V31, P38, DOI 10.1212/WNL.31.1.38
   STOHLMAN SA, 1982, J GEN VIROL, V63, P265, DOI 10.1099/0022-1317-63-2-265
   STOHLMAN SA, 1975, J VIROL, V16, P1017, DOI 10.1128/JVI.16.4.1017-1026.1975
   STOHLMAN SA, 1978, ARCH VIROL, V57, P53, DOI 10.1007/BF01315637
   STOHLMAN SA, 1983, VIROLOGY, V130, P527, DOI 10.1016/0042-6822(83)90106-X
   Sturman L S, 1984, Adv Exp Med Biol, V173, P25
   TAGUCHI F, 1985, J VIROL, V54, P429, DOI 10.1128/JVI.54.2.429-435.1985
   TALBOT PJ, 1984, VIROLOGY, V132, P250, DOI 10.1016/0042-6822(84)90032-1
   WEGE H, 1984, J NEUROIMMUNOL, V6, P325, DOI 10.1016/0165-5728(84)90022-5
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WEGE H, 1984, J GEN VIROL, V65, P1931, DOI 10.1099/0022-1317-65-11-1931
   WEINER LP, 1973, ARCH NEUROL-CHICAGO, V28, P298, DOI 10.1001/archneur.1973.00490230034003
   WIKTOR TJ, 1980, J EXP MED, V152, P99, DOI 10.1084/jem.152.1.99
   YEWDELL JW, 1981, ANNU REV MICROBIOL, V35, P185, DOI 10.1146/annurev.mi.35.100181.001153
NR 42
TC 268
Z9 269
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN
PY 1986
VL 58
IS 3
BP 869
EP 875
DI 10.1128/JVI.58.3.869-875.1986
PG 7
WC Virology
SC Virology
GA C4103
UT WOS:A1986C410300019
PM 3701929
OA Bronze
DA 2020-04-03
ER

PT J
AU Song, HD
   Tu, CC
   Zhang, GW
   Wang, SY
   Zheng, K
   Lei, LC
   Chen, QX
   Gao, YW
   Zhou, HQ
   Xiang, H
   Zheng, HJ
   Chern, SWW
   Cheng, F
   Pan, CM
   Xuan, H
   Chen, SJ
   Luo, HM
   Zhou, DH
   Liu, YF
   He, JF
   Qin, PZ
   Li, LH
   Ren, YQ
   Liang, WJ
   Yu, YD
   Anderson, L
   Wang, M
   Xu, RH
   Wu, XW
   Zheng, HY
   Chen, JD
   Liang, GD
   Gao, Y
   Liao, M
   Fang, L
   Jiang, LY
   Li, H
   Chen, F
   Di, B
   He, LJ
   Lin, JY
   Tong, SX
   Kong, XG
   Du, L
   Hao, P
   Tang, H
   Bernini, A
   Yu, XJ
   Spiga, O
   Guo, ZM
   Pan, HY
   He, WZ
   Manuguerra, JC
   Fontanet, A
   Danchin, A
   Niccolai, N
   Li, YX
   Wu, CI
   Zhao, GP
AF Song, HD
   Tu, CC
   Zhang, GW
   Wang, SY
   Zheng, K
   Lei, LC
   Chen, QX
   Gao, YW
   Zhou, HQ
   Xiang, H
   Zheng, HJ
   Chern, SWW
   Cheng, F
   Pan, CM
   Xuan, H
   Chen, SJ
   Luo, HM
   Zhou, DH
   Liu, YF
   He, JF
   Qin, PZ
   Li, LH
   Ren, YQ
   Liang, WJ
   Yu, YD
   Anderson, L
   Wang, M
   Xu, RH
   Wu, XW
   Zheng, HY
   Chen, JD
   Liang, GD
   Gao, Y
   Liao, M
   Fang, L
   Jiang, LY
   Li, H
   Chen, F
   Di, B
   He, LJ
   Lin, JY
   Tong, SX
   Kong, XG
   Du, L
   Hao, P
   Tang, H
   Bernini, A
   Yu, XJ
   Spiga, O
   Guo, ZM
   Pan, HY
   He, WZ
   Manuguerra, JC
   Fontanet, A
   Danchin, A
   Niccolai, N
   Li, YX
   Wu, CI
   Zhao, GP
TI Cross-host evolution of severe acute respiratory syndrome coronavirus in
   palm civet and human
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME-2; SARS-ASSOCIATED CORONAVIRUS;
   PHYLOGENETIC TREES; POSITIVE SELECTION; GENOME SEQUENCE; PROTEIN; CHINA;
   TESTS
AB The genomic sequences of severe acute respiratory syndrome coronaviruses from human and palm civet of the 2003/2004 outbreak in the city of Guangzhou, China, were nearly identical. Phylogenetic analysis suggested an independent viral invasion from animal to human in this new episode. Combining all existing data but excluding singletons, we identified 202 single-nucleotide variations. Among them, 17 are polymorphic in palm civets only. The ratio of nonsynonymous/synonymous nucleotide substitution in palm civets collected I yr apart from different geographic locations is very high, suggesting a rapid evolving process of viral proteins in civet as well, much like their adaptation in the human host in the early 2002-2003 epidemic. Major genetic variations in some critical genes, particularly the Spike gene, seemed essential for the transition from animal-to-human transmission to human-to-human transmission, which eventually caused the first severe acute respiratory syndrome outbreak of 2002/2003.
C1 Chinese Natl Human Genome Ctr, Shanghai 201203, Peoples R China.
   Shanghai Med Univ 2, Ruijin Hosp, State key Lab Med Genom Pole Sinofrancais Rech &, Shanghai 200025, Peoples R China.
   Changchun Univ Agr & Anim Sci, Changchun 130062, Peoples R China.
   Guangdong Ctr Dis Control & Prevent, Guangdong 510300, Peoples R China.
   CDC, Atlanta, GA 30333 USA.
   Guangzhou Ctr Dis Control & Prevent, Guangzhou 510080, Peoples R China.
   Guangdong Prov Vet Stn Epidem Prevent & Supervis, Guangzhou 510230, Peoples R China.
   S China Agr Univ, Coll Vet Med, Guangzhou 510246, Peoples R China.
   S China Agr Univ, Coll Vet Med, Guangzhou 510246, Peoples R China.
   Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing 100052, Peoples R China.
   Chinese Acad Agr Sci, Natl Key Lab Vet Biotechnol, Harbin Vet Res Inst, Harbin 150001, Peoples R China.
   Chinese Acad Sci, Shanghai Inst Biol Sci, Bioinformat Ctr, Inst Plant Physiol & Ecol,Hlth Sci Ctr, Shanghai 200031, Peoples R China.
   Shanghai Ctr Bioinformat Technol, Shanghai 200235, Peoples R China.
   Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA.
   Univ Siena, Biomol Struct Res Ctr, I-53100 Siena, Italy.
   Univ Siena, Dept Mol Biol, I-53100 Siena, Italy.
   Inst Pasteur, F-75724 Paris 15, France.
   Fudan Univ, State Key Lab Genet Engn, Dept Microbiol, Sch Life Sci, Shanghai 200433, Peoples R China.
RP Zhao, GP (reprint author), Chinese Natl Human Genome Ctr, 250 Bi Bo Rd,Zhang Jiang High Tech Pk, Shanghai 201203, Peoples R China.
EM gpzhao@sibs.ac.cn
RI Gao, Yang/C-7825-2009; Song, Huai-Dong/G-8961-2011; Bernini,
   Andrea/H-9412-2012
OI Bernini, Andrea/0000-0002-7528-2749; Danchin,
   Antoine/0000-0002-6350-5001
CR Bazykin GA, 2004, NATURE, V429, P558, DOI 10.1038/nature02601
   Bernini A, 2004, BIOCHEM BIOPH RES CO, V325, P1210, DOI 10.1016/j.bbrc.2004.10.156
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   GOLDMAN N, 1994, MOL BIOL EVOL, V11, P725
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Li W. H., 1997, MOL EVOLUTION
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liang GD, 2004, EMERG INFECT DIS, V10, P1774, DOI 10.3201/eid1010.040445
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MCLACHLAN AD, 1971, J MOL BIOL, V61, P409, DOI 10.1016/0022-2836(71)90390-1
   Pazos F, 2001, PROTEIN ENG, V14, P609, DOI 10.1093/protein/14.9.609
   Rocha EPC, 2002, TRENDS GENET, V18, P291, DOI 10.1016/S0168-9525(02)02690-2
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   TAJIMA F, 1993, GENETICS, V135, P599
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Yang ZH, 1998, MOL BIOL EVOL, V15, P568, DOI 10.1093/oxfordjournals.molbev.a025957
   Zeng R, 2004, J MOL BIOL, V341, P271, DOI 10.1016/j.jmb.2004.06.016
NR 23
TC 260
Z9 299
U1 3
U2 60
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 15
PY 2005
VL 102
IS 7
BP 2430
EP 2435
DI 10.1073/pnas.0409608102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 898JM
UT WOS:000227073100034
PM 15695582
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Gosert, R
   Kanjanahaluethai, A
   Egger, D
   Bienz, K
   Baker, SC
AF Gosert, R
   Kanjanahaluethai, A
   Egger, D
   Bienz, K
   Baker, SC
TI RNA replication of mouse hepatitis virus takes place at double-membrane
   vesicles
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MURINE CORONAVIRUS MHV-A59; PAPAIN-LIKE PROTEINASE;
   ENDOPLASMIC-RETICULUM; VIRAL-RNA; INFECTED-CELLS; CLEAVAGE SITE;
   ARTERIVIRUS REPLICASE; 3C-LIKE PROTEINASE; MOLECULAR-BIOLOGY; GENE
   POLYPROTEIN
AB The replication complexes (RCs) of positive-stranded RNA viruses are intimately associated with cellular membranes. To investigate membrane alterations and to characterize the RC of mouse hepatitis virus (MHV), we performed biochemical and ultrastructural studies using MHV-infected cells. Biochemical fractionation showed that all 10 of the MHV gene I polyprotein products examined pelleted with the membrane fraction, consistent with membrane association of the RC. Furthermore, MHV gene I products p290, p210, and p150 and the p150 cleavage product membrane protein 1 (MP1, also called p44) were resistant to extraction with Triton X-114, indicating that they are integral membrane proteins. The ultrastructural analysis revealed double-membrane vesicles (DMVs) in the cytoplasm of MRV-infected cells. The DMVs were found either as separate entities or as small clusters of vesicles. To determine whether MHV proteins and viral RNA were associated with the DMVs, we performed immunocytochemistry electron microscopy (IEM). We found that the DMVs were labeled using an antiserum directed against proteins derived from open reading frame la of MHV. By electron microscopy in situ hybridization (ISH) using MHV-specific RNA probes, DMVs were highly labeled for both gene I and gene 7 sequences. By combined ISH and IEM, positive-stranded RNA and viral proteins localized to the same DMVs. Finally, viral RNA synthesis was detected by labeling with 5-bromouridine 5'-triphosphate. Newly synthesized viral RNA was found to be associated with the DMVs. We conclude from these data that the DMVs carry the MHV RNA replication complex and are the site of MHV RNA synthesis.
C1 Loyola Univ, Dept Microbiol & Immunol, Stritch Sch Med, Maywood, IL 60153 USA.
   Univ Basel, Inst Med Microbiol, Basel, Switzerland.
   Chiang Mai Univ, Dept Microbiol, Chiang Mai 50000, Thailand.
RP Baker, SC (reprint author), Loyola Univ, Dept Microbiol & Immunol, Stritch Sch Med, 2160 S 1st Ave,Bldg 105,Rm 3929, Maywood, IL 60153 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 45798, R01 AI045798]
CR BAKER SC, 1989, J VIROL, V63, P3693, DOI 10.1128/JVI.63.9.3693-3699.1989
   Bi WZ, 1998, J NEUROVIROL, V4, P594, DOI 10.3109/13550289809114226
   BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992
   BIENZ K, 1995, HISTOCHEM CELL BIOL, V103, P325, DOI 10.1007/BF01457807
   BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8
   BONILLA PJ, 1995, VIROLOGY, V209, P489, DOI 10.1006/viro.1995.1281
   BONILLA PJ, 1994, VIROLOGY, V198, P736, DOI 10.1006/viro.1994.1088
   Bonilla PJ, 1997, J VIROL, V71, P900, DOI 10.1128/JVI.71.2.900-909.1997
   BORDIER C, 1981, J BIOL CHEM, V256, P1604
   Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   Chen JB, 2000, J VIROL, V74, P4310, DOI 10.1128/JVI.74.9.4310-4318.2000
   COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3
   DENISON MR, 1995, VIROLOGY, V207, P316, DOI 10.1006/viro.1995.1085
   Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999
   DUBOISDALCQ M, 1984, ASSEMBLY ENVELOPED R, P99
   Egger D, 2000, J VIROL, V74, P6570, DOI 10.1128/JVI.74.14.6570-6580.2000
   FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075
   FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103
   Gallagher TM, 1996, J VIROL, V70, P4683, DOI 10.1128/JVI.70.7.4683-4690.1996
   GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6
   HIRANO N, 1978, JPN J EXP MED, V48, P71
   Kanjanahaluethai A, 2000, J VIROL, V74, P7911, DOI 10.1128/JVI.74.17.7911-7921.2000
   KIM JC, 1995, VIROLOGY, V208, P1, DOI 10.1006/viro.1995.1123
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   Lu XT, 1998, J VIROL, V72, P2265, DOI 10.1128/JVI.72.3.2265-2271.1998
   Lu XT, 1996, VIROLOGY, V222, P375, DOI 10.1006/viro.1996.0434
   LU YQ, 1995, J VIROL, V69, P3554, DOI 10.1128/JVI.69.6.3554-3559.1995
   Magliano D, 1998, VIROLOGY, V240, P57, DOI 10.1006/viro.1997.8906
   Molenkamp R, 2000, J GEN VIROL, V81, P2491, DOI 10.1099/0022-1317-81-10-2491
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Pinon JD, 1999, VIROLOGY, V263, P471, DOI 10.1006/viro.1999.9954
   RestrepoHartwig MA, 1996, J VIROL, V70, P8908, DOI 10.1128/JVI.70.12.8908-8916.1996
   Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001
   Schaad MC, 1997, EMBO J, V16, P4049, DOI 10.1093/emboj/16.13.4049
   Schiller JJ, 1998, VIROLOGY, V242, P288, DOI 10.1006/viro.1997.9010
   Sethna PB, 1997, J VIROL, V71, P7744, DOI 10.1128/JVI.71.10.7744-7749.1997
   Shen XL, 2001, P NATL ACAD SCI USA, V98, P2717, DOI 10.1073/pnas.031424298
   Shi ST, 2000, EMBO J, V19, P4701, DOI 10.1093/emboj/19.17.4701
   Shi ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999
   SKINNER MA, 1983, NUCLEIC ACIDS RES, V11, P5045, DOI 10.1093/nar/11.15.5045
   Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961
   Snijder EJ, 2001, J GEN VIROL, V82, P985, DOI 10.1099/0022-1317-82-5-985
   STURMAN LS, 1972, INFECT IMMUN, V6, P501, DOI 10.1128/IAI.6.4.501-507.1972
   TETERINA NL, 1995, J VIROL, V69, P4245, DOI 10.1128/JVI.69.7.4245-4254.1995
   Thiel V, 2001, J VIROL, V75, P6676, DOI 10.1128/JVI.75.14.6676-6681.2001
   van der Meer Y, 1998, J VIROL, V72, P6689, DOI 10.1128/JVI.72.8.6689-6698.1998
   van der Meer Y, 1999, J VIROL, V73, P7641, DOI 10.1128/JVI.73.9.7641-7657.1999
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 50
TC 260
Z9 273
U1 0
U2 16
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD APR
PY 2002
VL 76
IS 8
BP 3697
EP 3708
DI 10.1128/JVI.76.8.3697-3708.2002
PG 12
WC Virology
SC Virology
GA 533GG
UT WOS:000174520600012
PM 11907209
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Morse, SS
   Mazet, JAK
   Woolhouse, M
   Parrish, CR
   Carroll, D
   Karesh, WB
   Zambrana-Torrelio, C
   Lipkin, WI
   Daszak, P
AF Morse, Stephen S.
   Mazet, Jonna A. K.
   Woolhouse, Mark
   Parrish, Colin R.
   Carroll, Dennis
   Karesh, William B.
   Zambrana-Torrelio, Carlos
   Lipkin, W. Ian
   Daszak, Peter
TI Zoonoses 3 Prediction and prevention of the next pandemic zoonosis
SO LANCET
LA English
DT Article
ID EMERGING INFECTIOUS-DISEASES; INFLUENZA-VIRUS; RISK-FACTORS; HOST-RANGE;
   TRANSMISSION; EMERGENCE; SURVEILLANCE; DYNAMICS; CORONAVIRUS;
   BIODIVERSITY
AB Most pandemics-eg, HIV/AIDS, severe acute respiratory syndrome, pandemic influenza-originate in animals, are caused by viruses, and are driven to emerge by ecological, behavioural, or socioeconomic changes. Despite their substantial effects on global public health and growing understanding of the process by which they emerge, no pandemic has been predicted before infecting human beings. We review what is known about the pathogens that emerge, the hosts that they originate in, and the factors that drive their emergence. We discuss challenges to their control and new efforts to predict pandemics, target surveillance to the most crucial interfaces, and identify prevention strategies. New mathematical modelling, diagnostic, communications, and informatics technologies can identify and report hitherto unknown microbes in other species, and thus new risk assessment approaches are needed to identify microbes most likely to cause human disease. We lay out a series of research and surveillance opportunities and goals that could help to overcome these challenges and move the global pandemic strategy from response to pre-emption.
C1 [Karesh, William B.; Zambrana-Torrelio, Carlos; Daszak, Peter] EcoHealth Alliance, New York, NY 10001 USA.
   [Morse, Stephen S.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
   [Lipkin, W. Ian] Columbia Univ, Ctr Infect & Immun, New York, NY USA.
   [Morse, Stephen S.; Mazet, Jonna A. K.] Univ Calif Davis, Hlth Inst 1, Sch Vet Med, Davis, CA 95616 USA.
   [Woolhouse, Mark] Univ Edinburgh, Ctr Immun Infect & Evolut, Edinburgh, Midlothian, Scotland.
   [Parrish, Colin R.] Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA.
   [Carroll, Dennis] US Agcy Int Dev, Washington, DC 20523 USA.
   [Karesh, William B.] IUCN Species Survival Commiss, Wildlife Hlth Specialist Grp, Gland, Switzerland.
RP Daszak, P (reprint author), EcoHealth Alliance, 460 W 34th St, New York, NY 10001 USA.
EM daszak@ecohealthalliance.org
RI Zambrana-Torrelio, Carlos/AAH-3911-2020; daszak, peter/U-4588-2017
OI Zambrana-Torrelio, Carlos/0000-0002-5614-7496; daszak,
   peter/0000-0002-2046-5695; Lipkin, W. Ian/0000-0002-8768-9386
FU US Agency for International Development (USAID) Emerging Pandemic
   Threats PREDICT project (USAID)United States Agency for International
   Development (USAID) [GHN-A-009-00010-00]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI079231, AI57158]; Defense Threat
   Reduction AgencyUnited States Department of DefenseDefense Threat
   Reduction Agency; Ecology and Evolution of Infectious Diseases award
   from the Fogarty International Center of the National Institutes of
   Health [2R01-TW005869]; National Science Foundation Human and Social
   Dynamics programme [BCS-0826779]; Wellcome-Trust-funded VIZIONS project;
   Arts and Letters Foundation
FX This research was funded by the US Agency for International Development
   (USAID) Emerging Pandemic Threats PREDICT project (USAID cooperative
   agreement GHN-A-009-00010-00). WIL is supported by grants from the
   National Institutes of Health (AI079231, AI57158), and the Defense
   Threat Reduction Agency. PD is supported by an Ecology and Evolution of
   Infectious Diseases award from the Fogarty International Center of the
   National Institutes of Health (2R01-TW005869) and the National Science
   Foundation Human and Social Dynamics programme (BCS-0826779). MW
   receives support from the Wellcome-Trust-funded VIZIONS project, and SSM
   is supported by the Arts and Letters Foundation. We thank Murray Trostle
   for his invaluable insights and Aleksei A Chmura (EcoHealth Alliance)
   for figure 2. The contents are the responsibility of the authors and do
   not necessarily reflect the views of USAID or the United States
   Government. This paper is dedicated to the memory of Prof Joshua
   Lederberg (1925-2008).
CR Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
   Anderson RM, 2004, PHILOS T ROY SOC B, V359, P1091, DOI 10.1098/rstb.2004.1490
   Antia R, 2003, NATURE, V426, P658, DOI 10.1038/nature02104
   Barber MRW, 2011, INFLUENZA OTHER RESP, V5, P8
   Baric RS, 2005, P NATL ACAD SCI USA, V102, P8073, DOI 10.1073/pnas.0503091102
   Beigel H, 2005, NEW ENGL J MED, V353, P1374
   Bull J, 2003, NATURE, V426, P609, DOI 10.1038/426609a
   Burke DS, 1998, PATHOLOGY EMERGING I, P1
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Chan EH, 2010, P NATL ACAD SCI USA, V107, P21701, DOI 10.1073/pnas.1006219107
   Chan J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001005
   Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0
   Cleaveland S, 2001, PHILOS T ROY SOC B, V356, P991, DOI 10.1098/rstb.2001.0889
   Cui J, 2007, EMERG INFECT DIS, V13, P1526, DOI 10.3201/eid1310.070448
   Damon IK, 2011, VACCINE, V29, pD54, DOI 10.1016/j.vaccine.2011.04.014
   Daszak P, 2000, SCIENCE, V287, P443, DOI 10.1126/science.287.5452.443
   Davies TJ, 2008, P ROY SOC B-BIOL SCI, V275, P1695, DOI 10.1098/rspb.2008.0284
   Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810
   Dorner M, 2011, NATURE, V474, P208, DOI 10.1038/nature10168
   DOWNS WG, 1982, ANNU REV MED, V33, P1, DOI 10.1146/annurev.me.33.020182.000245
   EWALD P, 1996, [No title captured]
   Fenner Frank, 1993, P176
   Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017
   Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997
   Fukuyama S, 2011, CURR OPIN IMMUNOL, V23, P481, DOI 10.1016/j.coi.2011.07.016
   Gilbert GS, 2007, P NATL ACAD SCI USA, V104, P4979, DOI 10.1073/pnas.0607968104
   Goldberg TL, 2008, EMERG INFECT DIS, V14, P1375, DOI [10.3201/eid14.9.071196, 10.3201/eid1409.071196]
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Grard G, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002924
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Herfst S, 2012, SCIENCE, V336, P1534, DOI 10.1126/science.1213362
   HOLMES EC, 2009, EVOLUTION EMERGENCE
   Hosseini P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012763
   Hufnagel L, 2004, P NATL ACAD SCI USA, V101, P15124, DOI 10.1073/pnas.0308344101
   Imai M, 2012, NATURE, V486, P420, DOI 10.1038/nature10831
   Janes CR, 2012, LANCET, V380, P1884, DOI 10.1016/S0140-6736(12)61725-5
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Kalscheuer H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003481
   Karesh WB, 2012, LANCET, V380, P1936, DOI 10.1016/S0140-6736(12)61678-X
   Karesh WB, 2009, CLIN MED, V9, P259, DOI 10.7861/clinmedicine.9-3-259
   Keele BF, 2006, SCIENCE, V313, P523, DOI 10.1126/science.1126531
   Keesing F, 2010, NATURE, V468, P647, DOI 10.1038/nature09575
   Keusch G.T., 2009, SUSTAINING GLOBAL SU
   Kilpatrick AM, 2012, LANCET, V380, P1946, DOI 10.1016/S0140-6736(12)61151-9
   Kimball AM, 2008, MED CLIN N AM, V92, P1459, DOI 10.1016/j.mcna.2008.06.001
   Kuiken T, 2006, SCIENCE, V312, P394, DOI 10.1126/science.1122818
   Lederberg J., 1992, EMERGING INFECT MICR
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Lipkin WI, 2010, MICROBIOL MOL BIOL R, V74, P363, DOI 10.1128/MMBR.00007-10
   Liu WM, 2010, NATURE, V467, P420, DOI 10.1038/nature09442
   Lloyd-Smith JO, 2009, SCIENCE, V326, P1362, DOI 10.1126/science.1177345
   Long WJ, 2011, PANDEMICS AND PEACE: PUBLIC HEALTH COOPERATION IN ZONES OF CONFLICT, P1
   Mackenzie JS, 1999, EMERG INFECT DIS, V5, P1, DOI 10.3201/eid0501.990101
   Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759
   Moresco EMY, 2011, CURR OPIN VIROL, V1, P513, DOI 10.1016/j.coviro.2011.10.005
   Moresco EMY, 2011, CURR BIOL, V21, pR488, DOI 10.1016/j.cub.2011.05.039
   Morse SS, 1996, HEALTH POLICY, V38, P135, DOI 10.1016/0168-8510(96)00863-9
   MORSE SS, 1990, ISSUES SCI TECHNOL, V7, P81
   MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102
   Morse SS, 2012, BIOSECUR BIOTERROR, V10, P6, DOI 10.1089/bsp.2011.0088
   Morse Stephen S., 1994, P1
   Murphy FA, 1998, EMERG INFECT DIS, V4, P429, DOI 10.3201/eid0403.980324
   National Biosurveillance Advisory Subcommittee, IMPR NAT AB DET RESP
   Parrish CR, 2008, MICROBIOL MOL BIOL R, V72, P457, DOI 10.1128/MMBR.00004-08
   Peiris JSM, 2012, SCIENCE, V335, P1173, DOI 10.1126/science.1219936
   Pepin KM, 2010, NAT REV MICROBIOL, V8, P802, DOI 10.1038/nrmicro2440
   Pulliam JRC, 2008, ECOHEALTH, V5, P80, DOI 10.1007/s10393-007-0149-6
   Pulliam JRC, 2012, J R SOC INTERFACE, V9, P89, DOI 10.1098/rsif.2011.0223
   Pulliam JRC, 2009, J INFECT DIS, V199, P565, DOI 10.1086/596510
   Rambaut A, 2008, NATURE, V453, P615, DOI 10.1038/nature06945
   Relman DA, 2011, NEW ENGL J MED, V365, P347, DOI 10.1056/NEJMra1003071
   Russell CA, 2012, SCIENCE, V336, P1541, DOI 10.1126/science.1222526
   Simini F, 2012, NATURE, V484, P96, DOI 10.1038/nature10856
   Smolinski Mark, 2003, MICROBIAL THREATS HL
   Ssematimba A, 2013, PREV VET MED, V109, P106, DOI 10.1016/j.prevetmed.2012.09.001
   Streicker DG, 2010, SCIENCE, V329, P676, DOI 10.1126/science.1188836
   Taylor LH, 2001, PHILOS T R SOC B, V356, P983, DOI 10.1098/rstb.2001.0888
   Vidal Jean-Marc, 2010, Cytokine, V51, P213, DOI 10.1016/j.cyto.2010.04.008
   Webby R, 2004, NAT MED, V10, pS77, DOI 10.1038/nm1151
   Weiss RA, 2004, NAT MED, V10, pS70, DOI 10.1038/nm1150
   *WHO, GLOB OUTBR AL RESP N
   Wolf B, 2012, CYTOKINE, V60, P828, DOI 10.1016/j.cyto.2012.08.018
   Wolfe ND, 2007, NATURE, V447, P279, DOI 10.1038/nature05775
   Wolfe ND, 2004, LANCET, V363, P932, DOI 10.1016/S0140-6736(04)15787-5
   Woolhouse M, 2012, PHILOS T R SOC B, V367, P2864, DOI 10.1098/rstb.2011.0354
   Woolhouse MEJ, 2001, SCIENCE, V292, P1109, DOI 10.1126/science.1059026
   Woolhouse MEJ, 2005, EMERG INFECT DIS, V11, P1842, DOI 10.3201/eid1112.050997
   World Health Organization, 2008, INT HLTH REG
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 90
TC 259
Z9 268
U1 17
U2 188
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD DEC 1
PY 2012
VL 380
IS 9857
BP 1956
EP 1965
DI 10.1016/S0140-6736(12)61684-5
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 046IK
UT WOS:000311758500032
PM 23200504
OA Green Accepted
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Hamming, I
   Timens, W
   Bulthuis, MLC
   Lely, AT
   Navis, GJ
   van Goor, H
AF Hamming, I
   Timens, W
   Bulthuis, MLC
   Lely, AT
   Navis, GJ
   van Goor, H
TI Tissue distribution of ACE2 protein, the functional receptor for SARS
   coronavirus. A first step in understanding SARS pathogenesis
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE severe acute respiratory syndrome (SARS); coronavirus;
   angiotensin-converting enzyme 2; SARS-CoV receptor
ID ACUTE RESPIRATORY SYNDROME; ANGIOTENSIN-CONVERTING ENZYME;
   CARBOXYPEPTIDASE; IDENTIFICATION; EXPRESSION; PATHOLOGY; OUTBREAK;
   HOMOLOG
AB Severe acute respiratory syndrome (SARS) is an acute infectious disease that spreads mainly via the respiratory route. A distinct coronavirus (SARS-CoV) has been identified as the aetiological agent of SARS. Recently, a metallopeptidase named angiotensin-converting enzyme 2 (ACE2) has been identified as the functional receptor for SARS-CoV. Although ACE2 mRNA is known to be present in virtually all organs, its protein expression is largely unknown. Since identifying the possible route of infection has major implications for understanding the pathogenesis and future treatment strategies for SARS, the present study investigated the localization of ACE2 protein in various human organs (oral and nasal mucosa, nasopharynx, lung, stomach, small intestine, colon, skin, lymph nodes, thymus, bone marrow, spleen, liver, kidney, and brain). The most remarkable finding was the surface expression of ACE2 protein on lung alveolar epithelial cells and enterocytes of the small intestine. Furthermore, ACE2 was present in arterial and venous endothelial cells and arterial smooth muscle cells in all organs studied. In conclusion, ACE2 is abundantly present in humans in the epithelia of the lung and small intestine, which might provide possible routes of entry for the SARS-CoV. This epithelial expression, together with the presence of ACE2 in vascular endothelium, also provides a first step in understanding the pathogenesis of the main SARS disease manifestations. Copyright (C) 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley Sons, Ltd.
C1 Univ Groningen Hosp, Dept Pathol & Lab Med, NL-9700 RB Groningen, Netherlands.
   Univ Groningen Hosp, Dept Nephrol, NL-9700 RB Groningen, Netherlands.
RP Timens, W (reprint author), Univ Groningen Hosp, Dept Pathol & Lab Med, POB 30-001, NL-9700 RB Groningen, Netherlands.
EM w.timens@poth.azg.nl
RI Timens, Wim/K-5570-2013
OI Timens, Wim/0000-0002-4146-6363; Lely, Titia/0000-0001-6356-7707
CR Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   LUIKEN TR, 2003, LANCET, V362, P263
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   O'Donnell R, 2003, BRIT MED J, V327, P620, DOI 10.1136/bmj.327.7415.620-b
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Tikellis C, 2003, HYPERTENSION, V41, P392, DOI 10.1161/01.HYP.0000060689.38912.CB
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   To K, 2004, J PATHOL, V202, P157, DOI 10.1002/path.1510
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Yagil Y, 2003, HYPERTENSION, V41, P871, DOI 10.1161/01.HYP.0000063886.71596.C8
   Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0
   CUMULATIVE NUMBER RE
NR 22
TC 259
Z9 283
U1 33
U2 43
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JUN
PY 2004
VL 203
IS 2
BP 631
EP 637
DI 10.1002/path.1570
PG 7
WC Oncology; Pathology
SC Oncology; Pathology
GA 823SP
UT WOS:000221633700004
PM 15141377
OA Bronze
DA 2020-04-03
ER

PT J
AU Wheeler, DL
   Church, DM
   Edgar, R
   Federhen, S
   Helmberg, W
   Madden, TL
   Pontius, JU
   Schuler, GD
   Schriml, LM
   Sequeira, E
   Suzek, TO
   Tatusova, TA
   Wagner, L
AF Wheeler, DL
   Church, DM
   Edgar, R
   Federhen, S
   Helmberg, W
   Madden, TL
   Pontius, JU
   Schuler, GD
   Schriml, LM
   Sequeira, E
   Suzek, TO
   Tatusova, TA
   Wagner, L
TI Database resources of the National Center for Biotechnology Information:
   update
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID GENE-EXPRESSION; PSI-BLAST; PROTEIN; SEQUENCE; ENTREZ; SEARCH; TOOL;
   HOMOLOGY
AB In addition to maintaining the GenBank(R) nucleic acid sequence database, the National Center for Biotechnology Information (NCBI) provides data analysis and retrieval resources for the data in GenBank and other biological data made available through NCBI's website. NCBI resources include Entrez, PubMed, PubMed Central, LocusLink, the NCBI Taxonomy Browser, BLAST, BLAST Link (BLink), Electronic PCR, OrfFinder, Spidey, RefSeq, UniGene, HomoloGene, ProtEST, dbMHC, dbSNP, Cancer Chromosome Aberration Project (CCAP), Entrez Genomes and related tools, the Map Viewer, Model Maker, Evidence Viewer, Clusters of Orthologous Groups (COGs) database, Retroviral Genotyping Tools, SARS Coronavirus Resource, SAGEmap, Gene Expression Omnibus (GEO), Online Mendelian Inheritance in Man (OMIM), the Molecular Modeling Database (MMDB), the Conserved Domain Database (CDD) and the Conserved Domain Architecture Retrieval Tool (CDART). Augmenting many of the web applications are custom implementations of the BLAST program optimized to search specialized data sets. All of the resources can be accessed through the NCBI home page at: http://www.ncbi.nim.nih.gov.
C1 Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.
RP Wheeler, DL (reprint author), Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bldg 38A,8600 Rockville Pike, Bethesda, MD 20894 USA.
EM wheeler@ncbi.nlm.nih.gov
RI Suzek, Tugba O/B-6943-2015
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276
   Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057
   Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095
   Chen J, 2003, NUCLEIC ACIDS RES, V31, P474, DOI 10.1093/nar/gkg086
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Ermolaeva O, 1998, NAT GENET, V20, P19
   Geer LY, 2002, GENOME RES, V12, P1619, DOI 10.1101/gr.278202
   Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051
   Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242
   Ma B, 2002, BIOINFORMATICS, V18, P440, DOI 10.1093/bioinformatics/18.3.440
   Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087
   McKusick V. A., 1998, MENDELIAN INHERITANC
   Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417
   Pruitt KD, 2003, NUCLEIC ACIDS RES, V31, P34, DOI 10.1093/nar/gkg111
   Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994
   Schuler GD, 1996, METHOD ENZYMOL, V266, P141
   Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155
   Sequeira E., 2003, ARL, V228, P5
   Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308
   Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33
   Tatusova TA, 1999, BIOINFORMATICS, V15, P536, DOI 10.1093/bioinformatics/15.7.536
   Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1111/j.1574-6968.1999.tb13575.x
   Wang YL, 2000, TRENDS BIOCHEM SCI, V25, P300, DOI 10.1016/S0968-0004(00)01561-9
   Westbrook J, 2003, NUCLEIC ACIDS RES, V31, P489, DOI 10.1093/nar/gkg068
   Wu CH, 2003, NUCLEIC ACIDS RES, V31, P345, DOI 10.1093/nar/gkg040
   Zhang Z, 2000, J COMPUT BIOL, V7, P203, DOI 10.1089/10665270050081478
NR 28
TC 259
Z9 274
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JAN 1
PY 2004
VL 32
SI SI
BP D35
EP D40
DI 10.1093/nar/gkh073
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 763HM
UT WOS:000188079000005
PM 14681353
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Sloots, TP
   McErlean, P
   Speicher, DJ
   Arden, KE
   Nissen, MD
   Mackay, IM
AF Sloots, TP
   McErlean, P
   Speicher, DJ
   Arden, KE
   Nissen, MD
   Mackay, IM
TI Evidence of human coronavirus HKU1 and human bocavirus in Australian
   children
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE human coronavirus; HCOV-HKU1; human bocavirus; epidemiology; acute
   respiratory tract disease
ID TRANSCRIPTASE-PCR ASSAY; RESPIRATORY-TRACT; INFECTIONS; SAMPLES; NL63
AB Undiagnosed cases of respiratory tract disease Suspected of an infectious aetiology peak during the winter months. Since studies applying molecular diagnostic assays usually report reductions in the number of undiagnosed cases of infectious disease compared to traditional techniques, we applied PCR assays to investigate the role of two recently described viruses, namely human coronavirus (HCoV) HKU1 and human bocavirus (HBoV), in a hospital-based paediatric population. Both viruses were found among Australia children with upper or lower respiratory tract disease during the autumn and winter of 2004, contributing to 21.1% of all microbial diagnoses. with individual incidences of 3.1% (HCoV-HKU1) and 5.6% (HBoV) among 324 specimens. HBoV was found to coincide with another virus in more than half of all instances and displayed a single genetic lineage, whilst HCoV-HKU1 was more likely to occur in the absence of another microbe and strains could be divided into two genetic lineages which we propose be termed HCoV-HKU1 type A and type B. Children under the age of 2 years were most at risk of infection by these viruses which contribute significantly to the microbial burden among patients with respiratory tract disease during the colder months. (C) 2005 Elsevier B.V. All rights reserved.
C1 Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, CVRU, Queensland Paediat Infect Dis Lab, Herston, Qld 4029, Australia.
   Univ Queensland, Clin & Med Virol Ctr, St Lucia, Qld 4067, Australia.
   Queensland Hlth Pathol Serv, Div Microbiol, Brisbane, Qld, Australia.
   Royal Childrens Hosp, Dept Paediat & Child Hlth, Brisbane, Qld, Australia.
RP Mackay, IM (reprint author), Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, CVRU, Queensland Paediat Infect Dis Lab, Herston Rd, Herston, Qld 4029, Australia.
EM ian.mackay@uq.edu.au
RI Nissen, Michael D/M-6823-2013; McErlean, Peter/O-5187-2016; DJ,
   Speicher/I-5841-2019; Arden, Katherine/D-7970-2017; Sloots, Theo
   P/E-6118-2011; Mackay, Ian M./B-2537-2010
OI Nissen, Michael D/0000-0003-1686-3313; DJ, Speicher/0000-0002-1745-3263;
   Arden, Katherine/0000-0003-3195-124X; Mackay, Ian M./0000-0003-3598-2350
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   Fouchier Ron Am, 2005, Curr Opin Infect Dis, V18, P141
   Hall, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507
   Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406
   Heikkinen T, 2003, LANCET, V361, P51, DOI 10.1016/S0140-6736(03)12162-9
   Klig JE, 2005, CURR OPIN PEDIATR, V17, P111, DOI 10.1097/01.mop.0000150599.31091.f0
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Maertzdorf J, 2004, J CLIN MICROBIOL, V42, P981, DOI 10.1128/JCM.42.3.981-986.2004
   SELWYN BJ, 1990, REV INFECT DIS, V12, pS870
   Syrmis MW, 2004, J MOL DIAGN, V6, P125, DOI 10.1016/S1525-1578(10)60500-4
   van der Hoek L, 2005, PLOS MED, V2, P764, DOI 10.1371/journal.pmed.0020240
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
NR 14
TC 255
Z9 315
U1 2
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JAN
PY 2006
VL 35
IS 1
BP 99
EP 102
DI 10.1016/j.jcv.2005.09.008
PG 4
WC Virology
SC Virology
GA 010IY
UT WOS:000235182800016
PM 16257260
OA Bronze
DA 2020-04-03
ER

PT J
AU Choi, EH
   Lee, HJ
   Kim, SJ
   Eun, BW
   Kim, NH
   Lee, JA
   Lee, JH
   Song, EK
   Park, SHKJY
   Sung, JY
AF Choi, Eun Hwa
   Lee, Hoan Jong
   Kim, Sun Jung
   Eun, Byung Wook
   Kim, Nam Hee
   Lee, Jin A.
   Lee, Jun Ho
   Song, Eun Kyung
   Park, So Hee Kim Ji Yong
   Sung, Ji Yeon
TI The association of newly identified respiratory viruses with lower
   respiratory tract infections in Korean children, 2000-2005
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN CORONAVIRUS NL63; HUMAN METAPNEUMOVIRUS INFECTION; YOUNG-CHILDREN;
   PEDIATRIC PRACTICE; CLINICAL-FEATURES; SYNCYTIAL VIRUS; DISEASE;
   RHINOVIRUS; INFANTS; BRONCHIOLITIS
AB Background. This study was performed to evaluate the associations of newly recognized viruses, namely, human metapneumovirus (hMPV), human coronavirus (HCoV)-NL63, and human bocavirus (HBoV) with lower respiratory tract infections (LRTIs) in previously healthy children.
   Methods. To determine the prevalences of 11 viruses-respiratory syncytial virus ( RSV), adenovirus, rhinovirus, parainfluenza viruses (PIVs) 1 and 3, influenza viruses A and B, hMPV, HCoV, HCoV-NL63, and HBoV-among infants or children with LRTIs, in association with their epidemiologic characteristics, we performed multiplex reverse-transcriptase polymerase chain reaction on nasopharyngeal aspirates obtained from 515 children <= 5 years old with LRTIs during the period 2000-2005.
   Results. Viruses were identified in 312 (60.6%) of the 515 patients. RSV was detected in 122 (23.7%), HBoV in 58 (11.3%), adenovirus in 35 (6.8%), PIV-3 in 32 (6.2%), rhinovirus in 30 (5.8%), hMPV in 24 (4.7%), influenza A in 24 (4.7%), PIV-1 in 9 (1.7%), influenza B in 9 (1.7%), and HCoV-NL63 in 8 (1.6%). Coinfections with >= 2 viruses were observed in 36 patients (11.5%). Twenty-two patients (37.9%) infected with HBoV had a coinfection. Bronchiolitis was frequently diagnosed in patients who tested positive for RSV, PIV-3, or rhinovirus, whereas influenza A, PIV-1, and HCoV-NL63 were commonly found in patients with croup. The age distributions of patients with viral infections differed; notably, RSV was responsible for 77% of LRTIs that occurred in infants <= 3 months old. The number of hMPV infections peaked between February and April, whereas the number of HCoV-NL63 infections peaked between April and May.
   Conclusions. This study describes the features of LRTIs associated with newly identified viruses in children, compared with those associated with known viruses. Additional investigations are required to define the role of HBoV in LRTI.
C1 Seoul Natl Univ, Coll Med, Dept Pediat, Seoul 110744, South Korea.
   Seoul Natl Univ Hosp, Virus Res Ctr, Clin Res Inst, Seoul 110744, South Korea.
   Seoul Natl Univ, Bundang Hosp, Seoul Med Sci Res Inst, Seoul, South Korea.
RP Lee, HJ (reprint author), Seoul Natl Univ, Coll Med, Dept Pediat, 28,Yeongeon Dong, Seoul 110744, South Korea.
EM hoanlee@snu.ac.kr
RI Choi, Eun Hwa/J-5691-2012; Lee, Hoan Jong/J-5616-2012
OI Eun, Byung Wook/0000-0003-3147-9061
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   Bastien N, 2005, J CLIN MICROBIOL, V43, P4567, DOI 10.1128/JCM.43.9.4567-4573.2005
   Boivin G, 2003, EMERG INFECT DIS, V9, P634
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   Choi EH, 2000, J INFECT DIS, V181, P1547, DOI 10.1086/315468
   Class ECJ, 1992, J VIROL METHODS, V39, P1
   DENNY FW, 1986, J PEDIATR-US, V108, P635, DOI 10.1016/S0022-3476(86)81034-4
   DENNY FW, 1983, PEDIATRICS, V71, P871
   Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289
   Ebihara T, 2004, J CLIN MICROBIOL, V42, P126, DOI 10.1128/JCM.42.1.126-132.2004
   Esper F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003
   Galiano M, 2004, J MED VIROL, V72, P299, DOI 10.1002/jmv.10536
   Gruteke P, 2004, J CLIN MICROBIOL, V42, P5596, DOI 10.1128/JCM.42.12.5596-5603.2004
   Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507
   HALL CB, 1990, J INFECT DIS, V162, P1283, DOI 10.1093/infdis/162.6.1283
   HENDERSON FW, 1979, J PEDIATR-US, V95, P183
   Hong JY, 2001, CLIN INFECT DIS, V32, P1423, DOI 10.1086/320146
   Kaiser L, 2005, PEDIATR INFECT DIS J, V24, P1015, DOI 10.1097/01.inf.0000183773.80217.12
   Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   Kim YK, 2005, PEDIATR INFECT DIS J, V24, P1111, DOI 10.1097/01.inf.0000190042.65120.23
   Lee JA, 2005, J CLIN MICROBIOL, V43, P5509, DOI 10.1128/JCM.43.11.5509-5514.2005
   McAdam AJ, 2004, J INFECT DIS, V190, P20, DOI 10.1086/421120
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC
   Papadopoulos NG, 1999, J VIROL METHODS, V80, P179, DOI 10.1016/S0166-0934(99)00045-2
   Robinson JL, 2005, J MED VIROL, V76, P98, DOI 10.1002/jmv.20329
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Suzuki A, 2005, PEDIATR INFECT DIS J, V24, P645, DOI 10.1097/01.inf.0000168846.71517.ee
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2005, PLOS MED, V2, P764, DOI 10.1371/journal.pmed.0020240
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Williams JV, 2006, J INFECT DIS, V193, P387, DOI 10.1086/499274
   Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472
   Xatzipsaiti M, 2005, AM J RESP CRIT CARE, V172, P1037, DOI 10.1164/rccm.200502-315OC
   Yun BY, 1995, PEDIATR INFECT DIS J, V14, P1054, DOI 10.1097/00006454-199512000-00005
NR 38
TC 251
Z9 278
U1 3
U2 10
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 1
PY 2006
VL 43
IS 5
BP 585
EP 592
DI 10.1086/506350
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 071TY
UT WOS:000239627000007
PM 16886150
OA Bronze
DA 2020-04-03
ER

PT J
AU Huang, YW
   Dickerman, AW
   Pineyro, P
   Li, L
   Fang, L
   Kiehne, R
   Opriessnig, T
   Meng, XJ
AF Huang, Yao-Wei
   Dickerman, Allan W.
   Pineyro, Pablo
   Li, Long
   Fang, Li
   Kiehne, Ross
   Opriessnig, Tanja
   Meng, Xiang-Jin
TI Origin, Evolution, and Genotyping of Emergent Porcine Epidemic Diarrhea
   Virus Strains in the United States
SO MBIO
LA English
DT Article
ID COMPLETE GENOME SEQUENCE; SUBGENOMIC RNA-SYNTHESIS; STEM-LOOP;
   5'-UNTRANSLATED REGION; CHINA; REPLICATION; CORONAVIRUSES; ELEMENT
AB Coronaviruses are known to infect humans and other animals and cause respiratory and gastrointestinal diseases. Here we report the emergence of porcine epidemic diarrhea virus (PEDV) in the United States and determination of its origin, evolution, and genotypes based on temporal and geographical evidence. Histological lesions in small intestine sections of affected pigs and the complete genomic sequences of three emergent strains of PEDV isolated from outbreaks in Minnesota and Iowa were characterized. Genetic and phylogenetic analyses of the three U. S. strains revealed a close relationship with Chinese PEDV strains and their likely Chinese origin. The U.S. PEDV strains underwent evolutionary divergence, which can be classified into two sublineages. The three emergent U.S. strains are most closely related to a strain isolated in 2012 from Anhui Province in China, which might be the result of multiple recombination events between different genetic lineages or sublineages of PEDV. Molecular clock analysis of the divergent time based on the complete genomic sequences is consistent with the actual time difference, approximately 2 to 3 years, of the PED outbreaks between China (December 2010) and the United States (May 2013). The finding that the emergent U.S. PEDV strains share unique genetic features at the 5'-untranslated region with a bat coronavirus provided further support of the evolutionary origin of PEDV from bats and potential cross-species transmission. The data from this study have important implications for understanding the ongoing PEDV outbreaks in the United States and will guide future efforts to develop effective preventive and control measures against PEDV.
   IMPORTANCE The sudden emergence of porcine epidemic diarrhea virus (PEDV), a coronavirus, for the first time in the United States causes significant economic and public health concerns. Since its recognition in May 2013, PEDV has rapidly spread across the United States, resulting in high mortality in piglets in more than 17 States now. The ongoing outbreaks of Middle East respiratory syndrome coronavirus in humans from countries in or near the Arabian Peninsula and the historical deadly nature of the 2002 outbreaks of severe acute respiratory syndrome coronavirus create further anxiety over the emergence of PEDV in the United States due to the lack of scientific information about the origin and evolution of this emerging coronavirus. Here we report the detailed genetic characterization, origin, and evolution of emergent PEDV strains in the United States. The results provide much needed information to devise effective preventive and control strategies against PEDV in the United States.
C1 [Huang, Yao-Wei; Pineyro, Pablo; Meng, Xiang-Jin] Virginia Polytech Inst & State Univ, Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA.
   [Huang, Yao-Wei] Zhejiang Univ, Coll Anim Sci, Hangzhou 310003, Zhejiang, Peoples R China.
   [Dickerman, Allan W.] Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA.
   [Li, Long; Fang, Li] Hangzhou Beta Vet Diagnost Lab, Hangzhou, Zhejiang, Peoples R China.
   [Kiehne, Ross] Swine Vet Ctr PA, St Peter, MN USA.
   [Opriessnig, Tanja] Iowa State Univ, Coll Vet Med, Dept Vet Diagnost & Prod Anim Med, Ames, IA USA.
   [Opriessnig, Tanja] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.
   [Opriessnig, Tanja] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh EH9 1QH, Midlothian, Scotland.
RP Meng, XJ (reprint author), Virginia Polytech Inst & State Univ, Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA.
EM yhuang@vt.edu; xjmeng@vt.edu
RI Huang, Yaowei/Q-9409-2019; Meng, X.J./B-8769-2009; Huang,
   Yaowei/B-1468-2009; Opriessnig, Tanja/F-2984-2012
OI Huang, Yaowei/0000-0001-9755-8411; Meng, X.J./0000-0002-2739-1334;
   Huang, Yaowei/0000-0001-9755-8411; Opriessnig, Tanja/0000-0001-9642-0904
CR Bi J, 2012, J VIROL, V86, P10910, DOI 10.1128/JVI.01919-12
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Groot de RJ, 2011, VIRUS TAXONOMY, P806
   HAVE P, 1992, VET MICROBIOL, V31, P1, DOI 10.1016/0378-1135(92)90135-G
   Kocherhans R, 2001, VIRUS GENES, V23, P137, DOI 10.1023/A:1011831902219
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee DK, 2010, VIRUS RES, V149, P175, DOI 10.1016/j.virusres.2010.01.015
   LI B, 2013, GENOME ANNOUNC, V1, DOI DOI 10.1128/GENOMEA.00105-13
   Li WT, 2012, EMERG INFECT DIS, V18, P1350, DOI 10.3201/eid1808.120002
   Liu PH, 2007, RNA, V13, P763, DOI 10.1261/rna.261807
   Marthaler D, 2013, MICROBIOL RESOUR ANN, V1, DOI 10.1128/genomeA.00555-13
   Mole B, 2013, NATURE, V499, P388, DOI 10.1038/499388a
   Pan YF, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-195
   PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606
   Raman S, 2005, J VIROL, V79, P12434, DOI 10.1128/JVI.79.19.12434-12446.2005
   Sola I, 2005, J VIROL, V79, P2506, DOI 10.1128/JVI.79.4.2506-2516.2005
   Song D, 2012, VIRUS GENES, V44, P167, DOI 10.1007/s11262-012-0713-1
   Stevenson GW, 2013, J VET DIAGN INVEST, V25, P649, DOI 10.1177/1040638713501675
   Tang XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Yang D, 2011, J VIROL, V85, P9199, DOI 10.1128/JVI.05092-11
   Zhao MJ, 2012, J VIROL, V86, P13858, DOI 10.1128/JVI.02674-12
   Zuniga S, 2004, J VIROL, V78, P980, DOI 10.1128/JVI.78.2.980-994.2004
NR 25
TC 249
Z9 282
U1 5
U2 71
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2013
VL 4
IS 5
AR e00737-13
DI 10.1128/mBio.00737-13
PG 8
WC Microbiology
SC Microbiology
GA 250UQ
UT WOS:000326881800036
PM 24129257
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Olsen, SJ
   Chang, H
   Cheung, TY
   Tang, AF
   Fisk, TL
   Ooi, SP
   Kuo, H
   Jiang, DD
   Chen, K
   Lando, J
   Hsu, K
   Chen, T
   Dowell, SF
AF Olsen, SJ
   Chang, H
   Cheung, TY
   Tang, AF
   Fisk, TL
   Ooi, SP
   Kuo, H
   Jiang, DD
   Chen, K
   Lando, J
   Hsu, K
   Chen, T
   Dowell, SF
TI Transmission of the severe acute respiratory syndrome on aircraft
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID CLINICAL-FEATURES; SYNDROME SARS
AB BACKGROUND: The severe acute respiratory syndrome (SARS) spread rapidly around the world, largely because persons infected with the SARS-associated coronavirus (SARS-CoV) traveled on aircraft to distant cities. Although many infected persons traveled on commercial aircraft, the risk, if any, of in-flight transmission is unknown.
   METHODS: We attempted to interview passengers and crew members at least 10 days after they had taken one of three flights that transported a patient or patients with SARS. All index patients met the criteria of the World Health Organization for a probable case of SARS, and index or secondary cases were confirmed to be positive for SARS-CoV on reverse-transcriptase polymerase chain reaction or serologic testing.
   RESULTS: After one flight carrying a symptomatic person and 119 other persons, laboratory-confirmed SARS developed in 16 persons, 2 others were given diagnoses of probable SARS, and 4 were reported to have SARS but could not be interviewed. Among the 22 persons with illness, the mean time from the flight to the onset of symptoms was four days (range, two to eight), and there were no recognized exposures to patients with SARS before or after the flight. Illness in passengers was related to the physical proximity to the index patient, with illness reported in 8 of the 23 persons who were seated in the three rows in front of the index patient, as compared with 10 of the 88 persons who were seated elsewhere (relative risk, 3.1; 95 percent confidence interval, 1.4 to 6.9). In contrast, another flight carrying four symptomatic persons resulted in transmission to at most one other person, and no illness was documented in passengers on the flight that carried a person who had presymptomatic SARS.
   CONCLUSIONS: Transmission of SARS may occur on an aircraft when infected persons fly during the symptomatic phase of illness. Measures to reduce the risk of transmission are warranted.
C1 Ctr Dis Control & Prevent, Int Emerging Infect Program, Nonthaburi, Thailand.
   Taiwan Ctr Dis Control, Dept Hlth, Taipei, Taiwan.
   Dept Hlth, Hong Kong, Hong Kong, Peoples R China.
   Emory Univ, Sch Med, Atlanta, GA USA.
   Minist Hlth, Epidemiol & Dis Control Div, Singapore, Singapore.
   Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA.
RP Olsen, SJ (reprint author), Ctr Dis Control & Prevent, Int Emerging Infect Program, Box 68,Amer Embassy, APO, AP 96546 USA.
CR [Anonymous], 2003, WKLY EPIDEMIOL REC, V78, P97
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Booth CM, 2003, JAMA-J AM MED ASSOC, V290, P334
   *CDCP, 2003, INT GUID CLEAN COMM
   *CDCP, 2003, INT GUID SEV AC RESP
   Demers RR, 2001, CHEST, V120, P1377, DOI 10.1378/chest.120.4.1377
   GARNER JS, 1997, GUIDELINE ISOLATION
   Hsu LY, 2003, EMERG INFECT DIS, V9, P713
   *IATA, 2003, DID YOU KNOW FACTS I
   KAHN J, 2003, INT HERALD TRIBUNE T, V1, P4
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   LAKSHMANAN IAR, 2003, BOSTON GLOBE    0518
   MOSER MR, 1979, AM J EPIDEMIOL, V110, P1
   Musher DM, 2003, NEW ENGL J MED, V348, P1256, DOI 10.1056/NEJMra021771
   Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6
   Wenzel RP, 1996, NEW ENGL J MED, V334, P981, DOI 10.1056/NEJM199604113341509
   WHO, 2003, SUMM PROB SARS CAS O
   *WHO, 2003, CAS DEF SURV SEV AC
   *WHO, 2003, UPD 59 REP GUANGX CH
   *WHO, 2003, UPD 62 MOR 8000 CAS
   World Health Organization, 2003, UPD 11 WHO REC NEW M
   2003, MMWR MORB MORTAL WKL, V52, P248
   2003, MMWR MORB MORTAL WKL, V52, P284
   1995, MMWR MORB MORTAL WKL, V44, P137
   2003, MMWR MORB MORTAL WKL, V52, P241
   1995, MMWR MORB MORTAL WKL, V44, P175
   2003, MMWR MORB MORTAL WKL, V52, P405
NR 28
TC 249
Z9 259
U1 2
U2 23
PU MASSACHUSETTS MEDICAL SOC/NEJM
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 18
PY 2003
VL 349
IS 25
BP 2416
EP 2422
DI 10.1056/NEJMoa031349
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 754PJ
UT WOS:000187326200007
PM 14681507
OA Bronze
DA 2020-04-03
ER

PT J
AU Mahony, J
   Chong, S
   Merante, F
   Yaghoubian, S
   Sinha, T
   Lisle, C
   Janeczko, R
AF Mahony, J.
   Chong, S.
   Merante, F.
   Yaghoubian, S.
   Sinha, T.
   Lisle, C.
   Janeczko, R.
TI Development of a respiratory virus panel test for detection of twenty
   human respiratory viruses by use of multiplex PCR and a fluid
   microbead-based assay
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; SYNCYTIAL-VIRUS; HUMAN METAPNEUMOVIRUS;
   PARAINFLUENZA VIRUS; INFECTIONS; DIAGNOSIS; SPECIMENS
AB Virology laboratories historically have used direct fluorescent-antibody assay (DFA) and culture to detect six or seven respiratory viruses. Following the discovery of five new human respiratory viruses since 2000, there is an increasing need for diagnostic tests to detect these emerging viruses. We have developed a new test that can detect 20 different respiratory virus types/subtypes in a single 5-h test. The assay employs multiplex PCR using 14 virus-specific primer pairs, followed by a multiplexed target-specific primer extension (TSPE) reaction using 21 primers for specific respiratory virus types and subtypes. TSPE products were sorted and identified by using a fluid microsphere-based array (Universal Array; TmBioscience Corporation, Toronto, Canada) and the Luminex x-MAIP system. The assay detected influenza A and B viruses; influenza A virus subtypes 111, 113, and H5 (including subtype 115N1 of the Asian lineage); parainfluenza virus types 1, 2, 3, and 4; respiratory syncytial virus types A and 13; adenovirus; metapneumovirus; rhinovirus; enterovirus; and coronaviruses OC43, 229E, severe acute respiratory syndrome coronavirus, NL63, and HKUL In a prospective evaluation using 294 nasopharyngeal swab specimens, DFA/culture detected 119 positives and the respiratory virus panel (RVP) test detected 1112 positives, for a sensitivity of 97%. The RVP test detected an additional 61 positive specimens that either were not detected by DFA/culture or were positive for viruses not tested for by DFA/culture. After resolution of discordant results by using a second unique PCR assay and by using a combined reference standard of positivity, the RVP test detected 180 of 183 true positives, for a sensitivity of 98.5%, whereas DFA and culture detected only 126 of 183 true positives, for a sensitivity of 68.8%. The RVP test should improve the capabilities of hospital and public health laboratories for diagnosing viral respiratory tract infections and should assist public health agencies in identifying etiologic agents in respiratory tract infection outbreaks.
C1 St Josephs Healthcare, Reg Virol Lab, Hamilton, ON L8N 4A6, Canada.
   McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
   TmBiosci Corp, Toronto, ON, Canada.
RP Mahony, J (reprint author), St Josephs Healthcare, Reg Virol Lab, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.
EM mahonyj@mcmaster.ca
CR Bellau-Pujol S, 2005, J VIROL METHODS, V126, P53, DOI 10.1016/j.jviromet.2005.01.020
   Bortolin S, 2004, CLIN CHEM, V50, P2028, DOI 10.1373/clinchem.2004.035071
   Coiras MT, 2004, J MED VIROL, V72, P484, DOI 10.1002/jmv.20008
   Falsey AR, 2006, J CLIN VIROL, V35, P46, DOI 10.1016/j.jcv.2005.04.004
   Fan J, 1998, CLIN INFECT DIS, V26, P1397, DOI 10.1086/516357
   Kaye M, 2006, EPIDEMIOL INFECT, V134, P792, DOI 10.1017/S0950268805005364
   MAHONY JB, 2006, 106 ANN GEN M AM SOC
   Osiowy C, 1998, J CLIN MICROBIOL, V36, P3149, DOI 10.1128/JCM.36.11.3149-3154.1998
   Scheltinga SA, 2005, J CLIN VIROL, V33, P306, DOI 10.1016/j.jcv.2004.08.021
   Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004
NR 10
TC 248
Z9 270
U1 0
U2 23
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD SEP
PY 2007
VL 45
IS 9
BP 2965
EP 2970
DI 10.1128/JCM.02436-06
PG 6
WC Microbiology
SC Microbiology
GA 211EK
UT WOS:000249506900032
PM 17596360
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Xue, B
   Dunker, AK
   Uversky, VN
AF Xue, Bin
   Dunker, A. Keith
   Uversky, Vladimir N.
TI Orderly order in protein intrinsic disorder distribution: disorder in
   3500 proteomes from viruses and the three domains of life
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
DE intrinsic disorder; proteome complexity; evolution; viruses; archaea;
   bacteria; prokaryotes; eukaryotes
ID MOLECULAR RECOGNITION FEATURES; UNSTRUCTURED PROTEINS; FUNCTIONAL
   ANTHOLOGY; HALOPHILIC PROTEINS; STRUCTURAL DISORDER; MEMBRANE-PROTEINS;
   SCAFFOLD PROTEINS; ESCHERICHIA-COLI; COMPLEXITY; SEQUENCE
AB Intrinsically disordered proteins and intrinsically disordered protein regions are highly abundant in nature. However, the quantitative and qualitative measures of protein intrinsic disorder in species with known genomes are still not available. Furthermore, although the correlation between high fraction of disordered residues and advanced species has been reported, the details of this correlation and the connection between the disorder content and proteome complexity have not been reported as of yet. To fill this gap, we analysed entire proteomes of 3484 species from three domains of life (archaea, bacteria and eukaryotes) and from viruses. Our analysis revealed that the evolution process is characterized by distinctive patterns of changes in the protein intrinsic disorder content. We are showing here that viruses are characterized by the widest spread of the proteome disorder content (the percentage of disordered residues ranges from 7.3% in human coronavirus NL63 to 77.3% in Avian carcinoma virus). For several organisms, a clear correlation is seen between their disorder contents and habitats. In multicellular eukaryotes, there is a weak correlation between the complexity of an organism (evaluated as a number of different cell types) and its overall disorder content. For both the prokaryotes and eukaryotes, the disorder content is generally independent of the proteome size. However, disorder shows a sharp increase associated with the transition from prokaryotic to eukaryotic cells. This suggests that the increased disorder content in eukaryotic proteomes might be used by nature to deal with the increased cell complexity due to the appearance of the various cellular compartments.
C1 [Xue, Bin; Uversky, Vladimir N.] Univ S Florida, Coll Med, Dept Mol Med, Tampa, FL 33612 USA.
   [Xue, Bin; Dunker, A. Keith; Uversky, Vladimir N.] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA.
   [Uversky, Vladimir N.] Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142290, Moscow Region, Russia.
RP Uversky, VN (reprint author), Univ S Florida, Coll Med, Dept Mol Med, Tampa, FL 33612 USA.
EM vuversky@health.usf.edu
RI Uversky, Vladimir N./F-4515-2011; xue, bin/E-5617-2011
OI Uversky, Vladimir N./0000-0002-4037-5857; xue, bin/0000-0002-6344-0623
FU National Science FoundationNational Science Foundation (NSF) [EF
   0849803]; Programme of the Russian Academy of Sciences for the Molecular
   and Cellular Biology
FX This work was supported in part by the grant EF 0849803 from the
   National Science Foundation (to A. K. D and V.N.U.) and the Programme of
   the Russian Academy of Sciences for the Molecular and Cellular Biology
   (to V.N.U.).
CR Bell G, 1997, BIOL J LINN SOC, V60, P345, DOI 10.1111/j.1095-8312.1997.tb01500.x
   Berezovsky IN, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/3/035002
   Bergqvist S, 2003, BIOCHEM SOC T, V31, P677, DOI 10.1042/bst0310677
   Bordoli L, 2007, PROTEINS, V69, P129, DOI 10.1002/prot.21671
   Burra PV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012069
   Cheng YG, 2007, BIOCHEMISTRY-US, V46, P13468, DOI 10.1021/bi7012273
   Clamp M, 2007, P NATL ACAD SCI USA, V104, P19428, DOI 10.1073/pnas.0709013104
   Claverie JM, 2009, ANNU REV GENET, V43, P49, DOI 10.1146/annurev-genet-102108-134255
   Claverie JM, 2001, SCIENCE, V291, P1255, DOI 10.1126/science.1058969
   De Biasio A, 2008, J PROTEOME RES, V7, P2496, DOI 10.1021/pr800063u
   Dunker A K, 2000, Genome Inform Ser Workshop Genome Inform, V11, P161
   Dunker AK, 2008, CURR OPIN STRUC BIOL, V18, P756, DOI 10.1016/j.sbi.2008.10.002
   Dunker AK, 2005, FEBS J, V272, P5129, DOI 10.1111/j.1742-4658.2005.04948.x
   Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+
   Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8
   Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589
   Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0
   Elcock AH, 1998, J MOL BIOL, V280, P731, DOI 10.1006/jmbi.1998.1904
   Feng ZP, 2006, MOL BIOCHEM PARASIT, V150, P256, DOI 10.1016/j.molbiopara.2006.08.011
   Forterre P, 2006, VIRUS RES, V117, P5, DOI 10.1016/j.virusres.2006.01.010
   Forterre P, 2005, BIOCHIMIE, V87, P793, DOI 10.1016/j.biochi.2005.03.015
   Forterre P, 2011, RES MICROBIOL, V162, P77, DOI 10.1016/j.resmic.2010.10.005
   Fukuchi S, 2003, J MOL BIOL, V327, P347, DOI 10.1016/S0022-2836(03)00150-5
   Galea CA, 2009, J PROTEOME RES, V8, P211, DOI 10.1021/pr800308v
   Garner E, 1999, GENOME INFORM SER WO, V10, P41
   Gray MW, 2001, GENOME BIOL, V2
   Gray MW, 1999, CURR OPIN GENET DEV, V9, P678, DOI 10.1016/S0959-437X(99)00030-1
   Gregory TR, 2004, PALEOBIOLOGY, V30, P179, DOI 10.1666/0094-8373(2004)030<0179:MHTATC>2.0.CO;2
   Hahn MW, 2002, EVOL DEV, V4, P73, DOI 10.1046/j.1525-142X.2002.01069.x
   Hartman H, 2002, P NATL ACAD SCI USA, V99, P1420, DOI 10.1073/pnas.032658599
   Hedges SB, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-2
   Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5
   Jin YM, 2005, PROTEINS, V61, P167, DOI 10.1002/prot.20734
   Le Gall T, 2007, J BIOMOL STRUCT DYN, V24, P325
   Madern D, 2000, EXTREMOPHILES, V4, P91, DOI 10.1007/s007920050142
   Magidovich E, 2007, P NATL ACAD SCI USA, V104, P13022, DOI 10.1073/pnas.0704059104
   Magidovich E, 2006, BIOINFORMATICS, V22, P1546, DOI 10.1093/bioinformatics/btl137
   Margulis L, 1975, Symp Soc Exp Biol, P21
   Mevarech M, 2000, BIOPHYS CHEM, V86, P155, DOI 10.1016/S0301-4622(00)00126-5
   Minezaki Y, 2007, J MOL BIOL, V368, P902, DOI 10.1016/j.jmb.2007.02.033
   MIRSKY AE, 1951, J GEN PHYSIOL, V34, P451, DOI 10.1085/jgp.34.4.451
   Mizianty MJ, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-245
   Mohan A, 2008, MOL BIOSYST, V4, P328, DOI 10.1039/b719168e
   Mohan A, 2006, J MOL BIOL, V362, P1043, DOI 10.1016/j.jmb.2006.07.087
   Obradovic Z, 2003, PROTEINS, V53, P566, DOI 10.1002/prot.10532
   Oldfield CJ, 2005, BIOCHEMISTRY-US, V44, P12454, DOI 10.1021/bi050736e
   Oldfield CJ, 2005, BIOCHEMISTRY-US, V44, P1989, DOI 10.1021/bi047993o
   Parfrey LW, 2008, MOL BIOL EVOL, V25, P787, DOI 10.1093/molbev/msn032
   Paul S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-4-r70
   Peng K, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-208
   Radivojac P, 2007, BIOPHYS J, V92, P1439, DOI 10.1529/biophysj.106.094045
   Ringe D, 1986, Methods Enzymol, V131, P389
   Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3
   Roy S, 2006, COMPUT BIOL CHEM, V30, P241, DOI 10.1016/j.compbiolchem.2006.04.005
   Ryan JF, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r64
   Schad E, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-r120
   Siglioccolo A, 2011, BMC STRUCT BIOL, V11, DOI 10.1186/1472-6807-11-50
   SWIFT H, 1950, P NATL ACAD SCI USA, V36, P643, DOI 10.1073/pnas.36.11.643
   SWIFT HH, 1950, PHYSIOL ZOOL, V23, P169, DOI 10.1086/physzool.23.3.30152074
   Tadeo X, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000257
   THOMAS CA, 1971, ANNU REV GENET, V5, P237, DOI 10.1146/annurev.ge.05.120171.001321
   Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2
   Tompa P, 2006, J PROTEOME RES, V5, P1996, DOI 10.1021/pr0600881
   Uversky VN, 2010, BBA-PROTEINS PROTEOM, V1804, P1231, DOI 10.1016/j.bbapap.2010.01.017
   Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.0.CO;2-7
   Uversky VN, 2005, J MOL RECOGNIT, V18, P343, DOI 10.1002/jmr.747
   Vacic V, 2007, J PROTEOME RES, V6, P2351, DOI 10.1021/pr0701411
   Valentine JW, 2000, PALEOBIOLOGY, V26, P513, DOI 10.1666/0094-8373(2000)026<0513:TGPTTE>2.0.CO;2
   Vogel C, 2006, PLOS COMPUT BIOL, V2, P370, DOI 10.1371/journal.pcbi.0020048
   VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0
   Vucetic S, 2003, PROTEINS, V52, P573, DOI 10.1002/prot.10437
   Vucetic S, 2007, J PROTEOME RES, V6, P1899, DOI 10.1021/pr060393m
   Wallin E, 1998, PROTEIN SCI, V7, P1029, DOI 10.1002/pro.5560070420
   Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002
   Wright DB, 2002, J MOL BIOL, V323, P327, DOI 10.1016/S0022-2836(02)00916-6
   Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110
   Xie HB, 2007, J PROTEOME RES, V6, P1917, DOI 10.1021/pr060394e
   Xie HB, 2007, J PROTEOME RES, V6, P1882, DOI 10.1021/pr060392u
   Xue B, 2010, PROTEIN PEPTIDE LETT, V17, P932, DOI 10.2174/092986610791498984
   Xue B, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S1-S1
   Xue B, 2010, BBA-PROTEINS PROTEOM, V1804, P996, DOI 10.1016/j.bbapap.2010.01.011
   Xue B, 2009, MOL BIOSYST, V5, P1688, DOI [10.1039/B905913J, 10.1039/b905913j]
   Xue B, 2009, FEBS LETT, V583, P1469, DOI 10.1016/j.febslet.2009.03.070
   ZACCAI G, 1990, TRENDS BIOCHEM SCI, V15, P333, DOI 10.1016/0968-0004(90)90068-M
NR 84
TC 243
Z9 243
U1 1
U2 65
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PY 2012
VL 30
IS 2
BP 137
EP 149
DI 10.1080/07391102.2012.675145
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 958QP
UT WOS:000305255800001
PM 22702725
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Huang, IC
   Bailey, CC
   Weyer, JL
   Radoshitzky, SR
   Becker, MM
   Chiang, JJ
   Brass, AL
   Ahmed, AA
   Chi, XL
   Dong, LA
   Longobardi, LE
   Boltz, D
   Kuhn, JH
   Elledge, SJ
   Bavari, S
   Denison, MR
   Choe, H
   Farzan, M
AF Huang, I-Chueh
   Bailey, Charles C.
   Weyer, Jessica L.
   Radoshitzky, Sheli R.
   Becker, Michelle M.
   Chiang, Jessica J.
   Brass, Abraham L.
   Ahmed, Asim A.
   Chi, Xiaoli
   Dong, Lian
   Longobardi, Lindsay E.
   Boltz, Dutch
   Kuhn, Jens H.
   Elledge, Stephen J.
   Bavari, Sina
   Denison, Mark R.
   Choe, Hyeryun
   Farzan, Michael
TI Distinct Patterns of IFITM-Mediated Restriction of Filoviruses, SARS
   Coronavirus, and Influenza A Virus
SO PLOS PATHOGENS
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME-2; MEMBRANE-FUSION; RECEPTOR-BINDING;
   CATHEPSIN-L; CELLS; ENTRY; GLYCOPROTEIN; ENDOCYTOSIS; INFECTION; PROTEIN
AB Interferon-inducible transmembrane proteins 1, 2, and 3 (IFITM1, 2, and 3) are recently identified viral restriction factors that inhibit infection mediated by the influenza A virus (IAV) hemagglutinin (HA) protein. Here we show that IFITM proteins restricted infection mediated by the entry glycoproteins (GP(1,2)) of Marburg and Ebola filoviruses (MARV, EBOV). Consistent with these observations, interferon-beta specifically restricted filovirus and IAV entry processes. IFITM proteins also inhibited replication of infectious MARV and EBOV. We observed distinct patterns of IFITM-mediated restriction: compared with IAV, the entry processes of MARV and EBOV were less restricted by IFITM3, but more restricted by IFITM1. Moreover, murine Ifitm5 and 6 did not restrict IAV, but efficiently inhibited filovirus entry. We further demonstrate that replication of infectious SARS coronavirus (SARS-CoV) and entry mediated by the SARS-CoV spike (S) protein are restricted by IFITM proteins. The profile of IFITM-mediated restriction of SARS-CoV was more similar to that of filoviruses than to IAV. Trypsin treatment of receptor-associated SARS-CoV pseudovirions, which bypasses their dependence on lysosomal cathepsin L, also bypassed IFITM-mediated restriction. However, IFITM proteins did not reduce cellular cathepsin activity or limit access of virions to acidic intracellular compartments. Our data indicate that IFITM-mediated restriction is localized to a late stage in the endocytic pathway. They further show that IFITM proteins differentially restrict the entry of a broad range of enveloped viruses, and modulate cellular tropism independently of viral receptor expression.
C1 [Huang, I-Chueh; Bailey, Charles C.; Weyer, Jessica L.; Chiang, Jessica J.; Farzan, Michael] Harvard Univ, Sch Med, New England Primate Res Ctr, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA.
   [Radoshitzky, Sheli R.; Chi, Xiaoli; Dong, Lian; Longobardi, Lindsay E.; Boltz, Dutch; Bavari, Sina] USA, Med Res Inst Infect Dis, Frederick, MD USA.
   [Becker, Michelle M.; Denison, Mark R.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
   [Becker, Michelle M.; Denison, Mark R.] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA.
   [Becker, Michelle M.; Denison, Mark R.] Vanderbilt Univ, Med Ctr, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA.
   [Brass, Abraham L.] Ragon Inst Massachusetts Gen Hosp MIT & Harvard M, Charlestown, MA USA.
   [Ahmed, Asim A.; Choe, Hyeryun] Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA.
   [Kuhn, Jens H.] NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD USA.
   [Kuhn, Jens H.] Tunnell Consulting Inc, King Of Prussia, PA USA.
   [Elledge, Stephen J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Howard Hughes Med Inst,Dept Genet, Boston, MA 02115 USA.
RP Huang, IC (reprint author), Harvard Univ, Sch Med, New England Primate Res Ctr, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA.
EM I-Chueh_Huang@hms.harvard.edu; farzan@hms.harvard.edu
RI Radoshitzky, Sheli S/F-2766-2019; Radoshitzky, Sheli/L-8410-2019;
   Denison, Mark/O-7258-2018; Kuhn, Jens H./B-7615-2011; Bavari,
   Sina/L-3642-2019
OI Radoshitzky, Sheli/0000-0001-8976-8056; Denison,
   Mark/0000-0003-2655-0900; Kuhn, Jens H./0000-0002-7800-6045; Bavari,
   Sina/0000-0001-8424-5635; Farzan, Michael/0000-0002-2990-5319
FU New England Regional Center for Excellence/Biodefense and Emerging
   Infectious Disease [U54 AI057159]; Burroughs Welcome FundBurroughs
   Wellcome Fund; Southeast Regional Center of Excellence for Emerging
   Infections and BiodefenseUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U54 AI057157]
FX This work was supported by the New England Regional Center for
   Excellence/Biodefense and Emerging Infectious Disease (U54 AI057159), by
   the Burroughs Welcome Fund, and by Southeast Regional Center of
   Excellence for Emerging Infections and Biodefense (U54 AI057157). The
   content of this publication does not necessarily reflect the views or
   policies of the US Department of Health and Human Services, the US
   Department of Defense, the US Department of the Army or the institutions
   and companies affiliated with the authors. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Becker MM, 2008, P NATL ACAD SCI USA, V105, P19944, DOI 10.1073/pnas.0808116105
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bieniasz PD, 2004, NAT IMMUNOL, V5, P1109, DOI 10.1038/ni1125
   Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017
   Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656
   Chen C, 2008, P NATL ACAD SCI USA, V105, P11790, DOI 10.1073/pnas.0803711105
   FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   Huang IC, 2008, J VIROL, V82, P4834, DOI 10.1128/JVI.00079-08
   Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200
   Kuhn JH, 2006, J BIOL CHEM, V281, P15951, DOI 10.1074/jbc.M601796200
   Lange U C, 2003, BMC Dev Biol, V3, P1, DOI 10.1186/1471-213X-3-1
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Matsuyama S, 2005, P NATL ACAD SCI USA, V102, P12543, DOI 10.1073/pnas.0503203102
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Moffatt P, 2008, J BONE MINER RES, V23, P1497, DOI 10.1359/JBMR.080412
   Mpanju OM, 2006, VIRUS RES, V121, P205, DOI 10.1016/j.virusres.2006.06.002
   Radoshitzky SR, 2007, NATURE, V446, P92, DOI 10.1038/nature05539
   Schornberg K, 2006, J VIROL, V80, P4174, DOI 10.1128/JVI.80.8.4174-4178.2006
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531
   Stiasny K, 2006, J GEN VIROL, V87, P2755, DOI 10.1099/vir.0.82210-0
   Tanaka SS, 2005, DEV CELL, V9, P745, DOI 10.1016/j.devcel.2005.10.010
   Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629
   WONG AC, J VIROL, V84, P163
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
NR 26
TC 243
Z9 262
U1 9
U2 58
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD JAN
PY 2011
VL 7
IS 1
AR e1001258
DI 10.1371/journal.ppat.1001258
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 712GL
UT WOS:000286654100015
PM 21253575
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Zhong, NS
   Zheng, BJ
   Li, YM
   Poon, LLM
   Xie, ZH
   Chan, KH
   Li, PH
   Tan, SY
   Chang, Q
   Xie, JP
   Liu, XQ
   Xu, J
   Li, DX
   Yuen, KY
   Peiris, JSM
   Guan, Y
AF Zhong, NS
   Zheng, BJ
   Li, YM
   Poon, LLM
   Xie, ZH
   Chan, KH
   Li, PH
   Tan, SY
   Chang, Q
   Xie, JP
   Liu, XQ
   Xu, J
   Li, DX
   Yuen, KY
   Peiris, JSM
   Guan, Y
TI Epidemiology and cause of severe acute respiratory syndrome (SARS) in
   Guangdong, People's Republic of China, in February, 2003
SO LANCET
LA English
DT Article
ID HONG-KONG; CORONAVIRUS
AB Background An epidemic of severe acute respiratory syndrome (SARS) has been associated with an outbreak of atypical pneumonia originating in Guangdong Province, People's Republic of China. We aimed to identify the causative agent in the Guangdong outbreak and describe the emergence and spread of the disease within the province.
   Methods We analysed epidemiological information and collected serum and nasopharyngeal aspirates from patients with SARS in Guangdong in mid-February, 2003. We did virus isolation, serological tests, and molecular assays to identify the causative agent.
   Findings SARS had been circulating in other cities of Guangdong Province for about 2 months before causing a major outbreak in Guangzhou, the province's capital. A novel coronavirus, SARS coronavirus (CoV), was isolated from specimens from three patients with SARS. Viral antigens were also directly detected in nasopharyngeal aspirates from these patients. 48 of 55 (87%) patients had antibodies to SARS CoV in their convalescent sera. Genetic analysis showed that the SARS CoV isolates from Guangzhou shared the same origin with those in other countries, and had a phylogenetic pathway that matched the spread of SARS to the other parts of the world.
   Interpretation SARS CoV is the infectious agent responsible for the epidemic outbreak of SARS in Guangdong. The virus isolated from patients in Guangdong is the prototype of the SARS CoV in other regions and countries.
C1 Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Guangzhou Med Coll, Guangzhou Inst Resp Dis, Guangzhou, Guangdong Prov, Peoples R China.
   Guangzhou Chest Hosp, Guangzhou, Guangdong Prov, Peoples R China.
   Guangzhou Childrens Hosp, Guangzhou, Guangdong Prov, Peoples R China.
RP Guan, Y (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Univ Pathol Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
RI Poon, Leo/C-4382-2009; Yuen, Kwok Yung/C-4465-2009; Peiris, Joseph
   Sriyal Malik/C-4380-2009
OI Poon, Leo/0000-0002-9101-7953; li, yimin/0000-0003-0810-5256; Peiris,
   Joseph Sriyal Malik/0000-0001-8217-5995; Yuen,
   Kwok-yung/0000-0002-2083-1552
FU PHS HHSUnited States Public Health Service [A195357]
CR DEJONG JC, 1997, NATURE, V389, P544
   Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151
   Guan Y, 2002, P NATL ACAD SCI USA, V99, P8950, DOI 10.1073/pnas.132268999
   *GUANGD PUBL HLTH, 2003, 2 GUANGD PUBL HLTH O
   HOLLAND JJ, 1991, J VIROL, V65, P1960
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   [彭国文 Peng Guowen], 2003, [中华流行病学杂志, Chinese Journal of Epidemiology], V24, P350
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Severe acute respiratory syndrome (SARS), 2003, WKLY EPIDEMIOL REC, V78, P81
   SHORTRIDGE KF, 1982, LANCET, V2, P812
   Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   World Health Organization, CUM NUMB REP PROB CA
   World Health Organization, CAS DEF SURV SEV AC
   2003, MMWR MORB MORT WKL R, V52, P241
NR 20
TC 242
Z9 261
U1 28
U2 114
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD OCT 25
PY 2003
VL 362
IS 9393
BP 1353
EP 1358
DI 10.1016/S0140-6736(03)14630-2
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 735YX
UT WOS:000186143300008
PM 14585636
OA Bronze
DA 2020-04-03
ER

PT J
AU Radoshitzky, SR
   Abraham, J
   Spiropoulou, CF
   Kuhn, JH
   Nguyen, D
   Li, WH
   Nagel, J
   Schmidt, PJ
   Nunberg, JH
   Andrews, NC
   Farzan, M
   Choe, H
AF Radoshitzky, Sheli R.
   Abraham, Jonathan
   Spiropoulou, Christina F.
   Kuhn, Jens H.
   Nguyen, Dan
   Li, Wenhui
   Nagel, Jane
   Schmidt, Paul J.
   Nunberg, Jack H.
   Andrews, Nancy C.
   Farzan, Michael
   Choe, Hyeryun
TI Transferrin receptor 1 is a cellular receptor for New World haemorrhagic
   fever arenaviruses
SO NATURE
LA English
DT Article
ID LYMPHOCYTIC CHORIOMENINGITIS VIRUS; ANGIOTENSIN-CONVERTING ENZYME-2;
   ALPHA-DYSTROGLYCAN; SARS CORONAVIRUS; CELLS; ENDOTHELIUM; JUNIN;
   ANTIBODIES; BIOLOGY; BINDING
AB At least five arenaviruses cause viral haemorrhagic fevers in humans. Lassa virus, an Old World arenavirus, uses the cellular receptor alpha-dystroglycan to infect cells(1). Machupo, Guanarito, Junin and Sabia viruses are New World haemorrhagic fever viruses that do not use alpha-dystroglycan(2). Here we show a specific, high-affinity association between transferrin receptor 1 (TfR1) and the entry glycoprotein ( GP) of Machupo virus. Expression of human TfR1, but not human transferrin receptor 2, in hamster cell lines markedly enhanced the infection of viruses pseudotyped with the GP of Machupo, Guanarito and Junin viruses, but not with those of Lassa or lymphocytic choriomeningitis viruses. An anti-TfR1 antibody efficiently inhibited the replication of Machupo, Guanarito, Junin and Sabia viruses, but not that of Lassa virus. Iron depletion of culture medium enhanced, and iron supplementation decreased, the efficiency of infection by Junin and Machupo but not Lassa pseudoviruses. These data indicate that TfR1 is a cellular receptor for New World haemorrhagic fever arenaviruses.
C1 Harvard Univ, Sch Med, Dept Pediat, Childrens Hosp,Pulm Div, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, New England Primate Res Ctr, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA.
   Ctr Dis Control & Prevent, Special Pathogens Branch, Atlanta, GA 30333 USA.
   Free Univ Berlin, Dept Biol Chem Pharm, D-14195 Berlin, Germany.
   Harvard Univ, Sch Med, Dept Pediat, Childrens Hosp,Div Hematol Oncol, Boston, MA 02115 USA.
   Univ Montana, Montana Biotechnol Ctr, Missoula, MT 59812 USA.
RP Choe, H (reprint author), Harvard Univ, Sch Med, Dept Pediat, Childrens Hosp,Pulm Div, Boston, MA 02115 USA.
EM hyeryun.choe@childrens.harvard.edu
RI Radoshitzky, Sheli S/F-2766-2019; Radoshitzky, Sheli/L-8410-2019; Kuhn,
   Jens H./B-7615-2011
OI Radoshitzky, Sheli/0000-0001-8976-8056; Kuhn, Jens
   H./0000-0002-7800-6045; Li, Wenhui/0000-0003-1305-7404; Farzan,
   Michael/0000-0002-2990-5319; Andrews, Nancy/0000-0003-0243-4462
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI074879]; NIGMS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS) [T32
   GM007753]
CR ANDERSON GJ, 1990, GASTROENTEROLOGY, V98, P576, DOI 10.1016/0016-5085(90)90276-7
   Andrews N C, 1999, Curr Opin Hematol, V6, P61, DOI 10.1097/00062752-199903000-00001
   Borio L, 2002, JAMA-J AM MED ASSOC, V287, P2391, DOI 10.1001/jama.287.18.2391
   BUCHMEIER MJ, 1987, J VIROL, V61, P982, DOI 10.1128/JVI.61.4.982-985.1987
   BURNS JW, 1991, VIROLOGY, V183, P620, DOI 10.1016/0042-6822(91)90991-J
   Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079
   Castilla V, 1996, ARCH VIROL, V141, P1307, DOI 10.1007/BF01718832
   Charrel RN, 2003, ANTIVIR RES, V57, P89, DOI 10.1016/S0166-3542(02)00202-4
   Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010
   JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0
   Kasvosve I, 2002, CLIN CHEM LAB MED, V40, P1014, DOI 10.1515/CCLM.2002.176
   Kunz S, 2005, J VIROL, V79, P5979, DOI 10.1128/JVI.79.10.5979-5987.2005
   Kunz S, 2002, CURR TOP MICROBIOL, V262, P111
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   MATTIA E, 1984, J BIOL CHEM, V259, P2689
   MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207
   Oldstone MBA, 2002, CURR TOP MICROBIOL, V263, pV
   Oldstone MBA, 2002, CURR TOP MICROBIOL, V262, pV
   Parker JSL, 2001, J VIROL, V75, P3896, DOI 10.1128/JVI.75.8.3896-3902.2001
   Peters CJ, 2002, CRIT CARE MED, V30, pS268, DOI 10.1097/00003246-200205001-00016
   Raya G, 2001, CLIN CHEM LAB MED, V39, P1162, DOI 10.1515/CCLM.2001.183
   Reignier T, 2006, VIROLOGY, V353, P111, DOI 10.1016/j.virol.2006.05.018
   Rojek JM, 2006, VIROLOGY, V349, P476, DOI 10.1016/j.virol.2006.02.033
   Ross SR, 2002, P NATL ACAD SCI USA, V99, P12386, DOI 10.1073/pnas.192360099
   SODA R, 1984, BLOOD, V63, P270
   Spiropoulou CF, 2002, J VIROL, V76, P5140, DOI 10.1128/JVI.76.10.5140-5146.2002
   Templeton DM, 2003, BBA-GEN SUBJECTS, V1619, P113, DOI 10.1016/S0304-4165(02)00497-X
   WARD JH, 1982, J BIOL CHEM, V257, P317
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   York J, 2006, J VIROL, V80, P7775, DOI 10.1128/JVI.00642-06
NR 30
TC 240
Z9 249
U1 1
U2 27
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAR 1
PY 2007
VL 446
IS 7131
BP 92
EP 96
DI 10.1038/nature05539
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 140RY
UT WOS:000244525600044
PM 17287727
OA Green Accepted
DA 2020-04-03
ER

PT J
AU STURMAN, LS
   HOLMES, KV
   BEHNKE, J
AF STURMAN, LS
   HOLMES, KV
   BEHNKE, J
TI ISOLATION OF CORONAVIRUS ENVELOPE GLYCOPROTEINS AND INTERACTION WITH THE
   VIRAL NUCLEOCAPSID
SO JOURNAL OF VIROLOGY
LA English
DT Article
C1 UNIFORMED SERV UNIV HLTH SCI, DEPT PATHOL, BETHESDA, MD 20014 USA.
RP STURMAN, LS (reprint author), NEW YORK STATE DEPT HLTH, DIV LABS & RES, ALBANY, NY 12201 USA.
CR BINGHAM RW, 1975, ARCH VIROL, V49, P207, DOI 10.1007/BF01317539
   Birnie G D, 1978, Methods Cell Biol, V18, P23
   BOND CW, 1979, VIROLOGY, V94, P371, DOI 10.1016/0042-6822(79)90468-9
   BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x
   BURKE DJ, 1976, J VIROL, V20, P676, DOI 10.1128/JVI.20.3.676-686.1976
   CALIGUIRI LA, 1978, VIROLOGY, V90, P119, DOI 10.1016/0042-6822(78)90339-2
   CALLEBAUT PE, 1978, INT VIROLOGY, V4, P452
   CARTWRIG.B, 1970, J GEN VIROL, V7, P19, DOI 10.1099/0022-1317-7-1-19
   CAUL EO, 1979, FEMS MICROBIOL LETT, V5, P101, DOI 10.1111/j.1574-6968.1979.tb03256.x
   CHAN RTL, 1974, J CELL BIOL, V61, P780, DOI 10.1083/jcb.61.3.780
   COLLINS MS, 1976, ARCH VIROL, V50, P55, DOI 10.1007/BF01318001
   DALRYMPL.JM, 1973, J VIROL, V12, P1034, DOI 10.1128/JVI.12.5.1034-1042.1973
   DALRYMPLE JM, 1976, VIROLOGY, V69, P93, DOI 10.1016/0042-6822(76)90197-5
   EMERSON SU, 1972, J VIROL, V10, P297, DOI 10.1128/JVI.10.2.297-309.1972
   GAROFF H, 1974, VIROLOGY, V62, P385, DOI 10.1016/0042-6822(74)90400-0
   GARWES DJ, 1975, J GEN VIROL, V29, P25, DOI 10.1099/0022-1317-29-1-25
   GARWES DJ, 1976, J GEN VIROL, V32, P283, DOI 10.1099/0022-1317-32-2-283
   GYORGY E, 1971, J VIROL, V8, P649
   HAJER I, 1979, ARCH VIROL, V59, P47, DOI 10.1007/BF01317894
   HELENIUS A, 1976, BIOCHIM BIOPHYS ACTA, V436, P895, DOI 10.1016/0005-2736(76)90421-1
   HELENIUS A, 1973, BIOCHIM BIOPHYS ACTA, V307, P287, DOI 10.1016/0005-2736(73)90096-5
   HELENIUS A, 1972, J BIOL CHEM, V247, P3656
   HIERHOLZER JC, 1972, VIROLOGY, V48, P516, DOI 10.1016/0042-6822(72)90062-1
   HIERHOLZER JC, 1976, VIROLOGY, V75, P155, DOI 10.1016/0042-6822(76)90014-3
   KENNEDY DA, 1976, INTERVIROLOGY, V6, P197
   KESSLER SW, 1975, J IMMUNOL, V115, P1617
   LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978
   LANSER JA, 1978, INT VIROLOGY, V4, P454
   LAPORTE J, 1978, INT VIROLOGY, V4, P454
   MACNAUGHTON MR, 1977, ARCH VIROL, V55, P47, DOI 10.1007/BF01314478
   MACNAUGHTON MR, 1978, INT VIROLOGY, V4, P448
   MAKINO S, 1973, J BIOL CHEM, V248, P4926
   OBERT G, 1978, INT VIROLOGY, V4, P455
   OSHIRO LS, 1973, ULTRASTRUCTURE ANIMA, P331
   POCOCK DH, 1977, J GEN VIROL, V37, P487, DOI 10.1099/0022-1317-37-3-487
   ROBINSON NC, 1977, BIOCHEMISTRY-US, V16, P375, DOI 10.1021/bi00622a006
   ROBINSON NC, 1975, BIOCHEMISTRY-US, V14, P369, DOI 10.1021/bi00673a025
   SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1
   SCHEID A, 1973, J VIROL, V11, P263, DOI 10.1128/JVI.11.2.263-271.1973
   SCHEID A, 1972, VIROLOGY, V50, P640, DOI 10.1016/0042-6822(72)90418-7
   SCHOCHETMAN G, 1977, VIROLOGY, V77, P772, DOI 10.1016/0042-6822(77)90498-6
   SIMONS K, 1973, J MOL BIOL, V80, P119, DOI 10.1016/0022-2836(73)90236-2
   STROMBERG K, 1972, J VIROL, V9, P684, DOI 10.1128/JVI.9.4.684-697.1972
   STURMAN LS, 1977, VIROLOGY, V77, P650, DOI 10.1016/0042-6822(77)90489-5
   STURMAN LS, 1977, VIROLOGY, V77, P637, DOI 10.1016/0042-6822(77)90488-3
   STURMAN LS, 1972, INFECT IMMUN, V6, P501, DOI 10.1128/IAI.6.4.501-507.1972
   WEGE H, 1979, J GEN VIROL, V42, P37, DOI 10.1099/0022-1317-42-1-37
   WEGE H, 1978, J GEN VIROL, V41, P217, DOI 10.1099/0022-1317-41-2-217
   ZIEMIECKI A, 1978, J MOL BIOL, V122, P259, DOI 10.1016/0022-2836(78)90189-4
NR 49
TC 240
Z9 246
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PY 1980
VL 33
IS 1
BP 449
EP 462
DI 10.1128/JVI.33.1.449-462.1980
PG 14
WC Virology
SC Virology
GA JB835
UT WOS:A1980JB83500043
PM 6245243
OA Bronze
DA 2020-04-03
ER

PT J
AU Warren, TK
   Wells, J
   Panchal, RG
   Stuthman, KS
   Garza, NL
   Van Tongeren, SA
   Dong, L
   Retterer, CJ
   Eaton, BP
   Pegoraro, G
   Honnold, S
   Bantia, S
   Kotian, P
   Chen, XL
   Taubenheim, BR
   Welch, LS
   Minning, DM
   Babu, YS
   Sheridan, WP
   Bavari, S
AF Warren, Travis K.
   Wells, Jay
   Panchal, Rekha G.
   Stuthman, Kelly S.
   Garza, Nicole L.
   Van Tongeren, Sean A.
   Dong, Lian
   Retterer, Cary J.
   Eaton, Brett P.
   Pegoraro, Gianluca
   Honnold, Shelley
   Bantia, Shanta
   Kotian, Pravin
   Chen, Xilin
   Taubenheim, Brian R.
   Welch, Lisa S.
   Minning, Dena M.
   Babu, Yarlagadda S.
   Sheridan, William P.
   Bavari, Sina
TI Protection against filovirus diseases by a novel broad-spectrum
   nucleoside analogue BCX4430
SO NATURE
LA English
DT Article
ID SMALL-MOLECULE INHIBITOR; EBOLA-VIRUS INFECTION; NONHUMAN-PRIMATES;
   HEMORRHAGIC-FEVER; MARBURG-VIRUS; POSTEXPOSURE PROTECTION; ANTIVIRAL
   ACTIVITY; MOUSE MODEL; REPLICATION; CHALLENGE
AB Filoviruses are emerging pathogens and causative agents of viral haemorrhagic fever. Case fatality rates of filovirus disease outbreaks are among the highest reported for any human pathogen, exceeding 90% (ref. 1). Licensed therapeutic or vaccine products are not available to treat filovirus diseases. Candidate therapeutics previously shown to be efficacious in non-human primate disease models are based on virus-specific designs and have limited broad-spectrum antiviral potential. Here we show that BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells. Biochemical, reporter-based and primer-extension assays indicate that BCX4430 inhibits viral RNA polymerase function, acting as a non-obligate RNA chain terminator. Post-exposure intramuscular administration of BCX4430 protects against Ebola virus and Marburg virus disease in rodent models. Most importantly, BCX4430 completely protects cynomolgus macaques from Marburg virus infection when administered as late as 48 hours after infection. In addition, BCX4430 exhibits broad-spectrum antiviral activity against numerous viruses, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. This is the first report, to our knowledge, of non-human primate protection from filovirus disease by a synthetic drug-like small molecule. We provide additional pharmacological characterizations supporting the potential development of BCX4430 as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats.
C1 [Warren, Travis K.; Wells, Jay; Panchal, Rekha G.; Stuthman, Kelly S.; Garza, Nicole L.; Van Tongeren, Sean A.; Dong, Lian; Retterer, Cary J.; Eaton, Brett P.; Pegoraro, Gianluca; Honnold, Shelley; Welch, Lisa S.; Bavari, Sina] US Army Med Res Inst Infect Dis USAMRIID, Therapeut Discovery Ctr, Div Mol & Translat Sci, Ft Detrick, MD 21702 USA.
   [Bantia, Shanta; Kotian, Pravin; Chen, Xilin; Taubenheim, Brian R.; Babu, Yarlagadda S.; Sheridan, William P.] BioCryst Pharmaceut Inc, Durham, NC 27703 USA.
   [Minning, Dena M.] MedExpert Consulting Inc, Indialantic, FL 32903 USA.
RP Bavari, S (reprint author), US Army Med Res Inst Infect Dis USAMRIID, Therapeut Discovery Ctr, Div Mol & Translat Sci, Ft Detrick, MD 21702 USA.
EM sina.bavari.civ@mail.mil
RI Eaton, Brett/G-1796-2019; Bavari, Sina/L-3642-2019; Pegoraro,
   Gianluca/K-4233-2016; Panchal, Rekha/None
OI Eaton, Brett/0000-0002-3060-2913; Bavari, Sina/0000-0001-8424-5635;
   Pegoraro, Gianluca/0000-0003-2843-9464; Sheridan,
   William/0000-0001-8320-1323; Panchal, Rekha/0000-0001-8621-9078
FU Science and Technology Office for Chemical and Biological Defense of the
   Defense Threat Reduction Agency [TMTI0048_09_RD_T, CB3675]; National
   Institute of Allergy and Infectious Diseases (NIAID)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201100019I]; BioQual Inc. under NIAID [HHSN27220110005I];
   University of Alabama Birmingham under NIAID [HHSN272201100016I]
FX J. Kuhn and J. Huggins provided insightful discussions and critically
   reviewed the manuscript. R. Kincaid and G. Feuerstein provided advice
   and guidance for BCX4430 development efforts. These studies were in part
   supported by The Joint Science and Technology Office for Chemical and
   Biological Defense of the Defense Threat Reduction Agency (proposal
   #TMTI0048_09_RD_T and CB3675) to S. Bavari. S. Radoshitzky assisted with
   the EBOV minigenome replicon assay. J. Reifman was essential to
   algorithm development of HCI image assessments. C. Basler provided the
   BHK-21-derived cell line constitutively expressing the T7 RNA
   polymerase. Plasmids encoding viral products and the EBOV minigenome
   replicon were provided by P. Kranzusch and S. Whelan. Neutral-red uptake
   antiviral assays were conducted by: D. L. Barnard, G. W. Day, B. Gowan,
   J. G. Julander, B. Tarbet, D. F. Smee and J. D. Morrey of Utah State
   University under National Institute of Allergy and Infectious Diseases
   (NIAID) contract HHSN272201100019I, BioQual Inc. under NIAID contract
   HHSN27220110005I, and at the University of Alabama Birmingham under
   NIAID contract HHSN272201100016I. Cell-based metabolism studies were
   conducted by C. Parker, X. Cheng, R. Upshaw and Y. Luo. A. Nalca, E. E.
   Zumbrun, H. Bloomfield, D. Dyer and J. Yeager assisted with virus
   aerosolization. C. Cooper provided assistance with the culture of human
   macrophage cell culture and R. Zamani provided assistance with
   high-content image assessments. S. Tritsch assisted with Nipah virus
   antiviral assays. Opinions, interpretations, conclusions and
   recommendations are those of the authors and are not necessarily
   endorsed by the US Army.
CR Alves DA, 2010, VET PATHOL, V47, P831, DOI 10.1177/0300985810378597
   Aman MJ, 2009, ANTIVIR RES, V83, P245, DOI 10.1016/j.antiviral.2009.06.001
   Barnard DL, 2001, ANTIVIR CHEM CHEMOTH, V12, P241, DOI 10.1177/095632020101200405
   Bausch DG, 2007, J INFECT DIS, V196, pS142, DOI 10.1086/520545
   Bente D, 2009, DIS MODEL MECH, V2, P12, DOI 10.1242/dmm.000471
   Bray M, 1998, J INFECT DIS, V178, P651, DOI 10.1086/515386
   Bray M, 2002, ANTIVIR RES, V55, P151, DOI 10.1016/S0166-3542(02)00018-9
   Bray M, 2000, ANTIVIR RES, V45, P135, DOI 10.1016/S0166-3542(00)00066-8
   Dye JM, 2012, P NATL ACAD SCI USA, V109, P5034, DOI 10.1073/pnas.1200409109
   Geisbert TW, 2010, LANCET, V375, P1896, DOI 10.1016/S0140-6736(10)60357-1
   Geisbert TW, 2008, VACCINE, V26, P6894, DOI 10.1016/j.vaccine.2008.09.082
   Hevey M, 1998, VIROLOGY, V251, P28, DOI 10.1006/viro.1998.9367
   HUGGINS JW, 1989, REV INFECT DIS, V11, pS750
   Kinch MS, 2009, AM J TRANSL RES, V1, P87
   Kobinger GP, 2011, J INFECT DIS, V204, P200, DOI 10.1093/infdis/jir077
   Kortepeter MG, 2011, J INFECT DIS, V204, pS810, DOI 10.1093/infdis/jir299
   KUHN JH, 2008, FILOVIRUSES COMPENDI
   Lou H, 2003, VIROLOGY, V317, P65, DOI 10.1016/j.virol.2003.08.038
   Muhlberger E, 1999, J VIROL, V73, P2333
   Panchal RG, 2012, ANTIVIR RES, V93, P23, DOI 10.1016/j.antiviral.2011.10.011
   Panchal RG, 2010, J BIOMOL SCREEN, V15, P755, DOI 10.1177/1087057110374357
   SMITH DH, 1982, LANCET, V1, P816
   Smither S. J., 2014, ANTIVIRAL RES
   Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108
   Towner JS, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000212
   Warfield KL, 2007, J INFECT DIS, V196, pS430, DOI 10.1086/520583
   Warfield KL, 2009, J VIROL, V83, P6404, DOI 10.1128/JVI.00126-09
   Warren TK, 2010, NAT MED, V16, P991, DOI 10.1038/nm.2202
   Warren TK, 2010, ANTIMICROB AGENTS CH, V54, P2152, DOI 10.1128/AAC.01315-09
NR 29
TC 237
Z9 258
U1 11
U2 140
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD APR 17
PY 2014
VL 508
IS 7496
BP 402
EP +
DI 10.1038/nature13027
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AF0KP
UT WOS:000334403000053
PM 24590073
OA Green Published
HC Y
HP N
DA 2020-04-03
ER

PT J
AU BRIERLEY, I
   BOURSNELL, MEG
   BINNS, MM
   BILIMORIA, B
   BLOK, VC
   BROWN, TDK
   INGLIS, SC
AF BRIERLEY, I
   BOURSNELL, MEG
   BINNS, MM
   BILIMORIA, B
   BLOK, VC
   BROWN, TDK
   INGLIS, SC
TI AN EFFICIENT RIBOSOMAL FRAME-SHIFTING SIGNAL IN THE POLYMERASE-ENCODING
   REGION OF THE CORONAVIRUS IBV
SO EMBO JOURNAL
LA English
DT Article
C1 HOUGHTON POULTRY RES STN,HUNTINGDON PE17 2DA,CAMBS,ENGLAND.
RP BRIERLEY, I (reprint author), UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.
OI Boursnell, Mike/0000-0002-2554-8190
CR ANDERSON SJ, 1979, J VIROL, V32, P507, DOI 10.1128/JVI.32.2.507-516.1979
   ATKINS JF, 1983, EMBO J, V2, P1345, DOI 10.1002/j.1460-2075.1983.tb01590.x
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BRAYTON PR, 1982, J VIROL, V42, P847, DOI 10.1128/JVI.42.3.847-853.1982
   BROWN TDK, 1984, J GEN VIROL, V65, P1437, DOI 10.1099/0022-1317-65-8-1437
   CLARE J, 1985, P NATL ACAD SCI USA, V82, P2829, DOI 10.1073/pnas.82.9.2829
   CRAIGEN WJ, 1987, CELL, V50, P1, DOI 10.1016/0092-8674(87)90652-0
   DICKSON C, 1979, CELL, V17, P1003, DOI 10.1016/0092-8674(79)90339-8
   DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4
   ENDERS GH, 1985, CELL, V42, P297, DOI 10.1016/S0092-8674(85)80125-2
   FOX TD, 1980, NATURE, V288, P60, DOI 10.1038/288060a0
   Hames BD, 1981, GEL ELECTROPHORESIS, P1
   HAMILTON WDO, 1987, IN PRESS J GEN VIROL
   HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8
   HUNT T, 1974, MODERN TRENDS HUMAN, P300
   INGLIS SC, 1977, VIROLOGY, V78, P522, DOI 10.1016/0042-6822(77)90128-3
   JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298
   JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054
   JACOBSON AB, 1984, NUCLEIC ACIDS RES, V12, P54
   KOHNO T, 1978, J MOL BIOL, V126, P37, DOI 10.1016/0022-2836(78)90278-4
   LAI MMC, 1983, J VIROL, V46, P1027, DOI 10.1128/JVI.46.3.1027-1033.1983
   LIEBOWITZ JL, 1981, VIROLOGY, V114, P39
   LOPEZ S, 1985, VIROLOGY, V141, P235, DOI 10.1016/0042-6822(85)90254-5
   MANIATIS T, 1982, MOL CLONING LABORATO
   MELLOR J, 1985, NATURE, V313, P243, DOI 10.1038/313243a0
   MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035
   MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987
   MORCH MD, 1980, EUR J BIOCHEM, V105, P445, DOI 10.1111/j.1432-1033.1980.tb04519.x
   OPPERMANN H, 1977, CELL, V12, P993, DOI 10.1016/0092-8674(77)90164-7
   PELHAM HRB, 1978, NATURE, V272, P469, DOI 10.1038/272469a0
   PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x
   RICE NR, 1985, VIROLOGY, V142, P357, DOI 10.1016/0042-6822(85)90344-7
   ROTH JR, 1981, CELL, V24, P601, DOI 10.1016/0092-8674(81)90086-6
   SAIGO K, 1984, NATURE, V312, P659, DOI 10.1038/312659a0
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHOCHETMAN G, 1977, VIROLOGY, V77, P772, DOI 10.1016/0042-6822(77)90498-6
   SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761
   STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x
   STERN DF, 1980, J VIROL, V36, P440, DOI 10.1128/JVI.36.2.440-449.1980
   STERN DF, 1980, J VIROL, V34, P665, DOI 10.1128/JVI.34.3.665-674.1980
   STRAUSS EG, 1983, P NATL ACAD SCI-BIOL, V80, P5271, DOI 10.1073/pnas.80.17.5271
   YOSHINAKA Y, 1986, J VIROL, V57, P826, DOI 10.1128/JVI.57.3.826-832.1986
   YOSHINAKA Y, 1985, P NATL ACAD SCI USA, V82, P1618, DOI 10.1073/pnas.82.6.1618
   YOSHINAKA Y, 1985, J VIROL, V55, P870, DOI 10.1128/JVI.55.3.870-873.1985
   YOUNG JF, 1983, ORIGIN PANDEMIC INFL, P129
NR 45
TC 237
Z9 241
U1 0
U2 1
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0261-4189
J9 EMBO J
JI Embo J.
PD DEC
PY 1987
VL 6
IS 12
BP 3779
EP 3785
DI 10.1002/j.1460-2075.1987.tb02713.x
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA K9486
UT WOS:A1987K948600030
PM 3428275
DA 2020-04-03
ER

PT J
AU Sir, D
   Chen, WL
   Choi, J
   Wakita, T
   Yen, TSB
   Ou, JHJ
AF Sir, Donna
   Chen, Wen-ling
   Choi, Jinah
   Wakita, Takaji
   Yen, T. S. Benedict
   Ou, Jing-hsiung James
TI Induction of incomplete autophagic response by hepatitis C virus via the
   unfolded protein response
SO HEPATOLOGY
LA English
DT Article
ID HUMAN HEPATOMA-CELLS; ER STRESS; REPLICATION COMPLEX; CELLULAR
   AUTOPHAGY; CORONAVIRUS; CULTURE; DEATH; LC3
AB Autophagy is important for cellular homeostasis and can serve as innate immunity to remove intracellular pathogens. Here, we demonstrate by a battery of morphological and biochemical assays that hepatitis C virus (HCV) induces the accumulation of autophagosomes in cells without enhancing autophagic protein degradation. This induction of autophagosomes depended on the unfolded protein response (UPR), as the suppression of UPR signaling pathways suppressed HCV-induced lipidation of the microtubule-associated protein light chain 3 (LC3) protein, a necessary step for the formation of autophagosomes. The suppression of UPR or the suppression of expression of LC3 or Atg7, a protein that mediates LC3 lipidation, suppressed HCV replication, indicating a positive role of UPR and the incomplete autophagic response in HCV replication. Conclusion: Our studies delineate the molecular pathway by which HCV induces autophagic vacuoles and also demonstrate the perturbation of the autophagic response by HCV. These unexpected effects of HCV on the host cell likely play an important role in HCV pathogenesis.
C1 [Sir, Donna; Chen, Wen-ling; Choi, Jinah; Ou, Jing-hsiung James] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
   [Wakita, Takaji] Natl Inst Infect Dis, Dept Virol 2, Shinju Ku, Tokyo, Japan.
   [Yen, T. S. Benedict] Univ Calif San Francisco, Vet Affairs Med Ctr, Pathol Serv, San Francisco, CA 94143 USA.
   [Yen, T. S. Benedict] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA.
RP Ou, JHJ (reprint author), Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
EM jamesou@hsc.usc.edu
FU PHSUnited States Public Health Service [A1060559, P30DK26743]; VA Merit
   ReviewUS Department of Veteran Affairs
FX Supported by PHS grants (A1060559 to J.O. and P30DK26743 to the UCSF
   Liver Center) and a VA Merit Review grant (to T.S.B.Y).
CR Ait-Goughoulte M, 2008, J VIROL, V82, P2241, DOI 10.1128/JVI.02093-07
   Benali-Furet NL, 2005, ONCOGENE, V24, P4921, DOI 10.1038/sj.onc.1208673
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Cai ZH, 2005, J VIROL, V79, P13963, DOI 10.1128/JVI.79.22.13963-13973.2005
   Chan SW, 2005, FASEB J, V19, P1510, DOI 10.1096/fj.04-3455fje
   Choi JN, 2004, HEPATOLOGY, V39, P81, DOI 10.1002/hep.20001
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   LEE HK, 2008, CURR OPIN IMMUNOL
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liberman E, 1999, J VIROL, V73, P3718, DOI 10.1128/JVI.73.5.3718-3722.1999
   Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016
   Moradpour D, 2007, NAT REV MICROBIOL, V5, P453, DOI 10.1038/nrmicro1645
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Shang J, 2007, J CELL BIOL, V176, P605, DOI 10.1083/jcb.200607007
   Tardif KD, 2004, J BIOL CHEM, V279, P17158, DOI 10.1074/jbc.M312144200
   Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yoshida H, 2006, J CELL BIOL, V172, P565, DOI 10.1083/jcb.200508145
   Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102
   Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524
NR 28
TC 236
Z9 246
U1 2
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2008
VL 48
IS 4
BP 1054
EP 1061
DI 10.1002/hep.22464
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 356CT
UT WOS:000259757000006
PM 18688877
OA Green Accepted
DA 2020-04-03
ER

PT J
AU Zumla, A
   Hui, DS
   Perlman, S
AF Zumla, Alimuddin
   Hui, David S.
   Perlman, Stanley
TI Middle East respiratory syndrome
SO LANCET
LA English
DT Article
ID SYNDROME CORONAVIRUS INFECTION; CRITICALLY-ILL PATIENTS; TO-HUMAN
   TRANSMISSION; MERS-COV; SAUDI-ARABIA; DROMEDARY CAMELS; NEUTRALIZING
   ANTIBODIES; FUNCTIONAL RECEPTOR; IMMUNE-RESPONSES; CLINICAL-ASPECTS
AB Middle East respiratory syndrome (MERS) is a highly lethal respiratory disease caused by a novel single-stranded, positive-sense RNA betacoronavirus (MERS-CoV). Dromedary camels, hosts for MERS-CoV, are implicated in direct or indirect transmission to human beings, although the exact mode of transmission is unknown. The virus was first isolated from a patient who died from a severe respiratory illness in June, 2012, in Jeddah, Saudi Arabia. As of May 31, 2015, 1180 laboratory-confirmed cases (483 deaths; 40% mortality) have been reported to WHO. Both community-acquired and hospital-acquired cases have been reported with little human-to-human transmission reported in the community. Although most cases of MERS have occurred in Saudi Arabia and the United Arab Emirates, cases have been reported in Europe, the USA, and Asia in people who travelled from the Middle East or their contacts. Clinical features of MERS range from asymptomatic or mild disease to acute respiratory distress syndrome and multiorgan failure resulting in death, especially in individuals with underlying comorbidities. No specific drug treatment exists for MERS and infection prevention and control measures are crucial to prevent spread in health-care facilities. MERS-CoV continues to be an endemic, low-level public health threat. However, the virus could mutate to have increased interhuman transmissibility, increasing its pandemic potential.
C1 [Zumla, Alimuddin] UCL, Div Infect & Immun, London, England.
   [Zumla, Alimuddin] UCL Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Hui, David S.] Chinese Univ Hong Kong, Prince Wales Hosp, Div Resp Med, Hong Kong, Hong Kong, Peoples R China.
   [Hui, David S.] Chinese Univ Hong Kong, Prince Wales Hosp, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Perlman, Stanley] Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.
   [Perlman, Stanley] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
RP Perlman, S (reprint author), Univ Iowa, Dept Microbiol, BSB 3-712, Iowa City, IA 52242 USA.
EM stanley-perlman@uiowa.edu
OI Hui, David/0000-0003-4382-2445; Zumla, Alimuddin/0000-0002-5111-5735;
   Perlman, Stanley/0000-0003-4213-2354
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI091322, AI060699]
FX AZ, DSH, and SP have served MERS-CoV expert advisory groups and
   participated in the deliberations on MERS-CoV at Global Centre for Mass
   Gatherings Medicine Conferences, Riyadh, Saudi Arabia. SP was supported
   in part by grants from the National Institutes of Health (AI091322,
   AI060699). We thank Dr Yaseen Arabi and Dr Abdullah Assiri for critical
   review of the report.
CR Abroug F, 2014, EMERG INFECT DIS, V20, P1527, DOI 10.3201/eid2009.140378
   Aburizaiza AS, 2014, J INFECT DIS, V209, P243, DOI 10.1093/infdis/jit589
   Adney DR, 2014, EMERG INFECT DIS, V20, P1999, DOI 10.3201/eid2012.141280
   Agrawal AS, 2015, J VIROL, V89, P3659, DOI 10.1128/JVI.03427-14
   Ajlan AM, 2014, AM J ROENTGENOL, V203, P782, DOI 10.2214/AJR.14.13021
   Al-Abdallat MM, 2014, CLIN INFECT DIS, V59, P1225, DOI 10.1093/cid/ciu359
   Al-Tawfiq JA, 2014, INT J INFECT DIS, V27, P26, DOI 10.1016/j.ijid.2014.07.001
   Al-Tawfiq JA, 2014, CLIN INFECT DIS, V59, P160, DOI 10.1093/cid/ciu226
   Al-Tawfiq JA, 2014, INT J INFECT DIS, V20, P42, DOI 10.1016/j.ijid.2013.12.003
   Almazan F, 2013, MBIO, V4, DOI 10.1128/mBio.00650-13
   [Anonymous], 2014, INT INF PREV CONTR R
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Barlan A, 2014, J VIROL, V88, P4953, DOI 10.1128/JVI.00161-14
   Bergmann CC, 2006, NAT REV MICROBIOL, V4, P121, DOI 10.1038/nrmicro1343
   Briese T, 2014, MBIO, V5, DOI 10.1128/mBio.01146-14
   Cameron MJ, 2007, J VIROL, V81, P8692, DOI 10.1128/JVI.00527-07
   CDC, 2014, MIDDL E RESP SYNDR M
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Chan RWY, 2013, J VIROL, V87, P6604, DOI 10.1128/JVI.00009-13
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Choi KW, 2003, ANN INTERN MED, V139, P715, DOI 10.7326/0003-4819-139-9-200311040-00005
   Chowell G, 2014, EPIDEMICS-NETH, V9, P40, DOI 10.1016/j.epidem.2014.09.011
   Christian MD, 2004, CLIN INFECT DIS, V38, P1420, DOI 10.1086/420743
   Chu H, 2014, VIROLOGY, V454, P197, DOI 10.1016/j.virol.2014.02.018
   Corman VM, 2014, EMERG INFECT DIS, V20, P1319, DOI 10.3201/eid2008.140596
   Corman VM, 2014, J VIROL, V88, P11297, DOI 10.1128/JVI.01498-14
   Corman VM, 2014, J VIROL, V88, P717, DOI 10.1128/JVI.01600-13
   Corman VM, 2012, EURO SURVEILL, V17
   Cotten M, 2014, MBIO, V5, DOI 10.1128/mBio.01062-13
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   de Wit E, 2013, P NATL ACAD SCI USA, V110, P16598, DOI 10.1073/pnas.1310744110
   Drosten C, 2015, CLIN INFECT DIS, V60, P369, DOI 10.1093/cid/ciu812
   Drosten C, 2014, NEW ENGL J MED, V371, P828, DOI 10.1056/NEJMoa1405858
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Falzarano D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004250
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   Fowler RA, 2003, JAMA-J AM MED ASSOC, V290, P367, DOI 10.1001/jama.290.3.367
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gossner C, 2016, ZOONOSES PUBLIC HLTH, V63, P1, DOI 10.1111/zph.12171
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Hemida MG, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.23.20828
   Hemida MG, 2015, EMERG INFECT DIS, V21, P699, DOI 10.3201/eid2104.141949
   Hui DS, 2014, CURR OPIN PULM MED, V20, P233, DOI 10.1097/MCP.0000000000000046
   ISARIC PHE, TREATM MERS COV INF
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Jiang LW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008140
   Kindler E, 2013, MBIO, V4, DOI 10.1128/mBio.00611-12
   Lambeir AM, 2003, CRIT REV CL LAB SCI, V40, P209, DOI 10.1080/713609354
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Madani TA, 2014, LANCET INFECT DIS, V14, P911, DOI 10.1016/S1473-3099(14)70918-1
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Masters P.S., 2013, FIELDS VIROLOGY, P825
   Matthews KL, 2014, J GEN VIROL, V95, P874, DOI 10.1099/vir.0.062059-0
   Memish ZA, 2014, CLIN MICROBIOL INFEC, V20, P469, DOI 10.1111/1469-0691.12562
   Memish ZA, 2014, INT J INFECT DIS, V29, P307, DOI 10.1016/j.ijid.2014.10.002
   Memish ZA, 2014, J INFECT DIS, V210, P1590, DOI 10.1093/infdis/jiu292
   Memish ZA, 2014, INT J INFECT DIS, V25, P186, DOI 10.1016/j.ijid.2014.06.003
   Memish ZA, 2014, LANCET, V383, P2073, DOI 10.1016/S0140-6736(14)60381-0
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Memish ZA, 2013, NEW ENGL J MED, V369, P884, DOI 10.1056/NEJMc1308698
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Muller MA, 2015, LANCET INFECT DIS, V15, P559, DOI 10.1016/S1473-3099(15)70090-3
   Muller MA, 2014, EMERG INFECT DIS, V20, P2093, DOI 10.3201/eid2012.141026
   Niemeyer D, 2013, J VIROL, V87, P12489, DOI 10.1128/JVI.01845-13
   Oboho IK, 2015, NEW ENGL J MED, V372, P846, DOI 10.1056/NEJMoa1408636
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Poissy J, 2014, J CLIN VIROL, V61, P275, DOI 10.1016/j.jcv.2014.07.002
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reusken CB, 2014, EUROSURVEILLANCE, V19, P8, DOI 10.2807/1560-7917.ES2014.19.23.20829
   Reusken CB, 2013, EUROSURVEILLANCE, V18, P14, DOI 10.2807/1560-7917.ES2013.18.50.20662
   Reusken CBEM, 2014, EMERG INFECT DIS, V20, P1370, DOI 10.3201/eid2008.140590
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478
   Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003
   Samara EM, 2014, MBIO, V5, DOI 10.1128/mBio.01430-14
   Scientific Advisory Council Ministry of Health Saudi Arabia, INF PREV CONTR MAN G
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Tang XC, 2014, P NATL ACAD SCI USA, V111, pE2018, DOI 10.1073/pnas.1402074111
   The WHO and the MERS-CoV Research Group, 2013, PLOS CURR, DOI [10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8, DOI 10.1371/CURRENTS.0UTBREAKS.0BF719E352E7478F8AD85FA30127DDB8]
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   van Doremalen N, 2014, EMERG INFECT DIS, V20, P1263, DOI 10.3201/eid2007.140500
   Wang JT, 2004, EMERG INFECT DIS, V10, P818, DOI 10.3201/eid1005.030640
   Wang QH, 2014, CELL HOST MICROBE, V16, P328, DOI 10.1016/j.chom.2014.08.009
   WHO, 2014, INF PREV CONTR EP PA
   WHO, GLOB AL RESP COR INF
   WHO, 2014, UPD MERS COV TRANSM
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   World Health Organization, LAB TEST MIDDL E RES
   Yang Y, 2014, P NATL ACAD SCI USA, V111, P12516, DOI 10.1073/pnas.1405889111
   Yao YF, 2014, J INFECT DIS, V209, P236, DOI 10.1093/infdis/jit590
   Ying TL, 2014, J VIROL, V88, P7796, DOI 10.1128/JVI.00912-14
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504
   Zielecki F, 2013, J VIROL, V87, P5300, DOI 10.1128/JVI.03496-12
   Zumla A, 2014, LANCET, V383, P1869, DOI 10.1016/S0140-6736(14)60852-7
NR 120
TC 235
Z9 246
U1 28
U2 120
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD SEP 5
PY 2015
VL 386
IS 9997
BP 995
EP 1007
DI 10.1016/S0140-6736(15)60454-8
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA CR2TE
UT WOS:000361182700032
PM 26049252
OA Green Published, Green Accepted, Other Gold
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Bisht, H
   Roberts, A
   Vogel, L
   Bukreyev, A
   Collins, PL
   Murphy, BR
   Subbarao, K
   Moss, B
AF Bisht, H
   Roberts, A
   Vogel, L
   Bukreyev, A
   Collins, PL
   Murphy, BR
   Subbarao, K
   Moss, B
TI Severe acute respiratory syndrome coronavirus spike protein expressed by
   attenuated vaccinia virus protectively immunizes mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID INFECTIOUS PERITONITIS VIRUS; ANTIBODY-DEPENDENT ENHANCEMENT; SARS
   CORONAVIRUS; REPLICATION; CHALLENGE; MVA; NEUTRALIZATION; PROPAGATION;
   SEQUENCE; RECEPTOR
AB The spike protein (S), a membrane component of severe acute respiratory syndrome coronavirus (SARS-CoV) is anticipated to be an important component of candidate vaccines. We constructed recombinant forms of the highly attenuated modified vaccinia virus Ankara (MVA) containing the gene encoding full-length SARS-CoV S with and without a C-terminal epitope tag called MVA/S-HA and MVA/S, respectively. Cells infected with MVA/S or MVA/S-HA synthesized a 200-kDa protein, which was recognized by antibody raised against a synthetic peptide of SARS-CoV S or the epitope tag in Western blot analyses. Further studies indicated that S was N-glycosylated and migrated in SDS polyacrylamide gels with an apparent mass of approximate to160 kDa after treatment with peptide N-glycosiclase F. The acquisition of resistance to endoglycosidase H indicated trafficking of S to the medial Golgi compartment, and confocal microscopy showed that S was transported to the cell surface. Intranasal or intramuscular inoculations of BALB/c mice with MVA/S produced serum antibodies that recognized the SARS S in ELISA and neutralized SARS-CoV in vitro. Moreover, MVA/S administered by either route elicited protective immunity, as shown by reduced titers of SARS-CoV in the upper and lower respiratory tracts of mice after challenge. Passive transfer of serum from mice immunized with MVA/S to naive mice also reduced the replication of SARS-CoV in the respiratory tract after challenge, demonstrating a role for antibody to S in protection. The attenuated nature of MVA and the ability of MVA/S to induce neutralizing antibody that protects mice support further development of this candidate vaccine.
C1 NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
   NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
RP Moss, B (reprint author), NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
EM bmoss@niaid.nih.gov
OI Subbarao, Kanta/0000-0003-1713-3056
CR Antoine G, 1998, VIROLOGY, V244, P365, DOI 10.1006/viro.1998.9123
   Blanchard TJ, 1998, J GEN VIROL, V79, P1159, DOI 10.1099/0022-1317-79-5-1159
   Carroll MW, 1997, VIROLOGY, V238, P198, DOI 10.1006/viro.1997.8845
   CORAPI WV, 1992, J VIROL, V66, P6695, DOI 10.1128/JVI.66.11.6695-6705.1992
   Drexler I, 1998, J GEN VIROL, V79, P347, DOI 10.1099/0022-1317-79-2-347
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   EARL PL, 1998, CURRENT PROTOCOLS MO, V2
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI200318819, 10.1172/JCI18819]
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lai M. M. C., 2001, Fundamental virology, P641
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MAYR A, 1967, ZENTRALBL BAKTERIO B, P183
   MEYER H, 1991, J GEN VIROL, V72, P1031, DOI 10.1099/0022-1317-72-5-1031
   Moss B, 1996, P NATL ACAD SCI USA, V93, P11341, DOI 10.1073/pnas.93.21.11341
   Navas-Martin S, 2003, VIRAL IMMUNOL, V16, P461, DOI 10.1089/088282403771926292
   OLSEN CW, 1992, J VIROL, V66, P956, DOI 10.1128/JVI.66.2.956-965.1992
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Stittelaar KJ, 2001, VACCINE, V19, P3700, DOI 10.1016/S0264-410X(01)00075-5
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   Wyatt LS, 2004, P NATL ACAD SCI USA, V101, P4590, DOI 10.1073/pnas.0401165101
   Wyatt LS, 1996, VACCINE, V14, P1451, DOI 10.1016/S0264-410X(96)00072-2
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
NR 32
TC 234
Z9 256
U1 1
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 27
PY 2004
VL 101
IS 17
BP 6641
EP 6646
DI 10.1073/pnas.0401939101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 816KD
UT WOS:000221107900057
PM 15096611
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Kuo, LL
   Godeke, GJ
   Raamsman, MJB
   Masters, PS
   Rottier, PJM
AF Kuo, LL
   Godeke, GJ
   Raamsman, MJB
   Masters, PS
   Rottier, PJM
TI Retargeting of coronavirus by substitution of the spike glycoprotein
   ectodomain: Crossing the host cell species barrier
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; INFECTIOUS PERITONITIS VIRUS; TARGETED RNA
   RECOMBINATION; HUMAN AMINOPEPTIDASE-N; MURINE CORONAVIRUS;
   MEMBRANE-PROTEIN; MONOCLONAL-ANTIBODIES; NUCLEOCAPSID GENE; RECEPTOR
   FUNCTION; EPITHELIAL-CELLS
AB Coronaviruses generally have a narrow host range, infecting one or just a few species. Using targeted RNA recombination, we constructed a mutant of the coronavirus mouse hepatitis virus (MHV) in which the ectodomain of the spike glycoprotein (S) was replaced with the highly divergent ectodomain of the S protein of feline infectious peritonitis virus. The resulting chimeric virus, designated fMHV, acquired the ability to infect feline cells and simultaneously lost the ability to infect murine cells in tissue culture. This reciprocal switch of species specificity strongly supports the notion that coronavirus host cell range is determined primarily at the level of interactions between the S protein and the virus receptor. The isolation of fMHV allowed the localization of the region responsible for S protein incorporation into virions to the carboxy-terminal 64 of the 1,324 residues of this protein. This establishes a basis for further definition of elements involved in virion assembly. In addition, fMHV is potentially the ideal recipient virus for carrying out reverse genetics of MHV by targeted RNA recombination, since it presents the possibility of selecting recombinants, no matter how defective, that have regained the ability to replicate in murine cells.
C1 New York State Dept Hlth, Wadsworth Ctr Labs & Res, David Axelrod Inst, Albany, NY 12201 USA.
   Univ Utrecht, Fac Vet Med, Dept Immunol & Infect Dis, Inst Virol, NL-3584 CL Utrecht, Netherlands.
   Univ Utrecht, Inst Biomembranes, NL-3584 CL Utrecht, Netherlands.
RP Masters, PS (reprint author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, David Axelrod Inst, New Scotland Ave,POB 22002, Albany, NY 12201 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI039544, AI 39544]
CR Baric RS, 1997, J VIROL, V71, P1946, DOI 10.1128/JVI.71.3.1946-1955.1997
   Baudoux P, 1998, J VIROL, V72, P8636, DOI 10.1128/JVI.72.11.8636-8643.1998
   Bos ECW, 1995, VIROLOGY, V214, P453, DOI 10.1006/viro.1995.0056
   Bos ECW, 1996, VIROLOGY, V218, P52, DOI 10.1006/viro.1996.0165
   Bos ECW, 1997, J VIROL, V71, P9427, DOI 10.1128/JVI.71.12.9427-9433.1997
   de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998
   de Haan CAM, 1998, J BIOL CHEM, V273, P29905, DOI 10.1074/jbc.273.45.29905
   DEGROOT RJ, 1987, J GEN VIROL, V68, P2639, DOI 10.1099/0022-1317-68-10-2639
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   FICHOT O, 1990, NUCLEIC ACIDS RES, V18, P6162, DOI 10.1093/nar/18.20.6162
   Fischer F, 1998, J VIROL, V72, P7885, DOI 10.1128/JVI.72.10.7885-7894.1998
   Fischer F, 1997, J VIROL, V71, P5148, DOI 10.1128/JVI.71.7.5148-5160.1997
   Fischer F, 1997, J VIROL, V71, P996, DOI 10.1128/JVI.71.2.996-1003.1997
   FLEMING JO, 1989, VIROLOGY, V168, P162, DOI 10.1016/0042-6822(89)90415-7
   Godeke GJ, 2000, J VIROL, V74, P1566, DOI 10.1128/JVI.74.3.1566-1571.2000
   GODET M, 1992, VIROLOGY, V188, P666, DOI 10.1016/0042-6822(92)90521-P
   GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994
   Hansen GH, 1998, J VIROL, V72, P527, DOI 10.1128/JVI.72.1.527-534.1998
   Hegyi A, 1998, J GEN VIROL, V79, P1387, DOI 10.1099/0022-1317-79-6-1387
   Hohdatsu T, 1998, ARCH VIROL, V143, P839, DOI 10.1007/s007050050336
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   Horton R.M., 1991, DIRECTED MUTAGENESIS, P217
   Hsue B, 1999, J VIROL, V73, P6128, DOI 10.1128/JVI.73.7.6128-6135.1999
   Hsue B, 1997, J VIROL, V71, P7567, DOI 10.1128/JVI.71.10.7567-7578.1997
   KINGSMAN SM, 1980, VIROLOGY, V101, P458, DOI 10.1016/0042-6822(80)90459-6
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   KOETZNER CA, 1992, J VIROL, V66, P1841, DOI 10.1128/JVI.66.4.1841-1848.1992
   Kolb AF, 1997, J GEN VIROL, V78, P2795, DOI 10.1099/0022-1317-78-11-2795
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Laude H, 1995, CORONAVIRIDAE, P141, DOI 10.1007/978-1-4899-1531-3_7
   Leparc-Goffart I, 1998, J VIROL, V72, P9628, DOI 10.1128/JVI.72.12.9628-9636.1998
   LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   MASTERS PS, 1994, J VIROL, V68, P328, DOI 10.1128/JVI.68.1.328-337.1994
   Nguyen VP, 1997, J VIROL, V71, P9278, DOI 10.1128/JVI.71.12.9278-9284.1997
   OLSEN CW, 1992, J VIROL, V66, P956, DOI 10.1128/JVI.66.2.956-965.1992
   OPSTELTEN DJE, 1995, J CELL BIOL, V131, P339, DOI 10.1083/jcb.131.2.339
   OPSTELTEN DJE, 1993, J VIROL, V67, P7394, DOI 10.1128/JVI.67.12.7394-7401.1993
   PENG D, 1995, J VIROL, V69, P3449, DOI 10.1128/JVI.69.6.3449-3457.1995
   PENG D, 1995, J VIROL, V69, P5475, DOI 10.1128/JVI.69.9.5475-5484.1995
   Phillips JJ, 1999, J VIROL, V73, P7752, DOI 10.1128/JVI.73.9.7752-7760.1999
   Risco C, 1998, J VIROL, V72, P4022, DOI 10.1128/JVI.72.5.4022-4031.1998
   Risco C, 1996, J VIROL, V70, P4773, DOI 10.1128/JVI.70.7.4773-4777.1996
   ROSSEN JWA, 1995, VIROLOGY, V210, P54, DOI 10.1006/viro.1995.1316
   Rossen JWA, 1996, VIROLOGY, V224, P345, DOI 10.1006/viro.1996.0540
   ROTTIER P, 1985, J BIOL CHEM, V260, P4648
   Rottier P.J.M., 1995, CORONAVIRIDAE, P115
   ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981
   Sambrook J., 1989, MOL CLONING LAB MANU
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Schickli JH, 1997, J VIROL, V71, P9499, DOI 10.1128/JVI.71.12.9499-9507.1997
   SENANAYAKE SD, 1992, J VIROL, V66, P5277, DOI 10.1128/JVI.66.9.5277-5283.1992
   SHIEH CK, 1989, J VIROL, V63, P3729, DOI 10.1128/JVI.63.9.3729-3736.1989
   SIDDELL SG, 1995, CORONAVIRIDAE, P1
   STURMAN LS, 1977, VIROLOGY, V77, P637, DOI 10.1016/0042-6822(77)90488-3
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   TRESNAN DB, 1996, J VIROL, V70, pS669
   VANDERMOST RG, 1992, NUCLEIC ACIDS RES, V20, P3375, DOI 10.1093/nar/20.13.3375
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   YU X, 1994, VIROLOGY, V202, P1018, DOI 10.1006/viro.1994.1430
NR 63
TC 234
Z9 244
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD FEB
PY 2000
VL 74
IS 3
BP 1393
EP 1406
DI 10.1128/JVI.74.3.1393-1406.2000
PG 14
WC Virology
SC Virology
GA 273YZ
UT WOS:000084738100036
PM 10627550
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Lu, GW
   Hu, YW
   Wang, QH
   Qi, JX
   Gao, F
   Li, Y
   Zhang, YF
   Zhang, W
   Yuan, Y
   Bao, JK
   Zhang, BC
   Shi, Y
   Yan, JH
   Gao, GF
AF Lu, Guangwen
   Hu, Yawei
   Wang, Qihui
   Qi, Jianxun
   Gao, Feng
   Li, Yan
   Zhang, Yanfang
   Zhang, Wei
   Yuan, Yuan
   Bao, Jinku
   Zhang, Buchang
   Shi, Yi
   Yan, Jinghua
   Gao, George F.
TI Molecular basis of binding between novel human coronavirus MERS-CoV and
   its receptor CD26
SO NATURE
LA English
DT Article
ID CRYSTAL-STRUCTURE; SPIKE PROTEIN; FUNCTIONAL RECEPTOR; AMINOPEPTIDASE-N;
   MIDDLE-EAST; REVEALS; MEMBRANE; COMPLEX; ORIGIN; VIRUS
AB The newly emergent Middle East respiratory syndrome coronavirus (MERS-CoV) can cause severe pulmonary disease in humans(1,2), representing the second example of a highly pathogenic coronavirus, the first being SARS-CoV3. CD26 (also known as dipeptidyl peptidase 4, DPP4) was recently identified as the cellular receptor for MERS-CoV4. The engagement of the MERS-CoV spike protein with CD26 mediates viral attachment to host cells and virus-cell fusion, thereby initiating infection. Here we delineate the molecular basis of this specific interaction by presenting the first crystal structures of both the free receptor binding domain (RBD) of the MERS-CoV spike protein and its complex with CD26. Furthermore, binding between the RBD and CD26 is measured using real-time surface plasmon resonance with a dissociation constant of 16.7 nM. The viral RBD is composed of a core subdomain homologous to that of the SARS-CoV spike protein, and a unique strand-dominated external receptor binding motif that recognizes blades IV and V of the CD26 beta-propeller. The atomic details at the interface between the two binding entities reveal a surprising protein-protein contact mediated mainly by hydrophilic residues. Sequence alignment indicates, among beta-coronaviruses, a possible structural conservation for the region homologous to the MERS-CoV RBD core, but a high variation in the external receptor binding motif region for virus-specific pathogenesis such as receptor recognition.
C1 [Lu, Guangwen; Wang, Qihui; Qi, Jianxun; Li, Yan; Zhang, Yanfang; Zhang, Wei; Yuan, Yuan; Yan, Jinghua; Gao, George F.] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.
   [Hu, Yawei; Zhang, Buchang] Anhui Univ, Sch Life Sci, Hefei 230039, Peoples R China.
   [Gao, Feng] Chinese Acad Sci, Inst Biophys, Lab Noncoding RNA, Beijing 100101, Peoples R China.
   [Gao, Feng; Bao, Jinku] Sichuan Univ, Sch Life Sci, Chengdu 610064, Sichuan, Peoples R China.
   [Zhang, Yanfang; Gao, George F.] Tianjin Inst Ind Biotechnol, Lab Prot Engn & Vaccines, Tianjin 300308, Peoples R China.
   [Yuan, Yuan; Gao, George F.] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Peoples R China.
   [Shi, Yi; Gao, George F.] Chinese Acad Sci, Beijing Inst Life Sci, RNIH, Beijing 100101, Peoples R China.
   [Gao, George F.] Chinese Ctr Dis Control & Prevent China CDC, Beijing 102206, Peoples R China.
RP Gao, GF (reprint author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.
EM gaof@im.ac.cn
FU Ministry of Science and Technology of China (MOST)Ministry of Science
   and Technology, China [2011CB504703]; National Natural Science
   Foundation of China (NSFC)National Natural Science Foundation of China
   [81290342]; NSFC Innovative Research Group [81021003]
FX This work was supported by the Ministry of Science and Technology of
   China (MOST) 973 Project (Grant no. 2011CB504703) and the National
   Natural Science Foundation of China (NSFC, Grant no. 81290342).
   Assistance by the staff at the Shanghai Synchrotron Radiation Facility
   (SSRF) of China and the High Energy Accelerator Research Organization
   (KEK) of Japan is acknowledged. We thank Z. Fan and T. Zhao for their
   technical assistance. G. F. G. is a leading principal investigator of
   the NSFC Innovative Research Group (Grant no. 81021003). We thank M.
   Yang from Tsinghua University for his help with data collection.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100
   Gao GF, 2007, COMBATING THE THREAT OF PANDEMIC INFLUENZA: DRUG DISCOVERY APPROACHES, P226, DOI 10.1002/9780470179727.ch10
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   Gorrell MD, 2001, SCAND J IMMUNOL, V54, P249, DOI 10.1046/j.1365-3083.2001.00984.x
   Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305
   Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366
   Lai M.M.C., 2007, FIELDS VIROLOGY, V1, P1305
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2012, J VIROL, V86, P2856, DOI 10.1128/JVI.06882-11
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu GW, 2012, PROTEIN CELL, V3, P803, DOI 10.1007/s13238-012-2811-1
   Muller MA, 2012, MBIO, V3, DOI 10.1128/mBio.00515-12
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Peng GQ, 2011, P NATL ACAD SCI USA, V108, P10696, DOI 10.1073/pnas.1104306108
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882
   Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471
   Reguera J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002859
   Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9
   Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Weihofen WA, 2004, J BIOL CHEM, V279, P43330, DOI 10.1074/jbc.M405001200
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   *WHO, 2013, NOV COR INF UPD
   World Health Organization, CUM NUMB REP PROB CA
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang W, 2010, PROTEIN CELL, V1, P459, DOI 10.1007/s13238-010-0059-1
   Zhu JQ, 2004, BIOCHEM BIOPH RES CO, V319, P283, DOI 10.1016/j.bbrc.2004.04.141
NR 38
TC 233
Z9 253
U1 24
U2 199
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD AUG 8
PY 2013
VL 500
IS 7461
BP 227
EP +
DI 10.1038/nature12328
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 197CH
UT WOS:000322825500039
PM 23831647
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Memish, ZA
   Zumla, AI
   Al-Hakeem, RF
   Al-Rabeeah, AA
   Stephens, GM
AF Memish, Ziad A.
   Zumla, Alimuddin I.
   Al-Hakeem, Rafat F.
   Al-Rabeeah, Abdullah A.
   Stephens, Gwen M.
TI Family Cluster of Middle East Respiratory Syndrome Coronavirus
   Infections
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PNEUMONIA
AB A human coronavirus, called the Middle East respiratory syndrome coronavirus (MERS-CoV), was first identified in September 2012 in samples obtained from a Saudi Arabian businessman who died from acute respiratory failure. Since then, 49 cases of infections caused by MERS-CoV (previously called a novel coronavirus) with 26 deaths have been reported to date. In this report, we describe a family case cluster of MERS-CoV infection, including the clinical presentation, treatment outcomes, and household relationships of three young men who became ill with MERS-CoV infection after the hospitalization of an elderly male relative, who died of the disease. Twenty-four other family members living in the same household and 124 attending staff members at the hospitals did not become ill. MERS-CoV infection may cause a spectrum of clinical illness. Although an animal reservoir is suspected, none has been discovered. Meanwhile, global concern rests on the ability of MERS-CoV to cause major illness in close contacts of patients.
C1 [Memish, Ziad A.; Zumla, Alimuddin I.; Al-Hakeem, Rafat F.; Al-Rabeeah, Abdullah A.; Stephens, Gwen M.] Minist Hlth, Global Ctr Mass Gatherings Med, Riyadh 11176, Saudi Arabia.
   [Memish, Ziad A.] Al Faisal Univ, Riyadh, Saudi Arabia.
   [Zumla, Alimuddin I.] UCL, Div Infect & Immun, London WC1E 6BT, England.
   [Zumla, Alimuddin I.] UCL Hosp NHS Fdn Trust, Dept Med Microbiol, London, England.
RP Memish, ZA (reprint author), Minist Hlth, WHO Collaborating Ctr Mass Gathering Med, Riyadh 11176, Saudi Arabia.
EM zmemish@yahoo.com
OI Zumla, Alimuddin/0000-0002-5111-5735
CR AlBarrak AM, 2012, SAUDI MED J, V33, P1265
   Corman V. M., 2012, EUROSURVEILLANCE, V17
   Health Protection Agency, 2012, GEN SEQ INF SCI NOV
   Hoffman C, 2003, SARS REFERENCE 10 20
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   World Health Organization, 2003, WHO FIN SUMM SARS
   World Health Organization, 2013, INT SURV REC HUM INF
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zumla A, 2013, LANCET RESP MED 0520
NR 10
TC 233
Z9 246
U1 8
U2 35
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 27
PY 2013
VL 368
IS 26
BP 2487
EP 2494
DI 10.1056/NEJMoa1303729
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 171KQ
UT WOS:000320926900009
PM 23718156
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Lau, SKP
   Yip, CCY
   Tsoi, HW
   Lee, RA
   So, LY
   Lau, YL
   Chan, KH
   Woo, PCY
   Yuen, KY
AF Lau, Susanna K. P.
   Yip, Cyril C. Y.
   Tsoi, Hoi-wah
   Lee, Rodney A.
   So, Lok-yee
   Lau, Yu-lung
   Chan, Kwok-hung
   Woo, Patrick C. Y.
   Yuen, Kwok-yung
TI Clinical features and complete genome characterization of a distinct
   human rhinovirus (HRV) genetic previously undetected HRV cluster,
   probably representing a species, HRV-C, associated with acute
   respiratory illness in children
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID COMMON COLD VIRUS; COMMUNITY-ACQUIRED PNEUMONIA; COMPLETE
   NUCLEOTIDE-SEQUENCE; CAPSID PROTEIN VP1; HUMAN ENTEROVIRUSES; PROTOTYPE
   STRAINS; CORONAVIRUS HKU1; TRACT INFECTIONS; YOUNG-CHILDREN; CODING
   REGION
AB Although human rhinoviruses (HRVs) are common causes of respiratory illness, their molecular epidemiology has been poorly investigated. Despite the recent findings of new HRV genotypes, their clinical disease spectrum and phylogenetic positions were not fully understood. In this study, 203 prospectively collected nasopharyngeal aspirates (NPAs), negative for common respiratory viruses (83 were human bocavirus [HBoV] positive and 120 HBoV negative), from hospitalized children during a 1-year period were subjected to reverse transcription-PCR for HRV. HRV was detected in 14 NPAs positive and 12 NPAs negative for HBoV. Upon VP4 gene analysis, 5 of these 26 HRV strains were found to belong to HRV-A while 21 belonged to a genetic clade probably representing a previously undetected HRV species, HRV-C, that is phylogenetically distinct from the two known HRV species, HRV-A and HRV-B. The VP4 sequences of these HRV-C strains were closely related to the newly identified HRV strains from the United States and Australia. Febrile wheeze or asthma was the most common presentation (76%) of HRV-C infection, which peaked in fall and winter. Complete genome sequencing of three HRV-C strains revealed that HRV-C represents an additional HRV species, with features distinct from HRV-A and HRV-B. Analysis of VP1 of HRV-C revealed major deletions in regions important for neutralization in other HRVs, which may be signs of a distinct species, while within-clade amino acid variation in potentially antigenic regions may indicate the existence of different serotypes among HRV-C strains. A newly identified HRV species, HRV-C, is circulating worldwide and is an important cause of febrile wheeze and asthmatic exacerbations in children requiring hospitalization.
C1 Univ Hong Kong, Queen Mary Hosp, State Key Lab Emerging Infect Dis, Dept Pediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Res Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Pamela Youde Nethersole Eastern Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   Pamela Youde Nethersole Eastern Hosp, Dept Pediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
RP Woo, PCY (reprint author), Univ Hong Kong, Queen Mary Hosp, State Key Lab Emerging Infect Dis, Dept Pediat & Adolescent Med, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.
EM pcywoo@hkucc.hku.hk; kyyuen@hkucc.hku.hk
RI Lau, Susanna Kar Pui/AAJ-6848-2020; Yuen, Kwok Yung/C-4465-2009; Yip,
   Chik Yan/B-7078-2013; Lau, Susanna/C-4321-2009; Tsoi, Hoi
   Wah/C-4428-2009; Woo, Patrick Chiu Yat/C-4449-2009; Lau, Yu
   Lung/C-4322-2009
OI Lau, Susanna Kar Pui/0000-0002-1383-7374; Woo, Patrick Chiu
   Yat/0000-0001-9401-1832; Yuen, Kwok-yung/0000-0002-2083-1552; Lau, Yu
   Lung/0000-0002-4780-0289
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Blom N, 1996, PROTEIN SCI, V5, P2203, DOI 10.1002/pro.5560051107
   Blomqvist S, 2002, J CLIN MICROBIOL, V40, P4218, DOI 10.1128/JCM.40.11.4218-4223.2002
   Brown B, 2003, J VIROL, V77, P8973, DOI 10.1128/JVI.77.16.8973-8984.2003
   CALLAHAN PL, 1985, P NATL ACAD SCI USA, V82, P732, DOI 10.1073/pnas.82.3.732
   DUECHLER M, 1987, P NATL ACAD SCI USA, V84, P2605, DOI 10.1073/pnas.84.9.2605
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Harris JR, 2005, J VIROL, V79, P5363, DOI 10.1128/JVI.79.9.5363-5373.2005
   He YN, 2002, P NATL ACAD SCI USA, V99, P10325, DOI 10.1073/pnas.152161599
   HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839
   HUGHES PJ, 1988, J GEN VIROL, V69, P49, DOI 10.1099/0022-1317-69-1-49
   Kaiser L, 2006, AM J RESP CRIT CARE, V174, P1392, DOI 10.1164/rccm.200604-489OC
   Laine P, 2006, J GEN VIROL, V87, P129, DOI 10.1099/vir.0.81137-0
   Laine P, 2005, J GEN VIROL, V86, P697, DOI 10.1099/vir.0.80445-0
   Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551
   LAU SKP, IN PRESS J INFECT DI
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Ledford RM, 2004, J VIROL, V78, P3663, DOI 10.1128/JVI.78.7.3663-3674.2004
   Lee J.-L., 1995, ETRI Journal, V16, P1
   MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L
   McErlean P, 2007, J CLIN VIROL, V39, P67, DOI 10.1016/j.jcv.2007.03.012
   Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821
   Oberste MS, 1999, J VIROL, V73, P1941, DOI 10.1128/JVI.73.3.1941-1948.1999
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, EMERG INFECT DIS, V9, P628
   Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411
   ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0
   RUECKERT RR, 1996, FIELDS VIROLOGY, P609
   Ruiz M, 1999, AM J RESP CRIT CARE, V160, P397, DOI 10.1164/ajrccm.160.2.9808045
   Savolainen C, 2004, J GEN VIROL, V85, P2271, DOI 10.1099/vir.0.79897-0
   Savolainen C, 2002, J GEN VIROL, V83, P333, DOI 10.1099/0022-1317-83-2-333
   SHERRY B, 1985, J VIROL, V53, P137, DOI 10.1128/JVI.53.1.137-143.1985
   SKERN T, 1985, NUCLEIC ACIDS RES, V13, P2111, DOI 10.1093/nar/13.6.2111
   STANWAY G, 1984, NUCLEIC ACIDS RES, V12, P7859, DOI 10.1093/nar/12.20.7859
   Tapparel C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-224
   Turner RB, 2007, J INFECT DIS, V195, P765, DOI 10.1086/511829
   UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vlasak M, 2003, J VIROL, V77, P6923, DOI 10.1128/JVI.77.12.6923-6930.2003
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997
NR 43
TC 233
Z9 240
U1 2
U2 19
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD NOV
PY 2007
VL 45
IS 11
BP 3655
EP 3664
DI 10.1128/JCM.01254-07
PG 10
WC Microbiology
SC Microbiology
GA 231FU
UT WOS:000250932700027
PM 17804649
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Guery, B
   Poissy, J
   el Mansouf, L
   Sejourne, C
   Ettahar, N
   Lemaire, X
   Vuotto, F
   Goffard, A
   Behillil, S
   Enouf, V
   Caro, V
   Mailles, A
   Che, D
   Manuguerra, JC
   Mathieu, D
   Fontanet, A
   van der Werf, S
AF Guery, Benoit
   Poissy, Julien
   el Mansouf, Loubna
   Sejourne, Caroline
   Ettahar, Nicolas
   Lemaire, Xavier
   Vuotto, Fanny
   Goffard, Anne
   Behillil, Sylvie
   Enouf, Vincent
   Caro, Valerie
   Mailles, Alexandra
   Che, Didier
   Manuguerra, Jean-Claude
   Mathieu, Daniel
   Fontanet, Arnaud
   van der Werf, Sylvie
CA MERS-CoV Study Grp
TI Clinical features and viral diagnosis of two cases of infection with
   Middle East Respiratory Syndrome coronavirus: a report of nosocomial
   transmission
SO LANCET
LA English
DT Article
ID SARS; PNEUMONIA
AB Background Human infection with a novel coronavirus named Middle East Respiratory Syndrome coronavirus (MERS-CoV) was first identified in Saudi Arabia and the Middle East in September, 2012, with 44 laboratory-confirmed cases as of May 23, 2013. We report detailed clinical and virological data for two related cases of MERS-CoV disease, after nosocomial transmission of the virus from one patient to another in a French hospital.
   Methods Patient 1 visited Dubai in April, 2013; patient 2 lives in France and did not travel abroad. Both patients had underlying immunosuppressive disorders. We tested specimens from the upper (nasopharyngeal swabs) or the lower (bronchoalveolar lavage, sputum) respiratory tract and whole blood, plasma, and serum specimens for MERS-CoV by real-time RT-PCR targeting the upE and Orf1A genes of MERS-CoV.
   Findings Initial clinical presentation included fever, chills, and myalgia in both patients, and for patient 1, diarrhoea. Respiratory symptoms rapidly became predominant with acute respiratory failure leading to mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Both patients developed acute renal failure. MERS-CoV was detected in lower respiratory tract specimens with high viral load (eg, cycle threshold [Ct] values of 22.9 for upE and 24 for Orf1a for a bronchoalveolar lavage sample from patient 1; Ct values of 22.5 for upE and 23.9 for Orf1a for an induced sputum sample from patient 2), whereas nasopharyngeal specimens were weakly positive or inconclusive. The two patients shared the same room for 3 days. The incubation period was estimated at 9-12 days for the second case. No secondary transmission was documented in hospital staff despite the absence of specific protective measures before the diagnosis of MERS-CoV was suspected. Patient 1 died on May 28, due to refractory multiple organ failure.
   Interpretation Patients with respiratory symptoms returning from the Middle East or exposed to a confirmed case should be isolated and investigated for MERS-CoV with lower respiratory tract sample analysis and an assumed incubation period of 12 days. Immunosuppression should also be taken into account as a risk factor.
C1 [Guery, Benoit; Vuotto, Fanny] Univ Lille 2, Ctr Hosp Reg & Univ Lille, Hop Huriez, Serv Gest Risque Infect Vigilances & Infectiol, Lille, France.
   [Poissy, Julien; Mathieu, Daniel] Univ Lille 2, Ctr Hosp Reg & Univ Lille, Hop Roger Salengro, Pole Reanimat, Lille, France.
   [el Mansouf, Loubna; Lemaire, Xavier] Ctr Hosp Douai, Serv Malad Infect, Douai, France.
   [Sejourne, Caroline] Ctr Hosp Douai, Serv Reanimat, Douai, France.
   [Ettahar, Nicolas] Ctr Hosp Valenciennes, Unite Malad Infect, Valenciennes, France.
   [Goffard, Anne] Univ Lille 2, Ctr Hosp Reg & Univ Lille, Ctr Biol Pathol, Virol Lab, Lille, France.
   [Behillil, Sylvie; Enouf, Vincent; van der Werf, Sylvie] Inst Pasteur, Natl Reference Ctr Influenza Viruses, F-75015 Paris, France.
   [Behillil, Sylvie; Enouf, Vincent; van der Werf, Sylvie] Inst Pasteur, Unit Mol Genet RNA Viruses, F-75015 Paris, France.
   [Behillil, Sylvie; Enouf, Vincent; van der Werf, Sylvie] Univ Paris Diderot, Sorbonne Paris Cite, Unit Mol Genet RNA Viruses, Paris, France.
   [Behillil, Sylvie; Enouf, Vincent; van der Werf, Sylvie] CNRS, UMR3569, Paris, France.
   [Caro, Valerie; Manuguerra, Jean-Claude] Inst Pasteur, F-75015 Paris, France.
   [Mailles, Alexandra; Che, Didier] Inst Veille Sanit, St Maurice, France.
   [Fontanet, Arnaud] Conservatoire Natl Arts & Metiers, Paris, France.
   [Fontanet, Arnaud] Inst Pasteur, Emerging Dis Epidemiol Unit, F-75015 Paris, France.
RP van der Werf, S (reprint author), Inst Pasteur, Natl Reference Ctr Influenza Viruses, F-75015 Paris, France.
EM bguery@invivo.edu; sylvie.van-der-werf@pasteur.fr
RI Guery, Benoit/D-8089-2017; Goffard, Anne/G-5488-2016; Behillil,
   sylvie/H-6496-2017; ENOUF, Vincent/H-6494-2017
OI Guery, Benoit/0000-0002-6526-0714; Goffard, Anne/0000-0002-6521-9711;
   Mailles, Alexandra/0000-0002-8739-1168; , julien/0000-0001-6017-5353;
   Vincentelli, Andre/0000-0003-4081-786X; van der WERF,
   Sylvie/0000-0002-1148-4456; rousse, natacha/0000-0003-2837-4285;
   Behillil, sylvie/0000-0002-1520-5020; Faure, Karine/0000-0002-2608-9790;
   ENOUF, Vincent/0000-0001-7609-4742
FU French Institute for Public Health Surveillance (Institut de veille
   sanitaire, InVS); ANR grant Labex Integrative Biology of Emerging
   Infectious Diseases (IBEID) from the French Government's Investissement
   d'Avenir programmeFrench National Research Agency (ANR)
   [ANR-10-LABX-62-IBEID]; European CommunityEuropean Community (EC)
   [223498, 278433]
FX The National Reference Center for Influenza Viruses and the CIBU are
   supported in part by funds from the French Institute for Public Health
   Surveillance (Institut de veille sanitaire, InVS). Work related to
   collection of data, implementation of the assays, and sequencing was
   done with funds from ANR grant Labex Integrative Biology of Emerging
   Infectious Diseases (IBEID, grant number ANR-10-LABX-62-IBEID from the
   French Government's Investissement d'Avenir programme) and from the
   European Community's Seventh Framework Programme (FP7/2007-2013) under
   the project EMPERIE (European Community grant agreement number 223498)
   and under the project PREDEMICS (grant agreement number 278433). We
   thank the nurses and all health-care workers from the hospitals in
   Valenciennes, Douai, and Lille who, in this crisis situation, took care
   of the patients and controlled the spread of this disease. We thank P
   Despres, S Paulous, and M P Frenkiel (Unit of Flavivirus-Host Molecular
   Interactions, Institut Pasteur) for preliminary serological analyses. We
   thank Eric Kipnis for editing of the report.
CR Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Buchholz U., 2013, Eurosurveillance, V18, P20406
   Cheng PKC, 2004, LANCET, V363, P1699, DOI 10.1016/S0140-6736(04)16255-7
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   Cotten M, 2013, EMERG INFECT DIS, V19, P736, DOI 10.3201/eid1905.130057
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Gomersall CD, 2004, INTENS CARE MED, V30, P381, DOI 10.1007/s00134-003-2143-y
   Gulland A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3114
   Lessler J, 2009, LANCET INFECT DIS, V9, P291, DOI 10.1016/S1473-3099(09)70069-6
   McCloskey B, 2013, LANCET INFECT DIS, V13, P384, DOI 10.1016/S1473-3099(13)70082-3
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Tahir M, 2013, EUROSURVEILLANCE, V18, P4
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   van der Hoek L, 2007, ANTIVIR THER, V12, P651
   WHO, 2013, NOV COR INF UPD MAY
   World Health Organization, NOV COR SUMM LIT UPD
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 23
TC 232
Z9 243
U1 10
U2 73
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUN 29
PY 2013
VL 381
IS 9885
BP 2265
EP 2272
DI 10.1016/S0140-6736(13)60982-4
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 173SU
UT WOS:000321100300030
PM 23727167
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Nicholson, KG
   Kent, J
   Hammersley, V
   Cancio, E
AF Nicholson, KG
   Kent, J
   Hammersley, V
   Cancio, E
TI Acute viral infections of upper respiratory tract in elderly people
   living in the community: comparative, prospective, population based
   study of disease burden
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID INFLUENZA-A INFECTION; SYNCYTIAL VIRUS; RHINOVIRUS INFECTIONS; ILLNESS;
   TECUMSEH; CHILDREN; RIMANTADINE; MORTALITY; FREQUENCY; ENGLAND
AB Objective: To evaluate the disease burden of upper respiratory infections in elderly people living at home.
   Design: Prospective surveillance of elderly people.
   Intervention: None.
   Setting: Leicestershire, England
   Subjects: 533 subjects 60 to 90 years of age.
   Main outcome measures: Pathogens, symptoms, restriction of activity, duration of illness, medical consultations, interval between onset of illness and medical consultation, antibiotic use, admission to hospital, and death.
   Results: 231 pathogens were identified for 211 (43%) of 497 episodes for which diagnostic specimens were available: 121 (52%) were rhinoviruses, 59 (26%) were coronaviruses, 22 (9.5%) were influenza A or B, 17 (7%) were respiratory syncytial virus, 7 (3%) were parainfluenza viruses, and 3 (1%) were Chlamydia species; an adenovirus and Mycoplasma pneumoniae caused one infection each. Infections occurred at a rate of 1.2 episodes per person per annum (95% confidence interval 1.0 to 1.7; range 0-10) and were clinically indistinguishable. Lower respiratory tract symptoms complicated 65% of upper respiratory infections and increased the medical consultation rate 2.4-fold (chi(2) test P < 0.001). The median interval between onset of illness and medical consultation was 3 days for influenza and 5 days for other infections. Rhinoviruses caused the greatest disease burden overall followed by episodes of unknown aetiology, coronaviruses, influenza A and B, and respiratory syncytial virus.
   Conclusions: Respiratory viruses cause substantial morbidity in elderly people. Although respiratory syncytial virus and influenza cause considerable individual morbidity, the burden of disease from rhinovirus infections and infections of unknown aetiology seems greater overall. The interval between onset of illness and consultation together with diagnostic difficulties raises concern regarding the role of antiviral drugs in treating influenza.
RP Nicholson, KG (reprint author), UNIV LEICESTER,SCH MED,DEPT MICROBIOL & IMMUNOL,LEICESTER LE1 9HN,LEICS,ENGLAND.
CR *COMM ISS PRIOR NE, 1985, NEW VACC DEV EST PRI, V1, P51
   *DEP HLTH, 1992, IMM INF DIS
   FALSEY AR, 1995, J AM GERIATR SOC, V43, P30, DOI 10.1111/j.1532-5415.1995.tb06238.x
   FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389
   FALSEY AR, 1992, J AM GERIATR SOC, V40, P115, DOI 10.1111/j.1532-5415.1992.tb01929.x
   FLEMING DM, 1993, EUR J EPIDEMIOL, V9, P571, DOI 10.1007/BF00211429
   GALBRAIT.AW, 1969, B WORLD HEALTH ORGAN, V41, P677
   HALL CB, 1987, PEDIATRICS, V80, P275
   HORN MEC, 1975, J HYG-CAMBRIDGE, V74, P157, DOI 10.1017/S0022172400024220
   IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204
   KELLNER G, 1989, ACTA PAEDIATR SCAND, V78, P390, DOI 10.1111/j.1651-2227.1989.tb11098.x
   MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779
   MONTO AS, 1974, JAMA-J AM MED ASSOC, V227, P164, DOI 10.1001/jama.227.2.164
   MONTO AS, 1971, AM J EPIDEMIOL, V94, P280, DOI 10.1093/oxfordjournals.aje.a121321
   MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43
   Nicholson KG, 1996, BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   Nicholson KG, 1996, EPIDEMIOL INFECT, V116, P51, DOI 10.1017/S0950268800058957
   NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251
   TANNOCK GA, 1993, FAM PRACT, V10, P378, DOI 10.1093/fampra/10.4.378
   THOMPSON J, 1987, J MED VIROL, V21, P249, DOI 10.1002/jmv.1890210308
   TYRRELL DAJ, 1993, EPIDEMIOL INFECT, V111, P143, DOI 10.1017/S0950268800056764
   WINGFIELD WL, 1969, NEW ENGL J MED, V281, P579, DOI 10.1056/NEJM196909112811102
NR 23
TC 232
Z9 241
U1 0
U2 6
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0959-8138
J9 BRIT MED J
JI Br. Med. J.
PD OCT 25
PY 1997
VL 315
IS 7115
BP 1060
EP 1064
DI 10.1136/bmj.315.7115.1060
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA YD445
UT WOS:A1997YD44500026
PM 9366736
OA Green Published
DA 2020-04-03
ER

PT J
AU Subbarao, K
   McAuliffe, J
   Vogel, L
   Fahle, G
   Fischer, S
   Tatti, K
   Packard, M
   Shieh, WJ
   Zaki, S
   Murphy, B
AF Subbarao, K
   McAuliffe, J
   Vogel, L
   Fahle, G
   Fischer, S
   Tatti, K
   Packard, M
   Shieh, WJ
   Zaki, S
   Murphy, B
TI Prior infection and passive transfer of neutralizing antibody prevent
   replication of severe acute respiratory syndrome coronavirus in the
   respiratory tract of mice
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SYNCYTIAL VIRUS-INFECTION; CRITICALLY-ILL PATIENTS; INFLUENZA-VIRUS;
   PERITONITIS VIRUS; HEMORRHAGIC-FEVER; SARS CORONAVIRUS; HONG-KONG;
   IMMUNITY; PATHOGENESIS; CHALLENGE
AB Following intranasal administration, the severe acute respiratory syndrome (SARS) coronavirus replicated to high titers in the respiratory tracts of BALB/c mice. Peak replication was seen in the absence of disease on day 1 or 2, depending on the dose administered, and the virus was cleared within a week. Viral antigen and nucleic acid were detected in bronchiolar epithelial cells during peak viral replication. Mice developed a neutralizing antibody response and were protected from reinfection 28 days following primary infection. Passive transfer of immune serum to naive mice prevented virus replication in the lower respiratory tract following intranasal challenge. Thus, antibodies, acting alone, can prevent replication of the SARS coronavirus in the lung, a promising observation for the development of vaccines, immunotherapy, and immunoprophylaxis regimens.
C1 NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   NIH, Microbiol Serv, Ctr Clin, Bethesda, MD 20892 USA.
RP Subbarao, K (reprint author), NIAID, Infect Dis Lab, NIH, Bldg 50,Room 6132,50 South Dr,MSC 8007, Bethesda, MD 20892 USA.
EM Ksubbarao@niaid.nih.gov
RI Tatti, Kathleen M/H-5912-2012
OI Tatti, Kathleen M/0000-0001-9414-7887; Subbarao,
   Kanta/0000-0003-1713-3056
CR Bankamp B, 2002, J VIROL, V76, P7073, DOI 10.1128/JVI.76.14.7073-7081.2002
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Burt FJ, 1997, ARCH PATHOL LAB MED, V121, P839
   CROWE JE, 1994, VACCINE, V12, P691, DOI 10.1016/0264-410X(94)90218-6
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Epstein SL, 1997, J IMMUNOL, V158, P1222
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Fowler RA, 2003, JAMA-J AM MED ASSOC, V290, P367, DOI 10.1001/jama.290.3.367
   GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI200318819, 10.1172/JCI18819]
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   MURPHY BR, 1999, MUCOSAL IMMUNOLOGY, P695
   NOVAK M, 1993, VACCINE, V11, P55, DOI 10.1016/0264-410X(93)90339-Y
   OLSEN CW, 1993, VET MICROBIOL, V36, P1, DOI 10.1016/0378-1135(93)90126-R
   PEDERSEN NC, 1980, AM J VET RES, V41, P868
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   PRINCE GA, 1985, J VIROL, V55, P517, DOI 10.1128/JVI.55.3.517-520.1985
   RAMPHAL R, 1979, INFECT IMMUN, V25, P992, DOI 10.1128/IAI.25.3.992-997.1979
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   RENEGAR KB, 1992, LAB ANIM SCI, V42, P222
   Stack AM, 2000, VACCINE, V18, P1412, DOI 10.1016/S0264-410X(99)00399-0
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   WEISS RC, 1981, AM J VET RES, V42, P2036
   WEISS RC, 1981, AM J VET RES, V42, P382
   WEISS RC, 1981, COMP IMMUNOL MICROB, V4, P175, DOI 10.1016/0147-9571(81)90003-5
   WELLS MA, 1981, J IMMUNOL, V126, P1042
   WYDE PR, 1977, INFECT IMMUN, V15, P221, DOI 10.1128/IAI.15.1.221-229.1977
NR 35
TC 230
Z9 253
U1 1
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD APR
PY 2004
VL 78
IS 7
BP 3572
EP 3577
DI 10.1128/JVI.78.7.3572-3577.2004
PG 6
WC Virology
SC Virology
GA 804IY
UT WOS:000220293600040
PM 15016880
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Frias-Staheli, N
   Giannakopoulos, NV
   Kikkert, M
   Taylor, SL
   Bridgen, A
   Paragas, J
   Richt, JA
   Rowland, RR
   Schmaljohn, CS
   Lenschow, DJ
   Snijder, EJ
   Garcia-Sastre, A
   Virgin, HW
AF Frias-Staheli, Natalia
   Giannakopoulos, Nadia V.
   Kikkert, Marjolein
   Taylor, Shannon L.
   Bridgen, Anne
   Paragas, Jason
   Richt, Juergen A.
   Rowland, Raymond R.
   Schmaljohn, Connie S.
   Lenschow, Deborah J.
   Snijder, Eric J.
   Garcia-Sastre, Adolfo
   Virgin, Herbert Whiting
TI Ovarian tumor domain-containing viral proteases evade ubiquitin- and
   ISG15-dependent innate immune responses
SO CELL HOST & MICROBE
LA English
DT Article
ID NF-KAPPA-B; RESPIRATORY SYNDROME CORONAVIRUS; CONGO-HEMORRHAGIC-FEVER;
   PAPAIN-LIKE PROTEASE; INFLUENZA-A VIRUS; DEUBIQUITINATING ENZYME; NS1
   PROTEIN; ANTIVIRAL MOLECULE; STIMULATED GENE-15; CYSTEINE PROTEASES
AB Ubiquitin (Ub) and interferon-stimulated gene product 15 (ISG15) reversibly conjugate to proteins and mediate important innate antiviral responses. The ovarian tumor (OTU) domain represents a superfamily of predicted proteases found in eukaryotic, bacterial, and viral proteins, some of which have Ub-deconjugating activity. We show that the OTU domain-containing proteases f rom nairoviruses and arteriviruses, two unrelated groups of RNA viruses, hydrolyze Ub and ISG15 from cellular target proteins. This broad activity contrasts with the target specificity of known mammalian OTU domain-containing proteins. Expression of a viral OTU domain-containing protein antagonizes the antiviral effects of ISG15 and enhances susceptibility to Sindbis virus infection in vivo. We also show that viral OTU domain-containing proteases inhibit NF-kappa B-dependent signaling. Thus, the deconjugating activity of viral OTU proteases represents a unique viral strategy to inhibit Ub- and ISG15dependent antiviral pathways.
C1 [Frias-Staheli, Natalia; Garcia-Sastre, Adolfo] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
   [Garcia-Sastre, Adolfo] Mt Sinai Sch Med, Dept Med, Div Infect Dis, New York, NY 10029 USA.
   [Garcia-Sastre, Adolfo] Mt Sinai Sch Med, Emerging Pathogens Inst, New York, NY 10029 USA.
   [Giannakopoulos, Nadia V.; Lenschow, Deborah J.; Virgin, Herbert Whiting] Washington Univ, Sch Med, Dept Pathol & Immunol, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Lenschow, Deborah J.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Kikkert, Marjolein; Snijder, Eric J.] Leiden Univ, Med Ctr, Ctr Infect Dis,LUMC, Dept Med Microbiol,Mol Virol Lab, NL-2300 RC Leiden, Netherlands.
   [Taylor, Shannon L.; Schmaljohn, Connie S.] USA, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA.
   [Bridgen, Anne] Univ Ulster, Dept Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland.
   [Paragas, Jason] NIH, NIAID, Emerging Viral Pathogens Sect, Bethesda, MD 20892 USA.
   [Richt, Juergen A.] USDA ARS, Natl Anim Dis Ctr, Ames, IA 50010 USA.
   [Rowland, Raymond R.] Kansas State Univ, Manhattan, KS 66506 USA.
RP Garcia-Sastre, A (reprint author), Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
EM adolfo.garcia-sastre@mssm.edu; virgin@wustl.edu
RI Snijder, Eric J./E-6073-2018
OI Snijder, Eric J./0000-0003-3297-2309; Giannakopoulos,
   Nadia/0000-0001-7543-088X; Garcia-Sastre, Adolfo/0000-0002-6551-1827
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U54 AI057158-010003, U19 AI062623-010003,
   U19 AI062623, U54 AI057160, U19 AI62623, U54 AI057158]
CR Allende R, 1999, J GEN VIROL, V80, P307, DOI 10.1099/0022-1317-80-2-307
   Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824
   Balakirev MY, 2002, J VIROL, V76, P6323, DOI 10.1128/JVI.76.12.6323-6331.2002
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Behr M, 2001, J INTERF CYTOK RES, V21, P981, DOI 10.1089/107999001753289596
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110
   Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758
   Dunn GP, 2005, NAT IMMUNOL, V6, P722, DOI 10.1038/ni1213
   Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200
   Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377
   FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775
   Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732
   Giannakopoulos NV, 2005, BIOCHEM BIOPH RES CO, V336, P496, DOI 10.1016/j.bbrc.2005.08.132
   HAAS AL, 1987, J BIOL CHEM, V262, P11315
   Heise MT, 2000, J VIROL, V74, P4207, DOI 10.1128/JVI.74.9.4207-4213.2000
   Honig JE, 2004, VIROLOGY, V321, P29, DOI 10.1016/j.virol.2003.09.042
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kim KI, 2004, MOL CELL BIOL, V24, P9592, DOI 10.1128/MCB.24.21.9592-9600.2004
   Kinsella E, 2004, VIROLOGY, V321, P23, DOI 10.1016/j.virol.2003.09.046
   Kirkin V, 2007, CURR OPIN CELL BIOL, V19, P199, DOI 10.1016/j.ceb.2007.02.002
   Lenschow DJ, 2007, P NATL ACAD SCI USA, V104, P1371, DOI 10.1073/pnas.0607038104
   Lenschow DJ, 2005, J VIROL, V79, P13974, DOI 10.1128/JVI.79.22.13974-13983.2005
   Levine B, 1996, P NATL ACAD SCI USA, V93, P4810, DOI 10.1073/pnas.93.10.4810
   Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102
   Lin RT, 2006, J VIROL, V80, P6072, DOI 10.1128/JVI.02495-05
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Liu YC, 2005, NAT REV IMMUNOL, V5, P941, DOI 10.1038/nri1731
   LOEB KR, 1992, J BIOL CHEM, V267, P7806
   Loureiro J, 2006, ADV IMMUNOL, V92, P225, DOI 10.1016/S0065-2776(06)92006-9
   Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3
   Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200
   Nanao MH, 2004, EMBO REP, V5, P783, DOI 10.1038/sj.embor.7400201
   Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324
   Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007
   Okumura A, 2006, P NATL ACAD SCI USA, V103, P1440, DOI 10.1073/pnas.0510518103
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Shin JS, 2006, NATURE, V444, P115, DOI 10.1038/nature05261
   Snijder EJ, 1996, J BIOL CHEM, V271, P4864, DOI 10.1074/jbc.271.9.4864
   SNIJDER EJ, 1995, J BIOL CHEM, V270, P16671, DOI 10.1074/jbc.270.28.16671
   SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994
   Sudo Kenji, 2005, Antiviral Chemistry & Chemotherapy, V16, P385
   Tergaonkar V, 2006, INT J BIOCHEM CELL B, V38, P1647, DOI 10.1016/j.biocel.2006.03.023
   TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9
   Wang XY, 2000, J VIROL, V74, P11566, DOI 10.1128/JVI.74.24.11566-11573.2000
   Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010
   Weck KE, 1999, J VIROL, V73, P4651, DOI 10.1128/JVI.73.6.4651-4661.1999
   Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794
   Whitehouse CA, 2004, ANTIVIR RES, V64, P145, DOI 10.1016/j.antiviral.2004.08.001
   Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362
   Yuan WM, 2002, VIROLOGY, V304, P291, DOI 10.1006/viro.2002.1663
   Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 53
TC 229
Z9 240
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1931-3128
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD DEC
PY 2007
VL 2
IS 6
BP 404
EP 416
DI 10.1016/j.chom.2007.09.014
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 244GY
UT WOS:000251855600006
PM 18078692
OA Green Accepted
DA 2020-04-03
ER

PT J
AU Prentice, E
   Jerome, WG
   Yoshimori, T
   Mizushima, N
   Denison, MR
AF Prentice, E
   Jerome, WG
   Yoshimori, T
   Mizushima, N
   Denison, MR
TI Coronavirus replication complex formation utilizes components of
   cellular autophagy
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; ACUTE RESPIRATORY SYNDROME; 3C-LIKE PROTEINASE
   ACTIVITY; DOUBLE-MEMBRANE VESICLES; EMBRYONIC STEM-CELLS; MURINE
   CORONAVIRUS; ENDOPLASMIC-RETICULUM; POLIOVIRUS INFECTION; VIRAL-RNA;
   IN-VITRO
AB The coronavirus mouse hepatitis virus (MHV) performs RNA replication on double membrane vesicles (DMVs) in the cytoplasm of the host cell. However, the mechanism by which these DMVs form has not been determined. Using genetic, biochemical, and cell imaging approaches, the role of autophagy in DMV formation and MHV replication was investigated. The results demonstrated that replication complexes co-localize with the autophagy proteins, microtubule-associated protein light-chain 3 and Apg12. MHV infection induces autophagy by a mechanism that is resistant to 3-methyladenine inhibition. MHV replication is impaired in autophagy knockout, APG5-/-, embryonic stem cell lines, but wild-type levels of MHV replication are restored by expression of Apg5 in the APG5-/- cells. In MHV-infected APG5-/- cells, DMVs were not detected; rather, the rough endoplasmic reticulum was dramatically swollen. The results of this study suggest that autophagy is required for formation of double membrane-bound MHV replication complexes and that DMV formation significantly enhances the efficiency of replication. Furthermore, the rough endoplasmic reticulum is implicated as the possible source of membranes for replication complexes.
C1 Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37221 USA.
   Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37221 USA.
   Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37221 USA.
   Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37221 USA.
   Vanderbilt Univ, Med Ctr, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37221 USA.
   Natl Inst Genet, Dept Cell Genet, Mishima, Shizuoka 4118540, Japan.
   Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan.
   Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Unit Proc & Combines Circuit, Kawaguchi 3320012, Japan.
   Japan Sci & Technol Corp, Core Res Evolutionary Sci & Technol Program, Kawaguchi 3320012, Japan.
RP Denison, MR (reprint author), Vanderbilt Univ, Med Ctr, Dept Pediat, D6217 MCN, Nashville, TN 37232 USA.
EM mark.denison@vanderbilt.edu
RI Mizushima, Noboru/C-3635-2009; Denison, Mark/O-7258-2018
OI Mizushima, Noboru/0000-0002-6258-6444; Denison, Mark/0000-0003-2655-0900
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA68485]; NHLBI NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [5 T32HL07751]; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AI50083]; NIDDK NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK20593]
CR Bi WZ, 1998, J NEUROVIROL, V4, P594, DOI 10.3109/13550289809114226
   Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000
   Bost AG, 2001, VIROLOGY, V285, P21, DOI 10.1006/viro.2001.0932
   Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999
   Denison MR, 2001, ADV EXP MED BIOL, V494, P655
   DONG SH, 1994, VIROLOGY, V204, P541, DOI 10.1006/viro.1994.1567
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hegyi A, 2002, J GEN VIROL, V83, P581, DOI 10.1099/0022-1317-83-3-581
   HIRANO N, 1984, JPN J VET SCI, V46, P757
   HIRANO N, 1974, ARCH GES VIRUSFORSCH, V44, P298, DOI 10.1007/BF01240618
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200
   Kyuwa S, 1997, EXP ANIM TOKYO, V46, P311, DOI 10.1538/expanim.46.311
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Lu XT, 1998, J VIROL, V72, P2265, DOI 10.1128/JVI.72.3.2265-2271.1998
   Lu XT, 1996, VIROLOGY, V222, P375, DOI 10.1006/viro.1996.0434
   Lu YQ, 1997, VIROLOGY, V230, P335, DOI 10.1006/viro.1997.8479
   LU YQ, 1995, J VIROL, V69, P3554, DOI 10.1128/JVI.69.6.3554-3559.1995
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Okumura A, 1996, J VIROL, V70, P4146, DOI 10.1128/JVI.70.6.4146-4149.1996
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002
   Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996
   Shi ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999
   Sims AC, 2000, J VIROL, V74, P5647, DOI 10.1128/JVI.74.12.5647-5654.2000
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000
   Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299
NR 34
TC 228
Z9 247
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 12
PY 2004
VL 279
IS 11
BP 10136
EP 10141
DI 10.1074/jbc.M306124200
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 800TK
UT WOS:000220050400059
PM 14699140
OA Bronze
DA 2020-04-03
ER

PT J
AU Bermingham, A
   Chand, MA
   Brown, CS
   Aarons, E
   Tong, C
   Langrish, C
   Hoschler, K
   Brown, K
   Galiano, M
   Myers, R
   Pebody, RG
   Green, HK
   Boddington, NL
   Gopal, R
   Price, N
   Newsholme, W
   Drosten, C
   Fouchier, RA
   Zambon, M
AF Bermingham, A.
   Chand, M. A.
   Brown, C. S.
   Aarons, E.
   Tong, C.
   Langrish, C.
   Hoschler, K.
   Brown, K.
   Galiano, M.
   Myers, R.
   Pebody, R. G.
   Green, H. K.
   Boddington, N. L.
   Gopal, R.
   Price, N.
   Newsholme, W.
   Drosten, C.
   Fouchier, R. A.
   Zambon, M.
TI Severe respiratory illness caused by a novel coronavirus, in a patient
   transferred to the United Kingdom from the Middle East, September 2012
SO EUROSURVEILLANCE
LA English
DT Article
ID SARS
AB Coronaviruses have the potential to cause severe transmissible human disease, as demonstrated by the severe acute respiratory syndrome (SARS) outbreak of 2003. We describe here the clinical and virological features of a novel coronavirus infection causing severe respiratory illness in a patient transferred to London, United Kingdom, from the Gulf region of the Middle East.
C1 [Bermingham, A.; Chand, M. A.; Brown, C. S.; Hoschler, K.; Brown, K.; Galiano, M.; Myers, R.; Pebody, R. G.; Green, H. K.; Boddington, N. L.; Gopal, R.; Zambon, M.] Hlth Protect Agcy HPA, London, England.
   [Aarons, E.; Tong, C.; Langrish, C.; Price, N.; Newsholme, W.] Guys & St Thomas NHS Fdn Trust, London, England.
   [Aarons, E.; Tong, C.; Langrish, C.; Price, N.; Newsholme, W.] Kings Hlth Partners, London, England.
   [Drosten, C.] Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
   [Fouchier, R. A.] Erasmus MC, Dept Virol, Rotterdam, Netherlands.
RP Bermingham, A (reprint author), Hlth Protect Agcy HPA, London, England.
EM meera.chand@hpa.org.uk
RI Tong, Cheuk Yan William/C-1312-2012; Fouchier, Ron/Y-3755-2019;
   Fouchier, Ron A/A-1911-2014
OI Tong, Cheuk Yan William/0000-0001-8401-6832; Fouchier,
   Ron/0000-0001-8095-2869; Fouchier, Ron A/0000-0001-8095-2869; Pebody,
   Richard/0000-0002-9069-2885; Chand, Meera/0000-0001-9697-0340; Brown,
   Colin/0000-0003-4776-3403
CR Anderson LJ, 2010, INT J ANTIMICROB AG, V36, pS21, DOI 10.1016/j.ijantimicag.2010.06.016
   Bermingham A, 2004, PHILOS T R SOC B, V359, P1083, DOI 10.1098/rstb.2004.1493
   Corman VM, 2012, EURO SURVEILL, V17
   Drexler JF, 2010, J VIROL, V84, P11336, DOI 10.1128/JVI.00650-10
   Health Protection Agency (HPA), PART GEN SEQ INF SCI
   Pebody R, 2012, EURO SURVEILL, V17
   ProMED-mail, NOV COR SAUD AR HUM
   Shi ZL, 2008, VIRUS RES, V133, P74, DOI 10.1016/j.virusres.2007.03.012
   TYRRELL DAJ, 1965, BMJ-BRIT MED J, V1, P1467, DOI 10.1136/bmj.1.5448.1467
   *WHO, 2003, SUMM TABL SARS CAS C
NR 10
TC 227
Z9 251
U1 2
U2 32
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD OCT 4
PY 2012
VL 17
IS 40
BP 6
EP 10
AR 20290
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 020AN
UT WOS:000309780800002
PM 23078800
OA DOAJ Gold
DA 2020-04-03
ER

PT J
AU Oboho, IK
   Tomczyk, SM
   Al-Asmari, AM
   Banjar, AA
   Al-Mugti, H
   Aloraini, MS
   Alkhaldi, KZ
   Almohammadi, EL
   Alraddadi, BM
   Gerber, SI
   Swerdlow, DL
   Watson, JT
   Madani, TA
AF Oboho, Ikwo K.
   Tomczyk, Sara M.
   Al-Asmari, Ahmad M.
   Banjar, Ayman A.
   Al-Mugti, Hani
   Aloraini, Muhannad S.
   Alkhaldi, Khulud Z.
   Almohammadi, Emad L.
   Alraddadi, Basem M.
   Gerber, Susan I.
   Swerdlow, David L.
   Watson, John T.
   Madani, Tariq A.
TI 2014 MERS-CoV Outbreak in Jeddah - A Link to Health Care Facilities
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; SAUDI-ARABIA
AB BACKGROUND
   A marked increase in the number of cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection occurred in Jeddah, Saudi Arabia, in early 2014. We evaluated patients with MERS-CoV infection in Jeddah to explore reasons for this increase and to assess the epidemiologic and clinical features of this disease.
   METHODS
   We identified all cases of laboratory-confirmed MERS-CoV infection in Jeddah that were reported to the Saudi Arabian Ministry of Health from January 1 through May 16, 2014. We conducted telephone interviews with symptomatic patients who were not health care personnel, and we reviewed hospital records. We identified patients who were reported as being asymptomatic and interviewed them regarding a history of symptoms in the month before testing. Descriptive analyses were performed.
   RESULTS
   Of 255 patients with laboratory-confirmed MERS-CoV infection, 93 died (case fatality rate, 36.5%). The median age of all patients was 45 years (interquartile range, 30 to 59), and 174 patients (68.2%) were male. A total of 64 patients (25.1%) were reported to be asymptomatic. Of the 191 symptomatic patients, 40 (20.9%) were health care personnel. Among the 151 symptomatic patients who were not health care personnel, 112 (74.2%) had data that could be assessed, and 109 (97.3%) of these patients had had contact with a health care facility, a person with a confirmed case of MERS-CoV infection, or someone with severe respiratory illness in the 14 days before the onset of illness. The remaining 3 patients (2.7%) reported no such contacts. Of the 64 patients who had been reported as asymptomatic, 33 (52%) were interviewed, and 26 of these 33 (79%) reported at least one symptom that was consistent with a viral respiratory illness.
   CONCLUSIONS
   The majority of patients in the Jeddah MERS-CoV outbreak had contact with a health care facility, other patients, or both. This highlights the role of health care-associated transmission.
C1 [Oboho, Ikwo K.; Tomczyk, Sara M.; Gerber, Susan I.; Swerdlow, David L.; Watson, John T.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
   [Oboho, Ikwo K.; Tomczyk, Sara M.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Al-Asmari, Ahmad M.; Banjar, Ayman A.; Alkhaldi, Khulud Z.; Almohammadi, Emad L.; Alraddadi, Basem M.; Madani, Tariq A.] Minist Hlth, Jeddah, Saudi Arabia.
   [Al-Mugti, Hani] Minist Natl Guard, Natl Guard Hlth Affairs, Community & Prevent Med Ctr, Jeddah, Saudi Arabia.
   [Alraddadi, Basem M.] King Faisal Specialist Hosp & Res Ctr, Jeddah, Saudi Arabia.
   [Madani, Tariq A.] King Abdulaziz Univ, Fac Med, Dept Med, Jeddah 21413, Saudi Arabia.
   [Aloraini, Muhannad S.] Al Qassim Univ, Fac Med, Dept Family & Community Med, Al Qassim, Saudi Arabia.
RP Madani, TA (reprint author), King Abdulaziz Univ, Dept Med, POB 80215, Jeddah 21589, Saudi Arabia.
EM tmadani@kau.edu.sa
RI Alraddadi, Basem/AAB-1085-2019
OI Tomczyk, Sara/0000-0001-6975-2663
FU Ministry of Health, Saudi Arabia; U.S. Centers for Disease Control and
   PreventionUnited States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA
FX Supported by the Ministry of Health, Saudi Arabia, and by the U.S.
   Centers for Disease Control and Prevention.
CR Al-Abdallat MM, 2014, CLIN INFECT DIS, V59, P1225, DOI 10.1093/cid/ciu359
   [Anonymous], 2014, SCI INSIDER
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Drosten C, 2015, CLIN INFECT DIS, V60, P369, DOI 10.1093/cid/ciu812
   Gulland A, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2968
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Madani TA, 2014, LANCET INFECT DIS, V14, P911, DOI 10.1016/S1473-3099(14)70918-1
   Madani TA, 2014, SAUDI MED J, V35, P897
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Poissy J, 2014, J CLIN VIROL, V61, P275, DOI 10.1016/j.jcv.2014.07.002
   The WHO MERS-CoV Research Group, 2013, PLOS CURR OUTBR
   WHO, 2014, WHO RISK ASS MIDDL E
   WHO, 2014, UPD MERS COV TRANSM
   World Health Organization, 2014, MIDDL E RESP SYNDR C
   World Health Organization, 2014, CAS CONTR STUD ASS P
NR 16
TC 225
Z9 234
U1 8
U2 23
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD FEB 26
PY 2015
VL 372
IS 9
BP 846
EP 854
DI 10.1056/NEJMoa1408636
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA CB8SQ
UT WOS:000349901700009
PM 25714162
OA Green Accepted, Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Wong, J
   Zhang, JC
   Si, XN
   Gao, G
   Mao, I
   McManus, BM
   Luo, HL
AF Wong, Jerry
   Zhang, Jingchun
   Si, Xiaoning
   Gao, Guang
   Mao, Ivy
   McManus, Bruce M.
   Luo, Honglin
TI Autophagosome supports coxsackievirus B3 replication in host cells
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ISOLATED RAT HEPATOCYTES; CORONAVIRUS REPLICATION; MONITORING AUTOPHAGY;
   CELLULAR AUTOPHAGY; HIGHER EUKARYOTES; 3-KINASE COMPLEX; MACROAUTOPHAGY;
   VIRUS; TRANSLATION; DEGRADATION
AB Recent studies suggest a possible takeover of host antimicrobial autophagy machinery by positive-stranded RNA viruses to facilitate their own replication. In the present study, we investigated the role of autophagy in coxsackievirus replication. Coxsackievirus B3 (CVB3), a picornavirus associated with viral myocarditis, causes pronounced intracellular membrane reorganization after infection. We demonstrate that CVB3 infection induces an increased number of double-membrane vesicles, accompanied by an increase of the LC3-II/LC3-I ratio and an accumulation of punctate GFP-LC3-expressing cells, two hallmarks of cellular autophagosome formation. However, protein expression analysis of p62, a marker for autophagy-mediated protein degradation, showed no apparent changes after CVB3 infection. These results suggest that CVB3 infection triggers autophagosome formation without promoting protein degradation by the lysosome. We further examined the role of the autophagosome in CVB3 replication. We demonstrated that inhibition of autophagosome formation by 3-methyladenine or small interfering RNAs targeting the genes critical for autophagosome formation (ATG7, Beclin-1, and VPS34 genes) significantly reduced viral replication. Conversely, induction of autophagy by rapamycin or nutrient deprivation resulted in increased viral replication. Finally, we examined the role of autophagosome-lysosome fusion in viral replication. We showed that blockage of the fusion by gene silencing of the lysosomal protein LAMP2 significantly promoted viral replication. Taken together, our results suggest that the host's autophagy machinery is activated during CVB3 infection to enhance the efficiency of viral replication.
C1 [Wong, Jerry; Zhang, Jingchun; Si, Xiaoning; Gao, Guang; Mao, Ivy; McManus, Bruce M.; Luo, Honglin] Univ British Columbia, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Dept Pathol & Lab Med, St Pauls Hosp,Providence Heart & Lung Inst, Vancouver, BC V6Z 1Y6, Canada.
RP Luo, HL (reprint author), Univ British Columbia, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Dept Pathol & Lab Med, St Pauls Hosp,Providence Heart & Lung Inst, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM hluo@mrl.ubc.ca
RI Wong, Tse Yuan/G-3029-2011
FU Heart and Stroke Foundation of British Columbia and Yukon; Canadian
   Institutes of Health Research (CIHR)Canadian Institutes of Health
   Research (CIHR); Canada Foundation for InnovationCanada Foundation for
   Innovation; Michael Smith Foundation for Health Research (MSFHR)Michael
   Smith Foundation for Health Research; CIHR IMPACTCanadian Institutes of
   Health Research (CIHR); CIHR/St. Paul's Hospital FoundationCanadian
   Institutes of Health Research (CIHR)
FX This work was supported by grants from the Heart and Stroke Foundation
   of British Columbia and Yukon (H. L.), the Canadian Institutes of Health
   Research (CIHR) (H.L.), and the Canada Foundation for Innovation (H.L.).
   J.W. is the recipient of master studentships from the Michael Smith
   Foundation for Health Research (MSFHR) and from the CIHR. X. S. is
   supported by a CIHR IMPACT postdoctoral fellowship and a CIHR Michael
   Smith postdoctoral fellowship. G. G. is supported by doctoral
   traineeships from the MSFHR and from the Heart and Stroke Foundation. H.
   L. is a new investigator under a CIHR/St. Paul's Hospital Foundation
   award and an MSFHR scholar.
CR Alexander DE, 2007, J VIROL, V81, P12128, DOI 10.1128/JVI.01356-07
   Andrade RM, 2006, J CLIN INVEST, V116, P2366, DOI 10.1172/JCI28796
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Brabec-Zaruba M, 2007, J VIROL, V81, P10815, DOI 10.1128/JVI.00143-07
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Esfandiarei M, 2004, J VIROL, V78, P4289, DOI 10.1128/JVI.78.8.4289-4298.2004
   Espert L, 2007, J MOL MED, V85, P811, DOI 10.1007/s00109-007-0173-6
   Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Kim KS, 2001, REV MED VIROL, V11, P355, DOI 10.1002/rmv.326
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Klionsky DJ, 2005, AUTOPHAGY, V1, P65, DOI 10.4161/auto.1.2.1899
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine Beth, 2003, Harvey Lect, V99, P47
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Mohr I, 2004, INT REV IMMUNOL, V23, P199, DOI 10.1080/08830180490265600
   Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   PILIPENKO EV, 1992, NUCLEIC ACIDS RES, V20, P1739, DOI 10.1093/nar/20.7.1739
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Schmid D, 2007, IMMUNITY, V27, P11, DOI 10.1016/j.immuni.2007.07.004
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Si XN, 2007, J VIROL, V81, P3142, DOI 10.1128/JVI.02028-06
   Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971
   Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299
   Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595
   Wileman T, 2006, SCIENCE, V312, P875, DOI 10.1126/science.1126766
   Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735
   Zhao ZJ, 2007, AUTOPHAGY, V3, P581, DOI 10.4161/auto.4782
   Zhou B, 1997, J CLIN INVEST, V100, P3070, DOI 10.1172/JCI119862
NR 41
TC 225
Z9 240
U1 1
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD SEP
PY 2008
VL 82
IS 18
BP 9143
EP 9153
DI 10.1128/JVI.00641-08
PG 11
WC Virology
SC Virology
GA 347OX
UT WOS:000259152000019
PM 18596087
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Bellau-Pujol, S
   Vabret, A
   Legrand, L
   Dina, J
   Gouarin, S
   Petitjean-Lecherbonnier, J
   Pozzetto, B
   Ginevra, C
   Freymuth, F
AF Bellau-Pujol, S
   Vabret, A
   Legrand, L
   Dina, J
   Gouarin, S
   Petitjean-Lecherbonnier, J
   Pozzetto, B
   Ginevra, C
   Freymuth, F
TI Development of three multiplex RT-PCR assays for the detection of 12
   respiratory RNA viruses
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE multiplex RT-PCR assay; respiratory syncytial virus; influenza virus;
   parainfluenza virus; human metapneumovirus; rhinovirus; human
   coronavirus
ID REVERSE TRANSCRIPTION-PCR; POLYMERASE-CHAIN-REACTION; ENZYME
   HYBRIDIZATION ASSAY; SYNCYTIAL-VIRUS; PARAINFLUENZA VIRUS; INFLUENZA-A;
   HOSPITALIZED CHILDREN; HUMAN METAPNEUMOVIRUS; PEDIATRIC-PATIENTS; TRACT
   INFECTIONS
AB Three multiplex hemi-nested RT-PCR assays were developed to detect simultaneously 12 RNA respiratory viruses: influenza viruses A, B and C, human respiratory syncytial virus (hRSV), human metapneumovirus (hMPV), parainfluenza virus types 1-4 (PIV- 1, -2, -3 and -4), human coronavirus OC43 and 229E (HCoV) and rhinovirus (hRV). An internal amplification control was included in one of the RT-PCR assays. The RT-PCR multiplex I and the hemi-nested multiplex I detected I and 0. 1 TCID50 of RSV A, respectively, and 0.01 and 0.00 1 TCID50 of influenza virus AWN2, respectively. Two hundred and three nasal aspirates from hospitalised children were retrospectively tested in comparison with two conventional methods: direct immunofluorescence assay and viral isolation technique. Almost all samples (89/9 1) that were positive by immunofluorescence assay and/or viral isolation technique were detected by the multiplex assay. This method also-detected an additional 85 viruses and 33 co-infections. The overall sensitivity (98%), rapidity and enhanced efficiency of these multiplex hemi-nested RT-PCR assays suggest that they would be a significant improvement over conventional methods for the detection of a broad spectrum of respiratory viruses. (c) 2005 Elsevier B.V. All rights reserved.
C1 Univ Hosp, Lab Human & Mol Virol, F-14033 Caen, France.
   CHU St Etienne, Virol Lab, F-42055 St Etienne, France.
RP Freymuth, F (reprint author), Univ Hosp, Lab Human & Mol Virol, Av Georges Clemenceau, F-14033 Caen, France.
EM freymuth-f@chu-caen.fr
RI Ginevra, Christophe/AAC-6109-2019
OI Ginevra, Christophe/0000-0002-5597-094X; POZZETTO,
   Bruno/0000-0002-2603-8467; VABRET, Astrid/0000-0002-8940-7645
CR Aguilar JC, 2000, J CLIN MICROBIOL, V38, P1191, DOI 10.1128/JCM.38.3.1191-1195.2000
   Boivin G, 2003, EMERG INFECT DIS, V9, P634
   Brouard J, 2000, ARCH PEDIATRIE, V7, p531S, DOI 10.1016/S0929-693X(00)80180-3
   CANE PA, 1991, J GEN VIROL, V72, P349, DOI 10.1099/0022-1317-72-2-349
   Casiano-Colon AE, 2003, J CLIN VIROL, V28, P169, DOI 10.1016/S1386-6532(03)00002-7
   Coiras MT, 2004, J MED VIROL, V72, P484, DOI 10.1002/jmv.20008
   Coiras MT, 2003, J MED VIROL, V69, P132, DOI 10.1002/jmv.10255
   Dingle KE, 2004, J CLIN MICROBIOL, V42, P1003, DOI 10.1128/JCM.42.3.1003-1011.2004
   Donofrio J C, 1992, PCR Methods Appl, V1, P263
   Echevarria JE, 1998, J CLIN MICROBIOL, V36, P1388
   Elnifro EM, 2000, CLIN MICROBIOL REV, V13, P559, DOI 10.1128/CMR.13.4.559-570.2000
   Eugene-Ruellan G, 1998, J CLIN MICROBIOL, V36, P796, DOI 10.1128/JCM.36.3.796-801.1998
   Fan J, 1998, CLIN INFECT DIS, V26, P1397, DOI 10.1086/516357
   FREYMUTH F, 1995, J CLIN MICROBIOL, V33, P3352, DOI 10.1128/JCM.33.12.3352-3355.1995
   FREYMUTH F, 1987, ANN PEDIATR-PARIS, V34, P493
   Freymuth F, 1996, J CLIN MICROBIOL, V34, P1601
   Freymuth F, 1997, CLIN DIAGN VIROL, V8, P31, DOI 10.1016/S0928-0197(97)00060-3
   Freymuth F, 2003, PEDIATR INFECT DIS J, V22, P92, DOI 10.1097/00006454-200301000-00024
   FREYMUTH F, 2001, INFECT VIRALES RESP, V2, P107
   GARDNER PS, 1968, BMJ-BRIT MED J, V3, P340, DOI 10.1136/bmj.3.5614.340
   Gilbert LL, 1996, J CLIN MICROBIOL, V34, P140, DOI 10.1128/JCM.34.1.140-143.1996
   GLEZEN WP, 1980, JAMA-J AM MED ASSOC, V243, P1345
   Grondahl B, 1999, J CLIN MICROBIOL, V37, P1
   Gueudin M, 2003, J VIROL METHODS, V109, P39, DOI 10.1016/S0166-0934(03)00042-9
   Guittet V, 2003, ARCH PEDIATRIE, V10, P417, DOI 10.1016/S0929-693X(03)00090-3
   Hindiyeh M, 2001, AM J CLIN PATHOL, V116, P218
   Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027
   KARRON RA, 1994, J CLIN MICROBIOL, V32, P484, DOI 10.1128/JCM.32.2.484-488.1994
   Kehl SC, 2001, J CLIN MICROBIOL, V39, P1696, DOI 10.1128/JCM.39.5.1696-1701.2001
   Lindquist SW, 1997, PEDIATR INFECT DIS J, V16, P34, DOI 10.1097/00006454-199701000-00008
   Liolios L, 2001, J CLIN MICROBIOL, V39, P2779, DOI 10.1128/JCM.39.8.2779-2783.2001
   MALETZKY AJ, 1971, J PEDIATR-US, V78, P407, DOI 10.1016/S0022-3476(71)80219-6
   MANUGUERRA JC, 1992, J INFECTION, V24, P91, DOI 10.1016/0163-4453(92)91150-A
   MEISSNER HC, 1984, J PEDIATR-US, V104, P680, DOI 10.1016/S0022-3476(84)80943-9
   NAKABAYASHI N, 1977, J BIOMED MATER RES, V11, P395, DOI 10.1002/jbm.820110307
   Osiowy C, 1998, J CLIN MICROBIOL, V36, P3149, DOI 10.1128/JCM.36.11.3149-3154.1998
   PORTNOY B, 1965, AM J EPIDEMIOL, V82, P262, DOI 10.1093/oxfordjournals.aje.a120548
   Puppe W, 2004, J CLIN VIROL, V30, P165, DOI 10.1016/j.jcv.2003.10.003
   Savolainen C, 2002, VIRUS RES, V85, P41, DOI 10.1016/S0168-1702(02)00016-3
   Savolainen Carita, 2003, Paediatr Respir Rev, V4, P91, DOI 10.1016/S1526-0542(03)00030-7
   Syrmis MW, 2004, J MOL DIAGN, V6, P125, DOI 10.1016/S1525-1578(10)60500-4
   Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004
   TRISTRAM DA, 1988, AM J DIS CHILD, V142, P834, DOI 10.1001/archpedi.1988.02150080040017
   Vabret A, 2000, J CLIN VIROL, V17, P167, DOI 10.1016/S1386-6532(00)00095-0
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   Vabret A, 2001, J VIROL METHODS, V97, P59, DOI 10.1016/S0166-0934(01)00343-3
   Vabret A, 1998, PRESSE MED, V27, P1813
   VALENTI WM, 1982, J PEDIATR-US, V100, P722, DOI 10.1016/S0022-3476(82)80571-4
   Van den Hoogen BG, 2004, PEDIATR INFECT DIS J, V23, pS25, DOI 10.1097/01.inf.0000108190.09824.e8
   ZHANG WD, 1991, J VIROL METHODS, V33, P165, DOI 10.1016/0166-0934(91)90017-T
NR 50
TC 224
Z9 247
U1 3
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUN
PY 2005
VL 126
IS 1-2
BP 53
EP 63
DI 10.1016/j.jviromet.2005.01.020
PG 11
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 924TJ
UT WOS:000229003000007
PM 15847919
DA 2020-04-03
ER

PT J
AU GORBALENYA, AE
   KOONIN, EV
   DONCHENKO, AP
   BLINOV, VM
AF GORBALENYA, AE
   KOONIN, EV
   DONCHENKO, AP
   BLINOV, VM
TI CORONAVIRUS GENOME - PREDICTION OF PUTATIVE FUNCTIONAL DOMAINS IN THE
   NON-STRUCTURAL POLYPROTEIN BY COMPARATIVE AMINO-ACID SEQUENCE-ANALYSIS
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
RP GORBALENYA, AE (reprint author), ACAD MED SCI USSR,INST POLIOMYELITIS & VIRAL ENCEPHALITIDES,MOSCOW 142782,USSR.
RI Gorbalenya, Alexander E/J-4818-2012
OI Gorbalenya, Alexander E/0000-0002-4967-7341
CR ALLISON R, 1986, VIROLOGY, V154, P9, DOI 10.1016/0042-6822(86)90425-3
   APPELLA E, 1988, FEBS LETT, V241, P1
   ARGOS P, 1984, NUCLEIC ACIDS RES, V12, P7251, DOI 10.1093/nar/12.18.7251
   ARGOS P, 1987, J MOL BIOL, V193, P385, DOI 10.1016/0022-2836(87)90226-9
   BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409
   Boursnell M. E. G., 1987, Coronaviruses, P15
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BRAYTON PR, 1984, VIROLOGY, V133, P197, DOI 10.1016/0042-6822(84)90439-2
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391
   CARROLL AR, 1984, NUCLEIC ACIDS RES, V12, P2461, DOI 10.1093/nar/12.5.2461
   DOMIER LL, 1987, VIROLOGY, V158, P20, DOI 10.1016/0042-6822(87)90233-9
   EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3
   FRANKEL AD, 1988, CELL, V53, P675, DOI 10.1016/0092-8674(88)90083-9
   GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2
   GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0
   GORBALENYA AE, 1986, FEBS LETT, V194, P253, DOI 10.1016/0014-5793(86)80095-3
   GORBALENYA AE, 1988, IN PRESS J MOL EVOL, V28
   GORBALENYA AE, 1989, IN PRESS FEBS LETT
   GOUDHERTY WG, 1988, EMBO J, V7, P1281
   GREIF C, 1988, J GEN VIROL, V69, P1517, DOI 10.1099/0022-1317-69-7-1517
   GUSTAFSON G, 1987, VIROLOGY, V158, P394, DOI 10.1016/0042-6822(87)90211-X
   HARTSHORNE TA, 1986, NATURE, V320, P283, DOI 10.1038/320283a0
   HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0
   KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269
   KOONIN EV, 1987, MOL GENETIKA, V7, P27
   KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413
   LAI MMC, 1986, BIOESSAYS, V5, P257, DOI 10.1002/bies.950050606
   LAIN S, 1988, VIRUS RES, V10, P325, DOI 10.1016/0168-1702(88)90074-3
   LOMONOSSOFF GP, 1983, EMBO J, V2, P2253, DOI 10.1002/j.1460-2075.1983.tb01731.x
   MCLACHLAN AD, 1971, J MOL BIOL, V61, P409, DOI 10.1016/0022-2836(71)90390-1
   NAJARIAN R, 1985, P NATL ACAD SCI USA, V82, P2627, DOI 10.1073/pnas.82.9.2627
   PALMENBERG AC, 1987, J CELL BIOCHEM, V33, P191, DOI 10.1002/jcb.240330306
   PALMENBERG AC, 1984, NUCLEIC ACIDS RES, V12, P2969, DOI 10.1093/nar/12.6.2969
   PAYRE F, 1988, FEBS LETT, V234, P245, DOI 10.1016/0014-5793(88)80091-7
   POZDNYAKOV VI, 1981, INT J PEPT PROT RES, V17, P284
   PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x
   RACANIELLO VR, 1981, P NATL ACAD SCI-BIOL, V78, P4887, DOI 10.1073/pnas.78.8.4887
   SANKOFF D, 1972, P NATL ACAD SCI USA, V69, P4, DOI 10.1073/pnas.69.1.4
   SIDDELL SG, 1983, INTERVIROLOGY, V20, P181, DOI 10.1159/000149390
   SKERN T, 1985, NUCLEIC ACIDS RES, V13, P7859
   SOE LH, 1987, J VIROL, V61, P3968, DOI 10.1128/JVI.61.12.3968-3976.1987
   STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   TAI JY, 1976, J BIOL CHEM, V251, P1955
   WELLINK J, 1988, ARCH VIROL, V98, P1, DOI 10.1007/BF01321002
   ZIMMERN D, 1988, IN PRESS RNA GENETIC
NR 47
TC 223
Z9 236
U1 1
U2 4
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUN 26
PY 1989
VL 17
IS 12
BP 4847
EP 4861
DI 10.1093/nar/17.12.4847
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AD050
UT WOS:A1989AD05000034
PM 2526320
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Kopecky-Bromberg, SA
   Martinez-Sobrido, L
   Frieman, M
   Baric, RA
   Palese, P
AF Kopecky-Bromberg, Sarah A.
   Martinez-Sobrido, Luis
   Frieman, Matthew
   Baric, Ralph A.
   Palese, Peter
TI Severe acute respiratory syndrome coronavirus open reading frame (ORF)
   3b, ORF 6, and nucleocapsid proteins function as interferon antagonists
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID VIRUS NS1 PROTEIN; DOUBLE-STRANDED-RNA; REVERSE GENETICS; V-PROTEIN;
   W-PROTEIN; INHIBITION; ACTIVATION; BINDING; LOCALIZATION; ALPHA/BETA
AB The severe acute respiratory syndrome coronavirus (SARS-CoV) is highly pathogenic in humans, with a death rate near 10%. This high pathogenicity suggests that SARS-CoV has developed mechanisms to overcome the host innate immune response. It has now been determined that SARS-CoV open reading frame (ORF) 3b, ORF 6, and N proteins antagonize interferon, a key component of the innate immune response. All three proteins inhibit the expression of beta interferon (IFN-beta), and further examination revealed that these SARS-CoV proteins inhibit a key protein necessary for the expression of IFN-beta, IRF-3. N protein dramatically inhibited expression from an NF-kappa B-responsive promoter. All three proteins were able to inhibit expression from an interferon-stimulated response element (ISRE) promoter after infection with Sendai virus, while only ORF 3b and ORF 6 proteins were able to inhibit expression from the ISRE promoter after treatment with interferon. This indicates that N protein inhibits only the synthesis of interferon, while ORF 3b and ORF 6 proteins inhibit both interferon synthesis and signaling. ORF 6 protein, but not ORF 3b or N protein, inhibited nuclear translocation but not phosphorylation of STAT1. Thus, it appears that these three interferon antagonists of SARS-CoV inhibit the interferon response by different mechanisms.
C1 Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
   Univ N Carolina, Chapel Hill, NC 27599 USA.
RP Palese, P (reprint author), Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
EM peter.palese@mssm.edu
OI Palese, Peter/0000-0002-0337-5823
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24
   CA095823, 5R24 CA095823-04]; NCRR NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [1 S10 RR0 0145-01]; NIAID
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [F32 AI66542, F32 AI066542, P01 AI059443,
   P01 AI059443-01A1]; PHS HHSUnited States Public Health Service [T32
   A1007645]
CR Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297
   Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000
   Cardenas WB, 2006, J VIROL, V80, P5168, DOI 10.1128/JVI.02199-05
   Chan WS, 2005, MODERN PATHOL, V18, P1432, DOI 10.1038/modpathol.3800439
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508
   Garcia-Sastre A, 2002, MICROBES INFECT, V4, P647, DOI 10.1016/S1286-4579(02)01583-6
   Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676
   Geng H, 2005, FEBS LETT, V579, P6763, DOI 10.1016/j.febslet.2005.11.007
   HATADA E, 1992, J GEN VIROL, V73, P3325, DOI 10.1099/0022-1317-73-12-3325
   Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004
   Jennings S, 2005, VIROLOGY, V331, P63, DOI 10.1016/j.virol.2004.10.015
   Kopecky-Bromberg SA, 2006, J VIROL, V80, P785, DOI 10.1128/JVI.80.2.785-793.2006
   LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937
   Martinez-Sobrido L, 2006, J VIROL, V80, P9192, DOI 10.1128/JVI.00555-06
   Park MS, 2003, J VIROL, V77, P1501, DOI 10.1128/JVI.77.2.1501-1511.2003
   Pewe L, 2005, J VIROL, V79, P11335, DOI 10.1128/JVI.79.17.11335-11342.2005
   Reid SP, 2006, J VIROL, V80, P5156, DOI 10.1128/JVI.02349-05
   Rodriguez JJ, 2004, J VIROL, V78, P5358, DOI 10.1128/JVI.78.10.5358-5367.2004
   Shaw ML, 2005, J VIROL, V79, P6078, DOI 10.1128/JVI.79.10.6078-6088.2005
   Shaw ML, 2004, J VIROL, V78, P5633, DOI 10.1128/JVI.78.11.5633-5641.2004
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Surjit M, 2006, J BIOL CHEM, V281, P10669, DOI 10.1074/jbc.M509233200
   Surjit M, 2004, BIOCHEM J, V383, P13, DOI 10.1042/BJ20040984
   Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000
   Yan XH, 2006, INT J BIOCHEM CELL B, V38, P1417, DOI 10.1016/j.biocel.2006.02.003
   You JW, 2005, J GEN VIROL, V86, P3303, DOI 10.1099/vir.0.81076-0
   Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Yuan XL, 2006, MOL CELLS, V21, P186
   Yuan XL, 2005, VIRUS RES, V114, P70, DOI 10.1016/j.virusres.2005.06.001
   Zhao G, 2006, CELL BIOL TOXICOL, V22, P313, DOI 10.1007/s10565-006-0077-1
   Zheng BJ, 2004, J INTERF CYTOK RES, V24, P388, DOI 10.1089/1079990041535610
NR 33
TC 221
Z9 236
U1 3
U2 17
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JAN
PY 2007
VL 81
IS 2
BP 548
EP 557
DI 10.1128/JVI.01782-06
PG 10
WC Virology
SC Virology
GA 124EK
UT WOS:000243350100013
PM 17108024
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU SAWICKI, SG
   SAWICKI, DL
AF SAWICKI, SG
   SAWICKI, DL
TI CORONAVIRUS TRANSCRIPTION - SUBGENOMIC MOUSE HEPATITIS-VIRUS REPLICATIVE
   INTERMEDIATES FUNCTION IN RNA-SYNTHESIS
SO JOURNAL OF VIROLOGY
LA English
DT Article
RP SAWICKI, SG (reprint author), MED COLL OHIO, DEPT MICROBIOL, TOLEDO, OH 43699 USA.
FU NCRR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [2SO7-RR05700]; NIAID NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [AI-15123]
CR ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0
   ARMSTRONG J, 1983, NUCLEIC ACIDS RES, V11, P883, DOI 10.1093/nar/11.3.883
   BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BOZARTH RF, 1976, BIOCHIM BIOPHYS ACTA, V432, P329, DOI 10.1016/0005-2787(76)90142-8
   BUDZILOWICZ CJ, 1985, J VIROL, V53, P834, DOI 10.1128/JVI.53.3.834-840.1985
   GARGOURI R, 1989, VIROLOGY, V171, P386, DOI 10.1016/0042-6822(89)90606-5
   JACOBS L, 1981, J VIROL, V39, P401, DOI 10.1128/JVI.39.2.401-406.1981
   KAARIAINEN L, 1987, J CELL SCI, P231
   KONINGS DAM, 1988, NUCLEIC ACIDS RES, V16, P10849, DOI 10.1093/nar/16.22.10849
   KRUG RM, 1985, CELL, V41, P651, DOI 10.1016/S0092-8674(85)80041-6
   LAI MMC, 1983, J VIROL, V46, P1027, DOI 10.1128/JVI.46.3.1027-1033.1983
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   LAI MMC, 1988, RNA GENETICS, V1, P115
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   PACHUK CJ, 1989, VIROLOGY, V171, P141, DOI 10.1016/0042-6822(89)90520-5
   SAWICKI DL, 1978, J VIROL, V25, P19, DOI 10.1128/JVI.25.1.19-27.1978
   SAWICKI SG, 1986, J VIROL, V57, P328, DOI 10.1128/JVI.57.1.328-334.1986
   SAWICKI SG, 1986, VIROLOGY, V152, P507, DOI 10.1016/0042-6822(86)90157-1
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   SIMMONS DT, 1972, J MOL BIOL, V71, P615
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   STRAUSS JH, 1988, RNA GENETICS, V1
NR 25
TC 221
Z9 227
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAR
PY 1990
VL 64
IS 3
BP 1050
EP 1056
DI 10.1128/JVI.64.3.1050-1056.1990
PG 7
WC Virology
SC Virology
GA CN825
UT WOS:A1990CN82500011
PM 2154591
OA Bronze
DA 2020-04-03
ER

PT J
AU Vennema, H
   Poland, A
   Foley, J
   Pedersen, NC
AF Vennema, H
   Poland, A
   Foley, J
   Pedersen, NC
TI Feline infectious peritonitis viruses arise by mutation from endemic
   feline enteric coronaviruses
SO VIROLOGY
LA English
DT Article
ID PORCINE RESPIRATORY CORONAVIRUS; TRANSMISSIBLE GASTROENTERITIS VIRUS;
   RNA RECOMBINATION; SEQUENCE-ANALYSIS; 3' END; CATS; DELETIONS; MEMBRANE;
   KITTENS; STRAINS
AB Feline infectious peritonitis virus (FIPV) strains from six cats and three different geographic areas were compared genetically with feline enteric coronavirus (FECV) isolates obtained from cats inhabiting the same environments, Sequence comparisons were made from 1.2- to 8.9-kb segments on the 3' end of the genome. FECV/FIPV pairs from the same catteries or shelters were 97.3-99.5% related but were genetically distinct from FIPV and FECV strains obtained from cats living in geographically distinct environments. The high generic similarity between FECVs and FIPVs from the same environment strongly suggested a common ancestry Based on the presence of deletion mutations in the FIPVs and not in the FECVs, it was concluded that FIPVs evolved as mutants of FECVs. The mutations are deletions in the FIPVs and not insertions in the FECVs since similar sequences are present in other strains that have segregated earlier from a common ancestor. Therefore, the order of descent is from FECV to FIPV. Mutations unique to FIPVs were found in open reading frames (ORFs) 3c in 4 of 6 isolates and/or 7b in 3 of 6 isolates. When the study was extended to include 7 additional FIPV isolates, 11/13 of the FIPVs sequenced were found to have mutated 3c ORFs. (C) 1998 Academic Press.
C1 Univ Calif Davis, Ctr Compan Anim Hlth, Davis, CA 95616 USA.
   Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA.
RP Vennema, H (reprint author), I&I, Div Virol, POB 80-165, NL-3508 TD Utrecht, Netherlands.
EM H.Vennema@vetmic.dgk.ruu.nl
CR BLACK JW, 1980, VET MED SM ANIM CLIN, V75, P811
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   COMPTON SR, 1993, LAB ANIM SCI, V43, P15
   DEGROOT RJ, 1988, VIROLOGY, V167, P370, DOI 10.1016/0042-6822(88)90097-9
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   Foley JE, 1997, J AM VET MED ASSOC, V210, P1313
   Foley JE, 1996, FELINE PRACT, V24, P14
   *GEN COMP GROUP, 1994, PROGR MAN WISC PACK
   HERREWEGH AAPM, 1995, VIROLOGY, V212, P622, DOI 10.1006/viro.1995.1520
   HICKMAN MA, 1995, FELINE PRACT, V23, P96
   HOLZWORTH J, 1963, CORNELL VET, V53, P157
   HORSBURGH BC, 1992, J GEN VIROL, V66, P6931
   JACOBS L, 1986, J VIROL, V57, P1010, DOI 10.1128/JVI.57.3.1010-1015.1986
   KECK JG, 1988, J VIROL, V62, P1989, DOI 10.1128/JVI.62.6.1989-1998.1988
   KECK JG, 1988, J VIROL, V62, P1810, DOI 10.1128/JVI.62.5.1810-1813.1988
   KUSTERS JG, 1990, VACCINE, V8, P605, DOI 10.1016/0264-410X(90)90018-H
   LAUDE H, 1993, VET RES, V24, P125
   Motokawa K, 1996, MICROBIOL IMMUNOL, V40, P425, DOI 10.1111/j.1348-0421.1996.tb01089.x
   PEDERSEN NC, 1981, AM J VET RES, V42, P368
   PEDERSEN NC, 1976, AM J VET RES, V37, P1449
   PEDERSEN NC, 1985, COMP CONT EDUC PRACT, V7, P1001
   PEDERSEN NC, 1981, AM J VET RES, V42, P363
   PEDERSEN NC, 1995, FELINE PRACT, V23, P7
   PEDERSEN NC, 1984, ADV EXP MED BIOL, V173, P37
   Poland AM, 1996, J CLIN MICROBIOL, V34, P3180, DOI 10.1128/JCM.34.12.3180-3184.1996
   POSTORINOREEVES NC, 1995, FELINE PRACT, V23, P81
   RASSCHAERT D, 1990, J GEN VIROL, V71, P2599, DOI 10.1099/0022-1317-71-11-2599
   VAUGHN EM, 1994, J CLIN MICROBIOL, V32, P1809, DOI 10.1128/JCM.32.7.1809-1812.1994
   VENNEMA H, 1992, VIROLOGY, V191, P134, DOI 10.1016/0042-6822(92)90174-N
   VENNEMA H, 1991, VIROLOGY, V181, P327, DOI 10.1016/0042-6822(91)90499-2
   VENNEMA H, 1992, J VIROL, V66, P4951, DOI 10.1128/JVI.66.8.4951-4956.1992
   VENNEMA H, 1995, FELINE PRACT, V23, P40
   WARD JM, 1970, VIROLOGY, V41, P191, DOI 10.1016/0042-6822(70)90070-X
   WESLEY RD, 1991, J VIROL, V65, P3369, DOI 10.1128/JVI.65.6.3369-3373.1991
NR 34
TC 220
Z9 229
U1 0
U2 34
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAR 30
PY 1998
VL 243
IS 1
BP 150
EP 157
DI 10.1006/viro.1998.9045
PG 8
WC Virology
SC Virology
GA ZF672
UT WOS:000072920500015
PM 9527924
OA Bronze
DA 2020-04-03
ER

PT J
AU CHAMBERS, P
   PRINGLE, CR
   EASTON, AJ
AF CHAMBERS, P
   PRINGLE, CR
   EASTON, AJ
TI HEPTAD REPEAT SEQUENCES ARE LOCATED ADJACENT TO HYDROPHOBIC REGIONS IN
   SEVERAL TYPES OF VIRUS FUSION GLYCOPROTEINS
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID COMPLETE NUCLEOTIDE-SEQUENCE; AMINO-ACID-SEQUENCES; INFLUENZA-VIRUS;
   LEUKEMIA-VIRUS; SENDAI VIRUS; ENV GENE; SECONDARY STRUCTURE;
   PROTEIN-SEQUENCE; LEUCINE ZIPPER; MEASLES-VIRUS
AB Extensive regions of heptad repeat units consistent with an alpha-helical coiled coil conformation are located adjacent to hydrophobic, potentially fusion-related regions in the amino acid sequences of paramyxovirus fusion and retrovirus envelope glycoproteins.  Similar arrangements of hydrophobic peptides and heptad repeat units exist in coronavirus peplomer proteins and influenza virus haemagglutinins.  This suggests that there may be similarities in the structures of these proteins and in the functions of the hydrophobic fusion-related regions during virus entry.
C1 UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.
CR AIR GM, 1985, VIROLOGY, V145, P117, DOI 10.1016/0042-6822(85)90206-5
   AUPERIN DD, 1986, VIROLOGY, V154, P155, DOI 10.1016/0042-6822(86)90438-1
   BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0
   BINNS MM, 1985, J GEN VIROL, V66, P719, DOI 10.1099/0022-1317-66-4-719
   BLUMBERG BM, 1985, J GEN VIROL, V66, P317, DOI 10.1099/0022-1317-66-2-317
   BUCKLAND R, 1989, NATURE, V338, P547, DOI 10.1038/338547a0
   BUCKLAND R, 1987, J GEN VIROL, V68, P1695, DOI 10.1099/0022-1317-68-6-1695
   BZIK DJ, 1984, VIROLOGY, V133, P301, DOI 10.1016/0042-6822(84)90397-0
   CHAMBERS P, 1990, J VIROL, V64, P1869, DOI 10.1128/JVI.64.4.1869-1872.1990
   CHAMBERS P, 1986, J GEN VIROL, V67, P2685, DOI 10.1099/0022-1317-67-12-2685
   COHEN C, 1981, P NATL ACAD SCI-BIOL, V78, P5303, DOI 10.1073/pnas.78.9.5303
   COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6
   COLLINS PL, 1984, P NATL ACAD SCI-BIOL, V81, P7683, DOI 10.1073/pnas.81.24.7683
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   FLUGEL RM, 1987, EMBO J, V6, P2077, DOI 10.1002/j.1460-2075.1987.tb02473.x
   FREYMANN DM, 1984, NATURE, V311, P167, DOI 10.1038/311167a0
   GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5
   GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8
   GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737
   HITI AL, 1981, VIROLOGY, V111, P113, DOI 10.1016/0042-6822(81)90658-9
   HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824
   HSU M, 1982, P NATL ACAD SCI-BIOL, V79, P5862, DOI 10.1073/pnas.79.19.5862
   HUANG RTC, 1980, VIROLOGY, V104, P294, DOI 10.1016/0042-6822(80)90334-7
   HUNTER E, 1983, J VIROL, V46, P920, DOI 10.1128/JVI.46.3.920-936.1983
   KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6
   KRYSTAL M, 1982, P NATL ACAD SCI-BIOL, V79, P4800, DOI 10.1073/pnas.79.15.4800
   LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117
   MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0
   NAKADA S, 1984, J VIROL, V50, P118, DOI 10.1128/JVI.50.1.118-124.1984
   PATERSON RG, 1984, P NATL ACAD SCI-BIOL, V81, P6706, DOI 10.1073/pnas.81.21.6706
   PELLETT PE, 1985, J VIROL, V56, P807, DOI 10.1128/JVI.56.3.807-813.1985
   PEPINSKY RB, 1980, VIROLOGY, V102, P205, DOI 10.1016/0042-6822(80)90081-1
   PINTER A, 1979, J VIROL, V30, P157, DOI 10.1128/JVI.30.1.157-165.1979
   POWER MD, 1986, SCIENCE, V231, P1567, DOI 10.1126/science.3006247
   RASSCHAERT D, 1987, J GEN VIROL, V68, P1883, DOI 10.1099/0022-1317-68-7-1883
   RICHARDSON C, 1986, VIROLOGY, V155, P508, DOI 10.1016/0042-6822(86)90212-6
   RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3
   RIMA BK, 1989, GENETICS AND PATHOGENICITY OF NEGATIVE STRAND VIRUSES, P254
   RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x
   RUSHLOW K, 1986, VIROLOGY, V155, P309, DOI 10.1016/0042-6822(86)90195-9
   SCHMIDT I, 1987, J GEN VIROL, V68, P47, DOI 10.1099/0022-1317-68-1-47
   SECHOY O, 1987, J BIOL CHEM, V262, P11519
   SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618
   SERVER AC, 1985, VIROLOGY, V144, P373, DOI 10.1016/0042-6822(85)90279-X
   SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0
   SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968
   SONIGO P, 1985, CELL, V42, P369, DOI 10.1016/S0092-8674(85)80132-X
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   VERHOEYEN M, 1980, NATURE, V286, P771, DOI 10.1038/286771a0
   WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4
   WATERFIELD MD, 1979, BRIT MED B, V35, P5763
   WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0
NR 52
TC 220
Z9 224
U1 0
U2 6
PU SOC GENERAL MICROBIOLOGY
PI READING
PA HARVEST HOUSE 62 LONDON ROAD, READING, BERKS, ENGLAND RG1 5AS
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD DEC
PY 1990
VL 71
BP 3075
EP 3080
DI 10.1099/0022-1317-71-12-3075
PN 12
PG 6
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA EP009
UT WOS:A1990EP00900040
PM 2177097
OA Bronze
DA 2020-04-03
ER

PT J
AU Mordstein, M
   Neugebauer, E
   Ditt, V
   Jessen, B
   Rieger, T
   Falcone, V
   Sorgeloos, F
   Ehl, S
   Mayer, D
   Kochs, G
   Schwemmle, M
   Gunther, S
   Drosten, C
   Michiels, T
   Staeheli, P
AF Mordstein, Markus
   Neugebauer, Eva
   Ditt, Vanessa
   Jessen, Birthe
   Rieger, Toni
   Falcone, Valeria
   Sorgeloos, Frederic
   Ehl, Stephan
   Mayer, Daniel
   Kochs, Georg
   Schwemmle, Martin
   Guenther, Stephan
   Drosten, Christian
   Michiels, Thomas
   Staeheli, Peter
TI Lambda Interferon Renders Epithelial Cells of the Respiratory and
   Gastrointestinal Tracts Resistant to Viral Infections
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID INFLUENZA-A VIRUS; ANTIVIRAL ACTIVITY; SYNCYTIAL VIRUS; RECEPTOR;
   CORONAVIRUS; PROTEIN; IDENTIFICATION; DISEASE; SYSTEM; FAMILY
AB Virus-infected cells secrete a broad range of interferons (IFN) which confer resistance to yet uninfected cells by triggering the synthesis of antiviral factors. The relative contributions of the various IFN subtypes to innate immunity against virus infections remain elusive. IFN-alpha, IFN-beta, and other type I IFN molecules signal through a common, universally expressed cell surface receptor, whereas type III IFN (IFN-lambda) uses a distinct cell-type-specific receptor complex for signaling. Using mice lacking functional receptors for type I IFN, type III IFN, or both, we found that IFN-lambda plays an important role in the defense against several human pathogens that infect the respiratory tract, such as influenza A virus, influenza B virus, respiratory syncytial virus, human metapneumovirus, and severe acute respiratory syndrome (SARS) coronavirus. These viruses were more pathogenic and replicated to higher titers in the lungs of mice lacking both IFN receptors than in mice with single IFN receptor defects. In contrast, Lassa fever virus, which infects via the respiratory tract but primarily replicates in the liver, was not influenced by the IFN-lambda receptor defect. Careful analysis revealed that expression of functional IFN-lambda receptor complexes in the lung and intestinal tract is restricted to epithelial cells and a few other, undefined cell types. Interestingly, we found that SARS coronavirus was present in feces from infected mice lacking receptors for both type I and type III IFN but not in those from mice lacking single receptors, supporting the view that IFN-lambda contributes to the control of viral infections in epithelial cells of both respiratory and gastrointestinal tracts.
C1 [Mordstein, Markus; Falcone, Valeria; Mayer, Daniel; Kochs, Georg; Schwemmle, Martin; Staeheli, Peter] Univ Freiburg, Dept Virol, D-79104 Freiburg, Germany.
   [Mordstein, Markus] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, D-79104 Freiburg, Germany.
   [Neugebauer, Eva; Ditt, Vanessa; Drosten, Christian] Univ Med Ctr, Inst Virol, D-53127 Bonn, Germany.
   [Jessen, Birthe; Ehl, Stephan] Univ Freiburg, Ctr Chron Immunodeficiency, D-79106 Freiburg, Germany.
   [Rieger, Toni; Guenther, Stephan] Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany.
   [Sorgeloos, Frederic; Michiels, Thomas] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium.
RP Staeheli, P (reprint author), Univ Freiburg, Dept Virol, Hermann Herder Str 11, D-79104 Freiburg, Germany.
EM peter.staeheli@uniklinik-freiburg.de
OI Sorgeloos, Frederic/0000-0002-6492-8524; Michiels,
   Thomas/0000-0001-9615-8053; Gunther, Stephan/0000-0002-6562-0230
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SFB
   620]; German Ministry of Education and ResearchFederal Ministry of
   Education & Research (BMBF); University of Louvain
FX This work was supported by grants from the Deutsche
   Forschungsgemeinschaft (SFB 620) to P. S. and S. E., the German Ministry
   of Education and Research (Project Code "Okologie und Pathogenese von
   SARS") to C. D., FRSM to T. M., and the University of Louvain (FSR) to
   F. S.
CR Ank N, 2008, J IMMUNOL, V180, P2474, DOI 10.4049/jimmunol.180.4.2474
   Asper M, 2004, J VIROL, V78, P3162, DOI 10.1128/JVI.78.6.3162-3169.2004
   Bartlett NW, 2005, J GEN VIROL, V86, P1589, DOI 10.1099/vir.0.80904-0
   Bouloy M, 2001, J VIROL, V75, P1371, DOI 10.1128/JVI.75.3.1371-1377.2001
   Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770
   Cheng PKC, 2004, LANCET, V363, P1699, DOI 10.1016/S0140-6736(04)16255-7
   Childs RA, 2009, NAT BIOTECHNOL, V27, P797, DOI 10.1038/nbt0909-797
   Dare R, 2007, J CLIN MICROBIOL, V45, P548, DOI 10.1128/JCM.01621-06
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Dumoutier L, 2004, J BIOL CHEM, V279, P32269, DOI 10.1074/jbc.M404789200
   Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1
   Gunther S, 2000, EMERG INFECT DIS, V6, P466, DOI 10.3201/eid0605.000504
   Haller O, 2006, VIROLOGY, V344, P119, DOI 10.1016/j.virol.2005.09.024
   Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004
   Holler O, 2009, REV SCI TECH OIE, V28, P219, DOI 10.20506/rst.28.1.1867
   HORISBERGER MA, 1983, P NATL ACAD SCI-BIOL, V80, P1910, DOI 10.1073/pnas.80.7.1910
   Huck B, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-6
   Johnson TR, 2005, J IMMUNOL, V174, P7234, DOI 10.4049/jimmunol.174.11.7234
   Kochs G, 2007, J GEN VIROL, V88, P1403, DOI 10.1099/vir.0.82764-0
   Koerner I, 2007, J VIROL, V81, P2025, DOI 10.1128/JVI.01718-06
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   Lasfar A, 2006, CANCER RES, V66, P4468, DOI 10.1158/0008-5472.CAN-05-3653
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Levraud JP, 2007, J IMMUNOL, V178, P4385, DOI 10.4049/jimmunol.178.7.4385
   MEIER E, 1988, J VIROL, V62, P2386, DOI 10.1128/JVI.62.7.2386-2393.1988
   Mordstein M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000151
   Peebles R Stokes Jr, 2005, Proc Am Thorac Soc, V2, P110, DOI 10.1513/pats.200501-002AW
   Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873
   Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017
   van Pesch V, 2004, J VIROL, V78, P8219, DOI 10.1128/JVI.78.15.8219-8228.2004
   Witte K, 2009, GENES IMMUN, V10, P702, DOI 10.1038/gene.2009.72
   Zhou ZL, 2007, J VIROL, V81, P7749, DOI 10.1128/JVI.02438-06
NR 32
TC 219
Z9 229
U1 2
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUN
PY 2010
VL 84
IS 11
BP 5670
EP 5677
DI 10.1128/JVI.00272-10
PG 8
WC Virology
SC Virology
GA 592NQ
UT WOS:000277386700020
PM 20335250
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Jeffers, SA
   Tusell, SM
   Gillim-Ross, L
   Hemmila, EM
   Achenbach, JE
   Babcock, GJ
   Thomas, WD
   Thackray, LB
   Young, MD
   Mason, RJ
   Ambrosino, DM
   Wentworth, DE
   DeMartini, JC
   Holmes, KV
AF Jeffers, SA
   Tusell, SM
   Gillim-Ross, L
   Hemmila, EM
   Achenbach, JE
   Babcock, GJ
   Thomas, WD
   Thackray, LB
   Young, MD
   Mason, RJ
   Ambrosino, DM
   Wentworth, DE
   DeMartini, JC
   Holmes, KV
TI CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome
   coronavirus
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME-2; SARS-ASSOCIATED CORONAVIRUS;
   MESSENGER-RNA EXPRESSION; DENGUE VIRUS-INFECTION; HUMAN DENDRITIC CELLS;
   DC-SIGN; AMINOPEPTIDASE-N; ENDOTHELIAL-CELLS; FUNCTIONAL RECEPTOR;
   TISSUE DISTRIBUTION
AB Angiotensin-converting enzyme 2 (ACE2) is a receptor for SARS-CoV, the novel coronavirus that causes severe acute respiratory syndrome [Li, W. Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al (2003) Nature 426, 450-454]. We have identified a different human cellular glycoprotein that can serve as an alternative receptor for SARS-CoV. A human lung cDNA library in vesicular stomatitis virus G pseudotyped retrovirus was transduced into Chinese hamster ovary cells, and the cells were sorted for binding of soluble SARS-CoV spike (S) glycoproteins, S-590 and S-1180. Clones of transduced cells that bound SARS-CoV S glycoprotein were inoculated with SARS-CoV, and increases in subgenomic viral RNA from 1-16 h or more were detected by multiplex RT-PCR in four cloned cell lines. Sequencing of the human lung cDNA inserts showed that each of the cloned cell lines contained cDNA that encoded human CD209L, a C-type lectin (also called L-SIGN). When the cDNA encoding CD209L from clone 2.27 was cloned and transfected into Chinese hamster ovary cells, the cells expressed human CD209L glycoprotein and became susceptible to infection with SARS-CoV. Immunohistochemistry showed that CD209L is expressed in human lung in type II alveolar cells and endothelial cells, both potential targets for SARS-CoV. Several other enveloped viruses including Ebola and Sindbis also use CD209L as a portal of entry, and HIV and hepatitis C virus can bind to CD209L on cell membranes but do not use it to mediate virus entry. Our data suggest that the large S glycoprotein of SARS-CoV may use both ACE2 and CD209L in virus infection and pathogenesis.
C1 Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA.
   Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA.
   New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12202 USA.
   Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   Univ Massachusetts, Sch Med, Massachusetts Biol Labs, Boston, MA 02130 USA.
   Natl Jewish Med Res Ctr, Dept Med, Denver, CO 80206 USA.
   SUNY Albany, Dept Biomed Sci, Albany, NY 12202 USA.
RP Holmes, KV (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Microbiol, 4200 E 9th Ave,Campus Box B-175, Denver, CO 80262 USA.
EM kathryn.holmes@uchsc.edu
OI Wentworth, David/0000-0002-5190-980X
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30
   CA 046934, P30 CA046934]; NHLBI NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01 HL 67671, P01
   HL067671]; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [N01 AI 25490, N01 AI 25489,
   N01AI65315, R01 AI 25231, R01 AI025231, T32 AI007537, P01 AI 59576, N01
   AI 65315, N01AI25489, N01AI25490, T32 AI 07537-04, P01 AI059576]; ODCDC
   CDC HHS [901 CCU 216988]
CR Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002
   Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004
   Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671
   Chan KH, 2004, EMERG INFECT DIS, V10, P294, DOI 10.3201/eid1002.030610
   Chow KC, 2004, AM J CLIN PATHOL, V121, P574, DOI 10.1309/C0EDU0RAQBTXBHCE
   Clapham PR, 2001, BRIT MED BULL, V58, P43, DOI 10.1093/bmb/58.1.43
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   DANILCZYK U, 2002, J MOL MED, V532, P107
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   DVEKSLER GS, 1993, J VIROL, V67, P1
   Eriksson U, 2002, CURR BIOL, V12, pR745, DOI 10.1016/S0960-9822(02)01255-1
   Geijtenbeek TBH, 2002, J LEUKOCYTE BIOL, V71, P921
   Gillim-Ross L, 2004, J CLIN MICROBIOL, V42, P3196, DOI 10.1128/JCM.42.7.3196-3206.2004
   Grignani F, 1998, CANCER RES, V58, P14
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   HWANG DM, 2004, MOD PATHOL
   Jameson B, 2002, J VIROL, V76, P1866, DOI 10.1128/JVI.76.4.1866-1875.2002
   Klimstra WB, 2003, J VIROL, V77, P12022, DOI 10.1128/JVI.77.22.12022-12032.2003
   Komatsu T, 2002, DNA SEQUENCE, V13, P217, DOI 10.1080/1042517021000021608
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Manchester M, 2000, VIROLOGY, V274, P5, DOI 10.1006/viro.2000.0469
   Marovich M, 2001, J INVEST DERM SYMP P, V6, P219, DOI 10.1046/j.0022-202x.2001.00037.x
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mason RJ, 2000, AM J PATHOL, V156, P175, DOI 10.1016/S0002-9440(10)64717-7
   Mummidi S, 2001, J BIOL CHEM, V276, P33196, DOI 10.1074/jbc.M009807200
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003
   Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730
   Soilleux EJ, 2002, HUM PATHOL, V33, P652, DOI 10.1053/hupa.2002.124036
   Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937
   Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   To KF, 2004, J PATHOL, V203, P740, DOI 10.1002/path.1597
   Tresnan DB, 1996, J VIROL, V70, P8669, DOI 10.1128/JVI.70.12.8669-8674.1996
   Wentworth DE, 2001, J VIROL, V75, P9741, DOI 10.1128/JVI.75.20.9741-9752.2001
   WICKHAM TJ, 1993, BIOTECHNOL PROGR, V9, P25, DOI 10.1021/bp00019a004
   Yanagi Y, 2002, VIROLOGY, V299, P155, DOI 10.1006/viro.2002.1471
   Yanagi Y, 2001, REV MED VIROL, V11, P149, DOI 10.1002/rmv.308
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Zaitseva M, 2003, BBA-BIOMEMBRANES, V1614, P51, DOI 10.1016/S0005-2736(03)00162-7
NR 45
TC 219
Z9 248
U1 2
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 2
PY 2004
VL 101
IS 44
BP 15748
EP 15753
DI 10.1073/pnas.0403812101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 868OG
UT WOS:000224922300037
PM 15496474
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Simmons, G
   Reeves, JD
   Rennekamp, AJ
   Amberg, SM
   Piefer, AJ
   Bates, P
AF Simmons, G
   Reeves, JD
   Rennekamp, AJ
   Amberg, SM
   Piefer, AJ
   Bates, P
TI Characterization of severe acute respiratory syndrome-associated
   coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; MURINE CORONAVIRUS; CELL TROPISM; EBOLA; PROTEIN;
   ACTIVATION; IDENTIFICATION; TRANSDUCTION; LENTIVIRUS; EXPRESSION
AB Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is a rapidly emerging pathogen with potentially serious consequences for public health. Here we describe conditions that result not only in the efficient expression of the SARS-CoV spike (S) protein on the surface of cells, but in its incorporation into lentiviral particles that can be used to transduce cells in an S glycoprotein-dependent manner. We found that although some primate cell lines, including Vero E6, 293T and Huh-7 cells, could be efficiently transduced by SARS-CoV S glycoprotein pseudoviruses, other cells lines were either resistant or very poorly permissive to virus entry. Infection by pseudovirions could be inhibited by several lysosomotropic agents, suggesting a requirement for acidification of endosomes for efficient S-mediated viral entry. In addition, we were able to develop a cell-cell fusion assay that could be used to monitor S glycoprotein-dependent membrane fusion. Although proteolysis did not enhance the infectivity of cell-free pseudovirions, trypsin activation is required for cell-cell fusion. Additionally, there was no apparent pH requirement for S glycoprotein-mediated cell-cell fusion. Together, these studies describe important tools that can be used to study SARS-CoV S glycoprotein structure and function, including approaches that can be used to identify inhibitors of the entry of SARS-CoV into target cells.
C1 Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
RP Bates, P (reprint author), Univ Penn, Sch Med, Dept Microbiol, 225 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.
EM pbates@mail.med.upenn.edu
RI Reeves, Jacqueline/I-5379-2012; Bates, Paul/F-8823-2011; Simmons,
   Graham/G-3523-2012
OI Simmons, Graham/0000-0002-9615-7023; Bates, Paul/0000-0002-3918-5976;
   Rennekamp, Andrew/0000-0001-6174-7253
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA
   76256, R01 CA076256]; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01 AI043455, AI
   57172, R01 AI 43455]
CR ALEXANDER WA, 1992, J VIROL, V66, P2934, DOI 10.1128/JVI.66.5.2934-2942.1992
   Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756
   Besnier C, 2002, P NATL ACAD SCI USA, V99, P11920, DOI 10.1073/pnas.172384599
   BOULAY F, 1987, EMBO J, V6, P2643, DOI 10.1002/j.1460-2075.1987.tb02555.x
   BOYCOTT R, 1994, VIROLOGY, V203, P313, DOI 10.1006/viro.1994.1489
   DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Hingley ST, 1998, J VIROL, V72, P1606, DOI 10.1128/JVI.72.2.1606-1609.1998
   Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100
   Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6
   KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6
   KOOI C, 1991, VIROLOGY, V180, P108, DOI 10.1016/0042-6822(91)90014-3
   Krokhin O, 2003, MOL CELL PROTEOMICS, V2, P346, DOI 10.1074/mcp.M300048-MCP200
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Ma MH, 1999, VIRUS RES, V64, P23, DOI 10.1016/S0168-1702(99)00070-2
   Marsh M, 2000, TRAFFIC, V1, P525, DOI 10.1034/j.1600-0854.2000.010701.x
   MCCLURE MO, 1990, J GEN VIROL, V71, P767, DOI 10.1099/0022-1317-71-4-767
   Mothes W, 2000, CELL, V103, P679, DOI 10.1016/S0092-8674(00)00170-7
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Nash TC, 1997, VIROLOGY, V233, P1, DOI 10.1006/viro.1997.8609
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pekosz A, 1999, J VIROL, V73, P8808, DOI 10.1128/JVI.73.10.8808-8812.1999
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   ROAT PA, 2003, SCIENCE, V300, P1394
   Simmons G, 2002, J VIROL, V76, P2518, DOI 10.1128/JVI.76.5.2518-2528.2002
   STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985
   Takada A, 1997, P NATL ACAD SCI USA, V94, P14764, DOI 10.1073/pnas.94.26.14764
   Volchkov VE, 1998, VIROLOGY, V245, P110, DOI 10.1006/viro.1998.9143
   Watson DJ, 2002, MOL THER, V5, P528, DOI 10.1006/mthe.2002.0584
   Wool-Lewis RJ, 1998, J VIROL, V72, P3155, DOI 10.1128/JVI.72.4.3155-3160.1998
   Zelus BD, 2003, J VIROL, V77, P830, DOI 10.1128/JVI.77.2.830-840.2003
NR 33
TC 218
Z9 246
U1 3
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 23
PY 2004
VL 101
IS 12
BP 4240
EP 4245
DI 10.1073/pnas.0306446101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 806ZQ
UT WOS:000220472200046
PM 15010527
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Karesh, WB
   Cook, RA
   Bennett, EL
   Newcomb, J
AF Karesh, WB
   Cook, RA
   Bennett, EL
   Newcomb, J
TI Wildlife trade and global disease emergence
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID SARS CORONAVIRUS; INFLUENZA-VIRUS; TRANSMISSION; INFECTION
AB The global trade in wildlife provides disease transmission mechanisms that not only cause human disease outbreaks but also threaten livestock, international trade, rural livelihoods, native wildlife populations, and the health of ecosystems. Outbreaks resulting from wildlife trade have caused hundreds of billions of dollars of economic damage globally. Rather than attempting to eradicate pathogens or the wild species that may harbor them, a practical approach would include decreasing the contact rate among species, including humans, at the interface created by the wildlife trade. Since wildlife marketing functions as a system of scale-free networks with major hubs, these points provide control opportunities to maximize the effects of regulatory efforts.
C1 Wildlife Conservat Soc, Bronx, NY 10460 USA.
   Bioecon Res Associates, Boulder, CO USA.
RP Karesh, WB (reprint author), Wildlife Conservat Soc, 2300 So Blvd, Bronx, NY 10460 USA.
EM wkaresh@wcs.org
CR *AS AN FDN, 2005, SPEC LIST
   Bell D, 2004, PHILOS T ROY SOC B, V359, P1107, DOI 10.1098/rstb.2004.1492
   *BRIT BROADC CORP, 2003, AN SUFF WAR SARS
   Clayton Lynn, 2000, P473
   Dezso Z, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.055103
   FA JE, 2003, [No title captured], P203
   FENG G, 1999, NATURE, V397, P436
   Guarner J, 2004, EMERG INFECT DIS, V10, P426, DOI 10.3201/eid1003.030878
   Haydon DT, 2002, EMERG INFECT DIS, V8, P1468
   Institute of Medicine, 2003, MICR THREATS HLTH EM
   Kung NY, 2003, AVIAN DIS, V47, P1037, DOI 10.1637/0005-2086-47.s3.1037
   Leroy EM, 2004, SCIENCE, V303, P387, DOI 10.1126/science.1092528
   Lilley B, 1997, EMERG INFECT DIS, V3, P391, DOI 10.3201/eid0303.970321
   MATHER R, 2005, TURTLE RELEASE MERIT
   NEWCOMB J, 2004, BIOL BORDERS SARS NE
   Patz JA, 2000, INT J PARASITOL, V30, P1395, DOI 10.1016/S0020-7519(00)00141-7
   Peres CA, 2000, CONSERV BIOL, V14, P240, DOI 10.1046/j.1523-1739.2000.98485.x
   PERES CA, 2000, HUNTING SUSTAINABILI, P168
   ROBINSON JG, 1991, NEOTROPICAL WILDLIFE
   ROUND P D, 1990, Natural History Bulletin of the Siam Society, V38, P1
   ROUND PD, 2003, SURVEY BIRD TRADE BA, P86
   Taylor LH, 2001, PHILOS T R SOC B, V356, P983, DOI 10.1098/rstb.2001.0888
   Tu CC, 2004, EMERG INFECT DIS, V10, P2244, DOI 10.3201/eid1012.040520
   *US AN HLTH ASS, 1995, P 99 ANN M US AN HLT
   Van Borm S, 2005, EMERG INFECT DIS, V11, P702, DOI 10.3201/eid1105.050211
   WALSH JF, 1993, PARASITOLOGY, V106, P55
   Weldon C, 2004, EMERG INFECT DIS, V10, P2100, DOI 10.3201/eid1012.030804
   Wilkie DS, 1999, BIODIVERS CONSERV, V8, P927, DOI 10.1023/A:1008877309871
   World Health Organization, 2005, WHOCDS200529
   World Parrot Trust, 2004, DEADL NEWC DIS DISC
   World Wildlife Fund-United Kingdom, 2001, SOUV AL HIGHL DEADL
   1992, CONV BIOL DIV JAK MA
NR 32
TC 217
Z9 228
U1 1
U2 56
PU CENTER DISEASE CONTROL
PI ATLANTA
PA ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUL
PY 2005
VL 11
IS 7
BP 1000
EP 1002
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 939XS
UT WOS:000230106600002
PM 16022772
OA DOAJ Gold
DA 2020-04-03
ER

PT J
AU Coiras, MT
   Aguilar, JC
   Garcia, ML
   Casas, I
   Perez-Brena, P
AF Coiras, MT
   Aguilar, JC
   Garcia, ML
   Casas, I
   Perez-Brena, P
TI Simultaneous detection of fourteen respiratory viruses in clinical
   specimens by two multiplex reverse transcription nested-PCR assays
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE multiplex RT-PCR assay; diagnosis of respiratory infection;
   parainfluenza virus; human coronavirus; enterovirus; rhinovirus
ID POLYMERASE CHAIN-REACTION; ENZYME HYBRIDIZATION ASSAY; SYNCYTIAL-VIRUS;
   TRACT INFECTIONS; PARAINFLUENZA VIRUS; PEDIATRIC-PATIENTS;
   INFLUENZA-VIRUS; RHINOVIRUS INFECTIONS; RAPID DIAGNOSIS; CHILDREN
AB There is a need for rapid, sensitive, and accurate diagnosis of lower respiratory tract infections in children, elderly, and immunocompromised patients, who are susceptible to serious complications. The multiplex RT-nested PCR assay has been used widely for simultaneous detection of non-related viruses involved in infectious diseases because of its high specificity and sensitivity. A new multiplex RT-PCR assay is described in this report. This approach includes nested primer sets targeted to conserve regions of human parainfluenza virus haemagglutinin, human coronavirus spike protein, and human enterovirus and rhinovirus polyprotein genes. It permits rapid, sensitive, and simultaneous detection and typing of the four types of parainfluenza viruses (1, 2, 3, 4AB), human coronavirus 229E and OC43, and the generic detection of enteroviruses and rhinoviruses. The testing of 201 clinical specimens with this multiplex assay along with other one formerly described by our group to simultaneously detect and type the influenza viruses, respiratory syncytial viruses, and a generic detection of all serotypes of adenovirus, covers the detection of most viruses causing respiratory infectious disease in humans. The results obtained were compared with conventional viral culture, immunofluorescence assay, and a third multiplex RT-PCR assay for all human parainfluenza viruses types described previously. In conclusion, both multiplex RT-PCR assays provide a system capable of detecting and identifying simultaneously 14 different respiratory viruses in clinical specimens with high sensitivity and specificity, being useful for routine diagnosis and survey of these viruses within the population. (C) 2004 Wiley-Liss, Inc.
C1 Inst Salud Carlos III, Serv Virol, Ctr Nacl Microbiol, Madrid 28220, Spain.
RP Coiras, MT (reprint author), Inst Salud Carlos III, Serv Virol, Ctr Nacl Microbiol, Ctra Majadahonda Pozuelo,Km 2, Madrid 28220, Spain.
EM mcoiras@isciii.es
RI Casas, Inmaculada/X-7579-2019; Casas, Inmaculada/H-9442-2015; Coiras,
   Mayte/R-9530-2019
OI Casas, Inmaculada/0000-0003-1840-1198; Casas,
   Inmaculada/0000-0003-1840-1198; Coiras, Mayte/0000-0001-6464-5770
CR Aguilar JC, 2000, J CLIN MICROBIOL, V38, P1191, DOI 10.1128/JCM.38.3.1191-1195.2000
   Andreoletti L, 2000, J MED VIROL, V61, P341, DOI 10.1002/1096-9071(200007)61:3&lt;341::AID-JMV10&gt;3.0.CO;2-0
   APALSCH AM, 1995, CLIN INFECT DIS, V20, P394, DOI 10.1093/clinids/20.2.394
   Arbour N, 2000, J VIROL, V74, P8913, DOI 10.1128/JVI.74.19.8913-8921.2000
   Arola A, 1996, J CLIN MICROBIOL, V34, P313, DOI 10.1128/JCM.34.2.313-318.1996
   AROLA M, 1995, PEDIATR INFECT DIS J, V14, P690, DOI 10.1097/00006454-199508000-00008
   Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997
   ATMAR RL, 1993, J CLIN MICROBIOL, V31, P2544, DOI 10.1128/JCM.31.9.2544-2546.1993
   Atmar RL, 1996, J CLIN MICROBIOL, V34, P2604, DOI 10.1128/JCM.34.10.2604-2606.1996
   BALLABIO A, 1990, HUM GENET, V84, P571
   Casas I, 1999, J MED VIROL, V57, P145, DOI 10.1002/(SICI)1096-9071(199902)57:2&lt;145::AID-JMV10&gt;3.0.CO;2-N
   CASAS I, 1995, J VIROL METHODS, V53, P25, DOI 10.1016/0166-0934(94)00173-E
   Coiras MT, 2003, J MED VIROL, V69, P132, DOI 10.1002/jmv.10255
   DIEFFENBACH CW, 1993, PCR METH APPL, V3, pS30
   Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456
   EDWARDS MC, 1994, PCR METH APPL, V3, pS65
   Ellis JS, 1997, J CLIN MICROBIOL, V35, P2076, DOI 10.1128/JCM.35.8.2076-2082.1997
   Eugene-Ruellan G, 1998, J CLIN MICROBIOL, V36, P796, DOI 10.1128/JCM.36.3.796-801.1998
   Fan J, 1998, CLIN INFECT DIS, V26, P1397, DOI 10.1086/516357
   FLEMING DM, 1993, LANCET, V342, P1507, DOI 10.1016/S0140-6736(05)80082-0
   Freymuth F, 1997, CLIN DIAGN VIROL, V8, P31, DOI 10.1016/S0928-0197(97)00060-3
   Garcia Garcia M L, 2002, An Esp Pediatr, V57, P116
   Garcia Garcia M L, 2001, An Esp Pediatr, V55, P101
   Gilbert LL, 1996, J CLIN MICROBIOL, V34, P140, DOI 10.1128/JCM.34.1.140-143.1996
   GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571
   Grondahl B, 1999, J CLIN MICROBIOL, V37, P1
   Gwaltney J M Jr, 1980, Ann N Y Acad Sci, V353, P54, DOI 10.1111/j.1749-6632.1980.tb18905.x
   HALONEN P, 1995, J CLIN MICROBIOL, V33, P648, DOI 10.1128/JCM.33.3.648-653.1995
   Henegariu O, 1997, BIOTECHNIQUES, V23, P504, DOI 10.2144/97233rr01
   HRUSKOVA J, 1990, ACTA VIROL, V34, P346
   Huttunen P, 1996, J GEN VIROL, V77, P715, DOI 10.1099/0022-1317-77-4-715
   Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Kehl SC, 2001, J CLIN MICROBIOL, V39, P1696, DOI 10.1128/JCM.39.5.1696-1701.2001
   KENDAL AP, 1982, CONCEPTS PROCEDURES
   Liolios L, 2001, J CLIN MICROBIOL, V39, P2779, DOI 10.1128/JCM.39.8.2779-2783.2001
   MACNAUGHTON MR, 1982, INFECT IMMUN, V38, P419, DOI 10.1128/IAI.38.2.419-423.1982
   MCINTOSH K, 1970, AM J EPIDEMIOL, V91, P585, DOI 10.1093/oxfordjournals.aje.a121171
   MCMILLAN JA, 1993, PEDIATR INFECT DIS J, V12, P321, DOI 10.1097/00006454-199304000-00011
   Myint S, 2002, BRIT MED BULL, V61, P97, DOI 10.1093/bmb/61.1.97
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   Osiowy C, 1998, J CLIN MICROBIOL, V36, P3149, DOI 10.1128/JCM.36.11.3149-3154.1998
   Tantivanich Surang, 1995, Southeast Asian Journal of Tropical Medicine and Public Health, V26, P684
   Trallero G, 2000, EPIDEMIOL INFECT, V124, P497, DOI 10.1017/S0950268899003726
   Valassina M, 1997, CLIN DIAGN VIROL, V8, P227, DOI 10.1016/S0928-0197(97)10001-0
   Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997
   Yun BY, 1995, PEDIATR INFECT DIS J, V14, P1054, DOI 10.1097/00006454-199512000-00005
NR 48
TC 217
Z9 242
U1 1
U2 14
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD MAR
PY 2004
VL 72
IS 3
BP 484
EP 495
DI 10.1002/jmv.20008
PG 12
WC Virology
SC Virology
GA 767YA
UT WOS:000188500400019
PM 14748074
DA 2020-04-03
ER

PT J
AU STURMAN, LS
   RICARD, CS
   HOLMES, KV
AF STURMAN, LS
   RICARD, CS
   HOLMES, KV
TI PROTEOLYTIC CLEAVAGE OF THE E2-GLYCOPROTEIN OF MURINE CORONAVIRUS -
   ACTIVATION OF CELL-FUSING ACTIVITY OF VIRIONS BY TRYPSIN AND SEPARATION
   OF 2 DIFFERENT 90K-CLEAVAGE FRAGMENTS
SO JOURNAL OF VIROLOGY
LA English
DT Article
C1 UNIFORMED SERV UNIV HLTH SCI, DEPT PATHOL, BETHESDA, MD 20814 USA.
   NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 18997]; NIGMS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS) [GM
   31698]
CR BINGHAM RW, 1975, J GEN VIROL, V28, P381, DOI 10.1099/0022-1317-28-3-381
   BOSCH FX, 1979, VIROLOGY, V95, P197, DOI 10.1016/0042-6822(79)90414-8
   CALLEBAUT PE, 1980, J GEN VIROL, V48, P193, DOI 10.1099/0022-1317-48-1-193
   CAVANAGH D, 1983, J GEN VIROL, V64, P2577, DOI 10.1099/0022-1317-64-12-2577
   CAVANAGH D, 1981, J GEN VIROL, V53, P93, DOI 10.1099/0022-1317-53-1-93
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   CORBO LJ, 1959, AM J VET RES, V20, P876
   FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985
   GARTEN W, 1980, J GEN VIROL, V50, P135, DOI 10.1099/0022-1317-50-1-135
   GARWES DJ, 1981, J GEN VIROL, V52, P153, DOI 10.1099/0022-1317-52-1-153
   HOLMES KV, 1982, ADV EXP MED BIOL, V142, P133
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   HUANG RTC, 1981, VIROLOGY, V110, P243, DOI 10.1016/0042-6822(81)90030-1
   KAYE HS, 1969, J INFECT DIS, V120, P576, DOI 10.1093/infdis/120.5.576
   KING B, 1982, J VIROL, V42, P700, DOI 10.1128/JVI.42.2.700-707.1982
   Klenk H D, 1980, Curr Top Microbiol Immunol, V90, P19
   KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6
   LAZAROWI.SG, 1973, VIROLOGY, V52, P199, DOI 10.1016/0042-6822(73)90409-1
   LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8
   MAEDA T, 1981, P NATL ACAD SCI-BIOL, V78, P4133, DOI 10.1073/pnas.78.7.4133
   MOSS B, 1972, J BIOL CHEM, V247, P5194
   NAGAI Y, 1976, VIROLOGY, V72, P494, DOI 10.1016/0042-6822(76)90178-1
   NAGAI Y, 1977, VIROLOGY, V77, P125, DOI 10.1016/0042-6822(77)90412-3
   NIEMANN H, 1981, J MOL BIOL, V153, P993, DOI 10.1016/0022-2836(81)90463-0
   OTSUKI K, 1981, ARCH VIROL, V70, P315, DOI 10.1007/BF01320246
   POCOCK DH, 1978, J GEN VIROL, V40, P93, DOI 10.1099/0022-1317-40-1-93
   POCOCK DH, 1977, J GEN VIROL, V37, P487, DOI 10.1099/0022-1317-37-3-487
   RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3
   RICHARDSON CD, 1983, VIROLOGY, V131, P518, DOI 10.1016/0042-6822(83)90517-2
   ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981
   ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981
   SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1
   SCHEID A, 1976, VIROLOGY, V69, P265, DOI 10.1016/0042-6822(76)90213-0
   SIDDELL S, 1981, J GEN VIROL, V53, P145, DOI 10.1099/0022-1317-53-1-145
   SIDDELL S, 1982, ADV EXP MED BIOL, V142, P193
   STERN DF, 1982, J VIROL, V44, P794, DOI 10.1128/JVI.44.3.794-803.1982
   STORZ J, 1981, INFECT IMMUN, V31, P1214, DOI 10.1128/IAI.31.3.1214-1222.1981
   Sturman L S, 1984, Adv Exp Med Biol, V173, P25
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   STURMAN LS, 1977, VIROLOGY, V77, P650, DOI 10.1016/0042-6822(77)90489-5
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   STURMAN LS, 1982, ADV EXP MED BIOL, V142, P1
   STURMAN LS, 1977, VIROLOGY, V77, P637, DOI 10.1016/0042-6822(77)90488-3
   STURMAN LS, 1972, INFECT IMMUN, V6, P501, DOI 10.1128/IAI.6.4.501-507.1972
   WEGE H, 1984, J GEN VIROL, V65, P1931, DOI 10.1099/0022-1317-65-11-1931
   WELCH WJ, 1979, J VIROL, V29, P1186, DOI 10.1128/JVI.29.3.1186-1195.1979
   WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674
   YOSHIKURA H, 1981, VIROLOGY, V113, P503, DOI 10.1016/0042-6822(81)90178-1
NR 48
TC 217
Z9 224
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PY 1985
VL 56
IS 3
BP 904
EP 911
DI 10.1128/JVI.56.3.904-911.1985
PG 8
WC Virology
SC Virology
GA AUB03
UT WOS:A1985AUB0300031
PM 2999443
OA Bronze
DA 2020-04-03
ER

PT J
AU Li, WH
   Zhang, CS
   Sui, JH
   Kuhn, JH
   Moore, MJ
   Luo, SW
   Wong, SK
   Huang, IC
   Xu, KM
   Vasilieva, N
   Murakami, A
   He, YQ
   Marasco, WA
   Guan, Y
   Choe, HY
   Farzan, M
AF Li, WH
   Zhang, CS
   Sui, JH
   Kuhn, JH
   Moore, MJ
   Luo, SW
   Wong, SK
   Huang, IC
   Xu, KM
   Vasilieva, N
   Murakami, A
   He, YQ
   Marasco, WA
   Guan, Y
   Choe, HY
   Farzan, M
TI Receptor and viral determinants of SARS-coronavirus adaptation to human
   ACE2
SO EMBO JOURNAL
LA English
DT Article
DE angiotensin-converting enzyme 2; coronavirus; severe acute respiratory
   syndrome; viral adaptation
ID ACUTE-RESPIRATORY-SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; SPIKE
   PROTEIN; S-PROTEIN; FUNCTIONAL RECEPTOR; CELL TROPISM; DC-SIGN;
   GLYCOPROTEIN; VIRUS; EXPRESSION
AB Human angiotensin-converting enzyme 2 (ACE2) is a functional receptor for SARS coronavirus (SARS-CoV). Here we identify the SARS-CoV spike (S)-protein-binding site on ACE2. We also compare S proteins of SARS-CoV isolated during the 2002-2003 SARS outbreak and during the much less severe 2003-2004 outbreak, and from palm civets, a possible source of SARS-CoV found in humans. All three S proteins bound to and utilized palm-civet ACE2 efficiently, but the latter two S proteins utilized human ACE2 markedly less efficiently than did the S protein obtained during the earlier human outbreak. The lower affinity of these S proteins could be complemented by altering specific residues within the S-protein-binding site of human ACE2 to those of civet ACE2, or by altering S-protein residues 479 and 487 to residues conserved during the 2002-2003 outbreak. Collectively, these data describe molecular interactions important to the adaptation of SARS-CoV to human cells, and provide insight into the severity of the 2002-2003 SARS epidemic.
C1 Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA.
   McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
   Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.
   Free Univ Berlin, Dept Biol Chem Pharm, D-1000 Berlin, Germany.
   Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA.
   Ctr Dis Control & Prevent Shenzhen, Shenzhen, Guangdong Prov, Peoples R China.
RP Guan, Y (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
EM yguan@hkucc.hku.hk; hyeryun.choe@tch.harvard.edu; farzan@hms.harvard.edu
RI Kuhn, Jens H./B-7615-2011; Xu, Kemin/G-2825-2011
OI Kuhn, Jens H./0000-0002-7800-6045; Farzan, Michael/0000-0002-2990-5319;
   SUI, JIANHUA/0000-0002-1272-9662; Guan, Yi/0000-0001-6057-9243; Li,
   Wenhui/0000-0003-1305-7404
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI043891]
CR Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004
   Casais R, 2003, J VIROL, V77, P9084, DOI 10.1128/JVI.77.16.9084-9089.2003
   Chan PKS, 2004, J MED VIROL, V74, P1, DOI 10.1002/jmv.20138
   Dales NA, 2002, J AM CHEM SOC, V124, P11852, DOI 10.1021/ja0277226
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   GUAN Y, 2003, SCIENCE, V4, P4
   Haijema BJ, 2003, J VIROL, V77, P4528, DOI 10.1128/JVI.77.8.4528-4538.2003
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Hofmann H, 2004, TRENDS MICROBIOL, V12, P466, DOI 10.1016/j.tim.2004.08.008
   Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114
   Holmes KV, 2003, NEW ENGL J MED, V348, P1948, DOI 10.1056/NEJMp030078
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004
   Liang GD, 2004, EMERG INFECT DIS, V10, P1774, DOI 10.3201/eid1010.040445
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Marzi A, 2004, J VIROL, V78, P12090, DOI 10.1128/JVI.78.21.12090-12095.2004
   Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004
   Nie YC, 2004, BIOCHEM BIOPH RES CO, V321, P994, DOI 10.1016/j.bbrc.2004.07.060
   Normile D, 2004, SCIENCE, V304, P659, DOI 10.1126/science.304.5671.659
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Schickli JH, 2004, J VIROL, V78, P9073, DOI 10.1128/JVI.78.17.9073-9083.2004
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   SUI J, 2005, IN PRESS J VIROL
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Webby R, 2004, NAT MED, V10, pS77, DOI 10.1038/nm1151
   Wentworth DE, 2004, EMERG INFECT DIS, V10, P1293, DOI 10.3201/eid1007.031119
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wu DL, 2005, J VIROL, V79, P2620, DOI 10.1128/JVI.79.4.2620-2625.2005
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Zhang H, 2001, J BIOL CHEM, V276, P17132, DOI 10.1074/jbc.M006723200
   Zhang Y, 2004, CHINESE SCI BULL, V49, P1311, DOI 10.1360/04wc0153
   Zhong NS, 2004, PHILOS T R SOC B, V359, P1115, DOI 10.1098/rstb.2004.1491
NR 45
TC 216
Z9 239
U1 14
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD APR 20
PY 2005
VL 24
IS 8
BP 1634
EP 1643
DI 10.1038/sj.emboj.7600640
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 923XW
UT WOS:000228943900013
PM 15791205
OA Green Published
DA 2020-04-03
ER

PT J
AU Palacios, G
   Quan, PL
   Jabado, OJ
   Conlan, S
   Hirschberg, DL
   Liu, Y
   Zhai, J
   Renwick, N
   Hui, J
   Hegyi, H
   Grolla, A
   Strong, JE
   Towner, JS
   Geisbert, TW
   Jahrling, PB
   Buechen-Osmond, C
   Ellerbrok, H
   Sanchez-Seco, MP
   Lussier, Y
   Formenty, P
   Nichol, ST
   Feldmann, H
   Briese, T
   Lipkin, WI
AF Palacios, Gustavo
   Quan, Phenix-Lan
   Jabado, Omar J.
   Conlan, Sean
   Hirschberg, David L.
   Liu, Yang
   Zhai, Junhui
   Renwick, Neil
   Hui, Jeffrey
   Hegyi, Hedi
   Grolla, Allen
   Strong, James E.
   Towner, Jonathan S.
   Geisbert, Thomas W.
   Jahrling, Peter B.
   Buechen-Osmond, Cornelia
   Ellerbrok, Heinz
   Sanchez-Seco, Maria Paz
   Lussier, Yves
   Formenty, Pierre
   Nichol, Stuart T.
   Feldmann, Heinz
   Briese, Thomas
   Lipkin, W. Ian
TI Panmicrobial oligonucleotide array for diagnosis of infectious diseases
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; VIRUS-INFECTION; HUMAN MONKEYPOX;
   CORONAVIRUS; OUTBREAK; CONGO
AB To facilitate rapid, unbiased, differential diagnosis of infectious diseases, we designed GreeneChipPm, a panmicrobial microarray comprising 29,455 sixty-mer oligonucleotide probes for vertebrate viruses, bacteria, fungi, and parasites. Methods for nucleic acid preparation, random primed PCR amplification, and labeling were optimized to allow the sensitivity required for application with nucleic acid extracted from clinical materials and cultured isolates. Analysis of nasopharyngeal aspirates, blood, urine, and tissue from persons with various infectious diseases confirmed the presence of viruses and bacteria identified by other methods, and implicated Plasmodium falciparum in an unexplained fatal case of hemorrhagic feverlike disease during the Marburg hemorrhagic fever outbreak in Angola in 2004-2005.
C1 Columbia Univ, Jerome L & Dawn Greene Infect Dis Lab, Mailman Sch Publ Hlth, New York, NY 10032 USA.
   Stanford Univ, Stanford, CA 94305 USA.
   Univ Chicago, Chicago, IL 60637 USA.
   Inst Enzymol, Budapest, Hungary.
   Publ Hlth Agcy Canada, Winnipeg, MB, Canada.
   Ctr Dis Control & Prevent, Atlanta, GA USA.
   USA, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA.
   Natl Inst Hlth, Integrated Res Facil, Ft Detrick, MD 21702 USA.
   Robert Koch Inst, D-1000 Berlin, Germany.
   Inst Salud Carlos III, Madrid, Spain.
   World Hlth Org, Geneva, Switzerland.
   Univ Manitoba, Winnipeg, MB, Canada.
RP Lipkin, WI (reprint author), Columbia Univ, Jerome L & Dawn Greene Infect Dis Lab, Mailman Sch Publ Hlth, 722 W 168th St,Rm 1801, New York, NY 10032 USA.
EM wil2001@columbia.edu
RI Jabado, Omar/B-3406-2008; Renwick, Neil M/A-3744-2012; Palacios,
   Gustavo/I-7773-2015; Lussier, Yves/N-4891-2017; Conlan,
   Sean/B-4401-2008; Hegyi, Hedi/AAF-2062-2020; Renwick, Neil/V-3980-2019
OI Jabado, Omar/0000-0003-4305-348X; Renwick, Neil M/0000-0001-6695-8236;
   Palacios, Gustavo/0000-0001-5062-1938; Lussier,
   Yves/0000-0001-9854-1005; Conlan, Sean/0000-0001-6848-3465; Renwick,
   Neil/0000-0001-6695-8236; SANCHEZ-SECO, MARIA PAZ/0000-0001-9033-7704
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI056118, U01AI070411, R21 AI056118,
   AI55466, AI51292, U54 AI057158, R21 AI055466, R01 AI051292, U01
   AI070411, U54AI57158]; NLM NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Library of Medicine (NLM) [K22 LM008308-04, K22 LM008308]
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   [Anonymous], 2005, Wkly Epidemiol Rec, V80, P370
   Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48
   Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1
   Briese T, 2005, EMERG INFECT DIS, V11, P310, DOI 10.3201/eid1102.040492
   Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149
   Hutin YJF, 2001, EMERG INFECT DIS, V7, P434
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551
   Lin BC, 2006, GENOME RES, V16, P527, DOI 10.1101/gr.4337206
   Mahanty S, 2004, LANCET INFECT DIS, V4, P487, DOI 10.1016/S1473-3099(04)01103-X
   Meyer H, 2002, J CLIN MICROBIOL, V40, P2919, DOI 10.1128/JCM.40.8.2919-2921.2002
   Newman RD, 2004, ANN INTERN MED, V141, P547, DOI 10.7326/0003-4819-141-7-200410050-00012
   Palacios G, 2006, EMERG INFECT DIS, V12, P692, DOI 10.3201/eid1204.051515
   Peters CJ, 2002, CRIT CARE MED, V30, pS268, DOI 10.1097/00003246-200205001-00016
   Rooney AP, 2004, MOL BIOL EVOL, V21, P1704, DOI 10.1093/molbev/msh178
   Towner JS, 2006, J VIROL, V80, P6497, DOI 10.1128/JVI.00069-06
   van Elden LJR, 2003, J CLIN MICROBIOL, V41, P4378, DOI 10.1128/JCM.41.9.4378-4381.2003
   Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699
   WITSO E, 2006, J CLIN MICROBIOL
   Zhai JH, 2004, EMERG INFECT DIS, V10, P300
   1997, MALARIA IMPORTED FAT
   1997, EBOLA FALSE ALARM IM
NR 24
TC 215
Z9 226
U1 1
U2 12
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JAN
PY 2007
VL 13
IS 1
BP 73
EP 81
DI 10.3201/eid1301.060837
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 128XH
UT WOS:000243692500011
PM 17370518
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Almazan, F
   Gonzalez, JM
   Penzes, Z
   Izeta, A
   Calvo, E
   Plana-Duran, J
   Enjuanes, L
AF Almazan, F
   Gonzalez, JM
   Penzes, Z
   Izeta, A
   Calvo, E
   Plana-Duran, J
   Enjuanes, L
TI Engineering the largest RNA virus genome as an infectious bacterial
   artificial chromosome
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS; MOUSE HEPATITIS-VIRUS;
   FACTOR-BASED VECTOR; EXPRESSION VECTORS; ENTERIC TROPISM; HUMAN DNA;
   RECOMBINATION; CDNA; MUTAGENESIS; MUTATIONS
AB The construction of cDNA clones encoding large-size RNA molecules of biological interest, like coronavirus genomes, which are among the largest mature RNA molecules known to biology, has been hampered by the instability of those cDNAs in bacteria. Herein, we show that the application of two strategies, cloning of the cDNAs into a bacterial artificial chromosome and nuclear expression of RNAs that are typically produced within the cytoplasm, is useful for the engineering of large RNA molecules. A cDNA encoding an infectious coronavirus RNA genome has been cloned as a bacterial artificial chromosome. The rescued coronavirus conserved ail of the genetic markers introduced throughout the sequence and showed a standard mRNA pattern and the antigenic characteristics expected for the synthetic virus. The cDNA was transcribed within the nucleus, and the RNA translocated to the cytoplasm. Interestingly, the recovered virus had essentially the same sequence as the original one, and no splicing was observed. The cDNA was derived from an attenuated isolate that replicates exclusively in the respiratory tract of swine. During the engineering of the infectious cDNA, the spike gene of the virus was replaced by the spike gene of an enteric isolate. The synthetic virus replicated abundantly in the enteric tract and was fully virulent, demonstrating that the tropism and virulence of the recovered coronavirus can be modified. This demonstration opens up the possibility of employing this infectious cDNA as a Vector for Vaccine development in human, porcine, canine, and feline species susceptible to group 1 coronaviruses.
C1 CSIC, Ctr Nacl Biotecnol, Dept Mol & Cell Biol, E-28049 Madrid, Spain.
   Ft Dodge Vet, Olot 17183, Spain.
RP Enjuanes, L (reprint author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cell Biol, Campus Univ Autonoma, E-28049 Madrid, Spain.
RI Enjuanes, Luis/F-7845-2016; Izeta, Ander/H-6376-2011; Almazan,
   Fernando/K-8781-2015
OI Almazan, Fernando/0000-0002-5752-8469; Gonzalez, Jose
   M/0000-0001-5569-0705; Enjuanes, Luis/0000-0002-0854-0226; Izeta,
   Ander/0000-0003-1879-7401
CR AHLQUIST P, 1984, P NATL ACAD SCI-BIOL, V81, P7066, DOI 10.1073/pnas.81.22.7066
   Ballesteros ML, 1997, VIROLOGY, V227, P378, DOI 10.1006/viro.1996.8344
   Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151
   Dubensky TW, 1996, J VIROL, V70, P508, DOI 10.1128/JVI.70.1.508-519.1996
   ELEOUET JF, 1995, VIROLOGY, V206, P817, DOI 10.1006/viro.1995.1004
   Enjuanes L., 1995, The coronaviridae., P337
   ENJUANES L, 1998, CORONAVIRUSES ARTERI
   ENJUANES L, 1999, VIRUS TAXONOMY, P835
   Fodor E, 1999, J VIROL, V73, P9679, DOI 10.1128/JVI.73.11.9679-9682.1999
   GEBAUER F, 1991, VIROLOGY, V183, P225, DOI 10.1016/0042-6822(91)90135-X
   Izeta A, 1999, J VIROL, V73, P1535, DOI 10.1128/JVI.73.2.1535-1545.1999
   KIM UJ, 1992, NUCLEIC ACIDS RES, V20, P1083, DOI 10.1093/nar/20.5.1083
   KOETZNER CA, 1992, J VIROL, V66, P1841, DOI 10.1128/JVI.66.4.1841-1848.1992
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356
   MASTERS PS, 1994, J VIROL, V68, P328, DOI 10.1128/JVI.68.1.328-337.1994
   Masters PS, 1999, ADV VIRUS RES, V53, P245, DOI 10.1016/S0065-3527(08)60351-6
   MCCLURKIN AW, 1966, CAN J COMP MED VET S, V30, P190
   Mendez A, 1996, VIROLOGY, V217, P495, DOI 10.1006/viro.1996.0144
   Messerle M, 1997, P NATL ACAD SCI USA, V94, P14759, DOI 10.1073/pnas.94.26.14759
   RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391
   RICE C M, 1989, New Biologist, V1, P285
   RICE CM, 1987, J VIROL, V61, P3809, DOI 10.1128/JVI.61.12.3809-3819.1987
   SACHS DH, 1976, TRANSPLANTATION, V22, P559, DOI 10.1097/00007890-197612000-00004
   Sambrook J., 1989, MOL CLONING LAB MANU
   Sanchez CM, 1999, J VIROL, V73, P7607
   SANCHEZ CM, 1990, VIROLOGY, V174, P410, DOI 10.1016/0042-6822(90)90094-8
   SANCHEZ CM, 1992, VIROLOGY, V190, P92, DOI 10.1016/0042-6822(92)91195-Z
   Satyanarayana T, 1999, P NATL ACAD SCI USA, V96, P7433, DOI 10.1073/pnas.96.13.7433
   SCHNELL MJ, 1994, EMBO J, V13, P4195, DOI 10.1002/j.1460-2075.1994.tb06739.x
   SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794
   SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156
   VANDERMOST RG, 1992, NUCLEIC ACIDS RES, V20, P3375, DOI 10.1093/nar/20.13.3375
   vanDinten LC, 1997, P NATL ACAD SCI USA, V94, P991, DOI 10.1073/pnas.94.3.991
   Wang K, 1997, BIOTECHNIQUES, V23, P992, DOI 10.2144/97236bm04
NR 35
TC 215
Z9 256
U1 1
U2 19
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 9
PY 2000
VL 97
IS 10
BP 5516
EP 5521
DI 10.1073/pnas.97.10.5516
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 313KH
UT WOS:000086998500092
PM 10805807
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Zheng, BJ
   Chan, KW
   Lin, YP
   Zhao, GY
   Chan, C
   Zhang, HJ
   Chen, HL
   Wong, SSY
   Lau, SKP
   Woo, PCY
   Chan, KH
   Jin, DY
   Yuen, KY
AF Zheng, Bo-Jian
   Chan, Kwok-Wah
   Lin, Yong-Ping
   Zhao, Guang-Yu
   Chan, Chris
   Zhang, Hao-Jie
   Chen, Hong-Lin
   Wong, Samson S. Y.
   Lau, Susanna K. P.
   Woo, Patrick C. Y.
   Chan, Kwok-Hung
   Jin, Dong-Yan
   Yuen, Kwok-Yung
TI Delayed antiviral plus immunomodulator treatment still reduces mortality
   in mice infected by high inoculum of influenza A/H5N1 virus
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE zanamivir; celecoxib; mesalazine
ID A H5N1 VIRUS; AVIAN INFLUENZA; CORONAVIRUS; OSELTAMIVIR; PATHOGENESIS;
   INHIBITION; ZANAMIVIR; RESPONSES; DISEASE; HUMANS
AB The mortality of human infection by influenza A/H5N1 virus can exceed 80%. The high mortality and its poor response to the neuraminidase inhibitor oseltamivir have been attributed to uncontrolled virus-induced cytokine storm. We challenged BALB/c mice with 1,000 LD50 of influenza A/Vietnam/1194/04. Survival, body weight, histopathology, inflammatory markers, viral loads, T lymphocyte counts, and neutralizing antibody response were documented in infected mice treated individually or in combination with zanamvir, celecoxib, gemfibrozil, and mesalazine. To imitate the real-life scenario, treatment was initiated at 48 h after viral challenge. There were significant improvements in survival rate (P = 0.02), survival time (P < 0.02), and inflammatory markers (P < 0.01) in the group treated-with a triple combination of zanamivir, celecoxib, and mesalazine when compared with zanamivir alone. Zanamivir with or without immunomodulators reduced viral load to a similar extent. Insignificant prolongation of survival was observed when individual agents were used alone. Significantly higher levels of CD4(+) and CD8(+) T lymphocytes and less pulmonary inflammation were also found in the group receiving triple therapy. Zanamivir alone reduced viral load but not inflammation and mortality. The survival benefits of adding celecoxib and mesalazine to zanamivir could be caused by their synergistic effects in reducing cytokine dysfunction and preventing apoptosis. Combinations of a neuraminidase inhibitor with these immunomodulators should be considered in randomized controlled treatment trials of patients suffering from H5N1 infection.
C1 [Zheng, Bo-Jian; Chen, Hong-Lin; Wong, Samson S. Y.; Lau, Susanna K. P.; Woo, Patrick C. Y.; Chan, Kwok-Hung; Yuen, Kwok-Yung] Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Zheng, Bo-Jian; Lin, Yong-Ping; Zhao, Guang-Yu; Chan, Chris; Zhang, Hao-Jie; Chen, Hong-Lin; Wong, Samson S. Y.; Lau, Susanna K. P.; Woo, Patrick C. Y.; Chan, Kwok-Hung; Yuen, Kwok-Yung] Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   [Zheng, Bo-Jian; Chen, Hong-Lin; Wong, Samson S. Y.; Lau, Susanna K. P.; Woo, Patrick C. Y.; Chan, Kwok-Hung; Yuen, Kwok-Yung] Univ Hong Kong, Res Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China.
   [Chan, Kwok-Wah] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Jin, Dong-Yan] Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
EM kyyuen@hkucc.hku.hk
RI Lau, Susanna Kar Pui/AAJ-6848-2020; Chen, Honglin/C-4224-2009
OI Lau, Susanna Kar Pui/0000-0002-1383-7374; Chen,
   Honglin/0000-0001-5108-8338; Yuen, Kwok-yung/0000-0002-2083-1552
CR Beigel H, 2005, NEW ENGL J MED, V353, P1374
   Budd A, 2007, ANTIMICROB AGENTS CH, V51, P2965, DOI 10.1128/AAC.00219-07
   Carey MA, 2005, J IMMUNOL, V175, P6878, DOI 10.4049/jimmunol.175.10.6878
   Carter MJ, 2007, J MED MICROBIOL, V56, P875, DOI 10.1099/jmm.0.47124-0
   Catalano A, 2004, INT J CANCER, V109, P322, DOI 10.1002/ijc.11710
   Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622
   Du LY, 2008, J IMMUNOL, V180, P948, DOI 10.4049/jimmunol.180.2.948
   Gomez-Munoz A, 2001, BBA-MOL CELL BIOL L, V1533, P110, DOI 10.1016/S1388-1981(01)00149-4
   Govorkova EA, 2001, ANTIMICROB AGENTS CH, V45, P2723, DOI 10.1128/AAC.45.10.2723-2732.2001
   Kumar MS, 2003, MUTAT RES-FUND MOL M, V527, P7, DOI 10.1016/S0027-5107(03)00052-6
   La Gruta NL, 2007, IMMUNOL CELL BIOL, V85, P85, DOI 10.1038/sj.icb.7100026
   Leneva IA, 2000, ANTIVIR RES, V48, P101, DOI 10.1016/S0166-3542(00)00123-6
   Li BJ, 2005, NAT MED, V11, P944, DOI 10.1038/nm1280
   Nielsen OH, 2007, NAT CLIN PRACT GASTR, V4, P160, DOI 10.1038/ncpgasthep0696
   Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5
   RYAN DM, 1994, ANTIMICROB AGENTS CH, V38, P2270, DOI 10.1128/AAC.38.10.2270
   Salomon R, 2007, P NATL ACAD SCI USA, V104, P12479, DOI 10.1073/pnas.0705289104
   Sidwell RW, 2007, ANTIMICROB AGENTS CH, V51, P845, DOI 10.1128/AAC.01051-06
   Simmons CP, 2007, PLOS MED, V4, P928, DOI 10.1371/journal.pmed.0040178
   Smith PW, 1998, J MED CHEM, V41, P787, DOI 10.1021/jm970374b
   Szretter KJ, 2007, J VIROL, V81, P2736, DOI 10.1128/JVI.02336-06
   Uiprasertkui M, 2007, EMERG INFECT DIS, V13, P708, DOI 10.3201/eid1305.060572
   Wong SSY, 2006, CHEST, V129, P156, DOI 10.1378/chest.129.1.156
   Yen HL, 2005, J INFECT DIS, V192, P665, DOI 10.1086/432008
   Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9
   Zheng BJ, 2005, ANTIVIR THER, V10, P393
NR 26
TC 214
Z9 224
U1 2
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 10
PY 2008
VL 105
IS 23
BP 8091
EP 8096
DI 10.1073/pnas.0711942105
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 314AT
UT WOS:000256781800035
PM 18523003
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Yang, ZY
   Huang, Y
   Ganesh, L
   Leung, K
   Kong, WP
   Schwartz, O
   Subbarao, K
   Nabel, GJ
AF Yang, ZY
   Huang, Y
   Ganesh, L
   Leung, K
   Kong, WP
   Schwartz, O
   Subbarao, K
   Nabel, GJ
TI pH-dependent entry of Severe acute respiratory syndrome coronavirus is
   mediated by the spike glycoprotein and enhanced by dendritic cell
   transfer through DC-SIGN
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; EBOLA-VIRUS; SARS-CORONAVIRUS;
   MEMBRANE-FUSION; HONG-KONG; T-CELLS; INFECTION; ENVELOPE; RECEPTOR; HIV
AB The severe acute respiratory syndrome coronavirus (SARS-CoV) synthesizes several putative viral envelope proteins, including the spike (S), membrane (M), and small envelope (E) glycoproteins. Although these proteins likely are essential for viral replication, their specific roles in SARS-CoV entry have not been defined. In this report, we show that the SARS-CoV S glycoprotein mediates viral entry through pH-dependent endocytosis. Further, we define its cellular tropism and demonstrate that virus transmission occurs through cell-mediated transfer by dendritic cells. The S glycoprotein was used successfully to pseudotype replication-defective retroviral and lentiviral vectors that readily infected Vero cells as well as primary pulmonary and renal epithelial cells from human, nonhuman primate, and, to a lesser extent, feline species. The tropism of this reporter virus was similar to that of wild-type, replication-competent SARS-CoV, and binding of purified S to susceptible target cells was demonstrated by flow cytometry. Although myeloid dendritic cells were able to interact with S and to bind virus, these cells could not be infected by SARS-CoV. However, these cells were able to transfer the virus to susceptible target cells through a synapse-like structure. Both cell-mediated infection and direct infection were inhibited by anti-S antisera, indicating that strategies directed toward this gene product are likely to confer a therapeutic benefit for antiviral drugs or the development of a SARS vaccine.
C1 NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   NIAID, Biol Imaging Facil, NIH, Bethesda, MD 20892 USA.
   NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
RP Nabel, GJ (reprint author), NIAID, Vaccine Res Ctr, NIH, Bldg 40,Room 4502,MSC-3005,40 Convent Dr, Bethesda, MD 20892 USA.
EM gnabel@nih.gov
OI Subbarao, Kanta/0000-0003-1713-3056
CR Abrahamsen T G, 1991, J Clin Apher, V6, P48, DOI 10.1002/jca.2920060110
   Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002
   Anon, 2003, MMWR-MORBID MORTAL W, V52, P986
   BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0
   BURGARD M, 1992, NEW ENGL J MED, V327, P1192, DOI 10.1056/NEJM199210223271702
   Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821
   *CHIN SARS MOL EP, 2004, SCIENCE
   CORAPI WV, 1995, J VIROL, V69, P2858, DOI 10.1128/JVI.69.5.2858-2862.1995
   de Haan CAM, 1999, J VIROL, V73, P7441, DOI 10.1128/JVI.73.9.7441-7452.1999
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8
   HOLMES KV, 1993, ADV EXP MED BIOL, V342, P261
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5
   Lai M.M.C., 2001, FIELDS VIROLOGY, P1163
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lim KP, 2001, J BIOL CHEM, V276, P17515, DOI 10.1074/jbc.M009731200
   Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150
   Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382
   NUSSBAUM O, 1993, J VIROL, V67, P7402, DOI 10.1128/JVI.67.12.7402-7405.1993
   Perlman S, 1998, ADV EXP MED BIOL, V440, P503
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Rest JS, 2003, INFECT GENET EVOL, V3, P219, DOI 10.1016/j.meegid.2003.08.001
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sanders DA, 2002, CURR OPIN BIOTECH, V13, P437, DOI 10.1016/S0958-1669(02)00374-9
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674
   WOOD KV, 1984, BIOCHEM BIOPH RES CO, V124, P592, DOI 10.1016/0006-291X(84)91595-X
   Wool-Lewis RJ, 1998, J VIROL, V72, P3155, DOI 10.1128/JVI.72.4.3155-3160.1998
   World Health Organization, 2003, CONS DOC EP SEV AC R
   Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
NR 46
TC 212
Z9 230
U1 2
U2 21
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUN
PY 2004
VL 78
IS 11
BP 5642
EP 5650
DI 10.1128/JVI.78.11.5642-5650.2004
PG 9
WC Virology
SC Virology
GA 822CW
UT WOS:000221513400012
PM 15140961
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Liu, SW
   Xiao, GF
   Chen, YB
   He, YX
   Niu, JK
   Escalante, CR
   Xiong, HB
   Farmar, J
   Debnath, AK
   Tien, P
   Jiang, SB
AF Liu, SW
   Xiao, GF
   Chen, YB
   He, YX
   Niu, JK
   Escalante, CR
   Xiong, HB
   Farmar, J
   Debnath, AK
   Tien, P
   Jiang, SB
TI Interaction between heptad repeat 1 and 2 regions in spike protein of
   SARS-associated coronavirus: implications for virus fusogenic mechanism
   and identification of fusion inhibitors
SO LANCET
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; GP41 CORE STRUCTURE; INFECTION IN-VITRO;
   HIV-1 GP41; POTENT INHIBITORS; COILED-COIL; ENVELOPE GLYCOPROTEIN;
   SYNTHETIC PEPTIDES; MEMBRANE-FUSION; TYPE-1 GP41
AB Background Studies on the fusion-inhibitory peptides derived from the heptad repeat 1 and 2 (HR1 and HR2) regions of the HIV-1 envelope glycoprotein gp41 provided crucial information on the viral fusogenic mechanism. We used a similar approach to study the fusogenic mechanism of severe-acute-respiratory-syndrome-associated coronavirus (SARS-CoV).
   Methods We tested the inhibitory activity against infection of two sets of peptides corresponding to sequences of SARS-CoV spike protein HR1 and HR2 regions and investigated the interactions between the HR1 and HR2 peptides by surface plasmon resonance, sedimentation equilibration analysis, circular dichroism, native polyacrylamide-gel electrophoresis, size exclusion high-performance liquid chromatography, and computer-aided homology modelling and molecule docking analysis.
   Findings One peptide, CP-1, derived from the HR2 region, inhibited SARS-CoV infection in the micromolar range. CP-1 bound with high affinity to a peptide from the HR1 region, NP-1. CIPA alone had low alpha-helicity and self-associated to form a trimer in phosphate buffer (pH 7.2). CP-1 and NP-1 mixed in equimolar concentrations formed a six-helix bundle, similar to the fusogenic core structure of HIV-1 gp41.
   Interpretation After binding to the target cell, the transmembrane spike protein might change conformation by association between the HR1 and HR2 regions to form an oligomeric structure, leading to fusion between the viral and target-cell membranes. At the prefusion intermediate state, CP-1 could bind to the HR1 region and interfere with the conformational changes, resulting in inhibition of SARS-CoV fusion with the target cells. CP-1 might be modifiable to increase its anti-SARS-CoV activity and could be further developed as an antiviral agent for treatment or prophylaxis of SARS-CoV infection.
C1 New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA.
   Wuhan Univ, Modern Virol Res Ctr, Wuhan 430072, Peoples R China.
   Mt Sinai Sch Med, New York, NY USA.
RP Jiang, SB (reprint author), New York Blood Ctr, Lindsley F Kimball Res Inst, 310 E 67th St, New York, NY 10021 USA.
EM SJiang@DNYBloodcenter.org
RI Jiang, Shibo/L-4500-2014
CR BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Cavanagh D., 1995, CORONAVIRIDAE, P73
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Debnath AK, 1999, J MED CHEM, V42, P3203, DOI 10.1021/jm990154t
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Dwyer JJ, 2003, BIOCHEMISTRY-US, V42, P4945, DOI 10.1021/bi027283n
   Gallagher TM, 1997, J VIROL, V71, P3129, DOI 10.1128/JVI.71.4.3129-3137.1997
   GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Holmes KV, 2003, NEW ENGL J MED, V348, P1948, DOI 10.1056/NEJMp030078
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0
   JIANG SB, 1993, BIOCHEM BIOPH RES CO, V195, P533, DOI 10.1006/bbrc.1993.2078
   Jiang SB, 1999, J VIROL METHODS, V80, P85, DOI 10.1016/S0166-0934(99)00041-5
   Jiang SB, 2002, CURR PHARM DESIGN, V8, P563
   Jiang SB, 1995, PEPTIDE RES, V8, P345
   JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4
   Jones DK, 1998, BIOCHEM J, V330, P983
   KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195
   Krueger DK, 2001, J VIROL, V75, P2792, DOI 10.1128/JVI.75.6.2792-2802.2001
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013
   Lombardi S, 1996, VIROLOGY, V220, P274, DOI 10.1006/viro.1996.0315
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Luo ZL, 1999, J VIROL, V73, P8152, DOI 10.1128/JVI.73.10.8152-8159.1999
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Qin E, 2003, CHINESE SCI BULL, V48, P941, DOI 10.1007/BF03184203
   Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399
   Rost B, 1996, METHOD ENZYMOL, V266, P525
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vakser IA, 1999, P NATL ACAD SCI USA, V96, P8477, DOI 10.1073/pnas.96.15.8477
   Wang EX, 2003, BIOCHEM BIOPH RES CO, V302, P469, DOI 10.1016/S0006-291X(03)00197-9
   Watanabe S, 2000, J VIROL, V74, P10194, DOI 10.1128/JVI.74.21.10194-10201.2000
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803
   WHO, 2003, SUMM PROB SARS CAS O
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606
   Yao QZ, 1996, VIROLOGY, V223, P103, DOI 10.1006/viro.1996.0459
   Yu M, 2002, J GEN VIROL, V83, P623, DOI 10.1099/0022-1317-83-3-623
   Zhao Q, 2002, AIDS RES HUM RETROV, V18, P989, DOI 10.1089/08892220260235353
NR 50
TC 212
Z9 239
U1 4
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAR 20
PY 2004
VL 363
IS 9413
BP 938
EP 947
DI 10.1016/S0140-6736(04)15788-7
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 804OS
UT WOS:000220308600010
PM 15043961
OA Bronze
DA 2020-04-03
ER

PT J
AU Lee, YR
   Lei, HY
   Liu, MT
   Wang, JR
   Chen, SH
   Jiang-Shieh, YF
   Lin, YS
   Yeh, TM
   Liu, CC
   Liu, HS
AF Lee, Ying-Ray
   Lei, Huan-Yao
   Liu, Ming-Tao
   Wang, Jen-Ren
   Chen, Shun-Hua
   Jiang-Shieh, Ya-Fen
   Lin, Yee-Shin
   Yeh, Trai-Ming
   Liu, Ching-Chang
   Liu, Hsiao-Sheng
TI Autophagic machinery activated by dengue virus enhances virus
   replication
SO VIROLOGY
LA English
DT Article
DE dengue virus; autophagy; autophagosome; viral replication
ID ANTIBODY-DEPENDENT ENHANCEMENT; ENDOPLASMIC-RETICULUM STRESS; CELLULAR
   AUTOPHAGY; CORONAVIRUS REPLICATION; HEMORRHAGIC-FEVER; PATHWAY;
   INFECTION; CELLS; MATURATION; HOMOLOG
AB Autophagy is a cellular response against stresses which include the infection of viruses and bacteria. We unravel that Dengue virus-2 (DV2) can trigger autophagic process in various infected cell lines demonstrated by GFP-LC3 dot formation and increased LC3-II formation. Autophagosome formation was also observed under the transmission electron microscope. DV2-induced autophagy further enhances the titers of extracellular and intracellular viruses indicating that autophagy can promote viral replication in the infected cells. Moreover, our data show that ATG5 protein is required to execute DV2-induced autophagy. All together, we are the first to demonstrate that DV can activate autophagic machinery that is favorable for viral replication. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Lei, Huan-Yao; Chen, Shun-Hua; Lin, Yee-Shin; Liu, Hsiao-Sheng] Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 70101, Taiwan.
   [Lee, Ying-Ray; Lei, Huan-Yao] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan.
   [Liu, Ming-Tao] Tainan Hosp, Dept Hlth, Tainan, Taiwan.
   [Wang, Jen-Ren; Yeh, Trai-Ming] Natl Cheng Kung Univ, Coll Med, Dept Med Lab Sci & Biotechnol, Tainan, Taiwan.
   [Jiang-Shieh, Ya-Fen] Natl Cheng Kung Univ, Coll Med, Dept Cell Biol & Anat, Tainan, Taiwan.
   [Liu, Ching-Chang] Natl Cheng Kung Univ, Coll Med, Dept Pediat, Tainan, Taiwan.
RP Liu, HS (reprint author), Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, 1 Univ Rd, Tainan 70101, Taiwan.
EM a713@mail.ncku.edu.tw
RI Yeh, Trai-Ming/C-7193-2011
OI Yeh, Trai-Ming/0000-0003-3172-7432; Wang, Jen-Ren/0000-0002-4127-4046;
   Lee, Ying-Ray/0000-0002-0349-0960
CR Alexander DE, 2007, J VIROL, V81, P12128, DOI 10.1128/JVI.01356-07
   Amer AO, 2005, CELL MICROBIOL, V7, P765, DOI 10.1111/j.1462-5822.2005.00509.x
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Gutierrez MG, 2005, CELL MICROBIOL, V7, P981, DOI 10.1111/j.1462-5822.2005.00527.x
   HOYVIK H, 1986, EXP CELL RES, V166, P1, DOI 10.1016/0014-4827(86)90503-3
   Huang KJ, 2006, J IMMUNOL, V176, P2825, DOI 10.4049/jimmunol.176.5.2825
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Jounai N, 2007, P NATL ACAD SCI USA, V104, P14050, DOI 10.1073/pnas.0704014104
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kato J, 2002, J MED VIROL, V66, P187, DOI 10.1002/jmv.2129
   KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444
   Kopecky-Bromberg SA, 2006, J VIROL, V80, P785, DOI 10.1128/JVI.80.2.785-793.2006
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Lei HY, 2001, J BIOMED SCI, V8, P377, DOI 10.1007/BF02255946
   Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Nakashima A, 2006, VIROLOGY, V349, P254, DOI 10.1016/j.virol.2006.03.029
   Nemoto T, 2003, J BIOL CHEM, V278, P39517, DOI 10.1074/jbc.M300550200
   Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299
   Wileman T, 2006, SCIENCE, V312, P875, DOI 10.1126/science.1126766
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Yorimitsu T, 2007, AUTOPHAGY, V3, P160, DOI 10.4161/auto.3653
   Yu CY, 2006, J VIROL, V80, P11868, DOI 10.1128/JVI.00879-06
   Zhang HY, 2006, AUTOPHAGY, V2, P91, DOI 10.4161/auto.2.2.2297
   Zhao ZJ, 2007, AUTOPHAGY, V3, P581, DOI 10.4161/auto.4782
NR 27
TC 210
Z9 219
U1 1
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAY 10
PY 2008
VL 374
IS 2
BP 240
EP 248
DI 10.1016/j.virol.2008.02.016
PG 9
WC Virology
SC Virology
GA 299DL
UT WOS:000255735900003
PM 18353420
DA 2020-04-03
ER

PT J
AU Yount, B
   Curtis, KM
   Fritz, EA
   Hensley, LE
   Jahrling, PB
   Prentice, E
   Denison, MR
   Geisbert, TW
   Baric, RS
AF Yount, B
   Curtis, KM
   Fritz, EA
   Hensley, LE
   Jahrling, PB
   Prentice, E
   Denison, MR
   Geisbert, TW
   Baric, RS
TI Reverse genetics with a full-length infectious cDNA of severe acute
   respiratory syndrome coronavirus
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS VIRUS; MOUSE HEPATITIS-VIRUS; MURINE
   CORONAVIRUS; BRONCHITIS VIRUS; SEQUENCE-ANALYSIS; SARS-CORONAVIRUS;
   GENOME SEQUENCE; VACCINIA VIRUS; HONG-KONG; IN-VITRO
AB A previously undescribed coronavirus (CoV) is the etiologic agent responsible for severe acute respiratory syndrome (SARS). Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones. Recombinant viruses replicated as efficiently as WT virus and both were inhibited by treatment with the cysteine proteinase inhibitor (2S,3S)-transepoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester. In addition, subgenomic transcripts were initiated from the consensus sequence ACGAAC in both the WT and infectious clone SARS-CoV. Availability of a SARS-CoV full-length cDNA provides a template for manipulation of the viral genome, allowing for the rapid and rational development and testing of candidate vaccines and therapeutics against this important human pathogen.
C1 Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Dept Microbiol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Dept Immunol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Carolina Vaccine Inst, Chapel Hill, NC 27599 USA.
   USA, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA.
   Vanderbilt Univ, Med Ctr, Elizabeth B Lamb Ctr Pediat Res, Dept Pediat, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Elizabeth B Lamb Ctr Pediat Res, Dept Microbiol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Elizabeth B Lamb Ctr Pediat Res, Dept Immunol, Nashville, TN 37232 USA.
RP Baric, RS (reprint author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
RI Denison, Mark/O-7258-2018
OI Denison, Mark/0000-0003-2655-0900
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 26603, R01 AI023946, AI 23946, R01
   AI026603]; NIGMS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [GM 63228, R01 GM063228]
CR Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Baric RS, 1999, J VIROL, V73, P638, DOI 10.1128/JVI.73.1.638-649.1999
   Baric RS, 1997, J VIROL, V71, P1946, DOI 10.1128/JVI.71.3.1946-1955.1997
   Baron MD, 1999, J GEN VIROL, V80, P2031, DOI 10.1099/0022-1317-80-8-2031
   Casais R, 2001, J VIROL, V75, P12359, DOI 10.1128/JVI.75.24.12359-12369.2001
   Crouch CF, 2000, VACCINE, V19, P189, DOI 10.1016/S0264-410X(00)00177-8
   Curtis KM, 2002, J VIROL, V76, P1422, DOI 10.1128/JVI.76.3.1422-1434.2002
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   DUARTE M, 1994, VIROLOGY, V198, P466, DOI 10.1006/viro.1994.1058
   Enjuanes L., 1995, The coronaviridae., P337
   Fischer F, 1998, J VIROL, V72, P7885, DOI 10.1128/JVI.72.10.7885-7894.1998
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6
   Kanjanahaluethai A, 2003, J VIROL, V77, P7376, DOI 10.1128/JVI.77.13.7376-7382.2003
   KIM JC, 1995, VIROLOGY, V208, P1, DOI 10.1006/viro.1995.1123
   KOMATSU K, 1986, EXP NEUROL, V91, P23, DOI 10.1016/0014-4886(86)90022-1
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Ladman BS, 2002, AVIAN DIS, V46, P938, DOI 10.1637/0005-2086(2002)046[0938:POCALA]2.0.CO;2
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lu XT, 1998, J VIROL, V72, P2265, DOI 10.1128/JVI.72.3.2265-2271.1998
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Ortego J, 2002, J VIROL, V76, P11518, DOI 10.1128/JVI.76.22.11518-11529.2002
   Park SK, 1998, AM J VET RES, V59, P1002
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   PENSAERT M, 1986, VET QUART, V8, P257, DOI 10.1080/01652176.1986.9694050
   PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Rottier PJM, 1999, VET MICROBIOL, V69, P117, DOI 10.1016/S0378-1135(99)00099-1
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Saif LJ, 1999, ADV VET MED-ACAD PR, V41, P429
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   SOLA I, 2002, J VIROL, V77, P4357
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   VANNIEUWSTADT AP, 1989, VET REC, V125, P58, DOI 10.1136/vr.125.3.58
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   von Grotthuss M, 2003, CELL, V113, P701, DOI 10.1016/S0092-8674(03)00424-0
   Wang XQ, 2002, AVIAN DIS, V46, P831, DOI 10.1637/0005-2086(2002)046[0831:CAISOR]2.0.CO;2
   Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000
   Yount B, 2002, J VIROL, V76, P11065, DOI 10.1128/JVI.76.21.11065-11078.2002
NR 44
TC 210
Z9 234
U1 1
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 28
PY 2003
VL 100
IS 22
BP 12995
EP 13000
DI 10.1073/pnas.1735582100
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 738RF
UT WOS:000186301100088
PM 14569023
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Herrewegh, AAPM
   Smeenk, I
   Horzinek, MC
   Rottier, PJM
   de Groot, RJ
AF Herrewegh, AAPM
   Smeenk, I
   Horzinek, MC
   Rottier, PJM
   de Groot, RJ
TI Feline coronavirus type II strains 79-1683 and 79-1146 originate from a
   double recombination between feline coronavirus type I and canine
   coronavirus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID INFECTIOUS PERITONITIS VIRUS; RNA RECOMBINATION; MONOCLONAL-ANTIBODIES;
   BRONCHITIS VIRUS; GENOMIC RNA; NUCLEOCAPSID PROTEINS; PORCINE
   CORONAVIRUSES; MURINE CORONAVIRUSES; NUCLEOTIDE-SEQUENCE; LETHAL
   INFECTION
AB Recent evidence suggests that the type II feline coronavirus (FCoV) strains 79-1146 and 79-1683 have arisen from a homologous RNA recombination event between FCoV type I and canine coronavirus (CCV). In both cases, the template switch apparently took place between the S and M genes, giving rise to recombinant viruses which encode a CCV-like S protein and the M, N, 7a, and 7b proteins of FCoV type I (K. Motowaka, T. Hohdatsu, H. Hashimoto, and H. Koyama, Microbiol. Immunol. 40:425-433, 1996; H. Vennema, A. Poland, K. Floyd Hawkins, and N. C. Pedersen, Feline Pract. 23:40-44, 1995). In the present study, we have looked for additional FCoV-CCV recombination sites. Four regions in the pol gene were selected for comparative sequence analysis of the type II FCoV strains 79-1683 and 79-1146, the type I FCoV strains TN406 and UCD1, the CCV strain K378, and the TGEV strain Purdue. Our data show that the type II FCoVs have arisen from double recombination events: additional crossover sites were mapped in the ORF1ab frameshifting region of strain 79-1683 and in the 5' half of ORF1b of strain 79-1146.
C1 Univ Utrecht, Dept Immunol & Infect Dis, Virol Unit, Fac Vet Med, NL-3508 TD Utrecht, Netherlands.
RP de Groot, RJ (reprint author), Univ Utrecht, Dept Immunol & Infect Dis, Virol Unit, Fac Vet Med, POB 80-165, NL-3508 TD Utrecht, Netherlands.
EM R.Groot@vetmic.dgk.ruu.nl
CR BANNER LR, 1991, VIROLOGY, V185, P441, DOI 10.1016/0042-6822(91)90795-D
   BARIC RS, 1990, VIROLOGY, V177, P646, DOI 10.1016/0042-6822(90)90530-5
   BARLOUGH JE, 1984, LAB ANIM SCI, V34, P592
   BROWN CS, 1994, VIROLOGY, V198, P477, DOI 10.1006/viro.1994.1059
   CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435
   CHAO L, 1990, NATURE, V348, P454, DOI 10.1038/348454a0
   COOPER PD, 1974, J GEN VIROL, V23, P41, DOI 10.1099/0022-1317-23-1-41
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   DEGROOT RJ, 1987, J GEN VIROL, V68, P995, DOI 10.1099/0022-1317-68-4-995
   ELEOUET JF, 1995, VIROLOGY, V206, P817, DOI 10.1006/viro.1995.1004
   Groot R. J. de, 1995, The coronaviridae., P293
   HASONY HJ, 1981, ARCH VIROL, V69, P33, DOI 10.1007/BF01315263
   HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419
   HERREWEGH AAP, 1997, Y13921 EMBL
   Herrewegh AAPM, 1997, VIROLOGY, V234, P349, DOI 10.1006/viro.1997.8663
   HERREWEGH AAPM, 1995, VIROLOGY, V212, P622, DOI 10.1006/viro.1995.1520
   HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151
   HOHDATSU T, 1992, J VET MED SCI, V54, P557, DOI 10.1292/jvms.54.557
   HOHDATSU T, 1991, ARCH VIROL, V117, P85, DOI 10.1007/BF01310494
   HOHDATSU T, 1991, VET MICROBIOL, V28, P13, DOI 10.1016/0378-1135(91)90096-X
   HORSBURGH BC, 1992, J GEN VIROL, V73, P2849, DOI 10.1099/0022-1317-73-11-2849
   JIA W, 1995, ARCH VIROL, V140, P259, DOI 10.1007/BF01309861
   KECK JG, 1988, J VIROL, V62, P1810, DOI 10.1128/JVI.62.5.1810-1813.1988
   KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8
   KOOLEN MJM, 1990, J VIROL, V64, P6270, DOI 10.1128/JVI.64.12.6270-6273.1990
   KOTIER SA, 1995, VIROLOGY, V213, P569, DOI 10.1006/viro.1995.0029
   KUSTERS JG, 1990, VACCINE, V8, P605, DOI 10.1016/0264-410X(90)90018-H
   Lai MMC, 1996, SEMIN VIROL, V7, P381, DOI 10.1006/smvy.1996.0046
   LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985
   LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992
   LIAO CL, 1992, J VIROL, V66, P6117, DOI 10.1128/JVI.66.10.6117-6124.1992
   LUYTJES W, 1995, CORONAVIRIDAE, P33
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MCARDLE F, 1992, AM J VET RES, V53, P1500
   MCARDLE F, 1990, ADV EXP MED BIOL, V276, P475
   Motokawa K, 1996, MICROBIOL IMMUNOL, V40, P425, DOI 10.1111/j.1348-0421.1996.tb01089.x
   MOTOKAWA K, 1995, ARCH VIROL, V140, P469, DOI 10.1007/BF01718424
   NAKANAGA K, 1986, J VIROL, V59, P168, DOI 10.1128/JVI.59.1.168-171.1986
   Pedersen N. C., 1984, Molecular biology and pathogenesis of coronaviruses, P365
   RASSCHAERT D, 1987, BIOCHIMIE, V69, P591, DOI 10.1016/0300-9084(87)90178-7
   SIDDELL SG, 1995, CORONAVIRIDAE, P1
   SNEATH PHA, 1973, NUMERICAL TAXONOMY, P230, DOI DOI 10.1111/J.1523-1739.2007.00775.X
   STODDART CA, 1988, RES VET SCI, V45, P383, DOI 10.1016/S0034-5288(18)30970-6
   VANDERMOST RG, 1992, NUCLEIC ACIDS RES, V20, P3375, DOI 10.1093/nar/20.13.3375
   VENNEMA H, 1991, VIROLOGY, V181, P327, DOI 10.1016/0042-6822(91)90499-2
   VENNEMA H, 1995, FELINE PRACT, V23, P40
   VENNEMA H, COMMUNICATION
   WANG L, 1993, VIROLOGY, V192, P710, DOI 10.1006/viro.1993.1093
   WESSELING JG, 1993, J GEN VIROL, V74, P2061, DOI 10.1099/0022-1317-74-10-2061
   WESSELING JG, 1994, J GEN VIROL, V75, P1789, DOI 10.1099/0022-1317-75-7-1789
NR 50
TC 210
Z9 227
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 1998
VL 72
IS 5
BP 4508
EP 4514
DI 10.1128/JVI.72.5.4508-4514.1998
PG 7
WC Virology
SC Virology
GA ZH268
UT WOS:000073090100123
PM 9557750
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Thai, HTC
   Le, MQ
   Vuong, CD
   Parida, M
   Minekawa, H
   Notomi, T
   Hasebe, F
   Morita, K
AF Thai, HTC
   Le, MQ
   Vuong, CD
   Parida, M
   Minekawa, H
   Notomi, T
   Hasebe, F
   Morita, K
TI Development and evaluation of a novel loop-mediated isothermal
   amplification method for rapid detection of severe acute respiratory
   syndrome coronavirus
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID DIAGNOSIS; OUTBREAK
AB The development and evaluation of a one-step single-tube accelerated real-time quantitative reverse transcription (RT) loop-mediated isothermal amplification (LAMP) assay is reported for rapid detection of the severe acute respiratory syndrome coronavirus (SARS-CoV) replicase gene. A total of 49 samples (15 throat washes, 13 throat swabs, and 21 combined throat and nasal swabs) collected from patients admitted to the Hanoi-French and Ninhbinh hospitals in Vietnam during the SARS epidemic were evaluated and compared to conventional RT-PCR. The RT-LAMP assay demonstrated 100-fold-greater sensitivity, with a detection limit of 0.01 PFU. The sensitivity and specificity of RT-LAMP assay for detecting viral RNA in clinical specimens with regard to RT-PCR were 100 and 87%, respectively. The specificity of the RT-LAMP assay was further validated by restriction analysis as well as nucleotide sequencing of the amplified product. The concentration of virus in most of the clinical samples was 0.1 PFU (0.1 to 10(2) PFU), as determined from the standard curve of SARS RT-LAMP and based on the time of positivity. The assay procedure is quite simple, wherein the amplification is carried out in a single tube under isothermal conditions at 63degreesC, and the result can be obtained in less than 1 h (as early as 11 min). Thus, the RT-LAMP assay reported here has the advantages of rapid amplification, simple operation, and easy detection and will be useful for rapid and reliable clinical diagnosis of SARS-CoV in developing countries.
C1 Nagasaki Univ, Inst Trop Med, Dept Virol, Nagasaki 8528523, Japan.
   Eiken Chem Co Ltd, Ohtawara, Tochigi 3240036, Japan.
   Natl Inst Hyg & Epidemiol, Dept Virol, Hanoi, Vietnam.
RP Morita, K (reprint author), Nagasaki Univ, Inst Trop Med, Dept Virol, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.
EM moritak@net.nagasaki-u.ac.jp
CR Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P226
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   EPSTEIN RP, 2003, ENV HLTH PERSPECT, V111, pA506
   Iwamoto T, 2003, J CLIN MICROBIOL, V41, P2616, DOI 10.1128/JCM.41.6.2616-2622.2003
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mori Y, 2001, BIOCHEM BIOPH RES CO, V289, P150, DOI 10.1006/bbrc.2001.5921
   Nagamine K, 2002, MOL CELL PROBE, V16, P223, DOI 10.1006/mcpr.2002.0415
   Nie QH, 2003, WORLD J GASTROENTERO, V9, P1139, DOI 10.3748/wjg.v9.i6.1139
   Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Poon LLM, 2003, CLIN CHEM, V49, P953, DOI 10.1373/49.6.953
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Rainer TH, 2003, BRIT MED J, V326, P1354, DOI 10.1136/bmj.326.7403.1354
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SCHMIDT NJ, 1979, DIAGNOSTISC PROCEDUR
   Stohr K, 2003, LANCET, V361, P1730, DOI 10.1016/S0140-6736(03)13376-4
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   World Health Organization, 2003, WKLY EPIDEMIOL REC, V78, P86
   Yam WC, 2003, J CLIN MICROBIOL, V41, P4521, DOI 10.1128/JCM.41.10.4521-4524.2003
NR 23
TC 209
Z9 262
U1 5
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 2004
VL 42
IS 5
BP 1956
EP 1961
DI 10.1128/JCM.42.5.1956-1961.2004
PG 6
WC Microbiology
SC Microbiology
GA 820XU
UT WOS:000221424100014
PM 15131154
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU MAKINO, S
   KECK, JG
   STOHLMAN, SA
   LAI, MMC
AF MAKINO, S
   KECK, JG
   STOHLMAN, SA
   LAI, MMC
TI HIGH-FREQUENCY RNA RECOMBINATION OF MURINE CORONAVIRUSES
SO JOURNAL OF VIROLOGY
LA English
DT Article
C1 UNIV SO CALIF,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90033.
RP MAKINO, S (reprint author), UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033, USA.
RI Makino, Shinji/E-8014-2015; Lai, Michael M. C./I-7001-2012
OI Makino, Shinji/0000-0002-7831-1576; 
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 19244]
CR BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   BARIC RS, 1985, VIRUS RES, V3, P19, DOI 10.1016/0168-1702(85)90038-3
   BARRELL BG, 1971, PROCEDURES NUCLEIC A, V2, P751
   BRAYTON PR, 1982, J VIROL, V42, P847, DOI 10.1128/JVI.42.3.847-853.1982
   BRAYTON PR, 1984, VIROLOGY, V133, P197, DOI 10.1016/0042-6822(84)90439-2
   BRAYTON PR, 1981, J GEN VIROL, V50, P457
   Fields B N, 1981, Curr Top Microbiol Immunol, V91, P1
   HERNDON RM, 1975, ARCH NEUROL-CHICAGO, V33, P32
   JACOBS L, 1981, J VIROL, V39, P401, DOI 10.1128/JVI.39.2.401-406.1981
   JUNGHANS RP, 1982, CELL, V30, P53, DOI 10.1016/0092-8674(82)90011-3
   KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777
   KING AMQ, 1982, CELL, V29, P921, DOI 10.1016/0092-8674(82)90454-8
   KNOBLER RL, 1981, J NEUROIMMUNOL, V1, P81, DOI 10.1016/0165-5728(81)90010-2
   LAI MMC, 1983, J VIROL, V46, P1027, DOI 10.1128/JVI.46.3.1027-1033.1983
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985
   LAI MMC, 1982, J VIROL, V41, P557, DOI 10.1128/JVI.41.2.557-565.1982
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   LAI MMC, 1978, J VIROL, V26, P235
   LANGRIDGE J, 1980, ANAL BIOCHEM, V103, P264, DOI 10.1016/0003-2697(80)90266-3
   LEIBOWITZ JL, 1982, J VIROL, V43, P905, DOI 10.1128/JVI.43.3.905-913.1982
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   MAKINO S, 1985, J VIROL, V54, P329, DOI 10.1128/JVI.54.2.329-336.1985
   MAKINO S, 1984, VIROLOGY, V139, P138, DOI 10.1016/0042-6822(84)90335-0
   MAKINO S, 1984, VIROLOGY, V133, P9, DOI 10.1016/0042-6822(84)90420-3
   MILLS DR, 1978, CELL, V15, P541, DOI 10.1016/0092-8674(78)90022-3
   NAGASHIMA K, 1978, ACTA NEUROPATHOL, V44, P63, DOI 10.1007/BF00691641
   SCHOLTISSEK C, 1978, VIROLOGY, V87, P13, DOI 10.1016/0042-6822(78)90153-8
   SIDDELL S, 1983, J GEN VIROL, V64, P113, DOI 10.1099/0022-1317-64-1-113
   SPAAN W, 1983, EMBO J, V2, P1939
   STOHLMAN SA, 1982, J GEN VIROL, V63, P265, DOI 10.1099/0022-1317-63-2-265
   WEGE H, 1978, J GEN VIROL, V41, P217, DOI 10.1099/0022-1317-41-2-217
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WILHELMSEN KC, 1981, VIROLOGY, V110, P225, DOI 10.1016/0042-6822(81)90027-1
NR 35
TC 209
Z9 214
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAR
PY 1986
VL 57
IS 3
BP 729
EP 737
DI 10.1128/JVI.57.3.729-737.1986
PG 9
WC Virology
SC Virology
GA A0384
UT WOS:A1986A038400003
PM 3005623
OA Bronze
DA 2020-04-03
ER

PT J
AU Arruda, E
   Pitkaranta, A
   Witek, TJ
   Doyle, CA
   Hayden, FG
AF Arruda, E
   Pitkaranta, A
   Witek, TJ
   Doyle, CA
   Hayden, FG
TI Frequency and natural history of rhinovirus infections in adults during
   autumn
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; MIDDLE-EAR; COLDS; PCR; HYBRIDIZATION;
   DIAGNOSIS; NASAL; DNA
AB Human rhinovirus (HRV) accounts for a significant portion of common-cold illness, with the peak incidence being in the early fall, Three hundred forty-six adults mho had self-diagnosed colds of 48 h or less were enrolled in a study during September and October 1994 to determine the frequency and clinical course of HRV infections, Nasal wash specimens for viral culture anal reverse transcription-PCR (RT-PCR) for HRV RNA and human coronavirus OC43 and 229E RNA detection were collected an enrollment, and participants recorded their symptoms twice daily for 14 days, Middle ear pressure (MEP) was measured with a digital tympanometer on days 1 and 7, Picornaviruses (224 HRV and 7 enterovirus isolates) were detected by culture in 67% (231 of 346) of the subjects, Among 114 samples negative by culture, HRV was detected by RT-PCR in 52 (46%) for an overall picornavirus infection rate of 82% (283 of 346 subjects), among the remaining 62 negative samples, human coronavirus RNA was detected bg RT-PCR in 5 patients, so that 288 (83%) of patients had documented viral infection, The first symptom noticed most often was sore throat (40%) in HRV culture-or PCR-positive patients and stuffy nose in HRV-negative patients (27%), No differences in symptom scores over time or in the presence of individual symptoms were noted between groups. The median duration of the cold episodes was 11 days in HRV culture-positive patients, 9.5 days in HRV RT-PCR-positive patients, and 11.5 days in HRV-negative patients, On enrollment, abnormal MEPs (less than or equal to -100 or greater than or equal to +100 mm of H2O) were found for 21% of HRV culture-positive patients, 14% of HRV RT-PCR-positive patients, and 10% of HRV-negative patients, No important differences in the clinical course of HRV culture-positive, HRV culture-negative and RT-PCR-positive, or HRV-negative colds were found, These results represent the highest frequency of virologically confirmed natural colds to date and document the importance of rhinoviruses as the cause of colds during fall months.
C1 UNIV VIRGINIA,HLTH SCI CTR,SCH MED,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908.
   UNIV VIRGINIA,SCH MED,DEPT PATHOL,CHARLOTTESVILLE,VA 22908.
   BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877.
   UNIV SAO PAULO,SCH MED,BR-14049900 RIBEIRAO PRET,SP,BRAZIL.
   UNIV HELSINKI HOSP,HELSINKI,FINLAND.
RI Arruda, Eurico/E-4101-2012
CR ARRUDA E, 1993, MOL CELL PROBE, V7, P373, DOI 10.1006/mcpr.1993.1055
   Arruda E, 1996, J CLIN MICROBIOL, V34, P1277, DOI 10.1128/JCM.34.5.1277-1279.1996
   ARRUDA E, 95 GEN M AM SOC MIC, P41
   Arruda E, 1991, J INFECT DIS, V164, P1261
   BONI J, 1993, MOL CELL PROBE, V7, P361, DOI 10.1006/mcpr.1993.1054
   Doyle W.J., 1988, AM J RHINOL, V2, P149, DOI DOI 10.2500/105065888781692961
   DOYLE WJ, 1988, PEDIATR INFECT DIS J, V7, P215
   ELKHATIEB A, 1993, J INFECT DIS, V168, P618, DOI 10.1093/infdis/168.3.618
   GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301
   GWALTNEY JM, 1989, VIRAL INFECT HUMANS, P593
   GWALTNEY JM, 1984, T AM CLIN CLIMAT ASS, V96, P159
   HALONEN P, 1995, J CLIN MICROBIOL, V33, P648, DOI 10.1128/JCM.33.3.648-653.1995
   Harris JM, 1996, CLIN INFECT DIS, V23, P1287, DOI 10.1093/clinids/23.6.1287
   HAYDEN FG, 1988, ANTIMICROB AGENTS CH, V32, P224, DOI 10.1128/AAC.32.2.224
   HAYDEN FG, 1995, ANTIMICROB AGENTS CH, V39, P290, DOI 10.1128/AAC.39.2.290
   HYYPIA T, 1989, J GEN VIROL, V70, P3261, DOI 10.1099/0022-1317-70-12-3261
   IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993
   MCBRIDE TP, 1989, ARCH OTOLARYNGOL, V115, P1054
   MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052
   MYINT S, 1990, J MED VIROL, V31, P165, DOI 10.1002/jmv.1890310216
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791
   RAO SS, 1995, AM J RHINOL, V9, P49, DOI 10.2500/105065895781874114
   Vesanen M, 1996, J VIROL METHODS, V59, P1, DOI 10.1016/0166-0934(95)01991-X
NR 25
TC 208
Z9 214
U1 6
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD NOV
PY 1997
VL 35
IS 11
BP 2864
EP 2868
DI 10.1128/JCM.35.11.2864-2868.1997
PG 5
WC Microbiology
SC Microbiology
GA YD173
UT WOS:A1997YD17300028
PM 9350748
OA Bronze
DA 2020-04-03
ER

PT J
AU Templeton, KE
   Scheltinga, SA
   van den Eeden, WCJFM
   Graffelman, AW
   van den Broek, PJ
   Claas, ECJ
AF Templeton, KE
   Scheltinga, SA
   van den Eeden, WCJFM
   Graffelman, AW
   van den Broek, PJ
   Claas, ECJ
TI Improved diagnosis of the etiology of community-acquired pneumonia with
   real-time polymerase chain reaction
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY-TRACT INFECTIONS; RHINOVIRUS INFECTIONS; VIRAL CULTURE;
   ADULTS; PCR; VIRUSES; DISEASE; MANAGEMENT; PROGNOSIS; MORTALITY
AB Background. Community- acquired pneumonia ( CAP) remains an important cause of morbidity and mortality. Polymerase chain reaction ( PCR) has been shown to be more sensitive than current standard microbiological methods and, therefore, may improve the accuracy of microbiological diagnosis for patients with CAP.
   Methods. Conventional detection techniques and multiplex real- time PCR for atypical bacteria and respiratory viruses were performed on samples collected from 105 adults enrolled in a prospective study. An infiltrate was visible on each patient's chest radiograph, and a pneumonia severity index score was determined for each patient.
   Results. Microbiological diagnoses were determined for 52 ( 49.5%) of 105 patients by conventional techniques and for 80 ( 76%) of 105 patients by real- time PCR. The time to obtain the result of real- time PCR could be reduced to 6 h. PCR methodology was significantly more sensitive for the detection of atypical pathogens and viruses (). Respiratory viral infections and mixed infections were detected in 15 ( 14.2%) and 3 ( 2.8%) of P <=.001 105 patients, respectively, by conventional methods, but were detected in 59 ( 56.2%) and 28 ( 26.5%) of 105, respectively, by real- time PCR. Presence of a mixed infection was significantly associated with severe pneumonia (). Human rhinoviruses and coronaviruses, OC43 and 229E, were frequently identified pathogens. Pp. 002
   Conclusions. The combined real- time PCR assay is more sensitive for diagnosis of the main viruses and atypical bacteria that cause CAP compared with conventional methods, and obtains results in a clinically relevant time period.
C1 Leiden Univ, Med Ctr, Dept Med Microbiol, NL-2300 RC Leiden, Netherlands.
   Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands.
   Leiden Univ, Med Ctr, Ctr Infect Dis, NL-2300 RC Leiden, Netherlands.
   Leiden Univ, Med Ctr, Dept Gen Practice & Nursing Home Med, NL-2300 RC Leiden, Netherlands.
RP Claas, ECJ (reprint author), Leiden Univ, Med Ctr, Dept Med Microbiol, POB 9600, NL-2300 RC Leiden, Netherlands.
EM E.Claas@lumc.nl
OI Templeton, Kate/0000-0001-7414-1277
CR Bakaletz Lauren O., 1995, Trends in Microbiology, V3, P110, DOI 10.1016/S0966-842X(00)88892-7
   BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408
   Benin AL, 2002, CLIN INFECT DIS, V35, P1039, DOI 10.1086/342903
   BOHTE R, 1995, THORAX, V50, P543, DOI 10.1136/thx.50.5.543
   Campbell SG, 2003, EMERG MED J, V20, P521, DOI 10.1136/emj.20.6.521
   Drosten C, 2004, J CLIN MICROBIOL, V42, P2043, DOI 10.1128/JCM.42.5.2043-2047.2004
   Falsey AR, 2002, J INFECT DIS, V185, P1338, DOI 10.1086/339881
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   Folz RJ, 1999, CHEST, V115, P901, DOI 10.1378/chest.115.3.901
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1
   Graffelman AW, 2004, BRIT J GEN PRACT, V54, P15
   Guest JF, 1997, EUR RESPIR J, V10, P1530, DOI 10.1183/09031936.97.10071530
   Guthrie R, 2001, CHEST, V120, P2021, DOI 10.1378/chest.120.6.2021
   Ison MG, 2003, CLIN INFECT DIS, V36, P1139, DOI 10.1086/374340
   Jokinen C, 2001, CLIN INFECT DIS, V32, P1141, DOI 10.1086/319746
   LEROY O, 1995, INTENS CARE MED, V21, P24, DOI 10.1007/BF02425150
   Lidman C, 2002, SCAND J INFECT DIS, V34, P873, DOI 10.1080/0036554021000026967
   Lim WS, 2001, THORAX, V56, P296, DOI 10.1136/thorax.56.4.296
   Luna CM, 2000, CHEST, V118, P1344, DOI 10.1378/chest.118.5.1344
   MACFARLANE JT, 1982, LANCET, V2, P255
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Malcolm E, 2001, J CLIN VIROL, V21, P9, DOI 10.1016/S1386-6532(00)00180-3
   Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4
   Nicholson KG, 1996, BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119
   Niederman MS, 2004, AM J MED, V117, P51, DOI 10.1016/j.amjmed.2004.07.008
   PACHON J, 1990, AM REV RESPIR DIS, V142, P369, DOI 10.1164/ajrccm/142.2.369
   Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   Rello J, 2003, CHEST, V123, P174, DOI 10.1378/chest.123.1.174
   Roson B, 2001, CLIN INFECT DIS, V33, P158, DOI 10.1086/321808
   SCHELTINGA SA, IN PRESS J CLIN VIRO
   Simpson JL, 2003, J CLIN VIROL, V26, P339, DOI 10.1016/S1386-6532(02)00084-7
   Skerrett S J, 1997, Semin Respir Infect, V12, P308
   Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004
   Templeton KE, 2003, J CLIN MICROBIOL, V41, P4366, DOI 10.1128/JCM.41.9.4366-4371.2003
   Templeton KE, 2003, J CLIN MICROBIOL, V41, P4016, DOI 10.1128/JCM.41.9.4016-4021.2003
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   van Elden LJR, 2004, J INFECT DIS, V189, P652, DOI 10.1086/381207
   van Elden LJR, 2002, CLIN INFECT DIS, V34, P177, DOI 10.1086/338238
   Waites KB, 2004, CLIN MICROBIOL REV, V17, P697, DOI 10.1128/CMR.17.4.697-728.2004
   Weinberg GA, 2004, J INFECT DIS, V189, P706, DOI 10.1086/381456
NR 42
TC 207
Z9 213
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2005
VL 41
IS 3
BP 345
EP 351
DI 10.1086/431588
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 942TK
UT WOS:000230305300012
PM 16007532
OA Bronze
DA 2020-04-03
ER

PT J
AU Anand, K
   Palm, GJ
   Mesters, JR
   Siddell, SG
   Ziebuhr, J
   Hilgenfeld, R
AF Anand, K
   Palm, GJ
   Mesters, JR
   Siddell, SG
   Ziebuhr, J
   Hilgenfeld, R
TI Structure of coronavirus main proteinase reveals combination of a
   chymotrypsin fold with an extra alpha-helical domain
SO EMBO JOURNAL
LA English
DT Article
DE 3C-like; catalytic dyad; coronavirus; proteinase; X-ray crystallography
ID VIRUS 3C-LIKE PROTEINASE; PROTEOLYTIC PRODUCTS; CYSTEINE PROTEASES;
   SERINE PROTEASES; RNA; SEQUENCE; IDENTIFICATION; POLYPROTEIN;
   POLIOVIRUS; QUALITY
AB The key enzyme in coronavirus polyprotein processing is the viral main proteinase, M-pro, a protein with extremely low sequence similarity to other viral and cellular proteinases. Here, the crystal structure of the 33.1 kDa transmissible gastroenteritis (corona)virus M-pro is reported. The structure was refined to 1.96 Angstrom resolution and revealed three dimers in the asymmetric unit. The mutual arrangement of the protomers in each of the dimers suggests that M-pro self-processing occurs in trans. The active site, comprised of Cys144 and His41, is part of a chymotrypsin-like fold that is connected by a 16 residue loop to an extra domain featuring a novel alpha-helical fold. Molecular modelling and mutagenesis data implicate the loop in substrate binding and elucidate S1 and S2 subsites suitable to accommodate the side chains of the P1 glutamine and P2 leucine residues of M-pro substrates. Interactions involving the N-terminus and the alpha-helical domain stabilize the loop in the orientation required for trans-cleavage activity. The study illustrates that RNA viruses have evolved unprecedented variations of the classical chymotrypsin fold.
C1 Univ Wurzburg, Inst Immunol & Virol, D-97078 Wurzburg, Germany.
   Inst Mol Biotechnol, Dept Struct Biol & Crystallog, D-07745 Jena, Germany.
RP Ziebuhr, J (reprint author), Univ Wurzburg, Inst Immunol & Virol, D-97078 Wurzburg, Germany.
EM ziebuhr@vim.uni-wuerzburg.de; hilgenfd@imb-jena.de
RI Ziebuhr, John/G-7669-2015; Hilgenfeld, Rolf/C-9675-2011; Palm, Gottfried
   J./AAC-5020-2020
OI Ziebuhr, John/0000-0002-5741-8825
CR ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0
   ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x
   BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872
   Bergmann EM, 1997, J VIROL, V71, P2436, DOI 10.1128/JVI.71.3.2436-2448.1997
   BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   ELEOUET JF, 1995, VIROLOGY, V206, P817, DOI 10.1006/viro.1995.1004
   Enjuanes L., 1995, The coronaviridae., P337
   FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7
   FUJINAGA M, 1987, J MOL BIOL, V195, P397, DOI 10.1016/0022-2836(87)90659-0
   Gilbert D, 1999, BIOINFORMATICS, V15, P317, DOI 10.1093/bioinformatics/15.4.317
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7
   HAUPTMAN HA, 1991, CRYSTALLOGRAPHIC COM, V5, P324
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hegyi A, 2002, J GEN VIROL, V83, P581, DOI 10.1099/0022-1317-83-3-581
   HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x
   HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489
   JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X
   LEONG LEC, 1993, J BIOL CHEM, V268, P25735
   Liu Z, 1995, WIREL NETW, V1, P1, DOI 10.1007/BF01196254
   Lu XT, 1996, VIROLOGY, V222, P375, DOI 10.1006/viro.1996.0434
   Lu YQ, 1997, VIROLOGY, V230, P335, DOI 10.1006/viro.1997.8479
   LU YQ, 1995, J VIROL, V69, P3554, DOI 10.1128/JVI.69.6.3554-3559.1995
   MALCOLM BA, 1995, PROTEIN SCI, V4, P1439, DOI 10.1002/pro.5560040801
   MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2
   Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000
   MATTHEWS K, 1994, EXP ASTRON, V3, P77
   Mosimann SC, 1997, J MOL BIOL, V273, P1032, DOI 10.1006/jmbi.1997.1306
   Ng LFP, 2000, VIROLOGY, V272, P27, DOI 10.1006/viro.2000.0330
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131
   Penzes Z, 2001, VIRUS GENES, V23, P105, DOI 10.1023/A:1011147832586
   Petersen JFW, 1999, EMBO J, V18, P5463, DOI 10.1093/emboj/18.20.5463
   POLGAR L, 1974, FEBS LETT, V47, P15, DOI 10.1016/0014-5793(74)80415-1
   SAIF LJ, 1999, DIS SWINE, P295
   Schiller JJ, 1998, VIROLOGY, V242, P288, DOI 10.1006/viro.1997.9010
   Seybert A, 1997, J GEN VIROL, V78, P71, DOI 10.1099/0022-1317-78-1-71
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   TSUKADA H, 1985, J MOL BIOL, V184, P703, DOI 10.1016/0022-2836(85)90314-6
   Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684
   VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V
   Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504
   Weiss MS, 1997, J APPL CRYSTALLOGR, V30, P203, DOI 10.1107/S0021889897003907
   XIANG WK, 1995, J VIROL, V69, P3658, DOI 10.1128/JVI.69.6.3658-3667.1995
   Yao Z, 1992, PCR Methods Appl, V1, P205
   Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   ZIEBUHR J, 1995, J VIROL, V69, P4331, DOI 10.1128/JVI.69.7.4331-4338.1995
   Ziebuhr J, 1999, J VIROL, V73, P177, DOI 10.1128/JVI.73.1.177-185.1999
NR 61
TC 207
Z9 226
U1 5
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD JUL 1
PY 2002
VL 21
IS 13
BP 3213
EP 3224
DI 10.1093/emboj/cdf327
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 572PL
UT WOS:000176784100001
PM 12093723
OA Green Published
DA 2020-04-03
ER

PT J
AU Sung, VMH
   Shimodaira, S
   Doughty, AL
   Picchio, GR
   Can, H
   Yen, TSB
   Lindsay, KL
   Levine, AM
   Lai, MMC
AF Sung, VMH
   Shimodaira, S
   Doughty, AL
   Picchio, GR
   Can, H
   Yen, TSB
   Lindsay, KL
   Levine, AM
   Lai, MMC
TI Establishment of B-cell lymphoma cell lines persistently infected with
   hepatitis C virus in vivo and in vitro: the apototic effects of virus
   infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID BLOOD MONONUCLEAR-CELLS; FAS-MEDIATED APOPTOSIS; NON-HODGKINS-LYMPHOMA;
   MINUS-STRAND RNA; CORE PROTEIN; SJOGRENS-SYNDROME; MURINE CORONAVIRUS;
   LIVER-DISEASE; LOW-LEVEL; IN-VITRO
AB Hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Studies of HCV replication and pathogenesis have so far been hampered by the lack of an efficient tissue culture system for propagating HCV in vitro. Although HCV is primarily a hepatotropic virus, an increasing body of evidence suggests that HCV also replicates in extrahepatic tissues in natural infection. In this study, we established a B-cell line (SB) from an HCV-infected non-Hodgkin's B-cell lymphoma. HCV RNA and proteins were detectable by RNase protection assay and immunoblotting. The cell line continuously produces infectious HCV virions in culture. The virus particles produced from the culture had a buoyant density of 1.13 to 1.15 g/ml in sucrose and could infect primary human hepatocytes, peripheral blood mononuclear cells (PBMCs), and an established B-cell line (Raji cells) in vitro. The virus from SB cells belongs to genotype 2b. Single-stranded conformational polymorphism and sequence analysis of the viral RNA quasispecies indicated that the virus present in SB cells most likely originated from the patient's spleen and had an HCV RNA quasispecies pattern distinct from that in the serum. The virus production from the infected primary hepatocytes showed cyclic variations. In addition, we have succeeded in establishing several Epstein-Barr virus-immortalized B-cell lines from PBMCs of HCV-positive patients. Two of these cell lines are positive for HCV RNA as detected by reverse transcriptase PCR and for the nonstructural protein NS3 by immunofluorescence staining. These observations unequivocally establish that HCV infects B cells in vivo and in vitro. HCV-infected cell lines show significantly enhanced apoptosis. These B-cell lines provide a reproducible cell culture system for studying the complete replication cycle and biology of HCV infections.
C1 Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA.
   Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94121 USA.
   Vet Affairs Med Ctr, Pathol Serv, San Francisco, CA 94121 USA.
   Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.
RP Lai, MMC (reprint author), Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, 2011 Zonal Ave, Los Angeles, CA 90033 USA.
RI Lai, Michael M. C./I-7001-2012
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R03AI45873, N01AI40038, AI 40038]; NIDDK
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [P30DK48522, P30 DK048522]
CR Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002
   Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972
   Bouvier-Alias M, 2002, HEPATOLOGY, V36, P211, DOI 10.1053/jhep.2002.34130
   Cerny A, 1999, HEPATOLOGY, V30, P595, DOI 10.1002/hep.510300312
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Doughty AL, 2000, J HEPATOL, V32, P126, DOI 10.1016/S0168-8278(00)80199-3
   Farrell Paul J., 1995, Trends in Microbiology, V3, P105, DOI 10.1016/S0966-842X(00)88891-5
   FERRI C, 1994, BRIT J HAEMATOL, V88, P392, DOI 10.1111/j.1365-2141.1994.tb05036.x
   Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179
   HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O
   Hahn CS, 2000, VIROLOGY, V276, P127, DOI 10.1006/viro.2000.0541
   HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711
   Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002
   Ito T, 2001, HEPATOLOGY, V34, P566, DOI 10.1053/jhep.2001.26752
   Ivanovski M, 1998, BLOOD, V91, P2433, DOI 10.1182/blood.V91.7.2433.2433_2433_2442
   Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729
   KANTO T, 1994, HEPATOLOGY, V19, P296
   KATO N, 1995, BIOCHEM BIOPH RES CO, V206, P863, DOI 10.1006/bbrc.1995.1123
   Kitay-Cohen Y, 2000, BLOOD, V96, P2910
   Kuramoto IK, 2002, J VIRAL HEPATITIS, V9, P36, DOI 10.1046/j.1365-2893.2002.00333.x
   LANFORD RE, 1995, J VIROL, V69, P8079, DOI 10.1128/JVI.69.12.8079-8083.1995
   Laskus T, 2000, J VIROL, V74, P1014, DOI 10.1128/JVI.74.2.1014-1017.2000
   Lerat H, 1996, J CLIN INVEST, V97, P845, DOI 10.1172/JCI118485
   LIN YJ, 1994, J VIROL, V68, P8131, DOI 10.1128/JVI.68.12.8131-8140.1994
   Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110
   MAKINO S, 1988, VIROLOGY, V163, P104, DOI 10.1016/0042-6822(88)90237-1
   MARIETTE X, 1993, ARTHRITIS RHEUM, V36, P280, DOI 10.1002/art.1780360225
   Mellor J, 1998, J GEN VIROL, V79, P705, DOI 10.1099/0022-1317-79-4-705
   Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053
   Morsica G, 1999, BLOOD, V94, P1138
   Nakajima N, 1996, J VIROL, V70, P3325, DOI 10.1128/JVI.70.5.3325-3329.1996
   NISSEN E, 1994, J HEPATOL, V20, P437, DOI 10.1016/S0168-8278(94)80023-5
   Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002
   Radkowski M, 2002, J VIROL, V76, P600, DOI 10.1128/JVI.76.2.600-608.2002
   Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996
   Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420
   Selva-O'Callaghan A, 1999, ARTHRITIS RHEUM, V42, P2489, DOI 10.1002/1529-0131(199911)42:11<2489::AID-ANR28>3.0.CO;2-1
   SHIMIZU YK, 1990, P NATL ACAD SCI USA, V87, P6441, DOI 10.1073/pnas.87.16.6441
   SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477
   Shimizu YK, 1998, J GEN VIROL, V79, P1383, DOI 10.1099/0022-1317-79-6-1383
   Song ZQ, 2001, WORLD J GASTROENTERO, V7, P685
   Sung VMH, 2002, J VIROL, V76, P912, DOI 10.1128/JVI.76.2.912-917.2002
   TOSATO G, 2000, CURRENT PROTOCOLS IM
   Trestard A, 1998, ARCH VIROL, V143, P2241, DOI 10.1007/s007050050455
   WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468
   Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998
   Zignego AL, 1999, J HEPATOL, V31, P369, DOI 10.1016/S0168-8278(99)80239-6
   Zignego AL, 2000, HEPATOLOGY, V31, P474, DOI 10.1002/hep.510310230
   Zuckerman E, 1997, ANN INTERN MED, V127, P423, DOI 10.7326/0003-4819-127-6-199709150-00002
NR 49
TC 202
Z9 206
U1 1
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD FEB
PY 2003
VL 77
IS 3
BP 2134
EP 2146
DI 10.1128/JVI.77.3.2134-2146.2003
PG 13
WC Virology
SC Virology
GA 637AD
UT WOS:000180488700050
PM 12525648
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Chonmaitree, T
   Revai, K
   Grady, JJ
   Clos, A
   Patel, JA
   Nair, S
   Fan, J
   Henrickson, KJ
AF Chonmaitree, Tasnee
   Revai, Krystal
   Grady, James J.
   Clos, Audra
   Patel, Janak A.
   Nair, Sangeeta
   Fan, Jiang
   Henrickson, Kelly J.
TI Viral upper respiratory tract infection and otitis media complication in
   young children
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 9th International Symposium on Recent Advances in Otitis Media
CY JUN 03-07, 2007
CL St Pete Beach, FL
ID POLYMERASE-CHAIN-REACTION; EXPERIMENTAL RHINOVIRUS COLDS; A
   VIRUS-INFECTION; SYNCYTIAL VIRUS; HUMAN METAPNEUMOVIRUS; NASAL
   SECRETIONS; ASSOCIATION; CYTOKINE; BACTERIA; DISEASE
AB Background. The common cold or upper respiratory infection (URI) is highly prevalent among young children and often results in otitis media (OM). The incidence and characteristics of OM complicating URI due to specific viruses have not been well studied.
   Methods. We performed a prospective, longitudinal cohort study of 294 healthy children (age range, 6 months to 3 years). Each child was observed for 1 year to assess the occurrence of URI, acute OM (AOM), and OM with effusion (OME) complicating URI due to specific viruses.
   Results. We documented 1295 URI episodes (5.06 episodes per child-year) and 440 AOM episodes (1.72 episodes per child-year). Virus studies were performed for 864 URI episodes; 63% were virus positive. Rhinovirus and adenovirus were most frequently detected during URI. The overall incidence of OM that complicated URI was 61%, including a 37% incidence of AOM and a 24% incidence of OME. Young age was the most important predictor of AOM that complicated URI. AOM occurred in approximately one-half of children with URI due to adenovirus, respiratory syncytial virus, or coronavirus and in approximately one-third of those with URI due to influenza virus, parainfluenza virus, enterovirus, or rhinovirus.
   Conclusions. More than 60% of episodes of symptomatic URI among young children were complicated by AOM and/or OME. Young age and specific virus types were predictors of URI complicated by AOM. For young children, the strategy to prevent OM should involve prevention of viral URI. The strategy may be more effective if the priority is given to development of means to prevent URI associated with adenovirus and respiratory syncytial virus.
C1 [Chonmaitree, Tasnee; Revai, Krystal; Clos, Audra; Patel, Janak A.; Nair, Sangeeta] Univ Texas Galveston, Med Branch, Dept Pediat, Div Infect Dis, Galveston, TX 77555 USA.
   [Chonmaitree, Tasnee] Univ Texas Galveston, Med Branch, Dept Pathol, Galveston, TX 77550 USA.
   [Grady, James J.] Univ Texas Galveston, Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77550 USA.
   [Fan, Jiang; Henrickson, Kelly J.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA.
RP Chonmaitree, T (reprint author), Univ Texas Galveston, Med Branch, Dept Pediat, Div Infect Dis, 301 Univ Blvd, Galveston, TX 77555 USA.
EM tchonmai@utmb.edu
FU NCRR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [M01 RR 00073, M01 RR000073]; NIDCD NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Deafness & Other
   Communication Disorders (NIDCD) [R01 DC005841-05, R01 DC005841-02, R01
   DC005841-04, R01 DC005841-06A1, R01 DC005841-03, R01 DC005841-02S1, DC
   005841-02S1, R01 DC005841, R01 DC005841-01]
CR Bluestone CD, 2007, OTITIS MEDIA INFANTS, P1
   CHONMAITREE T, 2000, PEDIAT INFECT DI S5, V19, P24
   Fan J, 1998, CLIN INFECT DIS, V26, P1397, DOI 10.1086/516357
   FOX JP, 1972, AM J EPIDEMIOL, V96, P270, DOI 10.1093/oxfordjournals.aje.a121458
   FRIEDLANDER SK, 1998, APPL OCCUP ENV HYG, V13, P1
   Fritz RS, 1999, J INFECT DIS, V180, P586, DOI 10.1086/314938
   Gates GA, 1996, OTOLARYNG HEAD NECK, V114, P525, DOI 10.1016/S0194-5998(96)70243-7
   Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355
   HEIKKINEN T, 1994, PEDIATR INFECT DIS J, V13, P659, DOI 10.1097/00006454-199407000-00016
   Heikkinen T, 1999, NEW ENGL J MED, V340, P260, DOI 10.1056/NEJM199901283400402
   Heikkinen T, 2000, PEDIAT INFECT DIS S5, V19, P17
   HENDERSON FW, 1982, NEW ENGL J MED, V306, P1377, DOI 10.1056/NEJM198206103062301
   Henrickson K. J., 2007, Clinical Microbiology Newsletter, V29, P113, DOI 10.1016/j.clinmicnews.2007.07.001
   Hornsleth A, 2001, J CLIN VIROL, V21, P163, DOI 10.1016/S1386-6532(01)00159-7
   Joki-Erkkila VP, 2000, INT J PEDIATR OTORHI, V55, P197, DOI 10.1016/S0165-5876(00)00398-0
   Kesebir D, 2006, J INFECT DIS, V194, P1276, DOI 10.1086/508213
   Koivunen P, 1999, PEDIATR INFECT DIS J, V18, P303, DOI 10.1097/00006454-199903000-00023
   Legg JP, 2005, PEDIATR INFECT DIS J, V24, P611, DOI 10.1097/01.inf.0000168747.94999.aa
   Lieberthal AS, 2004, PEDIATRICS, V113, P1451, DOI 10.1542/peds.113.5.1451
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   McCaig LF, 2002, JAMA-J AM MED ASSOC, V287, P3096, DOI 10.1001/jama.287.23.3096
   MISTCHENKO AS, 1994, J PEDIATR-US, V124, P714, DOI 10.1016/S0022-3476(05)81360-5
   MONTO AS, 1974, JAMA-J AM MED ASSOC, V227, P164, DOI 10.1001/jama.227.2.164
   Patel JA, 2007, VACCINE, V25, P1683, DOI 10.1016/j.vaccine.2006.10.045
   Pitkaranta A, 1998, PEDIATRICS, V102, P291, DOI 10.1542/peds.102.2.291
   Postma DS, 1997, INT J PEDIATR OTORHI, V41, P253, DOI 10.1016/S0165-5876(97)00086-4
   PROUD D, 1994, J INFECT DIS, V169, P1007, DOI 10.1093/infdis/169.5.1007
   Rihkanen H, 2004, INT J PEDIATR OTORHI, V68, P903, DOI 10.1016/j.ijporl.2004.02.005
   ROTHMAN K, 2004, SPREADSHEET ANAL EPI
   Ruohola A, 2006, CLIN INFECT DIS, V43, P1417, DOI 10.1086/509332
   RUUSKANEN O, 1989, PEDIATR INFECT DIS J, V8, P94
   *SAS I, 2004, AS STAT 9 1 US GUID
   Sheeran P, 1999, PEDIATR INFECT DIS J, V18, P115, DOI 10.1097/00006454-199902000-00007
   STAHLBERG MR, 1980, ACTA PAEDIATR SC   S, V282, P1
   STOOL SE, 1989, PEDIATR INFECT DIS J, V8, P11
   STUSSMAN BJ, 1996, ADV DATA, V271, P1
   TEELE DW, 1990, J INFECT DIS, V162, P685, DOI 10.1093/infdis/162.3.685
   Turner RB, 1998, CLIN INFECT DIS, V26, P840, DOI 10.1086/513922
   Vesa S, 2001, PEDIATR INFECT DIS J, V20, P574, DOI 10.1097/00006454-200106000-00006
   Williams JV, 2006, J INFECT DIS, V193, P387, DOI 10.1086/499274
   Williams JV, 2006, INT J PEDIATR OTORHI, V70, P1189, DOI 10.1016/j.ijporl.2005.12.007
   Winther B, 2006, J MED VIROL, V78, P644, DOI 10.1002/jmv.20588
   Winther B, 2007, PEDIATRICS, V119, P1069, DOI 10.1542/peds.2006-3294
   Winther B, 2006, INT J PEDIATR OTORHI, V70, P1725, DOI 10.1016/j.ijporl.2006.05.011
NR 44
TC 201
Z9 210
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAR 15
PY 2008
VL 46
IS 6
BP 815
EP 823
DI 10.1086/528685
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 266RD
UT WOS:000253453800005
PM 18279042
OA Green Accepted, Bronze
DA 2020-04-03
ER

PT J
AU Jartti, T
   Lehtinen, P
   Vuorinen, T
   Koskenvuo, M
   Ruuskanen, O
AF Jartti, T
   Lehtinen, P
   Vuorinen, T
   Koskenvuo, M
   Ruuskanen, O
TI Persistence of rhinovirus and enterovirus RNA after acute respiratory
   illness in children
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE rhinovirus; enterovirus; persistence; bronchiolitis; asthma and wheezing
ID POLYMERASE-CHAIN-REACTION; VIRAL-INFECTIONS; OTITIS-MEDIA; COMMON COLD;
   DIAGNOSIS; VIRUSES; PICORNAVIRUS; CORONAVIRUS; SYMPTOMS; FAMILIES
AB The persistence of rhinovirus and enterovirus RNAs was studied in the nasal secretions of children with acute expiratory wheezing (median age: 1.7 years). On admission, 84 samples from 161 (52%) children admitted to hospital were positive by reverse transcriptase-polymerase chain reaction (RT-PCR), which detects rhino-and enteroviruses simultaneously. Of the samples, 26 (16%) were positive for rhinovirus, 29 (18%) enterovirus and 29 (18%) nontypable rhino-enterovirus. After 2 weeks, 16 of these 84 (19%) samples were still positive. Rhinovirus RNA remained positive in 13 of 26 (50%) cases, whereas enterovirus RNA remained positive only in 1 of 29 (3%) cases (P=0.0001). Respiratory symptoms at 2 weeks or systemic glucocorticoid treatment during hospital stay were not related to the persistence of viral RNA. After 5 weeks, only one sample remained PCR-positive. Thirteen of the 79 (16%) asymptomatic control children were PCR-positive for respiratory picornavirus. Five of the 13 (38%) PCR-positive children developed respiratory symptoms in the following week. The study shows that after the onset of symptomatic respiratory infection enterovirus RNA may take 2-3 weeks and rhinovirus RNA 5-6 weeks to disappear from nasal mucus. (C) 2004Wiley-Liss, Inc.
C1 Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland.
   Univ Turku, Dept Virol, SF-20500 Turku, Finland.
RP Jartti, T (reprint author), Sirkkalankatu 4C 59, FIN-20520 Turku, Finland.
EM tuomasjartti@hus.fi
CR Arola A, 1996, J CLIN MICROBIOL, V34, P313, DOI 10.1128/JCM.34.2.313-318.1996
   Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997
   Couch R. B., 2001, FIELDS VIROLOGY, P777
   DEARRUDA E, 1991, J INFECT DIS, V164, P252, DOI 10.1093/infdis/164.2.252
   DICK EC, 1967, AM J EPIDEMIOL, V86, P386, DOI 10.1093/oxfordjournals.aje.a120749
   Gustafson LM, 1996, J ALLERGY CLIN IMMUN, V97, P1009, DOI 10.1016/S0091-6749(96)80077-7
   Gwaltney Jack M. Jr., 2002, P995
   Heikkinen T, 2002, J CLIN MICROBIOL, V40, P4337, DOI 10.1128/JCM.40.11.4337-4339.2002
   Hosoya M, 2002, ARCH DIS CHILD, V87, P316, DOI 10.1136/adc.87.4.316
   HYYPIA T, 1989, J GEN VIROL, V70, P3261, DOI 10.1099/0022-1317-70-12-3261
   Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   KETLER A, 1969, AM J EPIDEMIOL, V90, P244, DOI 10.1093/oxfordjournals.aje.a121067
   Kotikoski MJ, 2002, PEDIATR INFECT DIS J, V21, P636, DOI 10.1097/00006454-200207000-00007
   Lonnrot M, 1999, J MED VIROL, V59, P378, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;378::AID-JMV19&gt;3.0.CO;2-I
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Marin J, 2000, J INFECTION, V41, P69, DOI 10.1053/jinf.2000.0688
   MCINTOSH K, 1976, J ALLERGY CLIN IMMUN, V57, P595, DOI 10.1016/0091-6749(76)90011-7
   MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124
   Nokso-Koivisto J, 2002, J MED VIROL, V66, P417, DOI 10.1002/jmv.2161
   Pallansch MA, 2001, FIELDS VIROLOGY, P723
   Pitkaranta A, 1998, J PEDIATR-US, V133, P390, DOI 10.1016/S0022-3476(98)70276-8
   Puhakka T, 1998, J ALLERGY CLIN IMMUN, V101, P726, DOI 10.1016/S0091-6749(98)70301-X
   Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052
   ROTBART HA, 2002, CLIN MICROBIOLOGY, P995
   Vesa S, 2001, PEDIATR INFECT DIS J, V20, P574, DOI 10.1097/00006454-200106000-00006
NR 27
TC 199
Z9 201
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD APR
PY 2004
VL 72
IS 4
BP 695
EP 699
DI 10.1002/jmv.20027
PG 5
WC Virology
SC Virology
GA 800RT
UT WOS:000220046100026
PM 14981776
DA 2020-04-03
ER

PT J
AU Wong, CK
   Lam, CWK
   Wu, AKL
   Ip, WK
   Lee, NLS
   Chan, IHS
   Lit, LCW
   Hui, DSC
   Chan, MHM
   Chung, SSC
   Sung, JJY
AF Wong, CK
   Lam, CWK
   Wu, AKL
   Ip, WK
   Lee, NLS
   Chan, IHS
   Lit, LCW
   Hui, DSC
   Chan, MHM
   Chung, SSC
   Sung, JJY
TI Plasma inflammatory cytokines and chemokines in severe acute respiratory
   syndrome
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE chemokines; cytokines; inflammation; severe acute respiratory syndrome
   (SARS)
ID DISTRESS-SYNDROME; LUNG INFLAMMATION; INTERFERON-GAMMA; HONG-KONG;
   CORONAVIRUS; DISEASE; INTERLEUKIN-12; SARS; PNEUMONIA; IDENTIFICATION
AB Severe acute respiratory syndrome (SARS) is a recently emerged infectious disease caused by a novel coronavirus, but its immunopathological mechanisms have not yet been fully elucidated. We investigated changes in plasma T helper (Th) cell cytokines, inflammatory cytokines and chemokines in 20 patients diagnosed with SARS. Cytokine profile of SARS patients showed marked elevation of Th1 cytokine interferon (IFN)-gamma, inflammatory cytokines interleukin (IL)-1, IL-6 and IL-12 for at least 2 weeks after disease onset, but there was no significant elevation of inflammatory cytokine tumour necrosis factor (TNF)-alpha, anti-inflammatory cytokine IL-10, Th1 cytokine IL-2 and Th2 cytokine IL-4. The chemokine profile demonstrated significant elevation of neutrophil chemokine IL-8, monocyte chemoattractant protein-1 (MCP-1), and Th1 chemokine IFN-gamma-inducible protein-10 (IP-10). Corticosteroid reduced significantly IL-8, MCP-1 and IP-10 concentrations from 5 to 8 days after treatment (all P < 0.001). Together, the elevation of Th1 cytokine IFN-gamma, inflammatory cytokines IL-1, IL-6 and IL-12 and chemokines IL-8, MCP-1 and IP-10 confirmed the activation of Th1 cell-mediated immunity and hyperinnate inflammatory response in SARS through the accumulation of monocytes/macrophages and neutrophils.
C1 Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.
RP Lam, CWK (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China.
EM waikeilam@cuhk.edu.hk
RI Connor, Toni R/C-6964-2012; Sung, Joseph J. Y./R-3203-2018; Wong,
   CK/H-3256-2016; Hui, David SC/O-2754-2015; Lee, Nelson/B-6418-2008
OI Sung, Joseph J. Y./0000-0003-3125-5199; Wong, CK/0000-0002-5637-8331;
   Lee, Nelson/0000-0002-0783-6607; Hui, David/0000-0003-4382-2445
CR Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7
   CholletMartin S, 1996, AM J RESP CRIT CARE, V154, P594, DOI 10.1164/ajrccm.154.3.8810592
   Dhainaut JF, 2003, CRIT CARE MED, V31, pS258, DOI 10.1097/01.CCM.0000057901.92381.75
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   EVANS SW, 1993, ADV CLIN CHEM, V30, P1, DOI 10.1016/S0065-2423(08)60194-8
   Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593
   HENDRZAK JA, 1995, LAB INVEST, V72, P619
   Hon KLE, 2003, LANCET, V361, P1701, DOI 10.1016/S0140-6736(03)13364-8
   Kawabata K, 2002, EUR J PHARMACOL, V451, P1, DOI 10.1016/S0014-2999(02)02182-9
   KENNEDY MK, 1994, EUR J IMMUNOL, V24, P2271, DOI 10.1002/eji.1830241002
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kunkel S L, 1999, Forum (Genova), V9, P339
   Kurdowska A, 2001, AM J RESP CRIT CARE, V163, P463, DOI 10.1164/ajrccm.163.2.2005109
   Lamont AG, 1996, IMMUNOL TODAY, V17, P214, DOI 10.1016/0167-5699(96)30011-X
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Leemans JC, 2002, AM J RESP CRIT CARE, V165, P1445, DOI 10.1164/rccm.2106045
   Leon LR, 2002, J APPL PHYSIOL, V92, P2648, DOI 10.1152/japplphysiol.01005.2001
   Luster A D, 2001, Curr Opin Allergy Clin Immunol, V1, P561, DOI 10.1097/00130832-200112000-00012
   MALEFYT RD, 1991, J EXP MED, V174, P915
   MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MARTIN TR, 2003, CHEMOKINES LUNG, P189
   Meduri GU, 1997, CHEST, V112, P1154, DOI 10.1378/chest.112.5.1154
   MO XY, 1995, J VIROL, V69, P1288, DOI 10.1128/JVI.69.2.1288-1291.1995
   Mogensen TH, 2001, MICROBIOL MOL BIOL R, V65, P131, DOI 10.1128/MMBR.65.1.131-150.2001
   Neumann B, 1998, IMMUNOLOGY, V95, P512
   Ng EKO, 2003, CLIN CHEM, V49, P1976, DOI 10.1373/clinchem.2003.024125
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Poon LLM, 2003, CLIN CHEM, V49, P953, DOI 10.1373/49.6.953
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Proudfoot AEI, 2000, IMMUNOL REV, V177, P246, DOI 10.1034/j.1600-065X.2000.17721.x
   Rossion B, 2000, NEUROSCI LETT, V279, P25, DOI 10.1016/S0304-3940(99)00926-X
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   STANDIFORD TJ, 2003, CHEMOKINES LUNG, P145
   STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736
   Tarnok A, 2003, CLIN CHEM, V49, P1000, DOI 10.1373/49.6.1000
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Van Reeth K, 2002, VET IMMUNOL IMMUNOP, V87, P161, DOI 10.1016/S0165-2427(02)00047-8
   VILLARD J, 1995, AM J RESP CRIT CARE, V152, P1549, DOI 10.1164/ajrccm.152.5.7582292
   WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218
   *WHO, 2003, WKLY EPIDEMIOL REC, V78, P81
   WOLF SF, 1994, STEM CELLS, V12, P154, DOI 10.1002/stem.5530120203
   Wong CK, 2003, ADV CLIN CHEM, V37, P1, DOI 10.1016/S0065-2423(03)37005-2
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
NR 46
TC 199
Z9 217
U1 11
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD APR
PY 2004
VL 136
IS 1
BP 95
EP 103
DI 10.1111/j.1365-2249.2004.02415.x
PG 9
WC Immunology
SC Immunology
GA 804NV
UT WOS:000220306300014
PM 15030519
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Haagmans, BL
   Kuiken, T
   Martina, BE
   Fouchier, RAM
   Rimmelzwaan, GF
   van Amerongen, G
   van Riel, D
   de Jong, T
   Itamura, S
   Chan, KH
   Tashiro, M
   Osterhaus, ADME
AF Haagmans, BL
   Kuiken, T
   Martina, BE
   Fouchier, RAM
   Rimmelzwaan, GF
   van Amerongen, G
   van Riel, D
   de Jong, T
   Itamura, S
   Chan, KH
   Tashiro, M
   Osterhaus, ADME
TI Pegylated interferon-alpha protects type 1 pneumocytes against SARS
   coronavirus infection in macaques
SO NATURE MEDICINE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; REOVIRUS 1/L INDUCTION; DISTRESS-SYNDROME;
   LUNG PATHOLOGY; VIRUS; IDENTIFICATION; PNEUMONIA; OUTBREAK; FIBROSIS;
   MICE
AB The primary cause of severe acute respiratory syndrome (SARS) is a newly discovered coronavirus(1-7). Replication of this SARS coronavirus (SCV) occurs mainly in the lower respiratory tract, and causes diffuse alveolar damage(2,7,8). Lack of understanding of the pathogenesis of SARS has prevented the rational development of a therapy against this disease. Here we show extensive SCV antigen expression in type 1 pneumocytes of experimentally infected cynomolgus macaques (Macaca fascicularis) at 4 d postinfection (d. p. i.), indicating that this cell type is the primary target for SCV infection early in the disease, and explaining the subsequent pulmonary damage. We also show that prophylactic treatment of SCV-infected macaques with the antiviral agent pegylated interferon-alpha (IFN-alpha) significantly reduces viral replication and excretion, viral antigen expression by type 1 pneumocytes and pulmonary damage, compared with untreated macaques. Postexposure treatment with pegylated IFN- yielded intermediate results. We therefore suggest that pegylated IFN-alpha protects type 1 pneumocytes from SCV infection, and should be considered a candidate drug for SARS therapy
C1 Erasmus Med Ctr, Dept Virol, NL-3000 DR Rotterdam, Netherlands.
   Erasmus Med Ctr, Dept Immunol, NL-3000 DR Rotterdam, Netherlands.
   Erasmus Med Ctr, Dept Pathol, NL-3000 DR Rotterdam, Netherlands.
   Natl Inst Infect Dis, Dept Viral Dis & Vaccine Control, Tokyo 2080011, Japan.
   Univ Hong Kong, Queen Mary Hosp, Dept Pathol & Microbiol, Hong Kong, Hong Kong, Peoples R China.
RP Osterhaus, ADME (reprint author), Erasmus Med Ctr, Dept Virol, POB 1738, NL-3000 DR Rotterdam, Netherlands.
EM a.osterhaus@erasmusmc.nl
RI Fouchier, Ron/Y-3755-2019; Fouchier, Ron A/A-1911-2014
OI Fouchier, Ron/0000-0001-8095-2869; Fouchier, Ron A/0000-0001-8095-2869;
   Haagmans, Bart/0000-0001-6221-2015; Osterhaus,
   Albert/0000-0002-6074-1172; van Riel, Debby/0000-0001-9753-3564
CR BEDROSSIAN CWM, 1984, AM J CLIN PATHOL, V82, P148, DOI 10.1093/ajcp/82.2.148
   Bellum SC, 1997, AM J PATHOL, V150, P2243
   Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Bukowski RM, 2002, CANCER, V95, P389, DOI 10.1002/cncr.10663
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   FINTER NB, 1985, INTERFERONS IN VIVO, V4
   Fouchier RAM, 2000, J CLIN MICROBIOL, V38, P4096, DOI 10.1128/JCM.38.11.4096-4101.2000
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   London L, 2002, CLIN IMMUNOL, V103, P284, DOI 10.1006/clim.2002.5214
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Pei JW, 2001, J INTERF CYTOK RES, V21, P1071, DOI 10.1089/107999001317205204
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SMITH AL, 1987, ANTIVIR RES, V8, P239, DOI 10.1016/S0166-3542(87)80002-5
   TSNAG KW, 2003, NEW ENGL J MED, V348, P1977
   TURNER RB, 1986, J INFECT DIS, V154, P443, DOI 10.1093/infdis/154.3.443
   Van Gool AR, 2003, PSYCHIAT RES, V119, P125, DOI 10.1016/S0165-1781(03)00113-6
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   WILLIAMS MC, 1990, ELECT MICROSCOPY LUN, P121
NR 29
TC 199
Z9 210
U1 2
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2004
VL 10
IS 3
BP 290
EP 293
DI 10.1038/nm1001
PG 4
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 779LH
UT WOS:000189297700041
PM 14981511
OA Bronze
DA 2020-04-03
ER

PT J
AU WATANABE, R
   WEGE, H
   TERMEULEN, V
AF WATANABE, R
   WEGE, H
   TERMEULEN, V
TI ADOPTIVE TRANSFER OF EAE-LIKE LESIONS FROM RATS WITH CORONAVIRUS-INDUCED
   DEMYELINATING ENCEPHALOMYELITIS
SO NATURE
LA English
DT Article
RP WATANABE, R (reprint author), UNIV WURZBURG,INST VIROL & IMMUNOBIOL,D-8700 WURZBURG,FED REP GER.
CR DEIBLER GE, 1972, PREP BIOCHEM, V2, P139, DOI 10.1080/00327487208061467
   DRZENIEK R, 1969, INT ARCH ALLERGY, V36, P146
   LIPTON HL, 1976, SCIENCE, V192, P62, DOI 10.1126/science.176726
   LIPTON HL, 1979, J NEUROL SCI, V42, P391
   MASSANARI RM, 1979, J INFECT DIS, V139, P297, DOI 10.1093/infdis/139.3.297
   NAGASHIMA K, 1978, ACTA NEUROPATHOL, V44, P63, DOI 10.1007/BF00691641
   NAGASHIMA K, 1979, ACTA NEUROPATHOL, V45, P205, DOI 10.1007/BF00702672
   PANITCH H, 1976, LAB INVEST, V35, P452
   PANITCH HS, 1979, NEUROLOGY, V29, P548
   RICHERT JR, 1979, J IMMUNOL, V122, P494
   SORENSEN O, 1980, ARCH NEUROL-CHICAGO, V37, P478, DOI 10.1001/archneur.1980.00500570026003
   SORENSEN O, 1982, INFECT IMMUN, V37, P1248, DOI 10.1128/IAI.37.3.1248-1260.1982
   STECK AJ, 1981, J NEUROIMMUNOL, V1, P117, DOI 10.1016/0165-5728(81)90014-X
   ter Meulen V, 1978, J Gen Virol, V41, P1, DOI 10.1099/0022-1317-41-1-1
   TSCHANNEN R, 1979, NEUROSCI LETT, V15, P295, DOI 10.1016/0304-3940(79)96129-9
   VANDEVELDE M, 1982, ACTA NEUROPATHOL, V56, P285, DOI 10.1007/BF00691260
   WEGE H, 1983, INFECT IMMUN, V39, P1316, DOI 10.1128/IAI.39.3.1316-1324.1983
   WEINER LP, 1973, NEW ENGL J MED, V288, P1103, DOI 10.1056/NEJM197305242882106
NR 18
TC 199
Z9 200
U1 0
U2 0
PU MACMILLAN MAGAZINES LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW
SN 0028-0836
J9 NATURE
JI Nature
PY 1983
VL 305
IS 5930
BP 150
EP 153
DI 10.1038/305150a0
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA RF503
UT WOS:A1983RF50300047
PM 6310411
OA Bronze
DA 2020-04-03
ER

PT J
AU Drosten, C
   Seilmaier, M
   Corman, VM
   Hartmann, W
   Scheible, G
   Sack, S
   Guggemos, W
   Kallies, R
   Muth, D
   Junglen, S
   Muller, MA
   Haas, W
   Guberina, N
   Rohnisch, T
   Schmid-Wendtner, M
   Aldabbagh, S
   Dittmer, U
   Gold, H
   Graf, P
   Bonin, F
   Rambaut, A
   Wendtner, CM
AF Drosten, Christian
   Seilmaier, Michael
   Corman, Victor M.
   Hartmann, Wulf
   Scheible, Gregor
   Sack, Stefan
   Guggemos, Wolfgang
   Kallies, Rene
   Muth, Doreen
   Junglen, Sandra
   Muller, Marcel A.
   Haas, Walter
   Guberina, Nana
   Rohnisch, Tim
   Schmid-Wendtner, Monika
   Aldabbagh, Souhaib
   Dittmer, Ulf
   Gold, Hermann
   Graf, Petra
   Bonin, Frank
   Rambaut, Andrew
   Wendtner, Clemens-Martin
TI Clinical features and virological analysis of a case of Middle East
   respiratory syndrome coronavirus infection
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID VIRUS; TROPISM; ASSAY
AB Background The Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging virus involved in cases and case clusters of severe acute respiratory infection in the Arabian Peninsula, Tunisia, Morocco, France, Italy, Germany, and the UK. We provide a full description of a fatal case of MERS-CoV infection and associated phylogenetic analyses.
   Methods We report data for a patient who was admitted to the Klinikum Schwabing (Munich, Germany) for severe acute respiratory infection. We did diagnostic RT-PCR and indirect immunofluorescence. From time of diagnosis, respiratory, faecal, and urine samples were obtained for virus quantification. We constructed a maximum likelihood tree of the five available complete MERS-CoV genomes.
   Findings A 73-year-old man from Abu Dhabi, United Arab Emirates, was transferred to Klinikum Schwabing on March 19, 2013, on day 11 of illness. He had been diagnosed with multiple myeloma in 2008, and had received several lines of treatment. The patient died on day 18, due to septic shock. MERS-CoV was detected in two samples of bronchoalveolar fluid. Viral loads were highest in samples from the lower respiratory tract (up to 1.2x10(6) copies per mL). Maximum virus concentration in urine samples was 2691 RNA copies per mL on day 13; the virus was not present in the urine after renal failure on day 14. Stool samples obtained on days 12 and 16 contained the virus, with up to 1031 RNA copies per g (dose to the lowest detection limit of the assay). One of two oronasal swabs obtained on day 16 were positive, but yielded little viral RNA (5370 copies per mL). No virus was detected in blood. The full virus genome was combined with four other available full genome sequences in a maximum likelihood phylogeny, correlating branch lengths with dates of isolation. The time of the common ancestor was halfway through 2011. Addition of novel genome data from an unlinked case treated 6 months previously in Essen, Germany, showed a clustering of viruses derived from Qatar and the United Arab Emirates.
   Interpretation We have provided the first complete viral load profile in a case of MERS-CoV infection. MERS-CoV might have shedding patterns that are different from those of severe acute respiratory syndrome and so might need alternative diagnostic approaches.
C1 [Drosten, Christian; Corman, Victor M.; Kallies, Rene; Muth, Doreen; Junglen, Sandra; Muller, Marcel A.; Aldabbagh, Souhaib] Univ Bonn, Med Ctr, Inst Virol, D-53105 Bonn, Germany.
   [Seilmaier, Michael; Hartmann, Wulf; Scheible, Gregor; Sack, Stefan; Guggemos, Wolfgang; Schmid-Wendtner, Monika] Klinikum Schwabing, D-80804 Munich, Germany.
   [Haas, Walter] Robert Koch Inst, Dept Infect Epidemiol, Berlin, Germany.
   [Guberina, Nana] Univ Duisburg Essen, Dept Internal Med, Essen, Germany.
   [Dittmer, Ulf] Univ Duisburg Essen, Inst Virol, Essen, Germany.
   [Rohnisch, Tim; Schmid-Wendtner, Monika] Interdisziplinares Onkol Zentrum, Munich, Germany.
   [Gold, Hermann; Graf, Petra] Dept Hlth & Environm, Munich, Germany.
   [Bonin, Frank] Ruhrlandklinik, Dept Intens Care, Essen, Germany.
   [Rambaut, Andrew] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh, Midlothian, Scotland.
   [Rambaut, Andrew] NIH, Forgarty Int Ctr, Bethesda, MD 20892 USA.
RP Drosten, C (reprint author), Univ Bonn, Med Ctr, Inst Virol, D-53105 Bonn, Germany.
EM drosten@virology-bonn.de; clemens.wendtner@klinikum-muenchen.de
RI Mueller, Marcel/O-2425-2019; Corman, Victor Max/K-1319-2019; Rambaut,
   Andrew/B-2481-2009; Junglen, Sandra/I-3033-2012
OI Mueller, Marcel/0000-0003-2242-5117; Corman, Victor
   Max/0000-0002-3605-0136; Rambaut, Andrew/0000-0003-4337-3707; Junglen,
   Sandra/0000-0002-3799-6011; Kallies, Rene/0000-0002-9195-0276; Wendtner,
   Clemens-Martin/0000-0003-2866-2260; Rambaut FRSE, Professor
   Andrew/0000-0002-1278-598X
FU European research project on emerging diseases detection and response
   (EMPERIE) [223498]; German Centre for Infection Research and Education;
   German research councilGerman Research Foundation (DFG) [01KIO701, DR
   772/3-1]
FX This work was supported by a European research project on emerging
   diseases detection and response (EMPERIE; contract No 223498). CD has
   received infrastructural support from the German Centre for Infection
   Research, which included full funding of the position of VC. Virological
   analyses were partly support by the German Ministry for Research and
   Education and the German research council (grants 01KIO701 and DR
   772/3-1). We thank Tobias BIeicker, Sebastian Brunink, Monika
   Eschbach-Bludau, Stephan Kallies, Heike Kirberg, Tobias Klant, Ingrid
   Kroning, and Astrid Schneider (Institute of Virology, Bonn, Germany) for
   excellent technical assistance.
CR Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Buchholz U, 2013, EUROSURVEILLANCE, V18, P6
   Chan RWY, 2013, J VIROL, V87, P6604, DOI 10.1128/JVI.00009-13
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Cotten M, 2013, EMERG INFECT DIS, V19, P736, DOI 10.3201/eid1905.130057
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Herzog P, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-138
   Kessler HH, 2000, J CLIN MICROBIOL, V38, P2638, DOI 10.1128/JCM.38.7.2638-2642.2000
   Kindler E, 2013, MBIO, V4, DOI 10.1128/mBio.00611-12
   Lau SKP, 2013, J VIROL, V87, P8638, DOI 10.1128/JVI.01055-13
   Lu XY, 2008, J CLIN MICROBIOL, V46, P533, DOI 10.1128/JCM.01739-07
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Muller MA, 2012, MBIO, V3, DOI 10.1128/mBio.00515-12
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Poon LLM, 2004, LANCET INFECT DIS, V4, P663, DOI 10.1016/S1473-3099(04)01172-7
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   van den Brink JW, 2004, J CLIN VIROL, V30, P68, DOI 10.1016/j.jcv.2003.09.003
   World Health Organization, 2013, MIDDL E RESP SYNDR C
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zielecki F, 2013, J VIROL, V87, P5300, DOI 10.1128/JVI.03496-12
NR 25
TC 198
Z9 207
U1 5
U2 61
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD SEP
PY 2013
VL 13
IS 9
BP 745
EP 751
DI 10.1016/S1473-3099(13)70154-3
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 205SU
UT WOS:000323465900019
PM 23782859
OA Bronze
DA 2020-04-03
ER

PT J
AU VLASAK, R
   LUYTJES, W
   SPAAN, W
   PALESE, P
AF VLASAK, R
   LUYTJES, W
   SPAAN, W
   PALESE, P
TI HUMAN AND BOVINE CORONAVIRUSES RECOGNIZE SIALIC ACID-CONTAINING
   RECEPTORS SIMILAR TO THOSE OF INFLUENZA C-VIRUSES
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
C1 STATE UNIV UTRECHT,DEPT INFECT DIS & IMMUNOL,UTRECHT,NETHERLANDS.
RP VLASAK, R (reprint author), CUNY MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029, USA.
OI Palese, Peter/0000-0002-0337-5823
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-18998, AI-11823]
CR BINGHAM RW, 1975, J GEN VIROL, V28, P381, DOI 10.1099/0022-1317-28-3-381
   BOYLE JF, 1987, J VIROL, V61, P185, DOI 10.1128/JVI.61.1.185-189.1987
   Crowell RL, 1986, VIRUS ATTACHMENT ENT
   DEREGT D, 1987, VIROLOGY, V161, P410, DOI 10.1016/0042-6822(87)90134-6
   GRAVES PN, 1983, VIROLOGY, V126, P106, DOI 10.1016/0042-6822(83)90465-8
   HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x
   HERRLER G, 1985, VIROLOGY, V141, P144, DOI 10.1016/0042-6822(85)90190-4
   HIERHOLZER JC, 1972, VIROLOGY, V48, P516, DOI 10.1016/0042-6822(72)90062-1
   HIERHOLZER JC, 1988, IN PRESS LABORATORY, V2
   HIGA HH, 1985, VIROLOGY, V144, P279, DOI 10.1016/0042-6822(85)90325-3
   HIRST GK, 1950, J EXP MED, V91, P177, DOI 10.1084/jem.91.2.177
   HOGUE BG, 1984, J VIROL, V51, P384, DOI 10.1128/JVI.51.2.384-388.1984
   KAYE HS, 1969, J INFECT DIS, V120, P576, DOI 10.1093/infdis/120.5.576
   KENDAL AP, 1975, VIROLOGY, V65, P87, DOI 10.1016/0042-6822(75)90009-4
   LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978
   MCINTOSH K, 1970, AM J EPIDEMIOL, V91, P585, DOI 10.1093/oxfordjournals.aje.a121171
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   MONTO AS, 1974, J INFECT DIS, V129, P271, DOI 10.1093/infdis/129.3.271
   OHUCHI M, 1978, MICROBIOL IMMUNOL, V22, P197, DOI 10.1111/j.1348-0421.1978.tb00363.x
   PALESE P, 1974, VIROLOGY, V57, P227, DOI 10.1016/0042-6822(74)90123-8
   POKORNY J, 1975, ACTA VIROL, V19, P137
   RAUVALA H, 1979, EUR J BIOCHEM, V97, P555, DOI 10.1111/j.1432-1033.1979.tb13144.x
   RITCHEY MB, 1976, J VIROL, V18, P736
   ROGERS GN, 1986, J BIOL CHEM, V261, P5947
   SHARPEE RL, 1976, AM J VET RES, V37, P1031
   STAIR EL, 1972, AM J VET RES, V33, P1147
   STURMAN LS, 1977, VIROLOGY, V77, P650, DOI 10.1016/0042-6822(77)90489-5
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   SUGANO K, 1978, FEBS LETT, V89, P321, DOI 10.1016/0014-5793(78)80246-4
   SUGIYAMA K, 1980, ARCH VIROL, V66, P95, DOI 10.1007/BF01314978
   VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.biochem.56.1.365
   ZAKSTEL'SKAYA L Y, 1972, Vestnik Akademii Meditsinskikh Nauk SSSR, V27, P40
NR 34
TC 198
Z9 202
U1 2
U2 13
PU NATL ACAD PRESS
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN
PY 1988
VL 85
IS 12
BP 4526
EP 4529
DI 10.1073/pnas.85.12.4526
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA N9869
UT WOS:A1988N986900088
PM 3380803
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Wang, LD
   Wang, Y
   Jin, SG
   Wu, ZY
   Chin, DP
   Koplan, JP
   Wilson, ME
AF Wang, Longde
   Wang, Yu
   Jin, Shuigao
   Wu, Zunyou
   Chin, Daniel P.
   Koplan, Jeffrey P.
   Wilson, Mary Elizabeth
TI Health system reform in China 2 Emergence and control of infectious
   diseases in China
SO LANCET
LA English
DT Article
ID STREPTOCOCCUS-SUIS; AVIAN INFLUENZA; SARS; BATS; CORONAVIRUSES;
   TRANSMISSION; OUTBREAK; VIRUS
AB Infectious diseases remain the major causes of morbidity and mortality in China despite substantial progress in their control. China is a major contributor to the worldwide infectious disease burden because of its population size. The association of China with the rest of the world through travel and trade means that events in the country can affect distant populations. The ecological interaction of people with animals in China favours the emergence of new microbial threats. The public-health system has to be prepared to deal with the challenges of newly emerging infectious diseases and at the same time try to control existing diseases. To address the microbial threats, such as severe acute respiratory syndrome, the government has committed substantial resources to the implementation of new strategies, including the development of a real-time monitoring system as part of the infectious-disease surveillance. This strategy can serve as a model for worldwide surveillance and response to threats from infectious diseases.
C1 [Wang, Yu; Wu, Zunyou] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing 100050, Peoples R China.
   [Wang, Longde] Minist Hlth, Beijing, Peoples R China.
   [Jin, Shuigao] Chinese Ctr Dis Control & Prevent, Natl Ctr Publ Hlth Surveillance & Informat Serv, Beijing 100050, Peoples R China.
   [Chin, Daniel P.] Bill & Melinda Gates Fdn China Off, Beijing, Peoples R China.
   [Koplan, Jeffrey P.] Emory Univ, Emory Global Hlth Inst, Atlanta, GA 30322 USA.
   [Wilson, Mary Elizabeth] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
RP Wu, ZY (reprint author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, 27 Nanwei Rd, Beijing 100050, Peoples R China.
EM wuzy@263.net
FU FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [U2R TW006918-05, U2R TW006918-04, U2R TW06918]
CR Cavanagh D, 2005, AVIAN PATHOL, V34, P439, DOI 10.1080/03079450500367682
   Chen SL, 2007, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2007/11/010
   Chen XS, 2000, SEX TRANSM DIS, V27, P138, DOI 10.1097/00007435-200003000-00003
   *CHIN CTR DIS CONT, NAT DAT NOT DIS CHIN
   *CHIN MIN HLTH, 2006, NOT DIS CHIN 2005
   *CHIN MIN HLTH, 2005, NOT DIS CHIN 2005
   *CHIN MIN HLTH, 2007, NOT DIS CHIN 2006
   *CHIN MIN HLTH, 2007, CHIN ANN HLTH STAT 2
   Cook IG, 2004, HEALTH POLICY, V67, P329, DOI 10.1016/j.healthpol.2003.07.005
   Cui J, 2007, EMERG INFECT DIS, V13, P1526, DOI 10.3201/eid1310.070448
   Feng Ping, 2007, Sichuan Da Xue Xue Bao Yi Xue Ban, V38, P874
   Gil VE, 1996, SOC SCI MED, V42, P141, DOI 10.1016/0277-9536(95)00064-X
   Gottschalk Marcelo, 2007, Animal Health Research Reviews, V8, P29, DOI 10.1017/S1466252307001247
   Hais W, 2004, ASIAN ECON PAP, V3, P57, DOI DOI 10.1162/1535351041747905
   Halpin K, 2007, CLIN INFECT DIS, V44, P711, DOI 10.1086/511078
   Hampton T, 2005, JAMA-J AM MED ASSOC, V294, P2291, DOI 10.1001/jama.294.18.2291
   Ho G, 2006, NURS INQ, V13, P2, DOI 10.1111/j.1440-1800.2006.00301.x
   Hon CC, 2008, J VIROL, V82, P1819, DOI 10.1128/JVI.01926-07
   Lam WK, 2003, RESPIROLOGY, V8, pS2, DOI 10.1046/j.1440-1843.2003.00516.x
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Lim W, 2006, ANN ACAD MED SINGAP, V35, P354
   Lun ZR, 2007, LANCET INFECT DIS, V7, P201, DOI 10.1016/S1473-3099(07)70001-4
   Matsui S, 2005, WATER SCI TECHNOL, V51, P91
   Mcfee RB, 2007, DM-DIS MON, V53, P343, DOI 10.1016/j.disamonth.2007.05.005
   *NAT TECHN STEER G, 2002, CHIN J TUBERC RESP D, V25, P3
   Nguyen THM, 2008, CLIN INFECT DIS, V46, P659, DOI 10.1086/527385
   Normile D, 2005, SCIENCE, V309, P1308
   Osterholm MT, 2005, NEW ENGL J MED, V352, P1839, DOI 10.1056/NEJMp058068
   Poland GA, 2007, VACCINE, V25, P3057, DOI 10.1016/j.vaccine.2007.01.050
   RANDS G, 1989, J ROY SOC HEALTH, V109, P79, DOI 10.1177/146642408910900302
   Russell CA, 2008, SCIENCE, V320, P340, DOI 10.1126/science.1154137
   Shao C, 1996, Chin Med Sci J, V11, P252
   Shaw K, 2006, PUBLIC HEALTH, V120, P8, DOI 10.1016/j.puhe.2005.10.002
   *STAT COUNC AIDS W, 2007, UN THEM GROUP AIDS C
   TANG S, 2008, LANCET          1020, DOI DOI 10.1016/SO140-6736(08)6134-1
   Tang SL, 2005, HEALTH POLICY, V72, P93, DOI 10.1016/j.healthpol.2004.06.009
   United Nations Development Programme, 2007, HUM DEV REP 2007 200
   Wang H, 2008, LANCET, V371, P1427, DOI 10.1016/S0140-6736(08)60493-6
   WANG L, 2008, LANCET          1020, DOI DOI 10.1016/SO140-6736(08)61358-6
   Wang LF, 2007, CURR TOP MICROBIOL, V315, P325
   Wang LD, 2007, LANCET, V369, P691, DOI 10.1016/S0140-6736(07)60316-X
   Watts J, 2004, LANCET, V363, P1370, DOI 10.1016/S0140-6736(04)16087-X
   *WHO, 2008, CUM NUMB CONF HUM CA
   Ye CY, 2008, EMERG INFECT DIS, V14, P787, DOI 10.3201/eid1405.070437
   Yu HJ, 2006, EMERG INFECT DIS, V12, P914, DOI 10.3201/eid1206.051194
   Zhang FJ, 2006, CHINESE MED J-PEKING, V119, P1999, DOI 10.1097/00029330-200612010-00010
   ZHANG K, 2008, LANCET          1020, DOI DOI 10.1016/SO140-6736(08)61357-4
   Zhang XB, 1996, ARS COMBINATORIA, V42, P3
   ZHENG LQ, 2007, HLTH NEWS BEIJI 0608
   Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877
NR 51
TC 197
Z9 220
U1 6
U2 43
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD NOV 1
PY 2008
VL 372
IS 9649
BP 1598
EP 1605
DI 10.1016/S0140-6736(08)61365-3
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 367ZG
UT WOS:000260590500034
PM 18930534
DA 2020-04-03
ER

PT J
AU Barretto, N
   Jukneliene, D
   Ratia, K
   Chen, ZB
   Mesecar, AD
   Baker, SC
AF Barretto, N
   Jukneliene, D
   Ratia, K
   Chen, ZB
   Mesecar, AD
   Baker, SC
TI The papain-like protease of severe acute respiratory syndrome
   coronavirus has deubiquitinating activity
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; C-TERMINAL HYDROLASES; DOUBLE-MEMBRANE VESICLES;
   SARS CORONAVIRUS; MURINE CORONAVIRUS; CYSTEINE PROTEINASE;
   ENDOPLASMIC-RETICULUM; POLIOVIRUS INFECTION; REPLICATION COMPLEX;
   CELLULAR AUTOPHAGY
AB Replication of the genomic RNA of severe acute respiratory syndrome coronavirus (SARS-CoV) is mediated by replicase polyproteins that are processed by two viral proteases, papain-like protease (PLpro) and 3C-like protease (3CLpro). Previously, we showed that SARS-CoV PLpro processes the replicase polyprotein at three conserved cleavage sites. Here, we report the identification and characterization of a 316-amino-acid catalytic core domain of PLpro that can efficiently cleave replicase substrates in trans-cleavage assays and peptide substrates in fluorescent resonance energy transfer-based protease assays. We performed bioinformatics analysis on 16 papain-like protease domains from nine different coronaviruses and identified a putative catalytic triad (Cys1651-His1812-Asp1826) and zinc-binding site. Mutagenesis studies revealed that Asp1826 and the four cysteine residues involved in zinc binding are essential for SARS-CoV PLpro activity. Molecular modeling of SARS-CoV PLpro suggested that this catalytic core may also have deubiquitinating activity. We tested this hypothesis by measuring the deubiquitinating activity of PLpro by two independent assays. SARS CoV-PLpro hydrolyzed both diubiquitin and ubiquitin-7-amino-4-methylcoumarin (AMC) substrates, and hydrolysis of ubiquitin-AMC is approximately 180-fold more efficient than hydrolysis of a peptide substrate that mimics the PLpro replicase recognition sequence. To investigate the critical determinants recognized by PLpro, we performed site-directed mutagenesis on the P6 to P2' residues at each of the three PLpro cleavage sites. We found that PLpro recognizes the consensus cleavage sequence LXGG, which is also the consensus sequence recognized by cellular deubiquitinating enzymes. This similarity in the substrate recognition sites should be considered during the development of SARS-CoV PLpro inhibitors.
C1 Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL 60153 USA.
   Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL USA.
   Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL USA.
   Beijing Inst Radiat Med, Dept Biochem & Mol Biol, Beijing, Peoples R China.
RP Baker, SC (reprint author), Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, 2160 S 1st Ave,Bldg 105, Maywood, IL 60153 USA.
EM sbaker1@lumc.edu
RI Chen, Zhongbin/C-5259-2009
OI Mesecar, Andrew/0000-0002-1241-2577
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P01 AI060915, AI45798, R01 AI045798, T32
   AI007508]
CR Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   BAKER SC, 1989, J VIROL, V63, P3693, DOI 10.1128/JVI.63.9.3693-3699.1989
   BAKER SC, 1993, J VIROL, V67, P6056, DOI 10.1128/JVI.67.10.6056-6063.1993
   Balakirev MY, 2002, J VIROL, V76, P6323, DOI 10.1128/JVI.76.12.6323-6331.2002
   BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Bonilla PJ, 1997, J VIROL, V71, P900, DOI 10.1128/JVI.71.2.900-909.1997
   CUMMINS JM, 2004, NATURE, V428, P486, DOI DOI 10.1038/NATURE02501
   Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Han YS, 2005, BIOCHEMISTRY-US, V44, P10349, DOI 10.1021/bi0504761
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Herold J, 1998, J VIROL, V72, P910, DOI 10.1128/JVI.72.2.910-918.1998
   Herold J, 1999, J BIOL CHEM, V274, P14918, DOI 10.1074/jbc.274.21.14918
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877
   Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787
   Kanjanahaluethai A, 2003, J VIROL, V77, P7376, DOI 10.1128/JVI.77.13.7376-7382.2003
   Kanjanahaluethai A, 2000, J VIROL, V74, P7911, DOI 10.1128/JVI.74.17.7911-7921.2000
   KIM JC, 1995, VIROLOGY, V208, P1, DOI 10.1006/viro.1995.1123
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Lai M.M.C., 2001, FIELDS VIROLOGY, P1163
   Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438
   Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f
   Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d
   Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737
   Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1
   Lim KP, 2000, J VIROL, V74, P1674, DOI 10.1128/JVI.74.4.1674-1685.2000
   Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200
   MENARD R, 1991, BIOCHEMISTRY-US, V30, P8924, DOI 10.1021/bi00101a002
   Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133
   Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996
   Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0
   Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   STORER AC, 1994, METHOD ENZYMOL, V244, P486
   Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000
   Sulea T, 2005, J VIROL, V79, P4550, DOI 10.1128/JVI.79.7.4550-4551.2005
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164
   Wong TW, 2004, EMERG INFECT DIS, V10, P269, DOI 10.3201/eid1002.030452
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yu ITS, 2004, NEW ENGL J MED, V350, P1731, DOI 10.1056/NEJMoa032867
   Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 63
TC 196
Z9 211
U1 2
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD DEC
PY 2005
VL 79
IS 24
BP 15189
EP 15198
DI 10.1128/JVI.79.24.15189-15198.2005
PG 10
WC Virology
SC Virology
GA 997VK
UT WOS:000234276700020
PM 16306590
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Yount, B
   Denison, MR
   Weiss, SR
   Baric, RS
AF Yount, B
   Denison, MR
   Weiss, SR
   Baric, RS
TI Systematic assembly of a full-length infectious cDNA of mouse hepatitis
   virus strain A59
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MURINE CORONAVIRUS MHV-A59; REPLICASE GENE POLYPROTEIN; OPEN READING
   FRAME; RNA RECOMBINATION; ENVELOPE PROTEIN; POLYMERASE GENE; CLEAVAGE
   SITE; IN-VITRO; EXPRESSION; GENOME
AB A novel method was developed to assemble a full-length infectious cDNA of the group II coronavirus mouse hepatitis virus strain A59 (MHV-A59). Seven contiguous cDNA clones that spanned the 31.5-kb MHV genome were isolated. The ends of the cDNAs were engineered with unique junctions and assembled with only the adjacent cDNA subclones, resulting in an intact MHV-A59 cDNA construct of similar to31.5 kb in length. The interconnecting restriction site junctions that are located at the ends of each cDNA are systematically removed during the assembly of the complete full-length cDNA product, allowing reassembly without the introduction of nucleotide changes. RNA transcripts derived from the full-length MHV-A59 construct were infectious, although transfection frequencies were enhanced 10- to 15-fold in the presence of transcripts encoding the nucleocapsid protein N. Plaque-purified virus derived from the infectious construct replicated efficiently and displayed similar growth kinetics, plaque morphology, and cytopathology in murine cells as did wild-type MHV-A59. Molecularly cloned viruses recognized the MHV receptor (MHVR) for docking and entry, and pretreatment of cells with monoclonal antibodies against MHVR blocked virus entry and replication. Cells infected with molecularly cloned MHV-A59 virus expressed replicase (gene 1) proteins identical to those of laboratory MHV-A59. Importantly, the molecularly cloned viruses contained three marker mutations that had been derived from the engineered component clones. Full-length infectious constructs of MHV-A59 will permit genetic modifications of the entire coronavirus genome, particularly in the replicase gene. The method has the potential to be used to construct viral, microbial, or eukaryotic genomes approaching several million base pairs in length and used to insert restriction sites at any given nucleotide in a microbial genome.
C1 Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   Vanderbilt Univ, Med Ctr, Dept Pediat & Microbiol & Immunol, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA.
   Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
   Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
RP Baric, RS (reprint author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, McGaveran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA.
RI Denison, Mark/O-7258-2018; Jha, Babal/AAC-8337-2020
OI Denison, Mark/0000-0003-2655-0900; Jha, Babal/0000-0002-7660-5255
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI26603, AI17418, R01 AI026603, R01
   AI023946, R01 AI017418, AI23946]; NIGMS NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01 GM063228,
   GM63228]
CR Agapov EV, 1998, P NATL ACAD SCI USA, V95, P12989, DOI 10.1073/pnas.95.22.12989
   AHLQUIST P, 1984, P NATL ACAD SCI-BIOL, V81, P7066, DOI 10.1073/pnas.81.22.7066
   Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   Baric RS, 1999, J VIROL, V73, P638, DOI 10.1128/JVI.73.1.638-649.1999
   Baric RS, 2000, J VIROL, V74, P4039, DOI 10.1128/JVI.74.9.4039-4046.2000
   BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   Baric RS, 1997, J VIROL, V71, P1946, DOI 10.1128/JVI.71.3.1946-1955.1997
   BONILLA PJ, 1994, VIROLOGY, V198, P736, DOI 10.1006/viro.1994.1088
   Bonilla PJ, 1997, J VIROL, V71, P900, DOI 10.1128/JVI.71.2.900-909.1997
   Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000
   BOYER JC, 1994, VIROLOGY, V198, P415, DOI 10.1006/viro.1994.1053
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   Casais R, 2001, J VIROL, V75, P12359, DOI 10.1128/JVI.75.24.12359-12369.2001
   CAVANAGH D, 1993, ARCH VIROL, V128, P395, DOI 10.1007/BF01309450
   Chen W, 1996, J VIROL, V70, P3947, DOI 10.1128/JVI.70.6.3947-3960.1996
   Chen W, 1997, VIROLOGY, V228, P318, DOI 10.1006/viro.1996.8402
   CURTIS KM, 2001, J VIROL, V76, P1422
   de Haan CAM, 2000, J VIROL, V74, P4967, DOI 10.1128/JVI.74.11.4967-4978.2000
   DENISON MR, 1995, VIROLOGY, V207, P316, DOI 10.1006/viro.1995.1085
   Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999
   DVEKSLER GS, 1993, J VIROL, V67, P1
   DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   Enjuanes L, 2001, J BIOTECHNOL, V88, P183, DOI 10.1016/S0168-1656(01)00281-4
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   KOETZNER CA, 1992, J VIROL, V66, P1841, DOI 10.1128/JVI.66.4.1841-1848.1992
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   KYUWA S, 1990, SEMINARS VIROLOGY, V1, P273
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Leparc-Goffart I, 1997, VIROLOGY, V239, P1, DOI 10.1006/viro.1997.8877
   Lu XT, 1998, J VIROL, V72, P2265, DOI 10.1128/JVI.72.3.2265-2271.1998
   LU YQ, 1995, J VIROL, V69, P3554, DOI 10.1128/JVI.69.6.3554-3559.1995
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MURARO R, 1985, CANCER RES, V45, P5769
   PARKER MM, 1990, VIROLOGY, V179, P463, DOI 10.1016/0042-6822(90)90316-J
   Risco C, 1996, J VIROL, V70, P4773, DOI 10.1128/JVI.70.7.4773-4777.1996
   SAMBROOK J, 1989, MOL CLONING, V2, P1
   SCHAAD MC, 1994, J VIROL, V68, P8169, DOI 10.1128/JVI.68.12.8169-8179.1994
   Schickli JH, 1997, J VIROL, V71, P9499, DOI 10.1128/JVI.71.12.9499-9507.1997
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   SIDDELL SG, 1995, CORONAVIRIDAE, P1
   Sims AC, 2000, J VIROL, V74, P5647, DOI 10.1128/JVI.74.12.5647-5654.2000
   SNIJDER EJ, 1993, J GEN VIROL, V74, P2305, DOI 10.1099/0022-1317-74-11-2305
   Stalcup RP, 1998, VIROLOGY, V241, P112, DOI 10.1006/viro.1997.8957
   TAHARA SM, 1994, VIROLOGY, V202, P621, DOI 10.1006/viro.1994.1383
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   Thiel V, 2001, J VIROL, V75, P6676, DOI 10.1128/JVI.75.14.6676-6681.2001
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   YOKOMORI K, 1993, VIROLOGY, V192, P170, DOI 10.1006/viro.1993.1019
   Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000
   YU X, 1994, VIROLOGY, V202, P1018, DOI 10.1006/viro.1994.1430
   Zelus BD, 1998, J VIROL, V72, P7237, DOI 10.1128/JVI.72.9.7237-7244.1998
NR 54
TC 196
Z9 215
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 2002
VL 76
IS 21
BP 11065
EP 11078
DI 10.1128/JVI.76.21.11065-11078.2002
PG 14
WC Virology
SC Virology
GA 602NX
UT WOS:000178512300050
PM 12368349
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Parra, B
   Hinton, DR
   Marten, NW
   Bergmann, CC
   Lin, MT
   Yang, CS
   Stohlman, SA
AF Parra, B
   Hinton, DR
   Marten, NW
   Bergmann, CC
   Lin, MT
   Yang, CS
   Stohlman, SA
TI IFN-gamma is required for viral clearance from central nervous system
   oligodendroglial
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; INDUCED DEMYELINATING DISEASE; EXPERIMENTAL
   ALLERGIC ENCEPHALOMYELITIS; CELL-RESISTANT VARIANTS; MURINE CORONAVIRUS
   JHM; HERPES-SIMPLEX VIRUS; CD8+ T-CELLS; INTERFERON-GAMMA; NEUROTROPIC
   CORONAVIRUS; IN-VIVO
AB Infection of the central nervous system (CNS) by the JHM strain of mouse hepatitis virus (JHMV) is a rodent model of the human demyelinating disease multiple sclerosis, The inability of effective host immune responses to eliminate virus from the CNS results in a chronic infection associated with ongoing recurrent demyelination, JHMV infects a variety of CNS cell types during the acute phase of infection including ependymal cells, astrocytes, microglia, oligodendroglia, and rarely in neurons. Replication within the majority of CNS cell types is controlled by perforin-dependent virus-specific CTL, however, inhibition of viral replication in oligodendroglia occurs via a perforin-independent mechanism(s). The potential role for IFN-gamma as mediator controlling JHMV replication in oligodendroglia was examined in mice deficient in IFN-gamma secretion (IFN-gamma(0/0) mice). IFN-gamma(0/0) mice exhibited increased clinical symptoms and mortality associated with persistent virus, demonstrating an inability to control replication. Neither antiviral Ab nor CTL responses were diminished in the absence of IFN-gamma, although increased IgG1 was detected in IFN-gamma(0/0) mice. Increased virus Ag in the absence of IFN-gamma localized almost exclusively to oligodendrogIia and was associated with increased CD8(+) T cells localized within white matter. These data suggest that although perforin-dependent CTL control virus replication within astrocytes and microglia, which constitute the majority of infected CNS cells, IFN-gamma is critical for control of viral replication in oligodendroglia. Therefore, different mechanisms are used by the host defenses to control virus replication within the CNS, dependent upon the phenotype of the targets of virus replication.
C1 Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
   Univ So Calif, Sch Med, Dept Neurol, Los Angeles, CA 90033 USA.
   Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
RP Stohlman, SA (reprint author), Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, 1333 San Pablo St,MCH 12, Los Angeles, CA 90033 USA.
OI Bergmann, Cornelia/0000-0003-1319-402X
FU NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [NS18146]
CR ADAMI C, 1995, VIROLOGY, V209, P337, DOI 10.1006/viro.1995.1265
   Baumgarth N, 1996, J VIROL, V70, P4411, DOI 10.1128/JVI.70.7.4411-4418.1996
   Bergmann CC, 1996, J GEN VIROL, V77, P315, DOI 10.1099/0022-1317-77-2-315
   BIRON CA, 1994, CURR OPIN IMMUNOL, V6, P530, DOI 10.1016/0952-7915(94)90137-6
   BOULEY DM, 1995, J IMMUNOL, V155, P3964
   BUCHMEIER MJ, 1984, VIROLOGY, V132, P261, DOI 10.1016/0042-6822(84)90033-3
   CAMPBELL HD, 1988, EUR J BIOCHEM, V174, P345, DOI 10.1111/j.1432-1033.1988.tb14104.x
   CASTRO RF, 1995, J VIROL, V69, P8127, DOI 10.1128/JVI.69.12.8127-8131.1995
   CUA DJ, 1995, J IMMUNOL, V155, P4052
   DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300
   FINKE D, 1994, IMMUNOLOGY, V83, P184
   FINKE D, 1995, J VIROL, V69, P5469, DOI 10.1128/JVI.69.9.5469-5474.1995
   FLEMING JO, 1986, J VIROL, V58, P869, DOI 10.1128/JVI.58.3.869-875.1986
   FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1
   FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510
   GRAHAM MB, 1993, J EXP MED, V178, P1725, DOI 10.1084/jem.178.5.1725
   Houtman JJ, 1996, J NEUROVIROL, V2, P101, DOI 10.3109/13550289609146543
   Houtman JJ, 1996, J NEUROVIROL, V2, P361, DOI 10.3109/13550289609146902
   HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301
   Jones LS, 1997, J IMMUNOL, V158, P5997
   KOSZINOWSKI UH, 1991, CURR OPIN IMMUNOL, V3, P471, DOI 10.1016/0952-7915(91)90005-L
   Krakowski M, 1996, EUR J IMMUNOL, V26, P1641, DOI 10.1002/eji.1830260735
   KUNDIG TM, 1993, J IMMUNOL, V150, P2316
   KYUWA S, 1990, SEMINARS VIROLOGY, V1, P273
   LAMBERT PW, 1973, ACTA NEUROPATHOL, V24, P76
   Lane TE, 1997, J VIROL, V71, P2202, DOI 10.1128/JVI.71.3.2202-2210.1997
   Lane TE, 1997, TRENDS MICROBIOL, V5, P9, DOI 10.1016/S0966-842X(97)81768-4
   Lin MT, 1997, J VIROL, V71, P383, DOI 10.1128/JVI.71.1.383-391.1997
   LUCIN P, 1992, J VIROL, V66, P1977, DOI 10.1128/JVI.66.4.1977-1984.1992
   Njenga MK, 1997, LAB INVEST, V77, P71
   OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0
   PARRA B, 1997, VIROLOGY, V233
   PEARCE BD, 1994, J VIROL, V68, P5483, DOI 10.1128/JVI.68.9.5483-5495.1994
   PERLMAN S, 1987, MICROB PATHOGENESIS, V3, P309, DOI 10.1016/0882-4010(87)90064-7
   Pewe L, 1997, J VIROL, V71, P7640, DOI 10.1128/JVI.71.10.7640-7647.1997
   Pewe L, 1996, IMMUNITY, V5, P253, DOI 10.1016/S1074-7613(00)80320-9
   PULLEN LC, 1994, J NEUROIMMUNOL, V55, P143, DOI 10.1016/0165-5728(94)90004-3
   RODRIGUEZ M, 1983, AM J PATHOL, V110, P95
   RODRIGUEZ M, 1995, J VIROL, V69, P7286, DOI 10.1128/JVI.69.11.7286-7290.1995
   RUBY J, 1991, LYMPHOKINE CYTOK RES, V10, P353
   Sarawar SR, 1997, J VIROL, V71, P3916, DOI 10.1128/JVI.71.5.3916-3921.1997
   SEDWICK JD, 1991, NEUROSCIENCES, V3, P93
   SIMMONS A, 1992, J EXP MED, V175, P1337, DOI 10.1084/jem.175.5.1337
   SMITH AL, 1991, ARCH VIROL, V121, P89, DOI 10.1007/BF01316746
   STOHLMAN SA, 1995, J VIROL, V69, P684, DOI 10.1128/JVI.69.2.684-694.1995
   STOHLMAN SA, 1986, J IMMUNOL, V136, P3052
   STOHLMAN SA, 1995, J VIROL, V69, P5898, DOI 10.1128/JVI.69.9.5898-5903.1995
   STOHLMAN SA, 1998, J IMMUNOL, V160, P2986
   SUN N, 1995, J VIROL, V69, P633, DOI 10.1128/JVI.69.2.633-641.1995
   TORRES C, 1995, IMMUNOLOGY, V86, P250
   VANPOTTELSBERGHE C, 1979, LAB INVEST, V40, P99
   WANG FI, 1990, J NEUROIMMUNOL, V30, P31, DOI 10.1016/0165-5728(90)90050-W
   WILLIAMSON JSP, 1990, J VIROL, V64, P4589, DOI 10.1128/JVI.64.9.4589-4592.1990
   WILLIAMSON JSP, 1991, J NEUROIMMUNOL, V32, P199, DOI 10.1016/0165-5728(91)90189-E
   YAMAGUCHI K, 1991, J NEUROIMMUNOL, V32, P1, DOI 10.1016/0165-5728(91)90065-F
   YOUNG HA, 1995, J LEUKOCYTE BIOL, V58, P373
   Zhang XM, 1997, VIROLOGY, V233, P327, DOI 10.1006/viro.1997.8598
NR 57
TC 195
Z9 201
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 1999
VL 162
IS 3
BP 1641
EP 1647
PG 7
WC Immunology
SC Immunology
GA 160YM
UT WOS:000078261000053
PM 9973424
DA 2020-04-03
ER

PT J
AU PEDERSEN, NC
   BOYLE, JF
   FLOYD, K
   FUDGE, A
   BARKER, J
AF PEDERSEN, NC
   BOYLE, JF
   FLOYD, K
   FUDGE, A
   BARKER, J
TI AN ENTERIC CORONAVIRUS INFECTION OF CATS AND ITS RELATIONSHIP TO FELINE
   INFECTIOUS PERITONITIS
SO AMERICAN JOURNAL OF VETERINARY RESEARCH
LA English
DT Article
RP PEDERSEN, NC (reprint author), UNIV CALIF DAVIS,SCH VET MED,DEPT MED,DAVIS,CA 95616, USA.
CR APPEL MJG, 1979, 29TH GAIN VET S GAIN, P3
   BEARE AS, 1976, LANCET, V2, P4
   BRENNER S, 1959, BIOCHIM BIOPHYS ACTA, V34, P103, DOI 10.1016/0006-3002(59)90237-9
   HORZINEK MC, 1979, AM J VET RES, V40, P1487
   KEENAN KP, 1976, AM J VET RES, V37, P247
   LOEFFLER DG, 1978, FELINE PRACT, V8, P43
   MEBUS CA, 1978, J AM VET MED ASSOC, V173, P631
   OREILLY KJ, 1979, VET REC, V104, P348, DOI 10.1136/vr.104.15.348
   PEDERSEN NC, 1976, AM J VET RES, V37, P1449
   PEDERSEN NC, 1978, ARCH VIROL, V58, P45, DOI 10.1007/BF01315534
   PEDERSEN NC, 1981, AM J VET RES, V42, P363
   PEDERSEN NC, 1976, AM J VET RES, V37, P567
   PEDERSEN NC, 1980, AM J VET RES, V41, P868
   POMEROY KA, 1978, AM J VET RES, V39, P1348
   Post J. E., 1978, Proceedings of the American Association of Veterinary Laboratory Diagnosticians, V21, P427
   RISTIC M, 1968, ILLINOIS RES, V10, P12
   SHOPE RE, 1958, PUBLIC HEALTH REP, V73, P165, DOI 10.2307/4590072
   SMITH TF, 1976, NEW ENGL J MED, V294, P708, DOI 10.1056/NEJM197603252941308
   STUARTHARRIS C, 1976, LANCET, V2, P31
NR 19
TC 195
Z9 199
U1 2
U2 29
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360
SN 0002-9645
J9 AM J VET RES
JI Am. J. Vet. Res.
PY 1981
VL 42
IS 3
BP 368
EP 377
PG 10
WC Veterinary Sciences
SC Veterinary Sciences
GA LG100
UT WOS:A1981LG10000002
PM 6267960
DA 2020-04-03
ER

PT J
AU Kistler, A
   Avila, PC
   Rouskin, S
   Wang, D
   Ward, T
   Yagi, S
   Schnurr, D
   Ganem, D
   DeRisi, JL
   Boushey, HA
AF Kistler, Amy
   Avila, Pedro C.
   Rouskin, Silvi
   Wang, David
   Ward, Theresa
   Yagi, Shigeo
   Schnurr, David
   Ganem, Don
   DeRisi, Joseph L.
   Boushey, Homer A.
TI Pan-viral screening of respiratory tract infections in adults with and
   without asthma reveals unexpected human coronavirus and human rhinovirus
   diversity
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 8th International Symposium on Respiratory Viral Infection
CY MAR 16-19, 2006
CL Kohala Coast, HI
ID AIRWAY HYPERRESPONSIVENESS; SEQUENCE; EXACERBATIONS; VIRUSES; COLDS;
   HKU1
AB Background. Between 50% and 80% of asthma exacerbations are associated with viral respiratory tract infections (RTIs), yet the influence of viral pathogen diversity on asthma outcomes is poorly understood because of the limited scope and throughput of conventional viral detection methods.
   Methods. We investigated the capability of the Virochip, a DNA microarray-based viral detection platform, to characterize viral diversity in RTIs in adults with and without asthma.
   Results. The Virochip detected viruses in a higher proportion of samples (65%) than did culture isolation (17%) while exhibiting high concordance (98%) with and comparable sensitivity (97%) and specificity (98%) to pathogen-specific polymerase chain reaction. A similar spectrum of viruses was identified in the RTIs of each patient subgroup; however, unexpected diversity among human coronaviruses (HCoVs) and human rhinoviruses (HRVs) was revealed. All but one of the HCoVs corresponded to the newly recognized HCoV-NL63 and HCoV-HKU1 viruses, and >20 different serotypes of HRVs were detected, including a set of 5 divergent isolates that formed a distinct genetic subgroup.
   Conclusions. The Virochip can detect both known and novel variants of viral pathogens present in RTIs. Given the diversity detected here, larger-scale studies will be necessary to determine whether particular substrains of viruses confer an elevated risk of asthma exacerbation.
C1 Univ Calif San Francisco, Dept Med Biochem & Microbiol, Howard Hughes Med Inst, San Francisco, CA 94158 USA.
   Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA.
   Calif Dept Hlth Serv, Viral & Rickettsial Dis Lab, Richmond, CA USA.
   Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA.
   Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
RP Kistler, A (reprint author), Univ Calif San Francisco, Dept Med Biochem & Microbiol, Howard Hughes Med Inst, 1700 4th St,QB3 Rm, San Francisco, CA 94158 USA.
EM amy@derisilab.ucsf.edu
OI Rouskin, Silvi/0000-0003-2042-6642
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21 AI057506, P01 AI050496]
CR ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984
   Alper CM, 1996, LARYNGOSCOPE, V106, P1298, DOI 10.1097/00005537-199610000-00025
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   ANDRIES K, 1990, J VIROL, V64, P1117, DOI 10.1128/JVI.64.3.1117-1123.1990
   Bardin PG, 2000, EUR RESPIR J, V16, P980, DOI 10.1183/09031936.00.16598000
   Barrett B, 2005, J CLIN EPIDEMIOL, V58, P609, DOI 10.1016/j.jclinepi.2004.11.019
   CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282
   Chiu CY, 2007, J CLIN MICROBIOL, V45, P2340, DOI 10.1128/JCM.00364-07
   Chiu CY, 2006, CLIN INFECT DIS, V43, pE71, DOI 10.1086/507896
   COONEY MK, 1982, INFECT IMMUN, V37, P642, DOI 10.1128/IAI.37.2.642-647.1982
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Esper F, 2006, EMERG INFECT DIS, V12, P775, DOI 10.3201/eid1205.051316
   Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074
   FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879
   Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019
   Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195
   Grunberg K, 1999, AM J RESP CRIT CARE, V160, P1375
   Grunberg K, 1997, AM J RESP CRIT CARE, V155, P833
   Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609
   Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x
   HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976
   Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406
   Heikkinen T, 2003, LANCET, V361, P51, DOI 10.1016/S0140-6736(03)12162-9
   HENDLEY JO, 1972, AM REV RESPIR DIS, V105, P805
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601
   Kay AB, 2006, CHEM IMMUNOL ALLERGY, V91, P59
   Kistler AL, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-40
   Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551
   Loens K, 2006, J CLIN MICROBIOL, V44, P166, DOI 10.1128/JCM.44.1.166-171.2006
   McErlean P, 2007, J CLIN VIROL, V39, P67, DOI 10.1016/j.jcv.2007.03.012
   Message SD, 2002, BRIT MED BULL, V61, P29, DOI 10.1093/bmb/61.1.29
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   Savolainen C, 2002, J GEN VIROL, V83, P333, DOI 10.1099/0022-1317-83-2-333
   Tan WC, 2005, CURR OPIN PULM MED, V11, P21
   Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591
   Urisman A, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r78
   Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025
   van der Hoek L, 2006, FEMS MICROBIOL REV, V30, P760, DOI 10.1111/j.1574-6976.2006.00032.x
   Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699
   Wang D, 2003, PLOS BIOL, V1, P257, DOI 10.1371/journal.pbio.0000002
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
NR 43
TC 194
Z9 199
U1 1
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 15
PY 2007
VL 196
IS 6
BP 817
EP 825
DI 10.1086/520816
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 207LE
UT WOS:000249251800004
PM 17703411
OA Bronze
DA 2020-04-03
ER

PT J
AU Kuba, K
   Zhang, L
   Imai, Y
   Arab, S
   Chen, M
   Maekawa, Y
   Leschnik, M
   Leibbrandt, A
   Makovic, M
   Schwaighofer, J
   Beetz, N
   Musialek, R
   Neely, GG
   Komnenovic, V
   Kolm, U
   Metzler, B
   Ricci, R
   Hara, H
   Meixner, A
   Nghiem, M
   Chen, X
   Dawood, F
   Wong, KM
   Sarao, R
   Cukerman, E
   Kimura, A
   Hein, L
   Thalhammer, J
   Liu, PP
   Penninger, JM
AF Kuba, Keiji
   Zhang, Liyong
   Imai, Yumiko
   Arab, Sara
   Chen, Manyin
   Maekawa, Yuichiro
   Leschnik, Michael
   Leibbrandt, Andreas
   Makovic, Mato
   Schwaighofer, Julia
   Beetz, Nadine
   Musialek, Renata
   Neely, G. Greg
   Komnenovic, Vukoslav
   Kolm, Ursula
   Metzler, Bernhard
   Ricci, Romeo
   Hara, Hiromitsu
   Meixner, Arabella
   Nghiem, Mai
   Chen, Xin
   Dawood, Fayez
   Wong, Kit Man
   Sarao, Renu
   Cukerman, Eva
   Kimura, Akinori
   Hein, Lutz
   Thalhammer, Johann
   Liu, Peter P.
   Penninger, Josef M.
TI Impaired heart Contractility in apelin gene-deficient mice associated
   with aging and pressure overload
SO CIRCULATION RESEARCH
LA English
DT Article
DE aging; angiotensin; cardiac failure; cardiac function; pressure overload
ID ANGIOTENSIN-CONVERTING ENZYME-2; ENDOGENOUS PEPTIDE LIGAND; ORPHAN
   RECEPTOR APJ; FOOD-INTAKE; CARDIAC CONTRACTILITY; ENDOTHELIAL-CELLS;
   ANGIOGENIC FACTOR; SARS CORONAVIRUS; BLOOD-PRESSURE; IN-VIVO
AB Apelin constitutes a novel endogenous peptide system suggested to be involved in a broad range of physiological functions, including cardiovascular function, heart development, control of fluid homeostasis, and obesity. Apelin is also a catalytic substrate for angiotensin- converting enzyme 2, the key severe acute respiratory syndrome receptor. The in vivo physiological role of Apelin is still elusive. Here we report the generation of Apelin gene -targeted mice. Apelin mutant mice are viable and fertile, appear healthy, and exhibit normal body weight, water and food intake, heart rates, and heart morphology. Intriguingly, aged Apelin knockout mice developed progressive impairment of cardiac contractility associated with systolic dysfunction in the absence of histological abnormalities. We also report that pressure overload induces upregulation of Apelin expression in the heart. Importantly, in pressure overload -induced heart failure, loss of Apelin did not significantly affect the hypertrophy response, but Apelin mutant mice developed progressive heart failure. Global gene expression arrays and hierarchical clustering of differentially expressed genes in hearts of banded Apelin(-/y) and Apelin(-/y) mice showed concerted upregulation of genes involved in extracellular matrix remodeling and muscle contraction. These genetic data show that the endogenous peptide Apelin is crucial to maintain cardiac contractility in pressure overload and aging.
C1 Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria.
   Tokyo Med & Dent Univ, Med Res Inst, Med Top Track Program, Tokyo, Japan.
   Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pathogenesis, Tokyo, Japan.
   Univ Hlth Network, Heart & Stroke Richard Lewar Ctr Excellence, Toronto Gen Res Inst, Toronto, ON, Canada.
   Vet Univ Vienna, Vienna, Austria.
   Med Univ Innsbruck, Div Cardiol, Innsbruck, Austria.
   Univ Freiburg, Inst Expt & Clin Pharmacol & Toxicol, D-7800 Freiburg, Germany.
   Swiss Fed Inst Technol, Zurich, Switzerland.
RP Penninger, JM (reprint author), Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria.
EM josef.penninger@oeaw.ac.at
RI Ricci, Romeo/K-3009-2013; neely, graham/A-6511-2011; Penninger, Josef
   M/I-6860-2013; Neely, Greg/AAB-4642-2020
OI Ricci, Romeo/0000-0002-9766-4369; Penninger, Josef
   M/0000-0002-8194-3777; Neely, Greg/0000-0002-1957-9732
CR Ashley EA, 2005, CARDIOVASC RES, V65, P73, DOI 10.1016/j.cardiores.2004.08.018
   Berry MF, 2004, CIRCULATION, V110, pII187, DOI 10.1161/01.CIR.0000138382.57325.5c
   BHOOLA KD, 1992, PHARMACOL REV, V44, P1
   Boucher J, 2005, ENDOCRINOLOGY, V146, P1764, DOI 10.1210/en.2004-1427
   Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365
   Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524
   Chen MM, 2003, CIRCULATION, V108, P1432, DOI 10.1161/01.CIR.0000091235.94914.75
   Cheng X, 2003, EUR J PHARMACOL, V470, P171, DOI 10.1016/S0014-2999(03)01821-1
   Cox CM, 2006, DEV BIOL, V296, P177, DOI 10.1016/j.ydbio.2006.04.452
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Dai TY, 2006, EUR J PHARMACOL, V553, P222, DOI 10.1016/j.ejphar.2006.09.034
   De Mota N, 2004, P NATL ACAD SCI USA, V101, P10464, DOI 10.1073/pnas.0403518101
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   FERRARIO CM, 1990, J CARDIOVASC PHARM, V15, pS1, DOI 10.1097/00005344-199000153-00001
   Foldes G, 2003, BIOCHEM BIOPH RES CO, V308, P480, DOI 10.1016/S0006-291X(03)01424-4
   HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Inui M, 2006, DEV BIOL, V298, P188, DOI 10.1016/j.ydbio.2006.06.028
   Ishida J, 2004, J BIOL CHEM, V279, P26274, DOI 10.1074/jbc.M404149200
   Jaszberenyi M, 2004, NEUROSCIENCE, V129, P811, DOI 10.1016/j.neuroscience.2004.08.007
   Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042
   Kassiri Z, 2005, CIRC RES, V97, P380, DOI 10.1161/01.RES.0000178789.16929.cf
   Kleinz MJ, 2005, PHARMACOL THERAPEUT, V107, P198, DOI 10.1016/j.pharmthera.2005.04.001
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lee DK, 2006, TRENDS PHARMACOL SCI, V27, P190, DOI 10.1016/j.tips.2006.02.006
   Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x
   Lee DK, 2005, ENDOCRINOLOGY, V146, P231, DOI 10.1210/en.2004-0359
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Masri B, 2005, CELL SIGNAL, V17, P415, DOI 10.1016/j.cellsig.2004.09.018
   Masri B, 2004, FASEB J, V18, P1909, DOI 10.1096/fj.04-1930fje
   Messari SE, 2004, J NEUROCHEM, V90, P1290, DOI 10.1111/j.1471-4159.2004.02591.x
   O'Shea M, 2003, NUTR NEUROSCI, V6, P163, DOI 10.1080/1028415031000111273
   ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O
   Oudit GY, 2006, AM J PATHOL, V168, P1808, DOI 10.2353/ajpath.2006.051091
   Plehm Ralph, 2006, V129, P115
   Sunter D, 2003, NEUROSCI LETT, V353, P1, DOI 10.1016/S0304-3940(03)00351-3
   Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69
   Taheri S, 2002, BIOCHEM BIOPH RES CO, V291, P1208, DOI 10.1006/bbrc.2002.6575
   Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1
   Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489
   Tikellis C, 2003, HYPERTENSION, V41, P392, DOI 10.1161/01.HYP.0000060689.38912.CB
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200
   Yamamoto K, 2006, HYPERTENSION, V47, P718, DOI 10.1161/01.HYP.0000205833.89478.5b
NR 44
TC 194
Z9 199
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD AUG 17
PY 2007
VL 101
IS 4
BP E32
EP E42
DI 10.1161/CIRCRESAHA.107.158659
PG 11
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA 201DD
UT WOS:000248810800015
PM 17673668
OA Bronze
DA 2020-04-03
ER

PT J
AU Poon, LLM
   Chu, DKW
   Chan, KH
   Wong, OK
   Ellis, TM
   Leung, YHC
   Lau, SKP
   Woo, PCY
   Suen, KY
   Yuen, KY
   Guan, Y
   Peiris, JSM
AF Poon, LLM
   Chu, DKW
   Chan, KH
   Wong, OK
   Ellis, TM
   Leung, YHC
   Lau, SKP
   Woo, PCY
   Suen, KY
   Yuen, KY
   Guan, Y
   Peiris, JSM
TI Identification of a novel coronavirus in bats
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SARS-CORONAVIRUS; SEQUENCE-ANALYSIS; VIRUS-INFECTION; FUSION PROTEIN;
   POLYMERASE; ANIMALS; HUMANS; GENOME; FELINE; CORE
AB Exotic wildlife can act as reservoirs of diseases that are endemic in the area or can be the source of new emerging diseases through interspecies transmission. The recent emergence of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) highlights the importance of virus surveillance in wild animals. Here, we report the identification of a novel bat coronavirus through surveillance of coronaviruses in wildlife. Analyses of the RNA sequence from the ORF1b and S-gene regions indicated that the virus is a group 1 coronavirus. The virus was detected in fecal and respiratory samples from three bat species (Miniopterus spp.). In particular, 63% (12 of 19) of fecal samples from Miniopterus pusillus were positive for the virus. These findings suggest that this virus might be commonly circulating in M. pusillus in Hong Kong.
C1 Univ Hong Kong, Dept Microbiol, Hong Kong, Special Adminis, Peoples R China.
   Queen Mary Hosp, Dept Microbiol, Hong Kong, Special Adminis, Peoples R China.
   Dept Agr Fisheries & Conservat, Hong Kong, Special Adminis, Peoples R China.
   Wildlife Conservat Fdn Ltd, Hong Kong, Special Adminis, Peoples R China.
RP Poon, LLM (reprint author), Univ Hong Kong, Dept Microbiol, Queen Mary Hosp, Hong Kong, Special Adminis, Peoples R China.
EM llmpoon@hkucc.hku.hk
RI Poon, Leo/C-4382-2009; Leung, Connie/C-4600-2009; Lau,
   Susanna/C-4321-2009; Yuen, Kwok Yung/C-4465-2009; Woo, Patrick Chiu
   Yat/C-4449-2009; Peiris, Joseph Sriyal Malik/C-4380-2009
OI Poon, Leo/0000-0002-9101-7953; Chu, Daniel Ka Wing/0000-0002-9219-8979;
   Guan, Yi/0000-0001-6057-9243; Woo, Patrick Chiu Yat/0000-0001-9401-1832;
   Yuen, Kwok-yung/0000-0002-2083-1552; Peiris, Joseph Sriyal
   Malik/0000-0001-8217-5995
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01AI95357]
CR Bos ECW, 1996, VIROLOGY, V218, P52, DOI 10.1006/viro.1996.0165
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Breithaupt H, 2003, EMBO REP, V4, P921, DOI 10.1038/sj.embor.embor949
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Herrewegh AAPM, 1998, J VIROL, V72, P4508, DOI 10.1128/JVI.72.5.4508-4514.1998
   Holmes KV, 2003, SCIENCE, V300, P1377, DOI 10.1126/science.1086418
   Huang QL, 2004, BIOCHEMISTRY-US, V43, P6059, DOI 10.1021/bi036155b
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Kulasekera VL, 2001, EMERG INFECT DIS, V7, P722, DOI 10.3201/eid0704.010421
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746
   Navas-Martin S, 2003, VIRAL IMMUNOL, V16, P461, DOI 10.1089/088282403771926292
   Paton NI, 1999, LANCET, V354, P1253, DOI 10.1016/S0140-6736(99)04379-2
   POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x
   Poon LLM, 2003, CLIN CHEM, V49, P953, DOI 10.1373/49.6.953
   Riley SPD, 2004, J WILDLIFE DIS, V40, P11, DOI 10.7589/0090-3558-40.1.11
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   Tripet B, 2004, J BIOL CHEM, V279, P20836, DOI 10.1074/jbc.M400759200
   TSUNEMITSU H, 1995, J CLIN MICROBIOL, V33, P3264, DOI 10.1128/JCM.33.12.3264-3269.1995
   Xu X, 2003, NUCLEIC ACIDS RES, V31, P7117, DOI 10.1093/nar/gkg916
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 26
TC 193
Z9 216
U1 4
U2 30
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD FEB
PY 2005
VL 79
IS 4
BP 2001
EP 2009
DI 10.1128/JVI.79.4.2001-2009.2005
PG 9
WC Virology
SC Virology
GA 894DZ
UT WOS:000226772100003
PM 15681402
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU KRIJNSELOCKER, J
   ERICSSON, M
   ROTTIER, PJM
   GRIFFITHS, G
AF KRIJNSELOCKER, J
   ERICSSON, M
   ROTTIER, PJM
   GRIFFITHS, G
TI CHARACTERIZATION OF THE BUDDING COMPARTMENT OF MOUSE HEPATITIS-VIRUS -
   EVIDENCE THAT TRANSPORT FROM THE RER TO THE GOLGI-COMPLEX REQUIRES ONLY
   ONE VESICULAR TRANSPORT STEP
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID NEURONAL ENDOMEMBRANE SYSTEM; ROUGH ENDOPLASMIC-RETICULUM; SEMLIKI
   FOREST VIRUS; E1 GLYCOPROTEIN; MEMBRANE-GLYCOPROTEINS;
   PROTEIN-TRANSPORT; CIS ELEMENT; PRE-GOLGI; POST-ER; CELLS
AB Mouse hepatitis coronavirus (MHV) buds into pleomorphic membrane structures with features expected of the intermediate compartment between the ER and the Golgi complex. Here, we characterize the MHV budding compartment in more detail in mouse L cells using streptolysin O (SLO) permeabilization which allowed us to better visualize the membrane structures at the ER-Golgi boundary. The MHV budding compartment shares membrane continuities with the rough ER as well as with cisternal elements on one side of the Golgi stack. It also labeled with p58 and rab2, two markers of the intermediate compartment, and with PDI, usually considered to be a marker of the rough ER. The membranes of the budding compartment, as well as the budding virions themselves, but not the rough ER, labeled with the N-acetyl-galactosamine (GalNAc)-specific lectin Helix pomatia. When the SLO-permeabilized cells were treated with guanosine 5'-(3-O-thio)triphosphate (GTPgammaS), the budding compartment accumulated a large number of beta-cop-containing buds and vesicular profiles.
   Complementary biochemical experiments were carried out to determine whether vesicular transport was required for the newly synthesized M protein, that contains only O-linked oligosaccharides, to acquire first, GalNAc and second, the Golgi modifications galactose and sialic acid. The results from both in vivo studies and from the use of SLO-permeabilized cells showed that, while GalNAc addition occurred under conditions which block vesicular transport, both cytosol and ATP were prerequisites for the M protein oligosaccharides to acquire Golgi modifications. Collectively, our data argue that transport from the rough ER to the Golgi complex requires only one vesicular transport step and that the intermediate compartment is a specialized domain of the endoplasmatic reticulum that extends to the first cisterna on the cis side of the Golgi stack.
C1 EMBL, MEYERHOFSTR 1, D-69012 HEIDELBERG, GERMANY.
   UNIV UTRECHT, FAC VET MED, INST VIROL, 3584 CL UTRECHT, NETHERLANDS.
RI Locker, Jacomine Krijnse/E-1009-2016
CR AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63
   BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245
   BECKERS CJM, 1990, J BIOL CHEM, V265, P18298
   BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0
   CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P
   DENBOON JA, 1991, VIROLOGY, V182, P655, DOI 10.1016/0042-6822(91)90606-C
   DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452
   DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W
   Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G
   FLEMING JO, 1989, VIROLOGY, V168, P162, DOI 10.1016/0042-6822(89)90415-7
   GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6
   GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835
   Griffiths G, 1992, Semin Cell Biol, V3, P367, DOI 10.1016/1043-4682(92)90022-N
   GRIFFITHS G, 1993, FINE STRUCTURE IMMUN, P417
   HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q
   HENDRICKS LC, 1991, J BIOL CHEM, V266, P17559
   HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795
   HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0
   HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425
   IHIDA K, 1991, HISTOCHEMISTRY, V95, P329, DOI 10.1007/BF00266959
   JAMIESON JD, 1967, J CELL BIOL, V34, P577, DOI 10.1083/jcb.34.2.577
   KAARIAINEN L, 1980, J CELL BIOL, V87, P783, DOI 10.1083/jcb.87.3.783
   KRIJNSELOCKER J, 1992, J BIOL CHEM, V267, P14094
   LINDSEY JD, 1985, J NEUROSCI, V5, P3124
   LINDSEY JD, 1985, J NEUROSCI, V5, P3111
   LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221
   MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944
   MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5
   MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A
   NIEMANN H, 1984, EMBO J, V3, P665, DOI 10.1002/j.1460-2075.1984.tb01864.x
   OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49
   ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0
   PAVELKA M, 1985, J HISTOCHEM CYTOCHEM, V33, P905, DOI 10.1177/33.9.4020101
   PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245
   PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x
   PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2
   REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219
   ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399
   ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981
   ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981
   ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022
   SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021
   SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7
   SARASTE J, 1991, J CELL SCI, V100, P415
   SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O
   SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   TOOZE J, 1985, EUR J CELL BIOL, V37, P203
   TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475
   VANDERSLUIJS P, 1990, J CELL SCI, V95, P545
   WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0
   WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681
NR 53
TC 192
Z9 194
U1 1
U2 1
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD JAN
PY 1994
VL 124
IS 1-2
BP 55
EP 70
DI 10.1083/jcb.124.1.55
PG 16
WC Cell Biology
SC Cell Biology
GA MQ882
UT WOS:A1994MQ88200006
PM 8294506
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU SOMOGYI, P
   JENNER, AJ
   BRIERLEY, I
   INGLIS, SC
AF SOMOGYI, P
   JENNER, AJ
   BRIERLEY, I
   INGLIS, SC
TI RIBOSOMAL PAUSING DURING TRANSLATION OF AN RNA PSEUDOKNOT
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID EUKARYOTIC MESSENGER-RNA; ESCHERICHIA-COLI; FRAMESHIFTING SIGNAL;
   MUTATIONAL ANALYSIS; READ-THROUGH; VIRUS; POLYMERASE; REGION; INVITRO;
   CODON
AB The genomic RNA of the coronavirus infectious bronchitis virus contains an efficient ribosomal frameshift signal which comprises a heptanucleotide slippery sequence followed by an RNA pseudoknot structure. The presence of the pseudoknot is essential for high-efficiency frameshifting, and it has been suggested that its function may be to slow or stall the ribosome in the vicinity of the slippery sequence. To test this possibility, we have studied translational elongation in vitro on mRNAs engineered to contain a well-defined pseudoknot-forming sequence. Insertion of the pseudoknot at a specific location within the influenza virus PB1 mRNA resulted in the production of a new translational intermediate corresponding to the size expected for ribosomal arrest at the pseudoknot. The appearance of this protein was transient, indicating that it was a true paused intermediate rather than a dead-end product, and mutational analysis confirmed that its appearance was dependent on the presence of a pseudoknot structure within the mRNA. These observations raise the possibility that a pause is required for the frameshift process. The extent of pausing at the pseudoknot was compared with that observed at a sequence designed to form a simple stem-loop structure with the same base pairs as the pseudoknot. This structure proved to be a less effective barrier to the elongating ribosome than the pseudoknot and in addition was unable to direct efficient ribosomal frameshifting, as would be expected if pausing plays an important role in frameshifting. However, the stem-loop was still able to induce significant pausing, and so this effect alone may be insufficient to account for the contribution of the pseudoknot to frameshifting.
C1 UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.
FU Medical Research CouncilMedical Research Council UK (MRC)
   [MR/M011747/1]; Wellcome TrustWellcome Trust
CR ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   BRIERLEY I, 1991, J MOL BIOL, V220, P889, DOI 10.1016/0022-2836(91)90361-9
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   BRIERLEY I, UNPUB
   CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174
   DOTTO GP, 1981, VIROLOGY, V114, P463, DOI 10.1016/0042-6822(81)90226-9
   DRAPER DE, 1990, NATO ASI SERIES H, V49, P299
   FENG YX, 1992, J VIROL, V66, P5127, DOI 10.1128/JVI.66.8.5127-5132.1992
   GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215
   Hames BD, 1981, GEL ELECTROPHORESIS, P1
   HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8
   JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5
   JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1
   JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50
   JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R
   KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S
   KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850
   KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057
   KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   LINGELBACH K, 1988, NUCLEIC ACIDS RES, V16, P3405, DOI 10.1093/nar/16.8.3405
   MANS RMW, 1992, J MOL BIOL, V223, P221, DOI 10.1016/0022-2836(92)90727-2
   MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035
   MORIKAWA S, 1992, VIROLOGY, V186, P389, DOI 10.1016/0042-6822(92)90004-9
   RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6
   SNIJDER EJ, 1990, NUCLEIC ACIDS RES, V18, P4535, DOI 10.1093/nar/18.15.4535
   SORENSEN MA, 1989, J MOL BIOL, V207, P365, DOI 10.1016/0022-2836(89)90260-X
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   SZER W, 1970, Biochimica et Biophysica Acta, V224, P477, DOI 10.1016/0005-2787(70)90580-0
   TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2
   TSUCHIHASHI Z, 1991, NUCLEIC ACIDS RES, V19, P2457, DOI 10.1093/nar/19.9.2457
   TU CL, 1992, P NATL ACAD SCI USA, V89, P8636, DOI 10.1073/pnas.89.18.8636
   TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167
   TZENG TH, 1992, J VIROL, V66, P999, DOI 10.1128/JVI.66.2.999-1006.1992
   VEIWELWY I, 1992, J MOL BIOL, V227, P463
   WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991
   WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x
   WYATT JR, 1990, J MOL BIOL, V214, P455, DOI 10.1016/0022-2836(90)90193-P
   YOUNG JF, 1983, ORIGIN PANDEMIC INFL, P129
NR 43
TC 192
Z9 195
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD NOV
PY 1993
VL 13
IS 11
BP 6931
EP 6940
DI 10.1128/MCB.13.11.6931
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA MC844
UT WOS:A1993MC84400032
PM 8413285
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Van den Hoogen, BG
   Osterhaus, ADME
   Fouchier, RAM
AF Van den Hoogen, BG
   Osterhaus, ADME
   Fouchier, RAM
TI Clinical impact and diagnosis of human metapneumovirus infection
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article; Proceedings Paper
CT International Congress on Respiratory Viruses
CY 2003
CL CHANTILLY, VIRGINIA
DE human metapneumovirus; epidemiology; clinical impact; diagnosis
ID ACUTE RESPIRATORY SYNDROME; TURKEY RHINOTRACHEITIS VIRUS; GENE ORDER
   DIFFERENT; SYNCYTIAL VIRUS; YOUNG-CHILDREN; TRACT INFECTIONS; DISEASE;
   CORONAVIRUS; ILLNESS; IDENTIFICATION
AB Background. Acute respiratory infections are the most common illnesses experienced by people of all ages worldwide. A portion of hitherto unexplained viral respiratory tract illnesses (RTIs) can now be attributed to the human meta-pneumovirus (hMPV), which was discovered in 2001. Several surveys on the burden of disease of hMPV infection have been conducted in various study groups and with different diagnostic assays. To estimate the impact of hMPV infection in a hospital setting and in the community at large, we reviewed these surveys to establish the burden of disease of hMPV infection.
   Methods. Published data and our own additional unpublished data on the clinical impact of hMPV infection were reviewed.
   Results and conclusion. Worldwide, hMPV infections account for at least 5 to 7% of the RTI in hospitalized children, but immunocompromised and elderly individuals are also at risk. In the general community hMPV infections account for at least 3% of patients who visit a general practitioner for RTI. The seasonality of hMPV infections resembles that for respiratory syncytial virus and influenza virus infections, with recurrent epidemics during the winter months. Clinical symptoms and laboratory findings associated with hMPV infection exhibit a spectrum virtually indistinguishable from those associated with respiratory syncytial virus disease. The development of diagnostic assays must take into account the existence of two hMPV serotypes.
C1 Erasmus Med Ctr, Dept Virol, NL-3015 GD Rotterdam, Netherlands.
RP Van den Hoogen, BG (reprint author), Erasmus Med Ctr, Dept Virol, Dr Molewaterplein 50, NL-3015 GD Rotterdam, Netherlands.
RI Fouchier, Ron A/A-1911-2014; van den Hoogen, Bernadette/J-5461-2013;
   Fouchier, Ron/Y-3755-2019
OI Fouchier, Ron A/0000-0001-8095-2869; Fouchier, Ron/0000-0001-8095-2869
CR Boivin G, 2003, EMERG INFECT DIS, V9, P634
   Boivin G, 2002, J INFECT DIS, V186, P1330, DOI 10.1086/344319
   Cane PA, 2003, BONE MARROW TRANSPL, V31, P309, DOI 10.1038/sj.bmt.1703849
   Cohen Lance, 2003, Semin Respir Infect, V18, P3, DOI 10.1053/srin.2003.50001
   Cote S, 2003, J CLIN MICROBIOL, V41, P3631, DOI 10.1128/JCM.41.8.3631-3635.2003
   Cox NJ, 1999, LANCET, V354, P1277, DOI 10.1016/S0140-6736(99)01241-6
   Crowe James E Jr, 2003, Paediatr Respir Rev, V4, P112, DOI 10.1016/S1526-0542(03)00033-2
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Esper F, 2003, PEDIATRICS, V111, P1407, DOI 10.1542/peds.111.6.1407
   Falsey AR, 2003, J INFECT DIS, V187, P785, DOI 10.1086/367901
   Falsey AR, 2000, CLIN MICROBIOL REV, V13, P371, DOI 10.1128/CMR.13.3.371-384.2000
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Freymuth F, 2003, PEDIATR INFECT DIS J, V22, P92, DOI 10.1097/00006454-200301000-00024
   Greensill J, 2003, EMERG INFECT DIS, V9, P372, DOI 10.3201/eid0903.020289
   Hicks KL, 2003, CANCER-AM CANCER SOC, V97, P2576, DOI 10.1002/cncr.11353
   Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402
   Jartti T, 2002, LANCET, V360, P1393, DOI 10.1016/S0140-6736(02)11391-2
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lina B, 1996, J CLIN MICROBIOL, V34, P3007, DOI 10.1128/JCM.34.12.3007-3011.1996
   LING R, 1992, J GEN VIROL, V73, P1709, DOI 10.1099/0022-1317-73-7-1709
   Mackay IM, 2003, J CLIN MICROBIOL, V41, P100, DOI 10.1128/JCM.41.1.100-105.2003
   Maggi F, 2003, J CLIN MICROBIOL, V41, P2987, DOI 10.1128/JCM.41.7.2987-2991.2003
   MONTO AS, 1971, AM J EPIDEMIOL, V94, P280, DOI 10.1093/oxfordjournals.aje.a121321
   Nissen MD, 2002, MED J AUSTRALIA, V176, P188, DOI 10.5694/j.1326-5377.2002.tb04354.x
   Osur SL, 2002, ANN ALLERG ASTHMA IM, V89, P553, DOI 10.1016/S1081-1206(10)62101-1
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, EMERG INFECT DIS, V9, P628
   Pelletier G, 2002, EMERG INFECT DIS, V8, P976, DOI 10.3201/eid0809.020238
   Peret TCT, 2002, J INFECT DIS, V185, P1660, DOI 10.1086/340518
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411
   Simoes EAF, 2003, PEDIATR INFECT DIS J, V22, pS13, DOI 10.1097/00006454-200302001-00003
   Stockton J, 2002, EMERG INFECT DIS, V8, P897, DOI 10.3201/eid0809.020084
   van den Hoogen BG, 2002, VIROLOGY, V295, P119, DOI 10.1006/viro.2001.1355
   van den Hoogen BG, 2003, J INFECT DIS, V188, P1571, DOI 10.1086/379200
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   Viazov S, 2003, J CLIN MICROBIOL, V41, P3043, DOI 10.1128/JCM.41.7.3043-3045.2003
   Vicente D, 2003, EMERG INFECT DIS, V9, P602, DOI 10.3201/eid0905.020615
   WILBRINK B, 2002, INFECT B, V9, P360
   YU Q, 1992, VIROLOGY, V186, P426, DOI 10.1016/0042-6822(92)90007-C
NR 41
TC 191
Z9 201
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JAN
PY 2004
VL 23
IS 1
SU S
BP S25
EP S32
DI 10.1097/01.inf.0000108190.09824.e8
PG 8
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 770LF
UT WOS:000188731700007
PM 14730267
DA 2020-04-03
ER

PT J
AU Kushner, DB
   Lindenbach, BD
   Grdzelishvili, VZ
   Noueiry, AO
   Paul, SM
   Ahlquist, P
AF Kushner, DB
   Lindenbach, BD
   Grdzelishvili, VZ
   Noueiry, AO
   Paul, SM
   Ahlquist, P
TI Systematic, genome-wide identification of host genes affecting
   replication of a positive-strand RNA virus
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; IN-VIVO; PROTEIN 1A;
   ENDOPLASMIC-RETICULUM; EXPRESSION; POLYMERASE; YEAST; COMPLEX; HELICASE
AB Positive-strand RNA viruses are the largest virus class and include many pathogens such as hepatitis C virus and the severe acute respiratory syndrome coronavirus (SARS). Brome mosaic virus (BMV) is a representative positive-strand RNA virus whose RNA replication, gene expression, and encapsidation have been reproduced in the yeast Saccharomyces cerevisiae. By using traditional yeast genetics, host genes have been identified that function in controlling BMV translation, selecting BMV RNAs as replication templates, activating the replication complex, maintaining a lipid composition required for membrane-associated RNA replication, and other steps. To more globally and systematically identify such host factors, we used engineered BMV derivatives to assay viral RNA replication in each strain of an ordered, genome-wide set of yeast single-gene deletion mutants. Each deletion strain was transformed to express BMV replicase proteins and a BMV RNA replication template with the capsid gene replaced by a luciferase reporter. Luciferase expression, which is dependent on viral RNA replication and RNA-dependent mRNA synthesis, was measured in intact yeast cells. Approximately 4,500 yeast deletion strains (approximate to80% of yeast genes) were screened in duplicate and selected strains analyzed further. This functional genomics approach revealed nearly 100 genes whose absence inhibited or stimulated BMV RNA replication and/or gene expression by 3- to >25-fold. Several of these genes were shown previously to function in BMV replication, validating the approach. Newly identified genes include some in RNA, protein, or membrane modification pathways and genes of unknown function. The results further illuminate virus and cell pathways. Further refinement of virus screening likely will reveal contributions from additional host genes.
C1 Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA.
   Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA.
RP Ahlquist, P (reprint author), Univ Wisconsin, Inst Mol Virol, 1525 Linden Dr, Madison, WI 53706 USA.
OI Kushner, David/0000-0002-6260-5094
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32
   CA09075, T32 CA009075]; NIGMS NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [R01 GM035072, R37
   GM035072]
CR Ahlquist P, 2003, J VIROL, V77, P8181, DOI 10.1128/JVI.77.15.8181-8186.2003
   Ahola T, 2000, J VIROL, V74, P8803, DOI 10.1128/JVI.74.19.8803-8811.2000
   Araki Y, 2001, EMBO J, V20, P4684, DOI 10.1093/emboj/20.17.4684
   Benard L, 1999, J VIROL, V73, P2893, DOI 10.1128/JVI.73.4.2893-2900.1999
   Brachmann CB, 1998, YEAST, V14, P115
   CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659
   Chen JB, 2000, J VIROL, V74, P4310, DOI 10.1128/JVI.74.9.4310-4318.2000
   Coller JM, 2001, RNA, V7, P1717, DOI 10.1017/S135583820101994X
   DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967
   Diez J, 2000, P NATL ACAD SCI USA, V97, P3913, DOI 10.1073/pnas.080072997
   Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144
   Fischer N, 2002, EMBO J, V21, P2788, DOI 10.1093/emboj/21.11.2788
   FRENCH R, 1986, SCIENCE, V231, P1294, DOI 10.1126/science.231.4743.1294
   Gaigg B, 2001, MOL BIOL CELL, V12, P1147, DOI 10.1091/mbc.12.4.1147
   Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276
   Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198
   GUTHRIE C, 1991, METHODS ENZYMOL, V194
   Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5
   Ishikawa M, 1997, P NATL ACAD SCI USA, V94, P13810, DOI 10.1073/pnas.94.25.13810
   Ishikawa M, 1997, J VIROL, V71, P7781, DOI 10.1128/JVI.71.10.7781-7790.1997
   IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4
   JANDA M, 1993, CELL, V72, P961, DOI 10.1016/0092-8674(93)90584-D
   JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440
   Kao CC, 2000, MOL PLANT PATHOL, V1, P91, DOI 10.1046/j.1364-3703.2000.00017.x
   Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644
   Kim SH, 2002, EMBO J, V21, P2292, DOI 10.1093/emboj/21.9.2292
   Krol MA, 1999, P NATL ACAD SCI USA, V96, P13650, DOI 10.1073/pnas.96.24.13650
   Lai MMC, 1998, VIROLOGY, V244, P1, DOI 10.1006/viro.1998.9098
   Lee WM, 2003, J VIROL, V77, P12819, DOI 10.1128/JVI.77.23.12819-12828.2003
   Lee WM, 2001, J VIROL, V75, P2097, DOI 10.1128/JVI.75.5.2097-2106.2001
   MascorroGallardo JO, 1996, GENE, V172, P169, DOI 10.1016/0378-1119(96)00059-5
   MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767
   Noueiry AO, 2000, P NATL ACAD SCI USA, V97, P12985, DOI 10.1073/pnas.240460897
   Noueiry AO, 2003, ANNU REV PHYTOPATHOL, V41, P77, DOI 10.1146/annurev.phyto.41.052002.095717
   Noueiry AO, 2003, MOL CELL BIOL, V23, P4094, DOI 10.1128/MCB.23.12.4094-4106.2003
   RestrepoHartwig MA, 1996, J VIROL, V70, P8908, DOI 10.1128/JVI.70.12.8908-8916.1996
   Schwartz M, 2002, MOL CELL, V9, P505, DOI 10.1016/S1097-2765(02)00474-4
   SIKORSKI RS, 1989, GENETICS, V122, P19
   Srikantha T, 1996, J BACTERIOL, V178, P121, DOI 10.1128/jb.178.1.121-129.1996
   Sullivan ML, 1999, J VIROL, V73, P2622, DOI 10.1128/JVI.73.4.2622-2632.1999
   Tomita Y, 2003, J VIROL, V77, P2990, DOI 10.1128/JVI.77.5.2990-2997.2003
   Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893
   VIEITES JM, 1994, YEAST, V10, P1321, DOI 10.1002/yea.320101009
   Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996
   Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901
NR 45
TC 190
Z9 211
U1 0
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 23
PY 2003
VL 100
IS 26
BP 15764
EP 15769
DI 10.1073/pnas.2536857100
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 757GL
UT WOS:000187554600086
PM 14671320
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Varia, M
   Wilson, S
   Sarwal, S
   McGeer, A
   Gournis, E
   Galanis, E
   Henry, B
AF Varia, M
   Wilson, S
   Sarwal, S
   McGeer, A
   Gournis, E
   Galanis, E
   Henry, B
CA Hosp Outbreak Investigation Team
TI Investigation of a nosocomial outbreak of severe acute respiratory
   syndrome (SARS) in Toronto, Canada
SO CANADIAN MEDICAL ASSOCIATION JOURNAL
LA English
DT Article
ID HONG-KONG; IDENTIFICATION; CORONAVIRUS
AB Background: Severe acute respiratory syndrome (SARS) was introduced into Canada by a visitor to Hong Kong who returned to Toronto on Feb. 23, 2003. Transmission to a family member who was later admitted to a community hospital in Toronto led to a large nosocomial outbreak. In this report we summarize the preliminary results of the epidemiological investigation into the transmission of SARS between 128 cases associated with this hospital outbreak.
   Methods: We collected epidemiologic data on 128 probable and suspect cases of SARS associated with the hospital outbreak, including those who became infected in hospital and the next generation of illness arising among their contacts. Incubation periods were calculated based on cases with a single known exposure. Transmission chains from the index family to hospital contacts and within the hospital were mapped. Attack rates were calculated for nurses in 3 hospital wards where transmission occurred.
   Results: The cases ranged in age from 21 months to 86 years; 60.2% were female. Seventeen deaths were reported (case-fatality rate 13.3%). Of the identified cases, 36.7% were hospital staff. Other cases were household or social contacts of SARS cases (29.6%), hospital patients (14.1%), visitors (14.1 %) or other health care workers (5.5%). Of the 128 cases, 120 (93.8%) had documented contact with a SARS case or with a ward where there was a known SARS case. The remaining 8 cases without documented exposure are believed to have had exposure to an unidentified case and remain under investigation. The attack rates among nurses who worked in the emergency department, intensive care unit and coronary care unit ranged from 10.3% to 60.0%. Based on 42 of the 128 cases with a single known contact with a SARS case, the mean incubation period was 5 days (range 2 to 10 days).
   Interpretation: Evidence to date suggests that SARS is a severe respiratory illness spread mainly by respiratory droplets. There has been no evidence of further transmission within the hospital after the elapse of 2 full incubation periods (20 days).
C1 Toronto Publ Hlth, Toronto, ON M5B 1W2, Canada.
   Hlth Canada, Canadian Field Epidemiol Program, Ottawa, ON K1A 0L2, Canada.
   Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
RP Henry, B (reprint author), Toronto Publ Hlth, 277 Victoria St, Toronto, ON M5B 1W2, Canada.
RI mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020
OI mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137
CR Avendano M, 2003, CAN MED ASSOC J, V168, P1649
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Dwosh HA, 2003, CAN MED ASSOC J, V168, P1415
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Kondro W, 2003, LANCET, V361, P1876, DOI 10.1016/S0140-6736(03)13546-5
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6
   Spurgeon D, 2003, BRIT MED J, V326, P1162, DOI 10.1136/bmj.326.7400.1162-a
   Stohr K, 2003, LANCET, V361, P1730, DOI 10.1016/S0140-6736(03)13376-4
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   2003, CAN COMMUN DIS REP, V29, P71
   2003, MMWR MORBIT MORTAL W, V52, P433
   2003, MMWR MORBID MORTAL W, V52, P241
NR 18
TC 189
Z9 193
U1 2
U2 15
PU CANADIAN MEDICAL ASSOCIATION
PI OTTAWA
PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA
SN 0820-3946
J9 CAN MED ASSOC J
JI Can. Med. Assoc. J.
PD AUG 19
PY 2003
VL 169
IS 4
BP 285
EP 292
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 713JD
UT WOS:000184853200016
PM 12925421
DA 2020-04-03
ER

PT J
AU BRIERLEY, I
   JENNER, AJ
   INGLIS, SC
AF BRIERLEY, I
   JENNER, AJ
   INGLIS, SC
TI MUTATIONAL ANALYSIS OF THE SLIPPERY-SEQUENCE COMPONENT OF A CORONAVIRUS
   RIBOSOMAL FRAMESHIFTING SIGNAL
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE RIBOSOMAL FRAMESHIFTING; SLIPPERY SEQUENCE; TRANSFER RNA; FRAMESHIFT
   DIRECTION; RNA PSEUDOKNOT
ID COMPLETE NUCLEOTIDE-SEQUENCE; MAMMARY-TUMOR VIRUS; MURINE
   LEUKEMIA-VIRUS; TRANSFER-RNA; PROTEIN-SYNTHESIS; PLASMID DNA; GAG; POL;
   GENE; TRANSLATION
C1 CANTAB PHARMACEUT RES LTD, CAMBRIDGE CB4 4GN, ENGLAND.
RP BRIERLEY, I (reprint author), UNIV CAMBRIDGE, DEPT PATHOL, DIV VIROL, TENNIS COURT RD, CAMBRIDGE CB2 1QP, ENGLAND.
CR ATKINS JF, 1983, EMBO J, V2, P1345, DOI 10.1002/j.1460-2075.1983.tb01590.x
   ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
   BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BRIERLEY I, 1991, J MOL BIOL, V220, P889, DOI 10.1016/0022-2836(91)90361-9
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   CHAKRABURTTY K, 1975, NUCLEIC ACIDS RES, V2, P2069, DOI 10.1093/nar/2.11.2069
   CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713
   CHEN EY, 1978, BIOCHEM BIOPH RES CO, V82, P235, DOI 10.1016/0006-291X(78)90601-0
   CHEN EY, 1980, BIOCHIM BIOPHYS ACTA, V610, P272, DOI 10.1016/0005-2787(80)90009-X
   CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645
   DIGARD P, 1989, VIROLOGY, V171, P162, DOI 10.1016/0042-6822(89)90523-0
   DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174
   DOTTO GP, 1981, VIROLOGY, V114, P463, DOI 10.1016/0042-6822(81)90226-9
   DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4
   FOX TD, 1980, NATURE, V288, P60, DOI 10.1038/288060a0
   Hames BD, 1981, GEL ELECTROPHORESIS, P1
   HATFIELD D, 1989, VIROLOGY, V173, P736, DOI 10.1016/0042-6822(89)90589-8
   HATFIELD D, 1990, TRENDS BIOCHEM SCI, V15, P186, DOI 10.1016/0968-0004(90)90159-9
   HATFIELD DL, 1990, CRIT REV BIOCHEM MOL, V25, P71, DOI 10.3109/10409239009090606
   HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041
   HONIGMAN A, 1991, VIROLOGY, V183, P313, DOI 10.1016/0042-6822(91)90144-Z
   INGLIS SC, 1990, POSTTRANSCRIPTIONAL, V49, P603
   JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298
   JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054
   JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0
   JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1
   KEITH G, 1978, BIOCHIM BIOPHYS ACTA, V517, P133, DOI 10.1016/0005-2787(78)90041-2
   KINGSMAN AJ, 1990, POSTTRANSCRIPTIONAL, V49, P623
   KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057
   KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488
   LIN FK, 1980, J BIOL CHEM, V255, P6020
   LUSTIG F, 1981, J BIOL CHEM, V256, P2635
   MADHANI HD, 1988, CONTROL OF HUMAN RETROVIRUS GENE EXPRESSION, P119
   MANIATIS T, 1982, MOL CLONING
   MEIER F, 1985, EMBO J, V4, P823, DOI 10.1002/j.1460-2075.1985.tb03704.x
   MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987
   PIRTLE R, 1980, NUCLEIC ACIDS RES, V8, P805
   PLEIJ CWA, 1989, METHOD ENZYMOL, V180, P289
   RABA M, 1979, EUR J BIOCHEM, V97, P305, DOI 10.1111/j.1432-1033.1979.tb13115.x
   ROE BA, 1979, NUCLEIC ACIDS RES, V6, P673, DOI 10.1093/nar/6.2.673
   ROE BA, 1975, BIOCHEM BIOPH RES CO, V66, P1097, DOI 10.1016/0006-291X(75)90470-2
   RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1
   SPRINZL M, 1983, MODIFIED NUCLEOSIDES, V2, P129
   ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404
   TSUCHIHASHI Z, 1991, NUCLEIC ACIDS RES, V19, P2457, DOI 10.1093/nar/19.9.2457
   TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167
   WEISS R B, 1989, New Biologist, V1, P159
   WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991
   WILSON W, 1988, CELL, V55, P1159, DOI 10.1016/0092-8674(88)90260-7
   XIONG Z, 1989, VIROLOGY, V171, P543, DOI 10.1016/0042-6822(89)90624-7
   YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9
   YOKOYAMA S, 1985, P NATL ACAD SCI USA, V82, P4905, DOI 10.1073/pnas.82.15.4905
   YOUNG JF, 1983, ORIGIN PANDEMIC INFL, P129
NR 60
TC 189
Z9 192
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD SEP 20
PY 1992
VL 227
IS 2
BP 463
EP 479
DI 10.1016/0022-2836(92)90901-U
PG 17
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA JQ373
UT WOS:A1992JQ37300012
PM 1404364
DA 2020-04-03
ER

PT J
AU SETHNA, PB
   HUNG, SL
   BRIAN, DA
AF SETHNA, PB
   HUNG, SL
   BRIAN, DA
TI CORONAVIRUS SUBGENOMIC MINUS-STRAND RNAS AND THE POTENTIAL FOR
   MESSENGER-RNA REPLICONS
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
C1 UNIV TENNESSEE,DEPT MICROBIOL,KNOXVILLE,TN 37996.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI14367, R01 AI014367]
CR BALTIMORE D, 1971, BACTERIOL REV, V35, P235, DOI 10.1128/MMBR.35.3.235-241.1971
   BALTIMORE D, 1968, J MOL BIOL, V32, P359, DOI 10.1016/0022-2836(68)90015-6
   BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BRIAN DA, 1980, J VIROL, V34, P410, DOI 10.1128/JVI.34.2.410-415.1980
   BROWN TDK, 1986, J GEN VIROL, V67, P221, DOI 10.1099/0022-1317-67-2-221
   BROWN TDK, 1984, J GEN VIROL, V65, P1437, DOI 10.1099/0022-1317-65-8-1437
   BUDZILOWICZ CJ, 1985, J VIROL, V53, P834, DOI 10.1128/JVI.53.3.834-840.1985
   BUDZILOWICZ CJ, 1987, VIROLOGY, V157, P509, DOI 10.1016/0042-6822(87)90293-5
   DENNIS DE, 1982, J VIROL, V42, P153, DOI 10.1128/JVI.42.1.153-164.1982
   DENNISON M, 1987, VIROLOGY, V157, P565
   HOLLAND JJ, 1983, VIROLOGY, P77
   JACOBS L, 1986, J VIROL, V57, P1010, DOI 10.1128/JVI.57.3.1010-1015.1986
   JACOBS L, 1987, VIRUS RES, V8, P363, DOI 10.1016/0168-1702(87)90008-6
   KAPKE P A, 1989, Virus Genes, V2, P293, DOI 10.1007/BF00125345
   KAPKE PA, 1988, VIROLOGY, V165, P367, DOI 10.1016/0042-6822(88)90581-8
   KAPKE PA, 1986, VIROLOGY, V151, P41, DOI 10.1016/0042-6822(86)90102-9
   KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   LAI MMC, 1987, COLD SPRING HARB SYM, V52, P359, DOI 10.1101/SQB.1987.052.01.041
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   LAUDE H, 1987, J GEN VIROL, V68, P1687, DOI 10.1099/0022-1317-68-6-1687
   LEIBOWITZ JL, 1982, J VIROL, V43, P905, DOI 10.1128/JVI.43.3.905-913.1982
   LEIBOWITZ JL, 1988, VIROLOGY, V164, P156, DOI 10.1016/0042-6822(88)90631-9
   MANIATIS T, 1982, MOL CLONING LABORATO, P122
   Perrault J, 1981, Curr Top Microbiol Immunol, V93, P151
   RASSCHAERT D, 1987, J GEN VIROL, V68, P1883, DOI 10.1099/0022-1317-68-7-1883
   SCHOCHETMAN G, 1977, VIROLOGY, V77, P772, DOI 10.1016/0042-6822(77)90498-6
   SHIEH CK, 1987, VIROLOGY, V156, P321, DOI 10.1016/0042-6822(87)90412-0
   SIMMONS DT, 1972, J MOL BIOL, V71, P615
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   SPAAN WJM, 1982, J VIROL, V42, P432, DOI 10.1128/JVI.42.2.432-439.1982
   STERN DF, 1980, J VIROL, V36, P440, DOI 10.1128/JVI.36.2.440-449.1980
   STRAUSS EG, 1983, CURR TOP MICROBIOL, V105, P1
   TUNG FYT, 1987, THESIS U TENNESSEE K
   WEGE H, 1978, J GEN VIROL, V41, P217, DOI 10.1099/0022-1317-41-2-217
NR 37
TC 189
Z9 198
U1 0
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL
PY 1989
VL 86
IS 14
BP 5626
EP 5630
DI 10.1073/pnas.86.14.5626
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG359
UT WOS:A1989AG35900087
PM 2546161
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Berkley, JA
   Munywoki, P
   Ngama, M
   Kazungu, S
   Abwao, J
   Bett, A
   Lassauniere, R
   Kresfelder, T
   Cane, PA
   Venter, M
   Scott, JAG
   Nokes, DJ
AF Berkley, James A.
   Munywoki, Patrick
   Ngama, Mwanajuma
   Kazungu, Sidi
   Abwao, John
   Bett, Anne
   Lassauniere, Ria
   Kresfelder, Tina
   Cane, Patricia A.
   Venter, Marietjie
   Scott, J. Anthony G.
   Nokes, D. James
TI Viral Etiology of Severe Pneumonia Among Kenyan Infants and Children
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; INFLUENZAE TYPE-B; GAMBIAN CHILDREN;
   VACCINE CANDIDATE; CONJUGATE VACCINE; TRACT INFECTIONS; KILIFI DISTRICT;
   IMMUNIZATION; DISEASE; LIVE
AB Context Pneumonia is the leading cause of childhood death in sub-Saharan Africa. Comparative estimates of the contribution of causative pathogens to the burden of disease are essential for targeted vaccine development.
   Objective To determine the viral etiology of severe pneumonia among infants and children at a rural Kenyan hospital using comprehensive and sensitive molecular diagnostic techniques.
   Design, Setting, and Participants Prospective observational and case-control study during 2007 in a rural Kenyan district hospital. Participants were children aged 1 day to 12 years, residing in a systematically enumerated catchment area, and who either were admitted to Kilifi District Hospital meeting World Health Organization clinical criteria for severe pneumonia or very severe pneumonia; (2) presented with mild upper respiratory tract infection but were not admitted; or (3) were well infants and children attending for immunization.
   Main Outcome Measures The presence of respiratory viruses and the odds ratio for admission with severe disease.
   Results Of 922 eligible admitted patients, 759 were sampled (82% [median age, 9 months]). One or more respiratory viruses were detected in 425 of the 759 sampled (56% [95% confidence interval {CI}, 52%-60%]). Respiratory syncytial virus (RSV) was detected in 260 participants (34% [95% CI, 31%-38%]) and other respiratory viruses were detected in 219 participants (29%; 95% CI, 26%-32%), the most common being Human coronavirus 229E (n=51 [6.7%]), influenza type A (n=44 [5.8%]), Parainfluenza type 3 (n=29 [3.8%]), Human adenovirus (n=29 [3.8%]), and Human metapneumovirus (n=23 [3.0%]). Compared with well control participants, detection of RSV was associated with severe disease (5% in control participants; adjusted odds ratio, 6.11 [95% CI, 1.65-22.6]) while collectively, other respiratory viruses were not associated with severe disease (23% in control participants; adjusted odds ratio, 1.27 [95% CI, 0.64-2.52]).
   Conclusion In a sample of Kenyan infants and children admitted with severe pneumonia to a rural hospital, RSV was the predominant viral pathogen. JAMA. 2010;303(20):2051-2057 www.jama.com
C1 [Berkley, James A.; Munywoki, Patrick; Ngama, Mwanajuma; Kazungu, Sidi; Abwao, John; Bett, Anne; Scott, J. Anthony G.; Nokes, D. James] Ctr Geog Med Res Coast, Kenya Med Res Inst, Kilifi, Kenya.
   [Berkley, James A.; Scott, J. Anthony G.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Lassauniere, Ria; Kresfelder, Tina; Venter, Marietjie] Univ Pretoria, Dept Med Virol, Fac Hlth Sci, Resp & Zoonot Virus Programme, ZA-0001 Pretoria, South Africa.
   [Cane, Patricia A.] Hlth Protect Agcy, Ctr Infect, London, England.
   [Venter, Marietjie] Natl Inst Communicable Dis, Resp Virus Unit, Johannesburg, South Africa.
   [Nokes, D. James] Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.
RP Berkley, JA (reprint author), POB 230, Kilifi 80108, Kenya.
EM jberkley@kilifi.kemri-wellcome.org
RI Venter, Marietjie/H-3032-2011; Venter, Marietjie/P-9604-2016
OI Venter, Marietjie/0000-0003-2696-824X; Lassauniere,
   Ria/0000-0002-3910-7185; Munywoki, Patrick K./0000-0001-9419-7155;
   Berkley, James/0000-0002-1236-849X
FU Wellcome Trust (Great Britain)Wellcome Trust [081186]
FX The study was funded by a project grant (081186) from the Wellcome Trust
   (Great Britain). Drs Berkley, Scott, and Nokes report receipt of support
   by fellowships from the Wellcome Trust (Great Britain).
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Albargish K A, 1999, East Mediterr Health J, V5, P941
   [Anonymous], 2005, POCK BOOK HOSP CAR C
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Cowgill KD, 2006, JAMA-J AM MED ASSOC, V296, P671, DOI 10.1001/jama.296.6.671
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   DAGAN R, 1993, PEDIATR INFECT DIS J, V12, P381, DOI 10.1097/00006454-199305000-00006
   FLIESS JL, 1981, STAT METHODS RATES P
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   Johnson B R, 1993, West Afr J Med, V12, P11
   Karron RA, 2005, J INFECT DIS, V191, P1093, DOI 10.1086/427813
   Kuypers J, 2004, J CLIN VIROL, V31, P123, DOI 10.1016/j.jcv.2004.03.018
   Lassauniere R, 2010, J VIROL METHODS, V165, P254, DOI 10.1016/j.jviromet.2010.02.005
   Loscertales MP, 2002, PEDIATR INFECT DIS J, V21, P148, DOI 10.1097/00006454-200202000-00013
   Mahony JB, 2008, CLIN MICROBIOL REV, V21, P716, DOI 10.1128/CMR.00037-07
   Mulholland EK, 1999, PEDIATR INFECT DIS J, V18, pS35, DOI 10.1097/00006454-199910001-00007
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   Mulholland K, 1997, LANCET, V350, P524
   *NAT I HLTH CLIN T, STUD EV SAF TOL IMM
   Ndiritu M, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-132
   Nokes DJ, 2008, CLIN INFECT DIS, V46, P50, DOI 10.1086/524019
   Nokes DJ, 2009, CLIN INFECT DIS, V49, P1341, DOI 10.1086/606055
   Nokes DJ, 2004, J INFECT DIS, V190, P1828, DOI 10.1086/425040
   Nokes JD, 2008, CURR OPIN INFECT DIS, V21, P639, DOI 10.1097/QCO.0b013e3283184245
   PHILLIPS P A, 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P373
   Schmidt AC, 2001, J VIROL, V75, P4594, DOI 10.1128/JVI.75.10.4594-4603.2001
   Scott JAG, 2008, PLOS MED, V5, P548, DOI 10.1371/journal.pmed.0050086
   SOBESLAVSKY O, 1977, B WORLD HEALTH ORGAN, V55, P625
   Stempel HE, 2009, ACTA PAEDIATR, V98, P123, DOI 10.1111/j.1651-2227.2008.01023.x
   Vieira Sandra E., 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P125, DOI 10.1590/S0036-46652001000300002
   Wright PF, 2007, VACCINE, V25, P7372, DOI 10.1016/j.vaccine.2007.08.014
   Wright PF, 2000, J INFECT DIS, V182, P1331, DOI 10.1086/315859
NR 33
TC 187
Z9 198
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 26
PY 2010
VL 303
IS 20
BP 2051
EP 2057
DI 10.1001/jama.2010.675
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 600VY
UT WOS:000278018200029
PM 20501927
OA Green Accepted, Bronze
DA 2020-04-03
ER

PT J
AU DVEKSLER, GS
   DIEFFENBACH, CW
   CARDELLICHIO, CB
   MCCUAIG, K
   PENSIERO, MN
   JIANG, GS
   BEAUCHEMIN, N
   HOLMES, KV
AF DVEKSLER, GS
   DIEFFENBACH, CW
   CARDELLICHIO, CB
   MCCUAIG, K
   PENSIERO, MN
   JIANG, GS
   BEAUCHEMIN, N
   HOLMES, KV
TI SEVERAL MEMBERS OF THE MOUSE CARCINOEMBRYONIC ANTIGEN-RELATED
   GLYCOPROTEIN FAMILY ARE FUNCTIONAL RECEPTORS FOR THE CORONAVIRUS MOUSE
   HEPATITIS VIRUS-A59
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CELL-ADHESION MOLECULE; NERVOUS-SYSTEM DISEASE; IMMUNOGLOBULIN
   SUPERFAMILY; BILIARY GLYCOPROTEIN; GENETIC-RESISTANCE; MURINE
   CORONAVIRUS; ECTO-ATPASE; STRAIN JHM; EXPRESSION; REPLICATION
AB Mouse hepatitis virus-A59 (MHV-A59), a murine coronavirus, can utilize as a cellular receptor MHVR, a murine glycoprotein in the biliary glycoprotein (BGP) subfamily of the carcinoembryonic antigen (CEA) family in the immunoglobulin superfamily (G. S. Dveksler, M. N. Pensiero, C. B. Cardellichio, R. K. Williams, G.-S. Jiang, K. V. Holmes, and C. W. Dieffenbach, J. Virol. 65:6881-6891, 1991). Several different BGP isoforms are expressed in tissues of different mouse strains, and we have explored which of these glycoproteins can serve as functional receptors for MHV-A59. cDNA cloning, RNA-mediated polymerase chain reaction analysis, and Western immunoblotting with a monoclonal antibody, CC1, specific for the N-terminal domain of MHVR showed that the inbred mouse strains BALB/c, C3H, and C57BL/6 expressed transcripts and proteins of the MHVR isoform and/or its splice variants but not the mmCGM2 isoform. In contrast, adult SJL/J mice, which are resistant to infection with MHV-A59, express transcripts and proteins only of the mmCGM2-related isoforms, not MHVR. These data are compatible with the hypothesis that the MHVR and mmCGM2 glycoproteins may be encoded by different alleles of the same gene. We studied binding of anti-MHVR antibodies or MHV-A59 virions to proteins encoded by transcripts of MHVR and mmCGM2 and two splice variants of MHVR, one containing two immunoglobulin-like domains [MHVR(2d)) and the other with four domains as in MHVR but with a longer cytoplasmic domain [MHVR(4d)L]. We found that the three isoforms tested could serve as functional receptors for MHV-A59, although only isoforms that include the N-terminal domain of MHVR were recognized by monoclonal antibody CC1 in immunoblots or by MHV-A59 virions in virus overlay protein blot assays. Thus, in addition to MHVR, both the two-domain isoforms, mmCGM2 and MHVR(2d), and the MHVR(4d)L isoform served as functional virus receptors for MHV-A59. This is the first report of multiple related glycoprotein isoforms that can serve as functional receptors for a single enveloped virus.
C1 UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814.
   MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,QUEBEC,CANADA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-25231]
CR ARNHEITER H, 1982, J IMMUNOL, V129, P1275
   AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J
   BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267
   Barthold S. W., 1986, Viral and mycoplasmal infections of laboratory rodents. Effects on biomedical research., P571
   BARTHOLD SW, 1986, ARCH VIROL, V91, P247, DOI 10.1007/BF01314284
   BEAUCHEMIN N, 1989, CANCER RES, V49, P2017
   BEAUCHEMIN N, 1989, CARCINOEMBRYONIC ANT, P49
   BEDINGER P, 1988, NATURE, V334, P162, DOI 10.1038/334162a0
   BOYLE JF, 1987, J VIROL, V61, P185, DOI 10.1128/JVI.61.1.185-189.1987
   COMPTON SR, 1992, J VIROL, V66, P7420, DOI 10.1128/JVI.66.12.7420-7428.1992
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   DVEKSLER GS, UNPUB MOUSE CORONAVI
   KNOBLER RL, 1984, J GEN VIROL, V65, P1543, DOI 10.1099/0022-1317-65-9-1543
   LIN SH, 1989, J BIOL CHEM, V264, P14408
   MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X
   MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165
   MCCUAIG K, UNPUB CHARACTERIZATI
   MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9
   PENSIERO MN, 1988, J VIROL, V62, P696, DOI 10.1128/JVI.62.3.696-702.1988
   PENSIERO MN, 1992, J VIROL, V66, P4028, DOI 10.1128/JVI.66.7.4028-4039.1992
   ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527
   SMITH AL, 1991, J INFECT DIS, V163, P879, DOI 10.1093/infdis/163.4.879
   SMITH MS, 1984, J IMMUNOL, V133, P428
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   STAUNTON DE, 1992, J IMMUNOL, V148, P3271
   STOHLMAN SA, 1980, J IMMUNOL, V124, P1733
   STOHLMAN SA, 1978, IMMUNOGENETICS, V6, P277, DOI 10.1007/BF01563919
   STURMAN LS, 1972, INFECT IMMUN, V6, P501, DOI 10.1128/IAI.6.4.501-507.1972
   THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201
   THOMPSON J, 1992, GENOMICS, V12, P761, DOI 10.1016/0888-7543(92)90307-E
   TURBIDE C, 1991, J BIOL CHEM, V266, P309
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121
   WILLIAMS RK, 1990, J VIROL, V64, P3817, DOI 10.1128/JVI.64.8.3817-3823.1990
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585
NR 36
TC 187
Z9 193
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JAN
PY 1993
VL 67
IS 1
BP 1
EP 8
PG 8
WC Virology
SC Virology
GA KB970
UT WOS:A1993KB97000001
PM 8380065
DA 2020-04-03
ER

PT J
AU Khetsuriani, N
   Kazerouni, NN
   Erdman, DD
   Lu, XY
   Redd, SC
   Anderson, LJ
   Teague, WG
AF Khetsuriani, Nino
   Kazerouni, N. Neely
   Erdman, Dean D.
   Lu, Xiaoyan
   Redd, Stephen C.
   Anderson, Larry J.
   Teague, W. Gerald
TI Prevalence of viral respiratory tract infections in children with asthma
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article; Proceedings Paper
CT 100th International Conference of the American-Thoracic-Society
CY MAY 21-26, 2004
CL Orlando, FL
SP Amer Thorac Soc
DE respiratory viruses; asthma; asthma exacerbation; case-control study;
   PCR; rhinovirus
ID HUMAN METAPNEUMOVIRUS INFECTION; RHINOVIRUS INFECTIONS; SEPTEMBER
   EPIDEMIC; HUMAN BOCAVIRUS; YOUNG-CHILDREN; EXACERBATIONS; VIRUSES;
   ADULTS; ILLNESS; DISEASE
AB Background: Previous studies support a strong association between viral respiratory tract infections and asthma exacerbations. The effect of newly discovered viruses on asthma control is less well defined.
   Objective: We sought to determine the contribution of respiratory viruses to asthma exacerbations in children with a panel of PCR assays for common and newly discovered respiratory viruses.
   Methods: Respiratory specimens from children aged 2 to 17 years with asthma exacerbations (case patients, n = 65) and with well-controlled asthma (control subjects, n = 77), frequency matched by age and season of enrollment, were tested for rhinoviruses, enteroviruses, respiratory syncytial virus, human metapneumovirus, coronaviruses 229E and OC43, parainfluenza viruses 1 to 3, influenza viruses, adenoviruses, and human bocavirus.
   Results: Infection with respiratory viruses was associated with asthma exacerbations (63.1% in case patients vs 23.4% in control subjects; odds ratio, 5.6; 95% CI, 2.7- 11.6). Rhinovirus was by far the most prevalent virus (60% among case patients vs 18.2% among control subjects) and the only virus significantly associated with exacerbations (odds ratio, 6.8; 95% CI, 3.2-14.5). However, in children without clinically manifested viral respiratory tract illness, the prevalence of rhinovirus infection was similar in case patients (29.2%) versus control subjects (23.4%, P > .05). Other viruses detected included human metapneumovirus (4.6% in patients with acute asthma vs 2.6% in control subjects), enteroviruses (4.6% vs 0%), coronavirus 229E (0% vs 1.3%), and respiratory syncytial virus (1.5% vs 0%).
   Conclusion: Symptomatic rhinovirus infections are an important contributor to asthma exacerbations in children.
   Clinical implications: These results support the need for therapies effective against rhinovirus as a means to decrease asthma exacerbations.
C1 Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazard & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA.
   Emory Univ, Div Pulm Allergy Cyst Fibrosis & Sleep Med, Dept Pediat, Sch Med, Atlanta, GA 30322 USA.
RP Teague, WG (reprint author), Emory Pediat, Dept Pediat, 2015 Uppergate Dr, Atlanta, GA 30322 USA.
EM wteague@emory.edu
FU PHS HHSUnited States Public Health Service [200-1998-00103]
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453
   Bardin PG, 2000, EUR RESPIR J, V16, P980, DOI 10.1183/09031936.00.16598000
   BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679
   Carrat F, 2006, INTENS CARE MED, V32, P156, DOI 10.1007/s00134-005-2861-4
   CLARKE CW, 1979, THORAX, V34, P344, DOI 10.1136/thx.34.3.344
   Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9
   Erdman DD, 2003, J CLIN MICROBIOL, V41, P4298, DOI 10.1128/JCM.41.9.4298-4303.2003
   Foulongne V, 2006, EMERG INFECT DIS, V12, P862, DOI 10.3201/eid1205.051523
   Freymuth F, 1999, J CLIN VIROL, V13, P131, DOI 10.1016/S1386-6532(99)00030-X
   GEM JE, 1997, AM J RESP CRIT CARE, V155, P1872
   Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763
   Griffin Marie R, 2004, Pediatr Infect Dis J, V23, pS188, DOI 10.1097/01.inf.0000144660.53024.64
   GWALTNEY JM, 2000, MANDELL DOUGLAS BENN, P1940
   HALL CB, 2000, MANDELL DOUGLAS BENN, P1782
   HAMELIN ME, 2005, PEDIAT INFECT DIS S, V24, P203
   Hankinson JL, 2003, CHEST, V124, P1805, DOI 10.1378/chest.124.5.1805
   HARJU TH, 2006, THORAX
   Hayden FG, 2003, CLIN INFECT DIS, V36, P1523, DOI 10.1086/375069
   Heymann Peter W, 2005, Pediatr Infect Dis J, V24, pS217, DOI 10.1097/01.inf.0000188164.33856.f9
   Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006
   HOSMER DW, 2000, APPL LOGISTIC REGRES, P133
   Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027
   Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034
   Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Kluijver JC, 2003, AM J RESP CRIT CARE, V168, P1174, DOI 10.1164/rccm/200212-1520OC
   LAMBERT HP, 1972, BMJ-BRIT MED J, V3, P323, DOI 10.1136/bmj.3.5822.323
   Lu XY, 2006, J CLIN MICROBIOL, V44, P3231, DOI 10.1128/JCM.00889-06
   Ma XM, 2006, J CLIN MICROBIOL, V44, P1132, DOI 10.1128/JCM.44.3.1132-1134.2006
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   Oberste MS, 2004, J GEN VIROL, V85, P2577, DOI 10.1099/vir.0.79925-0
   Papadopoulos Nikolaos G, 2004, Paediatr Respir Rev, V5, P255, DOI 10.1016/j.prrv.2004.04.002
   PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x
   Pelaia G, 2006, RESP MED, V100, P775, DOI 10.1016/j.rmed.2005.08.025
   Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052
   Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411
   Schrag SJ, 2004, EMERG INFECT DIS, V10, P185, DOI 10.3201/eid1002.030752
   Turner RB, 2005, PEDIATR ANN, V34, P53, DOI 10.3928/0090-4481-20050101-12
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van Elden LJR, 2004, J INFECT DIS, V189, P652, DOI 10.1086/381207
   Venarske DL, 2006, J INFECT DIS, V193, P1536, DOI 10.1086/503809
   Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901
   Weinberger M, 2004, DRUG DISCOV TODAY, V9, P831, DOI 10.1016/S1359-6446(04)03239-8
   Williams JV, 2005, J INFECT DIS, V192, P1149, DOI 10.1086/444392
   Williams JV, 2005, J ALLERGY CLIN IMMUN, V115, P1311, DOI 10.1016/j.jaci.2005.02.001
   Winther B, 2006, J MED VIROL, V78, P644, DOI 10.1002/jmv.20588
   Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396
NR 50
TC 186
Z9 191
U1 0
U2 12
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2007
VL 119
IS 2
BP 314
EP 321
DI 10.1016/j.jaci.2006.08.041
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA 137YB
UT WOS:000244327900007
PM 17140648
DA 2020-04-03
ER

PT J
AU Mardassi, H
   Massie, B
   Dea, S
AF Mardassi, H
   Massie, B
   Dea, S
TI Intracellular synthesis, processing, and transport of proteins encoded
   by ORFs 5 to 7 of porcine reproductive and respiratory syndrome virus
SO VIROLOGY
LA English
DT Article
ID EQUINE ARTERITIS VIRUS; ISOLATE ATCC VR-2332; SYNDROME SIRS VIRUS;
   ENDOPLASMIC-RETICULUM; LELYSTAD VIRUS; SWINE INFERTILITY; LINKED
   OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; CELL-LINE; CORONAVIRUSES
AB Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), a small enveloped virus containing a positive-strand RNA genome, possesses at least three major structural proteins designated N, M, and 5. The N protein is considered as the major component of the nucleocapsid, whereas M and E are membrane-associated. Previous studies using peptide-specific antibodies assigned these proteins to ORFs 7, 6, and 5, respectively. In the present report, monospecific antisera raised against Escherichia coli-expressed ORFs 5, 6, and 7 products were used to study the synthesis and processing of PRRSV structural proteins in the highly permissive MARC-145 cell line, Treatment of viral proteins with various glycosidases showed that only E was modified by N-linked glycans. Pulse-chase experiments revealed that intracellular transport of the major envelope glycoprotein was delayed in the premedial Golgi compartmenl. During the first 30 min of chase, 5 undergoes a gradual downward shift of its apparent molecular weight, thought to result from trimming of the mannose-rich glycan structures, Once E is transported to the medial Golgi or proximal elements, some molecules undergo complete processing of all their high-mannose N-linked oligosaccharides to complex type, while in other molecules only a fraction of N-linked glycans are terminally glycosylated. These two differentially glycosylated forms of E were found to be incorporated into extracellular virions. In cells and virions, both M and 5 were shown to occur in heterodimeric complexes linked by disulfide bonds, The oligomerization process, as analyzed from pulse-chase experiments, showed that M and E are incorporated into M-E complexes with different kinetics and efficiencies, in a fashion similar to their counterparts in equine arteritis virus. Apparently, all steps of 5 protein N-glycans processing proceed after its association with M which occurs in the endoplasmic reticulum (ER). In the infected cells, E and M appear highly membrane-associated, while N is predominantly cytosolic. (C) 1996 Academic Press, Inc.
C1 UNIV QUEBEC, INST ARMAND FRAPPIER, CTR RECH VIROL, LAVAL, PQ H7N 4Z3, CANADA.
   INST RECH BIOTECHNOL, MONTREAL, PQ H4P 2R2, CANADA.
CR BENFIELD DA, 1992, J VET DIAGN INVEST, V4, P127, DOI 10.1177/104063879200400202
   BERGMAN LW, 1982, GLYCOCONJUGATES, V3, P82
   BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x
   COLLINS JE, 1992, J VET DIAGN INVEST, V4, P117, DOI 10.1177/104063879200400201
   CONZELMANN KK, 1993, VIROLOGY, V193, P329, DOI 10.1006/viro.1993.1129
   COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179
   DEA S, 1989, J GEN VIROL, V70, P1725, DOI 10.1099/0022-1317-70-7-1725
   DEA S, 1992, CAN VET J, V33, P801
   DEA S, 1989, AM J VET RES, V50, P1310
   DEA S, 1995, CORONA RELATED VIRUS, V380, P95
   DEVRIES AAF, 1995, J VIROL, V69, P4668, DOI 10.1128/JVI.69.8.4668-4674.1995
   DEVRIES AAF, 1995, J VIROL, V69, P3441, DOI 10.1128/JVI.69.6.3441-3448.1995
   DEVRIES AAF, 1992, J VIROL, V66, P6294, DOI 10.1128/JVI.66.11.6294-6303.1992
   DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164
   DUBOISDALCQ ME, 1984, ASSEMBLY RNA VIRUSES
   DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0
   FAABERG KS, 1995, VIROLOGY, V212, P512, DOI 10.1006/viro.1995.1509
   FAABERG KS, 1995, J VIROL, V69, P613, DOI 10.1128/JVI.69.1.613-617.1995
   GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0
   GODENY EK, 1995, J VIROL, V69, P2679, DOI 10.1128/JVI.69.4.2679-2683.1995
   HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913
   HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425
   KIM HS, 1993, ARCH VIROL, V133, P477, DOI 10.1007/BF01313785
   KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631
   LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720
   MAGNUSSON P, 1970, ARCH GES VIRUSFORSCH, V30, P105, DOI 10.1007/BF01250177
   MARDASSI H, 1994, CAN J VET RES, V58, P55
   MARDASSI H, 1995, ARCH VIROL, V140, P1405, DOI 10.1007/BF01322667
   MARDASSI H, 1994, J GEN VIROL, V75, P681, DOI 10.1099/0022-1317-75-3-681
   MEULENBERG JJM, 1995, VIROLOGY, V206, P155, DOI 10.1016/S0042-6822(95)80030-1
   MEULENBERG JJM, 1993, J GEN VIROL, V74, P1697, DOI 10.1099/0022-1317-74-8-1697
   MEULENBERG JJM, 1993, VIROLOGY, V192, P62, DOI 10.1006/viro.1993.1008
   MOUNIR S, 1995, CORONA RELATED VIRUS, V380, P317
   NELSON EA, 1993, J CLIN MICROBIOL, V31, P3184, DOI 10.1128/JCM.31.12.3184-3189.1993
   PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245
   PLAGEMANN PGW, 1992, ADV VIRUS RES, V41, P99, DOI 10.1016/S0065-3527(08)60036-6
   Pol J.M., 1992, AM ASS SWINE PRACT N, P29
   ROTTIER PJM, 1985, CORONAVINDAE, P115
   Sambrook J., 1989, MOL CLONING LAB MANU
   SCHLESINGER S, 1984, J BIOL CHEM, V259, P7597
   SCUDDER P, 1983, EUR J BIOCHEM, V168, P585
   SNIJDER EJ, 1993, ADV EXP MED BIOL, V342, P235
   TARENTINO AL, 1974, J BIOL CHEM, V249, P811
   TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028
   WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296
   WENSVOORT G, 1992, J VET DIAGN INVEST, V4, P134, DOI 10.1177/104063879200400203
NR 46
TC 186
Z9 211
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUL 1
PY 1996
VL 221
IS 1
BP 98
EP 112
DI 10.1006/viro.1996.0356
PG 15
WC Virology
SC Virology
GA UW442
UT WOS:A1996UW44200010
PM 8661418
DA 2020-04-03
ER

PT J
AU Shan, TL
   Li, LL
   Simmonds, P
   Wang, CL
   Moeser, A
   Delwart, E
AF Shan, Tongling
   Li, Linlin
   Simmonds, Peter
   Wang, Chunlin
   Moeser, Adam
   Delwart, Eric
TI The Fecal Virome of Pigs on a High-Density Farm
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID PORCINE CIRCOVIRUS TYPE-2; HOST GENETIC DIVERSITY; METAGENOMIC ANALYSIS;
   HUMAN BOCAVIRUS; GENOMIC ANALYSIS; ZOONOTIC ASPECTS; VIRUS EVOLUTION;
   VIRAL COMMUNITY; STOOL SAMPLES; UNITED-STATES
AB Swine are an important source of proteins worldwide but are subject to frequent viral outbreaks and numerous infections capable of infecting humans. Modern farming conditions may also increase viral transmission and potential zoonotic spread. We describe here the metagenomics-derived virome in the feces of 24 healthy and 12 diarrheic piglets on a high-density farm. An average of 4.2 different mammalian viruses were shed by healthy piglets, reflecting a high level of asymptomatic infections. Diarrheic pigs shed an average of 5.4 different mammalian viruses. Ninety-nine percent of the viral sequences were related to the RNA virus families Picornaviridae, Astroviridae, Coronaviridae, and Caliciviridae, while 1% were related to the small DNA virus families Circoviridae, and Parvoviridae. Porcine RNA viruses identified, in order of decreasing number of sequence reads, consisted of kobuviruses, astroviruses, enteroviruses, sapoviruses, sapeloviruses, coronaviruses, bocaviruses, and teschoviruses. The near-full genomes of multiple novel species of porcine astroviruses and bocaviruses were generated and phylogenetically analyzed. Multiple small circular DNA genomes encoding replicase proteins plus two highly divergent members of the Picornavirales order were also characterized. The possible origin of these viral genomes from pig-infecting protozoans and nematodes, based on closest sequence similarities, is discussed. In summary, an unbiased survey of viruses in the feces of intensely farmed animals revealed frequent coinfections with a highly diverse set of viruses providing favorable conditions for viral recombination. Viral surveys of animals can readily document the circulation of known and new viruses, facilitating the detection of emerging viruses and prospective evaluation of their pathogenic and zoonotic potentials.
C1 [Shan, Tongling; Li, Linlin; Delwart, Eric] BSRI, San Francisco, CA 94118 USA.
   [Shan, Tongling; Li, Linlin; Delwart, Eric] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Shan, Tongling] Shanghai Jiao Tong Univ, Zoonosis & Comparat Med Grp, Shanghai 200030, Peoples R China.
   [Shan, Tongling] Chinese Acad Agr Sci, Shanghai Vet Res Inst, Shanghai, Peoples R China.
   [Simmonds, Peter] Univ Edinburgh, Ctr Immunol Infect & Evolut, Edinburgh, Midlothian, Scotland.
   [Wang, Chunlin] Stanford Genome Technol Ctr, Stanford, CA USA.
   [Moeser, Adam] N Carolina State Univ, Coll Vet Med, Raleigh, NC USA.
RP Delwart, E (reprint author), BSRI, 270 Masonic Ave, San Francisco, CA 94118 USA.
EM delwarte@medicine.ucsf.edu
RI Li, Linlin/E-3335-2010
OI Simmonds, Peter/0000-0002-7964-4700; Delwart, Eric/0000-0002-6296-4484;
   Moeser, Adam/0000-0003-3068-627X
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL083254]; Blood Systems Research Institute;
   Shanghai Jiao Tong University; NSFNational Science Foundation (NSF)
   [CNS-0619926]
FX This work was supported by NHLBI grant R01HL083254 and the Blood Systems
   Research Institute (E.D.), Shanghai Jiao Tong University (T.S.), and NSF
   award CNS-0619926 to the Bio-X2 cluster at Stanford University for
   computing resources.
CR Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0
   Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Allander T, 2001, P NATL ACAD SCI USA, V98, P11609, DOI 10.1073/pnas.211424698
   Allander T, 2008, J CLIN VIROL, V41, P29, DOI 10.1016/j.jcv.2007.10.026
   Arthur JL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000391
   Bank-Wolf BR, 2010, VET MICROBIOL, V140, P204, DOI 10.1016/j.vetmic.2009.08.021
   Belyi VA, 2010, J VIROL, V84, P12458, DOI 10.1128/JVI.01789-10
   Blinkova O, 2010, J GEN VIROL, V91, P74, DOI 10.1099/vir.0.015446-0
   Blomstrom AL, 2009, VIRUS RES, V146, P125, DOI 10.1016/j.virusres.2009.09.006
   Blomstrom AL, 2010, J CLIN MICROBIOL, V48, P4392, DOI 10.1128/JCM.01040-10
   Blomstrom AL, 2010, VIRUS RES, V152, P59, DOI 10.1016/j.virusres.2010.06.004
   Breitbart M, 2003, J BACTERIOL, V185, P6220, DOI 10.1128/JB.185.20.6220-6223.2003
   Breitbart M, 2002, P NATL ACAD SCI USA, V99, P14250, DOI 10.1073/pnas.202488399
   Briese T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000455
   Brown KE, 2010, REV MED VIROL, V20, P231, DOI 10.1002/rmv.648
   Bull RA, 2007, J GEN VIROL, V88, P3347, DOI 10.1099/vir.0.83321-0
   Butler JE, 2009, DEV COMP IMMUNOL, V33, P321, DOI 10.1016/j.dci.2008.06.015
   Cann AJ, 2005, VIRUS GENES, V30, P151, DOI 10.1007/s11262-004-5624-3
   Ulloa JC, 2010, CAN J MICROBIOL, V56, P569, DOI [10.1139/W10-042, 10.1139/w10-042]
   Chen LH, 2009, EMERG INFECT DIS, V15, P1773, DOI 10.3201/eid1511.090945
   Cheng WX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013583
   Cheung AK, 2007, VIROLOGY, V363, P229, DOI 10.1016/j.virol.2007.01.017
   Cheung AK, 2010, ARCH VIROL, V155, P801, DOI 10.1007/s00705-010-0646-8
   Childs JE, 2009, MT SINAI J MED, V76, P421, DOI 10.1002/msj.20133
   Chiu CY, 2008, P NATL ACAD SCI USA, V105, P14124, DOI 10.1073/pnas.0805968105
   Costantini VP, 2007, APPL ENVIRON MICROB, V73, P5284, DOI 10.1128/AEM.00553-07
   Culley AI, 2003, NATURE, V424, P1054, DOI 10.1038/nature01886
   Culley AI, 2006, SCIENCE, V312, P1795, DOI 10.1126/science.1127404
   Curns AT, 2010, J INFECT DIS, V201, P1617, DOI 10.1086/652403
   Day JM, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-313
   Domingo E, 2010, VET RES, V41, DOI 10.1051/vetres/2010010
   Donaldson EF, 2010, J VIROL, V84, P13004, DOI 10.1128/JVI.01255-10
   Dunn CW, 2008, NATURE, V452, P745, DOI 10.1038/nature06614
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Elahi S, 2006, INFECT IMMUN, V74, P2619, DOI 10.1128/IAI.74.5.2619-2627.2006
   Elvinger F, 1996, VET MICROBIOL, V51, P229, DOI 10.1016/0378-1135(96)00037-5
   FAO OIE WHO UNICEF UNSIC and World Bank, 2008, CONTR ON WORLD ON HL
   Fauquet C. M., 2005, VIRUS TAXONOMY
   Felix MA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000586
   Finkbeiner SR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000011
   Finkbeiner SR, 2009, J VIROL, V83, P10836, DOI 10.1128/JVI.00998-09
   Finkbeiner SR, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-117
   Finsterbusch T, 2009, VIRUS RES, V143, P177, DOI 10.1016/j.virusres.2009.02.009
   Forrest Heather L., 2010, Animal Health Research Reviews, V11, P3, DOI 10.1017/S1466252310000071
   Gibbs MJ, 2006, MOL BIOL EVOL, V23, P1097, DOI 10.1093/molbev/msj122
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Haagmans BL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000557
   Hansman GS, 2007, REV MED VIROL, V17, P133, DOI 10.1002/rmv.533
   Haugegaard J, 2010, VET PARASITOL, V168, P156, DOI 10.1016/j.vetpar.2009.10.009
   Herikstad H, 2002, EPIDEMIOL INFECT, V129, P9, DOI 10.1017/S0950268801006628
   Hoelzer K, 2008, J VIROL, V82, P11096, DOI 10.1128/JVI.01003-08
   Indik S, 2006, VET MICROBIOL, V117, P276, DOI 10.1016/j.vetmic.2006.06.020
   Jonassen CM, 2003, VIRUS RES, V91, P195, DOI 10.1016/S0168-1702(02)00269-1
   Jonassen CM, 2001, J GEN VIROL, V82, P1061, DOI 10.1099/0022-1317-82-5-1061
   Kahn J, 2008, CURR OPIN PEDIATR, V20, P62, DOI 10.1097/MOP.0b013e3282f3f518
   Kapoor A, 2009, J GEN VIROL, V90, P2965, DOI 10.1099/vir.0.014449-0
   Kapoor A, 2009, J INFECT DIS, V199, P196, DOI 10.1086/595831
   Kapoor A, 2010, J INFECT DIS, V201, P1633, DOI 10.1086/652416
   Kapoor A, 2008, P NATL ACAD SCI USA, V105, P20482, DOI 10.1073/pnas.0807979105
   Katzourakis A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001191
   Kingsford C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006402
   Koonin EV, 2008, NAT REV MICROBIOL, V6, P925, DOI 10.1038/nrmicro2030
   Lau SKP, 2011, J GEN VIROL, V92, P2047, DOI 10.1099/vir.0.033688-0
   Lefeuvre P, 2009, J VIROL, V83, P2697, DOI 10.1128/JVI.02152-08
   Li LL, 2011, J VIROL, V85, P9909, DOI 10.1128/JVI.05026-11
   Li LL, 2011, J GEN VIROL, V92, P768, DOI 10.1099/vir.0.028704-0
   Li LL, 2010, J VIROL, V84, P6955, DOI 10.1128/JVI.00501-10
   Li LL, 2010, J VIROL, V84, P1674, DOI 10.1128/JVI.02109-09
   Lukashev AN, 2010, REV MED VIROL, V20, P327, DOI 10.1002/rmv.660
   Luo ZY, 2011, VET MICROBIOL, V149, P316, DOI 10.1016/j.vetmic.2010.11.026
   Manteufel J, 2008, INTERVIROLOGY, V51, P328, DOI 10.1159/000173734
   Martella V, 2010, VET MICROBIOL, V140, P246, DOI 10.1016/j.vetmic.2009.08.028
   Martin ET, 2010, J INFECT DIS, V201, P1625, DOI 10.1086/652405
   Mazet JAK, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000190
   Meng X. J., 2011, VIRUS RES, DOI [10.1016 j.viruses.2011.01.016., DOI 10.1016/J.VIRUSES.2011.01.016]
   Olival KJ, 2005, J NEUROVIROL, V11, P441, DOI 10.1080/13550280591002450
   Ostanello F, 2005, VET MICROBIOL, V108, P179, DOI 10.1016/j.vetmic.2005.04.010
   Pantin-Jackwood MJ, 2006, VIRUS GENES, V32, P187, DOI 10.1007/s11262-005-6875-3
   Phan TG, 2007, J MED VIROL, V79, P1388, DOI 10.1002/jmv.20924
   Pignatelli J, 2010, VET MICROBIOL, V146, P260, DOI 10.1016/j.vetmic.2010.05.023
   Quan PL, 2010, EMERG INFECT DIS, V16, P918, DOI 10.3201/eid1606.091536
   Reuter G, 2011, ARCH VIROL, V156, P125, DOI 10.1007/s00705-010-0827-5
   Rivera R, 2010, J GEN VIROL, V91, P166, DOI 10.1099/vir.0.015222-0
   Rosario K, 2011, J GEN VIROL, V92, P1302, DOI 10.1099/vir.0.030338-0
   Rosario K, 2009, J GEN VIROL, V90, P2418, DOI 10.1099/vir.0.012955-0
   Scallan E, 2011, EMERG INFECT DIS, V17, P16, DOI [10.3201/eid1701.P21101, 10.3201/eid1701.091101p2]
   Schildgen O, 2008, CLIN MICROBIOL REV, V21, P291, DOI 10.1128/CMR.00030-07
   Sestak K, 1996, AM J VET RES, V57, P664
   Shackelton LA, 2005, P NATL ACAD SCI USA, V102, P379, DOI 10.1073/pnas.0406765102
   Shackelton LA, 2007, J GEN VIROL, V88, P3294, DOI 10.1099/vir.0.83255-0
   Shan TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017292
   Sharp CP, 2010, J VIROL, V84, P10289, DOI 10.1128/JVI.01304-10
   Shi M, 2010, J VIROL, V84, P8700, DOI 10.1128/JVI.02551-09
   Simmonds P, 2006, J VIROL, V80, P11124, DOI 10.1128/JVI.01076-06
   Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182
   Smits SL, 2010, J GEN VIROL, V91, P2719, DOI 10.1099/vir.0.024067-0
   Steinfeldt T, 2001, VIROLOGY, V291, P152, DOI 10.1006/viro.2001.1203
   Taubenberger JK, 2010, CELL HOST MICROBE, V7, P440, DOI 10.1016/j.chom.2010.05.009
   Todd D, 2004, VET MICROBIOL, V98, P169, DOI 10.1016/j.vetmic.2003.10.010
   Toffan A, 2009, VET MICROBIOL, V139, P147, DOI 10.1016/j.vetmic.2009.04.031
   Ursic T, 2011, J CLIN MICROBIOL, V49, P1179, DOI 10.1128/JCM.02362-10
   Victoria JG, 2009, J VIROL, V83, P4642, DOI 10.1128/JVI.02301-08
   Victoria JG, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000163
   Wang QH, 2001, J MED VIROL, V64, P245, DOI 10.1002/jmv.1043
   Weingartl HM, 2010, J VIROL, V84, P2245, DOI 10.1128/JVI.02118-09
   Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851
   Wilson ME, 2005, CLIN INFECT DIS, V41, pS541, DOI 10.1086/432949
   Wolfaardt M, 2011, J CLIN MICROBIOL, V49, P728, DOI 10.1128/JCM.01093-10
   Wu QF, 2010, P NATL ACAD SCI USA, V107, P1606, DOI 10.1073/pnas.0911353107
   Zeng SL, 2011, J GEN VIROL, V92, P784, DOI 10.1099/vir.0.028340-0
   Zhai SL, 2010, ARCH VIROL, V155, P1313, DOI 10.1007/s00705-010-0698-9
   Zhang T, 2006, PLOS BIOL, V4, P108, DOI 10.1371/journal.pbio.0040003
   Ziemer CJ, 2010, J ANIM SCI, V88, pE84, DOI 10.2527/jas.2009-2331
   Zwickl D. J, 2006, THESIS U TEXAS AUSTI
NR 114
TC 185
Z9 190
U1 1
U2 34
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2011
VL 85
IS 22
BP 11697
EP 11708
DI 10.1128/JVI.05217-11
PG 12
WC Virology
SC Virology
GA 840FB
UT WOS:000296422700015
PM 21900163
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Xiao, XD
   Chakraborti, S
   Dimitrov, AS
   Gramatikoff, K
   Dimitrov, DS
AF Xiao, XD
   Chakraborti, S
   Dimitrov, AS
   Gramatikoff, K
   Dimitrov, DS
TI The SARS-CoV S glycoprotein: expression and functional characterization
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE SARS-CoV; S glycoprotein; receptor; binding; fusion; inhibitor; vaccine
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS; RECEPTOR; BIOLOGY; ENTRY
AB We have cloned, expressed, and characterized the full-length and various soluble fragments of the SARS-CoV (Tor2 isolate) S glycoprotein. Cells expressing S fused with receptor-expressing cells at neutral pH suggesting that the recombinant glycoprotein is functional, its membrane fusogenic activity does not require other viral proteins, and that low pH is not required for triggering membrane fusion; fusion was not observed at low receptor concentrations. S and its soluble ectodomain, S-e, were not cleaved to any significant degree. They ran at about 180-200 kDa in SDS gels suggesting post-translational modifications as predicted by previous computer analysis and observed for other coronaviruses. Fragments containing the N-terminal amino acid residues 17-537 and 272537 but not 17-276 bound specifically to Vero E6 cells and purified soluble receptor, ACE2, recently identified by M. Farzan and coworkers [Nature 426 (2003) 450-454]. Together with data for inhibition of binding by antibodies developed against peptides from S, these findings suggest that the receptor-binding domain is located between amino acid residues 303 and 537. These results also confirm that ACE2 is a functional receptor for the SARS virus and may help in the elucidation of the mechanisms of SARS-CoV entry and in the development of vaccine immunogens and entry inhibitors. Published by Elsevier Inc.
C1 NCI, Lab Expt & Computat Biol, NIH, Frederick, MD 21702 USA.
   Abgent, San Diego, CA 92121 USA.
RP Dimitrov, DS (reprint author), NCI, Lab Expt & Computat Biol, NIH, Frederick, MD 21702 USA.
CR Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   Dimitrov DS, 2000, CELL, V101, P697, DOI 10.1016/S0092-8674(00)80882-X
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Holmes KV, 2003, NEW ENGL J MED, V348, P1948, DOI 10.1056/NEJMp030078
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUNKEL F, 1993, VIROLOGY, V195, P195, DOI 10.1006/viro.1993.1360
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
NR 10
TC 185
Z9 214
U1 4
U2 23
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 26
PY 2003
VL 312
IS 4
BP 1159
EP 1164
DI 10.1016/j.bbrc.2003.11.054
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 753VW
UT WOS:000187252300044
PM 14651994
OA Bronze
DA 2020-04-03
ER

PT J
AU Gonzaalez, JM
   Gomez-Puertas, P
   Cavanagh, D
   Gorbalenya, AE
   Enjuanes, L
AF Gonzaalez, JM
   Gomez-Puertas, P
   Cavanagh, D
   Gorbalenya, AE
   Enjuanes, L
TI A comparative sequence analysis to revise the current taxonomy of the
   family Coronaviridae
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID INFECTIOUS PERITONITIS VIRUS; DEPENDENT RNA-POLYMERASES; EQUINE
   ARTERITIS VIRUS; PENAEUS-MONODON PRAWNS; GILL-ASSOCIATED VIRUS;
   HEPATITIS-E VIRUS; PHYLOGENETIC ANALYSIS; MULTIPLE-ALIGNMENTS; GENOME
   ORGANIZATION; FUNCTIONAL DOMAINS
AB The Coronaviridae family, comprising the Coronavirus and Torovirus genera, is part of the Nidovirales order that also includes two other families, Arteriviridae and Roniviridae. Based on genetic and serological relationships, groups 1, 2 and 3 were previously recognized in the Coronavirus genus. In this report we present results of comparative sequence analysis of the spike (S), envelope (E), membrane (M), and nucleoprotein (N) structural proteins, and the two most conserved replicase domains, putative RNA-dependent RNA polymerase (RdRp) and RNA helicase (HEL), aimed at a revision of the Coronaviridae taxonomy. The results of pairwise comparisons involving structural and replicase proteins of the Coronavirus genus were consistent and produced percentages of sequence identities that were distributed in discontinuous clusters. Inter-group pairwise scores formed a single cluster in the lowest percentile. No homologs of the N and E proteins have been found outside coronaviruses, and the only (very) distant homologs of S and M proteins were identified in toroviruses. Intragroup sequence conservation was higher, although for some pairs, especially those from the most diverse group 1, scores were close or even overlapped with those from the intergroup comparisons. Phylogenetic analysis of six proteins using a neighbor-joining algorithm confirmed three coronavirus groups. Comparative sequence analysis of RdRp and HEL domains were extended to include arterivirus and ronivirus homologs. The pairwise scores between sequences of the genera Coronavirus and Torovirus (22-25% and 21-25%) were found to be very close to or overlapped with the value ranges (12 to 22% and 17 to 25%) obtained for interfamily pairwise comparisons, but were much smaller than values derived from pairwise comparisons within the Coronavirus genus (63-71% and 59-67%). Phylogenetic analysis confirmed toroviruses and coronaviruses to be separated by a large distance that is comparable to those between established nidovirus families. Based on comparison of these scores with those derived from analysis of separate ranks of several multi-genera virus families, like the Picornaviridae, a revision of the Coronaviridae taxonomy is proposed. We suggest the Coronavirus and Torovirus genera to be re-defined as two subfamilies within the Coronavirdae or two families within Nidovirales, and the current three informal coronavirus groups to be converted into three genera within the Coronaviridae.
C1 CSIC, Ctr Nacl Biotecnol, Dept Mol & Cell Biol, Madrid 28049, Spain.
   CSIC, INTA, Ctr Astrobiol, Bioinformat Lab, Madrid, Spain.
   AFRC, Inst Anim Hlth, Compton Lab, Newbury RG16 0NN, Berks, England.
   Leiden Univ, Med Ctr, Ctr Infect Dis, NL-2333 ZA Leiden, Netherlands.
RP Enjuanes, L (reprint author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cell Biol, Campus Univ Autonoma, Madrid 28049, Spain.
EM a.e.gorbalenya@lumc.nl; L.Enjuanes@cnb.uam.es
RI Enjuanes, Luis/F-7845-2016; Gorbalenya, Alexander E/J-4818-2012;
   Gomez-Puertas, Paulino/G-8821-2014
OI Gorbalenya, Alexander E/0000-0002-4967-7341; Gomez-Puertas,
   Paulino/0000-0003-3131-729X; Gonzalez, Jose M/0000-0001-5569-0705;
   Gonzalez, Juan Miguel/0000-0003-4746-6775; Enjuanes,
   Luis/0000-0002-0854-0226
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260
   Berke T, 2000, ARCH VIROL, V145, P1421, DOI 10.1007/s007050070099
   BRADLEY DW, 1988, LANCET, V1, P819
   Brian DA, 1995, CORONAVIRIDAE, P165
   BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885
   CAVANAGH D, 1994, ARCH VIROL, V135, P227, DOI 10.1007/BF01309782
   Cavanagh D, 2002, AVIAN PATHOL, V31, P81, DOI 10.1080/03079450120106651
   Cavanagh D., 1995, CORONAVIRIDAE, P73
   Chouljenko VN, 2001, J GEN VIROL, V82, P2927, DOI 10.1099/0022-1317-82-12-2927
   Cornelissen LAHM, 1997, J VIROL, V71, P5277, DOI 10.1128/JVI.71.7.5277-5286.1997
   Cowley JA, 2000, J GEN VIROL, V81, P1473, DOI 10.1099/0022-1317-81-6-1473
   Cowley JA, 2002, ARCH VIROL, V147, P1977, DOI 10.1007/s00705-002-0847-x
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   DENBOON JA, 1991, VIROLOGY, V182, P655, DOI 10.1016/0042-6822(91)90606-C
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   Doolittle RF, 1986, URFS ORFS PRIMER ANA
   Duckmanton L, 1997, VIROLOGY, V239, P158, DOI 10.1006/viro.1997.8879
   Enjuanes LBD, 2000, VIRUS TAXONOMY CLASS, P835
   Escors D, 2001, J VIROL, V75, P1312, DOI 10.1128/JVI.75.3.1312-1324.2001
   Escors D, 2001, J VIROL, V75, P12228, DOI 10.1128/JVI.75.24.12228-12240.2001
   Felsenstein J., 1993, PHYLIP PHYLOGENY INF
   Gorbalenya AE, 2001, ADV EXP MED BIOL, V494, P1
   Gorbalenya AE, 2002, J MOL BIOL, V324, P47, DOI 10.1016/S0022-2836(02)01033-1
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2
   GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2
   Hegyi A, 2002, J GEN VIROL, V83, P581, DOI 10.1099/0022-1317-83-3-581
   Henikoff JG, 2000, NUCLEIC ACIDS RES, V28, P228, DOI 10.1093/nar/28.1.228
   HENIKOFF S, 1995, GENE, V163, pGC17, DOI 10.1016/0378-1119(95)00486-P
   HOGUE BG, 1984, J VIROL, V51, P384, DOI 10.1128/JVI.51.2.384-388.1984
   HORZINEK MC, 1987, INTERVIROLOGY, V27, P17, DOI 10.1159/000149710
   Johansson S, 2002, J VIROL, V76, P8920, DOI 10.1128/JVI.76.17.8920-8930.2002
   JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275
   Kadare G, 1997, J VIROL, V71, P2583
   King A.M.Q., 2000, VIRUS TAXONOMY, P657
   KOONIN EV, 1992, P NATL ACAD SCI USA, V89, P8259, DOI 10.1073/pnas.89.17.8259
   KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197
   Kroneman A, 1998, J VIROL, V72, P3507, DOI 10.1128/JVI.72.5.3507-3511.1998
   KUO L, 2002, 21 ANN M ASV
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Mayo MA, 2002, ARCH VIROL, V147, P1655, DOI 10.1007/s007050200039
   MCINTOSH K, 1974, CURR TOP MICROBIOL, V63, P86
   MOTOKAWA K, 1995, ARCH VIROL, V140, P469, DOI 10.1007/BF01718424
   MURPHY FA, 1995, VIRUS TAXONOMY, P1
   Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042
   O'Donovan Claire, 2002, Brief Bioinform, V3, P275
   Ortego J, 2003, VIROLOGY, V308, P13, DOI 10.1016/S0042-6822(02)00096-X
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   PEDERSEN NC, 1978, ARCH VIROL, V58, P45, DOI 10.1007/BF01315534
   Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7
   Petric M, 2000, EMERGING INFECTIONS 4, P23
   Pietrokovski S, 1996, NUCLEIC ACIDS RES, V24, P3836, DOI 10.1093/nar/24.19.3836
   PRINGLE CR, 1992, ASM NEWS, V58, P475
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   SANCHEZ CM, 1990, VIROLOGY, V174, P410, DOI 10.1016/0042-6822(90)90094-8
   Sapats SI, 1996, VIROLOGY, V226, P412, DOI 10.1006/viro.1996.0670
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304
   Seybert A, 2000, J VIROL, V74, P9586, DOI 10.1128/JVI.74.20.9586-9593.2000
   Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728
   Shukla DD, 1994, POTYVIRIDAE, P516
   SIDDELL SG, 1995, VIRUSES, P418
   SIDDELL SG, 1995, CORONAVIRIDAE, P1
   Snijder E. J., 1995, The coronaviridae., P219
   SNIJDER EJ, 1993, J GEN VIROL, V74, P2305, DOI 10.1099/0022-1317-74-11-2305
   SNIJDER EJ, 1990, NUCLEIC ACIDS RES, V18, P4535, DOI 10.1093/nar/18.15.4535
   Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961
   SNIJDER EJ, 1991, VIROLOGY, V180, P448, DOI 10.1016/0042-6822(91)90056-H
   SNIJDER EJ, 1990, VIROLOGY, V178, P355, DOI 10.1016/0042-6822(90)90332-L
   Spaan WJ, 1990, IMMUNOCHEMISTRY VIRU, V2, P359
   SPANN KM, 1995, DIS AQUAT ORGAN, V23, P127, DOI 10.3354/dao023127
   Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   van Marle G, 1999, P NATL ACAD SCI USA, V96, P12056, DOI 10.1073/pnas.96.21.12056
   van Vliet ALW, 2002, EMBO J, V21, P6571, DOI 10.1093/emboj/cdf635
   VANREGENMORTEL MHV, 2000, VIRUS TAXONOMY, P3
   WARD CW, 1993, RES VIROLOGY, V144, P419, DOI 10.1016/S0923-2516(06)80059-2
   WARD CW, 1992, ARCH VIROL, P283
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   Womble D D, 2000, Methods Mol Biol, V132, P3
   Wu CH, 2003, NUCLEIC ACIDS RES, V31, P345, DOI 10.1093/nar/gkg040
   Yuan YP, 1998, BIOINFORMATICS, V14, P285, DOI 10.1093/bioinformatics/14.3.285
   Zanotto PMD, 1996, J VIROL, V70, P6083, DOI 10.1128/JVI.70.9.6083-6096.1996
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Ziebuhr J, 2003, J VIROL, V77, P1415, DOI 10.1128/JVI.77.2.1415-1426.2003
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
NR 88
TC 185
Z9 210
U1 3
U2 11
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD NOV
PY 2003
VL 148
IS 11
BP 2207
EP 2235
DI 10.1007/s00705-003-0162-1
PG 29
WC Virology
SC Virology
GA 740JU
UT WOS:000186399900009
PM 14579179
OA Bronze
DA 2020-04-03
ER

PT J
AU MEBUS, CA
   STAIR, EL
   RHODES, MB
   TWIEHAUS, MJ
AF MEBUS, CA
   STAIR, EL
   RHODES, MB
   TWIEHAUS, MJ
TI NEONATAL CALF DIARRHEA - PROPAGATION, ATTENUATION, AND CHARACTERISTICS
   OF A CORONAVIRUS-LIKE AGENT
SO AMERICAN JOURNAL OF VETERINARY RESEARCH
LA English
DT Article
C1 UNIV NEBRASKA,COLL AGR,DEPT VET SCI,LINCOLN,NE 68503.
CR BRADBURNE AF, 1971, PROG MED VIROL, V13, P373
   CLARKE JK, 1971, J GEN VIROL, V13, P339, DOI 10.1099/0022-1317-13-2-339
   DUNN JW, 1967, 70 P ANN M US LIV, P139
   ESTOLA T, 1970, AVIAN DIS, V14, P330, DOI 10.2307/1588476
   MEBUS CA, 1972, VET MED SM ANIM CLIN, V67, P173
   MEBUS CA, 1971, CANADIAN VET J, V12, P69
   MEBUS CA, 1971, VET PATHOL, V8, P490, DOI 10.1177/0300985871008005-00612
   MEBUS CA, 1972, VET MED SMALL ANIM C, V67, P177
   MENGELING WL, 1972, AM J VET RES, V33, P297
   PARKER JC, 1970, ARCH GES VIRUSFORSCH, V31, P293, DOI 10.1007/BF01253764
   STAIR EL, 1972, AM J VET RES, V33, P1147
NR 11
TC 185
Z9 189
U1 0
U2 2
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360
SN 0002-9645
J9 AM J VET RES
JI Am. J. Vet. Res.
PY 1973
VL 34
IS 2
BP 145
EP 150
PG 6
WC Veterinary Sciences
SC Veterinary Sciences
GA O6144
UT WOS:A1973O614400001
PM 4568246
DA 2020-04-03
ER

PT J
AU Van Reeth, K
   Labarque, G
   Nauwynck, H
   Pensaert, M
AF Van Reeth, K
   Labarque, G
   Nauwynck, H
   Pensaert, M
TI Differential production of proinflammatory cytokines in the pig lung
   during different respiratory virus infections: correlations with
   pathogenicity
SO RESEARCH IN VETERINARY SCIENCE
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; INFLUENZA-VIRUS; INTERFERON-ALPHA; CDNA CLONING;
   INTERLEUKIN-1; REPLICATION; CORONAVIRUS; MACROPHAGES; EXPRESSION;
   BIOASSAY
AB The acute stages of infection with swine influenza virus (SIV), porcine respiratory coronavirus (PRCV) and porcine reproductive-respiratory syndrome virus (PRRSV) were shown to differ in terms of clinical and lung inflammatory effects and proinflammatory cytokine profiles in bronchoalveolar lavage (BAL) fluids. Caesarian-derived colostrum-deprived pigs were inoculated intratracheally with one of the three viruses. SRV infection was followed within 1 day post inoculation (d PI) by characteristic respiratory and general signs, and excessive lung epithelial desquamation and neutrophil infiltration (38 to 56 per cent of BAL cells at 1 d pr vs 0 to 1 per cent in controls). High concentrations of bioactive interferon-alpha (IFN-alpha), tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) coincided with peak symptoms and neutrophil infiltration. PRCV infection was asymptomatic and produced a mild bronchointerstitial pneumonitis and neutrophil infiltration (13 to 22 per cent of BAL. cells at 4 d pr). IFN-alpha titres parallelled those found during sly infection, TNF-alpha was negligible and Ir-l undetectable. PRRSV infection induced anorexia and lethargy between 3 and 5 d pr. There was marked infiltration with mononuclear cells in alveolar septa and Bps fluids between 7 and 10 d pr, while neutrophils remained at less than ii per cent of BAL cells at any time. IL-1 was produced from three throughout 10 d pr, while IFN-alpha production was minimal and TNF-alpha undetectable. These data strongly suggest that proinflammatory cytokines can be important mediators of viral respiratory disease.
C1 State Univ Ghent, Fac Vet Med, Lab Vet Virol, B-9820 Merelbeke, Belgium.
RP Van Reeth, K (reprint author), State Univ Ghent, Fac Vet Med, Lab Vet Virol, Salisburglaan, B-9820 Merelbeke, Belgium.
OI Nauwynck, Hans/0000-0001-5470-0713
CR Albina E, 1998, J INTERF CYTOK RES, V18, P485, DOI 10.1089/jir.1998.18.485
   ASAJ T, 1993, VET IMMUNOL IMMUNOP, V38, P253
   BAARSCH MJ, 1995, INFECT IMMUN, V63, P3587, DOI 10.1128/IAI.63.9.3587-3594.1995
   BERTONI G, 1993, J IMMUNOL METHODS, V160, P267, DOI 10.1016/0022-1759(93)90187-C
   Bielefeldt-Ohmann H., 1995, P291
   BROWN IH, 1993, VET REC, V132, P598, DOI 10.1136/vr.132.24.598
   COLLINS JE, 1992, J VET DIAGN INVEST, V4, P117, DOI 10.1177/104063879200400201
   COX E, 1990, RES VET SCI, V48, P165, DOI 10.1016/S0034-5288(18)30984-6
   Duan X, 1997, VET MICROBIOL, V56, P9, DOI 10.1016/S0378-1135(96)01347-8
   HAESEBROUCK F, 1986, VET MICROBIOL, V11, P239, DOI 10.1016/0378-1135(86)90026-X
   Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355
   Hill AG, 1997, ANN SURG, V225, P246, DOI 10.1097/00000658-199703000-00002
   HOPKINS SJ, 1989, J IMMUNOL METHODS, V120, P271, DOI 10.1016/0022-1759(89)90252-4
   HOPKINS SJ, 1990, J IMMUNOL METHODS, V133, P127, DOI 10.1016/0022-1759(90)90326-Q
   HOSANG K, 1994, BIOCHEM BIOPH RES CO, V199, P962, DOI 10.1006/bbrc.1994.1323
   HOSANG K, 1994, BIOCHEM BIOPH RES CO, V205, P148, DOI 10.1006/bbrc.1994.2642
   LABONNARDIERE C, 1981, INFECT IMMUN, V32, P28, DOI 10.1128/IAI.32.1.28-31.1981
   Murtaugh MP, 1996, VET IMMUNOL IMMUNOP, V54, P45, DOI 10.1016/S0165-2427(96)05698-X
   NAIN M, 1990, J IMMUNOL, V145, P1921
   Nielsen J, 1997, VET MICROBIOL, V55, P289, DOI 10.1016/S0378-1135(96)01334-X
   OTOOLE D, 1989, RES VET SCI, V47, P23, DOI 10.1016/S0034-5288(18)31226-8
   PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995
   PATON DJ, 1992, VET MICROBIOL, V33, P195, DOI 10.1016/0378-1135(92)90047-W
   Shibata I, 1997, J VET MED SCI, V59, P539, DOI 10.1292/jvms.59.539
   Tizard Ian R., 1995, P1
   VACHERON F, 1990, J GEN VIROL, V71, P477, DOI 10.1099/0022-1317-71-2-477
   Van Reeth K, 1998, J INFECT DIS, V177, P1076, DOI 10.1086/517398
   VANREETH K, 1994, AM J VET RES, V55, P1275
   VANREETH K, 1995, P 3 C EUR SOC VET VI, P197
   WYDE PR, 1982, INFECT IMMUN, V11, P239
   ZHOU Y, 1992, AM ASS SWINE PRACT N, V4, P28
   ZOJA C, 1991, AM J PATHOL, V138, P991
NR 32
TC 184
Z9 186
U1 0
U2 11
PU W B SAUNDERS CO LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0034-5288
J9 RES VET SCI
JI Res. Vet. Sci.
PD AUG
PY 1999
VL 67
IS 1
BP 47
EP 52
DI 10.1053/rvsc.1998.0277
PG 6
WC Veterinary Sciences
SC Veterinary Sciences
GA 224KL
UT WOS:000081897000008
PM 10425240
DA 2020-04-03
ER

PT J
AU Johnstone, J
   Majumdar, SR
   Fox, JD
   Marrie, TJ
AF Johnstone, Jennie
   Majumdar, Sumit R.
   Fox, Julie D.
   Marrie, Thomas J.
TI Viral Infection in Adults Hospitalized With Community-Acquired Pneumonia
   Prevalence, Pathogens, and Presentation
SO CHEST
LA English
DT Article
DE community-acquired pneumonia; respiratory viruses
ID HUMAN METAPNEUMOVIRUS INFECTION; POLYMERASE-CHAIN-REACTION; ACID
   AMPLIFICATION TESTS; REAL-TIME PCR; RESPIRATORY-TRACT INFECTION;
   TERM-CARE FACILITY; SYNCYTIAL-VIRUS; DIAGNOSIS; ETIOLOGY; ASSAY
AB Background: The potential role of respiratory viruses in the natural history of community-acquired pneumonia (CAP) in adults has not been well described since the advent of nucleic amplification tests (NATs).
   Methods: From 2004 to 2006, adults with CAP who were admitted to five hospitals were prospectively enrolled in the study, and clinical data, cultures, serology, and nasopharyngeal swabs were obtained. NATs from swabs were tested for influenza, human metapneumovirus (hMPV), respiratory syncytial virus (RSV), rhinovirus, parainfluenza virus 1-4, coronaviruses (OC43, 229E, and NL63), and adenovirus.
   Results: A total of 193 patients were included; the median age was 71 years, 51% of patients were male, and 47% of patients had severe CA-P. Overall, 75 patients (39%) had a pathogen identified. Of these pathogens, 29 were viruses (15%), 38 were bacteria (20%), 8 were mixed (4%), and the rest were "unknown." Influenza (n = 7), hMPV (n = 7), and RSV (n = 5) accounted for most viral infections; other infections included rhinovirus (n = 4), parainfluenza (n = 3), coronavirus (n = 4), and adenovirus (n = 2). Streptococcus pneumoniae. ae was the most common bacterial infection (37%). Compared with bacteria] infection, patients,with viral infection were older (76 vs 64 years, respectively; p = 0.01), were more likely to have cardiac disease (66% vs 32%, respectively; p = 0.006), and were more frail (eg, 48% with limited ambulation vs 21% of bacterial infections; p = 0.02). There were few clinically nicaningful differences in presentation and no differences in outcomes according to the presence or absence of viral infection.
   Conclusions: Viral infections are common in adults with pneumonia. Easily transmissible viruses such as influenza, hMPV, and RSV were the most common, raising concerns about infection control. Routine testing for respiratory viruses may be warranted for adults who have been hospitalized with pneumonia. (CHEST 2008; 134:1141-1148)
C1 [Johnstone, Jennie; Majumdar, Sumit R.; Marrie, Thomas J.] Univ Alberta, Dept Med, Fac Med & Dent, Edmonton, AB T6G 2R7, Canada.
   [Fox, Julie D.] Prov Lab Publ Hlth, Dept Microbiol, Calgary, AB, Canada.
RP Marrie, TJ (reprint author), Univ Alberta, Dept Med, Fac Med & Dent, 2J200 WC Mackenzie Hlt Sci Ctr,8440 112th St, Edmonton, AB T6G 2R7, Canada.
EM tom.marrie@ualberta.ca
CR Basi SK, 2004, AM J MED, V117, P305, DOI 10.1016/j.amjmed.2004.03.029
   BATES JH, 1992, CHEST, V101, P1005, DOI 10.1378/chest.101.4.1005
   Boivin G, 2007, CLIN INFECT DIS, V44, P1152, DOI 10.1086/513204
   Bonner AB, 2003, PEDIATRICS, V112, P363, DOI 10.1542/peds.112.2.363
   Casiano-Colon AE, 2003, J CLIN VIROL, V28, P169, DOI 10.1016/S1386-6532(03)00002-7
   Centers for Disease Control and Prevention (CDC), 2003, MMWR-MORBID MORTAL W, V53, P1
   de Roux AD, 2004, CHEST, V125, P1343, DOI 10.1378/chest.125.4.1343
   Diaz A, 2007, CHEST, V131, P779, DOI 10.1378/chest.06-1800
   El-Solh AA, 2001, AM J RESP CRIT CARE, V163, P645, DOI 10.1164/ajrccm.163.3.2005075
   Englund JA, 2006, ANN INTERN MED, V144, P344, DOI 10.7326/0003-4819-144-5-200603070-00010
   Falsey AR, 2007, CLIN GERIATR MED, V23, P535, DOI 10.1016/j.cger.2007.02.002
   Falsey AR, 2006, CLIN INFECT DIS, V42, P518, DOI 10.1086/499955
   FIELD PR, 1983, J INFECT DIS, V148, P477, DOI 10.1093/infdis/148.3.477
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   Flamaing J, 2003, EUR J CLIN MICROBIOL, V22, P720, DOI 10.1007/s10096-003-1042-z
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Fox JD, 2007, J CLIN VIROL, V40, pS15, DOI 10.1016/S1386-6532(07)70005-7
   Fox JD, 2007, FUTURE MICROBIOL, V2, P199, DOI 10.2217/17460913.2.2.199
   Hamelin ME, 2005, CLIN INFECT DIS, V41, P498, DOI 10.1086/431981
   Howard LSGE, 2005, J INFECTION, V50, P107, DOI 10.1016/j.jinf.2004.05.003
   Ison MG, 2002, CURR OPIN INFECT DIS, V15, P355, DOI 10.1097/00001432-200208000-00002
   Jennings LC, 2008, THORAX, V63, P42, DOI 10.1136/thx.2006.075077
   Kahn JS, 2007, PEDIATR INFECT DIS J, V26, P745, DOI 10.1097/INF.0b013e3181376428
   Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551
   Lee BE, 2006, J MED VIROL, V78, P702, DOI 10.1002/jmv.20595
   Liolios L, 2001, J CLIN MICROBIOL, V39, P2779, DOI 10.1128/JCM.39.8.2779-2783.2001
   Louie JK, 2007, J INFECT DIS, V196, P705, DOI 10.1086/519846
   Luna CM, 2000, CHEST, V118, P1344, DOI 10.1378/chest.118.5.1344
   MACFARLANE JT, 2001, THORAX S4, V56, P1
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   Marcos MA, 2006, ANTIVIR THER, V11, P351
   Marrie TJ, 2001, COMMUNITY-ACQUIRED PNEUMONIA, P29
   Pabbaraju K, 2007, J CLIN VIROL, V40, P186, DOI 10.1016/j.jcv.2007.08.004
   Petitjean J, 2002, J CLIN MICROBIOL, V40, P165, DOI 10.1128/JCM.40.1.165-171.2002
   Templeton KE, 2005, CLIN INFECT DIS, V41, P345, DOI 10.1086/431588
   Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van Elden LJR, 2002, CLIN INFECT DIS, V34, P177, DOI 10.1086/338238
   Wang SP, 2000, J INFECT DIS, V181, pS421, DOI 10.1086/315622
   WILKINSON HW, 1983, J INFECT DIS, V147, P23, DOI 10.1093/infdis/147.1.23
   Williams JV, 2005, J INFECT DIS, V192, P1061, DOI 10.1086/432732
   Wong S, 2008, J MED VIROL, V80, P856, DOI 10.1002/jmv.21136
NR 42
TC 182
Z9 189
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0012-3692
J9 CHEST
JI Chest
PD DEC
PY 2008
VL 134
IS 6
BP 1141
EP 1148
DI 10.1378/chest.08-0888
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 384OW
UT WOS:000261755100009
PM 18689592
DA 2020-04-03
ER

PT J
AU Lau, SKP
   Woo, PCY
   Yip, CCY
   Tse, H
   Tsoi, HW
   Cheng, VCC
   Lee, P
   Tang, BSF
   Cheung, CHY
   Lee, RA
   So, LY
   Lau, YL
   Chan, KH
   Yuen, KY
AF Lau, Susanna K. P.
   Woo, Patrick C. Y.
   Yip, Cyril C. Y.
   Tse, Herman
   Tsoi, Hol-wah
   Cheng, Vincent C. C.
   Lee, Paul
   Tang, Bone S. F.
   Cheung, Chris H. Y.
   Lee, Rodney A.
   So, Lok-yee
   Lau, Yu-lung
   Chan, Kwok-hung
   Yuen, Kwok-yung
TI Coronavirus HKU1 and other coronavirus infections in Hong Kong
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID RESPIRATORY-TRACT INFECTIONS; SARS-CORONAVIRUS; GENOME SEQUENCE; NL63
   INFECTION; YOUNG-CHILDREN; DISEASE; EPIDEMIOLOGY; PNEUMONIA; OUTBREAK;
   ETIOLOGY
AB We have recently described the discovery of a novel coronavirus, coronavirus HKU1 (CoV-HKU1), associated with community-acquired pneumonia. However, the clinical spectrum of disease and the epidemiology of CoV-HKU1 infections in relation to infections with other respiratory viruses are unknown. In this 12-month prospective study, 4,181 nasopharyngeal aspirates from patients with acute respiratory tract infections were subjected to reverse transcription-PCRs specific for CoV-HKU1 and human coronaviruses NL63 (HCoV-NL63), OC43 (HCoV-OC43), and 229E (HCoV-229E). Coronaviruses were detected in 87 (2.1%) patients, with 13 (0.3%) positive for CoV-HKU1, 17 (0.4%) positive for HCoV-NL63, 53 (1.3%) positive for HCoV-OC43, and 4 (0.1%) positive for HCoV-229E. Of the 13 patients with CoV-HKU1 infections, 11 were children and 8 had underlying diseases. Similar to the case for other coronaviruses, upper respiratory infection was the most common presentation of CoV-HKU1 infections, although pneumonia, acute bronchiolitis, and asthmatic exacerbation also occurred. Despite a shorter duration of fever (mean, 1.7 days) and no difference in maximum temperature in children with CoV-HKU1 infections compared to patients with most other respiratory virus infections, a high incidence of febrile seizures (50%) was noted, which was significantly higher than those for HCoV-OC43 (14%), adenovirus (9%), human parainfluenza virus 1 (0%), and respiratory syncytial virus (8%) infections. CoV-HKU1 and HCoV-OC43 infections peaked in winter, although cases of the former also occurred in spring to early summer. This is in contrast to HCoV-NL63 infections, which mainly occurred in early summer and autumn but were absent in winter. Two genotypes of CoV-HKU1 cocirculated during the study period. Continuous studies over a longer period are warranted to ascertain the seasonal variation and relative importance of the different coronaviruses. Similar studies in other countries are required to better determine the epidemiology and genetic diversity of CoV-HKU1.
C1 Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Res Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   Pamela Youde Nethersole Eastern Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Pamela Youde Nethersole Eastern Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.
EM hkumicro@hkucc.hku.hk
RI Woo, Patrick/C-4449-2009; Tse, Herman/C-4425-2009; Yip, Chik
   Yan/B-7078-2013; Tsoi, Hoi Wah/C-4428-2009; Lau, Yu Lung/C-4322-2009;
   Yuen, Kwok Yung/C-4465-2009; Lau, Susanna/C-4321-2009
OI Yuen, Kwok-yung/0000-0002-2083-1552
CR Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869
   Cheng VCC, 2004, CLIN INFECT DIS, V38, P467, DOI 10.1086/382681
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   Chiu SS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e63
   Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289
   Eickmann M, 2003, SCIENCE, V302, P1504
   Esper F, 2005, J INFECT DIS, V191, P499, DOI 10.1086/428291
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Guan Y, 2004, LANCET, V363, P99, DOI 10.1016/S0140-6736(03)15259-2
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MCINTOSH K, 1970, AM J EPIDEMIOL, V91, P585, DOI 10.1093/oxfordjournals.aje.a121171
   Moes E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-6
   Mori SI, 1999, ARCH VIROL, V144, P147, DOI 10.1007/s007050050491
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Peiris JSM, 2003, EMERG INFECT DIS, V9, P628
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruiz M, 1999, AM J RESP CRIT CARE, V160, P397, DOI 10.1164/ajrccm.160.2.9808045
   Shimizu C, 2005, J INFECT DIS, V192, P1767, DOI 10.1086/497170
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   Woo PCY, 2004, LANCET, V363, P841, DOI 10.1016/S0140-6736(04)15729-2
   Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 34
TC 182
Z9 197
U1 3
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2006
VL 44
IS 6
BP 2063
EP 2071
DI 10.1128/JCM.02614-05
PG 9
WC Microbiology
SC Microbiology
GA 053VD
UT WOS:000238332900019
PM 16757599
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Zhao, JC
   Li, K
   Wohlford-Lenane, C
   Agnihothram, SS
   Fett, C
   Zhao, JX
   Gale, MJ
   Baric, RS
   Enjuanes, L
   Gallagher, T
   McCray, PB
   Perlman, S
AF Zhao, Jincun
   Li, Kun
   Wohlford-Lenane, Christine
   Agnihothram, Sudhakar S.
   Fett, Craig
   Zhao, Jingxian
   Gale, Michael J., Jr.
   Baric, Ralph S.
   Enjuanes, Luis
   Gallagher, Tom
   McCray, Paul B., Jr.
   Perlman, Stanley
TI Rapid generation of a mouse model for Middle East respiratory syndrome
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE emerging pathogen; interferon; SARS
ID INNATE IMMUNE-RESPONSES; HUMAN CORONAVIRUS; C VIRUS; ADENOVIRUS;
   INFECTION; DISEASE; MICE; EXPRESSION; PNEUMONIA; TROPISM
AB In this era of continued emergence of zoonotic virus infections, the rapid development of rodent models represents a critical barrier to public health preparedness, including the testing of antivirus therapy and vaccines. The Middle East respiratory syndrome coronavirus (MERS-CoV) was recently identified as the causative agent of a severe pneumonia. Given the ability of coronavirus to rapidly adapt to new hosts, a major public health concern is that MERS-CoV will further adapt to replication in humans, triggering a pandemic. No small-animal model for this infection is currently available, but studies suggest that virus entry factors can confer virus susceptibility. Here, we show that mice were sensitized to MERS-CoV infection by prior transduction with adenoviral vectors expressing the human host-cell receptor dipeptidyl peptidase 4. Mice developed a pneumonia characterized by extensive inflammatory-cell infiltration with virus clearance occurring 6-8 d after infection. Clinical disease and histopathological changes were more severe in the absence of type-I IFN signaling whereas the T-cell response was required for virus clearance. Using these mice, we demonstrated the efficacy of a therapeutic intervention (poly I:C) and a potential vaccine [Venezuelan equine encephalitis replicon particles expressing MERS-CoV spike protein]. We also found little protective cross-reactivity between MERS-CoV and the severe acute respiratory syndrome-CoV. Our results demonstrate that this system will be useful for MERS-CoV studies and for the rapid development of relevant animal models for emerging respiratory viral infections.
C1 [Zhao, Jincun; Fett, Craig; Zhao, Jingxian; Perlman, Stanley] Univ Iowa, Dept Microbiol, Iowa City, IA 52240 USA.
   [Li, Kun; Wohlford-Lenane, Christine; McCray, Paul B., Jr.] Univ Iowa, Dept Pediat, Iowa City, IA 52240 USA.
   [Agnihothram, Sudhakar S.; Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Agnihothram, Sudhakar S.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Gale, Michael J., Jr.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98109 USA.
   [Enjuanes, Luis] Ctr Nacl Biotecnol, Consejo Super Invest Cient, Dept Mol & Cell Biol, Madrid 28049, Spain.
   [Gallagher, Tom] Loyola Univ, Med Ctr, Dept Microbiol & Immunol, Maywood, IL 60153 USA.
RP Perlman, S (reprint author), Univ Iowa, Dept Microbiol, Iowa City, IA 52240 USA.
EM stanley-perlman@uiowa.edu
RI Enjuanes, Luis/F-7845-2016; Li, Kun/E-5255-2017
OI Li, Kun/0000-0002-8582-2913; McCray, Paul/0000-0002-4067-577X; Gale,
   Michael/0000-0002-6332-7436; Perlman, Stanley/0000-0003-4213-2354;
   Enjuanes, Luis/0000-0002-0854-0226
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [RO1AI091322,
   PO106099, AI074973, AI083019, AI057157]
FX We thank Drs. Bart Haagmans and Ron Fouchier (Erasmus Medical Center)
   for providing MERS-CoV (isolate HCoV-EMC/2012) and Dr. David Meyerholz
   for analysis of lung sections. We thank Beverly Davidson for helpful
   discussions. We acknowledge the excellent technical support of the
   University of Iowa Gene Transfer Vector Core. This research was
   supported in part by National Institutes of Health Grants RO1AI091322
   (to S.P.), PO106099 (to S.P., P.B.M., T.G., and L.E.), AI074973 and
   AI083019 (to M.J.G.), and AI057157 (to R.S.B.).
CR Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8
   Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Barber DL, 2003, J IMMUNOL, V171, P27, DOI 10.4049/jimmunol.171.1.27
   Butowski N, 2009, J NEURO-ONCOL, V91, P175, DOI 10.1007/s11060-008-9693-3
   Chan RWY, 2013, J VIROL, V87, P6604, DOI 10.1128/JVI.00009-13
   Coleman CM, 2014, J GEN VIROL, V95, P408, DOI 10.1099/vir.0.060640-0
   CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42
   Davis NL, 2002, IUBMB LIFE, V53, P209, DOI 10.1080/15216540212657
   de Wit E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069127
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Dorner M, 2011, NATURE, V474, P208, DOI 10.1038/nature10168
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Heise MT, 2000, J VIROL, V74, P4207, DOI 10.1128/JVI.74.9.4207-4213.2000
   Kindler E, 2013, MBIO, V4, DOI 10.1128/mBio.00611-12
   KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Liu Q, 2003, GENE THER, V10, P935, DOI 10.1038/sj.gt.3302036
   Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Munster VJ, 2013, NEW ENGL J MED, V368, P1560, DOI 10.1056/NEJMc1215691
   Nabel GJ, 2004, NAT MED, V10, P135, DOI 10.1038/nm990
   Okada H, 2011, J CLIN ONCOL, V29, P330, DOI 10.1200/JCO.2010.30.7744
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pietzsch J, 2012, P NATL ACAD SCI USA, V109, P15859, DOI 10.1073/pnas.1213409109
   Pushko P, 1997, VIROLOGY, V239, P389, DOI 10.1006/viro.1997.8878
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595
   Reche PA, 2004, IMMUNOGENETICS, V56, P405, DOI 10.1007/s00251-004-0709-7
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Suthar MS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000757
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Tseng CTK, 2007, J VIROL, V81, P1162, DOI 10.1128/JVI.01702-06
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhao JC, 2011, J CLIN INVEST, V121, P4921, DOI 10.1172/JCI59777
   Zhao JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000636
   Zielecki F, 2013, J VIROL, V87, P5300, DOI 10.1128/JVI.03496-12
NR 42
TC 181
Z9 190
U1 13
U2 49
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 1
PY 2014
VL 111
IS 13
BP 4970
EP 4975
DI 10.1073/pnas.1323279111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AD9IX
UT WOS:000333579700067
PM 24599590
OA Green Published, Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Annan, A
   Baldwin, HJ
   Corman, VM
   Klose, SM
   Owusu, M
   Nkrumah, EE
   Badu, EK
   Anti, P
   Agbenyega, O
   Meyer, B
   Oppong, S
   Sarkodie, YA
   Kalko, EKV
   Lina, PHC
   Godlevska, EV
   Reusken, C
   Seebens, A
   Gloza-Rausch, F
   Vallo, P
   Tschapka, M
   Drosten, C
   Drexler, JF
AF Annan, Augustina
   Baldwin, Heather J.
   Corman, Victor Max
   Klose, Stefan M.
   Owusu, Michael
   Nkrumah, Evans Ewald
   Badu, Ebenezer Kofi
   Anti, Priscilla
   Agbenyega, Olivia
   Meyer, Benjamin
   Oppong, Samuel
   Sarkodie, Yaw Adu
   Kalko, Elisabeth K. V.
   Lina, Peter H. C.
   Godlevska, Elena V.
   Reusken, Chantal
   Seebens, Antje
   Gloza-Rausch, Florian
   Vallo, Peter
   Tschapka, Marco
   Drosten, Christian
   Drexler, Jan Felix
TI Human Betacoronavirus 2c EMC/2012-related Viruses in Bats, Ghana and
   Europe
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUSES
AB We screened fecal specimens of 4,758 bats from Ghana and 272 bats from 4 European countries for betacoronaviruses. Viruses related to the novel human betacoronavirus EMC/2012 were detected in 46 (24.9%) of 185 Nycteris bats and 40 (14.7%) of 272 Pipistrellus bats. Their genetic relatedness indicated EMC/2012 originated from bats.
C1 [Annan, Augustina; Owusu, Michael] Kumasi Ctr Collaborat Res Trop Med, Kumasi, Ghana.
   [Baldwin, Heather J.] Macquarie Univ, Sydney, NSW 2109, Australia.
   [Baldwin, Heather J.; Klose, Stefan M.; Kalko, Elisabeth K. V.; Vallo, Peter; Tschapka, Marco] Univ Ulm, D-89069 Ulm, Germany.
   [Corman, Victor Max; Meyer, Benjamin; Gloza-Rausch, Florian; Drosten, Christian; Drexler, Jan Felix] Univ Bonn, Med Ctr, Bonn, Germany.
   [Nkrumah, Evans Ewald; Badu, Ebenezer Kofi; Anti, Priscilla; Agbenyega, Olivia; Oppong, Samuel; Sarkodie, Yaw Adu] Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana.
   [Kalko, Elisabeth K. V.; Tschapka, Marco] Smithsonian Trop Res Inst, Balboa, Panama.
   [Lina, Peter H. C.] Nat Biodivers Ctr, Leiden, Netherlands.
   [Godlevska, Elena V.] Schmalhausen Inst Zool, Kiev, Ukraine.
   [Reusken, Chantal] Netherlands Ctr Infect Dis Control, Bilthoven, Netherlands.
   [Seebens, Antje; Gloza-Rausch, Florian] Ctr Bat Protect & Informat, Noctalis, Bad Segeberg, Germany.
   [Vallo, Peter] Acad Sci Czech Republic, Vvi, Brno, Czech Republic.
RP Drexler, JF (reprint author), Univ Bonn, Inst Virol, Med Ctr, D-53127 Bonn, Germany.
EM drexler@virology-bonn.de
RI Vallo, Peter/F-9650-2014; Meyer, Bernhard/Q-9413-2016; Drexler, Jan
   Felix/C-1004-2014; Meyer, Benjamin/F-3285-2018; Godlevska,
   Lena/O-4131-2016; Corman, Victor Max/K-1319-2019; Godlevska,
   Lena/K-6926-2019
OI Meyer, Benjamin/0000-0003-0601-3550; Godlevska,
   Lena/0000-0001-6792-6543; Corman, Victor Max/0000-0002-3605-0136;
   Godlevska, Lena/0000-0001-6792-6543; SYLVERKEN,
   AUGUSTINA/0000-0002-7691-914X; Drexler, Jan Felix/0000-0002-3509-0232;
   Owusu, Michael/0000-0001-5066-150X
FU European UnionEuropean Union (EU) [223498, 278976]; German Research
   Foundation (DFG)German Research Foundation (DFG) [DR 772/3-1,
   KA1241/18-1]
FX This study was supported by the European Union FP7 projects EMPERIE
   (contract number 223498) and ANTIGONE (contract number 278976) and by
   the German Research Foundation (DFG grant DR 772/3-1, KA1241/18-1).
CR Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   Luna LKD, 2007, J CLIN MICROBIOL, V45, P1049, DOI 10.1128/JCM.02426-06
   Drexler JF, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1796
   Drexler JF, 2011, EMERG INFECT DIS, V17, P449, DOI 10.3201/eid1703.100526
   Drexler JF, 2010, J VIROL, V84, P11336, DOI 10.1128/JVI.00650-10
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gloza-Rausch F, 2008, EMERG INFECT DIS, V14, P626, DOI 10.3201/eid1404.071439
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Mickleburgh S, 2009, ORYX, V43, P217, DOI 10.1017/S0030605308000938
   Pfefferle S, 2009, EMERG INFECT DIS, V15, P1377, DOI 10.3201/eid1509.090224
   Reusken CBEM, 2010, VECTOR-BORNE ZOONOT, V10, P785, DOI 10.1089/vbz.2009.0173
   Saif LJ, 2004, REV SCI TECH OIE, V23, P643, DOI 10.20506/rst.23.2.1513
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 15
TC 181
Z9 185
U1 4
U2 38
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD MAR
PY 2013
VL 19
IS 3
BP 456
EP 459
DI 10.3201/eid1903.121503
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 268LU
UT WOS:000328173000014
PM 23622767
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Jang, H
   Kim, YK
   Kwon, HM
   Yeo, WS
   Kim, DE
   Min, DH
AF Jang, Hongje
   Kim, Young-Kwan
   Kwon, Hyun-Mi
   Yeo, Woon-Seok
   Kim, Dong-Eun
   Min, Dal-Hee
TI A Graphene-Based Platform for the Assay by Helicase
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE biosensors; DNA; fluorescence spectroscopy; graphene; viruses
ID SARS CORONAVIRUS HELICASE; HEPATITIS-C VIRUS; GRAPHITE OXIDE; PRIMASE
   INHIBITORS; RING HELICASE; NS3 HELICASE; DNA HELICASE; MECHANISM;
   DISEASE; T7
C1 [Jang, Hongje; Kim, Young-Kwan; Min, Dal-Hee] Korea Adv Inst Sci & Technol, Dept Chem, Inst BioCentury, Taejon 305701, South Korea.
   [Kwon, Hyun-Mi; Yeo, Woon-Seok; Kim, Dong-Eun] Konkuk Univ, Dept Biosci & Biotechnol, Seoul 143701, South Korea.
RP Min, DH (reprint author), Korea Adv Inst Sci & Technol, Dept Chem, Inst BioCentury, 373-1 Guseong Dong, Taejon 305701, South Korea.
EM dalheemin@kaist.ac.kr
RI Yeo, Woon-Seok/D-8303-2011; Kim, Dong-Eun/D-8304-2011
OI Kim, Dong-Eun/0000-0001-6545-8387
FU Korean governmentKorean Government [313-2008-2-000538, 2008-0062074,
   2009-0071058]; Nano RD program [2008-2004457]; WCU Project [R33-10128];
   National Honor Scientist ProgramMinistry of Education, Science and
   Technology, Republic of Korea
FX This work was supported by the Basic Science Research Program and
   Mid-career Researcher Program through the National Research Foundation
   of Korea (NRF) funded by the Korean government (the Ministry of
   Education, Science, and Technology, MEST; grant nos. 313-2008-2-000538,
   2008-0062074, and 2009-0071058), by the Nano R&D program (2008-2004457)
   and WCU Project (R33-10128), and by the National Honor Scientist
   Program.
CR Artsaenko O, 2003, J GEN VIROL, V84, P2323, DOI 10.1099/vir.0.19299-0
   BACHUR NR, 1992, MOL PHARMACOL, V41, P993
   Bernini A, 2006, BIOCHEM BIOPH RES CO, V343, P1101, DOI 10.1016/j.bbrc.2006.03.069
   Borowski P, 2001, J VIROL, V75, P3220, DOI 10.1128/JVI.75.7.3220-3229.2001
   Cote LJ, 2009, J AM CHEM SOC, V131, P1043, DOI 10.1021/ja806262m
   Crute JJ, 2002, NAT MED, V8, P386, DOI 10.1038/nm0402-386
   de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768
   Eoff RL, 2006, NAT STRUCT MOL BIOL, V13, P242, DOI 10.1038/nsmb1055
   Gilje S, 2007, NANO LETT, V7, P3394, DOI 10.1021/nl0717715
   He SJ, 2010, ADV FUNCT MATER, V20, P453, DOI 10.1002/adfm.200901639
   Hsu CC, 1998, BIOCHEM BIOPH RES CO, V253, P594, DOI 10.1006/bbrc.1998.9813
   Huang J D, 2008, Hong Kong Med J, V14 Suppl 4, P36
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Jang KJ, 2008, BIOCHEM BIOPH RES CO, V366, P738, DOI 10.1016/j.bbrc.2007.12.020
   Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101
   Kim DE, 2002, J MOL BIOL, V321, P807, DOI 10.1016/S0022-2836(02)00733-7
   Kleymann G, 2002, NAT MED, V8, P392, DOI 10.1038/nm0402-392
   Kovtyukhova NI, 1999, CHEM MATER, V11, P771, DOI 10.1021/cm981085u
   Kwong AD, 2005, NAT REV DRUG DISCOV, V4, P845, DOI 10.1038/nrd1853
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Luo ZT, 2009, J AM CHEM SOC, V131, P898, DOI 10.1021/ja807934n
   Minczuk M, 2002, NUCLEIC ACIDS RES, V30, P5074, DOI 10.1093/nar/gkf647
   RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644
   Rasnik I, 2006, NUCLEIC ACIDS RES, V34, P4225, DOI 10.1093/nar/gkl452
   Schniepp HC, 2006, J PHYS CHEM B, V110, P8535, DOI 10.1021/jp060936f
   Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5
   Swathi RS, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2956498
   Swathi RS, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3077292
   van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409
   Varghese N, 2009, CHEMPHYSCHEM, V10, P206, DOI 10.1002/cphc.200800459
   Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3
   Yang N, 2007, CHEM COMMUN, P4413, DOI 10.1039/b709515e
   Zhang LT, 2001, ANAL BIOCHEM, V293, P31, DOI 10.1006/abio.2001.5093
NR 33
TC 180
Z9 184
U1 3
U2 93
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PY 2010
VL 49
IS 33
BP 5703
EP 5707
DI 10.1002/anie.201001332
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA 638JP
UT WOS:000280891000017
PM 20818755
DA 2020-04-03
ER

PT J
AU Lambert, DW
   Yarski, M
   Warner, FJ
   Thornhill, P
   Parkin, ET
   Smith, AI
   Hooper, NM
   Turner, AJ
AF Lambert, DW
   Yarski, M
   Warner, FJ
   Thornhill, P
   Parkin, ET
   Smith, AI
   Hooper, NM
   Turner, AJ
TI Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated
   ectodomain shedding of the severe-acute respiratory syndrome-coronavirus
   (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID AMYLOID PRECURSOR PROTEIN; FUNCTIONAL RECEPTOR; PROTEOLYTIC RELEASE;
   CLEAVAGE SITE; CELL-ADHESION; ENZYME; EXPRESSION; DISINTEGRIN;
   IDENTIFICATION; JUXTAMEMBRANE
AB Angiotensin-converting enzyme-2 (ACE2) is a critical regulator of heart function and a cellular receptor for the causative agent of severe-acute respiratory syndrome (SARS), SARS- CoV (coronavirus). ACE2 is a type I transmembrane protein, with an extracellular N-terminal domain containing the active site and a short intracellular C-terminal tail. A soluble form of ACE2, lacking its cytosolic and transmembrane domains, has been shown to block binding of the SARS- CoV spike protein to its receptor. In this study, we examined the ability of ACE2 to undergo proteolytic shedding and investigated the mechanisms responsible for this shedding event. We demonstrated that ACE2, heterologously expressed in HEK293 cells and endogenously expressed in Huh7 cells, undergoes metalloproteinase-mediated, phorbol ester-inducible ectodomain shedding. By using inhibitors with differing potency toward different members of the ADAM (a disintegrin and metalloproteinase) family of proteases, we identified ADAM17 as a candidate mediator of stimulated ACE2 shedding. Furthermore, ablation of ADAM17 expression using specific small interfering RNA duplexes reduced regulated ACE2 shedding, whereas overexpression of ADAM17 significantly increased shedding. Taken together, these data provided direct evidence for the involvement of ADAM17 in the regulated ectodomain shedding of ACE2. The identification of ADAM17 as the protease responsible for ACE2 shedding may provide new insight into the physiological roles of ACE2.
C1 Univ Leeds, Sch Biochem & Microbiol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England.
   Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia.
RP Lambert, DW (reprint author), Univ Leeds, Sch Biochem & Microbiol, Proteolysis Res Grp, Leeds LS2 9JT, W Yorkshire, England.
EM d.w.lambert@leeds.ac.uk
OI Hooper, Nigel/0000-0002-5811-3484; Smith, Ian/0000-0002-4143-2892;
   Parkin, Edward/0000-0003-3270-3184
CR Allinson TMJ, 2004, EUR J BIOCHEM, V271, P2539, DOI 10.1111/j.1432-1033.2004.04184.x
   Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3
   Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8
   Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X
   Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t
   ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433
   Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35
   BELDENT V, 1993, J BIOL CHEM, V268, P26428
   Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0
   BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95
   Brosnihan KB, 2003, HYPERTENSION, V42, P749, DOI 10.1161/01.HYP.0000085220.53285.11
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Donoghue M, 2003, J MOL CELL CARDIOL, V35, P1043, DOI 10.1016/S0022-2828(03)00177-9
   DONOGHUE M, 2000, CIRC RES, V87, P1
   Ehlers MRW, 1996, BIOCHEMISTRY-US, V35, P9549, DOI 10.1021/bi9602425
   EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001
   ERDOS EG, 1975, CIRC RES, V36, P247, DOI 10.1161/01.RES.36.2.247
   Eriksson U, 2002, CURR BIOL, V12, pR745, DOI 10.1016/S0960-9822(02)01255-1
   Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200
   Gillim-Ross L, 2004, J CLIN MICROBIOL, V42, P3196, DOI 10.1128/JCM.42.7.3196-3206.2004
   Gough PJ, 2004, J IMMUNOL, V172, P3678, DOI 10.4049/jimmunol.172.6.3678
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879
   Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775
   Hussain I, 2003, J BIOL CHEM, V278, P36264, DOI 10.1074/jbc.M304186200
   Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371
   Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524
   Pang S, 2001, BIOCHEM J, V358, P185, DOI 10.1042/0264-6021:3580185
   Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200
   Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y
   Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281
   Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588
   Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Wang PG, 2004, BIOCHEM BIOPH RES CO, V315, P439, DOI 10.1016/j.bbrc.2004.01.076
   Wang XD, 2002, J BIOL CHEM, V277, P50510, DOI 10.1074/jbc.M208738200
   WOODMAN ZL, 2005, IN PRESS BIOCH J
   Zisman LS, 2003, CIRCULATION, V108, P1707, DOI 10.1161/01.CIR.0000094734.67990.99
NR 40
TC 180
Z9 188
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 26
PY 2005
VL 280
IS 34
BP 30113
EP 30119
DI 10.1074/jbc.M505111200
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 957IC
UT WOS:000231362500017
PM 15983030
OA Bronze
DA 2020-04-03
ER

PT J
AU Lane, TE
   Liu, MT
   Chen, BP
   Asensio, VC
   Samawi, RM
   Paoletti, AD
   Campbell, IL
   Kunkel, SL
   Fox, HS
   Buchmeier, MJ
AF Lane, TE
   Liu, MT
   Chen, BP
   Asensio, VC
   Samawi, RM
   Paoletti, AD
   Campbell, IL
   Kunkel, SL
   Fox, HS
   Buchmeier, MJ
TI A central role for CD4(+) T cells and RANTES in virus-induced central
   nervous system inflammation and demyelination
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;
   EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MURINE CORONAVIRUS;
   MULTIPLE-SCLEROSIS; CHEMOKINE EXPRESSION; MEDIATED CLEARANCE; IN-VIVO;
   DISEASE; MICE
AB Infection of C57BL/6 mice with mouse hepatitis virus (MHV) results in a demyelinating encephalomyelitis characterized by mononuclear cell infiltration and white matter destruction similar to the pathology of the human demyelinating disease multiple sclerosis, The contributions of CD4(+) and CD8(+) T cells in the pathogenesis of the disease were investigated. Significantly less severe inflammation and demyelination were observed in CD4(-/-) mice than in CD8(-/-) and C57BL/6 mice (P less than or equal to 0.002 and P less than or equal to 0.001, respectively). Immunophenotyping of central nervous system (CNS) infiltrates revealed that CD4(-/-) mice had a significant reduction in numbers of activated macrophages/microglial cells in the brain compared to the numbers in CD8(-/-) and C57BL/6 mice, indicating a role for these cells in myelin destruction. Furthermore, CD4(-/-) mice displayed lower levels of RANTES (a C-C chemokine) mRNA transcripts and protein, suggesting a role for this molecule in the pathogenesis of MEN-induced neurologic disease. Administration of RANTES antisera to MEN-infected C57BL/6 mice resulted in a significant reduction in macrophage infiltration and demyelination (P less than or equal to 0.001) compared to those in control mice. These data indicate that CD4(+) T cells have a pivotal role in accelerating CNS inflammation and demyelination within infected mice, possibly by regulating RANTES expression, which in turn coordinates the trafficking of macrophages into the CNS, leading to myelin destruction.
C1 Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA 92697 USA.
   Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA USA.
   Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA.
RP Lane, TE (reprint author), Univ Calif Irvine, Dept Biochem & Mol Biol, 3205 Biol Sci 2, Irvine, CA 92697 USA.
OI Fox, Howard/0000-0003-2032-374X
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI025913]; NINDS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [NS37336-01]; CSR NIH HHS [RG 3093A1/T, RG 2966-A-2]
CR Asensio VC, 1997, J VIROL, V71, P7832, DOI 10.1128/JVI.71.10.7832-7840.1997
   BROSNAN CF, 1981, J IMMUNOL, V126, P614
   BURDICK MD, 1993, IMMUNOL INVEST, V22, P441, DOI 10.3109/08820139309063422
   DALZIEL RG, 1986, J VIROL, V59, P463, DOI 10.1128/JVI.59.2.463-471.1986
   Fleming John O., 1993, Regional Immunology, V5, P37
   FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8
   Glabinski AR, 1997, AM J PATHOL, V150, P617
   GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P
   HASPEL MV, 1978, P NATL ACAD SCI USA, V75, P4033, DOI 10.1073/pnas.75.8.4033
   HEEGER P, 1992, KIDNEY INT, V41, P220, DOI 10.1038/ki.1992.31
   HIRANO N, 1978, JPN J EXP MED, V48, P71
   Houtman JJ, 1996, J NEUROVIROL, V2, P101, DOI 10.3109/13550289609146543
   Houtman JJ, 1996, J NEUROVIROL, V2, P361, DOI 10.3109/13550289609146902
   Hvas J, 1997, SCAND J IMMUNOL, V46, P195, DOI 10.1046/j.1365-3083.1997.d01-100.x
   KARPUS WJ, 1995, J IMMUNOL, V155, P5003
   Karpus WJ, 1998, J IMMUNOL, V161, P2667
   Kennedy KJ, 1998, J NEUROIMMUNOL, V92, P98, DOI 10.1016/S0165-5728(98)00187-8
   Lane TE, 1997, J VIROL, V71, P2202, DOI 10.1128/JVI.71.3.2202-2210.1997
   Lane TE, 1998, J IMMUNOL, V160, P970
   Lane TE, 1997, TRENDS MICROBIOL, V5, P9, DOI 10.1016/S0966-842X(97)81768-4
   Lane TE, 1999, J NEUROVIROL, V5, P48, DOI 10.3109/13550289909029745
   Lavi E, 1995, Adv Exp Med Biol, V380, P145
   Lipton HL, 1997, INTERVIROLOGY, V40, P143
   MCINTOSH K, 1996, FIELDS VIROLOGY, P1095
   MILLER SD, 1994, IMMUNOL TODAY, V15, P356, DOI 10.1016/0167-5699(94)90173-2
   Murray PD, 1998, J VIROL, V72, P7320, DOI 10.1128/JVI.72.9.7320-7329.1998
   PEARCE BD, 1994, J VIROL, V68, P5483, DOI 10.1128/JVI.68.9.5483-5495.1994
   Pewe L, 1998, J VIROL, V72, P5912, DOI 10.1128/JVI.72.7.5912-5918.1998
   RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0
   SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0
   Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150
   Stinissen P, 1998, MULT SCLER, V4, P203, DOI 10.1177/135245859800400322
   SUSSMAN MA, 1989, J VIROL, V63, P3051, DOI 10.1128/JVI.63.7.3051-3056.1989
   Sutherland RM, 1997, J NEUROVIROL, V3, P225, DOI 10.3109/13550289709018297
   WANG FI, 1990, J NEUROIMMUNOL, V30, P31, DOI 10.1016/0165-5728(90)90050-W
   WEINER LP, 1973, ARCH NEUROL-CHICAGO, V28, P298, DOI 10.1001/archneur.1973.00490230034003
   WILLIAMSON JSP, 1990, J VIROL, V64, P4589, DOI 10.1128/JVI.64.9.4589-4592.1990
   YAMAGUCHI K, 1991, J NEUROIMMUNOL, V32, P1, DOI 10.1016/0165-5728(91)90065-F
NR 38
TC 180
Z9 182
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD FEB
PY 2000
VL 74
IS 3
BP 1415
EP 1424
DI 10.1128/JVI.74.3.1415-1424.2000
PG 10
WC Virology
SC Virology
GA 273YZ
UT WOS:000084738100038
PM 10627552
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Walter, TS
   Meier, C
   Assenberg, R
   Au, KF
   Ren, JS
   Verma, A
   Nettleship, JE
   Owens, RJ
   Stuart, DI
   Grimes, JM
AF Walter, Thomas S.
   Meier, Christoph
   Assenberg, Rene
   Au, Kin-Fai
   Ren, Jingshan
   Verma, Anil
   Nettleship, Joanne E.
   Owens, Raymond J.
   Stuart, David I.
   Grimes, Jonathan M.
TI Lysine methylation as a routine rescue strategy for protein
   crystallization
SO STRUCTURE
LA English
DT Article
ID HIGH-THROUGHPUT TECHNOLOGIES; REDUCTIVE METHYLATION; STRUCTURAL
   GENOMICS; HIGH-RESOLUTION; THERMOTOGA-MARITIMA; CRYSTAL-STRUCTURE;
   SARS-CORONAVIRUS; SURFACE RESIDUES; DEHYDRATION; DIFFRACTION
AB Crystallization remains a critical step in X-ray structure determination. Because it is not generally possible to rationally predict crystallization conditions, commercial screens have been developed which sample a wide range of crystallization space. While this approach has proved successful in many cases, a significant number of proteins fail to crystallize despite being soluble and monodispersed. It is established that chemical modification can facilitate the crystallization of otherwise intractable proteins. Here we describe a method for the reductive methylation of lysine residues which is simple, inexpensive, and efficient, and report on its application to ten proteins. We describe the effect of methylation on the physicochemical properties of these proteins, and show that it led to diffraction-quality crystals from four proteins and structures for three that had hitherto proved refractory to crystallization. The method is suited to both low- and high-throughput laboratories.
C1 Univ Oxford, Oxford Prot Prod Facil, Oxford OX3 7BN, England.
   Univ Oxford, Div Struct Biol, Oxford OX3 7BN, England.
RP Grimes, JM (reprint author), Univ Oxford, Oxford Prot Prod Facil, Henry Wellcome Bldg Genom Med,Roosevelt Dr, Oxford OX3 7BN, England.
EM jonathan@strubi.ox.ac.uk
RI Walter, Thomas/S-8636-2017; Walter, Thomas S/S-5104-2019
OI Walter, Thomas/0000-0002-0030-7235; Walter, Thomas
   S/0000-0002-0030-7235; Owens, Ray/0000-0002-3705-2993; Stuart,
   David/0000-0002-3426-4210; Ren, Jingshan/0000-0003-4015-1404;
   Nettleship, Joanne/0000-0002-1258-1733
FU Medical Research CouncilMedical Research Council UK (MRC) [G0400717];
   Wellcome TrustWellcome Trust
CR Adams MWW, 2003, ACCOUNTS CHEM RES, V36, P191, DOI 10.1021/ar0101382
   Albeck S, 2006, ACTA CRYSTALLOGR D, V62, P1184, DOI 10.1107/S090744490602991X
   Au K, 2006, ACTA CRYSTALLOGR D, V62, P1267, DOI 10.1107/S0907444906033555
   Brown G, 2003, LAT TRADE, V11, P36
   Canaves JM, 2004, J MOL BIOL, V344, P977, DOI 10.1016/j.jmb.2004.09.076
   Derewenda ZS, 2006, ACTA CRYSTALLOGR D, V62, P116, DOI 10.1107/S0907444905035237
   Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757
   Esnouf RM, 1998, ACTA CRYSTALLOGR D, V54, P938, DOI 10.1107/S0907444998004284
   Esnouf RM, 2006, ACTA CRYSTALLOGR D, V62, P1260, DOI 10.1107/S0907444906033580
   Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290
   Fogg MJ, 2006, ACTA CRYSTALLOGR D, V62, P1196, DOI 10.1107/S0907444906030915
   Geerlof A, 2006, ACTA CRYSTALLOGR D, V62, P1125, DOI 10.1107/S0907444906030307
   Heras B, 2003, STRUCTURE, V11, P139, DOI 10.1016/S0969-2126(03)00005-4
   IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0
   Kobayashi M, 1999, ACTA CRYSTALLOGR D, V55, P931, DOI 10.1107/S0907444999002115
   Kurinov IV, 2000, BIOCHEM BIOPH RES CO, V275, P549, DOI 10.1006/bbrc.2000.3329
   LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0
   Lesley SA, 2002, P NATL ACAD SCI USA, V99, P11664, DOI 10.1073/pnas.142413399
   Longenecker KL, 2001, ACTA CRYSTALLOGR D, V57, P679, DOI 10.1107/S0907444901003122
   Mateja A, 2002, ACTA CRYSTALLOGR D, V58, P1983, DOI 10.1107/S090744490201394X
   MCELROY HE, 1992, J CRYST GROWTH, V122, P265, DOI 10.1016/0022-0248(92)90255-H
   MEANS GE, 1968, BIOCHEMISTRY-US, V7, P2192, DOI 10.1021/bi00846a023
   Meier C, 2006, STRUCTURE, V14, P1157, DOI 10.1016/j.str.2006.05.012
   RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857
   Rayment I, 1997, METHOD ENZYMOL, V276, P171, DOI 10.1016/S0076-6879(97)76058-0
   Ren JS, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-13
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   RICE RH, 1971, J BIOL CHEM, V246, P831
   RYPNIEWSKI WR, 1993, BIOCHEMISTRY-US, V32, P9851, DOI 10.1021/bi00088a041
   Saxena AK, 2006, NAT STRUCT MOL BIOL, V13, P90, DOI 10.1038/nsmb1024
   Schubot FD, 2004, ACTA CRYSTALLOGR D, V60, P1981, DOI 10.1107/S090744490402.1005
   Siebold C, 2005, P NATL ACAD SCI USA, V102, P16836, DOI 10.1073/pnas.0504997102
   Stroh JG, 2005, J AM SOC MASS SPECTR, V16, P38, DOI 10.1016/j.jasms.2004.08.018
   Sutton G, 2004, STRUCTURE, V12, P341, DOI 10.1016/j.str.2004.01.016
   Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808
   Walter TS, 2003, J APPL CRYSTALLOGR, V36, P308, DOI 10.1107/S0021889803001997
   Yang ZR, 2005, BIOINFORMATICS, V21, P3369, DOI 10.1093/bioinformatics/bti534
NR 37
TC 178
Z9 186
U1 0
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0969-2126
EI 1878-4186
J9 STRUCTURE
JI Structure
PD NOV
PY 2006
VL 14
IS 11
BP 1617
EP 1622
DI 10.1016/j.str.2006.09.005
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 106UQ
UT WOS:000242127800005
PM 17098187
DA 2020-04-03
ER

PT J
AU Towner, JS
   Khristova, ML
   Sealy, TK
   Vincent, MJ
   Erickson, BR
   Bawiec, DA
   Hartman, AL
   Comer, JA
   Zaki, SR
   Stroher, U
   da Silva, FG
   del Castillo, F
   Rollin, PE
   Ksiazek, TG
   Nichol, ST
AF Towner, Jonathan S.
   Khristova, Marina L.
   Sealy, Tara K.
   Vincent, Martin J.
   Erickson, Bobbie R.
   Bawiec, Darcy A.
   Hartman, Amy L.
   Comer, James A.
   Zaki, Sherif R.
   Stroher, Ute
   da Silva, Filomena Gomes
   del Castillo, Fernando
   Rollin, Pierre E.
   Ksiazek, Thomas G.
   Nichol, Stuart T.
TI Marburgvirus Genomics and association with a large hemorrhagic fever
   outbreak in Angola
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NUCLEOTIDE-SEQUENCE ANALYSIS; EBOLA-VIRUS; L-GENE; SARS CORONAVIRUS;
   FILOVIRUS; PROTEIN; TRANSCRIPTION; REPLICATION; VP35; VP24
AB In March 2005, the Centers for Disease Control and Prevention (CDC) investigated a large hemorrhagic fever (HF) outbreak in Uige Province in northern Angola, West Africa. In total, 15 initial specimens were sent to CDC, Atlanta, Ga., for testing for viruses associated with viral HFs known to be present in West Africa, including ebolavirus. Marburgvirus was also included despite the fact that the origins of all earlier outbreaks were linked directly to East Africa. Surprisingly, marburgvirus was confirmed (12 of 15 specimens) as the cause of the outbreak. The outbreak likely began in October 2004 and ended in July 2005, and it included 252 cases and 227 (90%) fatalities (report from the Ministry of Health, Republic of Angola, 2005), making it the largest Marburg HF outbreak on record. A real-time quantitative reverse transcription-PCR assay utilized and adapted during the outbreak proved to be highly sensitive and sufficiently robust for field use. Partial marburgvirus RNA sequence analysis revealed up to 21% nucleotide divergence among the previously characterized East African strains, with the most distinct being Ravn from Kenya (1987). The Angolan strain was less different (similar to 7%) from the main group of East African marburgviruses than one might expect given the large geographic separation. To more precisely analyze the virus genetic differences between outbreaks and among viruses within the Angola outbreak itself, a total of 16 complete virus genomes were determined, including those of the virus isolates Ravn (Kenya, 1987) and 05DRC, 07DRC, and 09DRC (Democratic Republic of Congo, 1998) and the reference Angolan virus isolate (Ang1379v). In addition, complete genome sequences were obtained from RNAs extracted from 10 clinical specimens reflecting various stages of the disease and locations within the Angolan outbreak. While the marburgviruses exhibit high overall genetic diversity (up to 22%), only 6.8% nucleotide difference was found between the West African Angolan viruses and the majority of East African viruses, suggesting that the virus reservoir species in these regions are not substantially distinct. Remarkably few nucleotide differences were found among the Angolan clinical specimens (0 to 0.07%), consistent with an outbreak scenario in which a single (or rare) introduction of virus from the reservoir species into the human population was followed by person-to-person transmission with little accumulation of mutations. This is in contrast to the 1998 to 2000 marburgvirus outbreak, where evidence of several virus genetic lineages (with up to 21% divergence) and multiple virus introductions into the human population was found.
C1 Ctr Dis Control & Prevent, Special Pathogens Branch, Atlanta, GA 30333 USA.
   Ctr Dis Control & Prevent, DVRD, Biotechnol Core Facil Branch, Atlanta, GA 30333 USA.
   Ctr Dis Control & Prevent, SRP, Atlanta, GA 30333 USA.
   Ctr Dis Control & Prevent, Infect Dis Pathol Activ, Atlanta, GA 30333 USA.
   Ctr Dis Control & Prevent, DVRD, NCID, Atlanta, GA 30333 USA.
   Ctr Dis Control & Prevent, Global Aids Program, Atlanta, GA 30333 USA.
   Publ Hlth Agcy Canada, Natl Microbiol Lab, Special Pathogens Program, Winnipeg, MB R3E 3R2, Canada.
   Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0W3, Canada.
   Inst Nacl Saude Publ, Minist Saude, Luanda, Angola.
RP Nichol, ST (reprint author), 1600 Clifton Rd,Mailstop G14, Atlanta, GA 30333 USA.
EM Stn1@cdc.gov
OI Hartman, Amy/0000-0002-0857-2973
CR Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422
   Bamberg S, 2005, J VIROL, V79, P13421, DOI 10.1128/JVI.79.21.13421-13433.2005
   BARIK S, 1990, VIROLOGY, V175, P332, DOI 10.1016/0042-6822(90)90218-G
   Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003
   Bausch DG, 2003, EMERG INFECT DIS, V9, P1531, DOI 10.3201/eid0912.030355
   Borroto R J, 1997, Rev Panam Salud Publica, V1, P3
   Bray M, 1998, J INFECT DIS, V178, P651, DOI 10.1086/515386
   BUKREYEV AA, 1995, ARCH VIROL, V140, P1589, DOI 10.1007/BF01322532
   *CDCP WHO, 1998, INF CONTR VIR HAEM F, P1
   Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P308
   Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997
   Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151
   Duprex WP, 2002, J VIROL, V76, P7322, DOI 10.1128/JVI.76.14.7322-7328.2002
   FELDMANN H, 1992, VIRUS RES, V24, P1, DOI 10.1016/0168-1702(92)90027-7
   Feldmann H, 1999, CURR TOP MICROBIOL, V235, P1
   Geisbert TW, 2000, LAB INVEST, V80, P171, DOI 10.1038/labinvest.3780021
   Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2
   Hartlieb B, 2003, J BIOL CHEM, V278, P41830, DOI 10.1074/jbc.M307036200
   Hartman AL, 2004, VIROLOGY, V328, P177, DOI 10.1016/j.virol.2004.07.006
   Johnson ED, 1996, ARCH VIROL, P101
   KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269
   Ksiazek TG, 1999, J INFECT DIS, V179, pS177, DOI 10.1086/514321
   Ksiazek TG, 1999, J INFECT DIS, V179, pS192, DOI 10.1086/514313
   Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a
   Leroy EM, 2004, SCIENCE, V303, P387, DOI 10.1126/science.1092528
   Leroy EM, 2002, J GEN VIROL, V83, P67, DOI 10.1099/0022-1317-83-1-67
   Liu JJ, 2005, PLOS MED, V2, P162, DOI 10.1371/journal.pmed.0020043
   Lotfering B, 1999, VIROLOGY, V255, P50, DOI 10.1006/viro.1998.9577
   MARTINI G A, 1971, P1
   MARTINI GA, 1971, MARBURG VIRUS DIS, pR5
   McIlhatton MA, 1997, J GEN VIROL, V78, P571, DOI 10.1099/0022-1317-78-3-571
   *MIN HLTH REP ANG, 2005, DECL TERM MARB VIR H
   Modrof J, 2003, J VIROL, V77, P3334, DOI 10.1128/JVI.77.5.3334-3338.2003
   Modrof J, 2001, VIROLOGY, V287, P171, DOI 10.1006/viro.2001.1027
   Moller P, 2005, J VIROL, V79, P14876, DOI 10.1128/JVI.79.23.14876-14886.2005
   MUHLBERGER E, 1992, VIROLOGY, V187, P534, DOI 10.1016/0042-6822(92)90456-Y
   NICHOL ST, COMMUNICATION
   Peters CJ, 1999, CURR TOP MICROBIOL, V235, P85
   Peterson AT, 2004, EMERG INFECT DIS, V10, P2073, DOI 10.3201/eid1012.040346
   Peterson AT, 2004, EMERG INFECT DIS, V10, P40, DOI 10.3201/eid1001.030125
   Reid SP, 2006, J VIROL, V80, P5156, DOI 10.1128/JVI.02349-05
   Rodriguez LL, 1999, J INFECT DIS, V179, pS170, DOI 10.1086/514291
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Sanchez A, 2005, VIRUS RES, V113, P16, DOI 10.1016/j.virusres.2005.03.028
   Sanchez A, 1998, VIROLOGY, V240, P138, DOI 10.1006/viro.1997.8902
   Sanger C, 2002, VIROLOGY, V295, P20, DOI 10.1006/viro.2002.1374
   Swanepoel R, 1996, EMERG INFECT DIS, V2, P321, DOI 10.3201/eid0204.960407
   Towner JS, 2004, J VIROL, V78, P4330, DOI 10.1128/JVI.78.8.4330-4341.2004
   TOWNER JS, 2006, UNPUB DATA
   Vega VB, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-32
   Volchkov VE, 2000, VIROLOGY, V277, P147, DOI 10.1006/viro.2000.0572
   VOLCHKOV VE, 1992, FEBS LETT, V305, P181, DOI 10.1016/0014-5793(92)80662-Z
   Volchkov VE, 1999, J GEN VIROL, V80, P355, DOI 10.1099/0022-1317-80-2-355
   Volchkov VE, 2000, VIROLOGY, V268, P1, DOI 10.1006/viro.1999.0110
   *WHO, 1967, WKLY EPIDEMIOL REC, V42, P479
   *WHO, 2005, WKLY EPIDEMIOL REC, V80, P115
   *WHO, 1999, WKLY EPIDEMIOL REC, V74, P145
   WILL C, 1993, J VIROL, V67, P1203, DOI 10.1128/JVI.67.3.1203-1210.1993
   YADDANAPUDI K, UNPUB IMPLICATION RE
   Zaki SR, 1999, J INFECT DIS, V179, pS36, DOI 10.1086/514319
NR 60
TC 178
Z9 203
U1 2
U2 23
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUL
PY 2006
VL 80
IS 13
BP 6497
EP 6516
DI 10.1128/JVI.00069-06
PG 20
WC Virology
SC Virology
GA 054MJ
UT WOS:000238380700031
PM 16775337
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Albina, E
   Carrat, C
   Charley, B
AF Albina, E
   Carrat, C
   Charley, B
TI Interferon-alpha response to swine arterivirus (PoAV), the porcine
   reproductive and respiratory syndrome virus
SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
LA English
DT Article
ID AUJESZKYS-DISEASE VIRUS; TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS;
   EPIDEMIC ABORTION; CAUSATIVE AGENT; INFLUENZA-VIRUS; LELYSTAD VIRUS;
   FEEDER PIGS; INFECTION; PATHOGENICITY; REPLICATION
AB We studied the interferon-alpha (IFN-alpha) system in relation to the porcine arterivirus (PoAV), porcine reproductive and respiratory syndrome virus (PRRSV). Recombinant porcine IFN-alpha inhibited the growth of this virus in alveolar macrophage cultures, When pigs were challenged intranasally with PoAV, their serum contained IFN-alpha in relatively low concentrations on the second day after challenge and up to 5 days at the latest. Most animals had no IFN-alpha in their lung secretions, even though PoAV replicates in the respiratory tract. In vitro, PoAV replicates in alveolar macrophages, but neither these nor peripheral blood mononuclear cells (PBMC) produced IFN-alpha in response to infection. This may be because PoAV suppresses IFN-alpha production. When macrophages treated with PoAV were superinfected with swine transmissible gastroenteritis virus (TGEV), a known good inducer of IFN, no IFN-alpha was detected. This suppressive effect was lost when the virus was inactivated by UV light. Our results suggest that downregulation of IFN-alpha production may play an important part in enabling PoAV to replicate in cell cultures and in pigs.
C1 CNEVA Ploufragan, Unite Virol & Immunol Porcines, F-22440 Ploufragan, France.
   INRA, Unite Virol & Immunol Mol, Jouy En Josas, France.
RP Albina, E (reprint author), CNEVA Ploufragan, Unite Virol & Immunol Porcines, BP 53, F-22440 Ploufragan, France.
CR ALBINA E, 1994, VET REC, V134, P567, DOI 10.1136/vr.134.22.567
   ALBINA E, 1997, IN PRESS VET IMMUNOL
   ANDRIES K, 1978, AM J VET RES, V39, P1282
   ARTURSSON K, 1995, SCAND J IMMUNOL, V41, P121, DOI 10.1111/j.1365-3083.1995.tb03543.x
   BARON S, 1994, ANTIVIR RES, V24, P97, DOI 10.1016/0166-3542(94)90058-2
   BARON T, 1992, ANN RECH VET, V23, P161
   BOHL EH, 1972, INFECT IMMUN, V6, P289, DOI 10.1128/IAI.6.3.289-301.1972
   CHARLEY B, 1988, J VIROL, V62, P8, DOI 10.1128/JVI.62.1.8-11.1988
   DEARCE HD, 1992, VET IMMUNOL IMMUNOP, V30, P319, DOI 10.1016/0165-2427(92)90102-V
   DERBYSHIRE JB, 1989, CAN J VET RES, V53, P52
   HALBUR PG, 1994, J VET DIAGN INVEST, V6, P254, DOI 10.1177/104063879400600219
   HALBUR PG, 1995, VET PATHOL, V32, P648, DOI 10.1177/030098589503200606
   Halbur PG, 1996, J VET DIAGN INVEST, V8, P11, DOI 10.1177/104063879600800103
   JORDAN LT, 1995, VET MICROBIOL, V45, P59, DOI 10.1016/0378-1135(94)00118-G
   KAERBER G, 1931, N-S ARCH PHARMACOL, V142, P480
   LABONNARDIERE C, 1981, INFECT IMMUN, V32, P28, DOI 10.1128/IAI.32.1.28-31.1981
   LAU AS, 1994, RES IMMUNOL, V145, P668, DOI 10.1016/S0923-2494(05)80052-5
   LAUDE H, 1984, J GEN VIROL, V65, P327, DOI 10.1099/0022-1317-65-2-327
   LEFEVRE F, 1990, J GEN VIROL, V71, P1057, DOI 10.1099/0022-1317-71-5-1057
   LOEWEN KG, 1988, CAN J VET RES, V52, P149
   MEULENBERG JJM, 1993, VIROLOGY, V192, P62, DOI 10.1006/viro.1993.1008
   MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221
   NAUWYNCK HJ, 1995, VET MICROBIOL, V43, P307, DOI 10.1016/0378-1135(94)00103-4
   NOWACKI W, 1993, RES IMMUNOL, V144, P111, DOI 10.1016/0923-2494(93)80066-8
   PLAGEMANN PGW, 1995, SPRINGER SEMIN IMMUN, V17, P167
   PLAGEMANN PGW, 1996, FIELDS VIROLOGY, P1105
   PLANA J, 1992, VET MICROBIOL, V33, P203, DOI 10.1016/0378-1135(92)90048-X
   POL JMA, 1991, VET QUART, V13, P137, DOI 10.1080/01652176.1991.9694298
   Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996
   Riffault S, 1996, J INTERF CYTOK RES, V16, P1007, DOI 10.1089/jir.1996.16.1007
   SANDBERG K, 1994, J VIROL, V68, P7358, DOI 10.1128/JVI.68.11.7358-7366.1994
   Smith GL, 1996, CURR OPIN IMMUNOL, V8, P467, DOI 10.1016/S0952-7915(96)80032-X
   VanReeth K, 1996, VET MICROBIOL, V48, P325, DOI 10.1016/0378-1135(95)00145-X
   VANREETH K, 1994, AM J VET RES, V55, P1275
   VENGRIS VE, 1972, CAN J COMPARAT MED, V36, P288
   WITTMANN G, 1980, ARCH VIROL, V66, P227, DOI 10.1007/BF01314736
NR 36
TC 178
Z9 190
U1 0
U2 6
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1079-9907
J9 J INTERF CYTOK RES
JI J. Interferon Cytokine Res.
PD JUL
PY 1998
VL 18
IS 7
BP 485
EP 490
DI 10.1089/jir.1998.18.485
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 106DG
UT WOS:000075114100006
PM 9712364
DA 2020-04-03
ER

PT J
AU Snijder, EJ
   van der Meer, Y
   Zevenhoven-Dobbe, J
   Onderwater, JJM
   van der Meulen, J
   Koerten, HK
   Mommaas, AM
AF Snijder, Eric J.
   van der Meer, Yvonne
   Zevenhoven-Dobbe, Jessika
   Onderwater, Jos J. M.
   van der Meulen, Jannes
   Koerten, Henk K.
   Mommaas, A. Mieke
TI Ultrastructure and origin of membrane vesicles associated with the
   severe acute respiratory syndrome coronavirus replication complex
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; SARS-CORONAVIRUS; ENDOPLASMIC-RETICULUM; VIRAL
   REPLICATION; RNA REPLICATION; GOLGI-COMPLEX; PROTEIN; IDENTIFICATION;
   GENOME; LOCALIZATION
AB The RNA replication complexes of mammalian positive-stranded RNA viruses are generally associated with (modified) intracellular membranes, a feature thought to be important for creating an environment suitable for viral RNA synthesis, recruitment of host components, and possibly evasion of host defense mechanisms. Here, using a panel of replicase-specific antisera, we have analyzed the earlier stages of severe acute respiratory syndrome coronavirus (SARS-CoV) infection in Vero E6 cells, in particular focusing on the subcellular localization of the replicase and the ultrastructure of the associated membranes. Confocal immunofluorescence microscopy demonstrated the colocalization, throughout infection, of replicase cleavage products containing different key enzymes for SARS-CoV replication. Electron microscopy revealed the early formation and accumulation of typical double-membrane vesicles, which probably carry the viral replication complex. The vesicles appear to be fragile, and their preservation was significantly improved by using cryofixation protocols and freeze substitution methods. In immunoelectron microscopy, the virus-induced vesicles could be labeled with replicase-specific antibodies. Opposite to what was described for mouse hepatitis virus, we did not observe the late relocalization of specific replicase subunits to the presumed site of virus assembly, which was labeled using an antiserum against the viral membrane protein. This conclusion was further supported using organelle-specific marker proteins and electron microscopy. Similar morphological studies and labeling experiments argued against the previously proposed involvement of the autophagic pathway as the source for the vesicles with which the replicase is associated and instead suggested the endoplasmic reticulum to be the most likely donor of the membranes that carry the SARS-CoV replication complex.
C1 Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, NL-2300 RC Leiden, Netherlands.
   Leiden Univ, Med Ctr, Ctr Electron Microscopy, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands.
RP Snijder, EJ (reprint author), Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, LUMC P4-26,POB 9600, NL-2300 RC Leiden, Netherlands.
EM e.j.snijder@lumc.nl
RI Snijder, Eric J./E-6073-2018
OI Snijder, Eric J./0000-0003-3297-2309
CR Ahlquist P, 2003, J VIROL, V77, P8181, DOI 10.1128/JVI.77.15.8181-8186.2003
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004
   BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992
   Bost AG, 2001, VIROLOGY, V285, P21, DOI 10.1006/viro.2001.0932
   Boucrot E, 2003, J BIOL CHEM, V278, P14196, DOI 10.1074/jbc.M207901200
   Brockway SM, 2004, J VIROL, V78, P11551, DOI 10.1128/JVI.78.21.11551-11562.2004
   de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Egloff MP, 2004, P NATL ACAD SCI USA, V101, P3792, DOI 10.1073/pnas.0307877101
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Guarino LA, 2005, J MOL BIOL, V353, P1106, DOI 10.1016/j.jmb.2005.09.007
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55
   KRIJNSELOCKER J, 1992, J BIOL CHEM, V267, P14094
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lai M.M.C., 2001, FIELDS VIROLOGY, P1163
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944
   Mackenzie J, 2005, TRAFFIC, V6, P967, DOI 10.1111/j.1600-0854.2005.00339.x
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Martinet W, 2006, J HISTOCHEM CYTOCHEM, V54, P85, DOI 10.1369/jhc.5A6743.2005
   Miller DJ, 2003, J VIROL, V77, P12193, DOI 10.1128/JVI.77.22.12193-12202.2003
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Nal B, 2005, J GEN VIROL, V86, P1423, DOI 10.1099/vir.0.80671-0
   Ng ML, 2003, J GEN VIROL, V84, P3291, DOI 10.1099/vir.0.19505-0
   Novoa RR, 2005, BIOL CELL, V97, P147, DOI 10.1042/BC20040058
   Pasternak AO, 2006, J GEN VIROL, V87, P1403, DOI 10.1099/vir.0.81611-0
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peti W, 2005, J VIROL, V79, P12905, DOI 10.1128/JVI.79.20.12905-12913.2005
   Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Putics A, 2005, J VIROL, V79, P12721, DOI 10.1128/JVI.79.20.12721-12731.2005
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Salanueva IJ, 1999, J VIROL, V73, P7952, DOI 10.1128/JVI.73.10.7952-7964.1999
   Salonen A, 2005, CURR TOP MICROBIOL, V285, P139
   Sawicki SG, 2005, CURR TOP MICROBIOL, V287, P31, DOI 10.1007/3-540-26765-4_2
   Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996
   SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643
   Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728
   Shi ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999
   SIDDELL SG, 2005, TOPLEY WILSONS MICRO, P823
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994
   Snijder EJ, 2001, J GEN VIROL, V82, P985, DOI 10.1099/0022-1317-82-5-985
   SNIJDER EJ, 2005, TOPLEY WILSONS MICRO, V1, P390
   Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000
   Sutton G, 2004, STRUCTURE, V12, P341, DOI 10.1016/j.str.2004.01.016
   Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   van der Meer Y, 1998, J VIROL, V72, P6689, DOI 10.1128/JVI.72.8.6689-6698.1998
   van der Meer Y, 1999, J VIROL, V73, P7641, DOI 10.1128/JVI.73.9.7641-7657.1999
   VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0
   von Grotthuss M, 2003, CELL, V113, P701, DOI 10.1016/S0092-8674(03)00424-0
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhang QF, 2004, J MED VIROL, V73, P332, DOI 10.1002/jmv.20095
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 73
TC 177
Z9 189
U1 2
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUN
PY 2006
VL 80
IS 12
BP 5927
EP 5940
DI 10.1128/JVI.02501-05
PG 14
WC Virology
SC Virology
GA 050QV
UT WOS:000238103900028
PM 16731931
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Namy, O
   Moran, SJ
   Stuart, DI
   Gilbert, RJC
   Brierley, I
AF Namy, O
   Moran, SJ
   Stuart, DI
   Gilbert, RJC
   Brierley, I
TI A mechanical explanation of RNA pseudoknot function in programmed
   ribosomal frameshifting
SO NATURE
LA English
DT Article
ID ELECTRON-DENSITY MAPS; MESSENGER-RNA; GENE-EXPRESSION; 80S RIBOSOME;
   SIGNAL; TRANSLOCATION; MICROSCOPY
AB The triplet-based genetic code requires that translating ribosomes maintain the reading frame of a messenger RNA faithfully to ensure correct protein synthesis(1). However, in programmed -1 ribosomal frameshifting(2), a specific subversion of frame maintenance takes place, wherein the ribosome is forced to shift one nucleotide backwards into an overlapping reading frame and to translate an entirely new sequence of amino acids. This process is indispensable in the replication of numerous viral pathogens, including HIV and the coronavirus associated with severe acute respiratory syndrome(3), and is also exploited in the expression of several cellular genes(4). Frameshifting is promoted by an mRNA signal composed of two essential elements: a heptanucleotide 'slippery' sequence(5) and an adjacent mRNA secondary structure, most often an mRNA pseudoknot(6). How these components operate together to manipulate the ribosome is unknown. Here we describe the observation of a ribosome - mRNA pseudoknot complex that is stalled in the process of -1 frameshifting. Cryoelectron microscopic imaging of purified mammalian 80S ribosomes from rabbit reticulocytes paused at a coronavirus pseudoknot reveals an intermediate of the frameshifting process. From this it can be seen how the pseudoknot interacts with the ribosome to block the mRNA entrance channel, compromising the translocation process and leading to a spring-like deformation of the P-site transfer RNA. In addition, we identify movements of the likely eukaryotic ribosomal helicase and confirm a direct interaction between the translocase eEF2 and the P-site tRNA. Together, the structural changes provide a mechanical explanation of how the pseudoknot manipulates the ribosome into a different reading frame.
C1 Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England.
   Univ Oxford, Div Struct Biol, Oxford OX3 7BN, England.
   Univ Oxford, Cent Chem Lab, Oxford Ctr Mol Sci, Oxford OX1 3QH, England.
RP Brierley, I (reprint author), Univ Cambridge, Dept Pathol, Div Virol, Tennis Court Rd, Cambridge CB2 1QP, England.
EM gilbert@strubi.ox.ac.uk; ib103@mole.bio.cam.ac.uk
RI Namy, olivier/B-8906-2008
OI Stuart, David/0000-0002-3426-4210; Namy, Olivier/0000-0002-1143-5961
FU Biotechnology and Biological Sciences Research CouncilBiotechnology and
   Biological Sciences Research Council (BBSRC) [BB/D009499/1,
   BB/D013305/1]; Medical Research CouncilMedical Research Council UK (MRC)
   [G0500365]; Wellcome TrustWellcome Trust
CR Atkins JF, 2001, COLD SPRING HARB SYM, V66, P217, DOI 10.1101/sqb.2001.66.217
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   BRIERLEY I, 1992, J MOL BIOL, V227, P463, DOI 10.1016/0022-2836(92)90901-U
   BRIERLEY I, 2005, VIRUS RES       1128
   Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363
   Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996
   Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597
   Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030
   JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054
   JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Jorgensen R, 2003, NAT STRUCT BIOL, V10, P379, DOI 10.1038/nsb923
   Kontos H, 2001, MOL CELL BIOL, V21, P8657, DOI 10.1128/MCB.21.24.8657-8670.2001
   Lopinski JD, 2000, MOL CELL BIOL, V20, P1095, DOI 10.1128/MCB.20.4.1095-1103.2000
   MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396
   Namy O, 2004, MOL CELL, V13, P157, DOI 10.1016/S1097-2765(04)00031-0
   Navaza J, 2002, ACTA CRYSTALLOGR D, V58, P1820, DOI 10.1107/S0907444902013707
   Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440
   Plant EP, 2003, RNA, V9, P168, DOI 10.1261/rna.2132503
   SOMOGYI P, 1993, MOL CELL BIOL, V13, P6931, DOI 10.1128/MCB.13.11.6931
   Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6
   Spahn CMT, 2004, EMBO J, V23, P1008, DOI 10.1038/sj.emboj.7600102
   Takyar S, 2005, CELL, V120, P49, DOI 10.1016/j.cell.2004.11.042
   TU CL, 1992, P NATL ACAD SCI USA, V89, P8636, DOI 10.1073/pnas.89.18.8636
   Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003
   vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004
   WEISS R B, 1989, New Biologist, V1, P159
   YELVERTON E, 1994, MOL MICROBIOL, V11, P303, DOI 10.1111/j.1365-2958.1994.tb00310.x
   Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4
NR 29
TC 177
Z9 182
U1 2
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAY 11
PY 2006
VL 441
IS 7090
BP 244
EP 247
DI 10.1038/nature04735
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 040YP
UT WOS:000237418800052
PM 16688178
DA 2020-04-03
ER

PT J
AU Wang, NS
   Shi, XL
   Jiang, LW
   Zhang, SY
   Wang, DL
   Tong, P
   Guo, DX
   Fu, LL
   Cui, Y
   Liu, X
   Arledge, KC
   Chen, YH
   Zhang, LQ
   Wang, XQ
AF Wang, Nianshuang
   Shi, Xuanling
   Jiang, Liwei
   Zhang, Senyan
   Wang, Dongli
   Tong, Pei
   Guo, Dongxing
   Fu, Lili
   Cui, Ye
   Liu, Xi
   Arledge, Kelly C.
   Chen, Ying-Hua
   Zhang, Linqi
   Wang, Xinquan
TI Structure of MERS-CoV spike receptor-binding domain complexed with human
   receptor DPP4
SO CELL RESEARCH
LA English
DT Article
DE MERS-CoV; DPP4; RBD; viral infection; complex structure
ID MIDDLE-EAST; FUNCTIONAL RECEPTOR; S PROTEIN; HCOV-EMC; CORONAVIRUS;
   BETACORONAVIRUS
AB The spike glycoprotein (S) of recently identified Middle East respiratory syndrome coronavirus (MERS-CoV) targets the cellular receptor, dipeptidyl peptidase 4 (DPP4). Sequence comparison and modeling analysis have revealed a putative receptor-binding domain (RBD) on the viral spike, which mediates this interaction. We report the 3.0 angstrom-resolution crystal structure of MERS-CoV RBD bound to the extracellular domain of human DPP4. Our results show that MERS-CoV RBD consists of a core and a receptor-binding subdomain. The receptor-binding subdomain interacts with DPP4 beta-propeller but not its intrinsic hydrolase domain. MERS-CoV RBD and related SARS-CoV RBD share a high degree of structural similarity in their core subdomains, but are notably divergent in the receptor-binding subdomain. Mutagenesis studies have identified several key residues in the receptor-binding subdomain that are critical for viral binding to DPP4 and entry into the target cell. The atomic details at the interface between MERS-CoV RBD and DPP4 provide structural understanding of the virus and receptor interaction, which can guide development of therapeutics and vaccines against MERS-CoV infection.
C1 [Wang, Nianshuang; Zhang, Senyan; Wang, Dongli; Tong, Pei; Cui, Ye; Liu, Xi; Chen, Ying-Hua; Wang, Xinquan] Tsinghua Univ, Sch Life Sci, Struct Biol Ctr, Minist Educ,Key Lab Prot Sci, Beijing 100084, Peoples R China.
   [Shi, Xuanling; Jiang, Liwei; Guo, Dongxing; Fu, Lili; Arledge, Kelly C.; Zhang, Linqi] Tsinghua Univ, Sch Med, Res Ctr Publ Hlth, Comprehens AIDS Res Ctr, Beijing 100084, Peoples R China.
RP Zhang, LQ (reprint author), Tsinghua Univ, Sch Med, Res Ctr Publ Hlth, Comprehens AIDS Res Ctr, Beijing 100084, Peoples R China.
EM zhanglinqi@tsinghua.edu.cn; xinquanwang@mail.tsinghua.edu.cn
RI Wang, Nianshuang/C-1463-2010
OI Wang, Nianshuang/0000-0002-7569-011X
FU Ministry of Science and TechnologyMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT) [2010CB912402,
   2011CB910502]; Ministry of HealthMinistry of Health - Turkey
   [2012ZX10001009]; Fok Ying Tung Education FoundationFok Ying Tung
   Education Foundation; National Outstanding Youth Award [30825035]
FX We thank Dr JW Wang for assistance with structural determination, and Dr
   JH He and other staff members at Shanghai Synchrotron Research Facility
   beam line BL17U for help with data collection. This work was supported
   by the Ministry of Science and Technology (2010CB912402 and
   2011CB910502), the Ministry of Health (2012ZX10001009), the Fok Ying
   Tung Education Foundation to X Wang and the National Outstanding Youth
   Award (30825035) to L Zhang.
CR BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Chan JFW, 2012, J INFECTION, V65, P477, DOI 10.1016/j.jinf.2012.10.002
   Cohen SX, 2008, ACTA CRYSTALLOGR D, V64, P49, DOI 10.1107/S0907444907047580
   Cowtan K, 2006, ACTA CRYSTALLOGR D, V62, P1002, DOI 10.1107/S0907444906022116
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   DeLano W.L.T., 2002, PYMOL MOL GRAPHICS S
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Gallagher T, 2013, NATURE, V495, P176, DOI 10.1038/495176a
   Jiang SB, 2013, J INFECTION, V67, P156, DOI 10.1016/j.jinf.2013.04.007
   Jiang SB, 2013, J INFECTION, V66, P464, DOI 10.1016/j.jinf.2012.12.003
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Shang H, 2011, J BIOL CHEM, V286, P14531, DOI 10.1074/jbc.M111.224527
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   WHO, WHO GLOB AL RESP COR
   Woo PCY, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.45
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 27
TC 176
Z9 186
U1 11
U2 59
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD AUG
PY 2013
VL 23
IS 8
BP 986
EP 993
DI 10.1038/cr.2013.92
PG 8
WC Cell Biology
SC Cell Biology
GA 193QD
UT WOS:000322574900007
PM 23835475
OA Green Published, Other Gold
DA 2020-04-03
ER

PT J
AU Roberts, A
   Deming, D
   Paddock, CD
   Cheng, A
   Yount, B
   Vogel, L
   Herman, BD
   Sheahan, T
   Heise, M
   Genrich, GL
   Zaki, SR
   Baric, R
   Subbarao, K
AF Roberts, Anjeanette
   Deming, Damon
   Paddock, Christopher D.
   Cheng, Aaron
   Yount, Boyd
   Vogel, Leatrice
   Herman, Brian D.
   Sheahan, Tim
   Heise, Mark
   Genrich, Gillian L.
   Zaki, Sherif R.
   Baric, Ralph
   Subbarao, Kanta
TI A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c
   mice
SO PLOS PATHOGENS
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; INFLUENZA-VIRUS VARIANT; AMINO-ACID CHANGE;
   MATRIX PROTEIN; ANIMAL-MODEL; REPLICATION; VIRULENCE; PATHOGENESIS;
   SEVERITY; MANIFESTATIONS
AB No single animal model for severe acute respiratory syndrome (SARS) reproduces all aspects of the human disease. Young inbred mice support SARS-coronavirus (SARS-CoV) replication in the respiratory tract and are available in sufficient numbers for statistical evaluation. They are relatively inexpensive and easily accessible, but their use in SARS research is limited because they do not develop illness following infection. Older (12- to 14-mo-old) BALB/c mice develop clinical illness and pneumonitis, but they can be hard to procure, and immune senescence complicates pathogenesis studies. We adapted the SARS-CoV (Urbani strain) by serial passage in the respiratory tract of young BALB/c mice. Fifteen passages resulted in a virus (MA15) that is lethal for mice following intranasal inoculation. Lethality is preceded by rapid and high titer viral replication in lungs, viremia, and dissemination of virus to extrapulmonary sites accompanied by lymphopenia, neutrophilia, and pathological changes in the lungs. Abundant viral antigen is extensively distributed in bronchial epithelial cells and alveolar pneumocytes, and necrotic cellular debris is present in airways and alveoli, with only mild and focal pneumonitis. These observations suggest that mice infected with MA15 die from an overwhelming viral infection with extensive, virally mediated destruction of pneumocytes and ciliated epithelial cells. The MA15 virus has six coding mutations associated with adaptation and increased virulence; when introduced into a recombinant SARS-CoV, these mutations result in a highly virulent and lethal virus (rMA15), duplicating the phenotype of the biologically derived MA15 virus. Intranasal inoculation with MA15 reproduces many aspects of disease seen in severe human cases of SARS. The availability of the MA15 virus will enhance the use of the mouse model for SARS because infection with MA15 causes morbidity, mortality, and pulmonary pathology. This virus will be of value as a stringent challenge in evaluation of the efficacy of vaccines and antivirals.
C1 NIAID, Lab Infect Dis, NIH, Bethesda, MD 20892 USA.
   Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA.
   Ctr Dis Control & Prevent, Infect Dis Pathol Act, Atlanta, GA USA.
   Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
   Univ N Carolina, Carolina Vaccine Inst, Chapel Hill, NC USA.
   Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
RP Subbarao, K (reprint author), NIAID, Lab Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM ksubbarao@niaid.nih.gov
OI Subbarao, Kanta/0000-0003-1713-3056
FU Intramural NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; NIAID NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01 AI059136, AI059443, P01 AI059443, AI059136]
CR BROWN EG, 1990, J VIROL, V64, P4523, DOI 10.1128/JVI.64.9.4523-4533.1990
   Brown EG, 1999, VIRUS RES, V61, P63, DOI 10.1016/S0168-1702(99)00027-1
   Chan HLY, 2005, WORLD J GASTROENTERO, V11, P2148, DOI 10.3748/wjg.v11.i14.2148
   Chu CM, 2004, CAN MED ASSOC J, V171, P1349, DOI 10.1503/cmaj.1040398
   Farcas GA, 2005, J INFECT DIS, V191, P193, DOI 10.1086/426870
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Heise MT, 2000, J VIROL, V74, P4207, DOI 10.1128/JVI.74.9.4207-4213.2000
   Ho PL, 2005, EUR RESPIR J, V26, P474, DOI 10.1183/09031936.05.1076704
   Hung IFN, 2004, EMERG INFECT DIS, V10, P1550, DOI 10.3201/eid1009.040058
   Lau YL, 2005, CURR OPIN IMMUNOL, V17, P404, DOI 10.1016/j.coi.2005.05.009
   Lawler JV, 2006, PLOS MED, V3, P677, DOI 10.1371/journal.pmed.0030149
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Leung CW, 2004, PEDIATRICS, V113, pE535, DOI 10.1542/peds.113.6.e535
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li Ming-hui, 2004, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V18, P137
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lin CL, 2004, CHEST, V126, P509, DOI 10.1378/chest.126.2.509
   Manocha S, 2003, CRIT CARE MED, V31, P2684, DOI 10.1097/01.CCM.0000091929.51288.5F
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   McCullers JA, 2005, VIROLOGY, V336, P318, DOI 10.1016/j.virol.2005.03.028
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Roberts A, 2006, J INFECT DIS, V193, P685, DOI 10.1086/500143
   Roberts A, 2005, J VIROL, V79, P5833, DOI 10.1128/JVI.79.9.5833-5838.2005
   Roberts A, 2006, VACCINE, V24, P7056, DOI 10.1016/j.vaccine.2006.07.009
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Shieh WJ, 2005, HUM PATHOL, V36, P303, DOI 10.1016/j.humpath.2004.11.006
   Sims AC, 2006, ADV EXP MED BIOL, V581, P535
   SMEENK CA, 1994, J VIROL, V68, P530, DOI 10.1128/JVI.68.1.530-534.1994
   Smeenk CA, 1996, VIRUS RES, V44, P79, DOI 10.1016/0168-1702(96)01329-9
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Subbarao K, 2006, TRENDS MICROBIOL, V14, P299, DOI 10.1016/j.tim.2006.05.007
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Wong WM, 2003, JAMA-J AM MED ASSOC, V290, P2663, DOI 10.1001/jama.290.20.2663
   Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
NR 37
TC 176
Z9 178
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JAN
PY 2007
VL 3
IS 1
BP 23
EP 37
AR e5
DI 10.1371/journal.ppat.0030005
PG 15
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 196OS
UT WOS:000248492500003
PM 17222058
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU FRANA, MF
   BEHNKE, JN
   STURMAN, LS
   HOLMES, KV
AF FRANA, MF
   BEHNKE, JN
   STURMAN, LS
   HOLMES, KV
TI PROTEOLYTIC CLEAVAGE OF THE E2-GLYCOPROTEIN OF MURINE CORONAVIRUS -
   HOST-DEPENDENT DIFFERENCES IN PROTEOLYTIC CLEAVAGE AND CELL-FUSION
SO JOURNAL OF VIROLOGY
LA English
DT Article
C1 UNIFORMED SERV UNIV HLTH SCI, DEPT PATHOL, BETHESDA, MD 20814 USA.
   NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 18997]; NIGMS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [GM31698]
CR AOYAGI T, 1975, COLD SPRING HARBOR C, V2, P429
   APPLEYARD G, 1985, J GEN VIROL, V66, P363, DOI 10.1099/0022-1317-66-2-363
   BANG FB, 1982, ADV EXP MED BIOL, V142, P359
   BANG FB, 1960, P NATL ACAD SCI USA, V46, P1065, DOI 10.1073/pnas.46.8.1065
   BARTHOLD SW, 1984, ARCH VIROL, V81, P103, DOI 10.1007/BF01309300
   BOSCH FX, 1979, VIROLOGY, V95, P197, DOI 10.1016/0042-6822(79)90414-8
   CAVANAGH D, 1981, J GEN VIROL, V53, P93, DOI 10.1099/0022-1317-53-1-93
   CHELEY S, 1981, VIROLOGY, V115, P310, DOI 10.1016/0042-6822(81)90113-6
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   DUBOISDALCQ ME, 1982, VIROLOGY, V119, P317, DOI 10.1016/0042-6822(82)90092-7
   DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453
   GARTEN W, 1981, VIROLOGY, V115, P361, DOI 10.1016/0042-6822(81)90117-3
   GARTEN W, 1980, J GEN VIROL, V50, P135, DOI 10.1099/0022-1317-50-1-135
   HARTLEY JW, 1963, P SOC EXP BIOL MED, V113, P403
   HIRANO N, 1974, ARCH GES VIRUSFORSCH, V44, P298, DOI 10.1007/BF01240618
   HOLMES KV, 1982, ADV EXP MED BIOL, V142, P133
   HOLMES KV, 1966, J EXP MED, V124, P501, DOI 10.1084/jem.124.3.501
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6
   KOOLEN MJM, 1983, VIROLOGY, V125, P393, DOI 10.1016/0042-6822(83)90211-8
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8
   LAZAROWITZ SG, 1973, VIROLOGY, V52, P119
   LUCAS A, 1977, CELL, V12, P553, DOI 10.1016/0092-8674(77)90131-3
   MAEDA T, 1981, P NATL ACAD SCI-BIOL, V78, P4133, DOI 10.1073/pnas.78.7.4133
   McIntosh K., 1974, Current Topics in Microbiology and Immunology, V63, P85
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   MIZZEN L, 1983, VIROLOGY, V128, P407, DOI 10.1016/0042-6822(83)90266-0
   NAGAI Y, 1976, VIROLOGY, V72, P494, DOI 10.1016/0042-6822(76)90178-1
   NAGAI Y, 1977, VIROLOGY, V77, P125, DOI 10.1016/0042-6822(77)90412-3
   NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x
   NIEMANN H, 1981, J MOL BIOL, V153, P993, DOI 10.1016/0022-2836(81)90463-0
   ROBB JA, 1979, VIROLOGY, V94, P352, DOI 10.1016/0042-6822(79)90467-7
   ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981
   SCHEID A, 1976, VIROLOGY, V69, P265, DOI 10.1016/0042-6822(76)90213-0
   SIDDELL S, 1981, J GEN VIROL, V53, P145, DOI 10.1099/0022-1317-53-1-145
   SIDDELL S, 1982, CURR TOP MICROBIOL, V99, P131
   SIDDELL SG, 1980, J VIROL, V33, P10, DOI 10.1128/JVI.33.1.10-17.1980
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   STERN DF, 1982, J VIROL, V44, P794, DOI 10.1128/JVI.44.3.794-803.1982
   STORZ J, 1981, INFECT IMMUN, V31, P1214, DOI 10.1128/IAI.31.3.1214-1222.1981
   STURMAN L, 1985, TRENDS BIOCHEM SCI, V10, P17, DOI 10.1016/0968-0004(85)90010-6
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985
   STURMAN LS, 1977, VIROLOGY, V77, P650, DOI 10.1016/0042-6822(77)90489-5
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   STURMAN LS, 1977, VIROLOGY, V77, P637, DOI 10.1016/0042-6822(77)90488-3
   STURMAN LS, 1972, INFECT IMMUN, V6, P501, DOI 10.1128/IAI.6.4.501-507.1972
   TAGUCHI F, 1979, ARCH VIROL, V62, P333, DOI 10.1007/BF01318107
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   TYRRELL DAJ, 1967, ARCH GES VIRUSFORSCH, V22, P417, DOI 10.1007/BF01242962
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674
   YOSHIKURA H, 1981, VIROLOGY, V113, P503, DOI 10.1016/0042-6822(81)90178-1
NR 54
TC 176
Z9 179
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PY 1985
VL 56
IS 3
BP 912
EP 920
DI 10.1128/JVI.56.3.912-920.1985
PG 9
WC Virology
SC Virology
GA AUB03
UT WOS:A1985AUB0300032
PM 2999444
OA Bronze
DA 2020-04-03
ER

PT J
AU SPAAN, W
   DELIUS, H
   SKINNER, M
   ARMSTRONG, J
   ROTTIER, P
   SMEEKENS, S
   VANDERZEIJST, BAM
   SIDDELL, SG
AF SPAAN, W
   DELIUS, H
   SKINNER, M
   ARMSTRONG, J
   ROTTIER, P
   SMEEKENS, S
   VANDERZEIJST, BAM
   SIDDELL, SG
TI CORONAVIRUS MESSENGER-RNA SYNTHESIS INVOLVES FUSION OF NON-CONTIGUOUS
   SEQUENCES
SO EMBO JOURNAL
LA English
DT Article
C1 EUROPEAN MOLEC BIOL LAB,D-6900 HEIDELBERG,FED REP GER.
   INST VIROL & IMMUNOBIOL,D-8700 WURZBURG,FED REP GER.
RP SPAAN, W (reprint author), STATE UNIV UTRECHT,INST VIROL,3805 TD UTRECHT,NETHERLANDS.
RI Van der Zeijst, Bernard/AAH-1415-2020; Van der Zeijst, Bernard
   B.A./A-3847-2013; Smeekens, Sjef C/B-6683-2011; Skinner, Michael
   A/B-7112-2012
OI Van der Zeijst, Bernard/0000-0001-9316-2161; Van der Zeijst, Bernard
   B.A./0000-0001-9316-2161; Smeekens, Sjef C/0000-0001-6631-9426; Skinner,
   Michael/0000-0002-0050-4167
CR ARMSTRONG J, 1983, NUCLEIC ACIDS RES, V11, P883, DOI 10.1093/nar/11.3.883
   BRAYTON PR, 1981, J GEN VIROL, V56, P457, DOI 10.1099/0022-1317-56-2-457
   CHELEY S, 1981, VIROLOGY, V112, P596, DOI 10.1016/0042-6822(81)90305-6
   DELIUS H, 1973, J MOL BIOL, V74, P677, DOI 10.1016/0022-2836(73)90056-9
   FIELDS S, 1982, CELL, V28, P303, DOI 10.1016/0092-8674(82)90348-8
   Flint S J, 1981, Curr Top Microbiol Immunol, V93, P47
   GAROFF H, 1981, ANAL BIOCHEM, V115, P450, DOI 10.1016/0003-2697(81)90031-2
   JACOBS L, 1981, J VIROL, V39, P401, DOI 10.1128/JVI.39.2.401-406.1981
   KING AMQ, 1982, CELL, V29, P921, DOI 10.1016/0092-8674(82)90454-8
   Kozak M, 1981, Curr Top Microbiol Immunol, V93, P81
   LAI MMC, 1981, J VIROL, V38, P661, DOI 10.1128/JVI.38.2.661-670.1981
   LAI MMC, 1983, J VIROL, V46, P1027, DOI 10.1128/JVI.46.3.1027-1033.1983
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1982, J VIROL, V41, P557, DOI 10.1128/JVI.41.2.557-565.1982
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   LAZZARINI RA, 1981, CELL, V26, P145, DOI 10.1016/0092-8674(81)90298-1
   LEIBOWITZ JL, 1982, J VIROL, V43, P905, DOI 10.1128/JVI.43.3.905-913.1982
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   MAHY BWJ, 1983, J GEN VIROL, V64, P103, DOI 10.1099/0022-1317-64-1-103
   MCREYNOLDS L, 1978, NATURE, V273, P723, DOI 10.1038/273723a0
   Perrault J, 1981, Curr Top Microbiol Immunol, V93, P151
   PRIESS H, 1980, MOL GEN GENET, V178, P27, DOI 10.1007/BF00267209
   ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SIDDELL S, 1983, J GEN VIROL, V64, P113, DOI 10.1099/0022-1317-64-1-113
   SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761
   SIDDELL SG, 1980, J VIROL, V33, P10, DOI 10.1128/JVI.33.1.10-17.1980
   SKINNER MA, 1983, NUCLEIC ACIDS RES, V11, P5045, DOI 10.1093/nar/11.15.5045
   Smith A J, 1980, Methods Enzymol, V65, P560
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   SPAAN WJM, 1982, J VIROL, V42, P432, DOI 10.1128/JVI.42.2.432-439.1982
   STURMAN LS, 1983, ADV VIRUS RES, V28
   WILHELMSEN KC, 1981, VIROLOGY, V110, P225, DOI 10.1016/0042-6822(81)90027-1
   ZAIN BS, 1979, J MOL BIOL, V131, P341, DOI 10.1016/0022-2836(79)90080-9
   ZIMMERN D, 1978, P NATL ACAD SCI USA, V75, P4257, DOI 10.1073/pnas.75.9.4257
NR 35
TC 176
Z9 184
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP
SN 0261-4189
J9 EMBO J
JI Embo J.
PY 1983
VL 2
IS 10
BP 1839
EP 1844
DI 10.1002/j.1460-2075.1983.tb01667.x
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA RK499
UT WOS:A1983RK49900033
PM 6196191
DA 2020-04-03
ER

PT J
AU Memish, ZA
   Cotten, M
   Meyer, B
   Watson, SJ
   Alsahafi, AJ
   Al Rabeeah, AA
   Corman, VM
   Sieberg, A
   Makhdoom, HQ
   Assiri, A
   Al Masri, M
   Aldabbagh, S
   Bosch, BJ
   Beer, M
   Muller, MA
   Kellam, P
   Drosten, C
AF Memish, Ziad A.
   Cotten, Matthew
   Meyer, Benjamin
   Watson, Simon J.
   Alsahafi, Abdullah J.
   Al Rabeeah, Abdullah A.
   Corman, Victor Max
   Sieberg, Andrea
   Makhdoom, Hatem Q.
   Assiri, Abdullah
   Al Masri, Malaki
   Aldabbagh, Souhaib
   Bosch, Berend-Jan
   Beer, Martin
   Mueller, Marcel A.
   Kellam, Paul
   Drosten, Christian
TI Human Infection with MERS Coronavirus after Exposure to Infected Camels,
   Saudi Arabia, 2013
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; DROMEDARY CAMELS; ANTIBODIES;
   LIVESTOCK
AB We investigated a case of human infection with Middle East respiratory syndrome coronavirus (MERS-CoV) after exposure to infected camels. Analysis of the whole human-derived virus and 15% of the camel-derived virus sequence yielded nucleotide polymorphism signatures suggestive of cross-species transmission. Camels may act as a direct source of human MERS-CoV infection.
C1 [Memish, Ziad A.] Al Faisal Univ, Riyadh, Saudi Arabia.
   [Memish, Ziad A.; Al Rabeeah, Abdullah A.] Global Ctr Mass Gatherings Med, Riyadh, Saudi Arabia.
   [Memish, Ziad A.; Al Rabeeah, Abdullah A.; Assiri, Abdullah; Al Masri, Malaki] Minist Hlth, Riyadh, Saudi Arabia.
   [Cotten, Matthew; Watson, Simon J.; Kellam, Paul] Wellcome Trust Sanger Inst, Hinxton, England.
   [Meyer, Benjamin; Corman, Victor Max; Sieberg, Andrea; Aldabbagh, Souhaib; Mueller, Marcel A.; Drosten, Christian] Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
   [Alsahafi, Abdullah J.] Reg Hlth Directoracte, Jeddah, Saudi Arabia.
   [Makhdoom, Hatem Q.] Jeddah Reg Lab, Jeddah, Saudi Arabia.
   [Bosch, Berend-Jan] Univ Utrecht, NL-3508 TC Utrecht, Netherlands.
   [Beer, Martin] Friedrich Loeffler Inst, Inst Virus Diagnost, Greifswald, Riems, Germany.
   [Kellam, Paul] UCL, London, England.
RP Memish, ZA (reprint author), Minist Hlth, Riyadh 11176, Saudi Arabia.
EM zmemish@yahoo.com; drosten@virology-bonn.de
RI Corman, Victor Max/K-1319-2019; Meyer, Benjamin/F-3285-2018; Meyer,
   Bernhard/Q-9413-2016; Mueller, Marcel/O-2425-2019
OI Corman, Victor Max/0000-0002-3605-0136; Meyer,
   Benjamin/0000-0003-0601-3550; Mueller, Marcel/0000-0003-2242-5117;
   Cotten, Matthew/0000-0002-3361-3351; Assiri,
   Abdullah/0000-0002-5605-2876; Kellam, Paul/0000-0003-3166-4734; Sieberg,
   Andrea/0000-0003-3716-9996
FU European CommunityEuropean Community (EC) [223498]; ANTIGONE [278976]
FX The work was funded by the European Community's Seventh Framework
   Programme (FP7/2007-2013) under the project EMPERIE, European Community
   grant agreement number 223498 and ANTIGONE, contract number 278976. C.D.
   has received infrastructural support from the German Centre for
   Infection Research.
CR Alagaili AN, 2014, MBIO, V5, DOI 10.1128/mBio.00884-14
   Buchholz U., 2013, Eurosurveillance, V18, P20406
   Chu DKW, 2014, EMERG INFECT DIS
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   Cotten M, 2014, MBIO, V5, DOI 10.1128/mBio.01062-13
   Cotten M, 2013, EMERG INFECT DIS, V19, P736, DOI 10.3201/eid1905.130057
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hemida MG, 2013, EUROSURVEILLANCE, V18, P21, DOI 10.2807/1560-7917.ES2013.18.50.20659
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reusken CB, 2013, EUROSURVEILLANCE, V18, P14, DOI 10.2807/1560-7917.ES2013.18.50.20662
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 15
TC 175
Z9 183
U1 6
U2 49
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUN
PY 2014
VL 20
IS 6
BP 1012
EP 1015
DI 10.3201/eid2006.140402
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AI0SZ
UT WOS:000336561600013
PM 24857749
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Xu, BL
   Liu, LC
   Huang, XY
   Ma, H
   Zhang, Y
   Du, YH
   Wang, PZ
   Tang, XY
   Wang, HF
   Kang, K
   Zhang, SQ
   Zhao, GH
   Wu, WL
   Yang, YH
   Chen, HM
   Mu, F
   Chen, WJ
AF Xu, Bianli
   Liu, Licheng
   Huang, Xueyong
   Ma, Hong
   Zhang, Yuan
   Du, Yanhua
   Wang, Pengzhi
   Tang, Xiaoyan
   Wang, Haifeng
   Kang, Kai
   Zhang, Shiqiang
   Zhao, Guohua
   Wu, Weili
   Yang, Yinhui
   Chen, Haomin
   Mu, Feng
   Chen, Weijun
TI Metagenomic Analysis of Fever, Thrombocytopenia and Leukopenia Syndrome
   (FTLS) in Henan Province, China: Discovery of a New Bunyavirus
SO PLOS PATHOGENS
LA English
DT Article
ID REAL-TIME PCR; PROGRAM; VIRUS; CORONAVIRUS; PROTEIN; ASSAY; DNA
AB Since 2007, many cases of fever, thrombocytopenia and leukopenia syndrome (FTLS) have emerged in Henan Province, China. Patient reports of tick bites suggested that infection could contribute to FTLS. Many tick-transmitted microbial pathogens were tested for by PCR/RT-PCR and/or indirect immunofluorescence assay (IFA). However, only 8% (24/285) of samples collected from 2007 to 2010 tested positive for human granulocytic anaplasmosis (HGA), suggesting that other pathogens could be involved. Here, we used an unbiased metagenomic approach to screen and survey for microbes possibly associated with FTLS. BLASTx analysis of deduced protein sequences revealed that a novel bunyavirus (36% identity to Tehran virus, accession: HQ412604) was present only in sera from FTLS patients. A phylogenetic analysis further showed that, although closely related to Uukuniemi virus of the Phlebovirus genus, this virus was distinct. The candidate virus was examined for association with FTLS among samples collected from Henan province during 2007-2010. RT-PCR, viral cultures, and a seroepidemiologic survey were undertaken. RT-PCR results showed that 223 of 285 (78.24%) acute-phase serum samples contained viral RNA. Of 95 patients for whom paired acute and convalescent sera were available, 73 had serologic evidence of infection, with 52 seroconversions and 21 exhibiting a 4-fold increase in antibody titer to the virus. The new virus was isolated from patient acute-phase serum samples and named Henan Fever Virus (HNF virus). Whole-genome sequencing confirmed that the virus was a novel bunyavirus with genetic similarity to known bunyaviruses, and was most closely related to the Uukuniemi virus (34%, 24%, and 29% of maximum identity, respectively, for segment L, M, S at maximum query coverage). After the release of the GenBank sequences of SFTSV, we found that they were nearly identical (>99% identity). These results show that the novel bunyavirus (HNF virus) is strongly correlated with FTLS.
C1 [Xu, Bianli; Huang, Xueyong; Ma, Hong; Du, Yanhua; Tang, Xiaoyan; Wang, Haifeng; Kang, Kai; Chen, Haomin] Ctr Dis Control & Prevent Henan Prov, Zhengzhou, Peoples R China.
   [Liu, Licheng; Wang, Pengzhi; Mu, Feng; Chen, Weijun] Beijing Genom Inst Wuhan, Wuhan, Peoples R China.
   [Zhang, Yuan; Wu, Weili; Chen, Weijun] Chinese Acad Sci, Beijing Inst Genom, Key Lab Genome Sci & Informat, Beijing, Peoples R China.
   [Zhang, Shiqiang; Zhao, Guohua] Ctr Dis Control & Prevent Xinyang City, Xinyang, Peoples R China.
   [Yang, Yinhui; Chen, Weijun] Acad Mil Med Sci, Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.
RP Xu, BL (reprint author), Ctr Dis Control & Prevent Henan Prov, Zhengzhou, Peoples R China.
EM xubl@hncdc.com.cn; chenwj@genomics.org.cn
FU Infectious Diseases Special Project [2008ZX10004-001-B, 2009ZX10004-103,
   2009ZX10004-109]; Henan Medical Science Project [200702016];
   China-Australia Health and HIV/AIDS Facility [EID35]
FX This work was sponsored by Infectious Diseases Special Project, Minister
   of Health of China (2008ZX10004-001-B, 2009ZX10004-103,
   2009ZX10004-109), Henan Medical Science Project (200702016) and
   China-Australia Health and HIV/AIDS Facility (EID35). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Bai ZJ, 2008, J MED MICROBIOL, V57, P1547, DOI 10.1099/jmm.0.2008/003418-0
   BISHOP DHL, 1980, INTERVIROLOGY, V14, P125, DOI 10.1159/000149174
   BOHLANDER SK, 1992, GENOMICS, V13, P1322, DOI 10.1016/0888-7543(92)90057-Y
   Chinikar S, 2008, TRANSBOUND EMERG DIS, V55, P200, DOI 10.1111/j.1865-1682.2008.01028.x
   Cox-Foster DL, 2007, SCIENCE, V318, P283, DOI 10.1126/science.1146498
   Du P, 1982, MED EXPT VIROLOGY, P211
   Dumler JS, 2005, EMERG INFECT DIS, V11, P1828, DOI 10.3201/eid1112.050898
   ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Fang MY, 1997, MICROBIOL IMMUNOL, V41, P209, DOI 10.1111/j.1348-0421.1997.tb01192.x
   Finkbeiner SR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000011
   FRANCHINI G, 1987, AIDS RES HUM RETROV, V3, P11, DOI 10.1089/aid.1987.3.11
   Garcia S, 2001, J CLIN MICROBIOL, V39, P4456, DOI 10.1128/JCM.39.12.4456-4461.2001
   Greene CE, 2006, INFECT DIS DOG CAT, P78
   He JG, 2006, WORLD J INFECT, V5, P343
   Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868
   Jin Q, 2001, MED MOL VIROLOGY
   Kang XP, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-284
   Li RQ, 2008, BIOINFORMATICS, V24, P713, DOI 10.1093/bioinformatics/btn025
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Mayo MA, 2002, ARCH VIROL, V147, P1271, DOI 10.1007/s007050200037
   MOH of the people's republic of China, 2008, GUID HUM GRAN AN CON
   Palacios G, 2008, NEW ENGL J MED, V358, P991, DOI 10.1056/NEJMoa073785
   Paul S, 2001, DICT MICROBIOLOGY MO, P1
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Santhosh SR, 2007, J CLIN VIROL, V39, P188, DOI 10.1016/j.jcv.2007.04.015
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Suzuki A, 2004, EMERG INFECT DIS, V10, P2127, DOI 10.3201/eid1012.040295
   Wen BH, 2002, J CLIN MICROBIOL, V40, P3286, DOI 10.1128/JCM.40.9.3286-3290.2002
   Wootton SC, 2011, AM J RESP CRIT CARE, V183, P1698, DOI 10.1164/rccm.201010-1752OC
   Xie Rong-Hui, 2009, Zhonghua Liu Xing Bing Xue Za Zhi, V30, P277
   Xu BL, 2006, HENAN J PREV MED, V17, P3
NR 33
TC 175
Z9 214
U1 1
U2 45
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD NOV
PY 2011
VL 7
IS 11
AR e1002369
DI 10.1371/journal.ppat.1002369
PG 10
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 852EZ
UT WOS:000297337300032
PM 22114553
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Bastien, N
   Brandt, K
   Dust, K
   Ward, D
   Li, Y
AF Bastien, N
   Brandt, K
   Dust, K
   Ward, D
   Li, Y
TI Human bocavirus infection, Canada
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN CORONAVIRUS NL63; RESPIRATORY-TRACT DISEASE; HUMAN
   METAPNEUMOVIRUS; VIRUS-INFECTIONS; HUMAN PARVOVIRUS; CHILDREN
AB Human Bocavirus was detected in 18 (1.5%) of 1,209 respiratory specimens collected in 2003 and 2004 in Canada. The main symptoms of affected patients were cough (78%), fever (67%), and sore throat (44%). Nine patients were hospitalized; of these, 8 (89%) were < 5 years of age.
C1 Canadian Sci Ctr Human & Anim Hlth, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada.
   Saskatchewan Hlth, Regina, SK, Canada.
RP Li, Y (reprint author), Canadian Sci Ctr Human & Anim Hlth, Natl Microbiol Lab, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada.
EM yan_li@phac-aspc.gc.ca
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869
   Bastien N, 2003, J CLIN MICROBIOL, V41, P4642, DOI 10.1128/JCM.41.10.4642-4646.2003
   Bloom M. E., 2001, FIELDS VIROLOGY, P2361
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   Collins PL, 2001, FIELDS VIROLOGY, P1443
   Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289
   El-Sahly HM, 2000, CLIN INFECT DIS, V31, P96, DOI 10.1086/313937
   Esper F, 2004, J INFECT DIS, V189, P1388, DOI 10.1086/382482
   Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499
   Heegaard ED, 2002, CLIN MICROBIOL REV, V15, P485, DOI 10.1128/CMR.15.3.485-505.2002
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
NR 15
TC 175
Z9 206
U1 1
U2 1
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD MAY
PY 2006
VL 12
IS 5
BP 848
EP 850
DI 10.3201/eid1205.051424
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 037ZP
UT WOS:000237187200027
PM 16704852
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU LUYTJES, W
   BREDENBEEK, PJ
   NOTEN, AFH
   HORZINEK, MC
   SPAAN, WJM
AF LUYTJES, W
   BREDENBEEK, PJ
   NOTEN, AFH
   HORZINEK, MC
   SPAAN, WJM
TI SEQUENCE OF MOUSE HEPATITIS-VIRUS A59 MESSENGER RNA-2 - INDICATIONS FOR
   RNA RECOMBINATION BETWEEN CORONAVIRUSES AND INFLUENZA-C VIRUS
SO VIROLOGY
LA English
DT Article
C1 STATE UNIV UTRECHT,FAC VET,INST VIROL,POB 80165,UTRECHT,NETHERLANDS.
CR BINNS MM, 1985, J GEN VIROL, V66, P719, DOI 10.1099/0022-1317-66-4-719
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BREDENBEEK PJ, 1987, CORONAVIRUSES, V218, P65
   BUDZILOWICZ CJ, 1987, VIROLOGY, V157, P509, DOI 10.1016/0042-6822(87)90293-5
   DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524
   DEGROOT RJ, 1987, J GEN VIROL, V68, P995, DOI 10.1099/0022-1317-68-4-995
   DEGROOT RJ, 1987, J GEN VIROL, V68, P2639, DOI 10.1099/0022-1317-68-10-2639
   DEREGT D, 1987, J GEN VIROL, V68, P2863, DOI 10.1099/0022-1317-68-11-2863
   DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814
   DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907
   GOLBACH R, 1987, MICROBIOL SCI, V4, P197
   HOGUE BG, 1984, J VIROL, V51, P384, DOI 10.1128/JVI.51.2.384-388.1984
   HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255
   JACOBS L, 1987, VIRUS RES, V8, P363, DOI 10.1016/0168-1702(87)90008-6
   KATAGIRI S, 1983, J INFECT DIS, V148, P51, DOI 10.1093/infdis/148.1.51
   KECK JG, 1987, CORONAVIRUSES, V218, P157
   King A. M. Q., 1987, The molecular biology of the positive strand RNA viruses, P129
   KING B, 1985, VIRUS RES, V2, P53, DOI 10.1016/0168-1702(85)90059-0
   KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   LAPPS W, 1985, ARCH VIROL, V86, P101, DOI 10.1007/BF01314116
   LAPPS W, 1987, VIROLOGY, V157, P47, DOI 10.1016/0042-6822(87)90312-6
   LEIBOWITZ JL, 1982, J VIROL, V43, P905, DOI 10.1128/JVI.43.3.905-913.1982
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MCINTOSH K, 1969, J IMMUNOL, V102, P1109
   MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X
   MESSING J, 1983, METHOD ENZYMOL, V101, P20
   MORCH MD, 1987, MOL BASIS VIRAL REPL, P113
   NAKADA S, 1984, J VIROL, V50, P118, DOI 10.1128/JVI.50.1.118-124.1984
   NIESTERS HGM, 1986, VIRUS RES, V5, P253, DOI 10.1016/0168-1702(86)90022-5
   PFEIFER JB, 1984, VIRUS RES, V1, P281, DOI 10.1016/0168-1702(84)90017-0
   RASSCHAERT D, 1987, J GEN VIROL, V68, P1883, DOI 10.1099/0022-1317-68-7-1883
   ROBERTS C, 1985, FOCUS, V7, P16
   ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHEPART BS, 1986, J IMMUNOL, V136, P3489
   SIDDELL S, 1981, J GEN VIROL, V53, P145, DOI 10.1099/0022-1317-53-1-145
   SIDDELL S, 1983, J GEN VIROL, V64, P113, DOI 10.1099/0022-1317-64-1-113
   SIDDELL S, 1982, CURR TOP MICROBIOL, V99, P131
   SIDDELL S, 1987, MOL BIOL POSITIVE ST, P117
   SIDDELL SG, 1982, J GEN VIROL, V62, P259, DOI 10.1099/0022-1317-62-2-259
   SKINNER MA, 1985, J GEN VIROL, V66, P581, DOI 10.1099/0022-1317-66-3-581
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   SPAAN WJM, 1982, J VIROL, V42, P432, DOI 10.1128/JVI.42.2.432-439.1982
   STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217
   STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951
   STRAUSS EG, 1983, P NATL ACAD SCI-BIOL, V80, P5271, DOI 10.1073/pnas.80.17.5271
   TAGUCHI F, 1985, J VIROL, V54, P429, DOI 10.1128/JVI.54.2.429-435.1985
   TAGUCHI F, 1986, VIROLOGY, V155, P267, DOI 10.1016/0042-6822(86)90187-X
   VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4
   VLASAK R, 1988, IN PRESS P NATL ACAD, V85
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WEISS SR, 1983, VIROLOGY, V126, P669, DOI 10.1016/S0042-6822(83)80022-1
   WEISS SR, 1983, J GEN VIROL, V64, P127, DOI 10.1099/0022-1317-64-1-127
NR 62
TC 175
Z9 179
U1 1
U2 2
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PD OCT
PY 1988
VL 166
IS 2
BP 415
EP 422
DI 10.1016/0042-6822(88)90512-0
PG 8
WC Virology
SC Virology
GA Q5201
UT WOS:A1988Q520100013
PM 2845655
DA 2020-04-03
ER

PT J
AU Marzi, A
   Gramberg, T
   Simmons, G
   Moller, P
   Rennekamp, AJ
   Krumbiegel, M
   Geier, M
   Eisemann, J
   Turza, N
   Saunier, B
   Steinkasserer, A
   Becker, S
   Bates, P
   Hofmann, H
   Pohlmann, S
AF Marzi, A
   Gramberg, T
   Simmons, G
   Moller, P
   Rennekamp, AJ
   Krumbiegel, M
   Geier, M
   Eisemann, J
   Turza, N
   Saunier, B
   Steinkasserer, A
   Becker, S
   Bates, P
   Hofmann, H
   Pohlmann, S
TI DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and
   the S protein of severe acute respiratory syndrome coronavirus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID C-TYPE LECTIN; HUMAN-IMMUNODEFICIENCY-VIRUS; SINUSOIDAL
   ENDOTHELIAL-CELLS; MARGINAL ZONE MACROPHAGES; DENDRITIC-CELL;
   ASIALOGLYCOPROTEIN RECEPTOR; EBOLA-VIRUS; SPIKE GLYCOPROTEIN; INDUCED
   EXPRESSION; LANGERHANS CELLS
AB The lectins DC-SIGN and DC-SIGNR can augment viral infection; however, the range of pathogens interacting with these attachment factors is incompletely defined. Here we show that DC-SIGN and DC-SIGNR enhance infection mediated by the glycoprotein (GP) of Marburg virus (MARV) and the S protein of severe acute respiratory syndrome coronavirus and might promote viral dissemination. SIGNR1, a murine DC-SIGN homologue, also enhanced infection driven by MARV and Ebola virus GP and could be targeted to assess the role of attachment factors in filovirus infection in vivo.
C1 Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr, D-91054 Erlangen, Germany.
   Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany.
   Univ Erlangen Nurnberg, Dept Dermatol, D-91054 Erlangen, Germany.
   Univ Marburg, Inst Virol, D-3550 Marburg, Germany.
   Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA.
   Ohio Univ, Coll Osteopath Med, Athens, OH 45701 USA.
   Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA.
RP Pohlmann, S (reprint author), Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr, Gluckstr 6, D-91054 Erlangen, Germany.
EM stefan.poehlmann@viro.med.uni-erlangen.de
RI Simmons, Graham/G-3523-2012; Bates, Paul/F-8823-2011; Becker,
   Stephan/A-1065-2010; Marzi, Andrea/AAF-4617-2020; Pohlmann,
   Stefan/H-2395-2011
OI Simmons, Graham/0000-0002-9615-7023; Becker,
   Stephan/0000-0002-2794-5659; Marzi, Andrea/0000-0003-0186-9587;
   Pohlmann, Stefan/0000-0001-6086-9136; Bates, Paul/0000-0002-3918-5976;
   Rennekamp, Andrew/0000-0001-6174-7253
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21 AI059172]
CR Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002
   Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635
   Baribaud F, 2002, J VIROL, V76, P9135, DOI 10.1128/JVI.76.18.9135-9142.2002
   Baribaud FD, 2001, J VIROL, V75, P10281, DOI 10.1128/JVI.75.21.10281-10289.2001
   Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671
   BECKER S, 1995, J GEN VIROL, V76, P393, DOI 10.1099/0022-1317-76-2-393
   Bosio CM, 2003, J INFECT DIS, V188, P1630, DOI 10.1086/379199
   Caminschi I, 2001, MOL IMMUNOL, V38, P365, DOI 10.1016/S0161-5890(01)00067-0
   Chau TN, 2004, HEPATOLOGY, V39, P302, DOI 10.1002/hep.20111
   Chehimi J, 2003, J LEUKOCYTE BIOL, V74, P757, DOI 10.1189/jlb.0503231
   CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Duan Zhong-ping, 2003, Zhonghua Gan Zang Bing Za Zhi, V11, P493
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   Gardner JP, 2003, P NATL ACAD SCI USA, V100, P4498, DOI 10.1073/pnas.0831128100
   Geijtenbeek TBH, 2002, BLOOD, V100, P2908, DOI 10.1182/blood-2002-04-1044
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2
   Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   Hong PWP, 2002, J VIROL, V76, P12855, DOI 10.1128/JVI.76.24.12855-12865.2002
   Kang YS, 2003, INT IMMUNOL, V15, P177, DOI 10.1093/intimm/dxg019
   Klimstra WB, 2003, J VIROL, V77, P12022, DOI 10.1128/JVI.77.22.12022-12032.2003
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lang ZW, 2003, CHINESE MED J-PEKING, V116, P976
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Limmer A, 2001, ARCH IMMUNOL THER EX, V49, pS7
   Limmer A, 2000, NAT MED, V6, P1348
   Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003
   Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200
   Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866
   Nguyen DG, 2003, EUR J IMMUNOL, V33, P483, DOI 10.1002/immu.200310024
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Park CG, 2001, INT IMMUNOL, V13, P1283, DOI 10.1093/intimm/13.10.1283
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003
   Pohlmann S, 2001, J VIROL, V75, P4664, DOI 10.1128/JVI.75.10.4664-4672.2001
   Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398
   Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634
   Ryabchikova EI, 1999, J INFECT DIS, V179, pS199, DOI 10.1086/514293
   Ryabchikova EI, 1999, CURR TOP MICROBIOL, V235, P145
   Saunier B, 2003, J VIROL, V77, P546, DOI 10.1128/JVI.77.1.546-559.2003
   Schnittler HJ, 1999, CURR TOP MICROBIOL, V235, P175
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730
   Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445
   Soilleux EJ, 2001, J PATHOL, V195, P586, DOI 10.1002/path.1026
   STOCKERT RJ, 1995, PHYSIOL REV, V75, P591
   Takada A, 2004, J VIROL, V78, P2943, DOI 10.1128/JVI.78.6.2943-2947.2004
   Takahara K, 2004, INT IMMUNOL, V16, P819, DOI 10.1093/intimm/dxh084
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Tong Yu-wei, 2003, Zhonghua Gan Zang Bing Za Zhi, V11, P418
   Treichel U, 1997, ARCH VIROL, V142, P493, DOI 10.1007/s007050050095
   Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841
   Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0
   Valladeau J, 1999, EUR J IMMUNOL, V29, P2695, DOI 10.1002/(SICI)1521-4141(199909)29:09<2695::AID-IMMU2695>3.3.CO;2-H
   van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182
   Wang Chen, 2003, Zhonghua Jiehe He Huxi Zazhi, V26, P586
   Wu J, 2002, FRONT BIOSCI, V7, pD717, DOI 10.2741/wu2
   Wu L, 2004, VIROLOGY, V318, P17, DOI 10.1016/j.virol.2003.09.028
   Wu L, 2002, J VIROL, V76, P5905, DOI 10.1128/JVI.76.12.5905-5914.2002
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Zhang Qing-ling, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P1125
NR 66
TC 174
Z9 189
U1 3
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2004
VL 78
IS 21
BP 12090
EP 12095
DI 10.1128/JVI.78.21.12090-12095.2004
PG 6
WC Virology
SC Virology
GA 863DM
UT WOS:000224540900066
PM 15479853
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Bosch, BJ
   Martina, BEE
   van der Zee, R
   Lepault, J
   Haijema, BJ
   Versluis, C
   Heck, AJR
   de Groot, R
   Osterhaus, ADME
   Rottier, PJM
AF Bosch, BJ
   Martina, BEE
   van der Zee, R
   Lepault, J
   Haijema, BJ
   Versluis, C
   Heck, AJR
   de Groot, R
   Osterhaus, ADME
   Rottier, PJM
TI Severe acute respiratory syndrome coroavirus (SARS-CoV) infection
   inhibition using spike protein heptad repeat-derived peptides
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID VIRUS FUSION PROTEIN; IMMUNODEFICIENCY-VIRUS; MEMBRANE-FUSION;
   CELL-FUSION; FUNCTIONAL-CHARACTERIZATION; PARAMYXOVIRUS FUSION;
   HYDROPHOBIC REGIONS; POTENT INHIBITORS; RECEPTOR-BINDING; HIV-1 GP41
AB The coronavirus SARS-CoV is the primary cause of the life-threatening severe acute respiratory syndrome (SARS). With the aim of developing therapeutic agents, we have tested peptides derived from the membrane-proximal (HR2) and membrane-distal (HR1) heptad repeat region of the spike protein as inhibitors of SARS-CoV infection of Vero cells. It appeared that HR2 peptides, but not HR1 peptides, were inhibitory. Their efficacy was, however, significantly lower than that of corresponding HR2 peptides of the murine coronavirus mouse hepatitis virus (MHV) in inhibiting MHV infection. Biochemical and electron microscopical analyses showed that, when mixed, SARS-CoV HR1 and HR2 peptides assemble into a six-helix bundle consisting of HR1 as a central triple-stranded coiled coil in association with three HR2 a-helices oriented in an antiparallel manner. The stability of this complex, as measured by its resistance to heat dissociation, appeared to be much lower than that of the corresponding MHV complex, which may explain the different inhibitory potencies of the HR2 peptides. Analogous to other class I viral fusion proteins, the six-helix complex supposedly represents a postfusion conformation that is formed after insertion of the fusion peptide, proposed here for coronaviruses to be located immediately upstream of HR1, into the target membrane. The resulting close apposition of fusion peptide and spike transmembrane domain facilitates membrane fusion. The inhibitory potency of the SARS-CoV HR2-peptides provides an attractive basis for the development of a therapeutic drug for SARS.
C1 Univ Utrecht, Fac Vet Med, Div Virol, NL-3584 CL Utrecht, Netherlands.
   Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Immunol, NL-3584 CL Utrecht, Netherlands.
   Univ Utrecht, Inst Biomembranes, NL-3584 CL Utrecht, Netherlands.
   Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands.
   Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands.
   CNRS, F-91190 Gif Sur Yvette, France.
   Erasmus Med Ctr, Dept Virol, NL-3015 GE Rotterdam, Netherlands.
RP Rottier, PJM (reprint author), Univ Utrecht, Fac Vet Med, Div Virol, NL-3584 CL Utrecht, Netherlands.
EM p.rottier@vet.uu.nl
RI van der Zee, Ruurd/O-5256-2015; Heck, Albert/D-7098-2011
OI van der Zee, Ruurd/0000-0002-4331-2755; Heck,
   Albert/0000-0002-2405-4404; Osterhaus, Albert/0000-0002-6074-1172
CR Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X
   BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   DEHAAN CAM, 2004, IN PRESS J VIROL
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777
   Fass D, 1995, CURR BIOL, V5, P1377, DOI 10.1016/S0960-9822(95)00275-2
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Joshi SB, 1998, VIROLOGY, V248, P20, DOI 10.1006/viro.1998.9242
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186
   Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8
   Lewicki DN, 2002, J BIOL CHEM, V277, P19727, DOI 10.1074/jbc.M201837200
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Luo ZL, 1998, VIROLOGY, V244, P483, DOI 10.1006/viro.1998.9121
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Medinas RJ, 2002, J VIROL, V76, P9079, DOI 10.1128/JVI.76.18.9079-9086.2002
   RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x
   ROTTIER P, 1985, J BIOL CHEM, V260, P4648
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   TAGUCHI F, 1995, J VIROL, V69, P7260, DOI 10.1128/JVI.69.11.7260-7263.1995
   Van Berkel WJH, 2000, PROTEIN SCI, V9, P435
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   YOO D, 1991, VIROLOGY, V180, P395, DOI 10.1016/0042-6822(91)90045-D
   Zhao X, 2000, P NATL ACAD SCI USA, V97, P14172, DOI 10.1073/pnas.260499197
NR 33
TC 174
Z9 193
U1 2
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 1
PY 2004
VL 101
IS 22
BP 8455
EP 8460
DI 10.1073/pnas.0400576101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 826LY
UT WOS:000221831800037
PM 15150417
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Cinatl, J
   Morgenstern, B
   Bauer, G
   Chandra, P
   Rabenau, H
   Doerr, HW
AF Cinatl, J
   Morgenstern, B
   Bauer, G
   Chandra, P
   Rabenau, H
   Doerr, HW
TI Treatment of SARS with human interferons
SO LANCET
LA English
DT Article
ID IDENTIFICATION; CORONAVIRUS; VIRUS
AB Effective antiviral agents are needed to treat severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection. We assessed the antiviral potential of recombinant interferons against two clinical isolates of SARS-CoV-FFM-1, from Frankfurt patients, and Hong Kong-replicated in Vero and Caco2 cells. Interferon beta was five to ten times more effective in Caco2 cells. Interferon alpha effectively inhibited SARS-CoV replication, but with a selectivity index 50-90 times lower than that for interferon beta. Interferon gamma was slightly better than interferon alpha in Vero cell cultures, but was completely ineffective in Caco2 cell cultures. Interferon beta could be useful alone or in combination with other antiviral drugs for the treatment of SARS.
C1 Univ Frankfurt, Sch Med, Inst Med Virol, D-60596 Frankfurt, Germany.
RP Cinatl, J (reprint author), Univ Frankfurt, Sch Med, Inst Med Virol, Paul Ehrlich Str 40, D-60596 Frankfurt, Germany.
CR Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Garcia S, 2001, J CLIN MICROBIOL, V39, P4456, DOI 10.1128/JCM.39.12.4456-4461.2001
   Pitkaranta A, 1999, J CLIN VIROL, V14, P199, DOI 10.1016/S1386-6532(99)00056-6
NR 5
TC 174
Z9 198
U1 8
U2 15
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 26
PY 2003
VL 362
IS 9380
BP 293
EP 294
DI 10.1016/S0140-6736(03)13973-6
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 705UL
UT WOS:000184413400013
PM 12892961
DA 2020-04-03
ER

PT J
AU Palacios, G
   Hornig, M
   Cisterna, D
   Savji, N
   Bussetti, AV
   Kapoor, V
   Hui, J
   Tokarz, R
   Briese, T
   Baumeister, E
   Lipkin, WI
AF Palacios, Gustavo
   Hornig, Mady
   Cisterna, Daniel
   Savji, Nazir
   Bussetti, Ana Valeria
   Kapoor, Vishal
   Hui, Jeffrey
   Tokarz, Rafal
   Briese, Thomas
   Baumeister, Elsa
   Lipkin, W. Ian
TI Streptococcus pneumoniae Coinfection Is Correlated with the Severity of
   H1N1 Pandemic Influenza
SO PLOS ONE
LA English
DT Article
ID A H1N1; BACTERIAL PNEUMONIA; UNITED-STATES; NEURAMINIDASE; PATHOGENS
AB Background: Initial reports in May 2009 of the novel influenza strain H1N1pdm estimated a case fatality rate (CFR) of 0.6%, similar to that of seasonal influenza. In July 2009, however, Argentina reported 3056 cases with 137 deaths, representing a CFR of 4.5%. Potential explanations for increased CFR included virus reassortment or genetic drift, or infection of a more vulnerable population. Virus genomic sequencing of 26 Argentinian samples representing both severe and mild disease indicated no evidence of reassortment, mutations associated with resistance to antiviral drugs, or genetic drift that might contribute to virulence. Furthermore, no evidence was found for increased frequency of risk factors for H1N1pdm disease.
   Methods/Principal Findings: We examined nasopharyngeal swab samples (NPS) from 199 cases of H1N1pdm infection from Argentina with MassTag PCR, testing for 33 additional microbial agents. The study population consisted of 199 H1N1pdm-infected subjects sampled between 23 June and 4 July 2009. Thirty-nine had severe disease defined as death (n = 20) or hospitalization (n = 19); 160 had mild disease. At least one additional agent of potential pathogenic importance was identified in 152 samples (76%), including Streptococcus pneumoniae (n = 62); Haemophilus influenzae (n = 104); human respiratory syncytial virus A (n = 11) and B (n = 1); human rhinovirus A (n = 1) and B (n = 4); human coronaviruses 229E (n = 1) and OC43 (n = 2); Klebsiella pneumoniae (n = 2); Acinetobacter baumannii (n = 2); Serratia marcescens (n = 1); and Staphylococcus aureus (n = 35) and methicillin-resistant S. aureus (MRSA, n = 6). The presence of S. pneumoniae was strongly correlated with severe disease. S. pneumoniae was present in 56.4% of severe cases versus 25% of mild cases; more than one-third of H1N1pdm NPS with S. pneumoniae were from subjects with severe disease (22 of 62 S. pneumoniae-positive NPS, p = 0.0004). In subjects 6 to 55 years of age, the adjusted odds ratio (OR) of severe disease in the presence of S. pneumoniae was 125.5 (95% confidence interval [CI], 16.95, 928.72; p < 0.0001).
   Conclusions/Significance: The association of S. pneumoniae with morbidity and mortality is established in the current and previous influenza pandemics. However, this study is the first to demonstrate the prognostic significance of non-invasive antemortem diagnosis of S. pneumoniae infection and may provide insights into clinical management.
C1 [Palacios, Gustavo; Hornig, Mady; Savji, Nazir; Bussetti, Ana Valeria; Kapoor, Vishal; Hui, Jeffrey; Tokarz, Rafal; Briese, Thomas; Lipkin, W. Ian] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10027 USA.
   [Cisterna, Daniel; Baumeister, Elsa] Inst Nacl Enfermedades Infecciosas, Adm Nacl Labs, Buenos Aires, DF, Argentina.
   [Cisterna, Daniel; Baumeister, Elsa] Inst Salud Dr Carlos G Malbran, Buenos Aires, DF, Argentina.
RP Palacios, G (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10027 USA.
EM gp2050@columbia.edu; wil2001@columbia.edu
RI Palacios, Gustavo/I-7773-2015; Hornig, Mady/AAE-8431-2020
OI Palacios, Gustavo/0000-0001-5062-1938; Hornig, Mady/0000-0001-7572-3092
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI051292, U54 AI5715,
   R01 AI300278]; Department of DefenseUnited States Department of Defense
FX This work was supported by the National Institutes of Health awards
   AI051292, U54 AI57158 (Northeast Biodefense Center - Lipkin), and R01
   AI30027, and the Department of Defense. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Briese T, 2005, EMERG INFECT DIS, V11, P310, DOI 10.3201/eid1102.040492
   Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062
   Hackett S, 2009, LANCET, V374, P605, DOI 10.1016/S0140-6736(09)61511-7
   Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551
   Louie J., 2009, Morbidity and Mortality Weekly Report, V58, P1071
   Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   *MSAL, 2009, INFL PAND H1N1 2009
   Peltola VT, 2005, J INFECT DIS, V192, P249, DOI 10.1086/430954
   Peltola VT, 2004, PEDIATR INFECT DIS J, V23, pS87, DOI 10.1097/01.inf.0000108197.81270.35
   Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   Vaillant L, 2009, EURO SURVEILL, P14
   WHO, 2009, CDC PROT REAL TIM RT
NR 14
TC 173
Z9 178
U1 2
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2009
VL 4
IS 12
AR e8540
DI 10.1371/journal.pone.0008540
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 538JK
UT WOS:000273180200019
PM 20046873
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Miller, S
   Sparacio, S
   Bartenschlager, R
AF Miller, S
   Sparacio, S
   Bartenschlager, R
TI Subcellular localization and membrane topology of the dengue virus type
   2 non-structural protein 4B
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HEPATITIS-C VIRUS; YELLOW-FEVER VIRUS; TRANSMISSIBLE GASTROENTERITIS
   CORONAVIRUS; RNA-POLYMERASE ACTIVITY; LARGE ENVELOPE PROTEIN;
   WEST-NILE-VIRUS; FLAVIVIRUS KUNJIN; TRANSMEMBRANE TOPOLOGY;
   ENDOPLASMIC-RETICULUM; DIFFERENTIAL PHOSPHORYLATION
AB Dengue virus (DV) is a member of the family Flaviviridae. These positive strand RNA viruses encode a polyprotein that is processed in case of DV into 10 proteins. Although for most of these proteins distinct functions have been defined, this is less clear for the highly hydrophobic non-structural protein (NS) 4B. Despite its possible role as an antagonist of the interferon-induced antiviral response, this protein may play an additional more direct role for viral replication. In this study we determined the subcellular localization, membrane association, and membrane topology of DV NS4B. We found that NS4B resides primarily in cytoplasmic foci originating from the endoplasmic reticulum. NS4B colocalizes with NS3 and double-stranded RNA, an intermediate of viral replication, arguing that NS4B is part of the membrane-bound viral replication complex. Biochemical analysis revealed that NS4B is an integral membrane protein, and that its preceding 2K signal sequence is not required for this integration. We identified three membrane-spanning segments in the COOH-terminal part of NS4B that are sufficient to target a cytosolic marker protein to intracellular membranes. Furthermore, we established a membrane topology model of NS4B in which the NH2-terminal part of the protein is localized in the endoplasmic reticulum lumen, whereas the COOH-terminal part is composed of three trans-membrane domains with the COOH-terminal tail localized in the cytoplasm. This topology model provides a good starting point for a detailed investigation of the function of NS4B in the DV life cycle.
C1 Univ Heidelberg, Dept Mol Virol, D-69120 Heidelberg, Germany.
RP Sparacio, S (reprint author), Neuenheimer Feld 345, D-69120 Heidelberg, Germany.
EM sandra_sparacio@med.uni-heidelberg.de;
   ralf_bartenschlager@med.uni-heidelberg.de
RI Bartenschlager, Ralf/L-2582-2015
OI Bartenschlager, Ralf/0000-0001-5601-9307
CR AMBERG SM, 1994, J VIROL, V68, P3794, DOI 10.1128/JVI.68.6.3794-3802.1994
   Appel N, 2005, J VIROL, V79, P3187, DOI 10.1128/JVI.79.5.3187-3194.2005
   Benarroch D, 2004, J BIOL CHEM, V279, P35638, DOI 10.1074/jbc.M400460200
   Blaney JE, 2003, VACCINE, V21, P4317, DOI 10.1016/S0264-410X(03)00487-0
   BRUSS V, 1994, EMBO J, V13, P2273, DOI 10.1002/j.1460-2075.1994.tb06509.x
   BUCKLEY A, 1992, J GEN VIROL, V73, P1125, DOI 10.1099/0022-1317-73-5-1125
   CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992
   CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898
   CHAMBERS TJ, 1989, VIROLOGY, V169, P100, DOI 10.1016/0042-6822(89)90045-7
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   CHU PWG, 1992, ARCH VIROL, V125, P177, DOI 10.1007/BF01309636
   CHU PWG, 1992, J VIROL METHODS, V37, P219, DOI 10.1016/0166-0934(92)90049-J
   Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002
   Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757
   Einav S, 2004, J VIROL, V78, P11288, DOI 10.1128/JVI.78.20.11288-11295.2004
   Elazar M, 2004, J VIROL, V78, P11393, DOI 10.1128/JVI.78.20.11393-11400.2004
   Escors D, 2001, J VIROL, V75, P12228, DOI 10.1128/JVI.75.24.12228-12240.2001
   FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991
   FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995
   Florese RH, 2002, VIRUS RES, V90, P119, DOI 10.1016/S0168-1702(02)00146-6
   FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889
   Grassmann CW, 2001, J VIROL, V75, P7791, DOI 10.1128/JVI.75.17.7791-7802.2001
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Guo JT, 2005, J VIROL, V79, P1343, DOI 10.1128/JVI.79.3.1343-1350.2005
   Hanley KA, 2003, VIROLOGY, V312, P222, DOI 10.1016/S0042-6822(03)00197-1
   Hugle T, 2001, VIROLOGY, V284, P70, DOI 10.1006/viro.2001.0873
   KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100
   Kato J, 2002, J MED VIROL, V66, P187, DOI 10.1002/jmv.2129
   Khromykh AA, 2000, J VIROL, V74, P3253, DOI 10.1128/JVI.74.7.3253-3263.2000
   Kim M, 2004, J VIROL METHODS, V120, P179, DOI 10.1016/j.jviromet.2004.05.005
   Kretzschmar E, 1996, VIROLOGY, V220, P37, DOI 10.1006/viro.1996.0283
   Lambert C, 2001, J BIOL CHEM, V276, P22265, DOI 10.1074/jbc.M100956200
   LEARY K, 1980, J ULTRA MOL STRUCT R, V72, P123, DOI 10.1016/S0022-5320(80)90050-7
   LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993
   Lindenbach BD, 1999, J VIROL, V73, P4611, DOI 10.1128/JVI.73.6.4611-4621.1999
   Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997
   Liu WJ, 2005, J VIROL, V79, P1934, DOI 10.1128/JVI.79.3.1934-1942.2005
   Lundin M, 2003, J VIROL, V77, P5428, DOI 10.1128/JVI.77.9.5428-5438.2003
   Mackenzie JM, 1998, VIROLOGY, V245, P203, DOI 10.1006/viro.1998.9156
   Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307
   MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0
   Munoz-Jordan JL, 2005, J VIROL, V79, P8004, DOI 10.1128/JVI.79.13.8004-8013.2005
   Munoz-Jordan JL, 2003, P NATL ACAD SCI USA, V100, P14333, DOI 10.1073/pnas.2335168100
   MURRAY JM, 1993, J GEN VIROL, V74, P175, DOI 10.1099/0022-1317-74-2-175
   NAKABAYASHI H, 1982, CANCER RES, V42, P3858
   NG ML, 1983, ARCH VIROL, V78, P177
   NG ML, 1989, ARCH VIROL, V106, P103, DOI 10.1007/BF01311042
   OSTAPCHUK P, 1994, EMBO J, V13, P1048, DOI 10.1002/j.1460-2075.1994.tb06353.x
   Park JS, 2000, BIOCHEM BIOPH RES CO, V267, P581, DOI 10.1006/bbrc.1999.1999
   Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200
   PRANGE R, 1995, EMBO J, V14, P247, DOI 10.1002/j.1460-2075.1995.tb06998.x
   PREUGSCHAT F, 1991, VIROLOGY, V185, P689, DOI 10.1016/0042-6822(91)90540-R
   Qu L, 2001, J VIROL, V75, P10651, DOI 10.1128/JVI.75.22.10651-10662.2001
   RISCO C, 1995, J VIROL, V69, P5269, DOI 10.1128/JVI.69.9.5269-5277.1995
   Sambrook J, 2001, MOL CLONING LAB MANU
   SELBY MJ, 1993, J GEN VIROL, V74, P1103, DOI 10.1099/0022-1317-74-6-1103
   Stadler K, 1997, J VIROL, V71, P8475, DOI 10.1128/JVI.71.11.8475-8481.1997
   Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067
   WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587
   Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997
   Westaway EG, 1997, VIROLOGY, V234, P31, DOI 10.1006/viro.1997.8629
NR 62
TC 173
Z9 181
U1 2
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 31
PY 2006
VL 281
IS 13
BP 8854
EP 8863
DI 10.1074/jbc.M512697200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 025EC
UT WOS:000236247100065
PM 16436383
OA Bronze
DA 2020-04-03
ER

PT J
AU DEBOUCK, P
   PENSAERT, M
AF DEBOUCK, P
   PENSAERT, M
TI EXPERIMENTAL-INFECTION OF PIGS WITH A NEW PORCINE ENTERIC CORONAVIRUS,
   CV-777
SO AMERICAN JOURNAL OF VETERINARY RESEARCH
LA English
DT Article
RP DEBOUCK, P (reprint author), UNIV GENT,FAC VET MED,VIROL LAB,B-9000 GENT,BELGIUM.
CR CAUL EO, 1977, ARCH VIROL, V54, P107, DOI 10.1007/BF01314383
   CHASEY D, 1978, RES VET SCI, V25, P255, DOI 10.1016/S0034-5288(18)32994-1
   DEBOUCK P, 1979, ZBL VET MED B, V26, P517
   DOYLE LP, 1946, J AM VET MED ASSOC, V108, P257
   HAELTERMAN EO, 1956, AM J VET RES, V17, P129
   HOOPER BE, 1966, AM J VET RES, V27, P286
   KEENAN KP, 1976, AM J VET RES, V37, P247
   LECCE JG, 1976, INFECT IMMUN, V14, P816, DOI 10.1128/IAI.14.3.816-825.1976
   MEBUS CA, 1975, AM J VET RES, V36, P1719
   PENSAERT M, 1978, ANN MED VET, V122, P301
   PENSAERT M, 1978, JUN P INT PIG VEG C
   PENSAERT MB, 1974, ARCH GES VIRUSFORSCH, V44, P35, DOI 10.1007/BF01242179
   PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606
   PENSAERT MB, 1968, CAN J COMPARAT MED, V32, P555
   TYRELL DA, 1975, INTERVIROLOGY, V5, P76
   TYRELL DAJ, 1968, NATURE, V220, P650
   WITTE KH, 1971, ARCH GES VIRUSFORSCH, V33, P171, DOI 10.1007/BF01254174
   WOOD EN, 1977, VET REC, V100, P243, DOI 10.1136/vr.100.12.243
   WOODE GN, 1976, J MED MICROBIOL, V9, P203, DOI 10.1099/00222615-9-2-203
NR 19
TC 173
Z9 200
U1 0
U2 8
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360
SN 0002-9645
J9 AM J VET RES
JI Am. J. Vet. Res.
PY 1980
VL 41
IS 2
BP 219
EP 223
PG 5
WC Veterinary Sciences
SC Veterinary Sciences
GA JF181
UT WOS:A1980JF18100013
PM 6245603
DA 2020-04-03
ER

PT J
AU Arabi, YM
   Arifi, AA
   Balkhy, HH
   Najm, H
   Aldawood, AS
   Ghabashi, A
   Hawa, H
   Alothman, A
   Khaldi, A
   Al Raiy, B
AF Arabi, Yaseen M.
   Arifi, Ahmed A.
   Balkhy, Hanan H.
   Najm, Hani
   Aldawood, Abdulaziz S.
   Ghabashi, Alaa
   Hawa, Hassan
   Alothman, Adel
   Khaldi, Abdulaziz
   Al Raiy, Basel
TI Clinical Course and Outcomes of Critically Ill Patients With Middle East
   Respiratory Syndrome Coronavirus Infection
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID HIGH-FREQUENCY OSCILLATION; ACUTE LUNG INJURY; DISTRESS-SYNDROME;
   NITRIC-OXIDE; MERS-COV; SARS; CORTICOSTEROIDS; REPLICATION
AB Background: Since September 2012, 170 confirmed infections with Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported to the World Health Organization, including 72 deaths. Data on critically ill patients with MERS-CoV infection are limited.
   Objective: To describe the critical illness associated with MERS-CoV.
   Design: Case series.
   Setting: 3 intensive care units (ICUs) at 2 tertiary care hospitals in Saudi Arabia.
   Patients: 12 patients with confirmed or probable MERS-CoV infection.
   Measurements: Presenting symptoms, comorbid conditions, pulmonary and extrapulmonary manifestations, measures of severity of illness and organ failure, ICU course, and outcome are described, as are the results of surveillance of health care workers (HCWs) and patients with potential exposure.
   Results: Between December 2012 and August 2013, 114 patients were tested for suspected MERS-CoV; of these, 11 ICU patients (10%) met the definition of confirmed or probable cases. Three of these patients were part of a health care-associated cluster that also included 3 HCWs. One HCW became critically ill and was the 12th patient in this case series. Median Acute Physiology and Chronic Health Evaluation II score was 28 (range, 16 to 36). All 12 patients had underlying comorbid conditions and presented with acute severe hypoxemic respiratory failure. Most patients (92%) had extrapulmonary manifestations, including shock, acute kidney injury, and thrombocytopenia. Five (42%) were alive at day 90. Of the 520 exposed HCWs, only 4 (1%) were positive.
   Limitation: The sample size was small.
   Conclusion: MERS-CoV causes severe acute hypoxemic respiratory failure and considerable extrapulmonary organ dysfunction and is associated with high mortality. Community-acquired and health care-associated MERS-CoV infection occurs in patients with chronic comorbid conditions. The health care-associated cluster suggests that human-to-human transmission does occur with unprotected exposure.
C1 King Saud bin Abdulaziz Univ Hlth Sci, Riyadh 11426, Saudi Arabia.
   King Abdulaziz Hosp, Al Hasa 31982, Saudi Arabia.
RP Arabi, YM (reprint author), King Saud bin Abdulaziz Univ Hlth Sci, Coll Med, Dept Intens Care, Mail Code 1425,POB 22490, Riyadh 11426, Saudi Arabia.
EM arabi@ngha.med.sa
OI Arabi, Yaseen/0000-0001-5735-6241
CR Afshari A, 2011, ANESTH ANALG, V112, P1411, DOI 10.1213/ANE.0b013e31820bd185
   Akerstrom S, 2009, VIROLOGY, V395, P1, DOI 10.1016/j.virol.2009.09.007
   Annane D, 2006, CRIT CARE MED, V34, P22, DOI 10.1097/01.CCM.0000194723.78632.62
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Brun-Buisson C, 2011, AM J RESP CRIT CARE, V183, P1200, DOI 10.1164/rccm.201101-0135OC
   Delclaux C, 2000, JAMA-J AM MED ASSOC, V284, P2352, DOI 10.1001/jama.284.18.2352
   Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3
   Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554
   Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC
   Fowler RA, 2003, JAMA-J AM MED ASSOC, V290, P367, DOI 10.1001/jama.290.3.367
   Gomersall CD, 2004, CRIT CARE, V8, P105, DOI 10.1186/cc2452
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Kuri T, 2010, VIRULENCE, V1, P273, DOI 10.4161/viru.1.4.11465
   Lu L, 2013, MICROBES INFECT, V15, P625, DOI 10.1016/j.micinf.2013.06.003
   Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159
   Memish ZA, 2013, NEW ENGL J MED, V369, P884, DOI 10.1056/NEJMc1308698
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Mer M, 1998, CHEST, V114, P426, DOI 10.1378/chest.114.2.426
   Momattin H, 2013, INT J INFECT DIS, V17, pE792, DOI 10.1016/j.ijid.2013.07.002
   Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   Paragas J, 2005, ANTIVIR RES, V66, P99, DOI 10.1016/j.antiviral.2005.01.002
   Perlman S, 2013, MBIO, V4
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   Sweeney AM, 2005, CRIT CARE MED, V33, P204
   Tahir M, 2013, EUROSURVEILLANCE, V18, P4
   Tang BMP, 2009, CRIT CARE MED, V37, P1594, DOI 10.1097/CCM.0b013e31819fb507
   Tran K, 2013, CADTH Technol Overv, V3, pe3201
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   World Health Organization, 2013, GLOB AL RESP REV INT
   World Health Organization, 2013, GLOB AL RESP MODDL E
   Young D, 2013, NEW ENGL J MED, V368, P806, DOI 10.1056/NEJMoa1215716
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 35
TC 172
Z9 177
U1 5
U2 23
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAR 18
PY 2014
VL 160
IS 6
BP 389
EP +
DI 10.7326/M13-2486
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA AD8MW
UT WOS:000333521300015
PM 24474051
OA Green Published, Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Perera, RA
   Wang, P
   Gomaa, MR
   El-Shesheny, R
   Kandeil, A
   Bagato, O
   Siu, LY
   Shehata, MM
   Kayed, AS
   Moatasim, Y
   Li, M
   Poon, LL
   Guan, Y
   Webby, RJ
   Ali, MA
   Peiris, JS
   Kayali, G
AF Perera, R. A.
   Wang, P.
   Gomaa, M. R.
   El-Shesheny, R.
   Kandeil, A.
   Bagato, O.
   Siu, L. Y.
   Shehata, M. M.
   Kayed, A. S.
   Moatasim, Y.
   Li, M.
   Poon, L. L.
   Guan, Y.
   Webby, R. J.
   Ali, M. A.
   Peiris, J. S.
   Kayali, G.
TI Seroepidemiology for MERS coronavirus using microneutralisation and
   pseudoparticle virus neutralisation assays reveal a high prevalence of
   antibody in dromedary camels in Egypt, June 2013
SO EUROSURVEILLANCE
LA English
DT Article
ID PROTEIN
AB We describe a novel spike pseudoparticle neutralisation assay (ppNT) for seroepidemiological studies on Middle East respiratory syndrome coronavirus (MERS-CoV) and apply this assay together with conventional microneutralisation (MN) tests to investigate 1,343 human and 625 animal sera. The sera were collected in Egypt as a region adjacent to areas where MERS has been described, and in Hong Kong, China as a control region. Sera from dromedary camels had a high prevalence of antibody reactive to MERS-CoV by MERS NT (93.6%) and MERS ppNT (98.2%) assay. The antibody titres ranged up to 1,280 and higher in MN assays and 10,240 and higher in ppNT assays. No other investigated species had any antibody reactivity to MERS-CoV. While seropositivity does not exclude the possibility of infection with a closely related virus, our data highlight the need to attempt detection of MERS-CoV or related coronaviruses in dromedary camels. The data show excellent correlation between the conventional MN assay and the novel ppNT assay. The newly developed ppNT assay does not require Biosafety Level 3 containment and is thus a relatively high-throughput assay, well suited for large-scale seroepidemiology studies which are needed to better understand the ecology and epidemiology of MERS-CoV.
C1 [Perera, R. A.; Poon, L. L.; Guan, Y.; Peiris, J. S.] Univ Hong Kong, Sch Publ Hlth, Influenza Res Ctr, Hong Kong, Hong Kong, Peoples R China.
   [Wang, P.; Siu, L. Y.; Li, M.] Univ Hong Kong, Hong Kong Univ Pasteur Res Pole, Hong Kong, Hong Kong, Peoples R China.
   [Wang, P.] Chinese Acad Sci Univ Tokyo Joint Lab Struct Viro, Key Lab Prot & Peptide Pharmaceut, Beijing, Peoples R China.
   [Gomaa, M. R.; El-Shesheny, R.; Kandeil, A.; Bagato, O.; Shehata, M. M.; Kayed, A. S.; Moatasim, Y.; Ali, M. A.] Natl Res Ctr, Div Environm Res, Giza, Egypt.
   [Webby, R. J.; Kayali, G.] St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, Memphis, TN 38105 USA.
RP Perera, RA (reprint author), Univ Hong Kong, Sch Publ Hlth, Influenza Res Ctr, Hong Kong, Hong Kong, Peoples R China.
EM malik@hku.hk; ghazi.kayali@stjude.org
RI Kandeil, Ahmed Mohamed/B-3345-2016; elshesheny, Rabeh/S-7927-2016;
   Perera, Ranawaka A.P.M/N-8263-2015; Webby, Richard J/N-5657-2018;
   Shehata, Mahmoud M/R-7703-2016; Ali, Mohamed A/N-8768-2017; Kandeil,
   Ahmed/N-5473-2019; Poon, Leo/C-4382-2009
OI Kandeil, Ahmed Mohamed/0000-0003-3253-6961; elshesheny,
   Rabeh/0000-0002-8798-2240; Perera, Ranawaka A.P.M/0000-0003-3936-1535;
   Shehata, Mahmoud M/0000-0001-7556-9398; Ali, Mohamed
   A/0000-0002-5615-3212; Kandeil, Ahmed/0000-0003-3253-6961; Poon,
   Leo/0000-0002-9101-7953; Kayed, Ahmed/0000-0002-0439-3476; Guan,
   Yi/0000-0001-6057-9243; Wang, Peigang/0000-0001-6045-2007
FU National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [HHSN266200700005C]; European CommunityEuropean
   Community (EC) [223498]
FX We thank Dr CYH Leung for providing wild bird sera from Hong Kong. This
   study was supported in part by research contract from the National
   Institute of Allergy and Infectious Diseases (NIAID) contract
   HHSN266200700005C and a grant from the European Community Seventh
   Framework Programme (FP7/2007-2013) under project European management
   Platform for Emerging and Re-emerging Disease entities (Grant agreement
   No. 223498) (EMPERIE).
CR Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Bermingham A., 2012, EURO SURVEILL, V17
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Corman VM, 2012, EURO SURVEILL, V17
   Garcia JM, 2010, J CLIN VIROL, V47, P29, DOI 10.1016/j.jcv.2009.10.009
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Reusken C, 2013, EUROSURVEILLANCE, V18, P2, DOI 10.2807/1560-7917.ES2013.18.14.20441
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Saif LJ, 2004, REV SCI TECH OIE, V23, P643, DOI 10.20506/rst.23.2.1513
   World Health Organization, 2013, MIDDL E RESP SYNDR C
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 16
TC 172
Z9 181
U1 2
U2 31
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD SEP 5
PY 2013
VL 18
IS 36
BP 8
EP 14
AR UNSP 20574
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 212XR
UT WOS:000324016600002
OA DOAJ Gold
DA 2020-04-03
ER

PT J
AU Cervantes-Barragan, L
   Zust, R
   Weber, F
   Spiegel, M
   Lang, KS
   Akira, S
   Thiel, V
   Ludewig, B
AF Cervantes-Barragan, Luisa
   Zuest, Roland
   Weber, Friedernann
   Spiegel, Martin
   Lang, Karl S.
   Akira, Shizuo
   Thiel, Volker
   Ludewig, Burkhard
TI Control of coronavirus infection through plasmacytoid
   dendritic-cell-derived type I interferon
SO BLOOD
LA English
DT Article
ID ACUTE-RESPIRATORY-SYNDROME; CENTRAL-NERVOUS-SYSTEM; SARS-CORONAVIRUS;
   IMMUNE-RESPONSES; IFN-ALPHA/BETA; CYTOKINE RESPONSES; VIRAL-INFECTION;
   LYMPH-NODES; VIRUS; EXPRESSION
AB This study demonstrates a unique and crucial role of plasmacytold dendritic cells (pDCs) and pDC-derived type I interferons (IFNs) in the pathogenesis of mouse coronavirus infection. pDCs controlled the fast replicating mouse hepatitis virus (MHV) through the immediate production of type I IFNs. Recognition of MHV by pDCs was mediated via TLR7 ensuring a swift IFN-alpha production following encounter with this cytopathic RNA virus. Furthermore, the particular type I IFN response pattern was not restricted to the murine coronavirus, but was also found in infection with the highly cytopathic human severe acute respiratory syndrome (SARS) coronavirus. Taken together, our results suggest that rapid production of type I IFNs by pDCs is essential for the control of potentially lethal coronavirus infections.
C1 Kantonsspital, Res Dept, CH-9007 St Gallen, Switzerland.
   Hosp Especialidades Ctr Med La Raza, Unidad Invest Med Inmunoquim, Mexico City, DF, Mexico.
   Univ Freiburg, Inst Med Microbiol & Hyg, Abt Virol, D-7800 Freiburg, Germany.
   Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland.
   Osaka Univ, Dept Host Def, Suita, Osaka 565, Japan.
RP Thiel, V (reprint author), Kantonsspital, Res Dept, CH-9007 St Gallen, Switzerland.
EM volker.thiel@kssg.ch; burkhard.ludewig@kssg.ch
RI Thiel, Volker/AAI-2391-2019; Akira, Shizuo/C-3134-2009; Weber,
   Friedemann/AAB-3425-2019; Spiegel, Martin/H-7843-2019; Jha,
   Babal/AAC-8337-2020; Lang, Karl S/R-2505-2016
OI Jha, Babal/0000-0002-7660-5255; Thiel, Volker/0000-0002-5783-0887;
   Weber, Friedemann/0000-0001-9737-337X
CR Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8
   Ashkar AA, 2004, J INFECT DIS, V190, P1841, DOI 10.1086/425079
   Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736
   Barchet W, 2002, J EXP MED, V195, P507, DOI 10.1084/jem.20011666
   Bergmann CC, 2006, NAT REV MICROBIOL, V4, P121, DOI 10.1038/nrmicro1343
   Bergmann CC, 2004, J VIROL, V78, P1739, DOI 10.1128/JVI.78.4.1739-1750.2004
   Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Cinatl J, 2004, EXPERT OPIN BIOL TH, V4, P827, DOI 10.1517/14712598.4.6.827
   Coley SE, 2005, J VIROL, V79, P3097, DOI 10.1128/JVI.79.5.3097-3106.2005
   Dalod M, 2002, J EXP MED, V195, P517, DOI 10.1084/jem.20011672
   Delale T, 2005, J IMMUNOL, V175, P6723, DOI 10.4049/jimmunol.175.10.6723
   Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623
   Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758
   Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464
   Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100
   Horsmans Y, 2005, HEPATOLOGY, V42, P724, DOI 10.1002/hep.20839
   Izaguirre A, 2003, J LEUKOCYTE BIOL, V74, P1125, DOI 10.1189/jlb.0603255
   Jones BM, 2004, CLIN EXP IMMUNOL, V135, P467, DOI 10.1111/j.1365-2249.2003.02391.x
   Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010
   Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U
   Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Law HKW, 2005, BLOOD, V106, P2366, DOI 10.1182/blood-2004-10-4166
   Lin MT, 1999, J IMMUNOL, V162, P7358
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162
   Marten NW, 2003, J VIROL, V77, P2775, DOI 10.1128/JVI.77.4.2775-2778.2003
   MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221
   Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171
   Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Ramakrishna C, 2002, J IMMUNOL, V168, P1204, DOI 10.4049/jimmunol.168.3.1204
   Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2
   Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835
   Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Spiegel M, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-17
   Spies JJ, 2000, BOTHALIA, V30, P211
   Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Turner BC, 2004, J VIROL, V78, P5486, DOI 10.1128/JVI.78.10.5486-5490.2004
   vandenBroek MF, 1995, IMMUNOL REV, V148, P5
   Yilla M, 2005, VIRUS RES, V107, P93, DOI 10.1016/j.virusres.2004.09.004
   Yu SY, 2005, WORLD J GASTROENTERO, V11, P5037, DOI 10.3748/wjg.v11.i32.5037
   Zheng BJ, 2004, J INTERF CYTOK RES, V24, P388, DOI 10.1089/1079990041535610
   Zhou HX, 2006, J VIROL, V80, P2506, DOI 10.1128/JVI.80.5.2506-2514.2006
   Ziegler T, 2005, J VIROL, V79, P13800, DOI 10.1128/JVI.79.21.13800-13805.2005
NR 54
TC 172
Z9 180
U1 3
U2 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 1
PY 2007
VL 109
IS 3
BP 1131
EP 1137
DI 10.1182/blood-2006-05-023770
PG 7
WC Hematology
SC Hematology
GA 135CX
UT WOS:000244132800046
PM 16985170
OA Bronze
DA 2020-04-03
ER

PT J
AU DEVRIES, AAF
   CHIRNSIDE, ED
   HORZINEK, MC
   ROTTIER, PJM
AF DEVRIES, AAF
   CHIRNSIDE, ED
   HORZINEK, MC
   ROTTIER, PJM
TI STRUCTURAL PROTEINS OF EQUINE ARTERITIS VIRUS
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID DEHYDROGENASE-ELEVATING VIRUS; LINKED OLIGOSACCHARIDES;
   BETA-GALACTOSIDASE; VACCINIA VIRUS; SITES; RNAS; GLYCOPROTEIN;
   TOGAVIRIDAE; INFLUENZA; SEQUENCE
AB We have recently shown that the genome of equine arteritis virus (EAV) contains seven open reading frames (ORFs). We now present data on the structural proteins of EAV and the assignment of their respective genes. Virions are composed of a 14-kDa nucleocapsid protein (N) and three membrane proteins designated M, G(S), and G(L). M is an unglycosylated protein of 16 kDa, and G(S) and G(L) are N-glycosylated proteins of 25 and 30 to 42 kDa, respectively. The broad size distribution of G(L) results from heterogeneous N-acetyllactosamine addition since it is susceptible to digestion by endo-beta-galactosidase. Using monospecific antisera as well as an antivirion serum, and by expression of individual ORFs, the genes for the structural proteins were identified: ORF 7 codes for N, ORF 6 for M, ORF 5 for G(L), and ORF 2 for G(S). With the exception of G(S), the proteins are about equally abundant in EAV virions, being present at a molar ratio of 3 (N):2 (M):3 (G(L)). The G(S) protein, which is expressed at a level similar to that of M in infected cells, is strikingly underrepresented in virus particles (I to 2%). Our data justify a distinct taxonomic position for EAV, together with lactate dehydrogenase-elevating virus and simian hemorrhagic fever virus; although coronavirus- and toroviruslike in features of transcription and translation, the virion architecture of EAV is fundamentally different.
C1 UNIV UTRECHT, FAC VET,DEPT INFECT DIS & IMMUNOL,INST VIROL, YALELAAN 1, 3584 CL UTRECHT, NETHERLANDS.
CR BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241
   BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x
   BRINTONDARNELL M, 1975, J VIROL, V16, P420, DOI 10.1128/JVI.16.2.420-433.1975
   CAVANAGH D, 1986, VIRUS RES, V4, P145, DOI 10.1016/0168-1702(86)90038-9
   CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403
   CHIRNSIDE ED, 1992, COMMUNICATION
   DENBOON JA, 1991, VIROLOGY, V182, P655, DOI 10.1016/0042-6822(91)90606-C
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   DEVRIES AAF, 1990, NUCLEIC ACIDS RES, V18, P3241, DOI 10.1093/nar/18.11.3241
   DOLL E. R., 1957, CORNELL VET, V47, P3
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   FUKUDA M, 1988, J BIOL CHEM, V263, P5314
   GODENY EK, 1990, VIROLOGY, V177, P768, DOI 10.1016/0042-6822(90)90546-4
   Gorman C, 1985, DNA CLONING PRACTICA, VII, P143
   GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x
   HARTY JT, 1988, J VIROL, V62, P3210, DOI 10.1128/JVI.62.9.3210-3216.1988
   HORZINEK M, 1971, ARCH GES VIRUSFORSCH, V33, P306, DOI 10.1007/BF01254687
   HORZINEK MC, 1991, 6TH P INT C EQ INF D, P201
   HORZINEK MC, 1981, NNARTHROPOD BORNE TO
   HUNTINGTON PJ, 1990, AUST VET J, V67, P429, DOI 10.1111/j.1751-0813.1990.tb03050.x
   HUNTINGTON PJ, 1990, AUST VET J, V67, P432, DOI 10.1111/j.1751-0813.1990.tb03052.x
   HYLLSETH B, 1973, ARCH GES VIRUSFORSCH, V40, P177, DOI 10.1007/BF01242536
   HYLLSETH B, 1970, 2ND P INT C EQ INF D, P140
   KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631
   KUO L, 1992, VIRUS RES, V23, P55
   KUO LL, 1991, J VIROL, V65, P5118, DOI 10.1128/JVI.65.9.5118-5123.1991
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEE N, 1990, J BIOL CHEM, V265, P20476
   MACKETT M, 1985, DNA CLONING PRACTICA, V2, P191
   MAGNUSSON P, 1970, ARCH GES VIRUSFORSCH, V30, P105, DOI 10.1007/BF01250177
   McCollum WH, 1973, 3RD P INT C EQ INF D, P256
   MICHAELIDES MC, 1973, VIROLOGY, V55, P211, DOI 10.1016/S0042-6822(73)81023-2
   MORAILLON A, 1978, 4TH P INT C EQ INF D, P467
   MUMFORD JA, 1985, EQUINE VET J, V17, P6, DOI 10.1111/j.2042-3306.1985.tb02026.x
   MURPHY TW, 1988, 5TH P INT C EQ INF D, P3
   NEU SM, 1988, 5TH P INT C EQ INF D, P149
   OHLINGER VF, 1991, TIERARZTL UMSCHAU, V46, P703
   PLAGEMANN PGW, 1992, ADV VIRUS RES, V41, P99, DOI 10.1016/S0065-3527(08)60036-6
   PORTERFIELD JS, 1978, INTERVIROLOGY, V9, P129, DOI 10.1159/000148930
   ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421
   ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022
   Sambrook J., 1989, MOL CLONING LABORATO
   SAMPATH D, 1992, J BIOL CHEM, V267, P4440
   SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485
   STEWART JM, 1984, SOLID PHASE PEPTIDE
   TROUSDALE MD, 1975, P SOC EXP BIOL MED, V150, P707, DOI 10.3181/00379727-150-39111
   VANBERLO MF, 1983, ZBL VET MED B, V30, P297
   VANBERLO MF, 1986, J GEN VIROL, V67, P1543, DOI 10.1099/0022-1317-67-8-1543
   VANBERLO MF, 1982, VIROLOGY, V118, P345, DOI 10.1016/0042-6822(82)90354-3
   VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461
   VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683
   WESTAWAY EG, 1985, INTERVIROLOGY, V24, P125, DOI 10.1159/000149632
   WILLIAMS MA, 1988, MOL CELL BIOL, V8, P1186, DOI 10.1128/MCB.8.3.1186
   ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988
   ZEEGERS JJW, 1976, VIROLOGY, V73, P200, DOI 10.1016/0042-6822(76)90074-X
NR 58
TC 172
Z9 177
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 1992
VL 66
IS 11
BP 6294
EP 6303
DI 10.1128/JVI.66.11.6294-6303.1992
PG 10
WC Virology
SC Virology
GA JT700
UT WOS:A1992JT70000007
PM 1328669
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU TOOZE, J
   TOOZE, S
   WARREN, G
AF TOOZE, J
   TOOZE, S
   WARREN, G
TI REPLICATION OF CORONAVIRUS MHV-A59 IN SAC- CELLS - DETERMINATION OF THE
   1ST SITE OF BUDDING OF PROGENY VIRIONS
SO EUROPEAN JOURNAL OF CELL BIOLOGY
LA English
DT Article
RP TOOZE, J (reprint author), EUROPEAN MOLEC BIOL LAB, POSTFACH 102209, D-6900 HEIDELBERG, GERMANY.
OI Tooze, Sharon/0000-0002-2182-3116
CR ASH JF, 1977, P NATL ACAD SCI USA, V74, P5584, DOI 10.1073/pnas.74.12.5584
   Becker W B, 1967, J Virol, V1, P1019
   BRAYTON PR, 1981, J GEN VIROL, V56, P457, DOI 10.1099/0022-1317-56-2-457
   CHELEY S, 1981, VIROLOGY, V112, P596, DOI 10.1016/0042-6822(81)90305-6
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   DAVIDFERREIRA JF, 1965, J CELL BIOL, V24, P57, DOI 10.1083/jcb.24.1.57
   DUBOISDALCQ ME, 1982, VIROLOGY, V119, P317, DOI 10.1016/0042-6822(82)90092-7
   FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s
   GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835
   HELENIUS A, 1982, J GEN VIROL, V58, P47, DOI 10.1099/0022-1317-58-1-47
   HOLMES KV, 1982, ADV EXP MED BIOL, V142, P287
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   JONES AL, 1966, J HISTOCHEM CYTOCHEM, V14, P215, DOI 10.1177/14.3.215
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92
   LOUVARD D, 1983, EMBO J, V2, P1655, DOI 10.1002/j.1460-2075.1983.tb01640.x
   MORI H, 1980, J CELL BIOL, V84, P340, DOI 10.1083/jcb.84.2.340
   NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x
   NIEMANN H, 1981, J MOL BIOL, V153, P993, DOI 10.1016/0022-2836(81)90463-0
   NOVIKOFF AB, 1961, P NATL ACAD SCI USA, V47, P802, DOI 10.1073/pnas.47.6.802
   NOVIKOFF AB, 1976, P NATL ACAD SCI USA, V73, P2781, DOI 10.1073/pnas.73.8.2781
   OHTSUKI I, 1978, BIOL CELLULAIRE, V31, P119
   PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303
   ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428
   ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981
   ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35
   STURMAN LS, 1977, VIROLOGY, V77, P650, DOI 10.1016/0042-6822(77)90489-5
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   TERNYNCK T, 1976, SCAND J IMMUNOL, P29
   TOUGARD C, 1980, AM J ANAT, V158, P471, DOI 10.1002/aja.1001580409
   WACHSTEIN M, 1956, J HISTOCHEM CYTOCHEM, V4, P592, DOI 10.1177/4.6.592
   WEILAND E, 1978, J EXP MED, V148, P408, DOI 10.1084/jem.148.2.408
   WILHELMSEN KC, 1981, VIROLOGY, V110, P225, DOI 10.1016/0042-6822(81)90027-1
NR 35
TC 172
Z9 177
U1 0
U2 4
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0171-9335
EI 1618-1298
J9 EUR J CELL BIOL
JI Eur. J. Cell Biol.
PY 1984
VL 33
IS 2
BP 281
EP 293
PG 13
WC Cell Biology
SC Cell Biology
GA SL330
UT WOS:A1984SL33000014
PM 6325194
DA 2020-04-03
ER

PT J
AU Breban, R
   Riou, J
   Fontanet, A
AF Breban, Romulus
   Riou, Julien
   Fontanet, Arnaud
TI Interhuman transmissibility of Middle East respiratory syndrome
   coronavirus: estimation of pandemic risk
SO LANCET
LA English
DT Article
ID SARS; EVOLUTION
AB Background The new Middle East respiratory syndrome coronavirus (MERS-CoV) infection shares many clinical, epidemiological, and virological similarities with that of severe acute respiratory syndrome (SARS)-CoV. We aimed to estimate virus transmissibility and the epidemic potential of MERS-CoV, and to compare the results with similar findings obtained for prepandemic SARS.
   Methods We retrieved data for MERS-CoV clusters from the WHO summary and subsequent reports, and published descriptions of cases, and took into account 55 of the 64 laboratory-confirmed cases of MERS-CoV reported as of June 21, 2013, excluding cases notified in the previous 2 weeks. To assess the interhuman transmissibility of MERS-CoV, we used Bayesian analysis to estimate the basic reproduction number (R-0) and compared it to that of prepandemic SARS. We considered two scenarios, depending on the interpretation of the MERS-CoV cluster-size data.
   Results With our most pessimistic scenario (scenario 2), we estimated MERS-CoV R-0 to be 0.69 (95% CI 0.50-0.92); by contrast, the R-0 for prepandemic SARS-CoV was 0.80 (0.54-1.13). Our optimistic scenario (scenario 1) yielded a MERS-CoV R-0 of 0.60 (0.42-0.80). Because of recent implementation of effective contact tracing and isolation procedures, further MERS-CoV transmission data might no longer describe an entire cluster, but only secondary infections directly caused by the index patient. Hence, we calculated that, under scenario 2, eight or more secondary infections caused by the next index patient would translate into a 5% or higher chance that the revised MERS-CoV R-0 would exceed 1-ie, that MERS-CoV might have pandemic potential.
   Interpretation Our analysis suggests that MERS-CoV does not yet have pandemic potential. We recommend enhanced surveillance, active contact tracing, and vigorous searches for the MERS-CoV animal hosts and transmission routes to human beings.
C1 [Breban, Romulus; Riou, Julien; Fontanet, Arnaud] Inst Pasteur, Emerging Dis Epidemiol Unit, F-75015 Paris, France.
   [Fontanet, Arnaud] Conservatoire Natl Arts & Metiers, Paris, France.
RP Fontanet, A (reprint author), Inst Pasteur, Emerging Dis Epidemiol Unit, F-75015 Paris, France.
EM fontanet@pasteur.fr
FU Agence Nationale de la Recherche (Labex Integrative Biology of Emerging
   Infectious Diseases)French National Research Agency (ANR); European
   Community's Seventh Framework Programme project PREDEMICS
FX Agence Nationale de la Recherche (Labex Integrative Biology of Emerging
   Infectious Diseases), and the European Community's Seventh Framework
   Programme project PREDEMICS.
CR Antia R, 2003, NATURE, V426, P658, DOI 10.1038/nature02104
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Blumberg S, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002993
   Buchholz U., 2013, Eurosurveillance, V18, P20406
   Cauchemez S., 2013, Eurosurveillance, V18, P20503
   Danielsson N, 2012, EUROSURVEILLANCE, V17, P9
   Drosten C, 2013, LANCET INFECT DIS
   European Center for Disease Prevention and Control, 2013, UPD RAP RISK ASS SEV
   Guery B, 2013, LANCET
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Hijawi B, 2013, E MEDITERR HEALTH J, V19, pS12
   Holmes KV, 2005, SCIENCE, V309, P1822, DOI 10.1126/science.1118817
   Leung GM, 2004, EMERG INFECT DIS, V10, P1653, DOI 10.3201/eid1009.040155
   Memish ZA, 2013, NEW ENGL J MED, DOI [10.1056/NEJMoa1303729, DOI 10.1056/NEJM3A1303729]
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Tahir M, 2013, EUROSURVEILLANCE, V18, P4
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   WHO, MERS COV SUMM LIT UP
   WHO, 2006, SARS GLOB EP WAS STO
   Xu RH, 2004, EMERG INFECT DIS, V10, P1030, DOI 10.3201/eid1006.030852
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 25
TC 171
Z9 178
U1 9
U2 65
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 24
PY 2013
VL 382
IS 9893
BP 694
EP 699
DI 10.1016/S0140-6736(13)61492-0
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 206SI
UT WOS:000323542400027
PM 23831141
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Tang, XC
   Zhang, JX
   Zhang, SY
   Wang, P
   Fan, XH
   Li, LF
   Li, G
   Dong, BQ
   Liu, W
   Cheung, CL
   Xu, KM
   Song, WJ
   Vijaykrishna, D
   Poon, LLM
   Peiris, JSM
   Smith, GJD
   Chen, H
   Guan, Y
AF Tang, X. C.
   Zhang, J. X.
   Zhang, S. Y.
   Wang, P.
   Fan, X. H.
   Li, L. F.
   Li, G.
   Dong, B. Q.
   Liu, W.
   Cheung, C. L.
   Xu, K. M.
   Song, W. J.
   Vijaykrishna, D.
   Poon, L. L. M.
   Peiris, J. S. M.
   Smith, G. J. D.
   Chen, H.
   Guan, Y.
TI Prevalence and genetic diversity of coronaviruses in bats from China
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ACUTE-RESPIRATORY-SYNDROME; INFECTIOUS-BRONCHITIS VIRUS;
   SARS-CORONAVIRUS; MURINE CORONAVIRUSES; SEQUENCE ALIGNMENT; GENOME
   SEQUENCE; IDENTIFICATION; PROTEIN; HOST; RECOMBINATION
AB Coronaviruses can infect a variety of animals including poultry, livestock, and humans and are currently classified into three groups. The interspecies transmissions of coronaviruses between different hosts form a complex ecosystem of which little is known. The outbreak of severe acute respiratory syndrome (SARS) and the recent identification of new coronaviruses have highlighted the necessity for further investigation of coronavirus ecology, in particular the role of bats and other wild animals. In this study, we sampled bat populations in 15 provinces of China and reveal that approximately 6.5% of the bats, from diverse species distributed throughout the region, harbor coronaviruses. Full genomes of four coronavirues from bats were sequenced and analyzed. Phylogenetic analyses of the spike, envelope, membrane, and nucleoprotein structural proteins and the two conserved replicase domains, putative RNA-dependent RNA polymerase and RNA hellicase, revealed that bat coronaviruses cluster in three different groups: group 1, another group that includes all SARS and SARS-like coronaviruses (putative group 4), and an independent bat coronavirus group (putative group 5). Further genetic analyses showed that different species of bats maintain coronaviruses from different groups and that a single bat species from different geographic locations supports similar coronaviruses. Thus, the findings of this study suggest that bats may play an integral role in the ecology and evolution of coronaviruses.
C1 Univ Hong Kong, State Key Lab Emerging Infect Dis, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Chinese Acad Sci, Inst Zool, Beijing 100080, Peoples R China.
   Chinese Acad Sci, Grad Sch, Beijing 100080, Peoples R China.
   Guangxi Ctr Dis Control & Prevent, Nanning 530021, Peoples R China.
   Guangxi Med Univ, Dept Microbiol & Immunol, Nanning 530021, Peoples R China.
RP Chen, H (reprint author), Univ Hong Kong, State Key Lab Emerging Infect Dis, Dept Microbiol, Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.
EM hlchen@hku.hk; yguan@hku.hk
RI Zhang, Shuyi/B-5117-2011; Chen, Honglin/C-4224-2009; Poon,
   Leo/C-4382-2009; Peiris, Joseph/C-4380-2009; Vijaykrishna,
   Dhanasekaran/AAG-2077-2020; Chen, Guanhua/D-3056-2009; Dhanasekaran,
   Vijaykrishna/D-1011-2010; Tang, Xianchun/A-4003-2010; li,
   gang/E-5640-2014; Zhang, Jinxia/C-4470-2009; Xu, Kemin/G-2825-2011
OI Chen, Honglin/0000-0001-5108-8338; Poon, Leo/0000-0002-9101-7953;
   Vijaykrishna, Dhanasekaran/0000-0003-3293-6279; Dhanasekaran,
   Vijaykrishna/0000-0003-3293-6279; li, gang/0000-0001-7400-5486; Guan,
   Yi/0000-0001-6057-9243; Smith, Gavin JD/0000-0001-5031-468X
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01AI95357, AI 95357]
CR ALTRINGHAM J.D., 1996, BATS BIOL BEHAV, P1
   Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI 10.1093/nar/gkh121
   Bininda-Emonds ORP, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-156
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Chen W, 1996, J VIROL, V70, P3947, DOI 10.1128/JVI.70.6.3947-3960.1996
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   Eaton BT, 2001, MICROBES INFECT, V3, P277, DOI 10.1016/S1286-4579(01)01380-6
   Gao F, 2003, FEBS LETT, V553, P451, DOI 10.1016/S0014-5793(03)01091-3
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Guan Y, 2005, SEVERE ACUTE RESPIRATORY SYNDROME, P79
   Holmes EC, 2004, PHILOS T R SOC B, V359, P1059, DOI 10.1098/rstb.2004.1478
   HOLMES GL, 1987, J CLIN NEUROPHYSIOL, V4, P1, DOI 10.1097/00004691-198701000-00001
   Jonassen CM, 1998, J GEN VIROL, V79, P715, DOI 10.1099/0022-1317-79-4-715
   Jonassen CM, 2005, J GEN VIROL, V86, P1597, DOI 10.1099/vir.0.80927-0
   Kan B, 2005, J VIROL, V79, P11892, DOI 10.1128/JVI.79.18.11892-11900.2005
   KECK JG, 1988, J VIROL, V62, P1989, DOI 10.1128/JVI.62.6.1989-1998.1988
   KOTIER SA, 1995, VIROLOGY, V213, P569, DOI 10.1006/viro.1995.0029
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Leparc-Goffart I, 1997, VIROLOGY, V239, P1, DOI 10.1006/viro.1997.8877
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Liu SW, 2005, J GEN VIROL, V86, P719, DOI 10.1099/vir.0.80546-0
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Martin D, 2000, BIOINFORMATICS, V16, P562, DOI 10.1093/bioinformatics/16.6.562
   Milne I, 2004, BIOINFORMATICS, V20, P1806, DOI 10.1093/bioinformatics/bth155
   Moya A, 2004, NAT REV MICROBIOL, V2, P279, DOI 10.1038/nrmicro863
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   RAMBAUT A, 1996, SE AL SEQUENCE ALIGN
   Robertson MP, 2005, PLOS BIOL, V3, P86, DOI 10.1371/journal.pbio.0030005
   Rose TM, 2003, NUCLEIC ACIDS RES, V31, P3763, DOI 10.1093/nar/gkg524
   Schickli JH, 1997, J VIROL, V71, P9499, DOI 10.1128/JVI.71.12.9499-9507.1997
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Song WJ, 2004, J VIROL, V78, P12576, DOI 10.1128/JVI.78.22.12576-12590.2004
   Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9
   Stoffel W., 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143
   SWOFFORD DL, 2001, PAUPASTERISK PHYLOGE
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Wang H, 2003, FOLIA ZOOL, V52, P259
   Wang YX, 2003, COMPLETE CHECKLIST M
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   WILLIAMS AK, 1993, VIRUS RES, V28, P19, DOI 10.1016/0168-1702(93)90086-3
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   ZHANG XM, 1992, VIROLOGY, V186, P318, DOI 10.1016/0042-6822(92)90089-8
NR 48
TC 171
Z9 212
U1 2
U2 34
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD AUG
PY 2006
VL 80
IS 15
BP 7481
EP 7490
DI 10.1128/JVI.00697-06
PG 10
WC Virology
SC Virology
GA 065VX
UT WOS:000239189100020
PM 16840328
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Hofmann, H
   Pyrc, K
   van der Hoek, L
   Geier, M
   Berkhout, B
   Pohlmann, S
AF Hofmann, H
   Pyrc, K
   van der Hoek, L
   Geier, M
   Berkhout, B
   Pohlmann, S
TI Human coronavirus NL63 employs the severe acute respiratory syndrome
   coronavirus receptor for cellular entry
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME-2; SARS CORONAVIRUS; S-PROTEIN; FUNCTIONAL
   RECEPTOR; SPIKE GLYCOPROTEIN; REVERSE GENETICS; AMINOPEPTIDASE-N;
   YOUNG-CHILDREN; TRACT DISEASE; VIRAL ENTRY
AB Coronavirus (CoV) infection of humans is usually not associated with severe disease. However, discovery of the severe acute respiratory syndrome (SARS) CoV revealed that highly pathogenic human CoVs (HCoVs) can evolve. The identification and characterization of new HCoVs is, therefore, an important task. Recently, a HCoV termed NL63 was discovered in patients with respiratory tract illness. Here, cell tropism and receptor usage of HCoV-NL63 were analyzed. The NL63 spike (S) protein mediated infection of different target cells compared with the closely related 229E-S protein but facilitated entry into cells known to be permissive to SARS-CoV-S-driven infection. An analysis of receptor engagement revealed that NL63-S binds angiotensin-converting enzyme (ACE) 2, the receptor for SARS-CoV, and HCoV-NL63 uses ACE2 as a receptor for infection of target cells. Potent neutralizing activity directed against NL63- but not 229E-S protein was detected in virtually all sera from patients 8 years of age or older, suggesting that HCoV-NL63 infection of humans is common and usually acquired during childhood. Here, we show that SARS-CoV shares its receptor ACE2 with HCoV-NL63. Because the two viruses differ dramatically in their ability to induce disease, analysis of HCoV-NL63 might unravel pathogenicity factors in SARS-CoV. The frequent HCoV-NL63 infection of humans suggests that highly pathogenic variants have ample opportunity to evolve, underlining the need for vaccines against HCoVs.
C1 Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr, D-91054 Erlangen, Germany.
   Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany.
   Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands.
RP Pohlmann, S (reprint author), Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr, Gluckstr 6, D-91054 Erlangen, Germany.
EM snpoehlm@viro.med.uni-erlangen.de
RI Pohlmann, Stefan/H-2395-2011; van der Hoek, Lia/Y-6412-2019
OI Pohlmann, Stefan/0000-0001-6086-9136; Pyrc,
   Krzysztof/0000-0002-3867-7688
CR Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869
   Birkmann A, 2001, J VIROL, V75, P11583, DOI 10.1128/JVI.75.23.11583-11593.2001
   Blau DM, 2001, ADV EXP MED BIOL, V494, P193
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Danilczyk U, 2003, J MOL MED, V81, P227, DOI 10.1007/s00109-003-0419-x
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289
   Esper F, 2005, J INFECT DIS, V191, P499, DOI 10.1086/428291
   Esper F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Giroglou T, 2004, J VIROL, V78, P9007, DOI 10.1128/JVI.78.17.9007-9015.2004
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Han DP, 2004, VIROLOGY, V326, P140, DOI 10.1016/j.virol.2004.05.017
   Hofmann H, 2004, TRENDS MICROBIOL, V12, P466, DOI 10.1016/j.tim.2004.08.008
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Moes E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-6
   Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004
   Nie YC, 2004, BIOCHEM BIOPH RES CO, V321, P994, DOI 10.1016/j.bbrc.2004.07.060
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Pyrc K, 2004, VIROL J, V1, DOI 10.1186/1743-422X-1-7
   Rice GI, 2004, BIOCHEM J, V383, P45, DOI 10.1042/BJ20040634
   ROTA PA, 2000, SCIENCE, V300, P1394
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Wang PG, 2004, BIOCHEM BIOPH RES CO, V315, P439, DOI 10.1016/j.bbrc.2004.01.076
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
NR 43
TC 171
Z9 191
U1 7
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 31
PY 2005
VL 102
IS 22
BP 7988
EP 7993
DI 10.1073/pnas.0409465102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 932CE
UT WOS:000229531000038
PM 15897467
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Pavia, AT
AF Pavia, Andrew T.
TI Viral Infections of the Lower Respiratory Tract: Old Viruses, New
   Viruses, and the Role of Diagnosis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; CELL TRANSPLANT RECIPIENTS; RAPID
   INFLUENZA TEST; HUMAN BOCAVIRUS; HOSPITALIZED CHILDREN; HUMAN
   METAPNEUMOVIRUS; FEBRILE INFANTS; YOUNG-CHILDREN; IMMUNOCOMPROMISED
   PATIENTS; RHINOVIRUS INFECTIONS
AB Viral infections of the lower respiratory tract cause an enormous disease burden in children, and the role of respiratory viruses in serious lower respiratory tract infections (LRTIs) in older adults is increasingly appreciated. Although viruses are responsible for a large proportion LRTIs, antibiotics are often prescribed. New diagnostic platforms have the potential to detect a wider range of established and newly discovered viruses with greater sensitivity. This will create additional challenges. Although it is clear that influenza, parainfluenza, respiratory syncytial virus, human metapneumovirus, and adenovirus are important causes of pneumonia, the role of rhinoviruses and some of the newly described viruses, including human coronaviruses and bocavirus, is harder to determine. Better diagnostic tests that establish the cause of LRTIs in children have the potential to both reduce overall antibiotic use and to improve the targeted use of antibiotics. In addition, rapid identification of viral infections can help control nosocomial transmission.
C1 Univ Utah, Dept Pediat, Div Pediat Infect Dis, Salt Lake City, UT 84108 USA.
RP Pavia, AT (reprint author), Univ Utah, Dept Pediat, Div Pediat Infect Dis, 295 Chipeta Way, Salt Lake City, UT 84108 USA.
EM andy.pavia@hsc.utah.edu
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA
   [1U01AI082184-01]; Centers for Disease Control and PreventionUnited
   States Department of Health & Human ServicesCenters for Disease Control
   & Prevention - USA [1U181P000303]; Food and Drug AdministrationUnited
   States Department of Health & Human Services; Infectious Diseases
   Society of America; AstraZeneca PharmaceuticalsAstraZeneca; Bio Merieux,
   Inc.; Cepheid; Gilead SciencesGilead Sciences; Intelligent MDX, Inc.;
   Inverness Medical Innovations; Roche Molecular Systems
FX This work was supported by National Institutes of Health (NIH;
   1U01AI082184-01 to ATP) and the Centers for Disease Control and
   Prevention (1U181P000303 to ATP). ATP received travel support from the
   Food and Drug Administration to attend this meeting. He is also a
   co-investigator on NIH-funded research in which scientists from Idaho
   Technologies are co-investigators.; This article was published as part
   of a supplement entitled "Workshop on Molecular Diagnostics for
   Respiratory Tract Infections." The Food and Drug Administration and the
   Infectious Diseases Society of America sponsored the workshop.
   AstraZeneca Pharmaceuticals, Bio Merieux, Inc., Cepheid, Gilead
   Sciences, Intelligent MDX, Inc., Inverness Medical Innovations, and
   Roche Molecular Systems provided financial support solely for the
   purpose of publishing the supplement.
CR Abanses JC, 2006, PEDIATR EMERG CARE, V22, P145, DOI 10.1097/01.pec.0000202454.19237.b0
   Aitken C, 2001, CLIN MICROBIOL REV, V14, P528, DOI 10.1128/CMR.14.3.528-546.2001
   Allander T, 2008, J CLIN VIROL, V41, P29, DOI 10.1016/j.jcv.2007.10.026
   Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196
   Arden KE, 2009, GENOME MED, V1, DOI 10.1186/gm44
   Boeckh M, 2008, BRIT J HAEMATOL, V143, P455, DOI 10.1111/j.1365-2141.2008.07295.x
   Bonner AB, 2003, PEDIATRICS, V112, P363, DOI 10.1542/peds.112.2.363
   Bosis S, 2008, J CLIN VIROL, V42, P286, DOI 10.1016/j.jcv.2008.03.029
   Brieu N, 2008, PEDIATR INFECT DIS J, V27, P969, DOI 10.1097/INF.0b013e31817acfaa
   Brownlee JW, 2008, CURR OPIN PEDIATR, V20, P67, DOI 10.1097/MOP.0b013e3282f41cb6
   Byington CL, 2004, PEDIATRICS, V113, P1662, DOI 10.1542/peds.113.6.1662
   Byington CL, 2002, ARCH PEDIAT ADOL MED, V156, P1230, DOI 10.1001/archpedi.156.12.1230
   Cevey-Macherel M, 2009, EUR J PEDIATR, V168, P1429, DOI 10.1007/s00431-009-0943-y
   Cheuk DKL, 2007, PEDIATR INFECT DIS J, V26, P995, DOI 10.1097/INF.0b013e3181586b63
   Doan QH, 2009, J PEDIATR-US, V154, P91, DOI 10.1016/j.jpeds.2008.07.043
   Falsey AR, 2007, ARCH INTERN MED, V167, P354, DOI 10.1001/archinte.167.4.ioi60207
   Fry AM, 2007, J INFECT DIS, V195, P1038, DOI 10.1086/512163
   Gerna G, 2009, J MED VIROL, V81, P1498, DOI 10.1002/jmv.21548
   GLEZEN P, 1973, NEW ENGL J MED, V288, P498, DOI DOI 10.1056/NEJM197303082881005
   Goldmann DA, 2001, EMERG INFECT DIS, V7, P249, DOI 10.3201/eid0702.010220
   Harris JAS, 2007, PEDIATRICS, V120, P890, DOI 10.1542/peds.2007-1305
   Henrickson KJ, 2004, PEDIATR INFECT DIS J, V23, pS11, DOI 10.1097/01.inf.0000108188.37237.48
   Heugel J, 2007, PEDIATR INFECT DIS J, V26, P753, DOI 10.1097/INF.0b013e318054e31b
   Ison MG, 2006, CLIN INFECT DIS, V43, P331, DOI 10.1086/505498
   Ison MG, 2003, CLIN INFECT DIS, V36, P1139, DOI 10.1086/374340
   Ison MG, 2007, ANTIVIR THER, V12, P627
   Iyer SB, 2006, ACAD EMERG MED, V13, P1259, DOI [10.1197/j.aem.2006.07.026, 10.1111/j.1553-2712.2006.tb00287.x]
   Jacques J, 2008, J CLIN VIROL, V43, P142, DOI 10.1016/j.jcv.2008.05.010
   Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907
   Jartti T, 2008, PEDIATR INFECT DIS J, V27, P1103, DOI 10.1097/INF.0b013e31817e695d
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   Kahn J, 2008, CURR OPIN PEDIATR, V20, P62, DOI 10.1097/MOP.0b013e3282f3f518
   Kim YJ, 2007, SEMIN RESP CRIT CARE, V28, P222, DOI 10.1055/s-2007-976494
   Kuypers J, 2007, PEDIATRICS, V119, pE70, DOI 10.1542/peds.2006-1406
   Leung TF, 2009, J CLIN MICROBIOL, V47, P3486, DOI 10.1128/JCM.00832-09
   Mackay IM, 2008, J CLIN VIROL, V42, P297, DOI 10.1016/j.jcv.2008.04.002
   Mahony JB, 2008, CLIN MICROBIOL REV, V21, P716, DOI 10.1128/CMR.00037-07
   Martin ET, 2009, J CLIN MICROBIOL, V47, P4131, DOI 10.1128/JCM.01508-09
   Martin ET, 2008, DIAGN MICR INFEC DIS, V62, P382, DOI 10.1016/j.diagmicrobio.2008.08.002
   McCracken GH, 2000, PEDIATR INFECT DIS J, V19, P924
   Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701
   Milder E, 2009, PEDIATR RES, V65, p78R, DOI 10.1203/PDR.0b013e31819db90c
   Mintegi S, 2009, PEDIATR INFECT DIS J, V28, P1026, DOI 10.1097/INF.0b013e3181ab603c
   Nichols WG, 2008, CLIN MICROBIOL REV, V21, P274, DOI 10.1128/CMR.00045-07
   Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peltola V, 2008, J INFECT DIS, V197, P382, DOI 10.1086/525542
   Peterson LR, 2004, J ANTIMICROB CHEMOTH, V53, P902, DOI 10.1093/jac/dkh187
   Poehling KA, 2006, ARCH PEDIAT ADOL MED, V160, P713, DOI 10.1001/archpedi.160.7.713
   Renwick N, 2007, J INFECT DIS, V196, P1754, DOI 10.1086/524312
   Rocholl C, 2004, PEDIATRICS, V113, pE51, DOI 10.1542/peds.113.1.e51
   Schildgen O, 2008, CLIN MICROBIOL REV, V21, P291, DOI 10.1128/CMR.00030-07
   Simon A, 2006, INT J HYG ENVIR HEAL, V209, P317, DOI 10.1016/j.ijheh.2006.02.003
   Spellberg B, 2008, CLIN INFECT DIS, V46, P155, DOI 10.1086/524891
   Stempel HE, 2009, ACTA PAEDIATR, V98, P123, DOI 10.1111/j.1651-2227.2008.01023.x
   Talbot HKB, 2009, J MED VIROL, V81, P853, DOI 10.1002/jmv.21443
   Tsolia MN, 2004, CLIN INFECT DIS, V39, P681, DOI 10.1086/422996
   Vallet C, 2009, J PEDIATR-US, V155, P286, DOI 10.1016/j.jpeds.2009.01.069
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   VANDERHOEK L, J CLIN VIROL
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   Yorita KL, 2008, PEDIATRICS, V121, P244, DOI 10.1542/peds.2007-1392
NR 62
TC 170
Z9 180
U1 1
U2 16
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 1
PY 2011
VL 52
SU 4
BP S284
EP S289
DI 10.1093/cid/cir043
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 745KT
UT WOS:000289165000002
PM 21460286
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Minskaia, E
   Hertzig, T
   Gorbalenya, AE
   Campanacci, V
   Cambillau, C
   Canard, B
   Ziebuhr, J
AF Minskaia, E
   Hertzig, T
   Gorbalenya, AE
   Campanacci, V
   Cambillau, C
   Canard, B
   Ziebuhr, J
TI Discovery of an RNA virus 3 '-> 5 ' exoribonuclease that is critically
   involved in coronavirus RNA synthesis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE replication; ribonuclease; severe acute respiratory syndrome
ID ACUTE RESPIRATORY SYNDROME; DNA-POLYMERASE-I; MOUSE HEPATITIS-VIRUS;
   ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; SARS-CORONAVIRUS; STRUCTURAL
   BASIS; ACTIVE-SITE; AMINO-ACID; GENOME
AB Replication of the giant RNA genome of severe acute respiratory syndrome (SARS) coronavirus (CoV) and synthesis of as many as eight subgenomic (sg) mRNAs are mediated by a viral replicase-transcriptase of outstanding complexity that includes an essential endoribonuclease activity. Here, we show that the CoV replicative machinery, unlike that of other RNA viruses, also uses an exoribonuclease (ExoN) activity, which is associated with nonstructural protein (nsp) 14. Bacterially expressed forms of SARS-CoV nsp14 were shown to act on both ssRNAs and dsRNAs in a 3'-> 5' direction. The activity depended on residues that are conserved in the DEDD exonuclease superfamily. The protein did not hydrolyze DNA or ribose-2'-O-methylated RNA substrates and required divalent metal ions for activity. A range of 5'-labeled ssRNA substrates were processed to final products of approximate to 8-12 nucleotides. When part of dsRNA or in the presence of nonlabeled dsRNA, the 5'-labeled RNA substrates were processed to significantly smaller products, indicating that binding to dsRNA in cis or trans modulates the exonucleolytic activity of nsp14. Characterization of human CoV 229E ExoN active-site mutants revealed severe defects in viral RNA synthesis, and no viable virus could be recovered. Besides strongly reduced genome replication, specific defects in sg RNA synthesis, such as aberrant sizes of specific sg RNAs and changes in the molar ratios between individual sg RNA species, were observed. Taken together, the study identifies an RNA virus ExoN activity that is involved in the synthesis of multiple RNAs from the exceptionally large genomic RNA templates of CoVs.
C1 Univ Wurzburg, Inst Immunol & Virol, D-97078 Wurzburg, Germany.
   Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, NL-2300 RC Leiden, Netherlands.
   Univ Aix Marseille 1, UMR 6098, F-13288 Marseille 09, France.
   Univ Aix Marseille 2, UMR 6098, F-13288 Marseille 09, France.
   CNRS, F-13288 Marseille 09, France.
RP Ziebuhr, J (reprint author), Queens Univ Belfast, Sch Biomed Sci, Belfast BT9 7BL, Antrim, North Ireland.
EM j.ziebuhr@qub.ac.uk
RI Ziebuhr, John/G-7669-2015; Gorbalenya, Alexander E/J-4818-2012
OI Gorbalenya, Alexander E/0000-0002-4967-7341; Canard,
   Bruno/0000-0003-4924-1991; Campanacci, Valerie/0000-0001-6407-6395;
   Ziebuhr, John/0000-0002-5741-8825; Minskaia,
   Ekaterina/0000-0002-1137-373X
CR BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x
   Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   Cheng Y, 2004, J MOL BIOL, V343, P305, DOI 10.1016/j.jmb.2004.08.055
   COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004
   DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x
   DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946
   DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067
   Domingo E, 2005, VIRUS RES, V107, P129, DOI 10.1016/j.virusres.2004.11.003
   Elisseeva E, 1999, J BIOL CHEM, V274, P25151, DOI 10.1074/jbc.274.35.25151
   FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   Gorbalenya AE, 2001, ADV EXP MED BIOL, V494, P1
   Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101
   JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.biochem.63.1.777
   LEHMAN IR, 1964, J BIOL CHEM, V239, P233
   Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Perrino FW, 2005, J BIOL CHEM, V280, P15212, DOI 10.1074/jbc.M500108200
   Ren YG, 2004, J BIOL CHEM, V279, P48702, DOI 10.1074/jbc.M403858200
   Sawicki DL, 2001, J GEN VIROL, V82, P385, DOI 10.1099/0022-1317-82-2-385
   Sawicki S G, 1995, Adv Exp Med Biol, V380, P499
   Schelle B, 2005, J VIROL, V79, P6620, DOI 10.1128/JVI.79.11.6620-6630.2005
   SIDDELL SG, 2005, TOPLEY WILSONS MICRO, P823
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   Sperry SM, 2005, J VIROL, V79, P3391, DOI 10.1128/JVI.79.6.3391-3400.2005
   STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498
   Taft-Benz SA, 1998, NUCLEIC ACIDS RES, V26, P4005, DOI 10.1093/nar/26.17.4005
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   Thore S, 2003, EMBO REP, V4, P1150, DOI 10.1038/sj.embor.7400020
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Zuniga S, 2004, J VIROL, V78, P980, DOI 10.1128/JVI.78.2.980-994.2004
   Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017
NR 39
TC 170
Z9 182
U1 2
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 28
PY 2006
VL 103
IS 13
BP 5108
EP 5113
DI 10.1073/pnas.0508200103
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 028FO
UT WOS:000236472500057
PM 16549795
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Ratia, K
   Saikatendu, KS
   Santarsiero, BD
   Barretto, N
   Baker, SC
   Stevens, RC
   Mesecar, AD
AF Ratia, K
   Saikatendu, KS
   Santarsiero, BD
   Barretto, N
   Baker, SC
   Stevens, RC
   Mesecar, AD
TI Severe acute respiratory syndrome coronavirus papain-like protease:
   Structure of a viral deubiquitinating enzyme
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE membrane-associated protease; ubiquitin-like domain
ID DOUBLE-MEMBRANE VESICLES; SARS-CORONAVIRUS; REPLICATION COMPLEX;
   CYSTEINE PROTEASES; CRYSTAL-STRUCTURE; HEPATITIS-VIRUS; MAIN PROTEINASE;
   FAMILY; RNA; IDENTIFICATION
AB Replication of severe acute respiratory syndrome (SARS) Coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV. In this work, we describe the 1.85-angstrom crystal structure of the catalytic core of SARS-CoV PLpro and show that the overall architecture adopts a fold closely resembling that of known deubiquitinating enzymes. Key features, however, distinguish PLpro from characterized deubiquitinating enzymes, including an intact zinc-binding motif, an unobstructed catalytically competent active site, and the presence of an intriguing, ubiquitin-like N-terminal domain. To gain insight into the active-site recognition of the C-terminal tail of ubiquitin and the related LXGG motif, we propose a model of PLpro in complex with ubiquitin-aldehyde that reveals well defined sites within the catalytic cleft that help to account for strict substrate-recognition motifs.
C1 Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA.
   Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA.
   Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.
   Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
   Loyola Univ, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL 60153 USA.
RP Mesecar, AD (reprint author), Univ Illinois, Ctr Pharmaceut Biotechnol, 900 S Ashland Ave,M-C 870, Chicago, IL 60607 USA.
EM mesecar@uic.edu
RI Santarsiero, Bernard D/N-9249-2018; Stevens, Raymond/K-7272-2015
OI Santarsiero, Bernard D/0000-0002-9032-9699; Stevens,
   Raymond/0000-0002-4522-8725; Mesecar, Andrew/0000-0002-1241-2577
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [Y1-CO-1020]; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P01 AI060915,
   AI266200400058C]; NIGMS NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [Y1-GM-1104]
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Andres G, 2001, J BIOL CHEM, V276, P780, DOI 10.1074/jbc.M006844200
   Balakirev MY, 2002, J VIROL, V76, P6323, DOI 10.1128/JVI.76.12.6323-6331.2002
   Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Chernova TA, 2003, J BIOL CHEM, V278, P52102, DOI 10.1074/jbc.M310283200
   Ghosh AK, 2005, J MED CHEM, V48, P6767, DOI 10.1021/JM050548m
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Guarne A, 2000, J MOL BIOL, V302, P1227, DOI 10.1006/jmbi.2000.4115
   Han YS, 2005, BIOCHEMISTRY-US, V44, P10349, DOI 10.1021/bi0504761
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Herold J, 1999, J BIOL CHEM, V274, P14918, DOI 10.1074/jbc.274.21.14918
   Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6
   Hu M, 2005, EMBO J, V24, P3747, DOI 10.1038/sj.emboj.7600832
   Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kanjanahaluethai A, 2003, J VIROL, V77, P7376, DOI 10.1128/JVI.77.13.7376-7382.2003
   Kattenhorn LM, 2005, MOL CELL, V19, P547, DOI 10.1016/j.molcel.2005.07.003
   Kim KI, 2003, BIOCHEM BIOPH RES CO, V307, P431, DOI 10.1016/S0006-291X(03)01216-6
   Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161
   Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X
   Lim KP, 2000, J VIROL, V74, P1674, DOI 10.1128/JVI.74.4.1674-1685.2000
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Schlieker C, 2005, J VIROL, V79, P15582, DOI 10.1128/JVI.79.24.15582-15585.2005
   Shi ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Sugawara K, 2005, J BIOL CHEM, V280, P40058, DOI 10.1074/jbc.M509158200
   Sulea T, 2005, J VIROL, V79, P4550, DOI 10.1128/JVI.79.7.4550-4551.2005
   Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839
   Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Wyndham AM, 1999, PROTEIN SCI, V8, P1268, DOI 10.1110/ps.8.6.1268
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
NR 51
TC 169
Z9 180
U1 0
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 11
PY 2006
VL 103
IS 15
BP 5717
EP 5722
DI 10.1073/pnas.0510851103
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 034AK
UT WOS:000236896200017
PM 16581910
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU CAVANAGH, D
   DAVIS, PJ
   COOK, JKA
   LI, D
   KANT, A
   KOCH, G
AF CAVANAGH, D
   DAVIS, PJ
   COOK, JKA
   LI, D
   KANT, A
   KOCH, G
TI LOCATION OF THE AMINO-ACID DIFFERENCES IN THE S1 SPIKE GLYCOPROTEIN
   SUBUNIT OF CLOSELY RELATED SEROTYPES OF INFECTIOUS-BRONCHITIS VIRUS
SO AVIAN PATHOLOGY
LA English
DT Article
ID AVIAN CORONAVIRUS-IBV; HEMAGGLUTINATION-INHIBITING ANTIBODY; INFLUENZA-B
   VIRUS; PEPLOMER PROTEIN; MOUTH-DISEASE; SEQUENCE; STRAINS; M41;
   NUCLEOTIDE; BEAUDETTE
AB Four UK strains of three different serotypes were found to differ by only 2-3% of their S1 amino acids. The S1 sequences were also very similar to those of three Dutch isolates (D207, D274 and D3896), the greatest difference between two of the seven isolates being 4.4%. The few amino acid differences between the seven isolates were located largely between residues 19-122 and 251-347 of the mature S1 subunit.
   The seven isolates could be differentiated using 16 monoclonal antibodies in an enzyme-linked immunosorbent assay. Some virus neutralizing (VN) antibody-inducing epitopes were common to all seven isolates even though the strains had been differentiated into three serotypes by polyclonal sera. The results indicate that the most antigenic of the VN antibody-inducing epitopes are formed by very few amino acids and that these occur in the first and third quarters of the S1 subunit. We suggest that serology-based epizootiological studies of IBV should, therefore, be augmented by the inclusion of nucleic acid sequencing and/or monoclonal antibody analysis.
C1 CENT VET INST,8200 AJ LELYSTAD,NETHERLANDS.
RP CAVANAGH, D (reprint author), AFRC,INST ANIM HLTH,HOUGHTON LAB,HUNTINGDON PE17 2DA,CAMBS,ENGLAND.
CR ARCHETTI I, 1950, J EXP MED, V92, P441, DOI 10.1084/jem.92.5.441
   BINNS MM, 1986, J GEN VIROL, V67, P2825, DOI 10.1099/0022-1317-67-12-2825
   BOOTMAN JS, 1988, VIROLOGY, V166, P271, DOI 10.1016/0042-6822(88)90173-0
   BROWN TDK, 1984, VIRUS RES, V1, P15, DOI 10.1016/0168-1702(84)90031-5
   CAVANAGH D, 1984, AVIAN PATHOL, V13, P573, DOI 10.1080/03079458408418556
   CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435
   CAVANAGH D, 1988, J GEN VIROL, V69, P621, DOI 10.1099/0022-1317-69-3-621
   CAVANAGH D, 1988, VIRUS RES, V11, P141, DOI 10.1016/0168-1702(88)90039-1
   CAVANAGH D, 1983, J GEN VIROL, V64, P1787, DOI 10.1099/0022-1317-64-8-1787
   CAVANAGH D, 1990, VIROLOGY, V176, P306, DOI 10.1016/0042-6822(90)90259-T
   CAVANAGH D, 1988, 1ST P INT S INF BRON
   COOK JKA, 1986, AVIAN PATHOL, V15, P129, DOI 10.1080/03079458608436272
   COOK JKA, 1984, AVIAN PATHOL, V13, P733, DOI 10.1080/03079458408418570
   DARBYSHIRE JH, 1979, ARCH VIROL, V61, P227, DOI 10.1007/BF01318057
   DAVELAAR FG, 1984, VET QUART, V6, P114, DOI 10.1080/01652176.1984.9693924
   HOPKINS SR, 1974, AVIAN DIS, V18, P231, DOI 10.2307/1589131
   JORDI BJAM, 1989, NUCLEIC ACIDS RES, V17, P6726, DOI 10.1093/nar/17.16.6726
   KING DJ, 1990, DISEASES POULTRY, P471
   KOCH G, 1990, J GEN VIROL, V71, P1929, DOI 10.1099/0022-1317-71-9-1929
   KOCH G, 1990, NUCLEIC ACIDS RES, V18, P3063, DOI 10.1093/nar/18.10.3063
   KOCH G, 1985, ISRAEL J VET MED, V42, P89
   KOCH G, 1990, 8TH INT C VIR BERL 1, P346
   KUSTERS JG, 1989, VIROLOGY, V169, P217, DOI 10.1016/0042-6822(89)90058-5
   MARTINEZ MA, 1988, GENE, V62, P75, DOI 10.1016/0378-1119(88)90581-1
   MOCKETT APA, 1984, J GEN VIROL, V65, P2281, DOI 10.1099/0022-1317-65-12-2281
   NIESTERS HGM, 1986, VIRUS RES, V5, P253, DOI 10.1016/0168-1702(86)90022-5
   PICCONE ME, 1988, J VIROL, V62, P1469, DOI 10.1128/JVI.62.4.1469-1473.1988
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   SOBRINO F, 1986, GENE, V50, P149, DOI 10.1016/0378-1119(86)90320-3
   YAMASHITA M, 1988, VIROLOGY, V163, P112, DOI 10.1016/0042-6822(88)90238-3
NR 30
TC 169
Z9 196
U1 0
U2 6
PU CARFAX PUBL CO
PI ABINGDON
PA PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE
SN 0307-9457
J9 AVIAN PATHOL
JI Avian Pathol.
PY 1992
VL 21
IS 1
BP 33
EP 43
DI 10.1080/03079459208418816
PG 11
WC Veterinary Sciences
SC Veterinary Sciences
GA HK352
UT WOS:A1992HK35200002
PM 18670913
OA Bronze
DA 2020-04-03
ER

PT J
AU MEYERS, G
   TAUTZ, N
   DUBOVI, EJ
   THIEL, HJ
AF MEYERS, G
   TAUTZ, N
   DUBOVI, EJ
   THIEL, HJ
TI VIRAL CYTOPATHOGENICITY CORRELATED WITH INTEGRATION OF UBIQUITIN-CODING
   SEQUENCES
SO VIROLOGY
LA English
DT Article
ID DEFECTIVE INTERFERING PARTICLES; HOG-CHOLERA VIRUS; DIARRHEA VIRUS;
   MOLECULAR-CLONING; MURINE CORONAVIRUSES; NUCLEOTIDE-SEQUENCE; PUTATIVE
   HELICASES; RNA RECOMBINATION; MUCOSAL DISEASE; SINDBIS VIRUS
C1 FED RES CTR VIRUS DIS ANIM, POB 1149, W-7400 TUBINGEN, GERMANY.
   CORNELL UNIV, NEW YORK STATE COLL VET MED, ITHACA, NY 14853 USA.
RI Tautz, Norbert/D-4252-2011
CR BAKER JC, 1987, J AM VET MED ASSOC, V190, P1449
   BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7
   BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279
   BOLIN SR, 1985, AM J VET RES, V46, P573
   BROWNLIE J, 1984, VET REC, V114, P535, DOI 10.1136/vr.114.22.535
   BUTT TR, 1988, J BIOL CHEM, V263, P16364
   COLLETT MS, 1988, J GEN VIROL, V69, P2637, DOI 10.1099/0022-1317-69-10-2637
   COLLETT MS, 1989, J GEN VIROL, V70, P253, DOI 10.1099/0022-1317-70-2-253
   COLLETT MS, 1988, VIROLOGY, V165, P191, DOI 10.1016/0042-6822(88)90672-1
   COLLETT MS, 1988, VIROLOGY, V165, P200, DOI 10.1016/0042-6822(88)90673-3
   CORAPI WV, 1988, J VIROL, V62, P2823, DOI 10.1128/JVI.62.8.2823-2827.1988
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   DONIS RO, 1987, AM J VET RES, V48, P1549
   DONIS RO, 1987, J GEN VIROL, V68, P1597, DOI 10.1099/0022-1317-68-6-1597
   EINSPANIER R, 1987, DNA-J MOLEC CELL BIO, V6, P395, DOI 10.1089/dna.1987.6.395
   FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2
   FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889
   GUTEKUNST DE, 1963, CAN J COMP MED VET S, V27, P121
   HARLOW E, 1988, ANTIBODIES LABORATOR, P460
   HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156
   Kessler S W, 1981, Methods Enzymol, V73, P442
   KHATCHIKIAN D, 1989, ANTURE LONDON, V340, P156
   King A. M. Q., 1987, The molecular biology of the positive strand RNA viruses, P129
   KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985
   LAZZARINI RA, 1981, CELL, V26, P145, DOI 10.1016/0092-8674(81)90298-1
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MANIATIS T, 1982, MOL CLONING
   MEYERS G, 1989, VIROLOGY, V171, P555, DOI 10.1016/0042-6822(89)90625-9
   MEYERS G, 1989, NATURE, V341, P491, DOI 10.1038/341491a0
   MEYERS G, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P25
   MONROE SS, 1983, P NATL ACAD SCI-BIOL, V80, P3279, DOI 10.1073/pnas.80.11.3279
   OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x
   POCOCK DH, 1987, ARCH VIROL, V94, P43, DOI 10.1007/BF01313724
   PURCHIO AF, 1984, J VIROL, V50, P666, DOI 10.1128/JVI.50.2.666-669.1984
   RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245
   REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0
   RENARD A, 1985, DNA-J MOLEC CELL BIO, V4, P429, DOI 10.1089/dna.1985.4.429
   RENARD A, 1987, Patent No. 86870095
   RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3
   RUMENAPF T, 1989, VIROLOGY, V171, P18, DOI 10.1016/0042-6822(89)90506-0
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SAUNDERS K, 1985, J VIROL, V56, P921, DOI 10.1128/JVI.56.3.921-929.1985
   STEINHAUER DA, 1987, ANN REV MCIROBIOL, V41, P4109
   STRAUSS JH, 1988, ANNU REV MICROBIOL, V42, P657, DOI 10.1146/annurev.mi.42.100188.003301
   SUZICH JA, 1988, VIROLOGY, V164, P478, DOI 10.1016/0042-6822(88)90562-4
   TSIANG M, 1985, J VIROL, V54, P38, DOI 10.1128/JVI.54.1.38-44.1985
   WESTAWAY EG, 1985, INTERVIROLOGY, V24, P125, DOI 10.1159/000149632
NR 51
TC 169
Z9 178
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD FEB
PY 1991
VL 180
IS 2
BP 602
EP 616
DI 10.1016/0042-6822(91)90074-L
PG 15
WC Virology
SC Virology
GA ET825
UT WOS:A1991ET82500015
PM 1846490
DA 2020-04-03
ER

PT J
AU Smith, RD
AF Smith, Richard D.
TI Responding to global infectious disease outbreaks: Lessons from SARS on
   the role of risk perception, communication and management
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE risk perception; risk communication; infectious disease; SARS; economy
ID ACUTE RESPIRATORY SYNDROME; MAD-COW-DISEASE; HONG-KONG; TRANSMISSION
   DYNAMICS; EPIDEMIC; REPRESENTATIONS; SURVEILLANCE; CORONAVIRUS;
   NETHERLANDS; VALUATION
AB With increased globalisation comes the likelihood that infectious disease appearing in one country will spread rapidly to another, severe acute respiratory syndrome (SARS) being a recent example. However, although SARS infected some 10,000 individuals, killing around 1000, it did not lead to the devastating health impact that many feared, but a rather disproportionate economic impact. The disproportionate scale and nature of this impact has caused concern that outbreaks of more serious disease could cause catastrophic impacts on the global economy. Understanding factors that led to the impact of SARS might help to deal with the possible impact and management of such other infectious disease outbreaks. In this respect, the role of risk-its perception, communication and management-is critical.
   This paper looks at the role that risk, and especially the perception of risk, its communication and management, played in driving the economic impact of SARS. It considers the public and public health response to SARS, the role of the media and official organisations, and proposes policy and research priorities for establishing a system to better deal with the next global infectious disease outbreak. It is concluded that the potential for the rapid spread of infectious disease is not necessarily a greater threat than it has always been, but the effect that an outbreak can have on the economy is, which requires further research and policy development. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ E Anglia, Hlth Econ Grp, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England.
RP Smith, RD (reprint author), Univ E Anglia, Hlth Econ Grp, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England.
EM Richard.Smith@uea.ac.uk
OI Smith, Richard/0000-0003-3837-6559
CR [Anonymous], 2003, LEARN SARS REN PUBL
   Baker SJ, 2003, LANCET, V361, P1905, DOI 10.1016/S0140-6736(03)13508-8
   Barreto ML, 2003, J EPIDEMIOL COMMUN H, V57, P644, DOI 10.1136/jech.57.9.644
   Beck Ulrich, 1992, RISK SOC NEW MODERNI
   Bergeron SL, 2005, EMERG INFECT DIS, V11, P732, DOI 10.3201/eid1105.040512
   BIKCHANDANI S, 2001, IMF STAFF PAPERS, V47, P279
   Blendon RJ, 2004, CLIN INFECT DIS, V38, P925, DOI 10.1086/382355
   Brown EG, 2003, LANCET, V361, P1756, DOI 10.1016/S0140-6736(03)13444-7
   Brug J, 2004, EMERG INFECT DIS, V10, P1486, DOI 10.3201/eid1008.040283
   CHANG I, 2003, NY TIMES, V152, pA31
   Chang SM, 2005, J EMERG MED, V28, P395, DOI 10.1016/j.jemermed.2004.11.022
   CHOU J, 2004, POTENTIAL IMPACTS SA
   *DEP HLTH, 2003, SOC AMPL RISK MED PU
   Donnelly C., 2004, SIGNIFICANCE, V1, P176, DOI 10.1111/j.1740-9713.2004.00066.x
   Douglas M., 1992, RISK AND BLAME
   Drazen JM, 2003, NEW ENGL J MED, V349, P319, DOI 10.1056/NEJMp038118
   EDMUNDS J, 2006, IN PRESS RAPID ASSES, pCH8
   FAN X, 2003, POLICY BRIEF, V15
   FENG PH, 2003, J RHEUMATOL, V6, P158
   FISCHHOFF B., 1983, ANAL ACTUAL VERSUS P, P235
   FISCHHOFF B, 2002, OXFORD TXB PUBLIC HL, P1105
   GATEHOUSE J, 2003, MACLEANS, V116, P18
   Gostin LO, 2003, JAMA-J AM MED ASSOC, V290, P3229, DOI 10.1001/jama.290.24.3229
   Greaves F, 2004, J PUBLIC HEALTH, V26, P288, DOI 10.1093/pubmed/fdh155
   Griffin RJ, 1998, RISK ANAL, V18, P367, DOI 10.1111/j.1539-6924.1998.tb00350.x
   HANNA D, 2004, IMPACT SARS ASIAN EC
   HARRABIN R, 2003, HLTH NEWS RISK REPOR
   Hesketh T, 2003, BRIT MED J, V326, P1095, DOI 10.1136/bmj.326.7398.1095
   Heymann DL, 2004, EMERG INFECT DIS, V10, P173, DOI 10.3201/eid1002.031038
   Hill A, 2001, J RISK RES, V4, P209, DOI [10.1080/13669870152023773, DOI 10.1080/13669870152023773]
   Hughes JM, 2004, EMERG INFECT DIS, V10, P171, DOI 10.3201/eid1002.031043
   HURST MD, 2003, ED WEEK, V22, P10
   Joffe H, 2003, BRIT J SOC PSYCHOL, V42, P55, DOI 10.1348/014466603763276126
   Joffe H, 2002, SOC SCI MED, V54, P955, DOI 10.1016/S0277-9536(01)00068-5
   Joffe H., 1999, RISK OTHER
   KAHNEMAN D, 1982, JUDGEMENT UNCERTAINT
   Kitzinger J, 1997, EUR J COMMUN, V12, P319, DOI 10.1177/0267323197012003002
   Lam WK, 2003, RESPIROLOGY, V8, pS2, DOI 10.1046/j.1440-1843.2003.00516.x
   LARKIN M, 2003, LANCET INFECT DIS, V3, P453
   Lau JTF, 2005, EMERG INFECT DIS, V11, P417
   Lau JTF, 2004, EPIDEMIOL INFECT, V132, P727, DOI 10.1017/S0950268804002225
   Lau JTF, 2004, EMERG INFECT DIS, V10, P587, DOI 10.3201/eid1004.030628
   LEE JW, 2004, GLOBALIZATION DIS CA
   Lee M. L., 2003, Morbidity and Mortality Weekly Report, V52, P680
   LICHTENBERG J, 1991, TECHNOLOGY RISK SOC, V4, P157
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Liu JT, 2005, HEALTH ECON, V14, P83, DOI 10.1002/hec.911
   Lupton Deborah, 1999, RISK
   McFee RB, 2004, VET HUM TOXICOL, V46, P347
   MCINNES C, 2005, HLTH SECURITY RISK S
   Muzzatti Stephen L., 2005, ILLNESS CRISIS LOSS, V13, P117
   NESMITH J, 2003, ATLANTA J CONST 1001
   Pang XH, 2003, JAMA-J AM MED ASSOC, V290, P3215, DOI 10.1001/jama.290.24.3215
   Person B, 2004, EMERG INFECT DIS, V10, P358, DOI 10.3201/eid1002.030750
   Pickles H., 2006, EUROHEALTH, V12, P10
   Razum O, 2003, LANCET, V361, P1739, DOI 10.1016/S0140-6736(03)13335-1
   Rezza G, 2004, EMERG INFECT DIS, V10, P381, DOI 10.3201/eid1002.030743
   Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478
   SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507
   SLOVIC P, 2000, PERCEPTION RISK
   Smith R. D., 2003, ASSESSING EC IMPACT
   Smith RD, 2005, J HEALTH ECON, V24, P515, DOI 10.1016/j.jhealeco.2004.08.002
   SMITH RD, 2006, IN PRESS RAPID ASSES
   Stegeman A, 2004, J INFECT DIS, V190, P2088, DOI 10.1086/425583
   Stohr K, 2003, LANCET, V361, P1730, DOI 10.1016/S0140-6736(03)13376-4
   Svoboda T, 2004, NEW ENGL J MED, V350, P2352, DOI 10.1056/NEJMoa032111
   Tomlinson B, 2003, LANCET, V361, P1486, DOI 10.1016/S0140-6736(03)13218-7
   Ungar S, 1998, BRIT J SOCIOL, V49, P36, DOI 10.2307/591262
   Wallis P, 2005, SOC SCI MED, V60, P2629, DOI 10.1016/j.socscimed.2004.11.031
   Wang MD, 2004, B WORLD HEALTH ORGAN, V82, P547
   Washer P, 2006, SOC SCI MED, V62, P457, DOI 10.1016/j.socscimed.2005.06.001
   Washer P, 2004, SOC SCI MED, V59, P2561, DOI 10.1016/j.socscimed.2004.03.038
   WEN H, 2004, SHORT TERM IMPACT SA
   *WHO, 2003, GLOB C SEV AC RESP S
   *WHO, 2003, WHOCDSCSRGAR200311
   Wilson N, 2004, EMERG INFECT DIS, V10, P1461, DOI 10.3201/eid1008.031096
   Yardley L., 1997, MAT DISCOURSES HLTH
   Zambon M, 2003, BRIT MED J, V326, P831, DOI 10.1136/bmj.326.7394.831
NR 78
TC 168
Z9 173
U1 31
U2 89
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD DEC
PY 2006
VL 63
IS 12
BP 3113
EP 3123
DI 10.1016/j.socscimed.2006.08.004
PG 11
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 111PX
UT WOS:000242467000010
PM 16978751
DA 2020-04-03
ER

PT J
AU Arnold, JC
   Singh, KK
   Spector, SA
   Sawyer, MH
AF Arnold, JC
   Singh, KK
   Spector, SA
   Sawyer, MH
TI Human bocavirus: Prevalence and clinical spectrum at a children's
   hospital
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY-TRACT DISEASE; HUMAN CORONAVIRUS; PARVOVIRUS B19;
   YOUNG-CHILDREN; INFECTION; PERTUSSIS; VIRUSES
AB Background. Molecular methods of pathogen discovery have recently led to the description of several new respiratory viruses. Human bocavirus (HBoV), a proposed member of the family Parvoviridae, is one of the most recently described respiratory viruses. Initial reports indicate that HBoV is a common cause of respiratory tract infection in children.
   Methods. A total of 1474 nasal scraping specimens collected over a 20-month period were screened by polymerase chain reaction for the presence of HBoV nucleic acid. Positive results were confirmed with a second polymerase chain reaction assay from a different genomic region. The medical records of patients with positive results were reviewed for demographic and clinical data.
   Results. HBoV DNA was identified in 82 samples (5.6%). The peak rate of HBoV infection occurred during the period of March through May in both 2004 and 2005. Sixty-three percent of infected patients were < 12 months of age. The most common symptoms were cough, rhinorrhea, and fever. Other symptoms of interest included diarrhea and a "paroxysmal" cough that was clinically suspected to be caused by Bordetella pertussis.
   Conclusions. HBoV DNA is commonly present in children with upper and lower respiratory tract infections. The presence of a pertussis-like cough and diarrhea in association with HBoV infection merits further investigation.
C1 Univ Calif San Diego, Ctr AIDS Res, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Pediat, Div Infect Dis, La Jolla, CA 92093 USA.
RP Arnold, JC (reprint author), Childrens Hosp San Diego, Dept Infect Dis, 3020 Childrens Wy,MC 5041, San Diego, CA 92123 USA.
EM jcarnold@ucsd.edu
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-36214]
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P15712, DOI 10.1073/pnas.0508068102
   Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Bateman HE, 1999, J RHEUMATOL, V26, P2482
   Cappelletty D, 1998, PEDIATR INFECT DIS J, V17, pS55, DOI 10.1097/00006454-199808001-00002
   Esper F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138
   FEIGIN RD, 2004, TXB PEDIAT INFECT DS, V1
   Hamilton BE, 2004, BIRTHS PRELIMINARY D
   Jennings LC, 2004, PEDIATR INFECT DIS J, V23, P1003, DOI 10.1097/01.inf.0000143648.04673.6c
   Matano S, 2003, INTERNAL MED, V42, P903, DOI 10.2169/internalmedicine.42.903
   OLIVER AR, 1988, J MED VIROL, V24, P211, DOI 10.1002/jmv.1890240211
   PARTON R, 1994, J MED MICROBIOL, V40, P307, DOI 10.1099/00222615-40-5-307
   Rovers MM, 2004, LANCET, V363, P465, DOI 10.1016/S0140-6736(04)15495-0
   Scharre J E, 1996, J Am Optom Assoc, V67, P763
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Squires RA, 2003, NEW ZEAL VET J, V51, P252, DOI 10.1080/00480169.2003.36379
   Tan WC, 2005, CURR OPIN PULM MED, V11, P21
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   VONKONIG CHW, 1994, EUR J CLIN MICROBIOL, V13, P455, DOI 10.1007/BF01974634
   Young NS, 2004, NEW ENGL J MED, V350, P586, DOI 10.1056/NEJMra030840
NR 19
TC 168
Z9 199
U1 1
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 1
PY 2006
VL 43
IS 3
BP 283
EP 288
DI 10.1086/505399
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 057XK
UT WOS:000238628300003
PM 16804840
OA Bronze
DA 2020-04-03
ER

PT J
AU Kumar, D
   Erdman, D
   Keshavjee, S
   Peret, T
   Tellier, R
   Hadjiliadis, D
   Johnson, G
   Ayers, M
   Siegal, D
   Humar, A
AF Kumar, D
   Erdman, D
   Keshavjee, S
   Peret, T
   Tellier, R
   Hadjiliadis, D
   Johnson, G
   Ayers, M
   Siegal, D
   Humar, A
TI Clinical impact of community-acquired respiratory viruses on
   bronchiolitis obliterans after lung transplant
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE bronchiolitis obliterans; lung transplant; respiratory virus
AB Community-acquired viral respiratory tract infections (RTI) in lung transplant recipients may have a high rate of progression to pneumonia and can be a trigger for immunologically mediated detrimental effects on lung function. A cohort of 100 patients was enrolled from 2001 to 2003 in which 50 patients had clinically diagnosed viral RTI and 50 were asymptomatic. All patients had nasopharyngeal and throat swabs taken for respiratory virus antigen detection, culture and RT-PCR. All patients had pulmonary function tests at regular intervals for 12 months. Rates of rejection, decline in forced expiratory volume (L) in 1 s (FEV-1) and bacterial and fungal superinfection were compared at the 3-month primary endpoint. In the 50 patients with RTI, a microbial etiology was identified in 33 of 50 (66%) and included rhinovirus (9), coronavirus (8), RSV (6), influenza A (5), parainfluenza (4) and human metapneumovirus (1). During the 3-month primary endpoint, 8 of 50 (16%) RTI patients had acute rejection versus 0 of 50 non-RTI patients (p = 0.006). The number of patients experiencing a 20% or more decline in FEV-1 by 3 months was 9 of 50 (18%) RTI versus 0 of 50 non-RTI (0%) (p = 0.003). In six of these nine patients, the decline in FEV-1 was sustained over a 1-year period consistent with bronchiolitis obliterans syndrome (BOS). Community-acquired respiratory viruses may be associated with the development of acute rejection and BOS.
C1 Univ Toronto, Toronto, ON, Canada.
   Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, Atlanta, GA USA.
   Hosp Sick Children, Div Microbiol, Toronto, ON M5G 1X8, Canada.
   Hosp Sick Children, Metab Res Program, Toronto, ON M5G 1X8, Canada.
RP Kumar, D (reprint author), Univ Toronto, 100 Coll St, Toronto, ON, Canada.
EM deepali.kumar@uhn.on.ca
OI Keshavjee, Shaf/0000-0003-4547-8094; Siegal, Deborah/0000-0003-3806-3245
CR Adachi D, 2004, J VIROL METHODS, V122, P29, DOI 10.1016/j.jviromet.2004.07.008
   *AM SOC TRANSPL, 2004, AM J TRANSPLANT, V4, P105
   Arcasoy SM, 1999, NEW ENGL J MED, V340, P1081, DOI 10.1056/NEJM199904083401406
   Billings J L, 2001, Transpl Infect Dis, V3, P138, DOI 10.1034/j.1399-3062.2001.003003138.x
   COOPER JD, 1993, J HEART LUNG TRANSPL, V12, P713
   Erdman DD, 2003, J CLIN MICROBIOL, V41, P4298, DOI 10.1128/JCM.41.9.4298-4303.2003
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   FOX JP, 1975, AM J EPIDEMIOL, V101, P122, DOI 10.1093/oxfordjournals.aje.a112078
   Garantziotis S, 2001, CHEST, V119, P1277, DOI 10.1378/chest.119.4.1277
   Garbino J, 2004, AM J RESP CRIT CARE, V170, P1197, DOI 10.1164/rccm.200406-781OC
   Garbino J, 2004, CHEST, V125, P1033, DOI 10.1378/chest.125.3.1033
   Hayden FG, 2003, CLIN INFECT DIS, V36, P1523, DOI 10.1086/375069
   Hodges T. N., 2001, Journal of Heart and Lung Transplantation, V20, P169, DOI 10.1016/S1053-2498(00)00334-X
   Husain Shahid, 2002, Semin Respir Infect, V17, P310, DOI 10.1053/srin.2002.36442
   Khalifah AP, 2004, AM J RESP CRIT CARE, V170, P181, DOI 10.1164/rccm.200310-1359OC
   Mazzulli T, 1999, J INFECT DIS, V180, P1686, DOI 10.1086/315085
   McCurdy LH, 2003, J HEART LUNG TRANSPL, V22, P745, DOI 10.1016/S1053-2498(02)00569-7
   Monto AS, 2002, AM J MED, V112, p4S
   Mullins JA, 2004, EMERG INFECT DIS, V10, P700, DOI 10.3201/eid1004.030555
   Palmer SM, 1998, CHEST, V113, P944, DOI 10.1378/chest.113.4.944
   Sharples LD, 2002, J HEART LUNG TRANSPL, V21, P271, DOI 10.1016/S1053-2498(01)00360-6
   Speich R, 2001, CLIN INFECT DIS, V33, pS58, DOI 10.1086/320906
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vilchez R, 2002, TRANSPLANTATION, V73, P1075, DOI 10.1097/00007890-200204150-00010
   Vilchez RA, 2003, AM J TRANSPLANT, V3, P245, DOI 10.1034/j.1600-6143.2003.00056.x
   WENDT CH, 1995, J HEART LUNG TRANSPL, V14, P479
   Whimbey E, 1996, CLIN INFECT DIS, V22, P778, DOI 10.1093/clinids/22.5.778
   Yousem SA, 1996, J HEART LUNG TRANSPL, V15, P1
NR 28
TC 168
Z9 170
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD AUG
PY 2005
VL 5
IS 8
BP 2031
EP 2036
DI 10.1111/j.1600-6143.2005.00971.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 942OK
UT WOS:000230291500035
PM 15996256
DA 2020-04-03
ER

PT J
AU MACHAMER, CE
   ROSE, JK
AF MACHAMER, CE
   ROSE, JK
TI A SPECIFIC TRANSMEMBRANE DOMAIN OF A CORONAVIRUS E1 GLYCOPROTEIN IS
   REQUIRED FOR ITS RETENTION IN THE GOLGI REGION
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
C1 SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, SAN DIEGO, CA 92138 USA.
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA-14195]; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI-15481]; NIGMS NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS) [GM-33840]
CR ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7
   ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0
   BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x
   BOS TJ, 1984, P NATL ACAD SCI-BIOL, V81, P2327, DOI 10.1073/pnas.81.8.2327
   BOURSNELL MEG, 1984, VIRUS RES, V1, P303, DOI 10.1016/0168-1702(84)90019-4
   BRANDS R, 1985, J CELL BIOL, V101, P1724, DOI 10.1083/jcb.101.5.1724
   CAVANAGH D, 1986, VIRUS RES, V4, P145, DOI 10.1016/0168-1702(86)90038-9
   CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403
   DECARVALHO S, 1964, NATURE, V202, P255, DOI 10.1038/202255a0
   DUBOISDALCQ ME, 1982, VIROLOGY, V119, P317, DOI 10.1016/0042-6822(82)90092-7
   FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0
   GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8
   GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6
   HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338
   KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4
   LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169
   MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074
   MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984
   MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560
   MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1
   MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2
   NIEMANN H, 1981, J MOL BIOL, V153, P993, DOI 10.1016/0022-2836(81)90463-0
   PORUCHYNSKY MS, 1985, J CELL BIOL, V101, P2199, DOI 10.1083/jcb.101.6.2199
   PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756
   PUDDINGTON L, 1986, J CELL BIOL, V102, P2147, DOI 10.1083/jcb.102.6.2147
   ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7
   ROSE JK, 1982, CELL, V30, P753, DOI 10.1016/0092-8674(82)90280-X
   ROSE JK, 1984, P NATL ACAD SCI-BIOL, V81, P2050, DOI 10.1073/pnas.81.7.2050
   ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223
   ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271
   ROTHMAN JE, 1986, NATURE, V319, P96, DOI 10.1038/319096b0
   ROTTIER P, 1985, J BIOL CHEM, V260, P4648
   ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421
   ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987
   ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022
   SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1
   SLY WS, 1982, J CELL BIOCHEM, V18, P67, DOI 10.1002/jcb.1982.240180107
   SPRAGUE J, 1983, J VIROL, V45, P773, DOI 10.1128/JVI.45.2.773-781.1983
   STERN DF, 1982, J VIROL, V44, P794, DOI 10.1128/JVI.44.3.794-803.1982
   STERN DF, 1982, J VIROL, V44, P804, DOI 10.1128/JVI.44.3.804-812.1982
   STERN DF, 1983, THESIS U CALIF, P207
   STURMAN L, 1985, TRENDS BIOCHEM SCI, V10, P17, DOI 10.1016/0968-0004(85)90010-6
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   STURMAN LS, 1977, VIROLOGY, V77, P650, DOI 10.1016/0042-6822(77)90489-5
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   STURMAN LS, 1977, VIROLOGY, V77, P637, DOI 10.1016/0042-6822(77)90488-3
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   TOOZE J, 1985, EUR J CELL BIOL, V37, P203
   VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429
   WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8
   ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487
NR 53
TC 168
Z9 172
U1 0
U2 1
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD SEP
PY 1987
VL 105
IS 3
BP 1205
EP 1214
DI 10.1083/jcb.105.3.1205
PG 10
WC Cell Biology
SC Cell Biology
GA K1999
UT WOS:A1987K199900018
PM 2821010
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU STAIR, EL
   WHITE, RG
   RHODES, MB
   MEBUS, CA
AF STAIR, EL
   WHITE, RG
   RHODES, MB
   MEBUS, CA
TI NEONATAL CALF DIARRHEA - PURIFICATION AND ELECTRON-MICROSCOPY OF A
   CORONAVIRUS-LIKE AGENT
SO AMERICAN JOURNAL OF VETERINARY RESEARCH
LA English
DT Article
CR ALMEIDA JD, 1968, NATURE, V220, P650
   BALL EM, 1968, VIROLOGY, V36, P152, DOI 10.1016/0042-6822(68)90128-1
   BRAKKE MK, 1967, METHOD VIROL, V2, P93
   BRANDLY CA, 1954, ANN NY ACAD SCI, V66, P181
   ESTOLA T, 1970, AVIAN DIS, V14, P330, DOI 10.2307/1588476
   FRANK FW, 1970, AGR SCI REV, V8, P36
   MEBUS CA, 1971, CANADIAN VET J, V12, P69
   MEBUS CA, 1969, GERMFREE CALVES IMPO, P4
   MEBUS CA, 1969, 233 U NEBR AGR EXP S, P1
   MOLL T., 1957, Veterinary Medicine, V52, P115
   OKANIWA A, 1968, NATL I ANIM HEALTH Q, V8, P175
   VINOGRAD J, 1962, FORTSCHR CHEM ORG NA, V20, P372
   WELCH AB, 1971, CAN J COMPARAT MED, V35, P195
   WHITE RG, 1970, VET MED SM ANIM CLIN, V65, P487
   1970, AM J VET RE, V31, P1915
NR 15
TC 168
Z9 169
U1 0
U2 1
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA
SN 0002-9645
J9 AM J VET RES
JI Am. J. Vet. Res.
PY 1972
VL 33
IS 6
BP 1147
EP +
PG 0
WC Veterinary Sciences
SC Veterinary Sciences
GA M6352
UT WOS:A1972M635200008
PM 4553881
DA 2020-04-03
ER

PT J
AU Corman, VM
   Eckerle, I
   Bleicker, T
   Zaki, A
   Landt, O
   Eschbach-Bludau, M
   van Boheemen, S
   Gopal, R
   Ballhause, M
   Bestebroer, TM
   Muth, D
   Muller, MA
   Drexler, JF
   Zambon, M
   Osterhaus, AD
   Fouchier, RM
   Drosten, C
AF Corman, V. M.
   Eckerle, I.
   Bleicker, T.
   Zaki, A.
   Landt, O.
   Eschbach-Bludau, M.
   van Boheemen, S.
   Gopal, R.
   Ballhause, M.
   Bestebroer, T. M.
   Muth, D.
   Mueller, M. A.
   Drexler, J. F.
   Zambon, M.
   Osterhaus, A. D.
   Fouchier, R. M.
   Drosten, C.
TI Detection of a novel human coronavirus by real-time
   reverse-transcription polymerase chain reaction
SO EUROSURVEILLANCE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; SARS; ASSAY
AB We present two real-time reverse-transcription polymerase chain reaction assays for a novel human coronavirus (CoV), targeting regions upstream of the E gene (upE) or within open reading frame (ORF) 1b, respectively. Sensitivity for upE is 3.4 copies per reaction (95% confidence interval (CI): 2.5-6.9 copies) or 291 copies/mL of sample. No cross-reactivity was observed with coronaviruses OC43, NL63, 229E, SARS-CoV, nor with 92 clinical specimens containing common human respiratory viruses. We recommend using upE for screening and ORF1b for confirmation.
C1 [Corman, V. M.; Eckerle, I.; Bleicker, T.; Eschbach-Bludau, M.; Muth, D.; Mueller, M. A.; Drexler, J. F.; Drosten, C.] Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
   [Zaki, A.] Dr Soliman Fakeeh Hosp, Virol Lab, Jeddah, Saudi Arabia.
   [Landt, O.; Ballhause, M.] TibMolbiol, Berlin, Germany.
   [van Boheemen, S.; Bestebroer, T. M.; Osterhaus, A. D.; Fouchier, R. M.] Erasmus MC, Dept Virol & Virosci, Rotterdam, Netherlands.
   [Gopal, R.; Zambon, M.] Hlth Protect Agcy, London, England.
RP Corman, VM (reprint author), Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
EM drosten@virology-bonn.de
RI Fouchier, Ron/Y-3755-2019; Drexler, Jan Felix/C-1004-2014; Fouchier, Ron
   A/A-1911-2014; Mueller, Marcel/O-2425-2019; Corman, Victor
   Max/K-1319-2019
OI Fouchier, Ron/0000-0001-8095-2869; Fouchier, Ron A/0000-0001-8095-2869;
   Mueller, Marcel/0000-0003-2242-5117; Corman, Victor
   Max/0000-0002-3605-0136
FU EMPERIE [223498]; European CommissionEuropean Commission Joint Research
   Centre [228292]
FX The development and provision of these assays was done by a European
   research project on emerging diseases detection and response, EMPERIE,
   http://www.emperie.eu/emp/, contract No 223498, co-ordinated by author
   A.D.M.E.O. Author C.D. has received infrastructural support from the
   German Centre for Infection Research (DZIF) that included full funding
   of the position of author V.M.C. Oligonucleotides can be ordered from
   stock at Tib-Molbiol, Berlin (www.tib-molbiol.de). In-vitro transcribed
   RNA controls can be acquired from author C. D. through the European
   Virus Archive platform (www.european-virus-archive.com), funded by the
   European Commission under contract number 228292. Further information
   and assay updates can be retrieved at www.virologybonn.de.
CR Abbott A, 2003, NATURE, V423, P114, DOI 10.1038/423114a
   Chan KH, 2004, EMERG INFECT DIS, V10, P294, DOI 10.3201/eid1002.030610
   Luna LKD, 2007, J CLIN MICROBIOL, V45, P1049, DOI 10.1128/JCM.02426-06
   Drosten C, 2004, J CLIN MICROBIOL, V42, P2043, DOI 10.1128/JCM.42.5.2043-2047.2004
   Drosten C, 2004, EMERG INFECT DIS, V10, P2200, DOI 10.3201/eid1012.040416
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Emery SL, 2004, EMERG INFECT DIS, V10, P311, DOI 10.3201/eid1002.030759
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Vijgen Leen, 2008, V454, P3, DOI 10.1007/978-1-59745-181-9_1
NR 11
TC 167
Z9 183
U1 5
U2 29
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD SEP 27
PY 2012
VL 17
IS 39
BP 3
EP 8
AR 20285
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 016NP
UT WOS:000309526100002
OA DOAJ Gold
DA 2020-04-03
ER

PT J
AU SWIFT, AM
   MACHAMER, CE
AF SWIFT, AM
   MACHAMER, CE
TI A GOLGI RETENTION SIGNAL IN A MEMBRANE-SPANNING DOMAIN OF CORONAVIRUS-E1
   PROTEIN
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID VESICULAR STOMATITIS-VIRUS; LUMINAL ER PROTEINS; ENDOPLASMIC-RETICULUM;
   E1 GLYCOPROTEIN; CELL-SURFACE; ADENOSINE-TRIPHOSPHATE; LINKED
   OLIGOSACCHARIDE; CYTOPLASMIC DOMAINS; PLASMA-MEMBRANE; TRANSPORT
AB The E1 glycoprotein from an avian coronavirus is a model protein for studying retention in the Golgi complex. In animal cells expressing the protein from cDNA, the E1 protein is targeted to cis Golgi cisternae (Machamer, C. E., S. A. Mentone, J. K. Rose, and M. G. Farquhar. 1990. Proc. Natl. Acad. Sci. USA. 87:6944-6948). We show that the first of the three membrane-spanning domains of the E1 protein can retain two different plasma membrane proteins in the Golgi region of transfected cells. Both the vesicular stomatitis virus G protein and the alpha-subunit of human chorionic gonadotropin (anchored to the membrane by fusion with the G protein membrane-spanning domain and cytoplasmic tail) were retained in the Golgi region of transfected cells when their single membrane-spanning domains were replaced with the first membrane-spanning domain from E1. Single amino acid substitutions in this sequence released retention of the chimeric G protein, as well as a mutant E1 protein which lacks the second and third membrane-spanning domains. The important feature of the retention sequence appears to be the uncharged polar residues which line one face of a predicted alpha helix. This is the first retention signal to be defined for a resident Golgi protein. The fact that it is present in a membrane-spanning domain suggests a novel mechanism of retention in which the membrane composition of the Golgi complex plays an instrumental role in retaining its resident proteins.
RP SWIFT, AM (reprint author), JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA.
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [GM-42522]
CR ARMSTRONG J, 1990, J CELL SCI, V95, P191
   BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x
   CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395
   COLLEY KJ, 1989, J BIOL CHEM, V264, P17619
   DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463
   DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957
   DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89
   DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270
   FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070
   FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650
   FUTERMAN AH, 1991, IN PRESS BIOCH J
   GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803
   GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253
   GUAN JL, 1988, MOL CELL BIOL, V8, P2869, DOI 10.1128/MCB.8.7.2869
   GUAN JL, 1988, J BIOL CHEM, V263, P5306
   KAPKE PA, 1988, VIROLOGY, V165, P367, DOI 10.1016/0042-6822(88)90581-8
   KELLY RB, 1990, NATURE, V345, P480, DOI 10.1038/345480a0
   KORNFELD S, 1990, BIOCHEM SOC T, V18, P367, DOI 10.1042/bst0180367
   KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEFRANCOIS L, 1982, VIROLOGY, V121, P168, DOI 10.1016/0042-6822(82)90126-X
   LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0
   LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097
   MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205
   MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944
   MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074
   MACHAMER CE, 1988, J BIOL CHEM, V263, P5948
   MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9
   NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0
   PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303
   PAULSON JC, 1989, J BIOL CHEM, V264, P17615
   PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245
   PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.bi.56.070187.004145
   PUDDINGTON L, 1986, J CELL BIOL, V102, P2147, DOI 10.1083/jcb.102.6.2147
   ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cb.04.110188.001353
   ROSE JK, 1991, BIOTECHNIQUES, V10, P520
   ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987
   RUSSO RN, 1990, THESIS J HOPKINS U
   Sambrook J., 1989, MOL CLONING LABORATO
   SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E
   SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K
   SPRAGUE J, 1983, J VIROL, V45, P773, DOI 10.1128/JVI.45.2.773-781.1983
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0
   WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cb.02.110186.002435
   WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8
NR 48
TC 167
Z9 170
U1 0
U2 2
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD OCT
PY 1991
VL 115
IS 1
BP 19
EP 30
DI 10.1083/jcb.115.1.19
PG 12
WC Cell Biology
SC Cell Biology
GA GH249
UT WOS:A1991GH24900002
PM 1655802
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU PEDERSEN, NC
   WARD, J
   MENGELING, WL
AF PEDERSEN, NC
   WARD, J
   MENGELING, WL
TI ANTIGENIC RELATIONSHIP OF FELINE INFECTIOUS PERITONITIS VIRUS TO
   CORONAVIRUSES OF OTHER SPECIES
SO ARCHIVES OF VIROLOGY
LA English
DT Article
C1 NIH,BETHESDA,MD 20014.
   NATL ANIM DIS CTR,AMES,IA.
RP PEDERSEN, NC (reprint author), UNIV CALIF DAVIS,SCH VET MED,DEPT MED,DAVIS,CA 95616, USA.
CR Binn L N, 1974, Proc Annu Meet U S Anim Health Assoc, P359
   BOHAC J, 1976, CAN J COMP MED, V40, P161
   BRADBURNE AF, 1970, ARCH GES VIRUSFORSCH, V31, P352, DOI 10.1007/BF01253769
   DICK GWA, 1956, BRIT J EXP PATHOL, V37, P90
   ESTOLA T, 1966, ACTA VET SCAND     S, V18
   GREIG AS, 1962, CAN J COMP MED VET S, V26, P49
   HAMBRE D, 1966, P SOC EXP BIOL MED, V121, P190
   HORZINEK MC, 1977, ZBL VET MED B, V24, P398
   KAYE HS, 1977, J INFECT DIS, V135, P201, DOI 10.1093/infdis/135.2.201
   MCINTOSH K, 1969, J IMMUNOL, V102, P1109
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   MONTO AS, 1977, P SOC EXP BIOL MED, V155, P143, DOI 10.3181/00379727-155-39761
   OSTERHAUS ADME, 1977, ZBL VET MED B, V24, P835
   PARKER JC, 1970, ARCH GES VIRUSFORSCH, V31, P293, DOI 10.1007/BF01253764
   Pedersen N. C., 1976, Feline Practice, V6, P42
   PEDERSEN NC, 1976, AM J VET RES, V37, P1449
   PEDERSEN NC, 1976, AM J VET RES, V37, P567
   PENSAERT MB, 1974, ARCH GES VIRUSFORSCH, V44, P35, DOI 10.1007/BF01242179
   REYNOLDS DJ, 1977, ARCH VIROL, V55, P77, DOI 10.1007/BF01314481
   SHARPEE RL, 1976, AM J VET RES, V37, P1031
   SHARPEE RL, 1976, THESIS U NEBRASKA
   Tajima M, 1970, Arch Gesamte Virusforsch, V29, P105, DOI 10.1007/BF01253886
   TYRRELL DAJ, 1975, INTERVIROLOGY, V5, P76, DOI 10.1159/000149883
   WARD JM, 1970, VIROLOGY, V41, P191, DOI 10.1016/0042-6822(70)90070-X
   WITTE KH, 1977, BERL MUNCH TIERARZTL, V90, P396
   ZOOK BC, 1968, PATHOL VET, V5, P91, DOI 10.1177/030098586800500112
NR 26
TC 167
Z9 168
U1 0
U2 4
PU SPRINGER-VERLAG WIEN
PI VIENNA
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA
SN 0304-8608
J9 ARCH VIROL
JI Arch. Virol.
PY 1978
VL 58
IS 1
BP 45
EP 53
DI 10.1007/BF01315534
PG 9
WC Virology
SC Virology
GA FM914
UT WOS:A1978FM91400005
PM 81044
OA Bronze
DA 2020-04-03
ER

PT J
AU Bukreyev, A
   Lamirande, EW
   Buchholz, UJ
   Vogel, LN
   Elkins, WR
   St Claire, M
   Murphy, BR
   Subbarao, K
   Collins, PL
AF Bukreyev, A
   Lamirande, EW
   Buchholz, UJ
   Vogel, LN
   Elkins, WR
   St Claire, M
   Murphy, BR
   Subbarao, K
   Collins, PL
TI Mucosal immunisation of African green monkeys (Cercopithecus aethiops)
   with an attenuated parainfluenza virus expressing the SARS coronavirus
   spike protein for the prevention of SARS
SO LANCET
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; HEMAGGLUTININ-NEURAMINIDASE; FUSION
   GLYCOPROTEINS; TYPE-3 PIV3; IMMUNOGENICITY; REPLICATION; INFECTION;
   VACCINE; BOVINE; IDENTIFICATION
AB Background The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus-SARS coronavirus (SARS-CoV). We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS-coronavirus transmission and disease.
   Methods We expressed the complete SARS coronavirus envelope spike (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as a live attenuated, intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3). We immunised eight African green monkeys, four with a single dose of BHPIV3/SARS-S and four with a control, BHPIV3/Ctrl, administered via the respiratory tract. A SARS-coronavirus challenge was given to all monkeys 28 days after immunisation.
   Findings Immunisation of animals with BHPIV3/SARS-S induced the production of SARS-coronavirus-neutralising serum antibodies, indicating that a systemic immune response resulted from mucosal immunisation. After challenge with SARS coronavirus, all monkeys in the control group shed SARS coronavirus, with shedding lasting 5-8 days. No viral shedding occurred in the group immunised with BHPIV3/SARS-S.
   Interpretation A vectored mucosal vaccine expressing the SARS-coronavirus S protein alone may be highly effective in a single-dose format for the prevention of SARS.
C1 NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   Bioqual, Rockville, MD 20850 USA.
RP Bukreyev, A (reprint author), NIAID, Infect Dis Lab, NIH, Bldg 50,Room 6505, Bethesda, MD 20892 USA.
EM AB176v@nih.gov
OI Subbarao, Kanta/0000-0003-1713-3056
CR Callebaut P, 1995, Adv Exp Med Biol, V380, P265
   CLEMENTS ML, 1991, J CLIN MICROBIOL, V29, P1175, DOI 10.1128/JCM.29.6.1175-1182.1991
   CROWE JE, 1993, VACCINE, V11, P1395, DOI 10.1016/0264-410X(93)90168-W
   DANIEL C, 1990, VIROLOGY, V174, P87, DOI 10.1016/0042-6822(90)90057-X
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Durbin AP, 2000, J VIROL, V74, P6821, DOI 10.1128/JVI.74.15.6821-6831.2000
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Karron RA, 1996, PEDIATR INFECT DIS J, V15, P650, DOI 10.1097/00006454-199608000-00003
   KARRON RA, 1995, J INFECT DIS, V172, P1445, DOI 10.1093/infdis/172.6.1445
   Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Murphy BR, 2002, J CLIN INVEST, V110, P21, DOI 10.1172/JCI200216077
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   *SARS, 2003, AY274119 SARS
   Schmidt AC, 2000, J VIROL, V74, P8922, DOI 10.1128/JVI.74.19.8922-8929.2000
   Schmidt AC, 2001, J VIROL, V75, P4594, DOI 10.1128/JVI.75.10.4594-4603.2001
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Tang RS, 2003, J VIROL, V77, P10819, DOI 10.1128/JVI.77.20.10819-10828.2003
   Tao T, 2000, J VIROL, V74, P6448, DOI 10.1128/JVI.74.14.6448-6458.2000
   Tao T, 1998, J VIROL, V72, P2955, DOI 10.1128/JVI.72.4.2955-2961.1998
   TUBOLY T, 1994, ARCH VIROL, V137, P55, DOI 10.1007/BF01311173
   WEISS RC, 1981, COMP IMMUNOL MICROB, V4, P175, DOI 10.1016/0147-9571(81)90003-5
   *WHO, COMM DIS SURV RESP S
   Zeng FY, 2003, EXP BIOL MED, V228, P866, DOI 10.1177/15353702-0322807-13
NR 29
TC 166
Z9 182
U1 5
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUN 26
PY 2004
VL 363
IS 9427
BP 2122
EP 2127
DI 10.1016/S0140-6736(04)16501-X
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 832LF
UT WOS:000222268300008
PM 15220033
OA Bronze
DA 2020-04-03
ER

PT J
AU Kruse, H
   Kirkemo, AM
   Handeland, K
AF Kruse, H
   Kirkemo, AM
   Handeland, K
TI Wildlife as source of zoonotic infections
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID WEST-NILE-VIRUS; SARS CORONAVIRUS; DISEASE; SVALBARD; HUMANS; RABIES;
   HEMISPHERE; ANIMALS; NORWAY; GREAT
AB Zoonoses with a wildlife reservoir represent a major public health problem, affecting all continents. Hundreds of pathogens and many different transmission modes are involved, and many factors influence the epidemiology of the various zoonoses. The importance and recognition of wildlife as a reservoir of zoonoses Eire increasing. Cost-effective prevention and control of these zoonoses necessitate an interdisciplinary and holistic approach and international cooperation. Surveillance, laboratory capability, research, training and education, and communication are key element.
C1 Natl Vet Inst, Norwegian Zoonosis Ctr, N-0033 Oslo, Norway.
RP Kruse, H (reprint author), Natl Vet Inst, Norwegian Zoonosis Ctr, POB 8156 DEP, N-0033 Oslo, Norway.
EM hilde.kruse@vetinst.no
CR Ballard WB, 2001, J WILDLIFE DIS, V37, P133, DOI 10.7589/0090-3558-37.1.133
   BARBOUR AG, 1993, SCIENCE, V260, P1610, DOI 10.1126/science.8503006
   Belay ED, 2004, EMERG INFECT DIS, V10, P977, DOI 10.3201/eid1006.031082
   Bell D, 2004, PHILOS T ROY SOC B, V359, P1107, DOI 10.1098/rstb.2004.1492
   Blancou J, 2003, HIST SURVEILLANCE CO
   Brown C, 2003, ASM NEWS, V69, P493
   COSIVI O, 1995, REV SCI TECH OIE, V14, P733, DOI 10.20506/rst.14.3.875
   de Lisle GW, 2002, REV SCI TECH OIE, V21, P317, DOI 10.20506/rst.21.2.1339
   Dumler JS, 2001, LANCET, P21, DOI 10.1016/S1473-3099(09)70296-8
   FENG G, 1999, NATURE, V397, P436
   FREDGA K, 1990, POLAR RES, V8, P283, DOI 10.1111/j.1751-8369.1990.tb00390.x
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Handeland K, 2002, EPIDEMIOL INFECT, V128, P523, DOI 10.1017/S0950268802007021
   Henttonen H, 2001, PARASITOLOGY, V123, P547, DOI 10.1017/S0031182001008800
   HOFSHAGEN M, 2004, TRENDS SOURCES ZOONO
   Hugh-Jones ME, 2002, REV SCI TECH OIE, V21, P359, DOI 10.20506/rst.21.2.1336
   Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746
   Marr JS, 2003, EMERG INFECT DIS, V9, P1599, DOI 10.3201/eid0912.030288
   Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35
   PRESTRUD P, 1992, J WILDLIFE DIS, V28, P57, DOI 10.7589/0090-3558-28.1.57
   Rappole JH, 2000, EMERG INFECT DIS, V6, P319, DOI 10.3201/eid0604.000401
   Redmond C, 1998, NATURE, V393, P747, DOI 10.1038/31612
   Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299
   Refsum T, 2002, APPL ENVIRON MICROB, V68, P5595, DOI 10.1128/AEM.68.11.5595-5599.2002
   Schellenberg RS, 2003, J INFECT DIS, V188, P835, DOI 10.1086/378094
   Schmaljohn C, 1997, EMERG INFECT DIS, V3, P95, DOI 10.3201/eid0302.970202
   Sihvonen L., 2003, Rabies Bulletin Europe, V27, P5
   SMITH JS, 1984, J INFECT DIS, V149, P769, DOI 10.1093/infdis/149.5.769
   Sohn AH, 2003, EMERG INFECT DIS, V9, P485, DOI 10.3201/eid0904.020576
   Taylor LH, 2001, PHILOS T R SOC B, V356, P983, DOI 10.1098/rstb.2001.0888
   WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992
   Wheelis M, 2002, EMERG INFECT DIS, V8, P971, DOI 10.3201/eid0809.010536
   *WHO, COMM DIS SURV RESP C
   *WHO, 1999, [No title captured]
NR 34
TC 165
Z9 182
U1 3
U2 22
PU CENTER DISEASE CONTROL
PI ATLANTA
PA ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD DEC
PY 2004
VL 10
IS 12
BP 2067
EP 2072
DI 10.3201/eid1012.040707
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 876WA
UT WOS:000225528000002
PM 15663840
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU de Haan, CAM
   Masters, PS
   Shen, XL
   Weiss, S
   Rottier, PJM
AF de Haan, CAM
   Masters, PS
   Shen, XL
   Weiss, S
   Rottier, PJM
TI The group-specific murine coronavirus genes are not essential, but their
   deletion, by reverse genetics, is attenuating in the natural host
SO VIROLOGY
LA English
DT Article
DE coronavirus; mouse hepatitis virus; reverse genetics; targeted
   recombination; group-specific genes
ID MOUSE HEPATITIS-VIRUS; NONSTRUCTURAL PROTEIN NS2; RNA RECOMBINATION;
   MHV-JHM; BOVINE CORONAVIRUS; MEMBRANE-PROTEIN; MESSENGER RNA-2;
   EXPRESSION; GENOME; SEQUENCE
AB In addition to a characteristic set of essential genes coronaviruses contain several so-called group-specific genes, These genes differ distinctly among the three coronavirus groups and are specific for each group. While the essential genes encode replication and structural functions, hardly anything is known about the products and functions of the group-specific genes. As a first step to elucidate their significance, we deleted the group-specific genes from the group 2 mouse hepatitis virus (MHV) genome via a novel targeted recombination system based on host switching (L. Kuo, G. J.Godeke, M. J. Raamsman, F. S. Masters, and P. J. M. Rottier, 2000, J. 1 74, 1393-1406). Thus, we obtained recombinant viruses from which the two clusters of group-specific genes were deleted either separately or in combination in a controlled genetic background. As all recombinant deletion mutant viruses appeared to be viable, we conclude that the MHV group-specific genes are nonessential, accessory genes. Importantly, all deletion mutant viruses were attenuated when inoculated into their natural host, the mouse. Therefore, deletion of the coronavinus group-specific genes seems to provide an attractive approach to generate attenuated live coronavinus vaccines. (C) 2002 Elsevier Science (USA).
C1 Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Virol, NL-3584 CL Utrecht, Netherlands.
   Univ Utrecht, Inst Biomembranes, NL-3584 CL Utrecht, Netherlands.
   New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA.
   Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
RP de Haan, CAM (reprint author), Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Virol, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.
EM x.haan@vet.uu.nl
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-45695, AI-17418]
CR Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   BREDENBEEK PJ, 1990, VIROLOGY, V175, P303, DOI 10.1016/0042-6822(90)90212-A
   Brian DA, 1995, CORONAVIRIDAE, P165
   BROWN TDK, 1995, CORONAVIRIDAE, P191
   Chen DY, 1999, VIROLOGY, V265, P120, DOI 10.1006/viro.1999.0029
   COX GJ, 1991, VIROLOGY, V185, P509, DOI 10.1016/0042-6822(91)90810-X
   de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998
   EBNER D, 1988, J GEN VIROL, V69, P1041, DOI 10.1099/0022-1317-69-5-1041
   Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880
   Fischer F, 1998, J VIROL, V72, P7885, DOI 10.1128/JVI.72.10.7885-7894.1998
   Fischer F, 1997, J VIROL, V71, P5148, DOI 10.1128/JVI.71.7.5148-5160.1997
   HINGLEY ST, 1994, VIROLOGY, V200, P1, DOI 10.1006/viro.1994.1156
   Hsue B, 1999, J VIROL, V73, P6128, DOI 10.1128/JVI.73.7.6128-6135.1999
   Hsue B, 2000, J VIROL, V74, P6911, DOI 10.1128/JVI.74.15.6911-6921.2000
   JACOBS L, 1981, J VIROL, V39, P401, DOI 10.1128/JVI.39.2.401-406.1981
   Jendrach M, 1999, ARCH VIROL, V144, P921, DOI 10.1007/s007050050556
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   LABONTE P, 1995, J GEN VIROL, V76, P431, DOI 10.1099/0022-1317-76-2-431
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   LOCKER JK, 1992, J BIOL CHEM, V267, P14094
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   LUYTJES W, 1995, CORONAVIRIDAE, P33
   MASTERS PS, 1994, J VIROL, V68, P328, DOI 10.1128/JVI.68.1.328-337.1994
   Masters PS, 1999, ADV VIRUS RES, V53, P245, DOI 10.1016/S0065-3527(08)60351-6
   MOUNIR S, 1993, VIROLOGY, V192, P355, DOI 10.1006/viro.1993.1043
   Ontiveros E, 2001, VIROLOGY, V289, P230, DOI 10.1006/viro.2001.1167
   OPSTELTEN DJE, 1995, THESIS UTRECHT U NET
   Pasternak AO, 2000, J VIROL, V74, P11642, DOI 10.1128/JVI.74.24.11642-11653.2000
   Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248
   Raamsman MJB, 2000, J VIROL, V74, P2333, DOI 10.1128/JVI.74.5.2333-2342.2000
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   SCHWARZ B, 1990, J VIROL, V64, P4784, DOI 10.1128/JVI.64.10.4784-4791.1990
   SKINNER MA, 1985, J GEN VIROL, V66, P593, DOI 10.1099/0022-1317-66-3-593
   SNIJDER EJ, 1991, VIROLOGY, V180, P448, DOI 10.1016/0042-6822(91)90056-H
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   WEISS SR, 1993, ARCH VIROL, V129, P301, DOI 10.1007/BF01316905
   YOKOMORI K, 1993, VIROLOGY, V192, P170, DOI 10.1006/viro.1993.1019
   YOKOMORI K, 1991, J VIROL, V65, P5605, DOI 10.1128/JVI.65.10.5605-5608.1991
   YOKOMORI K, 1991, VIROLOGY, V183, P647, DOI 10.1016/0042-6822(91)90994-M
   Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000
   ZOLTICK PW, 1990, VIROLOGY, V174, P605, DOI 10.1016/0042-6822(90)90114-7
NR 46
TC 165
Z9 177
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD APR 25
PY 2002
VL 296
IS 1
BP 177
EP 189
DI 10.1006/viro.2002.1412
PG 13
WC Virology
SC Virology
GA 563FC
UT WOS:000176244700018
PM 12036329
OA Bronze
DA 2020-04-03
ER

PT J
AU Pitkaranta, A
   Virolainen, A
   Jero, J
   Arruda, E
   Hayden, FG
AF Pitkaranta, A
   Virolainen, A
   Jero, J
   Arruda, E
   Hayden, FG
TI Detection of rhinovirus, respiratory syncytial virus, and coronavirus
   infections in acute otitis media by reverse transcriptase polymerase
   chain reaction
SO PEDIATRICS
LA English
DT Article; Proceedings Paper
CT 37th Interscience Conference on Antimicrobial Agents and Chemotherapy
CY SEP 28-OCT 03, 1997
CL TORONTO, CANADA
SP S African Med Res Council, Harry Crossley Fdn, Univ Stellenbosch
DE acute otitis media; rhinovirus; respiratory syncytial virus; coronavirus
ID MIDDLE-EAR FLUID; CHILDREN; PCR; HYBRIDIZATION; PREVENTION; RNA
AB Objective. To determine the frequencies of human rhinovirus (HRV), respiratory syncytial virus (RSV), and coronavirus (HCV) infection in children with acute otitis media (AOM).
   Methods. Middle ear fluids (MEF) collected by tympanocentesis and nasopharyngeal aspirates (NPA) at the time of the AOM diagnosis were examined by reverse transcriptase polymerase chain reaction for HRV, RSV, and HCV RNA.
   Patients. Ninety-two children aged 3 months to 7 years during a 1-year period.
   Results. Virus RNA was detected in a total of 69 children (75%) and in 44 MEF samples (48%) and 57 NPA samples (62%) at the time of AOM diagnosis. HRV RNA was detected in both MEF and NPA in 18 (20%), in MEF alone in 4 (4%), and in NPA alone in 10 (11%). :RSV was detected in both MEF and NPA in 12 (13%), in MEF alone in 5 (5%), and in NPA alone in 9 (10%). HCV RNA was detected in both MEF and NPA in 5 (5%), in MEF alone in 2 (2%), and in NPA alone in 9 (10%). Dual viral infections were detected in 5% of children. HRV and RSV were detected simultaneously in 2 MEF samples and in 2 NP,4 samples; RSV and HCV were detected in 1 NPA sample. Bacterial pathogens were detected in 56 (62%) MEF from 91 children. Viral RNA was detected in 20 (57%) MEF of 35 bacteria-negative and in 25 (45%) of 56 bacteria-positive MEF samples. No important differences in the risk of treatment failure, relapse, or occurrence of late secretory otitis media were noted between children with virus-positive and virus-negative MEF aspirates.
   Conclusion. These findings highlight the importance of common respiratory viruses, particularly HRV and RSV, ire predisposing to and causing AOM in young children.
C1 Univ Virginia, Hlth Sci Ctr, Dept Med, Charlottesville, VA 22908 USA.
   Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA.
   Univ Helsinki, Dept Otorhinolaryngol, Helsinki, Finland.
   Univ Helsinki, Dept Bacteriol & Immunol, Helsinki, Finland.
   Univ Sao Paulo, Sch Med, Dept Microbiol Immunol & Parasitol, Ribeirao Preto, SP, Brazil.
RP Hayden, FG (reprint author), Univ Virginia, Hlth Sci Ctr, Dept Med, Box 473, Charlottesville, VA 22908 USA.
RI Arruda, Eurico/E-4101-2012
CR AROLA M, 1988, J PEDIATR-US, V113, P693, DOI 10.1016/S0022-3476(88)80380-9
   AROLA M, 1990, J PEDIATR-US, V116, P697, DOI 10.1016/S0022-3476(05)82650-2
   AROLA M, 1990, PEDIATRICS, V86, P848
   ARRUDA E, 1993, MOL CELL PROBE, V7, P373, DOI 10.1006/mcpr.1993.1055
   Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997
   CHONMAITREE T, 1990, J INFECT DIS, V162, P546, DOI 10.1093/infdis/162.2.546
   CHONMAITREE T, 1992, J PEDIATR-US, V120, P856, DOI 10.1016/S0022-3476(05)81950-X
   COLLINS PL, 1984, P NATL ACAD SCI-BIOL, V81, P7683, DOI 10.1073/pnas.81.24.7683
   FREYMUTH F, 1995, J CLIN MICROBIOL, V33, P3352, DOI 10.1128/JCM.33.12.3352-3355.1995
   Freymuth F, 1996, J CLIN MICROBIOL, V34, P1601
   Gilbert LL, 1996, J CLIN MICROBIOL, V34, P140, DOI 10.1128/JCM.34.1.140-143.1996
   HALONEN P, 1995, J CLIN MICROBIOL, V33, P648, DOI 10.1128/JCM.33.3.648-653.1995
   HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   KLEIN BS, 1982, J PEDIATR-US, V101, P16, DOI 10.1016/S0022-3476(82)80172-8
   OKAMOTO Y, 1993, J INFECT DIS, V168, P1277, DOI 10.1093/infdis/168.5.1277
   PATEL JA, 1995, J PEDIATR-US, V126, P799, DOI 10.1016/S0022-3476(95)70415-9
   PATON AW, 1992, J CLIN MICROBIOL, V30, P901, DOI 10.1128/JCM.30.4.901-904.1992
   Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791
   SARKKINEN H, 1985, J INFECT DIS, V151, P444, DOI 10.1093/infdis/151.3.444
   Simoes EAF, 1996, J PEDIATR-US, V129, P214, DOI 10.1016/S0022-3476(96)70245-7
   SUNG BS, 1993, CLIN INFECT DIS, V17, P38, DOI 10.1093/clinids/17.1.38
   VANMILAAN AJ, 1994, J MED VIROL, V44, P80, DOI 10.1002/jmv.1890440115
   VIROLAINEN A, 1994, J CLIN MICROBIOL, V32, P2667, DOI 10.1128/JCM.32.11.2667-2670.1994
NR 24
TC 165
Z9 167
U1 4
U2 12
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD AUG
PY 1998
VL 102
IS 2
BP 291
EP 295
DI 10.1542/peds.102.2.291
PG 5
WC Pediatrics
SC Pediatrics
GA 106JH
UT WOS:000075125800001
PM 9685428
DA 2020-04-03
ER

PT J
AU Lindner, HA
   Fotouhi-Ardakani, N
   Lytvyn, V
   Lachance, P
   Sulea, T
   Menard, R
AF Lindner, HA
   Fotouhi-Ardakani, N
   Lytvyn, V
   Lachance, P
   Sulea, T
   Menard, R
TI The papain-like protease from the severe acute respiratory syndrome
   coronavirus is a deubiquitinating enzyme
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SWINE-FEVER VIRUS; SARS-CORONAVIRUS; UBP43 USP18; UBIQUITIN; ISG15;
   EXPRESSION; PURIFICATION; PROTEINASE; QUANTITIES; SUBSTRATE
AB The severe acute respiratory syndrome coronavirus papain-like protease (SARS-CoV PLpro) is involved in the processing of the viral polyprotein and, thereby, contributes to the biogenesis of the virus replication complex. Structural bioinformatics has revealed a relationship for the SARS-CoV PLpro to herpesvirus-associated ubiquitin-specific protease (HAUSP), a ubiquitin-specific protease, indicating potential deubiquitinating activity in addition to its function in polyprotein processing (T. Sulea, H. A. Lindner, E. O. Purisima, and R. Menard, J. Virol. 79:4550-4551, 2005). In order to confirm this prediction, we overexpressed and purified SARS-CoV PLpro (amino acids [aa] 1507 to 1858) from Escherichia coli. The purified enzyme hydrolyzed ubiquitin-7-amino-4-methylcoumarin (Ub-AMC), a general deubiquitinating enzyme substrate, with a catalytic efficiency of 13,100 M(-1)s(-1), 220-fold more efficiently than the small synthetic peptide substrate Z-LRGG-AMC, which incorporates the C-terminal four residues of ubiquitin. In addition, SARS-CoV PLpro was inhibited by the specific deubiquitinating enzyme inhibitor ubiquitin aldehyde, with an inhibition constant of 210 nM. The purified SARS-CoV PLpro disassembles branched polyubiquitin chains with lengths of two to seven (Ub2-7) or four (Ub4) units, which involves isopeptide bond cleavage. SARS-CoV PLpro processing activity was also detected against a protein fused to the C terminus of the ubiquitin-like modifier ISG15, both in vitro using the purified enzyme and in HeLa cells by coexpression with SARS-CoV PLpro (aa 1198 to 2009). These results clearly establish that SARS-CoV PLpro is a deubiquitinating enzyme, thereby confirming our earlier prediction. This unexpected activity for a coronavirus papain-like protease suggests a novel viral strategy to modulate the host cell ubiquitination machinery to its advantage.
C1 Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada.
RP Menard, R (reprint author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.
EM robert.menard@nrc-cnrc.gc.ca
RI Lindner, Holger A/C-5106-2014
CR Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003
   Andres G, 2001, J BIOL CHEM, V276, P780, DOI 10.1074/jbc.M006844200
   Baker RT, 1996, CURR OPIN BIOTECH, V7, P541, DOI 10.1016/S0958-1669(96)80059-0
   Balakirev MY, 2002, J VIROL, V76, P6323, DOI 10.1128/JVI.76.12.6323-6331.2002
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Butt TR, 2005, PROTEIN EXPRES PURIF, V43, P1, DOI 10.1016/j.pep.2005.03.016
   Cass B, 2005, PROTEIN EXPRES PURIF, V40, P77, DOI 10.1016/j.pep.2004.10.023
   Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360
   Dao CT, 2005, FRONT BIOSCI-LANDMRK, V10, P2701, DOI 10.2741/1730
   DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170
   Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Hemelaar J, 2004, MOL CELL BIOL, V24, P84, DOI 10.1128/MCB.24.1.84-95.2004
   Herold J, 1999, J BIOL CHEM, V274, P14918, DOI 10.1074/jbc.274.21.14918
   HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829
   Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6
   Hui DSC, 2004, EXPERT OPIN PHARMACO, V5, P1687, DOI 10.1517/14656566.5.8.1687
   Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877
   Kim JH, 2003, J BIOCHEM, V134, P9, DOI 10.1093/jb/mvg107
   KNIGHT E, 1988, J BIOL CHEM, V263, P4520
   La Rocca SA, 2005, J VIROL, V79, P7239, DOI 10.1128/JVI.79.11.7239-7247.2005
   Lau YL, 2005, CURR OPIN IMMUNOL, V17, P404, DOI 10.1016/j.coi.2005.05.009
   Lee Jae Il, 1998, Biol Proced Online, V1, P92, DOI 10.1251/bpo11
   Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200
   MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035
   Quesada V, 2004, BIOCHEM BIOPH RES CO, V314, P54, DOI 10.1016/j.bbrc.2003.12.050
   Ritchie KJ, 2004, NAT MED, V10, P1374, DOI 10.1038/nm1133
   Sambrook J, 2001, MOL CLONING LAB MANU
   Schlicke M, 2005, PROTEIN EXPRES PURIF, V39, P247, DOI 10.1016/j.pep.2004.10.022
   Skowronski DA, 2005, ANNU REV MED, V56, P357, DOI 10.1146/annurev.med.56.091103.134135
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Soboleva TA, 2004, CURR PROTEIN PEPT SC, V5, P191, DOI 10.2174/1389203043379765
   Sulea T, 2005, J VIROL, V79, P4550, DOI 10.1128/JVI.79.7.4550-4551.2005
   Teng H, 1999, J VIROL, V73, P2658, DOI 10.1128/JVI.73.4.2658-2666.1999
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563
   Wilkinson KD, 1997, FASEB J, V11, P1245
   World Health Organization, 2004, SUMM PROB SARS CAS O
   Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
NR 46
TC 164
Z9 174
U1 2
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2005
VL 79
IS 24
BP 15199
EP 15208
DI 10.1128/JVI.79.24.15199-15208.2005
PG 10
WC Virology
SC Virology
GA 997VK
UT WOS:000234276700021
PM 16306591
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU CAVANAGH, D
   DAVIS, PJ
   MOCKETT, APA
AF CAVANAGH, D
   DAVIS, PJ
   MOCKETT, APA
TI AMINO-ACIDS WITHIN HYPERVARIABLE REGION-1 OF AVIAN CORONAVIRUS IBV
   (MASSACHUSETTS SEROTYPE) SPIKE GLYCOPROTEIN ARE ASSOCIATED WITH
   NEUTRALIZATION EPITOPES
SO VIRUS RESEARCH
LA English
DT Article
RP CAVANAGH, D (reprint author), AFRC,INST ANIM HLTH,HOUGHTON LAB,HUNTINGDON PE17 2DA,CAMBS,ENGLAND.
CR BINNS MM, 1986, J GEN VIROL, V67, P2825, DOI 10.1099/0022-1317-67-12-2825
   BINNS MM, 1985, J GEN VIROL, V66, P719, DOI 10.1099/0022-1317-66-4-719
   CAVANAGH D, 1983, J GEN VIROL, V64, P2577, DOI 10.1099/0022-1317-64-12-2577
   CAVANAGH D, 1986, VIRUS RES, V4, P133, DOI 10.1016/0168-1702(86)90037-7
   CAVANAGH D, 1984, AVIAN PATHOL, V13, P573, DOI 10.1080/03079458408418556
   CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435
   CAVANAGH D, 1988, J GEN VIROL, V69, P621, DOI 10.1099/0022-1317-69-3-621
   COOK JKA, 1986, AVIAN PATHOL, V15, P129, DOI 10.1080/03079458608436272
   COOK JKA, 1976, ARCH VIROL, V50, P109, DOI 10.1007/BF01318005
   DARBYSHIRE JH, 1979, ARCH VIROL, V61, P227, DOI 10.1007/BF01318057
   JACOBS L, 1987, VIRUS RES, V8, P363, DOI 10.1016/0168-1702(87)90008-6
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   MACDONALD J W, 1976, Avian Pathology, V5, P157, DOI 10.1080/03079457608418182
   MOCKETT APA, 1984, J GEN VIROL, V65, P2281, DOI 10.1099/0022-1317-65-12-2281
   NIESTERS HGM, 1986, VIRUS RES, V5, P253, DOI 10.1016/0168-1702(86)90022-5
   NIESTERS HGM, 1987, THESIS U UTRECHT NET
   NOVOTNY J, 1987, IMMUNOL TODAY, V8, P26, DOI 10.1016/0167-5699(87)90828-0
   SCHEID A, 1976, VIROLOGY, V69, P265, DOI 10.1016/0042-6822(76)90213-0
   Schulz G. E., 1979, PRINCIPLES PROTEIN S
   VANREGENMORTEL MHV, 1987, TRENDS BIOCHEM SCI, V12, P237, DOI 10.1016/0968-0004(87)90117-4
NR 20
TC 164
Z9 181
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
J9 VIRUS RES
JI Virus Res.
PD SEP
PY 1988
VL 11
IS 2
BP 141
EP 150
DI 10.1016/0168-1702(88)90039-1
PG 10
WC Virology
SC Virology
GA Q1378
UT WOS:A1988Q137800004
PM 2462314
DA 2020-04-03
ER

PT J
AU Alagaili, AN
   Briese, T
   Mishra, N
   Kapoor, V
   Sameroff, SC
   de Wit, E
   Munster, VJ
   Hensley, LE
   Zalmout, IS
   Kapoor, A
   Epstein, JH
   Karesh, WB
   Daszak, P
   Mohammed, OB
   Lipkin, WI
AF Alagaili, Abdulaziz N.
   Briese, Thomas
   Mishra, Nischay
   Kapoor, Vishal
   Sameroff, Stephen C.
   de Wit, Emmie
   Munster, Vincent J.
   Hensley, Lisa E.
   Zalmout, Iyad S.
   Kapoor, Amit
   Epstein, Jonathan H.
   Karesh, William B.
   Daszak, Peter
   Mohammed, Osama B.
   Lipkin, W. Ian
TI Middle East Respiratory Syndrome Coronavirus Infection in Dromedary
   Camels in Saudi Arabia
SO MBIO
LA English
DT Article
ID BATS
AB The Middle East respiratory syndrome (MERS) is proposed to be a zoonotic disease; however, the reservoir and mechanism for transmission of the causative agent, the MERS coronavirus, are unknown. Dromedary camels have been implicated through reports that some victims have been exposed to camels, camels in areas where the disease has emerged have antibodies to the virus, and viral sequences have been recovered from camels in association with outbreaks of the disease among humans. Nonetheless, whether camels mediate transmission to humans is unresolved. Here we provide evidence from a geographic and temporal survey of camels in the Kingdom of Saudi Arabia that MERS coronaviruses have been circulating in camels since at least 1992, are distributed countrywide, and can be phylogenetically classified into clades that correlate with outbreaks of the disease among humans. We found no evidence of infection in domestic sheep or domestic goats.
   IMPORTANCE This study was undertaken to determine the historical and current prevalence of Middle East respiratory syndrome (MERS) coronavirus infection in dromedary camels and other livestock in the Kingdom of Saudi Arabia, where the index case and the majority of cases of MERS have been reported.
C1 [Alagaili, Abdulaziz N.; Zalmout, Iyad S.; Mohammed, Osama B.] King Saud Univ, Coll Med, Dept Zool, KSU Mammals Res Chair, Riyadh 11461, Saudi Arabia.
   [Alagaili, Abdulaziz N.] Saudi Wildlife Author, Riyadh, Saudi Arabia.
   [Briese, Thomas; Mishra, Nischay; Kapoor, Vishal; Sameroff, Stephen C.; Kapoor, Amit; Lipkin, W. Ian] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY USA.
   [de Wit, Emmie; Munster, Vincent J.] NIAID, Virol Lab, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT USA.
   [Hensley, Lisa E.] NIAID, Integrated Res Facil, NIH, Frederick, MD USA.
   [Epstein, Jonathan H.; Karesh, William B.; Daszak, Peter] EcoHlth Alliance, New York, NY USA.
RP Alagaili, AN (reprint author), King Saud Univ, Coll Med, Dept Zool, KSU Mammals Res Chair, Riyadh 11461, Saudi Arabia.
EM aalagaili@ksu.edu.sa; tb2047@columbia.edu
RI de Wit, Emmie/A-1549-2019; daszak, peter/U-4588-2017; Mohammed,
   Osama/C-3226-2011; Munster, Vincent/I-7607-2018; Alagaili,
   Abdulaziz/C-4278-2018
OI de Wit, Emmie/0000-0002-9763-7758; daszak, peter/0000-0002-2046-5695;
   Mohammed, Osama/0000-0001-5457-2555; Munster,
   Vincent/0000-0002-2288-3196; Lipkin, W. Ian/0000-0002-8768-9386;
   Alagaili, Abdulaziz/0000-0002-9733-4220
FU Deanship of Scientific Research, King Saud UniversityDeanship of
   Scientific Research at King Saud University; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI057158]; United States Agency for
   International Development Emerging Pandemic Threats program, PREDICT
   projectUnited States Agency for International Development (USAID)
   [GHN-A-OO-09-00010-00]; Intramural Research Program of the National
   Institute of Allergy and Infectious Diseases, National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID)
FX The KSU Mammals Research Chair is supported by the Deanship of
   Scientific Research, King Saud University. Work in the Center for
   Infection and Immunity and EcoHealth Alliance is supported by awards
   from the National Institutes of Health (AI057158) and the United States
   Agency for International Development Emerging Pandemic Threats program,
   PREDICT project, under the terms of cooperative agreement
   GHN-A-OO-09-00010-00. Work in the Rocky Mountain Laboratories (E. de
   Wit, V. J. Munster) and Integrated Research Facility (L. E. Hensley) was
   supported by the Intramural Research Program of the National Institute
   of Allergy and Infectious Diseases, National Institutes of Health.
CR Agnihothram S, 2013, J INFECT DIS
   Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Burbelo PD, 2010, EXPERT REV VACCINES, V9, P567, DOI 10.1586/ERV.10.50
   Corman VM, 2012, EURO SURVEILL, V17
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hemida MG, 2013, EUROSURVEILLANCE, V18, P21, DOI 10.2807/1560-7917.ES2013.18.50.20659
   Memish ZA, 2013, MERS COV E MEDITERRA
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Nishiura H, 2014, LANCET INFECT DIS, V14, P100, DOI 10.1016/S1473-3099(13)70699-6
   Perera RA, 2013, EURO SURVEILL, V18
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reusken C, 2013, EURO SURVEILL, V18
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   The WHO MERS-CoV Research Group, 2013, PLOS CURR       1112
   World Health Organization, 2013, MIDDL E RESP SYNDR C
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 19
TC 162
Z9 173
U1 3
U2 29
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD MAR-APR
PY 2014
VL 5
IS 2
AR e00884-14
DI 10.1128/mBio.00884-14
PG 6
WC Microbiology
SC Microbiology
GA AH1XR
UT WOS:000335915600002
PM 24570370
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2020-04-03
ER

PT J
AU KUBO, H
   YAMADA, YK
   TAGUCHI, F
AF KUBO, H
   YAMADA, YK
   TAGUCHI, F
TI LOCALIZATION OF NEUTRALIZING EPITOPES AND THE RECEPTOR-BINDING SITE
   WITHIN THE AMINO-TERMINAL 330 AMINO-ACIDS OF THE MURINE CORONAVIRUS
   SPIKE PROTEIN
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; JHMV VARIANT CL-2; MONOCLONAL-ANTIBODIES;
   NUCLEOTIDE-SEQUENCE; SURFACE GLYCOPROTEIN; CELLULAR RECEPTOR; EXPRESSION
   SYSTEM; MOLECULAR-CLONING; FUSION; POLIOVIRUS
AB To localize the epitopes recognized by monoclonal antibodies (MAbs) specific for the S1 subunit of the murine coronavirus JHMV spike protein, we have expressed S1 proteins with different deletions from the C terminus of S1. S1utt is composed of the entire 769-amino-acid (aa) S1 protein; S1NM, S1N, S1N(330), and S1N(220) are deletion mutants with 594, 453, 330, and 220 aa from the N terminus of the 81 protein. The expressed S1 deletion mutant proteins were examined for reactivities to a panel of MAbs. All MAbs classified in groups A and B, those reactive to most mouse hepatitis virus (MHV) strains and those specific for isolate JHMV, respectively, recognized S1N(330) and the larger S1 deletion mutants but failed to react with S1N(220). MAbs in group C, specific for the larger S protein of JHMV, reacted only with the S1utt protein without any deletion. These results indicated that the domain composed of the N-terminal 330 aa comprised the cluster of conformational epitopes recognized by MAbs in groups A and B. It was also shown that the epitopes of MAbs in group C were not restricted to the region missing in the smaller S protein. These results together with the fact that all MAbs in group B retained high neutralizing activity suggested the possibility that the N-terminal 330 aa are responsible for binding to the MHV-specific receptors. In investigate this possibility, we expressed the receptor protein and examined the binding of each S1 deletion mutant to the receptor. It was demonstrated that the S1N(330) protein as well as other S1 deletion mutants larger than S1N(330) bound to the receptor. These results indicated that a domain composed of 330 aa at the N terminus of the S1 protein is responsible for binding to the MHV-specific receptor.
C1 NCNP,NATL INST NEUROSCI,KODAIRA,TOKYO 187,JAPAN.
   NATL INST HLTH,TOKYO 19012,JAPAN.
CR CAVANAGH D, 1986, J GEN VIROL, V67, P1442
   CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   DALZIEL RG, 1986, J VIROL, V59, P463, DOI 10.1128/JVI.59.2.463-471.1986
   DANIEL C, 1993, J VIROL, V67, P1185, DOI 10.1128/JVI.67.3.1185-1194.1993
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   DVEKSLER GS, 1993, J VIROL, V67, P1
   DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   FAZAKERLEY JK, 1992, VIROLOGY, V187, P178, DOI 10.1016/0042-6822(92)90306-A
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   FLEMING JO, 1986, J VIROL, V58, P869, DOI 10.1128/JVI.58.3.869-875.1986
   FUNAHASHI SI, 1991, J VIROL, V65, P5584, DOI 10.1128/JVI.65.10.5584-5588.1991
   HIRANO N, 1974, ARCH GES VIRUSFORSCH, V44, P298, DOI 10.1007/BF01240618
   Holmes K V, 1981, Adv Exp Med Biol, V142, P133
   KOIKE S, 1991, P NATL ACAD SCI USA, V88, P4104, DOI 10.1073/pnas.88.10.4104
   KUBO H, 1993, J GEN VIROL, V74, P1421, DOI 10.1099/0022-1317-74-7-1421
   KUBO H, 1993, J GEN VIROL, V74, P2373, DOI 10.1099/0022-1317-74-11-2373
   KYUWA S, 1990, SEMINARS VIROLOGY, V1, P273
   LUYTJES W, 1989, J VIROL, V63, P1408, DOI 10.1128/JVI.63.3.1408-1412.1989
   MATSUBARA Y, 1991, VIRUS RES, V20, P45
   MCCUAIG K, 1993, GENE, V127, P173, DOI 10.1016/0378-1119(93)90716-G
   MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9
   ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0
   ROUTLEDGE E, 1991, J VIROL, V65, P254, DOI 10.1128/JVI.65.1.254-262.1991
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHMIDT I, 1987, J GEN VIROL, V68, P47, DOI 10.1099/0022-1317-68-1-47
   SELINKA HC, 1991, P NATL ACAD SCI USA, V88, P3598, DOI 10.1073/pnas.88.9.3598
   SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761
   SKINNER MA, 1983, NUCLEIC ACIDS RES, V11, P5045, DOI 10.1093/nar/11.15.5045
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   STAUBER R, 1993, J GEN VIROL, V74, P183, DOI 10.1099/0022-1317-74-2-183
   STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2
   STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O
   Sturman L S, 1984, Adv Exp Med Biol, V173, P25
   TAGUCHI F, 1993, J VIROL, V67, P1195, DOI 10.1128/JVI.67.3.1195-1202.1993
   TAGUCHI F, 1985, J VIROL, V54, P429, DOI 10.1128/JVI.54.2.429-435.1985
   TAGUCHI F, 1989, VIROLOGY, V169, P233, DOI 10.1016/0042-6822(89)90061-5
   TAGUCHI F, 1992, J GEN VIROL, V73, P1065, DOI 10.1099/0022-1317-73-5-1065
   TAGUCHI F, 1980, INFECT IMMUN, V29, P42, DOI 10.1128/IAI.29.1.42-49.1980
   TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466
   TYRELL DAJ, 1968, NATURE, V220, P650
   VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WEISMILLER DG, 1990, J VIROL, V64, P3051, DOI 10.1128/JVI.64.6.3051-3055.1990
   WGITE JM, 1990, ANN REV PHYSL, V52, P675
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   YAMADA YK, 1993, LAB ANIM SCI, V43, P285
   YOKOMORI K, 1992, J VIROL, V66, P6194, DOI 10.1128/JVI.66.10.6194-6199.1992
NR 49
TC 162
Z9 173
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD SEP
PY 1994
VL 68
IS 9
BP 5403
EP 5410
DI 10.1128/JVI.68.9.5403-5410.1994
PG 8
WC Virology
SC Virology
GA PB785
UT WOS:A1994PB78500008
PM 7520090
OA Bronze
DA 2020-04-03
ER

PT J
AU Greenberg, SB
   Allen, M
   Wilson, J
   Atmar, RL
AF Greenberg, SB
   Allen, M
   Wilson, J
   Atmar, RL
TI Respiratory viral infections in adults with and without chronic
   obstructive pulmonary disease
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
ID MYCOPLASMA-PNEUMONIAE INFECTIONS; POLYMERASE CHAIN-REACTION;
   CHRONIC-BRONCHITIS; VIRUS-INFECTIONS; SYNCYTIAL VIRUS; LUNG-DISEASE;
   ILLNESS; TRACT; HOSPITALIZATION; MORTALITY
AB A longitudinal cohort study of older adults with chronic obstructive pulmonary disease (COPD) who were stratified by FEV1 at enrollment was done to define the etiology, frequency, severity, and medical-care impact of respiratory tract viral infections (RTVIs). Controls consisted of a group of subjects of comparable age with the patients. RTVIs were documented in 44% of observed acute respiratory illnesses in control subjects and in 27% of COPD subjects, who were followed for mean periods of 35 and 26 mo, respectively. In this heavily influenza-vaccinated cohort (similar to 90% vaccinated each year), picornaviruses, parainfluenza viruses, and coronaviruses were most commonly identified. Mean time to return to clinical baseline was approximately 2 wk in each group. Control and COPD subjects with mild airways obstruction (baseline FEV1 greater than or equal to 50% predicted) had few emergency-center visits or hospitalizations. Approximately half of COPD subjects with moderate/severe COPD (baseline FEV1 < 50% predicted) had at least one emergency-center visit and/or hospitalization for acute respiratory illness. RTVIs were documented in 23% of hospitalizations and in 45% of patients admitted between December and March. RTVIs have a major impact on utilization of health care resources for COPD patients with moderate/severe airways obstruction.
C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA.
RP Greenberg, SB (reprint author), Baylor Coll Med, Dept Med, 1 Baylor Plaza,Room 559E, Houston, TX 77030 USA.
EM stepheng@bcm.tmc.edu
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01AI15103]
CR ABRAHAM GN, 1996, REPORT TASK FORCE IM
   [Anonymous], 1987, Am Rev Respir Dis, V136, P1285
   Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453
   ATMAR RL, 1993, J CLIN MICROBIOL, V31, P2544, DOI 10.1128/JCM.31.9.2544-2546.1993
   Atmar RL, 1996, CLIN DIAGN VIROL, V7, P77, DOI 10.1016/S0928-0197(96)00254-1
   BAXTER BD, 1977, J CLIN MICROBIOL, V6, P19
   Ben-Yehuda A, 1992, Clin Geriatr Med, V8, P701
   BLAIR HT, 1976, AM REV RESPIR DIS, V114, P95
   CAMPBELL AH, 1985, THORAX, V40, P741, DOI 10.1136/thx.40.10.741
   CATE TR, 1973, AM REV RESPIR DIS, V108, P858
   CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77
   Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137
   FOX JP, 1968, YALE J BIOL MED, V40, P484
   FRANK AL, 1980, J CLIN MICROBIOL, V12, P426, DOI 10.1128/JCM.12.3.426-432.1980
   GILL EP, 1994, J CLIN MICROBIOL, V32, P2372, DOI 10.1128/JCM.32.10.2372-2376.1994
   Grasso ME, 1998, AM J RESP CRIT CARE, V158, P133, DOI 10.1164/ajrccm.158.1.9710041
   GUMP DW, 1976, AM REV RESPIR DIS, V113, P465
   Kessler R, 1999, AM J RESP CRIT CARE, V159, P158, DOI 10.1164/ajrccm.159.1.9803117
   Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092
   Kramarow E., 1999, HLTH AGING CHARTBOOK
   Mannino DM, 1997, AM J RESP CRIT CARE, V156, P814, DOI 10.1164/ajrccm.156.3.9702026
   MONTO AS, 1978, AM REV RESPIR DIS, V118, P1101
   MONTO AS, 1995, AM J RESP CRIT CARE, V151, P1653, DOI 10.1164/ajrccm.151.5.7735629
   MONTO AS, 1971, AM J EPIDEMIOL, V94, P290, DOI 10.1093/oxfordjournals.aje.a121322
   MURPHY TF, 1992, AM REV RESPIR DIS, V146, P1067, DOI 10.1164/ajrccm/146.4.1067
   *NAT CTR HLTH STAT, 1995, DAT NAT HLTH SURV, V193
   Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003
   Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060
   PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3
   SMITH CB, 1980, AM REV RESPIR DIS, V121, P225
   SMITH CB, 1976, J INFECT DIS, V134, P552, DOI 10.1093/infdis/134.6.552
   SMITH CB, 1980, J INFECT DIS, V141, P271, DOI 10.1093/infdis/141.3.271
   VonHertzen L, 1997, EPIDEMIOL INFECT, V118, P155, DOI 10.1017/S095026889600725X
   Walsh EE, 1999, AM J RESP CRIT CARE, V160, P791, DOI 10.1164/ajrccm.160.3.9901004
   WISELKA MJ, 1993, EPIDEMIOL INFECT, V111, P337, DOI 10.1017/S0950268800057046
NR 35
TC 161
Z9 162
U1 0
U2 4
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JUL
PY 2000
VL 162
IS 1
BP 167
EP 173
DI 10.1164/ajrccm.162.1.9911019
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 333JH
UT WOS:000088126800028
PM 10903237
DA 2020-04-03
ER

PT J
AU van Marle, G
   Dobbe, JC
   Gultyaev, AP
   Luytjes, W
   Spaan, WJM
   Snijder, EJ
AF van Marle, G
   Dobbe, JC
   Gultyaev, AP
   Luytjes, W
   Spaan, WJM
   Snijder, EJ
TI Arterivirus discontinuous mRNA transcription is guided by base pairing
   between sense and antisense transcription-regulating sequences
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID EQUINE ARTERITIS VIRUS; MOUSE HEPATITIS-VIRUS; DEFECTIVE INTERFERING
   RNA; CORONAVIRUS MESSENGER-RNAS; GENETIC ALGORITHM; MOLECULAR-BIOLOGY;
   LEADER; IDENTIFICATION; RECOMBINATION; REPLICATION
AB To generate an extensive set of subgenomic (sg) mRNAs, nidoviruses (arteriviruses and coronaviruses) use a mechanism of discontinuous transcription. During this process, mRNAs are generated that represent the genomic 5' sequence, the so-called leader RNA, fused at specific positions to different 3' regions of the genome. The fusion of the leader to the mRNA bodies occurs at a short, conserved sequence element, the transcription-regulating sequence (TRS), which precedes every transcription unit in the genome and is also present at the 3' end of the leader sequence. Here, we have used site-directed mutagenesis of the infectious cDNA clone of the arterivirus equine arteritis virus to show that sg mRNA synthesis requires a base-pairing interaction between the leader TRS and the complement of a body TRS in the viral negative strand. Mutagenesis of the body TRS of equine arteritis virus RNA7 reduced sg RNA7 transcription severely or abolished it completely. Mutations in the leader TRS dramatically influenced the synthesis of all sg mRNAs. The construction of double mutants in which a mutant leader TRS was combined with the corresponding mutant RNA7 body TRS resulted in the specific restoration of mRNA7 synthesis. The analysis of the mRNA leader-body junctions of a number of mutants with partial transcriptional activity provided support for a mechanism of discontinuous minus-strand transcription that resembles similarity-assisted, copy-choice RNA recombination.
C1 Leiden Univ, Med Ctr, Dept Virol, NL-2300 RC Leiden, Netherlands.
   Leiden Univ, Leiden Inst Chem, NL-2300 RC Leiden, Netherlands.
   Leiden Univ, Inst Evolutionary & Ecol Sci, Sect Theoret Biol & Phylogenet, NL-2300 RC Leiden, Netherlands.
RP Snijder, EJ (reprint author), Leiden Univ, Med Ctr, Dept Virol, LUMC P4-26,POB 9600, NL-2300 RC Leiden, Netherlands.
RI Snijder, Eric J./E-6073-2018
OI Snijder, Eric J./0000-0003-3297-2309; van Marle,
   Guido/0000-0002-5148-6229
CR Adkins S, 1998, RNA, V4, P455
   BAKER SC, 1990, EMBO J, V9, P4173, DOI 10.1002/j.1460-2075.1990.tb07641.x
   BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   Brian DA, 1997, SEMIN VIROL, V8, P101, DOI 10.1006/smvy.1997.0109
   Chang RY, 1996, J VIROL, V70, P2720, DOI 10.1128/JVI.70.5.2720-2729.1996
   CHANG RY, 1994, J VIROL, V68, P8223, DOI 10.1128/JVI.68.12.8223-8231.1994
   denBoon JA, 1996, J VIROL, V70, P4291, DOI 10.1128/JVI.70.7.4291-4298.1996
   DENBOON JA, 1995, VIROLOGY, V213, P364, DOI 10.1006/viro.1995.0009
   DEVRIES AAF, 1990, NUCLEIC ACIDS RES, V18, P3241, DOI 10.1093/nar/18.11.3241
   Gerdes K, 1997, ANNU REV GENET, V31, P1, DOI 10.1146/annurev.genet.31.1.1
   GLASER AL, 1995, J GEN VIROL, V76, P2223, DOI 10.1099/0022-1317-76-9-2223
   GULTYAEV AP, 1995, J MOL BIOL, V250, P37, DOI 10.1006/jmbi.1995.0356
   JACOBS L, 1981, J VIROL, V39, P401, DOI 10.1128/JVI.39.2.401-406.1981
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Li HP, 1999, J VIROL, V73, P772, DOI 10.1128/JVI.73.1.772-777.1999
   Li HP, 1997, P NATL ACAD SCI USA, V94, P9544, DOI 10.1073/pnas.94.18.9544
   MacLachlan NJ, 1998, J VET DIAGN INVEST, V10, P229, DOI 10.1177/104063879801000302
   MAKINO S, 1991, J VIROL, V65, P6031, DOI 10.1128/JVI.65.11.6031-6041.1991
   MCKNIGHT SL, 1992, TRANSCRIPTIONAL REGU
   Nagy PD, 1997, VIROLOGY, V235, P1, DOI 10.1006/viro.1997.8681
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   SAWICKI SG, 1995, CORONA RELATED VIRUS, P499
   SCHAAD MC, 1994, J VIROL, V68, P8169, DOI 10.1128/JVI.68.12.8169-8179.1994
   SETHNA PB, 1991, J VIROL, V65, P320, DOI 10.1128/JVI.65.1.320-325.1991
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   Siegel RW, 1998, P NATL ACAD SCI USA, V95, P11613, DOI 10.1073/pnas.95.20.11613
   SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994
   Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   van der Meer Y, 1998, J VIROL, V72, P6689, DOI 10.1128/JVI.72.8.6689-6698.1998
   van Marle G, 1999, J VIROL, V73, P5274, DOI 10.1128/JVI.73.7.5274-5281.1999
   VANBATENBURG FHD, 1995, J THEOR BIOL, V174, P269, DOI 10.1006/jtbi.1995.0098
   vanDinten LC, 1997, P NATL ACAD SCI USA, V94, P991, DOI 10.1073/pnas.94.3.991
   von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660
   WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433
   White KA, 1995, RNA, V1, P1029
NR 36
TC 161
Z9 165
U1 1
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 12
PY 1999
VL 96
IS 21
BP 12056
EP 12061
DI 10.1073/pnas.96.21.12056
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 246MD
UT WOS:000083166800068
PM 10518575
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Cilla, G
   Onate, E
   Perez-Yarza, EG
   Montes, M
   Vicente, D
   Perez-Trallero, E
AF Cilla, Gustavo
   Onate, Eider
   Perez-Yarza, Eduardo G.
   Montes, Milagrosa
   Vicente, Diego
   Perez-Trallero, Emilio
TI Viruses in community-acquired pneumonia in children aged less than 3
   years old: High rate of viral coinfection
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE viral coinfections; human bocavirus; human metapneumovirus;
   parainfluenza virus type 4
ID RESPIRATORY-TRACT INFECTIONS; POLYMERASE-CHAIN-REACTION; HUMAN
   METAPNEUMOVIRUS; HUMAN BOCAVIRUS; YOUNG-CHILDREN; HUMAN CORONAVIRUS;
   SYNCYTIAL VIRUS; MULTIPLEX PCR; DISEASE; IDENTIFICATION
AB The occurrence of viral coinfections in childhood pneumonia has received little attention, probably because suitable detection methods have been lacking. Between November 2004 and October 2006, the presence of 14 respiratory viruses in children aged less than 3 years old with community-acquired pneumonia were investigated using molecular or immunochromatographic techniques and/or viral culture. A total of 315 children (338 episodes) were included, and hospitalization was required in 178 episodes. At least one virus was detected in 66.9% of the episodes and Simultaneous detection of two or more viruses was frequent (27% of the episodes with viral detection). The most frequently detected virus was respiratory syncytial virus (n = 67: 33 subgroup A, 33 subgroup B, I not typed), followed by human bocavirus (n = 48), rhinovirus (n = 46), human metapneumovirus (n = 39: 13 genotype A2, 8 B1, 5 B2, 1 A1, 12 not genotyped) and parainfluenza viruses (n = 38: 1 type 1, 3 type 2, 22 type 3, 11 type 4 and 1 not typed). The 14 viruses investigated were found in viral coinfections, which were more frequent in children aged less than 12 months. Except for adenovirus, the incidence of which was low, the percentage of viral coinfection range between 28.2% and 68.8%. Children with viral coinfection more frequently required hospital admission than those with single viral infection. It is concluded that viral coinfections are frequent in children aged less than 3 years old with community-acquired pneumonia and can be a poor prognostic factor.
C1 [Perez-Trallero, Emilio] Hosp Donostia, Microbiol Serv, Dept Microbiol, San Sebastian 20014, Spain.
   [Onate, Eider; Perez-Yarza, Eduardo G.] Hosp Donostia, Dept Pediat, San Sebastian 20014, Spain.
   [Montes, Milagrosa; Vicente, Diego; Perez-Trallero, Emilio] CIBERes 26, San Sebastian, Spain.
   [Perez-Trallero, Emilio] Univ Basque Country, San Sebastian, Spain.
RP Perez-Trallero, E (reprint author), Hosp Donostia, Microbiol Serv, Dept Microbiol, Paseo Dr Beguiristain S-N, San Sebastian 20014, Spain.
EM mikrobiol@terra.es
OI Perez-Yarza, Eduardo G./0000-0002-8004-7110
FU Department of Health of the Basque Government [200411079]
FX Grant sponsor: Department of Health of the Basque Government (partial
   support); Grant number: 200411079
CR Aberle JH, 2005, PEDIATR INFECT DIS J, V24, P605, DOI 10.1097/01.inf.0000168741.59747.2d
   Allander T, 2005, P NATL ACAD SCI USA, V102, P15712, DOI 10.1073/pnas.0508068102
   Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196
   Bastien N, 2006, EMERG INFECT DIS, V12, P848, DOI 10.3201/eid1205.051424
   Choi EH, 2006, CLIN INFECT DIS, V43, P585, DOI 10.1086/506350
   Coiras MT, 2004, J MED VIROL, V72, P484, DOI 10.1002/jmv.20008
   Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2000, J CLIN MICROBIOL, V38, P4096, DOI 10.1128/JCM.38.11.4096-4101.2000
   Foulongne V, 2006, PEDIATR INFECT DIS J, V25, P354, DOI 10.1097/01.inf.0000207480.55201.f6
   Fry AM, 2007, J INFECT DIS, V195, P1038, DOI 10.1086/512163
   Garcia Garcia M L, 2002, An Esp Pediatr, V57, P116
   Greensill J, 2003, EMERG INFECT DIS, V9, P372, DOI 10.3201/eid0903.020289
   Henrickson KJ, 2004, PEDIATR INFECT DIS J, V23, pS11, DOI 10.1097/01.inf.0000108188.37237.48
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   Kaida A, 2006, J CLIN VIROL, V35, P394, DOI 10.1016/j.jcv.2005.12.009
   Lau SKP, 2005, J CLIN MICROBIOL, V43, P4515, DOI 10.1128/JCM.43.9.4515-4521.2005
   Michel E, 2004, J MOLLUS STUD, V70, P1, DOI 10.1093/mollus/70.1.1
   Peck AJ, 2005, PEDIATR INFECT DIS J, V24, P342, DOI 10.1097/01.inf.0000157250.95880.91
   Ruuskanen O, 1999, Semin Respir Infect, V14, P163
   Schildgen O, 2008, CLIN MICROBIOL REV, V21, P291, DOI 10.1128/CMR.00030-07
   Sinaniotis CA, 2005, CURR OPIN PULM MED, V11, P218, DOI 10.1097/01.mcp.0000159831.82529.85
   Steininger C, 2001, J CLIN MICROBIOL, V39, P129, DOI 10.1128/JCM.39.1.129-133.2001
   Stockton J, 1998, J CLIN MICROBIOL, V36, P2990, DOI 10.1128/JCM.36.10.2990-2995.1998
   Templeton KE, 2005, CLIN INFECT DIS, V41, P345, DOI 10.1086/431588
   Tsolia MN, 2004, CLIN INFECT DIS, V39, P681, DOI 10.1086/422996
   Vabret A, 2005, EMERG INFECT DIS, V11, P1225, DOI 10.3201/eid1108.050110
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2005, PLOS MED, V2, P764, DOI 10.1371/journal.pmed.0020240
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vicente D, 2007, EMERG INFECT DIS, V13, P636, DOI 10.3201/eid1304.061501
   WHO Pneumonia Vaccine Trial Investigators' Group, 2001, STAND INT CHEST RAD
   Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0
   Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472
   Wolf DG, 2006, PEDIATR INFECT DIS J, V25, P320, DOI 10.1097/01.inf.0000207395.80657.cf
   Xu WH, 2000, J CLIN MICROBIOL, V38, P4114, DOI 10.1128/JCM.38.11.4114-4120.2000
NR 36
TC 160
Z9 175
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD OCT
PY 2008
VL 80
IS 10
BP 1843
EP 1849
DI 10.1002/jmv.21271
PG 7
WC Virology
SC Virology
GA 341SE
UT WOS:000258734400024
PM 18712820
DA 2020-04-03
ER

PT J
AU Woo, PCY
   Lau, SKP
   Li, KSM
   Poon, RWS
   Wong, BHL
   Tsoi, HW
   Yip, BCK
   Huang, Y
   Chan, KH
   Yuen, KY
AF Woo, Patrick C. Y.
   Lau, Susanna K. P.
   Li, Kenneth S. M.
   Poon, Rosana W. S.
   Wong, Beatrice H. L.
   Tsoi, Hoi-wah
   Yip, Bethanie C. K.
   Huang, Yi
   Chan, Kwok-hung
   Yuen, Kwok-yung
TI Molecular diversity of coronaviruses in bats
SO VIROLOGY
LA English
DT Article
DE bats; coronavirus; diversity
ID ACUTE RESPIRATORY SYNDROME; SARS-CORONAVIRUS; GENOME SEQUENCE;
   PNEUMONIA; IDENTIFICATION; BIOLOGY; HKU1; REPLICATION; FEATURES; UNIQUE
AB The existence of coronaviruses in bats is unknown until the recent discovery of bat-SARS-CoV in Chinese horseshoe bats and a novel group 1 coronavirus in other bat species. Among 309 bats of 13 species captured from 20 different locations in rural areas of Hong Kong over a 16-month period, coronaviruses were amplified from anal swabs of 37 (12%) bats by RT-PCR. Phylogenetic analysis of RNA-dependent-RNA-polymerase (pol) and helicase genes revealed six novel coronaviruses from six different bat species, in addition to the two previously described coronaviruses. Among the six novel coronaviruses, four were group I coronaviruses (bat-CoV HKU2 from Chinese horseshoe bat, bat-CoV HKU6 from rickett's big-footed bat, bat-CoV HKU7 from greater bent-winged bat and bat-CoV HKU8 from lesser bent-winged bat) and two were group 2 coronaviruses (bat-CoV HKU4 from lesser bamboo bats and bat-CoV HKU5 from Japanese pipistrelles). An astonishing diversity of coronaviruses was observed in bats. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Res Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.
EM hkumicro@hkucc.hku.hk
RI Yuen, Kwok Yung/C-4465-2009; Woo, Patrick/C-4449-2009; Lau,
   Susanna/C-4321-2009; Tsoi, Hoi Wah/C-4428-2009; Li, Kenneth/C-4602-2009
OI Yuen, Kwok-yung/0000-0002-2083-1552
CR Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Eickmann M, 2003, SCIENCE, V302, P1504
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Jonassen CM, 2005, J GEN VIROL, V86, P1597, DOI 10.1099/vir.0.80927-0
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Liu SW, 2005, J GEN VIROL, V86, P719, DOI 10.1099/vir.0.80546-0
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Rest JS, 2003, INFECT GENET EVOL, V3, P219, DOI 10.1016/j.meegid.2003.08.001
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2005, MICROBIOL IMMUNOL, V49, P899, DOI 10.1111/j.1348-0421.2005.tb03681.x
   Woo PCY, 2005, ARCH VIROL, V150, P2299, DOI 10.1007/s00705-005-0573-2
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   Woo PCY, 2004, J CLIN MICROBIOL, V42, P2306, DOI 10.1128/JCM.42.5.2306-2309.2004
   Woo PCY, 2004, LANCET, V363, P841, DOI 10.1016/S0140-6736(04)15729-2
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
NR 25
TC 160
Z9 173
U1 5
U2 25
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUL 20
PY 2006
VL 351
IS 1
BP 180
EP 187
DI 10.1016/j.virol.2006.02.041
PG 8
WC Virology
SC Virology
GA 067RI
UT WOS:000239319900017
PM 16647731
OA Bronze
DA 2020-04-03
ER

PT J
AU KLUMPERMAN, J
   LOCKER, JK
   MEIJER, A
   HORZINEK, MC
   GEUZE, HJ
   ROTTIER, PJM
AF KLUMPERMAN, J
   LOCKER, JK
   MEIJER, A
   HORZINEK, MC
   GEUZE, HJ
   ROTTIER, PJM
TI CORONAVIRUS M-PROTEINS ACCUMULATE IN THE GOLGI-COMPLEX BEYOND THE SITE
   OF VIRION BUDDING
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS VIRUS; VESICULAR STOMATITIS-VIRUS; E1
   GLYCOPROTEIN; INTERMEDIATE COMPARTMENT; LINKED OLIGOSACCHARIDES;
   ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; CELLS; EXPRESSION;
   IDENTIFICATION
AB The prevailing hypothesis is that the intracellular site of budding of coronaviruses is determined by the localization of its membrane protein M (previously called E1). We tested this by analyzing the site of budding of four different coronaviruses in relation to the intracellular localization of their M proteins. Mouse hepatitis virus (MHV) and infectious bronchitis virus (IBV) grown in Sac(-) cells, and feline infectious peritonitis virus (Fl[PV) and transmissible gastroenteritis virus (TGEV) grown in CrFK cells, all budded exclusively into smooth-walled, tubulovesicular membranes located intermediately between the rough endoplasmic reticulum and Golgi complex, identical to the so-called budding compartment previously identified for MHV. Indirect immunofluorescence staining of the infected cells showed that all four M proteins accumulated in a perinuclear region. Immunogold microscopy localized MHV M and IBV M in the budding compartment; in addition, a dense labeling in the Golgi complex occurred, MHV M predominantly in trans-Golgi cisternae and trans-Golgi reticulum and IBV M mainly in the cis and medial Golgi cisternae. The corresponding M proteins of the four viruses, when independently expressed in a recombinant vaccinia virus system, also accumulated in the perinuclear area. Quantitative pulse-chase analysis of metabolically labeled cells showed that in each case the majority of the M glycoproteins carried oligosaccharide side chains with Golgi-specific modifications within 4 h after synthesis. Immunoelectron microscopy localized recombinant MHV M and IBV M to the same membranes as the respective proteins in coronavirus-infected cells, with the same cis-trans distribution over the Golgi complex. Our results demonstrate that some of the M proteins of the four viruses are transported beyond the budding compartment and are differentially retained by intrinsic retention signals; in addition to M, other viral and/or cellular factors are probably required to determine the site of budding.
C1 UNIV UTRECHT, CTR ELECTRON MICROSCOPY, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS.
   UNIV UTRECHT, DEPT INFECT DIS & IMMUNOL, DIV VIROL, 3584 CL UTRECHT, NETHERLANDS.
RI Locker, Jacomine Krijnse/E-1009-2016; Meijer, Annemarie/W-3726-2019
CR ARMSTRONG J, 1991, J CELL SCI, V95, P191
   Becker W B, 1967, J Virol, V1, P1019
   CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403
   CHEN SSL, 1988, J VIROL, V62, P2552, DOI 10.1128/JVI.62.8.2552-2556.1988
   DAVIDFERREIRA JF, 1965, J CELL BIOL, V24, P57, DOI 10.1083/jcb.24.1.57
   DENBOON JA, 1991, VIROLOGY, V182, P655, DOI 10.1016/0042-6822(91)90606-C
   DUBOISDALCQ ME, 1982, VIROLOGY, V119, P317, DOI 10.1016/0042-6822(82)90092-7
   GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253
   GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949
   Griffiths G, 1992, Semin Cell Biol, V3, P367, DOI 10.1016/1043-4682(92)90022-N
   HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q
   HILLE A, 1992, EUR J CELL BIOL, V59, P106
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0
   JACOBS L, 1987, VIRUS RES, V8, P363, DOI 10.1016/0168-1702(87)90008-6
   JACOBSEGEELS HEL, 1983, J GEN VIROL, V64, P1859, DOI 10.1099/0022-1317-64-9-1859
   JAMIESON JD, 1967, J CELL BIOL, V34, P577, DOI 10.1083/jcb.34.2.577
   KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997
   KLUMPERMAN J, 1990, EUR J CELL BIOL, V54, P76
   KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631
   KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55
   LAUDE H, 1987, J GEN VIROL, V68, P1687, DOI 10.1099/0022-1317-68-6-1687
   LAVIADA MD, 1990, VIRUS RES, V16, P247, DOI 10.1016/0168-1702(90)90051-C
   Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F
   LOCKER JK, 1992, J BIOL CHEM, V267, P21911
   LOCKER JK, 1992, J BIOL CHEM, V267, P14094
   LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43
   MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205
   MACHAMER CE, 1993, MOL BIOL CELL, V4, P695
   MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944
   MCKEIRNAN AJ, 1981, FELINE PRACT, V11, P16
   METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x
   NIEMANN H, 1984, EMBO J, V3, P665, DOI 10.1002/j.1460-2075.1984.tb01864.x
   Niemann H, 1987, Adv Exp Med Biol, V218, P83
   NIEMANN H, 1989, SUBCELLULAR BIOCH, V19, P307
   OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49
   ORCI L, 1985, P NATL ACAD SCI USA, V82, P5385, DOI 10.1073/pnas.82.16.5385
   PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V
   Pettersson R F, 1991, Curr Top Microbiol Immunol, V170, P67
   PULFORD DJ, 1990, VIRUS RES, V18, P203
   ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987
   ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981
   Sambrook J., 1989, MOL CLONING LABORATO
   SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021
   SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643
   SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185
   SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9
   SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   STERN DF, 1982, J VIROL, V44, P794, DOI 10.1128/JVI.44.3.794-803.1982
   STURMAN L, 1985, TRENDS BIOCHEM SCI, V10, P17, DOI 10.1016/0968-0004(85)90010-6
   SUISSA M, 1983, ANAL BIOCHEM, V133, P511, DOI 10.1016/0003-2697(83)90117-3
   SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19
   TO LT, 1991, VET MICROBIOL, V29, P361, DOI 10.1016/0378-1135(91)90143-4
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   TOOZE J, 1985, EUR J CELL BIOL, V37, P203
   TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475
   VENNEMA H, 1991, GENE, V108, P201, DOI 10.1016/0378-1119(91)90435-E
   Weibel E, 1979, STEREOLOGICAL METHOD
NR 60
TC 160
Z9 174
U1 1
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD OCT
PY 1994
VL 68
IS 10
BP 6523
EP 6534
DI 10.1128/JVI.68.10.6523-6534.1994
PG 12
WC Virology
SC Virology
GA PG541
UT WOS:A1994PG54100041
PM 8083990
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Drosten, C
   Meyer, B
   Muller, MA
   Corman, VM
   Al-Masri, M
   Hossain, R
   Madani, H
   Sieberg, A
   Bosch, BJ
   Lattwein, E
   Alhakeem, RF
   Assiri, AM
   Hajomar, W
   Albarrak, AM
   Al-Tawfiq, JA
   Zumla, AI
   Memish, ZA
AF Drosten, Christian
   Meyer, Benjamin
   Mueller, Marcel A.
   Corman, Victor M.
   Al-Masri, Malak
   Hossain, Raheela
   Madani, Hosam
   Sieberg, Andrea
   Bosch, Berend Jan
   Lattwein, Erik
   Alhakeem, Raafat F.
   Assiri, Abdullah M.
   Hajomar, Waleed
   Albarrak, Ali M.
   Al-Tawfiq, Jaffar A.
   Zumla, Alimuddin I.
   Memish, Ziad A.
TI Transmission of MERS-Coronavirus in Household Contacts
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID SAUDI-ARABIA; ANTIBODIES; SEROLOGY; WORKERS; CAMELS
AB BACKGROUND
   Strategies to contain the Middle East respiratory syndrome coronavirus (MERS-CoV) depend on knowledge of the rate of human-to-human transmission, including subclinical infections. A lack of serologic tools has hindered targeted studies of transmission.
   METHODS
   We studied 26 index patients with MERS-CoV infection and their 280 household contacts. The median time from the onset of symptoms in index patients to the latest blood sampling in contact patients was 17.5 days (range, 5 to 216; mean, 34.4). Probable cases of secondary transmission were identified on the basis of reactivity in two reverse-transcriptase polymerase-chain-reaction (RT-PCR) assays with independent RNA extraction from throat swabs or reactivity on enzyme-linked immuno-sorbent assay against MERS-CoV 51 antigen, supported by reactivity on recombinant S-protein immunofluorescence and demonstration of neutralization of more than 50% of the infectious virus seed dose on plaque-reduction neutralization testing.
   RESULTS
   Among the 280 household contacts of the 26 index patients, there were 12 probable cases of secondary transmission (4%; 95% confidence interval, 2 to 7). Of these cases, 7 were identified by means of RT-PCR, all in samples obtained within 14 days after the onset of symptoms in index patients, and 5 were identified by means of serologic analysis, all in samples obtained 13 days or more after symptom onset in index patients. Probable cases of secondary transmission occurred in 6 of 26 clusters (23%). Serologic results in contacts who were sampled 13 days or more after exposure were similar to overall study results for combined RT-PCR and serologic testing.
   CONCLUSIONS
   The rate of secondary transmission among household contacts of patients with MERS-CoV infection has been approximately 5%. Our data provide insight into the rate of subclinical transmission of MERS-CoV in the home.
C1 [Drosten, Christian; Meyer, Benjamin; Mueller, Marcel A.; Corman, Victor M.; Sieberg, Andrea] Univ Bonn, Inst Virol, Med Ctr, D-53105 Bonn, Germany.
   [Lattwein, Erik] Euroimmun, Lubeck, Germany.
   [Al-Masri, Malak; Alhakeem, Raafat F.; Assiri, Abdullah M.; Zumla, Alimuddin I.; Memish, Ziad A.] Minist Hlth, Global Ctr Mass Gatherings Med, Riyadh, Saudi Arabia.
   [Albarrak, Ali M.] Prince Sultan Mil Med City, Riyadh, Saudi Arabia.
   [Memish, Ziad A.] Alfaisal Univ, Riyadh 11514, Saudi Arabia.
   [Al-Tawfiq, Jaffar A.] Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
   [Hossain, Raheela; Madani, Hosam] Minist Hlth, Reg Lab, Jeddah, Saudi Arabia.
   [Hajomar, Waleed] Minist Hlth, Reg Lab, Riyadh, Saudi Arabia.
   [Al-Tawfiq, Jaffar A.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [Bosch, Berend Jan] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Utrecht, Netherlands.
   [Zumla, Alimuddin I.] UCL, Div Infect & Immun, London, England.
   [Zumla, Alimuddin I.] UCL Hosp, Natl Inst Hlth Res Biomed Res Ctr, London, England.
RP Memish, ZA (reprint author), Alfaisal Univ, POB 54146, Riyadh 11514, Saudi Arabia.
EM drosten@virology-bonn.de; zmemish@yahoo.com
RI Meyer, Benjamin/F-3285-2018; Corman, Victor Max/K-1319-2019; Meyer,
   Bernhard/Q-9413-2016; Mueller, Marcel/O-2425-2019
OI Meyer, Benjamin/0000-0003-0601-3550; Corman, Victor
   Max/0000-0002-3605-0136; Mueller, Marcel/0000-0003-2242-5117; Assiri,
   Abdullah/0000-0002-5605-2876; Sieberg, Andrea/0000-0003-3716-9996;
   Zumla, Alimuddin/0000-0002-5111-5735
FU European Commission EMPERIE program [223498]; ANTIGONE program [278976];
   German Center for Infection Research; German Ministry for Research and
   EducationFederal Ministry of Education & Research (BMBF); German
   Research CouncilGerman Research Foundation (DFG) [01KIO701, DR 772/3-1];
   University College London (UCL) Hospitals NHS Foundation Trust; National
   Institute of Health Research, Biomedical Research Centre, UCL Hospitals;
   European and Developing Countries Clinical Trials Partnership; Seventh
   Framework Program of the European Commission for Rapid Identification of
   Respiratory Tract Infections
FX Dr. Drosten reports receiving grant support from the European Commission
   EMPERIE program (contract no. 223498) and ANTIGONE program (contract no.
   278976) and from the German Center for Infection Research, the German
   Ministry for Research and Education, and the German Research Council
   (grants 01KIO701 and DR 772/3-1); and Dr. Zumla, receiving support from
   the University College London (UCL) Hospitals NHS Foundation Trust, the
   National Institute of Health Research, Biomedical Research Centre, UCL
   Hospitals, the European and Developing Countries Clinical Trials
   Partnership, and the Seventh Framework Program of the European
   Commission for Rapid Identification of Respiratory Tract Infections. No
   other potential conflict of interest relevant to this article was
   reported.
CR Aburizaiza AS, 2014, J INFECT DIS, V209, P243, DOI 10.1093/infdis/jit589
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Breban R, 2013, LANCET, V382, P694, DOI 10.1016/S0140-6736(13)61492-0
   Buchholz U., 2013, Eurosurveillance, V18, P20406
   Cauchemez S, 2014, LANCET INFECT DIS, V14, P50, DOI 10.1016/S1473-3099(13)70304-9
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   Cotten M, 2014, MBIO, V5, DOI 10.1128/mBio.01062-13
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3
   Gierer S, 2013, EMERG INFECT DIS, V19, P2034, DOI 10.3201/eid1912.130701
   Ho HT, 2006, CHEST, V129, P95, DOI 10.1378/chest.129.1.95
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Meyer B., 2014, VIRUS RES
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Muller MA, 2012, MBIO, V3
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reusken C, 2013, EUROSURVEILLANCE, V18, P2, DOI 10.2807/1560-7917.ES2013.18.14.20441
   Reusken CB, 2013, EUROSURVEILLANCE, V18, P14, DOI 10.2807/1560-7917.ES2013.18.50.20662
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 21
TC 159
Z9 167
U1 8
U2 33
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD AUG 28
PY 2014
VL 371
IS 9
BP 828
EP 835
DI 10.1056/NEJMoa1405858
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA AN7ZN
UT WOS:000340819800009
PM 25162889
OA Green Published, Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Falzarano, D
   de Wit, E
   Rasmussen, AL
   Feldmann, F
   Okumura, A
   Scott, DP
   Brining, D
   Bushmaker, T
   Martellaro, C
   Baseler, L
   Benecke, AG
   Katze, MG
   Munster, VJ
   Feldmann, H
AF Falzarano, Darryl
   de Wit, Emmie
   Rasmussen, Angela L.
   Feldmann, Friederike
   Okumura, Atsushi
   Scott, Dana P.
   Brining, Doug
   Bushmaker, Trenton
   Martellaro, Cynthia
   Baseler, Laura
   Benecke, Arndt G.
   Katze, Michael G.
   Munster, Vincent J.
   Feldmann, Heinz
TI Treatment with interferon-alpha 2b and ribavirin improves outcome in
   MERS-CoV-infected rhesus macaques
SO NATURE MEDICINE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; SONIC HEDGEHOG; CONVALESCENT PLASMA; HUMAN
   CORONAVIRUS; TGF-BETA; SARS; PNEUMONIA; GROWTH; EXPRESSION; INFLUENZA
AB The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) is of global concern: the virus has caused severe respiratory illness, with 111 confirmed cases and 52 deaths1 at the time of this article's publication. Therapeutic interventions have not been evaluated in vivo; thus, patient management relies exclusively on supportive care, which, given the high case-fatality rate, is not highly effective. The rhesus macaque is the only known model organism for MERS-CoV infection, developing an acute localized to widespread pneumonia with transient clinical disease(2,3) that recapitulates mild to moderate human MERSCoV cases(4,5). The combination of interferon-alpha 2b and ribavirin was effective in reducing MERS-CoV replication in vitro(6); therefore, we initiated this treatment 8 h after inoculation of rhesus macaques. In contrast to untreated, infected macaques, treated animals did not develop breathing abnormalities and showed no or very mild radiographic evidence of pneumonia. Moreover, treated animals showed lower levels of systemic (serum) and local (lung) proinflammatory markers, in addition to fewer viral genome copies, distinct gene expression and less severe histopathological changes in the lungs. Taken together, these data suggest that treatment of MERS-CoV infected rhesus macaques with IFN-alpha 2b and ribavirin reduces virus replication, moderates the host response and improves clinical outcome. As these two drugs are already used in combination in the clinic for other infections, IFN-alpha 2b and ribavirin should be considered for the management of MERS-CoV cases.
C1 [Falzarano, Darryl; de Wit, Emmie; Martellaro, Cynthia; Baseler, Laura; Feldmann, Heinz] NIAID, Dis Modeling & Transmiss Unit, Virol Lab, Div Intramural Res,NIH,Rocky Mt Labs, Hamilton, MT USA.
   [Rasmussen, Angela L.; Okumura, Atsushi; Benecke, Arndt G.; Katze, Michael G.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
   [Feldmann, Friederike; Scott, Dana P.; Brining, Doug] NIAID, Rocky Mt Vet Branch, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT USA.
   [Bushmaker, Trenton; Munster, Vincent J.] NIAID, Virus Ecol Unit, Virol Lab, Div Intramural Res,NIH,Rocky Mt Labs, Hamilton, MT USA.
   [Baseler, Laura] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA.
   [Benecke, Arndt G.] Univ Paris 06, CNRS, UMR7224, Paris, France.
   [Katze, Michael G.] Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98195 USA.
   [Feldmann, Heinz] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada.
RP Feldmann, H (reprint author), NIAID, Dis Modeling & Transmiss Unit, Virol Lab, Div Intramural Res,NIH,Rocky Mt Labs, Hamilton, MT USA.
EM feldmannh@niaid.nih.gov
RI Munster, Vincent/I-7607-2018; de Wit, Emmie/A-1549-2019; Okumura,
   Atsushi/E-8012-2015
OI Munster, Vincent/0000-0002-2288-3196; de Wit, Emmie/0000-0002-9763-7758;
   Okumura, Atsushi/0000-0002-7779-3059; Rasmussen,
   Angela/0000-0001-9462-3169
FU Intramural Research Program, NIAID, NIH; NIAID Regional Centers of
   Excellence [U54 AI081680]; Systems Virology (NIH/ NIAID)
   [HHSN272200800060C]; Washington National Primate Research Center
   [P51OD010425]
FX D.F., E.d.W., V.J.M. and H.F. conceived of and designed the study. D.F.,
   E.d.W., A.L.R., F.F., A.O., D.P.S., T.B., C.M. and D.B. performed the
   experiments. D.F., E.d.W., A.L.R., A.O., D.P.S., L.B., A.G.B., V.J.M.,
   M.G.K. and H.F. analyzed the data. D.F., A.L.R., M.G.K. and H.F. wrote
   the manuscript. This work was supported in part by the Intramural
   Research Program, NIAID, NIH, in addition to the NIAID Regional Centers
   of Excellence (U54 AI081680), Systems Virology (NIH/ NIAID contract
   number HHSN272200800060C) and Washington National Primate Research
   Center (P51OD010425) to M.G.K.
CR [Anonymous], 2013, PROMED
   Becavin C, 2011, BIOINFORMATICS, V27, P1413, DOI 10.1093/bioinformatics/btr143
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Brining DL, 2010, COMPARATIVE MED, V60, P389
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cigna N, 2012, AM J PATHOL, V181, P2126, DOI 10.1016/j.ajpath.2012.08.019
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   de Wit E., PROC NATL ACAD SCI U
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Fitch PM, 2011, INT J EXP PATHOL, V92, P8, DOI 10.1111/j.1365-2613.2010.00743.x
   Gastanaduy PA, 2013, MMWR-MORBID MORTAL W, V62, P480
   Ho JC, 2004, INT J TUBERC LUNG D, V8, P1173
   Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495
   Li M, 2008, J BIOL CHEM, V283, P36257, DOI 10.1074/jbc.M806786200
   Liu L, 2013, AM J RESP CELL MOL, V48, P703, DOI 10.1165/rcmb.2012-0347OC
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Menshykau D, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002377
   Munster VJ, 2013, NEW ENGL J MED, V368, P1560, DOI 10.1056/NEJMc1215691
   Noth Sebastian, 2006, Genomics Proteomics & Bioinformatics, V4, P90, DOI 10.1016/S1672-0229(06)60021-1
   Omrani AS, 2013, INT J INFECT DIS, V17, pE668, DOI 10.1016/j.ijid.2013.07.001
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Pogach MS, 2007, J CELL BIOCHEM, V100, P1415, DOI 10.1002/jcb.21142
   Sarasin-Filipowicz M., 2013, P NATL ACAD SCI USA, V105, P7034
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076
   Tahir M, 2013, EUROSURVEILLANCE, V18, P4
   Thomas E, 2011, HEPATOLOGY, V53, P32, DOI 10.1002/hep.23985
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Wang GS, 2010, BBA-MOL CELL RES, V1803, P1359, DOI 10.1016/j.bbamcr.2010.09.002
   White AC, 2006, DEVELOPMENT, V133, P1507, DOI 10.1242/dev.02313
   White AC, 2007, DEVELOPMENT, V134, P3743, DOI 10.1242/dev.004879
   Yang Y, 2011, MOL BIOL REP, V38, P3615, DOI 10.1007/s11033-010-0473-8
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang MF, 2010, HISTOCHEM CELL BIOL, V134, P327, DOI 10.1007/s00418-010-0738-2
NR 37
TC 159
Z9 176
U1 14
U2 37
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD OCT
PY 2013
VL 19
IS 10
BP 1313
EP +
DI 10.1038/nm.3362
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 232YW
UT WOS:000325531700031
PM 24013700
OA Green Accepted, Bronze
DA 2020-04-03
ER

PT J
AU Wu, CY
   Jan, JT
   Ma, SH
   Kuo, CJ
   Juan, HF
   Cheng, YSE
   Hsu, HH
   Huang, HC
   Wu, D
   Brik, A
   Liang, FS
   Liu, RS
   Fang, JM
   Chen, ST
   Liang, PH
   Wong, CH
AF Wu, CY
   Jan, JT
   Ma, SH
   Kuo, CJ
   Juan, HF
   Cheng, YSE
   Hsu, HH
   Huang, HC
   Wu, D
   Brik, A
   Liang, FS
   Liu, RS
   Fang, JM
   Chen, ST
   Liang, PH
   Wong, CH
TI Small molecules targeting severe acute respiratory syndrome human
   coronavirus
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID SARS-ASSOCIATED CORONAVIRUS; MAIN PROTEASE; 3C-LIKE PROTEINASE; GENOME
   SEQUENCE; HONG-KONG; INHIBITORS; SUBSTRATE; ASSAY; IDENTIFICATION;
   REPLICATION
AB Severe acute respiratory syndrome (SARS) is an infectious disease caused by a novel human coronavirus. Currently, no effective antiviral agents exist against this type of virus. A cell-based assay, with SARS virus and Vero E6 cells, was developed to screen existing drugs, natural products, and synthetic compounds to identify effective anti-SARS agents. of >10,000 agents tested, approximate to50 compounds were found active at 10 muM; among these compounds, two are existing drugs (Reserpine 13 and Aescin 5) and several are in clinical development. These 50 active compounds were tested again, and compounds 2-6, 10, and 13 showed active at 3 muM. The 50% inhibitory concentrations for the inhibition of viral replication (EC50) and host growth (CC50) were then measured and the selectivity index (SI = CC50/EC50) was determined. The EC50, based on ELISA, and SI for Reserpine, Aescim, and Valinomycin are 3.4 muM (SI = 7.3), 6.0 muM (SI = 2.5), and 0.85 muM (SI = 80), respectively. Additional studies were carried out to further understand the mode of action of some active compounds, including ELISA, Western blot analysis, immunofluorescence and flow cytometry assays, and inhibition against the 3CL protease and viral entry. Of particular interest are the two anti-HIV agents, one as an entry blocker and the other as a 3CL protease inhibitor (K-i = 0.6 muM).
C1 Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   Natl Tsing Hua Univ, Dept Chem, Hsinchu 300, Taiwan.
   Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   Natl Taiwan Univ, Dept Chem, Taipei 106, Taiwan.
   Natl Taiwan Univ Technol, Dept Chem Engn, Taipei 106, Taiwan.
   Natl Def Univ, Natl Def Med Ctr, Inst Prevent Med, Taipei 114, Taiwan.
   Acad Sinica, Genomics Res Ctr, Taipei 115, Taiwan.
   Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.
RP Jan, JT (reprint author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM tsrong33@pchome.com.tw1; wong@scripps.edu
RI Liang, Po-Huang/H-6610-2015; Huang, Hsuan-Cheng/C-7266-2011; Brik,
   Ashraf/F-1583-2012
OI Liang, Po-Huang/0000-0003-1207-5256; Huang,
   Hsuan-Cheng/0000-0002-3386-0934; JUAN, HSUEH-FEN/0000-0003-4876-3309;
   Fang, Jim-Min/0000-0002-6070-3408
CR ANNAD K, 2003, SCIENCE, V300, P1763
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   BAZZONI G, 1991, HAEMATOLOGICA, V76, P491
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Brik A, 2002, CHEM BIOL, V9, P891, DOI 10.1016/S1074-5521(02)00184-9
   BRIK A, 2003, ORG BIOMOL CHEM, V1, P1
   BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L
   Chan JWM, 2003, THORAX, V58, P686, DOI 10.1136/thorax.58.8.686
   CHAN SYW, 1984, CONTRACEPTION, V30, P363, DOI 10.1016/S0010-7824(84)80028-1
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Fraser HS, 1996, CLIN PHARMACOL THER, V60, P368, DOI 10.1016/S0009-9236(96)90193-9
   Frick RW, 2000, ANGIOLOGY, V51, P197, DOI 10.1177/000331970005100303
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Hemila H, 2003, J ANTIMICROB CHEMOTH, V52, P1049, DOI 10.1093/jac/dkh002
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q
   HUITRONRESENDIZ S, 2004, IN PRESS VIROLOGY
   Jeong CS, 2003, ARCH PHARM RES, V26, P906, DOI 10.1007/BF02980198
   Khabar KSA, 1996, J INTERF CYTOK RES, V16, P31, DOI 10.1089/jir.1996.16.31
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuo CJ, 2004, BIOCHEM BIOPH RES CO, V318, P862, DOI 10.1016/j.bbrc.2004.04.098
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lee YJ, 2003, ARCH PHARM RES, V26, P58, DOI 10.1007/BF03179933
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Martin TL, 2001, IEEE T VLSI SYST, V9, P29, DOI 10.1109/92.920816
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   SCHNEIDER JA, 1974, EUR J PHARMACOL, V27, P349, DOI 10.1016/0014-2999(74)90011-9
   Shiu SYW, 2003, J PINEAL RES, V35, P69, DOI 10.1034/j.1600-079X.2003.00068.x
   Sirtori CR, 2001, PHARMACOL RES, V44, P183, DOI 10.1006/phrs.2001.0847
   So LKY, 2003, LANCET, V361, P1615, DOI 10.1016/S0140-6736(03)13265-5
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Tsai SC, 2003, CHINESE J PHYSIOL, V46, P1
   Tsang Kenneth, 2004, Curr Opin Investig Drugs, V5, P179
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Tsui PT, 2003, EMERG INFECT DIS, V9, P1064
   WILHELM K, 1977, MED KLIN, V72, P128
   Wu CY, 2003, ANGEW CHEM INT EDIT, V42, P4661, DOI 10.1002/anie.200351823
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang JL, 1998, VIROLOGY, V244, P530, DOI 10.1006/viro.1998.9115
NR 47
TC 159
Z9 173
U1 3
U2 31
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 6
PY 2004
VL 101
IS 27
BP 10012
EP 10017
DI 10.1073/pnas.0403596101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 836CZ
UT WOS:000222534200014
PM 15226499
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Towler, P
   Staker, B
   Prasad, SG
   Menon, S
   Tang, J
   Parsons, T
   Ryan, D
   Fisher, M
   Williams, D
   Dales, NA
   Patane, MA
   Pantoliano, MW
AF Towler, P
   Staker, B
   Prasad, SG
   Menon, S
   Tang, J
   Parsons, T
   Ryan, D
   Fisher, M
   Williams, D
   Dales, NA
   Patane, MA
   Pantoliano, MW
TI ACE2 X-ray structures reveal a large hinge-bending motion important for
   inhibitor binding and catalysis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME; CRYSTAL-STRUCTURE; ACTIVE-SITE; CHLORIDE
   DEPENDENCE; MOLECULAR-CLONING; BLOOD-PRESSURE; CARBOXYPEPTIDASE;
   THERMOLYSIN; SUBSTRATE; GLYCOPROTEIN
AB The angiotensin-converting enzyme (ACE)-related carboxypeptidase, ACE2, is a type I integral membrane protein of 805 amino acids that contains one HEXXH + E zinc-binding consensus sequence. ACE2 has been implicated in the regulation of heart function and also as a functional receptor for the coronavirus that causes the severe acute respiratory syndrome (SARS). To gain further insights into this enzyme, the first crystal structures of the native and inhibitor-bound forms of the ACE2 extracellular domains were solved to 2.2- and 3.0-Angstrom resolution, respectively. Comparison of these structures revealed a large inhibitor-dependent hinge-bending movement of one catalytic subdomain relative to the other (similar to16degrees) that brings important residues into position for catalysis. The potent inhibitor MLN-4760 ((S, S)- 2-{1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol4-yl]- ethylamino}-4-methylpentanoic acid) makes key binding interactions within the active site and offers insights regarding the action of residues involved in catalysis and substrate specificity. A few active site residue substitutions in ACE2 relative to ACE appear to eliminate the S(2)' substrate-binding subsite and account for the observed reactivity change from the peptidyl dipeptidase activity of ACE to the carboxypeptidase activity of ACE2.
C1 Millennium Pharmaceut Inc, Drug Discovery, Cambridge, MA 02139 USA.
   Millennium Pharmaceut Inc, Prot Sci, Cambridge, MA 02139 USA.
   Emerald BioStruct Inc, Bainbridge Isl, WA 98110 USA.
RP Pantoliano, MW (reprint author), Millennium Pharmaceut Inc, Drug Discovery, 270 Albany St, Cambridge, MA 02139 USA.
EM pantoliano@mpi.com
OI Staker, Bart/0000-0001-9570-5086
CR Abrahams JP, 1998, CURR OPIN STRUC BIOL, V8, P601, DOI 10.1016/S0959-440X(98)80151-6
   Arndt JW, 2002, STRUCTURE, V10, P215, DOI 10.1016/S0969-2126(02)00698-6
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BERNSTEIN KE, 1990, BIOCHEM BIOPH RES CO, V167, P310, DOI 10.1016/0006-291X(90)91766-L
   Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694
   Brown CK, 2001, P NATL ACAD SCI USA, V98, P3127, DOI 10.1073/pnas.051633198
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Dales NA, 2002, J AM CHEM SOC, V124, P11852, DOI 10.1021/ja0277226
   Danilczyk U, 2003, J MOL MED, V81, P227, DOI 10.1007/s00109-003-0419-x
   DONOGHUE M, 2000, CIRC RES, V87, P1
   EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741
   Esther CR, 1996, LAB INVEST, V74, P953
   Fernandez M, 2001, J BIOL CHEM, V276, P4998, DOI 10.1074/jbc.M009009200
   FOLOP V, 1998, CELL, V94, P161
   Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412
   GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001
   Gerstein M, 1998, NUCLEIC ACIDS RES, V26, P4280, DOI 10.1093/nar/26.18.4280
   Gordon K, 2003, BIOCHEM J, V371, P437, DOI 10.1042/BJ20021842
   Grams F, 1996, NAT STRUCT BIOL, V3, P671, DOI 10.1038/nsb0896-671
   Guy JL, 2003, BIOCHEMISTRY-US, V42, P13185, DOI 10.1021/bi035268s
   Hauptman HA, 1997, METHOD ENZYMOL, V277, P3, DOI 10.1016/S0076-6879(97)77003-4
   Higgins DG, 1996, METHOD ENZYMOL, V266, P383
   HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008
   HOLLAND DR, 1992, BIOCHEMISTRY-US, V31, P11310, DOI 10.1021/bi00161a008
   Kim HM, 2003, FEBS LETT, V538, P65, DOI 10.1016/S0014-5793(03)00128-5
   KNOWLES JR, 1991, PHILOS T ROY SOC B, V332, P115, DOI 10.1098/rstb.1991.0039
   KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385
   KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu XF, 2001, J BIOL CHEM, V276, P33518, DOI 10.1074/jbc.M101495200
   MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003
   MCREE DE, 1999, PRACTICAL PROTEIN CR
   Natesh R, 2003, NATURE, V421, P551, DOI 10.1038/nature01370
   Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8
   Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80
   Oudit GY, 2003, TRENDS CARDIOVAS MED, V13, P93, DOI 10.1016/S1050-1738(02)00233-5
   PANTOLIANO MW, 1984, BIOCHEMISTRY-US, V23, P1037, DOI 10.1021/bi00300a036
   PATCHETT AA, 1980, NATURE, V288, P280, DOI 10.1038/288280a0
   RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183
   Rockel B, 2002, EMBO J, V21, P5979, DOI 10.1093/emboj/cdf601
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X
   SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P3850, DOI 10.1021/bi00285a021
   SHAPIRO R, 1984, BIOCHEMISTRY-US, V23, P5234, DOI 10.1021/bi00317a022
   SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386
   Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Turner AJ, 2002, TRENDS PHARMACOL SCI, V23, P177, DOI 10.1016/S0165-6147(00)01994-5
   Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Zhang H, 2001, J BIOL CHEM, V276, P17132, DOI 10.1074/jbc.M006723200
NR 51
TC 159
Z9 178
U1 4
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 23
PY 2004
VL 279
IS 17
BP 17996
EP 18007
DI 10.1074/jbc.M311191200
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 812WU
UT WOS:000220870400135
PM 14754895
OA Bronze
DA 2020-04-03
ER

PT J
AU Casais, R
   Dove, B
   Cavanagh, D
   Britton, P
AF Casais, R
   Dove, B
   Cavanagh, D
   Britton, P
TI Recombinant avian infectious bronchitis virus expressing a heterologous
   spike gene demonstrates that the spike protein is a determinant of cell
   tropism
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CORONAVIRUS; HEPATITIS; ABILITY; FUSION; DOMAIN
AB A recombinant infectious bronchitis virus (IBV), BeauR-M41(S), was generated using our reverse genetics system (R. Casais, V. Thiel, S. G. Siddell, D. Cavanagh, and P. Britton, J. Virol. 75:12359-12369, 2001), in which the ectodomain region of the spike gene from IBV M41-CK replaced the corresponding region of the IBV Beaudette genome. BeauR-M41(S) acquired the same cell tropism phenotype as IBV M41-CK in four different cell types, demonstrating that the IBV spike glycoprotein is a determinant of cell tropism.
C1 Inst Anim Hlth, Div Mol Biol, Compton Lab, Newbury RG20 7NN, Berks, England.
RP Britton, P (reprint author), Inst Anim Hlth, Div Mol Biol, Compton Lab, Newbury RG20 7NN, Berks, England.
CR BRITTON P, 1991, NATURE, V353, P394, DOI 10.1038/353394a0
   Casais R, 2001, J VIROL, V75, P12359, DOI 10.1128/JVI.75.24.12359-12369.2001
   Cavanagh D, 2002, AVIAN PATHOL, V31, P81, DOI 10.1080/03079450120106651
   Cavanagh D, 2001, AVIAN PATHOL, V30, P109, DOI 10.1080/03079450120044506
   CAVANAGH D, 2003, DIS POULTRY, P101
   CAVANAGH D, 2001, AVIAN PATHOL, V30, P365
   Cook JKA, 2001, AVIAN PATHOL, V30, P423, DOI 10.1080/03079450120066421
   DARBYSHIRE JH, 1979, ARCH VIROL, V61, P227, DOI 10.1007/BF01318057
   Das Sarma J, 2000, J VIROL, V74, P9206, DOI 10.1128/JVI.74.19.9206-9213.2000
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   Godeke GJ, 2000, J VIROL, V74, P1566, DOI 10.1128/JVI.74.3.1566-1571.2000
   Hiscox JA, 2001, J VIROL, V75, P506, DOI 10.1128/JVI.75.1.506-512.2001
   KOCH G, 1990, J GEN VIROL, V71, P1929, DOI 10.1099/0022-1317-71-9-1929
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Luo ZL, 1999, J VIROL, V73, P8152, DOI 10.1128/JVI.73.10.8152-8159.1999
   Luo ZL, 1998, VIROLOGY, V244, P483, DOI 10.1006/viro.1998.9121
   Navas S, 2001, J VIROL, V75, P2452, DOI 10.1128/JVI.75.5.2452-2457.2001
   OTSUKI K, 1979, ARCH VIROL, V60, P115, DOI 10.1007/BF01348027
   Phillips JJ, 1999, J VIROL, V73, P7752, DOI 10.1128/JVI.73.9.7752-7760.1999
   Sanchez CM, 1999, J VIROL, V73, P7607
   SCHULTZE B, 1992, VIROLOGY, V89, P792
   SIDDELL SG, 1995, CORONAVIRIDAE, P1
NR 24
TC 159
Z9 179
U1 0
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD AUG
PY 2003
VL 77
IS 16
BP 9084
EP 9089
DI 10.1128/JVI.77.16.9084-9089.2003
PG 6
WC Virology
SC Virology
GA 706PU
UT WOS:000184462800048
PM 12885925
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU CAVANAGH, D
   DAVIS, PJ
   DARBYSHIRE, JH
   PETERS, RW
AF CAVANAGH, D
   DAVIS, PJ
   DARBYSHIRE, JH
   PETERS, RW
TI CORONAVIRUS IBV - VIRUS RETAINING SPIKE GLYCOPOLYPEPTIDE-S2 BUT NOT S1
   IS UNABLE TO INDUCE VIRUS-NEUTRALIZING OR HEMAGGLUTINATION-INHIBITING
   ANTIBODY, OR INDUCE CHICKEN TRACHEAL PROTECTION
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
RP CAVANAGH, D (reprint author), HOUGHTON POULTRY RES STN,HUNTINGDON PE17 2DA,CAMBS,ENGLAND.
CR BINNS MM, 1985, J GEN VIROL, V66, P719, DOI 10.1099/0022-1317-66-4-719
   BUCHMEIER MJ, 1984, VIROLOGY, V132, P262
   CAVANAGH D, 1983, J GEN VIROL, V64, P2577, DOI 10.1099/0022-1317-64-12-2577
   CAVANAGH D, 1986, VIRUS RES, V4, P133, DOI 10.1016/0168-1702(86)90037-7
   CAVANAGH D, 1984, AVIAN PATHOL, V13, P573, DOI 10.1080/03079458408418556
   CAVANAGH D, 1986, VIRUS RES, V4, P145, DOI 10.1016/0168-1702(86)90038-9
   CAVANAGH D, 1983, J GEN VIROL, V64, P1787, DOI 10.1099/0022-1317-64-8-1787
   DARBYSHIRE JH, 1980, AVIAN PATHOL, V9, P179, DOI 10.1080/03079458008418401
   DARBYSHIRE JH, 1985, AVIAN PATHOL, V14, P497, DOI 10.1080/03079458508436252
   DARBYSHIRE JH, 1984, RES VET SCI, V37, P77, DOI 10.1016/S0034-5288(18)31932-5
   DARBYSHIRE JH, 1979, ARCH VIROL, V61, P227, DOI 10.1007/BF01318057
   Garwes D.J., 1978, VET MICROBIOL, V3, P179
   HASONY HJ, 1981, ARCH VIROL, V69, P33, DOI 10.1007/BF01315263
   HAWKES RA, 1983, AVIAN PATHOL, V12, P331, DOI 10.1080/03079458308436175
   MOCKETT APA, 1981, AVIAN PATHOL, V10, P1, DOI 10.1080/03079458108418453
   MOCKETT APA, 1984, J GEN VIROL, V65, P2281, DOI 10.1099/0022-1317-65-12-2281
   MOREIN B, 1985, VACCINE, V3, P83, DOI 10.1016/0264-410X(85)90055-6
   SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0
   STERN DF, 1982, J VIROL, V44, P794, DOI 10.1128/JVI.44.3.794-803.1982
   WEGE H, 1984, J GEN VIROL, V65, P1931, DOI 10.1099/0022-1317-65-11-1931
NR 20
TC 159
Z9 188
U1 1
U2 2
PU SOC GENERAL MICROBIOLOGY
PI READING
PA HARVEST HOUSE 62 LONDON ROAD, READING, BERKS, ENGLAND RG1 5AS
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD JUL
PY 1986
VL 67
BP 1435
EP 1442
DI 10.1099/0022-1317-67-7-1435
PN 7
PG 8
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA D2948
UT WOS:A1986D294800020
PM 3014053
OA Bronze
DA 2020-04-03
ER

PT J
AU Liu, MT
   Keirstead, HS
   Lane, TE
AF Liu, MT
   Keirstead, HS
   Lane, TE
TI Neutralization of the chemokine CXCL10 reduces inflammatory cell
   invasion and demyelination and improves neurological function in a viral
   model of multiple sclerosis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; MOUSE HEPATITIS-VIRUS; T-CELLS; CORONAVIRUS
   INFECTION; IN-VIVO; EXPRESSION; MIG; PATHOGENESIS; RECEPTOR; LESIONS
AB Intracerebral infection of mice with mouse hepatitis virus (MHV) results in an acute encephalomyelitis followed by a chronic demyelinating disease with clinical and histological similarities with the human demyelinating disease multiple sclerosis (MS). Following MHV infection, chemokines including CXC chemokine ligand (CXCL)10 (IFN inducible protein 10 kDa), CXCL9 (monokine induced by IFN-gamma), and CC chemokine ligand 5 (RANTES) are expressed during both acute and chronic stages of disease suggesting a role for these molecules in disease exacerbation. Previous studies have shown that during the acute phase of infection, T lymphocytes are recruited into the CNS by the chemokines CXCL10 and CXCL9. In the present study, MHV-infected mice with established demyelination were treated with antisera against these two chemokines, and disease severity was assessed. Treatment with anti-CXCL10 reduced CD4(+) T lymphocyte and macrophage invasion, diminished expression of IFN-gamma and CC chemokine ligand 5, inhibited progression of demyelination, and increased remyelination. Anti-CXCL10 treatment also resulted in an impediment of clinical disease progression that was characterized by a dramatic improvement in neurological function. Treatment with antisera against CXCL9 was without effect, demonstrating a critical role for CXCL10 in inflammatory demyelination in this model. These findings document a novel therapeutic strategy using Ab-mediated neutralization of a key chemokine as a possible treatment for chronic human inflammatory demyelinating diseases such as MS.
C1 Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.
   Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.
   Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA 92697 USA.
RP Lane, TE (reprint author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3205 Biol Sci 2, Irvine, CA 92697 USA.
FU NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [NS37336-01, T32 NS07444]
CR Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873
   Bergmann CC, 1999, J IMMUNOL, V163, P3379
   Biddison WE, 1998, J IMMUNOL, V160, P444
   Blakemore WF, 1999, J NEUROIMMUNOL, V98, P69, DOI 10.1016/S0165-5728(99)00083-1
   Haring JS, 2001, J VIROL, V75, P3043, DOI 10.1128/JVI.75.6.3043-3047.2001
   HASPEL MV, 1978, P NATL ACAD SCI USA, V75, P4033, DOI 10.1073/pnas.75.8.4033
   Horwitz MS, 1997, NAT MED, V3, P1037, DOI 10.1038/nm0997-1037
   Houtman JJ, 1996, J NEUROVIROL, V2, P361, DOI 10.3109/13550289609146902
   Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A
   KOCSIS JD, 1999, J NEUROTRAUM, V8, P695
   Lane TE, 1998, J IMMUNOL, V160, P970
   Lane TE, 1997, TRENDS MICROBIOL, V5, P9, DOI 10.1016/S0966-842X(97)81768-4
   Lane TE, 2000, J VIROL, V74, P1415, DOI 10.1128/JVI.74.3.1415-1424.2000
   Liu MT, 2001, J IMMUNOL, V166, P1790, DOI 10.4049/jimmunol.166.3.1790
   Liu MT, 2000, J IMMUNOL, V165, P2327, DOI 10.4049/jimmunol.165.5.2327
   Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963
   Nagasato K, 1997, J NEUROIMMUNOL, V72, P21, DOI 10.1016/S0165-5728(96)00137-3
   PEARCE BD, 1994, J VIROL, V68, P5483, DOI 10.1128/JVI.68.9.5483-5495.1994
   Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4
   Redwine JM, 1998, J NEUROBIOL, V37, P413, DOI 10.1002/(SICI)1097-4695(19981115)37:3<413::AID-NEU7>3.0.CO;2-8
   Simpson JE, 2000, NEUROPATH APPL NEURO, V26, P133, DOI 10.1046/j.1365-2990.2000.026002133.x
   SMITH KJ, 1982, J NEUROL SCI, V54, P13, DOI 10.1016/0022-510X(82)90215-5
   Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150
   STOHLMAN SA, 1995, J VIROL, P69684
   Storch M, 1997, CURR OPIN NEUROL, V10, P186, DOI 10.1097/00019052-199706000-00004
   Tannenbaum CS, 1998, J IMMUNOL, V161, P927
   WANG FI, 1990, J NEUROIMMUNOL, V30, P31, DOI 10.1016/0165-5728(90)90050-W
   WANG FI, 1992, VIROLOGY, V186, P742, DOI 10.1016/0042-6822(92)90041-M
   WEINER LP, 1973, ARCH NEUROL-CHICAGO, V28, P298, DOI 10.1001/archneur.1973.00490230034003
   WILLIAMSON JSP, 1990, J VIROL, V64, P4589, DOI 10.1128/JVI.64.9.4589-4592.1990
   WILLIAMSON JSP, 1991, J NEUROIMMUNOL, V32, P199, DOI 10.1016/0165-5728(91)90189-E
   Wu GF, 1999, J VIROL, V73, P8771, DOI 10.1128/JVI.73.10.8771-8780.1999
   Wu GF, 2000, J IMMUNOL, V165, P2278, DOI 10.4049/jimmunol.165.4.2278
   YAMAGUCHI K, 1991, J NEUROIMMUNOL, V32, P1, DOI 10.1016/0165-5728(91)90065-F
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
NR 35
TC 158
Z9 169
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 1
PY 2001
VL 167
IS 7
BP 4091
EP 4097
DI 10.4049/jimmunol.167.7.4091
PG 7
WC Immunology
SC Immunology
GA 496JH
UT WOS:000172392100069
PM 11564831
OA Bronze
DA 2020-04-03
ER

PT J
AU Kocherhans, R
   Bridgen, A
   Ackermann, M
   Tobler, K
AF Kocherhans, R
   Bridgen, A
   Ackermann, M
   Tobler, K
TI Completion of the porcine epidemic diarrhoea coronavirus (PEDV) genome
   sequence
SO VIRUS GENES
LA English
DT Article
DE porcine epidemic diarrhoea virus; coronavirus; ORF1; replicase gene
ID TRANSMISSIBLE GASTROENTERITIS VIRUS; RNA-POLYMERASE; STRAIN A59; GENE;
   NIDOVIRALES; POLYPROTEIN; TRANSLATION; PSEUDOKNOT; KILOBASES; PROTEIN
AB The sequence of the replicase gene of porcine epidemic diarrhoea virus (PEDV) has been determined. This completes the sequence of the entire genome of strain CV777, which was found to be 28,033 nucleotides (nt) in length (excluding the poly A-tail). A cloning strategy, which involves primers based on conserved regions in the predicted ORF1 products from other coronaviruses whose genome sequence has been determined, was used to amplify the equivalent, but as yet unknown, sequence of PEDV. Primary sequences derived from these products were used to design additional primers resulting in the amplification and sequencing of the entire ORF1 of PEDV. Analysis of the nucleotide sequences revealed a small open reading frame (ORF) located near the 5' end (no 99-137), and two large, slightly overlapping ORFs, ORF1a (nt 297-12650) and ORF1b (nt 12605-20641). The ORF1a and ORF1b sequences overlapped at a potential ribosomal frame shift site. The amino acid sequence analysis suggested the presence of several functional motifs within the putative ORF1 protein. By analogy to other coronavirus replicase gene products, three protease and one growth factor-like motif were seen in ORF1a, and one polymerase domain, one metal ion-binding domain, and one helicase motif could be assigned within ORF1b. Comparative amino acid sequence alignments revealed that PEDV is most closely related to human coronavirus (HCoV)-229E and transmissible gastroenteritis virus (TGEV) and less related to murine hepatitis virus (MHV) and infectious bronchitis virus (IBV). These results thus confirm and extend the findings from sequence analysis of the structural genes of PEDV.
C1 Univ Zurich, Fak Vet Med, Inst Virol, CH-8057 Zurich, Switzerland.
   Univ Glasgow, Inst Biomed & Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland.
RP Tobler, K (reprint author), Univ Zurich, Fak Vet Med, Inst Virol, Winterthurerstr 266A, CH-8057 Zurich, Switzerland.
CR Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   BONILLA PJ, 1994, VIROLOGY, V198, P736, DOI 10.1006/viro.1994.1088
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   BRIDGEN A, 1993, J GEN VIROL, V74, P1795, DOI 10.1099/0022-1317-74-9-1795
   Bridgen A, 1998, ADV EXP MED BIOL, V440, P781
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   DUARTE M, 1994, J GEN VIROL, V75, P1195, DOI 10.1099/0022-1317-75-5-1195
   DUARTE M, 1994, VIROLOGY, V198, P4665
   EGBERINK HF, 1988, AM J VET RES, V49, P1320
   ELEOUET JF, 1995, VIROLOGY, V206, P817, DOI 10.1006/viro.1995.1004
   ELEOUET JF, 1995, ADV EXP MED BIOL, V3850, P459
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419
   Herold J, 1993, Arch Virol Suppl, V7, P63
   HEROLD J, 1993, NUCLEIC ACIDS RES, V21, P5838
   HOFMANN M, 1988, J CLIN MICROBIOL, V26, P2235, DOI 10.1128/JCM.26.11.2235-2239.1988
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   PACHUK CJ, 1989, VIROLOGY, V171, P141, DOI 10.1016/0042-6822(89)90520-5
   PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606
   PENSAERT MB, 1989, PORCINE EPIDEMIC DIA, P167
   SOE LH, 1987, J VIROL, V61, P3968, DOI 10.1128/JVI.61.12.3968-3976.1987
   THIEL V, 2000, EUR C VIR GLASG
   Tobler K, 1995, Adv Exp Med Biol, V380, P541
   UTIGER A, 1995, VIRUS GENES, V10, P137, DOI 10.1007/BF01702594
   Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 30
TC 157
Z9 203
U1 1
U2 41
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0920-8569
J9 VIRUS GENES
JI Virus Genes
PY 2001
VL 23
IS 2
BP 137
EP 144
DI 10.1023/A:1011831902219
PG 8
WC Genetics & Heredity; Virology
SC Genetics & Heredity; Virology
GA 473TP
UT WOS:000171064400002
PM 11724265
OA Bronze
DA 2020-04-03
ER

PT J
AU Reggiori, F
   Monastyrska, I
   Verheije, MH
   Cali, T
   Ulasli, M
   Bianchi, S
   Bernasconi, R
   de Haan, CAM
   Molinari, M
AF Reggiori, Fulvio
   Monastyrska, Iryna
   Verheije, Monique H.
   Cali, Tito
   Ulasli, Mustafa
   Bianchi, Siro
   Bernasconi, Riccardo
   de Haan, Cornelis A. M.
   Molinari, Maurizio
TI Coronaviruses Hijack the LC3-I-Positive EDEMosomes, ER-Derived Vesicles
   Exporting Short-Lived ERAD Regulators, for Replication
SO CELL HOST & MICROBE
LA English
DT Article
ID MISFOLDED GLYCOPROTEINS; ENDOPLASMIC-RETICULUM; MEMBRANE TOPOLOGY;
   QUALITY-CONTROL; CALNEXIN CYCLE; AUTOPHAGY; COMPLEX; MICE;
   IDENTIFICATION; DEGRADATION
AB Coronaviruses (CoV), including SARS and mouse hepatitis virus (MHV), are enveloped RNA viruses that induce formation of double-membrane vesicles (DMVs) and target their replication and transcription complexes (RTCs) on the DMV-limiting membranes. The DMV biogenesis has been connected with the early secretory pathway. Coy-induced DMVs, however, lack conventional endoplasmic reticulum (ER) or Golgi protein markers, leaving their membrane origins in question. We show that MHV co-opts the host cell machinery for COPII-independent vesicular ER export of a short-living regulator of ER-associated degradation (ERAD), EDEM1, to derive cellular membranes for replication. MHV infection causes accumulation of EDEM1 and OS-9, another short-living ER chaperone, in the DMVs. DMVs are coated with the nonlipidated LC3/Atg8 autophagy marker. Downregulation of LC3, but not inactivation of host cell autophagy, protects cells from CoV infection. Our study identifies the host cellular pathway hijacked for supplying Coy replication membranes and describes an autophagy-independent role for nonlipidated LC3-I.
C1 [Reggiori, Fulvio; Monastyrska, Iryna; Ulasli, Mustafa] Univ Med Ctr Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands.
   [Verheije, Monique H.; de Haan, Cornelis A. M.] Univ Utrecht, Dept Infect Dis & Immunol, Div Virol, NL-3508 TC Utrecht, Netherlands.
   [Cali, Tito; Bianchi, Siro; Bernasconi, Riccardo; Molinari, Maurizio] Inst Biomed Res, CH-6500 Bellinzona, Switzerland.
   [Cali, Tito] Univ Padua, Dept Biochem, I-35122 Padua, Italy.
   [Molinari, Maurizio] Ecole Polytech Fed Lausanne, Sch Life Sci, CH-1015 Lausanne, Switzerland.
RP Reggiori, F (reprint author), Univ Med Ctr Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands.
EM f.reggiori@umcutrecht.nl; c.a.m.dehaan@uu.nl;
   maurizio.molinari@irb.unisi.ch
RI Reggiori, Fulvio/U-8327-2019; Cali, Tito/K-5064-2016; Molinari,
   Maurizio/N-2587-2019
OI Cali, Tito/0000-0002-8901-1659; Molinari, Maurizio/0000-0002-7636-5829;
   Reggiori, Fulvio/0000-0003-2652-2686; Bianchi, Siro/0000-0002-5100-8905
FU Utrecht University; Foundation for Research on Neurodegenerative
   Diseases; Fondazione San Salvatore; Swiss National Center of Competence
   in Research on Neural Plasticity and Repair; Swiss National Science
   FoundationSwiss National Science Foundation (SNSF); ONELIFE Advisors SA
FX The authors thank S. Baker, A. Helenius, K. Kirkegaard, M. Komatsu, S.
   Siddell, and S. Tooze for reagents; P. van Kerkhof and E. te Lintelo for
   technical advices; and I. Pen for guidance on the statistics. C.A.M.d.H.
   and F.R. are supported by the Utrecht University (High Potential grant).
   M.M. is supported by grants from the Foundation for Research on
   Neurodegenerative Diseases, the Fondazione San Salvatore, the Swiss
   National Center of Competence in Research on Neural Plasticity and
   Repair, the Swiss National Science Foundation, and ONELIFE Advisors SA.
CR Bernasconi R, 2008, J BIOL CHEM, V283, P16446, DOI 10.1074/jbc.M802272200
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Cali T, 2008, PROG MOL BIOL TRANSL, V83, P135, DOI 10.1016/S0079-6603(08)00604-1
   Christianson JC, 2008, NAT CELL BIOL, V10, P272, DOI 10.1038/ncb1689
   de Haani CAM, 2008, AUTOPHAGY, V4, P276, DOI 10.4161/auto.5241
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Hebert DN, 2007, PHYSIOL REV, V87, P1377, DOI 10.1152/physrev.00050.2006
   Kanjanahaluethai A, 2007, VIROLOGY, V361, P391, DOI 10.1016/j.virol.2006.12.009
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Knoops K, 2010, J VIROL, V84, P833, DOI 10.1128/JVI.01826-09
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Le Fourn V, 2009, CELL MOL LIFE SCI, V66, P1434, DOI 10.1007/s00018-009-9038-1
   Miller S, 2008, NAT REV MICROBIOL, V6, P363, DOI 10.1038/nrmicro1890
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181
   Oostra M, 2007, J VIROL, V81, P12323, DOI 10.1128/JVI.01506-07
   Oostra M, 2008, J VIROL, V82, P12392, DOI 10.1128/JVI.01219-08
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Raaben M, 2007, CELL MICROBIOL, V9, P2218, DOI 10.1111/j.1462-5822.2007.00951.x
   Salonen A, 2005, CURR TOP MICROBIOL, V285, P139
   Sato K, 2007, FEBS LETT, V581, P2076, DOI 10.1016/j.febslet.2007.01.091
   Schiller JJ, 1998, VIROLOGY, V242, P288, DOI 10.1006/viro.1997.9010
   Slot JW, 2007, NAT PROTOC, V2, P2480, DOI 10.1038/nprot.2007.365
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Solda T, 2006, J BIOL CHEM, V281, P6219, DOI 10.1074/jbc.M513595200
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Ulasli M, 2010, CELL MICROBIOL, V12, P844, DOI 10.1111/j.1462-5822.2010.01437.x
   Verheije MH, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000088
   Waguri S, 2009, METHOD ENZYMOL, V453, P181, DOI 10.1016/S0076-6879(08)04009-3
   Yoshimori T, 2008, CURR OPIN CELL BIOL, V20, P401, DOI 10.1016/j.ceb.2008.03.010
   Zhao ZJ, 2007, AUTOPHAGY, V3, P581, DOI 10.4161/auto.4782
   Zuber C, 2007, P NATL ACAD SCI USA, V104, P4407, DOI 10.1073/pnas.0700154104
NR 38
TC 156
Z9 160
U1 0
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1931-3128
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD JUN 17
PY 2010
VL 7
IS 6
BP 500
EP 508
DI 10.1016/j.chom.2010.05.013
PG 9
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 616KV
UT WOS:000279209200010
PM 20542253
OA Bronze
DA 2020-04-03
ER

PT J
AU Gao, WT
   Tamin, A
   Soloff, A
   D'Aiuto, L
   Nwanegbo, E
   Robbins, PD
   Bellini, WJ
   Barratt-Boyes, S
   Gambotto, A
AF Gao, WT
   Tamin, A
   Soloff, A
   D'Aiuto, L
   Nwanegbo, E
   Robbins, PD
   Bellini, WJ
   Barratt-Boyes, S
   Gambotto, A
TI Effects of a SARS-associated coronavirus vaccine in monkeys
SO LANCET
LA English
DT Article
ID VIRUS
AB The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of coronavirus. Here, we have investigated the ability of adenoviral delivery of codon-optimised SARS-CoV strain Urbani structural antigens spike protein S1 fragment, membrane protein, and nucleocapsid protein to induce virus-specific broad immunity in rhesus macaques. We immunised rhesus macaques intramuscularly with a combination of the three Ads-SARS-CoV vectors or a control vector and gave a booster vaccination on day 28. The vaccinated animals all had antibody responses against spike protein S1 fragment and T-cell responses against the nucleocapsid protein. All vaccinated animals showed strong neutralising antibody responses to SARS-CoV infection in vitro. These results show that an adenoviral-based vaccine can induce strong SARS-CoV-specific immune responses in the monkey, and hold promise for development of a protective vaccine against the SARS causal agent.
C1 Univ Pittsburgh, Sch Med, Inst Mol Med, Dept Surg,Div Infect Dis, Pittsburgh, PA 15219 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
   Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA.
   Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Div Infect Dis, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15261 USA.
RP Gambotto, A (reprint author), Univ Pittsburgh, Sch Med, Inst Mol Med, Dept Surg,Div Infect Dis, Suite 412,300 Technol Dr, Pittsburgh, PA 15219 USA.
OI Soloff, Adam/0000-0002-1467-8168; D'Aiuto, Leonardo/0000-0002-7102-2093;
   Barratt Boyes, Simon/0000-0002-8869-4945
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [U01 HL66949-01S1]
CR Anton IM, 1996, VIRUS RES, V46, P111, DOI 10.1016/S0168-1702(96)01390-1
   BROWN K, IN PRESS J IMMUNOL
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   WEISS RC, 1981, COMP IMMUNOL MICROB, V4, P175, DOI 10.1016/0147-9571(81)90003-5
NR 5
TC 156
Z9 179
U1 5
U2 22
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD DEC 6
PY 2003
VL 362
IS 9399
BP 1895
EP 1896
DI 10.1016/S0140-6736(03)14962-8
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 750RN
UT WOS:000187011600012
PM 14667748
OA Bronze
DA 2020-04-03
ER

PT J
AU vanDinten, LC
   denBoon, JA
   Wassenaar, ALM
   Spaan, WJM
   Snijder, EJ
AF vanDinten, LC
   denBoon, JA
   Wassenaar, ALM
   Spaan, WJM
   Snijder, EJ
TI An infectious arterivirus cDNA clone: Identification of a replicase
   point mutation that abolishes discontinuous mRNA transcription
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE equine arteritis virus; nidoviruses; coronaviruses; replication;
   heterologous gene expression
ID EQUINE ARTERITIS VIRUS; MOUSE HEPATITIS-VIRUS; CORONAVIRUS
   TRANSCRIPTION; RNA-SYNTHESIS; EXPRESSION VECTORS; CYSTEINE PROTEASE;
   MESSENGER-RNAS; LENGTH CDNA; PAPAIN-LIKE; GENOME
AB Equine arteritis virus (EAV) is a positive- strand RNA virus that uses a discontinuous transcription mechanism to generate a nested set of six subgenomic mRNAs from which its structural genes are expressed, A stable bacterial plasmid (pEAV030) containing a full-length cDNA copy of the 12.7-kb EAV genome was constructed, After removal of a single point mutation in the replicase gene, RNA transcripts generated in vitro from pEAV030 were shown to be infectious upon electroporation into BHK-21 cells. A genetic marker mutation was introduced at the cDNA level and recovered from the genome of the progeny virus, The potential of pEAV030 as a tool to express foreign genes was demonstrated by the efficient expression of the chloramphenicol acetyltransferase (CAT) reporter gene from two different subgenomic mRNAs. The point mutation that initially rendered the full-length clone noninfectious was found to result in a particularly intriguing phenotype: RNA carrying this mutation can replicate efficiently but does not produce the subgenomic mRNAs required for structural protein expression. To our knowledge, this mutant provides the first evidence that the requirements for arterivirus genome replication and discontinuous mRNA synthesis are, at least partially, different and that these processes may be separated experimentally.
C1 LEIDEN UNIV,DEPT VIROL,INST MED MICROBIOL,NL-2300 RC LEIDEN,NETHERLANDS.
RI Snijder, Eric J./E-6073-2018
OI Snijder, Eric J./0000-0003-3297-2309
CR BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   BOYER JC, 1994, VIROLOGY, V198, P415, DOI 10.1006/viro.1994.1053
   BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993
   BREDENBEEK PJ, 1992, SEMIN VIROL, V3, P297
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   BROWN TDK, 1995, CORONAVIRIDAE, P191
   denBoon JA, 1996, J VIROL, V70, P4291, DOI 10.1128/JVI.70.7.4291-4298.1996
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   DENBOON JA, 1996, VIROLOGY, V213, P364
   DEVRIES AAF, 1995, J VIROL, V69, P4668, DOI 10.1128/JVI.69.8.4668-4674.1995
   DEVRIES AAF, 1992, J VIROL, V66, P6294, DOI 10.1128/JVI.66.11.6294-6303.1992
   DEVRIES AAF, 1990, NUCLEIC ACIDS RES, V18, P3241, DOI 10.1093/nar/18.11.3241
   DOLL E. R., 1957, CORNELL VET, V47, P3
   Dumas J. B., 1991, Nucleic Acids Research, V19, P5227, DOI 10.1093/nar/19.19.5227
   FICHOT O, 1990, NUCLEIC ACIDS RES, V18, P6162, DOI 10.1093/nar/18.20.6162
   GLASER AL, 1995, J GEN VIROL, V76, P2223, DOI 10.1099/0022-1317-76-9-2223
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2
   JEONG YS, 1992, J VIROL, V66, P3339, DOI 10.1128/JVI.66.6.3339-3346.1992
   LAI CJ, 1991, P NATL ACAD SCI USA, V88, P5139, DOI 10.1073/pnas.88.12.5139
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q
   LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356
   Meyers G, 1996, J VIROL, V70, P1588, DOI 10.1128/JVI.70.3.1588-1595.1996
   Moormann RJM, 1996, J VIROL, V70, P763, DOI 10.1128/JVI.70.2.763-770.1996
   PLAGEMANN PGW, 1996, FIELDS VIROLOGY, P1105
   RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391
   RICE C M, 1989, New Biologist, V1, P285
   RICE CM, 1987, J VIROL, V61, P3809, DOI 10.1128/JVI.61.12.3809-3819.1987
   Sambrook J., 1989, MOL CLONING LAB MANU
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   SAWICKI SG, 1995, CORONA RELATED VIRUS, P499
   SETHNA PB, 1991, J VIROL, V65, P320, DOI 10.1128/JVI.65.1.320-325.1991
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   Snijder E. J., 1995, The coronaviridae., P239
   Snijder EJ, 1996, J BIOL CHEM, V271, P4864, DOI 10.1074/jbc.271.9.4864
   SNIJDER EJ, 1992, J VIROL, V66, P7040, DOI 10.1128/JVI.66.12.7040-7048.1992
   SNIJDER EJ, 1995, J BIOL CHEM, V270, P16671, DOI 10.1074/jbc.270.28.16671
   SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   VANBERLO MF, 1982, VIROLOGY, V118, P345, DOI 10.1016/0042-6822(82)90354-3
   VANDERMOST RG, 1994, J VIROL, V68, P3656, DOI 10.1128/JVI.68.6.3656-3666.1994
   VANDERMOST RG, 1995, CORONAVIRIDAE, P11
   VANDERZEIJST BAM, 1975, VIROLOGY, V68, P418, DOI 10.1016/0042-6822(75)90283-4
   vanDinten LC, 1996, J VIROL, V70, P6625, DOI 10.1128/JVI.70.10.6625-6633.1996
   WANG CY, 1994, J VIROL, V68, P3550, DOI 10.1128/JVI.68.6.3550-3557.1994
   YOO D, 1995, CORONA RELATED VIRUS, P437
NR 48
TC 156
Z9 165
U1 1
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 4
PY 1997
VL 94
IS 3
BP 991
EP 996
DI 10.1073/pnas.94.3.991
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA WG234
UT WOS:A1997WG23400040
PM 9023370
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Chu, DKW
   Poon, LLM
   Guan, Y
   Peiris, JSM
AF Chu, D. K. W.
   Poon, L. L. M.
   Guan, Y.
   Peiris, J. S. M.
TI Novel astroviruses in insectivorous bats
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOLECULAR CHARACTERIZATION; GASTROENTERITIS; IDENTIFICATION;
   CORONAVIRUSES; CHILDREN; TURKEY; RNA; SEROTYPE-1; EXPRESSION; SEQUENCES
AB Bats are increasingly recognized to harbor a wide range of viruses, and in most instances these viruses appear to establish long-term persistence in these animals. They are the reservoir of a number of human zoonotic diseases including Nipah, Ebola, and severe acute respiratory syndrome. We report the identification of novel groups of astroviruses in apparently healthy insectivorous bats found in Hong Kong, in particular, bats belonging to the genera Miniopterus and Myotis. Astroviruses are important causes of diarrhea in many animal species, including humans. Many of the bat astroviruses form distinct phylogenetic clusters in the genus Mamastrovirus within the family Astroviridae. Virus detection rates of 36% to 100% and 50% to 70% were found in Miniopterus magnater and Miniopterus pusillus bats, respectively, captured within a single bat habitat during four consecutive visits spanning 1 year. There was high genetic diversity of viruses in bats found within this single habitat. Some bat astroviruses may be phylogenetically related to human astroviruses, and further studies with a wider range of bat species in different geographic locations are warranted. These findings are likely to provide new insights into the ecology and evolution of astroviruses and reinforce the role of bats as a reservoir of viruses with potential to pose a zoonotic threat to human health.
C1 [Chu, D. K. W.; Poon, L. L. M.; Guan, Y.; Peiris, J. S. M.] Univ Hong Kong, Dept Microbiol, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Peiris, J. S. M.] HKU Pasteur Res Ctr, Hong Kong, Hong Kong, Peoples R China.
RP Poon, LLM (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Univ Pathol Bldg, Pokfulam, Hong Kong, Peoples R China.
EM llmpoon@hkucc.hku.hk; malik@hkucc.hku.hk
RI Poon, Leo/C-4382-2009
OI Poon, Leo/0000-0002-9101-7953; Chu, Daniel Ka Wing/0000-0002-9219-8979;
   Guan, Yi/0000-0001-6057-9243
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HHSN266200700005C];
   University of Hong KongUniversity of Hong Kong; Department of
   Agriculture, Fisheries and Conservation, Hong Kong, Special
   Administrative Region, People's Republic of China
FX This project was supported by the National Institutes of Health (NIAID
   contract HHSN266200700005C) and by a Research Excellence Award to
   J.S.M.P. from The University of Hong Kong. The study was approved and
   supported by the Department of Agriculture, Fisheries and Conservation,
   Hong Kong, Special Administrative Region, People's Republic of China.
CR Caballero S, 2003, J MED VIROL, V71, P245, DOI 10.1002/jmv.10476
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Chu DKW, 2008, J GEN VIROL, V89, P1282, DOI 10.1099/vir.0.83605-0
   Chu DKW, 2006, J GEN VIROL, V87, P2461, DOI 10.1099/vir.0.82203-0
   Dalton RM, 2002, PEDIATR INFECT DIS J, V21, P1038, DOI 10.1097/00006454-200211000-00012
   Gallimore CI, 2005, J CLIN MICROBIOL, V43, P3890, DOI 10.1128/JCM.43.8.3890-3894.2005
   Geigenmuller U, 2002, J GEN VIROL, V83, P1691, DOI 10.1099/0022-1317-83-7-1691
   HERRMANN JE, 1991, NEW ENGL J MED, V324, P1757, DOI 10.1056/NEJM199106203242501
   JIANG BM, 1993, P NATL ACAD SCI USA, V90, P10539, DOI 10.1073/pnas.90.22.10539
   Jonassen CM, 1998, J GEN VIROL, V79, P715, DOI 10.1099/0022-1317-79-4-715
   Jonassen CM, 2003, VIRUS RES, V91, P195, DOI 10.1016/S0168-1702(02)00269-1
   Krishna NK, 2005, VIRAL IMMUNOL, V18, P17, DOI 10.1089/vim.2005.18.17
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   LEWIS DC, 1989, J HOSP INFECT, V14, P9, DOI 10.1016/0195-6701(89)90128-X
   Lewis TL, 1996, J VIROL, V70, P2869, DOI 10.1128/JVI.70.5.2869-2875.1996
   LEWIS TL, 1994, J VIROL, V68, P77, DOI 10.1128/JVI.68.1.77-83.1994
   Mendez E, 2002, J VIROL, V76, P7996, DOI 10.1128/JVI.76.16.7996-8002.2002
   Mendez E, 2007, FIELDS VIROLOGY, P981
   Mihindukulasuriya KA, 2008, J VIROL, V82, P5084, DOI 10.1128/JVI.02722-07
   Mittelholzer C, 2003, J GEN VIROL, V84, P3087, DOI 10.1099/vir.0.19267-0
   Pantin-Jackwood MJ, 2006, AVIAN DIS, V50, P397, DOI 10.1637/7512-020606R.1
   Pantin-Jackwood MJ, 2006, VIRUS GENES, V32, P187, DOI 10.1007/s11262-005-6875-3
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Silva PA, 2006, ARCH VIROL, V151, P1405, DOI 10.1007/s00705-005-0704-9
   Strain E, 2008, J VIROL, V82, P5099, DOI 10.1128/JVI.01993-07
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vijaykrishna D, 2007, J VIROL, V81, P4012, DOI 10.1128/JVI.02605-06
NR 30
TC 155
Z9 160
U1 0
U2 27
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2008
VL 82
IS 18
BP 9107
EP 9114
DI 10.1128/JVI.00857-08
PG 8
WC Virology
SC Virology
GA 347OX
UT WOS:000259152000015
PM 18550669
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Devaraj, SG
   Wang, N
   Chen, Z
   Chen, Z
   Tseng, M
   Barretto, N
   Lin, R
   Peters, CJ
   Tseng, CTK
   Baker, SC
   Li, K
AF Devaraj, Santhana G.
   Wang, Nan
   Chen, Zhongbin
   Chen, Zihong
   Tseng, Monica
   Barretto, Naina
   Lin, Rongtuan
   Peters, Clarence J.
   Tseng, Chien-Te K.
   Baker, Susan C.
   Li, Kui
TI Regulation of IRF-3-dependent innate immunity by the papain-like
   protease domain of the severe acute respiratory syndrome coronavirus
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NF-KAPPA-B; DOUBLE-STRANDED-RNA; MOUSE HEPATITIS-VIRUS; RIG-I; ADAPTER
   PROTEIN; INTERFERON INDUCTION; ANTIVIRAL RESPONSES; CELLULAR-RESPONSE;
   IKK-EPSILON; ACTIVATION
AB Severe acute respiratory syndrome coronavirus ( SARS-CoV) is a novel coronavirus that causes a highly contagious respiratory disease, SARS, with significant mortality. Although factors contributing to the highly pathogenic nature of SARS-CoV remain poorly understood, it has been reported that SARS-CoV infection does not induce type I interferons ( IFNs) in cell culture. However, it is uncertain whether SARS-CoV evades host detection or has evolved mechanisms to counteract innate host defenses. We show here that infection of SARS-CoV triggers a weak IFN response in cultured human lung/bronchial epithelial cells without inducing the phosphorylation of IFN-regulatory factor 3 ( IRF-3), a latent cellular transcription factor that is pivotal for type I IFN synthesis. Furthermore, SARS-CoV infection blocked the induction of IFN antiviral activity and the up-regulation of protein expression of a subset of IFN-stimulated genes triggered by double-stranded RNA or an unrelated paramyxovirus. In searching for a SARS-CoV protein capable of counteracting innate immunity, we identified the papain-like protease ( PLpro) domain as a potent IFN antagonist. The inhibition of the IFN response does not require the protease activity of PLpro. Rather, PLpro interacts with IRF-3 and inhibits the phosphorylation and nuclear translocation of IRF-3, thereby disrupting the activation of type I IFN responses through either Toll-like receptor 3 or retinoic acid-inducible gene I/melanoma differentiation-associated gene 5 pathways. Our data suggest that regulation of IRF-3-dependent innate antiviral defenses by PLpro may contribute to the establishment of SARS-CoV infection.
C1 Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   Univ Texas, Med Branch, Ctr Biodef & Emerging Infect Dis, Inst Human Infect & Immun, Galveston, TX 77555 USA.
   Loyola Univ, Dept Microbiol & Immunol, Maywood, IL 60153 USA.
   Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
RP Li, K (reprint author), Univ Texas, Med Branch, Dept Microbiol & Immunol, 4-142G Blocker Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.
EM kuli@utmb.edu
RI Lin, Rongtuan/A-1442-2008; Chen, Zhongbin/C-5259-2009
OI Lin, Rongtuan/0000-0002-2238-3503; 
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U54 AI057156-05S10038, R01 AI069285-01A2,
   AI057156, R01 AI045798-01A2, N01 AI030039-009, R56 AI069285, R01
   AI069285, AI45798, AI069285, U54 AI057156, AI060915, N01AI30039, R01
   AI045798, P01 AI060915, P01 AI060915-030001, AI30039]; NIDA NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [R21 DA018054-01, DA018054, R21 DA018054]
CR Akazawa T, 2007, P NATL ACAD SCI USA, V104, P252, DOI 10.1073/pnas.0605978104
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770
   Chen ZH, 2007, VIROLOGY, V366, P277, DOI 10.1016/j.virol.2007.04.023
   Chen ZH, 2007, J VIROL, V81, P964, DOI 10.1128/JVI.02076-06
   Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758
   Collins SE, 2004, J VIROL, V78, P1706, DOI 10.1128/JVI.78.4.1706-1717.2004
   Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616
   Ehrhardt C, 2004, FEBS LETT, V567, P230, DOI 10.1016/j.febslet.2004.04.069
   Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933
   EMENY JM, 1979, J GEN VIROL, V43, P247, DOI 10.1099/0022-1317-43-1-247
   Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921
   Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604
   Fries KL, 1999, VIROLOGY, V264, P159, DOI 10.1006/viro.1999.9980
   Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Goutagny N, 2006, NAT IMMUNOL, V7, P555, DOI 10.1038/ni0606-555
   Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505
   Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734
   Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243
   Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   KRIKOS A, 1992, J BIOL CHEM, V267, P17971
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Langford M P, 1981, Methods Enzymol, V78, P339
   Li K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200
   Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102
   Li K, 2002, HEPATOLOGY, V35, P1237, DOI 10.1053/jhep.2002.32968
   Li ZJ, 2006, J VIROL, V80, P11115, DOI 10.1128/JVI.00993-06
   Lin RT, 2006, J BIOL CHEM, V281, P2095, DOI 10.1074/jbc.M510326200
   Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Liu YC, 2005, NAT REV IMMUNOL, V5, P941, DOI 10.1038/nri1731
   Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MCKIMMBRESCHKIN JL, 1982, INFECT IMMUN, V36, P857, DOI 10.1128/IAI.36.3.857-863.1982
   Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193
   Meylan E, 2006, MOL CELL, V22, P561, DOI 10.1016/j.molcel.2006.05.012
   Mossel EC, 2005, J VIROL, V79, P3846, DOI 10.1128/JVI.79.6.3846-3850.2005
   Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199
   Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998
   Quinlivan M, 2005, J VIROL, V79, P8431, DOI 10.1128/JVI.79.13.8431-8439.2005
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887
   Ronni T, 1998, J INTERF CYTOK RES, V18, P773, DOI 10.1089/jir.1998.18.773
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sen GC, 2005, CYTOKINE GROWTH F R, V16, P1, DOI 10.1016/j.cytogfr.2005.01.006
   Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255
   Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200
   Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012
   Seth RB, 2006, CELL RES, V16, P141, DOI 10.1038/sj.cr.7310019
   Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Solorzano A, 2005, J VIROL, V79, P7535, DOI 10.1128/JVI.79.12.7535-7543.2005
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Stetson DB, 2006, IMMUNITY, V25, P373, DOI 10.1016/j.immuni.2006.08.007
   Tseng CTK, 2005, J VIROL, V79, P9470, DOI 10.1128/JVI.79.15.9470-9479.2005
   Versteeg GA, 2007, VIROLOGY, V361, P18, DOI 10.1016/j.virol.2007.01.020
   Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359
   Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014
   Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668
   Yang Y, 2007, P NATL ACAD SCI USA, V104, P7253, DOI 10.1073/pnas.0611506104
   Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087
   Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087
   Yoneyama M, 2002, J INTERF CYTOK RES, V22, P73, DOI 10.1089/107999002753452674
   Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005
   Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110
   Zhou HX, 2007, J VIROL, V81, P568, DOI 10.1128/JVI.01512-06
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
   Ziebuhr J, 2006, ADV EXP MED BIOL, V581, P3
NR 80
TC 155
Z9 171
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 2
PY 2007
VL 282
IS 44
BP 32208
EP 32221
DI 10.1074/jbc.M704870200
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 224WY
UT WOS:000250480300044
PM 17761676
OA Green Accepted, Bronze
DA 2020-04-03
ER

PT J
AU Lee, WM
   Grindle, K
   Pappas, T
   Marshall, DJ
   Moser, MJ
   Beaty, EL
   Shult, PA
   Prudent, JR
   Gern, JE
AF Lee, Wai-Ming
   Grindle, Kris
   Pappas, Tressa
   Marshall, David J.
   Moser, Michael J.
   Beaty, Edward L.
   Shult, Peter A.
   Prudent, James R.
   Gern, James E.
TI High-throughput, sensitive, and accurate multiplex PCR-microsphere flow
   Cytometry system for large-scale comprehensive detection of respiratory
   viruses
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID ENZYME HYBRIDIZATION ASSAY; REVERSE TRANSCRIPTION-PCR;
   POLYMERASE-CHAIN-REACTION; SYNCYTIAL-VIRUS; CORONAVIRUS HKU1; CLINICAL
   SPECIMENS; TRACT INFECTIONS; HUMAN BOCAVIRUS; VIRAL CULTURE;
   UNITED-STATES
AB Human respiratory viruses are a diverse group of pathogens composed of hundreds of virus strains, and this presents a major challenge for diagnostic laboratories. To efficiently detect numerous viruses in a large epidemiologic study, we developed a fast, multitarget, sensitive, and specific assay named the Respiratory MultiCode-PLx Assay (RMA). The RMA utilizes improved multiplex PCR chemistry (EraGen MultiCode-PLx technology) coupled with high-throughput microsphere flow cytometry (Luminex). Eighteen sets of virus-specific multiplex PCR primers were developed based on the conserved sequences of all available respiratory-virus sequences for eight distinct groups: human rhinovirus (HRV), respiratory syncytial virus (RSV), parainfluenza virus (PIV), influenza virus (InfV), metapneumovirus, adenovirus (Ad), coronavirus, and enterovirus. Each primer set detected 20 cDNA copies of the intended target per sample and had no reaction with 60,000 copies of human genomic DNA. The accuracy and sensitivity of the RMA for detecting respiratory viruses in human samples were tested with two sets of clinical specimens. First, 101 nasal-wash specimens that were positive for HRV, RSV, InfV, PIV, or Ad by traditional techniques were reanalyzed by RMA, and all target viruses were detected with an overall sensitivity of 94% and specificity of 99%. Second, 103 nasal-wash samples from 5-year-old children with asthma and respiratory symptoms were analyzed; RMA detected viruses in 74 specimens (71.8%) compared to only 24 (23.3%) by traditional culture and immunofluorescent-staining techniques. These results show that RMA is an accurate, sensitive, and practical test for respiratory-virus infections.
C1 Univ Wisconsin, Dept Pediat & Med, Madison, WI USA.
   Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA.
   EraGen Biosci Inc, Madison, WI USA.
RP Lee, WM (reprint author), Univ Wisconsin Hosp, H4-469,600 Highland Ave, Madison, WI 53792 USA.
EM wlee5@wisc.edu
OI Prudent, James/0000-0002-8948-1781
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI070503]
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   AUSUBEL FM, CURRENT PROTOCOLS MO, P87
   Beasley R, 2002, J ALLERGY CLIN IMMUN, V109, pS482, DOI 10.1067/mai.2002.122716
   CHAPMAN NM, 1990, J CLIN MICROBIOL, V28, P843, DOI 10.1128/JCM.28.5.843-850.1990
   Coiras MT, 2005, J MED VIROL, V76, P256, DOI 10.1002/jmv.20350
   Coiras MT, 2004, J MED VIROL, V72, P484, DOI 10.1002/jmv.20008
   COUCH RB, 2001, FIELDS VIROLOGY, V1, P777
   DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Esper F, 2006, EMERG INFECT DIS, V12, P775, DOI 10.3201/eid1205.051316
   Fan J, 1998, CLIN INFECT DIS, V26, P1397, DOI 10.1086/516357
   Foulongne V, 2006, EMERG INFECT DIS, V12, P862, DOI 10.3201/eid1205.051523
   Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x
   Gern JE, 2003, PEDIATR CLIN N AM, V50, P555, DOI 10.1016/S0031-3955(03)00040-3
   Grondahl B, 1999, J CLIN MICROBIOL, V37, P1
   Henrickson KJ, 2004, PEDIATR INFECT DIS J, V23, pS6, DOI 10.1097/01.inf.0000108187.63151.ea
   Hindiyeh M, 2001, AM J CLIN PATHOL, V116, P218
   Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390
   Johnson SC, 2004, CLIN CHEM, V50, P2019, DOI 10.1373/clinchem.2004.034330
   Johnston Sebastian L, 2005, Proc Am Thorac Soc, V2, P150, DOI 10.1513/pats.200502-018AW
   Keller MB, 2002, SEMIN RESP CRIT CARE, V23, P317, DOI 10.1055/s-2002-34327
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee SH, 2003, J MICROELECTROMECH S, V12, P848, DOI 10.1109/JMEMS.2003.820292
   Lee WM, 2003, J VIROL, V77, P6235, DOI 10.1128/JVI.77.11.6235-6244.2003
   LEE WM, 1993, J VIROL, V67, P2110, DOI 10.1128/JVI.67.4.2110-2122.1993
   Lemanske RF, 2002, PEDIATR ALLERGY IMMU, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x
   Lemanske RF, 2004, J ALLERGY CLIN IMMUN, V114, P1023, DOI 10.1016/j.jaci.2004.08.031
   Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024
   Liolios L, 2001, J CLIN MICROBIOL, V39, P2779, DOI 10.1128/JCM.39.8.2779-2783.2001
   Ma XM, 2006, J CLIN MICROBIOL, V44, P1132, DOI 10.1128/JCM.44.3.1132-1134.2006
   MIFFLIN TE, 2003, [No title captured], P5
   Nolan JP, 2006, CYTOM PART A, V69A, P318, DOI 10.1002/cyto.a.20266
   Novinska MS, 2006, GENE, V376, P95, DOI 10.1016/j.gene.2006.02.016
   Pehler-Harrington K, 2004, J CLIN MICROBIOL, V42, P4072, DOI 10.1128/JCM.42.9.4072-4076.2004
   Pietz BC, 2005, HUM IMMUNOL, V66, P1174, DOI 10.1016/j.humimm.2005.08.243
   Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC
   Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076
   Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5
   STORCH GA, 2001, FIELDS VIROLOGY, P493
   Syrmis MW, 2004, J MOL DIAGN, V6, P125, DOI 10.1016/S1525-1578(10)60500-4
   Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vabret A, 2006, CLIN INFECT DIS, V42, P634, DOI 10.1086/500136
   Van den Hoogen BG, 2004, PEDIATR INFECT DIS J, V23, pS25, DOI 10.1097/01.inf.0000108190.09824.e8
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   van Elden LJR, 2002, CLIN INFECT DIS, V34, P177, DOI 10.1086/338238
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
NR 48
TC 155
Z9 166
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD AUG
PY 2007
VL 45
IS 8
BP 2626
EP 2634
DI 10.1128/JCM.02501-06
PG 9
WC Microbiology
SC Microbiology
GA 200WK
UT WOS:000248793300039
PM 17537928
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Ding, YQ
   Wang, HJ
   Shen, H
   Li, ZG
   Geng, J
   Han, HX
   Cai, JJ
   Li, X
   Kang, W
   Weng, DS
   Lu, YD
   Wu, DH
   He, L
   Yao, KT
AF Ding, YQ
   Wang, HJ
   Shen, H
   Li, ZG
   Geng, J
   Han, HX
   Cai, JJ
   Li, X
   Kang, W
   Weng, DS
   Lu, YD
   Wu, DH
   He, L
   Yao, KT
TI The clinical pathology of severe acute respiratory syndrome (SARS): a
   report from China
SO JOURNAL OF PATHOLOGY
LA English
DT Article
AB In order to investigate the clinical pathology of severe acute respiratory syndrome (SARS), the autopsies of three patients who died from SARS in Nan Fang Hospital Guangdong, China were studied retrospectively. Routine haematoxylin and eosin (H&E) staining was used to study all of the tissues from the three cases. The lung tissue specimens were studied further with Macchiavello staining, viral inclusion body staining, reticulin staining, PAS staining, immunohistochemistry, ultrathin sectioning and staining, light microscopy, and transmission electron microscopy. The first symptom was hyperpyrexia in all three cases, followed by progressive dyspnoea and lung field shadowing. The pulmonary lesions included bilateral extensive consolidation, localized haemorrhage and necrosis, desquamative pulmonary alveolitis and bronchitis, proliferation and desquamation of alveolar epithelial cells, exudation of protein and monocytes, lymphocytes and plasma cells in alveoli, hyaline membrane formation, and viral inclusion bodies in alveolar epithelial cells. There was also massive necrosis of splenic lymphoid tissue and localized necrosis in lymph nodes. Systemic vasculitis included oedema, localized fibrinoid necrosis, and infiltration of monocytes, lymphocytes, and plasma cells into vessel walls in the heart, lung, liver, kidney, adrenal gland, and the stroma of striated muscles. Thrombosis was present in small veins. Systemic toxic changes included degeneration and necrosis of the parenchyma cells in the lung, liver, kidney, heart, and adrenal gland. Electron microscopy demonstrated clusters of viral particles, consistent with coronavirus, in lung tissue. SARS is a systemic disease that injures many organs. The lungs, immune organs, and systemic small vessels are the main targets of virus attack, so that extensive consolidation of the lung, diffuse alveolar damage with hyaline membrane formation, respiratory distress, and decreased immune function are the main causes of death. Copyright (C) 2003 John Wiley Sons, Ltd.
C1 First Mil Med Univ, Dept Pathol, Nan Fang Hosp, Guangzhou 510515, Guangdong Prov, Peoples R China.
RP Ding, YQ (reprint author), First Mil Med Univ, Dept Pathol, Nan Fang Hosp, Guangzhou 510515, Guangdong Prov, Peoples R China.
RI KANG, Wei/C-5451-2016
OI KANG, Wei/0000-0002-4651-677X
CR Luby JP, 1999, J CLIN VIROL, V12, P43, DOI 10.1016/S0928-0197(98)00067-1
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1
   THOMAS G, 2003, NEW ENGL J MED, V348, P1953
   TSANG KW, 2003, NEW ENGL J MED, V348, P1
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   2003, MORB MORTAL WKLY REP, V52, P241
NR 6
TC 155
Z9 175
U1 8
U2 19
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0022-3417
J9 J PATHOL
JI J. Pathol.
PD JUL
PY 2003
VL 200
IS 3
BP 282
EP 289
DI 10.1002/path.1440
PG 8
WC Oncology; Pathology
SC Oncology; Pathology
GA 697FJ
UT WOS:000183931300002
PM 12845623
OA Bronze
DA 2020-04-03
ER

PT J
AU Pizzichini, MMM
   Pizzichini, E
   Efthimiadis, A
   Chauhan, AJ
   Johnston, SL
   Hussack, P
   Mahony, J
   Dolovich, J
   Hargreave, FE
AF Pizzichini, MMM
   Pizzichini, E
   Efthimiadis, A
   Chauhan, AJ
   Johnston, SL
   Hussack, P
   Mahony, J
   Dolovich, J
   Hargreave, FE
TI Asthma and natural colds - Inflammatory indices in induced sputum: A
   feasibility study
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
ID COMMON COLD; AIRWAY INFLAMMATION; VIRUS; RHINOVIRUS; INFECTION;
   CHILDREN; INTERLEUKIN-8; EXACERBATIONS; EXPRESSION; ACTIVATION
AB We examined the feasibility of using induced sputum to evaluate the airway inflammatory response to natural acute respiratory virus infections. We recruited eight asthmatics and nine healthy subjects on Day 4 of a cold. Viral infection was confirmed in six of the asthmatics (influenza A or B) and six of the healthy subjects (influenza A, rhinovirus, adenovirus, respiratory syncytial virus, and coronavirus). In the subjects with confirmed virus infection, five of the asthmatics had an objective exacerbation of asthma during the cold. Their sputum on Day 4 showed a high median total cell count of 19.7 x 10(6) cells/ml with a modest neutrophilia (58.5%) and high levels of interleukin-8 (IL-8) (16,000 pg/ml), eosinophilic cationic protein (ECP) (1,880 mu g/L) and very high levels of fibrinogen (250 mg/L). In contrast, the proportion (1.3%) and absolute number of eosinophils was low. IL-2 levels were within the normal range, whereas IL-5 and interferon gamma were under the limit of detection of the assays. In the healthy subjects with a confirmed virus infection the sputum findings were qualitatively similar but significantly less prominent. Sputum IL-8 on Day 4 was strongly correlated with neutrophils (rs = 0.8, p < 0.001). This correlation was also significant when each group was analyzed separately. On Day 21 there was a fall in the absolute number of neutrophils and in ECP and fibrinogen levels in both groups. Similar results were found in the two asthmatic and three healthy subjects with a cold of comparable severity but in whom viral infection was not confirmed. We conclude that induced sputum examination can be used to study the effects of natural colds and influenza on the airways of the lungs. The results also suggest that natural colds, on Day 4 cause neutrophilic lower airway inflammation that is greater in asthmatics than in healthy subjects. The greater inflammatory response in asthmatics may be due to the changes associated with trivial eosinophilia or to the different viruses involved.
C1 St Josephs Hosp, Firestone Reg Chest & Allergy Unit, Asthma Res Grp, Dept Med, Hamilton, ON L8N 4A6, Canada.
   St Josephs Hosp, Dept Paediat, Hamilton, ON L8N 4A6, Canada.
   McMaster Univ, Hamilton, ON, Canada.
   Univ Southampton, Dept Med, Southampton, Hants, England.
RP Hargreave, FE (reprint author), St Josephs Hosp, Firestone Reg Chest & Allergy Unit, Asthma Res Grp, Dept Med, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.
RI Pizzichini, Marcia/K-5168-2013; Johnston, Sebastian Lennox/I-2423-2012;
   Pizzichini, Emilio/L-2252-2014
OI Pizzichini, Marcia/0000-0001-7409-7536; Johnston, Sebastian
   Lennox/0000-0003-3009-9200; Pizzichini, Emilio/0000-0001-7046-9996;
   Pizzichini, Marcia/0000-0001-6336-7203
CR AKERLUND A, 1993, ACTA OTO-LARYNGOL, V113, P642, DOI 10.3109/00016489309135878
   [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285
   BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265
   Busse WW, 1997, J ALLERGY CLIN IMMUN, V100, P147, DOI 10.1016/S0091-6749(97)70216-1
   CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581
   CHAUHAN AJ, 1997, ADV DIAGNOSIS RESP V
   CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659
   Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858
   Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163
   FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879
   GREIFF L, 1994, THORAX, V49, P121, DOI 10.1136/thx.49.2.121
   Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609
   GRUNBERG K, 1995, CLIN EXP ALLERGY, V156, P609
   HENNET T, 1992, J IMMUNOL, V149, P932
   HSIA J, 1990, J INFECT DIS, V162, P591, DOI 10.1093/infdis/162.3.591
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601
   JUNIPER EF, 1994, HISTAMINE METHACHOLI
   Keatings VM, 1997, AM J RESP CRIT CARE, V155, P449, DOI 10.1164/ajrccm.155.2.9032177
   Mastronarde JG, 1996, J INFECT DIS, V174, P262, DOI 10.1093/infdis/174.2.262
   Matsukura S, 1996, J ALLERGY CLIN IMMUN, V98, P1080, DOI 10.1016/S0091-6749(96)80195-3
   MESCHIEVITZ CK, 1984, J INFECT DIS, V150, P195, DOI 10.1093/infdis/150.2.195
   NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133
   Pepys J., 1975, CLIN ASPECTS IMMUNOL, P55
   PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25
   Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799
   PIZZICHINI E, 1998, IN PRESS AM J RESP C
   Pizzichini M. M. M., 1997, European Respiratory Journal Supplement, V10, p183S
   Pizzichini MMM, 1997, AM J RESP CRIT CARE, V155, P1501, DOI 10.1164/ajrccm.155.5.9154849
   SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067
   Sur S, 1998, J LEUKOCYTE BIOL, V63, P715
   Teran LM, 1997, AM J RESP CRIT CARE, V155, P1362, DOI 10.1164/ajrccm.155.4.9105080
   Trigg CJ, 1996, CLIN EXP ALLERGY, V26, P665, DOI 10.1046/j.1365-2222.1996.1070446.x
   Wimalasundera SS, 1997, J INFECT DIS, V176, P755, DOI 10.1086/514101
NR 34
TC 155
Z9 160
U1 0
U2 2
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD OCT
PY 1998
VL 158
IS 4
BP 1178
EP 1184
DI 10.1164/ajrccm.158.4.9712082
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 129FN
UT WOS:000076453300027
PM 9769279
DA 2020-04-03
ER

PT J
AU Tresnan, DB
   Levis, R
   Holmes, KV
AF Tresnan, DB
   Levis, R
   Holmes, KV
TI Feline aminopeptidase N serves as a receptor for feline, canine,
   porcine, and human coronaviruses in serogroup I
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID INFECTIOUS PERITONITIS VIRUS; TRANSMISSIBLE GASTROENTERITIS VIRUS;
   AMINO-ACID SEQUENCE; EXPERIMENTAL INOCULATION; SUBSEQUENT CHALLENGE;
   BOVINE CORONAVIRUS; CATS; GLYCOPROTEIN; KIDNEY; DETERMINANT
AB Two members of coronavirus serogroup I, human respiratory coronavirus HCV-229E and porcine transmissible gastroenteritis virus (TGEV), use aminopeptidase N (APN) as their cellular receptors. These viruses show marked species specificity in receptor utilization, as HCV-229E can utilize human but not porcine APN, while TGEV can utilize porcine but not human APN. To determine whether feline APN could serve as a receptor for two feline coronaviruses in serogroup I, feline infectious peritonitis virus (FIPV) and feline enteric coronavirus (FeCV), we cloned the cDNA encoding feline APN (fAPN) by PCR from cDNA isolated from a feline cell line and stably expressed it in FIPV- and FeCV-resistant mouse and hamster cells. The predicted amino acid sequence of fAPN shows 78 and 77% identity with human and porcine APN, respectively, When inoculated with either of two biologically different strains of FIPV or with FeCV, fAPN-transfected mouse and hamster cells became infected and viral antigens developed in the cytoplasm, Infectious FIPV was released from hamster cells stably transfected with fAPN, The fAPN-transfected mouse and hamster cells were challenged with other coronaviruses in serogroup I including canine coronavirus, porcine coronavirus TGEV, and human coronavirus HCV-229E. In addition to serving as a receptor for the feline coronaviruses, fAPN also served as a functional receptor for each of these serogroup I coronaviruses as shown by development of viral antigens in the cytoplasm of infected mouse or hamster cells stably transfected with fAPN, In contrast, fAPN did not serve as a functional receptor for mouse hepatitis virus (MHV-A59), which is in serogroup II and utilizes mouse biliary glycoprotein receptors unrelated to APN, Thus, fAPN serves as a receptor for a much broader range of group I coronaviruses than human and porcine APNs. The human, porcine, and canine coronaviruses in serogroup I that are able to use fAPN as a receptor have previously been shown to infect cats without causing disease, Therefore, host factors in addition to receptor specificity apparently affect the virulence and transmissibility of nonfeline serogroup I coronaviruses in the cat.
C1 UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814.
RP Tresnan, DB (reprint author), UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL,4200 E 9TH AVE,BOX B-175,DENVER,CO 80262, USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [K11 AI01151, AI26075]
CR BARLOUGH JE, 1985, CAN J COMP MED, V49, P303
   BARLOUGH JE, 1984, LAB ANIM SCI, V34, P592
   BARLOUGH JE, 1990, INFECT DIS, P300
   Boyle J F, 1984, Adv Exp Med Biol, V173, P133
   CASTRUCCI MR, 1993, VIROLOGY, V193, P503, DOI 10.1006/viro.1993.1155
   COMPTON SR, 1992, J VIROL, V66, P7420, DOI 10.1128/JVI.66.12.7420-7428.1992
   DELMAS B, 1994, J VIROL, V68, P5216, DOI 10.1128/JVI.68.8.5216-5224.1994
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   DELMAS B, 1994, ADV EXP MED BIOL, V342, P293
   DVEKSLER GS, 1993, J VIROL, V67, P1
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255
   Holmberg C. A., 1973, Feline Practice, V3, P11
   HOLMES KV, 1995, CORONAVIRIDAE, P55
   Holmes KV, 1996, VIROLOGY, P1075
   Keck J G, 1987, Adv Exp Med Biol, V218, P99
   KENNY AJ, 1982, PHYSIOL REV, V62, P91
   Levis R, 1995, Adv Exp Med Biol, V380, P337
   LEVIS R, UNPUB
   LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MCKEIRNAN AJ, 1981, FELINE PRACT, V11, P16
   MONTALI RJ, 1972, VET PATHOL, V9, P109, DOI 10.1177/030098587200900204
   OBRIEN SJ, 1985, SCIENCE, V227, P1428, DOI 10.1126/science.2983425
   OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7
   Pedersen N C, 1987, Adv Exp Med Biol, V218, P529
   PEDERSEN NC, 1981, AM J VET RES, V42, P368
   PEDERSEN NC, 1976, AM J VET RES, V37, P567
   PEDERSEN NC, 1983, FELINE PRACT, V13, P5
   PEDERSEN NC, 1980, AM J VET RES, V41, P868
   PFEIFER ML, 1983, J AM VET MED ASSOC, V183, P1317
   REYNOLDS DJ, 1979, ARCH VIROL, V60, P161, DOI 10.1007/BF01348032
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHULTZE B, 1992, J GEN VIROL, V73, P901, DOI 10.1099/0022-1317-73-4-901
   SCHULTZE B, 1991, J VIROL, V65, P6232, DOI 10.1128/JVI.65.11.6232-6237.1991
   SCOTT FW, 1986, ADV EXP MED BIOL, V218, P569
   SCOTT FW, 1986, CURRENT VET THERAPY, V9, P1059
   SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255
   SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761
   STODDART CA, 1989, J VIROL, V63, P436, DOI 10.1128/JVI.63.1.436-440.1989
   WATT VM, 1989, J BIOL CHEM, V264, P5480
   WEBSTER RG, 1982, NATURE, V296, P115, DOI 10.1038/296115a0
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WOODS RD, 1981, AM J VET RES, V42, P1163
   YANG XF, 1993, BIOCHEM CELL BIOL, V71, P278, DOI 10.1139/o93-042
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   YOKOMORI K, 1992, J VIROL, V66, P6194, DOI 10.1128/JVI.66.10.6194-6199.1992
NR 47
TC 155
Z9 178
U1 2
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD DEC
PY 1996
VL 70
IS 12
BP 8669
EP 8674
DI 10.1128/JVI.70.12.8669-8674.1996
PG 6
WC Virology
SC Virology
GA VT704
UT WOS:A1996VT70400050
PM 8970993
OA Bronze
DA 2020-04-03
ER

PT J
AU Ivanov, KA
   Hertzig, T
   Rozanov, M
   Bayer, S
   Thiel, V
   Gorbalenya, AE
   Ziebuhr, J
AF Ivanov, KA
   Hertzig, T
   Rozanov, M
   Bayer, S
   Thiel, V
   Gorbalenya, AE
   Ziebuhr, J
TI Major genetic marker of nidoviruses encodes a replicative
   endoribonuclease
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; SUBGENOMIC RNA-SYNTHESIS; CORONAVIRUS
   GENOME; SARS-CORONAVIRUS; SEQUENCE MOTIFS; IN-VITRO; VIRUS;
   TRANSCRIPTION; PROTEINASE; IDENTIFICATION
AB Coronaviruses are important pathogens that cause acute respiratory diseases in humans. Replication of the approximate to30-kb positive-strand RNA genome of coronaviruses and discontinuous synthesis of an extensive set of subgenome-length RNAs (transcription) are mediated by the replicase-transcriptase, a barely characterized protein complex that comprises several cellular proteins and up to 16 viral subunits. The coronavirus replicase-transcriptase was recently predicted to contain RNA-processing enzymes that are extremely rare or absent in other RNA viruses. Here,we established and characterized the activity of one of these enzymes, replicative nidoviral uridylate-specific endoribonuclease (NendoU). It is considered a major genetic marker that discriminates nidoviruses (Coronaviridae, Arteriviridae, and Roniviridae) from all other RNA virus families. Bacterially expressed forms of NendoU of severe acute respiratory syndrome coronavirus and human coronavirus 229E were revealed to cleave single-stranded and double-stranded RNA in a Mn2+-dependent manner. Single-stranded RNA was cleaved less specifically and effectively, suggesting that double-stranded RNA is the biologically relevant NendoU substrate. Double-stranded RNA substrates were cleaved upstream and downstream of uridylates at GUU or GU sequences to produce molecules with 2'-3'cyclic phosphate ends. 2'-O-ribose-methylated RNA substrates proved to be resistant to cleavage by NendoU, indicating a functional link with the 2'-O-ribose methyltransferase located adjacent to NendoU in the coronavirus replicative polyprotein. A mutagenesis study verified potential active-site residues and allowed us to inactivate NendoU in the full-length human coronavirus 229E clone. Substitution of D6408 by Ala was shown to abolish viral RNA synthesis, demonstrating that NendoU has critical functions in viral replication and transcription.
C1 Univ Wurzburg, Inst Immunol & Virol, D-97078 Wurzburg, Germany.
   NIH, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA.
   Cantonal Hosp, Res Dept, CH-9007 St Gallen, Switzerland.
   Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, NL-2300 RC Leiden, Netherlands.
RP Ziebuhr, J (reprint author), Univ Wurzburg, Inst Immunol & Virol, Versbacher Str 7, D-97078 Wurzburg, Germany.
EM j.ziebuhr@mail.uni-wuerzburg.de
RI Gorbalenya, Alexander E/J-4818-2012; Ziebuhr, John/G-7669-2015; Thiel,
   Volker/AAI-2391-2019; Jha, Babal/AAC-8337-2020
OI Gorbalenya, Alexander E/0000-0002-4967-7341; Jha,
   Babal/0000-0002-7660-5255; Thiel, Volker/0000-0002-5783-0887; Ziebuhr,
   John/0000-0002-5741-8825
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bartlett GJ, 2002, J MOL BIOL, V324, P105, DOI 10.1016/S0022-2836(02)01036-7
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   Gorbalenya AE, 2001, ADV EXP MED BIOL, V494, P1
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   Hausmann Y, 2004, J VIROL, V78, P5507, DOI 10.1128/JVI.78.10.5507-5512.2004
   Herold J, 1998, J VIROL, V72, P910, DOI 10.1128/JVI.72.2.910-918.1998
   HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   LAI MMC, 2001, FIELDS VIROLOGY, V1, P1163
   Laneve P, 2003, J BIOL CHEM, V278, P13026, DOI 10.1074/jbc.M211937200
   MYINT SH, 1995, CORONAVIRIDAE, P389
   PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001
   Pasternak AO, 2001, EMBO J, V20, P7220, DOI 10.1093/emboj/20.24.7220
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728
   SNIJDER EJ, 1990, NUCLEIC ACIDS RES, V18, P4535, DOI 10.1093/nar/18.15.4535
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   Thiel V, 2001, J VIROL, V75, P6676, DOI 10.1128/JVI.75.14.6676-6681.2001
   Xu HY, 2001, VIROLOGY, V288, P212, DOI 10.1006/viro.2001.1098
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   ZIEBUHR J, 1995, J VIROL, V69, P4331, DOI 10.1128/JVI.69.7.4331-4338.1995
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
   ZIEBUHR J, 2004, IN PRESS CURR TOP MI, V287
   Zuniga S, 2004, J VIROL, V78, P980, DOI 10.1128/JVI.78.2.980-994.2004
NR 29
TC 154
Z9 165
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 24
PY 2004
VL 101
IS 34
BP 12694
EP 12699
DI 10.1073/pnas.0403127101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 850FI
UT WOS:000223596200054
PM 15304651
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Lundin, M
   Monne, M
   Widell, A
   von Heijne, G
   Persson, MAA
AF Lundin, M
   Monne, M
   Widell, A
   von Heijne, G
   Persson, MAA
TI Topology of the membrane-associated hepatitis C virus protein NS4B
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS; ENDOPLASMIC-RETICULUM
   MEMBRANE; VIRAL REPLICATION COMPLEX; LARGE ENVELOPE PROTEIN;
   SUBCELLULAR-LOCALIZATION; TRANSMEMBRANE TOPOLOGY; NONSTRUCTURAL
   PROTEINS; SERINE PROTEINASE; INFECTED CELLS; RNA-SYNTHESIS
AB Hepatitis C virus (HCV) belongs to the Hepacivirus genus in the Flaviviridae family. Among the least known viral proteins in this family is the nonstructural protein NS4B, which has been suggested to be a part of the replication complex. Hydrophobicity plots indicate a common profile among the NS4B proteins from different members of the Flaviviridae family, suggesting a common function. In order to gain a deeper understanding of the nature of HCV NS4B, we have determined localization and topology of this protein by using recombinant HCV NS4B constructs. The protein localized to the endoplasmic reticulum (ER), but also induced a pattern of cytoplasmic foci positive for markers of the ER. Computer predictions of the membrane topology of NS4B suggested that it has four transmembrane segments. The N and C termini were anticipated to be localized in the cytoplasm, because they are processed by the cytoplasmic NS3 protein. By introducing glycosylation sites at various positions in HCV NS4B, we show that the C terminus is cytoplasmic and the loop around residue 161 is lumenal as predicted. Surprisingly, the N-terminal tail was translocated into the lumen in a considerable fraction of the NS4B molecules, most likely by a posttranslational process. Interestingly, NS4B proteins of the yellow fever and dengue viruses also have their N termini located in the ER lumen due to an N-terminal signal peptide not found in NS4B of HCV. A shared topology achieved in two different ways supports the notion of a common function for NS4B in Flaviviridae.
C1 Karolinska Hosp, Karolinska Inst, Ctr Mol Med L8 01, Dept Med, S-17176 Stockholm, Sweden.
   Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.
   Lund Univ, Malmo Gen Hosp, Dept Clin Microbiol, S-20502 Malmo, Sweden.
RP Persson, MAA (reprint author), Karolinska Hosp, Karolinska Inst, Ctr Mol Med L8 01, Dept Med, S-17176 Stockholm, Sweden.
EM Mats.Persson@cmm.ki.se
RI von Heijne, Gunnar/F-5576-2011; Monne, Magnus/D-5642-2012; von Heijne,
   Gunnar/AAH-9389-2019
OI von Heijne, Gunnar/0000-0002-4490-8569; Monne,
   Magnus/0000-0003-2344-3878; Persson, Mats/0000-0002-5118-6584
CR BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993
   BIENZ K, 1994, ARCH VIROL, P147
   Blum R, 1999, J CELL SCI, V112, P537
   BORDIER C, 1981, J BIOL CHEM, V256, P1604
   BRUSS V, 1994, EMBO J, V13, P2273, DOI 10.1002/j.1460-2075.1994.tb06509.x
   CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992
   CHOO QL, 1991, INT CONGR SER, V895, P47
   CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451
   Egger D, 2000, J VIROL, V74, P6570, DOI 10.1128/JVI.74.14.6570-6580.2000
   Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002
   Escors D, 2001, J VIROL, V75, P12228, DOI 10.1128/JVI.75.24.12228-12240.2001
   GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993
   Grassmann CW, 2001, J VIROL, V75, P7791, DOI 10.1128/JVI.75.17.7791-7802.2001
   HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773
   HOUGHTON M, 1996, FIELDS VIROLOGY, P1035
   Hugle T, 2001, VIROLOGY, V284, P70, DOI 10.1006/viro.2001.0873
   JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625
   JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037
   Kato J, 2002, J MED VIROL, V66, P187, DOI 10.1002/jmv.2129
   Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198
   Khromykh AA, 2000, J VIROL, V74, P3253, DOI 10.1128/JVI.74.7.3253-3263.2000
   Kim JE, 1999, ARCH VIROL, V144, P329, DOI 10.1007/s007050050507
   Koch JO, 1999, J VIROL, V73, P7138
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   Lambert C, 2001, J BIOL CHEM, V276, P22265, DOI 10.1074/jbc.M100956200
   Li Y, 2001, VIRUS GENES, V23, P149, DOI 10.1023/A:1011836003128
   LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993
   Lin C, 1997, J VIROL, V71, P6465, DOI 10.1128/JVI.71.9.6465-6471.1997
   LIN C, 1995, P NATL ACAD SCI USA, V92, P7622, DOI 10.1073/pnas.92.17.7622
   Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001
   Mackenzie JM, 1999, J VIROL, V73, P9555, DOI 10.1128/JVI.73.11.9555-9567.1999
   Monne M, 1999, J MOL BIOL, V288, P141, DOI 10.1006/jmbi.1999.2657
   Mottola G, 2002, VIROLOGY, V293, P31, DOI 10.1006/viro.2001.1229
   Neddermann P, 1999, J VIROL, V73, P9984, DOI 10.1128/JVI.73.12.9984-9991.1999
   NILSSON I, 1993, J BIOL CHEM, V268, P5798
   OSTAPCHUK P, 1994, EMBO J, V13, P1048, DOI 10.1002/j.1460-2075.1994.tb06353.x
   Ota K, 2000, J BIOL CHEM, V275, P29743, DOI 10.1074/jbc.M002468200
   Park JS, 2000, BIOCHEM BIOPH RES CO, V267, P581, DOI 10.1006/bbrc.1999.1999
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325
   PRANGE R, 1995, EMBO J, V14, P247, DOI 10.1002/j.1460-2075.1995.tb06998.x
   Qu L, 2001, J VIROL, V75, P10651, DOI 10.1128/JVI.75.22.10651-10662.2001
   REED KE, 1998, CURR STUD HEMATOL BL, V62, P1
   RISCO C, 1995, J VIROL, V69, P5269, DOI 10.1128/JVI.69.9.5269-5277.1995
   ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0
   Schaad MC, 1997, EMBO J, V16, P4049, DOI 10.1093/emboj/16.13.4049
   SELBY MJ, 1993, J GEN VIROL, V74, P1103, DOI 10.1099/0022-1317-74-6-1103
   Serafino A, 1998, RES VIROLOGY, V149, P299, DOI 10.1016/S0923-2516(99)89009-8
   Steffan AM, 2001, MICROBES INFECT, V3, P193, DOI 10.1016/S1286-4579(01)01369-7
   TANJI Y, 1995, J VIROL, V69, P1575, DOI 10.1128/JVI.69.3.1575-1581.1995
   Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107
   Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997
   Wolk B, 2000, J VIROL, V74, P2293, DOI 10.1128/JVI.74.5.2293-2304.2000
   Yan YW, 1998, PROTEIN SCI, V7, P837
   Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738
NR 55
TC 154
Z9 160
U1 0
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 2003
VL 77
IS 9
BP 5428
EP 5438
DI 10.1128/JVI.77.9.5428-5438.2003
PG 11
WC Virology
SC Virology
GA 668MF
UT WOS:000182297200040
PM 12692244
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Casais, R
   Thiel, V
   Siddell, SG
   Cavanagh, D
   Britton, P
AF Casais, R
   Thiel, V
   Siddell, SG
   Cavanagh, D
   Britton, P
TI Reverse genetics system for the avian coronavirus infectious bronchitis
   virus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID BACTERIAL ARTIFICIAL CHROMOSOME; MESSENGER-RNA TRANSCRIPTION; MOUSE
   HEPATITIS-VIRUS; OPEN READING FRAME; DEFECTIVE RNAS;
   NUCLEOTIDE-SEQUENCE; MAMMALIAN-CELLS; FOWLPOX VIRUS; GENOME; DNA
AB Major advances in the study of the molecular biology of RNA viruses have resulted from the ability to generate and manipulate full-length genomic cDNAs of the viral genomes with the subsequent synthesis of infectious RNA for the generation of recombinant viruses. Coronaviruses have the largest RNA virus genomes and, together with genetic instability of some cDNA sequences in Escherichia coli, this has hampered the generation of a reverse-genetics system for this group of viruses. In this report, we describe the assembly of a full-length cDNA from the positive-sense genomic RNA of the avian coronavirus, infectious bronchitis virus (IBV), an important poultry pathogen. The IBV genomic cDNA was assembled immediately downstream of a T7 RNA polymerase promoter by in vitro ligation and cloned directly into the vaccinia virus genome. Infectious IBV RNA was generated in situ after the transfection of restricted recombinant vaccinia virus DNA into primary chick kidney cells previously infected with a recombinant fowlpox virus expressing T7 RNA polymerase. Recombinant IBV, containing two marker mutations, was recovered from the transfected cells. These results describe a reverse-genetics system for studying the molecular biology of IBV and establish a paradigm for generating genetically defined vaccines for IBV.
C1 Inst Anim Hlth, Div Mol Biol, Compton Lab, Newbury RG20 7NN, Berks, England.
   Univ Wurzburg, Inst Virol & Immunol, D-97078 Wurzburg, Germany.
RP Britton, P (reprint author), Inst Anim Hlth, Div Mol Biol, Compton Lab, Newbury RG20 7NN, Berks, England.
RI Thiel, Volker/AAI-2391-2019; CASAIS, ROSA/C-1405-2014
OI CASAIS, ROSA/0000-0001-8349-5878; Thiel, Volker/0000-0002-5783-0887
CR Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   ATYANARAYANA T, 2001, VIROLOGY, V280, P87
   BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   Britton P, 1996, J GEN VIROL, V77, P963, DOI 10.1099/0022-1317-77-5-963
   CAPLEN FVA, 1984, VIRUS RES, V1, P153
   CAVANAGH D, 1986, VIRUS RES, V4, P133, DOI 10.1016/0168-1702(86)90037-7
   Cavanagh D, 2001, AVIAN PATHOL, V30, P109, DOI 10.1080/03079450120044506
   Cavanagh D, 1997, DIS POULTRY, P511
   Dalton K, 2001, J VIROL, V75, P125, DOI 10.1128/JVI.75.1.125-133.2001
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   Evans S, 2000, J GEN VIROL, V81, P2855, DOI 10.1099/0022-1317-81-12-2855
   Hiscox JA, 2001, J VIROL, V75, P506, DOI 10.1128/JVI.75.1.506-512.2001
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LAMBRECHTS C, 1993, AVIAN PATHOL, V22, P577, DOI 10.1080/03079459308418945
   LIU DX, 1994, J VIROL, V68, P5772, DOI 10.1128/JVI.68.9.5772-5780.1994
   MACKETT M, 1985, DNA CLONING PRACTICA, V2, P191
   MAYR A., 1966, ZENTRALBL VETERINARMED REIHE B, V13, P1
   MERCHLINSKY M, 1992, VIROLOGY, V190, P522, DOI 10.1016/0042-6822(92)91246-Q
   MOCKETT APA, 1985, J VIROL METHODS, V12, P271, DOI 10.1016/0166-0934(85)90138-7
   Molenkamp R, 2000, J GEN VIROL, V81, P2491, DOI 10.1099/0022-1317-81-10-2491
   PENZES Z, 1994, VIROLOGY, V203, P286, DOI 10.1006/viro.1994.1486
   Penzes Z, 1996, J VIROL, V70, P8660
   Polo S, 1997, J VIROL, V71, P5366, DOI 10.1128/JVI.71.7.5366-5374.1997
   RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391
   RICE C M, 1989, New Biologist, V1, P285
   Ruggli N, 1996, J VIROL, V70, P3478, DOI 10.1128/JVI.70.6.3478-3487.1996
   Sambrook J., 1989, MOL CLONING LAB MANU
   Satyanarayana T, 1999, P NATL ACAD SCI USA, V96, P7433, DOI 10.1073/pnas.96.13.7433
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   SIDDELL SG, 1995, CORONAVIRIDAE, P1
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   STERN DF, 1980, J VIROL, V34, P665, DOI 10.1128/JVI.34.3.665-674.1980
   Stirrups K, 2000, J GEN VIROL, V81, P791, DOI 10.1099/0022-1317-81-3-791
   Stirrups K, 2000, J GEN VIROL, V81, P1687, DOI 10.1099/0022-1317-81-7-1687
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   Thiel V, 2001, J VIROL, V75, P6676, DOI 10.1128/JVI.75.14.6676-6681.2001
   Tibbles KW, 1999, VIRUS RES, V60, P137, DOI 10.1016/S0168-1702(99)00011-8
   USUBEL FM, 1987, CURRENT PROTOCOLS MO
   vanDinten LC, 1997, P NATL ACAD SCI USA, V94, P991, DOI 10.1073/pnas.94.3.991
   Wang K, 1997, BIOTECHNIQUES, V23, P992, DOI 10.2144/97236bm04
   Yamshchikov V, 2001, VIROLOGY, V281, P272, DOI 10.1006/viro.2000.0793
   Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 46
TC 154
Z9 184
U1 0
U2 22
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD DEC
PY 2001
VL 75
IS 24
BP 12359
EP 12369
DI 10.1128/JVI.75.24.12359-12369.2001
PG 11
WC Virology
SC Virology
GA 495RZ
UT WOS:000172355300043
PM 11711626
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Zhou, Z
   Jiang, XJ
   Liu, D
   Fan, Z
   Hu, XD
   Yan, JG
   Wang, M
   Gao, GF
AF Zhou, Zhi
   Jiang, Xuejun
   Liu, Di
   Fan, Zheng
   Hu, Xudong
   Yan, Jinguo
   Wang, Ming
   Gao, George F.
TI Autophagy is involved in influenza A virus replication
SO AUTOPHAGY
LA English
DT Article
DE autophagy; influenza A virus; Beclin 1; LC3; electron microscopy
ID CORONAVIRUS REPLICATION; MOLECULAR-MECHANISM; AMINO-ACID; CELL-DEATH;
   INFECTION; ENDOCYTOSIS; INDUCTION; PATHWAY; BINDING; PROTEIN
AB Autophagy is involved in the replication of viruses, especially those that perform RNA assembly on the surface of cytoplasmic membrane in host cells. However, little is known about the regulatory role of autophagy in influenza A virus replication. Using fluorescence and electron microscopy, we observed that autophagosomes can be induced and identified upon influenza A virus infection. The virus increased the amount of the autophagosome marker protein micro tubule-associated protein light chain 3-II (LC3-II) and enhanced autophagic flux. When autophagy was pharmacologically inhibited by either 3-methylademine or wortmannin, the titers of influenza A virus were remarkably decreased. Viral reduction via autophagy inhibition was further confirmed by RNA interference, through which two different proteins required for autophagy were depleted. Noticeably, the compounds utilized had no marked effect on virus entry or cell viability, either of which might limit viral replication. Furthermore, alteration of cellular autophagy via pharmacological reagents or RNA interference impaired viral protein accumulation. Taken together, these findings indicate that autophagy is actively involved in influenza A virus replication.
C1 [Gao, George F.] Chinese Acad Sci, Inst Microbiol, Ctr Mol Immunol, Beijing 100101, Peoples R China.
   [Zhou, Zhi; Jiang, Xuejun; Liu, Di; Fan, Zheng; Hu, Xudong; Yan, Jinguo; Gao, George F.] China Agr Univ, Coll Vet Med, Beijing 100094, Peoples R China.
RP Gao, GF (reprint author), Chinese Acad Sci, Inst Microbiol, Ctr Mol Immunol, Jia 3 DaTun Rd, Beijing 100101, Peoples R China.
EM gaof@im.ac.cn
RI Liu, Di/G-6135-2014
OI Liu, Di/0000-0003-3693-2726
FU National Basic Research Program 973National Basic Research Program of
   China [2005CB523001]; Hi-Teck Research & Development Project 863National
   High Technology Research and Development Program of China
   [2006AA02A205]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [NSFC 30599434]
FX We are grateful to Dr. Tamotsu Yoshimori for providing the GFP-LC3
   plasmid, Dr. Jinhua Liu for providing H9N2 virus, and Dr. Wenjun Liu for
   providing anti-NP antibody. This study was supported by grants from the
   National Basic Research Program 973 (2005CB523001), Hi-Teck Research &
   Development Project 863 (2006AA02A205) and the National Natural Science
   Foundation of China (NSFC, 30599434).
CR Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001
   Amer AO, 2005, CELL MICROBIOL, V7, P765, DOI 10.1111/j.1462-5822.2005.00509.x
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133
   Ehrhardt C, 2006, CELL MICROBIOL, V8, P1336, DOI 10.1111/j.1462-5822.2006.00713.x
   Espert L, 2007, AUTOPHAGY, V3, P32, DOI 10.4161/auto.3275
   Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185
   Gubareva LV, 2002, J GEN VIROL, V83, P2683, DOI 10.1099/0022-1317-83-11-2683
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Hoyer-Hansen M, 2005, CELL DEATH DIFFER, V12, P1297, DOI 10.1038/sj.cdd.4401651
   Hui EKW, 2002, J GEN VIROL, V83, P3055, DOI 10.1099/0022-1317-83-12-3055
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303
   Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Lakadamyali M, 2004, MICROBES INFECT, V6, P929, DOI 10.1016/j.micinf.2004.05.002
   Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100
   LARDEUX BR, 1987, J BIOL CHEM, V262, P14514
   Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200
   Li MQ, 2008, AUTOPHAGY, V4, P54, DOI 10.4161/auto.5209
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu J, 2005, SCIENCE, V309, P1206, DOI 10.1126/science.1115273
   Ludwig S, 2006, CELL MICROBIOL, V8, P375, DOI 10.1111/j.1462-5822.2005.00678.x
   MANN SS, 1994, J BIOL CHEM, V269, P11492
   McCown MF, 2006, J VIROL, V80, P8178, DOI 10.1128/JVI.00627-06
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2007, AUTOPHAGY, V3, P542
   MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002
   Schmid D, 2006, J MOL MED-JMM, V84, P194, DOI 10.1007/s00109-005-0014-4
   SCHWARTZ AL, 1992, AM J PHYSIOL, V262, pC1031
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Shin YK, 2007, J GEN VIROL, V88, P942, DOI 10.1099/vir.0.82483-0
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Shortridge KF, 2000, VET MICROBIOL, V74, P141, DOI 10.1016/S0378-1135(00)00174-7
   Sieczkarski SB, 2003, TRAFFIC, V4, P333, DOI 10.1034/j.1600-0854.2003.00090.x
   Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823
   Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211
   TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347
   Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299
   Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200
   Thompson CI, 2004, J ANTIMICROB CHEMOTH, V53, P759, DOI 10.1093/jac/dkh155
   van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545
   Vergne I, 2006, AUTOPHAGY, V2, P175, DOI 10.4161/auto.2830
   Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040
   Webster RG, 1999, P NATL ACAD SCI USA, V96, P1164, DOI 10.1073/pnas.96.4.1164
   Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279
   Yan CH, 2007, ACTA PHARMACOL SIN, V28, P540, DOI 10.1111/j.1745-7254.2007.00530.x
   Yang YP, 2005, ACTA PHARMACOL SIN, V26, P1421, DOI 10.1111/j.1745-7254.2005.00235.x
   Zhao ZJ, 2007, AUTOPHAGY, V3, P581, DOI 10.4161/auto.4782
   Zhou DJ, 2008, AIDS, V22, P695, DOI 10.1097/QAD.0b013e3282f4a836
NR 58
TC 153
Z9 164
U1 0
U2 35
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD APR 1
PY 2009
VL 5
IS 3
BP 321
EP 328
DI 10.4161/auto.5.3.7406
PG 8
WC Cell Biology
SC Cell Biology
GA 439KP
UT WOS:000265626300007
PM 19066474
OA Bronze
DA 2020-04-03
ER

PT J
AU Pelletier, AJ
   Mansbach, JM
   Camargo, CA
AF Pelletier, Andrea J.
   Mansbach, Jonathan M.
   Camargo, Carlos A., Jr.
TI Direct medical costs of bronchiolitis hospitalizations in the United
   States
SO PEDIATRICS
LA English
DT Article
DE bronchiolitis; cost; HCUP
ID RESPIRATORY SYNCYTIAL VIRUS; YOUNG-CHILDREN; ECONOMIC-EVALUATION; TRACT
   DISEASE; US CHILDREN; INFECTION; INFLUENZA; INFANTS; CORONAVIRUS; BURDEN
AB OBJECTIVES. Although bronchiolitis is the leading cause of hospitalization for infants, there are limited data describing the epidemiology of bronchiolitis hospitalizations, and the associated cost is unknown. Our objective was to determine nationally representative estimates of the frequency of bronchiolitis hospitalizations and its associated costs.
   PATIENTS AND METHODS. We analyzed the 2002 Health Care Utilization Project-National Inpatient Sample, a federal, stratified random survey of hospital discharges. For admissions age < 2 years with a discharge diagnosis of bronchiolitis (International Classification of Diseases, Ninth Revision, Clinical Modification, code 466.1), we used nationally representative weighted estimates to determine frequency and total hospital charges. Costs were estimated from reported charges by applying hospital-specific cost/charge ratios based on all-payer inpatient cost.
   RESULTS. In 2002, an estimated 149 000 patients were hospitalized with bronchiolitis. Frequency of hospitalizations was higher among children age < 1 year of age, male gender, and nonwhite race. Mean length of stay was 3.3 days. Total annual costs for bronchiolitis-related hospitalizations were $543 million, with a mean cost of $3799 per hospitalization. Mean cost of bronchiolitis with a codiagnosis of pneumonia was $6191. In a multivariate analysis controlling for 3 confounding factors (including length of stay), cost per hospitalization was higher for children < 1 year and lower for those in the South versus Northeast.
   CONCLUSIONS. Bronchiolitis admissions cost more than $500 million annually. A codiagnosis of bronchiolitis and pneumonia almost doubles the cost of the hospitalization. Inpatient health care costs of bronchiolitis are higher than estimated previously and highlight the need for initiatives to safely reduce bronchiolitis hospitalizations and thereby decrease health care costs.
C1 Massachusetts Gen Hosp, EMNet Coordinating Ctr, Dept Emergency Med, Boston, MA 02114 USA.
   Boston Childrens Hosp, Dept Med, Boston, MA USA.
RP Pelletier, AJ (reprint author), Massachusetts Gen Hosp, EMNet Coordinating Ctr, Dept Emergency Med, 216 Cambridge St,4th Floor, Boston, MA 02114 USA.
EM apelletier1@partners.org
RI Camargo, Carlos A./C-2145-2008
OI Camargo, Carlos A./0000-0002-5071-7654
CR *AG HEALTHC RES QU, OV NAT INP SAMP NIS
   Bordley WC, 2004, ARCH PEDIAT ADOL MED, V158, P119, DOI 10.1001/archpedi.158.2.119
   Bradenberg HK, 2001, PEDIATR INFECT DIS J, V20, P1100, DOI 10.1097/00006454-200111000-00026
   Christakis DA, 2005, PEDIATRICS, V115, P878, DOI 10.1542/peds.2004-1299
   Creery David, 2005, Int J Circumpolar Health, V64, P38
   Deshpande SA, 2003, ARCH DIS CHILD, V88, P1065, DOI 10.1136/adc.88.12.1065
   Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125
   EDWARDS KM, 1985, PEDIATRICS, V76, P420
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026
   *HEALTHC COST UT P, COST CHARG RAT FIL 2
   HENDERSON FW, 1979, J PEDIATR-US, V95, P183
   Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758
   KATZ BZ, 2003, PHARMACOL THERAPEUT, V28, P343
   Korppi M, 2004, PEDIATR INFECT DIS J, V23, P995, DOI 10.1097/01.inf.0000143642.72480.53
   Langley JM, 1997, J PEDIATR-US, V131, P113, DOI 10.1016/S0022-3476(97)70133-1
   Leader S, 2003, J PEDIATR-US, V143, pS127, DOI 10.1067/S0022-3476(03)00510-9
   Leader S, 2003, VALUE HEALTH, V6, P100, DOI 10.1046/j.1524-4733.2003.00220.x
   Leader S, 2002, PEDIATR INFECT DIS J, V21, P629, DOI 10.1097/00006454-200207000-00005
   LIEU TA, 1999, PEDIATRICS, V103
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   Miedema CJ, 2001, PEDIATR INFECT DIS J, V20, P160, DOI 10.1097/00006454-200102000-00008
   Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401
   Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513
   Paramore LC, 2004, PHARMACOECONOMICS, V22, P275, DOI 10.2165/00019053-200422050-00001
   Randolph AG, 2004, PEDIATR INFECT DIS J, V23, P990, DOI 10.1097/01.inf.0000143647.88873.66
   Rocholl C, 2004, PEDIATRICS, V113, pE51, DOI 10.1542/peds.113.1.e51
   Sannier N, 2001, ARCH PEDIATRIE, V8, P922, DOI 10.1016/S0929-693X(01)00556-5
   SHAW KN, 1991, AM J DIS CHILD, V145, P151, DOI 10.1001/archpedi.1991.02160020041012
   Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440
   Shay DK, 2001, J INFECT DIS, V183, P16, DOI 10.1086/317655
   Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072
   Stang P, 2001, ARCH PEDIAT ADOL MED, V155, P95, DOI 10.1001/archpedi.155.1.95
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304
   Zaw W, 2003, SCOT MED J, V48, P108, DOI 10.1177/003693300304800404
NR 37
TC 153
Z9 158
U1 0
U2 4
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD DEC
PY 2006
VL 118
IS 6
BP 2418
EP 2423
DI 10.1542/peds.2006-1193
PG 6
WC Pediatrics
SC Pediatrics
GA 111TX
UT WOS:000242478900019
PM 17142527
DA 2020-04-03
ER

PT J
AU Atmar, RL
   Guy, E
   Guntupalli, KK
   Zimmerman, JL
   Bandi, VD
   Baxter, BD
   Greenberg, SB
AF Atmar, RL
   Guy, E
   Guntupalli, KK
   Zimmerman, JL
   Bandi, VD
   Baxter, BD
   Greenberg, SB
TI Respiratory tract viral infections in inner-city asthmatic adults
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; INFLUENZA-VIRUS; PULMONARY-FUNCTION;
   UNITED-STATES; IN-VIVO; EXACERBATIONS; RHINOVIRUS; CHILDREN;
   HYPERRESPONSIVENESS; HYPERREACTIVITY
AB Background: Respiratory tract viral infections (RTVIs) have been identified frequently in association with asthma exacerbations in children, but few studies have shown similar rates of viral infections in adults with asthma. Further studies using newer diagnostic techniques to evaluate the frequency of RTVIs in adults with acute exacerbations of asthma need to be performed.
   Methods: Twenty-nine asthmatic adults were recruited from the pulmonary clinic of an urban county hospital and were followed up in a longitudinal cohort study for signs and symptoms of asthma and RTVI. One hundred twenty-two asthmatic adults presenting to the emergency department (ED) of the same hospital with acute symptoms of asthma underwent evaluation for RTVI in a cross-sectional prevalence study. In both studies, respiratory secretions and paired serum samples were collected from subjects with acute wheezing episodes and evaluated using virus culture, serologic testing, and reverse transcription-polymerase chain reaction (RT-PCR).
   Results: In the longitudinal cohort study, 138 respiratory illnesses, of which 87 were asthma exacerbations, were evaluated; 41% of all illnesses and 44% of asthma exacerbations were associated with an RTVI. In the ED study, 148 asthma exacerbations were evaluated; 55% were associated with an RTVI. An RTVI was identified in 21 (50%) of 42 of the subjects hospitalized in the ED study. Picornaviruses (rhinoviruses), coronaviruses, and influenza viruses were the most commonly identified causes of RTVI. Forty-six (60%) of the 77 picornavirus infections and 22 (71%) of the 31 coronavirus infections were identified only using RT-PCR.
   Conclusions: Asthmatic exacerbations in adults are frequently associated with an RTVI. Identification of such infections often requires newer diagnostic methods, such as virus-specific RT-PCR. The high frequency of RTVIs identified in association with asthmatic exacerbations in adults from the inner city suggests that strategies for the prevention of RTVI should be targeted toward this population.
C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA.
   Ben Taub Gen Hosp, Med Serv, Houston, TX 77030 USA.
RP Greenberg, SB (reprint author), Baylor Coll Med, Dept Med, 1 Baylor Plaza,Room 559E, Houston, TX 77030 USA.
EM stepheng@bcm.tmc.edu
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01-AI-15103, N01-AI-65298]
CR ADAMS PF, 1995, VITAL HLTH STAT, V10, P94
   ATMAR RL, 1990, VACCINE, V8, P217, DOI 10.1016/0264-410X(90)90049-R
   ATMAR RL, 1993, APPL ENVIRON MICROB, V59, P631, DOI 10.1128/AEM.59.2.631-635.1993
   ATMAR RL, 1993, J CLIN MICROBIOL, V31, P2544, DOI 10.1128/JCM.31.9.2544-2546.1993
   Atmar RL, 1996, J CLIN MICROBIOL, V34, P2604, DOI 10.1128/JCM.34.10.2604-2606.1996
   Atmar RL, 1996, CLIN DIAGN VIROL, V7, P77, DOI 10.1016/S0928-0197(96)00254-1
   BARDIN PG, 1992, CLIN EXP ALLERGY, V22, P809, DOI 10.1111/j.1365-2222.1992.tb02825.x
   BAXTER BD, 1977, J CLIN MICROBIOL, V6, P19
   BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679
   BERKOVICH S, 1970, ANN ALLERGY, V28, P43
   BUSSE WW, 1985, CHEST, V87, pS44, DOI 10.1378/chest.87.1_Supplement.44S
   CALHOUN WJ, 1991, AM REV RESPIR DIS, V144, P1267, DOI 10.1164/ajrccm/144.6.1267
   CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4
   Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350
   CLARKE CW, 1979, THORAX, V34, P344, DOI 10.1136/thx.34.3.344
   Corne JM, 1997, THORAX, V52, P380, DOI 10.1136/thx.52.4.380
   Donofrio J C, 1992, PCR Methods Appl, V1, P263
   Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514
   EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131
   EVANS R, 1987, CHEST S, V91, P65
   FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879
   FRANK AL, 1980, J CLIN MICROBIOL, V12, P426, DOI 10.1128/JCM.12.3.426-432.1980
   GHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156
   GILL EP, 1994, J CLIN MICROBIOL, V32, P2372, DOI 10.1128/JCM.32.10.2372-2376.1994
   GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28
   Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x
   HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225
   HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976
   HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393
   HUHTI E, 1974, ANN ALLERGY, V33, P145
   Jamason PF, 1997, AM J RESP CRIT CARE, V156, P1781, DOI 10.1164/ajrccm.156.6.96-05028
   JENKINS CR, 1984, AM REV RESPIR DIS, V130, P879
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   KRAAIJEVELD CA, 1980, J CLIN MICROBIOL, V12, P493, DOI 10.1128/JCM.12.4.493-497.1980
   LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843
   MALVEAUX FJ, 1993, J ASTHMA, V30, P431, DOI 10.3109/02770909309056751
   MATUS I, 1979, PSYCHOSOM MED, V41, P629, DOI 10.1097/00006842-197912000-00004
   MINOR TE, 1976, AM REV RESPIR DIS, V113, P149
   MURRAY AB, 1992, CHEST, V101, P16, DOI 10.1378/chest.101.1.16
   Murray MD, 1997, J CLIN EPIDEMIOL, V50, P167, DOI 10.1016/S0895-4356(96)00333-2
   MURRAY RS, 1992, VIROLOGY, V188, P274, DOI 10.1016/0042-6822(92)90757-G
   NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x
   PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3
   PlattsMills TAE, 1997, NEW ENGL J MED, V336, P1382, DOI 10.1056/NEJM199705083361909
   Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904
   SOKHANDAN M, 1995, CHEST, V107, P1570, DOI 10.1378/chest.107.6.1570
   STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193
   Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591
   TOWNLEY RJ, 1987, J ALLERGY CLIN IMMUN, V80, P111, DOI 10.1016/0091-6749(87)90116-3
   WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6.362S
   WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683
   WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304
   WEISS ST, 1980, AM REV RESPIR DIS, V122, P697, DOI 10.1164/arrd.1980.122.5.697
   WING JS, 1993, J ASTHMA, V30, P427, DOI 10.3109/02770909309056750
NR 57
TC 153
Z9 156
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9926
EI 1538-3679
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD DEC 7
PY 1998
VL 158
IS 22
BP 2453
EP 2459
DI 10.1001/archinte.158.22.2453
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 146QF
UT WOS:000077441300006
PM 9855383
DA 2020-04-03
ER

PT J
AU Cotten, M
   Watson, SJ
   Kellam, P
   Al-Rabeeah, AA
   Makhdoom, HQ
   Assiri, A
   Al-Tawfiq, JA
   Alhakeem, RF
   Madani, H
   AlRabiah, FA
   Al Hajjar, S
   Al-Nassir, WN
   Albarrak, A
   Flemban, H
   Balkhy, HH
   Alsubaie, S
   Palser, AL
   Gall, A
   Bashford-Rogers, R
   Rambaut, A
   Zumla, AI
   Memish, ZA
AF Cotten, Matthew
   Watson, Simon J.
   Kellam, Paul
   Al-Rabeeah, Abdullah A.
   Makhdoom, Hatem Q.
   Assiri, Abdullah
   Al-Tawfiq, Jaffar A.
   Alhakeem, Rafat F.
   Madani, Hossam
   AlRabiah, Fahad A.
   Al Hajjar, Sami
   Al-Nassir, Wafa N.
   Albarrak, Ali
   Flemban, Hesham
   Balkhy, Hanan H.
   Alsubaie, Sarah
   Palser, Anne L.
   Gall, Astrid
   Bashford-Rogers, Rachael
   Rambaut, Andrew
   Zumla, Alimuddin I.
   Memish, Ziad A.
TI Transmission and evolution of the Middle East respiratory syndrome
   coronavirus in Saudi Arabia: a descriptive genomic study
SO LANCET
LA English
DT Article
ID PHYLOGENETIC ANALYSIS; SPIKE PROTEIN; ACTIVATION; RECEPTOR; INFERENCE;
   CLEAVAGE
AB Background Since June, 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) has, worldwide, caused 104 infections in people including 49 deaths, with 82 cases and 41 deaths reported from Saudi Arabia. In addition to confirming diagnosis, we generated the MERS-CoV genomic sequences obtained directly from patient samples to provide important information on MERS-CoV transmission, evolution, and origin.
   Methods Full genome deep sequencing was done on nucleic acid extracted directly from PCR-confirmed clinical samples. Viral genomes were obtained from 21 MERS cases of which 13 had 100%, four 85-95%, and four 30-50% genome coverage. Phylogenetic analysis of the 21 sequences, combined with nine published MERS-CoV genomes, was done.
   Findings Three distinct MERS-CoV genotypes were identified in Riyadh. Phylogeographic analyses suggest the MERS-CoV zoonotic reservoir is geographically disperse. Selection analysis of the MERS-CoV genomes reveals the expected accumulation of genetic diversity including changes in the S protein. The genetic diversity in the Al-Hasa cluster suggests that the hospital outbreak might have had more than one virus introduction.
   Interpretation We present the largest number of MERS-CoV genomes (21) described so far. MERS-CoV full genome sequences provide greater detail in tracking transmission. Multiple introductions of MERS-CoV are identified and suggest lower R 0 values. Transmission within Saudi Arabia is consistent with either movement of an animal reservoir, animal products, or movement of infected people. Further definition of the exposures responsible for the sporadic introductions of MERS-CoV into human populations is urgently needed.
C1 [Al-Rabeeah, Abdullah A.; Assiri, Abdullah; Alhakeem, Rafat F.; Zumla, Alimuddin I.; Memish, Ziad A.] Minist Hlth, Global Ctr Mass Gatherings Med, Riyadh 11176, Saudi Arabia.
   [Cotten, Matthew; Watson, Simon J.; Kellam, Paul; Palser, Anne L.; Gall, Astrid; Bashford-Rogers, Rachael] Wellcome Trust Sanger Inst, Hinxton, England.
   [Makhdoom, Hatem Q.; Madani, Hossam] Minist Hlth, Jeddah Reg Lab, Jeddah, Saudi Arabia.
   [Al-Tawfiq, Jaffar A.] Saudi Aramco Med Serv Org, Dhahran, Saudi Arabia.
   [Rambaut, Andrew] Ashworth Labs, Inst Evolutionary Biol, Edinburgh, Midlothian, Scotland.
   [Rambaut, Andrew] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
   [AlRabiah, Fahad A.; Al Hajjar, Sami] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia.
   [Al-Nassir, Wafa N.] Natl Guard Hlth Affairs Dammam, Imam Abdulrahman Bin Mohamed Hosp, Dammam, Saudi Arabia.
   [Albarrak, Ali] Prince Sultan Mil Med City, Riyadh, Saudi Arabia.
   [Flemban, Hesham] Alhada Mil Hosp, Riyadh, Saudi Arabia.
   [Balkhy, Hanan H.] King Abdul Aziz Med City, Riyadh, Saudi Arabia.
   [Alsubaie, Sarah] King Saud Univ, Riyadh 11451, Saudi Arabia.
   [Kellam, Paul; Zumla, Alimuddin I.] UCL, Div Infect & Immun, London, England.
   [Zumla, Alimuddin I.] UCL Hosp NHS Fdn Trust, London, England.
RP Memish, ZA (reprint author), Minist Hlth, Global Ctr Mass Gatherings Med, Riyadh 11176, Saudi Arabia.
EM zmemish@yahoo.com
RI Rambaut, Andrew/B-2481-2009
OI Rambaut, Andrew/0000-0003-4337-3707; Cotten,
   Matthew/0000-0002-3361-3351; Rambaut FRSE, Professor
   Andrew/0000-0002-1278-598X; Bashford-Rogers,
   Rachael/0000-0002-6838-0711; Gall, Astrid/0000-0001-6452-5816; Kellam,
   Paul/0000-0003-3166-4734; Alsubaie, Sarah/0000-0002-3128-5921; Assiri,
   Abdullah/0000-0002-5605-2876; Zumla, Alimuddin/0000-0002-5111-5735
FU Saudi Arabian Ministry of Health; Wellcome TrustWellcome Trust; European
   CommunityEuropean Community (EC); National Institute of Health Research
   University College London Hospitals Biomedical Research Centre
FX Funding Saudi Arabian Ministry of Health, Wellcome Trust, European
   Community, and National Institute of Health Research University College
   London Hospitals Biomedical Research Centre.
CR AlBarrak AM, 2012, SAUDI MED J, V33, P1265
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bottcher E, 2006, J VIROL, V80, P9896, DOI 10.1128/JVI.01118-06
   Breban R, 2013, LANCET, V382, P694, DOI 10.1016/S0140-6736(13)61492-0
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   Cotten M, 2013, EMERG INFECT DIS, V19, P736, DOI 10.3201/eid1905.130057
   Delport W, 2010, BIOINFORMATICS, V26, P2455, DOI 10.1093/bioinformatics/btq429
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013
   Guan Y, 2004, LANCET, V363, P99, DOI 10.1016/S0140-6736(03)15259-2
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Minin VN, 2008, MOL BIOL EVOL, V25, P1459, DOI 10.1093/molbev/msn090
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rambaut A., NOVEL HUMAN BETACORO
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Sheahan T, 2008, J VIROL, V82, P2274, DOI 10.1128/JVI.02041-07
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   World Health Organization, 2013, MIDDL E RESP SYNDR C
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 32
TC 152
Z9 169
U1 3
U2 54
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD DEC 14
PY 2013
VL 382
IS 9909
BP 1993
EP 2002
DI 10.1016/S0140-6736(13)61887-5
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 269EI
UT WOS:000328223700026
PM 24055451
OA Green Published, Green Accepted, Other Gold
DA 2020-04-03
ER

PT J
AU van der Hoek, L
   Sure, K
   Ihorst, G
   Stang, A
   Pyrc, K
   Jebbink, MF
   Petersen, G
   Forster, J
   Berkhout, B
   Uberla, K
AF van der Hoek, L
   Sure, K
   Ihorst, G
   Stang, A
   Pyrc, K
   Jebbink, MF
   Petersen, G
   Forster, J
   Berkhout, B
   Uberla, K
TI Croup is associated with the novel coronavirus NL63
SO PLOS MEDICINE
LA English
DT Article
ID RESPIRATORY-TRACT INFECTIONS; YOUNG-CHILDREN; DISEASE; IDENTIFICATION;
   ASSAY; AGE
AB Background The clinical relevance of infections with the novel human coronavirus NL63 (HCoV-NL63) has not been investigated systematically. We therefore determined its association with disease in young children with lower respiratory tract infection (LRTI).
   Methods and Findings Nine hundred forty-nine samples of nasopharyngeal secretions from children under 3 y of age with LRTIs were analysed by a quantitative HCoV-NL63-specific real-time PCR. The samples had been collected from hospitalised patients and outpatients from December 1999 to October 2001 in four different regions in Germany as part of the prospective population-based PRI.DE study and analysed for RNA from respiratory viruses. Forty-nine samples (5.2%), mainly derived from the winter season, were positive for HCoV-NL63 RNA. The viral RNA was more prevalent in samples from outpatients (7.9%) than from hospitalised patients (3.2%, p = 0.003), and co-infection with either respiratory syncytial virus or parainfluenza virus 3 was observed frequently. Samples in which only HCoV-NL63 RNA could be detected had a significantly higher viral load than samples containing additional respiratory viruses (median 2.1 x 10(6) versus 2.7 x 10(2) copies/ml, p = 0.0006). A strong association with croup was apparent: 43% of the HCoV-NL63-positive patients with high HCoV-NL63 load and absence of co-infection suffered from croup, compared to 6% in the HCoV-NL63-negative group, p < 0.0001. A significantly higher fraction (17.4%) of samples from croup patients than from non-croup patients (4.2%) contained HCoV-NL63 RNA.
   Conclusion HCoV-NL63 infections occur frequently in young children with LRTI and show a strong association with croup, suggesting a causal relationship.
C1 Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands.
   Ruhr Univ Bochum, Dept Mol & Med Virol, D-4630 Bochum, Germany.
   Univ Hosp, Ctr Clin Trials, Freiburg, Germany.
   Univ Hosp, Inst Med Biometry & Med Informat, Freiburg, Germany.
   Wyeth Pharma, Munster, Germany.
   St Josefs Hosp, Freiburg, Germany.
RP van der Hoek, L (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM c.m.vanderhoek@amc.uva.nl
RI Uberla, Klaus/C-5676-2008; van der Hoek, Lia/Y-6412-2019
OI Pyrc, Krzysztof/0000-0002-3867-7688
CR Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869
   DENNY FW, 1986, J PEDIATR-US, V108, P635, DOI 10.1016/S0022-3476(86)81034-4
   DENNY FW, 1983, PEDIATRICS, V71, P871
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289
   ELLIS EF, 1983, J ALLERGY CLIN IMMUN, V72, P526, DOI 10.1016/0091-6749(83)90479-7
   Esper F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138
   Forster J, 2004, EUR J PEDIATR, V163, P709, DOI 10.1007/s00431-004-1523-9
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Kehl SC, 2001, J CLIN MICROBIOL, V39, P1696, DOI 10.1128/JCM.39.5.1696-1701.2001
   Konig B, 2004, J CLIN MICROBIOL, V42, P4632, DOI 10.1128/JCM.42.10.4632-4635.2004
   MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7
   Moes E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-6
   Osterhaus ADME, 2004, PHILOS T ROY SOC B, V359, P1081, DOI 10.1098/rstb.2004.1489
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pyrc K, 2004, VIROL J, V1, DOI 10.1186/1743-422X-1-7
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
NR 19
TC 152
Z9 161
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD AUG
PY 2005
VL 2
IS 8
BP 764
EP 770
AR e240
DI 10.1371/journal.pmed.0020240
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 961QM
UT WOS:000231676900024
PM 16104827
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Yount, B
   Curtis, KM
   Baric, RS
AF Yount, B
   Curtis, KM
   Baric, RS
TI Strategy for systematic assembly of large RNA and DNA genomes:
   Transmissible gastroenteritis virus model
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; PORCINE RESPIRATORY CORONAVIRUS; CDNA CLONES;
   BRONCHITIS VIRUS; AMINOPEPTIDASE-N; DELETION MUTANT; SEQUENCE;
   MUTAGENESIS; GENE; RECOMBINATION
AB A systematic method was developed to assemble functional full-length genomes of large RNA and DNA viruses. Coronaviruses contain the largest single-stranded positive-polarity RNA genome in nature. The similar to 30 kb genome, coupled with regions of genomic instability, has hindered the development of a full-length infectious cDNA construct. We have assembled a full-length infectious construct of transmissible gastroenteritis virus (TGEV), an important pathogen in swine. Using a novel approach, six adjoining cDNA subclones that span the entire TGEV genome were isolated. Each clone was engineered with unique flanking interconnecting junctions which determine a precise systematic assembly with only the adjacent cDNA subclones, resulting in an intact TGEV cDNA construct of similar to 28.5 kb in length. Transcripts derived from the full-length TGEV construct were infectious, and progeny virions were serially passaged in permissive host cells. Viral antigen production and subgenomic mRNA synthesis were evident during infection and throughout passage. Plaque-purified virus derived from the infectious construct replicated efficiently and displayed similar plaque morphology in permissive host cells. Host range phenotypes of the molecularly cloned and wild-type viruses were similar in cells of swine and feline origin. The recombinant viruses were sequenced across the unique interconnecting junctions, conclusively demonstrating the marker mutations and restriction sites that were engineered into the component clones. Pull-length infectious constructs of TGEV will permit the precise genetic modification of the coronavirus genome. The method that we have designed to generate an infectious cDNA construct of TGEV could theoretically be used to precisely reconstruct microbial or eukaryotic genomes approaching several million base pairs in length.
C1 Univ N Carolina, Dept Epidemiol, Sch Publ Hlth, Program Infect Dis, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
RP Baric, RS (reprint author), Univ N Carolina, Dept Epidemiol, Sch Publ Hlth, Program Infect Dis, Chapel Hill, NC 27599 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 23946, R01 AI023946]
CR Agapov EV, 1998, P NATL ACAD SCI USA, V95, P12989, DOI 10.1073/pnas.95.22.12989
   AHLQUIST P, 1984, P NATL ACAD SCI-BIOL, V81, P7066, DOI 10.1073/pnas.81.22.7066
   Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   Baric RS, 1999, J VIROL, V73, P638, DOI 10.1128/JVI.73.1.638-649.1999
   Baric RS, 2000, J VIROL, V74, P4039, DOI 10.1128/JVI.74.9.4039-4046.2000
   BARIC RS, 1990, VIROLOGY, V177, P646, DOI 10.1016/0042-6822(90)90530-5
   BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BOYER JC, 1994, VIROLOGY, V198, P415, DOI 10.1006/viro.1994.1053
   CAVANAGH D, 1993, ARCH VIROL, V128, P395, DOI 10.1007/BF01309450
   CHEN CM, 1995, VIRUS RES, V38, P83, DOI 10.1016/0168-1702(95)00046-S
   Cho MK, 1999, SCIENCE, V286, P2087, DOI 10.1126/science.286.5447.2087
   DAVIS NL, 1989, VIROLOGY, V171, P189, DOI 10.1016/0042-6822(89)90526-6
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999
   ELEOUET JF, 1995, VIROLOGY, V206, P817, DOI 10.1006/viro.1995.1004
   Enjuanes L., 1995, The coronaviridae., P337
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   Grimes B, 1998, HUM MOL GENET, V7, P1635, DOI 10.1093/hmg/7.10.1635
   Grundemann D, 1996, BIOTECHNIQUES, V21, P898
   HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419
   Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165
   KOETZNER CA, 1992, J VIROL, V66, P1841, DOI 10.1128/JVI.66.4.1841-1848.1992
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   Lyakhov DL, 1998, J MOL BIOL, V280, P201, DOI 10.1006/jmbi.1998.1854
   McGoldrick A, 1999, ARCH VIROL, V144, P763, DOI 10.1007/s007050050541
   Messerle M, 1997, P NATL ACAD SCI USA, V94, P14759, DOI 10.1073/pnas.94.26.14759
   Peters CJ, 1996, FIELDS VIROLOGY, P1161
   RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391
   RASSCHAERT D, 1987, J GEN VIROL, V68, P1883, DOI 10.1099/0022-1317-68-7-1883
   RICE C M, 1989, New Biologist, V1, P285
   RICE CM, 1987, J VIROL, V61, P3809, DOI 10.1128/JVI.61.12.3809-3819.1987
   Risco C, 1996, J VIROL, V70, P4773, DOI 10.1128/JVI.70.7.4773-4777.1996
   ROSE LRF, 1987, THEOR APPL FRACT MEC, V7, P125, DOI 10.1016/0167-8442(87)90026-7
   ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680
   SAMBROOK J, 1989, MOL CLONING, V2, P1
   SCHAAD MC, 1994, J VIROL, V68, P8169, DOI 10.1128/JVI.68.12.8169-8179.1994
   SCHOCHETMAN G, 1977, VIROLOGY, V77, P772, DOI 10.1016/0042-6822(77)90498-6
   SETHNA PB, 1991, J VIROL, V65, P320, DOI 10.1128/JVI.65.1.320-325.1991
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   SIDDELL SG, 1995, CORONAVIRIDAE, P1
   Smith GA, 2000, P NATL ACAD SCI USA, V97, P4873, DOI 10.1073/pnas.080502497
   SNIJDER EJ, 1993, J GEN VIROL, V74, P2305, DOI 10.1099/0022-1317-74-11-2305
   SOSNOVTSEV S, 1995, VIROLOGY, V210, P383, DOI 10.1006/viro.1995.1354
   SUMYOSHI H, 1992, J VIROL, V66, P5425
   TAHARA SM, 1994, VIROLOGY, V202, P621, DOI 10.1006/viro.1994.1383
   TONGCHUAN H, 1998, P NATL ACAD SCI USA, V95, P2509
   Tresnan DB, 1996, J VIROL, V70, P8669, DOI 10.1128/JVI.70.12.8669-8674.1996
   TUNG FYT, 1992, VIROLOGY, V186, P676, DOI 10.1016/0042-6822(92)90034-M
   VANDERMOST RG, 1992, NUCLEIC ACIDS RES, V20, P3375, DOI 10.1093/nar/20.13.3375
   vanDinten LC, 1997, P NATL ACAD SCI USA, V94, P991, DOI 10.1073/pnas.94.3.991
   VANZIJL M, 1988, J VIROL, V62, P2191, DOI 10.1128/JVI.62.6.2191-2195.1988
   VAUGHN EM, 1995, J VIROL, V69, P3176, DOI 10.1128/JVI.69.5.3176-3184.1995
   WESLEY RD, 1991, J VIROL, V65, P3369, DOI 10.1128/JVI.65.6.3369-3373.1991
   WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388
NR 58
TC 152
Z9 179
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 2000
VL 74
IS 22
BP 10600
EP 10611
DI 10.1128/JVI.74.22.10600-10611.2000
PG 12
WC Virology
SC Virology
GA 367WE
UT WOS:000090083800035
PM 11044104
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Freymuth, F
   Vabret, A
   Brouard, J
   Toutain, F
   Verdon, R
   Petitjean, J
   Gouarin, S
   Duhamel, JF
   Guillois, B
AF Freymuth, F
   Vabret, A
   Brouard, J
   Toutain, F
   Verdon, R
   Petitjean, J
   Gouarin, S
   Duhamel, JF
   Guillois, B
TI Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae
   infections in exacerbations of asthma in children
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE asthma; rhinovirus; respiratory syncytial virus; Chlamydia; mycoplasma
ID RESPIRATORY SYNCYTIAL VIRUS; POLYMERASE-CHAIN-REACTION;
   ENZYME-IMMUNOASSAY; TRACT INFECTIONS; RHINOVIRUS; INFANTS;
   HYBRIDIZATION; ADENOVIRUS; SPECIMENS; ADULTS
AB Background: A high frequency of virus infections has been recently pointed out in the exacerbations of asthma in children.
   Objectives: To confirm this, using conventional and molecular detection methods, and expanding the study to younger children.
   Study design: One hundred and thirty-two nasal aspirates from 75 children hospitalized for a severe attack of asthma were studied (32 infants, mean age 9.1 months; and 43 children, mean age 5.6 years). According to the virus, a viral isolation technique, immunofluorescence assays (IFA) or both were used for the detection of rhinovirus, enterovirus, respiratory syncytial (RS) virus, adenovirus, coronavirus 229E, influenza and parainfluenza virus. Polymerase chain reaction (PCR) assays were used for the detection of rhinovirus, enterovirus, RS virus, adenovirus, coronavirus 229E and OC43, Chlamydia pneumoniae and Mycoplasma pneumoniae.
   Results: Using IFA and viral isolation techniques, viruses were detected in 33.3% of cases, and by PCR techniques, nucleic acid sequences of virus, Chlamydia pneumoniae and Mycoplasma pneumoniae were obtained in 71.9% of cases. The combination of conventional and molecular techniques detects 81.8% of positive samples. Two organisms were identified in the same nasal sample in 20.4% of the cases. The percentage of detections was higher (85.9%) in the younger group than in the other (77%). The most frequently detected agents were rhinovirus (46.9%) and RS virus (21.2%). Using PCR rather than conventional techniques, the detection rates were increased 5.8- and 1.6-fold in rhinovirus and RS virus infections, respectively. The detection levels of the other organisms are as follows: 9.8, 5.1, 4.5, 4.5, 4.5, 3.7, and 2.2% for enterovirus, influenza virus, Chlamydia pneumoniae, adenovirus, coronavirus, parainfluenza virus, and Mycoplasma pneumoniae, respectively.
   Conclusion: These results confirm the previously reported high frequency of rhinovirus detection in asthmatic exacerbations in children. They also point out the frequency of RS virus detection, and emphasize the fact that PCR assays may be necessary to diagnose respiratory infections in asthma. (C) 1999 Published by Elsevier Science B.V. All rights reserved.
C1 Univ Hosp, Lab Human & Mol Virol, F-14033 Caen, France.
   Univ Hosp, Dept Pediatry, F-14033 Caen, France.
   Univ Hosp, Dept Infect Dis, F-14033 Caen, France.
RP Freymuth, F (reprint author), Univ Hosp, Lab Human & Mol Virol, Av G Clemenceau, F-14033 Caen, France.
RI Brouard, Jacques/AAH-3387-2020
OI VABRET, Astrid/0000-0002-8940-7645
CR DEBARBEYRAC B, 1993, CLIN INFECT DIS   S1, V17, P83
   DOUGLAS RG, 1966, AM REV RESPIR DIS, V94, P159
   FREYMUTH F, 1991, J CLIN MICROBIOL, V29, P653, DOI 10.1128/JCM.29.3.653-655.1991
   FREYMUTH F, 1995, J CLIN MICROBIOL, V33, P3352, DOI 10.1128/JCM.33.12.3352-3355.1995
   FREYMUTH F, 1986, ARCH FR PEDIATR, V43, P677
   FREYMUTH F, 1987, ANN PEDIATR-PARIS, V34, P493
   Freymuth F, 1996, J CLIN MICROBIOL, V34, P1601
   Freymuth F, 1997, CLIN DIAGN VIROL, V8, P31, DOI 10.1016/S0928-0197(97)00060-3
   GAMA RE, 1989, J MED VIROL, V28, P73, DOI 10.1002/jmv.1890280204
   Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003
   HALL CB, 1976, J PEDIATR-US, V89, P11, DOI 10.1016/S0022-3476(76)80918-3
   HIERHOLZER JC, 1993, J CLIN MICROBIOL, V31, P1886, DOI 10.1128/JCM.31.7.1886-1891.1993
   HYYPIA T, 1989, J GEN VIROL, V70, P3261, DOI 10.1099/0022-1317-70-12-3261
   JENNINGS LC, 1987, NZ MED J, V10, P488
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P11
   KELLNER G, 1989, ACTA PAEDIATR SCAND, V78, P390, DOI 10.1111/j.1651-2227.1989.tb11098.x
   MAMMES O, 1994, THESIS PARIS
   MIDULLA F, 1993, J INFECT DIS, V168, P1515, DOI 10.1093/infdis/168.6.1515
   Nadel JA, 1998, AM J RESP CRIT CARE, V157, pS130, DOI 10.1164/ajrccm.157.4.nhlb1-11
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x
   Petitjean J, 1998, J MED MICROBIOL, V47, P615, DOI 10.1099/00222615-47-7-615
NR 23
TC 152
Z9 157
U1 2
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
J9 J CLIN VIROL
JI J. Clin. Virol.
PD AUG
PY 1999
VL 13
IS 3
BP 131
EP 139
DI 10.1016/S1386-6532(99)00030-X
PG 9
WC Virology
SC Virology
GA 220DB
UT WOS:000081648300002
PM 10443789
DA 2020-04-03
ER

PT J
AU SUZUMURA, A
   LAVI, E
   WEISS, SR
   SILBERBERG, DH
AF SUZUMURA, A
   LAVI, E
   WEISS, SR
   SILBERBERG, DH
TI CORONAVIRUS INFECTION INDUCES H-2-ANTIGEN EXPRESSION ON OLIGODENDROCYTES
   AND ASTROCYTES
SO SCIENCE
LA English
DT Article
C1 UNIV PITTSBURGH,SCH MED,DEPT MICROBIOL,PITTSBURGH,PA 15261.
RP SUZUMURA, A (reprint author), UNIV PITTSBURGH,SCH MED,DEPT NEUROL,PITTSBURGH,PA 15261, USA.
FU NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [NS21954, NS11037]
CR COLLINS AR, 1983, INFECT IMMUN, V40, P1192, DOI 10.1128/IAI.40.3.1192-1197.1983
   COSTA J, 1977, NATURE, V269, P251, DOI 10.1038/269251a0
   FLEMING JO, 1983, IMMUNOLOGY NERVOUS S, P91
   FONTANA A, 1984, NATURE, V307, P273, DOI 10.1038/307273a0
   HAUSER SL, 1983, J NEUROIMMUNOL, V5, P197, DOI 10.1016/0165-5728(83)90010-3
   HELENIUS A, 1978, P NATL ACAD SCI USA, V75, P3846, DOI 10.1073/pnas.75.8.3846
   HIRAYAMA M, 1983, J NEUROPATH EXP NEUR, V42, P16, DOI 10.1097/00005072-198301000-00002
   HIRSCH MR, 1983, NEUROSCI LETT, V41, P199, DOI 10.1016/0304-3940(83)90247-1
   INADA T, 1984, NATURE, V309, P59, DOI 10.1038/309059a0
   JACOBSON S, 1984, J IMMUNOL, V133, P754
   KORNGOLD R, 1983, J IMMUNOL, V130, P2236
   LAMPSON LA, 1984, P NATL ACAD SCI-BIOL, V81, P6476, DOI 10.1073/pnas.81.20.6476
   LAMPSON LA, 1983, J IMMUNOL, V130, P2471
   LAVI E, 1984, J VIROL, V51, P563, DOI 10.1128/JVI.51.2.563-566.1984
   LAVI E, 1984, NEUROLOGY, V34, P597, DOI 10.1212/WNL.34.5.597
   LAVI E, UNPUB
   LISAK RP, 1983, BRAIN RES, V289, P285, DOI 10.1016/0006-8993(83)90029-X
   MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890
   MERRILL JE, 1984, SCIENCE, V224, P1428, DOI 10.1126/science.6610212
   RAHMAN AA, 1976, J IMMUNOL, V117, P253
   ROBB JA, 1979, VIROLOGY, V94, P385, DOI 10.1016/0042-6822(79)90469-0
   ROSENTHAL A, 1985, NATURE, V315, P579, DOI 10.1038/315579a0
   SCHNITZER J, 1981, J NEUROIMMUNOL, V1, P429, DOI 10.1016/0165-5728(81)90022-9
   SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0
   SUZUMURA A, 1984, BRAIN RES, V324, P379, DOI 10.1016/0006-8993(84)90054-4
   SUZUMURA A, 1985, BRAIN RES, V336, P171, DOI 10.1016/0006-8993(85)90431-7
   SUZUMURA A, J NEUROIMMUNOL
   TRAUGOTT U, 1983, SCIENCE, V219, P308, DOI 10.1126/science.6217550
   WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0
   ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0
   ZINKERNAGEL RM, 1976, P NATL ACAD SCI USA, V73, P3666, DOI 10.1073/pnas.73.10.3666
NR 31
TC 152
Z9 152
U1 0
U2 1
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005
SN 0036-8075
J9 SCIENCE
JI Science
PD MAY 23
PY 1986
VL 232
IS 4753
BP 991
EP 993
DI 10.1126/science.3010460
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA C3195
UT WOS:A1986C319500031
PM 3010460
DA 2020-04-03
ER

PT J
AU Buchholz, UJ
   Bukreyev, A
   Yang, LJ
   Lamirande, EW
   Murphy, BR
   Subbarao, K
   Collins, PL
AF Buchholz, UJ
   Bukreyev, A
   Yang, LJ
   Lamirande, EW
   Murphy, BR
   Subbarao, K
   Collins, PL
TI Contributions of the structural proteins of severe acute respiratory
   syndrome coronavirus to protective immunity
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID FELINE INFECTIOUS PERITONITIS; PARAINFLUENZA VIRUS TYPE-3; SYNCYTIAL
   VIRUS; HEMAGGLUTININ-NEURAMINIDASE; BRONCHITIS-VIRUS; CYTOPLASMIC TAILS;
   ENVELOPE PROTEIN; REPLICATION; RESISTANCE; PARTICLES
AB We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of 5, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.
C1 NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
RP Buchholz, UJ (reprint author), NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
EM ubuchholz@niaid.nih.gov
OI Subbarao, Kanta/0000-0003-1713-3056
CR Bos ECW, 1996, VIROLOGY, V218, P52, DOI 10.1006/viro.1996.0165
   Buchholz UJ, 1999, J VIROL, V73, P251, DOI 10.1128/JVI.73.1.251-259.1999
   BUKREYEV A, 2004, IN PRESS LANCET
   Collisson EW, 2000, DEV COMP IMMUNOL, V24, P187, DOI 10.1016/S0145-305X(99)00072-5
   CONNORS M, 1991, J VIROL, V65, P1634, DOI 10.1128/JVI.65.3.1634-1637.1991
   Corse E, 2003, VIROLOGY, V312, P25, DOI 10.1016/S0042-6822(03)00175-2
   Durbin AP, 2003, CLIN INFECT DIS, V37, P1668, DOI 10.1086/379775
   Godeke GJ, 2000, J VIROL, V74, P1566, DOI 10.1128/JVI.74.3.1566-1571.2000
   Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929
   KARRON RA, 1995, J INFECT DIS, V171, P1107, DOI 10.1093/infdis/171.5.1107
   Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998
   KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125
   KULKARNI AB, 1993, J VIROL, V67, P1044, DOI 10.1128/JVI.67.2.1044-1049.1993
   LAI MM, 2001, FIELDS VIROLOGY, V2, P1163
   Lim KP, 2001, J BIOL CHEM, V276, P17515, DOI 10.1074/jbc.M009731200
   LOCKER JK, 1995, J BIOL CHEM, V270, P8815, DOI 10.1074/jbc.270.15.8815
   Narayanan K, 2000, J VIROL, V74, P8127, DOI 10.1128/JVI.74.17.8127-8134.2000
   OPSTELTEN DJE, 1995, J CELL BIOL, V131, P339, DOI 10.1083/jcb.131.2.339
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Schmidt AC, 2000, J VIROL, V74, P8922, DOI 10.1128/JVI.74.19.8922-8929.2000
   Schmidt AC, 2002, J VIROL, V76, P1089, DOI [10.1128/JVI.76.3.1089-1099.2002, 10.1128/JVI.76.23.12355-12359.2002]
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Tao T, 2000, VACCINE, V18, P1359, DOI 10.1016/S0264-410X(99)00406-5
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   VENNEMA H, 1991, VIROLOGY, V181, P327, DOI 10.1016/0042-6822(91)90499-2
   Waning DL, 2002, J VIROL, V76, P9284, DOI 10.1128/JVI.76.18.9284-9297.2002
   WEISS RC, 1981, COMP IMMUNOL MICROB, V4, P175, DOI 10.1016/0147-9571(81)90003-5
   *WHO, 2003, WKLY EPIDEMIOL REC, V78, P81
NR 31
TC 151
Z9 167
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 29
PY 2004
VL 101
IS 26
BP 9804
EP 9809
DI 10.1073/pnas.0403492101
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 834IU
UT WOS:000222405600052
PM 15210961
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU LEIBOWITZ, JL
   WILHELMSEN, KC
   BOND, CW
AF LEIBOWITZ, JL
   WILHELMSEN, KC
   BOND, CW
TI THE VIRUS-SPECIFIC INTRACELLULAR RNA SPECIES OF 2 MURINE CORONAVIRUSES -
   MHV-A59 AND MHV-JHM
SO VIROLOGY
LA English
DT Article
RP LEIBOWITZ, JL (reprint author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093, USA.
FU NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [NS 13898, NS 07078, NS 15211]
CR BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8
   BAILEY OT, 1949, J EXP MED, V90, P195, DOI 10.1084/jem.90.3.195
   BOND CW, 1979, VIROLOGY, V94, P371, DOI 10.1016/0042-6822(79)90468-9
   BORUN TW, 1967, BIOCHIM BIOPHYS ACTA, V149, P302, DOI 10.1016/0005-2787(67)90715-0
   BREZESKI H, 1978, J VIROL, V25, P630
   GUY JS, 1979, J VIROL, V29, P293, DOI 10.1128/JVI.29.1.293-300.1979
   HORWITZ MS, 1971, J VIROL, V8, P675, DOI 10.1128/JVI.8.5.675-683.1971
   LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978
   LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1
   LEE YF, 1979, J GEN VIROL, V44, P311, DOI 10.1099/0022-1317-44-2-311
   LEIBOWITZ JL, P S BIOL BIOCH CORON
   LOMNICZI B, 1977, J VIROL, V24, P99, DOI 10.1128/JVI.24.1.99-107.1977
   LOMNICZI B, 1977, J GEN VIROL, V36, P531, DOI 10.1099/0022-1317-36-3-531
   MACNAUGHTON MR, 1978, J GEN VIROL, V39, P497, DOI 10.1099/0022-1317-39-3-497
   MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835
   MISHRA NK, 1973, AM J VET RES, V34, P185
   PETTERSSON U, 1973, J MOL BIOL, V73, P125, DOI 10.1016/0022-2836(73)90164-2
   PLAGEMANN PG, 1966, J BACTERIOL, V91, P2317, DOI 10.1128/JB.91.6.2317-2326.1966
   ROBB JA, 1979, VIROLOGY, V94, P385, DOI 10.1016/0042-6822(79)90469-0
   ROBB JA, 1979, VIROLOGY, V94, P352, DOI 10.1016/0042-6822(79)90467-7
   ROBB JA, 1979, COMPREHENSIVE VIROLO, V14, P193
   SCHOCHETMAN G, 1977, VIROLOGY, V77, P772, DOI 10.1016/0042-6822(77)90498-6
   SIDDELL SG, 1980, J VIROL, V33, P10, DOI 10.1128/JVI.33.1.10-17.1980
   STERN DF, 1980, J VIROL, V36, P440, DOI 10.1128/JVI.36.2.440-449.1980
   STERN DF, 1980, J VIROL, V34, P665, DOI 10.1128/JVI.34.3.665-674.1980
   STURMAN LS, 1977, VIROLOGY, V77, P637, DOI 10.1016/0042-6822(77)90488-3
   STURMAN LS, 1972, INFECT IMMUN, V6, P501, DOI 10.1128/IAI.6.4.501-507.1972
   TANNOCK GA, 1978, J GEN VIROL, V39, P29, DOI 10.1099/0022-1317-39-1-29
   TYRELL DAJ, 1978, INTERVIROLOGY, V10, P321
   VANDERZEIST B, P S BIOL BIOCH CORON
   WEGE H, 1979, J GEN VIROL, V42, P37, DOI 10.1099/0022-1317-42-1-37
   WEGE H, 1978, J GEN VIROL, V41, P217, DOI 10.1099/0022-1317-41-2-217
   WEISS SR, P S BIOL BIOCH CORON
   WILT FH, 1977, CELL, V11, P673, DOI 10.1016/0092-8674(77)90084-8
   YOGO Y, 1977, J BIOCHEM-TOKYO, V82, P1103, DOI 10.1093/oxfordjournals.jbchem.a131782
NR 35
TC 151
Z9 151
U1 0
U2 1
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PY 1981
VL 114
IS 1
BP 39
EP 51
DI 10.1016/0042-6822(81)90250-6
PG 13
WC Virology
SC Virology
GA MH568
UT WOS:A1981MH56800004
PM 7281517
DA 2020-04-03
ER

PT J
AU Huang, CL
   Wang, YM
   Li, XW
   Ren, LL
   Zhao, JP
   Hu, Y
   Zhang, L
   Fan, GH
   Xu, JY
   Gu, XY
   Cheng, ZS
   Yu, T
   Xia, JA
   Wei, Y
   Wu, WJ
   Xie, XL
   Yin, W
   Li, H
   Liu, M
   Xiao, Y
   Gao, H
   Guo, L
   Xie, JG
   Wang, GF
   Jiang, RM
   Gao, ZC
   Jin, Q
   Wang, JW
   Cao, B
AF Huang, Chaolin
   Wang, Yeming
   Li, Xingwang
   Ren, Lili
   Zhao, Jianping
   Hu, Yi
   Zhang, Li
   Fan, Guohui
   Xu, Jiuyang
   Gu, Xiaoying
   Cheng, Zhenshun
   Yu, Ting
   Xia, Jiaan
   Wei, Yuan
   Wu, Wenjuan
   Xie, Xuelei
   Yin, Wen
   Li, Hui
   Liu, Min
   Xiao, Yan
   Gao, Hong
   Guo, Li
   Xie, Jungang
   Wang, Guangfa
   Jiang, Rongmeng
   Gao, Zhancheng
   Jin, Qi
   Wang, Jianwei
   Cao, Bin
TI Clinical features of patients infected with 2019 novel coronavirus in
   Wuhan, China
SO LANCET
LA English
DT Article
ID EAST RESPIRATORY SYNDROME; INFLAMMATORY CYTOKINES; SARS
AB Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients.
   Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not.
   Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49.0 years (IQR 41.0-58.0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8.0 days [IQR 5.0-13.0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNF alpha.
   Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Huang, Chaolin; Zhang, Li; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei] Jin Yin tan Hosp, Wuhan, Peoples R China.
   [Wang, Yeming; Fan, Guohui; Gu, Xiaoying; Li, Hui; Cao, Bin] China Japan Friendship Hosp, Ctr Resp Med, Natl Clin Res Ctr Resp Dis, Dept Pulm & Crit Care Med, Beijing, Peoples R China.
   [Fan, Guohui; Gu, Xiaoying] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing, Peoples R China.
   [Liu, Min] China Japan Friendship Hosp, Dept Radiol, Beijing, Peoples R China.
   [Wang, Yeming; Fan, Guohui; Gu, Xiaoying; Li, Hui; Cao, Bin] Chinese Acad Med Sci, Inst Resp Med, Peking Union Med Coll, Beijing, Peoples R China.
   [Wang, Yeming; Li, Hui; Cao, Bin] Capital Med Univ, Dept Resp Med, Beijing, Peoples R China.
   [Li, Xingwang; Jiang, Rongmeng] Capital Med Univ, Beijing Ditan Hosp, Clin & Res Ctr Infect Dis, Beijing, Peoples R China.
   [Ren, Lili; Xiao, Yan; Guo, Li; Jin, Qi; Wang, Jianwei] Chinese Acad Med Sci & Peking Union Med Coll, NHC Key Lab Syst Biol Pathogens & Christophe Meri, Inst Pathogen Biol, Beijing 100730, Peoples R China.
   [Gao, Hong] Chinese Acad Med Sci & Peking Union Med Coll, Inst Lab Anim Sci, Beijing, Peoples R China.
   [Zhao, Jianping; Xie, Jungang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China.
   [Hu, Yi; Yin, Wen] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pulm & Crit Care Med, Cent Hosp Wuhan, Wuhan, Peoples R China.
   [Xu, Jiuyang] Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   [Cheng, Zhenshun] Wuhan Univ, Resp Med, Zhongnan Hosp, Wuhan, Peoples R China.
   [Wang, Guangfa] Peking Univ First Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China.
   [Gao, Zhancheng] Peking Univ Peoples Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China.
   [Cao, Bin] Tsinghua Univ Peking Univ Joint Ctr Life Sci, Beijing, Peoples R China.
RP Wang, JW (reprint author), Chinese Acad Med Sci & Peking Union Med Coll, NHC Key Lab Syst Biol Pathogens & Christophe Meri, Inst Pathogen Biol, Beijing 100730, Peoples R China.; Cao, B (reprint author), China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Beijing 100029, Peoples R China.
EM wangjw28@163.com; caobin_ben@163.com
RI Ribeiro, Nuno/AAH-2299-2020
FU Ministry of Science and Technology [2020YFC0841300]; Chinese Academy of
   Medical Sciences (CAMS) Innovation Fund for Medical Sciences [CIFMS
   2018-I2M-1-003]; National Science Grant for Distinguished Young Scholars
   [81425001/H0104]; National Key Research and Development Program of China
   [2018YFC1200102]; Beijing Science and Technology Project
   [Z19110700660000]; CAMS Innovation Fund for Medical Sciences
   [2016-I2M-1-014]; National Mega-projects for Infectious Diseases in
   China [2017ZX10103004, 2018ZX10305409]
FX This work is funded by the Special Project for Emergency of the Ministry
   of Science and Technology (2020YFC0841300) Chinese Academy of Medical
   Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS
   2018-I2M-1-003), a National Science Grant for Distinguished Young
   Scholars (81425001/H0104), the National Key Research and Development
   Program of China (2018YFC1200102), The Beijing Science and Technology
   Project (Z19110700660000), CAMS Innovation Fund for Medical Sciences
   (2016-I2M-1-014), and National Mega-projects for Infectious Diseases in
   China (2017ZX10103004 and 2018ZX10305409). We acknowledge all
   health-care workers involved in the diagnosis and treatment of patients
   in Wuhan; we thank the Chinese National Health Commission for
   coordinating data collection for patients with 2019-nCoV infection; we
   thank WHO and the International Severe Acute Respiratory and Emerging
   Infections Consortium (ISARIC) for sharing data collection templates
   publicly on the website; and we thank Prof Chen Wang and Prof George F
   Gao for guidance in study design and interpretation of results.
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   CDC, 2020, 1 TRAV REL CAS 2019
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   Gao Chang, 2020, Crit Care Med, V48, P451, DOI 10.1097/CCM.0000000000004207
   GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group, 2012, KDIGO CLIN PRACTICE
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lansbury L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub3
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Richman DD, 2016, CLIN VIROLOGY
   Sanz F, 2011, EUR RESP J S55, V38, P2492
   Sheahan Timothy P, 2020, Nat Commun, V11, P222, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tan W, 2019, NOVEL CORONAVIRUS GE
   Wang Manli, 2013, Virologica Sinica, V28, P315, DOI 10.1007/s12250-013-3402-x
   WHO, 2003, SUMM PROB SARS CAS O
   WHO, 2020, NOVEL CORONAVIR 0114
   WHO, 2020, NOVEL CORONAVIR 0112
   WHO, 2020, NOVEL CORONAVIR 0117
   WHO, 2020, NOVEL CORONAVIR 0121
   WHO, 2020, CLIN MAN SEV AC RESP
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   World Health Organization, 2019, MIDDL E RESP SYNDR C
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 37
TC 150
Z9 150
U1 505
U2 505
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD FEB 15
PY 2020
VL 395
IS 10223
BP 497
EP 506
DI 10.1016/S0140-6736(20)30183-5
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA KN1CG
UT WOS:000514576900032
PM 31986264
OA Bronze
DA 2020-04-03
ER

PT J
AU Kamitani, W
   Narayanan, K
   Huang, C
   Lokugamage, K
   Ikegami, T
   Ito, N
   Kubo, H
   Makino, S
AF Kamitani, Wataru
   Narayanan, Krishna
   Huang, Cheng
   Lokugamage, Kumari
   Ikegami, Tetsuro
   Ito, Naoto
   Kubo, Hideyuki
   Makino, Shinji
TI Severe acute respiratory syndrome coronavirus nsp1 protein suppresses
   host gene expression by promoting host mRNA degradation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE virus virulence; SARS; MRNA stability; translation inhibition; innate
   immunity
ID HERPES-SIMPLEX-VIRUS; PAPAIN-LIKE PROTEASE; SARS-CORONAVIRUS; 3A
   PROTEIN; TRANSCRIPTION; IDENTIFICATION; INHIBITION; GENOME; CELLS
AB Severe acute respiratory syndrome (SARS) coronavirus (SCoV) causes a recently emerged human disease associated with pneumonia. The 5' end two-thirds of the single-stranded positive-sense viral genomic RNA, gene 1, encodes 16 mature proteins. Expression of nsp1, the most N-terminal gene 1 protein, prevented Sendai virus-induced endogenous IFN-beta mRNA accumulation without inhibiting climerization of IFN regulatory factor 3, a protein that is essential for activation of the IFN-beta promoter. Furthermore, nsp1 expression promoted degradation of expressed RNA transcripts and host endogenous mRNAs, leading to a strong host protein synthesis inhibition. SCoV replication also promoted degradation of expressed RNA transcripts and host mRNAs, suggesting that nsp1 exerted its mRNA destabilization function in infected cells. In contrast to nsp1-induced mRNA destablization, no degradation of the 28S and 18S rRNAs occurred in either nsp1-expressing cells or SCoV-infected cells. These data suggested that, in infected cells, nsp1 promotes host mRNA degradation and thereby suppresses host gene expression, including proteins involved in host innate immune functions. SCoV nsp1-mediated promotion of host mRNA degradation may play an important role in SCoV pathogenesis.
C1 Univ Texas, Med Branch, Dept Microbiol, Galveston, TX 77555 USA.
   Univ Texas, Med Branch, Dept Immunol, Galveston, TX 77555 USA.
   Gifu Univ, Fac Appl Biol Sci, Lab Zoonot Dis, Div Vet Med, Gifu 5011193, Japan.
RP Makino, S (reprint author), Univ Texas, Med Branch, Dept Microbiol, Galveston, TX 77555 USA.
EM shmakino@utmb.edu
RI Makino, Shinji/E-8014-2015; Ikegami, Tetsuro/H-1329-2013; Narayanan,
   Krishna/A-7069-2009; Huang, Cheng/R-6619-2017
OI Makino, Shinji/0000-0002-7831-1576; Huang, Cheng/0000-0001-5402-353X
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21 AI029984, AI29984, R01 AI029984]
CR Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297
   An SW, 1998, J VIROL, V72, P8517, DOI 10.1128/JVI.72.11.8517-8524.1998
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004
   Billecocq A, 2004, J VIROL, V78, P9798, DOI 10.1128/JVI.78.18.9798-9806.2004
   Bouloy M, 2001, J VIROL, V75, P1371, DOI 10.1128/JVI.75.3.1371-1377.2001
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Everly DN, 2002, J VIROL, V76, P8560, DOI 10.1128/JVI.76.17.8560-8571.2002
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Graham RL, 2005, J VIROL, V79, P13399, DOI 10.1128/JVI.79.21.13399-13411.2005
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Hengel H, 2005, TRENDS IMMUNOL, V26, P396, DOI 10.1016/j.it.2005.05.004
   Huang C, 2006, J VIROL, V80, P210, DOI 10.1128/JVI.80.1.210-217.2006
   Ikegami T, 2005, J VIROL, V79, P5606, DOI 10.1128/JVI.79.9.5606-5615.2005
   Ito N, 2005, J VIROL, V79, P3182, DOI 10.1128/JVI.79.5.3182-3186.2005
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KWONG AD, 1987, P NATL ACAD SCI USA, V84, P1926, DOI 10.1073/pnas.84.7.1926
   Le May N, 2004, CELL, V116, P541, DOI 10.1016/S0092-8674(04)00132-1
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Lo K, 1998, VIROLOGY, V247, P178, DOI 10.1006/viro.1998.9253
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Mossel EC, 2005, J VIROL, V79, P3846, DOI 10.1128/JVI.79.6.3846-3850.2005
   Narayanan K, 2001, J VIROL, V75, P9059, DOI 10.1128/JVI.75.19.9059-9067.2001
   Nemeroff ME, 1998, MOL CELL, V1, P991, DOI 10.1016/S1097-2765(00)80099-4
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Prakash A, 2006, BIOCHEM BIOPH RES CO, V342, P50, DOI 10.1016/j.bbrc.2006.01.122
   Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004
   Smiley JR, 2004, J VIROL, V78, P1063, DOI 10.1128/JVI.78.3.1063-1068.2004
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Sulea T, 2005, J VIROL, V79, P4550, DOI 10.1128/JVI.79.7.4550-4551.2005
   Taddeo B, 2006, P NATL ACAD SCI USA, V103, P2827, DOI 10.1073/pnas.0510712103
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   von Kobbe C, 2000, MOL CELL, V6, P1243, DOI 10.1016/S1097-2765(00)00120-9
   Weidman MK, 2003, VIRUS RES, V95, P75, DOI 10.1016/S0168-1702(03)00164-3
   Yuan H, 1998, VIROLOGY, V251, P383, DOI 10.1006/viro.1998.9413
NR 41
TC 150
Z9 163
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 22
PY 2006
VL 103
IS 34
BP 12885
EP 12890
DI 10.1073/pnas.0603144103
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 077NI
UT WOS:000240035900044
PM 16912115
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Anderson, RM
   Fraser, C
   Ghani, AC
   Donnelly, CA
   Riley, S
   Ferguson, NM
   Leung, GM
   Lam, TH
   Hedley, AJ
AF Anderson, RM
   Fraser, C
   Ghani, AC
   Donnelly, CA
   Riley, S
   Ferguson, NM
   Leung, GM
   Lam, TH
   Hedley, AJ
TI Epidemiology, transmission dynamics and control of SARS: the 2002-2003
   epidemic
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES
   B-BIOLOGICAL SCIENCES
LA English
DT Article; Proceedings Paper
CT Discussion Meeting on Emerging Infections - What Have We Learnt from
   SARS
CY JAN   13, 2004
CL London, ENGLAND
SP Royal Soc
DE SARS; epidemiology; mathematical models
ID ACUTE-RESPIRATORY-SYNDROME; HONG-KONG; MOUTH EPIDEMIC; GREAT-BRITAIN;
   CORONAVIRUS; OUTBREAK; CHINA; IMPACT; INTERVENTIONS; INFLUENZA
AB This paper reviews current understanding of the epidemiology, transmission dynamics and control of the aetiological agent of severe acute respiratory syndrome (SARS). We present analyses of data on key parameters and distributions and discuss the processes of data capture, analysis and public health policy formulation during the SARS epidemic are discussed. The low transmissibility of the virus, combined with the onset of peak infectiousness following the onset of clinical symptoms of disease, transpired to make simple public health measures, such as isolating patients and quarantining their contacts, very effective in the control of the SARS epidemic. We conclude that we were lucky this time round, but may not be so with the next epidemic outbreak of a novel aetiological agent. We present analyses that help to further understanding of what intervention measures are likely to work best with infectious agents of defined biological and epidemiological properties. These lessons learnt from the SARS experience are presented in an epidemiological and public health context.
C1 Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London W2 1PG, England.
   Univ Hong Kong, Pokfulam, Hong Kong, Peoples R China.
RP Anderson, RM (reprint author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, St Marys Campus,Norfolk Pl, London W2 1PG, England.
EM roy.anderson@imperial.ac.uk
RI Hedley, Anthony/C-4305-2009; Ferguson, Neil/B-8578-2008; Hedley, Anthony
   J/A-9113-2013; Ghani, Azra/B-8560-2009; Leung, Gabriel/C-4336-2009;
   Fraser, Christophe/A-8109-2008; Lam, Tai Hing/C-4317-2009
OI Ferguson, Neil/0000-0002-1154-8093; Fraser,
   Christophe/0000-0003-2399-9657; Donnelly, Christl/0000-0002-0195-2463;
   Lam, Tai Hing/0000-0002-2033-9971; Anderson, Roy/0000-0002-9528-3175;
   Leung, Gabriel/0000-0002-2503-6283; Ghani, Azra/0000-0002-0007-4910;
   Riley, Steven/0000-0001-7904-4804
CR Anderson R. M., 1991, INFECT DIS HUMANS DY
   Breiman RF, 2003, EMERG INFECT DIS, V9, P1037
   Chow PKH, 2004, EMERG INFECT DIS, V10, P249, DOI 10.3201/eid1002.030397
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Ferguson NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116
   Ferguson NM, 2004, SCIENCE, V304, P968, DOI 10.1126/science.1096898
   Ferguson NM, 2001, SCIENCE, V292, P1155, DOI 10.1126/science.1061020
   Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101
   Galvani AP, 2003, EMERG INFECT DIS, V9, P991
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Hsu LY, 2003, EMERG INFECT DIS, V9, P713
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee M. L., 2003, Morbidity and Mortality Weekly Report, V52, P680
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   LEUNG GM, 2004, IN PRESS EMERG INFEC
   LEUNG GM, 2004, IN PRESS ANN INTERNA
   Li G, 2003, NEW ENGL J MED, V349, P508, DOI 10.1056/NEJM200307313490520
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Lloyd-Smith JO, 2003, P ROY SOC B-BIOL SCI, V270, P1979, DOI 10.1098/rspb.2003.2481
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Paterson R, 2004, LANCET INFECT DIS, V4, P64, DOI 10.1016/S1473-3099(04)00910-7
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478
   Shen Z, 2004, EMERG INFECT DIS, V10, P256, DOI 10.3201/eid1002.030732
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Varia M, 2003, CAN MED ASSOC J, V169, P285
   WALLINGA J, 2004, GLOB M EP SARS WHO G
   Watts J, 2004, LANCET, V363, P134, DOI 10.1016/S0140-6736(03)15313-5
   Webster RG, 2004, LANCET, V363, P234, DOI 10.1016/S0140-6736(03)15329-9
   *WHO, 2004, NEW CAS LAB CONF SAR
   World Health Organization, 2003, CONS DOC EP SEV AC R
   2004, LANCET, V363, P409
NR 34
TC 150
Z9 154
U1 27
U2 88
PU ROYAL SOC LONDON
PI LONDON
PA 6 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8436
J9 PHILOS T ROY SOC B
JI Philos. Trans. R. Soc. Lond. Ser. B-Biol. Sci.
PD JUL 29
PY 2004
VL 359
IS 1447
BP 1091
EP 1105
DI 10.1098/rstb.2004.1490
PG 15
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 838BN
UT WOS:000222688200008
PM 15306395
OA Green Published
DA 2020-04-03
ER

PT J
AU Meyer, B
   Muller, MA
   Corman, VM
   Reusken, CBEM
   Ritz, D
   Godeke, GJ
   Lattwein, E
   Kallies, S
   Siemens, A
   van Beek, J
   Drexler, JF
   Muth, D
   Bosch, BJ
   Wernery, U
   Koopmans, MPG
   Wernery, R
   Drosten, C
AF Meyer, Benjamin
   Mueller, Marcel A.
   Corman, Victor M.
   Reusken, Chantal B. E. M.
   Ritz, Daniel
   Godeke, Gert-Jan
   Lattwein, Erik
   Kallies, Stephan
   Siemens, Artem
   van Beek, Janko
   Drexler, Jan F.
   Muth, Doreen
   Bosch, Berend-Jan
   Wernery, Ulrich
   Koopmans, Marion P. G.
   Wernery, Renate
   Drosten, Christian
TI Antibodies against MERS Coronavirus in Dromedaries, United Arab
   Emirates, 2003 and 2013
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; BATS; BETACORONAVIRUS; RECEPTOR
AB Middle East respiratory syndrome coronavirus (MERS-CoV) has caused an ongoing outbreak of severe acute respiratory tract infection in humans in the Arabian Peninsula since 2012. Dromedaries have been implicated as possible viral reservoirs. We used serologic assays to analyze 651 dromedary serum samples from the United Arab Emirates; 151 of 651 samples were obtained in 2003, well before onset of the current epidemic, and 500 serum samples were obtained in 2013. Recombinant spike protein specific immunofluorescence and virus neutralization tests enabled clear discrimination between MERS-CoV and bovine CoV infections. Most (632/651, 97.1%) dromedaries had antibodies against MERS-CoV. This result included all 151 serum samples obtained in 2003. Most (389/651, 59.8%) serum samples had MERS-CoV neutralizing antibody titers >1,280. Dromedaries from the United Arab Emirates were infected at high rates with MERS-CoV or a closely related, probably conspecific, virus long before the first human MERS cases.
C1 [Meyer, Benjamin; Mueller, Marcel A.; Corman, Victor M.; Ritz, Daniel; Kallies, Stephan; Siemens, Artem; Drexler, Jan F.; Muth, Doreen; Drosten, Christian] Univ Bonn, Med Ctr, D-53105 Bonn, Germany.
   [Reusken, Chantal B. E. M.; Godeke, Gert-Jan; van Beek, Janko; Koopmans, Marion P. G.] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
   [Reusken, Chantal B. E. M.; Drexler, Jan F.; Koopmans, Marion P. G.] Erasmus MC, Rotterdam, Netherlands.
   [Lattwein, Erik] EUROIMMUN AG, Lubeck, Germany.
   [Bosch, Berend-Jan] Univ Utrecht, Utrecht, Netherlands.
   [Wernery, Ulrich; Wernery, Renate] Cent Vet Res Lab, Dubai, U Arab Emirates.
RP Drosten, C (reprint author), Univ Bonn, Med Ctr, Inst Virol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM drosten@virology-bonn.de
RI Mueller, Marcel/O-2425-2019; Meyer, Bernhard/Q-9413-2016; Corman, Victor
   Max/K-1319-2019; Koopmans, Marion/Y-9170-2019; Meyer,
   Benjamin/F-3285-2018
OI Mueller, Marcel/0000-0003-2242-5117; Corman, Victor
   Max/0000-0002-3605-0136; Koopmans, Marion/0000-0002-5204-2312; Meyer,
   Benjamin/0000-0003-0601-3550; Drexler, Jan Felix/0000-0002-3509-0232
FU European research project on emerging diseases detection and response
   (EMPERIE) [223498]; ANTIGONE [278976]; German Research CouncilGerman
   Research Foundation (DFG) [01KIO701, DR 772/3-1]
FX The work was supported by a European research project on emerging
   diseases detection and response (EMPERIE; www.emperie.eu/emp/) (contract
   no. 223498) and ANTIGONE (contract no. 278976). C.D. has received
   infrastructural support from the German Centre for Infection Research,
   the German Ministry for Research and Education, and the German Research
   Council (grants 01KIO701 and DR 772/3-1).
CR Aburizaiza AS, 2014, J INFECT DIS, V209, P243, DOI 10.1093/infdis/jit589
   Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Anthony SJ, 2013, J GEN VIROL, V94, P1028, DOI 10.1099/vir.0.049759-0
   Buchholz U., 2013, Eurosurveillance, V18, P20406
   Cauchemez S., 2013, Eurosurveillance, V18, P20503
   Chan CM, 2009, J CLIN VIROL, V45, P54, DOI 10.1016/j.jcv.2009.02.011
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   CVRL, 2013, 26 CVRL
   Luna LKD, 2007, J CLIN MICROBIOL, V45, P1049, DOI 10.1128/JCM.02426-06
   Drexler JF, 2010, J VIROL, V84, P11336, DOI 10.1128/JVI.00650-10
   Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   GERNA G, 1981, J GEN VIROL, V54, P91, DOI 10.1099/0022-1317-54-1-91
   Gloza-Rausch F, 2008, EMERG INFECT DIS, V14, P626, DOI 10.3201/eid1404.071439
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   HORZINEK MC, 1982, INFECT IMMUN, V37, P1148, DOI 10.1128/IAI.37.3.1148-1155.1982
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Jin L, 2007, VIROLOGY, V365, P198, DOI 10.1016/j.virol.2007.03.035
   Muller MA, 2012, MBIO, V3, DOI 10.1128/mBio.00515-12
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Pfefferle S, 2009, EMERG INFECT DIS, V15, P1377, DOI 10.3201/eid1509.090224
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reusken C, 2013, EUROSURVEILLANCE, V18, P2, DOI 10.2807/1560-7917.ES2013.18.14.20441
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   van der Linden RHJ, 1999, BBA-PROTEIN STRUCT M, V1431, P37, DOI 10.1016/S0167-4838(99)00030-8
   Wacharapluesadee S, 2013, EMERG INFECT DIS, V19, P1349, DOI 10.3201/eid1908.130119
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   World Health Organization, 2013, MIDDL E RESP SYNDR C
   Wunschmann A, 2002, J VET DIAGN INVEST, V14, P441
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 35
TC 149
Z9 160
U1 3
U2 47
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD APR
PY 2014
VL 20
IS 4
BP 552
EP 559
DI 10.3201/eid2004.131746
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AD8GO
UT WOS:000333504700004
PM 24655412
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Wu, ZQ
   Ren, XW
   Yang, L
   Hu, YF
   Yang, J
   He, GM
   Zhang, JP
   Dong, J
   Sun, LL
   Du, J
   Liu, LG
   Xue, Y
   Wang, JM
   Yang, F
   Zhang, SY
   Jin, Q
AF Wu, Zhiqiang
   Ren, Xianwen
   Yang, Li
   Hu, Yongfeng
   Yang, Jian
   He, Guimei
   Zhang, Junpeng
   Dong, Jie
   Sun, Lilian
   Du, Jiang
   Liu, Liguo
   Xue, Ying
   Wang, Jianmin
   Yang, Fan
   Zhang, Shuyi
   Jin, Qi
TI Virome Analysis for Identification of Novel Mammalian Viruses in Bat
   Species from Chinese Provinces
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID PAPILLOMAVIRUS TYPE-1; PORCINE CIRCOVIRUS; GENETIC DIVERSITY; MOLECULAR
   CHARACTERIZATION; METAGENOMIC ANALYSIS; INSECTIVOROUS BATS; RESERVOIR
   HOSTS; SAFFOLD VIRUS; SAMPLES; CHILDREN
AB Bats are natural hosts for a large variety of zoonotic viruses. This study aimed to describe the range of bat viromes, including viruses from mammals, insects, fungi, plants, and phages, in 11 insectivorous bat species (216 bats in total) common in six provinces of China. To analyze viromes, we used sequence-independent PCR amplification and next-generation sequencing technology (Solexa Genome Analyzer II; Illumina). The viromes were identified by sequence similarity comparisons to known viruses. The mammalian viruses included those of the Adenoviridae, Herpesviridae, Papillomaviridae, Retroviridae, Circoviridae, Rhabdoviridae, Astroviridae, Flaviridae, Coronaviridae, Picornaviridae, and Parvovirinae; insect viruses included those of the Baculoviridae, Iflaviridae, Dicistroviridae, Tetraviridae, and Densovirinae; fungal viruses included those of the Chrysoviridae, Hypoviridae, Partitiviridae, and Totiviridae; and phages included those of the Caudovirales, Inoviridae, and Microviridae and unclassified phages. In addition to the viruses and phages associated with the insects, plants, and bacterial flora related to the diet and habitation of bats, we identified the complete or partial genome sequences of 13 novel mammalian viruses. These included herpesviruses, papillomaviruses, a circovirus, a bocavirus, picornaviruses, a pestivirus, and a foamy virus. Pairwise alignments and phylogenetic analyses indicated that these novel viruses showed little genetic similarity with previously reported viruses. This study also revealed a high prevalence and diversity of bat astroviruses and coronaviruses in some provinces. These findings have expanded our understanding of the viromes of bats in China and hinted at the presence of a large variety of unknown mammalian viruses in many common bat species of mainland China.
C1 [Wu, Zhiqiang; Ren, Xianwen; Yang, Li; Hu, Yongfeng; Yang, Jian; Dong, Jie; Sun, Lilian; Du, Jiang; Liu, Liguo; Xue, Ying; Wang, Jianmin; Yang, Fan; Jin, Qi] Chinese Acad Med Sci, Inst Pathogen Biol, MOH Key Lab Syst Biol Pathogens, Beijing 100730, Peoples R China.
   [Wu, Zhiqiang; Ren, Xianwen; Yang, Li; Hu, Yongfeng; Yang, Jian; Dong, Jie; Sun, Lilian; Du, Jiang; Liu, Liguo; Xue, Ying; Wang, Jianmin; Yang, Fan; Jin, Qi] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [He, Guimei; Zhang, Junpeng; Zhang, Shuyi] E China Normal Univ, Inst Adv Interdisciplinary Res, Inst Mol Ecol & Evolut, Shanghai 200062, Peoples R China.
RP Jin, Q (reprint author), Chinese Acad Med Sci, Inst Pathogen Biol, MOH Key Lab Syst Biol Pathogens, Beijing 100730, Peoples R China.
EM syzhang@bio.ecnu.edu.cn; zdsys@vip.sina.com
FU National S&T Major Project China Mega-Project for Infectious Disease
   from the People's Republic of China [2011ZX10004-001]; Institute of
   Pathogen Biology, Chinese Academy of Medical Sciences & Beijing Union
   Medical College [2010IPB111]
FX This work was supported by the National S&T Major Project China
   Mega-Project for Infectious Disease (grant no. 2011ZX10004-001) from the
   People's Republic of China and Basic Research and Operating Expenses
   (grant no. 2010IPB111) from the Institute of Pathogen Biology, Chinese
   Academy of Medical Sciences & Beijing Union Medical College.
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002
   Betsem E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002306
   Blomstrom AL, 2009, VIRUS RES, V146, P125, DOI 10.1016/j.virusres.2009.09.006
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Chae C, 2005, VET J, V169, P326, DOI 10.1016/j.tvjl.2004.01.012
   Chu DKW, 2008, J VIROL, V82, P9107, DOI 10.1128/JVI.00857-08
   Chu DKW, 2008, J GEN VIROL, V89, P1282, DOI 10.1099/vir.0.83605-0
   Cui J, 2007, EMERG INFECT DIS, V13, P1526, DOI 10.3201/eid1310.070448
   Djikeng A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-5
   Donaldson EF, 2010, J VIROL, V84, P13004, DOI 10.1128/JVI.01255-10
   Drexler JF, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1796
   Ehlers B, 1999, VIRUS GENES, V18, P211, DOI 10.1023/A:1008064118057
   Fauquet CM, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-64
   Finsterbusch T, 2009, VIRUS RES, V143, P177, DOI 10.1016/j.virusres.2009.02.009
   Freuling CM, 2011, EMERG INFECT DIS, V17, P1519, DOI 10.3201/eid1708.110201
   Ge XY, 2012, J VIROL, V86, P4620, DOI 10.1128/JVI.06671-11
   Ge XY, 2011, J GEN VIROL, V92, P2646, DOI 10.1099/vir.0.034108-0
   Gravitt PE, 2011, J CLIN INVEST, V121, P4593, DOI 10.1172/JCI57149
   Guo L, 2011, EMERG INFECT DIS, V17, P1775, DOI 10.3201/eid1709.110078
   Himeda T, 2012, J VIROL, V86, P1292, DOI 10.1128/JVI.06087-11
   ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279
   Jones MS, 2005, J VIROL, V79, P8230, DOI 10.1128/JVI.79.13.8230-8236.2005
   Kantola K, 2011, J INFECT DIS, V204, P1403, DOI 10.1093/infdis/jir525
   Kapoor A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011948
   Kirkland PD, 2007, VIRUS RES, V129, P26, DOI 10.1016/j.virusres.2007.05.002
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2011, J VIROL, V85, P8819, DOI 10.1128/JVI.02364-10
   Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a
   Li LL, 2011, J VIROL, V85, P9909, DOI 10.1128/JVI.05026-11
   Li LL, 2010, J VIROL, V84, P6955, DOI 10.1128/JVI.00501-10
   Li LL, 2010, J VIROL, V84, P1674, DOI 10.1128/JVI.02109-09
   Li Y, 2010, J GEN VIROL, V91, P2601, DOI 10.1099/vir.0.020032-0
   Li Y, 2010, J VIROL, V84, P3889, DOI 10.1128/JVI.02497-09
   Lorincz M, 2010, ACTA VET HUNG, V58, P265, DOI 10.1556/AVet.58.2010.2.12
   Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626
   Mouinga-Ondeme A, 2012, J VIROL, V86, P1255, DOI 10.1128/JVI.06016-11
   Nielsen ACY, 2012, EMERG INFECT DIS, V18, P7, DOI 10.3201/eid1801.110725
   Phan TG, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002218
   Qiu J, 2007, J VIROL, V81, P12080, DOI 10.1128/JVI.00815-07
   Razafindratsimandresy R, 2009, J GEN VIROL, V90, P44, DOI 10.1099/vir.0.006825-0
   Rector A, 2005, J GEN VIROL, V86, P2029, DOI 10.1099/vir.0.80874-0
   Rector A, 2004, J VIROL, V78, P12698, DOI 10.1128/JVI.78.22.12698-12702.2004
   Rector A, 2006, VET MICROBIOL, V117, P267, DOI 10.1016/j.vetmic.2006.06.010
   Rosell C, 2000, VET REC, V146, P40, DOI 10.1136/vr.146.2.40
   Shan TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017292
   Shen H, 2011, VIRUS GENES, V43, P234, DOI 10.1007/s11262-011-0625-5
   Smith I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025275
   Stevens H, 2008, VET MICROBIOL, V129, P108, DOI 10.1016/j.vetmic.2007.11.037
   Sun YN, 2009, J VIROL, V83, P3956, DOI 10.1128/JVI.02569-08
   Swanepoel R, 2007, EMERG INFECT DIS, V13, P1847, DOI 10.3201/eid1312.071115
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Teeling EC, 2005, SCIENCE, V307, P580, DOI 10.1126/science.1105113
   Todd D, 2001, VIROLOGY, V286, P354, DOI 10.1006/viro.2001.0985
   Tracy S, 2006, CURR TOP MICROBIOL, V299, P193
   Victoria JG, 2009, J VIROL, V83, P4642, DOI 10.1128/JVI.02301-08
   Victoria JG, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000163
   Vilcek S, 2006, VET MICROBIOL, V116, P1, DOI 10.1016/j.vetmic.2006.06.003
   Wang LF, 2006, EMERG INFECT DIS, V12, P1834
   Wang YX, 2003, COMPLETE CHECKLIST M
   Watanabe S, 2010, EMERG INFECT DIS, V16, P986, DOI 10.3201/eid1606.091567
   Watanabe S, 2009, VIRUS GENES, V39, P90, DOI 10.1007/s11262-009-0368-8
   Wibbelt G, 2007, J GEN VIROL, V88, P2651, DOI 10.1099/vir.0.83045-0
   Wilson DE, 2005, MAMMAL SPECIES WORLD
   Xia HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028553
   Xiao JP, 2011, ARCH VIROL, V156, P1415, DOI 10.1007/s00705-011-1011-2
   Yang J, 2011, J CLIN MICROBIOL, V49, P3463, DOI 10.1128/JCM.00273-11
NR 67
TC 149
Z9 164
U1 2
U2 66
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD OCT
PY 2012
VL 86
IS 20
BP 10999
EP 11012
DI 10.1128/JVI.01394-12
PG 14
WC Virology
SC Virology
GA 010SR
UT WOS:000309114900008
PM 22855479
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Huang, WC
   Huang, LM
   Chang, IS
   Chang, LY
   Chiang, BL
   Chen, PJ
   Wu, MH
   Lue, HC
   Lee, CY
AF Huang, Wen-Chan
   Huang, Li-Min
   Chang, I-Shou
   Chang, Luan-Yin
   Chiang, Bor-Luen
   Chen, Pei-Jer
   Wu, Mei-Hwan
   Lue, Hung-Chi
   Lee, Chun-Yun
CA Kawasaki Dis Res Grp
TI Epidemiologic Features of Kawasaki Disease in Taiwan, 2003-2006
SO PEDIATRICS
LA English
DT Article
DE Kawasaki disease; incidence; seasonality; Taiwan
ID SYNDROME HOSPITALIZATIONS; HUMAN CORONAVIRUS; UNITED-STATES;
   ASSOCIATION; INFECTION; VIRUS
AB OBJECTIVE. Kawasaki disease is the leading cause of acquired heart disease in children worldwide. This study characterizes the epidemiology of Kawasaki disease in Taiwan between 2003 and 2006.
   METHODS. Using Taiwan's 2003-2006 national health insurance claims, we investigated the epidemiologic features of Kawasaki disease (ICD-9-CM code 446.1) and coronary artery aneurysm formation (International Classification of Diseases, Ninth Revision, Clinical Modification code 414.11) and compared the incidences of these diseases with those occurring between 1996 and 2002 in Taiwan and those reported by other countries.
   RESULTS. During our 4-year study period, 3877 children and adolescents <20 years of age were hospitalized for Kawasaki disease. Ninety percent of these children were <5 years of age, and the male/female ratio was 1.62:1. The annual incidence of Kawasaki disease was 153 in 100 000 children <1 year of age, 111 in children 1 year of age, 58 in children 2 years of age, 30 in children 3 years of age, 19 in children 4 years of age, and 5.2 in children 5 to 9 years of age. The overall incidence was 69 cases per 100 000 for children <5 years of age. Kawasaki disease recurred in 1.5% of all cases. Kawasaki disease occurred most frequently in the summer and least frequently in the winter. Coronary artery aneurysm occurred in 7.2% ( 279 of 3877) of all Kawasaki disease cases.
   CONCLUSIONS. The overall incidence of Kawasaki disease was 69 in 100 000 children <5 years of age between 2003 and 2006 in Taiwan, comparable with the incidence of 66 in 100 000 children between 1996 and 2002. Taiwan has the third highest incidence of Kawasaki disease in the world, after Japan and Korea. In Taiwan, it occurs more frequently during the summer. Pediatrics 2009; 123: e401-e405
C1 [Chang, Luan-Yin] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Pediat,Div Pediat Infect Dis, Taipei 100, Taiwan.
   [Chen, Pei-Jer] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Med Res, Taipei 100, Taiwan.
   [Chiang, Bor-Luen; Chen, Pei-Jer] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
   [Chang, I-Shou] Natl Hlth Res Inst, Dept Biostat & Bioinformat, Miaoli, Taiwan.
   [Lue, Hung-Chi] Lotung St Marys Hosp, Dept Pediat, Ilan, Taiwan.
RP Chang, LY (reprint author), Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Pediat,Div Pediat Infect Dis, 7 Chung Shan S Rd, Taipei 100, Taiwan.
EM ly7077@tpts6.seed.net.tw
RI Chang, I-Shou/D-2084-2010
OI CHIANG, BOR-LUEN/0000-0002-6705-0286; WU, MEI-HWAN/0000-0002-7074-8087;
   CHANG, LUAN-YIN/0000-0003-2632-1956; HUANG, LI-MIN/0000-0002-9291-260X
CR Anderson MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1824
   Belay ED, 2006, PEDIATR INFECT DIS J, V25, P245, DOI 10.1097/01.inf.0000202068.30956.16
   Burns JC, 2005, EPIDEMIOLOGY, V16, P220, DOI 10.1097/01.ede.0000152901.06689.d4
   Burns JC, 2004, LANCET, V364, P533, DOI 10.1016/S0140-6736(04)16814-1
   Chang LY, 2006, J INFECT DIS, V193, P283, DOI 10.1086/498875
   CHANG LY, 2004, PEDIATRICS, V114
   Chua PK, 2000, PEDIATR INFECT DIS J, V19, P477, DOI 10.1097/00006454-200005000-00019
   *DEP HLTH EX YUAN, STAT NAT HLTH INS 20
   Du ZD, 2007, PEDIATR INFECT DIS J, V26, P449, DOI 10.1097/01.inf.0000261196.79223.18
   Esper F, 2005, J INFECT DIS, V191, P499, DOI 10.1086/428291
   Fischer TK, 2007, PEDIATR INFECT DIS J, V26, P411, DOI 10.1097/01.inf.0000259964.47941.00
   Heaton P, 2006, J PAEDIATR CHILD H, V42, P184, DOI 10.1111/j.1440-1754.2006.00827.x
   Holman RC, 2005, PEDIATR INFECT DIS J, V24, P429, DOI 10.1097/01.inf.0000160946.05295.91
   Holman RC, 2003, PEDIATRICS, V112, P495, DOI 10.1542/peds.112.3.495
   Kato H, 1996, CIRCULATION, V94, P1379, DOI 10.1161/01.CIR.94.6.1379
   Kawasaki T., 1967, JAP J ALLERG, V16, P178
   Lynch M, 2003, PEDIATR INFECT DIS J, V22, P959, DOI 10.1097/01.inf.0000095194.83814.ee
   Minich LL, 2007, PEDIATRICS, V120, pE1434, DOI 10.1542/peds.2007-0815
   Newburger Jane W, 2003, Pediatr Res, V53, P153, DOI 10.1203/01.PDR.0000046932.18654.3F
   Ng Y. M., 2005, Hong Kong Medical Journal, V11, P331
   Park YW, 2007, PEDIATR INFECT DIS J, V26, P821, DOI 10.1097/INF.0b013e318124aa1a
   Shike H, 2005, PEDIATR INFECT DIS J, V24, P1011, DOI 10.1097/01.inf.0000183769.31951.1e
   TSAI YW, 2005, 5 WORLD C INT HLTH E, P316
   Wang CL, 2005, PEDIATR INFECT DIS J, V24, P998, DOI 10.1097/01.inf.0000183786.70519.fa
   Wilder MS, 2007, PEDIATR INFECT DIS J, V26, P256, DOI 10.1097/01.inf.0000256783.57041.66
   Yanagawa H, 2006, PEDIATR INT, V48, P356, DOI 10.1111/j.1442-200X.2006.02221.x
NR 26
TC 149
Z9 159
U1 0
U2 12
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD MAR
PY 2009
VL 123
IS 3
BP e401
EP e405
DI 10.1542/peds.2008-2187
PG 5
WC Pediatrics
SC Pediatrics
GA 413XH
UT WOS:000263825500052
PM 19237439
DA 2020-04-03
ER

PT J
AU Sanchez, CM
   Izeta, A
   Sanchez-Morgado, JM
   Alonso, S
   Sola, I
   Balasch, M
   Plana-Duran, J
   Enjuanes, L
AF Sanchez, CM
   Izeta, A
   Sanchez-Morgado, JM
   Alonso, S
   Sola, I
   Balasch, M
   Plana-Duran, J
   Enjuanes, L
TI Targeted recombination demonstrates that the spike gene of transmissible
   gastroenteritis coronavirus is a determinant of its enteric tropism and
   virulence
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID PORCINE RESPIRATORY CORONAVIRUS; MOUSE HEPATITIS-VIRUS;
   DECAY-ACCELERATING FACTOR; HUMAN AMINOPEPTIDASE-N; RECEPTOR-BINDING
   SITE; HERPES-SIMPLEX VIRUS; AMINO-ACID CHANGES; RNA RECOMBINATION;
   MOLECULAR CHARACTERIZATION; CELL ATTACHMENT
AB Targeted recombination within the S (spike) gene of transmissible gastroenteritis coronavirus (TGEV) was promoted by passage of helper respiratory virus isolates in cells transfected with a TGEV-derived defective minigenome carrying the S gene from an enteric isolate. The minigenome was efficiently replicated in trans and packaged by the helper virus, leading to the formation of true recombinant and pseudorecombinant viruses containing the S proteins of both enteric and respiratory TGEV strains in their envelopes. The recombinants acquired an enteric tropism, and their analysis showed that they were generated by homologous recombination that implied a double crossover in the S gene resulting in replacement of most of the respiratory, attenuated strain S gene (nucleotides 96 to 3700) by the S gene of the enteric, virulent isolate. The recombinant virus was virulent and rapidly evolved in swine testis cells by the introduction of point mutations and in-phase codon deletions in a domain of the S gene (nucleotides 217 to 665) previously implicated in the tropism of TGEV. The helper virus, with an original respiratory tropism, was also found in the enteric tract, probably because pseudorecombinant viruses carrying the spike proteins from the respiratory strain and the enteric virus in their envelopes were formed. These results demonstrated that a change in the tropism and virulence of TGEV can be engineered by sequence changes in the S gene.
C1 Campus Univ Autonoma, Ctr Nacl Biotecnol, CSIC, Dept Mol & Cell Biol, Madrid 28049, Spain.
   Ft Dodge Vet, Dept Res & Dev, Girona, Spain.
RP Enjuanes, L (reprint author), Campus Univ Autonoma, Ctr Nacl Biotecnol, CSIC, Dept Mol & Cell Biol, Madrid 28049, Spain.
RI Sanchez-Morgado, Jose/I-2220-2019; Enjuanes, Luis/F-7845-2016; Izeta,
   Ander/H-6376-2011; Sola, Isabel/E-1565-2017
OI Sola, Isabel/0000-0002-5704-1917; Sanchez Morgado, Jose
   M/0000-0002-6135-3278; Enjuanes, Luis/0000-0002-0854-0226; Izeta,
   Ander/0000-0003-1879-7401
CR BAI M, 1994, J VIROL, V68, P5925, DOI 10.1128/JVI.68.9.5925-5932.1994
   Ballesteros ML, 1997, VIROLOGY, V227, P378, DOI 10.1006/viro.1996.8344
   Benbacer L, 1997, J VIROL, V71, P734, DOI 10.1128/JVI.71.1.734-737.1997
   BERGAMASCO L, 1995, FRACTALS, V3, P55
   Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320
   BERNARD S, 1995, J GEN VIROL, V76, P2235, DOI 10.1099/0022-1317-76-9-2235
   BLOOM DC, 1994, J VIROL, V68, P3761, DOI 10.1128/JVI.68.6.3761-3772.1994
   BOHL EH, 1972, INFECT IMMUN, V6, P289, DOI 10.1128/IAI.6.3.289-301.1972
   BOHL EH, 1965, P US LIVESTOCK SANIT, V69, P343
   BOHL LEH, 1971, ANN NY ACAD SCI, V176, P150
   BRITTON P, 1991, VIRUS RES, V21, P181, DOI 10.1016/0168-1702(91)90032-Q
   CALLEBAUT P, 1988, J GEN VIROL, V69, P1725, DOI 10.1099/0022-1317-69-7-1725
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   CHEN CM, 1995, VIRUS RES, V38, P83, DOI 10.1016/0168-1702(95)00046-S
   DAYTON ET, 1993, J VIROL, V67, P2871, DOI 10.1128/JVI.67.5.2871-2878.1993
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   ELEOUET JF, 1995, VIROLOGY, V206, P817, DOI 10.1006/viro.1995.1004
   Enjuanes L., 1995, The coronaviridae., P337
   ENJUANES L, IN PRESS VIRUS TAXON
   FICHOT O, 1990, NUCLEIC ACIDS RES, V18, P6162, DOI 10.1093/nar/18.20.6162
   FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625
   GEBAUER F, 1991, VIROLOGY, V183, P225, DOI 10.1016/0042-6822(91)90135-X
   GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994
   HAELTERMAN EO, 1967, P 18 WORLD VET C PAR, P569
   Holmes Kathryn V., 1996, P541
   Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294
   Izeta A, 1999, J VIROL, V73, P1535, DOI 10.1128/JVI.73.2.1535-1545.1999
   JIMENEZ G, 1986, J VIROL, V60, P131
   KAPKE PA, 1986, VIROLOGY, V151, P41, DOI 10.1016/0042-6822(86)90102-9
   KOETZNER CA, 1992, J VIROL, V66, P1841, DOI 10.1128/JVI.66.4.1841-1848.1992
   Kolb AF, 1997, J GEN VIROL, V78, P2795, DOI 10.1099/0022-1317-78-11-2795
   Krempl C, 1997, J VIROL, V71, P3285, DOI 10.1128/JVI.71.4.3285-3287.1997
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   LEE KM, 1954, AM J VET RES, V15, P364
   Leparc-Goffart I, 1998, J VIROL, V72, P9628, DOI 10.1128/JVI.72.12.9628-9636.1998
   LEVINE AJ, 1984, CONCEPTS VIRAL PATHO, P130
   Lunney J.K., 1986, SWINE BIOMEDICAL RES, V3, P1821
   MASTERS PS, 1994, J VIROL, V68, P328, DOI 10.1128/JVI.68.1.328-337.1994
   MATLOUBIAN M, 1993, J VIROL, V67, P7340, DOI 10.1128/JVI.67.12.7340-7349.1993
   MCCLURKIN AW, 1966, CAN J COMP MED VET S, V30, P190
   MCKITTRICK SP, 1993, BIOTECHNIQUES, V15, P802
   Mendez A, 1996, VIROLOGY, V217, P495, DOI 10.1006/viro.1996.0144
   PENG D, 1995, J VIROL, V69, P5475, DOI 10.1128/JVI.69.9.5475-5484.1995
   PENZES Z, UNPUB COMPLETE NUCLE
   RASSCHAERT D, 1987, J GEN VIROL, V68, P1883, DOI 10.1099/0022-1317-68-7-1883
   RASSCHAERT D, 1987, BIOCHIMIE, V69, P591, DOI 10.1016/0300-9084(87)90178-7
   RASSCHAERT D, 1990, J GEN VIROL, V71, P2599, DOI 10.1099/0022-1317-71-11-2599
   REGISTER KB, 1994, J VET DIAGN INVEST, V6, P16, DOI 10.1177/104063879400600104
   SACHS DH, 1976, TRANSPLANTATION, V22, P559, DOI 10.1097/00007890-197612000-00004
   Saif L.J., 1992, DIS SWINE, P362
   SAIF LJ, 1979, AM J VET RES, V40, P115
   Sambrook J., 1989, MOL CLONING LAB MANU
   SANCHEZ CM, 1990, VIROLOGY, V174, P410, DOI 10.1016/0042-6822(90)90094-8
   SANCHEZ CM, 1992, VIROLOGY, V190, P92, DOI 10.1016/0042-6822(92)91195-Z
   Shafer G, 1997, ANN MATH ARTIF INTEL, V21, P1, DOI 10.1023/A:1018996831193
   SHAFREN DR, 1995, J VIROL, V69, P3873, DOI 10.1128/JVI.69.6.3873-3877.1995
   Sinzger C, 1996, INTERVIROLOGY, V39, P302, DOI 10.1159/000150502
   SUNE C, 1990, VIROLOGY, V177, P559, DOI 10.1016/0042-6822(90)90521-R
   Suzuki H, 1996, J VIROL, V70, P2632, DOI 10.1128/JVI.70.4.2632-2636.1996
   Takahashi Hidehiro, 1997, Leukemia (Basingstoke), V11, P26
   Tresnan DB, 1996, J VIROL, V70, P8669, DOI 10.1128/JVI.70.12.8669-8674.1996
   VANDERMOST RG, 1992, NUCLEIC ACIDS RES, V20, P3375, DOI 10.1093/nar/20.13.3375
   Ward T, 1998, J VIROL, V72, P5360, DOI 10.1128/JVI.72.7.5360-5365.1998
   WARD T, 1994, EMBO J, V13, P5070, DOI 10.1002/j.1460-2075.1994.tb06836.x
   Weiss RA, 1996, NATURE, V381, P647, DOI 10.1038/381647a0
   Welter C. J., 1987, Coronaviruses, P551
   WESLEY RD, 1991, J VIROL, V65, P3369, DOI 10.1128/JVI.65.6.3369-3373.1991
   WESLEY RD, 1990, J VIROL, V64, P4761, DOI 10.1128/JVI.64.10.4761-4766.1990
   WESLEY RD, 1999, COMMUNICATION
   WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E
   WOODS RD, 1978, J AM VET MED ASSOC, V173, P643
   WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   YOKOMORI K, 1993, VIROLOGY, V196, P45, DOI 10.1006/viro.1993.1453
   Zhang LN, 1997, VIROLOGY, V230, P93, DOI 10.1006/viro.1997.8460
NR 75
TC 149
Z9 170
U1 0
U2 14
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD SEP
PY 1999
VL 73
IS 9
BP 7607
EP 7618
PG 12
WC Virology
SC Virology
GA 225ME
UT WOS:000081964700057
PM 10438851
DA 2020-04-03
ER

PT J
AU JIA, W
   KARACA, K
   PARRISH, CR
   NAQI, SA
AF JIA, W
   KARACA, K
   PARRISH, CR
   NAQI, SA
TI A NOVEL VARIANT OF AVIAN INFECTIOUS-BRONCHITIS VIRUS RESULTING FROM
   RECOMBINATION AMONG 3 DIFFERENT STRAINS
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID RNA RECOMBINATION; CORONAVIRUS-IBV; MURINE CORONAVIRUSES; HYPERVARIABLE
   REGION; GENOMIC RNA; S1 GENE; SEROTYPES; SEQUENCE; HEMAGGLUTINATION;
   IDENTIFICATION
AB An antigenic variant of avian infectious bronchitis virus (IBV), a coronavirus, was isolated and characterized. This strain, CU-T2, possesses a number of unusual features, which have not been previously observed in IBV. The S1 glycoprotein of CU-T2 carries virus-neutralizing and serotype-specific epitopes of two IBV serotypes, Arkansas (Ark) and Massachusetts (Mass). Sequence analysis revealed that the virus, originally an Ark serotype, has acquired the Mass-specific epitope by mutation(s). This provides evidence that point mutations may lead to generation of IBV antigenic variants in the field. It was further observed that two independent recombination events involving three different IBV strains had occurred in the S2 glycoprotein gene and N protein gene of CU-T2, indicating that genomic RNA recombination in IBV may occur in multiple genes in nature. It was especially significant that a sequence of Holland 52 (a vaccine strain) had replaced half of the N gene of CU-T2. This proves that recombination among vaccine strains is contributing to the generation of IBV variants in the field. Based on these observations it is predicted that every IBV field isolate could have unique genetic nature. Therefore, several recently reported diagnostic and serotyping methods of IBV which are based on dot-blot hybridization, restriction fragment length polymorphism (RFLP), and polymerase chain reaction (PCR), may not reveal the true antigenic and/or genetic nature of IBV isolates, and may in fact yield misleading information.
C1 CORNELL UNIV,COLL VET MED,DEPT AVIAN & AQUAT ANIM MED,ITHACA,NY 14853.
   CORNELL UNIV,COLL VET MED,JAMES A BAKER INST ANIM HLTH,ITHACA,NY 14853.
CR BANNER LR, 1991, VIROLOGY, V185, P441, DOI 10.1016/0042-6822(91)90795-D
   BANNER LR, 1990, VIROLOGY, V175, P548, DOI 10.1016/0042-6822(90)90439-X
   BARIC RS, 1990, VIROLOGY, V177, P646, DOI 10.1016/0042-6822(90)90530-5
   BINNS MM, 1986, J GEN VIROL, V67, P2825, DOI 10.1099/0022-1317-67-12-2825
   BINNS MM, 1985, J GEN VIROL, V66, P719, DOI 10.1099/0022-1317-66-4-719
   BOOTS AMH, 1992, VACCINE, V10, P119, DOI 10.1016/0264-410X(92)90028-I
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BOURSNELL MEG, 1985, J GEN VIROL, V66, P573, DOI 10.1099/0022-1317-66-3-573
   BOURSNELL MEG, 1985, J GEN VIROL, V66, P2253, DOI 10.1099/0022-1317-66-10-2253
   CAVANAGH D, 1986, VIRUS RES, V4, P133, DOI 10.1016/0168-1702(86)90037-7
   CAVANAGH D, 1993, ARCH VIROL, V130, P471, DOI 10.1007/BF01309675
   CAVANAGH D, 1992, AVIAN PATHOL, V21, P401, DOI 10.1080/03079459208418858
   CAVANAGH D, 1986, J GEN VIROL, V67, P1443, DOI 10.1099/0022-1317-67-7-1443
   CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435
   CAVANAGH D, 1992, AVIAN PATHOL, V21, P33, DOI 10.1080/03079459208418816
   COWEN BS, 1975, AVIAN DIS, V19, P583, DOI 10.2307/1589084
   GELB J, 1991, AVIAN DIS, V35, P82, DOI 10.2307/1591298
   HOPKINS SR, 1974, AVIAN DIS, V18, P231, DOI 10.2307/1589131
   JOHNSON RB, 1973, AVIAN DIS, V17, P518, DOI 10.2307/1589149
   JUNGHERR EL, 1956, 60 P ANN M US LIV SA, P203
   KARACA K, 1992, AVIAN DIS, V36, P903, DOI 10.2307/1591549
   KECK JG, 1988, J VIROL, V62, P1989, DOI 10.1128/JVI.62.6.1989-1998.1988
   KECK JG, 1988, J VIROL, V62, P1810, DOI 10.1128/JVI.62.5.1810-1813.1988
   King D. J., 1991, Diseases of poultry., P471
   KUSTERS JG, 1990, VACCINE, V8, P605, DOI 10.1016/0264-410X(90)90018-H
   KWON HM, 1993, AVIAN DIS, V37, P194, DOI 10.2307/1591474
   LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985
   LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992
   LIAO CL, 1992, J VIROL, V66, P6117, DOI 10.1128/JVI.66.10.6117-6124.1992
   LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MARQUARDT WW, 1981, 16TH P NAT M POULTR
   NAGANO H, 1993, J VET MED SCI, V55, P735, DOI 10.1292/jvms.55.735
   NAQI SA, 1993, AVIAN PATHOL, V22, P555, DOI 10.1080/03079459308418943
   SIDDELL SG, 1983, INTERVIROLOGY, V20, P181, DOI 10.1159/000149390
   STERN DF, 1982, J VIROL, V44, P794, DOI 10.1128/JVI.44.3.794-803.1982
   SUTOU S, 1988, VIROLOGY, V165, P589, DOI 10.1016/0042-6822(88)90603-4
   WANG L, 1993, VIROLOGY, V192, P710, DOI 10.1006/viro.1993.1093
   WILLIAMS AK, 1993, VIRUS RES, V28, P19, DOI 10.1016/0168-1702(93)90086-3
   ZWAAGSTRA KA, 1992, J CLIN MICROBIOL, V30, P79, DOI 10.1128/JCM.30.1.79-84.1992
NR 40
TC 149
Z9 192
U1 0
U2 4
PU SPRINGER-VERLAG WIEN
PI VIENNA
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA
SN 0304-8608
J9 ARCH VIROL
JI Arch. Virol.
PY 1995
VL 140
IS 2
BP 259
EP 271
DI 10.1007/BF01309861
PG 13
WC Virology
SC Virology
GA QK493
UT WOS:A1995QK49300005
PM 7710354
DA 2020-04-03
ER

PT J
AU Woo, PCY
   Wang, M
   Lau, SKP
   Xu, HF
   Poon, RWS
   Guo, RT
   Wong, BHL
   Gao, K
   Tsoi, HW
   Huang, Y
   Li, KSM
   Lam, CSF
   Chan, KH
   Zheng, BJ
   Yuen, KY
AF Woo, Patrick C. Y.
   Wang, Ming
   Lau, Susanna K. P.
   Xu, Huifang
   Poon, Rosana W. S.
   Guo, Rongtong
   Wong, Beatrice H. L.
   Gao, Kai
   Tsoi, Hoi-wah
   Huang, Yi
   Li, Kenneth S. M.
   Lam, Carol S. F.
   Chan, Kwok-hung
   Zheng, Bo-jian
   Yuen, Kwok-yung
TI Comparative analysis of twelve genomes of three novel group 2c and group
   2d coronaviruses reveals unique group and subgroup features
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; FELINE INFECTIOUS PERITONITIS;
   SARS-CORONAVIRUS; MOLECULAR-BIOLOGY; PROTEIN FAMILIES; BATS; SEQUENCE;
   VIRUS; HKU1; IDENTIFICATION
AB Twelve complete genomes of three novel coronaviruses-bat coronavirus HKU4 (bat-CoV HKU4), bat-CoV HKU5 (putative group 2c), and bat-CoV HKU9 (putative group 2d)-were sequenced. Comparative genome analysis showed that the various open reading frames (ORFs) of the genomes of the three coronaviruses had significantly higher amino acid identities to those of other group 2 coronaviruses than group 1 and 3 coronaviruses. Phylogenetic trees constructed using chymotrypsin-like protease, RNA-dependent RNA polymerase, helicase, spike, and nucleocapsid all showed that the group 2a and 2b and putative group 2c and 2d coronaviruses are more closely related to each other than to group 1 and 3 coronaviruses. Unique genomic features distinguishing between these four subgroups, including the number of papain-like proteases, the presence or absence of hemagglutinin esterase, small ORFs between the membrane and nucleocapsid genes and ORFs (NS7a and NS7b), bulged stem-loop and pseudoknot structures downstream of the nucleocapsid gene, transcription regulatory sequence, and ribosomal recognition signal for the envelope gene, were also observed. This is the first time that NS7a and NS7b downstream of the nucleocapsid gene has been found in a group 2 coronavirus. The high Ka/Ks ratio of NS7a and NS7b in bat-CoV HKU9 implies that these two group 2d-specific genes are under high selective pressure and hence are rapidly evolving. The four subgroups of group 2 coronaviruses probably originated from a common ancestor. Further molecular epidemiological studies on coronaviruses in the bats of other countries, as well as in other animals, and complete genome sequencing will shed more light on coronavirus diversity and their evolutionary histories.
C1 Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Res Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China.
   Guangzhou Ctr Dis Control & Prevent, Guangzhou, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, State Key Lab Emerging Infect Dis, Dept Microbiol, Queen Mary Hosp, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.
EM hkumicro@hkucc.hku.hk
RI Lau, Susanna/C-4321-2009; Li, Kenneth/C-4602-2009; Tsoi, Hoi
   Wah/C-4428-2009; Lau, Susanna Kar Pui/AAJ-6848-2020; Jha,
   Babal/AAC-8337-2020; Yuen, Kwok Yung/C-4465-2009; Woo, Patrick Chiu
   Yat/C-4449-2009
OI Lau, Susanna Kar Pui/0000-0002-1383-7374; Jha,
   Babal/0000-0002-7660-5255; Woo, Patrick Chiu Yat/0000-0001-9401-1832;
   Yuen, Kwok-yung/0000-0002-2083-1552
CR Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37
   Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Eickmann M, 2003, SCIENCE, V302, P1504
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Haijema BJ, 2004, J VIROL, V78, P3863, DOI 10.1128/JVI.78.8.3863-3871.2004
   Herrewegh AAPM, 1998, J VIROL, V72, P4508, DOI 10.1128/JVI.72.5.4508-4514.1998
   Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005
   Johara MY, 2001, EMERG INFECT DIS, V7, P439
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   MAKINO S, 1993, J VIROL, V67, P3304, DOI 10.1128/JVI.67.6.3304-3311.1993
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   OLSEN CW, 1993, VET MICROBIOL, V36, P1, DOI 10.1016/0378-1135(93)90126-R
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175
   Stoffel W., 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143
   Tang XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06
   TUNG FYT, 1992, VIROLOGY, V186, P676, DOI 10.1016/0042-6822(92)90034-M
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   van der Hoek L, 2006, FEMS MICROBIOL REV, V30, P760, DOI 10.1111/j.1574-6976.2006.00032.x
   Woo PCY, 2006, CURR OPIN INFECT DIS, V19, P401, DOI 10.1097/01.qco.0000244043.08264.fc
   Woo PCY, 2006, J VIROL, V80, P7136, DOI 10.1128/JVI.00509-06
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2005, MICROBIOL IMMUNOL, V49, P899, DOI 10.1111/j.1348-0421.2005.tb03681.x
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   Woo PCY, 2004, LANCET, V363, P841, DOI 10.1016/S0140-6736(04)15729-2
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
NR 37
TC 148
Z9 184
U1 1
U2 19
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD FEB
PY 2007
VL 81
IS 4
BP 1574
EP 1585
DI 10.1128/JVI.02182-06
PG 12
WC Virology
SC Virology
GA 136RI
UT WOS:000244241400004
PM 17121802
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Callison, SA
   Hilt, DA
   Boynton, TO
   Sample, BF
   Robison, R
   Swayne, DE
   Jackwood, MW
AF Callison, Scott A.
   Hilt, Deborah A.
   Boynton, Tye O.
   Sample, Brenda F.
   Robison, Robert
   Swayne, David E.
   Jackwood, Mark W.
TI Development and evaluation of a real-time Taqman RT-PCR assay for the
   detection of infectious bronchitis virus from infected chickens
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE real-time RT-PCR; IBV; diagnostic test; coronavirus
ID SEROTYPE IDENTIFICATION; S-1 GENE; ANTIBODIES
AB It is important to rapidly differentiate infectious bronchitis virus (IBV) from disease agents like highly pathogenic avian influenza virus and exotic Newcastle disease virus, which can be extremely similar in the early stages of their pathogenesis. In this study, we report the development and testing of a real-time RT-PCR assay using a Taqman (R)-labeled probe for early and rapid detection of IBV. The assay amplifies a 143-bp product in the 5 '-UTR of the IBV genome and has a limit of detection and quantification of 100 template copies per reaction. All 15 strains of IBV tested as well as two Turkey coronavirus strains were amplified, whereas none of the other pathogens examined, tested positive. Evaluation of the assay was completed with 1329 tracheal swab samples. A total of 680 samples collected from IBV antibody negative birds were negative for IBV by the real-time RT-PCR assay. We tested 229 tracheal swabs submitted to two different diagnostic laboratories and found 79.04% of the tracheal swabs positive for IBV by real-time RT-PCR, whereas only 27.51% of the samples were positive by virus isolation, which is the reference standard test. We also collected a total of 120 tracheal swabs at six different time points from birds experimentally infected with different dosages of IBV and found that, independent of the dose given, the viral load in the trachea plateau at 5 days post-inoculation. In addition, an inverse relationship between the dose of virus given and the viral load at 14 days post-inoculation was observed. Finally, we tested 300 total tracheal swab samples, from a flock of commercial broilers spray vaccinated for IBV in the field. The percentage of birds infected with the IBV vaccine at 3, 7, and 14 days post-vaccination was 58%, 65%, and 83%, respectively, indicating that only slightly more than half the birds were initially infected then the vaccine was subsequently transmitted to other birds in the flock. This observation is significant because coronaviruses, which have a high mutation rate, can revert to pathogenicity when bird-to-bird transmission occurs. The real-time RT-PCR test described herein can be used to rapidly distinguish IBV from other respiratory pathogens, which is important for control of this highly infectious virus. The test was extremely sensitive and specific, and can be used to quantitate viral genomic RNA in clinical samples. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Georgia, Dept Populat Hlth, Poultry Diagnost & Res Ctr, Athens, GA 30602 USA.
   Univ Georgia, Dept Microbiol, Athens, GA 30602 USA.
   Univ Delaware, Agr Res Lab, Georgetown, DE 19947 USA.
   Maryland Diagnost Lab, Salisbury, MD 21801 USA.
   USDA ARS, SE Poultry Res Lab, Athens, GA 30605 USA.
RP Jackwood, MW (reprint author), Univ Georgia, Dept Populat Hlth, Poultry Diagnost & Res Ctr, 953 Coll Stn Rd, Athens, GA 30602 USA.
EM mjackwoo@uga.edu
OI Swayne, David/0000-0001-7472-1992
CR CAVANAGH D, 1990, ADV EXP MED BIOL, V276, P369
   Cavanagh D., 2003, INFECT BRONCHITIS DI, P101
   GELB J, 1998, ISOLATION IDENTIFICA, P169
   Guy JS, 2000, AVIAN PATHOL, V29, P207, DOI 10.1080/03079450050045459
   Jackwood MW, 1997, AVIAN DIS, V41, P105, DOI 10.2307/1592449
   JACKWOOD MW, 2004, P 4 INT S AV COR PNE, P158
   KARACA K, 1992, AVIAN DIS, V36, P903, DOI 10.2307/1591549
   KARACA K, 1993, VET MICROBIOL, V34, P249, DOI 10.1016/0378-1135(93)90015-Y
   Keeler CL, 1998, AVIAN DIS, V42, P275, DOI 10.2307/1592477
   Kingham BF, 2000, AVIAN DIS, V44, P325, DOI 10.2307/1592547
   KWON HM, 1993, AVIAN DIS, V37, P194, DOI 10.2307/1591474
   Lee CW, 2001, VIRUS RES, V80, P33, DOI 10.1016/S0168-1702(01)00345-8
   NAQI SA, 1993, AVIAN PATHOL, V22, P555, DOI 10.1080/03079459308418943
NR 13
TC 148
Z9 167
U1 1
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD DEC
PY 2006
VL 138
IS 1-2
BP 60
EP 65
DI 10.1016/j.jviromet.2006.07.018
PG 6
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 105TP
UT WOS:000242055500008
PM 16934878
DA 2020-04-03
ER

PT J
AU PRESTON, GM
   JUNG, JS
   GUGGINO, WB
   AGRE, P
AF PRESTON, GM
   JUNG, JS
   GUGGINO, WB
   AGRE, P
TI MEMBRANE TOPOLOGY OF AQUAPORIN CHIP - ANALYSIS OF FUNCTIONAL
   EPITOPE-SCANNING MUTANTS BY VECTORIAL PROTEOLYSIS
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MAJOR INTRINSIC PROTEIN; WATER CHANNELS; XENOPUS-OOCYTES; CDNA;
   IDENTIFICATION; RECONSTITUTION; PURIFICATION; EXPRESSION; TRANSPORT;
   DOMAIN
AB CHIP is the archetypal member of the aquaporins, a widely expressed family of membrane water channels. The NH2- and COOH-terminal halves of CHIP are sequence-related, and hydropathy analysis predicted six membrane-spanning domains with five connecting loops (A-E). Here, we determined the membrane topology of CHIP expressed in Xenopus oocytes using biologically active recombinant channels. CHIP is glycosylated at Asn-42, indicating loop A is exofacial. An epitope from the coronavirus E1 glycoprotein was inserted into CHIP and localized to the outer or inner leaflet of the membrane by alpha-chymotrypsin digestion of intact oocytes or inside-out membrane vesicles. The E1 epitope at Thr-120 was protease-sensitive in intact oocytes, indicating that loop C is exofacial. The E1 epitope at Lys-6, Arg-162, or Lys-267 was protease-sensitive in inside-out membrane vesicles, confirming the cytoplasmic location of the NH2 and COOH termini and loop D. Insertions into loops B and E did not produce active water channels, but their cleavage patterns were consistent with inner (loop B) and outer (loop E) leaflet locations. This study indicates that the functional CHIP molecule is a unique structure with two internal repeats oriented 180-degrees to each other within the membrane.
C1 JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA.
   JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA.
RP PRESTON, GM (reprint author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, 725 N WOLFE ST, BALTIMORE, MD 21205 USA.
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL48268, HL33991]; NIDDK NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [DK32753]
CR AERTS T, 1990, J BIOL CHEM, V265, P8675
   AGRE P, 1993, AM J PHYSIOL, V265, pF463
   AGRE P, 1993, AM J PHYSIOL, V265, pF461
   BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500
   DAVIS JQ, 1984, J BIOL CHEM, V259, P1874
   DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z
   DENKER BM, 1988, J BIOL CHEM, V263, P15634
   FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0
   GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9
   HORWITZ J, 1987, BIOCHEMISTRY-US, V26, P8092, DOI 10.1021/bi00399a012
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919
   LU L, 1990, BIOPHYS J, V57, P1117, DOI 10.1016/S0006-3495(90)82632-1
   MACEY RI, 1984, AM J PHYSIOL, V246, pC195
   MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205
   MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x
   MOON C, 1993, J BIOL CHEM, V268, P15772
   NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275
   NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371
   NISHIMURA H, 1993, J BIOL CHEM, V268, P8514
   PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x
   PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081
   PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385
   PRESTON GM, 1993, J BIOL CHEM, V268, P17
   PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110
   SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225
   SMITH BL, 1991, J BIOL CHEM, V266, P6407
   TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x
   VANHOEK AN, 1991, J BIOL CHEM, V266, P16633
   VANHOEK AN, 1992, J BIOL CHEM, V267, P18267
   WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4
   ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002
   ZHANG R, 1990, J BIOL CHEM, V265, P15375
   ZHANG RB, 1993, BIOCHEMISTRY-US, V32, P2938, DOI 10.1021/bi00063a002
   ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359
NR 35
TC 148
Z9 151
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 21
PY 1994
VL 269
IS 3
BP 1668
EP 1673
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA MR988
UT WOS:A1994MR98800022
PM 7507481
DA 2020-04-03
ER

PT J
AU KWON, HM
   JACKWOOD, MW
   GELB, J
AF KWON, HM
   JACKWOOD, MW
   GELB, J
TI DIFFERENTIATION OF INFECTIOUS-BRONCHITIS VIRUS SEROTYPES USING
   POLYMERASE CHAIN-REACTION AND RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM
   ANALYSIS
SO AVIAN DISEASES
LA English
DT Article
ID HEMAGGLUTINATION-INHIBITION TEST; TRACHEAL ORGAN-CULTURES;
   CORONAVIRUS-IBV; NEUTRALIZATION TEST; BROILER-CHICKENS; STRAINS;
   PROTECTION; PROTEIN
AB Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis were used to differentiate between serotypes of several infectious bronchitis virus (IBV) strains. A sequence of 1720 base pairs (bp) that contains the Sl glycoprotein gene of IBV was amplified by PCR, purified, and digested with restriction enzymes. Eleven reference IBV strains were grouped according to the RFLP patterns. The IBV Holte, Arkansas DPI, SE 17, Md 27, and Iowa 97 strains could be differentiated from the other IBV strains using the restriction enzyme HaeIII. The Beaudette, Massachusetts 41, Connecticut, and Florida 88 strains had the same HaeIII RFLP pattern but could be differentiated using XcmI and BstYI restriction enzymes. The Gray and JMK strains could not be differentiated by their RFLP patterns following digestion with 23 different restriction enzymes. Twenty-six samples (field isolates and reference strains) of IBV, previously serotyped by the virus-neutralization (VN) test in embryonating eggs, were analyzed in a blind fashion. The results using the PCR and RFLP analysis agreed with the serotype for traditional and variant IBV viruses as determined by the VN test.
C1 UNIV GEORGIA,COLL VET MED,DEPT AVIAN MED,ATHENS,GA 30602.
   UNIV DELAWARE,COLL AGR SCI,DEPT ANIM SCI & AGR BIOCHEM,DELAWARE AGR EXPT STN,NEWARK,DE 19717.
CR BEAUDETTE F. R., 1937, Journal of the American Veterinary Medical Association, V90, P51
   BINNS MM, 1986, J GEN VIROL, V67, P2825, DOI 10.1099/0022-1317-67-12-2825
   BINNS MM, 1985, J GEN VIROL, V66, P719, DOI 10.1099/0022-1317-66-4-719
   CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435
   CAVANAGH D, 1983, J GEN VIROL, V64, P1787, DOI 10.1099/0022-1317-64-8-1787
   CLEWLEY JP, 1981, INFECT IMMUN, V32, P1227, DOI 10.1128/IAI.32.3.1227-1233.1981
   COOK JKA, 1987, AVIAN PATHOL, V16, P505, DOI 10.1080/03079458708436399
   COWEN BS, 1975, AVIAN DIS, V19, P583, DOI 10.2307/1589084
   DARBYSHIRE JH, 1979, ARCH VIROL, V61, P227, DOI 10.1007/BF01318057
   GELB J, 1981, AVIAN DIS, V25, P655, DOI 10.2307/1589996
   GELB J, 1991, AVIAN DIS, V35, P82, DOI 10.2307/1591298
   Gelb J. Jnr, 1989, LAB MANUAL ISOLATION, P124
   HOFSTAD MS, 1958, AM J VET RES, V19, P740
   HOFSTAD MS, 1981, AVIAN DIS, V25, P650, DOI 10.2307/1589995
   HOPKINS SR, 1974, AVIAN DIS, V18, P231, DOI 10.2307/1589131
   HOPKINS SR, 1969, AVIAN DIS, V13, P356, DOI 10.2307/1588504
   JACKWOOD MW, 1992, AVIAN DIS, V36, P403, DOI 10.2307/1591520
   JUNGHERR EL, 1956, 60 P ANN M US LIV SA, P203
   King D. J., 1991, Diseases of poultry., P471
   KING DJ, 1988, AVIAN DIS, V32, P362, DOI 10.2307/1590827
   KING DJ, 1984, AVIAN DIS, V28, P727, DOI 10.2307/1590241
   KOCH G, 1986, Israel Journal of Veterinary Medicine, V42, P89
   KOCH G, 1990, J GEN VIROL, V71, P1929, DOI 10.1099/0022-1317-71-9-1929
   KUSTERS JG, 1989, VIROLOGY, V169, P217, DOI 10.1016/0042-6822(89)90058-5
   KWON HM, 1993, AVIAN DIS, V37, P149, DOI 10.2307/1591468
   LIN Z, 1991, ARCH VIROL, V120, P145, DOI 10.1007/BF01310957
   LIN Z, 1991, ARCH VIROL, V116, P19, DOI 10.1007/BF01319228
   MAKINO S, 1988, VIROLOGY, V163, P104, DOI 10.1016/0042-6822(88)90237-1
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SIDDELL S, 1982, CURR TOP MICROBIOL, V99, P131
   WINTERFIELD RW, 1971, AVIAN DIS, V15, P305, DOI 10.2307/1588701
   WINTERFIELD RW, 1964, AVIAN DIS, V8, P40, DOI 10.2307/1587817
   WINTERFIELD RW, 1962, AM J VET RES, V23, P1273
NR 33
TC 148
Z9 172
U1 0
U2 4
PU AMER ASSOC AVIAN PATHOLOGISTS
PI KENNETT SQ
PA UNIV PENN, NEW BOLTON CENTER, KENNETT SQ, PA 19348-1692
SN 0005-2086
J9 AVIAN DIS
JI Avian Dis.
PD JAN-MAR
PY 1993
VL 37
IS 1
BP 194
EP 202
DI 10.2307/1591474
PG 9
WC Veterinary Sciences
SC Veterinary Sciences
GA KP174
UT WOS:A1993KP17400027
PM 8095782
DA 2020-04-03
ER

PT J
AU Wu, TJ
   Tzeng, YK
   Chang, WW
   Cheng, CA
   Kuo, Y
   Chien, CH
   Chang, HC
   Yu, J
AF Wu, Tsai-Jung
   Tzeng, Yan-Kai
   Chang, Wei-Wei
   Cheng, Chi-An
   Kuo, Yung
   Chien, Chin-Hsiang
   Chang, Huan-Cheng
   Yu, John
TI Tracking the engraftment and regenerative capabilities of transplanted
   lung stem cells using fluorescent nanodiamonds
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID IN-VIVO; STEM/PROGENITOR CELLS; SARS CORONAVIRUS; PROGENITOR CELLS;
   GENE-EXPRESSION; QUANTUM DOTS; INJURY; NICHE; DIFFERENTIATION;
   IDENTIFICATION
AB Lung stem/progenitor cells are potentially useful for regenerative therapy, for example in repairing damaged or lost lung tissue in patients. Several optical imaging methods and probes have been used to track how stem cells incorporate and regenerate themselves in vivo over time. However, these approaches are limited by photobleaching, toxicity and interference from background tissue autofluorescence. Here we show that fluorescent nanodiamonds, in combination with fluorescence-activated cell sorting, fluorescence lifetime imaging microscopy and immunostaining, can identify transplanted CD45(-)CD54(+)CD157(+) lung stem/progenitor cells in vivo, and track their engraftment and regenerative capabilities with single-cell resolution. Fluorescent nanodiamond labelling did not eliminate the cells' properties of self-renewal and differentiation into type I and type II pneumocytes. Time-gated fluorescence imaging of tissue sections of naphthalene-injured mice indicates that the fluorescent nanodiamond-labelled lung stem/progenitor cells preferentially reside at terminal bronchioles of the lungs for 7 days after intravenous transplantation.
C1 [Wu, Tsai-Jung; Chien, Chin-Hsiang; Yu, John] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Sch Life Sci, Program Mol Med, Taipei 112, Taiwan.
   [Wu, Tsai-Jung; Chang, Wei-Wei; Chang, Huan-Cheng; Yu, John] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   [Wu, Tsai-Jung; Chang, Wei-Wei; Yu, John] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.
   [Tzeng, Yan-Kai; Cheng, Chi-An; Kuo, Yung; Chang, Huan-Cheng] Acad Sinica, Inst Atom & Mol Sci, Taipei 106, Taiwan.
   [Tzeng, Yan-Kai; Kuo, Yung; Chang, Huan-Cheng] Natl Taiwan Univ, Dept Chem, Taipei 106, Taiwan.
   [Yu, John] Chang Gung Mem Hosp, Ctr Stem Cells & Translat Canc Res, Linkou 333, Taoyuan County, Taiwan.
RP Chang, HC (reprint author), Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
EM hchang@gate.sinica.edu.tw; johnyu@gate.sinica.edu.tw
RI Chang, Huan-Cheng/A-9358-2012; Cheng, Chi-An/AAC-7413-2019
OI CHENG, CHI-AN/0000-0002-6657-9137; Yu, John/0000-0002-3237-4272
FU National Science Council, TaiwanNational Science Council of Taiwan
   [100-2119M-001-028, 100-2321-B-001-036]; Academia SinicaAcademia Sinica
   - Taiwan
FX This work was supported by Academia Sinica and the National Science
   Council, Taiwan (grants nos. 100-2119M-001-028 and 100-2321-B-001-036).
   The authors thank the Division of Medical Biology, Genomics Research
   Center, for providing facilities and support for cell imaging and flow
   cytometric analysis.
CR Andersson-Sjoland A, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-76
   Billinton N, 2001, ANAL BIOCHEM, V291, P175, DOI 10.1006/abio.2000.5006
   CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295
   Chang CW, 2007, METHOD CELL BIOL, V81, P495, DOI 10.1016/S0091-679X(06)81024-1
   Chang YR, 2008, NAT NANOTECHNOL, V3, P284, DOI 10.1038/nnano.2008.99
   Chavakis E, 2008, J MOL CELL CARDIOL, V45, P514, DOI 10.1016/j.yjmcc.2008.01.004
   Chen HY, 2012, STEM CELLS, V30, P1948, DOI 10.1002/stem.1150
   Chen YX, 2007, J EXP MED, V204, P2529, DOI 10.1084/jem.20070462
   Chistiakov DA, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-92
   Edwards DF, 1985, HDB OPTICAL CONSTANT, P665, DOI DOI 10.1016/B978-0-08-054721-3.50035-6
   Faklaris O, 2008, SMALL, V4, P2236, DOI 10.1002/smll.200800655
   Fang CY, 2011, SMALL, V7, P3363, DOI 10.1002/smll.201101233
   Ferreira L, 2008, CELL STEM CELL, V3, P136, DOI 10.1016/j.stem.2008.07.020
   Fu CC, 2007, P NATL ACAD SCI USA, V104, P727, DOI 10.1073/pnas.0605409104
   Giangreco A, 2002, AM J PATHOL, V161, P173, DOI 10.1016/S0002-9440(10)64169-7
   Giangreco A, 2009, P NATL ACAD SCI USA, V106, P9286, DOI 10.1073/pnas.0900668106
   Huang H, 2007, NANO LETT, V7, P3305, DOI 10.1021/nl071521o
   Kajstura J, 2011, NEW ENGL J MED, V364, P1795, DOI 10.1056/NEJMoa1101324
   Kim CF, 2007, AM J PHYSIOL-LUNG C, V293, pL1092, DOI 10.1152/ajplung.00015.2007
   Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032
   Kircher MF, 2011, NAT REV CLIN ONCOL, V8, P677, DOI 10.1038/nrclinonc.2011.141
   Lau AN, 2012, MOL THER, V20, P1116, DOI 10.1038/mt.2012.37
   Ling TY, 2006, P NATL ACAD SCI USA, V103, P9530, DOI 10.1073/pnas.0510232103
   Liu KK, 2009, BIOMATERIALS, V30, P4249, DOI 10.1016/j.biomaterials.2009.04.056
   Lo Celso C, 2009, NATURE, V457, P92, DOI 10.1038/nature07434
   Lyons AB, 2000, J IMMUNOL METHODS, V243, P147, DOI 10.1016/S0022-1759(00)00231-3
   McGuinness LP, 2011, NAT NANOTECHNOL, V6, P358, DOI [10.1038/NNANO.2011.64, 10.1038/nnano.2011.64]
   McQualter JL, 2012, STEM CELLS, V30, P811, DOI 10.1002/stem.1055
   McQualter JL, 2010, P NATL ACAD SCI USA, V107, P1414, DOI 10.1073/pnas.0909207107
   Mochalin VN, 2012, NAT NANOTECHNOL, V7, P11, DOI [10.1038/nnano.2011.209, 10.1038/NNANO.2011.209]
   Mohan N, 2010, NANO LETT, V10, P3692, DOI 10.1021/nl1021909
   Morrisey EE, 2010, DEV CELL, V18, P8, DOI 10.1016/j.devcel.2009.12.010
   Pi QM, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-36
   Rosen AB, 2007, STEM CELLS, V25, P2128, DOI 10.1634/stemcells.2006-0722
   Schrand Amanda M., 2009, P159, DOI 10.1007/978-0-387-78608-7_8
   Solanki A, 2008, NANOMEDICINE-UK, V3, P567, DOI 10.2217/17435889.3.4.567
   Stripp BR, 1995, AM J PHYSIOL-LUNG C, V269, pL791
   Szilvassy SJ, 2001, BLOOD, V98, P2108, DOI 10.1182/blood.V98.7.2108
   Vaijayanthimala V, 2012, BIOMATERIALS, V33, P7794, DOI 10.1016/j.biomaterials.2012.06.084
   Vaijayanthimala V, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/42/425103
   Wang H, 2009, STEM CELLS, V27, P1548, DOI 10.1002/stem.81
   Weir C, 2008, HEART LUNG CIRC, V17, P395, DOI 10.1016/j.hlc.2008.01.006
   Xie YC, 2009, NATURE, V457, P97, DOI 10.1038/nature07639
   Yu SJ, 2005, J AM CHEM SOC, V127, P17604, DOI 10.1021/ja0567081
NR 44
TC 147
Z9 149
U1 6
U2 123
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD SEP
PY 2013
VL 8
IS 9
BP 682
EP 689
DI 10.1038/NNANO.2013.147
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 214XT
UT WOS:000324172800018
PM 23912062
DA 2020-04-03
ER

PT J
AU Yount, B
   Roberts, RS
   Sims, AC
   Deming, D
   Frieman, MB
   Sparks, J
   Denison, MR
   Davis, N
   Baric, RS
AF Yount, B
   Roberts, RS
   Sims, AC
   Deming, D
   Frieman, MB
   Sparks, J
   Denison, MR
   Davis, N
   Baric, RS
TI Severe acute respiratory syndrome coronavirus group-specific open
   reading frames encode nonessential functions for replication in cell
   cultures and mice
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; TRANSMISSIBLE GASTROENTERITIS VIRUS; LENGTH
   INFECTIOUS CDNA; SARS-CORONAVIRUS; MURINE CORONAVIRUS; STRUCTURAL
   PROTEIN; NUCLEOCAPSID PROTEIN; REVERSE GENETICS; GENOME SEQUENCE; IMMUNE
   EVASION
AB SARS coronavirus (SARS-CoV) encodes several unique group-specific open reading frames (ORFs) relative to other known coronaviruses. To determine the significance of the SARS-CoV group-specific ORFs in virus replication in vitro and in mice, we systematically deleted five of the eight group-specific ORFs, ORF3a, OF3b, ORF6, ORF7a, and ORF7b, and characterized recombinant virus replication and gene expression in vitro. Deletion of the group-specific ORFs of SARS-CoV, either alone or in various combinations, did not dramatically influence replication efficiency in cell culture or in the levels of viral RNA synthesis. The greatest reduction in virus growth was noted following ORF3a deletion. SARS-CoV spike (S) glycoprotein does not encode a rough endoplasmic reticulum (rER)/Golgi retention signal, and it has been suggested that ORF3a interacts with and targets S glycoprotein retention in the rER/Golgi apparatus. Deletion of ORF3a did not alter subcellular localization of the S glycoprotein from distinct punctuate localization in the rER/Golgi apparatus. These data suggest that ORF3a plays little role in the targeting of S localization in the rER/Golgi apparatus. In addition, insertion of the 29-bp deletion fusing ORF8a/b into the single ORF8, noted in early-stage SARS-CoV human and civet cat isolates, had little if any impact on in vitro growth or RNA synthesis. All recombinant viruses replicated to wild-type levels in the murine model, suggesting that either the group-specific ORFs play little role in in vivo replication efficiency or that the mouse model is not of sufficient quality for discerning the role of the group-specific ORFs in disease origin and development.
C1 Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Med, Carolina Vaccine Inst, Chapel Hill, NC 27599 USA.
   Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN USA.
   Vanderbilt Univ, Dept Pediat, Nashville, TN USA.
RP Baric, RS (reprint author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, 2105D McGavran Greenberg Hall, Chapel Hill, NC 27599 USA.
EM rbaric@email.unc.edu
RI Denison, Mark/O-7258-2018
OI Denison, Mark/0000-0003-2655-0900
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P01 AI059443, P01 AI059443-01A1, R01
   AI059136, AI059136]
CR Alcami A, 2000, IMMUNOL TODAY, V21, P447, DOI 10.1016/S0167-5699(00)01699-6
   Almazan F, 2004, J VIROL, V78, P12683, DOI 10.1128/JVI.78.22.12683-12688.2004
   Baric RS, 2000, J VIROL, V74, P4039, DOI 10.1128/JVI.74.9.4039-4046.2000
   Baric RS, 2002, J VIROL, V76, P3023, DOI 10.1128/JVI.76.6.3023-3030.2002
   BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   Baric RS, 1997, J VIROL, V71, P1946, DOI 10.1128/JVI.71.3.1946-1955.1997
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   Chen YY, 2005, CHINESE MED J-PEKING, V118, P267
   Chu CM, 2004, CAN MED ASSOC J, V171, P1349, DOI 10.1503/cmaj.1040398
   Corse E, 2002, J VIROL, V76, P1273, DOI 10.1128/JVI.76.3.1273-1284.2002
   Curtis KM, 2002, J VIROL, V76, P1422, DOI 10.1128/JVI.76.3.1422-1434.2002
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Egloff MP, 2004, P NATL ACAD SCI USA, V101, P3792, DOI 10.1073/pnas.0307877101
   Esper F, 2005, J INFECT DIS, V191, P499, DOI 10.1086/428291
   Fischer F, 1997, J VIROL, V71, P996, DOI 10.1128/JVI.71.2.996-1003.1997
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8
   Greenough TC, 2005, AM J PATHOL, V167, P455, DOI 10.1016/S0002-9440(10)62989-6
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Haijema BJ, 2004, J VIROL, V78, P3863, DOI 10.1128/JVI.78.8.3863-3871.2004
   Han Yun, 2003, J Tradit Chin Med, V23, P214
   Harrington PR, 2002, J VIROL, V76, P12335, DOI 10.1128/JVI.76.23.12335-12343.2002
   Harrington PR, 2002, J VIROL, V76, P730, DOI 10.1128/JVI.76.2.730-742.2002
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Hung IFN, 2004, EMERG INFECT DIS, V10, P1550, DOI 10.3201/eid1009.040058
   Ito N, 2005, J VIROL, V79, P3182, DOI 10.1128/JVI.79.5.3182-3186.2005
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuo LL, 2003, J VIROL, V77, P4597, DOI 10.1128/JVI.77.8.4597-4608.2003
   Lassnig C, 2005, P NATL ACAD SCI USA, V102, P8275, DOI 10.1073/pnas.0408589102
   Leung T F, 2003, Paediatr Respir Rev, V4, P334, DOI 10.1016/S1526-0542(03)00088-5
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   MARRA MA, 2003, SCIENCE, V300, P1309
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009
   Nelson CA, 2005, STRUCTURE, V13, P75, DOI 10.1016/j.str.2004.10.010
   Ontiveros E, 2001, VIROLOGY, V289, P230, DOI 10.1006/viro.2001.1167
   Pewe L, 2005, J VIROL, V79, P11335, DOI 10.1128/JVI.79.17.11335-11342.2005
   Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248
   Poon LLM, 2004, LANCET INFECT DIS, V4, P663, DOI 10.1016/S1473-3099(04)01172-7
   Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Robertson MP, 2005, PLOS BIOL, V3, P86, DOI 10.1371/journal.pbio.0030005
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   ROWE T, 2004, MACAQUE MODEL SEVERE, V78, P11401
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   SCHAAD MC, 1994, J VIROL, V68, P8169, DOI 10.1128/JVI.68.12.8169-8179.1994
   Schwegmann-Wessels C, 2004, J BIOL CHEM, V279, P43661, DOI 10.1074/jbc.M407233200
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Sperry SM, 2005, J VIROL, V79, P3391, DOI 10.1128/JVI.79.6.3391-3400.2005
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Supekar VM, 2004, P NATL ACAD SCI USA, V101, P17958, DOI 10.1073/pnas.0406128102
   Surjit M, 2004, BIOCHEM J, V383, P13, DOI 10.1042/BJ20040984
   SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19
   Tan YJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-5
   Tan YJ, 2004, J VIROL, V78, P14043, DOI 10.1128/JVI.78.24.14043-14047.2004
   Tan YJ, 2004, J VIROL, V78, P6723, DOI 10.1128/JVI.78.13.6723-6734.2004
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   WESLEY RD, 1991, J VIROL, V65, P3369, DOI 10.1128/JVI.65.6.3369-3373.1991
   Wieringa R, 2004, J VIROL, V78, P13019, DOI 10.1128/JVI.78.23.13019-13027.2004
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
   Youn S, 2005, VIROLOGY, V332, P206, DOI 10.1016/j.virol.2004.10.045
   Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Yount B, 2002, J VIROL, V76, P11065, DOI 10.1128/JVI.76.21.11065-11078.2002
   Zeng R, 2004, J MOL BIOL, V341, P271, DOI 10.1016/j.jmb.2004.06.016
NR 75
TC 147
Z9 157
U1 1
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD DEC
PY 2005
VL 79
IS 23
BP 14909
EP 14922
DI 10.1128/JVI.79.23.14909-14922.2005
PG 14
WC Virology
SC Virology
GA 984CE
UT WOS:000233279300045
PM 16282490
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Ivanov, KA
   Thiel, V
   Dobbe, JC
   van der Meer, Y
   Snijder, EJ
   Ziebuhr, J
AF Ivanov, KA
   Thiel, V
   Dobbe, JC
   van der Meer, Y
   Snijder, EJ
   Ziebuhr, J
TI Multiple enzymatic activities associated with Severe acute respiratory
   syndrome coronavirus helicase
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; STRAND RNA VIRUSES; ARTERIVIRUS REPLICATION
   COMPLEX; DOUBLE-MEMBRANE VESICLES; 229E 3C-LIKE PROTEINASE; LENGTH
   INFECTIOUS CDNA; EQUINE ARTERITIS VIRUS; LAMBDA 1 PROTEIN;
   CRYSTAL-STRUCTURES; 5'-TRIPHOSPHATASE ACTIVITY
AB Severe acute respiratory syndrome coronavirus (SARS-CoV), a newly identified group 2 coronavirus, is the causative agent of severe acute respiratory syndrome, a life-threatening form of pneumonia in humans. Coronavirus replication and transcription are highly specialized processes of cytoplasmic RNA synthesis that localize to virus-induced membrane structures and were recently proposed to involve a complex enzymatic machinery that, besides RNA-dependent RNA polymerase, helicase, and protease activities, also involves a series of RNA-processing enzymes that are not found in most other RNA virus families. Here, we characterized the enzymatic activities of a recombinant form of the SARS-CoV helicase (nonstructural protein [nsp] 13), a superfamily 1 helicase with an N-terminal zinc-binding domain. We report that nsp13 has both RNA and DNA duplex-unwinding activities. SARS-CoV nsp13 unwinds its substrates in a 5'-to-3' direction and features a remarkable processivity, allowing efficient strand separation of extended regions of double-stranded RNA and DNA. Characterization of the nsp13-associated (deoxy)nucleoside triphosphatase ([dNTPase) activities revealed that all natural nucleotides and deoxynucleotides are substrates of nsp13, with ATP, dATP, and GTP being hydrolyzed slightly more efficiently than other nucleotides. Furthermore, we established an RNA 5'-triphosphatase activity for the SARS-CoV nsp13 helicase which may be involved in the formation of the 5' cap structure of viral RNAs. The data suggest that the (d)NTPase and RNA 5'-triphosphatase activities of nsp13 have a common active site. Finally, we established that, in SARS-CoV-infected Vero E6 cells, nsp13 localizes to membranes that appear to be derived from the endoplasmic reticulum and are the likely site of SARS-CoV RNA synthesis.
C1 Univ Wurzburg, Inst Virol & Immunol, Wurzburg, Germany.
   Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, Leiden, Netherlands.
RP Ziebuhr, J (reprint author), Univ Wurzburg, Inst Virol & Immunol, Wurzburg, Germany.
EM j.ziebuhr@mail.uni-wuerzburg.de
RI Thiel, Volker/AAI-2391-2019; Snijder, Eric J./E-6073-2018; Ziebuhr,
   John/G-7669-2015
OI Snijder, Eric J./0000-0003-3297-2309; Ziebuhr, John/0000-0002-5741-8825;
   Thiel, Volker/0000-0002-5783-0887
CR Ahlquist P, 2003, J VIROL, V77, P8181, DOI 10.1128/JVI.77.15.8181-8186.2003
   Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bautista EM, 2002, VIROLOGY, V298, P258, DOI 10.1006/viro.2002.1495
   Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3
   Bisaillon M, 1997, J BIOL CHEM, V272, P18298, DOI 10.1074/jbc.272.29.18298
   Bisaillon M, 1997, J BIOL CHEM, V272, P29954, DOI 10.1074/jbc.272.47.29954
   Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000
   Bost AG, 2001, VIROLOGY, V285, P21, DOI 10.1006/viro.2001.0932
   Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1
   Casais R, 2001, J VIROL, V75, P12359, DOI 10.1128/JVI.75.24.12359-12369.2001
   Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852
   Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713
   GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6
   Gorbalenya AE, 2001, ADV EXP MED BIOL, V494, P1
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Hegyi A, 2002, J GEN VIROL, V83, P581, DOI 10.1099/0022-1317-83-3-581
   Herold J, 1996, METHOD ENZYMOL, V275, P68
   Heusipp G, 1997, J VIROL, V71, P5631, DOI 10.1128/JVI.71.7.5631-5634.1997
   HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0
   Kadare G, 1997, J VIROL, V71, P2583
   Kalinina NO, 2002, VIROLOGY, V296, P321, DOI 10.1006/viro.2001.1328
   KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440
   KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197
   Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kwong AD, 2000, CURR TOP MICROBIOL, V242, P171
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LAI MMC, 1982, J VIROL, V41, P557, DOI 10.1128/JVI.41.2.557-565.1982
   LAI MMC, 1982, ADV EXP MED BIOL, V142, P69
   LAI MMC, 2001, FIELDS VIROLOGY, V1, P1163
   LEE CG, 1992, J BIOL CHEM, V267, P4398
   Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999
   Li YI, 2001, J VIROL, V75, P12114, DOI 10.1128/JVI.75.24.12114-12120.2001
   Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125
   Mackenzie JM, 1999, J VIROL, V73, P9555, DOI 10.1128/JVI.73.11.9555-9567.1999
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Morgenstern KA, 1997, J VIROL, V71, P3767, DOI 10.1128/JVI.71.5.3767-3775.1997
   Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168
   Pasternak AO, 2001, EMBO J, V20, P7220, DOI 10.1093/emboj/20.24.7220
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449
   Rogers GW, 2001, J BIOL CHEM, V276, P12598, DOI 10.1074/jbc.M007560200
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001
   Salonen A, 2003, J VIROL, V77, P1691, DOI 10.1128/JVI.77.3.1691-1702.2003
   Sawicki S G, 1995, Adv Exp Med Biol, V380, P499
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   Seybert A, 2000, J VIROL, V74, P9586, DOI 10.1128/JVI.74.20.9586-9593.2000
   Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728
   Seybert A, 2001, ADV EXP MED BIOL, V494, P255
   Shi ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999
   Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1
   SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0
   SIJDER EJ, 2003, J MOL BIOL, V331, P991
   Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002
   SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994
   Snijder EJ, 2001, J GEN VIROL, V82, P985, DOI 10.1099/0022-1317-82-5-985
   Soultanas P, 1999, J MOL BIOL, V290, P137, DOI 10.1006/jmbi.1999.2873
   Tanner JA, 2003, J BIOL CHEM, V278, P39578, DOI 10.1074/jbc.C300328200
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Thiel V, 2003, J VIROL, V77, P9790, DOI 10.1128/JVI.77.18.9790-9798.2003
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   Thiel V, 2001, J VIROL, V75, P6676, DOI 10.1128/JVI.75.14.6676-6681.2001
   van der Meer Y, 1998, J VIROL, V72, P6689, DOI 10.1128/JVI.72.8.6689-6698.1998
   van der Meer Y, 1999, J VIROL, V73, P7641, DOI 10.1128/JVI.73.9.7641-7657.1999
   van Dinten LC, 2000, J VIROL, V74, P5213, DOI 10.1128/JVI.74.11.5213-5223.2000
   vanDinten LC, 1997, P NATL ACAD SCI USA, V94, P991, DOI 10.1073/pnas.94.3.991
   Vasiljeva L, 2000, J BIOL CHEM, V275, P17281, DOI 10.1074/jbc.M910340199
   VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0
   Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3
   von Grotthuss M, 2003, CELL, V113, P701, DOI 10.1016/S0092-8674(03)00424-0
   WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x
   WARRENER P, 1995, J VIROL, V69, P1720, DOI 10.1128/JVI.69.3.1720-1726.1995
   WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Yount B, 2002, J VIROL, V76, P11065, DOI 10.1128/JVI.76.21.11065-11078.2002
   Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   ZIEBUHR J, 1995, J VIROL, V69, P4331, DOI 10.1128/JVI.69.7.4331-4338.1995
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
NR 92
TC 147
Z9 160
U1 1
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUN
PY 2004
VL 78
IS 11
BP 5619
EP 5632
DI 10.1128/JVI.78.11.5619-5632.2004
PG 14
WC Virology
SC Virology
GA 822CW
UT WOS:000221513400010
PM 15140959
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Fan, KQ
   Wei, P
   Feng, Q
   Chen, SD
   Huang, CK
   Ma, L
   Lai, B
   Pei, JF
   Liu, Y
   Chen, JG
   Lai, LH
AF Fan, KQ
   Wei, P
   Feng, Q
   Chen, SD
   Huang, CK
   Ma, L
   Lai, B
   Pei, JF
   Liu, Y
   Chen, JG
   Lai, LH
TI Biosynthesis, purification, and substrate specificity of severe acute
   respiratory syndrome coronavirus 3C-like proteinase
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RHINOVIRUS 3C PROTEASE; STRUCTURE-BASED DESIGN; BIOLOGICAL EVALUATION;
   MAIN PROTEINASE; 2-PYRIDONE-CONTAINING PEPTIDOMIMETICS; AMINO-ACIDS;
   INHIBITORS; SARS; REVEALS; FOLD
AB The 3C-like proteinase of severe acute respiratory syndrome (SARS) coronavirus has been proposed to be a key target for structural-based drug design against SARS. In order to understand the active form and the substrate specificity of the enzyme, we have cloned, expressed, and purified SARS 3C-like proteinase. Analytic gel filtration shows a mixture of monomer and dimer at a protein concentration of 4 mg/ml and mostly monomer at 0.2 mg/ml, which correspond to the concentration used in the enzyme assays. The linear decrease of the enzymatic-specific activity with the decrease of enzyme concentration revealed that only the dimeric form is active and the dimeric interface could be targeted for structural-based drug design against SARS 3C-like proteinase. By using a high pressure liquid chromatography assay, SARS 3C-like proteinase was shown to cut the 11 peptides covering all of the 11 cleavage sites on the viral polyprotein with different efficiency. The two peptides corresponding to the two self-cleavage sites are the two with highest cleavage efficiency, whereas peptides with non-canonical residues at P2 or P1' positions react slower. The P2 position of the substrates seems to favor large hydrophobic residues. Secondary structure studies for the peptide substrates revealed that substrates with more beta-sheetlike structure tend to react fast. This study provides a basic understanding of the enzyme catalysis and a full substrate specificity spectrum for SARS 3C-like proteinase, which are helpful for structural-based inhibitor design against SARS and other coronavirus.
C1 Peking Univ, Coll Chem, State Key Lab Struct Chem Stable & Unstable Speci, Beijing 100871, Peoples R China.
   Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China.
   Peking Univ, Ctr Theoret Biol, Beijing 100871, Peoples R China.
RP Lai, LH (reprint author), Peking Univ, Coll Chem, State Key Lab Struct Chem Stable & Unstable Speci, Beijing 100871, Peoples R China.
EM lhlai@pku.edu.cn
RI Fan, Keqiang/E-5366-2012; Pei, Jianfeng/U-9790-2019; CHEN,
   SIDI/D-8284-2016
OI Fan, Keqiang/0000-0003-2420-1889; Pei, Jianfeng/0000-0002-8482-1185;
   CHEN, SIDI/0000-0002-3819-5005
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Chou KC, 2003, BIOCHEM BIOPH RES CO, V308, P148, DOI 10.1016/S0006-291X(03)01342-1
   CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062
   Dragovich PS, 2002, BIOORG MED CHEM LETT, V12, P733, DOI 10.1016/S0960-894X(02)00008-2
   Dragovich PS, 2002, J MED CHEM, V45, P1607, DOI 10.1021/jm010469k
   Dragovich PS, 2000, BIOORG MED CHEM LETT, V10, P45, DOI 10.1016/S0960-894X(99)00587-9
   Dragovich PS, 1999, BIOORG MED CHEM LETT, V9, P2189, DOI 10.1016/S0960-894X(99)00368-6
   Dragovich PS, 1999, J MED CHEM, V42, P1213, DOI 10.1021/jm9805384
   Dragovich PS, 1999, J MED CHEM, V42, P1203, DOI 10.1021/jm980537b
   Dragovich PS, 1998, J MED CHEM, V41, P2819, DOI 10.1021/jm9800696
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Liu Shiyong, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35 Suppl, P62
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Seipelt J, 1999, VIRUS RES, V62, P159, DOI 10.1016/S0168-1702(99)00043-X
   Xiong B, 2003, ACTA PHARMACOL SIN, V24, P497
   Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997
   ZIEBUHR J, 1995, J VIROL, V69, P4331, DOI 10.1128/JVI.69.7.4331-4338.1995
NR 24
TC 147
Z9 161
U1 1
U2 14
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 16
PY 2004
VL 279
IS 3
BP 1637
EP 1642
DI 10.1074/jbc.M310875200
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 762WT
UT WOS:000188005700011
PM 14561748
OA Bronze
DA 2020-04-03
ER

PT J
AU van der Meer, Y
   Snijder, EJ
   Dobbe, JC
   Schleich, S
   Denison, MR
   Spaan, WJM
   Locker, JK
AF van der Meer, Y
   Snijder, EJ
   Dobbe, JC
   Schleich, S
   Denison, MR
   Spaan, WJM
   Locker, JK
TI Localization of mouse hepatitis virus nonstructural proteins and RNA
   synthesis indicates a role for late endosomes in viral replication
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID EQUINE ARTERITIS VIRUS; TEMPERATURE-SENSITIVE MUTANTS; MANNOSE
   6-PHOSPHATE RECEPTOR; INFECTIOUS-BRONCHITIS VIRUS; PAPAIN-LIKE
   PROTEINASE; CLASS-II COMPARTMENTS; P-28 CLEAVAGE SITE; MURINE
   CORONAVIRUS; ENDOPLASMIC-RETICULUM; 3C-LIKE PROTEINASE
AB The aim of the present study was to define the site of replication of the coronavirus mouse hepatitis virus (MHV). Antibodies directed against several proteins derived from the gene 1 polyprotein, including the 3C-like protease (3CLpro), the putative polymerase (POL), helicase, and a recently described protein (p22) derived from the C terminus of the open reading frame la protein (CT1a), were used to probe MHV-infected cells by indirect immunofluorescence (IF) and electron microscopy (EM). At early times of infection, all of these proteins showed a distinct punctate labeling by IF. Antibodies to the nucleocapsid protein also displayed a punctate labeling that largely colocalized with the replicase proteins. When infected cells were metabolically labeled with 5-bromouridine 5'-triphosphate (BrUTP), the site of viral RNA synthesis was shown by IF to colocalize with CT1a and the 3CLpro. As shown by EM, CT1a localized to LAMP-1 positive late endosomes/lysosomes while POL accumulated predominantly in multilayered structures with the appearance of endocytic carrier vesicles. These latter structures were also labeled to some extent with both anti-CT1a and LAMP-1 antibodies and could be filled with fluid phase endocytic tracers; When EM was used to determine sites of BrUTP incorporation into viral RNA at early times of infection, the viral RNA localized to late endosomal membranes as well. These results demonstrate that MHV replication occurs on late endosomal membranes and that several nonstructural proteins derived from the gene 1 polyprotein may participate in the formation and function of the viral replication complexes.
C1 European Mol Biol Lab, D-69117 Heidelberg, Germany.
   Leiden Univ, Med Ctr, Dept Virol, NL-2300 RC Leiden, Netherlands.
   Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA.
RP Locker, JK (reprint author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.
EM KRIJNSE@EMBL-Heidelberg.DE
RI Snijder, Eric J./E-6073-2018; Denison, Mark/O-7258-2018; Locker,
   Jacomine Krijnse/E-1009-2016
OI Snijder, Eric J./0000-0003-3297-2309; Denison, Mark/0000-0003-2655-0900;
   
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-26603, R01 AI026603]
CR ANDERSON R, 1993, VIROLOGY, V194, P224, DOI 10.1006/viro.1993.1253
   ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373
   BAKER SC, 1993, J VIROL, V67, P6056, DOI 10.1128/JVI.67.10.6056-6063.1993
   BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   BARTON DJ, 1991, J VIROL, V65, P1496, DOI 10.1128/JVI.65.3.1496-1506.1991
   BERG T, 1995, BIOCHEM J, V307, P313, DOI 10.1042/bj3070313
   Bi WZ, 1998, J NEUROVIROL, V4, P594, DOI 10.3109/13550289809114226
   BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992
   BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8
   Bonilla PJ, 1997, J VIROL, V71, P900, DOI 10.1128/JVI.71.2.900-909.1997
   BRAYTON PR, 1982, J VIROL, V42, P847, DOI 10.1128/JVI.42.3.847-853.1982
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   CALIGUIRI LA, 1969, SCIENCE, V166, P885, DOI 10.1126/science.166.3907.885
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   CHEN JW, 1985, ARCH BIOCHEM BIOPHYS, V239, P574, DOI 10.1016/0003-9861(85)90727-1
   CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85
   COMPTON SR, 1987, J VIROL, V61, P1814, DOI 10.1128/JVI.61.6.1814-1820.1987
   DALES S, 1965, P NATL ACAD SCI USA, V54, P462, DOI 10.1073/pnas.54.2.462
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999
   DONG SH, 1994, VIROLOGY, V204, P541, DOI 10.1006/viro.1994.1567
   FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075
   GALLAGHER TM, 1991, J VIROL, V65, P1916, DOI 10.1128/JVI.65.4.1916-1928.1991
   GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6
   GRIFFITHS G, 1990, J CELL SCI, V95, P441
   Griffiths G, 1996, PROTOPLASMA, V195, P37, DOI 10.1007/BF01279185
   GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703
   GRIFFITHS G, 1993, FINE STRUCTURE IMMUN
   GRIMLEY PM, 1972, J VIROL, V10, P492, DOI 10.1128/JVI.10.3.492-503.1972
   GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301
   Gupta S, 1998, J VIROL, V72, P2655, DOI 10.1128/JVI.72.4.2655-2662.1998
   HAMAGUCHI M, 1985, VIROLOGY, V147, P295, DOI 10.1016/0042-6822(85)90132-1
   Herold J, 1998, J VIROL, V72, P910, DOI 10.1128/JVI.72.2.910-918.1998
   Heusipp G, 1997, J GEN VIROL, V78, P2789, DOI 10.1099/0022-1317-78-11-2789
   HILL VM, 1986, P NATL ACAD SCI USA, V83, P5410, DOI 10.1073/pnas.83.15.5410
   HUGHES SA, 1995, J VIROL, V69, P809, DOI 10.1128/JVI.69.2.809-813.1995
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   KOOI C, 1991, VIROLOGY, V180, P108, DOI 10.1016/0042-6822(91)90014-3
   KOOLEN MJM, 1983, VIROLOGY, V125, P393, DOI 10.1016/0042-6822(83)90211-8
   KRZYSTYNIAK K, 1984, J GEN VIROL, V65, P227, DOI 10.1099/0022-1317-65-1-227
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lavi E, 1996, VIROLOGY, V221, P325, DOI 10.1006/viro.1996.0382
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   LIU DX, 1995, VIROLOGY, V209, P420, DOI 10.1006/viro.1995.1274
   LOCKER JK, 1995, J BIOL CHEM, V270, P8815, DOI 10.1074/jbc.270.15.8815
   Lu XT, 1998, J VIROL, V72, P2265, DOI 10.1128/JVI.72.3.2265-2271.1998
   Lu XT, 1996, VIROLOGY, V222, P375, DOI 10.1006/viro.1996.0434
   LU YQ, 1995, J VIROL, V69, P3554, DOI 10.1128/JVI.69.6.3554-3559.1995
   Griffiths Gareth, 1993, Trends in Cell Biology, V3, P214, DOI 10.1016/0962-8924(93)90114-G
   Luytjes W, 1997, J VIROL, V71, P949, DOI 10.1128/JVI.71.2.949-955.1997
   Magliano D, 1998, VIROLOGY, V240, P57, DOI 10.1006/viro.1997.8906
   MCDOWALL A, 1989, EUR J CELL BIOL, V49, P281
   MIZZEN L, 1985, VIROLOGY, V142, P378, DOI 10.1016/0042-6822(85)90345-9
   MOREMEN KW, 1985, J BIOL CHEM, V260, P6654
   Nash TC, 1997, VIROLOGY, V233, P1, DOI 10.1006/viro.1997.8609
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   PETERS PJ, 1995, J EXP MED, V182, P325, DOI 10.1084/jem.182.2.325
   Pinon JD, 1997, VIROLOGY, V230, P309, DOI 10.1006/viro.1997.8503
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   RestrepoHartwig MA, 1996, J VIROL, V70, P8908, DOI 10.1128/JVI.70.12.8908-8916.1996
   Schaad MC, 1997, EMBO J, V16, P4049, DOI 10.1093/emboj/16.13.4049
   Schiller JJ, 1998, VIROLOGY, V242, P288, DOI 10.1006/viro.1997.9010
   Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996
   Sethna PB, 1997, J VIROL, V71, P7744, DOI 10.1128/JVI.71.10.7744-7749.1997
   SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769
   SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123
   Snijder EJ, 1996, J BIOL CHEM, V271, P4864, DOI 10.1074/jbc.271.9.4864
   SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994
   Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961
   SNIJDER EJ, 1995, CORONAVIRIDAE
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   TALBOT PJ, 1984, J IMMUNOL METHODS, V73, P177, DOI 10.1016/0022-1759(84)90043-7
   Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256
   Tibbles KW, 1996, J VIROL, V70, P1923, DOI 10.1128/JVI.70.3.1923-1930.1996
   van der Meer Y, 1998, J VIROL, V72, P6689, DOI 10.1128/JVI.72.8.6689-6698.1998
   van Dinten LC, 1999, J VIROL, V73, P2027, DOI 10.1128/JVI.73.3.2027-2037.1999
   VANDEURS B, 1989, [No title captured], V117, P131
   vanDinten LC, 1996, J VIROL, V70, P6625, DOI 10.1128/JVI.70.10.6625-6633.1996
   VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0
   Wassenaar ALM, 1997, J VIROL, V71, P9313, DOI 10.1128/JVI.71.12.9313-9322.1997
   WEISMILLER DG, 1990, J VIROL, V64, P3051, DOI 10.1128/JVI.64.6.3051-3055.1990
   Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997
   WILLIAMS MC, 1987, AM REV RESPIR DIS, V135, P744
   ZIEBUHR J, 1995, J VIROL, V69, P4331, DOI 10.1128/JVI.69.7.4331-4338.1995
NR 88
TC 147
Z9 157
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 1999
VL 73
IS 9
BP 7641
EP 7657
DI 10.1128/JVI.73.9.7641-7657.1999
PG 17
WC Virology
SC Virology
GA 225ME
UT WOS:000081964700061
PM 10438855
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU BREDENBEEK, PJ
   PACHUK, CJ
   NOTEN, AFH
   CHARITE, J
   LUYTJES, W
   WEISS, SR
   SPAAN, WJM
AF BREDENBEEK, PJ
   PACHUK, CJ
   NOTEN, AFH
   CHARITE, J
   LUYTJES, W
   WEISS, SR
   SPAAN, WJM
TI THE PRIMARY STRUCTURE AND EXPRESSION OF THE 2ND OPEN READING FRAME OF
   THE POLYMERASE GENE OF THE CORONAVIRUS MHV-A59 - A HIGHLY CONSERVED
   POLYMERASE IS EXPRESSED BY AN EFFICIENT RIBOSOMAL FRAMESHIFTING
   MECHANISM
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
C1 STATE UNIV UTRECHT,INST VIROL,DEPT INFECT DIS & IMMUNOL,POB 80165,UTRECHT,NETHERLANDS.
   UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104.
FU NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [NS-21954]; PHS HHSUnited States Public
   Health Service [T32 A1-07325, A1-17418]
CR ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909
   ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BRAYTON PR, 1982, J VIROL, V42, P847, DOI 10.1128/JVI.42.3.847-853.1982
   BRAYTON PR, 1984, VIROLOGY, V133, P197, DOI 10.1016/0042-6822(84)90439-2
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   COIA G, 1988, J GEN VIROL, V69, P1, DOI 10.1099/0022-1317-69-1-1
   COMPTON SR, 1987, J VIROL, V61, P1814, DOI 10.1128/JVI.61.6.1814-1820.1987
   DEGROOT RJ, 1987, J GEN VIROL, V68, P995, DOI 10.1099/0022-1317-68-4-995
   DENISON M, 1987, VIROLOGY, V157, P565, DOI 10.1016/0042-6822(87)90303-5
   DENISON MR, 1986, J VIROL, V60, P12, DOI 10.1128/JVI.60.1.12-18.1986
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   GOLDBACH R, 1988, INTERVIROLOGY, V29, P260, DOI 10.1159/000150054
   GORBALENYA AE, 1988, NUCLEIC ACIDS RES, V16, P7735, DOI 10.1093/nar/16.15.7735
   GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2
   Gorman C, 1985, DNA CLONING PRACTICA, VII, P143
   GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5
   HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8
   HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0
   JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054
   JACKS T, 1988, CELL, V55, P449
   LAI MMC, 1983, J VIROL, V46, P1027, DOI 10.1128/JVI.46.3.1027-1033.1983
   LAI MMC, 1982, J VIROL, V41, P557, DOI 10.1128/JVI.41.2.557-565.1982
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   LEIBOWITZ JL, 1982, J VIROL, V42, P1080, DOI 10.1128/JVI.42.3.1080-1087.1982
   LEIBOWITZ JL, 1988, VIROLOGY, V166, P66, DOI 10.1016/0042-6822(88)90147-X
   LENSTRA JA, 1988, GENE ANAL TECH, V5, P57, DOI 10.1016/0735-0651(88)90017-9
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   MAHY BWJ, 1983, J GEN VIROL, V64, P103, DOI 10.1099/0022-1317-64-1-103
   MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67
   MEINKOTH J, 1984, ANAL BIOCHEM, V138, P2672
   NIESTERS HGM, 1986, VIRUS RES, V5, P253, DOI 10.1016/0168-1702(86)90022-5
   PACHUK CJ, 1989, VIROLOGY, V171, P141, DOI 10.1016/0042-6822(89)90520-5
   Palmenberg A. C., 1987, The molecular biology of the positive strand RNA viruses, P1
   PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444
   ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P237
   SAWICKI SG, 1986, J VIROL, V57, P328, DOI 10.1128/JVI.57.1.328-334.1986
   SOE LH, 1987, J VIROL, V61, P3968, DOI 10.1128/JVI.61.12.3968-3976.1987
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217
   STRAUSS EG, 1987, VIROLOGY, V164, P165
   STRAUSS JH, 1988, ANNU REV MICROBIOL, V42, P657, DOI 10.1146/annurev.mi.42.100188.003301
   TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767
   TORDO N, 1988, VIROLOGY, V165, P565, DOI 10.1016/0042-6822(88)90600-9
NR 49
TC 147
Z9 154
U1 1
U2 4
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR 11
PY 1990
VL 18
IS 7
BP 1825
EP 1832
DI 10.1093/nar/18.7.1825
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CZ684
UT WOS:A1990CZ68400020
PM 2159623
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Kuiken, T
   Leighton, FA
   Fouchier, RAM
   LeDuc, JW
   Peiris, JSM
   Schudel, A
   Stohr, K
   Osterhaus, ADME
AF Kuiken, T
   Leighton, FA
   Fouchier, RAM
   LeDuc, JW
   Peiris, JSM
   Schudel, A
   Stohr, K
   Osterhaus, ADME
TI Public health - Pathogen surveillance in animals
SO SCIENCE
LA English
DT Article
ID SARS CORONAVIRUS; WILDLIFE
C1 Erasmus MC, Dept Virol, NL-3015 GE Rotterdam, Netherlands.
   Univ Saskatchewan, Canadian Cooperat Wildlife Hlth Ctr, Saskatoon, SK S7N 5B4, Canada.
   Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.
   Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   World Org Anim Hlth, Paris, France.
   World Hlth Org, Dept Communicable Dis Surveillance & Response, Geneva, Switzerland.
RP Osterhaus, ADME (reprint author), Erasmus MC, Dept Virol, NL-3015 GE Rotterdam, Netherlands.
EM a.osterhaus@erasmusmc.nl
RI Fouchier, Ron A/A-1911-2014; Fouchier, Ron/Y-3755-2019
OI Fouchier, Ron A/0000-0001-8095-2869; Fouchier, Ron/0000-0001-8095-2869;
   Kuiken, Thijs/0000-0001-5501-9049
CR Bell D, 2004, PHILOS T ROY SOC B, V359, P1107, DOI 10.1098/rstb.2004.1492
   *ENV CAN, 2004, CAN NAT WILDL DIS ST
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   KOCH G, 2003, INFECT ZIEKTEN B, V14, P112
   Kruse H, 2004, EMERG INFECT DIS, V10, P2067, DOI 10.3201/eid1012.040707
   LEIGHTON FA, 1995, REV SCI TECH OIE, V14, P819
   Morner T, 2002, REV SCI TECH OIE, V21, P67, DOI 10.20506/rst.21.1.1321
   *OIE, 2005, UPD AV INFL AN AS TY
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Taylor LH, 2001, PHILOS T R SOC B, V356, P983, DOI 10.1098/rstb.2001.0888
   *UNAIDS, 2004, 2004 REP GLOB AIDS E
   Walsh PD, 2003, NATURE, V422, P611, DOI 10.1038/nature01566
   WHO, CUM NUMB CONF HUM CA
   *WORLD ORG AN HLTH, 2004, TERR AN HLTH COD
NR 15
TC 146
Z9 157
U1 0
U2 29
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD SEP 9
PY 2005
VL 309
IS 5741
BP 1680
EP 1681
DI 10.1126/science.1113310
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 963WK
UT WOS:000231836700028
PM 16150997
DA 2020-04-03
ER

PT J
AU Chiu, SS
   Chan, KH
   Chu, KW
   Kwan, SW
   Guan, Y
   Poon, LLM
   Peiris, JSM
AF Chiu, SS
   Chan, KH
   Chu, KW
   Kwan, SW
   Guan, Y
   Poon, LLM
   Peiris, JSM
TI Human coronavirus NL63 infection and other coronavirus infections in
   children hospitalized with acute respiratory disease in Hong Kong, China
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID RAPID DIAGNOSIS; OUTBREAK; VIRUS; SARS; OC43
AB Background. Human coronavirus NL63 (HCoV- NL63) is a recently discovered human coronavirus found to cause respiratory illness in children and adults that is distinct from the severe acute respiratory syndrome (SARS) coronavirus and human coronaviruses 229E (HCoV- 229E) and OC43 (HCoV- OC43).
   Methods. We investigated the role that HCoV- NL63, HCoV- OC43, and HCoV- 229E played in children hospitalized with fever and acute respiratory symptoms in Hong Kong during the period from August 2001 through August 2002.
   Results. Coronavirus infections were detected in 26 (4.4%) of 587 children studied; 15 (2.6%) were positive for HCoV- NL63, 9 (1.5%) were positive for HCoV- OC43, and 2 (0.3%) were positive for HCoV- 229E. In addition to causing upper respiratory disease, we found that HCoV- NL63 can present as croup, asthma exacerbation, febrile seizures, and high fever. The mean age (+/- standard deviation [SD]) of the infected children was 30.7 +/- 19.8 months ( range, 6-57 months). The mean maximum temperature (+/- SD) for the 12 children who were febrile was 39.3 degrees C +/- 0.9 degrees C, and the mean total duration of fever (+/- SD) for all children was days (range, 1-5 days). 2.6 +/- 1.2 HCoV- NL63 infections were noted in the spring and summer months of 2002, whereas HCoV- OC43 infection mainly occurred in the fall and winter months of 2001. HCoV- NL63 viruses appeared to cluster into 2 evolutionary lineages, and viruses from both lineages cocirculated in the same season.
   Conclusions. HCoV- NL63 is a significant pathogen that contributes to the hospitalization of children, and it was estimated to have caused 224 hospital admissions per 100,000 population aged <= 6 years each year in Hong Kong.
C1 Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong Special Adm Reg, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Hong Kong Special Adm Reg, Hong Kong, Hong Kong, Peoples R China.
RP Peiris, JSM (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong Special Adm Reg, Univ Pathol Bldg,102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM malik@hkucc.hku.hk
RI Poon, Leo/C-4382-2009; Peiris, Joseph Sriyal Malik/C-4380-2009
OI Poon, Leo/0000-0002-9101-7953; Peiris, Joseph Sriyal
   Malik/0000-0001-8217-5995
CR *CENS STAT DEP, 2001, 2001 POP CENS
   Chan KH, 2002, J CLIN MICROBIOL, V40, P1675, DOI 10.1128/JCM.40.5.1675-1680.2002
   Chiu SS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e63
   DROSTEN G, 2003, NEW ENGL J MED, V348, P1967
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   ISAACS D, 1983, ARCH DIS CHILD, V58, P500, DOI 10.1136/adc.58.7.500
   Kaiser L, 1999, J CLIN VIROL, V14, P191, DOI 10.1016/S1386-6532(99)00058-X
   MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Peiris JSM, 2003, EMERG INFECT DIS, V9, P628
   Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791
   Poon LLM, 2003, CLIN CHEM, V49, P953, DOI 10.1373/49.6.953
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   van Elden LJR, 2004, J INFECT DIS, V189, P652, DOI 10.1086/381207
   WENZEL RP, 1974, AM REV RESPIR DIS, V109, P621
   Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997
NR 19
TC 146
Z9 160
U1 1
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 15
PY 2005
VL 40
IS 12
BP 1721
EP 1729
DI 10.1086/430301
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 927OW
UT WOS:000229204300002
PM 15909257
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Warren, TK
   Jordan, R
   Lo, MK
   Ray, AS
   Mackman, RL
   Soloveva, V
   Siegel, D
   Perron, M
   Bannister, R
   Hui, HC
   Larson, N
   Strickley, R
   Wells, J
   Stuthman, KS
   Van Tongeren, SA
   Garza, NL
   Donnelly, G
   Shurtleff, AC
   Retterer, CJ
   Gharaibeh, D
   Zamani, R
   Kenny, T
   Eaton, BP
   Grimes, E
   Welch, LS
   Gomba, L
   Wilhelmsen, CL
   Nichols, DK
   Nuss, JE
   Nagle, ER
   Kugelman, JR
   Palacios, G
   Doerffler, E
   Neville, S
   Carra, E
   Clarke, MO
   Zhang, LJ
   Lew, W
   Ross, B
   Wang, Q
   Chun, K
   Wolfe, L
   Babusis, D
   Park, Y
   Stray, KM
   Trancheva, I
   Feng, JY
   Barauskas, O
   Xu, YL
   Wong, P
   Braun, MR
   Flint, M
   McMullan, LK
   Chen, SS
   Fearns, R
   Swaminathan, S
   Mayers, DL
   Spiropoulou, CF
   Lee, WA
   Nichol, ST
   Cihlar, T
   Bavari, S
AF Warren, Travis K.
   Jordan, Robert
   Lo, Michael K.
   Ray, Adrian S.
   Mackman, Richard L.
   Soloveva, Veronica
   Siegel, Dustin
   Perron, Michel
   Bannister, Roy
   Hui, Hon C.
   Larson, Nate
   Strickley, Robert
   Wells, Jay
   Stuthman, Kelly S.
   Van Tongeren, Sean A.
   Garza, Nicole L.
   Donnelly, Ginger
   Shurtleff, Amy C.
   Retterer, Cary J.
   Gharaibeh, Dima
   Zamani, Rouzbeh
   Kenny, Tara
   Eaton, Brett P.
   Grimes, Elizabeth
   Welch, Lisa S.
   Gomba, Laura
   Wilhelmsen, Catherine L.
   Nichols, Donald K.
   Nuss, Jonathan E.
   Nagle, Elyse R.
   Kugelman, Jeffrey R.
   Palacios, Gustavo
   Doerffler, Edward
   Neville, Sean
   Carra, Ernest
   Clarke, Michael O.
   Zhang, Lijun
   Lew, Willard
   Ross, Bruce
   Wang, Queenie
   Chun, Kwon
   Wolfe, Lydia
   Babusis, Darius
   Park, Yeojin
   Stray, Kirsten M.
   Trancheva, Iva
   Feng, Joy Y.
   Barauskas, Ona
   Xu, Yili
   Wong, Pamela
   Braun, Molly R.
   Flint, Mike
   McMullan, Laura K.
   Chen, Shan-Shan
   Fearns, Rachel
   Swaminathan, Swami
   Mayers, Douglas L.
   Spiropoulou, Christina F.
   Lee, William A.
   Nichol, Stuart T.
   Cihlar, Tomas
   Bavari, Sina
TI Therapeutic efficacy of the small molecule GS-5734 against Ebola virus
   in rhesus monkeys
SO NATURE
LA English
DT Article
ID INFECTED NONHUMAN-PRIMATES; ANTIVIRAL ACTIVITY; T-705 FAVIPIRAVIR;
   HIGH-THROUGHPUT; POLYMERASE; INHIBITOR; MODEL; PROTECTION; MACAQUES;
   PROMOTER
AB The most recent Ebola virus outbreak in West Africa, which was unprecedented in the number of cases and fatalities, geographic distribution, and number of nations affected, highlights the need for safe, effective, and readily available antiviral agents for treatment and prevention of acute Ebola virus (EBOV) disease (EVD) or sequelae(1). No antiviral therapeutics have yet received regulatory approval or demonstrated clinical efficacy. Here we report the discovery of a novel small molecule GS-5734, a monophosphoramidate prodrug of an adenosine analogue, with antiviral activity against EBOV. GS-5734 exhibits antiviral activity against multiple variants of EBOV and other filoviruses in cell-based assays. The pharmacologically active nucleoside triphosphate (NTP) is efficiently formed in multiple human cell types incubated with GS-5734 in vitro, and the NTP acts as an alternative substrate and RNA-chain terminator in primer-extension assays using a surrogate respiratory syncytial virus RNA polymerase. Intravenous administration of GS-5734 to nonhuman primates resulted in persistent NTP levels in peripheral blood mononuclear cells (half-life, 14 h) and distribution to sanctuary sites for viral replication including testes, eyes, and brain. In a rhesus monkey model of EVD, once-daily intravenous administration of 10 mg kg(-1) GS-5734 for 12 days resulted in profound suppression of EBOV replication and protected 100% of EBOV-infected animals against lethal disease, ameliorating clinical disease signs and pathophysiological markers, even when treatments were initiated three days after virus exposure when systemic viral RNA was detected in two out of six treated animals. These results show the first substantive post-exposure protection by a small-molecule antiviral compound against EBOV in nonhuman primates. The broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenaviruses, and coronaviruses, suggests the potential for wider medical use. GS-5734 is amenable to large-scale manufacturing, and clinical studies investigating the drug safety and pharmacokinetics are ongoing.
C1 [Warren, Travis K.; Soloveva, Veronica; Wells, Jay; Stuthman, Kelly S.; Van Tongeren, Sean A.; Garza, Nicole L.; Donnelly, Ginger; Shurtleff, Amy C.; Retterer, Cary J.; Gharaibeh, Dima; Zamani, Rouzbeh; Kenny, Tara; Eaton, Brett P.; Grimes, Elizabeth; Welch, Lisa S.; Gomba, Laura; Wilhelmsen, Catherine L.; Nichols, Donald K.; Nuss, Jonathan E.; Nagle, Elyse R.; Kugelman, Jeffrey R.; Palacios, Gustavo; Mayers, Douglas L.; Bavari, Sina] US Army, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA.
   [Warren, Travis K.; Soloveva, Veronica; Gomba, Laura; Nuss, Jonathan E.; Bavari, Sina] US Army, Med Res Inst Infect Dis, Therapeut Dev Ctr, Ft Detrick, MD 21702 USA.
   [Jordan, Robert; Ray, Adrian S.; Mackman, Richard L.; Siegel, Dustin; Perron, Michel; Bannister, Roy; Hui, Hon C.; Larson, Nate; Strickley, Robert; Doerffler, Edward; Neville, Sean; Carra, Ernest; Clarke, Michael O.; Zhang, Lijun; Lew, Willard; Ross, Bruce; Wang, Queenie; Chun, Kwon; Wolfe, Lydia; Babusis, Darius; Park, Yeojin; Stray, Kirsten M.; Trancheva, Iva; Feng, Joy Y.; Barauskas, Ona; Xu, Yili; Wong, Pamela; Chen, Shan-Shan; Swaminathan, Swami; Lee, William A.; Cihlar, Tomas] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.
   [Lo, Michael K.; Flint, Mike; McMullan, Laura K.; Spiropoulou, Christina F.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
   [Braun, Molly R.; Fearns, Rachel] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Welch, Lisa S.] LOKET Consulting, Clarksburg, MD 20871 USA.
   [Mayers, Douglas L.] Cocrystal Pharma, Tucker, GA 30084 USA.
RP Bavari, S (reprint author), US Army, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA.; Bavari, S (reprint author), US Army, Med Res Inst Infect Dis, Therapeut Dev Ctr, Ft Detrick, MD 21702 USA.; Cihlar, T (reprint author), Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.
EM tomas.cihlar@gilead.com; sina.bavari.civ@mail.mil
RI Bavari, Sina/L-3642-2019; Wilhelmsen, Catherine/M-7560-2019; Palacios,
   Gustavo/I-7773-2015; Flint, Mike/L-8355-2019; Eaton, Brett/G-1796-2019
OI Bavari, Sina/0000-0001-8424-5635; Wilhelmsen,
   Catherine/0000-0003-4695-7177; Palacios, Gustavo/0000-0001-5062-1938;
   Eaton, Brett/0000-0002-3060-2913; Zamani, Rouzbeh/0000-0001-9559-6828;
   Ray, Adrian/0000-0002-3508-3008; McMullan, Laura/0000-0003-2748-5151;
   Lo, Michael/0000-0002-0409-7896
FU Joint Science and Technology Office for Chemical and Biological Defense
   (JSTO-CBD) of the Defense Threat Reduction Agency (DTRA) [CB10218];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01AI113321]
FX T. Bocan, A. Duplantier, R. Panchal, and C. Kane provided scientific
   input. B. Norquist assisted with manuscript preparation. C. Cooper
   provided scientific input with human macrophage cultures for
   high-content image assessments. S. Tritsch and G. Gomba assisted with
   GS-5734 dose preparations for efficacy studies. C. Rice provided animal
   husbandry support services. X. Wei, W. Garner, and L. Zhong provided
   additional support for statistical analyses. K. Wang, K. Brendza, T.
   Alfredson, and L. Serafini assisted with analytical methods; S. Bondy
   and R. Seemayer procured key raw materials; L. Heumann, R. Polniaszeck,
   E. Rueden, A. Chtchemelinine, K. Brak, and B. Hoang contributed to
   synthesis; and Y. Zherebina helped with chiral separations. G. Lee
   supported the RSV antiviral assay, and G. Stepan, S. Ahmadyar, and H. Yu
   conducted part of the cytotoxicity testing. J. Knox contributed to
   polymerase modelling. A. L. Rheingold performed the X-ray
   crystallographic analysis (Supplementary Information). Studies at
   USAMRIID were in part supported by The Joint Science and Technology
   Office for Chemical and Biological Defense (JSTO-CBD) of the Defense
   Threat Reduction Agency (DTRA) under plan #CB10218. Work in the Fearns
   laboratory was supported by NIH R01AI113321. Opinions, interpretations,
   conclusions, and recommendations are those of the authors and are not
   necessarily endorsed by the US Army or the Centers for Disease Control
   and Prevention, US Department of Health and Human Services.
CR Bahar FG, 2012, J PHARM SCI-US, V101, P3979, DOI 10.1002/jps.23258
   BioCryst Pharmaceuticals, 2014, BIOCRYST ANN STUD RE
   Chimerix, 2015, BRINC WILL NOT BE CO
   Cho A, 2012, BIOORG MED CHEM LETT, V22, P2705, DOI 10.1016/j.bmcl.2012.02.105
   Deen GF, 2015, NEW ENGL J MED, DOI [10.1056/NEJMoa1511410, DOI 10.1056/NEJM0A1511410]
   Durand-Gasselin L, 2009, MOL PHARMACEUT, V6, P1145, DOI 10.1021/mp900036s
   Hunt L, 2015, LANCET INFECT DIS, V15, P1292, DOI 10.1016/S1473-3099(15)00144-9
   Jacome R., 2015, PLOS ONE, V10
   Kugelman JR, 2015, CELL REP, V12, P2111, DOI 10.1016/j.celrep.2015.08.038
   Kugelman JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050316
   KUHN JH, 2008, FILOVIRUSES COMPENDI
   Kupferschmidt K, 2015, SCIENCE, V347, P701, DOI 10.1126/science.347.6223.701
   Lodeiro MF, 2010, J BIOL CHEM, V285, P16387, DOI 10.1074/jbc.M109.092676
   Mackman R. L., 2011, U.S. Patent, Patent No. 2011045102
   Martins K, 2015, VIRAL IMMUNOL, V28, P32, DOI 10.1089/vim.2014.0085
   Mason SW, 2004, NUCLEIC ACIDS RES, V32, P4758, DOI 10.1093/nar/gkh809
   Mate SE, 2015, NEW ENGL J MED, V373, P2448, DOI 10.1056/NEJMoa1509773
   McMullan LK, 2016, ANTIVIR RES, V125, P71, DOI 10.1016/j.antiviral.2015.10.010
   Murakami E, 2008, ANTIMICROB AGENTS CH, V52, P458, DOI 10.1128/AAC.01184-07
   Nanyonga M, 2016, CLIN INFECT DIS, V62, P125, DOI 10.1093/cid/civ795
   Noton SL, 2015, J VIROL, V89, P7786, DOI 10.1128/JVI.00530-15
   Noton SL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002980
   Oestereich L, 2014, ANTIVIR RES, V105, P17, DOI 10.1016/j.antiviral.2014.02.014
   Olinger GG, 2012, P NATL ACAD SCI USA, V109, P18030, DOI 10.1073/pnas.1213709109
   Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777
   Shao R, 2004, BIOCHEM BIOPH RES CO, V321, P788, DOI 10.1016/j.bbrc.2004.07.033
   Sissoko D, 2015, C RETR OPP INF SEATT
   Smither SJ, 2014, ANTIVIR RES, V104, P153, DOI 10.1016/j.antiviral.2014.01.012
   Tekmira Pharmaceuticals Corporation, 2015, TEKM PROV UPD TKM EB
   Thi EP, 2015, NATURE, V521, P362, DOI 10.1038/nature14442
   Towner JS, 2005, VIROLOGY, V332, P20, DOI 10.1016/j.virol.2004.10.048
   Tremaglio CZ, 2013, J VIROL, V87, P3196, DOI 10.1128/JVI.02862-12
   Uebelhoer LS, 2014, ANTIVIR RES, V106, P86, DOI 10.1016/j.antiviral.2014.03.018
   Varkey JB, 2015, NEW ENGL J MED, V372, P2423, DOI 10.1056/NEJMoa1500306
   Warren TK, 2014, VIRUSES-BASEL, V6, P4666, DOI 10.3390/v6114666
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   World Health Organization (WHO), 2016, EB SIT REP 3 FEBR 20
NR 37
TC 145
Z9 149
U1 88
U2 169
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAR 17
PY 2016
VL 531
IS 7594
BP 381
EP +
DI 10.1038/nature17180
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DG4TA
UT WOS:000372064300055
PM 26934220
OA Green Published, Green Accepted
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Thiel, V
   Herold, J
   Schelle, B
   Siddell, SG
AF Thiel, V
   Herold, J
   Schelle, B
   Siddell, SG
TI Infectious RNA transcribed in vitro from a cDNA copy of the human
   coronavirus genome cloned in vaccinia virus
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; NUCLEOTIDE-SEQUENCE; FOREIGN DNA; REPLICATION;
   MODEL; STRATEGY; HCV-229E; VECTORS
AB The coronavirus genome is a positive-strand RNA of extraordinary size and complexity. It is composed of approximately 30000 nucleotides and it is the largest known autonomously replicating RNA. It is also remarkable in that more than two-thirds of the genome is devoted to encoding proteins involved in the replication and transcription of viral RNA. Here, a reverse-genetic system is described for the generation of recombinant coronaviruses. This system is based upon the in vitro transcription of infectious RNA from a cDNA copy of the human coronavirus 229E genome that has been cloned and propagated in vaccinia virus. This system is expected to provide new insights into the molecular biology and pathogenesis of coronaviruses and to serve as a paradigm for the genetic analysis of large RNA virus genomes. It also provides a starting point for the development of a new class of eukaryotic, multi-gene RNA vectors that are able to express several proteins simultaneously.
C1 Univ Wurzburg, Inst Immunol & Virol, D-97078 Wurzburg, Germany.
RP Siddell, SG (reprint author), Univ Wurzburg, Inst Immunol & Virol, Versbacher Str 7, D-97078 Wurzburg, Germany.
RI Thiel, Volker/AAI-2391-2019
OI Thiel, Volker/0000-0002-5783-0887
CR Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   Ausubel FM, 1987, CURRENT PROTOCOLS MO
   BREDENBEEK PJ, 1992, SEMIN VIROL, V3, P297
   Cowley JA, 2000, J GEN VIROL, V81, P1473, DOI 10.1099/0022-1317-81-6-1473
   Fischer F, 1997, J VIROL, V71, P5148, DOI 10.1128/JVI.71.7.5148-5160.1997
   HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419
   Herold J, 1998, ADV EXP MED BIOL, V440, P265
   Hsue B, 1999, J VIROL, V73, P6128, DOI 10.1128/JVI.73.7.6128-6135.1999
   Izeta A, 1999, J VIROL, V73, P1535, DOI 10.1128/JVI.73.2.1535-1545.1999
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   MACKETT M, 1985, DNA CLONING PRACTICA, P191
   Mandl CW, 1998, NAT MED, V4, P1438, DOI 10.1038/4031
   Masters PS, 1999, ADV VIRUS RES, V53, P245, DOI 10.1016/S0065-3527(08)60351-6
   Mawassi M, 2000, VIROLOGY, V267, P360, DOI 10.1006/viro.1999.0128
   MAYR A., 1966, ZENTRALBL VETERINARMED REIHE B, V13, P1
   MCINTOSH K, 1996, FIELDS VIROLOGY, P1095
   MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X
   MERCHLINSKY M, 1992, VIROLOGY, V190, P522, DOI 10.1016/0042-6822(92)91246-Q
   MOSS B, 1996, FIELDS VIROLOGY, P2637
   MYINT S, 1990, J MED VIROL, V31, P165, DOI 10.1002/jmv.1890310216
   RAABE T, 1990, J GEN VIROL, V71, P1065, DOI 10.1099/0022-1317-71-5-1065
   RAABE T, 1989, NUCLEIC ACIDS RES, V17, P6387, DOI 10.1093/nar/17.15.6387
   RAABE T, 1989, ARCH VIROL, V107, P323, DOI 10.1007/BF01317928
   Repass JF, 1998, J VIROL, V72, P7926, DOI 10.1128/JVI.72.10.7926-7933.1998
   Ruggli N, 1999, ADV VIRUS RES, V53, P183, DOI 10.1016/S0065-3527(08)60348-6
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   SIDDELL SG, 1998, TOPLEY WILSONS MICRO, P463
   SMITH GL, 1983, GENE, V25, P21, DOI 10.1016/0378-1119(83)90163-4
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   Stalcup RP, 1998, VIROLOGY, V241, P112, DOI 10.1006/viro.1997.8957
   Thiel V, 1997, ANAL BIOCHEM, V252, P62, DOI 10.1006/abio.1997.2307
   van Marle G, 1999, P NATL ACAD SCI USA, V96, P12056, DOI 10.1073/pnas.96.21.12056
   Williams GD, 1999, J VIROL, V73, P8349, DOI 10.1128/JVI.73.10.8349-8355.1999
   Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 36
TC 145
Z9 174
U1 0
U2 8
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AE,
   BERKS, ENGLAND
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD JUN
PY 2001
VL 82
BP 1273
EP 1281
DI 10.1099/0022-1317-82-6-1273
PN 6
PG 9
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 435TE
UT WOS:000168896600003
PM 11369870
OA Bronze
DA 2020-04-03
ER

PT J
AU Wu, GF
   Dandekar, AA
   Pewe, L
   Perlman, S
AF Wu, GF
   Dandekar, AA
   Pewe, L
   Perlman, S
TI CD4 and CD8 T cells have redundant but not identical roles in
   virus-induced demyelination
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC
   ENCEPHALOMYELITIS; MURINE CORONAVIRUS JHM; NEUROTROPIC CORONAVIRUS;
   MULTIPLE-SCLEROSIS; VIRAL CLEARANCE; IFN-GAMMA; MICE; MACROPHAGES
AB A chronic demyelinating disease results from murine infection with the neurotropic strain JHM of mouse hepatitis virus (MHV-JHM), Demyelination is largely immune mediated. In this study, the individual roles of CD4 and CD8 T cells in MHV-induced demyelination were investigated using recombination-activating gene 1(-/-) (RAG1(-/-)) mice infected with an attenuated strain of MHV-JHM. These animals develop demyelination only after adoptive transfer of splenocytes front mice previously immunized to MHV, In this study, we show that, following adoptive transfer, virus-specific CD4 and CD8 T cells rapidly infiltrate the CNS of MIN-JHM-infected RAG1(-/-) mice. Adoptive transfer of CD4 T cell-enriched donors resulted in more severe clinical disease accompanied by less demyelination than was detected in the recipients of undepleted cells. Macrophage infiltration into the gray matter of CD4 T cell-enriched recipients was greater than that observed in mice receiving undepleted splenocytes, In contrast, CD8 T cell-enriched recipients developed delayed disease with extensive demyelination of the spinal cord. MHV-JHM-infected RAG1(-/-) mice receiving donors depleted of both CD4 and CD8 T cells did not develop demyelination, These results demonstrate that the development of demyelination following MHV infection may be initiated by either CD4 or CD8 T cells. Furthermore, they show that CD4 T cells contribute more prominently than CD8 T cells to the severity of clinical disease, and that this correlates with increased macrophage infiltration into the gray matter.
C1 Univ Iowa, Dept Pediat, Med Labs 2042, Iowa City, IA 52242 USA.
   Univ Iowa, Program Neurosci, Iowa City, IA 52242 USA.
   Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.
   Univ Iowa, Coll Med, Iowa City, IA 52242 USA.
RP Perlman, S (reprint author), Univ Iowa, Dept Pediat, Med Labs 2042, Iowa City, IA 52242 USA.
OI Perlman, Stanley/0000-0003-4213-2354
FU NIMH NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [MH2066-03]; NINDS NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [NS36592]
CR Bergmann CC, 1999, J IMMUNOL, V163, P3379
   Bergmann CC, 1996, J GEN VIROL, V77, P315, DOI 10.1099/0022-1317-77-2-315
   CASTRO RF, 1995, J VIROL, V69, P8127, DOI 10.1128/JVI.69.12.8127-8131.1995
   DORRIES R, 1986, J NEUROIMMUNOL, V12, P131, DOI 10.1016/0165-5728(86)90026-3
   FLEMING JO, 1986, J VIROL, V58, P869, DOI 10.1128/JVI.58.3.869-875.1986
   Houtman JJ, 1996, J NEUROVIROL, V2, P101, DOI 10.3109/13550289609146543
   Houtman JJ, 1996, J NEUROVIROL, V2, P361, DOI 10.3109/13550289609146902
   HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025
   LAMPERT PW, 1973, ACTA NEUROPATHOL, V24, P76, DOI 10.1007/BF00691421
   Lane TE, 2000, J VIROL, V74, P1415, DOI 10.1128/JVI.74.3.1415-1424.2000
   Lane TE, 1999, J NEUROVIROL, V5, P48, DOI 10.3109/13550289909029745
   Lin MT, 1997, J VIROL, V71, P383, DOI 10.1128/JVI.71.1.383-391.1997
   MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G
   Murray PD, 1998, J VIROL, V72, P7320, DOI 10.1128/JVI.72.9.7320-7329.1998
   Parra B, 1999, J IMMUNOL, V162, P1641
   Parra B, 2000, J VIROL, V74, P2447, DOI 10.1128/JVI.74.5.2447-2450.2000
   PERLMAN S, 1987, MICROB PATHOGENESIS, V2, P185, DOI 10.1016/0882-4010(87)90020-9
   Perlman S, 1998, ADV EXP MED BIOL, V440, P503
   Pewe L, 1999, VIROLOGY, V255, P106, DOI 10.1006/viro.1998.9576
   Pewe L, 1999, J IMMUNOL, V163, P6106
   Rivera-Quinones C, 1998, NAT MED, V4, P187, DOI 10.1038/nm0298-187
   Rossi CP, 1997, J VIROL, V71, P3336, DOI 10.1128/JVI.71.4.3336-3340.1997
   Schwender S, 1999, J NEUROVIROL, V5, P249, DOI 10.3109/13550289909015811
   Slifka MK, 1999, NATURE, V401, P76, DOI 10.1038/43454
   Sriram S, 1997, NEUROLOGY, V48, P464, DOI 10.1212/WNL.48.2.464
   Stohlman SA, 1998, J IMMUNOL, V160, P2896
   STOHLMAN SA, 1995, J VIROL, V69, P5898, DOI 10.1128/JVI.69.9.5898-5903.1995
   STOHLMAN SA, 1998, PERSISTENT VIRAL INF, P537
   Sutherland RM, 1997, J NEUROVIROL, V3, P225, DOI 10.3109/13550289709018297
   Tran EH, 1998, J IMMUNOL, V161, P3767
   WANG FI, 1990, J NEUROIMMUNOL, V30, P31, DOI 10.1016/0165-5728(90)90050-W
   White DW, 1998, J IMMUNOL, V160, P898
   WILLIAMSON JSP, 1990, J VIROL, V64, P4589, DOI 10.1128/JVI.64.9.4589-4592.1990
   Wu GF, 1999, J VIROL, V73, P8771, DOI 10.1128/JVI.73.10.8771-8780.1999
   WU GF, 2000, IN PRESS J VIROL
   Xue SR, 1997, VIROLOGY, V238, P68, DOI 10.1006/viro.1997.8819
   Xue SR, 1999, J VIROL, V73, P6327, DOI 10.1128/JVI.73.8.6327-6334.1999
   XUE SR, 1995, VIROLOGY, V208, P173, DOI 10.1006/viro.1995.1140
NR 38
TC 145
Z9 148
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2000
VL 165
IS 4
BP 2278
EP 2286
DI 10.4049/jimmunol.165.4.2278
PG 9
WC Immunology
SC Immunology
GA 342BW
UT WOS:000088626200071
PM 10925317
OA Bronze
DA 2020-04-03
ER

PT J
AU Yang, ZY
   Wei, CJ
   Kong, WP
   Wu, L
   Xu, L
   Smith, DF
   Nabel, GJ
AF Yang, Zhi-Yong
   Wei, Chih-Jen
   Kong, Wing-Pui
   Wu, Lan
   Xu, Ling
   Smith, David F.
   Nabel, Gary J.
TI Immunization by avian H5 influenza hemagglutinin mutants with altered
   receptor binding specificity
SO SCIENCE
LA English
DT Article
ID VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PANDEMIC INFLUENZA; ESCAPE
   MUTANTS; A VIRUSES; GLYCOPROTEIN; CORONAVIRUS; SITES; ENTRY
AB Influenza virus entry is mediated by the receptor binding domain (RBD) of its spike, the hemagglutinin (HA). Adaptation of avian viruses to humans is associated with HA specificity for alpha 2,6- rather than alpha 2,3-linked sialic acid (SA) receptors. Here, we define mutations in influenza A subtype H5N1 (avian) HA that alter its specificity for SA either by decreasing alpha 2,3- or increasing alpha 2,6- SA recognition. RBD mutants were used to develop vaccines and monoclonal antibodies that neutralized new variants. Structure-based modification of HA specificity can guide the development of preemptive vaccines and therapeutic monoclonal antibodies that can be evaluated before the emergence of human-adapted H5N1 strains.
C1 NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   Emory Univ, Sch Med, Atlanta, GA 30322 USA.
RP Nabel, GJ (reprint author), NIAID, Vaccine Res Ctr, NIH, Bldg 40,Room 4502,Mailstop Code MSC-3005,40 Conve, Bethesda, MD 20892 USA.
EM gnabel@nih.gov
RI Yang, Ziheng/C-1358-2008
FU Intramural NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [Z99 AI999999]
CR BEAN WJ, 1992, J VIROL, V66, P1129, DOI 10.1128/JVI.66.2.1129-1138.1992
   BIZEBARD T, 1995, NATURE, V376, P92, DOI 10.1038/376092a0
   Fleury D, 1999, NAT STRUCT BIOL, V6, P530, DOI 10.1038/9299
   Gamblin SJ, 2004, SCIENCE, V303, P1838, DOI 10.1126/science.1093155
   Ilyushina N, 2004, VIROLOGY, V329, P33, DOI 10.1016/j.virol.2004.08.002
   Kaverin NV, 2002, J GEN VIROL, V83, P2497, DOI 10.1099/0022-1317-83-10-2497
   Kong WP, 2006, P NATL ACAD SCI USA, V103, P15987, DOI 10.1073/pnas.0607564103
   Laeeq S, 1997, J VIROL, V71, P2600, DOI 10.1128/JVI.71.4.2600-2605.1997
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   MURPHY BR, 1996, FIELDS VIROLOGY, P1403
   Parrish CR, 2005, ANNU REV MICROBIOL, V59, P553, DOI 10.1146/annurev.micro.59.030804.121059
   PAULSON JC, 1987, METHOD ENZYMOL, V138, P162
   Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531
   Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513
   Stevens J, 2004, SCIENCE, V303, P1866, DOI 10.1126/science.1093373
   Stevens J, 2006, NAT REV MICROBIOL, V4, P857, DOI 10.1038/nrmicro1530
   Subbarao K, 2006, IMMUNITY, V24, P5, DOI 10.1016/j.immuni.2005.12.005
   Tumpey TM, 2007, SCIENCE, V315, P655, DOI 10.1126/science.1136212
   Vines A, 1998, J VIROL, V72, P7626, DOI 10.1128/JVI.72.9.7626-7631.1998
   WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0
   WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0
   Yamada S, 2006, NATURE, V444, P378, DOI 10.1038/nature05264
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034
NR 24
TC 144
Z9 153
U1 0
U2 8
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD AUG 10
PY 2007
VL 317
IS 5839
BP 825
EP 828
DI 10.1126/science.1135165
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 198JN
UT WOS:000248624500047
PM 17690300
OA Green Accepted
DA 2020-04-03
ER

PT J
AU Vijgen, L
   Keyaerts, E
   Moes, E
   Thoelen, I
   Wollants, E
   Lemey, P
   Vandamme, AM
   Van Ranst, M
AF Vijgen, L
   Keyaerts, E
   Moes, E
   Thoelen, I
   Wollants, E
   Lemey, P
   Vandamme, AM
   Van Ranst, M
TI Complete genomic sequence of human coronavirus OC43: Molecular clock
   analysis suggests a relatively recent zoonotic coronavirus transmission
   event
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID AMINO-ACID-SEQUENCES; HEMAGGLUTINATING ENCEPHALOMYELITIS VIRUS;
   RESPIRATORY-TRACT DISEASE; BOVINE CORONAVIRUS; MONOCLONAL-ANTIBODIES;
   SARS-CORONAVIRUS; C VIRUS; S GENE; PROTEIN; RNA
AB Coronaviruses are enveloped, positive-stranded RNA viruses with a genome of approximately 30 kb. Based on genetic similarities, coronaviruses are classified into three groups. Two group 2 coronaviruses, human coronavirus OC43 (HCoV-OC43) and bovine coronavirus (BCoV), show remarkable antigenic and genetic similarities. In this study, we report the first complete genome sequence (30,738 nucleotides) of the prototype HCoV-OC43 strain (ATCC VR759). Complete genome and open reading frame (ORF) analyses were performed in comparison to the BCoV genome. In the region between the spike and membrane protein genes, a 290-nucleotide deletion is present, corresponding to the absence of BCoV ORFs ns4.9 and ns4.8. Nucleotide and amino acid similarity percentages were determined for the major HCoV-OC43 ORFs and for those of other group 2 coronaviruses. The highest degree of similarity is demonstrated between HCoV-OC43 and BCoV in all ORFs with the exception of the E gene. Molecular clock analysis of the spike gene sequences of BCoV and HCoV-OC43 suggests a relatively recent zoonotic transmission event and dates their most recent common ancestor to around 1890. An evolutionary rate in the order of 4 X 10(-4) nucleotide changes per site per year was estimated. This is the first animal-human zoonotic pair of coronaviruses that can be analyzed in order to gain insights into the processes of adaptation of a nonhuman coronavirus to a human host, which is important for understanding the interspecies transmission events that led to the origin of the severe acute respiratory syndrome outbreak.
C1 Katholieke Univ Leuven, Rega Inst Med Res, Lab Clin & Epidemiol Virol, Dept Microbiol & Immunol, BE-3000 Leuven, Belgium.
RP Van Ranst, M (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Lab Clin & Epidemiol Virol, Dept Microbiol & Immunol, Minderbroederstr 10, BE-3000 Leuven, Belgium.
EM marc.vanranst@uz.kuleuven.ac.be
RI Van Ranst, Marc/P-7522-2017; Lemey, Philippe/C-3755-2018; Vandamme,
   Anne-Mieke/I-4127-2012; Keyaerts, Els/F-2305-2018
OI Van Ranst, Marc/0000-0002-1674-4157; Lemey,
   Philippe/0000-0003-2826-5353; Vandamme, Anne-Mieke/0000-0002-6594-2766;
   Keyaerts, Els/0000-0002-1849-3240; Wollants, Elke/0000-0002-4057-2236
CR Abbott A, 2003, NATURE, V423, P576, DOI 10.1038/423576b
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Arbour N, 2000, J VIROL, V74, P8913, DOI 10.1128/JVI.74.19.8913-8921.2000
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BUCHENOSMOND C, 2003, ICTVDB UNIVERSAL VIR
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   Chouljenko VN, 1998, VIRUS GENES, V17, P33, DOI 10.1023/A:1008048916808
   Chouljenko VN, 2001, J GEN VIROL, V82, P2927, DOI 10.1099/0022-1317-82-12-2927
   CROOKSHANK EM, 1897, TXB BACTERIOLOGY INC, P239
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   Dessau RB, 2001, ACTA NEUROPATHOL, V101, P601
   Domingo E., 1988, RNA GENETICS, VIII, P3
   Edwards JA, 2000, J NEUROIMMUNOL, V108, P73, DOI 10.1016/S0165-5728(00)00266-6
   Erles K, 2003, VIROLOGY, V310, P216, DOI 10.1016/S0042-6822(03)00160-0
   Gagneur A, 2002, J HOSP INFECT, V51, P59, DOI 10.1053/jhin.2002.1179
   Gelinas AM, 2001, VIRUS RES, V76, P43, DOI 10.1016/S0168-1702(01)00243-X
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   HOGUE BG, 1984, J VIROL, V51, P384, DOI 10.1128/JVI.51.2.384-388.1984
   HOGUE BG, 1986, VIRUS RES, V5, P131, DOI 10.1016/0168-1702(86)90013-4
   Holmes KV, 1996, FIELDS VIROLOGY, P1075
   Ismail MM, 2001, AVIAN DIS, V45, P157, DOI 10.2307/1593023
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Jenkins GM, 2002, J MOL EVOL, V54, P156, DOI 10.1007/s00239-001-0064-3
   KAMAHORA T, 1989, VIRUS RES, V12, P1
   Kiemer L, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-72
   Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789
   Kourtesis AB, 2001, ARCH VIROL, V146, P1219, DOI 10.1007/s007050170117
   Krempl C, 1995, Adv Exp Med Biol, V380, P371
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LAPPS W, 1985, ARCH VIROL, V86, P101, DOI 10.1007/BF01314116
   LAPPS W, 1987, VIROLOGY, V157, P47, DOI 10.1016/0042-6822(87)90312-6
   LARSON HE, 1980, J MED VIROL, V5, P221, DOI 10.1002/jmv.1890050306
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   MCEACHRAN D, 1879, 4 BOVINE SCOURGES PL, P206
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V58, P2268, DOI 10.1073/pnas.58.6.2268
   MOUNIR S, 1993, ADV EXP MED BIOL, V342, P61
   MOUNIR S, 1993, VIROLOGY, V192, P355, DOI 10.1006/viro.1993.1043
   MULDER J, 1958, LANCET, V1, P810
   Nicholas KB, 1997, EMBNEW NEWS, V4, P14
   Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995
   Pybus OG, 2003, MOL BIOL EVOL, V20, P381, DOI 10.1093/molbev/msg043
   Rambaut A, 2000, BIOINFORMATICS, V16, P395, DOI 10.1093/bioinformatics/16.4.395
   Salemi M, 2004, J VIROL, V78, P1602, DOI 10.1128/JVI.78.3.1602-1603.2004
   SANCHEZ CM, 1992, VIROLOGY, V190, P92, DOI 10.1016/0042-6822(92)91195-Z
   Sasseville AMJ, 2002, J GEN VIROL, V83, P2411, DOI 10.1099/0022-1317-83-10-2411
   SISLEY R, 1891, EPIDEMIC INFLUENZA N, P47
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   Storz J, 1996, J AM VET MED ASSOC, V208, P1452
   Storz J, 2000, J CLIN MICROBIOL, V38, P3291, DOI 10.1128/JCM.38.9.3291-3298.2000
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   VAUTHEROT JF, 1983, ANN RECH VET, V14, P437
   VIELER E, 1995, ARCH VIROL, V140, P1215, DOI 10.1007/BF01322747
   ZHANG XM, 1994, J MED VIROL, V44, P152, DOI 10.1002/jmv.1890440207
   ZHANG XM, 1992, VIROLOGY, V186, P318, DOI 10.1016/0042-6822(92)90089-8
   ZHANG XM, 1991, VIROLOGY, V183, P397, DOI 10.1016/0042-6822(91)90154-4
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
   1958, LANCET, V1, P833
NR 68
TC 144
Z9 164
U1 2
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD FEB
PY 2005
VL 79
IS 3
BP 1595
EP 1604
DI 10.1128/JVI.79.3.1595-1604.2005
PG 10
WC Virology
SC Virology
GA 892FB
UT WOS:000226634300026
PM 15650185
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Kapoor, A
   Victoria, J
   Simmonds, P
   Slikas, E
   Chieochansin, T
   Naeem, A
   Shaukat, S
   Sharif, S
   Alam, MM
   Angez, M
   Wang, CL
   Shafer, RW
   Zaidi, S
   Delwart, E
AF Kapoor, Amit
   Victoria, Joseph
   Simmonds, Peter
   Slikas, Elizabeth
   Chieochansin, Thaweesak
   Naeem, Asif
   Shaukat, Shahzad
   Sharif, Salmaan
   Alam, Muhammad Masroor
   Angez, Mehar
   Wang, Chunlin
   Shafer, Robert W.
   Zaidi, Sohail
   Delwart, Eric
TI A highly prevalent and genetically diversified Picornaviridae genus in
   South Asian children
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE Cardiovirus; Cosavirus; metagenomics; Picornavirus; polio
ID ACUTE FLACCID PARALYSIS; HUMAN ENTEROVIRUSES; HUMAN CORONAVIRUS; VIRAL
   COMMUNITY; RNA VIRUSES; HUMAN FECES; PREDICTION; EVOLUTION; SEQUENCE;
   IDENTIFICATION
AB Viral metagenomics focused on particle-protected nucleic acids was used on the stools of South Asian children with nonpolio acute flaccid paralysis (AFP). We identified sequences distantly related to Seneca Valley virus and cardioviruses that were then used as genetic footholds to characterize multiple viral species within a previously unreported genus of the Picornaviridae family. The picornaviruses were detected in the stools of >40% of AFP and healthy Pakistani children. A genetically diverse and highly prevalent enteric viral infection, characteristics similar to the Enterovirus genus, was therefore identified substantially expanding the genetic diversity of the RNA viral flora commonly found in children.
C1 [Kapoor, Amit; Victoria, Joseph; Slikas, Elizabeth; Delwart, Eric] Blood Syst Res Inst, San Francisco, CA 94118 USA.
   [Kapoor, Amit; Victoria, Joseph; Slikas, Elizabeth; Delwart, Eric] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94118 USA.
   [Simmonds, Peter; Chieochansin, Thaweesak] Univ Edinburgh, Ctr Infect Dis, Edinburgh EH9 1QH, Midlothian, Scotland.
   [Naeem, Asif; Shaukat, Shahzad; Sharif, Salmaan; Alam, Muhammad Masroor; Angez, Mehar; Zaidi, Sohail] Natl Inst Hlth, Dept Virol, Islamabad, Pakistan.
   [Wang, Chunlin; Shafer, Robert W.] Stanford Univ, Med Ctr, Div Infect Dis, Stanford, CA 94305 USA.
   [Wang, Chunlin] Stanford Genome Technol Ctr, Stanford, CA 94304 USA.
RP Delwart, E (reprint author), Blood Syst Res Inst, San Francisco, CA 94118 USA.
EM delwarte@medicine.ucsf.edu
RI Angez, Mehar/J-3792-2015; Slikas, Beth/E-7275-2013; Zaidi, Syed Sohail
   Zahoor/F-7432-2015
OI Delwart, Eric/0000-0002-6296-4484; Simmonds, Peter/0000-0002-7964-4700;
   Naeem, Asif/0000-0002-2088-0629
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL083254]
FX We thank Dr. M. P. Busch and the Blood Systems Research Institute for
   sustained support and Dr. H. Biswas for statistical analyses. This work
   was supported by National Heart, Lung, and Blood Institute Grant
   R01HL083254 (to E. D.).
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Allander T, 2001, P NATL ACAD SCI USA, V98, P11609, DOI 10.1073/pnas.211424698
   Breitbart M, 2003, J BACTERIOL, V185, P6220, DOI 10.1128/JB.185.20.6220-6223.2003
   Breitbart M, 2002, P NATL ACAD SCI USA, V99, P14250, DOI 10.1073/pnas.202488399
   Cox-Foster DL, 2007, SCIENCE, V318, P283, DOI 10.1126/science.1146498
   Culley AI, 2003, NATURE, V424, P1054, DOI 10.1038/nature01886
   Edwards RA, 2005, NAT REV MICROBIOL, V3, P504, DOI 10.1038/nrmicro1163
   Fauquet C.M., 2005, VIRUS TAXONOMY 8 REP
   Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586
   Finkbeiner SR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000011
   Hales LM, 2008, J GEN VIROL, V89, P1265, DOI 10.1099/vir.0.83570-0
   Hellen CUT, 2007, J VIROL, V81, P5850, DOI 10.1128/JVI.02403-06
   Jones MS, 2007, J CLIN MICROBIOL, V45, P2144, DOI 10.1128/JCM.00174-07
   Jones MS, 2005, J VIROL, V79, P8230, DOI 10.1128/JVI.79.13.8230-8236.2005
   Kapoor A, 2008, J VIROL, V82, P311, DOI 10.1128/JVI.01240-07
   Kistler A, 2007, J INFECT DIS, V196, P817, DOI 10.1086/520816
   Knudsen B, 2003, NUCLEIC ACIDS RES, V31, P3423, DOI 10.1093/nar/gkg614
   KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440
   KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2
   Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551
   Martinez-Salas E, 2008, J GEN VIROL, V89, P611, DOI 10.1099/vir.0.83426-0
   Modlin JF, 2007, NEW ENGL J MED, V356, P1204, DOI 10.1056/NEJMp078016
   MORENS DM, 1995, EPIDEMIOLOGY HUMAN E, P3
   Oberste MS, 1999, J VIROL, V73, P1941, DOI 10.1128/JVI.73.3.1941-1948.1999
   Palacios G, 2008, NEW ENGL J MED, V358, P991, DOI 10.1056/NEJMoa073785
   PALLANSCH MA, 2001, FIELDS VIROLOGY, P723
   Saeed M, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-6
   Simmonds P, 2004, RNA, V10, P1337, DOI 10.1261/rna.7640104
   Solomon T, 2003, CURR OPIN INFECT DIS, V16, P375, DOI 10.1097/00001432-200310000-00002
   STRIKAS RA, 1986, J INFECT DIS, V153, P346, DOI 10.1093/infdis/153.2.346
   Tseng CH, 2007, VIRUS RES, V123, P190, DOI 10.1016/j.virusres.2006.09.007
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Washietl S, 2005, P NATL ACAD SCI USA, V102, P2454, DOI 10.1073/pnas.0409169102
   Welch JB, 2001, VOX SANG, V80, P211, DOI 10.1046/j.1423-0410.2001.00035.x
   Witso E, 2006, J CLIN MICROBIOL, V44, P4095, DOI 10.1128/JCM.00653-06
   Zhang T, 2006, PLOS BIOL, V4, P108, DOI 10.1371/journal.pbio.0040003
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 38
TC 143
Z9 144
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 23
PY 2008
VL 105
IS 51
BP 20482
EP 20487
DI 10.1073/pnas.0807979105
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 388BP
UT WOS:000261995600083
PM 19033469
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Huang, KJ
   Su, IJ
   Theron, M
   Wu, YC
   Lai, SK
   Liu, CC
   Lei, HY
AF Huang, KJ
   Su, IJ
   Theron, M
   Wu, YC
   Lai, SK
   Liu, CC
   Lei, HY
TI An interferon-gamma-related cytokine storm in SARS patients
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Proceedings Paper
CT International Conference of Influenza and the Resurgence of Severe Acute
   Respiratory Syndrome
CY OCT 28-31, 2003
CL Taipei, TAIWAN
DE SARS; SARS-CoV; cytokine; interferon-gamma; enterovirus 71; pulmonary
   edema; dengue hemorrhagic fever
ID ACUTE RESPIRATORY SYNDROME; GROWTH-FACTOR-BETA; CORONAVIRUS INFECTION;
   CELL-DEATH; IN-VITRO; MECHANISMS; EXPRESSION; APOPTOSIS; VIRUS; ROLES
AB Fourteen cytokines or chemokines were analyzed on 88 RT-PCR-confirmed severe acute respiratory syndrome (SARS) patients. IFN-gamma, IL-18, TGF-beta, IL-6, IP-10, MCP-1, MIG, and IL-8, but not of TNF-alpha, IL-2, IL-4, IL-10, IL-13, or TNFRI, were highly elevated in the acute phase sera of Taiwan SARS patients. IFN-gamma was significantly higher in the Ab(+) group than in the Ab(-) group. IFN-gamma, IL-18, MCP-1, MIG, and IP-10 were already elevated at early days post fever onset. Furthermore, levels of IL-18, IP-10, MIG, and MCP-1 were significantly higher in the death group than in the survival group. For the survival group, IFN-gamma and MCP-1 were inversely associated with circulating lymphocytes count and monocytes count, but positively associated with circulating neutrophils count. It is concluded that an interferon-gamma-related cytokine storm was induced post SARS coronavirus infection, and this cytokine storm might be involved in the immunopathological damage in SARS patients. (C) 2004 Wiley-Liss, Inc.
C1 Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan, Taiwan.
   Natl Cheng Kung Univ, Coll Med, Dept Basic Med, Tainan, Taiwan.
   Ctr Dis Control, Dept Hlth, Taipei, Taiwan.
   Natl Hlth Res Inst, Div Clin Res, Tainan, Taiwan.
RP Lei, HY (reprint author), Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan, Taiwan.
EM hylei@mail.ncku.edu.tw
RI Theron, Michel/E-2067-2012; Su, Ih-Jen/B-2655-2010
CR Barber GN, 2000, SEMIN CANCER BIOL, V10, P103, DOI 10.1006/scbi.2000.0313
   Bernabei P, 2001, J LEUKOCYTE BIOL, V70, P950
   Cinatl J, 2004, CELL MOL LIFE SCI, V61, P2100, DOI 10.1007/s00018-004-4222-9
   Dhainaut JF, 2003, CRIT CARE MED, V31, pS258, DOI 10.1097/01.CCM.0000057901.92381.75
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   Ishiguro N, 2004, ARCH VIROL, V149, P17, DOI 10.1007/s00705-003-0208-4
   Krein PM, 2002, CHEST, V122, p289S, DOI 10.1378/chest.122.6_suppl.289S
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Liu DB, 2002, ENDOCRINOLOGY, V143, P1225, DOI 10.1210/en.143.4.1225
   Miller AL, 2004, J INFECT DIS, V189, P1419, DOI 10.1086/382958
   Ng PC, 2004, PEDIATRICS, V113, pE7, DOI 10.1542/peds.113.1.e7
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Pang BS, 2003, CHINESE MED J-PEKING, V116, P1283
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   So LKY, 2003, LANCET, V361, P1615, DOI 10.1016/S0140-6736(03)13265-5
   Sobek V, 2002, EUR J IMMUNOL, V32, P2490, DOI 10.1002/1521-4141(200209)32:9<2490::AID-IMMU2490>3.0.CO;2-G
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Wang SM, 2003, J INFECT DIS, V188, P564, DOI 10.1086/376998
   WEN LP, 1997, AM J PHYSIOL, V273, P921
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu HS, 2004, J BIOMED SCI, V11, P117, DOI [10.1007/BF02256554, 10.1159/000075294]
   Wu HS, 2004, EMERG INFECT DIS, V10, P304
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
NR 26
TC 143
Z9 153
U1 7
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD FEB
PY 2005
VL 75
IS 2
BP 185
EP 194
DI 10.1002/jmv.20255
PG 10
WC Virology
SC Virology
GA 883KG
UT WOS:000226009400002
PM 15602737
DA 2020-04-03
ER

PT J
AU Al-Abdallat, MM
   Payne, DC
   Alqasrawi, S
   Rha, B
   Tohme, RA
   Abedi, GR
   Al Nsour, M
   Iblan, I
   Jarour, N
   Farag, NH
   Haddadin, A
   Al-Sanouri, T
   Tamin, A
   Harcourt, JL
   Kuhar, DT
   Swerdlow, DL
   Erdman, DD
   Pallansch, MA
   Haynes, LM
   Gerber, SI
AF Al-Abdallat, Mohammad Mousa
   Payne, Daniel C.
   Alqasrawi, Sultan
   Rha, Brian
   Tohme, Rania A.
   Abedi, Glen R.
   Al Nsour, Mohannad
   Iblan, Ibrahim
   Jarour, Najwa
   Farag, Noha H.
   Haddadin, Aktham
   Al-Sanouri, Tarek
   Tamin, Azaibi
   Harcourt, Jennifer L.
   Kuhar, David T.
   Swerdlow, David L.
   Erdman, Dean D.
   Pallansch, Mark A.
   Haynes, Lia M.
   Gerber, Susan I.
CA Jordan MERS-Cov Investigation Team
TI Hospital-Associated Outbreak of Middle East Respiratory Syndrome
   Coronavirus: A Serologic, Epidemiologic, and Clinical Description
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE MERS-CoV; Middle East respiratory syndrome; novel coronavirus; Jordan;
   seroepidemiology
ID SARS-CORONAVIRUS; ANTIBODIES; FEATURES; PROTEIN
AB Background. In April 2012, the Jordan Ministry of Health investigated an outbreak of lower respiratory illnesses at a hospital in Jordan; 2 fatal cases were retrospectively confirmed by real-time reverse transcription polymerase chain reaction (rRT-PCR) to be the first detected cases of Middle East respiratory syndrome (MERS-CoV).
   Methods. Epidemiologic and clinical characteristics of selected potential cases were assessed through serum blood specimens, medical record reviews, and interviews with surviving outbreak members, household contacts, and healthcare personnel. Cases of MERS-CoV infection were identified using 3 US Centers for Disease Control and Prevention serologic tests for detection of anti-MERS-CoV antibodies.
   Results. Specimens and interviews were obtained from 124 subjects. Seven previously unconfirmed individuals tested positive for anti-MERS-CoV antibodies by at least 2 of 3 serologic tests, in addition to 2 fatal cases identified by rRT-PCR. The case-fatality rate among the 9 total cases was 22%. Six subjects were healthcare workers at the outbreak hospital, yielding an attack rate of 10% among potentially exposed outbreak hospital personnel. There was no evidence of MERS-CoV transmission at 2 transfer hospitals having acceptable infection control practices.
   Conclusions. Novel serologic tests allowed for the detection of otherwise unrecognized cases of MERS-CoV infection among contacts in a Jordanian hospital-associated respiratory illness outbreak in April 2012, resulting in a total of 9 test-positive cases. Serologic results suggest that further spread of this outbreak to transfer hospitals did not occur. Most subjects had no major, underlying medical conditions; none were on hemodialysis. Our observed case-fatality rate was lower than has been reported from outbreaks elsewhere.
C1 [Al-Abdallat, Mohammad Mousa; Alqasrawi, Sultan; Jarour, Najwa] Jordan Minist Hlth, Communicable Dis Directorate, Amman, Jordan.
   [Payne, Daniel C.; Rha, Brian; Abedi, Glen R.; Tamin, Azaibi; Harcourt, Jennifer L.; Swerdlow, David L.; Erdman, Dean D.; Pallansch, Mark A.; Haynes, Lia M.; Gerber, Susan I.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Rha, Brian] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.
   [Tohme, Rania A.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
   [Al Nsour, Mohannad] Jordan Minist Hlth, Eastern Mediterranean Publ Hlth Network, Amman, Jordan.
   [Iblan, Ibrahim] Jordan Minist Hlth, Field Epidemiol Training Program, Amman, Jordan.
   [Farag, Noha H.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
   [Haddadin, Aktham; Al-Sanouri, Tarek] Jordan Minist Hlth, Directorate Labs, Amman, Jordan.
   [Kuhar, David T.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.
RP Payne, DC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A34, Atlanta, GA 30333 USA.
EM dvp6@cdc.gov
FU US Global Disease Detection Operations Center Outbreak Response
   Contingency Fund
FX This work was supported by the US Global Disease Detection Operations
   Center Outbreak Response Contingency Fund.
CR Al-Tawfiq JA, 2014, CLIN INFECT DIS, V59, P160, DOI 10.1093/cid/ciu226
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Assiri A, 2013, NEW ENGL J MED, V369, P886, DOI 10.1056/NEJMx130039
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Bermingham A, 2012, EURO SURVEILL, V17
   Briese T, 2014, MBIO, V5, DOI 10.1128/mBio.01146-14
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   CDC, 2013, MMWR-MORBID MORTAL W, P1
   Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3
   Gierer S, 2013, EMERG INFECT DIS, V19, P2034, DOI 10.3201/eid1912.130701
   Guberina H, 2014, INFECTION, V42, P203, DOI 10.1007/s15010-013-0509-9
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Haynes LM, 2007, CLIN VACCINE IMMUNOL, V14, P331, DOI 10.1128/CVI.00351-06
   Hijawi B, 2013, E MEDITERR HEALTH J, V19, pS12
   Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469
   Memish ZA, 2013, NEW ENGL J MED, V13, P1
   Mo HY, 2006, RESPIROLOGY, V11, P49, DOI 10.1111/j.1440-1843.2006.00783.x
   Nie YC, 2004, J INFECT DIS, V190, P1119, DOI 10.1086/423286
   Payne D. C., 2014, J INFECT DIS
   Reuss A, 2014, EMERG INFECT DIS, V20, P620, DOI 10.3201/eid2004.131375
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   US Centers for Disease Control and Prevention, 2014, INT INF PREV CONTR R
   World Health Organization (WHO), GLOB AL RESP GAR NOV
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu MS, 2004, CELL MOL IMMUNOL, V1, P193
NR 25
TC 142
Z9 150
U1 3
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 1
PY 2014
VL 59
IS 9
BP 1225
EP 1233
DI 10.1093/cid/ciu359
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AT0TG
UT WOS:000344647100007
PM 24829216
OA Green Accepted, Bronze
DA 2020-04-03
ER

PT J
AU Wong, MS
   Chu, WC
   Sun, DS
   Huang, HS
   Chen, JH
   Tsai, PJ
   Lin, NT
   Yu, MS
   Hsu, SF
   Wang, SL
   Chang, HH
AF Wong, Ming-Show
   Chu, Wen-Chen
   Sun, Der-Shan
   Huang, Hsuan-Shun
   Chen, Jiann-Hwa
   Tsai, Pei-Jane
   Lin, Nien-Tsung
   Yu, Mei-Shiuan
   Hsu, Shang-Feng
   Wang, Shih-Lien
   Chang, Hsin-Hou
TI Visible-light-induced bactericidal activity of a nitrogen-doped titanium
   photocatalyst against human pathogens
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; MOLECULAR EPIDEMIOLOGY;
   STREPTOCOCCUS-PYOGENES; ANTIBIOTIC-RESISTANCE; SUPEROXIDE-DISMUTASE;
   OXIDE FILMS; CORONAVIRUS; TAIWAN; VIRULENCE; TIO2
AB The antibacterial activity of photocatalytic titanium dioxide (TiO2) substrates is induced primarily by UV light irradiation. Recently, nitrogen- and carbon-doped TiO2 substrates were shown to exhibit photocatalytic activities under visible-light illumination. Their antibacterial activity, however, remains to be quantified. In this study, we demonstrated that nitrogen-doped TiO2 substrates have superior visible-light-induced bactericidal activity against Escherichia coli compared to pure TiO2 and carbon-doped TiO2 substrates. We also found that protein- and light-absorbing contaminants partially reduce the bactericidal activity of nitrogen-doped TiO2 substrates due to their light-shielding effects. In the pathogen-killing experiment, a significantly higher proportion of all tested pathogens, including Shigella flexneri, Listeria monocytogenes, Vibrio parahaemolyticus, Staphylococcus aureus, Streptococcus pyogenes, and Acinelobacter baumannii, were killed by visible-light-illuminated nitrogen-doped TiO2 substrates than by pure TiO2 substrates. These findings suggest that nitrogen-doped TiO2 has potential application in the development of alternative disinfectants for environmental and medical usages.
C1 Tzu Chi Univ, Inst Med Sci, Hualien 970, Taiwan.
   Natl Dong Hwa Univ, Dept Mat Sci & Engn, Hualien, Taiwan.
   Natl Chung Hsing Univ, Inst Mol Biol, Taichung 40227, Taiwan.
   Tzu Chi Univ, Inst Mol & Cellular Biol, Hualien 970, Taiwan.
   Tzu Chi Univ, Inst Human Genet, Hualien 970, Taiwan.
   Tzu Chi Univ, Inst Med Biotechnol, Hualien 970, Taiwan.
   Tzu Chi Univ, Inst Microbiol Immunol & Mol Med, Hualien 970, Taiwan.
   Tzu Chi Univ, Ctr Vasc Med, Hualien 970, Taiwan.
RP Chang, HH (reprint author), Tzu Chi Univ, Inst Med Sci, Room D407,701,Sect 3,Chung Yang Rd, Hualien 970, Taiwan.
EM hhchang@mail.tcu.edu.tw
RI Tsai, Pei-Jane/G-3563-2011; Chang, Hsin-Hou/B-6225-2012
OI Chang, Hsin-Hou/0000-0002-8731-3485
CR Aiello AE, 2003, LANCET INFECT DIS, V3, P501, DOI 10.1016/S1473-3099(03)00723-0
   ALTERTHUM F, 1989, APPL ENVIRON MICROB, V55, P1943, DOI 10.1128/AEM.55.8.1943-1948.1989
   Angelo A, 2001, CURR OPIN INFECT DIS, V14, P547, DOI 10.1097/00001432-200110000-00007
   Asahi R, 2001, SCIENCE, V293, P269, DOI 10.1126/science.1061051
   BERNARD BK, 1990, J TOXICOL ENV HEALTH, V29, P417, DOI 10.1080/15287399009531402
   Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P64, DOI 10.1016/S0952-7915(99)00052-7
   Booth TF, 2005, J INFECT DIS, V191, P1472, DOI 10.1086/429634
   Chen KT, 2005, J INFECT DIS, V192, pS44, DOI 10.1086/431495
   Chiou CS, 2001, J CLIN MICROBIOL, V39, P1048, DOI 10.1128/JCM.39.3.1048-1056.2001
   Chiou CS, 2000, J CLIN MICROBIOL, V38, P4621, DOI 10.1128/JCM.38.12.4621-4625.2000
   Egerton TA, 2006, PHYS CHEM CHEM PHYS, V8, P398, DOI 10.1039/b507516e
   FRANZON VL, 1990, INFECT IMMUN, V58, P529, DOI 10.1128/IAI.58.2.529-535.1990
   FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0
   Hearing VJ, 2005, J DERMATOL SCI, V37, P3, DOI 10.1016/j.jdermsci.2004.08.014
   Hirakawa K, 2004, FREE RADICAL RES, V38, P439, DOI 10.1080/1071576042000206487
   Iwasaki M, 2000, J COLLOID INTERF SCI, V224, P202, DOI 10.1006/jcis.1999.6694
   Jacoby WA, 1998, ENVIRON SCI TECHNOL, V32, P2650, DOI 10.1021/es980036f
   Janulczyk R, 2003, INFECT IMMUN, V71, P2656, DOI 10.1128/IAI.71.5.2656-2664.2003
   Kampf G, 2004, CLIN MICROBIOL REV, V17, P863, DOI 10.1128/CMR.17.4.863-893.2004
   Kaneko M., 2002, PHOTOCATALYSIS
   Kau JH, 2005, J INFECT DIS, V192, P1465, DOI 10.1086/491477
   La Montagne JR, 2004, J INFECT DIS, V189, P634, DOI 10.1086/382225
   Lan YC, 2005, J INFECT DIS, V191, P1478, DOI 10.1086/428591
   LEGRINI O, 1993, CHEM REV, V93, P671, DOI 10.1021/cr00018a003
   MANDELL GL, 1975, J CLIN INVEST, V55, P561, DOI 10.1172/JCI107963
   Maness PC, 1999, APPL ENVIRON MICROB, V65, P4094
   Martino MC, 2005, J INFECT DIS, V192, P136, DOI 10.1086/430740
   McDonnell G, 1999, CLIN MICROBIOL REV, V12, P147, DOI 10.1128/CMR.12.1.147
   MURRAY PR, 2003, MANUAL CLIN MICROBIO
   Navon-Venezia S, 2005, CURR OPIN INFECT DIS, V18, P306, DOI 10.1097/01.qco.0000171920.44809.f0
   Rodger S, 2004, MICROB ECOL, V48, P358, DOI 10.1007/s00248-003-0201-1
   Russell AD, 2004, J HOSP INFECT, V57, P97, DOI 10.1016/j.jhin.2004.01.004
   Russell AD, 2003, LANCET INFECT DIS, V3, P794, DOI 10.1016/S1473-3099(03)00833-8
   SALYERS AA, 1994, ACTERIAL PATHOGENESI
   Sambrook J., 1989, MOL CLONING LAB MANU
   Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653
   Slominski A, 1998, CLIN DERMATOL, V16, P503, DOI 10.1016/S0738-081X(98)00023-6
   Tong TR, 2005, J INFECT DIS, V191, P1401, DOI 10.1086/429637
   Tsai PJ, 2006, MICROBES INFECT, V8, P1440, DOI 10.1016/j.micinf.2006.01.002
   Vohra A, 2005, J IND MICROBIOL BIOT, V32, P364, DOI 10.1007/s10295-005-0006-y
   Walther BA, 2004, BIOL REV, V79, P849, DOI 10.1017/S1464793104006475
   Wong HC, 2000, APPL ENVIRON MICROB, V66, P3981, DOI 10.1128/AEM.66.9.3981-3986.2000
   Wu HS, 2004, J BIOMED SCI, V11, P117, DOI [10.1007/BF02256554, 10.1159/000075294]
   Yang MC, 2004, THIN SOLID FILMS, V469, P1, DOI 10.1016/j.tsf.2004.06.189
   Yang TS, 2004, SURF SCI, V548, P75, DOI 10.1016/j.susc.2003.10.044
   Zhong MX, 2004, INFECT IMMUN, V72, P1057, DOI 10.1128/IAI.72.2.1057-1064.2004
NR 46
TC 142
Z9 145
U1 2
U2 41
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD SEP
PY 2006
VL 72
IS 9
BP 6111
EP 6116
DI 10.1128/AEM.02580-05
PG 6
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 083QT
UT WOS:000240474000055
PM 16957236
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Quan, PL
   Firth, C
   Conte, JM
   Williams, SH
   Zambrana-Torrelio, CM
   Anthony, SJ
   Ellison, JA
   Gilbert, AT
   Kuzmin, IV
   Niezgoda, M
   Osinubi, MOV
   Recuenco, S
   Markotter, W
   Breiman, RF
   Kalemba, L
   Malekani, J
   Lindblade, KA
   Rostal, MK
   Ojeda-Flores, R
   Suzan, G
   Davis, LB
   Blau, DM
   Ogunkoya, AB
   Castillo, DAA
   Moran, D
   Ngam, S
   Akaibe, D
   Agwanda, B
   Briese, T
   Epstein, JH
   Daszak, P
   Rupprecht, CE
   Holmes, EC
   Lipkin, WI
AF Quan, Phenix-Lan
   Firth, Cadhla
   Conte, Juliette M.
   Williams, Simon H.
   Zambrana-Torrelio, Carlos M.
   Anthony, Simon J.
   Ellison, James A.
   Gilbert, Amy T.
   Kuzmin, Ivan V.
   Niezgoda, Michael
   Osinubi, Modupe O. V.
   Recuenco, Sergio
   Markotter, Wanda
   Breiman, Robert F.
   Kalemba, Lems
   Malekani, Jean
   Lindblade, Kim A.
   Rostal, Melinda K.
   Ojeda-Flores, Rafael
   Suzan, Gerardo
   Davis, Lora B.
   Blau, Dianna M.
   Ogunkoya, Albert B.
   Alvarez Castillo, Danilo A.
   Moran, David
   Ngam, Sali
   Akaibe, Dudu
   Agwanda, Bernard
   Briese, Thomas
   Epstein, Jonathan H.
   Daszak, Peter
   Rupprecht, Charles E.
   Holmes, Edward C.
   Lipkin, W. Ian
TI Bats are a major natural reservoir for hepaciviruses and pegiviruses
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HEPATITIS-C VIRUS; RESPIRATORY SYNDROME CORONAVIRUS; NIPAH VIRUS;
   PROTEIN; EVOLUTION; PRODUCTS; HORSES; P7
AB Although there are over 1,150 bat species worldwide, the diversity of viruses harbored by bats has only recently come into focus as a result of expanded wildlife surveillance. Such surveys are of importance in determining the potential for novel viruses to emerge in humans, and for optimal management of bats and their habitats. To enhance our knowledge of the viral diversity present in bats, we initially surveyed 415 sera from African and Central American bats. Unbiased high-throughput sequencing revealed the presence of a highly diverse group of bat-derived viruses related to hepaciviruses and pegiviruses within the family Flaviridae. Subsequent PCR screening of 1,258 bat specimens collected worldwide indicated the presence of these viruses also in North America and Asia. A total of 83 bat-derived viruses were identified, representing an infection rate of nearly 5%. Evolutionary analyses revealed that all known hepaciviruses and pegiviruses, including those previously documented in humans and other primates, fall within the phylogenetic diversity of the bat-derived viruses described here. The prevalence, unprecedented viral biodiversity, phylogenetic divergence, and worldwide distribution of the bat-derived viruses suggest that bats are a major and ancient natural reservoir for both hepaciviruses and pegiviruses and provide insights into the evolutionary history of hepatitis C virus and the human GB viruses.
C1 [Quan, Phenix-Lan; Firth, Cadhla; Conte, Juliette M.; Williams, Simon H.; Anthony, Simon J.; Briese, Thomas; Lipkin, W. Ian] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10032 USA.
   [Zambrana-Torrelio, Carlos M.; Anthony, Simon J.; Rostal, Melinda K.; Epstein, Jonathan H.; Daszak, Peter] EcoHlth Alliance, New York, NY 10001 USA.
   [Ellison, James A.; Gilbert, Amy T.; Kuzmin, Ivan V.; Niezgoda, Michael; Osinubi, Modupe O. V.; Recuenco, Sergio; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot Infect Dis, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
   [Markotter, Wanda] Univ Pretoria, Dept Microbiol & Plant Pathol, ZA-0002 Pretoria, South Africa.
   [Breiman, Robert F.] Ctr Dis Control & Prevent Kenya, Nairobi, Kenya.
   [Kalemba, Lems; Malekani, Jean] Univ Kinshasa, Kinshasa 11, DEM REP CONGO.
   [Lindblade, Kim A.] Ctr Dis Control & Prevent Guatemala, Guatemala City 01015, Guatemala.
   [Ojeda-Flores, Rafael; Suzan, Gerardo] Univ Nacl Autonoma Mexico, Fac Med Vet & Zootecnia, Mexico City 04510, DF, Mexico.
   [Davis, Lora B.] Ctr Dis Control & Prevent Nigeria, Abuja, Nigeria.
   [Blau, Dianna M.] Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot Infect Dis, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA.
   [Ogunkoya, Albert B.] Ahmadu Bello Univ, Dept Vet Med, Zaria, Kaduna State, Nigeria.
   [Alvarez Castillo, Danilo A.; Moran, David] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City 01015, Guatemala.
   [Ngam, Sali] Natl Vet Lab, Garoua, Cameroon.
   [Akaibe, Dudu] Univ Kisangani, Ctr Surveillance Biodiversite, Kisangani, DEM REP CONGO.
   [Agwanda, Bernard] Natl Museums Kenya, Mammal Sect, Nairobi 00100, Kenya.
   [Holmes, Edward C.] Univ Sydney, Sch Biol Sci, Sydney Emerging Infect & Biosecur Inst, Sydney, NSW 2006, Australia.
   [Holmes, Edward C.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia.
RP Quan, PL (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10032 USA.
EM pq2106@columbia.edu
RI Holmes, Edward/Y-2789-2019; daszak, peter/U-4588-2017;
   Zambrana-Torrelio, Carlos/AAH-3911-2020; Rupprecht,
   Charles/AAI-1544-2020
OI Holmes, Edward/0000-0001-9596-3552; daszak, peter/0000-0002-2046-5695;
   Zambrana-Torrelio, Carlos/0000-0002-5614-7496; Markotter,
   Wanda/0000-0002-7550-0080; Ellison, James/0000-0003-4492-4857;
   Recuenco-Cabrera, Sergio/0000-0002-8446-7411; Williams,
   Simon/0000-0002-6276-4685; Firth, Cadhla/0000-0002-2040-8973; Lipkin, W.
   Ian/0000-0002-8768-9386
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI051292, AI57158];
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [5R01AI079231-02]; US Agency for International Development PREDICT
   GrantUnited States Agency for International Development (USAID) [GHNA
   0009 0001 000]; US Department of DefenseUnited States Department of
   Defense; Emerging Pandemic Threats Program of the US Agency for
   International DevelopmentUnited States Agency for International
   Development (USAID); National Center for Emerging and Zoonotic
   Infectious Diseases; Centers for Disease Control and Prevention
   (Atlanta, GA)United States Department of Health & Human ServicesCenters
   for Disease Control & Prevention - USA; Global Disease Detection Program
   of the Centers for Disease Control and Prevention (Atlanta, GA)
FX We thank the King and Chiefs of the Idanre community, Ondo State,
   Nigeria; the Federal Ministry of Health, Abuja, Nigeria; S. Wuyah, M.
   Lawal, M. Ari, A. Mohammed, I. Onaja, and G. Kia; the Faculty of
   Veterinary Medicine, Ahmadu Bello University (ABU), Zaria, Nigeria; and
   the Vice Chancellor and Management of ABU. We thank Luis Escobar,
   Alejandra Estevez, Maria Renee Lopez, Ramon Medrano, Maria E. Morales,
   and Maria Luisa Muller (Center for Health Studies, Universidad del Valle
   de Guatemala) and Julio Martinez (Guatemala Ministry of
   Agriculture-Animal Health Department). We thank Sophronia Yu, Edwin
   Danga, Evelyne Mulama, Solomon Gikundi, Leonard Nderitu, and Eric Ogola
   (Centers for Disease Control-Kenya), Rafael Ciraiz (Guatemala Ministry
   of Public Health and Social Assistance), and Arif Islam (from
   Bangladesh) for excellent technical assistance and logistics. This work
   was supported by National Institutes of Health Grants AI051292 and
   AI57158 (Northeast Biodefense Center) (to W. I. L.), National Institute
   of Allergy and Infectious Diseases Grant 5R01AI079231-02, US Agency for
   International Development PREDICT Grant GHNA 0009 0001 000, and an award
   from the US Department of Defense. This study was also supported by the
   Emerging Pandemic Threats Program of the US Agency for International
   Development, the National Center for Emerging and Zoonotic Infectious
   Diseases, the Centers for Disease Control and Prevention (Atlanta, GA),
   and Technical Support Corps funds from the Global Disease Detection
   Program of the Centers for Disease Control and Prevention (Atlanta, GA).
CR Alter H J, 1989, Transfus Med Rev, V3, P77, DOI 10.1016/S0887-7963(89)70071-7
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Branch AD, 2005, SEMIN LIVER DIS, V25, P105, DOI 10.1055/s-2005-864786
   Bukh J, 2001, J MED VIROL, V65, P694, DOI 10.1002/jmv.2092
   Burbelo PD, 2012, J VIROL, V86, P6171, DOI 10.1128/JVI.00250-12
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Charrel RN, 1999, J GEN VIROL, V80, P2329, DOI 10.1099/0022-1317-80-9-2329
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432
   Drexler JF, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1796
   Epstein JH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000972
   Griffin SDC, 2003, FEBS LETT, V535, P34, DOI 10.1016/S0014-5793(02)03851-6
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   INA Y, 1994, J MOL EVOL, V38, P50
   Johara MY, 2001, EMERG INFECT DIS, V7, P439
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Kapoor A, 2011, P NATL ACAD SCI USA, V108, P11608, DOI 10.1073/pnas.1101794108
   Kim WR, 2002, MICROBES INFECT, V4, P1219, DOI 10.1016/S1286-4579(02)01649-0
   Krey T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000762
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2010, J VIROL, V84, P2808, DOI 10.1128/JVI.02219-09
   Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994
   Luby SP, 2006, EMERG INFECT DIS, V12, P1888
   Luis AD, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2753
   Lyons S, 2012, EMERG INFECT DIS, V18, P1976, DOI 10.3201/eid1812.120498
   Moradpour D, 2007, NAT REV MICROBIOL, V5, P453, DOI 10.1038/nrmicro1645
   MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348
   Newman SH, 2011, FAO ANIMAL PRODUCTIO
   Palacios G, 2008, NEW ENGL J MED, V358, P991, DOI 10.1056/NEJMoa073785
   Patel MR, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001282
   R Core Team, 2012, R LANG ENV STAT COMP
   Sharp PM, 2011, CURR OPIN VIROL, V1, P436, DOI 10.1016/j.coviro.2011.10.018
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   Simmonds PB, 2012, VIRUS TAXONOMY, P1003
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Stapleton JT, 2011, J GEN VIROL, V92, P233, DOI 10.1099/vir.0.027490-0
   Takikawa S, 2006, P NATL ACAD SCI USA, V103, P3345, DOI 10.1073/pnas.0511297103
   Teeling EC, 2005, SCIENCE, V307, P580, DOI 10.1126/science.1105113
   Vassilaki N, 2009, IUBMB LIFE, V61, P739, DOI 10.1002/iub.201
   Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111
   Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840
   Zhang GJ, 2013, SCIENCE, V339, P456, DOI 10.1126/science.1230835
NR 44
TC 141
Z9 148
U1 2
U2 55
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 14
PY 2013
VL 110
IS 20
BP 8194
EP 8199
DI 10.1073/pnas.1303037110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 156EH
UT WOS:000319803500050
PM 23610427
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Frieman, M
   Yount, B
   Heise, M
   Kopecky-Bromberg, SA
   Palese, P
   Baric, RS
AF Frieman, Matthew
   Yount, Boyd
   Heise, Mark
   Kopecky-Bromberg, Sarah A.
   Palese, Peter
   Baric, Ralph S.
TI Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1
   function by sequestering nuclear import factors on the rough endoplasmic
   Reticulum/Golgi membrane
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NIPAH VIRUS-V; KARYOPHERIN ALPHA; INTERFERON RESPONSES; REVERSE
   GENETICS; ADAPTER PROTEIN; SARS-COV; BETA; INDUCTION; BINDING;
   ACTIVATION
AB The host innate immune response is an important deterrent of severe viral infection in humans and animals. Nuclear import factors function as key gatekeepers that regulate the transport of innate immune regulatory cargo to the nucleus of cells to activate the antiviral response. Using severe acute respiratory syndrome coronavirus (SARS-CoV) as a model, we demonstrate that SARS-COV ORF6 protein is localized to the endoplasmic reticulum (ER)/Golgi membrane in infected cells, where it binds to and disrupts nuclear import complex formation by tethering karyopherin alpha 2 and karyopherin beta 1 to the membrane. Retention of import factors at the ER/Golgi membrane leads to a loss of STAT1 transport into the nucleus in response to interferon signaling, thus blocking the expression of STAT1-activated genes that establish an antiviral state. We mapped the region of ORF6, which binds karyopherin alpha 2, to the C terminus of ORF6 and show that mutations in the C terminus no longer bind karyopherin alpha 2 or block the nuclear import of STAT1. We also show that N-terminal deletions of karyopherin alpha 2 that no longer bind to karyopherin beta I still retain ORF6 binding activity but no longer block STAT1 nuclear import. Recombinant SARS-CoV lacking ORF6 did not tether karyopherin alpha 2 to the ER/Golgi membrane and allowed the import of the STAT1 complex into the nucleus. We discuss the likely implications of these data on SARS-CoV replication and pathogenesis.
C1 Univ N Carolina, Dept Epidemiol, Sch Publ Hlth, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC USA.
   Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
   Univ N Carolina, Sch Med, Carolina Vacc Inst, Chapel Hill, NC USA.
   Mt Sinai Sch Med, Dept Microbiol, New York, NY USA.
RP Baric, RS (reprint author), Univ N Carolina, Dept Epidemiol, Sch Publ Hlth, 3304 Hooker Res Ctr, Chapel Hill, NC 27599 USA.
EM rbaric@email.unc.edu
OI Palese, Peter/0000-0002-0337-5823
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [F32 AI066542, P01 AI059443, F32 AI 066542,
   P01 AI 059443-02]
CR Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x
   Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Cardenas WB, 2006, J VIROL, V80, P5168, DOI 10.1128/JVI.02199-05
   Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770
   CHANGEUX SP, 2005, [No title captured]
   CHARLEY B, 1988, J VIROL, V62, P8, DOI 10.1128/JVI.62.1.8-11.1988
   Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0
   Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367
   Cunningham MD, 2003, BIOCHEM BIOPH RES CO, V300, P403, DOI 10.1016/S0006-291X(02)02863-2
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Frieman M, 2008, VIRUS RES, V133, P101, DOI 10.1016/j.virusres.2007.03.015
   Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x
   Hiscott J, 2006, TRENDS MOL MED, V12, P53, DOI 10.1016/j.molmed.2005.12.003
   Hiscott J, 2006, BIOCHEM PHARMACOL, V72, P1477, DOI 10.1016/j.bcp.2006.06.030
   Hogan RJ, 2004, J VIROL, V78, P11416, DOI 10.1128/JVI.78.20.11416-11421.2004
   Huang C, 2007, J VIROL, V81, P5423, DOI 10.1128/JVI.02307-06
   Huang C, 2006, J VIROL, V80, P7287, DOI 10.1128/JVI.00414-06
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   LABONNARDIERE C, 1983, ANN RECH VET, V14, P507
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102
   Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102
   Lin RT, 2006, J VIROL, V80, P6072, DOI 10.1128/JVI.02495-05
   Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876
   McBride Kevin M, 2003, Sci STKE, V2003, pRE13
   McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196
   McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754
   Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193
   Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572
   Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310
   Nyfeler B, 2005, P NATL ACAD SCI USA, V102, P6350, DOI 10.1073/pnas.0501976102
   Parisien JP, 2001, VIROLOGY, V283, P230, DOI 10.1006/viro.2001.0856
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1
   Pewe L, 2005, J VIROL, V79, P11335, DOI 10.1128/JVI.79.17.11335-11342.2005
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Pujol G, 2002, BIOCHEM BIOPH RES CO, V294, P354, DOI 10.1016/S0006-291X(02)00492-8
   Reid SP, 2006, J VIROL, V80, P5156, DOI 10.1128/JVI.02349-05
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Rodriguez JJ, 2002, J VIROL, V76, P11476, DOI 10.1128/JVI.76.22.11476-11483.2002
   Schaecher SR, 2007, J VIROL, V81, P718, DOI 10.1128/JVI.01691-06
   Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067
   Shabman RS, 2007, J VIROL, V81, P237, DOI 10.1128/JVI.01590-06
   Shaw ML, 2004, J VIROL, V78, P5633, DOI 10.1128/JVI.78.11.5633-5641.2004
   Shen S, 2005, BIOCHEM BIOPH RES CO, V330, P286, DOI 10.1016/j.bbrc.2005.02.153
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   TAGUCHI F, 1985, VIROLOGY, V147, P41, DOI 10.1016/0042-6822(85)90225-9
   Tangudu C, 2007, J VIROL, V81, P1220, DOI 10.1128/JVI.01515-06
   Vogel LN, 2007, VACCINE, V25, P2173, DOI 10.1016/j.vaccine.2006.11.055
   Yang WD, 2006, J CELL BIOL, V174, P951, DOI 10.1083/jcb.200605053
   Ye Y, 2007, J VIROL, V81, P2554, DOI 10.1128/JVI.01634-06
   Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Zheng BJ, 2004, EMERG INFECT DIS, V10, P176, DOI 10.3201/eid1002.030533
NR 63
TC 141
Z9 146
U1 1
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2007
VL 81
IS 18
BP 9812
EP 9824
DI 10.1128/JVI.01012-07
PG 13
WC Virology
SC Virology
GA 208JI
UT WOS:000249315200019
PM 17596301
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Freymuth, F
   Vabret, A
   Cuvillon-Nimal, D
   Simon, S
   Dina, J
   Legrand, L
   Gouarin, S
   Petitjean, J
   Eckart, P
   Brouard, J
AF Freymuth, Francois
   Vabret, Astrid
   Cuvillon-Nimal, Delphine
   Simon, Sandrine
   Dina, Julia
   Legrand, Loic
   Gouarin, Stephanie
   Petitjean, Joelle
   Eckart, Philippe
   Brouard, Jacques
TI Comparison of multiplex PCR assays and conventional techniques for the
   diagnostic of respiratory virus infections in children admitted to
   hospital with an acute respiratory illness
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE multiplex-PCR; respiratory virus; RSV; hMPV; influenza virus;
   coronavirus; rhinovirus
ID REVERSE TRANSCRIPTION-PCR; POLYMERASE-CHAIN-REACTION; ENZYME
   HYBRIDIZATION ASSAY; REAL-TIME PCR; TRACT INFECTIONS; SYNCYTIAL-VIRUS;
   CLINICAL-SAMPLES; INFLUENZA-B; PARAINFLUENZA VIRUS; PEDIATRIC-PATIENTS
AB The performances of four multiplex PCR (m-PCR) were compared to direct immunofluorescence assay (DFA) and HuH7 cell culture for the detection of viruses in 263 children admitted to hospital with an acute respiratory illness. One hundred fifty (57.6%) nasal aspirates were found DFA-positive; 188 (72.3%) were found positive by both DFA and HuH7 cell culture, and 242 (92%) were PCR-positive. The m-PCR detected 124 viruses which were not found by conventional methods: 68 rhinovirus, 17 human metapneumovirus, 15 respiratory syncytial virus (RSV), 8 parainfluenza virus (PIV), 5 coronavirus 229E, 3 OC43 and 3 NI-63, 4 enterovirus, 2 influenza virus B and C virus. The m-PCR were more sensitive, had the advantages of a shorter delay in specific diagnosis, and a lower cost than DFA and culture. Using these m-PCR, the prevalence of each virus was compared between in-patient and outpatient groups of children attending the emergency unit of the hospital. Nasal aspirates from 411 (91.5%) children were found positive by the PCRs. RSV, rhinovirus, and influenza virus were the most frequent viruses detected in this population, representing 43.6%, 31.8%, and 8.8% of the virus found, respectively, followed by human metapneumovirus (4.4%), coronavirus (3.4%), parainfluenza virus (3.2%), adenovirus (2.3%), and enterovirus (2.1%). RSVs were detected more significantly in the in-patient group than in the out-patient group, and influenza viruses were detected more frequently in the out-patient group than in the in-patient group. Moreover, the use of m-PCR pointed out the frequency of rhinovirus and mixed viral detections in these patients. In conclusion, according to the requirements of speed and low cost of the methods, and to achieve the highest rate of detection of respiratory viruses, the combined use of DFA and m-PCR is today likely to be the best way to improve diagnosis of respiratory illnesses in children.
C1 Univ Hosp, Lab Human & Mol Virol, F-14033 Caen, France.
   Univ Hosp, Dept Pediat, F-14033 Caen, France.
RP Freymuth, F (reprint author), Univ Hosp, Lab Human & Mol Virol, Av Georges Clemenceau, F-14033 Caen, France.
EM freymuth-f@chu-caen.fr
RI Brouard, Jacques/AAH-3387-2020
OI VABRET, Astrid/0000-0002-8940-7645
CR Aguilar JC, 2000, J CLIN MICROBIOL, V38, P1191, DOI 10.1128/JCM.38.3.1191-1195.2000
   Bellau-Pujol S, 2005, J VIROL METHODS, V126, P53, DOI 10.1016/j.jviromet.2005.01.020
   Coiras MT, 2004, J MED VIROL, V72, P484, DOI 10.1002/jmv.20008
   Coiras MT, 2003, J MED VIROL, V69, P132, DOI 10.1002/jmv.10255
   Donofrio J C, 1992, PCR Methods Appl, V1, P263
   Echevarria JE, 1998, J CLIN MICROBIOL, V36, P1388
   Eugene-Ruellan G, 1998, J CLIN MICROBIOL, V36, P796, DOI 10.1128/JCM.36.3.796-801.1998
   Fan J, 1998, CLIN INFECT DIS, V26, P1397, DOI 10.1086/516357
   FRANK AL, 1979, J CLIN MICROBIOL, V10, P32, DOI 10.1128/JCM.10.1.32-36.1979
   Freymuth F, 2005, J MED VIROL, V77, P295, DOI 10.1002/jmv.20449
   FREYMUTH F, 1987, ANN PEDIATR-PARIS, V34, P493
   Freymuth F, 1997, CLIN DIAGN VIROL, V8, P31, DOI 10.1016/S0928-0197(97)00060-3
   Gilbert LL, 1996, J CLIN MICROBIOL, V34, P140, DOI 10.1128/JCM.34.1.140-143.1996
   Grondahl B, 1999, J CLIN MICROBIOL, V37, P1
   Gruteke P, 2004, J CLIN MICROBIOL, V42, P5596, DOI 10.1128/JCM.42.12.5596-5603.2004
   Guittet V, 2003, ARCH PEDIATRIE, V10, P417, DOI 10.1016/S0929-693X(03)00090-3
   HIERHOLZER JC, 1993, J CLIN MICROBIOL, V31, P1504, DOI 10.1128/JCM.31.6.1504-1510.1993
   Hindiyeh M, 2001, AM J CLIN PATHOL, V116, P218
   Huang YT, 2000, J CLIN MICROBIOL, V38, P422
   Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027
   Kehl SC, 2001, J CLIN MICROBIOL, V39, P1696, DOI 10.1128/JCM.39.5.1696-1701.2001
   Kuypers J, 2006, J CLIN MICROBIOL, V44, P2382, DOI 10.1128/JCM.00216-06
   Liolios L, 2001, J CLIN MICROBIOL, V39, P2779, DOI 10.1128/JCM.39.8.2779-2783.2001
   Mullins JA, 2004, EMERG INFECT DIS, V10, P700, DOI 10.3201/eid1004.030555
   Nokso-Koivisto J, 2002, J MED VIROL, V66, P417, DOI 10.1002/jmv.2161
   Osiowy C, 1998, J CLIN MICROBIOL, V36, P3149, DOI 10.1128/JCM.36.11.3149-3154.1998
   Puppe W, 2004, J CLIN VIROL, V30, P165, DOI 10.1016/j.jcv.2003.10.003
   Rovida F, 2005, J MED VIROL, V75, P336, DOI 10.1002/jmv.20276
   Shih SR, 1999, J VIROL METHODS, V81, P77, DOI 10.1016/S0166-0934(99)00065-8
   Syrmis MW, 2004, J MOL DIAGN, V6, P125, DOI 10.1016/S1525-1578(10)60500-4
   Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004
   Tsai HP, 2001, J CLIN MICROBIOL, V39, P111, DOI 10.1128/JCM.39.1.111-118.2001
   Vabret A, 2005, EMERG INFECT DIS, V11, P1225, DOI 10.3201/eid1108.050110
   Vabret A, 2004, J CLIN VIROL, V31, P116, DOI 10.1016/j.jcv.2004.04.003
   Weinberg GA, 2004, J INFECT DIS, V189, P706, DOI 10.1086/381456
   WOODS GL, 1988, J CLIN MICROBIOL, V26, P1026, DOI 10.1128/JCM.26.5.1026-1028.1988
NR 36
TC 141
Z9 148
U1 2
U2 11
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD NOV
PY 2006
VL 78
IS 11
BP 1498
EP 1504
DI 10.1002/jmv.20725
PG 7
WC Virology
SC Virology
GA 091PZ
UT WOS:000241042100020
PM 16998894
DA 2020-04-03
ER

PT J
AU Franks, TJ
   Chong, PY
   Chui, P
   Galvin, JR
   Lourens, RM
   Reid, AH
   Selbs, E
   McEvoy, PL
   Hayden, DL
   Fukuoka, J
   Taubenberger, JK
   Travis, WD
AF Franks, TJ
   Chong, PY
   Chui, P
   Galvin, JR
   Lourens, RM
   Reid, AH
   Selbs, E
   McEvoy, PL
   Hayden, DL
   Fukuoka, J
   Taubenberger, JK
   Travis, WD
TI Lung pathology of severe acute respiratory syndrome (SARS): A study of 8
   autopsy cases from Singapore
SO HUMAN PATHOLOGY
LA English
DT Article
DE severe acute respiratory syndrome; SARS; SARS-associated corona virus;
   diffuse alveolar damage
ID INFECTIONS
AB Severe acute respiratory syndrome (SARS) is an infectious condition caused by the SARS-associated coronavirus (SARS-CoV), a new member in the family Coronaviridae. To evaluate the lung pathology in this life-threatening respiratory, illness, we studied postmortem lung sections from 8 patients who died from SARS during the spring 2003 Singapore outbreak. The predominant pattern of lung injury in all 8 cases was diffuse alveolar damage. The histology varied according to the duration of illness. Cases of 10 or fewer days' duration demonstrated acute-phase diffuse alveolar damage (DAD), airspace edema, and bronchiolar fibrin. Cases of more than 10 days' duration exhibited organizing-phase DAD, type II pneumocyte hyperplasia, squamous metaplasia, multinucleated giant cells, and acute bronchopneumonia. In acute-phase DAD, pancytokeratin staining was positive in hyaline membranes along alveolar walls and highlighted the absence of pneumocytes. Multinucleated cells were shown to be both type II pneumocytes and macrophages by pancytokeratin, thyroid transcription factor-1, and CD68 staining. SARS-CoV RNA was identified by reverse transcriptase-polymerase chain reaction in 7 of 8 cases in fresh autopsy tissue and in 8 of 8 cases in formalin-fixed, paraffin-embedded lung tissue, including the I negative case in fresh tissue. Understanding the pathology of DAD in SARS patients may provide the basis for therapeutic strategies. Further studies of the pathogenesis of SARS may reveal new insight into the mechanisms of DAD. (C) 2003 Elsevier Inc. All rights reserved.
C1 Armed Forces Inst Pathol, Dept Pulm & Mediastinal Pathol, Dept Radiol Pathol, Div Mol Pathol,Dept Cellular Pathol & Genet, Washington, DC 20306 USA.
   Armed Forces Inst Pathol, Div Trop & Infect Dis Pathol, Dept Trop & Infect Dis, Washington, DC 20306 USA.
   Tan Tock Seng Hosp, Dept Pathol & Lab Med, Singapore, Singapore.
   Hlth Sci Author, Ctr Forens Med, Singapore, Singapore.
RP Franks, TJ (reprint author), Armed Forces Inst Pathol, Dept Pulm & Mediastinal Pathol, Dept Radiol Pathol, Div Mol Pathol,Dept Cellular Pathol & Genet, 6825 16th St NW,Bldg 54,Rm M003B, Washington, DC 20306 USA.
OI Fukuoka, Junya/0000-0002-2496-3050
CR DROSTEN C, 2003, ENGL J MED, V348, P1967
   Katzenstein A L, 1976, Am J Pathol, V85, P209
   Krafft AE, 1997, MOL DIAGN, V2, P217, DOI 10.1016/S1084-8592(97)80032-X
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Sun AP, 2003, PATHOLOGY, V35, P120, DOI 10.1097/01268031-200335020-00004
   Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793
   Tomashefski JF, 2000, CLIN CHEST MED, V21, P435, DOI 10.1016/S0272-5231(05)70158-1
   WENZEL RP, 1974, AM REV RESPIR DIS, V109, P621
   *WHO, 2003, CAS DEF SURV SEV AC
   *WHO, 2003, COR NEV SEEN HUM CAU
NR 15
TC 141
Z9 153
U1 6
U2 10
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0046-8177
J9 HUM PATHOL
JI Hum. Pathol.
PD AUG
PY 2003
VL 34
IS 8
BP 743
EP 748
DI 10.1016/S0046-8177(03)00367-8
PG 6
WC Pathology
SC Pathology
GA 715VD
UT WOS:000184992200003
PM 14506633
OA Bronze
DA 2020-04-03
ER

PT J
AU WEISZ, OA
   SWIFT, AM
   MACHAMER, CE
AF WEISZ, OA
   SWIFT, AM
   MACHAMER, CE
TI OLIGOMERIZATION OF A MEMBRANE-PROTEIN CORRELATES WITH ITS RETENTION IN
   THE GOLGI-COMPLEX
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID VESICULAR STOMATITIS-VIRUS; BETA-GALACTOSIDE
   ALPHA-2,6-SIALYLTRANSFERASE; TRANSMEMBRANE DOMAIN; CELL-SURFACE; E1
   GLYCOPROTEIN; SPANNING DOMAIN; GLYCOPHORIN-A; TRANSPORT; SIGNAL;
   EXPRESSION
AB The first membrane-spanning domain (m1) of the M glycoprotein of avian coronavirus (formerly called E1) is sufficient to retain this protein in the cis-Golgi. When the membrane-spanning domain of a protein which is efficiently delivered to the plasma membrane (VSV G protein) is replaced with ml, the resulting chimera (Gm1) is retained in the Golgi (Swift, A. M., and C. E. Machamer. 1991. J. Cell Biol. 115:19-30). When assayed in sucrose gradients, we observed that Gm1 formed a large oligomer, and that much of this oligomer was SDS resistant and stayed near the top of the stacking gel of an SDS-polyacrylamide gel. The unusual stability of the oligomer allowed it to be detected easily. Gm1 mutants with single amino acid substitutions in the m1 domain that were retained in the Golgi complex formed SDS-resistant oligomers, whereas mutants that were rapidly released to the plasma membrane did not. Oligomerization was not detected immediately after synthesis of Gm1, but occurred gradually with a lag of approximately 10 min, suggesting that it is not merely aggregation of misfolded proteins. Furthermore, oligomerization did not occur under several conditions that block ER to Golgi transport. The lumenal domain was not required for oligomerization since another chimera (alpham1G), where the lumenal domain of Gm1 was replaced by the alpha subunit of human chorionic gonadotropin, also formed an SDS-resistant oligomer, and was able to form hetero-oligomers with Gm1 as revealed by coprecipitation experiments. SDS resistance was conferred by the cytoplasmic tail of VSV G, because proteolytic digestion of the tail in microsomes containing Gm1 oligomers resulted in loss of SDS resistance, although the protease-treated material continued to migrate as a large oligomer on sucrose gradients. Interestingly, treatment of cells with cytochalasin D blocked formation of SDS-resistant (but not SDS-sensitive) oligomers. Our data suggest that SDS-resistant oligomers form as newly synthesized molecules of Gm1 arrive at the Golgi complex and may interact (directly or indirectly) with an actin-based cytoskeletal matrix. The oligomerization of Gm1 and other resident proteins could serve as a mechanism for their retention in the Golgi complex.
C1 JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, 725 N WOLFE ST, BALTIMORE, MD 21205 USA.
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [GM42522, GM14114]
CR AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319
   BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x
   BORMANN BJ, 1989, J BIOL CHEM, V264, P4033
   BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255
   BURKE J, 1992, J BIOL CHEM, V267, P24433
   COLLEY KJ, 1992, J BIOL CHEM, V267, P7784
   COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208
   COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0
   DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957
   DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89
   DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164
   DOMS RW, 1993, J CELLBIOL, V193, P545
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028
   Griffiths G, 1992, Semin Cell Biol, V3, P367, DOI 10.1016/1043-4682(92)90022-N
   GUAN JL, 1988, MOL CELL BIOL, V8, P2869, DOI 10.1128/MCB.8.7.2869
   GUAN JL, 1988, J BIOL CHEM, V263, P5306
   KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEFRANCOIS L, 1982, VIROLOGY, V121, P168, DOI 10.1016/0042-6822(82)90126-X
   LEMMON MA, 1992, J BIOL CHEM, V267, P7683
   LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557
   Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P
   MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205
   MACHAMER CE, 1993, MOL BIOL CELL, V4, P695
   MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944
   MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074
   MACHAMER CE, 1988, J BIOL CHEM, V263, P5948
   MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801
   MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x
   NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5
   NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x
   ROSE JK, 1991, BIOTECHNIQUES, V10, P520
   RUSSO RN, 1992, J BIOL CHEM, V267, P9241
   SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7
   STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245
   SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19
   TANG BL, 1992, J BIOL CHEM, V267, P10122
   TEASDALE RD, 1992, J BIOL CHEM, V267, P4084
   WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245
NR 40
TC 141
Z9 143
U1 0
U2 2
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD SEP
PY 1993
VL 122
IS 6
BP 1185
EP 1196
DI 10.1083/jcb.122.6.1185
PG 12
WC Cell Biology
SC Cell Biology
GA LY150
UT WOS:A1993LY15000003
PM 8397214
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Jemielity, S
   Wang, JJ
   Chan, YK
   Ahmed, AA
   Li, WH
   Monahan, S
   Bu, X
   Farzan, M
   Freeman, GJ
   Umetsu, DT
   DeKruyff, RH
   Choe, H
AF Jemielity, Stephanie
   Wang, Jinyize J.
   Chan, Ying Kai
   Ahmed, Asim A.
   Li, Wenhui
   Monahan, Sheena
   Bu, Xia
   Farzan, Michael
   Freeman, Gordon J.
   Umetsu, Dale T.
   DeKruyff, Rosemarie H.
   Choe, Hyeryun
TI TIM-family Proteins Promote Infection of Multiple Enveloped Viruses
   through Virion-associated Phosphatidylserine
SO PLOS PATHOGENS
LA English
DT Article
ID FOLATE RECEPTOR-ALPHA; PH-DEPENDENT FUSION; HEPATITIS-A VIRUS;
   HEMORRHAGIC-FEVER ARENAVIRUSES; LAKE-VICTORIA-MARBURGVIRUS; T-CELL
   IMMUNOGLOBULIN; HUMAN DENDRITIC CELLS; NIEMANN-PICK C1; EBOLA-VIRUS;
   DENGUE VIRUS
AB Human T-cell Immunoglobulin and Mucin-domain containing proteins (TIM1, 3, and 4) specifically bind phosphatidylserine (PS). TIM1 has been proposed to serve as a cellular receptor for hepatitis A virus and Ebola virus and as an entry factor for dengue virus. Here we show that TIM1 promotes infection of retroviruses and virus-like particles (VLPs) pseudotyped with a range of viral entry proteins, in particular those from the filovirus, flavivirus, New World arenavirus and alphavirus families. TIM1 also robustly enhanced the infection of replication-competent viruses from the same families, including dengue, Tacaribe, Sindbis and Ross River viruses. All interactions between TIM1 and pseudoviruses or VLPs were PS-mediated, as demonstrated with liposome blocking and TIM1 mutagenesis experiments. In addition, other PS-binding proteins, such as Axl and TIM4, promoted infection similarly to TIM1. Finally, the blocking of PS receptors on macrophages inhibited the entry of Ebola VLPs, suggesting that PS receptors can contribute to infection in physiologically relevant cells. Notably, infection mediated by the entry proteins of Lassa fever virus, influenza A virus and SARS coronavirus was largely unaffected by TIM1 expression. Taken together our data show that TIM1 and related PS-binding proteins promote infection of diverse families of enveloped viruses, and may therefore be useful targets for broad-spectrum antiviral therapies.
C1 [Jemielity, Stephanie; Wang, Jinyize J.; Ahmed, Asim A.; Choe, Hyeryun] Harvard Univ, Sch Med, Div Resp Dis, Childrens Hosp Boston, Boston, MA 02115 USA.
   [Chan, Ying Kai; Farzan, Michael] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, New England Primate Ctr, Boston, MA USA.
   [Li, Wenhui] Natl Inst Biol Sci, Beijing, Peoples R China.
   [Monahan, Sheena; Umetsu, Dale T.; DeKruyff, Rosemarie H.] Harvard Univ, Sch Med, Div Immunol, Childrens Hosp Boston, Boston, MA USA.
   [Bu, Xia; Freeman, Gordon J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Jemielity, S (reprint author), Harvard Univ, Sch Med, Div Resp Dis, Childrens Hosp Boston, Boston, MA 02115 USA.
EM hchoe@scripps.edu
RI Freeman, Gordon/AAC-5380-2019
OI Freeman, Gordon/0000-0002-7210-5616; Li, Wenhui/0000-0003-1305-7404;
   Farzan, Michael/0000-0002-2990-5319
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI074879, AI057159, AI054456,
   AI089955]; Swiss National Science FoundationSwiss National Science
   Foundation (SNSF)
FX This project was supported by NIH grants AI074879 to HC, AI057159 to HC
   and MF and AI054456 and AI089955 to GJF, DTU and RHD
   (http://www.nih.gov). SJ was supported by a fellowship from the Swiss
   National Science Foundation (http://www.snf.ch/E/Pages/default.aspx).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abraham J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000358
   BELLOSTA P, 1995, MOL CELL BIOL, V15, P614
   BUTTERS TD, 1981, IN VITRO CELL DEV B, V17, P831, DOI 10.1007/BF02618451
   Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079
   Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348
   Chan SY, 2001, CELL, V106, P117, DOI 10.1016/S0092-8674(01)00418-4
   Cote M, 2011, NATURE, V477, P344, DOI 10.1038/nature10380
   DeKruyff RH, 2010, J IMMUNOL, V184, P1918, DOI 10.4049/jimmunol.0903059
   Diamond MS, 2000, J VIROL, V74, P7814, DOI 10.1128/JVI.74.17.7814-7823.2000
   Emoto K, 1997, EXP CELL RES, V232, P430, DOI 10.1006/excr.1997.3521
   FAST PG, 1966, LIPIDS, V1, P209, DOI 10.1007/BF02531874
   Feigelstock D, 1998, J VIROL, V72, P6621, DOI 10.1128/JVI.72.8.6621-6628.1998
   Freeman GJ, 2010, IMMUNOL REV, V235, P172, DOI 10.1111/j.0105-2896.2010.00903.x
   Frey B, 2011, SEMIN IMMUNOPATHOL, V33, P497, DOI 10.1007/s00281-010-0228-6
   Gautier I, 2003, EXP CELL RES, V289, P174, DOI 10.1016/S0014-4827(03)00258-1
   Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2
   Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442
   Gramberg T, 2005, VIROLOGY, V340, P224, DOI 10.1016/j.virol.2005.06.026
   HELENIUS A, 2007, FIELDS VIROLOGY, P99
   Helguera G, 2012, J VIROL, V86, P4024, DOI 10.1128/JVI.06397-11
   Hensley LE, 2011, J INFECT DIS, V204, pS1021, DOI 10.1093/infdis/jir339
   Huang IC, 2008, J VIROL, V82, P4834, DOI 10.1128/JVI.00079-08
   Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135
   Kallstrom G, 2005, J VIROL METHODS, V127, P1, DOI 10.1016/j.jviromet.2005.02.015
   Kaplan G, 1996, EMBO J, V15, P4282, DOI 10.1002/j.1460-2075.1996.tb00803.x
   Kobayashi N, 2007, IMMUNITY, V27, P927, DOI 10.1016/j.immuni.2007.11.011
   Kondratowicz AS, 2011, P NATL ACAD SCI USA, V108, P8426, DOI 10.1073/pnas.1019030108
   Kuchroo VK, 2003, NAT REV IMMUNOL, V3, P454, DOI 10.1038/nri1111
   Kuhn JH, 2006, J BIOL CHEM, V281, P15951, DOI 10.1074/jbc.M601796200
   Kyle JL, 2007, J INFECT DIS, V195, P1808, DOI 10.1086/518007
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Licata JM, 2004, J VIROL, V78, P7344, DOI 10.1128/JVI.78.14.7344-7351.2004
   Martinez O, 2007, VIROLOGY, V364, P342, DOI 10.1016/j.virol.2007.03.020
   Meertens L, 2012, CELL HOST MICROBE, V12, P544, DOI 10.1016/j.chom.2012.08.009
   Mercer J, 2008, SCIENCE, V320, P531, DOI 10.1126/science.1155164
   Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200
   Miller EH, 2012, EMBO J, V31, P1947, DOI 10.1038/emboj.2012.53
   Miyanishi M, 2007, NATURE, V450, P435, DOI 10.1038/nature06307
   Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a
   Morizono K, 2011, CELL HOST MICROBE, V9, P286, DOI 10.1016/j.chom.2011.03.012
   Nakayama M, 2009, BLOOD, V113, P3821, DOI 10.1182/blood-2008-10-185884
   Pierson TC, 2006, VIROLOGY, V346, P53, DOI 10.1016/j.virol.2005.10.030
   Radoshitzky SR, 2007, NATURE, V446, P92, DOI 10.1038/nature05539
   Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004
   Santiago C, 2007, IMMUNITY, V27, P941, DOI 10.1016/j.immuni.2007.11.008
   Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817
   Schornberg KL, 2009, P NATL ACAD SCI USA, V106, P8003, DOI 10.1073/pnas.0807578106
   Sherer NM, 2003, TRAFFIC, V4, P785, DOI 10.1034/j.1600-0854.2003.00135.x
   Shimojima M, 2006, J VIROL, V80, P10109, DOI 10.1128/JVI.01157-06
   Silberstein E, 2001, J VIROL, V75, P717, DOI 10.1128/JVI.75.2.717-725.2001
   Simmons G, 2003, J VIROL, V77, P13433, DOI 10.1128/JVI.77.24.13433-13438.2003
   Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730
   Sinn PL, 2003, J VIROL, V77, P5902, DOI 10.1128/JVI.77.10.5902-5910.2003
   Smit JM, 1999, J VIROL, V73, P8476, DOI 10.1128/JVI.73.10.8476-8484.1999
   Soares MM, 2008, NAT MED, V14, P1357, DOI 10.1038/nm.1885
   STEGMANN T, 1985, BIOCHEMISTRY-US, V24, P3107, DOI 10.1021/bi00334a006
   Takada A, 2004, J VIROL, V78, P2943, DOI 10.1128/JVI.78.6.2943-2947.2004
   Takada A, 2000, VIROLOGY, V278, P20, DOI 10.1006/viro.2000.0601
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Tscherne DM, 2010, J VIROL METHODS, V163, P336, DOI 10.1016/j.jviromet.2009.10.020
   Umetsu SE, 2005, NAT IMMUNOL, V6, P447, DOI 10.1038/ni1186
   van den Eijnde SM, 1998, APOPTOSIS, V3, P9, DOI 10.1023/A:1009650917818
   van der Schaar HM, 2007, J VIROL, V81, P12019, DOI 10.1128/JVI.00300-07
   WHITE J, 1980, P NATL ACAD SCI-BIOL, V77, P3273, DOI 10.1073/pnas.77.6.3273
   Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271
NR 66
TC 139
Z9 147
U1 1
U2 41
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAR
PY 2013
VL 9
IS 3
AR e1003232
DI 10.1371/journal.ppat.1003232
PG 14
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 117LB
UT WOS:000316953800032
PM 23555248
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Woo, PCY
   Lau, SKP
   Tsoi, HW
   Huang, Y
   Poon, RWS
   Chu, CM
   Lee, RA
   Luk, WK
   Wong, GKM
   Wong, BHL
   Cheng, VCC
   Tang, BSF
   Wu, AKL
   Yung, RWH
   Chen, HL
   Guan, Y
   Chan, KH
   Yuen, KY
AF Woo, PCY
   Lau, SKP
   Tsoi, HW
   Huang, Y
   Poon, RWS
   Chu, CM
   Lee, RA
   Luk, WK
   Wong, GKM
   Wong, BHL
   Cheng, VCC
   Tang, BSF
   Wu, AKL
   Yung, RWH
   Chen, HL
   Guan, Y
   Chan, KH
   Yuen, KY
TI Clinical and molecular epidemiological features of coronavirus
   HKU1-associated community-acquired pneumonia
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; SARS CORONAVIRUS; TRACT INFECTIONS; RAPID
   DIAGNOSIS; YOUNG-CHILDREN; DISEASE; ETIOLOGY; CHINA; NL63
AB Background. Recently, we described the discovery of a novel group 2 coronavirus, coronavirus HKU1 (CoV-HKU1), from a patient with pneumonia. However, the clinical and molecular epidemiological features of CoV-HKU1-associated pneumonia are unknown.
   Methods. Prospectively collected (during a 12-month period) nasopharyngeal aspirates (NPAs) from patients with community-acquired pneumonia from 4 hospitals were subjected to reverse-transcription polymerase chain reaction, for detection of CoV-HKU1. The epidemiological, clinical, and laboratory characteristics of patients with CoV-HKU1-associated pneumonia were analyzed. The pol, spike (S), and nucleocapsid (N) genes were also sequenced.
   Results. NPAs from 10 (2.4%) of 418 patients with community-acquired pneumonia were found to be positive for CoV-HKU1. All 10 cases occurred in spring and winter. Nine of these patients were adults, and 4 had underlying diseases of the respiratory tract. In the 6 patients from whom serum samples were available, all had a 4-fold change in immunoglobulin (Ig) G titer and/or presence of IgM against CoV-HKU1. The 2 patients who died had significantly lower hemoglobin levels, monocyte counts, albumin levels, and oxygen saturation levels on admission and had more-extensive involvement visible on chest radiographs. Sequence analysis of the pol, S, and N genes revealed 2 genotypes of CoV-HKU1.
   Conclusions. CoV-HKU1 accounts for 2.4% of community-acquired pneumonia, with 2 genotypes in the study population. Without performance of diagnostic tests, the illness was clinically indistinguishable from other community-acquired pneumonia illnesses.
C1 Univ Hong Kong, Div Infect Dis, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   United Christian Hosp, Dept Med, Div Resp Med, Hong Kong, Hong Kong, Peoples R China.
   Pamela Youde Nethersole Eastern Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Tseung Kwan O Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Div Infect Dis, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.
EM hkumicro@hkucc.hku.hk
RI Lau, Susanna/C-4321-2009; Tsoi, Hoi Wah/C-4428-2009; Yuen, Kwok
   Yung/C-4465-2009; Chen, Honglin/C-4224-2009; Woo, Patrick Chiu
   Yat/C-4449-2009
OI Chen, Honglin/0000-0001-5108-8338; Chu, Chung Ming/0000-0002-9959-1271;
   Woo, Patrick Chiu Yat/0000-0001-9401-1832; Yuen,
   Kwok-yung/0000-0002-2083-1552
CR Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869
   Cheng VCC, 2004, CLIN INFECT DIS, V38, P467, DOI 10.1086/382681
   Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Guan Y, 2004, LANCET, V363, P99, DOI 10.1016/S0140-6736(03)15259-2
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hung IFN, 2004, EMERG INFECT DIS, V10, P1550, DOI 10.3201/eid1009.040058
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L
   MCINTOSH K, 1970, AM J EPIDEMIOL, V91, P585, DOI 10.1093/oxfordjournals.aje.a121171
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Ruiz M, 1999, AM J RESP CRIT CARE, V160, P397, DOI 10.1164/ajrccm.160.2.9808045
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2004, LANCET, V363, P841, DOI 10.1016/S0140-6736(04)15729-2
   Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997
   Yam WC, 2003, J CLIN MICROBIOL, V41, P4521, DOI 10.1128/JCM.41.10.4521-4524.2003
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 22
TC 139
Z9 158
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 1
PY 2005
VL 192
IS 11
BP 1898
EP 1907
DI 10.1086/497151
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 980KU
UT WOS:000233018200007
PM 16267760
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU BRIERLEY, I
   ROLLEY, NJ
   JENNER, AJ
   INGLIS, SC
AF BRIERLEY, I
   ROLLEY, NJ
   JENNER, AJ
   INGLIS, SC
TI MUTATIONAL ANALYSIS OF THE RNA PSEUDOKNOT COMPONENT OF A CORONAVIRUS
   RIBOSOMAL FRAMESHIFTING SIGNAL
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE RNA PSEUDOKNOT; RIBOSOMAL FRAMESHIFTING; CORONAVIRUS; TRANSLATIONAL
   REGULATION; RNA STRUCTURE
ID MOSAIC-VIRUS RNA; PLANT VIRAL RNAS; MESSENGER-RNA; ESCHERICHIA-COLI;
   PLASMID DNA; REGION; SITE; POL; REQUIREMENTS; CONFORMATION
RP BRIERLEY, I (reprint author), UNIV CAMBRIDGE, DEPT PATHOL, DIV VIROL, TENNIS COURT RD, CAMBRIDGE CB2 1QP, ENGLAND.
CR ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   CRAIGEN WJ, 1987, CELL, V50, P1, DOI 10.1016/0092-8674(87)90652-0
   DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0
   DECKMAN IC, 1987, J MOL BIOL, V196, P313, DOI 10.1016/0022-2836(87)90692-9
   DOTTO GP, 1981, VIROLOGY, V114, P463, DOI 10.1016/0042-6822(81)90226-9
   DUMAS P, 1987, J BIOMOL STRUCT DYN, V4, P707, DOI 10.1080/07391102.1987.10507674
   Hames BD, 1981, GEL ELECTROPHORESIS, P1
   JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298
   JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054
   JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1
   JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2
   JOSHI RL, 1983, EMBO J, V2, P1123, DOI 10.1002/j.1460-2075.1983.tb01556.x
   KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057
   KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488
   MANIATIS T, 1982, MOL CLONING
   MANS RMW, 1990, NUCLEIC ACIDS RES, V18, P3479, DOI 10.1093/nar/18.12.3479
   MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1
   MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0
   MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987
   PHILIPPE C, 1990, J MOL BIOL, V211, P415, DOI 10.1016/0022-2836(90)90362-P
   PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717
   PLEIJ CWA, 1989, METHOD ENZYMOL, V180, P289
   PLEIJ CWA, 1990, TRENDS BIOCHEM SCI, V15, P143, DOI 10.1016/0968-0004(90)90214-V
   PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O
   RIETVELD K, 1983, EMBO J, V2, P1079, DOI 10.1002/j.1460-2075.1983.tb01549.x
   RIETVELD K, 1982, NUCLEIC ACIDS RES, V10, P1929, DOI 10.1093/nar/10.6.1929
   RIETVELD K, 1984, EMBO J, V3, P2613, DOI 10.1002/j.1460-2075.1984.tb02182.x
   RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6
   SAENGER W, 1984, SPRINGER ADV TEXTS C, pCH15
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2
   ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404
   TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167
   VANBELKUM A, 1985, NUCLEIC ACIDS RES, V13, P7673, DOI 10.1093/nar/13.21.7673
   WYATT JR, 1990, J MOL BIOL, V214, P455, DOI 10.1016/0022-2836(90)90193-P
   YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9
   YOUNG JF, 1983, ORIGIN PANDEMIC INFL, P129
NR 42
TC 139
Z9 144
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD AUG 20
PY 1991
VL 220
IS 4
BP 889
EP 902
DI 10.1016/0022-2836(91)90361-9
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA GC604
UT WOS:A1991GC60400008
PM 1880803
DA 2020-04-03
ER

PT J
AU Chang, SH
   Bae, JL
   Kang, TJ
   Kim, J
   Chung, GH
   Lim, CW
   Laude, H
   Yang, MS
   Jang, YS
AF Chang, SH
   Bae, JL
   Kang, TJ
   Kim, J
   Chung, GH
   Lim, CW
   Laude, H
   Yang, MS
   Jang, YS
TI Identification of the epitope region capable of inducing neutralizing
   antibodies against the porcine epidemic diarrhea virus
SO MOLECULES AND CELLS
LA English
DT Article
DE PEDV; TGEV
ID TRANSMISSIBLE GASTROENTERITIS VIRUS; ANTIGENIC STRUCTURE; SPIKE PROTEIN;
   CORONAVIRUS; GLYCOPROTEIN; EXPRESSION; SEQUENCE; GENOME
AB In order to identify the neutralizing epitope of the porcine epidemic diarrhea virus (PEDV), the spike protein region that is presumed to contain the virus-neutralizing epitope was determined. This was based on the sequence information for the neutralizing epitope of the transmissible gastroenteritis virus (TGEV). A recombinant protein that corresponds to the spike region of TGEV was produced, and polyclonal antisera were generated using the recombinant protein. It was discovered that polyclonal antisera significantly inhibited plaque formation by PEDV, suggesting that this region of the spike protein contains the epitope(s) that is capable of inducing PEDV-neutralizing antibodies. In addition, the region that corresponds to the neutralizing epitope of TGEV may also be involved in neutralizing PEDV although the two viruses are serologically quite distinct. Finally, the amino acid sequences that are deduced from the genes for the determined-neutralizing epitope were highly homologous among the PEDV strains that were isolated from different geographical areas, which suggests conservation of the antigen gene.
C1 Chonbuk Natl Univ, Div Biol Sci, Jeonju 561756, South Korea.
   Chonbuk Natl Univ, Inst Mol Biol & Genet, Jeonju 561756, South Korea.
   Chonbuk Natl Univ, Inst Basic Sci, Jeonju 561756, South Korea.
   Chonbuk Natl Univ, Dept Vet Pathol, Jeonju 561756, South Korea.
   INRA, Unite Virol & Immunol Mol, CR Jouy En Josas, F-78350 Jouy En Josas, France.
RP Jang, YS (reprint author), Chonbuk Natl Univ, Div Biol Sci, Jeonju 561756, South Korea.
CR CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   CORREA I, 1988, VIRUS RES, V10, P77, DOI 10.1016/0168-1702(88)90059-7
   DEBOUCK P, 1980, AM J VET RES, V41, P219
   Debouck P, 1982, P INT PIG VET SOC C, V7, P53
   DELMAS B, 1990, J GEN VIROL, V71, P1313, DOI 10.1099/0022-1317-71-6-1313
   DELMAS B, 1986, J GEN VIROL, V67, P1405, DOI 10.1099/0022-1317-67-7-1405
   DUARTE M, 1994, J GEN VIROL, V75, P1195, DOI 10.1099/0022-1317-75-5-1195
   DUARTE M, 1994, VIROLOGY, V198, P466, DOI 10.1006/viro.1994.1058
   DUCATELLE R, 1981, J VET MED B, V28, P483
   HOFMANN M, 1988, J CLIN MICROBIOL, V26, P2235, DOI 10.1128/JCM.26.11.2235-2239.1988
   HOFMANN M, 1989, VET MICROBIOL, V20, P131, DOI 10.1016/0378-1135(89)90036-9
   HORZINEK MC, 1982, INFECT IMMUN, V37, P1148, DOI 10.1128/IAI.37.3.1148-1155.1982
   Kim J, 2001, MOL CELLS, V12, P67
   Kweon CH, 1993, KOREAN J VET RES, V33, P249
   Pensaert M. B., 1999, DIS SWINE, P179
   PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
NR 18
TC 138
Z9 188
U1 3
U2 19
PU SPRINGER-VERLAG SINGAPORE PTE LTD
PI SINGAPORE
PA #04-01 CENCON I, 1 TANNERY RD, SINGAPORE 347719, SINGAPORE
SN 1016-8478
J9 MOL CELLS
JI Mol. Cells
PD OCT 31
PY 2002
VL 14
IS 2
BP 295
EP 299
PG 5
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 611CG
UT WOS:000178998400019
PM 12442904
DA 2020-04-03
ER

PT J
AU Phillips, JJ
   Chu, MM
   Lavi, E
   Weiss, SR
AF Phillips, JJ
   Chu, MM
   Lavi, E
   Weiss, SR
TI Pathogenesis of chimeric MHV4/MHV-A59 recombinant viruses: the murine
   coronavirus spike protein is a major determinant of neurovirulence
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; TARGETED RNA RECOMBINATION; TO-CELL FUSION;
   MONOCLONAL-ANTIBODIES; NEUROTROPIC CORONAVIRUS; PROTEOLYTIC CLEAVAGE;
   DELETION MUTANT; GLYCOPROTEIN; RECEPTOR; GENE
AB The mouse hepatitis virus (MHV) spike glycoprotein, S, has been implicated as a major determinant of viral pathogenesis. In the absence of a full-length molecular clone, however, it has been difficult to address the role of individual viral genes in pathogenesis, By using targeted RNA recombination to introduce the S gene of MHV4, a highly neurovirulent strain, into the genome of MHV-A59, a mildly neurovirulent strain, we have been able to directly address the role of the S gene in neurovirulence. In cell culture, the recombinants containing the MHV4 S gene, S4R22 and S4R21, exhibited a small-plaque phenotype and replicated to low levels, similar to wild-type MHV4. Intracranial inoculation of C57BL/6 mice with S4R22 and S4R21 revealed a marked alteration in pathogenesis. Relative to wild-type control recombinant viruses (wtR13 and wtR9), containing the MHV-A59 S gene, the MHV4 S gene recombinants exhibited a dramatic increase in virulence and an increase in both viral antigen staining and inflammation in the central nervous system, There was not, however, an increase in the level of viral replication in the brain. These studies demonstrate that the MHV4 S gene alone is sufficient to confer a highly neurovirulent phenotype to a recombinant virus deriving the remainder of its genome from a mildly neurovirulent virus, MHV-A59. This definitively confirms previous findings, suggesting that the spike is a major determinant of pathogenesis.
C1 Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA.
RP Weiss, SR (reprint author), Univ Penn, Sch Med, Dept Microbiol, 203A Johnson Pavil,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [GM-07229, T32 GM007229]; NINDS NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [P01 NS030606, NS-21954, NS-30606]
CR BAILEY OT, 1949, J EXP MED, V90, P195, DOI 10.1084/jem.90.3.195
   BARNETT EM, 1993, NEUROSCIENCE, V57, P1007, DOI 10.1016/0306-4522(93)90045-H
   Belyavskyi M, 1998, VIROLOGY, V250, P41, DOI 10.1006/viro.1998.9356
   Bergmann CC, 1996, J GEN VIROL, V77, P315, DOI 10.1099/0022-1317-77-2-315
   BOND CW, 1979, VIROLOGY, V94, P371, DOI 10.1016/0042-6822(79)90468-9
   Bos ECW, 1995, VIROLOGY, V214, P453, DOI 10.1006/viro.1995.0056
   CASTRO RF, 1995, J VIROL, V69, P8127, DOI 10.1128/JVI.69.12.8127-8131.1995
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   COMPTON SR, 1993, LAB ANIM SCI, V43, P15
   DALZIEL RG, 1986, J VIROL, V59, P463, DOI 10.1128/JVI.59.2.463-471.1986
   DANIEL C, 1993, J VIROL, V67, P1185, DOI 10.1128/JVI.67.3.1185-1194.1993
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   FAZAKERLEY JK, 1992, VIROLOGY, V187, P178, DOI 10.1016/0042-6822(92)90306-A
   Fischer F, 1997, J VIROL, V71, P5148, DOI 10.1128/JVI.71.7.5148-5160.1997
   FLEMING JO, 1986, J VIROL, V58, P869, DOI 10.1128/JVI.58.3.869-875.1986
   FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985
   Gallagher TM, 1997, J VIROL, V71, P3129, DOI 10.1128/JVI.71.4.3129-3137.1997
   GALLAGHER TM, 1991, J VIROL, V65, P1916, DOI 10.1128/JVI.65.4.1916-1928.1991
   GALLAGHER TM, 1990, J VIROL, V64, P731, DOI 10.1128/JVI.64.2.731-741.1990
   GILMORE W, 1987, P SOC EXP BIOL MED, V185, P177
   GOMBOLD JL, 1993, J VIROL, V67, P4504, DOI 10.1128/JVI.67.8.4504-4512.1993
   HIGUCHI R, 1990, PCR PROTOCOLS GUIDE, P177
   HINGLEY ST, 1994, VIROLOGY, V200, P1, DOI 10.1006/viro.1994.1156
   Houtman JJ, 1996, J NEUROVIROL, V2, P361, DOI 10.3109/13550289609146902
   KOETZNER CA, 1992, J VIROL, V66, P1841, DOI 10.1128/JVI.66.4.1841-1848.1992
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   KUO L, UNPUB RETARGETING CO
   Lane TE, 1999, J NEUROVIROL, V5, P48, DOI 10.3109/13550289909029745
   LAVI E, 1988, LAB INVEST, V58, P31
   LAVI E, 1990, LAB INVEST, V62, P570
   Leparc-Goffart I, 1998, J VIROL, V72, P9628, DOI 10.1128/JVI.72.12.9628-9636.1998
   Lewis J, 1996, J VIROL, V70, P1828, DOI 10.1128/JVI.70.3.1828-1835.1996
   Liang XH, 1999, J VIROL, V73, P2563, DOI 10.1128/JVI.73.3.2563-2567.1999
   Luo ZL, 1998, VIROLOGY, V244, P483, DOI 10.1006/viro.1998.9121
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   MASTERS PS, 1994, J VIROL, V68, P328, DOI 10.1128/JVI.68.1.328-337.1994
   PARKER SE, 1989, VIROLOGY, V173, P664, DOI 10.1016/0042-6822(89)90579-5
   Pope M, 1998, J VIROL, V72, P7084, DOI 10.1128/JVI.72.9.7084-7090.1998
   RAMIG RF, 1982, VIROLOGY, V120, P93, DOI 10.1016/0042-6822(82)90009-5
   Rao PV, 1998, J VIROL, V72, P3278, DOI 10.1128/JVI.72.4.3278-3288.1998
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Sasseville VG, 1996, AM J PATHOL, V149, P1459
   Smith Abigail L., 1997, P483
   STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985
   WEGE H, 1988, J GEN VIROL, V69, P87, DOI 10.1099/0022-1317-69-1-87
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
NR 46
TC 138
Z9 141
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD SEP
PY 1999
VL 73
IS 9
BP 7752
EP 7760
DI 10.1128/JVI.73.9.7752-7760.1999
PG 9
WC Virology
SC Virology
GA 225ME
UT WOS:000081964700071
PM 10438865
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU LAI, MMC
   BARIC, RS
   MAKINO, S
   KECK, JG
   EGBERT, J
   LEIBOWITZ, JL
   STOHLMAN, SA
AF LAI, MMC
   BARIC, RS
   MAKINO, S
   KECK, JG
   EGBERT, J
   LEIBOWITZ, JL
   STOHLMAN, SA
TI RECOMBINATION BETWEEN NONSEGMENTED RNA GENOMES OF MURINE CORONAVIRUSES
SO JOURNAL OF VIROLOGY
LA English
DT Article
C1 UNIV SO CALIF,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90033.
   UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL & LAB MED,HOUSTON,TX 77025.
RP LAI, MMC (reprint author), UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033, USA.
RI Lai, Michael M. C./I-7001-2012; Makino, Shinji/E-8014-2015
OI Makino, Shinji/0000-0002-7831-1576
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 19244]
CR ARMSTRONG J, 1983, NUCLEIC ACIDS RES, V11, P883, DOI 10.1093/nar/11.3.883
   BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   BARIC RS, 1985, VIRUS RES, V3, P19, DOI 10.1016/0168-1702(85)90038-3
   BARRELL BG, 1971, PROCEDURES NUCLEIC A, V2, P751
   BRAYTON PR, 1982, J VIROL, V42, P847, DOI 10.1128/JVI.42.3.847-853.1982
   BRAYTON PR, 1984, VIROLOGY, V133, P197, DOI 10.1016/0042-6822(84)90439-2
   Cooper PD, 1977, COMPREHENSIVE VIROLO, V9, P133
   Fields B N, 1981, Curr Top Microbiol Immunol, V91, P1
   HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255
   Horiuchi K., 1975, RNA PHAGES, P29
   KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777
   KING AMQ, 1982, CELL, V29, P921, DOI 10.1016/0092-8674(82)90454-8
   LAI MMC, 1981, J VIROL, V38, P661, DOI 10.1128/JVI.38.2.661-670.1981
   LAI MMC, 1983, J VIROL, V46, P1027, DOI 10.1128/JVI.46.3.1027-1033.1983
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   LAI MMC, 1982, J VIROL, V41, P557, DOI 10.1128/JVI.41.2.557-565.1982
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   LEIBOWITZ JL, 1982, J VIROL, V42, P1080, DOI 10.1128/JVI.42.3.1080-1087.1982
   MAKINO S, 1985, J VIROL, V54, P329, DOI 10.1128/JVI.54.2.329-336.1985
   MAKINO S, 1984, VIROLOGY, V139, P138, DOI 10.1016/0042-6822(84)90335-0
   PFEFFERKORN ER, 1977, COMPREHENSIVE VIROLO, V9, P209
   ROMANOVA LI, 1980, FEBS LETT, V118, P109, DOI 10.1016/0014-5793(80)81229-4
   SCHOLTISSEK C, 1978, VIROLOGY, V87, P13, DOI 10.1016/0042-6822(78)90153-8
   SKINNER MA, 1983, NUCLEIC ACIDS RES, V11, P5045, DOI 10.1093/nar/11.15.5045
   SPAAN W, 1983, EMBO J, V2, P1939
   STOHLMAN SA, 1982, J GEN VIROL, V63, P265, DOI 10.1099/0022-1317-63-2-265
   WEGE H, 1978, J GEN VIROL, V41, P217, DOI 10.1099/0022-1317-41-2-217
   WEGE H, 1981, BIOCH BIOL CORONAVIR, P91
NR 30
TC 138
Z9 139
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PY 1985
VL 56
IS 2
BP 449
EP 456
DI 10.1128/JVI.56.2.449-456.1985
PG 8
WC Virology
SC Virology
GA ASQ98
UT WOS:A1985ASQ9800015
PM 2997467
OA Bronze
DA 2020-04-03
ER

PT J
AU MEBUS, CA
   STAIR, EL
   RHODES, MB
   TWIEHAUS, MJ
AF MEBUS, CA
   STAIR, EL
   RHODES, MB
   TWIEHAUS, MJ
TI PATHOLOGY OF NEONATAL CALF DIARRHEA INDUCED BY A CORONAVIRUS-LIKE AGENT
SO VETERINARY PATHOLOGY
LA English
DT Article
C1 UNIV NEBRASKA,DEPT VET SCI,LINCOLN,NB 68503.
CR HOOPER BE, 1969, CAN J COMPARAT MED, V33, P29
   MEBUS CA, 1973, AM J VET RES, V34, P145
   MEBUS CA, 1972, VET MED SM ANIM CLIN, V67, P173
   MEBUS CA, 1972, AM J VET RES, V33, P2335
   MEBUS CA, 1971, CANADIAN VET J, V12, P69
   MEBUS CA, 1971, VET PATHOL, V8, P490, DOI 10.1177/0300985871008005-00612
   MEBUS CA, 1972, VET MED SMALL ANIM C, V67, P177
   MEBUS CA, 1969, U NEBR RES B, V233, P1
   MENGELING WL, 1972, AM J VET RES, V33, P297
   STAIR EL, 1972, AM J VET RES, V33, P1147
   TORRESMEDINA A, 1971, POULTRY SCI, V50, P1115, DOI 10.3382/ps.0501115
   1956, DIAGNOSTIC PROCEDURE
   1960, MANUAL HISTOLOGIC SP
NR 13
TC 138
Z9 142
U1 0
U2 2
PU AMER COLL VET PATHOLOGIST
PI LAWRENCE
PA 810 EAST 10TH STREET, LAWRENCE, KS 66044
SN 0300-9858
J9 VET PATHOL
JI Vet. Pathol.
PY 1973
VL 10
IS 1
BP 45
EP 64
DI 10.1177/030098587301000105
PG 20
WC Pathology; Veterinary Sciences
SC Pathology; Veterinary Sciences
GA R2001
UT WOS:A1973R200100005
PM 4584109
OA Bronze
DA 2020-04-03
ER

PT J
AU Muller, MA
   Raj, VS
   Muth, D
   Meyer, B
   Kallies, S
   Smits, SL
   Wollny, R
   Bestebroer, TM
   Specht, S
   Suliman, T
   Zimmermann, K
   Binger, T
   Eckerle, I
   Tschapka, M
   Zaki, AM
   Osterhaus, ADME
   Fouchier, RAM
   Haagmans, BL
   Drosten, C
AF Mueller, Marcel A.
   Raj, V. Stalin
   Muth, Doreen
   Meyer, Benjamin
   Kallies, Stephan
   Smits, Saskia L.
   Wollny, Robert
   Bestebroer, Theo M.
   Specht, Sabine
   Suliman, Tasnim
   Zimmermann, Katrin
   Binger, Tabea
   Eckerle, Isabella
   Tschapka, Marco
   Zaki, Ali M.
   Osterhaus, Albert D. M. E.
   Fouchier, Ron A. M.
   Haagmans, Bart L.
   Drosten, Christian
TI Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and
   Maintains Broad Replicative Capability in Mammalian Cell Lines
SO MBIO
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; BATS; BETACORONAVIRUS; IDENTIFICATION;
   PNEUMONIA
AB A new human coronavirus (hCoV-EMC) has emerged very recently in the Middle East. The clinical presentation resembled that of the severe acute respiratory syndrome (SARS) as encountered during the epidemic in 2002/2003. In both cases, acute renal failure was observed in humans. HCoV-EMC is a member of the same virus genus as SARS-CoV but constitutes a sister species. Here we investigated whether it might utilize angiotensin-converting enzyme 2 (ACE2), the SARS-CoV receptor. Knowledge of the receptor is highly critical because the restriction of the SARS receptor to deep compartments of the human respiratory tract limited the spread of SARS. In baby hamster kidney (BHK) cells, lentiviral transduction of human ACE2 (hACE2) conferred permissiveness and replication for SARS-CoV but not for hCoV-EMC. Monkey and human kidney cells (LLC-MK2, Vero, and 769-P) and swine kidney cells were permissive for both viruses, but only SARS-CoV infection could be blocked by anti-hACE2 antibody and could be neutralized by preincubation of virus with soluble ACE2. Our data show that ACE2 is neither necessary nor sufficient for hCoV-EMC replication. Moreover, hCoV-EMC, but not SARS-CoV, replicated in cell lines from Rousettus, Rhinolophus, Pipistrellus, Myotis, and Carollia bats, representing four major chiropteran families from both suborders. As human CoV normally cannot replicate in bat cells from different families, this suggests that hCoV-EMC might use a receptor molecule that is conserved in bats, pigs, and humans, implicating a low barrier against cross-host transmission.
   IMPORTANCE A new human coronavirus (hCoV) emerged recently in the Middle East. The disease resembled SARS (severe acute respiratory syndrome), causing a fatal epidemic in 2002/2003. Coronaviruses have a reservoir in bats and because this novel virus is related to SARS-CoV, we investigated whether it might replicate in bat cells and use the same receptor (angiotensinconverting enzyme 2 [ACE2]). This knowledge is highly critical, because the SARS-CoV receptor influenced pathology, and its localization in the deep respiratory tract is thought to have restricted the transmissibility of SARS. Our data show that hCoV-EMC does not need the SARS-CoV receptor to infect human cells. Moreover, the virus is capable of infecting human, pig, and bat cells. This is remarkable, as human CoVs normally cannot replicate in bat cells as a consequence of host adaptation. Our results implicate that the new virus might use a receptor that is conserved between bats, pigs and humans suggesting a low barrier against cross-host transmission.
C1 [Mueller, Marcel A.; Muth, Doreen; Meyer, Benjamin; Kallies, Stephan; Wollny, Robert; Suliman, Tasnim; Binger, Tabea; Eckerle, Isabella; Drosten, Christian] Univ Bonn, Inst Virol, Med Ctr, Bonn, Germany.
   [Raj, V. Stalin; Smits, Saskia L.; Bestebroer, Theo M.; Osterhaus, Albert D. M. E.; Fouchier, Ron A. M.; Haagmans, Bart L.] Erasmus MC, Virosci Lab, Rotterdam, Netherlands.
   [Specht, Sabine] Univ Bonn, Inst Med Microbiol Immunol & Parasitol, Med Ctr, Bonn, Germany.
   [Zimmermann, Katrin] Univ Bonn, Inst Pharmacol & Toxicol, Med Ctr, Bonn, Germany.
   [Tschapka, Marco] Univ Ulm, Inst Expt Ecol, D-89069 Ulm, Germany.
   [Zaki, Ali M.] Dr Soliman Fakeeh Hosp, Virol Lab, Jeddah, Saudi Arabia.
RP Haagmans, BL (reprint author), Erasmus MC, Virosci Lab, Rotterdam, Netherlands.
EM b.haagmans@erasmusmc.nl; drosten@virology-bonn.de
RI Mueller, Marcel/O-2425-2019; Meyer, Bernhard/Q-9413-2016; Fouchier,
   Ron/Y-3755-2019; Meyer, Benjamin/F-3285-2018; Smits, Saskia/A-2953-2014;
   Fouchier, Ron A/A-1911-2014; Victor, Stalin Raj/E-9670-2016
OI Mueller, Marcel/0000-0003-2242-5117; Fouchier, Ron/0000-0001-8095-2869;
   Meyer, Benjamin/0000-0003-0601-3550; Fouchier, Ron
   A/0000-0001-8095-2869; Osterhaus, Albert/0000-0002-6074-1172; Victor,
   Stalin Raj/0000-0003-2250-8481; Haagmans, Bart/0000-0001-6221-2015
FU European UnionEuropean Union (EU) [223498, 278976]; German Research
   Foundation (DFG)German Research Foundation (DFG) [DR 772/3-1,
   KA1241/18-1]; German Ministry of Education and Research (BMBF SARS
   II)Federal Ministry of Education & Research (BMBF)
FX This study was supported by the European Union FP7 project EMPERIE
   (contract number 223498), ANTIGONE (contract number 278976), the German
   Research Foundation (DFG grants DR 772/3-1 and KA1241/18-1), as well as
   the German Ministry of Education and Research (BMBF SARS II).
CR Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Biesold SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028131
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   Drexler JF, 2010, J VIROL, V84, P11336, DOI 10.1128/JVI.00650-10
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Gloza-Rausch F, 2008, EMERG INFECT DIS, V14, P626, DOI 10.3201/eid1404.071439
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Huynh J, 2012, J VIROL, V86, P12816, DOI 10.1128/JVI.00906-12
   Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lau SKP, 2010, J VIROL, V84, P11385, DOI 10.1128/JVI.01121-10
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Memish Z, 2012, NEW SAUDI NOVEL CORO
   PEBODY R, 2012, EUROSURVEILLANCE, V4, P17
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Saif LJ, 2004, REV SCI TECH OIE, V23, P643, DOI 10.20506/rst.23.2.1513
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 24
TC 137
Z9 147
U1 2
U2 30
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD NOV-DEC
PY 2012
VL 3
IS 6
AR e00515-12
DI 10.1128/mBio.00515-12
PG 5
WC Microbiology
SC Microbiology
GA 064UK
UT WOS:000313100700036
PM 23232719
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Lau, SKP
   Yip, CCY
   Que, TL
   Lee, RA
   Au-Yeung, RKH
   Zhou, B
   So, LY
   Lau, YL
   Chan, KH
   Woo, PCY
   Yuen, KY
AF Lau, Susanna K. P.
   Yip, Cyril C. Y.
   Que, Tak-lun
   Lee, Rodney A.
   Au-Yeung, Rex K. H.
   Zhou, Boping
   So, Lok-yee
   Lau, Yu-lung
   Chan, Kwok-hung
   Woo, Patrick C. Y.
   Yuen, Kwok-yung
TI Clinical and molecular epidemiology of human bocavirus in respiratory
   and fecal samples from children in Hong Kong
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; TRACT INFECTIONS; CORONAVIRUS HKU1;
   YOUNG-CHILDREN; DISEASE; VIRUS; IDENTIFICATION; PARVOVIRUSES;
   ASSOCIATION; ETIOLOGY
AB Background. Human bocavirus ( HBoV) is a recently discovered parvovirus associated with respiratory tract infections in children. We conducted the first systematic prospective clinical and molecular study using nasopharyngeal aspirates (NPAs) and fecal samples.
   Methods. NPAs negative for influenza virus, parainfluenza virus, respiratory syncytial virus, adenovirus, and coronavirus and fecal samples from patients with acute gastroenteritis were included. On the basis of results from a pilot study using 400 NPAs from all age groups, a prospective 12-month study was conducted to detect HBoV in 1200 NPAs and 1435 fecal samples from patients < 18 years old by polymerase chain reaction. The complete genome sequences of HBoVs from 12 NPAs and 12 fecal samples were determined.
   Results. Of the 400 NPAs collected in the pilot study, 20 (5.0%) were found to contain HBoV, all from children ! 5 years old. In the subsequent prospective study of pediatric patients, HBoV was detected in 83 (6.9%) of 1200 NPAs. Upper and lower respiratory tract infections were equally common. HBoV was detected in 30 (2.1%) of 1435 fecal samples. Fever and watery diarrhea were the most common symptoms. The seasonality of HBoV in NPAs and fecal samples was similar. Codetection with other pathogens occurred in 33% and 56% of NPAs and fecal samples, respectively, from patients with HBoV infection. Genomes of HBoVs from NPAs and fecal samples displayed minimal sequence variations.
   Conclusions. HBoV was detected in fecal specimens in children with acute gastroenteritis. A single lineage of HBoV was associated with both respiratory tract and enteric infections.
C1 Univ Hong Kong, Queen Mary Hosp, State Key Lab Emerging Infectious Diseases, Hong Kong, Hong Kong, Peoples R China.
RP Woo, PCY (reprint author), Univ Hong Kong, Queen Mary Hosp, State Key Lab Emerging Infectious Diseases, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.
EM pcywoo@hkucc.hku.hk; kyyuen@hkucc.hku.hk
RI Yip, Chik Yan/B-7078-2013; Yeung, Kwok Him Rex Au/A-2476-2019; Lau,
   Susanna/C-4321-2009; Yuen, Kwok Yung/C-4465-2009; Lau, Susanna Kar
   Pui/AAJ-6848-2020; Lau, Yu Lung/C-4322-2009; Woo, Patrick Chiu
   Yat/C-4449-2009
OI Yeung, Kwok Him Rex Au/0000-0002-3137-0886; Lau, Susanna Kar
   Pui/0000-0002-1383-7374; Yuen, Kwok-yung/0000-0002-2083-1552; Woo,
   Patrick Chiu Yat/0000-0001-9401-1832
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196
   Arnold JC, 2006, CLIN INFECT DIS, V43, P283, DOI 10.1086/505399
   Bastien N, 2006, EMERG INFECT DIS, V12, P848, DOI 10.3201/eid1205.051424
   BINN L N, 1970, Infection and Immunity, V1, P503
   Choi EH, 2006, CLIN INFECT DIS, V43, P585, DOI 10.1086/506350
   Chung JY, 2006, EMERG INFECT DIS, V12, P1254, DOI 10.3201/eid1708.060261
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Foulongne V, 2006, EMERG INFECT DIS, V12, P1251, DOI 10.3201/eid1708.060213.
   Kaplan NM, 2006, EMERG INFECT DIS, V12, P1418, DOI 10.3201/eid1209.060417
   Kesebir D, 2006, J INFECT DIS, V194, P1276, DOI 10.1086/508213
   Kupfer B, 2006, EMERG INFECT DIS, V12, P1614, DOI 10.3201/eid1210.060520
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Lin Feng, 2007, Infect Agent Cancer, V2, P3
   Ma XM, 2006, J CLIN MICROBIOL, V44, P1132, DOI 10.1128/JCM.44.3.1132-1134.2006
   MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L
   Manning A, 2006, J INFECT DIS, V194, P1283, DOI 10.1086/508219
   McIntosh K, 2006, J INFECT DIS, V194, P1197, DOI 10.1086/508228
   Mochizuki M, 2002, J CLIN MICROBIOL, V40, P3993, DOI 10.1128/JCM.40.11.3993-3998.2002
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, EMERG INFECT DIS, V9, P628
   Regamey N, 2007, PEDIATR INFECT DIS J, V26, P177, DOI 10.1097/01.inf.0000250623.43107.bc
   Ruiz M, 1999, AM J RESP CRIT CARE, V160, P397, DOI 10.1164/ajrccm.160.2.9808045
   Savolainen C, 2002, J GEN VIROL, V83, P333, DOI 10.1099/0022-1317-83-2-333
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   SPAHN GJ, 1966, CORNELL VET, V56, P377
   STORZ J, 1978, J AM VET MED ASSOC, V173, P624
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Weissbrich B, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-109
   Woo PCY, 2006, J VIROL, V80, P7136, DOI 10.1128/JVI.00509-06
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   Woo PCY, 2004, LANCET, V363, P1941, DOI 10.1016/S0140-6736(04)16407-6
   Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997
NR 35
TC 137
Z9 159
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 1
PY 2007
VL 196
IS 7
BP 986
EP 993
DI 10.1086/521310
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 212CZ
UT WOS:000249572500007
PM 17763318
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Weissbrich, B
   Neske, F
   Schubert, J
   Tollmann, F
   Blath, K
   Blessing, K
   Kreth, HW
AF Weissbrich, Benedikt
   Neske, Florian
   Schubert, Joerg
   Tollmann, Franz
   Blath, Katharina
   Blessing, Kerstin
   Kreth, Hans Wolfgang
TI Frequent detection of bocavirus DNA in German children with respiratory
   tract infections
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID CORONAVIRUS HKU1; VIRUS; GENOME
AB Background: In a substantial proportion of respiratory tract diseases of suspected infectious origin, the etiology is unknown. Some of these cases may be caused by the recently described human bocavirus (hBoV). The aim of this study was to investigate the frequency and the potential clinical relevance of hBoV in pediatric patients.
   Methods: We tested 835 nasopharyngeal aspirates (NPA) obtained between 2002 and 2005 from pediatric in-patients with acute respiratory tract diseases at the University of Wurzburg, Germany, for the presence of hBoV DNA. The specificity of positive PCR reactions was confirmed by sequencing.
   Results: HBoV DNA was found in 87 (10.3 %) of the NPAs. The median age of the infants and children with hBoV infection was 1.8 years (mean age 2.0 years; range 18 days -8 years). Infections with hBoV were found year-round, though most occurred in the winter months. Coinfections were found in 34 (39.1 %) of the hBoV positive samples. RSV, influenza A, and adenoviruses were most frequently detected as coinfecting agents. Sequence determination of the PCR products in the NP-1 region revealed high identity (99 %) between the nucleotide sequences obtained in different years and in comparison to the Swedish viruses ST1 and ST2. An association of hBoV with a distinct respiratory tract manifestation was not apparent.
   Conclusion: HBoV is frequently found in NPAs of hospitalized infants and children with acute respiratory tract diseases. Proving the clinical relevance of hBoV is challenging, because application of some of Koch's revised postulates is not possible. Because of the high rate of coinfections with hBoV and other respiratory tract pathogens, an association between hBoV and respiratory tract diseases remains unproven.
C1 Univ Wurzburg, Inst Virol & Immunbiol, D-97078 Wurzburg, Germany.
   Univ Wurzburg, Childrens Hosp, D-97080 Wurzburg, Germany.
RP Weissbrich, B (reprint author), Univ Wurzburg, Inst Virol & Immunbiol, Versbacher Str 7, D-97078 Wurzburg, Germany.
EM weissbrich@vim.uni-wuerzburg.de; florian.neske@gmx.de;
   schubert@vim.uni-wuerzburg.de; tollmann@vim.uni-wuerzburg.de;
   blathk@web.de; blessing_k@kinderklinik.uni-wuerzburg.de;
   kreth@mail.uni-wuerzburg.de
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Bastien N, 2006, EMERG INFECT DIS, V12, P848, DOI 10.3201/eid1205.051424
   Fouchier Ron Am, 2005, Curr Opin Infect Dis, V18, P141
   Foulongne V, 2006, EMERG INFECT DIS, V12, P862, DOI 10.3201/eid1205.051523
   Herrmann B, 2001, J CLIN MICROBIOL, V39, P134, DOI 10.1128/JCM.39.1.134-138.2001
   Hino S, 2002, REV MED VIROL, V12, P151, DOI 10.1002/rmv.351
   Ma XM, 2006, J CLIN MICROBIOL, V44, P1132, DOI 10.1128/JCM.44.3.1132-1134.2006
   Rivers TM, 1937, J BACTERIOL, V33, P1
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Stapleton JT, 2003, SEMIN LIVER DIS, V23, P137
   TATTERSALL P, 2005, VIRUS TAXONOMY, P353
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
NR 12
TC 137
Z9 158
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUL 11
PY 2006
VL 6
AR 109
DI 10.1186/1471-2334-6-109
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 077BK
UT WOS:000240002500001
PM 16834781
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Zhao, Z
   Zhang, F
   Xu, M
   Huang, K
   Zhong, W
   Cai, W
   Yin, Z
   Huang, S
   Deng, Z
   Wei, M
   Xiong, J
   Hawkey, PM
AF Zhao, Z
   Zhang, F
   Xu, M
   Huang, K
   Zhong, W
   Cai, W
   Yin, Z
   Huang, S
   Deng, Z
   Wei, M
   Xiong, J
   Hawkey, PM
TI Description and clinical treatment of an early outbreak of severe acute
   respiratory syndrome (SARS) in Guangzhou, PR China
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
ID HONG-KONG; CORONAVIRUS; IDENTIFICATION; VIRUS
AB Severe acute respiratory syndrome (SARS), now known to be caused by a coronavirus, probably originated in Guangdong province in southern China in late 2002. The first major outbreak occurred in Guangzhou, the capital of Guangdong, between January and March 2003. This study reviews the clinical presentation, laboratory findings and response to four different treatment protocols. Case notes and laboratory findings were analysed and outcome measures were collected prospectively. The SARS outbreak in Guangdong province and the outbreak in Guangzhou associated with hospitals in the city are described, documenting clinical and laboratory features in a cohort of 190 patients randomly allocated to four treatment regimens. Patients were infected by close contact in either family or health-care settings, particularly following procedures likely to generate aerosols of respiratory secretions (e.g. administration of nebulized drugs and bronchoscopy). The earliest symptom was a high fever followed, in most patients, by dyspnoea, cough and myalgia, with 24 % of patients complaining of diarrhoea. The most frequent chest X-ray changes were patchy consolidation with progression to bilateral bronchopneumonia over 5-10 days. Thirty-six cases developed adult respiratory distress syndrome (ARDS), of whom 11 died. There was no response to antibiotics. The best response (no deaths) was seen in the group of 60 patients receiving early high-dose steroids and nasal CPAP (continuous airway positive pressure) ventilation; the other three treatment groups had significant mortality. Cross-infection to medical and nursing staff was completely prevented in one hospital by rigid adherence to barrier precautions during contact with infected patients. The use of rapid case identification and quarantine has controlled the outbreak in Guangzhou, in which more than 350 patients have been infected. Early administration of high-dose steroids and CPAP ventilation appears to offer the best supportive treatment with a reduced mortality compared with other treatment regimens.
C1 First Municipal Peoples Hosp Guangzhou, Dept Resp Dis, Guangzhou, Peoples R China.
   First Municipal Peoples Hosp Guangzhou, Dept Lab Med, Guangzhou, Peoples R China.
   Eighth Municipal Peoples Hosp Guangzhou, Guangzhou 510180, Peoples R China.
   Second Affiliated Hosp, Guangzhou Med Coll, Guangzhou 510655, Peoples R China.
   Guangzhou Red Cross Hosp, Guangzhou 510220, Peoples R China.
   Sixth Municipal Peoples Hosp Guangzhou, Guangzhou 510260, Peoples R China.
   Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England.
RP Zhao, Z (reprint author), First Municipal Peoples Hosp Guangzhou, Dept Resp Dis, 1 Panfu Rd, Guangzhou, Peoples R China.
CR BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707
   Chan PKS, 2002, CLIN INFECT DIS, V34, pS58, DOI 10.1086/338820
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Lee SJ, 2002, JPN J INFECT DIS, V55, P157
   PEERS SH, 1990, AM REV RESPIR DIS, V141, pS18
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Saikku Pekka, 1997, Clin Microbiol Infect, V3, P599, DOI 10.1111/j.1469-0691.1997.tb00464.x
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   *WHO, 2003, SEV AC RESP SYNDR PR
   *WHO, 2003, CAS DEF SURV SEV AC
   WILLIAMS TJ, 1990, AM REV RESPIR DIS, V141, pS39
   World Health Organization (WHO), 2003, WKLY EPIDEMIOL REC, V78, P73
   Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9
NR 16
TC 137
Z9 152
U1 2
U2 15
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-2615
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD AUG
PY 2003
VL 52
IS 8
BP 715
EP 720
DI 10.1099/jmm.0.05320-0
PG 6
WC Microbiology
SC Microbiology
GA 712BL
UT WOS:000184776200018
PM 12867568
OA Bronze
DA 2020-04-03
ER

PT J
AU ALBRITTON, LM
   KIM, JW
   TSENG, L
   CUNNINGHAM, JM
AF ALBRITTON, LM
   KIM, JW
   TSENG, L
   CUNNINGHAM, JM
TI ENVELOPE-BINDING DOMAIN IN THE CATIONIC AMINO-ACID TRANSPORTER
   DETERMINES THE HOST RANGE OF ECOTROPIC MURINE RETROVIRUSES
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; LEUKEMIA-VIRUS; CONFERS SUSCEPTIBILITY; MEMBRANE
   RECEPTORS; GENE ENCODES; HUMAN-CELLS; INFECTION; RESISTANT;
   GLYCOPROTEIN; PROTEIN
AB Infection of rodent cells by ecotropic type C retroviruses requires the expression of a cationic amino acid transporter composed of multiple membrane-spanning domains. By exchanging portions of cDNAs encoding the permissive mouse and nonpermissive human transporters and examining their abilities to specify virus infection upon expression in human 293 cells, we have identified the amino acid residues in the extracellular loop connecting the fifth and sixth membrane-spanning segments of the mouse transporter that are required for both envelope gp70 binding and infection. These findings strongly suggest that the role of the mouse transporter in determining infection is to provide an envelope-binding site. This role is analogous to those of host membrane proteins composed of a single membrane-spanning domain that serve as binding proteins or receptors for other enveloped viruses such as human immunodeficiency virus, Epstein-Barr virus, and murine and human coronaviruses.
C1 HARVARD UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115.
   HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115.
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA47075]
CR ALBRITTON LM, 1992, GENOMICS, V12, P430, DOI 10.1016/0888-7543(92)90431-Q
   ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   DELARCO J, 1976, CELL, V8, P365, DOI 10.1016/0092-8674(76)90148-3
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510
   GOUD B, 1988, VIROLOGY, V163, P251, DOI 10.1016/0042-6822(88)90261-9
   KAPLAN G, 1990, SCIENCE, V250, P1596, DOI 10.1126/science.2177226
   KIM JH, UNPUB
   KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0
   KUNKEL TA, 1987, MOL BIOL REP, V1, P1
   LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917
   MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8
   NEDA H, 1991, J BIOL CHEM, V266, P14143
   OHARA B, 1990, CELL GROWTH DIFFER, V1, P119
   ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079
   SCHMIDT J, 1987, AM J PATHOL, V129, P503
   SCHMIDT J, 1984, J GEN VIROL, V65, P2237, DOI 10.1099/0022-1317-65-12-2237
   TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0
   WANG H, 1991, J VIROL, V65, P6468, DOI 10.1128/JVI.65.12.6468-6477.1991
   WILLIAMS DA, 1987, J EXP MED, V166, P210, DOI 10.1084/jem.166.1.210
   WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0
   WILLIAMS RK, 1990, J VIROL, V64, P3817, DOI 10.1128/JVI.64.8.3817-3823.1990
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
NR 24
TC 137
Z9 137
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD APR
PY 1993
VL 67
IS 4
BP 2091
EP 2096
DI 10.1128/JVI.67.4.2091-2096.1993
PG 6
WC Virology
SC Virology
GA KT980
UT WOS:A1993KT98000041
PM 8445722
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU PACHUK, CJ
   BREDENBEEK, PJ
   ZOLTICK, PW
   SPAAN, WJM
   WEISS, SR
AF PACHUK, CJ
   BREDENBEEK, PJ
   ZOLTICK, PW
   SPAAN, WJM
   WEISS, SR
TI MOLECULAR-CLONING OF THE GENE ENCODING THE PUTATIVE POLYMERASE OF MOUSE
   HEPATITIS CORONAVIRUS, STRAIN A59
SO VIROLOGY
LA English
DT Article
C1 UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104.
   STATE UNIV UTRECHT,INST VIROL,DEPT INFECT DIS & IMMUNOL,UTRECHT,NETHERLANDS.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-17418]; NINDS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [NS-21954]
CR ARMSTRONG J, 1983, NUCLEIC ACIDS RES, V11, P883, DOI 10.1093/nar/11.3.883
   Baric R S, 1987, Adv Exp Med Biol, V218, P137
   BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   BARIC RS, 1987, VIROLOGY, V156, P342, DOI 10.1016/0042-6822(87)90414-4
   BARIC RS, 1985, VIRUS RES, V3, P19, DOI 10.1016/0168-1702(85)90038-3
   BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BRAYTON PR, 1982, J VIROL, V42, P847, DOI 10.1128/JVI.42.3.847-853.1982
   BRAYTON PR, 1984, VIROLOGY, V133, P197, DOI 10.1016/0042-6822(84)90439-2
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRINTON MA, 1988, VIROLOGY, V162, P290, DOI 10.1016/0042-6822(88)90468-0
   BUDZILOWICZ CJ, 1985, J VIROL, V53, P834, DOI 10.1128/JVI.53.3.834-840.1985
   DENISON M, 1987, VIROLOGY, V157, P565, DOI 10.1016/0042-6822(87)90303-5
   DENISON MR, 1986, J VIROL, V60, P12, DOI 10.1128/JVI.60.1.12-18.1986
   GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5
   HENIKOFF S, 1983, CELL, V33, P607, DOI 10.1016/0092-8674(83)90441-5
   JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054
   LAI MMC, 1983, J VIROL, V46, P1027, DOI 10.1128/JVI.46.3.1027-1033.1983
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985
   LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033
   LEIBOWITZ JL, 1982, J VIROL, V43, P905, DOI 10.1128/JVI.43.3.905-913.1982
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   LEVIS R, 1986, CELL, V44, P137, DOI 10.1016/0092-8674(86)90492-7
   LOMNICZI B, 1977, J GEN VIROL, V36, P531, DOI 10.1099/0022-1317-36-3-531
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   MAKINO S, 1986, P NATL ACAD SCI USA, V83, P4204, DOI 10.1073/pnas.83.12.4204
   MANAKER RA, 1961, JNCI-J NATL CANCER I, V27, P29
   MANIATIS T, 1982, MOL CLONING
   MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309
   MILLS DR, 1978, CELL, V15, P541, DOI 10.1016/0092-8674(78)90022-3
   RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SHIEH CK, 1987, VIROLOGY, V156, P321, DOI 10.1016/0042-6822(87)90412-0
   SOE LH, 1987, J VIROL, V61, P3968, DOI 10.1128/JVI.61.12.3968-3976.1987
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   SPAAN WJM, 1982, J VIROL, V42, P432, DOI 10.1128/JVI.42.2.432-439.1982
   THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201
   WEISS SR, 1983, J GEN VIROL, V64, P127, DOI 10.1099/0022-1317-64-1-127
   ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2
   ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133
NR 46
TC 137
Z9 139
U1 0
U2 0
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUL
PY 1989
VL 171
IS 1
BP 141
EP 148
DI 10.1016/0042-6822(89)90520-5
PG 8
WC Virology
SC Virology
GA AC609
UT WOS:A1989AC60900017
PM 2545027
DA 2020-04-03
ER

PT J
AU FLEMING, JO
   STOHLMAN, SA
   HARMON, RC
   LAI, MMC
   FRELINGER, JA
   WEINER, LP
AF FLEMING, JO
   STOHLMAN, SA
   HARMON, RC
   LAI, MMC
   FRELINGER, JA
   WEINER, LP
TI ANTIGENIC RELATIONSHIPS OF MURINE CORONAVIRUSES - ANALYSIS USING
   MONOCLONAL-ANTIBODIES TO JHM (MHV-4) VIRUS
SO VIROLOGY
LA English
DT Article
C1 UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90089.
RP FLEMING, JO (reprint author), UNIV SO CALIF,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90089, USA.
RI Lai, Michael M. C./I-7001-2012; Frelinger, Jeffrey A/F-2448-2014
OI Frelinger, Jeffrey A/0000-0002-2503-6267
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA
   22662]; NINDS NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [NS 18146, NS-07149]
CR BAILEY OT, 1949, J EXP MED, V90, P195, DOI 10.1084/jem.90.3.195
   BOND CW, 1979, VIROLOGY, V94, P371, DOI 10.1016/0042-6822(79)90468-9
   CHELEY S, 1981, VIROLOGY, V115, P310, DOI 10.1016/0042-6822(81)90113-6
   CHILDS J, 1983, ARCH VIROL
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   DOEL TR, 1978, J GEN VIROL, V38, P351, DOI 10.1099/0022-1317-38-2-351
   FIELDS BN, 1982, NATURE, V300, P19, DOI 10.1038/300019a0
   FLEMING JO, 1983, J NEUROIMMUNOL, V4, P129, DOI 10.1016/0165-5728(83)90017-6
   GERHARD W, 1981, NATURE, V290, P713, DOI 10.1038/290713a0
   Gledhill A. W., 1955, Veterinary Bulletin, V1, P82
   HARMON RC, 1982, HYBRIDOMAS CANCER DI, P21
   HIERHOLZER JC, 1979, INFECT IMMUN, V24, P508, DOI 10.1128/IAI.24.2.508-522.1979
   HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255
   HOLMES KV, 1982, BIOCH BIOL CORONAVIR, P133
   ISHIDA T, 1978, LAB ANIM SCI, V28, P269
   ISHIDA T, 1978, JPN J VET SCI, V40, P739
   Kessler S W, 1981, Methods Enzymol, V73, P442
   KNOBLER RL, 1982, NATURE, V298, P279, DOI 10.1038/298279a0
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   LAI MMC, 1981, J VIROL, V38, P661, DOI 10.1128/JVI.38.2.661-670.1981
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAVER WG, 1976, VIROLOGY, V70, P105, DOI 10.1016/0042-6822(76)90240-3
   LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709
   MASSALSKI A, 1982, INTERVIROLOGY, V18, P135, DOI 10.1159/000149316
   MCMILLAN M, 1981, J EXP MED, V153, P936, DOI 10.1084/jem.153.4.936
   NIMAN HL, 1982, VIROLOGY, V123, P187, DOI 10.1016/0042-6822(82)90305-1
   NOTTAY BK, 1981, VIROLOGY, V108, P405, DOI 10.1016/0042-6822(81)90448-7
   ROBB JA, 1979, VIROLOGY, V94, P385, DOI 10.1016/0042-6822(79)90469-0
   ROTT R, 1979, ARCH VIROL, V59, P285, DOI 10.1007/BF01317469
   ROWE WP, 1963, P SOC EXP BIOL MED, V112, P161, DOI 10.3181/00379727-112-27980
   STOHLMAN SA, 1981, NEUROLOGY, V31, P38, DOI 10.1212/WNL.31.1.38
   STOHLMAN SA, 1982, J GEN VIROL, V63, P265, DOI 10.1099/0022-1317-63-2-265
   STOHLMAN SA, 1978, ARCH VIROL, V57, P53, DOI 10.1007/BF01315637
   STURMAN LS, 1982, BIOCH BIOL CORONAVIR, P1
   STURMAN LS, 1983, MOL BIOL CORONAVIRUS
   TERMEULEN V, 1982, BIOCH BIOL CORONAVIR
   VIRELIZIER JL, 1975, INFECT IMMUN, V12, P1127, DOI 10.1128/IAI.12.5.1127-1140.1975
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WEGE H, 1981, J GEN VIROL, V54, P67, DOI 10.1099/0022-1317-54-1-67
   WEINER LP, 1973, ARCH NEUROL-CHICAGO, V28, P298, DOI 10.1001/archneur.1973.00490230034003
NR 40
TC 137
Z9 139
U1 0
U2 0
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PY 1983
VL 131
IS 2
BP 296
EP 307
DI 10.1016/0042-6822(83)90498-1
PG 12
WC Virology
SC Virology
GA RY623
UT WOS:A1983RY62300004
PM 6318433
DA 2020-04-03
ER

PT J
AU LUYTJES, W
   STURMAN, LS
   BREDENBEEK, PJ
   CHARITE, J
   VANDERZEIJST, BAM
   HORZINEK, MC
   SPAAN, WJM
AF LUYTJES, W
   STURMAN, LS
   BREDENBEEK, PJ
   CHARITE, J
   VANDERZEIJST, BAM
   HORZINEK, MC
   SPAAN, WJM
TI PRIMARY STRUCTURE OF THE GLYCOPROTEIN-E2 OF CORONAVIRUS MHV-A59 AND
   IDENTIFICATION OF THE TRYPSIN CLEAVAGE SITE
SO VIROLOGY
LA English
DT Article
C1 STATE UNIV UTRECHT, FAC VET, INST VIROL, 3508 TD UTRECHT, NETHERLANDS.
   NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA.
   STATE UNIV UTRECHT, FAC VET, BACTERIOL SECT, 3508 TD UTRECHT, NETHERLANDS.
RI Van der Zeijst, Bernard B.A./A-3847-2013; Van der Zeijst,
   Bernard/AAH-1415-2020
OI Van der Zeijst, Bernard B.A./0000-0001-9316-2161; Van der Zeijst,
   Bernard/0000-0001-9316-2161
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [GM 31698]
CR Armstrong J, 1984, Adv Exp Med Biol, V173, P155
   ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0
   BINNS MM, 1985, J GEN VIROL, V66, P719, DOI 10.1099/0022-1317-66-4-719
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
   BREDENBEEK PJ, 1987, IN PRESS ADV EXP MED
   BUCHMEIER MJ, 1984, VIROLOGY, V132, P261, DOI 10.1016/0042-6822(84)90033-3
   CAVANAGH D, 1986, VIRUS RES, V4, P133, DOI 10.1016/0168-1702(86)90037-7
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   DALZIEL RG, 1986, J VIROL, V59, P463, DOI 10.1128/JVI.59.2.463-471.1986
   DEGROOT RJ, 1987, IN PRESS ADV EXP MED
   DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645
   DOWLING PC, 1983, P NATL ACAD SCI-BIOL, V80, P5213, DOI 10.1073/pnas.80.17.5213
   EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   FLEMING JO, 1986, J VIROL, V58, P869, DOI 10.1128/JVI.58.3.869-875.1986
   FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1
   FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985
   GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737
   GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5
   HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8
   HENDERSON LE, 1979, ANAL BIOCHEM, V93, P153, DOI 10.1016/S0003-2697(79)80058-5
   Hewett-Emmett D., 1982, P357
   HOLMES KC, 1984, ADV EXP MED BIOL, V170, P373
   LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033
   LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426
   MANIATIS T, 1982, MOL CLONING LABORATO
   MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X
   MESSING J, 1983, METHOD ENZYMOL, V101, P20
   NEI M, 1986, MOL BIOL EVOL, V3, P418
   Neuberger A, 1972, GLYCOPROTEINS THEIR, P450
   NIEMANN H, 1981, J MOL BIOL, V153, P993, DOI 10.1016/0022-2836(81)90463-0
   NIESTERS HGM, 1986, VIRUS RES, V5, P253, DOI 10.1016/0168-1702(86)90022-5
   PEACOCK SL, 1981, BIOCHIM BIOPHYS ACTA, V655, P243, DOI 10.1016/0005-2787(81)90014-9
   PFLEIDERER M, 1986, NUCLEIC ACIDS RES, V14, P6338, DOI 10.1093/nar/14.15.6338
   REPP R, 1985, J BIOL CHEM, V260, P5873
   RICARD CS, 1985, J CHROMATOGR, V326, P191, DOI 10.1016/S0021-9673(01)87445-8
   RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3
   ROBERTS C, 1985, FOCUS, V7, P16
   ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHMIDT I, 1987, J GEN VIROL, V68, P47, DOI 10.1099/0022-1317-68-1-47
   SIDDELL S, 1981, J GEN VIROL, V53, P145, DOI 10.1099/0022-1317-53-1-145
   SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761
   SIDDELL SG, 1983, INTERVIROLOGY, V20, P181, DOI 10.1159/000149390
   SKINNER MA, 1983, NUCLEIC ACIDS RES, V11, P5045, DOI 10.1093/nar/11.15.5045
   SMITH HO, 1976, NUCLEIC ACIDS RES, V3, P2387, DOI 10.1093/nar/3.9.2387
   Spaan W, 1984, Adv Exp Med Biol, V173, P173
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217
   STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951
   STURMAN L, 1985, TRENDS BIOCHEM SCI, V10, P17, DOI 10.1016/0968-0004(85)90010-6
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985
   STURMAN LS, 1977, VIROLOGY, V77, P650, DOI 10.1016/0042-6822(77)90489-5
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   STURMAN LS, 1977, VIROLOGY, V77, P637, DOI 10.1016/0042-6822(77)90488-3
   TALBOT PJ, 1985, VIRUS RES, V2, P317, DOI 10.1016/0168-1702(85)90028-0
   VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
NR 59
TC 136
Z9 142
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD DEC
PY 1987
VL 161
IS 2
BP 479
EP 487
DI 10.1016/0042-6822(87)90142-5
PG 9
WC Virology
SC Virology
GA L3032
UT WOS:A1987L303200025
PM 2825419
OA Green Published
DA 2020-04-03
ER

PT J
AU HOLMES, KV
   DOLLER, EW
   STURMAN, LS
AF HOLMES, KV
   DOLLER, EW
   STURMAN, LS
TI TUNICAMYCIN RESISTANT GLYCOSYLATION OF A CORONAVIRUS GLYCOPROTEIN -
   DEMONSTRATION OF A NOVEL TYPE OF VIRAL GLYCOPROTEIN
SO VIROLOGY
LA English
DT Article
C1 NEW YORK STATE DEPT HLTH, DIV LABS & RES, ALBANY, NY 12201 USA.
RP HOLMES, KV (reprint author), UNIFORMED SERV UNIV HLTH SCI, DEPT PATHOL, BETHESDA, MD 20014 USA.
CR ANDREWES C, 1978, VIRUSES VERTEBRATES, P174
   BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2
   BURKE D, 1979, J VIROL, V29, P546, DOI 10.1128/JVI.29.2.546-554.1979
   CASH P, 1980, VIROLOGY, V103, P235, DOI 10.1016/0042-6822(80)90142-7
   CHOPPIN PW, 1980, REV INFECT DIS, V2, P40
   COMPANS RW, 1966, VIROLOGY, V30, P411, DOI 10.1016/0042-6822(66)90119-X
   DIGGELMANN H, 1979, J VIROL, V30, P799, DOI 10.1128/JVI.30.3.799-804.1979
   DOLLER EW, 1980, DIFFERENT INTRACELLU, P267
   ELBEIN AD, 1979, ANNU REV PLANT PHYS, V30, P239, DOI 10.1146/annurev.pp.30.060179.001323
   GARWES DJ, 1979, VIRAL ENTERITIS HUMA
   GHOSH HP, 1980, REV INFECT DIS, V2, P26
   GIBSON R, 1979, J BIOL CHEM, V254, P3600
   HASILIK A, 1980, TRENDS BIOCHEM SCI, V5, P237, DOI 10.1016/S0968-0004(80)80810-3
   Klenk H D, 1980, Curr Top Microbiol Immunol, V90, P19
   LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978
   LEAVITT R, 1977, J BIOL CHEM, V252, P9018
   LEHLE L, 1976, FEBS LETT, V71, P167, DOI 10.1016/0014-5793(76)80922-2
   MACNAUGHTON MR, 1978, FEBS LETT, V94, P191, DOI 10.1016/0014-5793(78)80935-1
   MORRISON TG, 1978, J VIROL, V28, P368, DOI 10.1128/JVI.28.1.368-374.1978
   NAKAMURA K, 1978, VIROLOGY, V84, P303, DOI 10.1016/0042-6822(78)90250-7
   NAKAMURA K, 1978, VIROLOGY, V86, P432, DOI 10.1016/0042-6822(78)90083-1
   NIEMANN H, 1981, BIOCH BIOL CORONAVIR
   OLDEN K, 1978, CELL, V13, P461, DOI 10.1016/0092-8674(78)90320-3
   PIZER LI, 1980, J VIROL, V34, P142, DOI 10.1128/JVI.34.1.142-153.1980
   PREHM P, 1979, J BIOL CHEM, V254, P9669
   ROTHMAN JE, 1978, CELL, V15, P1447, DOI 10.1016/0092-8674(78)90068-5
   ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0
   ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981
   Schwarz RT, 1979, BIOCHEM SOC T, V7, P322, DOI 10.1042/bst0070322
   SCHWARZ RT, 1976, J VIROL, V19, P782, DOI 10.1128/JVI.19.3.782-791.1976
   SCHWARZ RT, 1980, TRENDS BIOCHEM SCI, V5, P65, DOI 10.1016/0968-0004(80)90070-5
   SHARON N, 1981, CHEM ENG NEWS, V59, P21, DOI 10.1021/cen-v059n013.p021
   SHIDA H, 1981, VIROLOGY, V111, P56, DOI 10.1016/0042-6822(81)90653-X
   SIDDELL SG, 1980, J VIROL, V33, P10, DOI 10.1128/JVI.33.1.10-17.1980
   SLOMIANY A, 1978, J BIOL CHEM, V253, P7301
   SPIRO RG, 1974, J BIOL CHEM, V249, P5704
   STAHL PD, 1980, TRENDS BIOCHEM SCI, V5, P194, DOI 10.1016/0968-0004(80)90238-8
   STALLCUP KC, 1981, VIROLOGY, V108, P391, DOI 10.1016/0042-6822(81)90447-5
   STURMAN LS, 1977, VIROLOGY, V77, P650, DOI 10.1016/0042-6822(77)90489-5
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   STURMAN LS, 1977, VIROLOGY, V77, P637, DOI 10.1016/0042-6822(77)90488-3
   STURMAN LS, 1972, INFECT IMMUN, V6, P501, DOI 10.1128/IAI.6.4.501-507.1972
   STURMAN LS, 1981, BIOCH BIOL CORONAVIR
   TAKATSUKI A, 1971, J ANTIBIOT, V24, P215, DOI 10.7164/antibiotics.24.215
   THOMAS DB, 1969, J BIOL CHEM, V244, P5943
   TOMITA M, 1975, P NATL ACAD SCI USA, V72, P2964, DOI 10.1073/pnas.72.8.2964
   TYRRELL DAJ, 1978, INTERVIROLOGY, V10, P321, DOI 10.1159/000148996
   WEGE H, 1978, J GEN VIROL, V41, P217, DOI 10.1099/0022-1317-41-2-217
   WEITZMAN S, 1979, ANAL BIOCHEM, V97, P438, DOI 10.1016/0003-2697(79)90099-X
NR 49
TC 136
Z9 141
U1 1
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PY 1981
VL 115
IS 2
BP 334
EP 344
DI 10.1016/0042-6822(81)90115-X
PG 11
WC Virology
SC Virology
GA MT800
UT WOS:A1981MT80000010
PM 7314449
DA 2020-04-03
ER

PT J
AU Egloff, MP
   Malet, H
   Putics, A
   Heinonen, M
   Dutartre, H
   Frangeul, A
   Gruez, A
   Campanacci, V
   Cambillau, C
   Ziebuhr, J
   Ahola, T
   Canard, B
AF Egloff, Marie-Pierre
   Malet, Helene
   Putics, Akos
   Heinonen, Maarit
   Dutartre, Helene
   Frangeul, Antoine
   Gruez, Arnaud
   Campanacci, Valerie
   Cambillau, Christian
   Ziebuhr, John
   Ahola, Tero
   Canard, Bruno
TI Structural and functional basis for ADP-ribose and poly(ADP-ribose)
   binding by viral macro domains
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SEQUENCE ALIGNMENT; CRYSTAL-STRUCTURE; SARS-CORONAVIRUS; CONSERVED
   DOMAIN; PROTEIN; VIRUS; IDENTIFICATION; TRANSCRIPTION; REPLICATION;
   METABOLITE
AB Macro domains constitute a protein module family found associated with specific histones and proteins involved in chromatin metabolism. In addition, a small number of animal RNA viruses, such as corona- and toroviruses, alphaviruses, and hepatitis E virus, encode macro domains for which, however, structural and functional information is extremely limited. Here, we characterized the macro domains from hepatitis E virus, Semliki Forest virus, and severe acute respiratory syndrome coronavirus (SARS-CoV). The crystal structure of the SARS-CoV macro domain was determined at 1.8-angstrom resolution in complex with ADP-ribose. Information derived from structural, mutational, and sequence analyses suggests a close phylogenetic and, most probably, functional relationship between viral and cellular macro domain homologs. The data revealed that viral macro domains have relatively poor ADP-ribose 1"-phosphohydrolase activities (which were previously proposed to be their biologically relevant function) but bind efficiently free and poly(ADP-ribose) polymerase I-bound poly(ADP-ribose) in vitro. Collectively, these results suggest to further evaluate the role of viral macro domains in host response to viral infection.
C1 Univ Aix Marseille 1, Architecture & Fonct Macromol Biol, ESIL, F-13288 Marseille 9, France.
   Univ Aix Marseille 2, Architecture & Fonct Macromol Biol, ESIL, F-13288 Marseille 9, France.
   Univ Wurzburg, Inst Virol & Immunol, D-97078 Wurzburg, Germany.
   Queens Univ Belfast, Sch Biomed Sci, Ctr Canc Res & Biol, Belfast BT9 7BL, Antrim, North Ireland.
   Univ Helsinki, Inst Biotechnol, Program Cell Biotechnol, Helsinki 00014, Finland.
RP Canard, B (reprint author), CNRS, UMR 6098, Campus de Luminy,Case 925,163 Ave Luminy, F-13288 Marseille 9, France.
EM Bruno.Canard@afmb.univ-mrs.fr
RI Dutartre, Helene/L-7463-2019; Dutartre, Helene/H-8837-2016; Ziebuhr,
   John/G-7669-2015
OI Dutartre, Helene/0000-0002-2682-4302; Dutartre,
   Helene/0000-0002-2682-4302; Canard, Bruno/0000-0003-4924-1991; Ziebuhr,
   John/0000-0002-5741-8825; Campanacci, Valerie/0000-0001-6407-6395;
   Neuvonen, Maarit/0000-0002-7209-3029; MALET, Helene/0000-0002-2834-7386
CR Aguiar RCT, 2005, J BIOL CHEM, V280, P33756, DOI 10.1074/jbc.M505408200
   Allen MD, 2003, J MOL BIOL, V330, P503, DOI 10.1016/S0022-2836(03)00473-X
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   Bick MJ, 2003, J VIROL, V77, P11555, DOI 10.1128/JVI.77.21.11555-11562.2003
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   Cohen SX, 2004, ACTA CRYSTALLOGR D, V60, P2222, DOI 10.1107/S0907444904027556
   Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892
   De I, 2003, J VIROL, V77, P13106, DOI 10.1128/JVI.77.24.13106-13116.2003
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543
   Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276
   GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6
   GORBALENYA AE, 2006, IN PRESS VIRUS RES
   Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305
   Hay S, 2002, J GEN VIROL, V83, P1547, DOI 10.1099/0022-1317-83-7-1547
   HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7
   Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664
   Kumaran D, 2005, PROTEIN SCI, V14, P719, DOI 10.1110/ps.041132005
   Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Malet H, 2006, ACTA CRYSTALLOGR F, V62, P405, DOI 10.1107/S1744309106009274
   Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153
   Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Nargi-Aizenman JL, 2002, VIROLOGY, V293, P164, DOI 10.1006/viro.2001.1253
   Nguewa PA, 2005, PROG BIOPHYS MOL BIO, V88, P143, DOI 10.1016/j.pbiomolbio.2004.01.001
   Otto H, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-139
   PEHRSON JR, 1992, SCIENCE, V257, P1398
   Putics A, 2006, J GEN VIROL, V87, P651, DOI 10.1099/vir.0.81596-0
   Putics A, 2005, J VIROL, V79, P12721, DOI 10.1128/JVI.79.20.12721-12731.2005
   ROUSSEL A, 1991, SILICON GRAPHICS DIR, P97
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Salonen A, 2005, CURR TOP MICROBIOL, V285, P139
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Scovassi AI, 2004, FASEB J, V18, P1487, DOI 10.1096/fj.04-1841rev
   Shull NP, 2005, NUCLEIC ACIDS RES, V33, P650, DOI 10.1093/nar/gki211
   SIDDELL SG, 2005, TOPLEY WILSONS MICRO, P823
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839
   Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
NR 43
TC 135
Z9 143
U1 2
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2006
VL 80
IS 17
BP 8493
EP 8502
DI 10.1128/JVI.00713-06
PG 10
WC Virology
SC Virology
GA 076CL
UT WOS:000239934500019
PM 16912299
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Spiegel, M
   Pichlmair, A
   Martinez-Sobrido, L
   Cros, J
   Garcia-Sastre, A
   Haller, O
   Weber, F
AF Spiegel, M
   Pichlmair, A
   Martinez-Sobrido, L
   Cros, J
   Garcia-Sastre, A
   Haller, O
   Weber, F
TI Inhibition of beta interferon induction by severe acute respiratory
   syndrome coronavirus suggests a two-step model for activation of
   interferon regulatory factor 3
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID DOUBLE-STRANDED-RNA; NONSTRUCTURAL PROTEIN NSS; IRF-3 TRANSCRIPTION
   FACTOR; CREB-BINDING PROTEIN/P300; MOUSE-HEPATITIS-VIRUS;
   VIRAL-DIARRHEA-VIRUS; NF-KAPPA-B; ALPHA/BETA INTERFERON; FEVER VIRUS;
   ANTIVIRAL RESPONSES
AB Severe acute respiratory syndrome (SARS) is caused by a novel coronavirus termed SARS-CoV. We and others have previously shown that the replication of SARS-CoV can be suppressed by exogenously added interferon (IFN), a cytokine which is normally synthesized by cells as a reaction to virus infection. Here, we demonstrate that SARS-CoV escapes IFN-mediated growth inhibition by preventing the induction of IFN-beta. In SARS-CoV-infected cells, no endogenous IFN-beta transcripts and no IFN-beta promoter activity were detected. Nevertheless, the transcription factor interferon regulatory factor 3 (IRF-3), which is essential for IFN-beta promoter activity, was transported from the cytoplasm to the nucleus early after infection with SARS-CoV. However, at a later time point in infection, IRF-3 was again localized in the cytoplasm. By contrast, IRF-3 remained in the nucleus of cells infected with the IFN-inducing control virus Bunyamwera deINSs. Other signs of IRF-3 activation such as hyperphosphorylation, homodimer formation, and recruitment of the coactivator CREB-binding protein (CBP) were found late after infection with the control virus but not with SARS-CoV. Our data suggest that nuclear transport of IRF-3 is an immediate-early reaction to virus infection and may precede its hyperphosphorylation, homodimer formation, and binding to CBP. In order to escape activation of the IFN system, SARS-CoV appears to block a step after the early nuclear transport of IRF-3.
C1 Univ Freiburg, Inst Med Mikrobiol & Hyg, Abt Virol, D-79008 Freiburg, Germany.
   Mt Sinai Sch Med, Dept Microbiol, New York, NY USA.
RP Weber, F (reprint author), Univ Freiburg, Inst Med Mikrobiol & Hyg, Abt Virol, D-79008 Freiburg, Germany.
EM friedemann.weber@uniklinik-freiburg.de
RI Weber, Friedemann/AAB-3425-2019; Spiegel, Martin/H-7843-2019; Cros,
   Jerome/X-7677-2019
OI Cros, Jerome/0000-0002-4935-3865; Garcia-Sastre,
   Adolfo/0000-0002-6551-1827; Weber, Friedemann/0000-0001-9737-337X
CR Aurisicchio L, 2000, J VIROL, V74, P4816, DOI 10.1128/JVI.74.10.4816-4823.2000
   Baigent SJ, 2002, J VIROL, V76, P8979, DOI 10.1128/JVI.76.18.8979-8988.2002
   Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003
   Basler Christopher F, 2002, Int Rev Immunol, V21, P305
   Baudoux P, 1998, ADV EXP MED BIOL, V440, P377
   Billecocq A, 2004, J VIROL, V78, P9798, DOI 10.1128/JVI.78.18.9798-9806.2004
   Bossert B, 2003, J VIROL, V77, P8661, DOI 10.1128/JVI.77.16.8661-8668.2003
   Bouloy M, 2001, J VIROL, V75, P1371, DOI 10.1128/JVI.75.3.1371-1377.2001
   Chang JB, 2003, ANN VASC SURG, V17, P323, DOI 10.1007/s10016-001-0249-7
   CHARLEY B, 1988, J VIROL, V62, P8, DOI 10.1128/JVI.62.1.8-11.1988
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912
   Deonarain R, 2000, J VIROL, V74, P3404, DOI 10.1128/JVI.74.7.3404-3409.2000
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Erlandsson L, 1998, CURR BIOL, V8, P223, DOI 10.1016/S0960-9822(98)70086-7
   Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Fridell RA, 1996, P NATL ACAD SCI USA, V93, P4421, DOI 10.1073/pnas.93.9.4421
   Fuchizaki U, 2003, J MED VIROL, V69, P188, DOI 10.1002/jmv.10286
   Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508
   Garcia-Sastre A, 2001, VIROLOGY, V279, P375, DOI 10.1006/viro.2000.0756
   Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Hagmaier K, 2003, J VIROL, V77, P2747, DOI 10.1128/JVI.77.4.2747-2752.2003
   He B, 2002, VIROLOGY, V303, P15, DOI 10.1006/viro.2002.1738
   Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360
   IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887
   Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x
   Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837
   Kawamoto SI, 2003, J VIROL, V77, P9622, DOI 10.1128/JVI.77.17.9622-9631.2003
   Kohl A, 2003, J VIROL, V77, P7999, DOI 10.1128/JVI.77.14.7999-8008.2003
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Kumar KS, 2000, WIND STRUCT, V3, P1
   Le May N, 2004, CELL, V116, P541, DOI 10.1016/S0092-8674(04)00132-1
   Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7
   Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998
   Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986
   Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937
   Lubyova B, 2000, J VIROL, V74, P8194, DOI 10.1128/JVI.74.17.8194-8201.2000
   Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660
   Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200
   Pei JW, 2001, J INTERF CYTOK RES, V21, P1071, DOI 10.1089/107999001317205204
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Poole E, 2002, VIROLOGY, V303, P33, DOI 10.1006/viro.2002.1737
   Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061
   Ruggli N, 2003, J VIROL, V77, P7645, DOI 10.1128/JVI.77.13.7645-7654.2003
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714
   Schweizer M, 2001, J VIROL, V75, P4692, DOI 10.1128/JVI.75.10.4692-4698.2001
   Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200
   Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200
   Sharmasarkar FC, 2000, J SUSTAIN AGR, V17, P17
   Spies JJ, 2000, BOTHALIA, V30, P211
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200
   Sun HY, 2003, LANCET, V362, P2025, DOI 10.1016/S0140-6736(03)15036-2
   Thomas D, 2004, J BIOL CHEM, V279, P31471, DOI 10.1074/jbc.M400938200
   van Pesch V, 2001, J VIROL, V75, P7811, DOI 10.1128/JVI.75.17.7811-7817.2001
   Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9
   Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359
   Weber F, 2003, J INTERF CYTOK RES, V23, P209, DOI 10.1089/107999003765027410
   Weber F, 2002, J VIROL, V76, P7949, DOI 10.1128/JVI.76.16.7949-7955.2002
   *WHO, 2003, SUMM TAB SARS COUNTR
   Xiang Y, 2002, J VIROL, V76, P5251, DOI 10.1128/JVI.76.10.5251-5259.2002
   Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087
   Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087
   Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998
   Zoll J, 2002, J VIROL, V76, P9664, DOI 10.1128/JVI.76.19.9664-9672.2002
NR 74
TC 135
Z9 155
U1 2
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD FEB
PY 2005
VL 79
IS 4
BP 2079
EP 2086
DI 10.1128/JVI.79.4.2079-2086.2005
PG 8
WC Virology
SC Virology
GA 894DZ
UT WOS:000226772100011
PM 15681410
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Sirois, S
   Wei, DQ
   Du, QS
   Chou, KC
AF Sirois, S
   Wei, DQ
   Du, QS
   Chou, KC
TI Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore
   pointst
SO JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES
LA English
DT Article
ID CORONAVIRUS MAIN PROTEINASE; TERTIARY STRUCTURE; PREDICTION; DOMAINS;
   COMPLEX; DESIGN; DRUGS; MODEL
AB Pharmacophore modeling can provide valuable insight into ligand-receptor interactions. It can also be used in 3D (dimensional) database searching for potentially finding biologically active compounds and providing new research ideas and directions for drug-discovery projects. To stimulate the structure-based drug design against SARS (severe acute respiratory syndrome), a pharmacophore search was conducted over 3.6 millions of compounds based on the atomic coordinates of the complex obtained by docking KZ7088 (a derivative of AG7088) to SARS CoV M-pro (coronavirus main proteinase), as reportedly recently (Chou, K. C.; Wei, D. Q.; Zhong, W. Z. Biochem. Biophys. Res. Commun. 2003, 308, 148-151). It has been found that, of the 3.6 millions of compounds screened, 0.07% are with the score satisfying five of the six pharmacophore points. Moreover, each of the hit compounds has been evaluated for duggability according to 13 metrics based on physical, chemical, and structural properties. Of the 0.07% compounds thus retrieved, 17% have a perfect score of 1.0; while 23% with one druggable rule violation, 13% two violations, and 47% more than two violations. If the criterion for druggability is set at a maximum allowance of two rule violations, we obtain that only about 0.03% of the compounds screened are worthy of further tests by experiments. These findings will significantly narrow down the search scope for potential compounds, saving substantial time and money. Finally, the featured templates derived from the current study will also be very useful for guiding the design and synthesis of effective drugs for SARS therapy.
C1 Tianjin Normal Univ, Tianjin 300074, Peoples R China.
   Tianjin Inst Bioinformat & Drug Discovery, Tianjin 300074, Peoples R China.
   Univ Quebec, Dept Chim, Montreal, PQ H3C 3P8, Canada.
   Inst Technol Montreal, Montreal, PQ H3W 3C3, Canada.
   Gordon Life Sci Inst, San Diego, CA 92130 USA.
   Concordia Univ, Ctr Res Mol Modeling, Montreal, PQ, Canada.
RP Chou, KC (reprint author), Tianjin Normal Univ, Tianjin 300074, Peoples R China.
EM kchou@san.rr.com
RI Chou, Kuo-Chen/A-8340-2009
CR Ajay, 1998, J MED CHEM, V41, P3314, DOI 10.1021/jm970666c
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   BAURIN N, 2002, ETUDE DEV TECHNIQUES
   Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3
   Chou JJ, 2001, NAT STRUCT BIOL, V8, P990, DOI 10.1038/nsb1101-990
   Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8
   Chou KC, 2003, BIOCHEM BIOPH RES CO, V308, P148, DOI 10.1016/S0006-291X(03)01342-1
   CHOU KC, 1995, FEBS LETT, V363, P123, DOI 10.1016/0014-5793(95)00240-A
   Chou KC, 1999, BIOCHEM BIOPH RES CO, V259, P420, DOI 10.1006/bbrc.1999.0792
   Chou KC, 2000, FEBS LETT, V470, P249, DOI 10.1016/S0014-5793(00)01333-8
   Chou KC, 2003, BIOCHEM BIOPH RES CO, V310, P675, DOI 10.1016/j.bbrc.2003.09.053
   Chou KC, 2002, BIOCHEM BIOPH RES CO, V292, P702, DOI 10.1006/bbrc.2002.6686
   Lipinski CA, 2000, J PHARMACOL TOXICOL, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Oba Y, 2003, NEW ENGL J MED, V348, P2034
   Oprea TI, 2000, J COMPUT AID MOL DES, V14, P251, DOI 10.1023/A:1008130001697
   Richards WG, 2002, NAT REV DRUG DISCOV, V1, P551, DOI 10.1038/nrd841
   Rishton GM, 2003, DRUG DISCOV TODAY, V8, P86, DOI 10.1016/S1359644602025722
   Rishton GM, 1997, DRUG DISCOV TODAY, V2, P382, DOI 10.1016/S1359-6446(97)01083-0
   Sadowski J, 1998, J MED CHEM, V41, P3325, DOI 10.1021/jm9706776
   *WDI, WORLD DRUG IND
   Wildman SA, 1999, J CHEM INF COMP SCI, V39, P868, DOI 10.1021/ci990307l
   Xu J, 2000, J CHEM INF COMP SCI, V40, P1177, DOI 10.1021/ci000026+
NR 22
TC 135
Z9 140
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0095-2338
J9 J CHEM INF COMP SCI
JI J. Chem. Inf. Comput. Sci.
PD MAY-JUN
PY 2004
VL 44
IS 3
BP 1111
EP 1122
DI 10.1021/ci034270n
PG 12
WC Chemistry, Multidisciplinary; Computer Science, Information Systems;
   Computer Science, Interdisciplinary Applications
SC Chemistry; Computer Science
GA 823JQ
UT WOS:000221608000038
PM 15154780
DA 2020-04-03
ER

PT J
AU WANG, PH
   KECK, JG
   LIEN, EJ
   LAI, MMC
AF WANG, PH
   KECK, JG
   LIEN, EJ
   LAI, MMC
TI DESIGN, SYNTHESIS, TESTING, AND QUANTITATIVE STRUCTURE ACTIVITY
   RELATIONSHIP ANALYSIS OF SUBSTITUTED SALICYLALDEHYDE SCHIFF-BASES OF
   1-AMINO-3-HYDROXYGUANIDINE TOSYLATE AS NEW ANTIVIRAL AGENTS AGAINST
   CORONAVIRUS
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
C1 UNIV SO CALIF,SCH PHARM,BIOMED CHEM SECT,LOS ANGELES,CA 90033.
   UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033.
RI Lai, Michael M. C./I-7001-2012
CR ADAMSON RH, 1972, NATURE, V236, P400, DOI 10.1038/236400a0
   ANDERSON LJ, 1983, MED CLIN N AM, V67, P1009, DOI 10.1016/S0025-7125(16)31164-6
   AULD DS, 1975, BIOCHEM BIOPH RES CO, V62, P296, DOI 10.1016/S0006-291X(75)80137-9
   BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001
   BOSCHKE FL, 1984, TOP CURR CHEM, V114, P58
   BRAYTON PR, 1982, J VIROL, V42, P847, DOI 10.1128/JVI.42.3.847-853.1982
   CARTER WA, 1973, SELECTIVE INHIBITORS, P213
   CORY JG, 1985, BIOCHEM PHARMACOL, V34, P2645, DOI 10.1016/0006-2952(85)90561-1
   CORY JG, 1981, ADV ENZYME REGUE, V47, P975
   DOMINGO E, 1988, RNA DIRECTED VIRUS R, V1, P116
   DRACH JC, 1981, ANNU REP MED CHEM, V16, P149
   Finny D. J., 1947, PROBIT ANAL, P20
   GANAPIN AC, 1973, VIOLOGY, V52, P264
   Hansch C., 1979, SUBSTITUENT CONSTANT
   KECK JG, 1989, VIRUS RES, V14, P57, DOI 10.1016/0168-1702(89)90069-5
   KELLEY JL, 1984, ANNU REP MED CHEM, V19, P117
   KRAKOFF IH, 1975, HDB EXPT PHARM 2, V38, P789
   LAI MMC, 1987, ADV EXPT MED BIOL CO, V218, P175
   LEIBOWITZ JL, 1988, VIROLOGY, V166, P66, DOI 10.1016/0042-6822(88)90147-X
   LENNETTE EH, 1981, B WORLD HEALTH ORGAN, V59, P305
   LEVINSON W, 1973, P NATL ACAD SCI USA, V70, P164, DOI 10.1073/pnas.70.1.164
   LIEN EJ, 1982, J PHARM SCI, V71, P641, DOI 10.1002/jps.2600710611
   LIEN EJ, 1989, ACTA PHARM JUGOSL, V39, P87
   LIEN EJ, 1987, SAR SIDE EFFECTS DRU, P163
   MAGEE PS, 1982, 5TH P INT C PEST CHE, V1, P251
   MCCLELLAN AC, 1979, TABLES EXPT DIPOLE M, V2
   Miller LC, 1944, P SOC EXP BIOL MED, V57, P261
   MOORE EC, 1970, BIOCHEMISTRY-US, V9, P44
   MOORE EC, 1971, CANCER RES, V31, P325
   SARTORELLI AC, 1971, BIOCHEM PHARMACOL, V20, P3119, DOI 10.1016/0006-2952(71)90116-X
   SIGEL H, 1973, MET IONS BIOL SYST, V16, P245
   STURMAN LS, 1985, J VIROL, V56, P905
   SWALLOW W, 1977, ANN NY ACAD SCI, V284, P385
   TAI AW, 1984, J MED CHEM, V27, P236, DOI 10.1021/jm00368a024
   TANG A, 1985, J MED CHEM, V28, P1103, DOI 10.1021/jm00146a022
   WECKBECKER G, 1988, J NATL CANCER I, V80, P491, DOI 10.1093/jnci/80.7.491
   WECKBECKER G, 1987, CANCER RES, V47, P975
NR 37
TC 135
Z9 137
U1 2
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD FEB
PY 1990
VL 33
IS 2
BP 608
EP 614
DI 10.1021/jm00164a023
PG 7
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CK744
UT WOS:A1990CK74400023
PM 2153821
DA 2020-04-03
ER

PT J
AU Corman, VM
   Ithete, NL
   Richards, LR
   Schoeman, MC
   Preiser, W
   Drosten, C
   Drexler, JF
AF Corman, Victor Max
   Ithete, Ndapewa Laudika
   Richards, Leigh Rosanne
   Schoeman, M. Corrie
   Preiser, Wolfgang
   Drosten, Christian
   Drexler, Jan Felix
TI Rooting the Phylogenetic Tree of Middle East Respiratory Syndrome
   Coronavirus by Characterization of a Conspecific Virus from an African
   Bat
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MERS-CORONAVIRUS; SAUDI-ARABIA; ANTIBODIES; SEQUENCE; RESERVOIRS;
   CAMELS; 2C
AB The emerging Middle East respiratory syndrome coronavirus (MERS-CoV) causes lethal respiratory infections mainly on the Arabian Peninsula. The evolutionary origins of MERS-CoV are unknown. We determined the full genome sequence of a CoV directly from fecal material obtained from a South African Neoromicia capensis bat (NeoCoV). NeoCoV shared essential details of genome architecture with MERS-CoV. Eighty-five percent of the NeoCoV genome was identical to MERS-CoV at the nucleotide level. Based on taxonomic criteria, NeoCoV and MERS-CoV belonged to one viral species. The presence of a genetically divergent S1 subunit within the NeoCoV spike gene indicated that intraspike recombination events may have been involved in the emergence of MERS-CoV. NeoCoV constitutes a sister taxon of MERS-CoV, placing the MERS-CoV root between a recently described virus from African camels and all other viruses. This suggests a higher level of viral diversity in camels than in humans. Together with serologic evidence for widespread MERS-CoV infection in camelids sampled up to 20 years ago in Africa and the Arabian Peninsula, the genetic data indicate that camels act as sources of virus for humans rather than vice versa. The majority of camels on the Arabian Peninsula is imported from the Greater Horn of Africa, where several Neoromicia species occur. The acquisition of MERS-CoV by camels from bats might have taken place in sub-Saharan Africa. Camelids may represent mixing vessels for MERS-CoV and other mammalian CoVs.
   IMPORTANCE
   It is unclear how, when, and where the highly pathogenic MERS-CoV emerged. We characterized the full genome of an African bat virus closely related to MERS-CoV and show that human, camel, and bat viruses belong to the same viral species. The bat virus roots the phylogenetic tree of MERS-CoV, providing evidence for an evolution of MERS-CoV in camels that preceded that in humans. The revised tree suggests that humans are infected by camels rather than vice versa. Although MERS-CoV cases occur mainly on the Arabian Peninsula, the data from this study together with serologic and molecular investigations of African camels indicate that the initial host switch from bats may have taken place in Africa. The emergence of MERS-CoV likely involved exchanges of genetic elements between different viral ancestors. These exchanges may have taken place either in bat ancestors or in camels acting as mixing vessels for viruses from different hosts.
C1 [Corman, Victor Max; Drosten, Christian; Drexler, Jan Felix] Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
   [Ithete, Ndapewa Laudika; Preiser, Wolfgang] Univ Stellenbosch, Natl Hlth Lab Serv, Div Med Virol, ZA-7505 Tygerberg, South Africa.
   [Richards, Leigh Rosanne] Durban Nat Sci Museum, Durban, South Africa.
   [Schoeman, M. Corrie] Univ KwaZulu Natal, Sch Life Sci, Durban, South Africa.
   [Corman, Victor Max] German Ctr Infect Res DZIF, Bonn, Germany.
RP Drosten, C (reprint author), Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
EM drosten@virology-bonn.de; drexler@virology-bonn.de
RI Schoeman, Corrie/G-2616-2010; Preiser, Wolfgang/J-4875-2016; Corman,
   Victor Max/K-1319-2019
OI Preiser, Wolfgang/0000-0002-0254-7910; Corman, Victor
   Max/0000-0002-3605-0136; Drexler, Jan Felix/0000-0002-3509-0232; Ithete,
   Ndapewa/0000-0003-4814-0240
FU European Union FP7 project EMPERIE [223498]; National Health Laboratory
   Service Research Trust; South African National Research
   FoundationNational Research Foundation - South Africa; German Research
   FoundationGerman Research Foundation (DFG) [KR1293/13-1, KR1293/9-1];
   European Union FP7 project ANTIGONE [278976]
FX This study was supported by funds from European Union FP7 projects
   EMPERIE (contract number 223498) and ANTIGONE (contract number 278976)
   granted to C.D. and by funds from the National Health Laboratory Service
   Research Trust, the South African National Research Foundation, and the
   German Research Foundation (project numbers KR1293/13-1 and KR1293/9-1)
   granted to W.P.
CR Aburizaiza AS, 2014, J INFECT DIS, V209, P243, DOI 10.1093/infdis/jit589
   Alagaili AN, 2014, MBIO, V5, DOI 10.1128/mBio.00884-14
   Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Bosch BJ, 2013, CELL RES, V23, P1069, DOI 10.1038/cr.2013.108
   Chu DKW, 2014, EMERG INFECT DIS, V20, P1049, DOI 10.3201/eid2006.140299
   Corman VM, 2014, EMERG INFECT DIS, V20, P1319, DOI 10.3201/eid2008.140596
   Corman VM, 2014, J VIROL, V88, P717, DOI 10.1128/JVI.01600-13
   Crossley BM, 2012, VIRUSES-BASEL, V4, P3689, DOI 10.3390/v4123689
   De Benedictis P, 2014, VIRUS GENES, V48, P366, DOI 10.1007/s11262-013-1008-x
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   de Groot RJ, 2012, VIRUS TAXONOMY, P806
   Drexler JF, 2014, ANTIVIR RES, V101, P45, DOI 10.1016/j.antiviral.2013.10.013
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gierer S, 2013, EMERG INFECT DIS, V19, P2034, DOI 10.3201/eid1912.130701
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Jin L, 2007, VIROLOGY, V365, P198, DOI 10.1016/j.virol.2007.03.035
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Lauber C, 2012, J VIROL, V86, P3890, DOI 10.1128/JVI.07173-11
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Ma W, 2009, ZOONOSES PUBLIC HLTH, V56, P326, DOI 10.1111/j.1863-2378.2008.01217.x
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Monadjem A., 2010, BATS SO CENTRAL AFRI
   Niemeyer D, 2013, J VIROL, V87, P12489, DOI 10.1128/JVI.01845-13
   Reusken CB, AFRICA EMERG INFECT, V20, P1370
   Reusken CBEM, 2010, VECTOR-BORNE ZOONOT, V10, P785, DOI 10.1089/vbz.2009.0173
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Simmonds Peter, 2012, BMC Res Notes, V5, P50, DOI 10.1186/1756-0500-5-50
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Wertheim JO, 2013, J VIROL, V87, P7039, DOI 10.1128/JVI.03273-12
   WHO, 2014, MERS COV UPD 16 SUMM
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 37
TC 134
Z9 139
U1 5
U2 71
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD OCT
PY 2014
VL 88
IS 19
BP 11297
EP 11303
DI 10.1128/JVI.01498-14
PG 7
WC Virology
SC Virology
GA AP1ZX
UT WOS:000341872700026
PM 25031349
OA Green Published, Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Paul, D
   Hoppe, S
   Saher, G
   Krijnse-Locker, J
   Bartenschlager, R
AF Paul, David
   Hoppe, Simone
   Saher, Gesine
   Krijnse-Locker, Jacomine
   Bartenschlager, Ralf
TI Morphological and Biochemical Characterization of the Membranous
   Hepatitis C Virus Replication Compartment
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID OXYSTEROL-BINDING PROTEIN; RNA REPLICATION; NONSTRUCTURAL PROTEINS; NS4B
   PROTEIN; COMPLEX; LOCALIZATION; ASSOCIATION; NS5A; IDENTIFICATION;
   DETERMINANT
AB Like all other positive-strand RNA viruses, hepatitis C virus (HCV) induces rearrangements of intracellular membranes that are thought to serve as a scaffold for the assembly of the viral replicase machinery. The most prominent membranous structures present in HCV-infected cells are double-membrane vesicles (DMVs). However, their composition and role in the HCV replication cycle are poorly understood. To gain further insights into the biochemcial properties of HCV-induced membrane alterations, we generated a functional replicon containing a hemagglutinin (HA) affinity tag in nonstructural protein 4B (NS4B), the supposed scaffold protein of the viral replication complex. By using HA-specific affinity purification we isolated NS4B-containing membranes from stable replicon cells. Complementing biochemical and electron microscopy analyses of purified membranes revealed predominantly DMVs, which contained viral proteins NS3 and NS5A as well as enzymatically active viral replicase capable of de novo synthesis of HCV RNA. In addition to viral factors, co-opted cellular proteins, such as vesicle-associated membrane protein-associated protein A (VAP-A) and VAP-B, that are crucial for viral RNA replication, as well as cholesterol, a major structural lipid of detergent-resistant membranes, are highly enriched in DMVs. Here we describe the first isolation and biochemical characterization of HCV-induced DMVs. The results obtained underline their central role in the HCV replication cycle and suggest that DMVs are sites of viral RNA replication. The experimental approach described here is a powerful tool to more precisely define the molecular composition of membranous replication factories induced by other positive-strand RNA viruses, such as picorna-, arteri- and coronaviruses.
C1 [Paul, David; Hoppe, Simone; Krijnse-Locker, Jacomine; Bartenschlager, Ralf] Heidelberg Univ, Dept Infect Dis, Heidelberg, Germany.
   [Hoppe, Simone; Krijnse-Locker, Jacomine] Heidelberg Univ, Electron Microscopy Core Facil, Heidelberg, Germany.
   [Saher, Gesine] Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany.
RP Bartenschlager, R (reprint author), Heidelberg Univ, Dept Infect Dis, Heidelberg, Germany.
EM david_paul@med.uni-heidelberg.de;
   ralf_bartenschlager@med.uni-heidelberg.de
RI Locker, Jacomine Krijnse/E-1009-2016; Bartenschlager, Ralf/L-2582-2015
OI Bartenschlager, Ralf/0000-0001-5601-9307; Paul,
   David/0000-0002-6652-331X
FU Deutsche Forschungsgemeinschaft (Teilprojekt 13) [SFB/TRR 83]
FX This work was supported by a grant from the Deutsche
   Forschungsgemeinschaft (SFB/TRR 83, Teilprojekt 13).
CR Alvisi G, 2011, RNA BIOL, V8, P258, DOI 10.4161/rna.8.2.15011
   Amarilio R, 2005, J BIOL CHEM, V280, P5934, DOI 10.1074/jbc.M409566200
   Arumugaswami V, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000182
   Bartenschlager R, 2004, ADV VIRUS RES, V63, P71, DOI 10.1016/S0065-3527(04)63002-8
   Belov GA, 2012, CURR OPIN VIROL, V2, P740, DOI 10.1016/j.coviro.2012.09.006
   Belov GA, 2012, J VIROL, V86, P302, DOI 10.1128/JVI.05937-11
   Bianco A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002576
   BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8
   Blight KJ, 2011, J VIROL, V85, P8158, DOI 10.1128/JVI.00858-11
   Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002
   Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972
   de Saint-Jean M, 2011, J CELL BIOL, V195, P965, DOI 10.1083/jcb.201104062
   den Boon JA, 2010, ANNU REV MICROBIOL, V64, P241, DOI 10.1146/annurev.micro.112408.134012
   Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002
   El-Hage N, 2003, J GEN VIROL, V84, P2761, DOI 10.1099/vir.0.19305-0
   Elazar M, 2004, J VIROL, V78, P11393, DOI 10.1128/JVI.78.20.11393-11400.2004
   Evans MJ, 2004, P NATL ACAD SCI USA, V101, P13038, DOI 10.1073/pnas.0405152101
   Ferraris P, 2013, CELL MOL LIFE SCI, V70, P1297, DOI 10.1007/s00018-012-1213-0
   Ferraris P, 2010, J GEN VIROL, V91, P2230, DOI 10.1099/vir.0.022186-0
   Friebe P, 2005, J VIROL, V79, P380, DOI 10.1128/JVI.79.1.380-392.2005
   Gao L, 2004, J VIROL, V78, P3480, DOI 10.1128/JVI.78.7.3480-3488.2004
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Gouttenoire J, 2010, J VIROL, V84, P12529, DOI 10.1128/JVI.01798-10
   Gouttenoire J, 2010, REV MED VIROL, V20, P117, DOI 10.1002/rmv.640
   Gouttenoire J, 2009, J VIROL, V83, P6257, DOI 10.1128/JVI.02663-08
   Gretton SN, 2005, J GEN VIROL, V86, P1415, DOI 10.1099/vir.0.80768-0
   Hagemeijer MC, 2012, J VIROL, V86, P5808, DOI 10.1128/JVI.07207-11
   Hamamoto I, 2005, J VIROL, V79, P13473, DOI 10.1128/JVI.79.21.13473-13482.2005
   Horscroft Nigel, 2005, Antiviral Chemistry & Chemotherapy, V16, P1
   Hsu NY, 2010, CELL, V141, P799, DOI 10.1016/j.cell.2010.03.050
   Jirasko V, 2008, J BIOL CHEM, V283, P28546, DOI 10.1074/jbc.M803981200
   Jirasko V, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001233
   Jones CT, 2007, J VIROL, V81, P8374, DOI 10.1128/JVI.00690-07
   Jones DM, 2009, J VIROL, V83, P2163, DOI 10.1128/JVI.01885-08
   Kato H, 2011, IMMUNOL REV, V243, P91, DOI 10.1111/j.1600-065X.2011.01052.x
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Kopek BG, 2007, PLOS BIOL, V5, P2022, DOI 10.1371/journal.pbio.0050220
   Kujala P, 1999, J VIROL, V73, P7805, DOI 10.1128/JVI.73.9.7805-7811.1999
   Kujala P, 2001, J VIROL, V75, P3873, DOI 10.1128/JVI.75.8.3873-3884.2001
   Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x
   Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201
   Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110
   Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997
   Lundin M, 2003, J VIROL, V77, P5428, DOI 10.1128/JVI.77.9.5428-5438.2003
   Lundin M, 2006, J GEN VIROL, V87, P3263, DOI 10.1099/vir.0.82211-0
   Merz A, 2011, J BIOL CHEM, V286, P3018, DOI 10.1074/jbc.M110.175018
   Miyanari Y, 2003, J BIOL CHEM, V278, P50301, DOI 10.1074/jbc.M305684200
   Mobius W, 2002, J HISTOCHEM CYTOCHEM, V50, P43
   Nagy PD, 2012, NAT REV MICROBIOL, V10, P137, DOI 10.1038/nrmicro2692
   Ngo MH, 2010, BIOCHEM J, V429, P13, DOI 10.1042/BJ20100263
   Paul David, 2013, World J Virol, V2, P32, DOI 10.5501/wjv.v2.i2.32
   Paul D, 2011, J VIROL, V85, P6963, DOI 10.1128/JVI.00502-11
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Pietschmann T, 2006, P NATL ACAD SCI USA, V103, P7408, DOI 10.1073/pnas.0504877103
   Quinkert D, 2005, J VIROL, V79, P13594, DOI 10.1128/JVI.79.21.13594-13605.2005
   Reiss S, 2011, CELL HOST MICROBE, V9, P32, DOI 10.1016/j.chom.2010.12.002
   Romero-Brey I, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003056
   Sarrazin C, 2012, J HEPATOL, V56, pS88, DOI 10.1016/S0168-8278(12)60010-5
   Schaller T, 2007, J VIROL, V81, P4591, DOI 10.1128/JVI.02144-06
   Schwartz M, 2002, MOL CELL, V9, P505, DOI 10.1016/S1097-2765(02)00474-4
   Shi ST, 2003, J VIROL, V77, P4160, DOI 10.1128/JVI.77.7.4160-4168.2003
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   Steinmann E, 2008, J VIROL, V82, P7034, DOI 10.1128/JVI.00118-08
   Steinmann E, 2007, PLOS PATHOG, V3, P962, DOI 10.1371/journal.ppat.0030103
   van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330
   VANREGENMORTEL MHV, 2000, 7 INT COMM TAX VIR
   Vermehren J, 2012, J VIRAL HEPATITIS, V19, P120, DOI 10.1111/j.1365-2893.2011.01449.x
   Vieyres G, 2013, J VIROL, V87, P1664, DOI 10.1128/JVI.02782-12
   von Hahn T, 2011, DISCOV MED, V12, P237
   Wyles JP, 2002, J BIOL CHEM, V277, P29908, DOI 10.1074/jbc.M201191200
NR 70
TC 134
Z9 135
U1 0
U2 37
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD OCT
PY 2013
VL 87
IS 19
BP 10612
EP 10627
DI 10.1128/JVI.01370-13
PG 16
WC Virology
SC Virology
GA 214WV
UT WOS:000324169200017
PM 23885072
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Huang, IC
   Bosch, BJ
   Li, F
   Li, WH
   Lee, KH
   Ghiran, S
   Vasilieva, N
   Dermody, TS
   Harrison, SC
   Dormitzer, PR
   Farzan, M
   Rottier, PJM
   Choe, H
AF Huang, IC
   Bosch, BJ
   Li, F
   Li, WH
   Lee, KH
   Ghiran, S
   Vasilieva, N
   Dermody, TS
   Harrison, SC
   Dormitzer, PR
   Farzan, M
   Rottier, PJM
   Choe, H
TI SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L
   to infect ACE2-expressing cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ACUTE-RESPIRATORY-SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; SPIKE
   GLYCOPROTEIN; RECEPTOR SPECIFICITY; FUNCTIONAL RECEPTOR; TISSUE
   DISTRIBUTION; REOVIRUS INFECTION; AMINOPEPTIDASE-N; YOUNG-CHILDREN;
   TRACT DISEASE
AB Viruses require specific cellular receptors to infect their target cells. Angiotensin-converting enzyme 2 ( ACE2) is a cellular receptor for two divergent coronaviruses, SARS coronavirus (SARS-CoV) and human coronavirus NL63 (HCoV-NL63). In addition to host-cell receptors, lysosomal cysteine proteases are required for productive infection by some viruses. Here we show that SARS-CoV, but not HCoV-NL63, utilizes the enzymatic activity of the cysteine protease cathepsin L to infect ACE2-expressing cells. Inhibitors of cathepsin L blocked infection by SARS-CoV and by a retrovirus pseudotyped with the SARS-CoV spike ( S) protein but not infection by HCoV-NL63 or a retrovirus pseudotyped with the HCoV-NL63 S protein. Expression of exogenous cathepsin L substantially enhanced infection mediated by the SARS-CoV S protein and by filovirus GP proteins but not by the HCoV-NL63 S protein or the vesicular stomatitis virus G protein. Finally, an inhibitor of endosomal acidification had substantially less effect on infection mediated by the HCoV-NL63 S protein than on that mediated by the SARS-CoV S protein. Our data indicate that two coronaviruses that utilize a common receptor nonetheless enter cells through distinct mechanisms.
C1 Univ Utrecht, Div Virol, Dept Infect Dis & Immunol, Fac Vet Med, NL-3584 CL Utrecht, Netherlands.
   Univ Utrecht, Biomembrane Inst, NL-3584 CL Utrecht, Netherlands.
   Harvard Univ, Sch Med, Div Pulm, Childrens Hosp, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, New England Reg Primate Res Ctr, Southborough, MA 01772 USA.
   Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA.
RP Rottier, PJM (reprint author), Univ Utrecht, Div Virol, Dept Infect Dis & Immunol, Fac Vet Med, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.
EM p.j.m.rottier@vet.uu.nl; hyeryun.choe@childrens.harvard.edu
OI Li, Wenhui/0000-0003-1305-7404; Farzan, Michael/0000-0002-2990-5319
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI43891, AI0616101]
CR Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999
   Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656
   Chandran K, 2003, J VIROL, V77, P13361, DOI 10.1128/JVI.77.24.13361-13375.2003
   Chandran K, 2002, J VIROL, V76, P9920, DOI 10.1128/JVI.76.19.9920-9933.2002
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Ebert DH, 2002, J BIOL CHEM, V277, P24609, DOI 10.1074/jbc.M201107200
   Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289
   Esper F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Golden JW, 2004, J BIOL CHEM, V279, P8547, DOI 10.1074/jbc.M309758200
   Golden JW, 2002, J VIROL, V76, P7430, DOI 10.1128/JVI.76.15.7430-7443.2002
   Guan Y, 2004, LANCET, V363, P99, DOI 10.1016/S0140-6736(03)15259-2
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   HOLMES KV, 1993, ADV EXP MED BIOL, V342, P261
   Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618
   Jane-Valbuena J, 2002, J VIROL, V76, P5184, DOI 10.1128/JVI.76.10.5184-5197.2002
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745
   Moes E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-6
   Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004
   Odegard AL, 2003, J VIROL, V77, P5389, DOI 10.1128/JVI.77.9.5389-5400.2003
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987
   To KF, 2004, J PATHOL, V203, P740, DOI 10.1002/path.1597
   Tresnan DB, 1998, ADV EXP MED BIOL, V440, P69
   Tsai JC, 2003, J VIROL, V77, P841, DOI 10.1128/JVI.77.2.841-850.2003
   Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629
   Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Wei BDL, 2005, J VIROL, V79, P5705, DOI 10.1128/JVI.79.9.5705-5712.2005
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Xiao X, 2004, CELL MOL LIFE SCI, V61, P2428, DOI 10.1007/s00018-004-4257-y
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
NR 49
TC 134
Z9 144
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 10
PY 2006
VL 281
IS 6
BP 3198
EP 3203
DI 10.1074/jbc.M508381200
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 009QV
UT WOS:000235128200023
PM 16339146
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Chu, CM
   Cheng, VCC
   Hung, IFN
   Wong, MML
   Chan, KH
   Chan, KS
   Kao, RYT
   Poon, LLM
   Wong, CLP
   Guan, Y
   Peiris, JSM
   Yuen, KY
AF Chu, CM
   Cheng, VCC
   Hung, IFN
   Wong, MML
   Chan, KH
   Chan, KS
   Kao, RYT
   Poon, LLM
   Wong, CLP
   Guan, Y
   Peiris, JSM
   Yuen, KY
CA HKU UCH SARS Study Grp
TI Role of lopinavir/ritonavir in the treatment of SARS: initial
   virological and clinical findings
SO THORAX
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; HONG-KONG; CORONAVIRUS; OUTCOMES;
   MANAGEMENT; OUTBREAK
AB Background: The clinical response of patients with severe acute respiratory syndrome (SARS) to a combination of lopinavir/ritonavir and ribavirin was examined after establishing the in vitro antiviral susceptibility of the SARS associated coronavirus to a panel of antiviral agents.
   Methods: The in vitro susceptibility of the prototype of SARS associated coronavirus to a panel of nucleoside analogues and protease inhibitors currently licensed for clinical use was studied. Forty one patients with SARS followed for 3 weeks were treated with a combination of lopinavir/ritonavir and ribavirin. The clinical progress and virological outcomes were monitored and compared with 111 patients treated with ribavirin only who served as historical controls.
   Results: In vitro antiviral activity against SARS associated coronavirus was demonstrated for lopinavir and ribavirin at concentrations of 4 mug/ml and 50 mg/ml, respectively, only at 48 hours. The adverse clinical outcome (ARDS or death) was significantly lower in the treatment group than in the historical controls (2.4% v 28.8%, p<0.001) at day 21 after the onset of symptoms. The adverse outcome remained significantly lower in the treatment group than in the controls-both those diagnosed early (p<0.001) and those diagnosed later in the course of the epidemic (p=0.002)-but there was no significant difference in adverse outcome rates between the two time periods (p=0.548). No time related difference in outcome was observed in the control groups. A reduction in steroid usage and nosocomial infections was seen in patients initially treated with lopinavir/ritonavir, and these patients had a decreasing viral load and rising peripheral lymphocyte count. Multivariate analysis showed that age, hepatitis B carrier status, and lack of treatment with this antiviral combination were independent predictors of an adverse outcome. Lopinavir/ritonavir treatment was associated with a better outcome even when adjusted for baseline lactate dehydrogenase level.
   Conclusions: The apparent favourable clinical response with lopinavir/ritonavir and ribavirin supports further randomised placebo controlled trials in patients with SARS.
C1 Univ Hong Kong, Queen Mary Hosp, Dept Microbiol & Med, Hong Kong, Hong Kong, Peoples R China.
   United Christian Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
   Caritas Med Ctr, Dept Med & Geriatr, Hong Kong, Hong Kong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM kyyuen@hkucc.hku.hk
RI Poon, Leo/C-4382-2009; Kao, Richard/C-4289-2009
OI Poon, Leo/0000-0002-9101-7953; Yuen, Kwok-yung/0000-0002-2083-1552;
   Guan, Yi/0000-0001-6057-9243; Hung, Ivan Fan Ngai/0000-0002-1556-2538;
   Chu, Chung Ming/0000-0002-9959-1271
CR BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Chan JWM, 2003, THORAX, V58, P686, DOI 10.1136/thorax.58.8.686
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Falsey AR, 2003, LANCET, V361, P1312, DOI 10.1016/S0140-6736(03)13084-X
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Hurst M, 2000, DRUGS, V60, P1371, DOI 10.2165/00003495-200060060-00009
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   So LKY, 2003, LANCET, V361, P1615, DOI 10.1016/S0140-6736(03)13265-5
   Tsang KW, 2003, AM J RESP CRIT CARE, V168, P417, DOI 10.1164/rccm.2305012
   *WHO, 2003, SUMM TABL SARS CAS C
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   2003, MMWR MORB MORTAL WKL, V52, P616
NR 20
TC 134
Z9 144
U1 9
U2 12
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0040-6376
EI 1468-3296
J9 THORAX
JI Thorax
PD MAR 1
PY 2004
VL 59
IS 3
BP 252
EP 256
DI 10.1136/thorax.2003.012658
PG 5
WC Respiratory System
SC Respiratory System
GA 778AP
UT WOS:000189217200016
PM 14985565
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Pitkaranta, A
   Arruda, E
   Malmberg, H
   Hayden, FG
AF Pitkaranta, A
   Arruda, E
   Malmberg, H
   Hayden, FG
TI Detection of rhinovirus in sinus brushings of patients with acute
   community-acquired sinusitis by reverse transcription-PCR
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; HUMAN CORONAVIRUSES; OTITIS-MEDIA; INFECTION;
   HYBRIDIZATION; DIAGNOSIS; SYMPTOMS; OC43; RNA
AB Of 20 adults with acute community-acquired sinusitis (ACAS), rhinovirus was detected in specimens from 10 (50%) patients, including maxillary aspirates from 8 (40%) patients and nasal swabs from 9 (45%) patients, by reverse transcription-PCR (RT-PCR). Human coronavirus was detected by RT-PCR in nasal swabs from 3 of 20 patients but in no sinus secretions. These findings suggest that rhinovirus is an important cause of ACAS and that viral invasion of the sinus cavity itself may be a common event during the disease.
C1 UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908.
   UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22908.
   UNIV HELSINKI HOSP,DEPT OTOLARYNGOL,FIN-00290 HELSINKI,FINLAND.
   UNIV SAO PAULO,FAC MED,BR-14049900 RIBEIRAO PRET,SP,BRAZIL.
RI Arruda, Eurico/E-4101-2012
CR AROLA M, 1990, J PEDIATR-US, V116, P697, DOI 10.1016/S0022-3476(05)82650-2
   ARRUDA E, 1993, MOL CELL PROBE, V7, P373, DOI 10.1006/mcpr.1993.1055
   Arruda E, 1996, J CLIN MICROBIOL, V34, P1277, DOI 10.1128/JCM.34.5.1277-1279.1996
   BONI J, 1993, MOL CELL PROBE, V7, P361, DOI 10.1006/mcpr.1993.1054
   EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502
   GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105
   Gwaltney Jr J.M., 1997, CLIN VIROLOGY, P1025
   HALONEN P, 1995, J CLIN MICROBIOL, V33, P648, DOI 10.1128/JCM.33.3.648-653.1995
   HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197
   HYYPIA T, 1989, J GEN VIROL, V70, P3261, DOI 10.1099/0022-1317-70-12-3261
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993
   KAMAHORA T, 1989, VIRUS RES, V12, P1
   MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052
   MYINT S, 1990, J MED VIROL, V31, P165, DOI 10.1002/jmv.1890310216
   MYINT SH, 1994, REV MED VIROL, V4, P35, DOI 10.1002/rmv.1980040108
   SUNG BS, 1993, CLIN INFECT DIS, V17, P38, DOI 10.1093/clinids/17.1.38
   TURNER BW, 1992, J ALLERGY CLIN IMMUN, V90, P474, DOI 10.1016/0091-6749(92)90172-X
   Vesanen M, 1996, J VIROL METHODS, V59, P1, DOI 10.1016/0166-0934(95)01991-X
NR 18
TC 134
Z9 137
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUL
PY 1997
VL 35
IS 7
BP 1791
EP 1793
PG 3
WC Microbiology
SC Microbiology
GA XE591
UT WOS:A1997XE59100029
PM 9196195
DA 2020-04-03
ER

PT J
AU Corman, VM
   Muller, MA
   Costabel, U
   Timm, J
   Binger, T
   Meyer, B
   Kreher, P
   Lattwein, E
   Eschbach-Bludau, M
   Nitsche, A
   Bleicker, T
   Landt, O
   Schweiger, B
   Drexler, JF
   Osterhaus, AD
   Haagmans, BL
   Dittmer, U
   Bonin, F
   Wolff, T
   Drosten, C
AF Corman, V. M.
   Mueller, M. A.
   Costabel, U.
   Timm, J.
   Binger, T.
   Meyer, B.
   Kreher, P.
   Lattwein, E.
   Eschbach-Bludau, M.
   Nitsche, A.
   Bleicker, T.
   Landt, O.
   Schweiger, B.
   Drexler, J. F.
   Osterhaus, A. D.
   Haagmans, B. L.
   Dittmer, U.
   Bonin, F.
   Wolff, T.
   Drosten, C.
TI Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC)
   infections
SO EUROSURVEILLANCE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; INACTIVATION; PNEUMONIA
C1 [Corman, V. M.; Mueller, M. A.; Binger, T.; Meyer, B.; Eschbach-Bludau, M.; Bleicker, T.; Drexler, J. F.; Drosten, C.] Univ Bonn, Inst Virol, Med Ctr, Bonn, Germany.
   [Costabel, U.; Bonin, F.] Univ Duisburg Essen, Ruhrlandklin, Essen, Germany.
   [Timm, J.; Dittmer, U.] Univ Duisburg Essen, Inst Virol, Essen, Germany.
   [Kreher, P.; Nitsche, A.; Schweiger, B.; Wolff, T.] Robert Koch Inst, Berlin, Germany.
   [Lattwein, E.] Euroimmun AG, Lubeck, Germany.
   [Landt, O.] TibMolbiol, Berlin, Germany.
   [Osterhaus, A. D.; Haagmans, B. L.] Erasmus MC, Virosci Lab, Rotterdam, Netherlands.
RP Corman, VM (reprint author), Univ Bonn, Inst Virol, Med Ctr, Bonn, Germany.
EM drosten@virology-bonn.de
RI Drexler, Jan Felix/C-1004-2014; Mueller, Marcel/O-2425-2019; Meyer,
   Benjamin/F-3285-2018; Corman, Victor Max/K-1319-2019; Timm,
   Jorg/P-7652-2019; Meyer, Bernhard/Q-9413-2016
OI Mueller, Marcel/0000-0003-2242-5117; Meyer,
   Benjamin/0000-0003-0601-3550; Corman, Victor Max/0000-0002-3605-0136;
   Timm, Jorg/0000-0001-7799-3045; 
FU European research project on emerging diseases detection and response,
   EMPERIE [223498]; European CommissionEuropean Commission Joint Research
   Centre [228292]
FX The development and provision of these assays was done by a European
   research project on emerging diseases detection and response, EMPERIE
   (www.emperie.eu/emp/), contract number 223498, coordinated by author
   A.D.O. Author C.D. has received infrastructural support from the German
   Centre for Infection Research (DZIF) that included full funding of the
   position of author V.M.C.; Oligonucleotides can be ordered from stock at
   Tib-Molbiol, Berlin (www.tib-molbiol.de). Limited numbers of IFA slides
   as well as in-vitro transcribed control RNA for the upE and 1A assays
   can be acquired from author C. D. through the European Virus Archive
   platform (www.european-virusarchive.com), funded by the European
   Commission under contract number 228292. Further information and assay
   updates can be obtained from www.virology-bonn.de.
CR Bermingham A., 2012, EURO SURVEILL, V17
   Corman VM, 2012, EURO SURVEILL, V17
   Drosten C, 2004, J CLIN MICROBIOL, V42, P2043, DOI 10.1128/JCM.42.5.2043-2047.2004
   He QG, 2004, CLIN DIAGN LAB IMMUN, V11, P417, DOI 10.1128/CDLI.11.2.417-422.2004
   Health Protection Agency (HPA), 2012, GEN SEQ INF SCI NOV
   Herzog P, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-138
   Kraus AA, 2005, INTERVIROLOGY, V48, P255, DOI 10.1159/000084603
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Rabenau HF, 2005, MED MICROBIOL IMMUN, V194, P1, DOI 10.1007/s00430-004-0219-0
   Tan YJ, 2004, CLIN DIAGN LAB IMMUN, V11, P362, DOI 10.1128/CDLI.11.2.362-371.2004
   Vijgen Leen, 2008, V454, P3, DOI 10.1007/978-1-59745-181-9_1
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 13
TC 133
Z9 139
U1 3
U2 32
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD DEC 6
PY 2012
VL 17
IS 49
BP 2
EP 10
AR 20334
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 055SQ
UT WOS:000312438000001
OA DOAJ Gold
DA 2020-04-03
ER

PT J
AU Gaunt, ER
   Hardie, A
   Claas, ECJ
   Simmonds, P
   Templeton, KE
AF Gaunt, E. R.
   Hardie, A.
   Claas, E. C. J.
   Simmonds, P.
   Templeton, K. E.
TI Epidemiology and Clinical Presentations of the Four Human Coronaviruses
   229E, HKU1, NL63, and OC43 Detected over 3 Years Using a Novel Multiplex
   Real-Time PCR Method
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID RESPIRATORY-SYNCYTIAL-VIRUS; IMMUNOCOMPROMISED PATIENTS;
   CROSS-REACTIVITY; TRACT INFECTIONS; HONG-KONG; CHILDREN; DISEASE;
   PNEUMONIA; POPULATION; TECUMSEH
AB Four human coronaviruses (HCoV-229E, HCoV-HKU1, HCoV-NL63, and HCoV-OC43) are associated with a range of respiratory outcomes, including bronchiolitis and pneumonia. Their epidemiologies and clinical characteristics are poorly described and are often reliant on case reports. To address these problems, we conducted a large-scale comprehensive screening for all four coronaviruses by analysis of 11,661 diagnostic respiratory samples collected in Edinburgh, United Kingdom, over 3 years between July 2006 and June 2009 using a novel four-way multiplex real-time reverse transcription-PCR (RT-PCR) assay. Coronaviruses were detected in 0.3 to 0.85% of samples in all age groups. Generally, coronaviruses displayed marked winter seasonality between the months of December and April and were not detected in summer months, which is comparable to the pattern seen with influenza viruses. HCoV-229E was the exception; detection was confined to the winter of 2008 and was sporadic in the following year. There were additional longer-term differences in detection frequencies between seasons, with HCoV-OC43 predominant in the first and third seasons and HCoV-HKU1 dominating in the second (see Results for definitions of seasons). A total of 11 to 41% of coronaviruses detected were in samples testing positive for other respiratory viruses, although clinical presentations of coronavirus monoinfections were comparable to those of viruses which have an established role in respiratory disease, such as respiratory syncytial virus, influenza virus, and parainfluenza viruses. The novel multiplex assay for real-time pan-coronavirus detection enhances respiratory virus diagnosis, overcomes potential diagnostic problems arising through seasonal variation in coronavirus frequency, and provides novel insights into the epidemiology and clinical implications of coronaviruses.
C1 [Hardie, A.; Templeton, K. E.] Royal Infirm, Dept Virol, Edinburgh EH16 4SA, Midlothian, Scotland.
   [Gaunt, E. R.; Simmonds, P.] Univ Edinburgh, Ctr Infect Dis, Edinburgh EH9 1QH, Midlothian, Scotland.
   [Claas, E. C. J.] Leiden Univ, Med Ctr, Dept Med Microbiol, Ctr Infect Dis, Leiden, Netherlands.
RP Templeton, KE (reprint author), Royal Infirm, Dept Virol, 51 Little France Crescent,Old Dalkeith Rd, Edinburgh EH16 4SA, Midlothian, Scotland.
EM ktemplet@staffmail.ed.ac.uk
OI Templeton, Kate/0000-0001-7414-1277; Simmonds, Peter/0000-0002-7964-4700
FU BBSRCBiotechnology and Biological Sciences Research Council (BBSRC);
   Lothian Regional Ethics Committee [08/S11/02/2]
FX This research was supported by a studentship awarded to E.R.G. by the
   BBSRC. This work represents no conflicts of interest. Ethical approval
   was provided by the Lothian Regional Ethics Committee (08/S11/02/2).
CR Chan CM, 2009, J CLIN VIROL, V45, P54, DOI 10.1016/j.jcv.2009.02.011
   Chan KH, 2005, CLIN DIAGN LAB IMMUN, V12, P1317, DOI 10.1128/CDLI.12.11.1317-1321.2005
   Che XY, 2005, J INFECT DIS, V191, P2033, DOI 10.1086/430355
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   Dijkman R, 2008, J CLIN MICROBIOL, V46, P2368, DOI 10.1128/JCM.00533-08
   Esper F, 2006, EMERG INFECT DIS, V12, P775, DOI 10.3201/eid1205.051316
   FIELDS BN, 1996, FIELDS VIROLOGY
   Gaunt E, 2009, J CLIN VIROL, V46, P318, DOI 10.1016/j.jcv.2009.09.016
   Gerna G, 2006, J MED VIROL, V78, P938, DOI 10.1002/jmv.20645
   GERNA G, 1985, J INFECT DIS, V151, P796, DOI 10.1093/infdis/151.5.796
   Gerna G, 2007, J CLIN VIROL, V38, P244, DOI 10.1016/j.jcv.2006.12.008
   HAMRE D, 1972, AM J EPIDEMIOL, V96, P94, DOI 10.1093/oxfordjournals.aje.a121445
   HASONY HJ, 1982, J MED VIROL, V9, P209, DOI 10.1002/jmv.1890090308
   Heim A, 2003, J MED VIROL, V70, P228, DOI 10.1002/jmv.10382
   KAYE HS, 1971, AM J EPIDEMIOL, V94, P43, DOI 10.1093/oxfordjournals.aje.a121293
   Koetz A, 2006, CLIN MICROBIOL INFEC, V12, P1089, DOI 10.1111/j.1469-0691.2006.01506.x
   Kuypers J, 2007, PEDIATRICS, V119, pE70, DOI 10.1542/peds.2006-1406
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Leung TF, 2009, J CLIN MICROBIOL, V47, P3486, DOI 10.1128/JCM.00832-09
   MCINTOSH K, 1970, AM J EPIDEMIOL, V91, P585, DOI 10.1093/oxfordjournals.aje.a121171
   MONTO AS, 1974, AM J EPIDEMIOL, V100, P458, DOI 10.1093/oxfordjournals.aje.a112058
   MONTO AS, 1974, J INFECT DIS, V129, P271, DOI 10.1093/infdis/129.3.271
   Oosterhof L, 2010, BONE MARROW TRANSPL, V45, P1115, DOI 10.1038/bmt.2009.292
   PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289, DOI 10.1093/oxfordjournals.aje.a121558
   Patrick David M, 2006, Can J Infect Dis Med Microbiol, V17, P330
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   RESTA S, 1985, SCIENCE, V229, P978, DOI 10.1126/science.2992091
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Suzuki A, 2005, PEDIATR INFECT DIS J, V24, P645, DOI 10.1097/01.inf.0000168846.71517.ee
   Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   van der Hoek L, 2005, PLOS MED, V2, P764, DOI 10.1371/journal.pmed.0020240
   van der Hoek L, 2006, FEMS MICROBIOL REV, V30, P760, DOI 10.1111/j.1574-6976.2006.00032.x
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   Woo PCY, 2004, J CLIN MICROBIOL, V42, P5885, DOI 10.1128/JCM.42.12.5885-5888.2004
   Wu PS, 2008, EUR J PEDIATR, V167, P75, DOI 10.1007/s00431-007-0429-8
   Zhao Q, 2008, J VIROL, V82, P8647, DOI 10.1128/JVI.00298-08
NR 38
TC 133
Z9 148
U1 1
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD AUG
PY 2010
VL 48
IS 8
BP 2940
EP 2947
DI 10.1128/JCM.00636-10
PG 8
WC Microbiology
SC Microbiology
GA 634AQ
UT WOS:000280550500044
PM 20554810
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Oosterheert, JJ
   van Loon, AM
   Schuurman, R
   Hoepelman, AIM
   Hak, E
   Thijsen, S
   Nossent, G
   Schneider, MME
   Hustinx, WMN
   Bonten, MJM
AF Oosterheert, JJ
   van Loon, AM
   Schuurman, R
   Hoepelman, AIM
   Hak, E
   Thijsen, S
   Nossent, G
   Schneider, MME
   Hustinx, WMN
   Bonten, MJM
TI Impact of rapid detection of viral and atypical bacterial pathogens by
   real-time polymerase chain reaction for patients with lower respiratory
   tract infection
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; ANTIBIOTIC-THERAPY; SYNCYTIAL VIRUS; BLOOD
   CULTURES; COST; DIAGNOSIS; MORTALITY; INFLUENZA; ETIOLOGY; SPUTUM
AB Background. Rapid diagnostic tests with a high sensitivity for lower respiratory tract infection (LRTI) could lead to improved patient care and reduce unnecessary antibiotic use and associated costs. Diagnostic yields, feasibility, and costs of real-time polymerase chain reaction (PCR) of nasopharyngeal and oropharyngeal swab specimens in the routine diagnostic work-up for LRTI were determined.
   Methods. In a randomized controlled trial, nasopharyngeal and oropharyngeal swab specimens from patients admitted for antibiotic treatment of LRTI were evaluated by means of real-time PCR for respiratory viruses and atypical pathogens, as well as by conventional diagnostic procedures. Real- time PCR results for patients in the intervention group were reported to the treating physician; results for patients in the control group were not made available.
   Results. A total of 107 patients ( mean age [ +/- standard deviation], years) were included, of whom 63.6 +/- 16.3 55 were allocated to the intervention group. The pathogens detected most frequently were influenza virus (14 patients), Streptococcus pneumoniae (8), coronavirus (6), Staphylococcus aureus ( 5), and rhinoviruses (5). Real- time PCR increased the diagnostic yield from 23 cases (21% of patients) to 47 cases (43% of patients), compared with conventional diagnostic tests. The detection of viral pathogens by PCR was associated with the winter season, less infiltrates on chest radiographs, lower C-reactive protein levels, and shorter duration of symptoms. Use of real-time PCR results resulted in partial or total cessation of antibiotic treatment for 6 patients (11%; 95% confidence interval, 2-19), but overall antibiotic use was comparable in the intervention group and the control group ( median duration of treatment, 10.0 vs. 9.0 days; significant). Use of real-time PCR increased treatment and P=not diagnostic costs with Euro318.17 per patient.
   Conclusions. Implementation of real-time PCR for the etiological diagnosis of LRTI increased the diagnostic yield considerably, but it did not reduce antibiotic use or costs.
C1 Univ Utrecht, Med Ctr, Dept Internal Med & Infect Dis, Div Med, NL-3508 GA Utrecht, Netherlands.
   Univ Utrecht, Med Ctr, Dept Virol, NL-3508 GA Utrecht, Netherlands.
   Univ Utrecht, Med Ctr, Wijkman Winkler Inst Infect Dis, NL-3508 GA Utrecht, Netherlands.
   Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands.
   Univ Utrecht, Med Ctr, Dept Resp Med, NL-3508 GA Utrecht, Netherlands.
   Diakonessenhuis Utrecht, Dept Med Microbiol, Utrecht, Netherlands.
   Diakonessenhuis Utrecht, Dept Internal Med, Utrecht, Netherlands.
RP Bonten, MJM (reprint author), Univ Utrecht, Med Ctr, Dept Internal Med & Infect Dis, Div Med, Rm F02,126 POB 85500, NL-3508 GA Utrecht, Netherlands.
EM M.J.M.Bonten@azu.nl
RI Schuurman, Rob/M-4687-2019
OI Schuurman, Rob/0000-0002-0060-9831
CR Ball P, 2002, J ANTIMICROB CHEMOTH, V49, P31, DOI 10.1093/jac/49.1.31
   Barenfanger J, 2000, J CLIN MICROBIOL, V38, P2824, DOI 10.1128/JCM.38.8.2824-2828.2000
   Christ-Crain M, 2004, LANCET, V363, P600, DOI 10.1016/S0140-6736(04)15591-8
   Corbo J, 2004, EMERG MED J, V21, P446, DOI 10.1136/emj.2003.005306
   de Roux AD, 2004, CHEST, V125, P1343, DOI 10.1378/chest.125.4.1343
   Ewig S, 2002, CHEST, V121, P1486, DOI 10.1378/chest.121.5.1486
   Ewig S, 1999, CLIN CHEST MED, V20, P575, DOI 10.1016/S0272-5231(05)70237-9
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1
   Guest JF, 1997, EUR RESPIR J, V10, P1530, DOI 10.1183/09031936.97.10071530
   Lave JR, 1999, SEM RESP CRIT CARE M, V20, P189, DOI 10.1055/s-2007-1021315
   Lieberman D, 1996, THORAX, V51, P179, DOI 10.1136/thx.51.2.179
   Lim WS, 2001, THORAX, V56, P296, DOI 10.1136/thorax.56.4.296
   Macfarlane J, 1997, BRIT MED J, V315, P1206, DOI 10.1136/bmj.315.7117.1206
   Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709
   MATTHEY S, 1992, J CLIN MICROBIOL, V30, P540, DOI 10.1128/JCM.30.3.540-544.1992
   *NETH NAT HLTH INS, MAN COST RES
   *NETH NAT HLTH INS, 2004, PHARM GUID
   Oosterheert JJ, 2003, J CLIN MICROBIOL, V41, P4708, DOI 10.1128/JCM.41.10.4708-4713.2003
   Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189
   Reed WW, 1996, WESTERN J MED, V165, P197
   Ruiz M, 1999, AM J RESP CRIT CARE, V160, P397, DOI 10.1164/ajrccm.160.2.9808045
   Smith PR, 2001, MED CLIN N AM, V85, P1381, DOI 10.1016/S0025-7125(05)70386-2
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   van Elden LJR, 2004, J INFECT DIS, V189, P652, DOI 10.1086/381207
   van Elden LJR, 2003, J CLIN MICROBIOL, V41, P4378, DOI 10.1128/JCM.41.9.4378-4381.2003
   van Elden LJR, 2001, J CLIN MICROBIOL, V39, P196, DOI 10.1128/JCM.39.1.196-200.2001
   Waterer GW, 1999, CHEST, V116, P1278, DOI 10.1378/chest.116.5.1278
   Weinberg GA, 2004, J INFECT DIS, V189, P706, DOI 10.1086/381456
   Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997
   1995, MMWR MORB MORTAL WKL, V44, P535
NR 34
TC 133
Z9 137
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD NOV 15
PY 2005
VL 41
IS 10
BP 1438
EP 1444
DI 10.1086/497134
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 975NY
UT WOS:000232670400006
PM 16231254
OA Bronze
DA 2020-04-03
ER

PT J
AU PEARCE, BD
   HOBBS, MV
   MCGRAW, TS
   BUCHMEIER, MJ
AF PEARCE, BD
   HOBBS, MV
   MCGRAW, TS
   BUCHMEIER, MJ
TI CYTOKINE INDUCTION DURING T-CELL-MEDIATED CLEARANCE OF MOUSE
   HEPATITIS-VIRUS FROM NEURONS IN-VIVO
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; MURINE CORONAVIRUS JHM;
   STRAIN JHM; GAMMA-INTERFERON; SUPEROXIDE-DISMUTASE; ANTIGEN EXPRESSION;
   ENDOTHELIAL-CELLS; LETHAL INFECTION; GENE-EXPRESSION
AB To investigate the mechanism by which viruses are cleared from neurons in the central nervous system, we have utilized a mouse model involving infection with a neurotropic variant of mouse hepatitis virus (OBLV60). After intranasal inoculation, OBLV60 grew preferentially in the olfactory bulbs of BALB/c mice. Using in situ hybridization, we found that viral RNA localized primarily in the outer layers of the olfactory bulb, including neurons of the mitral cell layer. Virus was cleared rapidly from the olfactory bulb between 5 and 11 days. Athymic nude mice failed to eliminate the virus, demonstrating a requirement for T lymphocytes. Immunosuppression of normal mice with cyclophosphamide also prevented clearance. Both CD4(+) and CD8(+) T-cell subsets were important, as depletion of either of these subsets delayed viral clearance. Gliosis and infiltrates of CD4(+) and CD8(+) cells were detected by immunohistochemical analysis at 6 days. The role of cytokines in clearance was investigated by using an RNase protection assay for interleukin-1 alpha. (IL-1 alpha), IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, tumor necrosis factor alpha (TNF-alpha), TNF-beta, and gamma interferon (IFN-gamma). In immunocompetent mice there was upregulation of RNA for IL-1 alpha, IL-1 beta, IL-6, TNF-alpha, and IFN-gamma at the time of clearance. Nude mice had comparable increases in these cytokine messages, with the exception of IFN-gamma. Induction of major histocompatibility complex class I (MHC-I) molecules on cells in infected brains was demonstrated by immunohistochemical analyses in normal and nude mice, suggesting that IFN-gamma may not be necessary for induction of MHC-I on neural cells in vivo.
C1 Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI25913]; NINDS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [NS22347, NS12428]
CR BARNETT EM, 1993, VIROLOGY, V194, P185, DOI 10.1006/viro.1993.1248
   BARTHOLD SW, 1990, LAB ANIM SCI, V40, P133
   BARTHOLD SW, 1988, ACTA NEUROPATHOL, V76, P502, DOI 10.1007/BF00686390
   BARTHOLD SW, 1992, ARCH VIROL, V122, P35, DOI 10.1007/BF01321116
   BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U
   BENVENISTE EN, 1992, AM J PHYSIOL, V263, P1
   BUCHMEIER MJ, 1988, J NEUROIMMUNOL, V20, P111, DOI 10.1016/0165-5728(88)90141-5
   CHUNG IY, 1990, J IMMUNOL, V144, P2999
   COMPTON SR, 1993, LAB ANIM SCI, V43, P15
   CSERR HF, 1992, IMMUNOL TODAY, V13, P507, DOI 10.1016/0167-5699(92)90027-5
   DESOUZA MS, 1991, LAB ANIM SCI, V41, P99
   DUGUID J, 1993, P NATL ACAD SCI USA, V90, P114, DOI 10.1073/pnas.90.1.114
   DUPUY J M, 1973, Federation Proceedings, V32, P963
   FAZAKERLEY J, UNPUB
   FAZAKERLEY JK, 1992, VIROLOGY, V187, P178, DOI 10.1016/0042-6822(92)90306-A
   FEDUCHI E, 1989, J VIROL, V63, P1354, DOI 10.1128/JVI.63.3.1354-1359.1989
   FLEMING JO, 1990, ADV EXP MED BIOL, V276, P565
   FLEMING JO, 1986, J VIROL, V58, P869, DOI 10.1128/JVI.58.3.869-875.1986
   FLEMING JO, 1987, MICROB PATHOGENESIS, V3, P9, DOI 10.1016/0882-4010(87)90033-7
   FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418
   GALLAGHER TM, 1991, J VIROL, V65, P1916, DOI 10.1128/JVI.65.4.1916-1928.1991
   GARLINGHOUSE LE, 1985, LAB ANIM SCI, V35, P469
   GIRI JG, 1985, J IMMUNOL, V134, P343
   GOMBOLD JL, 1992, MICROB PATHOGENESIS, V13, P493, DOI 10.1016/0882-4010(92)90015-G
   HARRIS CA, 1991, J IMMUNOL, V147, P149
   HAZDUA D, 1990, J BIOL CHEM, V265, P6318
   HOBBS MV, 1993, J IMMUNOL, V150, P3602
   HOFLER H, 1987, VIRCHOWS ARCH B, V54, P144, DOI 10.1007/BF02899206
   IWASAKI Y, 1990, ADV EXP MED BIOL, V276, P601
   JOLY E, 1991, SCIENCE, V253, P1283, DOI 10.1126/science.1891717
   JOSEPH J, 1993, J NEUROIMMUNOL, V42, P47, DOI 10.1016/0165-5728(93)90211-G
   JOSEPH J, 1991, J NEUROIMMUNOL, V33, P181, DOI 10.1016/0165-5728(91)90105-G
   JOSEPH J, 1990, ADV EXP MED BIOL, V276, P579
   KENNEDY JD, 1992, J IMMUNOL, V148, P1620
   KNOBLER RL, 1981, J EXP MED, V153, P832, DOI 10.1084/jem.153.4.832
   KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2
   KUNG JT, 1988, J IMMUNOL, V140, P3727
   KUPER CF, 1992, IMMUNOL TODAY, V13, P219
   KYUWA S, 1988, J VIROL, V62, P3506, DOI 10.1128/JVI.62.9.3506-3508.1988
   LAMPERT PW, 1973, ACTA NEUROPATHOL, V24, P76, DOI 10.1007/BF00691421
   LAVI E, 1988, LAB INVEST, V58, P31
   LAVI E, 1984, NEUROLOGY, V34, P597, DOI 10.1212/WNL.34.5.597
   LEVINE B, 1991, SCIENCE, V254, P856, DOI 10.1126/science.1658936
   LINDAHL P, 1973, P NATL ACAD SCI USA, V70, P2785, DOI 10.1073/pnas.70.10.2785
   LUCCHIARI MA, 1991, J GEN VIROL, V72, P1317, DOI 10.1099/0022-1317-72-6-1317
   LUCCHIARI MA, 1992, IMMUNOBIOLOGY, V185, P475
   MAEHLEN J, 1989, BRAIN RES, V481, P368, DOI 10.1016/0006-8993(89)90816-0
   MASSA PT, 1987, J EXP MED, V166, P259, DOI 10.1084/jem.166.1.259
   MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E
   MOBLEY J, 1992, VIROLOGY, V187, P443, DOI 10.1016/0042-6822(92)90446-V
   OLDSTONE MBA, 1993, AM J PATHOL, V143, P1241
   OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0
   PASICK JMM, 1992, MICROB PATHOGENESIS, V13, P1, DOI 10.1016/0882-4010(92)90027-L
   PATICK AK, 1990, SEMIN VIROL, V1, P281
   PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5
   RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R
   RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209
   Sambrook J., 1989, MOL CLONING LABORATO
   SCHIJNS V, 1989, J GEN VIROL, V72, P809
   SCHINDLER L, 1982, INFECT IMMUN, V35, P869, DOI 10.1128/IAI.35.3.869-873.1982
   Sedgwick JD, 1991, SEMIN NEUROSCI, V3, P93
   SLOAN DJ, 1992, TRENDS NEUROSCI, V15, P276, DOI 10.1016/0166-2236(92)90075-J
   SMITH AL, 1991, ARCH VIROL, V121, P89, DOI 10.1007/BF01316746
   STOHLMAN SA, 1986, J IMMUNOL, V136, P3052
   SUSSMAN MA, 1989, J VIROL, V63, P3051, DOI 10.1128/JVI.63.7.3051-3056.1989
   SUZUMURA A, 1988, J IMMUNOL, V140, P2068
   VIRELIZIER JL, 1976, J IMMUNOL, V117, P748
   WILLIAMSON J S P, 1992, Regional Immunology, V4, P145
   WILLIAMSON JSP, 1990, J VIROL, V64, P4589, DOI 10.1128/JVI.64.9.4589-4592.1990
   WILLIAMSON JSP, 1991, J NEUROIMMUNOL, V32, P199, DOI 10.1016/0165-5728(91)90189-E
   WONG GHW, 1988, J IMMUNOL, V140, P120
   WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6
   YAMAGUCHI K, 1991, J NEUROIMMUNOL, V32, P1, DOI 10.1016/0165-5728(91)90065-F
NR 73
TC 133
Z9 135
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD SEP
PY 1994
VL 68
IS 9
BP 5483
EP 5495
DI 10.1128/JVI.68.9.5483-5495.1994
PG 13
WC Virology
SC Virology
GA PB785
UT WOS:A1994PB78500017
PM 8057431
OA Bronze
DA 2020-04-03
ER

PT J
AU LAPPS, W
   HOGUE, BG
   BRIAN, DA
AF LAPPS, W
   HOGUE, BG
   BRIAN, DA
TI SEQUENCE-ANALYSIS OF THE BOVINE CORONAVIRUS NUCLEOCAPSID AND MATRIX
   PROTEIN GENES
SO VIROLOGY
LA English
DT Article
C1 UNIV TENNESSEE, DEPT MICROBIOL, KNOXVILLE, TN 37996 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [T32-AI-07123, AI-14367, R01 AI014367]
CR ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0
   ARMSTRONG J, 1983, NUCLEIC ACIDS RES, V11, P883, DOI 10.1093/nar/11.3.883
   AUPERIN DD, 1984, J VIROL, V52, P897, DOI 10.1128/JVI.52.3.897-904.1984
   BARIC RS, 1985, VIRUS RES, V3, P19, DOI 10.1016/0168-1702(85)90038-3
   BOURSNELL MEG, 1984, VIRUS RES, V1, P303, DOI 10.1016/0168-1702(84)90019-4
   BOURSNELL MEG, 1984, GENE, V29, P87, DOI 10.1016/0378-1119(84)90169-0
   BOURSNELL MEG, 1985, J GEN VIROL, V66, P573, DOI 10.1099/0022-1317-66-3-573
   BUDZILOWICZ CJ, 1985, J VIROL, V53, P834, DOI 10.1128/JVI.53.3.834-840.1985
   GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5
   GUY JS, 1979, J VIROL, V29, P293, DOI 10.1128/JVI.29.1.293-300.1979
   HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8
   HOGUE BG, 1984, J VIROL, V51, P384, DOI 10.1128/JVI.51.2.384-388.1984
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   HOUSE JA, 1978, J AM VET MED ASSOC, V173, P573
   JAMES R, 1984, ANAL BIOCHEM, V140, P456, DOI 10.1016/0003-2697(84)90193-3
   KAPKE PA, 1986, VIROLOGY, V151, P41, DOI 10.1016/0042-6822(86)90102-9
   KING B, 1985, VIRUS RES, V2, P53, DOI 10.1016/0168-1702(85)90059-0
   KING B, 1982, J VIROL, V42, P700, DOI 10.1128/JVI.42.2.700-707.1982
   Klenk H D, 1980, Curr Top Microbiol Immunol, V90, P19
   KOZAK M, 1983, MICROBIOL REV, V47, P1
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAPPS W, 1985, ARCH VIROL, V86, P101, DOI 10.1007/BF01314116
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MANIATIS T, 1982, MOL CLONING LABORATO
   Maxam A M, 1980, Methods Enzymol, V65, P499
   NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x
   NIEMANN H, 1981, J MOL BIOL, V153, P993, DOI 10.1016/0022-2836(81)90463-0
   Niemann H, 1984, Adv Exp Med Biol, V173, P201
   PEDERSEN NC, 1978, ARCH VIROL, V58, P45, DOI 10.1007/BF01315534
   QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581
   ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022
   Roychoudhury R, 1980, Methods Enzymol, V65, P43
   SKINNER MA, 1983, NUCLEIC ACIDS RES, V11, P5045, DOI 10.1093/nar/11.15.5045
   SMITH HO, 1976, NUCLEIC ACIDS RES, V3, P2387, DOI 10.1093/nar/3.9.2387
   STERN DF, 1980, J VIROL, V36, P440, DOI 10.1128/JVI.36.2.440-449.1980
   STOHLMAN SA, 1979, J VIROL, V32, P672, DOI 10.1128/JVI.32.2.672-675.1979
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
NR 39
TC 133
Z9 139
U1 1
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAR
PY 1987
VL 157
IS 1
BP 47
EP 57
DI 10.1016/0042-6822(87)90312-6
PG 11
WC Virology
SC Virology
GA G2611
UT WOS:A1987G261100006
PM 3029965
DA 2020-04-03
ER

PT J
AU Chu, DKW
   Poon, LLM
   Gomaa, MM
   Shehata, MM
   Perera, RAPM
   Abu Zeid, D
   El Rifay, AS
   Siu, LY
   Guan, Y
   Webby, RJ
   Ali, MA
   Peiris, M
   Kayali, G
AF Chu, Daniel K. W.
   Poon, Leo L. M.
   Gomaa, Mokhtar M.
   Shehata, Mahmoud M.
   Perera, Ranawaka A. P. M.
   Abu Zeid, Dina
   El Rifay, Amira S.
   Siu, Lewis Y.
   Guan, Yi
   Webby, Richard J.
   Ali, Mohamed A.
   Peiris, Malik
   Kayali, Ghazi
TI MERS Coronaviruses in Dromedary Camels, Egypt
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; SAUDI-ARABIA; ANTIBODIES; LIVESTOCK;
   BATS
AB We identified the near-full-genome sequence (29,908 nt, >99%) of Middle East respiratory syndrome coronavirus (MERS-CoV) from a nasal swab specimen from a dromedary camel in Egypt. We found that viruses genetically very similar to human MERS-CoV are infecting dromedaries beyond the Arabian Peninsula, where human MERS-CoV infections have not yet been detected.
C1 [Chu, Daniel K. W.; Poon, Leo L. M.; Perera, Ranawaka A. P. M.; Guan, Yi; Peiris, Malik] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
   [Gomaa, Mokhtar M.; Shehata, Mahmoud M.; Abu Zeid, Dina; El Rifay, Amira S.; Ali, Mohamed A.] Natl Res Ctr, Giza, Egypt.
   [Siu, Lewis Y.] HKU Pasteur Res Pole, Hong Kong, Hong Kong, Peoples R China.
   [Webby, Richard J.; Kayali, Ghazi] St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
RP Peiris, M (reprint author), Univ Hong Kong, Sch Publ Hlth, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.
EM malik@hlcu.hk; kayali@stjude.org
RI Webby, Richard J/N-5657-2018; Perera, Ranawaka A.P.M/N-8263-2015; Refay,
   Amira El/I-6183-2019; Poon, Leo/C-4382-2009; Shehata, Mahmoud
   M/R-7703-2016; Ali, Mohamed A/N-8768-2017
OI Perera, Ranawaka A.P.M/0000-0003-3936-1535; Refay, Amira
   El/0000-0002-6181-1072; Poon, Leo/0000-0002-9101-7953; Shehata, Mahmoud
   M/0000-0001-7556-9398; Ali, Mohamed A/0000-0002-5615-3212; Abu Zeid,
   Dina/0000-0002-3671-3067; Chu, Daniel Ka Wing/0000-0002-9219-8979; Guan,
   Yi/0000-0001-6057-9243; Gomaa, Mokhtar/0000-0001-7947-3609
FU National Research Centre, Giza, EgyptNational Research Centre (NRC);
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN266200700005C]; European CommunityEuropean Community (EC) [223498]
FX This research was supported by an internal research grant from the
   National Research Centre, Giza, Egypt; by a research contract from the
   National Institute of Allergy and Infectious Diseases contract
   HHSN266200700005C; and a grant from the European Community Seventh
   Framework Program (FP7/2007-2013) under project European management
   Platform for Emerging and Re-emerging Disease entities (grant agreement
   no. 223498) (EMPERIE).
CR Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Chu DKW, 2011, J VIROL, V85, P12815, DOI 10.1128/JVI.05838-11
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hemida MG, 2013, EUROSURVEILLANCE, V18, P21, DOI 10.2807/1560-7917.ES2013.18.50.20659
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Reusken CB, 2013, EUROSURVEILLANCE, V18, P14, DOI 10.2807/1560-7917.ES2013.18.50.20662
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   WHO, MIDDL E RESP SYNDR C
NR 14
TC 132
Z9 146
U1 3
U2 37
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUN
PY 2014
VL 20
IS 6
BP 1049
EP 1053
DI 10.3201/eid2006.140299
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AI0SZ
UT WOS:000336561600023
PM 24856660
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU de Wit, E
   Rasmussen, AL
   Falzarano, D
   Bushmaker, T
   Feldmann, F
   Brining, DL
   Fischer, ER
   Martellaro, C
   Okumura, A
   Chang, J
   Scott, D
   Benecke, AG
   Katze, MG
   Feldmann, H
   Munster, VJ
AF de Wit, Emmie
   Rasmussen, Angela L.
   Falzarano, Darryl
   Bushmaker, Trenton
   Feldmann, Friederike
   Brining, Douglas L.
   Fischer, Elizabeth R.
   Martellaro, Cynthia
   Okumura, Atsushi
   Chang, Jean
   Scott, Dana
   Benecke, Arndt G.
   Katze, Michael G.
   Feldmann, Heinz
   Munster, Vincent J.
TI Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient
   lower respiratory tract infection in rhesus macaques
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE emerging infectious disease; DPP4
ID CLINICAL-FEATURES; AFRICAN-GREEN; ANIMAL-MODEL; VIRUS; PNEUMONIA;
   SYSTEM; BATS
AB In 2012, a novel betacoronavirus, designated Middle East respiratory syndrome coronavirus or MERS-CoV and associated with severe respiratory disease in humans, emerged in the Arabian Peninsula. To date, 108 human cases have been reported, including cases of human-to-human transmission. The availability of an animal disease model is essential for understanding pathogenesis and developing effective countermeasures. Upon a combination of intratracheal, ocular, oral, and intranasal inoculation with 7 x 10(6) 50% tissue culture infectious dose of the MERS-CoV isolate HCoV-EMC/2012, rhesus macaques developed a transient lower respiratory tract infection. Clinical signs, virus shedding, virus replication in respiratory tissues, gene expression, and cytokine and chemokine profiles peaked early in infection and decreased over time. MERS-CoV caused a multifocal, mild to marked interstitial pneumonia, with virus replication occurring mainly in alveolar pneumocytes. This tropism of MERS-CoV for the lower respiratory tract may explain the severity of the disease observed in humans and the, up to now, limited human-to-human transmission.
C1 [de Wit, Emmie; Falzarano, Darryl; Bushmaker, Trenton; Martellaro, Cynthia; Feldmann, Heinz; Munster, Vincent J.] NIAID, Lab Virol, NIH, Hamilton, MT 59840 USA.
   [Feldmann, Friederike; Brining, Douglas L.; Scott, Dana] NIAID, Rocky Mt Vet Branch, NIH, Hamilton, MT 59840 USA.
   [Fischer, Elizabeth R.] NIAID, Microscopy Unit, Res Technol Branch, Div Intramural Res,NIH, Hamilton, MT 59840 USA.
   [Rasmussen, Angela L.; Okumura, Atsushi; Chang, Jean; Benecke, Arndt G.; Katze, Michael G.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
   [Benecke, Arndt G.] Univ Paris 06, Dept Biol, Ctr Natl Rech Sci, Unite Mixte Rech 7224, F-75005 Paris, France.
   [Feldmann, Heinz] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0J9, Canada.
RP Feldmann, H (reprint author), NIAID, Lab Virol, NIH, Hamilton, MT 59840 USA.
EM feldmannh@niaid.nih.gov; Vincent.Munster@nih.gov
RI Munster, Vincent/I-7607-2018; Okumura, Atsushi/E-8012-2015; de Wit,
   Emmie/A-1549-2019
OI Munster, Vincent/0000-0002-2288-3196; Okumura,
   Atsushi/0000-0002-7779-3059; de Wit, Emmie/0000-0002-9763-7758;
   Rasmussen, Angela/0000-0001-9462-3169
FU Intramural Research Program of the National Institute of Allergy and
   Infectious Diseases, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   National Institute of Allergy and Infectious Diseases Regional Centers
   of Excellence, National Institutes of Health/National Institute of
   Allergy and Infectious Diseases Contract [U54 AI081680,
   HHSN272200800060C]; National Institutes of Health (Washington National
   Primate Center)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P51OD010425]
FX We thank Drs. Bart Haagmans and Ron Fouchier at the Erasmus Medical
   Center for providing Middle East respiratory coronavirus isolate
   HCoV-EMC/2012; Ralph Baric at the University of North Carolina at Chapel
   Hill for subgenomic RNA primer sequences; Laura Baseler, Tina Thomas,
   Dan Long, and Rebecca Rosenke for histopathology; the staff of the Rocky
   Mountain Veterinary Branch for assistance with the animal experiments;
   and Anita Mora for figure preparation. This research was supported by
   the Intramural Research Program of the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health; A.L.R., A.G.B.,
   A.O., and M.G.K. are funded through Grant U54 AI081680, National
   Institute of Allergy and Infectious Diseases Regional Centers of
   Excellence, National Institutes of Health/National Institute of Allergy
   and Infectious Diseases Contract HHSN272200800060C, and National
   Institutes of Health Grant P51OD010425 (Washington National Primate
   Center).
CR Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Anthony SJ, 2013, J GEN VIROL, V94, P1028, DOI 10.1099/vir.0.049759-0
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Chan RWY, 2013, J VIROL, V87, P6604, DOI 10.1128/JVI.00009-13
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Greenough TC, 2005, AM J PATHOL, V167, P455, DOI 10.1016/S0002-9440(10)62989-6
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Haagmans BL, 2006, PLOS MED, V3, P598, DOI 10.1371/journal.pmed.0030194
   Jacquelin B, 2009, J CLIN INVEST, V119, P3544, DOI 10.1172/JCI40093
   Kindler E, 2013, MBIO, V4, DOI 10.1128/mBio.00611-12
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lawler JV, 2006, PLOS MED, V3, P677, DOI 10.1371/journal.pmed.0030149
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   Mentzel S, 1996, J HISTOCHEM CYTOCHEM, V44, P445, DOI 10.1177/44.5.8627002
   Munster VJ, 2013, NEW ENGL J MED, V368, P1560, DOI 10.1056/NEJMc1215691
   Munster VJ, 2012, SCI REP-UK, V2, DOI 10.1038/srep00736
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Qin C, 2005, J PATHOL, V206, P251, DOI 10.1002/path.1769
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rowe T, 2004, J VIROL, V78, P11401, DOI 10.1128/JVI.78.20.11401-11404.2004
   Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Tahir M, 2013, EUROSURVEILLANCE, V18, P4
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   van Riel D, 2006, SCIENCE, V312, P399, DOI 10.1126/science.1125548
   WHO, 2013, COR INF
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 30
TC 132
Z9 132
U1 3
U2 23
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 8
PY 2013
VL 110
IS 41
BP 16598
EP 16603
DI 10.1073/pnas.1310744110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 231ED
UT WOS:000325395600071
PM 24062443
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Worthington, KJ
   Currie, RJW
   Jones, RC
AF Worthington, K. J.
   Currie, R. J. W.
   Jones, R. C.
TI A reverse transcriptase-polymerase chain reaction survey of infectious
   bronchitis virus genotypes in Western Europe from 2002 to 2006
SO AVIAN PATHOLOGY
LA English
DT Article
ID MOLECULAR CHARACTERIZATION; AVIAN PNEUMOVIRUS; UNITED-STATES; ITALY 02;
   CHICKENS; CORONAVIRUS; MASSACHUSETTS; BROILERS; FIELD; EPIDEMIOLOGY
AB A survey of infectious bronchitis virus (IBV) genotypes in poultry flocks in selected countries in Western Europe was carried out between March 2002 and December 2006. Identification of IBV was by reverse transcriptase-polymerase chain reaction of RNA extracted from oropharyngeal swabs taken from poultry flocks exhibiting signs of clinical disease thought to be attributable to IBV. Part of the hypervariable S1 gene of IBV was sequenced to differentiate between the various genotypes. During the survey, 4103 samples were processed, of which 2419 (59%) were positive for IBV. The predominant IBV genotypes detected were 793B and Massachusetts. The third and fourth most common genotypes were two new economically important field types: Italy02, and a virus similar to genotypes originally detected in China called QX. Analysis of the partial S1 sequences of the genotypes detected suggested that approximately 50% of all 793B, Massachusetts types and D274 IBVs were identical to the homologous commercially available live vaccines. Since 2004 the prevalence of Italy02 (present in all countries from which samples were received) has been declining in all countries except Spain, where it appeared to be the predominant genotype. Since 2004 an IBV genotype has been detected in Holland, Germany, Belgium and France similar to QX and the incidence has increased. QX was not detected in the United Kingdom or Spain. When detections thought to be attributable to vaccines were removed, the dominant genotype in France and Europe overall was 793B; in Germany, Holland and Belgium, it was QX-like IBV; and in the United Kingdom and Spain the dominant genotype was Italy02. The present study is the first to identify the prevalence of both Italy02 and QX field-type variants in poultry flocks in Western Europe. Several novel genotypes have also been detected.
C1 [Worthington, K. J.; Jones, R. C.] Univ Liverpool, Dept Vet Pathol, Neston CH64 7TE, South Wirral, England.
   [Currie, R. J. W.] Ft Dodge Anim Hlth, NL-1411 GM Naarden, Netherlands.
RP Worthington, KJ (reprint author), Univ Liverpool, Dept Vet Pathol, Neston CH64 7TE, South Wirral, England.
EM k.j.worthington@liverpool.ac.uk
CR Adzhar A, 1996, AVIAN PATHOL, V25, P817, DOI 10.1080/03079459608419184
   Adzhar A, 1997, AVIAN PATHOL, V26, P625, DOI 10.1080/03079459708419239
   ALEXANDER DJ, 1977, RES VET SCI, V23, P344, DOI 10.1016/S0034-5288(18)33129-1
   Alvarado IR, 2006, AVIAN DIS, V50, P292, DOI 10.1637/7458-101805R.1
   Beato MS, 2005, VET REC, V156, P720, DOI 10.1136/vr.156.22.720
   Bochkov YA, 2007, VIRUS GENES, V35, P65, DOI 10.1007/s11262-006-0037-0
   Bochkov YA, 2006, AVIAN PATHOL, V35, P379, DOI 10.1080/03079450600921008
   Brown IH, 2006, DEV BIOLOGICALS, V124, P45
   Callison SA, 2001, AVIAN DIS, V45, P492, DOI 10.2307/1592994
   Capua I, 1999, AVIAN PATHOL, V28, P587, DOI 10.1080/03079459994380
   Cavanagh D, 2005, AVIAN PATHOL, V34, P439, DOI 10.1080/03079450500367682
   Cavanagh D, 1997, AVIAN PATHOL, V26, P63, DOI 10.1080/03079459708419194
   Cavanagh D, 1999, AVIAN PATHOL, V28, P593, DOI 10.1080/03079459994399
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   CRINION RAP, 1971, AVIAN DIS, V15, P42, DOI 10.2307/1588386
   Dolz R, 2006, AVIAN PATHOL, V35, P77, DOI 10.1080/03079450600597295
   Domanska-Blicharz K, 2006, VET REC, V158, P808, DOI 10.1136/vr.158.23.808-c
   Elhafi G, 2004, AVIAN PATHOL, V33, P303, DOI 10.1080/0307945042000205874
   Gelb J, 2005, AVIAN PATHOL, V34, P194, DOI 10.1080/03079450500096539
   Jackwood MW, 2005, AVIAN DIS, V49, P614, DOI 10.1637/7389-052905R.1
   Jonassen CM, 2005, J GEN VIROL, V86, P1597, DOI 10.1099/vir.0.80927-0
   Jones RC, 2005, VET REC, V156, P646, DOI 10.1136/vr.156.20.646
   Jones RC, 2005, VET REC, V156, P260
   JONES RC, 1972, RES VET SCI, V32, P52
   KUSTERS JG, 1989, VIROLOGY, V169, P217, DOI 10.1016/0042-6822(89)90058-5
   LI J, 1993, AVIAN PATHOL, V22, P771
   Liu SW, 2005, J GEN VIROL, V86, P719, DOI 10.1099/vir.0.80546-0
   MEULEMANS G, 1987, VET REC, V120, P205, DOI 10.1136/vr.120.9.205
   Meulemans G, 2001, AVIAN PATHOL, V30, P411, DOI 10.1080/03079450120066412
   Naqi S, 2003, AVIAN DIS, V47, P594, DOI 10.1637/6087
   Qian DH, 2006, AM J VET RES, V67, P1575, DOI 10.2460/ajvr.67.9.1575
   Sun L, 2007, VIRUS RES, V130, P121, DOI 10.1016/j.virusres.2007.06.003
   Wang YuDong, 1998, Chinese Journal of Animal Quarantine, V15, P1
   Worthington K. J., 2004, P 4 INT S AV COR PNE, P125
   Worthington KJ, 2006, VET REC, V159, P291, DOI 10.1136/vr.159.9.291-b
NR 35
TC 132
Z9 142
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0307-9457
J9 AVIAN PATHOL
JI Avian Pathol.
PY 2008
VL 37
IS 3
BP 247
EP 257
DI 10.1080/03079450801986529
PG 11
WC Veterinary Sciences
SC Veterinary Sciences
GA 318EZ
UT WOS:000257075700004
PM 18568650
DA 2020-04-03
ER

PT J
AU Prentice, E
   McAuliffe, J
   Lu, XT
   Subbarao, K
   Denison, MR
AF Prentice, E
   McAuliffe, J
   Lu, XT
   Subbarao, K
   Denison, MR
TI Identification and characterization of severe acute respiratory syndrome
   coronavirus replicase proteins
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; LENGTH INFECTIOUS CDNA; SARS-CORONAVIRUS; GENE
   POLYPROTEIN; REVERSE GENETICS; RNA-POLYMERASE; VIRAL-RNA; IN-VITRO;
   GENOME; LOCALIZATION
AB The severe acute respiratory syndrome coronavirus (SARS-CoV) encodes proteins required for RNA transcription and genome replication as large polyproteins that are proteolytically processed by virus-encoded proteinases to produce mature replicase proteins. In this report, we generated antibodies against SARS-CoV predicted replicase protein and used the antibodies to identify and characterize 12 of the 16 predicted mature replicase proteins (nsp1, nsp2, nsp3, nsp4, nsp5, nsp8, nsp9, nsp12, nsp13, nsp14, nsp15, and nsp16) in SARS-CoV-infected Vero cells. Immunoblot analysis of infected-cell lysates identified proteins of the predicted sizes. Immunofluorescence microscopy detected similar patterns of punctate perinuclear and distributed cytoplasmic foci with all replicase antibodies and as early as 6 h postinfection. Dual-labeling studies demonstrated colocalization of replicase protein nsp8 with nsp2 and nsp3 in cytoplasmic complexes and also with LC3, a protein marker for autophagic vacuoles. Antibodies directed against mouse hepatitis virus (MHV) virions and against the putative RNA-dependent RNA polymerase (Pol) detected SARS-CoV nucleocapsid and nsp12 (Pol), respectively, in SARS-CoV-infected Vero cells. These results confirm the predicted protein processing pattern for mature SARS-CoV replicase proteins, demonstrate localization of replicase proteins to cytoplasmic complexes containing markers for autophagosome membranes, and suggest conservation of protein epitopes in the replicase and nucleocapsid of SARS-CoV and the group II coronavirus, MHV. Further, the results demonstrate the ability of replicase antibodies to detect SARS-CoV-infected cells as early as 6 h postinfection and thus represent important tools for studies of SARS-CoV replication, inhibition, and diagnosis.
C1 Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA.
   NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
RP Denison, MR (reprint author), Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, D6217 MCN, Nashville, TN 37232 USA.
EM mark.denison@vanderbilt.edu
RI Denison, Mark/O-7258-2018
OI Denison, Mark/0000-0003-2655-0900; Subbarao, Kanta/0000-0003-1713-3056
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30
   CA068485, CA68485]; NHLBI NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [T32 HL007751, 5 T32 HL07751];
   NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI050083, AI50083-S1]; NIDDK NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [DK20593, P30 DK020593, P60
   DK020593]
CR Arbour N, 2000, J VIROL, V74, P8913, DOI 10.1128/JVI.74.19.8913-8921.2000
   Bi WZ, 1998, J NEUROVIROL, V4, P594, DOI 10.3109/13550289809114226
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000
   Bost AG, 2001, VIROLOGY, V285, P21, DOI 10.1006/viro.2001.0932
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   Brockway SM, 2003, J VIROL, V77, P10515, DOI 10.1128/JVI.77.19.10515-10527.2003
   Casais R, 2001, J VIROL, V75, P12359, DOI 10.1128/JVI.75.24.12359-12369.2001
   Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999
   DENISON MR, 1992, VIROLOGY, V189, P274, DOI 10.1016/0042-6822(92)90703-R
   DENISON MR, 1998, VIRAL INFECT LUNG, P253
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Gonzalez JM, 2001, ADV EXP MED BIOL, V494, P533
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Kanjanahaluethai A, 2003, J VIROL, V77, P7376, DOI 10.1128/JVI.77.13.7376-7382.2003
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   Lu XT, 1998, J VIROL, V72, P2265, DOI 10.1128/JVI.72.3.2265-2271.1998
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Navas S, 2003, J VIROL, V77, P4972, DOI 10.1128/JVI.77.8.4972-4978.2003
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   PRENTICE E, 2003, J BIOL CHEM, V279, P10136
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Schiller JJ, 1998, VIROLOGY, V242, P288, DOI 10.1006/viro.1997.9010
   Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728
   Shi ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   van der Meer Y, 1999, J VIROL, V73, P7641, DOI 10.1128/JVI.73.9.7641-7657.1999
   van Elden LJR, 2004, J INFECT DIS, V189, P652, DOI 10.1086/381207
   Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Yount B, 2002, J VIROL, V76, P11065, DOI 10.1128/JVI.76.21.11065-11078.2002
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 39
TC 132
Z9 145
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2004
VL 78
IS 18
BP 9977
EP 9986
DI 10.1128/JVI.78.18.9977-9986.2004
PG 10
WC Virology
SC Virology
GA 851QY
UT WOS:000223701100042
PM 15331731
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Babcock, GJ
   Esshaki, DJ
   Thomas, WD
   Ambrosino, DM
AF Babcock, GJ
   Esshaki, DJ
   Thomas, WD
   Ambrosino, DM
TI Amino acids 270 to 510 of the severe acute respiratory syndrome
   coronavirus spike protein are required for interaction with receptor
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS; MURINE CORONAVIRUS;
   CONFORMATIONAL-CHANGES; MEMBRANE-FUSION; HEPATITIS-VIRUS; GLYCOPROTEIN;
   BINDING; NEUTRALIZATION; IDENTIFICATION; DOMAIN
AB A novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV), has recently been identified as the causative agent of severe acute respiratory syndrome (SARS). SARS-CoV appears similar to other coronaviruses in both virion structure and genome organization. It is known for other coronaviruses that the spike (S) glycoprotein is required for both viral attachment to permissive cells and for fusion of the viral envelope with the host cell membrane. Here we describe the construction and expression of a soluble codon-optimized SARS-CoV S glycoprotein comprising the first 1,190 amino acids of the native S glycoprotein (S-1190). The codon-optimized and native S glycoproteins exhibit similar molecular weight as determined by Western blot analysis, indicating that synthetic S glycoprotein is modified correctly in a mammalian expression system. S-1190 binds to the surface of Vero E6 cells, a cell permissive to infection, as demonstrated by fluorescence-activated cell sorter analysis, suggesting that S-1190 maintains the biologic activity present in native S glycoprotein. This interaction is blocked with serum obtained from recovering SARS patients, indicating that the binding is specific. In an effort to map the ligand-binding domain of the SARS-CoV S glycoprotein, carboxy- and amino-terminal truncations of the S-1190 glycoprotein were constructed. Amino acids 270 to 510 were the minimal receptor-binding region of the SARS-CoV S glycoprotein as determined by How cytometry. We speculate that amino acids 1 to 510 of the SARS-CoV S glycoprotein represent a unique domain containing the receptor-binding site (amino acids 270 to 510), analogous to the S1 subunit of other coronavirus S glycoproteins.
C1 Univ Massachusetts, Sch Med, Massachusetts Biol Labs, Jamaica Plain, MA 02130 USA.
RP Babcock, GJ (reprint author), Univ Massachusetts, Sch Med, Massachusetts Biol Labs, 305 South St, Jamaica Plain, MA 02130 USA.
EM greg.babcock@umassmed.edu
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01AI65315, N01-AI-65315]
CR Bikker JA, 1998, J MED CHEM, V41, P2911, DOI 10.1021/jm970767a
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   DANIEL C, 1990, VIROLOGY, V174, P87, DOI 10.1016/0042-6822(90)90057-X
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985
   GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994
   Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7
   Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404
   Krempl C, 1997, J VIROL, V71, P3285, DOI 10.1128/JVI.71.4.3285-3287.1997
   Krueger DK, 2001, J VIROL, V75, P2792, DOI 10.1128/JVI.75.6.2792-2802.2001
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   Luo ZL, 1998, ADV EXP MED BIOL, V440, P17
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   PENSAERT M, 1986, VET QUART, V8, P257, DOI 10.1080/01652176.1986.9694050
   PIKE BV, 1979, J GEN VIROL, V42, P279, DOI 10.1099/0022-1317-42-2-279
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   STERN DF, 1982, J VIROL, V44, P794, DOI 10.1128/JVI.44.3.794-803.1982
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   SUNE C, 1990, VIROLOGY, V177, P559, DOI 10.1016/0042-6822(90)90521-R
   Tsai JC, 2003, J VIROL, V77, P841, DOI 10.1128/JVI.77.2.841-850.2003
   WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803
   Zelus BD, 2003, J VIROL, V77, P830, DOI 10.1128/JVI.77.2.830-840.2003
NR 27
TC 132
Z9 142
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAY
PY 2004
VL 78
IS 9
BP 4552
EP 4560
DI 10.1128/JVI.78.9.4552-4560.2004
PG 9
WC Virology
SC Virology
GA 813AO
UT WOS:000220880200018
PM 15078936
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Winther, B
   Hayden, FG
   Hendley, JO
AF Winther, B
   Hayden, FG
   Hendley, JO
TI Picornavirus infections in children diagnosed by RT-PCR during
   longitudinal surveillance with weekly sampling: Association with
   symptomatic illness and effect of season
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE rhinovirus; RT-PCR; viral respiratory illness; asymptomatic infection;
   longitudinal surveillance
ID POLYMERASE-CHAIN-REACTION; RESPIRATORY ILLNESS; RHINOVIRUS; VIRUS;
   HYBRIDIZATION; CORONAVIRUS; COMMUNITY; RNA
AB RT-PCR is more sensitive for rhinovirus detection than cell culture, but healthy controls are frequently rhinovirus (or picornavirus) positive in cross-sectional studies. Fifteen healthy children were followed over at least three seasons of the year with weekly sampling of nasal/nasopharyngeal secretion for RT-PCR testing for picornavirus and daily recording of respiratory symptoms. One sample positive for picornavirus was diagnosed as an infection;.consecutive positive weekly samples constituted a single infection. Picornavirus illness was diagnosed if RNA was detected 7 days prior through 21 days after onset. One hundred fifty-five (21%) of 740 weekly samples were picornavirus positive and associated with illness; 37(5%) positives were not associated with illness (P=0.001). The 192 positive samples occurred in 121 infections, 74 with a single positive and 47 with "runs" of positives in two or more consecutive samples. Forty five (96%) of the 47 runs comprised 2 or 3 consecutive positives. Ninety six (52%) of 185 reported illnesses during 235 child-months were picornavirus positive (0.4/child-month); 25 infections were asymptomatic (0.11/child-month). The infection rate was highest in fall (0.66/childmonth); the winter rate (0.44/child-month) was similar to that in spring (0.5) and summer (0.43). Picornavirus infections in healthy children were common (0.51/child-month), episodic, and usually associated with brief illness; one fifth of infections were asymptomatic. The infection rate was highest in fall; infections in winter occurred at the same rate as in spring and summer. (c) 2006 Wiley-Liss, Inc.
C1 Univ Virginia, Hlth Syst, Dept Otolaryngol Head & Neck Surg, Charlottesville, VA USA.
   Univ Virginia, Hlth Syst, Dept Internal Med, Charlottesville, VA USA.
   Univ Virginia, Hlth Syst, Dept Pediat, Charlottesville, VA USA.
RP Winther, B (reprint author), POB 800713, Charlottesville, VA 22908 USA.
EM bw8b@virginia.edu
CR Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997
   Fan J, 1998, CLIN INFECT DIS, V26, P1397, DOI 10.1086/516357
   Hendley JO, 2005, APMIS, V113, P213, DOI 10.1111/j.1600-0463.2005.apm1130310.x
   Hendley JO, 1998, CLIN INFECT DIS, V26, P847, DOI 10.1086/513921
   Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Nokso-Koivisto J, 2002, J MED VIROL, V66, P417, DOI 10.1002/jmv.2161
   Pitkaranta A, 1998, J PEDIATR-US, V133, P390, DOI 10.1016/S0022-3476(98)70276-8
   Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791
   Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052
   Vesanen M, 1996, J VIROL METHODS, V59, P1, DOI 10.1016/0166-0934(95)01991-X
   WINTHER B, 1986, JAMA-J AM MED ASSOC, V256, P1763, DOI 10.1001/jama.256.13.1763
   Winther B, 2002, PEDIATRICS, V109, P826, DOI 10.1542/peds.109.5.826
NR 13
TC 131
Z9 132
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD MAY
PY 2006
VL 78
IS 5
BP 644
EP 650
DI 10.1002/jmv.20588
PG 7
WC Virology
SC Virology
GA 030TH
UT WOS:000236657000017
PM 16555289
DA 2020-04-03
ER

PT J
AU Xu, YH
   Lou, ZY
   Liu, YW
   Pang, H
   Tien, P
   Gao, GF
   Rao, ZH
AF Xu, YH
   Lou, ZY
   Liu, YW
   Pang, H
   Tien, P
   Gao, GF
   Rao, ZH
TI Crystal structure of severe acute respiratory syndrome coronavirus spike
   protein fusion core
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SARS-ASSOCIATED CORONAVIRUS; EBOLA-VIRUS GLYCOPROTEIN; MEDIATED
   MEMBRANE-FUSION; COILED-COIL; HIV-1 ENTRY; ENVELOPE GLYCOPROTEIN;
   PEPTIDE INHIBITORS; POTENT INHIBITORS; RECEPTOR-BINDING;
   ATOMIC-STRUCTURE
AB Severe acute respiratory syndrome coronavirus is a newly emergent virus responsible for a recent outbreak of an atypical pneumonia. The coronavirus spike protein, an enveloped glycoprotein essential for viral entry, belongs to the class I fusion proteins and is characterized by the presence of two heptad repeat (HR) regions, HR1 and HR2. These two regions are understood to form a fusion-active conformation similar to those of other typical viral fusion proteins. This hairpin structure likely juxtaposes the viral and cellular membranes, thus facilitating membrane fusion and subsequent viral entry. The fusion core protein of severe acute respiratory syndrome coronavirus spike protein was crystallized, and the structure was determined at 2.8 of resolution. The fusion core is a six-helix bundle with three HR2 helices packed against the hydrophobic grooves on the surface of central coiled coil formed by three parallel HR1 helices in an oblique antiparallel manner. This structure shares significant similarity with the fusion core structure of mouse hepatitis virus spike protein and other viral fusion proteins, suggesting a conserved mechanism of membrane fusion. Drug discovery strategies aimed at inhibiting viral entry by blocking hairpin formation, which have been successfully used in human immunodeficiency virus 1 inhibitor development, may be applicable to the inhibition of severe acute respiratory syndrome coronavirus on the basis of structural information provided here. The relatively deep grooves on the surface of the central coiled coil will be a good target site for the design of viral fusion inhibitors.
C1 Tsing Hua Univ, Struct Biol Lab, Beijing 100084, Peoples R China.
   Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
   Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.
   Chinese Acad Sci, Inst Microbiol, Beijing 100080, Peoples R China.
RP Rao, ZH (reprint author), Tsing Hua Univ, Struct Biol Lab, Beijing 100084, Peoples R China.
EM raozh@xtal.tsinghua.edu.cn
RI Xu, Yanhui/D-5119-2019
CR Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   Bosch BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/pnas.0400576101
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   CAVANAGH D, 1983, J GEN VIROL, V64, P2577, DOI 10.1099/0022-1317-64-12-2577
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777
   Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898
   Eickmann M, 2003, SCIENCE, V302, P1504
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627
   Imai M, 2000, MICROBIOL IMMUNOL, V44, P205, DOI 10.1111/j.1348-0421.2000.tb02485.x
   Ingallinella P, 2004, P NATL ACAD SCI USA, V101, P8709, DOI 10.1073/pnas.0402753101
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761
   Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   TAGUCHI F, 1995, J VIROL, V69, P7260, DOI 10.1128/JVI.69.11.7260-7263.1995
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Tripet B, 2004, J BIOL CHEM, V279, P20836, DOI 10.1074/jbc.M400759200
   Tsang KW, 2003, RESPIROLOGY, V8, P259, DOI 10.1046/j.1440-1843.2003.00486.x
   Watanabe S, 2000, J VIROL, V74, P10194, DOI 10.1128/JVI.74.21.10194-10201.2000
   Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Xu YH, 2004, J BIOL CHEM, V279, P30514, DOI 10.1074/jbc.M403760200
   Yuan KH, 2004, BIOCHEM BIOPH RES CO, V319, P746, DOI 10.1016/j.bbrc.2004.05.046
   Zhu JQ, 2004, BIOCHEM BIOPH RES CO, V319, P283, DOI 10.1016/j.bbrc.2004.04.141
NR 51
TC 131
Z9 147
U1 2
U2 18
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 19
PY 2004
VL 279
IS 47
BP 49414
EP 49419
DI 10.1074/jbc.M408782200
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 870ZP
UT WOS:000225098100110
PM 15345712
OA Bronze
DA 2020-04-03
ER

PT J
AU ter Meulen, J
   Bakker, ABH
   van den Brink, EN
   Weverling, GJ
   Martina, BEE
   Haagmans, BL
   Kuiken, T
   de Kruif, J
   Preiser, W
   Spaan, W
   Gelderblom, HR
   Goudsmit, J
   Osterhaus, ADME
AF ter Meulen, J
   Bakker, ABH
   van den Brink, EN
   Weverling, GJ
   Martina, BEE
   Haagmans, BL
   Kuiken, T
   de Kruif, J
   Preiser, W
   Spaan, W
   Gelderblom, HR
   Goudsmit, J
   Osterhaus, ADME
TI Human monoclonal antibody as prophylaxis for SARS coronavirus infection
   in ferrets
SO LANCET
LA English
DT Article
AB SARS coronavirus continues to cause sporadic cases of severe acute respiratory syndrome (SARS) in China. No active or passive immunoprophylaxis for disease induced by SARS coronavirus is available. We investigated prophylaxis of SARS coronavirus infection with a neutralising human monoclonal antibody in ferrets, which can be readily infected with the virus. Prophylactic administration of the monoclonal antibody at 10 mg/kg reduced replication of SARS coronavirus in the lungs of infected ferrets by 3.3 logs (95% Cl 2.6-4.0 logs; p<0.001), completely prevented the development of SARS coronavirus-induced macroscopic lung pathology (p=0.013), and abolished shedding of virus in pharyngeal secretions. The data generated in this animal model show that administration of a human monoclonal antibody might offer a feasible and effective prophylaxis for the control of human SARS coronavirus infection.
C1 Crucell Holland BV, NL-2301 CA Leiden, Netherlands.
   Univ Frankfurt, Inst Med Virol, D-6000 Frankfurt, Germany.
   Robert Koch Inst, D-1000 Berlin, Germany.
   Leiden Univ, Med Ctr, Dept Med Microbiol, Leiden, Netherlands.
   Erasmus Med Ctr, Dept Virol, Rotterdam, Netherlands.
RP ter Meulen, J (reprint author), Crucell Holland BV, POB 2048, NL-2301 CA Leiden, Netherlands.
EM j.termeulen@crucell.com
RI Bakker, Arnold B./F-8494-2010; Preiser, Wolfgang/J-4875-2016
OI Bakker, Arnold B./0000-0003-1489-1847; Preiser,
   Wolfgang/0000-0002-0254-7910; Haagmans, Bart/0000-0001-6221-2015;
   Osterhaus, Albert/0000-0002-6074-1172
CR Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Parnes C, 2003, PEDIATR PULM, V35, P484, DOI 10.1002/ppul.10288
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Tsang OTY, 2003, EMERG INFECT DIS, V9, P1381, DOI 10.3201/eid0911.030400
NR 5
TC 131
Z9 139
U1 5
U2 10
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 26
PY 2004
VL 363
IS 9427
BP 2139
EP 2141
DI 10.1016/S0140-6736(04)16506-9
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 832LF
UT WOS:000222268300013
PM 15220038
OA Bronze
DA 2020-04-03
ER

PT S
AU Sawicki, SG
   Sawicki, DL
AF Sawicki, SG
   Sawicki, DL
BE Enjuanes, L
   Siddell, SG
   Spaan, W
TI A new model for coronavirus transcription
SO CORONAVIRUSES AND ARTERIVIRUSES
SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY
LA English
DT Article; Proceedings Paper
CT VIIth International Symposium on Coronaviruses and Arteriviruses
CY MAY 10-15, 1997
CL SEGOVIA, SPAIN
SP Int Comm Taxon Viruses, Ctr Nacl Biotecnol, Coronavirus Lab, Madrid
ID MOUSE HEPATITIS-VIRUS; DEFECTIVE INTERFERING RNA; RECOMBINATION;
   REPLICATION; POLYMERASE; INITIATION; SEQUENCES; GENOME
AB Coronaviruses contain an unusually long (27-32,000 ribonucleotide) positive sense RNA genome that is polyadenylated at the 3' end and capped at the 5' end. In addition to the genome, infected cells contain subgenomic mRNAs that form a 3' co-terminal nested set with the genome. In addition to their common 3' ends, the genome and the subgenomic mRNAs contain an identical 5' leader sequence. The transcription mechanism that coronaviruses use to produce subgenomic mRNA is not known and has been the subject of speculation since sequencing of the subgenomic mRNAs showed they must arise by discontinuous transcription. The current model called leader-primed transcription has subgenomic mRNAs transcribed directly from genome-length negative strands. It was based on the failure to find in coronavirus infected cells subgenome-length negative strands or replication intermediates containing subgenome-length negative strands. Clearly, these structures exist in infected cells and are transcriptionally active. We proposed a new model for coronavirus transcription which we called 3' discontinuous extension of negative strands. This model predicts that subgenome-length negative strands would be derived directly by transcription using the genome RNA as a template. The subgenome-length templates would contain the common 5' leader sequence and serve as templates for the production of subgenomic mRNAs. Our findings include showing that: 1. Replication intermediates (RIs) containing subgenome-length RNA exist in infected cells and are separable from RIs with genome-length templates. The RFs with subgenome-length templates are not derived by RNase treatment of RIs with genome-length templates. 2. The subgenome-length negative strands are formed early in infection when RIs are accumulating and the rate of viral RNA synthesis is increasing exponentially. 3. Subgenome-length negative strands contain at their 3' ends a complementary copy of the 72 nucleotide leader RNA that is found in the genome only at their 5' end. 4. RIs with subgenomic templates serve immediately as templates for transcription of subgenomic mRNAs. Because subgenomic mRNAs are not replicated, i.e., copied into negative strands that in turn are used as templates for subgenomic mRNA synthesis, we propose that the subgenome-length negative strands must arise directly by transcription of the genome and acquire their common 3' anti-leader sequence after polymerase jumping from the intergenic regions to the leader sequence at the 5' end of the genome. This would make negative strand synthesis discontinuous and subgenomic mRNA synthesis continuous, which is the opposite of what was proposed in the leader primed model.
C1 Med Coll Ohio, Dept Immunol & Microbiol, Toledo, OH 43699 USA.
RP Sawicki, SG (reprint author), Med Coll Ohio, Dept Immunol & Microbiol, Toledo, OH 43699 USA.
CR BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   BRAIN DA, 1994, ARCH VIROL         S, V9, P173
   Chang RY, 1996, J VIROL, V70, P2720, DOI 10.1128/JVI.70.5.2720-2729.1996
   Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   MAKINO S, 1991, J VIROL, V65, P6031, DOI 10.1128/JVI.65.11.6031-6041.1991
   MASTERS PS, 1994, J VIROL, V68, P328, DOI 10.1128/JVI.68.1.328-337.1994
   Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   Stillman EA, 1997, J VIROL, V71, P2127, DOI 10.1128/JVI.71.3.2127-2137.1997
   SWICKI SG, 1995, CORONA RELATED VIRUS, P499
   VANDERMOST RG, 1994, J VIROL, V68, P3656, DOI 10.1128/JVI.68.6.3656-3666.1994
NR 14
TC 131
Z9 137
U1 1
U2 9
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0065-2598
BN 0-306-45910-8
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 1998
VL 440
BP 215
EP 219
PG 5
WC Immunology; Medicine, Research & Experimental; Microbiology; Virology
SC Immunology; Research & Experimental Medicine; Microbiology; Virology
GA BL64J
UT WOS:000076154700026
PM 9782283
DA 2020-04-03
ER

PT J
AU Brister, JR
   Ako-adjei, D
   Bao, YM
   Blinkova, O
AF Brister, J. Rodney
   Ako-adjei, Danso
   Bao, Yiming
   Blinkova, Olga
TI NCBI Viral Genomes Resource
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; REFERENCE SEQUENCES REFSEQ;
   HEPATITIS-C VIRUS; NATIONAL-CENTER; BIOTECHNOLOGY-INFORMATION;
   STANDARDIZED NOMENCLATURE; FAMILY FILOVIRIDAE; COMPARISON PASC; SPECIES
   LEVEL; ANNOTATION
AB Recent technological innovations have ignited an explosion in virus genome sequencing that promises to fundamentally alter our understanding of viral biology and profoundly impact public health policy. Yet, any potential benefits from the billowing cloud of next generation sequence data hinge upon well implemented reference resources that facilitate the identification of sequences, aid in the assembly of sequence reads and provide reference annotation sources. The NCBI Viral Genomes Resource is a reference resource designed to bring order to this sequence shockwave and improve usability of viral sequence data. The resource can be accessed at http://www.ncbi.nlm.nih.gov/genome/viruses/ and catalogs all publicly available virus genome sequences and curates reference genome sequences. As the number of genome sequences has grown, so too have the difficulties in annotating and maintaining reference sequences. The rapid expansion of the viral sequence universe has forced a recalibration of the data model to better provide extant sequence representation and enhanced reference sequence products to serve the needs of the various viral communities. This, in turn, has placed increased emphasis on leveraging the knowledge of individual scientific communities to identify important viral sequences and develop well annotated reference virus genome sets.
C1 [Brister, J. Rodney; Ako-adjei, Danso; Bao, Yiming; Blinkova, Olga] Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.
RP Brister, JR (reprint author), Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.
EM jamesbr@ncbi.nlm.nih.gov
FU Intramural Research Program of the National Institutes of Health,
   National Library of MedicineUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Library of
   Medicine (NLM)
FX This research was supported by the Intramural Research Program of the
   National Institutes of Health, National Library of Medicine. Funding for
   open access charge: Intramural Research Program of National Institutes
   of Health, National Library of Medicine.
CR Acland A, 2014, NUCLEIC ACIDS RES, V42, pD7, DOI 10.1093/nar/gkt1146
   Alfson KJ, 2014, J VIROL METHODS, V208, P1, DOI 10.1016/j.jviromet.2014.07.023
   Baize S, 2014, NEW ENGL J MED, V371, P1418, DOI 10.1056/NEJMoa1404505
   Bao YM, 2008, J VIROL, V82, P596, DOI 10.1128/JVI.02005-07
   Bao Y, 2007, NUCLEIC ACIDS RES, V35, pW280, DOI 10.1093/nar/gkm354
   Bao YM, 2014, ARCH VIROL, V159, P3293, DOI 10.1007/s00705-014-2197-x
   Bao YM, 2012, VIRUSES-BASEL, V4, P1318, DOI 10.3390/v4081318
   Bao YM, 2004, J VIROL, V78, P7291, DOI 10.1128/JVI.78.14.7291-7298.2004
   Benson DA, 2014, NUCLEIC ACIDS RES, V42, pD32, DOI 10.1093/nar/gkt1030
   Boratyn GM, 2013, NUCLEIC ACIDS RES, V41, pW29, DOI 10.1093/nar/gkt282
   Borozan I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076935
   Brister JR, 2014, NUCLEIC ACIDS RES, V42, pD660, DOI 10.1093/nar/gkt1268
   Brister JR, 2012, VIROLOGY, V434, P175, DOI 10.1016/j.virol.2012.09.027
   Brister JR, 2010, VIRUSES-BASEL, V2, P2258, DOI 10.3390/v2102258
   Brooksbank C, 2014, NUCLEIC ACIDS RES, V42, pD18, DOI 10.1093/nar/gkt1206
   Cotten M, 2014, J VIROL, V88, P11056, DOI 10.1128/JVI.01333-14
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Davison AJ, 2010, VET MICROBIOL, V143, P52, DOI 10.1016/j.vetmic.2010.02.014
   Dennis AF, 2014, J VIROL, V88, P3789, DOI 10.1128/JVI.03516-13
   Dutilh BE, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5498
   Federhen S, 2012, NUCLEIC ACIDS RES, V40, pD136, DOI 10.1093/nar/gkr1178
   Fu W, 2009, NUCLEIC ACIDS RES, V37, pD417, DOI 10.1093/nar/gkn708
   Gaynor AM, 2007, PLOS PATHOG, V3, P595, DOI 10.1371/journal.ppat.0030064
   Gire SK, 2014, SCIENCE, V345, P1369, DOI 10.1126/science.1259657
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Holtz LR, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-86
   Jancovich J.K., 2012, VIRUS TAXONOMY CLASS
   Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201
   Karsch-Mizrachi I, 2012, NUCLEIC ACIDS RES, V40, pD33, DOI 10.1093/nar/gkr1006
   Kattenhorn LM, 2004, J VIROL, V78, P11187, DOI 10.1128/JVI.78.20.11187-11197.2004
   Klimke W, 2009, NUCLEIC ACIDS RES, V37, pD216, DOI 10.1093/nar/gkn734
   Kostic AD, 2011, NAT BIOTECHNOL, V29, P393, DOI 10.1038/nbt.1868
   Kosuge T, 2014, NUCLEIC ACIDS RES, V42, pD44, DOI 10.1093/nar/gkt1066
   Kuhn JH, 2013, ARCH VIROL, V158, P1425, DOI 10.1007/s00705-012-1594-2
   Kuhn JH, 2013, ARCH VIROL, V158, P301, DOI 10.1007/s00705-012-1454-0
   Lawrence JG, 2002, J BACTERIOL, V184, P4891, DOI 10.1128/JB.184.17.4891-4905.2002
   Maan S, 2007, J VIROL METHODS, V143, P132, DOI 10.1016/j.jviromet.2007.02.016
   Masson P, 2013, NUCLEIC ACIDS RES, V41, pD579, DOI 10.1093/nar/gks1220
   Matthijnssens J, 2011, ARCH VIROL, V156, P1397, DOI 10.1007/s00705-011-1006-z
   Mills R, 2003, NUCLEIC ACIDS RES, V31, P7041, DOI 10.1093/nar/gkg878
   Naccache SN, 2014, GENOME RES, V24, P1180, DOI 10.1101/gr.171934.113
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   Pourkarim MR, 2014, WORLD J GASTROENTERO, V20, P7152, DOI 10.3748/wjg.v20.i23.7152
   Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842
   Pruitt KD, 2012, NUCLEIC ACIDS RES, V40, pD130, DOI 10.1093/nar/gkr1079
   Rancurel C, 2009, J VIROL, V83, P10719, DOI 10.1128/JVI.00595-09
   Resch W, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-65
   Reyes A, 2012, NAT REV MICROBIOL, V10, P607, DOI 10.1038/nrmicro2853
   Rozanov M, 2004, NUCLEIC ACIDS RES, V32, pW654, DOI 10.1093/nar/gkh419
   Sabath N, 2012, MOL BIOL EVOL, V29, P3767, DOI 10.1093/molbev/mss179
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   Smith DB, 2014, HEPATOLOGY, V59, P318, DOI 10.1002/hep.26744
   Tanwar Sudeep, 2012, Curr Gastroenterol Rep, V14, P37, DOI 10.1007/s11894-011-0233-5
   *UNIPROT CONS, 2010, NUCL ACIDS RES, V0038
   Wang QG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064465
   Wang SL, 2012, NUCLEIC ACIDS RES, V40, pW186, DOI 10.1093/nar/gks528
   Wang SL, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-451
NR 57
TC 130
Z9 130
U1 1
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JAN 28
PY 2015
VL 43
IS D1
BP D571
EP D577
DI 10.1093/nar/gku1207
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CC2YF
UT WOS:000350210400085
PM 25428358
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Peng, XX
   Gralinski, L
   Armour, CD
   Ferris, MT
   Thomas, MJ
   Proll, S
   Bradel-Tretheway, BG
   Korth, MJ
   Castle, JC
   Biery, MC
   Bouzek, HK
   Haynor, DR
   Frieman, MB
   Heise, M
   Raymond, CK
   Baric, RS
   Katze, MG
AF Peng, Xinxia
   Gralinski, Lisa
   Armour, Christopher D.
   Ferris, Martin T.
   Thomas, Matthew J.
   Proll, Sean
   Bradel-Tretheway, Birgit G.
   Korth, Marcus J.
   Castle, John C.
   Biery, Matthew C.
   Bouzek, Heather K.
   Haynor, David R.
   Frieman, Matthew B.
   Heise, Mark
   Raymond, Christopher K.
   Baric, Ralph S.
   Katze, Michael G.
TI Unique Signatures of Long Noncoding RNA Expression in Response to Virus
   Infection and Altered Innate Immune Signaling
SO MBIO
LA English
DT Article
ID BIOINFORMATICS; IDENTIFICATION; TRANSCRIPTOME; DATABASE; GENOME; CELLS;
   SEQ
AB Studies of the host response to virus infection typically focus on protein-coding genes. However, non-protein-coding RNAs (ncRNAs) are transcribed in mammalian cells, and the roles of many of these ncRNAs remain enigmas. Using next-generation sequencing, we performed a whole-transcriptome analysis of the host response to severe acute respiratory syndrome coronavirus (SARS-CoV) infection across four founder mouse strains of the Collaborative Cross. We observed differential expression of approximately 500 annotated, long ncRNAs and 1,000 nonannotated genomic regions during infection. Moreover, studies of a subset of these ncRNAs and genomic regions showed the following. (i) Most were similarly regulated in response to influenza virus infection. (ii) They had distinctive kinetic expression profiles in type I interferon receptor and STAT1 knockout mice during SARS-CoV infection, including unique signatures of ncRNA expression associated with lethal infection. (iii) Over 40% were similarly regulated in vitro in response to both influenza virus infection and interferon treatment. These findings represent the first discovery of the widespread differential expression of long ncRNAs in response to virus infection and suggest that ncRNAs are involved in regulating the host response, including innate immunity. At the same time, virus infection models provide a unique platform for studying the biology and regulation of ncRNAs.
   IMPORTANCE Most studies examining the host transcriptional response to infection focus only on protein-coding genes. However, there is growing evidence that thousands of non-protein-coding RNAs (ncRNAs) are transcribed from mammalian genomes. While most attention to the involvement of ncRNAs in virus-host interactions has been on small ncRNAs such as microRNAs, it is becoming apparent that many long ncRNAs (> 200 nucleotides [nt]) are also biologically important. These long ncRNAs have been found to have widespread functionality, including chromatin modification and transcriptional regulation and serving as the precursors of small RNAs. With the advent of next-generation sequencing technologies, whole-transcriptome analysis of the host response, including long ncRNAs, is now possible. Using this approach, we demonstrated that virus infection alters the expression of numerous long ncRNAs, suggesting that these RNAs may be a new class of regulatory molecules that play a role in determining the outcome of infection.
C1 [Peng, Xinxia; Thomas, Matthew J.; Proll, Sean; Bradel-Tretheway, Birgit G.; Korth, Marcus J.; Katze, Michael G.] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA.
   [Gralinski, Lisa; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
   [Armour, Christopher D.; Castle, John C.; Biery, Matthew C.; Bouzek, Heather K.; Haynor, David R.; Raymond, Christopher K.] Rosetta Inpharmat LLC, Dept Mol Informat, Seattle, WA USA.
   [Frieman, Matthew B.] Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
   [Ferris, Martin T.; Heise, Mark] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
   [Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA.
RP Katze, MG (reprint author), Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA.
EM honey@u.washington.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U54 AI081680];
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human ServicesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [HHSN272200800060C]
FX This work was supported by the National Institutes of Health grant U54
   AI081680 (PNWRCE) and by funds from the National Institute of Allergy
   and Infectious Diseases, National Institutes of Health, Department of
   Health and Human Services, contract no. HHSN272200800060C.
CR Ahanda ML, 2009, IMMUNOGENETICS, V61, P55, DOI 10.1007/s00251-008-0337-8
   Armour CD, 2009, NAT METHODS, V6, P647, DOI [10.1038/NMETH.1360, 10.1038/nmeth.1360]
   Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133
   Dinger ME, 2009, NUCLEIC ACIDS RES, V37, pD122, DOI 10.1093/nar/gkn617
   Faulkner GJ, 2009, NAT GENET, V41, P563, DOI 10.1038/ng.368
   Frieman MB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000849
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gottwein E, 2008, CELL HOST MICROBE, V3, P375, DOI 10.1016/j.chom.2008.05.002
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Mituyama T, 2009, NUCLEIC ACIDS RES, V37, pD89, DOI 10.1093/nar/gkn805
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Pang KC, 2009, J IMMUNOL, V182, P7738, DOI 10.4049/jimmunol.0900603
   Ponjavic J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000617
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Ravasi T, 2006, GENOME RES, V16, P11, DOI 10.1101/gr.4200206
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Washietl S, 2005, P NATL ACAD SCI USA, V102, P2454, DOI 10.1073/pnas.0409169102
   Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909
NR 25
TC 130
Z9 150
U1 2
U2 27
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD NOV-DEC
PY 2010
VL 1
IS 5
AR e00206-10
DI 10.1128/mBio.00206-10
PG 9
WC Microbiology
SC Microbiology
GA 734XD
UT WOS:000288374300003
PM 20978541
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Leung, WK
   To, KF
   Chan, PKS
   Chan, HLY
   Wu, AKL
   Lee, N
   Yuen, KY
   Sung, JJY
AF Leung, WK
   To, KF
   Chan, PKS
   Chan, HLY
   Wu, AKL
   Lee, N
   Yuen, KY
   Sung, JJY
TI Enteric involvement of severe acute respiratory syndrome-associated
   coronavirus infection
SO GASTROENTEROLOGY
LA English
DT Article
ID HONG-KONG; SARS; GASTROENTERITIS; OUTBREAK; VIRUSES
AB Background & Aims: Severe acute respiratory syndrome (SARS) is a recently emerged infection from a novel coronavirus (CoV). Apart from fever and respiratory complications, gastrointestinal symptoms are frequently observed in patients with SARS but the significance remains undetermined. Herein, we describe the clinical, pathologic, and virologic features of the intestinal involvement of this new viral infection. Methods: A retrospective analysis of the gastrointestinal symptoms and other clinical parameters of the first 138 patients with confirmed SARS admitted for a major outbreak in Hong Kong in March 2003 was performed. Intestinal specimens were obtained by colonoscopy or postmortem examination to detect the presence of coronavirus by electron microscopy, virus culture, and reverse-transcription polymerase chain reaction. Results: Among these 138 patients with SARS, 28 (20.3%) presented with watery diarrhea and up to 38.4% of patients had symptoms of diarrhea during the course of illness. Diarrhea was more frequently observed during the first week of illness. The mean number of days with diarrhea was 3.7 +/- 2.7, and most diarrhea was self-limiting. Intestinal biopsy specimens obtained by colonoscopy or autopsy showed minimal architectural disruption but the presence of active viral replication within both the small and large intestine. Coronavirus was also isolated by culture from these specimens, and SARS-CoV RNA can be detected in the stool of patients for more than 10 weeks after symptom onset. Conclusions: Diarrhea is a common presenting symptom of SARS. The intestinal tropism of the SARS-CoV has major implications on clinical presentation and viral transmission.
C1 Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Dept Microbiol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
RP Leung, WK (reprint author), Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, 9-F,Clin Sci Bldg,30-32 Ngan Shing St, Shatin, Hong Kong, Peoples R China.
EM wkleung@cuhk.edu.hk
RI Chan, Henry Lik-Yuen/B-9636-2008; Sung, Joseph J. Y./R-3203-2018; Yuen,
   Kwok Yung/C-4465-2009; Lee, Nelson/B-6418-2008; Chan, Paul
   KS/J-9360-2013; Leung, Wai Keung/B-8140-2011
OI Chan, Henry Lik-Yuen/0000-0002-7790-1611; Sung, Joseph J.
   Y./0000-0003-3125-5199; Lee, Nelson/0000-0002-0783-6607; Chan, Paul
   KS/0000-0002-6360-4608; Yuen, Kwok-yung/0000-0002-2083-1552; Leung, Wai
   Keung/0000-0002-5993-1059
CR Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   GERNA G, 1985, J INFECT DIS, V151, P796, DOI 10.1093/infdis/151.5.796
   Holmes KV, 2001, NOVART FDN SYMP, V238, P258
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   RESTA S, 1985, SCIENCE, V229, P978, DOI 10.1126/science.2992091
   Sanchez CM, 1999, J VIROL, V73, P7607
   Schmidt W, 1996, J ACQ IMMUN DEF SYND, V13, P33, DOI 10.1097/00042560-199609000-00006
   SIMHON A, 1985, AM J TROP MED HYG, V34, P931, DOI 10.4269/ajtmh.1985.34.931
NR 14
TC 130
Z9 145
U1 4
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD OCT
PY 2003
VL 125
IS 4
BP 1011
EP 1017
DI 10.1053/S0016-5085(03)01215-0
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 728TB
UT WOS:000185731500006
PM 14517783
DA 2020-04-03
ER

PT J
AU Adney, DR
   van Doremalen, N
   Brown, VR
   Bushmaker, T
   Scott, D
   de Wit, E
   Bowen, RA
   Munster, VJ
AF Adney, Danielle R.
   van Doremalen, Neeltje
   Brown, Vienna R.
   Bushmaker, Trenton
   Scott, Dana
   de Wit, Emmie
   Bowen, Richard A.
   Munster, Vincent J.
TI Replication and Shedding of MERS-CoV in Upper Respiratory Tract of
   Inoculated Dromedary Camels
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID SYNDROME CORONAVIRUS; SAUDI-ARABIA; INFECTION; ANTIBODIES; LIVESTOCK;
   JUNE
AB In 2012, a novel coronavirus associated with severe respiratory disease in humans emerged in the Middle East. Epidemiologic investigations identified dromedary camels as the likely source of zoonotic transmission of Middle East respiratory syndrome coronavirus (MERS-CoV). Here we provide experimental support for camels as a reservoir for MERS-CoV. We inoculated 3 adult camels with a human isolate of MERS-CoV and a transient, primarily upper respiratory tract infection developed in each of the 3 animals. Clinical signs of the MERS-CoV infection were benign, but each of the camels shed large quantities of virus from the upper respiratory tract. We detected infectious virus in nasal secretions through 7 days postinoculation, and viral RNA up to 35 days postinoculation. The pattern of shedding and propensity for the upper respiratory tract infection in dromedary camels may help explain the lack of systemic illness among naturally infected camels and the means of efficient camel-to-camel and camel-to-human transmission.
C1 [Adney, Danielle R.; Brown, Vienna R.; Bowen, Richard A.] Colorado State Univ, Ft Collins, CO 80523 USA.
   [van Doremalen, Neeltje; Bushmaker, Trenton; Scott, Dana; de Wit, Emmie; Munster, Vincent J.] NIH, Hamilton, MT USA.
RP Bowen, RA (reprint author), Colorado State Univ, Dept Biomed Sci, W113 ARBL Bldg,Foothills Campus, Ft Collins, CO 80523 USA.
EM Richard.Bowen@colostate.edu
RI Munster, Vincent/I-7607-2018; de Wit, Emmie/A-1549-2019
OI Munster, Vincent/0000-0002-2288-3196; de Wit, Emmie/0000-0002-9763-7758
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); Animal Models Core at Colorado
   State University; Colorado State University
FX This work was supported by the Intramural Research Program of the
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, and the Animal Models Core at Colorado State
   University. D.R.A. was supported through the Infectious Disease:
   Translational Research Training Program at Colorado State University.
CR Alagaili A.N., 2014, MBIO, V5
   Alagaili AN, 2014, MBIO, V5, DOI 10.1128/mBio.00884-14
   AlBarrak AM, 2012, SAUDI MED J, V33, P1265
   Alexandersen S, 2014, TRANSBOUND EMERG DIS, V61, P105, DOI 10.1111/tbed.12212
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Briese T, 2014, MBIO, V5, DOI 10.1128/mBio.01146-14
   Buchholz U., 2013, Eurosurveillance, V18, P20406
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   de Wit E, 2013, P NATL ACAD SCI USA, V110, P16598, DOI 10.1073/pnas.1310744110
   Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hemida MG, 2013, EUROSURVEILLANCE, V18, P21, DOI 10.2807/1560-7917.ES2013.18.50.20659
   Hemida MG, 2014, EMERG INFECT DIS, V20, P1231, DOI 10.3201/eid2007.140571
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Memish ZA, 2013, NEW ENGL J MED, V369, P1761, DOI 10.1056/NEJMc1311004
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Milne-Price S, 2014, PATHOG DIS, V71, P119, DOI 10.1111/2049-632X.12166
   Nemeth NM, 2007, AM J TROP MED HYG, V76, P310, DOI 10.4269/ajtmh.2007.76.310
   Nowotny N, 2014, EUROSURVEILLANCE, V19, P11, DOI 10.2807/1560-7917.ES2014.19.16.20781
   Puzelli S, 2013, EUROSURVEILLANCE, V18, P2, DOI 10.2807/1560-7917.ES2013.18.34.20564
   Reusken CB, 2013, EUROSURVEILLANCE, V18, P14, DOI 10.2807/1560-7917.ES2013.18.50.20662
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Samara EM, 2014, MBIO, V5, DOI 10.1128/mBio.01430-14
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   WHO, 2014, GLOB AL RESP
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 29
TC 129
Z9 133
U1 1
U2 24
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD DEC
PY 2014
VL 20
IS 12
BP 1999
EP 2005
DI 10.3201/eid2012.141280
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AU6RP
UT WOS:000345729900004
PM 25418529
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Cauchemez, S
   Fraser, C
   Van Kerkhove, MD
   Donnelly, CA
   Riley, S
   Rambaut, A
   Enouf, V
   van der Werf, S
   Ferguson, NM
AF Cauchemez, Simon
   Fraser, Christophe
   Van Kerkhove, Maria D.
   Donnelly, Christi A.
   Riley, Steven
   Rambaut, Andrew
   Enouf, Vincent
   van der Werf, Sylvie
   Ferguson, Neil M.
TI Middle East respiratory syndrome coronavirus: quantification of the
   extent of the epidemic, surveillance biases, and transmissibility
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID INFECTIOUS-DISEASE; FAMILY CLUSTER; ANTIBODIES
AB Background The novel Middle East respiratory syndrome coronavirus (MERS-CoV) had, as of Aug 8, 2013, caused 111 virologically confirmed or probable human cases of infection worldwide. We analysed epidemiological and genetic data to assess the extent of human infection, the performance of case detection, and the transmission potential of MERS-CoV with and without control measures.
   Methods We assembled a comprehensive database of all confirmed and probable cases from public sources and estimated the incubation period and generation time from case cluster data. Using data of numbers of visitors to the Middle East and their duration of stay, we estimated the number of symptomatic cases in the Middle East. We did independent analyses, looking at the growth in incident dusters, the growth in viral population, the reproduction number of cluster index cases, and duster sizes to characterise the dynamical properties of the epidemic and the transmission scenario.
   Findings The estimated number of symptomatic cases up to Aug 8,2013, is 940 (95% CI 290-2200), indicating that at least 62% of human symptomatic cases have not been detected. We find that the case-fatality ratio of primary cases detected via routine surveillance (74%; 95% CI 49-91) is biased upwards because of detection bias; the case-fatality ratio of secondary cases was 20% (7-42). Detection of milder cases (or clinical management) seemed to have improved in recent months. Analysis of human clusters indicated that chains of transmission were not self-sustaining when infection control was implemented, but that Rin the absence of controls was in the range 0.8-1.3. Three independent data sources provide evidence that R cannot be much above 1, with an upper bound of 1-2-1.5.
   Interpretation By showing that a slowly growing epidemic is underway either in human beings or in an animal reservoir, quantification of uncertainty in transmissibility estimates, and provision of the first estimates of the scale of the epidemic and extent of case detection biases, we provide valuable information for more informed risk assessment.
   Funding Medical Research Council, Bill & Melinda Gates Foundation, EU FP 7, and National Institute of General Medical Sciences.
C1 [Cauchemez, Simon; Fraser, Christophe; Van Kerkhove, Maria D.; Donnelly, Christi A.; Riley, Steven; Ferguson, Neil M.] Univ London Imperial Coll Sci Technol & Med, Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, MRC, London W2 1PG, England.
   [Rambaut, Andrew] Univ Edinburgh, Ashworth Labs, Inst Evolutionary Biol, Edinburgh, Midlothian, Scotland.
   [Enouf, Vincent; van der Werf, Sylvie] Univ Paris Diderot, Sorbonne Paris Cite, Inst Pasteur, Unit Mol Genet RNA Viruses,UMR3569 CNRS, Paris, France.
RP Ferguson, NM (reprint author), Univ London Imperial Coll Sci Technol & Med, Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, Norfolk Pl, London W2 1PG, England.
EM neil.ferguson@imperial.ac.uk
RI Ferguson, Neil/B-8578-2008; Rambaut, Andrew/B-2481-2009; Fraser,
   Christophe/A-8109-2008; ENOUF, Vincent/H-6494-2017
OI Ferguson, Neil/0000-0002-1154-8093; Rambaut, Andrew/0000-0003-4337-3707;
   Fraser, Christophe/0000-0003-2399-9657; Riley,
   Steven/0000-0001-7904-4804; ENOUF, Vincent/0000-0001-7609-4742; Rambaut
   FRSE, Professor Andrew/0000-0002-1278-598X; Donnelly,
   Christl/0000-0002-0195-2463; van der WERF, Sylvie/0000-0002-1148-4456;
   Van Kerkhove, Maria/0000-0002-6135-0018
FU Medical Research CouncilMedical Research Council UK (MRC); Bill &
   Melinda Gates FoundationGates Foundation; EU FP7European Union (EU)
   [278433-PREDEMICS, 223498-EMPERIE]; National Institute of General
   Medical Sciences through its Models of Infectious Disease Agent Study
   (MIDAS) initiative; Medical Research CouncilMedical Research Council UK
   (MRC) [MR/K010174/1B, MR/K010174/1, G0800596, MR/J008761/1]; National
   Institute for Health ResearchNational Institute for Health Research
   (NIHR) [NF-SI-0508-10252]
FX This study was funded by the Medical Research Council, the Bill &
   Melinda Gates Foundation, EU FP7 (grants 278433-PREDEMICS and
   223498-EMPERIE), and the National Institute of General Medical Sciences
   through its Models of Infectious Disease Agent Study (MIDAS) initiative.
   We thank Paul Kellam, Jeremy Farrar, and David Heymann for useful
   discussions. We thank David Briancl for technical help with sequencing.
   This paper was only possible thanks to the countries and institutions
   who have shared epidemiological and sequence data on MERS-CoV.
CR Antia R, 2003, NATURE, V426, P658, DOI 10.1038/nature02104
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Breban R, 2013, LANCET, V382, P694, DOI 10.1016/S0140-6736(13)61492-0
   Cauchemez S, 2013, EURO SURVEILL, V18
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101
   Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062
   Ghani AC, 2005, AM J EPIDEMIOL, V162, P479, DOI 10.1093/aje/kwi230
   Hijawi B, 2013, E MEDITERR HEALTH J, V19, pS12
   Leung GM, 2006, EPIDEMIOL INFECT, V134, P211, DOI 10.1017/S0950268805004826
   Leung GM, 2004, EMERG INFECT DIS, V10, P1653, DOI 10.3201/eid1009.040155
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Omrani AS, 2013, INT J INFECT DIS, V17, pE668, DOI 10.1016/j.ijid.2013.07.001
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255
   WHO, GLOB AL RESP COR INF
   WHO, DIS OUTBR NEWS NOV C
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 20
TC 129
Z9 137
U1 1
U2 46
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JAN
PY 2014
VL 14
IS 1
BP 50
EP 56
DI 10.1016/S1473-3099(13)70304-9
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 281DC
UT WOS:000329079100021
PM 24239323
OA Other Gold, Green Published
DA 2020-04-03
ER

PT J
AU Clementz, MA
   Chen, ZB
   Banach, BS
   Wang, YH
   Sun, L
   Ratia, K
   Baez-Santos, YM
   Wang, J
   Takayama, J
   Ghosh, AK
   Li, K
   Mesecar, AD
   Baker, SC
AF Clementz, Mark A.
   Chen, Zhongbin
   Banach, Bridget S.
   Wang, Yanhua
   Sun, Li
   Ratia, Kiira
   Baez-Santos, Yahira M.
   Wang, Jie
   Takayama, Jun
   Ghosh, Arun K.
   Li, Kui
   Mesecar, Andrew D.
   Baker, Susan C.
TI Deubiquitinating and Interferon Antagonism Activities of Coronavirus
   Papain-Like Proteases
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; HEPATITIS-C-VIRUS; PATTERN-RECOGNITION
   RECEPTORS; INNATE ANTIVIRAL RESPONSE; HOST GENE-EXPRESSION; TOLL-LIKE
   RECEPTORS; NF-KAPPA-B; I-INTERFERON; REGULATORY FACTOR-3; ADAPTER
   PROTEIN
AB Coronaviruses encode multifunctional proteins that are critical for viral replication and for blocking the innate immune response to viral infection. One such multifunctional domain is the coronavirus papain-like protease (PLP), which processes the viral replicase polyprotein, has deubiquitinating (DUB) activity, and antagonizes the induction of type I interferon (IFN). Here we characterized the DUB and IFN antagonism activities of the PLP domains of human coronavirus NL63 and severe acute respiratory syndrome (SARS) coronavirus to determine if DUB activity mediates interferon antagonism. We found that NL63 PLP2 deconjugated ubiquitin (Ub) and the Ub-line molecule ISG15 from cellular substrates and processed both lysine-48-and lysine-63-linked polyubiquitin chains. This PLP2 DUB activity was dependent on an intact catalytic cysteine residue. We demonstrated that in contrast to PLP2 DUB activity, PLP2-mediated interferon antagonism did not require enzymatic activity. Furthermore, addition of an inhibitor that blocks coronavirus protease/DUB activity did not abrogate interferon antagonism. These results indicated that a component of coronavirus PLP-mediated interferon antagonism was independent of protease and DUB activity. Overall, these results demonstrate the multifunctional nature of the coronavirus PLP domain as a viral protease, DUB, and IFN antagonist and suggest that these independent activities may provide multiple targets for antiviral therapies.
C1 [Baker, Susan C.] Loyola Univ, Med Ctr, Dept Microbiol & Immunol, Chicago Stritch Sch Med, Maywood, IL 60153 USA.
   [Chen, Zhongbin; Wang, Yanhua; Sun, Li] Beijing Inst Radiat Med, Dept Electromagnet & Laser Biol, Div Infect & Immun, Beijing 100850, Peoples R China.
   [Ratia, Kiira; Baez-Santos, Yahira M.; Mesecar, Andrew D.] Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA.
   [Wang, Jie; Li, Kui] Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38163 USA.
   [Takayama, Jun; Ghosh, Arun K.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
RP Baker, SC (reprint author), Loyola Univ, Med Ctr, Dept Microbiol & Immunol, Chicago Stritch Sch Med, Bldg 105,Rm 3929,2160 S 1st Ave, Maywood, IL 60153 USA.
EM sbaker1@lumc.edu
OI Mesecar, Andrew/0000-0002-1241-2577
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P01AI060915, T32AI007508]; DoDUnited
   States Department of Defense [W81XWH-09-01-0391]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [30870536, 30972761]; Beijing Municipal Natural Science
   FoundationBeijing Natural Science Foundation [7092075]
FX The work was supported by NIH grant P01AI060915 (to S. C. B., A. K. G.,
   and A. D. M.), DoD grant W81XWH-09-01-0391 (to Gerald Byrne), and grants
   from the National Natural Science Foundation of China (30870536 and
   30972761 to Z. C.) and Beijing Municipal Natural Science Foundation
   (7092075 to Z. C.). M. A. C. and B. S. B. were supported by NIH training
   grant T32AI007508.
CR Banach BS, 2009, J VIROL METHODS, V156, P19, DOI 10.1016/j.jviromet.2008.10.022
   Barral PM, 2009, PHARMACOL THERAPEUT, V124, P219, DOI 10.1016/j.pharmthera.2009.06.012
   Barral PM, 2009, VIROLOGY, V391, P171, DOI 10.1016/j.virol.2009.06.045
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297
   Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003
   Bhoj VG, 2009, NATURE, V458, P430, DOI 10.1038/nature07959
   Bibeau-Poirier A, 2008, CYTOKINE, V43, P359, DOI 10.1016/j.cyto.2008.07.012
   Bowie AG, 2008, NAT REV IMMUNOL, V8, P911, DOI 10.1038/nri2436
   Chang TH, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000493
   Chen ZB, 2007, J VIROL, V81, P6007, DOI 10.1128/JVI.02747-06
   Chen ZH, 2007, VIROLOGY, V366, P277, DOI 10.1016/j.virol.2007.04.023
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377
   Frias-Staheli N, 2007, CELL HOST MICROBE, V2, P404, DOI 10.1016/j.chom.2007.09.014
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Frieman M, 2009, J VIROL, V83, P6689, DOI 10.1128/JVI.02220-08
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808
   Herzog P, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-138
   Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617
   Higgs R, 2008, J IMMUNOL, V181, P1780, DOI 10.4049/jimmunol.181.3.1780
   Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900
   Isaacson MK, 2009, CELL HOST MICROBE, V5, P559, DOI 10.1016/j.chom.2009.05.012
   Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Kayagaki N, 2007, SCIENCE, V318, P1628, DOI 10.1126/science.1145918
   Kirkin V, 2007, CURR OPIN CELL BIOL, V19, P199, DOI 10.1016/j.ceb.2007.02.002
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Koyama S, 2008, CYTOKINE, V43, P336, DOI 10.1016/j.cyto.2008.07.009
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lenschow DJ, 2007, P NATL ACAD SCI USA, V104, P1371, DOI 10.1073/pnas.0607038104
   Lenschow DJ, 2005, J VIROL, V79, P13974, DOI 10.1128/JVI.79.22.13974-13983.2005
   Li K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200
   Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Lindner HA, 2007, ARCH BIOCHEM BIOPHYS, V466, P8, DOI 10.1016/j.abb.2007.07.006
   Liu YC, 2005, NAT REV IMMUNOL, V5, P941, DOI 10.1038/nri1731
   Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103
   Lu G, 2006, CELL MOL BIOL, V52, P29, DOI 10.1170/T695
   Malakhova OA, 2008, J BIOL CHEM, V283, P8783, DOI 10.1074/jbc.C800030200
   Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609
   Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193
   Meylan E, 2006, MOL CELL, V22, P561, DOI 10.1016/j.molcel.2006.05.012
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Neznanov N, 2005, J BIOL CHEM, V280, P24153, DOI 10.1074/jbc.M502303200
   Nicholson B, 2008, PROTEIN SCI, V17, P1035, DOI 10.1110/ps.083450408
   Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007
   Ozato K, 2007, J BIOL CHEM, V282, P20065, DOI 10.1074/jbc.R700003200
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pichlmair A, 2007, IMMUNITY, V27, P370, DOI 10.1016/j.immuni.2007.08.012
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Roth-Cross JK, 2007, J VIROL, V81, P7189, DOI 10.1128/JVI.00013-07
   Schroder M, 2008, EMBO J, V27, P2147, DOI 10.1038/emboj.2008.143
   Sheahan T, 2008, J VIROL, V82, P2274, DOI 10.1128/JVI.02041-07
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Spiegel M, 2006, J GEN VIROL, V87, P1953, DOI 10.1099/vir.0.81624-0
   Swedan S, 2009, J VIROL, V83, P9682, DOI 10.1128/JVI.00715-09
   van der Hoek L, 2005, PLOS MED, V2, P764, DOI 10.1371/journal.pmed.0020240
   Van der Hoek L, 2006, ADV EXP MED BIOL, V581, P485
   Xia ZP, 2009, NATURE, V461, P114, DOI 10.1038/nature08247
   Ye Y, 2007, J VIROL, V81, P2554, DOI 10.1128/JVI.01634-06
   Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102
   Zheng DH, 2008, CELL RES, V18, P1105, DOI 10.1038/cr.2008.294
   Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110
   Zhong B, 2008, IMMUNITY, V29, P538, DOI 10.1016/j.immuni.2008.09.003
NR 72
TC 129
Z9 140
U1 1
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 2010
VL 84
IS 9
BP 4619
EP 4629
DI 10.1128/JVI.02406-09
PG 11
WC Virology
SC Virology
GA 579GW
UT WOS:000276358000047
PM 20181693
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Li, H
   McCormac, MA
   Estes, RW
   Sefers, SE
   Dare, RK
   Chappell, JD
   Erdman, DD
   Wright, PF
   Tang, YW
AF Li, Haijing
   McCormac, Melinda A.
   Estes, R. Wray
   Sefers, Susan E.
   Dare, Ryan K.
   Chappell, James D.
   Erdman, Dean D.
   Wright, Peter F.
   Tang, Yi-Wei
TI Simultaneous detection and high-throughput identification of a panel of
   RNA viruses causing respiratory tract infections
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID REVERSE TRANSCRIPTION-PCR; POLYMERASE-CHAIN-REACTION; ENZYME
   HYBRIDIZATION ASSAY; CONVENTIONAL VIRAL CULTURE; REAL-TIME PCR;
   SYNCYTIAL-VIRUS; MULTIPLEX PCR; BRONCHIOLITIS OBLITERANS; PARAINFLUENZA
   VIRUS; CLINICAL SPECIMENS
AB Clinical presentations for viral respiratory tract infections are often nonspecific, and a rapid, high-throughput laboratory technique that can detect a panel of common viral pathogens is clinically desirable. We evaluated two multiplex reverse transcription-PCR (RT-PCR) products coupled with microarray-based systems for simultaneous detection of common respiratory tract viral pathogens. The NGEN respiratory virus ana lyte- specific assay (Nanogen, San Diego, CA) detects influenza A virus (Flu-A) and Flu-B, parainfluenza virus I (PIV-1), PIV-2, and PIV-3, and respiratory syncytial virus (RSV), while the ResPlex II assay (Genaco Biomedical Products, Inc., Huntsville, AL) detects Flu-A, Flu-B, PIV-1, PIV-2, PIV-3, PIV-4, RSV, human metapneumovirus (hMPV), rhinoviruses (RhVs), enteroviruses (EnVs), and severe acute respiratory syndrome (SARS) coronavirus (CoV). A total of 360 frozen respiratory specimens collected for a full year were tested, and results were compared to those obtained with a combined reference standard of cell culture and monoplex real-time TaqMan RT-PCR assays. NGEN and ResPlex II gave comparable sensitivities for Flu-A (82.8 to 86.2%), Flu-B (90.0 to 100.0%), PIV-1 (87.5 to 93.8%), PIV-3 (66.7 to 72.2%), and RSV (63.3 to 73.3%); both assays achieved excellent specificities (99.1 to 100.0%) for these five common viruses. The ResPlex II assay detected hMPV in 13 (3.6%) specimens, with a sensitivity of 80.0% and specificity of 99.7%. The ResPlex II assay also differentiated RSV-A and RSV-B and gave positive results for RhV and EnV in 31 (8.6%) and 19 (5.3%) specimens, respectively. PIV-2, PIV-4, and SARS CoV were not detected in the specimens tested. The two systems can process 80 (NGEN) and 96 (ResPlex II) tests per run, with a hands-on time of approximately 60 min and test turnaround times of 6 h (ResPlex II) and 9 h (NGEN). Multiple-panel testing detected an additional unsuspected 9 (3.4%) PIV-1 and 10 (3.7%) PIV-3 infections. While test sensitivities for RSV and PIV-3 need improvement, both the NGEN and ResPlex II assays provide user-friendly and high-throughput tools for simultaneous detection and identification of a panel of common respiratory viral pathogens in a single test format. The multiplex approach enhances diagnosis through detection of respiratory viral etiologic agents in cases in which the presence of the agent was not suspected and a test was not ordered by the clinicians.
C1 Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA.
   Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA.
   Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA.
   Ctr Dis Control & Prevent, Div Viral Dis, Resp & Gastroenteritis Viruses Branch, Atlanta, GA 30333 USA.
RP Tang, YW (reprint author), Vanderbilt Univ Sch Med, Mol Infect Dis Lab, 4605 TVC, Nashville, TN 37232 USA.
EM yiwei.tang@vanderbilt.edu
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Allander T, 2007, J VIROL, V81, P4130, DOI 10.1128/JVI.00028-07
   Atmar RL, 1996, J CLIN MICROBIOL, V34, P2604, DOI 10.1128/JCM.34.10.2604-2606.1996
   Bellau-Pujol S, 2005, J VIROL METHODS, V126, P53, DOI 10.1016/j.jviromet.2005.01.020
   Bhat N, 2005, NEW ENGL J MED, V353, P2559, DOI 10.1056/NEJMoa051721
   Boivin G, 2004, J CLIN MICROBIOL, V42, P45, DOI 10.1128/JCM.42.1.45-51.2004
   Briese T, 2005, EMERG INFECT DIS, V11, P310, DOI 10.3201/eid1102.040492
   Brunstein J, 2006, DIAGN MOL PATHOL, V15, P169, DOI 10.1097/01.pdm.0000210430.35340.53
   Coiras MT, 2003, J MED VIROL, V69, P132, DOI 10.1002/jmv.10255
   Deng XQ, 2003, J VIROL METHODS, V107, P141, DOI 10.1016/S0166-0934(02)00211-2
   Fan J, 1998, CLIN INFECT DIS, V26, P1397, DOI 10.1086/516357
   Freymuth F, 2006, J MED VIROL, V78, P1498, DOI 10.1002/jmv.20725
   Garbino J, 2004, AM J RESP CRIT CARE, V170, P1197, DOI 10.1164/rccm.200406-781OC
   Grondahl B, 1999, J CLIN MICROBIOL, V37, P1
   Gruteke P, 2004, J CLIN MICROBIOL, V42, P5596, DOI 10.1128/JCM.42.12.5596-5603.2004
   Han J, 2006, J CLIN MICROBIOL, V44, P4157, DOI 10.1128/JCM.01762-06
   Henrickson KJ, 2005, PEDIATR ANN, V34, P24, DOI 10.3928/0090-4481-20050101-08
   Hindiyeh M, 2001, AM J CLIN PATHOL, V116, P218
   Hu AZ, 2005, J VIROL METHODS, V130, P145, DOI 10.1016/j.jviromet.2005.06.014
   Jaramillo A, 2005, PEDIATR TRANSPLANT, V9, P84, DOI 10.1111/j.1399-3046.2004.00270.x
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993
   Keen-Kim D, 2006, EXPERT REV MOL DIAGN, V6, P287, DOI 10.1586/14737159.6.3.287
   Kehl SC, 2001, J CLIN MICROBIOL, V39, P1696, DOI 10.1128/JCM.39.5.1696-1701.2001
   Kumar D, 2005, AM J TRANSPLANT, V5, P2031, DOI 10.1111/j.1600-6143.2005.00971.x
   Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551
   Landry ML, 2000, J CLIN MICROBIOL, V38, P708, DOI 10.1128/JCM.38.2.708-711.2000
   Liolios L, 2001, J CLIN MICROBIOL, V39, P2779, DOI 10.1128/JCM.39.8.2779-2783.2001
   Loens K, 2006, J CLIN MICROBIOL, V44, P166, DOI 10.1128/JCM.44.1.166-171.2006
   Ma XM, 2006, J CLIN MICROBIOL, V44, P1132, DOI 10.1128/JCM.44.3.1132-1134.2006
   Mackie P L, 2003, Paediatr Respir Rev, V4, P84, DOI 10.1016/S1526-0542(03)00031-9
   Markoulatos P, 2002, J CLIN LAB ANAL, V16, P47, DOI 10.1002/jcla.2058
   Osiowy C, 1998, J CLIN MICROBIOL, V36, P3149, DOI 10.1128/JCM.36.11.3149-3154.1998
   Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869
   Puppe W, 2004, J CLIN VIROL, V30, P165, DOI 10.1016/j.jcv.2003.10.003
   Sefers SE, 2006, J CLIN VIROL, V35, P141, DOI 10.1016/j.jcv.2005.05.011
   Syrmis MW, 2004, J MOL DIAGN, V6, P125, DOI 10.1016/S1525-1578(10)60500-4
   Tang YW, 1999, DIAGN MICR INFEC DIS, V34, P333, DOI 10.1016/S0732-8893(99)00049-8
   Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004
   Vuorinen T, 2003, CLIN INFECT DIS, V37, P452, DOI 10.1086/376635
   Weinberg GA, 2004, J INFECT DIS, V189, P706, DOI 10.1086/381456
   Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997
NR 41
TC 129
Z9 141
U1 1
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUL
PY 2007
VL 45
IS 7
BP 2105
EP 2109
DI 10.1128/JCM.00210-07
PG 5
WC Microbiology
SC Microbiology
GA 190QB
UT WOS:000248072900001
PM 17507510
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Gu, J
   Gong, EC
   Zhang, B
   Zheng, J
   Gao, ZF
   Zhong, YF
   Zou, WZ
   Zhan, J
   Wang, SL
   Xie, ZG
   Zhuang, H
   Wu, BQ
   Zhong, HH
   Shao, HQ
   Fang, WG
   Gao, DS
   Pei, F
   Li, XW
   He, ZP
   Xu, DZ
   Shi, XY
   Anderson, VM
   Leong, ASY
AF Gu, J
   Gong, EC
   Zhang, B
   Zheng, J
   Gao, ZF
   Zhong, YF
   Zou, WZ
   Zhan, J
   Wang, SL
   Xie, ZG
   Zhuang, H
   Wu, BQ
   Zhong, HH
   Shao, HQ
   Fang, WG
   Gao, DS
   Pei, F
   Li, XW
   He, ZP
   Xu, DZ
   Shi, XY
   Anderson, VM
   Leong, ASY
TI Multiple organ infection and the pathogenesis of SARS
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; SYNDROME-ASSOCIATED CORONAVIRUS; HONG-KONG;
   OUTBREAK; TISSUE; INVOLVEMENT; LYMPHOCYTES; PATHOLOGY
AB After > 8,000 infections and > 700 deaths worldwide, the pathogenesis of the new infectious disease, severe acute respiratory syndrome (SARS), remains poorly understood. We investigated 18 autopsies of patients who had suspected SARS; 8 cases were confirmed as SARS. We evaluated white blood cells from 22 confirmed SARS patients at various stages of the disease. T lymphocyte counts in 65 confirmed and 35 misdiagnosed SARS cases also were analyzed retrospectively. SARS viral particles and genomic sequence were detected in a large number of circulating lymphocytes, monocytes, and lymphoid tissues, as well as in the epithelial cells of the respiratory tract, the mucosa of the intestine, the epithelium of the renal distal tubules, the neurons of the brain, and macrophages in different organs. SARS virus seemed to be capable of infecting multiple cell types in several organs; immune cells and pulmonary epithelium were identified as the main sites of injury. A comprehensive theory of pathogenesis is proposed for SARS with immune and lung damage as key features.
C1 Peking Univ, Dept Pathol, Beijing 100083, Peoples R China.
   Peking Univ, Dept Microbiol, Beijing 100083, Peoples R China.
   Beijing Ditan Hosp, Beijing 100011, Peoples R China.
   SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA.
   Univ Newcastle, Hunter Area Pathol Serv, Newcastle, NSW 2310, Australia.
   Univ Newcastle, Discipline Anat Pathol, Newcastle, NSW 2310, Australia.
RP Gu, J (reprint author), Peking Univ, Dept Pathol, Beijing 100083, Peoples R China.
EM jgu@privatedoctor.org
CR BOOTH CM, 2003, JAMA-J AM MED ASSOC, V298, P2801
   Chan-Yeung M, 2003, BRIT MED J, V326, P850, DOI 10.1136/bmj.326.7394.850
   Cui W, 2003, CLIN INFECT DIS, V37, P857, DOI 10.1086/378587
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   [杜丽 Du Li], 2003, [第二军医大学学报, Academic Journal of Second Military Medical University], V24, P636
   Farcas GA, 2005, J INFECT DIS, V191, P193, DOI 10.1086/426870
   Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   GU J, 1994, CELL VISION, V1, P76
   Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI200318819, 10.1172/JCI18819]
   Hon KLE, 2003, LANCET, V361, P1701, DOI 10.1016/S0140-6736(03)13364-8
   Lang ZW, 2003, CHINESE MED J-PEKING, V116, P976
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Li Ming-hui, 2004, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V18, P137
   Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158
   LOSSI L, 2002, GOLD SILVER STAINING, P147
   Lu HY, 2005, WORLD J GASTROENTERO, V11, P2971, DOI 10.3748/wjg.v11.i19.2971
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mazzulli T, 2004, EMERG INFECT DIS, V10, P20, DOI 10.3201/eid1001.030404
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   SHI SR, 2000, ANTIGEN RETRIEVAL TE, P17
   Shi XY, 2005, AM J GASTROENTEROL, V100, P169, DOI 10.1111/j.1572-0241.2005.40377.x
   To K, 2004, J PATHOL, V202, P157, DOI 10.1002/path.1510
   TUOSTO L, 1994, EUR J IMMUNOL, V24, P1061, DOI 10.1002/eji.1830240508
   VANDELL IM, 1982, PEPTIDES, V3, P1
   *WHO, 2003, CAS DEF SURV SEV AC
   *WHO, 2005, COMM DIS SURV RES SE
   Wu Bing-quan, 2003, Zhonghua Bing Li Xue Za Zhi, V32, P212
   YANG SL, 2003, NANFANG J NURSING, V10, P27
   Zhang Bo, 2003, Applied Immunohistochemistry & Molecular Morphology, V11, P285
NR 34
TC 129
Z9 134
U1 5
U2 78
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD AUG 1
PY 2005
VL 202
IS 3
BP 415
EP 424
DI 10.1084/jem.20050828
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 951AW
UT WOS:000230902100011
PM 16043521
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Packer, C
   Altizer, S
   Appel, M
   Brown, E
   Martenson, J
   O'Brien, SJ
   Roelke-Parker, M
   Hofmann-Lehmann, R
   Lutz, H
AF Packer, C
   Altizer, S
   Appel, M
   Brown, E
   Martenson, J
   O'Brien, SJ
   Roelke-Parker, M
   Hofmann-Lehmann, R
   Lutz, H
TI Viruses of the Serengeti: patterns of infection and mortality in African
   lions
SO JOURNAL OF ANIMAL ECOLOGY
LA English
DT Article
DE epidemic; population density; seroprevalence; susceptibles; virulence
ID FELINE IMMUNODEFICIENCY VIRUS; WILD DOGS; PHYLOGENETIC ASPECTS;
   LEUKEMIA-VIRUS; DOMESTIC CATS; NATIONAL-PARK; MASAI-MARA; POPULATION;
   EVOLUTION; DISEASES
AB 1. We present data on the temporal dynamics of six viruses that infect lions (Panthera lee) in the Serengeti National Park and Ngorongoro Crater, Tanzania, These populations have been studied continuously for the past 30 years, and previous research has documented their seroprevalence for feline herpesvirus, feline immunodeficiency virus (FIV), feline calicivirus, feline parvovirus, feline coronavirus and canine distemper virus (CDV), A seventh virus, feline leukaemia virus (FeLV), was absent from these animals,
   2. Comprehensive analysis reveals that feline herpesvirus and FIV were consistently prevalent at high levels, indicating that they were endemic in the host populations. Feline calici-, parvo- and coronavirus, and CDV repeatedly showed a pattern of seroprevalence that was indicative of discrete disease epidemics: a brief period of high exposure for each virus was followed by declining seroprevalence.
   3. The timing of viral invasion suggests that different epidemic viruses are associated with different minimum threshold densities of susceptible hosts, Furthermore, the proportion of susceptibles that became infected during disease outbreaks was positively correlated with the number of susceptible hosts at the beginning of each outbreak.
   4. Examination of the relationship between disease outbreaks and host fitness suggest that these viruses do not affect birth and death rates in lions, with the exception of the 1994 outbreak of canine distemper virus. Although the endemic viruses (FHV and FIV) were too prevalent to measure precise health effects, there was no evidence that FIV infection reduced host longevity.
C1 Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA.
   Cornell Univ, Coll Vet Med, James A Baker Inst Anim Hlth, Ithaca, NY 14853 USA.
   NCI, Viral Carcinogenesis Lab, Frederick, MD USA.
   Univ Zurich, Dept Vet Internal Med, Clin Lab, CH-8001 Zurich, Switzerland.
RP Packer, C (reprint author), Univ Minnesota, Dept Ecol Evolut & Behav, 1987 Upper Buford Circle, St Paul, MN 55108 USA.
RI Hofmann-Lehmann, Regina/C-6528-2009
OI Hofmann-Lehmann, Regina/0000-0001-9750-4296
CR ALEXANDER KA, 1994, J WILDLIFE DIS, V30, P481, DOI 10.7589/0090-3558-30.4.481
   Alexander KA, 1995, J ZOO WILDLIFE MED, V26, P201
   Allison A. C., 1982, Population biology of infectious diseases. (Report of the Dahlem Workshop on Population Biology of Infectious Disease Agents, Berlin, 1982, March 14-19.) (Life Sciences Research Report, 25), P245
   Anderson R. M., 1991, INFECT DIS HUMANS DY
   ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0
   ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839
   Ballard WB, 1997, J WILDLIFE DIS, V33, P242, DOI 10.7589/0090-3558-33.2.242
   BROWN EW, 1994, J VIROL, V68, P5953, DOI 10.1128/JVI.68.9.5953-5968.1994
   CARPENTER MA, 1995, CURR OPIN GENET DEV, V5, P739, DOI 10.1016/0959-437X(95)80006-Q
   CLEAVELAND S, 1996, THESIS U LONDON
   Courchamp F, 1998, EPIDEMIOL INFECT, V121, P227, DOI 10.1017/S0950268898008875
   Courchamp F, 1997, P ROY SOC B-BIOL SCI, V264, P785, DOI 10.1098/rspb.1997.0111
   Creel S, 1997, J WILDLIFE DIS, V33, P823, DOI 10.7589/0090-3558-33.4.823
   Dobson A, 1996, ECOLOGY, V77, P1026, DOI 10.2307/2265573
   Dobson A. P., 1995, P52, DOI 10.1017/CBO9780511629396.003
   EWALD PW, 1983, ANNU REV ECOL SYST, V14, P465, DOI 10.1146/annurev.es.14.110183.002341
   Grenfell BT, 1995, PARASITOLOGY, V111, pS3, DOI 10.1017/S0031182000075788
   Hanby J. P., 1995, SERENGETI DYNAMICS E, P249
   Hanby JP, 1995, SERENGETI, P315
   HERRE EA, 1993, SCIENCE, V259, P1442, DOI 10.1126/science.259.5100.1442
   HofmannLehmann R, 1996, CLIN DIAGN LAB IMMUN, V3, P554, DOI 10.1128/CDLI.3.5.554-562.1996
   Jaenike J, 1998, AM NAT, V151, P84, DOI 10.1086/286104
   JAFFEE B, 1992, ECOLOGY, V73, P495, DOI 10.2307/1940755
   KAARE M, 1997, P S E AFR RAB GROUP
   KAT PW, 1995, P ROY SOC B-BIOL SCI, V262, P229, DOI 10.1098/rspb.1995.0200
   Laurenson K, 1998, ANIM CONSERV, V1, P273, DOI 10.1111/j.1469-1795.1998.tb00038.x
   LENSKI RE, 1994, J THEOR BIOL, V169, P253, DOI 10.1006/jtbi.1994.1146
   Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203
   MACDONALD DW, 1980, RABIES WILDLIFE
   Malik R, 1997, AUST VET J, V75, P323, DOI 10.1111/j.1751-0813.1997.tb15701.x
   MAY RM, 1983, AM SCI, V71, P36
   MAY RM, 1979, NATURE, V280, P455, DOI 10.1038/280455a0
   MCCALLUM H, 1995, TRENDS ECOL EVOL, V10, P190, DOI 10.1016/S0169-5347(00)89050-3
   OBRIEN SJ, 1987, NATL GEOGR RES, V3, P114
   OLMSTED RA, 1992, J VIROL, V66, P6008, DOI 10.1128/JVI.66.10.6008-6018.1992
   ONSTAD DW, 1990, ANNU REV ENTOMOL, V35, P399, DOI 10.1146/annurev.en.35.010190.002151
   OSTERHAUS ADME, 1988, NATURE, V335, P20, DOI 10.1038/335020a0
   Packer C, 1998, NATURE, V392, P807, DOI 10.1038/33910
   PACKER C, 1991, CONSERV BIOL, V5, P219, DOI 10.1111/j.1523-1739.1991.tb00127.x
   Packer C., 1988, P363
   PACKER C, 1991, NATURE, V351, P562, DOI 10.1038/351562a0
   PACKER C, 1993, NATURE, V362, P595, DOI 10.1038/362595a0
   PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650
   Plowright W., 1982, Symposia of the Zoological Society of London, V50, P1
   POLI A, 1995, J WILDLIFE DIS, V51, P70
   PUSEY AE, 1994, BEHAV ECOL, V5, P362, DOI 10.1093/beheco/5.4.362
   RIGBY MA, 1993, J GEN VIROL, V74, P425, DOI 10.1099/0022-1317-74-3-425
   RoelkeParker ME, 1996, NATURE, V379, P441, DOI 10.1038/379441a0
   SCHALLERGB, 1972, SERENGETI LION
   SilleroZubiri C, 1996, J WILDLIFE DIS, V32, P80, DOI 10.7589/0090-3558-32.1.80
   SPENCER JA, 1993, S AFR J WILDL RES, V23, P60
   THORNE E T, 1988, Conservation Biology, V2, P66, DOI 10.1111/j.1523-1739.1988.tb00336.x
   TORTEN M, 1991, J VIROL, V65, P2225, DOI 10.1128/JVI.65.5.2225-2230.1991
   WEILER GJ, 1995, J WILDLIFE DIS, V31, P79, DOI 10.7589/0090-3558-31.1.79
   YAMAMOTO JK, 1989, J AM VET MED ASSOC, V194, P213
   YAMAMOTO JK, 1988, AM J VET RES, V49, P1246
   YOUNG TP, 1994, CONSERV BIOL, V8, P410, DOI 10.1046/j.1523-1739.1994.08020410.x
NR 57
TC 129
Z9 132
U1 4
U2 91
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0021-8790
J9 J ANIM ECOL
JI J. Anim. Ecol.
PD NOV
PY 1999
VL 68
IS 6
BP 1161
EP 1178
DI 10.1046/j.1365-2656.1999.00360.x
PG 18
WC Ecology; Zoology
SC Environmental Sciences & Ecology; Zoology
GA 265BJ
UT WOS:000084218700008
DA 2020-04-03
ER

PT J
AU HERREWEGH, AAPM
   DEGROOT, RJ
   CEPICA, A
   EGBERINK, HF
   HORZINEK, MC
   ROTTIER, PJM
AF HERREWEGH, AAPM
   DEGROOT, RJ
   CEPICA, A
   EGBERINK, HF
   HORZINEK, MC
   ROTTIER, PJM
TI DETECTION OF FELINE CORONAVIRUS RNA IN FECES, TISSUES, AND BODY-FLUIDS
   OF NATURALLY INFECTED CATS BY REVERSE-TRANSCRIPTASE PCR
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID PERITONITIS VIRUS; CANINE CORONAVIRUS; 3' END; ANTIGENIC RELATIONSHIP;
   MONOCLONAL-ANTIBODIES; ENTERIC CORONAVIRUSES; PURIFICATION; ENHANCEMENT;
   SEQUENCE; KITTENS
AB A nested reverse transcriptase PCR (RT-nPCR) was developed for the detection of feline coronavirus (FCoV) RNA in the feces, tissues, and body fluids of infected cats. The RT-nPCR was targeted to the highly conserved 3'-untranslated region of the viral genome and will detect most, if not all, feline coronaviruses in the field. With the RT-nPCR FCoV RNA was detected in plasma samples from experimentally infected cats as early as 2 days postinoculation. FCoV RNA was also detected in serum, plasma, or ascitic fluid samples from 14 of 18 cats (78%) with naturally occurring feline infectious peritonitis (FIP). The use of RT-PCR for FLP diagnosis is limited because of the occurrence of apparently healthy FCoV carriers. These asymptomatic cats shed the virus in the feces and, in a number of cases, also had detectable virus in the plasma. Because of the nature of FCoV infections, our RT-PCR assay with plasma or serum cannot be used to establish a definite diagnosis of FIP. However, this assay does provide a new means to identify asymptomatic FCoV carriers. As such, RT-nPCR will be of use to screen cats before their introduction into FCoV-free catteries. Moreover, this assay provides ah important tool to study the epidemiology of FCoV.
C1 UNIV PRINCE EDWARD ISL,ATLANTIC VET COLL,DEPT PATHOL & MICROBIOL,CHARLOTTETOWN,PE C1A 4P3,CANADA.
RP HERREWEGH, AAPM (reprint author), UNIV UTRECHT,FAC VET,INST VIROL,DEPT IMMUNOL & INFECT DIS,YALELAAN 1,3584 CL UTRECHT,NETHERLANDS.
CR ADDIE DD, 1992, VET REC, V130, P133, DOI 10.1136/vr.130.7.133
   ADDIE DD, 1992, VET REC, V131, P202, DOI 10.1136/vr.131.9.202-a
   BARLOUGH JE, 1984, LAB ANIM SCI, V34, P592
   BARLOUGH JE, 1984, VET CLIN N AM-SMALL, V14, P955, DOI 10.1016/S0195-5616(84)50101-6
   BLACK JW, 1980, VET MED SM ANIM CLIN, V75, P811
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   Boyle J F, 1984, Adv Exp Med Biol, V173, P133
   CORAPI WV, 1992, J VIROL, V66, P6695, DOI 10.1128/JVI.66.11.6695-6705.1992
   CORAPI WV, 1994, COMMUNICATION
   DEGROOT RJ, 1988, VIROLOGY, V167, P370, DOI 10.1016/0042-6822(88)90097-9
   DEGROOT RJ, 1987, J GEN VIROL, V68, P995, DOI 10.1099/0022-1317-68-4-995
   EVERMANN JF, 1981, VET PATHOL, V18, P256, DOI 10.1177/030098588101800214
   FISCUS SA, 1987, J VIROL, V61, P2607, DOI 10.1128/JVI.61.8.2607-2613.1987
   GOITSUKA R, 1987, JPN J VET SCI, V49, P811
   HERREWEGH AAP, UNPUB
   HOHDATSU T, 1991, ARCH VIROL, V117, P85, DOI 10.1007/BF01310494
   HOHDATSU T, 1991, VET MICROBIOL, V28, P13, DOI 10.1016/0378-1135(91)90096-X
   HORSBURGH BC, 1992, J GEN VIROL, V73, P2849, DOI 10.1099/0022-1317-73-11-2849
   LOEFFLER DG, 1978, FELINE PRACT, V8, P43
   MCARDLE F, 1992, AM J VET RES, V53, P1500
   MCKEIRNAN AJ, 1981, FELINE PRACT, V11, P16
   MONTALI RJ, 1972, VET PATHOL, V9, P109, DOI 10.1177/030098587200900204
   OREILLY KJ, 1979, VET REC, V104, P348, DOI 10.1136/vr.104.15.348
   OSTERHAUS ADME, 1978, ZBL VET MED B, V25, P301
   Pedersen N C, 1987, Adv Exp Med Biol, V218, P529
   Pedersen N. C., 1976, Feline Practice, V6, P42
   PEDERSEN NC, 1981, AM J VET RES, V42, P368
   PEDERSEN NC, 1976, AM J VET RES, V37, P1449
   PEDERSEN NC, 1983, FELINE PRACT, V13, P13
   PEDERSEN NC, 1985, COMP CONT EDUC PRACT, V7, P1001
   PEDERSEN NC, 1981, AM J VET RES, V42, P363
   PEDERSEN NC, 1976, AM J VET RES, V37, P567
   PEDERSEN NC, 1983, FELINE PRACT, V13, P5
   PEDERSEN NC, 1983, ADV EXP MED BIOL, V173, P365
   SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4
   SPARKES AH, 1991, VET REC, V129, P209, DOI 10.1136/vr.129.10.209
   SPARKES AH, 1992, VET REC, V131, P35, DOI 10.1136/vr.131.2.35
   SPARKES AH, 1992, VET REC, V131, P223, DOI 10.1136/vr.131.10.223-a
   STODDART CA, 1989, J VIROL, V63, P436, DOI 10.1128/JVI.63.1.436-440.1989
   TOMA B, 1979, RECL MED VET, V155, P799
   VENNEMA H, 1992, VIROLOGY, V191, P134, DOI 10.1016/0042-6822(92)90174-N
   WARD JM, 1970, VIROLOGY, V41, P191, DOI 10.1016/0042-6822(70)90070-X
   WEISS RC, 1981, AM J VET RES, V42, P382
   WITTE KH, 1977, BERL MUNCH TIERARZTL, V90, P396
NR 44
TC 129
Z9 133
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAR
PY 1995
VL 33
IS 3
BP 684
EP 689
DI 10.1128/JCM.33.3.684-689.1995
PG 6
WC Microbiology
SC Microbiology
GA QG830
UT WOS:A1995QG83000033
PM 7751377
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU SANCHEZ, CM
   JIMENEZ, G
   LAVIADA, MD
   CORREA, I
   SUNE, C
   BULLIDO, MJ
   GEBAUER, F
   SMERDOU, C
   CALLEBAUT, P
   ESCRIBANO, JM
   ENJUANES, L
AF SANCHEZ, CM
   JIMENEZ, G
   LAVIADA, MD
   CORREA, I
   SUNE, C
   BULLIDO, MJ
   GEBAUER, F
   SMERDOU, C
   CALLEBAUT, P
   ESCRIBANO, JM
   ENJUANES, L
TI ANTIGENIC HOMOLOGY AMONG CORONAVIRUSES RELATED TO TRANSMISSIBLE
   GASTROENTERITIS VIRUS
SO VIROLOGY
LA English
DT Article
C1 UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN.
   INST NACL INVEST AGR,DEPT SANIDAD ANIM,E-28012 MADRID,SPAIN.
   FAC DIERGENEESKUNDE GENT,VIROL LAB,B-9000 GHENT,BELGIUM.
RI Bullido, Maria/C-8509-2014; Sune, Carlos/AAA-8198-2019; Enjuanes,
   Luis/F-7845-2016; Gebauer, Fatima/E-7725-2015
OI Bullido, Maria/0000-0002-6477-1117; Sune, Carlos/0000-0002-7991-0458;
   Gebauer, Fatima/0000-0001-7563-0013; Enjuanes, Luis/0000-0002-0854-0226;
   Smerdou, Cristian/0000-0002-6861-6579
CR AYNAUD JM, 1984, ANN RECH VET, V15, P347
   BOHL EH, 1972, INFECT IMMUN, V6, P289, DOI 10.1128/IAI.6.3.289-301.1972
   BOHL EH, 1965, 69 P ANN M US LIV SA, P343
   Boyle J F, 1984, Adv Exp Med Biol, V173, P133
   BRIAN DA, 1980, J VIROL, V34, P410, DOI 10.1128/JVI.34.2.410-415.1980
   BROWN I, 1986, VET REC, V119, P282, DOI 10.1136/vr.119.11.282
   BULLIDO MJ, 1989, J GEN VIROL, V70, P659, DOI 10.1099/0022-1317-70-3-659
   CALLEBAUT P, 1988, J GEN VIROL, V69, P1725, DOI 10.1099/0022-1317-69-7-1725
   CORREA I, 1988, VIRUS RES, V10, P77, DOI 10.1016/0168-1702(88)90059-7
   DOYLE LP, 1946, J AM VET MED ASSOC, V108, P257
   EVERMANN JF, 1981, VET PATHOL, V18, P256, DOI 10.1177/030098588101800214
   FISCUS SA, 1987, J VIROL, V61, P2607, DOI 10.1128/JVI.61.8.2607-2613.1987
   FURUUCHI S, 1976, AM J VET RES, V37, P1401
   GARCIABARRENO B, 1986, J VIROL, V58, P385
   GARWES DJ, 1975, J GEN VIROL, V29, P25, DOI 10.1099/0022-1317-29-1-25
   GARWES DJ, 1988, VET REC, V122, P86, DOI 10.1136/vr.122.4.86
   GARWES DJ, 1981, J GEN VIROL, V52, P153, DOI 10.1099/0022-1317-52-1-153
   HAELTERMAN EO, 1962, P US LIVESTOCK SANIT, V66, P305
   HARADA K, 1969, NATL I ANIM HEALTH Q, V9, P185
   HIERHOLZER JC, 1976, VIROLOGY, V75, P155, DOI 10.1016/0042-6822(76)90014-3
   HOOYBERGHS J, 1988, 10TH P INT PIG VET S, P200
   HORZINEK MC, 1982, INFECT IMMUN, V37, P1148, DOI 10.1128/IAI.37.3.1148-1155.1982
   JIMENEZ G, 1986, J VIROL, V60, P131
   Kemp M C, 1984, Adv Exp Med Biol, V173, P65
   Lai M M, 1987, Adv Exp Med Biol, V218, P7
   LAUDE H, 1986, J GEN VIROL, V67, P119, DOI 10.1099/0022-1317-67-1-119
   LAVIADA MD, 1988, MED VET, V5, P563
   LEE KM, 1954, AM J VET RES, V15, P364
   Macnaughton M R, 1981, Adv Exp Med Biol, V142, P19
   MAKINO S, 1986, P NATL ACAD SCI USA, V83, P4204, DOI 10.1073/pnas.83.12.4204
   MCCLURKIN AW, 1966, CAN J COMP MED VET S, V30, P190
   MENGELING WL, 1972, AM J VET RES, V33, P297
   PEDERSEN NC, 1978, ARCH VIROL, V58, P45, DOI 10.1007/BF01315534
   PEDERSEN NC, 1984, AM J VET RES, V45, P2580
   PENSAERT M, 1986, VET QUART, V8, P257, DOI 10.1080/01652176.1986.9694050
   PENSAERT M, 1987, 8 EXP S AN BARC, P40
   PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606
   REYNOLDS DJ, 1980, VET MICROBIOL, V5, P283, DOI 10.1016/0378-1135(80)90027-9
   Saif L.J., 1986, DISEASES SWINE, P255
   SCHMIDT OW, 1982, INFECT IMMUN, V35, P515, DOI 10.1128/IAI.35.2.515-522.1982
   SCHREIBER SS, 1989, VIROLOGY, V169, P142, DOI 10.1016/0042-6822(89)90050-0
   Scott F W, 1987, Adv Exp Med Biol, V218, P569
   SIDDELL S, 1982, CURR TOP MICROBIOL, V99, P131
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   STEINHAUER DA, 1987, ANNU REV MICROBIOL, V41, P409, DOI 10.1146/annurev.mi.41.100187.002205
   STURMAN LS, 1983, ADV VIRUS RES, V28, P36
   WOODS RD, 1981, AM J VET RES, V42, P1163
   YOUNG GA, 1955, AM J VET RES, V16, P529
NR 48
TC 129
Z9 134
U1 1
U2 10
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PD FEB
PY 1990
VL 174
IS 2
BP 410
EP 417
DI 10.1016/0042-6822(90)90094-8
PG 8
WC Virology
SC Virology
GA CL765
UT WOS:A1990CL76500008
PM 1689525
DA 2020-04-03
ER

PT J
AU Singeton, RJ
   Bulkow, LR
   Miernyk, K
   DeByle, C
   Pruitt, L
   Hummel, KB
   Bruden, D
   Englund, JA
   Anderson, LJ
   Lucher, L
   Holman, RC
   Hennessy, TW
AF Singeton, Rosalyn J.
   Bulkow, Lisa R.
   Miernyk, Karen
   DeByle, Carolynn
   Pruitt, Lori
   Hummel, Kimberlee Boyd
   Bruden, Dana
   Englund, Janet A.
   Anderson, Larry J.
   Lucher, Lynne
   Holman, Robert C.
   Hennessy, Thomas W.
TI Viral Respiratory Infections in Hospitalized and Community Control
   Children in Alaska
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE respiratory syncytial virus; RSV; respiratory infections; respiratory
   viruses; Alaska native; viral etiologies
ID SYNCYTIAL VIRUS HOSPITALIZATIONS; HUMAN METAPNEUMOVIRUS INFECTION;
   NATIVE CHILDREN; PCR ASSAYS; UNITED-STATES; PEDIATRIC-PATIENTS;
   HIGH-RISK; DISEASE; INFANTS; ILLNESS
AB Respiratory syncytial virus (RSV) in Alaska Native children from the Yukon Kuskokwim (YK) Delta is associated with a hospitalization rate five times higher than that reported for the general US child population. The role of other viral respiratory pathogens has not been studied in this population. YK Delta children <3 years of age hospitalized with respiratory infections and same aged community control children were prospectively enrolled between October 2005 and September 2007. Polymerase chain reaction detection of viruses was performed on nasopharyngeal samples. Characteristics of hospitalized and asymptomatic control children were analyzed. From October 2005 to September 2007, 440 hospitalized and 425 control children were analyzed. Respiratory viruses were detected in 90% (395) of hospitalized children: 194 (44%) rhinovirus, 131 (30%) adenovirus, 102 (23%) RSV, 77 (18%) para influenza viruses (Ply), 66 (15%) human meta-pneumovirus (hMPV), 23 (5%) influenza, and 25 (6%) coronavirus. Fifty-two percent (221) of control children had a virus detected, most commonly rhinovirus (33%), and adenovirus (16%). RSV, Ply, hMPV, and influenza were significantly more common in hospitalized cases than control children, but rhinovirus, adenovirus, and coronavirus were not. RSV and hMPV were associated with higher severity of illness. In this study, RSV remains the most important virus associated with respiratory hospitalization, although hMPV and PIV were also common. RSV and hMPV were associated with more severe illness. Rhinovirus and adenovirus were detected in two-thirds of hospitalized children, but their frequent detection in control children made theirrole in respiratory hospitalization uncertain. J. Med. Virol. 82:1282-1290,2010. (C) 2010 Wiley-Liss, Inc.
C1 [Singeton, Rosalyn J.; Bulkow, Lisa R.; Miernyk, Karen; DeByle, Carolynn; Hummel, Kimberlee Boyd; Bruden, Dana; Hennessy, Thomas W.] Centers Dis Control & Prevent CDC, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA.
   [Singeton, Rosalyn J.; Miernyk, Karen] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA.
   [Pruitt, Lori] Yukon Kuskokwim Hlth Corp, Bethel, AK USA.
   [Englund, Janet A.] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA.
   [Anderson, Larry J.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Lucher, Lynne] State Alaska, Div Hlth & Social Serv, Anchorage, AK USA.
   [Holman, Robert C.] CDC, Div Viral & Rickettsial Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA.
RP Singeton, RJ (reprint author), CDC, Arctic Invest Program, 4055 Tudor Ctr Dr Anchorage, Anchorage, AK 99508 USA.
EM ris2@cdc.gov
CR Aberle JH, 2005, PEDIATR INFECT DIS J, V24, P605, DOI 10.1097/01.inf.0000168741.59747.2d
   Bulkow LR, 2002, PEDIATRICS, V109, P210, DOI 10.1542/peds.109.2.210
   Freymuth F, 2006, J MED VIROL, V78, P1498, DOI 10.1002/jmv.20725
   Fry AM, 2006, CLIN INFECT DIS, V43, P1016, DOI 10.1086/507638
   Guittet V, 2003, ARCH PEDIATRIE, V10, P417, DOI 10.1016/S0929-693X(03)00090-3
   Hennessy T. W., 2008, AM J PUBLIC HEALTH, V98, P1
   Holman RC, 2004, PEDIATRICS, V114, pE437, DOI 10.1542/peds.2004-0049
   Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758
   Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027
   Karron RA, 1999, J INFECT DIS, V180, P41, DOI 10.1086/314841
   Klein MI, 2006, J INFECT DIS, V193, P1544, DOI 10.1086/503806
   KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES
   Kuypers J, 2004, J CLIN VIROL, V31, P123, DOI 10.1016/j.jcv.2004.03.018
   Kuypers J, 2007, PEDIATRICS, V119, pE70, DOI 10.1542/peds.2006-1406
   Kuypers J, 2006, J CLIN MICROBIOL, V44, P2382, DOI 10.1128/JCM.00216-06
   Lu X, 2006, ARCH VIROL, V151, P1587, DOI 10.1007/s00705-005-0722-7
   Lu XY, 2008, J CLIN MICROBIOL, V46, P533, DOI 10.1128/JCM.01739-07
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   MCCONNOCHIE KM, 1990, J PEDIATR-US, V117, P52, DOI 10.1016/S0022-3476(05)82443-6
   McLaughlin J., 2010, Morbidity and Mortality Weekly Report, V59, P6
   Mullins JA, 2004, EMERG INFECT DIS, V10, P700, DOI 10.3201/eid1004.030555
   Nokso-Koivisto J, 2002, J MED VIROL, V66, P417, DOI 10.1002/jmv.2161
   Panozzo C. A., 2008, Morbidity and Mortality Weekly Report, V57, P1355
   Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC
   Peck AJ, 2005, PEDIATR INFECT DIS J, V24, P342, DOI 10.1097/01.inf.0000157250.95880.91
   Pickering LK, 2009, RED BOOK 2009 REPORT
   Pierangeli A, 2007, J MED VIROL, V79, P463, DOI 10.1002/jmv.20832
   Robinson JL, 2005, J MED VIROL, V76, P98, DOI 10.1002/jmv.20329
   Singleton R, 2003, PEDIATR INFECT DIS J, V22, P540, DOI 10.1097/00006454-200306000-00010
   Singleton R, 2000, PEDIATR PULM, V29, P182, DOI 10.1002/(SICI)1099-0496(200003)29:3<182::AID-PPUL5>3.3.CO;2-K
   Singleton RJ, 2006, PEDIATR INFECT DIS J, V25, P1116, DOI 10.1097/01.inf.0000245104.26996.57
   Taylor TB, 1997, NUCLEIC ACIDS RES, V25, P3164, DOI 10.1093/nar/25.15.3164
   Thomazelli LM, 2007, J PEDIAT-BRAZIL, V83, P422, DOI 10.1590/S0021-75572007000600005
   van den Hoogen BG, 2003, J INFECT DIS, V188, P1571, DOI 10.1086/379200
   van Woensel JBM, 2006, PEDIATR PULM, V41, P872, DOI 10.1002/ppul.20459
   Watzinger F, 2004, J CLIN MICROBIOL, V42, P5189, DOI 10.1128/JCM.42.11.5189-5198.2004
   Weigl JAI, 2007, EUR J PEDIATR, V166, P957, DOI 10.1007/s00431-007-0496-x
   2009, STATE ALASKA EP 0120
NR 38
TC 128
Z9 132
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD JUL
PY 2010
VL 82
IS 7
BP 1282
EP 1290
DI 10.1002/jmv.21790
PG 9
WC Virology
SC Virology
GA 602XW
UT WOS:000278173400027
PM 20513097
DA 2020-04-03
ER

PT J
AU Brittain-Long, R
   Nord, S
   Olofsson, S
   Westin, J
   Anderson, LM
   Lindh, M
AF Brittain-Long, Robin
   Nord, Sandra
   Olofsson, Sigvard
   Westin, Johan
   Anderson, Lars-Magnus
   Lindh, Magnus
TI Multiplex real-time PCR for detection of respiratory tract infections
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE molecular diagnostics; respiratory infection; real-time PCR; taqman
ID INFLUENZA-A; RNA VIRUSES; ASSAYS; PATHOGENS; DIAGNOSIS; CHILDREN
AB Background: Broad diagnostics of respiratory infection by molecular assays has not yet won acceptance due to technical difficulties and high costs.
   Objectives: To evaluate clinical applicability of multiplex real-time PCR.
   Study design: An assay targeting influenza virus A (IfA) and B (IfB), parainfluenza 1-3 (PIV), human metapneumovirus (MPV), respiratory syncytial virus (RSV), rhinovirus (RV), enterovirus (EV), adenovirus (AdV), human coronaviruses (229E, OC43, NL63), M. pneumoniae and Ch. pneumoniae was developed and run daily on consecutive clinical nasopharyngeal swab samples.
   Results: An etiology was identified in 48% of the 954 samples, with IfA in 25%, RV in 20%, MPV in 10% and M. pneumoniae in 10% of the positive. By a rational procedure costs could be reduced and the customer price set relatively low (33 per sample).
   Conclusion: Streamlined testing and cost limitation is achievable and probably critical for implementation of a broad molecular diagnostics of respiratory infections. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Brittain-Long, Robin; Nord, Sandra; Olofsson, Sigvard; Westin, Johan; Anderson, Lars-Magnus; Lindh, Magnus] Univ Gothenburg, Sahlgrenska Acad, Dept Infect, S-41685 Gothenburg, Sweden.
RP Brittain-Long, R (reprint author), Univ Gothenburg, Sahlgrenska Acad, Dept Infect, S-41685 Gothenburg, Sweden.
EM Robin.bl@telia.com
CR Bellau-Pujol S, 2005, J VIROL METHODS, V126, P53, DOI 10.1016/j.jviromet.2005.01.020
   Creer DD, 2006, THORAX, V61, P75, DOI 10.1136/thx.2004.027441
   Diaz A, 2007, CHEST, V131, P779, DOI 10.1378/chest.06-1800
   Gruteke P, 2004, J CLIN MICROBIOL, V42, P5596, DOI 10.1128/JCM.42.12.5596-5603.2004
   Gunson RN, 2005, J CLIN VIROL, V33, P341, DOI 10.1016/j.jcv.2004.11.025
   Heim A, 2003, J MED VIROL, V70, P228, DOI 10.1002/jmv.10382
   Kuypers J, 2006, J CLIN MICROBIOL, V44, P2382, DOI 10.1128/JCM.00216-06
   Li H, 2007, J CLIN MICROBIOL, V45, P2105, DOI 10.1128/JCM.00210-07
   Liolios L, 2001, J CLIN MICROBIOL, V39, P2779, DOI 10.1128/JCM.39.8.2779-2783.2001
   Lundborg CS, 2002, SCAND J INFECT DIS, V34, P442, DOI 10.1080/00365540110080647
   Puppe W, 2004, J CLIN VIROL, V30, P165, DOI 10.1016/j.jcv.2003.10.003
   Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004
   Ward CL, 2004, J CLIN VIROL, V29, P179, DOI 10.1016/S1386-6532(03)00122-7
   Watzinger F, 2004, J CLIN MICROBIOL, V42, P5189, DOI 10.1128/JCM.42.11.5189-5198.2004
NR 14
TC 128
Z9 146
U1 1
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
J9 J CLIN VIROL
JI J. Clin. Virol.
PD JAN
PY 2008
VL 41
IS 1
BP 53
EP 56
DI 10.1016/j.jcv.2007.10.029
PG 4
WC Virology
SC Virology
GA 261DX
UT WOS:000253060400012
PM 18093871
DA 2020-04-03
ER

PT J
AU Tripet, B
   Howard, MW
   Jobling, M
   Holmes, RK
   Holmes, KV
   Hodges, RS
AF Tripet, B
   Howard, MW
   Jobling, M
   Holmes, RK
   Holmes, KV
   Hodges, RS
TI Structural characterization of the SARS-coronavirus spike S fusion
   protein core
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; TO-CELL FUSION; VIRUS ENVELOPE GLYCOPROTEIN;
   AMINO-ACID SUBSTITUTIONS; HELICAL COILED-COILS; MURINE CORONAVIRUS;
   MEMBRANE-FUSION; IMMUNODEFICIENCY-VIRUS; CRYSTAL-STRUCTURE; HIV-1 GP41
AB The spike (S) glycoprotein of coronaviruses mediates viral entry into host cells. It is a type 1 viral fusion protein that characteristically contains two heptad repeat regions, denoted HR-N and HR-C, that form coiled-coil structures within the ectodomain of the protein. Previous studies have shown that the two heptad repeat regions can undergo a conformational change from their native state to a 6-helix bundle ( trimer of dimers), which mediates fusion of viral and host cell membranes. Here we describe the biophysical analysis of the two predicted heptad repeat regions within the severe acute respiratory syndrome coronavirus S protein. Our results show that in isolation the HR-N region forms a stable alpha-helical coiled coil that associates in a tetrameric state. The HR-C region in isolation formed a weakly stable trimeric coiled coil. When mixed together, the two peptide regions (HR-N and HR-C) associated to form a very stable alpha-helical 6-stranded structure ( trimer of heterodimers). Systematic peptide mapping showed that the site of interaction between the HR-N and HR-C regions is between residues 916 - 950 of HR-N and residues 1151 - 1185 of HR-C. Additionally, interchain disulfide bridge experiments showed that the relative orientation of the HR-N and HR-C helices in the complex was antiparallel. Overall, the structure of the heterostranded complex is consistent with the structures observed for other type 1 viral fusion proteins in their fusion-competent state.
C1 Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA.
   Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA.
RP Hodges, RS (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.
EM robert.hodges@uchsc.edu
OI Jobling, Michael/0000-0001-7689-3093
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI 48717, R01 AI 25231]
CR Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X
   Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200
   Bos ECW, 1995, VIROLOGY, V214, P453, DOI 10.1006/viro.1995.0056
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306
   CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chen L, 2001, STRUCTURE, V9, P255, DOI 10.1016/S0969-2126(01)00581-0
   DEGROOT RJ, 1989, VIROLOGY, V171, P493, DOI 10.1016/0042-6822(89)90619-3
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   El-Sahly HM, 2000, CLIN INFECT DIS, V31, P96, DOI 10.1086/313937
   Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465
   Folz RJ, 1999, CHEST, V115, P901, DOI 10.1378/chest.115.3.901
   FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985
   Ghosh JK, 1998, J BIOL CHEM, V273, P27182, DOI 10.1074/jbc.273.42.27182
   Gibbons DL, 2000, J VIROL, V74, P7772, DOI 10.1128/JVI.74.17.7772-7780.2000
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779
   HAYES DB, 2003, SEDIMENTATION INTERP
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   Holtzer ME, 1997, BIOPHYS J, V73, P1031, DOI 10.1016/S0006-3495(97)78136-0
   JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4
   Kobe B, 1999, P NATL ACAD SCI USA, V96, P4319, DOI 10.1073/pnas.96.8.4319
   Kohn WD, 1998, J MOL BIOL, V283, P993, DOI 10.1006/jmbi.1998.2125
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Luo ZL, 1999, J VIROL, V73, P8152, DOI 10.1128/JVI.73.10.8152-8159.1999
   Luo ZL, 1998, VIROLOGY, V244, P483, DOI 10.1006/viro.1998.9121
   Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662
   Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Mathews JM, 2000, J VIROL, V74, P5911, DOI 10.1128/JVI.74.13.5911-5920.2000
   Matsuyama S, 2002, J VIROL, V76, P11819, DOI 10.1128/JVI.76.23.11819-11826.2002
   McIntosh K., 1974, Current Topics in Microbiology and Immunology, V63, P85
   Medinas RJ, 2002, J VIROL, V76, P9079, DOI 10.1128/JVI.76.18.9079-9086.2002
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pinon JD, 2003, J VIROL, V77, P3281, DOI 10.1128/JVI.77.5.3281-3290.2003
   Poon LLM, 2003, CLIN CHEM, V49, P953, DOI 10.1373/49.6.953
   Pritsker M, 1998, P NATL ACAD SCI USA, V95, P7287, DOI 10.1073/pnas.95.13.7287
   RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x
   SEMCHUK PD, 1996, PEPTIDES CHEM STRUCT, P73
   Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985
   TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074
   TAGUCHI F, 1995, J VIROL, V69, P7260, DOI 10.1128/JVI.69.11.7260-7263.1995
   Taguchi F, 2002, J VIROL, V76, P950, DOI 10.1128/JVI.76.3.950-958.2002
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Tomasi M, 2003, FEBS LETT, V536, P56, DOI 10.1016/S0014-5793(03)00010-3
   Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866
   TRIPET B, 2001, PEPTIDES WAVE FUTURE, P265
   WATOWICH SJ, 1994, STRUCTURE, V2, P719, DOI 10.1016/S0969-2126(00)00073-3
   Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8
   WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0
   Yang CL, 1997, J VIROL, V71, P8490, DOI 10.1128/JVI.71.11.8490-8496.1997
   Yang XZ, 2000, J VIROL, V74, P4746, DOI 10.1128/JVI.74.10.4746-4754.2000
   Yang XZ, 2000, J VIROL, V74, P5716, DOI 10.1128/JVI.74.12.5716-5725.2000
   Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116
   Young JK, 1997, VIROLOGY, V238, P291, DOI 10.1006/viro.1997.8834
   Zelus BD, 1998, J VIROL, V72, P7237, DOI 10.1128/JVI.72.9.7237-7244.1998
   Zelus BD, 2003, J VIROL, V77, P830, DOI 10.1128/JVI.77.2.830-840.2003
   Zhao X, 2000, P NATL ACAD SCI USA, V97, P14172, DOI 10.1073/pnas.260499197
   Zhou GF, 2000, BIOORGAN MED CHEM, V8, P2219, DOI 10.1016/S0968-0896(00)00155-3
   ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419
   ZHOU NE, 1992, J BIOL CHEM, V267, P2664
NR 68
TC 128
Z9 140
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 14
PY 2004
VL 279
IS 20
BP 20836
EP 20849
DI 10.1074/jbc.M400759200
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 818VY
UT WOS:000221273800035
PM 14996844
OA Bronze
DA 2020-04-03
ER

PT J
AU Corse, E
   Machamer, CE
AF Corse, E
   Machamer, CE
TI Infectious bronchitis virus E protein is targeted to the Golgi complex
   and directs release of virus-like particles
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; RECOMBINANT VACCINIA VIRUS; INTEGRAL
   MEMBRANE-PROTEIN; TRANSMEMBRANE DOMAIN; ENVELOPE PROTEIN; VIRION
   ENVELOPE; CELL SURFACE; M2 PROTEIN; CORONAVIRUS; GLYCOPROTEIN
AB The coronavirus E protein is a poorly characterized small envelope protein present in low levels in virions. We are interested in the role of E in the intracellular targeting of infectious bronchitis virus (IBV) membrane proteins. We generated a cDNA clone of IBV E and antibodies to the E protein to study its cell biological properties in the absence of virus infection. We show that IBV E is an integral membrane protein when expressed in cells from cDNA, Epitope-specific antibodies revealed that the C terminus of IBV E is cytoplasmic and the N terminus is translocated, The short luminal N terminus of IBV E contains a consensus site for N-linked glycosylation, but the site is not used. When expressed using recombinant vaccinia virus, the IBV E protein is released from cells at low levels in sedimentable particles that have a density similar to that of coronavirus virions. The IBV M protein is incorporated into these particles when present. Indirect immunofluorescence microscopy showed that E is localized to the Golgi complex in cells transiently expressing IBV E, When coexpressed with IBV M, both from cDNA and in IBV infection, the two proteins are colocalized in Golgi membranes, near the coronavirus budding site. Thus, even though IBV E is present at low levels in virions, it is apparently expressed at high levels in infected cells near the site of virus assembly.
C1 Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA.
RP Machamer, CE (reprint author), Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA.
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01 GM042522, GM42522]
CR ABRAHAM S, 1990, VIROLOGY, V177, P488, DOI 10.1016/0042-6822(90)90513-Q
   An SW, 1999, J VIROL, V73, P7853, DOI 10.1128/JVI.73.9.7853-7859.1999
   Baudoux P, 1998, J VIROL, V72, P8636, DOI 10.1128/JVI.72.11.8636-8643.1998
   Bos ECW, 1996, VIROLOGY, V218, P52, DOI 10.1006/viro.1996.0165
   Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261
   DEGROOT RJ, 1989, VIROLOGY, V171, P493, DOI 10.1016/0042-6822(89)90619-3
   Fischer F, 1998, J VIROL, V72, P7885, DOI 10.1128/JVI.72.10.7885-7894.1998
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   GODET M, 1992, VIROLOGY, V188, P666, DOI 10.1016/0042-6822(92)90521-P
   HAMMOND SA, 1995, J IMMUNOL, V154, P6140
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   Kim KMH, 1997, J VIROL, V71, P3922, DOI 10.1128/JVI.71.5.3922-3931.1997
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55
   LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9
   LANSER JA, 1980, J GEN VIROL, V46, P349, DOI 10.1099/0022-1317-46-2-349
   LEFRANCOIS L, 1982, VIROLOGY, V121, P168, DOI 10.1016/0042-6822(82)90126-X
   LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S
   LIU DX, 1991, VIROLOGY, V184, P531, DOI 10.1016/0042-6822(91)90423-9
   LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992
   LOCKER JK, 1992, J BIOL CHEM, V267, P14094
   MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205
   MACHAMER CE, 1993, MOL BIOL CELL, V4, P695
   MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944
   Maeda J, 1999, VIROLOGY, V263, P265, DOI 10.1006/viro.1999.9955
   Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715
   NILSSON IM, 1993, J BIOL CHEM, V268, P5768
   PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I
   PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097
   SMITH AR, 1990, J GEN VIROL, V71, P3, DOI 10.1099/0022-1317-71-1-3
   STERN DF, 1982, J VIROL, V44, P804, DOI 10.1128/JVI.44.3.804-812.1982
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19
   TOOZE J, 1987, J CELL BIOL, V105, P1215, DOI 10.1083/jcb.105.3.1215
   VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990
   VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671
   WEISZ OA, 1994, METHOD CELL BIOL, V43, P137
   YU X, 1994, VIROLOGY, V202, P1018, DOI 10.1006/viro.1994.1430
   ZEBEDEE SL, 1985, J VIROL, V56, P502, DOI 10.1128/JVI.56.2.502-511.1985
   ZEBEDEE SL, 1989, P NATL ACAD SCI USA, V86, P1061, DOI 10.1073/pnas.86.3.1061
   ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988
NR 43
TC 128
Z9 138
U1 1
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAY
PY 2000
VL 74
IS 9
BP 4319
EP 4326
DI 10.1128/JVI.74.9.4319-4326.2000
PG 8
WC Virology
SC Virology
GA 302KV
UT WOS:000086365000044
PM 10756047
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU van der Meer, Y
   van Tol, H
   Locker, JK
   Snijder, EJ
AF van der Meer, Y
   van Tol, H
   Locker, JK
   Snijder, EJ
TI ORF1a-encoded replicase subunits are involved in the membrane
   association of the arterivirus replication complex
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID EQUINE ARTERITIS VIRUS; VIRAL-RNA SYNTHESIS; PAPAIN-LIKE;
   ENDOPLASMIC-RETICULUM; MURINE CORONAVIRUS; CYSTEINE PROTEASE; ORF1A
   PROTEIN; IDENTIFICATION; TRANSCRIPTION; POLYMERASE
AB Among the functions of the replicase of equine arteritis virus (EAV; family Arteriviridae, order Nidovirales) are important viral enzyme activities such as proteases and the putative RNA polymerase and RNA helicase functions. The replicase is expressed in the form of two poIyproteins (open reading frame la [ORF1a] and ORF1ab), which are processed into 12 nonstructural proteins by three viral proteases. In immunofluorescence assays, the majority of these cleavage products localized to the perinuclear region of the cell. A dense granular and vesicular staining was observed, which strongly suggested membrane association. By using confocal microscopy and double-label immunofluorescence, the distribution of the EAV replicase was shown to overlap with that of PDI, a resident protein of the endoplasmic reticulum and intermediate compartment. An in situ labeling of nascent viral RNA with bromo-UTP demonstrated that the membrane-bound complex in which the replicase subunits accumulate is indeed the site of viral RNA synthesis. A number of ORF1a-encoded hydrophobic domains,were postulated to be involved in the membrane association of the arterivirus replication complex. By using various biochemical methods (Triton X-114 extraction, membrane purification, and sodium carbonate treatment), replicase subunits containing these domains were shown to behave as integral membrane proteins and to be membrane associated in infected cells. Thus, contribution to the formation of a membrane-bound scaffold for the viral replication-transcription complex appears to be an important novel function for the arterivirus ORF1a replicase polyprotein.
C1 Leiden Univ, Med Ctr, Dept Virol, NL-2300 RC Leiden, Netherlands.
   European Mol Biol Lab, Cell Biol Program, D-69117 Heidelberg, Germany.
RP Snijder, EJ (reprint author), Leiden Univ, Med Ctr, Dept Virol, AZL P4-26,POB 9600, NL-2300 RC Leiden, Netherlands.
EM Snijder@Virology.AZL.NL
RI Locker, Jacomine Krijnse/E-1009-2016; Snijder, Eric J./E-6073-2018
OI Snijder, Eric J./0000-0003-3297-2309
CR BAKER SC, 1993, J VIROL, V67, P6056, DOI 10.1128/JVI.67.10.6056-6063.1993
   BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992
   BONILLA PJ, 1995, VIROLOGY, V209, P489, DOI 10.1006/viro.1995.1281
   BORDIER C, 1981, J BIOL CHEM, V256, P1604
   Breese S.S.J., 1970, P 2 INT C EQ INF DIS, P133
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   DEGRAAFF M, 1993, VIROLOGY, V194, P878, DOI 10.1006/viro.1993.1335
   DENBOON JA, 1995, J VIROL, V69, P4500, DOI 10.1128/JVI.69.7.4500-4505.1995
   DENBOON JA, 1995, VIROLOGY, V213, P364, DOI 10.1006/viro.1995.0009
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   DEVRIES AAF, 1992, J VIROL, V66, P6294, DOI 10.1128/JVI.66.11.6294-6303.1992
   DOLL E. R., 1957, CORNELL VET, V47, P3
   Egger D, 1996, J VIROL, V70, P8675, DOI 10.1128/JVI.70.12.8675-8683.1996
   FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075
   FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97
   Gao HQ, 1996, VIRUS RES, V45, P101, DOI 10.1016/S0168-1702(96)01368-8
   GLASER AL, 1995, J GEN VIROL, V76, P2223, DOI 10.1099/0022-1317-76-9-2223
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   Haukenes G, 1997, BIOTECHNIQUES, V22, P308, DOI 10.2144/97222st03
   Heusipp G, 1997, J GEN VIROL, V78, P2789, DOI 10.1099/0022-1317-78-11-2789
   JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LIU DX, 1995, VIROLOGY, V209, P420, DOI 10.1006/viro.1995.1274
   LOCKER JK, 1994, J CELL BIOL, V124, P55
   LU YQ, 1995, J VIROL, V69, P3554, DOI 10.1128/JVI.69.6.3554-3559.1995
   PLAGEMANN PGW, 1996, FIELDS VIROLOGY, P1105
   Pol JMA, 1997, VET MICROBIOL, V55, P203, DOI 10.1016/S0378-1135(96)01329-6
   POMBO A, 1994, EMBO J, V13, P5075, DOI 10.1002/j.1460-2075.1994.tb06837.x
   RestrepoHartwig MA, 1996, J VIROL, V70, P8908, DOI 10.1128/JVI.70.12.8908-8916.1996
   ROST B, 1995, PROTEIN SCI, V4, P521
   Schaad MC, 1997, EMBO J, V16, P4049, DOI 10.1093/emboj/16.13.4049
   Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996
   Sethna PB, 1997, J VIROL, V71, P7744, DOI 10.1128/JVI.71.10.7744-7749.1997
   Snijder E. J., 1995, The coronaviridae., P239
   Snijder EJ, 1996, J BIOL CHEM, V271, P4864, DOI 10.1074/jbc.271.9.4864
   SNIJDER EJ, 1992, J VIROL, V66, P7040, DOI 10.1128/JVI.66.12.7040-7048.1992
   SNIJDER EJ, 1995, J BIOL CHEM, V270, P16671, DOI 10.1074/jbc.270.28.16671
   SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994
   Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961
   SNIJDER EJ, 1998, UNPUB
   Stelzer E H, 1991, Semin Cell Biol, V2, P145
   STUECKEMANN JA, 1982, J GEN VIROL, V59, P263, DOI 10.1099/0022-1317-59-2-263
   Towner JS, 1996, J BIOL CHEM, V271, P26810, DOI 10.1074/jbc.271.43.26810
   VANDERLAAN M, 1985, CYTOMETRY, V6, P501, DOI 10.1002/cyto.990060603
   VANDERMEER Y, 1998, UNPUB
   vanDinten LC, 1997, P NATL ACAD SCI USA, V94, P991, DOI 10.1073/pnas.94.3.991
   vanDinten LC, 1996, J VIROL, V70, P6625, DOI 10.1128/JVI.70.10.6625-6633.1996
   VANDINTEN LC, UNPUB
   VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0
   WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283
   Wassenaar ALM, 1997, J VIROL, V71, P9313, DOI 10.1128/JVI.71.12.9313-9322.1997
   Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997
   WOOD O, 1970, J GEN VIROL, V7, P129, DOI 10.1099/0022-1317-7-2-129
   ZIEBUHR J, 1995, J VIROL, V69, P4331, DOI 10.1128/JVI.69.7.4331-4338.1995
NR 55
TC 128
Z9 133
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD AUG
PY 1998
VL 72
IS 8
BP 6689
EP 6698
DI 10.1128/JVI.72.8.6689-6698.1998
PG 10
WC Virology
SC Virology
GA ZZ446
UT WOS:000074730200052
PM 9658116
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU HORZINEK, MC
   LUTZ, H
   PEDERSEN, NC
AF HORZINEK, MC
   LUTZ, H
   PEDERSEN, NC
TI ANTIGENIC RELATIONSHIPS AMONG HOMOLOGOUS STRUCTURAL POLYPEPTIDES OF
   PORCINE, FELINE, AND CANINE CORONAVIRUSES
SO INFECTION AND IMMUNITY
LA English
DT Article
C1 UNIV CALIF DAVIS,SCH VET MED,DEPT MED,DAVIS,CA 95616.
RP HORZINEK, MC (reprint author), STATE UNIV UTRECHT,FAC VET,INST VIROL,UTRECHT,NETHERLANDS.
CR Binn L N, 1974, Proc Annu Meet U S Anim Health Assoc, P359
   BRUGGMANN S, 1978, IMMUNOFLUORESCENCE R, P341
   Garwes D.J., 1978, VET MICROBIOL, V3, P179
   GARWES DJ, 1975, J GEN VIROL, V29, P25, DOI 10.1099/0022-1317-29-1-25
   GARWES DJ, 1976, J GEN VIROL, V32, P283, DOI 10.1099/0022-1317-32-2-283
   GARWES DJ, 1981, J GEN VIROL, V52, P153, DOI 10.1099/0022-1317-52-1-153
   GERNA G, 1981, J GEN VIROL, V54, P91, DOI 10.1099/0022-1317-54-1-91
   HORZINEK MC, 1979, ARCH VIROL, V59, P1, DOI 10.1007/BF01317889
   HORZINEK MC, 1981, EXPT VIROLOGY SERIES
   KAYE HS, 1975, LANCET, V2, P509
   LASKEY RA, 1977, FEBS LETT, V82, P314, DOI 10.1016/0014-5793(77)80609-1
   LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x
   MACNAUGHTON MR, 1981, INFECT IMMUN, V33, P734, DOI 10.1128/IAI.33.3.734-737.1981
   MACNAUGHTON MR, 1981, INFECT IMMUN, V31, P845, DOI 10.1128/IAI.31.3.845-849.1981
   NEVILLE DM, 1971, J BIOL CHEM, V246, P6328
   OLSON DP, 1973, AM J VET RES, V34, P1239
   PEDERSEN NC, 1978, ARCH VIROL, V58, P45, DOI 10.1007/BF01315534
   PIKE BV, 1979, J GEN VIROL, V42, P279, DOI 10.1099/0022-1317-42-2-279
   REYNOLDS DJ, 1977, ARCH VIROL, V55, P77, DOI 10.1007/BF01314481
   REYNOLDS DJ, 1980, VET MICROBIOL, V5, P283, DOI 10.1016/0378-1135(80)90027-9
   TYRRELL DAJ, 1978, INTERVIROLOGY, V10, P321, DOI 10.1159/000148996
   WITTE KH, 1977, BERL MUNCH TIERARZTL, V90, P396
   WOODS RD, 1981, AM J VET RES, V42, P1163
   WOODS RD, 1979, VET MICROBIOL, V4, P11, DOI 10.1016/0378-1135(79)90025-7
NR 24
TC 128
Z9 131
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PY 1982
VL 37
IS 3
BP 1148
EP 1155
DI 10.1128/IAI.37.3.1148-1155.1982
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA PE708
UT WOS:A1982PE70800046
PM 6182101
OA Bronze
DA 2020-04-03
ER

PT J
AU GODENY, EK
   CHEN, L
   KUMAR, SN
   METHVEN, SL
   KOONIN, EV
   BRINTON, MA
AF GODENY, EK
   CHEN, L
   KUMAR, SN
   METHVEN, SL
   KOONIN, EV
   BRINTON, MA
TI COMPLETE GENOMIC SEQUENCE AND PHYLOGENETIC ANALYSIS OF THE LACTATE
   DEHYDROGENASE-ELEVATING VIRUS (LDV)
SO VIROLOGY
LA English
DT Article
ID STRAND RNA VIRUSES; CYSTEINE PROTEASES; SERINE PROTEASES;
   CORONAVIRUS-IBV; RECOMBINATION; SUPERFAMILY; POLYMERASE; PROTEIN;
   IDENTIFICATION; REPLICATION
C1 GEORGIA STATE UNIV, DEPT BIOL, POB 4010, ATLANTA, GA 30302 USA.
   NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA.
FU NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [NS19013]
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872
   BAZAN JF, 1990, SEMIN VIROL, V1, P311
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   BRINTON MA, 1986, J GEN VIROL, V67, P2673, DOI 10.1099/0022-1317-67-12-2673
   BRINTON MA, 1982, MOUSE BIOMEDICAL RES, V2, P194
   BRINTONDARNELL M, 1975, J VIROL, V16, P420, DOI 10.1128/JVI.16.2.420-433.1975
   CLOSE TJ, 1983, GENE, V23, P131, DOI 10.1016/0378-1119(83)90044-6
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   DEVRIES AAF, 1992, J VIROL, V66, P6294, DOI 10.1128/JVI.66.11.6294-6303.1992
   Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   FENNER F, 1977, INTERVIROLOGY, V7, P44
   FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279
   FRANCKI RIB, 1991, ARCH VIROL         S, V2, P1
   GODENY EK, 1989, VIROLOGY, V172, P647, DOI 10.1016/0042-6822(89)90208-0
   GODENY EK, 1990, VIROLOGY, V177, P768, DOI 10.1016/0042-6822(90)90546-4
   GORBALENYA AE, 1989, J MOL EVOL, V28, P256, DOI 10.1007/BF02102483
   GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6
   GORBALENYA AE, 1988, FEBS LETT, V236, P287, DOI 10.1016/0014-5793(88)80039-5
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7
   GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2
   HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0
   JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1
   KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269
   KECK JG, 1988, J VIROL, V62, P1810, DOI 10.1128/JVI.62.5.1810-1813.1988
   KECK JG, 1987, VIROLOGY, V156, P331, DOI 10.1016/0042-6822(87)90413-2
   KOONIN EV, 1992, P NATL ACAD SCI USA, V89, P8259, DOI 10.1073/pnas.89.17.8259
   KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197
   KUO L, 1992, VIRUS RES, V23, P55
   KUO LL, 1991, J VIROL, V65, P5118, DOI 10.1128/JVI.65.9.5118-5123.1991
   KUSTERS JG, 1989, VIROLOGY, V169, P217, DOI 10.1016/0042-6822(89)90058-5
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MAKINO S, 1987, P NATL ACAD SCI USA, V84, P6567, DOI 10.1073/pnas.84.18.6567
   MANIATIS T, 1989, MOL CLONING
   MARTINEZ D, 1980, INFECT IMMUN, V27, P979, DOI 10.1128/IAI.27.3.979-987.1980
   MEULENBERG JJM, 1993, VIROLOGY, V192, P62, DOI 10.1006/viro.1993.1008
   NAINAN OV, 1991, J GEN VIROL, V72, P1685, DOI 10.1099/0022-1317-72-7-1685
   NOTKINS AL, 1965, BACTERIOL REV, V29, P143, DOI 10.1128/MMBR.29.2.143-160.1965
   OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161
   PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444
   PLAGEMANN PGW, 1992, ADV VIRUS RES, V41, P99, DOI 10.1016/S0065-3527(08)60036-6
   RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707
   ROWSON KEK, 1985, J GEN VIROL, V66, P2297, DOI 10.1099/0022-1317-66-11-2297
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304
   SMIT MJ, 1990, HEPATOLOGY, V12, P1192, DOI 10.1002/hep.1840120519
   SNIJDER EJ, 1990, NUCLEIC ACIDS RES, V18, P4535, DOI 10.1093/nar/18.15.4535
   SNIJDER EJ, 1992, J VIROL, V66, P7040, DOI 10.1128/JVI.66.12.7040-7048.1992
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   SPAAN WJM, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P12
   STRAUSS EG, 1983, CURR TOP MICROBIOL, V105, P1
   ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404
   WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266
NR 60
TC 127
Z9 138
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUN
PY 1993
VL 194
IS 2
BP 585
EP 596
DI 10.1006/viro.1993.1298
PG 12
WC Virology
SC Virology
GA LC575
UT WOS:A1993LC57500017
PM 8389075
DA 2020-04-03
ER

PT J
AU GALLAGHER, TM
   ESCARMIS, C
   BUCHMEIER, MJ
AF GALLAGHER, TM
   ESCARMIS, C
   BUCHMEIER, MJ
TI ALTERATION OF THE PH-DEPENDENCE OF CORONAVIRUS-INDUCED CELL-FUSION -
   EFFECT OF MUTATIONS IN THE SPIKE GLYCOPROTEIN
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID INFLUENZA-VIRUS HEMAGGLUTININ; MEDIATED MEMBRANE-FUSION; MURINE
   CORONAVIRUS; HEPATITIS-VIRUS; CONFORMATIONAL CHANGE; PROTEOLYTIC
   CLEAVAGE; PROTEIN; E2-GLYCOPROTEIN; JHM; EXPRESSION
AB Infection of susceptible murine cells with the coronavirus mouse hepatitis virus type 4 (MHV4) results in extensive cell-cell fusion at pHs from 5.5 to 8.5. The endosomotropic weak bases chloroquine and ammonium chloride do not prevent MHV4 infection. In marked contrast, we have selected variants from a neural cell line persistently infected with MHV4 which are entirely dependent on acid pH to fuse host cells and are strongly inhibited by endosomotropic weak bases. Wild-type and variant viruses were compared at the level of the fusion-active surface (S) glycoprotein gene. Cloning and sequencing of each 4,131-base open reading frame predicted a total of eight amino acid differences which fell into three distinct clusters. Each S glycoprotein, when expressed from cDNA, was synthesized in equivalent amounts, and similar proportions were transported to the cell surface. Wild-type S induced cell-cell fusion at neutral pH, whereas variant S required prolonged exposure to acidic pH to induce fusion. Expression of hybrid S genes prepared by exchange of restriction fragments between wild-type and variant cDNAs revealed that elimination of neutral pH fusion was solely dependent on amino acid alterations at positions 1067 (Q to H), 1094 (Q to H), and 1114 (L to R). These changes lie within a predicted heptad region of the transmembrane cleavage fragment of S (S2). These findings demonstrate that the pH dependence of coronavirus fusion is highly variable and that this variability can be determined by a few as three amino acid residues.
RP GALLAGHER, TM (reprint author), SCRIPPS CLIN & RES FDN, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-25913]; NIA NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Aging (NIA) [5-T32-AG00080]; NINDS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [NS-12428]
CR BAILEY OT, 1949, J EXP MED, V90, P195, DOI 10.1084/jem.90.3.195
   BAYBUTT HN, 1984, J GEN VIROL, V65, P915, DOI 10.1099/0022-1317-65-5-915
   BOYLE JF, 1987, J VIROL, V61, P185, DOI 10.1128/JVI.61.1.185-189.1987
   CAVANAGH D, 1983, J GEN VIROL, V64, P2577, DOI 10.1099/0022-1317-64-12-2577
   COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6
   DAYA M, 1988, VIROLOGY, V163, P276, DOI 10.1016/0042-6822(88)90267-X
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   DOMS RW, 1985, J BIOL CHEM, V260, P2973
   DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   GALLAGHER TM, 1990, J VIROL, V64, P731, DOI 10.1128/JVI.64.2.731-741.1990
   GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5
   HIRANO N, 1978, JPN J EXP MED, V48, P71
   HIRANO N, 1981, BIOCH BIOL CORONAVIR, P301
   HOLMES KV, 1987, POSITIVE STRAND RNA, P339
   JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7
   KESSLER SW, 1976, J IMMUNOL, V117, P1482
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7
   MIZZEN L, 1985, VIROLOGY, V142, P378, DOI 10.1016/0042-6822(85)90345-9
   NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x
   PARKER SE, 1989, VIROLOGY, V173, P664, DOI 10.1016/0042-6822(89)90579-5
   ROBB JA, 1989, COMPREHENSIVE VIROLO, V14, P193
   ROOS DS, 1990, VIROLOGY, V175, P345, DOI 10.1016/0042-6822(90)90419-R
   RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209
   Sambrook J., 1989, MOL CLONING LABORATO
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SHIEH CK, 1987, VIROLOGY, V156, P321, DOI 10.1016/0042-6822(87)90412-0
   SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155
   STEINHAUER DA, 1987, ANNU REV MICROBIOL, V41, P409, DOI 10.1146/annurev.mi.41.100187.002205
   STOHLMAN SA, 1982, J GEN VIROL, V63, P265, DOI 10.1099/0022-1317-63-2-265
   STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   STURMAN LS, 1990, J VIROL, V64, P3042, DOI 10.1128/JVI.64.6.3042-3050.1990
   TALBOT PJ, 1984, VIROLOGY, V132, P250, DOI 10.1016/0042-6822(84)90032-1
   TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475
   VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990
   VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683
   WEILAND E, 1978, J EXP MED, V148, P408, DOI 10.1084/jem.148.2.408
   WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887
   WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331
NR 46
TC 127
Z9 131
U1 1
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD APR
PY 1991
VL 65
IS 4
BP 1916
EP 1928
DI 10.1128/JVI.65.4.1916-1928.1991
PG 13
WC Virology
SC Virology
GA FC031
UT WOS:A1991FC03100033
PM 1848311
OA Bronze
DA 2020-04-03
ER

PT J
AU BARIC, RS
   NELSON, GW
   FLEMING, JO
   DEANS, RJ
   KECK, JG
   CASTEEL, N
   STOHLMAN, SA
AF BARIC, RS
   NELSON, GW
   FLEMING, JO
   DEANS, RJ
   KECK, JG
   CASTEEL, N
   STOHLMAN, SA
TI INTERACTIONS BETWEEN CORONAVIRUS NUCLEOCAPSID PROTEIN AND VIRAL RNAS -
   IMPLICATIONS FOR VIRAL TRANSCRIPTION
SO JOURNAL OF VIROLOGY
LA English
DT Article
C1 UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033.
   UNIV SO CALIF,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90033.
   UNIV N CAROLINA,SCH PUBL HLTH,DEPT PARASITOL & LAB PRACTICE,CHAPEL HILL,NC 27514.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 19244, AI 31386]; NINDS NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [NS 18146]
CR ARMSTRONG J, 1983, NUCLEIC ACIDS RES, V11, P883, DOI 10.1093/nar/11.3.883
   ARNHEITER H, 1985, CELL, V41, P259, DOI 10.1016/0092-8674(85)90079-0
   BANERJEE AK, 1987, MICROBIOL REV, V51, P66, DOI 10.1128/MMBR.51.1.66-87.1987
   BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   BARIC RS, 1987, VIROLOGY, V156, P342, DOI 10.1016/0042-6822(87)90414-4
   BARIC RS, 1985, VIRUS RES, V3, P19, DOI 10.1016/0168-1702(85)90038-3
   BLUMBERG BM, 1983, CELL, V32, P559, DOI 10.1016/0092-8674(83)90475-0
   BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1
   BRAYTON PR, 1982, J VIROL, V42, P847, DOI 10.1128/JVI.42.3.847-853.1982
   BRAYTON PR, 1984, VIROLOGY, V133, P197, DOI 10.1016/0042-6822(84)90439-2
   CHOU CC, 1987, P NATL ACAD SCI USA, V84, P2575, DOI 10.1073/pnas.84.9.2575
   COMPTON SR, 1987, J VIROL, V61, P1814, DOI 10.1128/JVI.61.6.1814-1820.1987
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1
   FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X
   GILMORE W, 1987, P SOC EXP BIOL MED, V185, P177
   GRUBMAN MJ, 1977, VIROLOGY, V8, P1
   HARMON RC, 1983, IMMUNOGENETICS, V18, P541, DOI 10.1007/BF00364395
   HILTON A, 1986, J GEN VIROL, V67, P923, DOI 10.1099/0022-1317-67-5-923
   KURILLA MG, 1983, CELL, V34, P837, DOI 10.1016/0092-8674(83)90541-X
   LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   LAI MMC, 1982, J VIROL, V41, P557, DOI 10.1128/JVI.41.2.557-565.1982
   MAKINO S, 1986, P NATL ACAD SCI USA, V83, P4204, DOI 10.1073/pnas.83.12.4204
   MAKINO S, 1985, J VIROL, V54, P329, DOI 10.1128/JVI.54.2.329-336.1985
   MANN R, 1985, J VIROL, V54, P401, DOI 10.1128/JVI.54.2.401-407.1985
   NAKANAGA K, 1986, J VIROL, V59, P168, DOI 10.1128/JVI.59.1.168-171.1986
   RAJU R, 1987, J VIROL, V61, P667, DOI 10.1128/JVI.61.3.667-672.1987
   ROBBINS SG, 1986, VIROLOGY, V150, P402, DOI 10.1016/0042-6822(86)90305-3
   ROSEN CA, 1982, J VIROL, V44, P932, DOI 10.1128/JVI.44.3.932-938.1982
   SAWICKI SG, 1986, J VIROL, V57, P328, DOI 10.1128/JVI.57.1.328-334.1986
   SHIEH CK, 1987, VIROLOGY, V156, P321, DOI 10.1016/0042-6822(87)90412-0
   SKINNER MA, 1983, NUCLEIC ACIDS RES, V11, P5045, DOI 10.1093/nar/11.15.5045
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   STOHLMAN SA, 1983, VIROLOGY, V130, P527, DOI 10.1016/0042-6822(83)90106-X
   STOHLMAN SA, 1979, J VIROL, V32, P672, DOI 10.1128/JVI.32.2.672-675.1979
   STOHLMAN SA, 1988, J VIROL, V62, P4288, DOI 10.1128/JVI.62.11.4288-4295.1988
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201
   XI J, 1987, APPL ENVIRON MICROB, V53, P2487, DOI 10.1128/AEM.53.10.2487-2495.1987
NR 41
TC 127
Z9 141
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 1988
VL 62
IS 11
BP 4280
EP 4287
DI 10.1128/JVI.62.11.4280-4287.1988
PG 8
WC Virology
SC Virology
GA Q4899
UT WOS:A1988Q489900046
PM 2845140
OA Bronze
DA 2020-04-03
ER

PT J
AU Memish, ZA
   Zumla, A
   Alhakeem, RF
   Assiri, A
   Turkestani, A
   Al Harby, KD
   Alyemni, M
   Dhafar, K
   Gautret, P
   Barbeschi, M
   McCloskey, B
   Heymann, D
   Al Rabeeah, AA
   Al-Tawfiq, JA
AF Memish, Ziad A.
   Zumla, Alimuddin
   Alhakeem, Rafat F.
   Assiri, Abdullah
   Turkestani, Abdulhafeez
   Al Harby, Khalid D.
   Alyemni, Mohamed
   Dhafar, Khalid
   Gautret, Philippe
   Barbeschi, Maurizio
   McCloskey, Brian
   Heymann, David
   Al Rabeeah, Abdullah A.
   Al-Tawfiq, Jaffar A.
TI Hajj: infectious disease surveillance and control
SO LANCET
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; MASS GATHERINGS; SAUDI-ARABIA;
   TUBERCULOSIS INFECTION; MENINGOCOCCAL DISEASE; IRANIAN PILGRIMS;
   SEROGROUP W135; PANDEMIC H1N1; OUTBREAK; PREVENTION
AB Religious festivals attract a large number of pilgrims from worldwide and are a potential risk for the transmission of infectious diseases between pilgrims, and to the indigenous population. The gathering of a large number of pilgrims could compromise the health system of the host country. The threat to global health security posed by infectious diseases with epidemic potential shows the importance of advanced planning of public health surveillance and response at these religious events. Saudi Arabia has extensive experience of providing health care at mass gatherings acquired through decades of managing millions of pilgrims at the Hajj. In this report, we describe the extensive public health planning, surveillance systems used to monitor public health risks, and health services provided and accessed during Hajj 2012 and Hajj 2013 that together attracted more than 5 million pilgrims from 184 countries. We also describe the recent establishment of the Global Center for Mass Gathering Medicine, a Saudi Government partnership with the WHO Collaborating Centre for Mass Gatherings Medicine, Gulf Co-operation Council states, UK universities, and public health institutions globally.
C1 [Memish, Ziad A.; Zumla, Alimuddin; Alhakeem, Rafat F.; Barbeschi, Maurizio; McCloskey, Brian; Heymann, David; Al-Tawfiq, Jaffar A.] Minist Hlth, Global Ctr Mass Gathering Med, Riyadh 11176, Saudi Arabia.
   [Memish, Ziad A.] WHO Collaborating Ctr Mass Gatherings Med, Riyadh, Saudi Arabia.
   [Memish, Ziad A.] Al Faisal Univ, Riyadh, Saudi Arabia.
   [Memish, Ziad A.; Alhakeem, Rafat F.; Assiri, Abdullah; Turkestani, Abdulhafeez; Al Harby, Khalid D.; Alyemni, Mohamed; Dhafar, Khalid; Al Rabeeah, Abdullah A.] Minist Hlth, Riyadh 11176, Saudi Arabia.
   [Zumla, Alimuddin] UCL, Div Infect & Immun, London, England.
   [Zumla, Alimuddin] Univ Coll London Hosp NHS Fdn Trust, London, England.
   [Gautret, Philippe] Aix Marseille Univ, Unite Rech Malad Infect & Trop Emergentes, INSERM, Marseille, France.
   [Gautret, Philippe] Inst Hosp Univ Mediterranee Infect, Marseille, France.
   [Barbeschi, Maurizio] WHO, CH-1211 Geneva, Switzerland.
   [McCloskey, Brian] WHO Collaborating Ctr Mass Gatherings & High Visi, Geneva, Switzerland.
   [Heymann, David] Chatham House, London, England.
   [Heymann, David] London Sch Hyg & Trop Med, London WC1, England.
   [Al-Tawfiq, Jaffar A.] Saudi Aramco Med Serv Org, Dhahran, Saudi Arabia.
   [Al-Tawfiq, Jaffar A.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
RP Memish, ZA (reprint author), Minist Hlth, Global Ctr Mass Gathering Med, Riyadh 11176, Saudi Arabia.
EM zmemish@yahoo.com
OI Assiri, Abdullah/0000-0002-5605-2876; Zumla,
   Alimuddin/0000-0002-5111-5735
FU European and Developing Countries Clinical Trials Partnership TB NEAT;
   European and Developing Countries Clinical Trials Partnership, PANACEA;
   European and Developing Countries Clinical Trials Partnership, REMox;
   UBS Optimus Foundation, Switzerland; National Institute for Health
   Research Biomedical Research Centre, University College London Hospitals
FX We thank the staff at the Ministry of Health for their support; Adam
   Zumla, University College London School of Pharmacy, London, UK, for
   technical and administrative assistance. AZ acknowledges support from
   the European and Developing Countries Clinical Trials Partnership TB
   NEAT, PANACEA, and REMox grants; UBS Optimus Foundation, Switzerland;
   and National Institute for Health Research Biomedical Research Centre,
   University College London Hospitals.
CR Abouzeid MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039478
   Abubakar I, 2012, LANCET INFECT DIS, V12, P66, DOI 10.1016/S1473-3099(11)70246-8
   Aguilera JF, 2002, EMERG INFECT DIS, V8, P761, DOI 10.3201/eid0808.010422
   Ahmed QA, 2009, TRAVEL MED INFECT DI, V7, P226, DOI 10.1016/j.tmaid.2009.01.005
   Al Rabeeah A, 2012, LANCET, V380, P3, DOI 10.1016/S0140-6736(12)61073-3
   Al-Ghamdi AS, 2011, SAUDI MED J, V32, P1161
   Al-Ghamdi SM, 2003, SAUDI MED J, V24, P1073
   Al-Hajoj S, 2013, ANTIMICROB AGENTS CH, V57, P2161, DOI 10.1128/AAC.02403-12
   Al-Joudi AS, 2007, J FAM COMMUNITY MED, V14, P29
   Al-Mazrou YY, 2004, SAUDI MED J, V25, P11
   Al-Orainey IO, 2013, SAUDI MED J, V34, P676
   Al-Tawfiq JA, 2013, E MEDITERR HEALTH J, V19, pS48
   Al-Tawfiq JA, 2012, EURO SURVEILL, V17, P20295
   Al-Tawfiq JA, 2013, CURR OPIN PULM MED, V19, P192, DOI 10.1097/MCP.0b013e32835f1ae8
   Al-Tawfiq JA, 2012, INFECT DIS CLIN N AM, V26, P725, DOI 10.1016/j.idc.2012.05.005
   AlGahtani YM, 1995, EPIDEMIOL INFECT, V115, P399, DOI 10.1017/S0950268800058556
   Alherabi AZ, 2011, SAUDI MED J, V32, P933
   Alzeer A, 1998, J INFECTION, V36, P303, DOI 10.1016/S0163-4453(98)94315-8
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Balkhy HH, 2004, J TRAVEL MED, V11, P82, DOI 10.2310/7060.2004.17027
   Benkouiten S, 2013, CLIN INFECT DIS, V57, P992, DOI 10.1093/cid/cit446
   Botelho-Nevers E, 2013, EURO SURVEILL, V18, P20426
   Buchholz U, 2013, EURO SURVEILL, V18
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   D'Alessandro Kenneth, 2013, JEMS, V38, P52
   Ebrahim SH, 2009, SCIENCE, V326, P938, DOI 10.1126/science.1183210
   Emamian MH, 2013, IRAN RED CRESCENT ME, V15, P317, DOI 10.5812/ircmj.3681
   Farid M.A., 1956, WHO EMRO INT C MAL E
   Gatrad AR, 2005, BRIT MED J, V330, P133, DOI 10.1136/bmj.330.7483.133
   Gautret P, 2013, CLIN MICROBIOL INFEC, V19, pE315, DOI 10.1111/1469-0691.12174
   Gautret P, 2009, J TRAVEL MED, V16, P377, DOI 10.1111/j.1708-8305.2009.00358.x
   Hymavathi P, 1993, Bull Indian Inst Hist Med Hyderabad, V23, P113
   Johansson A, 2012, LANCET INFECT DIS, V12, P150, DOI 10.1016/S1473-3099(11)70287-0
   Kandeel A, 2011, EMERG INFECT DIS, V17, P1266, DOI 10.3201/eid1707.101484
   Khan K, 2012, LANCET INFECT DIS, V12, P222, DOI 10.1016/S1473-3099(11)70313-9
   Khan K, 2010, CAN MED ASSOC J, V182, P579, DOI 10.1503/cmaj.100093
   Kraemer JL, 2000, HIST RELIGIONS, V40, P198, DOI 10.1086/463631
   Langley G, 2013, MMWR-MORBID MORTAL W, V62, P793
   Loncarevic G, 2009, EUROSURVEILLANCE, V14, P14
   Madani TA, 2007, ANN SAUDI MED, V27, P101, DOI 10.4103/0256-4947.51528
   Madani TA, 2006, ANN SAUDI MED, V26, P346, DOI 10.5144/0256-4947.2006.346
   Mailles A, 2013, EURO SURVEILL, V18
   Mandourah Y, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-117
   Mazroa Mohammed A A I, 2012, PLoS One, V7, pe45919, DOI 10.1371/journal.pone.0045919
   Memish Z, 2013, EURO SURVEILL, V18, P20581
   Memish ZA, 2010, EURO SURVEILL, V15
   Memish ZA, 2013, NEW ENGL J MED, V369, P884, DOI 10.1056/NEJMc1308698
   Memish ZA, 2013, J EPIDEMIOL GLOB HEA, V3, P59, DOI 10.1016/j.jegh.2013.03.001
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Memish Ziad A, 2012, J Infect Public Health, V5, P113, DOI 10.1016/j.jiph.2012.03.001
   Memish ZA, 2012, LANCET INFECT DIS, V12, P56, DOI 10.1016/S1473-3099(11)70337-1
   Memish ZA, 2011, TRAVEL MED INFECT DI, V9, P60, DOI 10.1016/j.tmaid.2011.01.004
   Meysamie A, 2006, SAUDI MED J, V27, P1049
   Momattin H, 2013, INT J INFECT DIS, V17, pE792, DOI 10.1016/j.ijid.2013.07.002
   Puzelli S, 2013, EURO SURVEILL, V18
   Rashid H, 2013, TRAVEL MED INFECT DI, V11, P288, DOI 10.1016/j.tmaid.2013.06.001
   Shafi Shuja, 2008, J Infect Public Health, V1, P27, DOI 10.1016/j.jiph.2008.08.008
   Shibl A, 2013, E MEDITERR HEALTH J, V19, P389
   Shibl A, 2012, CLIN MICROBIOL INFEC, V18, P1068, DOI 10.1111/1469-0691.12010
   Snow RW, 2013, ADV PARASIT, V82, P205, DOI 10.1016/B978-0-12-407706-5.00003-4
   Tahir M, 2013, EURO SURVEILL
   Tewari S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047291
   Thackway S, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-324
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Who Mers-Cov Research Group, 2013, PLoS Curr, V5, DOI 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8
   Wilder-Smith A, 2005, TROP MED INT HEALTH, V10, P336, DOI 10.1111/j.1365-3156.2005.01395.x
   Wilder-Smith A, 2003, CLIN INFECT DIS, V36, P679, DOI 10.1086/367858
   World Health Organization, 2008, COMM DIS AL RESP MAS
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Ziyaeyan M, 2012, INFLUENZA OTHER RESP, V6, pe80, DOI 10.1111/j.1750-2659.2012.00381.x
NR 70
TC 126
Z9 128
U1 3
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUN 14
PY 2014
VL 383
IS 9934
BP 2073
EP 2082
DI 10.1016/S0140-6736(14)60381-0
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI9VZ
UT WOS:000337292400027
PM 24857703
DA 2020-04-03
ER

PT J
AU Cotten, M
   Watson, SJ
   Zumla, AI
   Makhdoom, HQ
   Palser, AL
   Ong, SH
   Al Rabeeah, AA
   Alhakeem, RF
   Assiri, A
   Al-Tawfiq, JA
   Albarrak, A
   Barry, M
   Shibl, A
   Alrabiah, FA
   Hajjar, S
   Balkhy, HH
   Flemban, H
   Rambaut, A
   Kellam, P
   Memish, ZA
AF Cotten, Matthew
   Watson, Simon J.
   Zumla, Alimuddin I.
   Makhdoom, Hatem Q.
   Palser, Anne L.
   Ong, Swee Hoe
   Al Rabeeah, Abdullah A.
   Alhakeem, Rafat F.
   Assiri, Abdullah
   Al-Tawfiq, Jaffar A.
   Albarrak, Ali
   Barry, Mazin
   Shibl, Atef
   Alrabiah, Fahad A.
   Hajjar, Sami
   Balkhy, Hanan H.
   Flemban, Hesham
   Rambaut, Andrew
   Kellam, Paul
   Memish, Ziad A.
TI Spread, Circulation, and Evolution of the Middle East Respiratory
   Syndrome Coronavirus
SO MBIO
LA English
DT Article
ID HOST-RANGE EXPANSION; SAUDI-ARABIA; CLINICAL-FEATURES; SARS-CORONAVIRUS;
   DROMEDARY CAMELS; FUSION CORE; MERS-COV; TRANSMISSION; INFECTION;
   RECEPTOR
AB The Middle East respiratory syndrome coronavirus (MERS-CoV) was first documented in the Kingdom of Saudi Arabia (KSA) in 2012 and, to date, has been identified in 180 cases with 43% mortality. In this study, we have determined the MERS-CoV evolutionary rate, documented genetic variants of the virus and their distribution throughout the Arabian peninsula, and identified the genome positions under positive selection, important features for monitoring adaptation of MERS-CoV to human transmission and for identifying the source of infections. Respiratory samples from confirmed KSA MERS cases from May to September 2013 were subjected to whole-genome deep sequencing, and 32 complete or partial sequences (20 were >= 99% complete, 7 were 50 to 94% complete, and 5 were 27 to 50% complete) were obtained, bringing the total available MERS-CoV genomic sequences to 65. An evolutionary rate of 1.12 x 10(-3) substitutions per site per year (95% credible interval [95% CI], 8.76 x 10(-4); 1.37 x 10(-3)) was estimated, bringing the time to most recent common ancestor to March 2012 (95% CI, December 2011; June 2012). Only one MERS-CoV codon, spike 1020, located in a domain required for cell entry, is under strong positive selection. Four KSA MERS-CoV phylogenetic clades were found, with 3 clades apparently no longer contributing to current cases. The size of the population infected with MERS-CoV showed a gradual increase to June 2013, followed by a decline, possibly due to increased surveillance and infection control measures combined with a basic reproduction number (R-0) for the virus that is less than 1.
   IMPORTANCE MERS-CoV adaptation toward higher rates of sustained human-to-human transmission appears not to have occurred yet. While MERS-CoV transmission currently appears weak, careful monitoring of changes in MERS-CoV genomes and of the MERS epidemic should be maintained. The observation of phylogenetically related MERS-CoV in geographically diverse locations must be taken into account in efforts to identify the animal source and transmission of the virus.
C1 [Cotten, Matthew; Watson, Simon J.; Palser, Anne L.; Ong, Swee Hoe; Kellam, Paul] Wellcome Trust Sanger Inst, Hinxton, England.
   [Zumla, Alimuddin I.; Al Rabeeah, Abdullah A.; Alhakeem, Rafat F.; Assiri, Abdullah; Memish, Ziad A.] Global Ctr Mass Gatherings Med, Minist Hlth, Riyadh, Saudi Arabia.
   [Zumla, Alimuddin I.; Kellam, Paul] Univ Coll London Hosp, NHS Fdn Trust, Dept Med Microbiol, London, England.
   [Zumla, Alimuddin I.; Kellam, Paul] UCL, Div Infect & Immun, London, England.
   [Makhdoom, Hatem Q.] Minist Hlth, Jeddah Reg Lab, Jeddah, Saudi Arabia.
   [Al-Tawfiq, Jaffar A.] Saudi Aramco, Saudi Aramco Med Serv Org, Dhahran, Saudi Arabia.
   [Albarrak, Ali] Prince Sultan Mil Med City, Riyadh, Saudi Arabia.
   [Barry, Mazin; Shibl, Atef] King Saud Univ, Riyadh, Saudi Arabia.
   [Alrabiah, Fahad A.; Hajjar, Sami] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia.
   [Balkhy, Hanan H.] King Abdul Aziz Med City, Riyadh, Saudi Arabia.
   [Flemban, Hesham] Alhada Mil Hosp, Riyadh, Saudi Arabia.
   [Rambaut, Andrew] Inst Evolutionary Biol, Ashworth Labs, Edinburgh, Midlothian, Scotland.
   [Rambaut, Andrew] Fogarty Int Ctr, NIH, Bethesda, MD USA.
   [Memish, Ziad A.] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia.
RP Memish, ZA (reprint author), Global Ctr Mass Gatherings Med, Minist Hlth, Riyadh, Saudi Arabia.
EM zmemish@yahoo.com
RI Rambaut, Andrew/B-2481-2009; Barry, Mazin/AAJ-7615-2020
OI Rambaut, Andrew/0000-0003-4337-3707; Barry, Mazin/0000-0003-2274-007X;
   Ong, Swee Hoe/0000-0002-3629-5387; Assiri, Abdullah/0000-0002-5605-2876;
   Rambaut FRSE, Professor Andrew/0000-0002-1278-598X; Cotten,
   Matthew/0000-0002-3361-3351; Zumla, Alimuddin/0000-0002-5111-5735;
   Kellam, Paul/0000-0003-3166-4734
FU Saudi Arabian Ministry of Health; Wellcome Trust Sanger
   InstituteWellcome Trust; European CommunityEuropean Community (EC)
   [223498, 278433]; National Institute of Health Research Biomedical
   Research CentreNational Institute for Health Research (NIHR); University
   College London Hospitals; EDCTP; EC-FW7
FX This work was supported by the Saudi Arabian Ministry of Health, the
   Wellcome Trust Sanger Institute, and the European Community's Seventh
   Framework Programme (FP7/2007-2013) under the project EMPE-RIE, European
   Community grant agreement number 223498, and under the project
   PREDEMICS, grant agreement number 278433. A.I.Z. acknowledges support
   from the National Institute of Health Research Biomedical Research
   Centre, University College London Hospitals, the EDCTP, and the EC-FW7.
CR Aburizaiza AS, 2014, J INFECT DIS, V209, P243, DOI 10.1093/infdis/jit589
   AlBarrak AM, 2012, SAUDI MED J, V33, P1265
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Breban R, 2013, LANCET, V382, P694, DOI 10.1016/S0140-6736(13)61492-0
   Cauchemez S, 2014, LANCET INFECT DIS, V14, P50, DOI 10.1016/S1473-3099(13)70304-9
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Cotten M, 2013, EMERG INFECT DIS, V19, P736, DOI 10.3201/eid1905.130057
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Frieman M, 2009, J VIROL, V83, P6689, DOI 10.1128/JVI.02220-08
   Gao J, 2013, J VIROL, V87, P13134, DOI 10.1128/JVI.02433-13
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Lemey Philippe, 2009, PLoS Curr, V1, pRRN1031, DOI 10.1371/currents.RRN1031
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Mcroy WC, 2008, J VIROL, V82, P1414, DOI 10.1128/JVI.01674-07
   Memish Z., 2013, MERS COV E MEDITERRA
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Millet JK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049566
   Minin VN, 2008, MOL BIOL EVOL, V25, P1459, DOI 10.1093/molbev/msn090
   Murrell B, 2013, MOL BIOL EVOL, V30, P1196, DOI 10.1093/molbev/mst030
   Murrell B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002764
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   Ponstingl H., 2013, SMALT EFFICIENTLY AL
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Sheahan T, 2008, J VIROL, V82, P2274, DOI 10.1128/JVI.02041-07
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Watson SJ, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0205
   World Health Organization, 2014, MIDDL E RESP SYNDR C
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 44
TC 126
Z9 132
U1 3
U2 59
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD JAN-FEB
PY 2014
VL 5
IS 1
AR e01062-13
DI 10.1128/mBio.01062-13
PG 11
WC Microbiology
SC Microbiology
GA AC4YF
UT WOS:000332526500015
PM 24549846
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-04-03
ER

PT J
AU de Wilde, AH
   Raj, VS
   Oudshoorn, D
   Bestebroer, TM
   van Nieuwkoop, S
   Limpens, RWAL
   Posthuma, CC
   van der Meer, Y
   Barcena, M
   Haagmans, BL
   Snijder, EJ
   van den Hoogen, BG
AF de Wilde, Adriaan H.
   Raj, V. Stalin
   Oudshoorn, Diede
   Bestebroer, Theo M.
   van Nieuwkoop, Stefan
   Limpens, Ronald W. A. L.
   Posthuma, Clara C.
   van der Meer, Yvonne
   Barcena, Montserrat
   Haagmans, Bart L.
   Snijder, Eric J.
   van den Hoogen, Bernadette G.
TI MERS-coronavirus replication induces severe in vitro cytopathology and
   is strongly inhibited by cyclosporin A or interferon-alpha treatment
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; COMPLETE GENOME SEQUENCE; PAPAIN-LIKE PROTEASE;
   SARS-CORONAVIRUS; VIRAL-RNA; ARTERIVIRUS; INDUCTION; ASSOCIATION;
   RESPONSES; UNIQUE
AB Coronavirus (Coy) infections are commonly associated with respiratory and enteric disease in humans and animals. The 2003 outbreak of severe acute respiratory syndrome (SARS) highlighted the potentially lethal consequences of CoV-induced disease in humans. In 2012, a novel CoV (Middle East Respiratory Syndrome coronavirus; MERS-CoV) emerged, causing 49 human cases thus far, of which 23 had a fatal outcome. In this study, we characterized MERS-CoV replication and cytotoxicity in human and monkey cell lines. Electron microscopy of infected Vero cells revealed extensive membrane rearrangements, including the formation of double-membrane vesicles and convoluted membranes, which have been implicated previously in the RNA synthesis of SARS-CoV and other CoVs. Following infection, we observed rapidly increasing viral RNA synthesis and release of high titres of infectious progeny, followed by a pronounced cytopathology. These characteristics were used to develop an assay for antiviral compound screening in 96-well format, which was used to identify cyclosporin A as an inhibitor of MERS-CoV replication in cell culture. Furthermore, MERS-CoV was found to be 50-100 times more sensitive to alpha interferon (IFN-alpha) treatment than SARS-CoV, an observation that may have important implications for the treatment of MERS-CoV-infected patients. MERS-CoV infection did not prevent the IFN-induced nuclear translocation of phosphorylated STAT1, in contrast to infection with SARS-CoV where this block inhibits the expression of antiviral genes. These findings highlight relevant differences between these distantly related zoonotic CoVs in terms of their interaction with and evasion of the cellular innate immune response.
C1 [de Wilde, Adriaan H.; Oudshoorn, Diede; Posthuma, Clara C.; van der Meer, Yvonne; Snijder, Eric J.] Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, Leiden, Netherlands.
   [Raj, V. Stalin; Bestebroer, Theo M.; van Nieuwkoop, Stefan; Haagmans, Bart L.; van den Hoogen, Bernadette G.] Erasmus MC, Virosci Lab, Rotterdam, Netherlands.
   [Limpens, Ronald W. A. L.; Barcena, Montserrat] Leiden Univ, Med Ctr, Dept Mol Cell Biol, Sect Elect Microscopy, Leiden, Netherlands.
RP Snijder, EJ (reprint author), Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, Leiden, Netherlands.
EM E.J.Snijder@lumc.nl; b.vandenhoogen@erasmusmc.nl
RI Barcena, Montserrat/B-5823-2012; Snijder, Eric J./E-6073-2018; Raj, V
   Stalin/E-9670-2016; van den Hoogen, Bernadette/J-5461-2013
OI Barcena, Montserrat/0000-0002-7719-4443; Snijder, Eric
   J./0000-0003-3297-2309; Raj, V Stalin/0000-0003-2250-8481; Limpens,
   Ronald/0000-0002-6243-6729; Haagmans, Bart/0000-0001-6221-2015
FU Council for Chemical Sciences (CW) of the Netherlands Organization for
   Scientific Research (NWO) [700.57.301]; Council for Earth and Life
   Sciences (ALW) of the Netherlands Organization for Scientific Research
   (NWO) [836.10.003]; EU-FP7-Health project SILVER [260644]
FX We are grateful to Ron Fouchier, Chris Lauber and Alexander Gorbalenya
   for helpful discussions, and we thank Dennis Ninaber and Corrine
   Beugeling for technical assistance. This research was supported in part
   by the Council for Chemical Sciences (CW), TOP grant 700.57.301, and the
   Council for Earth and Life Sciences (ALW), MEERVOUD grant 836.10.003, of
   the Netherlands Organization for Scientific Research (NWO), and the
   EU-FP7-Health project SILVER (grant 260644).
CR Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bergman SJ, 2011, INFECT DIS CLIN N AM, V25, P819, DOI 10.1016/j.idc.2011.07.008
   Brockway SM, 2003, J VIROL, V77, P10515, DOI 10.1128/JVI.77.19.10515-10527.2003
   Cameron MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045842
   Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770
   de Groot R. J., 2013, J VIROL IN PRESS, V87, DOI [10.1128/JVI.01244-13, DOI 10.1128/JVI.01244-13)]
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   deGroot RJ, 2012, VIRUS TAXONOMY, P785
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   GARLINGHOUSE LE, 1984, ARCH VIROL, V82, P19, DOI 10.1007/BF01309365
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Hussain S, 2008, J VIROL, V82, P7212, DOI 10.1128/JVI.02406-07
   Huynh J, 2012, J VIROL, V86, P12816, DOI 10.1128/JVI.00906-12
   Kindler E, 2013, MBIO, V4, DOI 10.1128/mBio.00611-12
   Knoops K, 2012, J VIROL, V86, P2474, DOI 10.1128/JVI.06677-11
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Kopecky-Bromberg SA, 2006, J VIROL, V80, P785, DOI 10.1128/JVI.80.2.785-793.2006
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   Muller MA, 2012, MBIO, V3, DOI 10.1128/mBio.00515-12
   Nagy PD, 2011, VIROLOGY, V411, P374, DOI 10.1016/j.virol.2010.12.061
   Paragas J, 2005, ANTIVIR RES, V66, P99, DOI 10.1016/j.antiviral.2005.01.002
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Pfefferle S, 2009, EMERG INFECT DIS, V15, P1377, DOI 10.3201/eid1509.090224
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Roth-Cross JK, 2007, J VIROL, V81, P7189, DOI 10.1128/JVI.00013-07
   Sims AC, 2013, J VIROL, V87, P3885, DOI 10.1128/JVI.02520-12
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   TAGUCHI F, 1985, VIROLOGY, V147, P41, DOI 10.1016/0042-6822(85)90225-9
   Ulasli M, 2010, CELL MICROBIOL, V12, P844, DOI 10.1111/j.1462-5822.2010.01437.x
   van der Hoek L., 2004, NAT MED, V10, P368
   van der Meer Y, 1998, J VIROL, V72, P6689, DOI 10.1128/JVI.72.8.6689-6698.1998
   van Hemert MJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000054
   van Kasteren PB, 2013, P NATL ACAD SCI USA, V110, pE838, DOI 10.1073/pnas.1218464110
   Versteeg GA, 2007, VIROLOGY, V361, P18, DOI 10.1016/j.virol.2007.01.020
   Vijaykrishna D, 2007, J VIROL, V81, P4012, DOI 10.1128/JVI.02605-06
   Vijgen L, 2005, J VIROL, V79, P1595, DOI 10.1128/JVI.79.3.1595-1604.2005
   Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Worm S. H. Evanden, 2012, PLOS ONE, V7
   Yoshikawa T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008729
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zeng FY, 2003, EXP BIOL MED, V228, P866, DOI 10.1177/15353702-0322807-13
   Zhong YX, 2012, VIRUSES-BASEL, V4, P980, DOI 10.3390/v4060980
   Zust R, 2011, NAT IMMUNOL, V12, P137, DOI 10.1038/ni.1979
NR 59
TC 126
Z9 131
U1 6
U2 39
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD AUG
PY 2013
VL 94
BP 1749
EP 1760
DI 10.1099/vir.0.052910-0
PN 8
PG 12
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 197KN
UT WOS:000322850200007
PM 23620378
OA Green Published, Other Gold
DA 2020-04-03
ER

PT J
AU Esper, F
   Weibel, C
   Ferguson, D
   Landry, ML
   Kahn, JS
AF Esper, F
   Weibel, C
   Ferguson, D
   Landry, ML
   Kahn, JS
TI Evidence of a novel human coronavirus that is associated with
   respiratory tract disease in infants and young children
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID ANTIGENIC RELATIONSHIPS; HUMAN METAPNEUMOVIRUS; IDENTIFICATION;
   PNEUMONIA; INFECTION
AB Background. The etiological agents responsible for a substantial proportion of respiratory tract diseases have not been identified. We sought to determine whether novel human coronaviruses (HCoVs) are circulating in New Haven, Connecticut, and, if so, whether they are associated with respiratory tract disease in infants and young children.
   Methods. We developed a polymerase chain reaction (PCR)-based approach for screening specimens from the respiratory tracts of symptomatic children. PCR probes that target regions of the replicase 1a gene that are conserved among genetically diverse animal CoVs and HCoVs were designed. Using these probes, we identified genomic sequences of a novel HCoV, designated "New Haven coronavirus" (HCoV-NH). Thereafter, we designed specific probes to screen respiratory specimens from children <5 years old for this novel HCoV. Clinical features associated with HCoV-NH infection were identified.
   Results. Seventy-nine (8.8%) of 895 children tested positive for HCoV-NH. Cough, rhinorrhea, tachypnea, fever, abnormal breath sounds, and hypoxia were the most common findings associated with HCoV-NH infection. Sequence analysis revealed that HCoV-NH is closely related to a novel HCoV recently reported in The Netherlands.
   Conclusions. The novel HCoVs identified in New Haven and The Netherlands are similar and likely represent the same species. This newly discovered virus may have worldwide distribution and may account for a significant proportion of respiratory tract disease in infants and young children.
C1 Yale Univ, Sch Med, Dept Pediat, Div Infect Dis, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
RP Kahn, JS (reprint author), Yale Univ, Sch Med, Dept Pediat, Div Infect Dis, POB 208064, New Haven, CT 06520 USA.
EM jeffrey.kahn@yale.edu
FU NCRR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [M01-RR06022]; NIAID NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [T32
   AI07210-20]
CR BRADBURNE AF, 1970, ARCH GES VIRUSFORSCH, V31, P352, DOI 10.1007/BF01253769
   BRADBURNE AF, 1972, J HYG-CAMB, V70, P235, DOI 10.1017/S0022172400022294
   Davies HD, 1996, PEDIATR INFECT DIS J, V15, P371, DOI 10.1097/00006454-199604000-00017
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Esper F, 2004, J INFECT DIS, V189, P1388, DOI 10.1086/382482
   Esper F, 2003, PEDIATRICS, V111, P1407, DOI 10.1542/peds.111.6.1407
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   HOLMES KV, 1996, FUNDAMENTAL VIROLOGY, V1, P1075
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   MCINTOSH K, 1969, J IMMUNOL, V102, P1109
   MCINTOSH K, 1996, VIROLOGY, V1, P1095
   MURRAY CJL, 2001, GLOBAL PROGRAMME EVI
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruiz M, 1999, AM J RESP CRIT CARE, V160, P397, DOI 10.1164/ajrccm.160.2.9808045
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243
NR 20
TC 126
Z9 136
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB 15
PY 2005
VL 191
IS 4
BP 492
EP 498
DI 10.1086/428138
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 888ZM
UT WOS:000226413100002
PM 15655770
OA Bronze
DA 2020-04-03
ER

PT J
AU Lin, MT
   Stohlman, SA
   Hinton, DR
AF Lin, MT
   Stohlman, SA
   Hinton, DR
TI Mouse hepatitis virus is cleared from the central nervous systems of
   mice lacking perforin-mediated cytolysis
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T-CELL CLONES;
   MONOCLONAL-ANTIBODIES; NUCLEOCAPSID PROTEIN; CYTOTOXIC LYMPHOCYTES;
   MURINE CORONAVIRUSES; LETHAL INFECTION; STRAIN JHM; IN-VIVO;
   DEMYELINATION
AB Perforin-deficient [perforin (-/-)] mice were infected with two strains of JHM virus (JHMV) to analyze the role of perforin-mediated cytotoxicity in acute lethal and subacute central nervous system (CNS) infections. During both acute and subacute infections, the overall mortality of the perforin (-/-) mice was not different from that of the controls. Perforin (-/-) mice survived longer than the controls, consistent with reduced morbidity. Both strains of virus were cleared from the perforin (-/-) mice as in the controls; however, the rate of clearance was delayed in the perforin (-/-) mice, indicating that perforin-mediated cytolysis is involved in viral clearance. The absence of perforin-mediated cytolysis did not prevent encephalomyelitis or extensive demyelination. Cells undergoing apoptosis were detected in the CNS of both the perforin (-/-) and control groups, indicating that perforin is not essential for programmed cell death. Neutralizing antibodies were not detected in either group of mice until day 9 postinfection, when the majority of the virus had been cleared. These data further confirm the importance of cell-mediated cytotoxicity and suggest that additional components of the immune response contribute to the clearance of JHMV from the CNS.
C1 UNIV SO CALIF, SCH MED, DEPT NEUROL, LOS ANGELES, CA 90033 USA.
   UNIV SO CALIF, SCH MED, DEPT MOL MICROBIOL & IMMUNOL, LOS ANGELES, CA 90033 USA.
RP Lin, MT (reprint author), UNIV SO CALIF, MED CTR,SCH MED,DEPT PATHOL,MCH 142, 1333 SAN PABLO ST, LOS ANGELES, CA 90033 USA.
FU PHS HHSUnited States Public Health Service [N.S. 18146]
CR BERGMANN C, 1993, J VIROL, V67, P7041, DOI 10.1128/JVI.67.12.7041-7049.1993
   Bergmann CC, 1996, J GEN VIROL, V77, P315, DOI 10.1099/0022-1317-77-2-315
   BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.iy.12.040194.003511
   Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2
   BUCHMEIER MJ, 1984, VIROLOGY, V132, P261, DOI 10.1016/0042-6822(84)90033-3
   CASTRO RF, 1995, J VIROL, V69, P8127, DOI 10.1128/JVI.69.12.8127-8131.1995
   CASTRO RF, 1994, VIROLOGY, V200, P733, DOI 10.1006/viro.1994.1237
   Chisari FV, 1996, CURR TOP MICROBIOL, V206, P149
   COMPTON SR, 1993, LAB ANIM SCI, V43, P15
   DORRIES R, 1991, IMMUNOLOGY, V74, P539
   FLEMING JO, 1989, VIROLOGY, V168, P162, DOI 10.1016/0042-6822(89)90415-7
   FLEMING JO, 1986, J VIROL, V58, P869, DOI 10.1128/JVI.58.3.869-875.1986
   FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1
   Fleming John O., 1993, Regional Immunology, V5, P37
   FLEURY HJA, 1980, NEUROPATH APPL NEURO, V6, P165, DOI 10.1111/j.1365-2990.1980.tb00288.x
   Golstein P, 1995, Curr Top Microbiol Immunol, V198, P25
   GOMBOLD JL, 1995, MICROB PATHOGENESIS, V18, P211, DOI 10.1016/S0882-4010(95)90058-6
   GOTO N, 1987, JPN J VET SCI, V49, P779
   Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2
   Houtman JJ, 1996, J NEUROVIROL, V2, P101, DOI 10.3109/13550289609146543
   HUITINGA I, 1995, CLIN EXP IMMUNOL, V100, P344
   KAGI D, 1995, IMMUNOL REV, V146, P95, DOI 10.1111/j.1600-065X.1995.tb00686.x
   Kagi D, 1995, EUR J IMMUNOL, V25, P3256, DOI 10.1002/eji.1830251209
   KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0
   KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614
   KORNER H, 1991, J IMMUNOL, V147, P2317
   KUNDIG TM, 1993, J IMMUNOL, V150, P2316
   KYUWA S, 1990, SEMINARS VIROLOGY, V1, P273
   LAMPERT PW, 1973, ACTA NEUROPATHOL, V24, P76, DOI 10.1007/BF00691421
   LECOMTE J, 1987, ARCH VIROL, V97, P123, DOI 10.1007/BF01310740
   LEHMANNGRUBE F, 1988, ANN NY ACAD SCI, V532, P238, DOI 10.1111/j.1749-6632.1988.tb36343.x
   LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0
   MILLER SD, 1994, IMMUNOL TODAY, V15, P356, DOI 10.1016/0167-5699(94)90173-2
   MURRAY RS, 1992, VIROLOGY, V188, P274, DOI 10.1016/0042-6822(92)90757-G
   NAKANAGA K, 1986, J VIROL, V59, P168, DOI 10.1128/JVI.59.1.168-171.1986
   PEARCE BD, 1994, J VIROL, V68, P5483, DOI 10.1128/JVI.68.9.5483-5495.1994
   SHIBATA S, 1994, J VIROL, V68, P7540, DOI 10.1128/JVI.68.11.7540-7545.1994
   SMITH AL, 1991, ARCH VIROL, V121, P89, DOI 10.1007/BF01316746
   STOHLMAN SA, 1981, NEUROLOGY, V31, P38, DOI 10.1212/WNL.31.1.38
   STOHLMAN SA, 1982, J GEN VIROL, V63, P265, DOI 10.1099/0022-1317-63-2-265
   STOHLMAN SA, 1995, J VIROL, V69, P684, DOI 10.1128/JVI.69.2.684-694.1995
   STOHLMAN SA, 1994, VIROLOGY, V202, P146, DOI 10.1006/viro.1994.1330
   STOHLMAN SA, 1992, VIROLOGY, V189, P217
   STOHLMAN SA, 1986, J IMMUNOL, V136, P3052
   STOHLMAN SA, 1995, J VIROL, V69, P5898, DOI 10.1128/JVI.69.9.5898-5903.1995
   SUSSMAN MA, 1989, J VIROL, V63, P3051, DOI 10.1128/JVI.63.7.3051-3056.1989
   WALSH CM, 1994, P NATL ACAD SCI USA, V91, P10854, DOI 10.1073/pnas.91.23.10854
   WANG FI, 1990, J NEUROIMMUNOL, V30, P31, DOI 10.1016/0165-5728(90)90050-W
   WEINER LP, 1973, ARCH NEUROL-CHICAGO, V28, P298, DOI 10.1001/archneur.1973.00490230034003
   Wijburg OLC, 1996, IMMUNOLOGY, V87, P34
   WILLIAMSON JSP, 1990, J VIROL, V64, P4589, DOI 10.1128/JVI.64.9.4589-4592.1990
   WILLIAMSON JSP, 1991, J NEUROIMMUNOL, V32, P199, DOI 10.1016/0165-5728(91)90189-E
   YAMAGUCHI K, 1991, J NEUROIMMUNOL, V32, P1, DOI 10.1016/0165-5728(91)90065-F
   YOKOMORI K, 1992, J VIROL, V66, P2865, DOI 10.1128/JVI.66.5.2865-2874.1992
   Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173
NR 55
TC 126
Z9 129
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JAN
PY 1997
VL 71
IS 1
BP 383
EP 391
DI 10.1128/JVI.71.1.383-391.1997
PG 9
WC Virology
SC Virology
GA VX292
UT WOS:A1997VX29200046
PM 8985361
OA Bronze
DA 2020-04-03
ER

PT J
AU HERREWEGH, AAPM
   VENNEMA, H
   HORZINEK, MC
   ROTTIER, PJM
   DEGROOT, RJ
AF HERREWEGH, AAPM
   VENNEMA, H
   HORZINEK, MC
   ROTTIER, PJM
   DEGROOT, RJ
TI THE MOLECULAR-GENETICS OF FELINE CORONAVIRUSES - COMPARATIVE
   SEQUENCE-ANALYSIS OF THE ORF7A/7B TRANSCRIPTION UNIT OF DIFFERENT
   BIOTYPES
SO VIROLOGY
LA English
DT Article
ID INFECTIOUS PERITONITIS VIRUS; 3' END; MONOCLONAL-ANTIBODIES; ENTERIC
   CORONAVIRUSES; CATS; PORCINE; CANINE; GLYCOPROTEINS; KITTENS; GENOME
AB Feline coronaviruses (FCoVs) have been subdivided into feline enteric coronaviruses (FECVs) and feline infectious peritonitis viruses (FIPVs) on the basis of pathogenic properties. Serologically, a distinction has been made between type I and II FCoVs, the latter of which more closely resemble canine coronavirus (CCV). To gain more insight into the genetic relationships between different FCoV biotypes, we determined the nucleotide sequences of the ORF7a/7b transcription unit of nine strains. The following observations were made: (i) The sequences are 87-100% identical. In this part of the genome, type I and II FCoVs are more closely related to each other than to CCV. To explain the genetic and antigenic differences between the spike genes of type I and II FCoVs, we postulate that type II FCoVs have arisen by an RNA recombination event between a type I FCoV and CCV, (ii) The avirulent ''FECV'' strains UCD and 79-1683 are more similar to virulent ''FIPV'' strains than to each other. Our findings thus support the notion that FECV and FIPV are not different species but merely virulence variants. (iii) In contrast to FECV 79-1683, FECV UCD contains an intact ORF7b, indicating that ORF7b deletions are not a universal distinguishing property of FECVs. (iv) ORF7b deletions readily occur in vitro, correlating with loss of virulence. By reverse transcription- polymerase chain reaction analysis, we show that in naturally occurring FCoVs ORF7b is maintained. Thus, ORF7b seems to provide a distinct selective advantage during natural infection. (C) 1995 Academic Press, Inc.
C1 UNIV UTRECHT,FAC VET MED,DEPT INFECT DIS & IMMUNOL,VIROL UNIT,3584 CL UTRECHT,NETHERLANDS.
CR ADDIE DD, 1992, VET REC, V130, P133, DOI 10.1136/vr.130.7.133
   ADDIE DD, 1992, VET REC, V131, P202, DOI 10.1136/vr.131.9.202-a
   BARLOUGH JE, 1990, INFECT DIS, P300
   BLACK JW, 1980, VET MED SM ANIM CLIN, V75, P811
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   CHRISTIANSON KK, 1989, ARCH VIROL, V109, P185, DOI 10.1007/BF01311080
   DEGROOT RJ, 1988, VIROLOGY, V167, P370, DOI 10.1016/0042-6822(88)90097-9
   DEGROOT RJ, 1995, CORONAVIRIDAE
   EVERMANN JF, 1981, VET PATHOL, V18, P256, DOI 10.1177/030098588101800214
   FISCUS SA, 1987, J VIROL, V61, P2607, DOI 10.1128/JVI.61.8.2607-2613.1987
   GARWES DJ, 1989, J GEN VIROL, V70, P2495, DOI 10.1099/0022-1317-70-9-2495
   GERBER JD, 1990, ADV EXP MED BIOL, V276, P481
   GOODING LR, 1992, CELL, V71, P5
   HERREWEGH AAPM, 1995, J CLIN MICROBIOL, V33, P684, DOI 10.1128/JCM.33.3.684-689.1995
   HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151
   HOHDATSU T, 1992, J VET MED SCI, V54, P557, DOI 10.1292/jvms.54.557
   HOHDATSU T, 1991, ARCH VIROL, V117, P85, DOI 10.1007/BF01310494
   HOHDATSU T, 1991, VET MICROBIOL, V28, P13, DOI 10.1016/0378-1135(91)90096-X
   HORSBURGH BC, 1992, J GEN VIROL, V73, P2849, DOI 10.1099/0022-1317-73-11-2849
   KAPKE PA, 1986, VIROLOGY, V151, P41, DOI 10.1016/0042-6822(86)90102-9
   LAI MMC, 1992, CURR TOP MICROBIOL, V176, P21
   LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426
   LOEFFLER DG, 1978, FELINE PRACT, V8, P43
   MCKEIRNAN AJ, 1981, FELINE PRACT, V11, P16
   MOTOKAWA K, 1995, ARCH VIROL, V140, P469, DOI 10.1007/BF01718424
   OREILLY KJ, 1979, VET REC, V104, P348, DOI 10.1136/vr.104.15.348
   OSTERHAUS ADME, 1978, ZBL VET MED B, V25, P816
   Pedersen N. C., 1976, Feline Practice, V6, P42
   Pedersen N. C., 1987, Coronaviruses, P529
   PEDERSEN NC, 1981, AM J VET RES, V42, P368
   PEDERSEN NC, 1976, AM J VET RES, V37, P1449
   PEDERSEN NC, 1983, AM J VET RES, V44, P229
   PEDERSEN NC, 1983, FELINE PRACT, V13, P13
   PEDERSEN NC, 1985, COMP CONT EDUC PRACT, V7, P1001
   PEDERSEN NC, 1981, AM J VET RES, V42, P363
   PEDERSEN NC, 1984, AM J VET RES, V45, P2580
   Pedersen NC, 1984, MOL BIOL PATHOGENESI, P356
   REED PA, 1993, CORONAVIRUSES MOL BI, P17
   SMITH GL, 1993, J GEN VIROL, V74, P1725, DOI 10.1099/0022-1317-74-9-1725
   SNEATH PHA, 1973, NUMERICAL TAXONOMY, P230, DOI DOI 10.1111/J.1523-1739.2007.00775.X
   SPARKES AH, 1991, VET REC, V129, P209, DOI 10.1136/vr.129.10.209
   SPARKES AH, 1992, VET REC, V131, P35, DOI 10.1136/vr.131.2.35
   TUNG FYT, 1992, VIROLOGY, V186, P676, DOI 10.1016/0042-6822(92)90034-M
   VENNEMA H, 1992, VIROLOGY, V191, P134, DOI 10.1016/0042-6822(92)90174-N
   VENNEMA H, 1992, J VIROL, V66, P4951, DOI 10.1128/JVI.66.8.4951-4956.1992
   VENNEMA H, 1995, FELINE PRACT, V23, P40
   WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S
NR 47
TC 126
Z9 132
U1 0
U2 13
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PD OCT 1
PY 1995
VL 212
IS 2
BP 622
EP 631
DI 10.1006/viro.1995.1520
PG 10
WC Virology
SC Virology
GA RY725
UT WOS:A1995RY72500035
PM 7571432
OA Bronze
DA 2020-04-03
ER

PT J
AU Chua, KB
   Crameri, G
   Hyatt, A
   Yu, M
   Tompang, MR
   Rosli, J
   McEachern, J
   Crameri, S
   Kumarasamy, V
   Eaton, BT
   Wang, LF
AF Chua, Kaw Bing
   Crameri, Gary
   Hyatt, Alex
   Yu, Meng
   Tompang, Mohd Rosli
   Rosli, Juliana
   McEachern, Jennifer
   Crameri, Sandra
   Kumarasamy, Verasingam
   Eaton, Bryan T.
   Wang, Lin-Fa
TI A previously unknown reovirus of bat origin is associated with an acute
   respiratory disease in humans
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE respiratory infection; zoonosis; human-to-human transmission;
   orthoreovirus; pulau virus
ID EMERGENT DEADLY PARAMYXOVIRUS; FRUIT BATS; NIPAH VIRUS; FAMILY
   PARAMYXOVIRIDAE; FUNCTIONAL RECEPTOR; HOST-RANGE; SEQUENCE; CORONAVIRUS;
   SARS; RESERVOIRS
AB Respiratory infections constitute the most widespread human infectious disease, and a substantial proportion of them are caused by unknown etiological agents. Reoviruses (respiratory enteric orphan viruses) were first isolated from humans in the early 1950s and so named because they were not associated with any known disease. Here, we report a previously unknown reovirus (named "Melaka virus") isolated from a 39-year-old male patient in Melaka, Malaysia, who was suffering from high fever and acute respiratory disease at the time of virus isolation. Two of his family members developed similar symptoms approximate to 1 week later and had serological evidence of infection with the same virus. Epidemiological tracing revealed that the family was exposed to a bat in the house approximate to 1 week before the onset of the father's clinical symptoms. Genome sequence analysis indicated a close genetic relationship between Melaka virus and Pulau virus, a reovirus isolated in 1999 from fruit bats in Tioman Island, Malaysia. Screening of sera collected from human volunteers on the island revealed that 14 of 109 (13%) were positive for both Pulau and Melaka viruses. This is the first report of an orthoreovirus in association with acute human respiratory diseases. Melaka virus is serologically not related to the different types of mammalian reoviruses that were known to infect humans asymptomatically. These data indicate that batborne reoviruses can be transmitted to and cause clinical diseases in humans.
C1 Natl Publ Hlth Lab, Selangor 4700, Malaysia.
   CSIRO Livestock Ind, Australian Anim Hlth Lab, Geelong, Vic 3220, Australia.
   CSIRO Livestock Ind, Australian Biosecur Cooperat Res Ctr Emerging Inf, Geelong, Vic 3220, Australia.
RP Chua, KB (reprint author), Natl Publ Hlth Lab, Selangor 4700, Malaysia.
EM chuakawbing@yahoo.com.sg
RI Thorpe, Allison/A-2705-2011; Barr, Jennifer/H-9254-2013; Crameri,
   Gary/H-8441-2013; Crameri, Sandra/H-1887-2013
OI Wang, Lin-Fa/0000-0003-2752-0535; Barr, Jennifer/0000-0001-5266-9142
CR Attoui H, 2000, J VIROL METHODS, V89, P147, DOI 10.1016/S0166-0934(00)00212-3
   Bonaparte MI, 2005, P NATL ACAD SCI USA, V102, P10652, DOI 10.1073/pnas.0504887102
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Chant K, 1998, EMERG INFECT DIS, V4, P273, DOI 10.3201/eid0402.980215
   Chappell J., 2005, VIRUS TAXONOMY 8 REP, P455
   Childs JE, 2004, ARCH VIROL, P1
   Chong HT, 2003, NEUROL J SE ASIA, V8, P31
   Chua Kaw Bing, 2002, Malays J Pathol, V24, P15
   Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432
   Chua KB, 2003, MICROBES INFECT, V5, P487, DOI 10.1016/S1286-4579(03)00067-4
   Chua KB, 2001, VIROLOGY, V283, P215, DOI 10.1006/viro.2000.0882
   Cleaveland S, 2001, PHILOS T ROY SOC B, V356, P991, DOI 10.1098/rstb.2001.0889
   Drescher U, 2002, CURR OPIN GENET DEV, V12, P397, DOI 10.1016/S0959-437X(02)00316-7
   Duncan R, 1999, VIROLOGY, V260, P316, DOI 10.1006/viro.1999.9832
   Duncan R, 2004, VIROLOGY, V319, P131, DOI 10.1016/j.virol.2003.10.025
   Eaton BT, 2006, NAT REV MICROBIOL, V4, P23, DOI 10.1038/nrmicro1323
   GARD G, 1970, J VIROL, V6, P100, DOI 10.1128/JVI.6.1.100-106.1970
   GARD GP, 1973, ARCH GES VIRUSFORSCH, V43, P34, DOI 10.1007/BF01249346
   King DA, 2006, SCIENCE, V313, P1392, DOI 10.1126/science.1129134
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   MERTENS PPC, 2005, CIRUS TAXONOMY 8 REP, P447
   MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348
   Negrete OA, 2005, NATURE, V436, P401, DOI 10.1038/nature03838
   NIBERT ML, 2001, FIELDS VIROLOGY, P1679
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Philbey AW, 1998, EMERG INFECT DIS, V4, P269, DOI 10.3201/eid0402.980214
   Pritchard LI, 2006, ARCH VIROL, V151, P229, DOI 10.1007/s00705-005-0644-4
   Speare R, 1997, Commun Dis Intell, V21, P117
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Tyler K.L., 2001, FIELDS VIROLOGY, P1729
   VANDERHOEK L, 2004, NAT MED, V28, P444
   Wang LF, 2006, EMERG INFECT DIS, V12, P1834
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woolhouse MEJ, 2005, EMERG INFECT DIS, V11, P1842, DOI 10.3201/eid1112.050997
NR 38
TC 125
Z9 135
U1 1
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 3
PY 2007
VL 104
IS 27
BP 11424
EP 11429
DI 10.1073/pnas.0701372104
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 188DT
UT WOS:000247900000054
PM 17592121
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Harcourt, BH
   Jukneliene, D
   Kanjanahaluethai, A
   Bechill, J
   Severson, KM
   Smith, CM
   Rota, PA
   Baker, SC
AF Harcourt, BH
   Jukneliene, D
   Kanjanahaluethai, A
   Bechill, J
   Severson, KM
   Smith, CM
   Rota, PA
   Baker, SC
TI Identification of severe acute respiratory syndrome coronavirus
   replicase products and characterization of papain-like protease activity
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; INFECTIOUS-BRONCHITIS-VIRUS; DOUBLE-MEMBRANE
   VESICLES; SARS-CORONAVIRUS; CLEAVAGE SITE; CYSTEINE PROTEINASE; RNA;
   ASSOCIATION; POLYPROTEIN; COMPLEX
AB Gene 1 of the coronavirus associated with severe acute respiratory syndrome (SARS) encodes replicase polyproteins that are predicted to be processed into 16 nonstructural proteins (nsps 1 to 16) by two viral proteases, a papain-like protease (PLpro) and a 3C-like protease (3CLpro). Here, we identify SARS coronavirus amino-terminal replicase products nsp1, nsp2, and nsp3 and describe trans-cleavage assays that characterize the protease activity required to generate these products. We generated polyclonal antisera to glutathione S-transferase-replicase fusion proteins and used the antisera to detect replicase intermediates and products in pulse-chase experiments. We found that nsp1 (p20) is rapidly processed from the replicase polyprotein. In contrast, processing at the nsp2/3 site is less efficient, since a approximate to300-kDa intermediate (NSP2-3) is detected, but ultimately nsp2 (p71) and nsp3 (p213) are generated. We found that SARS coronavirus replicase products can be detected by 4 h postinfection in the cytoplasm of infected cells and that nsps 1 to 3 colocalize with newly synthesized viral RNA in punctate, perinuclear sites consistent with their predicted role in viral RNA synthesis. To determine if PLpro is responsible for processing these products, we cloned and expressed the PLpro domain and the predicted substrates and established PLpro trans-cleavage assays. We found that the PLpro domain is sufficient for processing the predicted nsp1/2 and nsp2/3 sites. Interestingly, expression of an extended region of PLpro that includes the downstream hydrophobic domain was required for processing at the predicted nsp3/4 site. We found that the hydrophobic domain is inserted into membranes and that the lumenal domain is glycosylated at asparagine residues 2249 and 2252. Thus, the hydrophobic domain may anchor the replication complex to intracellular membranes. These studies revealed that PLpro, can cleave in trans at the three predicted cleavage sites and that it requires membrane association to process the nsp3/4 cleavage site.
C1 Loyola Univ, Dept Microbiol & Immunol, Stritch Sch Med, Maywood, IL 60153 USA.
   Ctr Dis Control & Prevent, Atlanta, GA USA.
   Chiang Mai Univ, Fac Med, Dept Microbiol, Chiang Mai 50000, Thailand.
RP Baker, SC (reprint author), Loyola Univ, Dept Microbiol & Immunol, Stritch Sch Med, 2160 S 1st Ave,Bldg 105,Rm 3929, Maywood, IL 60153 USA.
EM sbaker1@lumc.edu
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI045798, AI 45798]
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   BAKER SC, 1989, J VIROL, V63, P3693, DOI 10.1128/JVI.63.9.3693-3699.1989
   BONILLA PJ, 1995, VIROLOGY, V209, P489, DOI 10.1006/viro.1995.1281
   Bonilla PJ, 1997, J VIROL, V71, P900, DOI 10.1128/JVI.71.2.900-909.1997
   Brockway SM, 2003, J VIROL, V77, P10515, DOI 10.1128/JVI.77.19.10515-10527.2003
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   GRAY J, 1999, VIRUS CULTURE PRACTI
   Herold J, 1998, J VIROL, V72, P910, DOI 10.1128/JVI.72.2.910-918.1998
   Herold J, 1999, J BIOL CHEM, V274, P14918, DOI 10.1074/jbc.274.21.14918
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Kanjanahaluethai A, 2003, J VIROL, V77, P7376, DOI 10.1128/JVI.77.13.7376-7382.2003
   Kanjanahaluethai A, 2000, J VIROL, V74, P7911, DOI 10.1128/JVI.74.17.7911-7921.2000
   KIM JC, 1995, VIROLOGY, V208, P1, DOI 10.1006/viro.1995.1123
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lai M.M.C., 2001, FIELDS VIROLOGY, P1163
   Lim KP, 1998, VIROLOGY, V245, P303, DOI 10.1006/viro.1998.9164
   Lim KP, 2000, J VIROL, V74, P1674, DOI 10.1128/JVI.74.4.1674-1685.2000
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Ng ML, 2003, J GEN VIROL, V84, P3291, DOI 10.1099/vir.0.19505-0
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Schiller JJ, 1998, VIROLOGY, V242, P288, DOI 10.1006/viro.1997.9010
   Schmidt-Mende J, 2001, J BIOL CHEM, V276, P44052, DOI 10.1074/jbc.M103358200
   Shi ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Wang D, 2003, PLOS BIOL, V1, P257, DOI 10.1371/journal.pbio.0000002
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Ziebuhr J, 2001, J BIOL CHEM, V276, P33220, DOI 10.1074/jbc.M104097200
NR 35
TC 125
Z9 137
U1 1
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD DEC
PY 2004
VL 78
IS 24
BP 13600
EP 13612
DI 10.1128/JVI.78.24.13600-13612.2004
PG 13
WC Virology
SC Virology
GA 875HC
UT WOS:000225409900022
PM 15564471
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Poland, AM
   Vennema, H
   Foley, JE
   Pedersen, NC
AF Poland, AM
   Vennema, H
   Foley, JE
   Pedersen, NC
TI Two related strains of feline infectious peritonitis virus isolated from
   immunocompromised cats infected with a feline enteric coronavirus
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS VIRUS; PORCINE RESPIRATORY CORONAVIRUS;
   SEQUENCE-ANALYSIS; EVOLUTION; DISEASE; RNA
AB Two groups of cats were experimentally infected orally with the cat-passaged RM strain of feline enteric coronavirus (FECV-RM). One group of cats (n = 19) had been chronically infected with feline immunodeficiency virus (FIV) for over 6 years, while a second control group (n = 20) consisted of FIV-naive siblings, Fecal virus shedding of FECV occurred in both groups starting on day 3 postinfection, nearly ceased by 4 weeks in FIV-uninfected cats, but remained at high levels in FIV-infected animals, FIV-infectcd cats shed virus for a longer period of time and at levels 10 to 100 times greater than those for FIV-uninfected cats, The coronavirus antibody response of the FIV-infected cats was delayed and of reduced titer compared with that of the FIV-uninfected animals, Cats in both groups remained asymptomatic for the first mo months following FECV-RM infection; however, 8 to 10 weeks postinfection two cats in the FIV=infected group developed feline infectious peritonitis (FIP), The FIP viruses (designated FIPV-UCD9 and -UCD10) isolated from these two cats had almost complete genetic homology to each other and to the infecting FECV-RM. However, unlike FECV-RM, they readily induced FIP when inoculated intraperitoneally into specific-pathogen-free cats. This study confirms that FIPVs are frequently and rapidly arising mutants of FECV. Immunosuppression caused by chronic FIV infection may have enhanced the creation and selection of FIPV mutants by increasing the rate of FECV replication in the bowel and inhibiting the host's ability to combat the mutant viruses once they occurred.
C1 UNIV CALIF DAVIS,SCH VET MED,CTR COMPAN ANIM HLTH,DAVIS,CA 95616.
   UNIV CALIF DAVIS,SCH VET MED,DEPT MED & EPIDEMIOL,DAVIS,CA 95616.
CR BOOM R, 1990, J CLIN MICROBIOL, V29, P1804
   CAVANAGH D, 1993, ARCH VIROL, V130, P471, DOI 10.1007/BF01309675
   CHEUNG RC, 1994, J CLIN MICROBIOL, V32, P2593, DOI 10.1128/JCM.32.10.2593-2597.1994
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   DOUGHERTY RM, 1993, J VIROL METHODS, V41, P235, DOI 10.1016/0166-0934(93)90130-J
   *GEN COMP GROUP, 1994, PROGR MAN WISC PACK
   HERREWEGH AAPM, 1995, VIROLOGY, V212, P622, DOI 10.1006/viro.1995.1520
   HICKMAN MA, 1995, FELINE PRACT, V23, P96
   HORZINEK MC, 1995, FELINE PRACT, V23, P34
   KUSTERS JG, 1990, VACCINE, V8, P605, DOI 10.1016/0264-410X(90)90018-H
   PEDERSEN NC, 1981, AM J VET RES, V42, P368
   PEDERSEN NC, 1995, FELINE PRACT, V23, P46
   PEDERSEN NC, 1976, AM J VET RES, V37, P1449
   PEDERSEN NC, 1985, COMP CONT EDUC PRACT, V7, P1001
   PEDERSEN NC, 1984, AM J VET RES, V45, P2580
   PEDERSEN NC, 1995, FELINE PRACT, V23, P7
   PEDERSEN NC, 1980, AM J VET RES, V41, P868
   RASSCHAERT D, 1990, J GEN VIROL, V71, P2599, DOI 10.1099/0022-1317-71-11-2599
   REUBEL GH, 1994, VET MICROBIOL, V39, P335, DOI 10.1016/0378-1135(94)90169-4
   REUBEL GH, 1992, VET IMMUNOL IMMUNOP, V35, P95, DOI 10.1016/0165-2427(92)90124-9
   REUBEL GH, 1994, J ACQ IMMUN DEF SYND, V7, P1003
   TORTEN M, 1991, J VIROL, V65, P2225, DOI 10.1128/JVI.65.5.2225-2230.1991
   VENNEMA H, 1995, FELINE PRACT, V23, P40
   VENNEMA H, UNPUB
   WESLEY RD, 1991, J VIROL, V65, P3369, DOI 10.1128/JVI.65.6.3369-3373.1991
NR 25
TC 125
Z9 128
U1 0
U2 18
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD DEC
PY 1996
VL 34
IS 12
BP 3180
EP 3184
DI 10.1128/JCM.34.12.3180-3184.1996
PG 5
WC Microbiology
SC Microbiology
GA VV005
UT WOS:A1996VV00500055
PM 8940468
OA Bronze
DA 2020-04-03
ER

PT J
AU SNIJDER, EJ
   WASSENAAR, ALM
   SPAAN, WJM
AF SNIJDER, EJ
   WASSENAAR, ALM
   SPAAN, WJM
TI PROTEOLYTIC PROCESSING OF THE REPLICASE ORF1A PROTEIN OF EQUINE
   ARTERITIS VIRUS
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID DEHYDROGENASE-ELEVATING VIRUS; SUBGENOMIC MESSENGER-RNAS; OPEN READING
   FRAME; MURINE CORONAVIRUS; EXPRESSION SYSTEM; VACCINIA VIRUS; STRUCTURAL
   PROTEINS; CYSTEINE PROTEASES; SEQUENCE-ANALYSIS; SERINE PROTEASES
AB To study the proteolytic processing of the equine arteritis virus (EAV) replicase open reading frame 1a (ORF1a) protein, specific antisera were raised in rabbits, with six synthetic peptides and abacterial fusion protein as antigens. The processing of the EAV ORF1a product in infected cells was analyzed with Western blot (immunoblot) and immunoprecipitation techniques. Additional information was obtained from transient expression of ORF1a cDNA constructs. The 187-kDa ORF1a protein was found to be subject to at least five proteolytic cleavages. The processing scheme, which covers the entire ORF1a protein,results in cleavage products of approximately 29, 61, 22, 31, 41, and 3 kDa, which were named nonstructural proteins (nsps) 1 through 6, respectively. Pulse-chase experiments revealed that the cleavages at the nsp1/2 and nsp2/3 junctions are the most rapid processing steps. The remaining nsp3456 precursor is first cleaved at the nsp4/5 site. Final processing of the nsp34 and nsp56 intermediates is extremely slow. As predicted from previous in vitro translation experiments (E. J. Snijder, A. L. M. Wassenaar, and W. J. M. Spaan, J. Virol. 66:7040-7048, 1992), a cysteine protease domain in nsp1 was shown to be responsible for the nsp1/2 cleavage. The other processing steps are carried out by the putative EAV serine protease in nsp4 and by a third protease, which remains to be identified.
RP SNIJDER, EJ (reprint author), LEIDEN UNIV,FAC MED,INST MED MICROBIOL,DEPT VIROL,POSTBUS 320,2300 AH LEIDEN,NETHERLANDS.
RI Snijder, Eric J./E-6073-2018
OI Snijder, Eric J./0000-0003-3297-2309
CR BAKER SC, 1993, J VIROL, V67, P6056, DOI 10.1128/JVI.67.10.6056-6063.1993
   BARIC RS, 1990, VIROLOGY, V177, P646, DOI 10.1016/0042-6822(90)90530-5
   BARTON DJ, 1991, J VIROL, V65, P1496, DOI 10.1128/JVI.65.3.1496-1506.1991
   BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872
   BONILLA PJ, 1994, VIROLOGY, V198, P736, DOI 10.1006/viro.1994.1088
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   CHEN ZY, 1993, J GEN VIROL, V74, P643, DOI 10.1099/0022-1317-74-4-643
   DEGROOT RJ, 1990, EMBO J, V9, P2631, DOI 10.1002/j.1460-2075.1990.tb07445.x
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   DENISON MR, 1992, VIROLOGY, V189, P274, DOI 10.1016/0042-6822(92)90703-R
   DENISON MR, 1991, J VIROL, V65, P3076, DOI 10.1128/JVI.65.6.3076-3082.1991
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   DEVRIES AAF, 1992, J VIROL, V66, P6294, DOI 10.1128/JVI.66.11.6294-6303.1992
   DEVRIES AAF, 1990, NUCLEIC ACIDS RES, V18, P3241, DOI 10.1093/nar/18.11.3241
   DOLL E. R., 1957, CORNELL VET, V47, P3
   DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993
   ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   GODENY EK, 1993, VIROLOGY, V194, P585, DOI 10.1006/viro.1993.1298
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7
   HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419
   JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988
   JORE JB, 1989, J GEN VIROL, V69, P1627
   KAO CC, 1992, J VIROL, V66, P6322, DOI 10.1128/JVI.66.11.6322-6329.1992
   KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   LEMM JA, 1993, J VIROL, V67, P1916, DOI 10.1128/JVI.67.4.1916-1926.1993
   MEULENBERG JJM, 1993, VIROLOGY, V192, P62, DOI 10.1006/viro.1993.1008
   PLAGEMANN PGW, 1992, ADV VIRUS RES, V41, P99, DOI 10.1016/S0065-3527(08)60036-6
   Reichlin M, 1980, Methods Enzymol, V70, P159
   SCHAAD MC, 1990, VIROLOGY, V177, P634, DOI 10.1016/0042-6822(90)90529-Z
   SHIRAKO Y, 1994, J VIROL, V68, P1874, DOI 10.1128/JVI.68.3.1874-1885.1994
   SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4
   SNIJDER EJ, 1993, J GEN VIROL, V74, P2305, DOI 10.1099/0022-1317-74-11-2305
   SNIJDER EJ, 1990, NUCLEIC ACIDS RES, V18, P4535, DOI 10.1093/nar/18.15.4535
   SNIJDER EJ, 1992, J VIROL, V66, P7040, DOI 10.1128/JVI.66.12.7040-7048.1992
   SNIJDER EJ, UNPUB
   TROXLER M, 1992, VIROLOGY, V191, P687, DOI 10.1016/0042-6822(92)90244-J
   VANBERLO MF, 1983, ZBL VET MED B, V30, P297
   VENNEMA H, 1991, GENE, V108, P201, DOI 10.1016/0378-1119(91)90435-E
   YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9
NR 45
TC 125
Z9 133
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD SEP
PY 1994
VL 68
IS 9
BP 5755
EP 5764
DI 10.1128/JVI.68.9.5755-5764.1994
PG 10
WC Virology
SC Virology
GA PB785
UT WOS:A1994PB78500047
PM 8057457
OA Bronze
DA 2020-04-03
ER

PT J
AU TOOZE, J
   TOOZE, SA
   FULLER, SD
AF TOOZE, J
   TOOZE, SA
   FULLER, SD
TI SORTING OF PROGENY CORONAVIRUS FROM CONDENSED SECRETORY PROTEINS AT THE
   EXIT FROM THE TRANS-GOLGI NETWORK OF ATT20 CELLS
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
RP TOOZE, J (reprint author), EUROPEAN MOLEC BIOL LAB,D-6900 HEIDELBERG,FED REP GER.
OI Tooze, Sharon/0000-0002-2182-3116
CR ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838
   ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0
   ASH JF, 1977, P NATL ACAD SCI USA, V74, P5584, DOI 10.1073/pnas.74.12.5584
   BORDIER C, 1981, J BIOL CHEM, V256, P1604
   BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639
   CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261
   DUBOISDALCQ M, 1984, ASSEMBLY ENVELOPED R, P100
   FULLER S, 1984, CELL, V38, P65, DOI 10.1016/0092-8674(84)90527-0
   FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x
   GAHMBERG N, 1986, EMBO J, V5, P3111, DOI 10.1002/j.1460-2075.1986.tb04617.x
   GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4
   GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253
   GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9
   KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224
   KNIPE DM, 1977, J VIROL, V21, P1121, DOI 10.1128/JVI.21.3.1121-1127.1977
   MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131
   MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4
   MOORE HP, 1983, NATURE, V302, P434, DOI 10.1038/302434a0
   MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773
   NIEMANN H, 1984, EMBO J, V3, P665, DOI 10.1002/j.1460-2075.1984.tb01864.x
   NIEMANN H, 1981, J MOL BIOL, V153, P993, DOI 10.1016/0022-2836(81)90463-0
   PFEIFFER S, 1985, J CELL BIOL, V101, P470, DOI 10.1083/jcb.101.2.470
   REGGIO H, 1983, METHOD ENZYMOL, V98, P379
   RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   TOOZE J, 1985, EUR J CELL BIOL, V37, P203
   TOOZE J, 1986, J CELL BIOL, V103, P839, DOI 10.1083/jcb.103.3.839
   TOOZE SA, 1986, J VIROL, V60, P928, DOI 10.1128/JVI.60.3.928-934.1986
NR 28
TC 125
Z9 130
U1 0
U2 1
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021
SN 0021-9525
J9 J CELL BIOL
JI J. Cell Biol.
PD SEP
PY 1987
VL 105
IS 3
BP 1215
EP 1226
DI 10.1083/jcb.105.3.1215
PG 12
WC Cell Biology
SC Cell Biology
GA K1999
UT WOS:A1987K199900019
PM 2821011
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Muller, MA
   Corman, VM
   Jores, J
   Meyer, B
   Younan, M
   Liljander, A
   Bosch, BJ
   Lattwein, E
   Hilali, M
   Musa, BE
   Bornstein, S
   Drosten, C
AF Mueller, Marcel A.
   Corman, Victor Max
   Jores, Joerg
   Meyer, Benjamin
   Younan, Mario
   Liljander, Anne
   Bosch, Berend-Jan
   Lattwein, Erik
   Hilali, Mosaad
   Musa, Bakri E.
   Bornstein, Set
   Drosten, Christian
TI MERS Coronavirus Neutralizing Antibodies in Camels, Eastern Africa,
   1983-1997
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; DROMEDARY CAMELS; SAUDI-ARABIA; SERUM
AB To analyze the distribution of Middle East respiratory syndrome coronavirus (MERS-CoV)-seropositive dromedary camels in eastern Africa, we tested 189 archived serum samples accumulated during the past 30 years. We identified MERS-CoV neutralizing antibodies in 81.0% of samples from the main camel-exporting countries, Sudan and Somalia, suggesting long-term virus circulation in these animals.
C1 [Mueller, Marcel A.; Corman, Victor Max; Meyer, Benjamin; Drosten, Christian] Univ Bonn, Med Ctr, D-53105 Bonn, Germany.
   [Corman, Victor Max] German Ctr Infect Res, Bonn, Germany.
   [Jores, Joerg; Liljander, Anne] Int Livestock Res Inst, Nairobi, Kenya.
   [Younan, Mario] Vet Sans Frontieres Germany, Nairobi, Kenya.
   [Bosch, Berend-Jan] Univ Utrecht, Utrecht, Netherlands.
   [Lattwein, Erik] EUROIMMUN AG, Lubeck, Germany.
   [Hilali, Mosaad] Cairo Univ, Giza, Egypt.
   [Musa, Bakri E.] Minist Sci & Commun, Khartoum, Sudan.
   [Bornstein, Set] Natl Vet Inst, S-75007 Uppsala, Sweden.
RP Muller, MA (reprint author), Univ Bonn, Med Ctr, Inst Virol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM muller@virology-bonn.de
RI Meyer, Bernhard/Q-9413-2016; Meyer, Benjamin/F-3285-2018; Corman, Victor
   Max/K-1319-2019; Mueller, Marcel/O-2425-2019; Hilali, Mosaad/O-9443-2016
OI Meyer, Benjamin/0000-0003-0601-3550; Corman, Victor
   Max/0000-0002-3605-0136; Mueller, Marcel/0000-0003-2242-5117; A. Hilali,
   Mosaad/0000-0002-9930-8501; Jores, Joerg/0000-0003-3790-5746
FU European Commission (FP7-EMPERIE) [223498]; European Commission
   (FP7-ANTIGONE) [278976]; German Research Foundation (DFG)German Research
   Foundation (DFG) [DR772/3-1]; Consultative Group for International
   Agricultural Research (CGIAR) program on Agriculture for Nutrition and
   Health; Centrum of International Migration (CIM)
FX The work was funded by the European Commission (FP7-EMPERIE no. 223498,
   FP7-ANTIGONE no. 278976) and the German Research Foundation (DFG grant
   DR772/3-1 to C.D.). This work was supported by the Consultative Group
   for International Agricultural Research (CGIAR) program on Agriculture
   for Nutrition and Health. The Centrum of International Migration (CIM)
   supported A.L. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Aburizaiza AS, 2014, J INFECT DIS, V209, P243, DOI 10.1093/infdis/jit589
   BORNSTEIN S, 1987, J VET MED B, V34, P364, DOI 10.1111/j.1439-0450.1987.tb00409.x
   Chu DKW, 2014, EMERG INFECT DIS, V20, P1049, DOI 10.3201/eid2006.140299
   Corman VM, 2014, EMERG INFECT DIS, V20, P1319, DOI 10.3201/eid2008.140596
   European Centre for Disease Prevention and Control, 2014, EP UPD MIDDL E RESP
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hemida MG, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.23.20828
   Hemida MG, 2014, EMERG INFECT DIS, V20, P1231, DOI 10.3201/eid2007.140571
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Reusken CBEM, 2014, EMERG INFECT DIS, V20, P1370, DOI 10.3201/eid2008.140590
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 14
TC 124
Z9 125
U1 2
U2 19
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD DEC
PY 2014
VL 20
IS 12
BP 2093
EP 2095
DI 10.3201/eid2012.141026
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AU6RP
UT WOS:000345729900019
PM 25425139
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Kuypers, J
   Martin, ET
   Heugel, J
   Wright, N
   Morrow, R
   Englund, JA
AF Kuypers, Jane
   Martin, Emily T.
   Heugel, Judson
   Wright, Nancy
   Morrow, Rhoda
   Englund, Janet A.
TI Clinical disease in children associated with newly described coronavirus
   subtypes
SO PEDIATRICS
LA English
DT Article
DE coronavirus; epidemiology; respiratory viruses; children; real-time
   RT-PCR
ID RESPIRATORY-TRACT INFECTIONS; NL63 INFECTION; HKU1; INFANTS
AB OBJECTIVES. Coronaviruses cause upper respiratory illness and occasionally lower tract disease in susceptible populations. In this study we examined the prevalence of 4 human coronaviruses, including subtypes OC43, 229E, and the recently described NL63 and HKU1 in a pediatric population presenting to a children's hospital.
   PATIENTS AND METHODS. Specimens collected over a 1-year period from pediatric patients presenting with acute respiratory illness were analyzed for the presence of 4 coronavirus subtypes using consensus and subtype-specific real-time reverse-transcription polymerase chain reaction assays. The demographic and clinical characteristics associated with coronavirus infection were examined retrospectively.
   RESULTS. Coronaviruses were detected in 66 of 1043 children. Eight, 11, 19, and 28 specimens were positive for subtypes 229E, NL63, OC43, and HKU1, respectively. Coronaviruses were detected throughout the study period; all 4 of the subtypes were present simultaneously in December. The acute clinical features were similar across subtypes. Of 32 children infected with a coronavirus as the sole respiratory pathogen, 13 had lower respiratory tract disease. Children whose only detectable respiratory virus was a coronavirus were more likely to have underlying chronic disease than were children coinfected with another respiratory virus.
   CONCLUSIONS. Although 4 subtypes of coronavirus were detected, the recently discovered coronavirus subtypes NL63 and HKU1 accounted for the majority of coronaviruses detected in our cohort of mostly hospitalized children with respiratory symptoms. New subtypes likely represent a substantial portion of previously unexplained respiratory illnesses.
C1 Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.
   Univ Washington, Dept Pediat, Sect Infect Dis Immunol & Rheumatol, Seattle, WA 98195 USA.
   Childrens Hosp & Reg Med Ctr, Seattle, WA USA.
   Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
RP Kuypers, J (reprint author), 4800 Sand Point Way NE,Room W8814, Seattle, WA 98105 USA.
EM jane.kuypers@seattlechildrens.org
CR Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   Bastien N, 2005, J CLIN MICROBIOL, V43, P4567, DOI 10.1128/JCM.43.9.4567-4573.2005
   Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869
   Boivin G, 2005, PEDIATR INFECT DIS J, V24, P1045, DOI 10.1097/01.inf.0000183743.68569.c7
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289
   Esper F, 2006, EMERG INFECT DIS, V12, P775, DOI 10.3201/eid1205.051316
   Esper F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138
   Falsey AR, 2002, J INFECT DIS, V185, P1338, DOI 10.1086/339881
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Gerna G, 2006, J MED VIROL, V78, P938, DOI 10.1002/jmv.20645
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   Kuypers J, 2004, J CLIN VIROL, V31, P123, DOI 10.1016/j.jcv.2004.03.018
   Kuypers J, 2006, J CLIN MICROBIOL, V44, P2382, DOI 10.1128/JCM.00216-06
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Limaye AP, 2001, J INFECT DIS, V183, P377, DOI 10.1086/318089
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   Moes E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-6
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Vabret A, 2006, CLIN INFECT DIS, V42, P634, DOI 10.1086/500136
   Vabret A, 2005, EMERG INFECT DIS, V11, P1225, DOI 10.3201/eid1108.050110
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
NR 26
TC 124
Z9 127
U1 1
U2 4
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JAN
PY 2007
VL 119
IS 1
BP E70
EP E76
DI 10.1542/peds.2006-1406
PG 7
WC Pediatrics
SC Pediatrics
GA 121YB
UT WOS:000243191800011
PM 17130280
DA 2020-04-03
ER

PT J
AU Yang, HT
   Xie, WQ
   Xue, XY
   Yang, KL
   Ma, J
   Liang, WX
   Zhao, Q
   Zhou, Z
   Pei, DQ
   Ziebuhr, J
   Hilgenfeld, R
   Yuen, KY
   Wong, L
   Gao, GX
   Chen, SJ
   Chen, Z
   Ma, DW
   Bartlam, M
   Rao, Z
AF Yang, HT
   Xie, WQ
   Xue, XY
   Yang, KL
   Ma, J
   Liang, WX
   Zhao, Q
   Zhou, Z
   Pei, DQ
   Ziebuhr, J
   Hilgenfeld, R
   Yuen, KY
   Wong, L
   Gao, GX
   Chen, SJ
   Chen, Z
   Ma, DW
   Bartlam, M
   Rao, Z
TI Design of wide-spectrum inhibitors targeting coronavirus main proteases
SO PLOS BIOLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; INFECTIOUS-BRONCHITIS VIRUS;
   SARS-CORONAVIRUS; HEALTHY-VOLUNTEERS; POTENT INHIBITORS; GENOME
   SEQUENCE; PROTEINASE; IDENTIFICATION; 3CL(PRO); RECEPTOR
AB The genus Coronavirus contains about 25 species of coronaviruses (CoVs), which are important pathogens causing highly prevalent diseases and often severe or fatal in humans and animals. No licensed specific drugs are available to prevent their infection. Different host receptors for cellular entry, poorly conserved structural proteins ( antigens), and the high mutation and recombination rates of CoVs pose a significant problem in the development of wide-spectrum anti-CoV drugs and vaccines. CoV main proteases (M-pro s), which are key enzymes in viral gene expression and replication, were revealed to share a highly conservative substrate-recognition pocket by comparison of four crystal structures and a homology model representing all three genetic clusters of the genus Coronavirus. This conclusion was further supported by enzyme activity assays. Mechanism-based irreversible inhibitors were designed, based on this conserved structural region, and a uniform inhibition mechanism was elucidated from the structures of M pro-inhibitor complexes from severe acute respiratory syndrome-CoV and porcine transmissible gastroenteritis virus. A structure-assisted optimization program has yielded compounds with fast in vitro inactivation of multiple CoV M pro s, potent antiviral activity, and extremely low cellular toxicity in cell-based assays. Further modification could rapidly lead to the discovery of a single agent with clinical potential against existing and possible future emerging CoV-related diseases.
C1 Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, 345 Lingling Lu, Shanghai 200032, Peoples R China.
   Tsinghua Univ, Tsinghua IBP Joint Res Grp Struct Biol, Beijing 100084, Peoples R China.
   Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100080, Peoples R China.
   Shanghai Med Univ 2, Shanghai Inst Hematol, Rui Jin Hosp, Shanghai, Peoples R China.
   Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou, Peoples R China.
   Univ Wurzburg, Inst Immunol & Virol, Wurzburg, Germany.
   Med Univ Lubeck, Inst Biochem, D-23538 Lubeck, Germany.
   Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   Univ Oxford, Inorgan Chem Lab, Dept Chem, Oxford, England.
RP Ma, DW (reprint author), Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, 345 Lingling Lu, Shanghai 200032, Peoples R China.
EM madw@mail.sioc.ac.cn; raozh@xtal.tsinghua.edu.cn
RI Yang, Haitao/G-9116-2012; xue, xiaoyu/G-9574-2012; Hilgenfeld,
   Rolf/C-9675-2011; Yang, Kailin/D-7966-2013; Zhao, Qi/H-7974-2012; Yang,
   Kailin/L-2205-2013; Zhao, Qi/C-6344-2013; Ziebuhr, John/G-7669-2015
OI Yang, Kailin/0000-0001-5968-6738; Ziebuhr, John/0000-0002-5741-8825;
   Yuen, Kwok-yung/0000-0002-2083-1552
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gagneur A, 2002, J HOSP INFECT, V51, P59, DOI 10.1053/jhin.2002.1179
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   HANZLIK RP, 1984, J MED CHEM, V27, P711, DOI 10.1021/jm00372a001
   Hayden FG, 2003, ANTIMICROB AGENTS CH, V47, P3907, DOI 10.1128/AAC.47.12.3907-3916.2003
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   Hsyu PH, 2002, ANTIMICROB AGENTS CH, V46, P392, DOI 10.1128/AAC.46.2.392-397.2002
   Jain RP, 2004, J MED CHEM, V47, P6113, DOI 10.1021/jm0494873
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kao RY, 2004, CHEM BIOL, V11, P1293, DOI 10.1016/j.chembiol.2004.07.013
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   KUSTERS JG, 1990, VACCINE, V8, P605, DOI 10.1016/0264-410X(90)90018-H
   Lai M.M.C., 2001, FIELDS VIROLOGY, P1163
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   LIU S, 1992, J MED CHEM, V35, P1067, DOI 10.1021/jm00084a012
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000
   MEARA JP, 1995, BIOORG MED CHEM LETT, V5, P2277, DOI 10.1016/0960-894X(95)00396-B
   MYINT SH, 1995, CORONAVIRIDAE, P389
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   PEREIRA HG, 1989, ANDREWES VIRUSES VER, P42
   Roberts A, 2005, J VIROL, V79, P5833, DOI 10.1128/JVI.79.9.5833-5838.2005
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SIDDELL SG, 2005, TOPLEY WILSONS MICRO, P823
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   SPAAN WJM, 2004, VIRUS TAXONOMY 8 REP, P945
   STEINHAUER DA, 1986, J VIROL, V57, P219, DOI 10.1128/JVI.57.1.219-228.1986
   Tanner JA, 2005, CHEM BIOL, V12, P303, DOI 10.1016/j.chembiol.2005.01.006
   TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   VANDERMOST RG, 1995, CORONAVIRIDAE, P11
   Vijgen L, 2005, J VIROL, V79, P1595, DOI 10.1128/JVI.79.3.1595-1604.2005
   WANG L, 1993, VIROLOGY, V192, P710, DOI 10.1006/viro.1993.1093
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Ziebuhr J, 1997, J VIROL, V71, P3992, DOI 10.1128/JVI.71.5.3992-3997.1997
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 52
TC 124
Z9 142
U1 5
U2 32
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1545-7885
J9 PLOS BIOL
JI PLoS. Biol.
PD OCT
PY 2005
VL 3
IS 10
BP 1742
EP 1752
AR e324
DI 10.1371/journal.pbio.0030324
PG 11
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA 971SJ
UT WOS:000232404600009
PM 16128623
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Zuniga, S
   Sola, I
   Alonso, S
   Enjuanes, L
AF Zuniga, S
   Sola, I
   Alonso, S
   Enjuanes, L
TI Sequence motifs involved in the regulation of discontinuous coronavirus
   subgenomic RNA synthesis
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS VIRUS; LENGTH INFECTIOUS CDNA; EXPRESSION
   VECTOR; TRANSCRIPTION; GENOME; RECOMBINATION; EVOLUTION; REVEALS; CLONE;
   SWINE
AB Coronavirus transcription leads to the synthesis of a nested set of mRNAs with a leader sequence derived from the 5' end of the genome. The mRNAs are produced by a discontinuous transcription in which the leader is linked to the mRNA coding sequences. This process is regulated by transcription-regulating sequences (TRSs) preceding each mRNA, including a highly conserved core sequence (CS) with high identity to sequences present in the virus genome and at the 3' end of the leader (TRS-L). The role of TRSs was analyzed by reverse genetics using a full-length infectious coronavirus cDNA and site-directed mutagenesis of the CS. The canonical CS-B was nonessential for the generation of subgenomic mRNAs (sgmRNAs), but its presence led to transcription levels at least 10(3)-fold higher than those in its absence. The data obtained are compatible with a transcription mechanism including three steps: (i) formation of 5'-3' complexes in the genomic RNA, (ii) base-pairing scanning of the nascent negative RNA strand by the TRS-L, and (iii) template switching during synthesis of the negative strand to complete the negative sgRNA. This template switch takes place after copying the CS sequence and was predicted in silico based on high base-pairing score between the nascent negative RNA strand and the TRS-L and minimum DeltaG.
C1 CSIC, Ctr Nacl Biotecnol, Dept Mol & Cell Biol, Madrid 28049, Spain.
RP Enjuanes, L (reprint author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cell Biol, Campus Univ Autonoma,Cantoblanco, Madrid 28049, Spain.
EM L.Enjuanes@cnb.uam.es
RI Sola, Isabel/E-1565-2017; Enjuanes, Luis/F-7845-2016; Zuniga,
   Sonia/O-8548-2016
OI Sola, Isabel/0000-0002-5704-1917; Zuniga, Sonia/0000-0003-2549-6826;
   Enjuanes, Luis/0000-0002-0854-0226
CR Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   Alonso S, 2002, J VIROL, V76, P1293, DOI 10.1128/JVI.76.3.1293-1308.2002
   Brian DA, 1997, SEMIN VIROL, V8, P101, DOI 10.1006/smvy.1997.0109
   CALLEBAUT P, 1988, J GEN VIROL, V69, P1725, DOI 10.1099/0022-1317-69-7-1725
   Choi KS, 2002, VIROLOGY, V303, P58, DOI 10.1006/viro.2002.1675
   de Vries AAF, 2001, VIROLOGY, V284, P259, DOI 10.1006/viro.2001.0908
   DELMAS B, 1993, ADV EXP MED BIOL, V342, P293
   Domingo E, 1996, FASEB J, V10, P859
   Enjuanes L, 2000, VIRUS TAXONOMY CLASS, P827
   Enjuanes LBD, 2000, VIRUS TAXONOMY CLASS, P835
   Fischer F, 1997, J VIROL, V71, P5148, DOI 10.1128/JVI.71.7.5148-5160.1997
   Gonzalez JM, 2002, J VIROL, V76, P4655, DOI 10.1128/JVI.76.9.4655-4661.2002
   Huang PY, 2001, J VIROL, V75, P5009, DOI 10.1128/JVI.75.11.5009-5017.2001
   HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D
   IVERSON LE, 1981, CELL, V23, P477, DOI 10.1016/0092-8674(81)90143-4
   JIMENEZ G, 1986, J VIROL, V60, P131
   JOO M, 1995, J VIROL, V69, P272, DOI 10.1128/JVI.69.1.272-280.1995
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700
   MCCLURKIN AW, 1966, CAN J COMP MED VET S, V30, P190
   Nagy PD, 1997, VIROLOGY, V235, P1, DOI 10.1006/viro.1997.8681
   Ortego J, 2003, VIROLOGY, V308, P13, DOI 10.1016/S0042-6822(02)00096-X
   Ozdarendeli A, 2001, J VIROL, V75, P7362, DOI 10.1128/JVI.75.16.7362-7374.2001
   Pasternak AO, 2003, J VIROL, V77, P1175, DOI 10.1128/JVI.77.2.1175-1183.2003
   Pasternak AO, 2001, EMBO J, V20, P7220, DOI 10.1093/emboj/20.24.7220
   Pasternak AO, 2000, J VIROL, V74, P11642, DOI 10.1128/JVI.74.24.11642-11653.2000
   PASTERNAK AO, IN PRESS J VIROL
   Penzes Z, 2001, VIRUS GENES, V23, P105, DOI 10.1023/A:1011147832586
   SANCHEZ CM, 1990, VIROLOGY, V174, P410, DOI 10.1016/0042-6822(90)90094-8
   SAWICKI DL, 2001, J GEN VIROL, V82, P386
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   SCHAAD MC, 1994, J VIROL, V68, P8169, DOI 10.1128/JVI.68.12.8169-8179.1994
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   Shi ST, 2000, EMBO J, V19, P4701, DOI 10.1093/emboj/19.17.4701
   Sola I, 2003, J VIROL, V77, P4357, DOI 10.1128/JVI.77.7.4357-4369.2003
   van Marle G, 1999, P NATL ACAD SCI USA, V96, P12056, DOI 10.1073/pnas.96.21.12056
   VANDERMOST RG, 1995, CORONAVIRIDAE, P11
   Wertz GW, 1998, P NATL ACAD SCI USA, V95, P3501, DOI 10.1073/pnas.95.7.3501
   WESLEY RD, 1989, VIRUS RES, V13, P87, DOI 10.1016/0168-1702(89)90008-7
   Yount B, 2002, J VIROL, V76, P11065, DOI 10.1128/JVI.76.21.11065-11078.2002
NR 41
TC 124
Z9 130
U1 1
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JAN
PY 2004
VL 78
IS 2
BP 980
EP 994
DI 10.1128/JVI.78.2.980-994.2004
PG 15
WC Virology
SC Virology
GA 762EG
UT WOS:000187957700044
PM 14694129
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU KANT, A
   KOCH, G
   VANROOZELAAR, DJ
   KUSTERS, JG
   POELWIJK, FAJ
   VANDERZEIJST, BAM
AF KANT, A
   KOCH, G
   VANROOZELAAR, DJ
   KUSTERS, JG
   POELWIJK, FAJ
   VANDERZEIJST, BAM
TI LOCATION OF ANTIGENIC SITES DEFINED BY NEUTRALIZING
   MONOCLONAL-ANTIBODIES ON THE S1 AVIAN INFECTIOUS-BRONCHITIS VIRUS
   GLYCOPOLYPEPTIDE
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS VIRUS; CORONAVIRUS-IBV; PEPLOMER PROTEIN;
   NUCLEOTIDE-SEQUENCE; SPIKE GLYCOPROTEIN; VIRION PROTEINS; EPITOPES;
   STRAIN; GENE; M41
AB Neutralizing monoclonal antibodies directed against five antigenic sites on the spike (S) S1 glycopolypeptide of avian infectious bronchitis virus (IBV) were used to select neutralization-resistant variants of the virus. By comparing the nucleotide sequence of such variants with the sequence of the IBV parent strain, we located five antigenic sites on the amino acid sequence of the S1 glycopolypeptide. The variants had mutations within three regions corresponding to amino acid residues 24 to 61, 132 to 149 and 291 to 398 of the S1 glycopolypeptide. The location of three overlapping antigenic sites on the IBV spike protein was similar to the location of antigenic sites on the spike protein of other coronaviruses.
C1 CENT VET INST,DEPT VIROL,POB 365,8200 AJ LELYSTAD,NETHERLANDS.
   UNIV UTRECHT,SCH VET MED,INST INFECT DIS & IMMUNOL,3508 TD UTRECHT,NETHERLANDS.
RI Van der Zeijst, Bernard B.A./A-3847-2013; Van der Zeijst,
   Bernard/AAH-1415-2020
OI Van der Zeijst, Bernard B.A./0000-0001-9316-2161; Van der Zeijst,
   Bernard/0000-0001-9316-2161
CR AIR GM, 1979, VIROLOGY, V97, P468, DOI 10.1016/0042-6822(79)90358-1
   CAVANAGH D, 1983, J GEN VIROL, V64, P2577, DOI 10.1099/0022-1317-64-12-2577
   CAVANAGH D, 1986, J GEN VIROL, V67, P1443, DOI 10.1099/0022-1317-67-7-1443
   CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435
   CAVANAGH D, 1988, VIRUS RES, V11, P141, DOI 10.1016/0168-1702(88)90039-1
   CAVANAGH D, 1983, J GEN VIROL, V64, P1787, DOI 10.1099/0022-1317-64-8-1787
   CAVANAGH D, 1992, IN PRESS AVIAN PATHO
   CORREA I, 1990, J GEN VIROL, V71, P271, DOI 10.1099/0022-1317-71-2-271
   DAVELAAR FG, 1984, VET QUART, V6, P114, DOI 10.1080/01652176.1984.9693924
   DEBORDE DC, 1986, ANAL BIOCHEM, V157, P275, DOI 10.1016/0003-2697(86)90626-3
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   DELMAS B, 1990, J GEN VIROL, V71, P1313, DOI 10.1099/0022-1317-71-6-1313
   FICHOT O, 1990, NUCLEIC ACIDS RES, V18, P6162, DOI 10.1093/nar/18.20.6162
   FLEMING JO, 1986, J VIROL, V58, P869, DOI 10.1128/JVI.58.3.869-875.1986
   GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998
   Groot R. J. de, 1987, Coronaviruses, P31
   JACOBS L, 1987, VIRUS RES, V8, P363, DOI 10.1016/0168-1702(87)90008-6
   KOCH G, 1990, J GEN VIROL, V71, P1929, DOI 10.1099/0022-1317-71-9-1929
   KOCH G, 1990, CORONAVIRUSES THEIR
   KUSTERS JG, 1989, VIROLOGY, V169, P217, DOI 10.1016/0042-6822(89)90058-5
   KUSTERS JG, 1989, J IMMUNOL, V143, P2692
   LENSTRA JA, 1990, ARCH VIROL, V110, P1, DOI 10.1007/BF01310699
   LENSTRA JA, 1989, MOL IMMUNOL, V1, P7
   MOCKETT APA, 1984, J GEN VIROL, V65, P2281, DOI 10.1099/0022-1317-65-12-2281
   NIESTERS HGM, 1986, VIRUS RES, V5, P253, DOI 10.1016/0168-1702(86)90022-5
   NIESTERS HGM, 1987, VIROLOGY, V161, P511, DOI 10.1016/0042-6822(87)90145-0
   PARKER MD, 1990, J GEN VIROL, V71, P263, DOI 10.1099/0022-1317-71-2-263
   PARKER SE, 1989, VIROLOGY, V173, P664, DOI 10.1016/0042-6822(89)90579-5
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   STERN DF, 1982, J VIROL, V44, P794, DOI 10.1128/JVI.44.3.794-803.1982
   STERN DF, 1982, J VIROL, V42, P208, DOI 10.1128/JVI.42.1.208-219.1982
   THOMAS AAM, 1988, J VIROL, V62, P2782, DOI 10.1128/JVI.62.8.2782-2789.1988
   WEGE H, 1988, J GEN VIROL, V69, P87, DOI 10.1099/0022-1317-69-1-87
NR 33
TC 124
Z9 141
U1 0
U2 1
PU SOC GENERAL MICROBIOLOGY
PI READING
PA HARVEST HOUSE 62 LONDON ROAD, READING, BERKS, ENGLAND RG1 5AS
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD MAR
PY 1992
VL 73
BP 591
EP 596
DI 10.1099/0022-1317-73-3-591
PN 3
PG 6
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA HH456
UT WOS:A1992HH45600012
PM 1372036
OA Bronze
DA 2020-04-03
ER

PT J
AU CAVANAGH, D
   DAVIS, PJ
AF CAVANAGH, D
   DAVIS, PJ
TI CORONAVIRUS IBV - REMOVAL OF SPIKE GLYCOPOLYPEPTIDE-S1 BY UREA ABOLISHES
   INFECTIVITY AND HEMAGGLUTINATION BUT NOT ATTACHMENT TO CELLS
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
RP CAVANAGH, D (reprint author), HOUGHTON POULTRY RES STN,HUNTINGDON PE17 2DA,CAMBS,ENGLAND.
CR ALEXANDER DJ, 1977, AVIAN PATHOL, V6, P9, DOI 10.1080/03079457708418208
   BINGHAM RW, 1975, J GEN VIROL, V28, P381, DOI 10.1099/0022-1317-28-3-381
   BINNS MM, 1985, J GEN VIROL, V66, P719, DOI 10.1099/0022-1317-66-4-719
   BOURSNELL MEG, 1984, VIRUS RES, V1, P303, DOI 10.1016/0168-1702(84)90019-4
   BRUNS M, 1984, J GEN VIROL, V65, P1431, DOI 10.1099/0022-1317-65-8-1431
   CAVANAGH D, 1983, J GEN VIROL, V64, P2577, DOI 10.1099/0022-1317-64-12-2577
   CAVANAGH D, 1986, VIRUS RES, V4, P133, DOI 10.1016/0168-1702(86)90037-7
   CAVANAGH D, 1986, VIRUS RES, V4, P145, DOI 10.1016/0168-1702(86)90038-9
   CAVANAGH D, 1981, J GEN VIROL, V53, P93, DOI 10.1099/0022-1317-53-1-93
   CAVANAGH D, 1983, J GEN VIROL, V64, P1787, DOI 10.1099/0022-1317-64-8-1787
   DARBYSHIRE JH, 1976, BRIT J EXP PATHOL, V57, P443
   LAKSHMI MV, 1978, VIROLOGY, V88, P314, DOI 10.1016/0042-6822(78)90288-X
   LAVER WG, 1984, VIROLOGY, V137, P314, DOI 10.1016/0042-6822(84)90223-X
   MARKWELL MAK, 1985, P NATL ACAD SCI USA, V82, P978, DOI 10.1073/pnas.82.4.978
   MOCKETT APA, 1981, AVIAN PATHOL, V10, P1, DOI 10.1080/03079458108418453
   MOCKETT APA, 1984, J GEN VIROL, V65, P2281, DOI 10.1099/0022-1317-65-12-2281
   NOTTER MFD, 1982, J VIROL, V41, P958, DOI 10.1128/JVI.41.3.958-964.1982
   STERN DF, 1982, J VIROL, V44, P794, DOI 10.1128/JVI.44.3.794-803.1982
   STERN DF, 1982, J VIROL, V42, P208, DOI 10.1128/JVI.42.1.208-219.1982
   STURMAN LS, 1983, ADV VIRUS RES, V28, P36
   WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072
NR 21
TC 124
Z9 137
U1 0
U2 0
PU SOC GENERAL MICROBIOLOGY
PI READING
PA HARVEST HOUSE 62 LONDON ROAD, READING, BERKS, ENGLAND RG1 5AS
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD JUL
PY 1986
VL 67
BP 1443
EP 1448
DI 10.1099/0022-1317-67-7-1443
PN 7
PG 6
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA D2948
UT WOS:A1986D294800021
PM 3014054
OA Bronze
DA 2020-04-03
ER

PT J
AU Liu, SW
   Kong, XG
AF Liu, SW
   Kong, XG
TI A new genotype of nephropathogenic infectious bronchitis virus
   circulating in vaccinated and non-vaccinated flocks in China
SO AVIAN PATHOLOGY
LA English
DT Article
ID CORONAVIRUS-IBV; SPIKE PROTEIN; GREAT-BRITAIN; SEQUENCE; STRAINS;
   CHICKENS; RECOMBINATION; SEROTYPE; GENE
AB Five strains of infectious bronchitis virus (IBV) were isolated from five layer flocks that had nephropathogenic infection in four provinces in China. Among them, three of the five flocks had been vaccinated against infectious bronchitis. Virulence studies indicated that the five Chinese IBV isolates caused 10 to 30% mortality in 15-day-old specific pathogen free chickens and gross lesions were mainly confined to the kidneys in all of the dead chickens. Two oligonucleotide pairs, S1Uni2 and S1Oligo3' or S1Oligo5' and S1Oligo3', were used after propagation of the isolates in embryonated eggs to amplify the S1 protein genes of the spike protein. The cDNA derived by reverse transcriptase-polymerase chain reaction was cloned and sequenced. The nucleotide and amino acid sequence of S1 protein gene had a similar degree of identity (greater than or equal to 92%) among the five Chinese IBV isolates. The nucleotide and amino acid identity of the S1 protein gene between the five Chinese IBV isolates and 16 strains of other IBVs varied from 60 to 81%. This clearly showed that the five Chinese IBV isolates comprised a separate genotype. These results demonstrated, for the first time, that there is a new genotype of nephropathogenic IBV circulating in vaccinated and non-vaccinated flocks in China.
C1 Chinese Acad Agr Sci, Haerbin Vet Res Inst, Natl Key Lab Vet Biotechnol, Haerbin 150001, Peoples R China.
RP Kong, XG (reprint author), Chinese Acad Agr Sci, Haerbin Vet Res Inst, Natl Key Lab Vet Biotechnol, Haerbin 150001, Peoples R China.
EM xgkong@hvri.ac.cn
CR Adzhar A, 1997, AVIAN PATHOL, V26, P625, DOI 10.1080/03079459708419239
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   CAVANAGH D, 1992, AVIAN PATHOL, V21, P401, DOI 10.1080/03079459208418858
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   CAVANAGH D, 2003, DIS POULTRY, P101
   Cumming RB, 1962, AUST VET J, V38, P554, DOI DOI 10.1111/J.1751-0813.1962.TB04027.X
   De Wit JJ, 2000, AVIAN PATHOL, V29, P71, DOI 10.1080/03079450094108
   Farsang A, 2002, AVIAN PATHOL, V31, P229, DOI 10.1080/03079450220136530
   GOUGH RE, 1992, VET REC, V130, P493, DOI 10.1136/vr.130.22.493
   JIA W, 1995, ARCH VIROL, V140, P259, DOI 10.1007/BF01309861
   JORDI BJAM, 1989, NUCLEIC ACIDS RES, V17, P6726, DOI 10.1093/nar/17.16.6726
   KUSTERS JG, 1989, VIROLOGY, V169, P217, DOI 10.1016/0042-6822(89)90058-5
   KWON HM, 1993, AVIAN DIS, V37, P194, DOI 10.2307/1591474
   Lee AHW, 2001, ENERG ENG, V98, P45, DOI 10.1092/YBWM-LDCW-VANW-YNQV
   Li H, 2001, AVIAN PATHOL, V30, P535, DOI 10.1080/03079450120078734
   Meulemans G, 1998, WORLD POULTRY SCI J, V54, P145, DOI 10.1079/WPS19980011
   NIESTERS HGM, 1986, VIRUS RES, V5, P253, DOI 10.1016/0168-1702(86)90022-5
   Shaw K, 1996, AVIAN PATHOL, V25, P607, DOI 10.1080/03079459608419165
   SUTOU S, 1988, VIROLOGY, V165, P589, DOI 10.1016/0042-6822(88)90603-4
   Wang CH, 1996, AVIAN DIS, V40, P620, DOI 10.2307/1592273
   Wang HN, 1997, AVIAN DIS, V41, P279, DOI 10.2307/1592178
   WANG L, 1994, VIRUS RES, V34, P327
   WINTERFIELD RW, 1962, AM J VET RES, V23, P1273
   Wu ZQ, 1998, AVIAN PATHOL, V27, P578, DOI 10.1080/03079459808419387
   Yu L, 2001, AVIAN DIS, V45, P201, DOI 10.2307/1593029
   Ziegler AF, 2002, AVIAN DIS, V46, P847, DOI 10.1637/0005-2086(2002)046[0847:NIBIPC]2.0.CO;2
NR 26
TC 123
Z9 160
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0307-9457
EI 1465-3338
J9 AVIAN PATHOL
JI Avian Pathol.
PD JUN
PY 2004
VL 33
IS 3
BP 321
EP 327
DI 10.1080/0307945042000220697
PG 7
WC Veterinary Sciences
SC Veterinary Sciences
GA 841NM
UT WOS:000222937200009
PM 15223561
DA 2020-04-03
ER

PT J
AU Gu, WJ
   Zhou, T
   Ma, JM
   Sun, X
   Lu, ZH
AF Gu, WJ
   Zhou, T
   Ma, JM
   Sun, X
   Lu, ZH
TI Analysis of synonymous codon usage in SARS Coronavirus and other viruses
   in the Nidovirales
SO VIRUS RESEARCH
LA English
DT Article
DE synonymous codon usage; mutational bias; selection pressure; base
   composition; SARS; Coronavirus
ID ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PROTEIN-STRUCTURE;
   CLUSTER-ANALYSIS; BASE COMPOSITION; RNA VIRUSES; GENE LENGTH; BIAS;
   SELECTION; POSITIONS
AB In this study, we calculated the codon usage bias in severe acute respiratory syndrome Coronavirus (SARSCoV) and per-formed a comparative analysis of synonymous codon usage patterns in SARSCoV and 10 other evolutionary related viruses in the Nidovirales. Although there is a significant variation in codon usage bias among different SARSCoV genes, codon usage bias in SARSCoV is a little slight, which is mainly determined by the base compositions on the third codon position. By comparing synonymous codon usage patterns in different viruses, we observed that synonymous codon usage pattern in these virus genes was virus specific and phylogenetically conserved, but it was not host specific. Phylogenetic analysis based on codon usage pattern suggested that SARSCoV was diverged far from all three known groups of Coronavirus. Compositional constraints could explain most of the variation of synonymous codon usage among these virus genes, while gene function is also correlated to synonymous codon usages to a certain extent. However, translational selection and gene length have no effect on the variations of synonymous codon usage in these virus genes. (C) 2004 Elsevier B.V. All rights reserved.
C1 SE Univ, Minist Educ, Key Lab Mol & Biomol Elect, Nanjing 210096, Jiangsu, Peoples R China.
RP Lu, ZH (reprint author), SE Univ, Minist Educ, Key Lab Mol & Biomol Elect, Nanjing 210096, Jiangsu, Peoples R China.
EM zhlu@seu.edu.cn
RI Gu, Wanjun/P-5389-2019; Lu, Zuhong/A-5448-2013; Gu, Wanjun/B-3998-2010
OI Gu, Wanjun/0000-0003-4501-0539; 
CR Chan-Yeung M, 2003, BRIT MED J, V326, P850, DOI 10.1136/bmj.326.7394.850
   Chiapello H, 1999, NUCLEIC ACIDS RES, V27, P2848, DOI 10.1093/nar/27.14.2848
   Chiapello H, 1998, GENE, V209, pGC1, DOI 10.1016/S0378-1119(97)00671-9
   Chiusano ML, 2000, GENE, V261, P63, DOI 10.1016/S0378-1119(00)00521-7
   Chiusano ML, 1999, GENE, V238, P23, DOI 10.1016/S0378-1119(99)00258-9
   Coghlan A, 2000, YEAST, V16, P1131, DOI 10.1002/1097-0061(20000915)16:12<1131::AID-YEA609>3.0.CO;2-F
   Comeron JM, 1998, J MOL EVOL, V47, P268, DOI 10.1007/PL00006384
   Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910
   Drazen Jeffrey M, 2003, N Engl J Med, V348, pe6, DOI 10.1056/NEJMe030062
   Epstein RJ, 2000, GENE, V245, P291, DOI 10.1016/S0378-1119(00)00042-1
   EWENS W, 2001, STAT METHODS BIOINFO
   Francino HP, 1999, NATURE, V400, P30, DOI 10.1038/21804
   Ghosh TC, 2000, INT J PARASITOL, V30, P715, DOI 10.1016/S0020-7519(00)00042-4
   GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055
   GRANTHAM R, 1981, NUCLEIC ACIDS RES, V9, P43
   GRANTHAM R, 1980, NUCLEIC ACIDS RES, V8, P49
   Gupta SK, 2000, BIOCHEM BIOPH RES CO, V269, P692, DOI 10.1006/bbrc.2000.2351
   IKEMURA T, 1981, J MOL BIOL, V151, P389, DOI 10.1016/0022-2836(81)90003-6
   IKEMURA T, 1985, MOL BIOL EVOL, V2, P13
   Jenkins GM, 2003, VIRUS RES, V92, P1, DOI 10.1016/S0168-1702(02)00309-X
   Jenkins GM, 2001, J MOL EVOL, V52, P383, DOI 10.1007/s002390010168
   Karlin S, 1996, J MOL BIOL, V262, P459, DOI 10.1006/jmbi.1996.0528
   Lesnik T, 2000, J THEOR BIOL, V202, P175, DOI 10.1006/jtbi.1999.1047
   Levin DB, 2000, J GEN VIROL, V81, P2313, DOI 10.1099/0022-1317-81-9-2313
   LLOYD AT, 1992, NUCLEIC ACIDS RES, V20, P5289, DOI 10.1093/nar/20.20.5289
   Ma JM, 2002, BIOSYSTEMS, V65, P199, DOI 10.1016/S0303-2647(02)00016-3
   Majumdar S, 1999, BIOCHEM BIOPH RES CO, V266, P66, DOI 10.1006/bbrc.1999.1774
   Marais G, 2001, J MOL EVOL, V52, P275, DOI 10.1007/s002390010155
   Mardia K.V., 1979, MULTIVARIATE ANAL
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MARTIN A, 1989, NUCLEIC ACIDS RES, V17, P6181
   McInerney JO, 1998, P NATL ACAD SCI USA, V95, P10698, DOI 10.1073/pnas.95.18.10698
   Moriyama EN, 1998, NUCLEIC ACIDS RES, V26, P3188, DOI 10.1093/nar/26.13.3188
   Oresic M, 1998, J MOL BIOL, V281, P31, DOI 10.1006/jmbi.1998.1921
   PAUL AR, 2003, SCIENCE, V300, P1394
   Qin E, 2003, CHINESE SCI BULL, V48, P941, DOI 10.1007/BF03184203
   SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P5125, DOI 10.1093/nar/14.13.5125
   SHARP PM, 1986, NUCLEIC ACIDS RES, V14, P7737, DOI 10.1093/nar/14.19.7737
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   WRIGHT F, 1990, GENE, V87, P23, DOI 10.1016/0378-1119(90)90491-9
   Xie T, 1998, FEBS LETT, V434, P93
NR 41
TC 123
Z9 136
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD MAY
PY 2004
VL 101
IS 2
BP 155
EP 161
DI 10.1016/j.virusres.2004.01.006
PG 7
WC Virology
SC Virology
GA 812LO
UT WOS:000220841200007
PM 15041183
OA Bronze
DA 2020-04-03
ER

PT J
AU WHITE, KA
   MORRIS, TJ
AF WHITE, KA
   MORRIS, TJ
TI NONHOMOLOGOUS RNA RECOMBINATION IN TOMBUSVIRUSES - GENERATION AND
   EVOLUTION OF DEFECTIVE INTERFERING RNAS BY STEPWISE DELETIONS
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID BUSHY STUNT VIRUS; TURNIP CRINKLE VIRUS; YELLOW MOSAIC-VIRUS; DENOVO
   GENERATION; MURINE CORONAVIRUS; POLIOVIRUS RNA; REPLICATION; SEQUENCE;
   GENOME; PARTICLES
AB We used a protoplast system to study the mechanisms involved in the generation and evolution of defective interfering (DI) RNAs of tomato bushy stunt tombusvirus (TBSV). Synthetic transcripts corresponding to different naturally occurring TBSV DI RNAs, or to various artificially constructed TBSV defective RNAs, were analyzed. The relative levels of competitiveness of different DI RNAs were determined by coinoculating their corresponding transcripts into protoplasts along with helper genomic RNA transcripts and monitoring the level of DI RNA accumulation. Further studies were performed to assess the contribution of naked DI RNA stability and DI RNA encapsidation efficiency to the observed levels of competitiveness. In addition, the ability of various defective RNAs to evolve to alternative forms was tested by serially passaging protoplast infections initiated with transcripts corresponding to helper genomic RNA and a single type of defective RNA. These studies, and the analysis of the sequences of observed recombinants, indicate that (i) replication competence is a major factor dictating DI RNA competitiveness and is likely a primary determinant in DI RNA evolution, (ii) DI RNAs are capable of evolving to both smaller and larger forms, and the rates at which various transitions occur differ, (iii) DI RNA-DI RNA recombination and/or rearrangement is responsible for the formation of the evolved RNA molecules which were examined, and (iv) sequence complementarities between positive- and negative-sense strands in the regions of the junctions suggest that, in some cases, base pairing between an incomplete replicase-associated nascent strand and acceptor template may mediate selection of recombination sites. On the basis of our data, we propose a stepwise deletion model to describe the temporal order of events leading to the formation of tombusvirus DI RNAs.
C1 UNIV NEBRASKA, SCH BIOL SCI, LINCOLN, NE 68588 USA.
CR BIEBRICHER CK, 1992, EMBO J, V11, P5129, DOI 10.1002/j.1460-2075.1992.tb05620.x
   BUJARSKI JJ, 1991, J VIROL, V65, P4153, DOI 10.1128/JVI.65.8.4153-4159.1991
   BURGYAN J, 1989, J GEN VIROL, V70, P235, DOI 10.1099/0022-1317-70-1-235
   BURGYAN J, 1991, J GEN VIROL, V72, P505, DOI 10.1099/0022-1317-72-3-505
   CASCONE PJ, 1990, EMBO J, V9, P1709, DOI 10.1002/j.1460-2075.1990.tb08294.x
   CASCONE PJ, 1993, SCIENCE, V260, P801, DOI 10.1126/science.8484119
   DEGROOT RJ, 1992, J VIROL, V66, P5898, DOI 10.1128/JVI.66.10.5898-5905.1992
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   FURUYA T, 1993, VIROLOGY, V194, P408, DOI 10.1006/viro.1993.1277
   HEARNE PQ, 1990, VIROLOGY, V177, P141, DOI 10.1016/0042-6822(90)90468-7
   HILLMAN BI, 1987, CELL, V51, P427, DOI 10.1016/0092-8674(87)90638-6
   JARVIS TC, 1992, EMBO J, V11, P3135, DOI 10.1002/j.1460-2075.1992.tb05386.x
   JONES RW, 1990, VIROLOGY, V176, P539, DOI 10.1016/0042-6822(90)90024-L
   KIM YN, 1993, VIROLOGY, V194, P244, DOI 10.1006/viro.1993.1255
   KING AMQ, 1988, NUCLEIC ACIDS RES, V16, P11705, DOI 10.1093/nar/16.24.11705
   KNORR DA, 1991, VIROLOGY, V181, P193, DOI 10.1016/0042-6822(91)90484-S
   KNORR DA, 1991, PLANT MOL BIOL, V2, P57
   LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992
   LAZZARINI RA, 1981, CELL, V26, P145, DOI 10.1016/0092-8674(81)90298-1
   LI XH, 1989, P NATL ACAD SCI USA, V86, P9173, DOI 10.1073/pnas.86.23.9173
   LI Y, 1993, J VIROL, V67, P3854, DOI 10.1128/JVI.67.7.3854-3860.1993
   MAKINO S, 1985, J VIROL, V54, P329, DOI 10.1128/JVI.54.2.329-336.1985
   MAKINO S, 1988, VIROLOGY, V166, P550, DOI 10.1016/0042-6822(88)90526-0
   MANIATIS T, 1982, MOL CLONING
   MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560
   NAGY PD, 1992, J VIROL, V66, P6824, DOI 10.1128/JVI.66.11.6824-6828.1992
   Perrault J, 1981, Curr Top Microbiol Immunol, V93, P151
   RESENDE RD, 1992, J GEN VIROL, V73, P2509
   ROCHON DM, 1989, VIROLOGY, V169, P251, DOI 10.1016/0042-6822(89)90150-5
   ROCHON DM, 1991, VIROLOGY, V181, P656, DOI 10.1016/0042-6822(91)90899-M
   ROCHON DM, 1991, P NATL ACAD SCI USA, V88, P11153, DOI 10.1073/pnas.88.24.11153
   ROMERO J, 1993, VIROLOGY, V194, P576, DOI 10.1006/viro.1993.1297
   ROUX L, 1991, ADV VIRUS RES, V40, P181
   SCHLESINGER S, 1988, RNA GENETICS, V2, P167
   SCHOLTHOF HB, 1993, MOL PLANT MICROBE IN, V6, P309, DOI 10.1094/MPMI-6-309
   WHITE KA, 1991, VIROLOGY, V183, P479, DOI 10.1016/0042-6822(91)90977-J
   WHITE KA, 1992, J VIROL, V66, P3069, DOI 10.1128/JVI.66.5.3069-3076.1992
NR 37
TC 123
Z9 128
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JAN
PY 1994
VL 68
IS 1
BP 14
EP 24
DI 10.1128/JVI.68.1.14-24.1994
PG 11
WC Virology
SC Virology
GA MW251
UT WOS:A1994MW25100003
PM 8254723
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU CAVANAGH, D
AF CAVANAGH, D
TI CORONAVIRUS IBV - STRUCTURAL CHARACTERIZATION OF THE SPIKE PROTEIN
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
RP CAVANAGH, D (reprint author), HOUGHTON POULTRY RES STN,DEPT MICROBIOL,HUNTINGDON PE17 2DA,CAMBS,ENGLAND.
CR CAVANAGH D, 1981, J GEN VIROL, V53, P93, DOI 10.1099/0022-1317-53-1-93
   CAVANAGH D, 1983, J GEN VIROL, V64, P1787, DOI 10.1099/0022-1317-64-8-1787
   CAVANAGH D, 1983, J GEN VIROL, V64, P1187, DOI 10.1099/0022-1317-64-5-1187
   CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4
   DAVIES HA, 1981, J GEN VIROL, V53, P67, DOI 10.1099/0022-1317-53-1-67
   DAVIES HA, 1979, ARCH VIROL, V59, P25, DOI 10.1007/BF01317891
   EASON R, 1978, CENTRIFUGAL SEPARATI, P251
   Hofstad M. S., 1978, Diseases of poultry, P487
   MACNAUGHTON MR, 1980, ARCH VIROL, V63, P75, DOI 10.1007/BF01320763
   MACNAUGHTON MR, 1977, J VIROL, V24, P821, DOI 10.1128/JVI.24.3.821-825.1977
   MARTIN RG, 1961, J BIOL CHEM, V236, P1372
   MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1
   NIEMANN H, 1981, J MOL BIOL, V153, P993, DOI 10.1016/0022-2836(81)90463-0
   POCOCK DH, 1978, J GEN VIROL, V40, P93, DOI 10.1099/0022-1317-40-1-93
   SCHMIDT MFG, 1982, VIROLOGY, V116, P327, DOI 10.1016/0042-6822(82)90424-X
   SIDDELL S, 1982, CURR TOP MICROBIOL, V99, P131
   STERN DF, 1982, J VIROL, V44, P794, DOI 10.1128/JVI.44.3.794-803.1982
   STERN DF, 1982, J VIROL, V44, P804, DOI 10.1128/JVI.44.3.804-812.1982
   STERN DF, 1982, J VIROL, V42, P208, DOI 10.1128/JVI.42.1.208-219.1982
   STURMAN LS, 1981, BIOCH BIOL CORONAVIR, V142, P1
   Tanford C., 1961, PHYSICAL CHEM MACROM
   ZIEMIECKI A, 1978, J MOL BIOL, V122, P259, DOI 10.1016/0022-2836(78)90189-4
NR 22
TC 123
Z9 139
U1 0
U2 3
PU SOC GENERAL MICROBIOLOGY
PI READING
PA HARVEST HOUSE 62 LONDON ROAD, READING, BERKS, ENGLAND RG1 5AS
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PY 1983
VL 64
IS DEC
BP 2577
EP 2583
DI 10.1099/0022-1317-64-12-2577
PG 7
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA RW637
UT WOS:A1983RW63700004
PM 6319549
OA Bronze
DA 2020-04-03
ER

PT J
AU Muller, MA
   Meyer, B
   Corman, VM
   Al-Masri, M
   Turkestani, A
   Ritz, D
   Sieberg, A
   Aldabbagh, S
   Bosch, BJ
   Lattwein, E
   Alhakeem, RF
   Assiri, AM
   Albarrak, AM
   Al-Shangiti, AM
   Al-Tawfiq, JA
   Wikramaratna, P
   Alrabeeah, AA
   Drosten, C
   Memish, ZA
AF Mueller, Marcel A.
   Meyer, Benjamin
   Corman, Victor M.
   Al-Masri, Malak
   Turkestani, Abdulhafeez
   Ritz, Daniel
   Sieberg, Andrea
   Aldabbagh, Souhaib
   Bosch, Berend-J
   Lattwein, Erik
   Alhakeem, Raafat F.
   Assiri, Abdullah M.
   Albarrak, Ali M.
   Al-Shangiti, Ali M.
   Al-Tawfiq, Jaffar A.
   Wikramaratna, Paul
   Alrabeeah, Abdullah A.
   Drosten, Christian
   Memish, Ziad A.
TI Presence of Middle East respiratory syndrome coronavirus antibodies in
   Saudi Arabia: a nationwide, cross-sectional, serological study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID MERS-CORONAVIRUS; DROMEDARY CAMELS; NEUTRALIZING ANTIBODIES;
   TRANSMISSION; KINGDOM; JEDDAH; ASSAYS
AB Background Scientific evidence suggests that dromedary camels are the intermediary host for the Middle East respiratory syndrome coronavirus (MERS-CoV). However, the actual number of infections in people who have had contact with camels is unknown and most index patients cannot recall any such contact. We aimed to do a nationwide serosurvey in Saudi Arabia to establish the prevalence of MERS-CoV antibodies, both in the general population and in populations of individuals who have maximum exposure to camels.
   Methods In the cross-sectional serosurvey, we tested human serum samples obtained from healthy individuals older than 15 years who attended primary health-care centres or participated in a national burden-of-disease study in all 13 provinces of Saudi Arabia. Additionally, we tested serum samples from shepherds and abattoir workers with occupational exposure to camels. Samples were screened by recombinant ELISA and MERS-CoV seropositivity was confirmed by recombinant immunofluorescence and plaque reduction neutralisation tests. We used two-tailed Mann Whitney U exact tests, chi(2), and Fisher's exact tests to analyse the data.
   Findings Between Dec 1, 2012, and Dec 1, 2013, we obtained individual serum samples from 10 009 individuals. Anti-MERS-CoV antibodies were confirmed in 15 (0.15%; 95% CI 0.09-0.24) of 10 009 people in six of the 13 provinces. The mean age of seropositive individuals was significantly younger than that of patients with reported, laboratory-confirmed, primary Middle Eastern respiratory syndrome (43.5 years [SD 17.3] vs 53.8 years [17.5]; p=0.008). Men had a higher antibody prevalence than did women (11 [0.25%] of 4341 vs two [0.05%] of 4378; p=0.028) and antibody prevalence was significantly higher in central versus coastal provinces (14 [0.26%] of 5479 vs one [0.02%] of 4529; p=0.003). Compared with the general population, seroprevalence of MERS-CoV antibodies was significantly increased by 15 times in shepherds (two [2.3%] of 87, p=0.0004) and by 23 times in slaughterhouse workers (five [3.6%] of 140; p<0.0001).
   Interpretation Seroprevalence of MERS-CoV antibodies was significantly higher in camel-exposed individuals than in the general population. By simple multiplication, a projected 44951 (95% CI 26971-71922) individuals older than 15 years might be seropositive for MERS-CoV in Saudi Arabia. These individuals might be the source of infection for patients with confirmed MERS who had no previous exposure to camels.
C1 [Mueller, Marcel A.; Meyer, Benjamin; Corman, Victor M.; Ritz, Daniel; Sieberg, Andrea; Aldabbagh, Souhaib; Drosten, Christian] Univ Bonn, Med Ctr, Inst Virol, D-53127 Bonn, Germany.
   [Corman, Victor M.; Drosten, Christian] German Ctr Infect Res, Bonn, Germany.
   [Albarrak, Ali M.] King Abdul Aziz Med City, Saudi Ctr Dis Control, Riyadh, Saudi Arabia.
   [Al-Shangiti, Ali M.] King Abdul Aziz Med City, Natl Hlth Lab, Riyadh, Saudi Arabia.
   [Al-Masri, Malak; Turkestani, Abdulhafeez; Alhakeem, Raafat F.; Assiri, Abdullah M.; Alrabeeah, Abdullah A.; Memish, Ziad A.] Advisor Royal Court, Riyadh, Saudi Arabia.
   [Turkestani, Abdulhafeez] Makkah Reg Hlth Affairs, Minist Hlth, Mecca, Saudi Arabia.
   [Bosch, Berend-J] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Utrecht, Netherlands.
   [Lattwein, Erik] Euroimmun AG, Lubeck, Germany.
   [Al-Tawfiq, Jaffar A.] Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
   [Al-Tawfiq, Jaffar A.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [Wikramaratna, Paul] Univ Edinburgh, Inst Evolutionary Biol, Ctr Infect Immun & Evolut, Edinburgh, Midlothian, Scotland.
   [Memish, Ziad A.] Alfaisal Univ, Riyadh, Saudi Arabia.
RP Memish, ZA (reprint author), Minist Hlth, Prevent Med, POB 54146, Riyadh 11514, Saudi Arabia.
EM drosten@virology-bonn.de; zmemish@yahoo.com
RI Mueller, Marcel/O-2425-2019; Corman, Victor Max/K-1319-2019; Meyer,
   Bernhard/Q-9413-2016
OI Mueller, Marcel/0000-0003-2242-5117; Corman, Victor
   Max/0000-0002-3605-0136; Assiri, Abdullah/0000-0002-5605-2876; Sieberg,
   Andrea/0000-0003-3716-9996
FU European UnionEuropean Union (EU); German Centre for Infection Research;
   Federal Ministry of Education and ResearchFederal Ministry of Education
   & Research (BMBF); German Research CouncilGerman Research Foundation
   (DFG); Ministry of Health of Saudi Arabia
FX European Union, German Centre for Infection Research, Federal Ministry
   of Education and Research, German Research Council, and Ministry of
   Health of Saudi Arabia.
CR Aburizaiza AS, 2014, J INFECT DIS, V209, P243, DOI 10.1093/infdis/jit589
   Alagaili AN, 2014, MBIO, V5, DOI 10.1128/mBio.00884-14
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Basulaiman M, 2014, ANN EPIDEMIOL, V24, P801, DOI 10.1016/j.annepidem.2014.08.001
   Breban R, 2013, LANCET, V382, P694, DOI 10.1016/S0140-6736(13)61492-0
   Buchholz U., 2013, Eurosurveillance, V18, P20406
   Cauchemez S, 2013, EUROSURVEILLANCE, P18
   Cauchemez S, 2014, LANCET INFECT DIS, V14, P50, DOI 10.1016/S1473-3099(13)70304-9
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Drosten C, 2015, CLIN INFECT DIS, V60, P369, DOI 10.1093/cid/ciu812
   Drosten C, 2014, NEW ENGL J MED, V371, P828, DOI 10.1056/NEJMoa1405858
   European Centre for Disease Prevention and Control, 2015, EPID UPD MIDDL E RES
   Gierer S, 2013, EMERG INFECT DIS, V19, P2034, DOI 10.3201/eid1912.130701
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Murray CJL, 2014, LANCET, V384, P1005, DOI 10.1016/S0140-6736(14)60844-8
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reusken CB, 2014, EUROSURVEILLANCE, V19, P8, DOI 10.2807/1560-7917.ES2014.19.23.20829
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Wilcramaratna P, 2013, MERS COV SPATIAL TEM
   Woo PCY, 2004, CLIN DIAGN LAB IMMUN, V11, P665, DOI 10.1128/CDLI.11.4.665-668.2004
NR 23
TC 122
Z9 125
U1 4
U2 36
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD MAY
PY 2015
VL 15
IS 5
BP 559
EP 564
DI 10.1016/S1473-3099(15)70090-3
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA CG9WK
UT WOS:000353670600042
PM 25863564
OA Bronze
DA 2020-04-03
ER

PT J
AU He, YX
   Lu, H
   Siddiqui, P
   Zhou, YS
   Jiang, SB
AF He, YX
   Lu, H
   Siddiqui, P
   Zhou, YS
   Jiang, SB
TI Receptor-binding domain of severe acute respiratory syndrome coronavirus
   spike protein contains multiple conformation-dependent epitopes that
   induce highly potent neutralizing antibodies
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SYNDROME SARS CORONAVIRUS; INFECTIVITY-ENHANCING ANTIBODIES;
   ANGIOTENSIN-CONVERTING ENZYME-2; MONOCLONAL-ANTIBODIES; EBOLA-VIRUS;
   FUNCTIONAL-CHARACTERIZATION; STRUCTURAL-CHARACTERIZATION; PROTECTIVE
   IMMUNITY; MURINE CORONAVIRUS; PERITONITIS VIRUS
AB The spike (S) protein of severe acute respiratory syndrome associated coronavirus (SARS-CoV) is a major antigenic determinant capable of inducing protective immunity. Recently, a small fragment on the SARS-CoV S protein (residues 318-510) was characterized as a minimal receptor-binding domain (RBD), which mediates virus binding to angiotensin-converting enzyme 2, the functional receptor on susceptible cells. In this study, we demonstrated that a fusion protein containing RBD linked to human IgG1 Fe fragment (designated RBD-Fc) induced high titer of RBD-specific Abs in the immunized mice. The mouse antisera effectively neutralized infection by both SARS-CoV and SARS pseudovirus with mean 50 % neutralization titers of 1/15,360 and 1/24,737, respectively. The neutralization determinants on the RBD of S protein were characterized by a panel of 27 mAbs isolated from the immunized mice. Six groups of conformation-dependent epitopes, designated as Conf I-VI, and two adjacent linear epitopes were identified by ELISA and binding competition assays. The Conf IV and Conf V mAbs significantly blocked RBD-Fc binding to angiotensin-converting enzyme 2, suggesting that their epitopes overlap with the receptor-binding sites in the S protein. Most of the mAbs (23 of 25) that recognized the conformational epitopes possessed potent neutralizing activities against SARS pseudovirus with 50 % neutralizing dose ranging from 0.005 to 6.569 mu g/ml. Therefore, the RBD of SARS S protein contains multiple conformational epitopes capable of inducing potent neutralizing Ab responses, and is an important target site for developing vaccines and immunotherapeutics.
C1 Lindsley F Kimball Res Inst, New York Blood Ctr, New York, NY 10021 USA.
   Beijing Inst Microbiol & Epidemiol, Dept Mol Biol, Beijing, Peoples R China.
RP Jiang, SB (reprint author), Lindsley F Kimball Res Inst, New York Blood Ctr, 310 E 67th St, New York, NY 10021 USA.
EM SJiang@NYBloodcenter.org
RI Jiang, Shibo/L-4500-2014
CR Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   Bosch BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/pnas.0400576101
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Breedveld FC, 2000, LANCET, V355, P735, DOI 10.1016/S0140-6736(00)01034-5
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X
   Cavanagh D., 1995, CORONAVIRIDAE, P73
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   CORAPI WV, 1992, J VIROL, V66, P6695, DOI 10.1128/JVI.66.11.6695-6705.1992
   Dimitrov DS, 2003, CELL, V115, P652, DOI 10.1016/S0092-8674(03)00976-0
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Enserink M, 2004, SCIENCE, V304, P1097, DOI 10.1126/science.304.5674.1097
   Fleck F, 2004, B WORLD HEALTH ORGAN, V82, P152
   FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985
   Geisbert TW, 2002, VIROLOGY, V293, P15, DOI 10.1006/viro.2001.1279
   GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   He YX, 2004, J IMMUNOL, V173, P4050, DOI 10.4049/jimmunol.173.6.4050
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI200318819, 10.1172/JCI18819]
   Holmes KV, 2003, SCIENCE, V300, P1377, DOI 10.1126/science.1086418
   Ingallinella P, 2004, P NATL ACAD SCI USA, V101, P8709, DOI 10.1073/pnas.0402753101
   JIANG S, 1991, J EXP MED, V174, P1557, DOI 10.1084/jem.174.6.1557
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Lu LQ, 2004, J CLIN MICROBIOL, V42, P1570, DOI 10.1128/JCM.42.4.1570-1576.2004
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Marshall E, 2004, SCIENCE, V303, P944, DOI 10.1126/science.303.5660.944
   Nie YC, 2004, J INFECT DIS, V190, P1119, DOI 10.1086/423286
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Prabakaran P, 2004, BIOCHEM BIOPH RES CO, V314, P235, DOI 10.1016/j.bbrc.2003.12.081
   Qin E, 2003, CHINESE SCI BULL, V48, P941, DOI 10.1007/BF03184203
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SAIF LJ, 1993, VET MICROBIOL, V37, P285, DOI 10.1016/0378-1135(93)90030-B
   Spiga O, 2003, BIOCHEM BIOPH RES CO, V310, P78, DOI 10.1016/j.bbrc.2003.08.122
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Takada A, 2003, REV MED VIROL, V13, P387, DOI 10.1002/rmv.405
   Takada A, 2001, J VIROL, V75, P2324, DOI 10.1128/JVI.75.5.2324-2330.2001
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Tripet B, 2004, J BIOL CHEM, V279, P20836, DOI 10.1074/jbc.M400759200
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   Wang PG, 2004, BIOCHEM BIOPH RES CO, V315, P439, DOI 10.1016/j.bbrc.2004.01.076
   WELT S, 1990, J CLIN ONCOL, V8, P1894, DOI 10.1200/JCO.1990.8.11.1894
   Welt S, 1999, SEMIN ONCOL, V26, P683
   Wilson JA, 2000, SCIENCE, V287, P1664, DOI 10.1126/science.287.5458.1664
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Xu YH, 2004, J BIOL CHEM, V279, P30514, DOI 10.1074/jbc.M403760200
   Xu ZK, 2002, BIOCHEM BIOPH RES CO, V298, P552, DOI 10.1016/S0006-291X(02)02491-9
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zhang H, 2004, J VIROL, V78, P6938, DOI 10.1128/JVI.78.13.6938-6945.2004
   Zwick MB, 2001, J VIROL, V75, P6692, DOI 10.1128/JVI.75.14.6692-6699.2001
NR 60
TC 122
Z9 136
U1 1
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD APR 15
PY 2005
VL 174
IS 8
BP 4908
EP 4915
DI 10.4049/jimmunol.174.8.4908
PG 8
WC Immunology
SC Immunology
GA 914NN
UT WOS:000228234600058
PM 15814718
OA Bronze
DA 2020-04-03
ER

PT J
AU Svoboda, T
   Henry, B
   Shulman, L
   Kennedy, E
   Rea, E
   Ng, W
   Wallington, T
   Yaffe, B
   Gournis, E
   Vicencio, E
   Basrur, S
   Glazier, RH
AF Svoboda, T
   Henry, B
   Shulman, L
   Kennedy, E
   Rea, E
   Ng, W
   Wallington, T
   Yaffe, B
   Gournis, E
   Vicencio, E
   Basrur, S
   Glazier, RH
TI Public health measures to control the spread of the severe acute
   respiratory syndrome during the outbreak in Toronto
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID SARS; CANADA; CORONAVIRUS
AB Background: Toronto was the site of North America's largest outbreak of the severe acute respiratory syndrome (SARS). An understanding of the patterns of transmission and the effects on public health in relation to control measures that were taken will help health officials prepare for any future outbreaks.
   Methods: We analyzed SARS case, quarantine, and hotline records in relation to control measures. The two phases of the outbreak were compared.
   Results: Toronto Public Health investigated 2132 potential cases of SARS, identified 23,103 contacts of SARS patients as requiring quarantine, and logged 316,615 calls on its SARS hotline. In Toronto, 225 residents met the case definition of SARS, and all but 3 travel-related cases were linked to the index patient, from Hong Kong. SARS spread to 11 (58 percent) of Toronto's acute care hospitals. Unrecognized SARS among in-patients with underlying illness caused a resurgence, or a second phase, of the outbreak, which was finally controlled through active surveillance of hospitalized patients. In response to the control measures of Toronto Public Health, the number of persons who were exposed to SARS in nonhospital and nonhousehold settings dropped from 20 (13 percent) before the control measures were instituted (phase 1) to 0 afterward (phase 2). The number of patients who were exposed while in a hospital ward rose from 25 (17 percent) in phase 1 to 68 (88 percent) in phase 2, and the number exposed while in the intensive care unit dropped from 13 (9 percent) in phase 1 to 0 in phase 2. Community spread (the length of the chains of transmission outside of hospital settings) was significantly reduced in phase 2 of the outbreak (P<0.001).
   Conclusions: The transmission of SARS in Toronto was limited primarily to hospitals and to households that had had contact with patients. For every case of SARS, health authorities should expect to quarantine up to 100 contacts of the patients and to investigate 8 possible cases. During an outbreak, active in-hospital surveillance for SARS-like illnesses and heightened infection-control measures are essential.
C1 Univ Toronto, Inner City Hlth Res Unit, Toronto Publ Hlth, Toronto, ON M5C 1N8, Canada.
   Univ Toronto, Dept Publ Hlth Sci, Toronto, ON M5C 1N8, Canada.
   Univ Toronto, Dept Family & Community Med, Toronto, ON M5C 1N8, Canada.
   St Michaels Hosp, Inner City Hlth Res Unit, Toronto, ON M5B 1W8, Canada.
RP Svoboda, T (reprint author), Univ Toronto, Inner City Hlth Res Unit, Toronto Publ Hlth, 70 Richmond St E,4th Fl, Toronto, ON M5C 1N8, Canada.
EM tomislav.svoboda@utoronto.ca
RI Glazier, Richard/E-5255-2012
CR Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Booth CM, 2003, JAMA-J AM MED ASSOC, V290, P334
   Dyer O, 2003, BRIT MED J, V326, P999, DOI 10.1136/bmj.326.7397.999
   *GREAT TOR AIRP AU, 2002, 6 YEARS ACC ANN REP
   *HLTH CAN, 2003, OUTBR PER NAT CAS DE
   Hoey J, 2003, CAN MED ASSOC J, V168, P1013
   *KPMG CAN, 2003, TOR TOUR REV LOSS EX
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   National Cancer Policy Board of the Institute of Medicine and Division on Earth and Life Studies of the National Research Council, 2003, LEARN SARS REN PUBL, P1
   Oyranoski D, 2003, NATURE, V423, P4, DOI 10.1038/423004a
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   So LKY, 2003, LANCET, V361, P1615, DOI 10.1016/S0140-6736(03)13265-5
   *TOR BOARD TRAD, 2003, IMP SARS TOR BUS COM
   Varia M, 2003, CAN MED ASSOC J, V169, P285
   *WHO, 2003, SEV AC RESP SYNDR VI
   World Health Organization, CUM NUMB REP PROB CA
   World Health Organization, MAN SEV AC RESP SYND
   2003, JAMA, V289, P2788
   2003, MMWR MORB MORTAL WKL, V52, P547
NR 21
TC 122
Z9 126
U1 2
U2 10
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 3
PY 2004
VL 350
IS 23
BP 2352
EP 2361
DI 10.1056/NEJMoa032111
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 825JY
UT WOS:000221754200006
PM 15175437
OA Bronze
DA 2020-04-03
ER

PT J
AU Narayanan, K
   Maeda, A
   Maeda, J
   Makino, S
AF Narayanan, K
   Maeda, A
   Maeda, J
   Makino, S
TI Characterization of the coronavirus M protein and nucleocapsid
   interaction in infected cells
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; DEFECTIVE INTERFERING RNAS; MURINE CORONAVIRUS;
   PACKAGING SIGNAL; VIRAL RNAS; GLYCOPROTEIN INTERACTIONS;
   MEMBRANE-PROTEIN; ENVELOPE PROTEIN; VIRION ENVELOPE; MESSENGER-RNAS
AB Coronavirus contains three envelope proteins, M, E and S, and a nucleocapsid, which consists of genomic RNA and N protein, within the viral envelope. me studied the macromolecular interactions involved in coronavirus assembly in cells infected with a murine coronavirus, mouse hepatitis virus (MHV). Coimmunoprecipitation analyses demonstrated an interaction between N protein and M protein in infected cells. Pulse-labeling experiments showed that newly synthesized, unglycosylated M protein interacted with N protein in a pre-Golgi compartment, which is part of the MHV budding site. Coimmunoprecipitation analyses further revealed that M protein interacted with only genomic-length MHV mRNA, mRNA 1, while N protein interacted with all MHV mRNAs. These data indicated that M protein interacted with the nucleocapsid, consisting of N protein and mRNA 1, in infected cells. The M protein-nucleocapsid interaction occurred in the absence of S and E proteins. Intracellular M protein-N protein interaction was maintained after removal of viral RNAs by RNase treatment. However, the M protein-N protein interaction did not occur in cells coexpressing M protein and N protein alone. These data indicated that while the M protein-N protein interaction, which is independent of viral RNA, occurred in the M protein-nucleocapsid complex, some MHV function(s) was necessary for the initiation of M protein-nucleocapsid interaction. The M protein-nucleocapsid interaction, which occurred near or at the MHV budding site, most probably represented the process of specific packaging of the MHV genome into MHV particles.
C1 Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA.
   Univ Texas, Dept Microbiol, Austin, TX 78712 USA.
RP Makino, S (reprint author), Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
RI Makino, Shinji/E-8014-2015; Narayanan, Krishna/A-7069-2009
OI Makino, Shinji/0000-0002-7831-1576; 
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21 AI029984, AI29984, R01 AI029984]
CR ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0
   BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   Bos ECW, 1997, J VIROL, V71, P5684, DOI 10.1128/JVI.71.7.5684-5687.1997
   Bos ECW, 1996, VIROLOGY, V218, P52, DOI 10.1006/viro.1996.0165
   BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993
   CAPONE J, 1984, J BIOCH CELL BIOL, V62, P1174
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   Cologna R, 2000, J VIROL, V74, P580, DOI 10.1128/JVI.74.1.580-583.2000
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   Fischer F, 1998, J VIROL, V72, P7885, DOI 10.1128/JVI.72.10.7885-7894.1998
   FOSMIRE JA, 1992, J VIROL, V66, P3522, DOI 10.1128/JVI.66.6.3522-3530.1992
   FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985
   GODET M, 1992, VIROLOGY, V188, P666, DOI 10.1016/0042-6822(92)90521-P
   HIRANO N, 1974, ARCH GES VIRUSFORSCH, V44, P298, DOI 10.1007/BF01240618
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   KIM KH, 1995, J VIROL, V69, P2313, DOI 10.1128/JVI.69.4.2313-2321.1995
   Kim KMH, 1997, J VIROL, V71, P3922, DOI 10.1128/JVI.71.5.3922-3931.1997
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S
   LOCKER JK, 1992, J BIOL CHEM, V267, P14094
   LOPEZ S, 1994, J VIROL, V68, P1316, DOI 10.1128/JVI.68.3.1316-1323.1994
   LUSTIG S, 1988, J VIROL, V62, P2329, DOI 10.1128/JVI.62.7.2329-2336.1988
   Maeda J, 1999, VIROLOGY, V263, P265, DOI 10.1006/viro.1999.9955
   MAKINO S, 1988, VIROLOGY, V163, P104, DOI 10.1016/0042-6822(88)90237-1
   MAKINO S, 1985, J VIROL, V54, P329, DOI 10.1128/JVI.54.2.329-336.1985
   MAKINO S, 1984, VIROLOGY, V139, P138, DOI 10.1016/0042-6822(84)90335-0
   MAKINO S, 1991, J VIROL, V65, P6031, DOI 10.1128/JVI.65.11.6031-6041.1991
   MAKINO S, 1990, J VIROL, V64, P6045, DOI 10.1128/JVI.64.12.6045-6053.1990
   Molenkamp R, 1997, VIROLOGY, V239, P78, DOI 10.1006/viro.1997.8867
   OPSTELTEN DJE, 1995, J CELL BIOL, V131, P339, DOI 10.1083/jcb.131.2.339
   Pettersson R F, 1991, Curr Top Microbiol Immunol, V170, P67
   PORTNER A, 1986, VIROLOGY, V150, P469, DOI 10.1016/0042-6822(86)90311-9
   Raamsman MJB, 2000, J VIROL, V74, P2333, DOI 10.1128/JVI.74.5.2333-2342.2000
   Risco C, 1996, J VIROL, V70, P4773, DOI 10.1128/JVI.70.7.4773-4777.1996
   ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981
   SETHNA PB, 1991, J VIROL, V65, P320, DOI 10.1128/JVI.65.1.320-325.1991
   SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   STEPHENS EB, 1988, ANNU REV MICROBIOL, V42, P489
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   SUOMALAINEN M, 1992, J VIROL, V66, P4737, DOI 10.1128/JVI.66.8.4737-4747.1992
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   TUNG FYT, 1992, VIROLOGY, V186, P676, DOI 10.1016/0042-6822(92)90034-M
   VANDERMOST RG, 1991, J VIROL, V65, P3219, DOI 10.1128/JVI.65.6.3219-3226.1991
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   Woo KM, 1997, J VIROL, V71, P824, DOI 10.1128/JVI.71.1.824-827.1997
   YU X, 1994, VIROLOGY, V202, P1018, DOI 10.1006/viro.1994.1430
NR 51
TC 122
Z9 138
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD SEP
PY 2000
VL 74
IS 17
BP 8127
EP 8134
DI 10.1128/JVI.74.17.8127-8134.2000
PG 8
WC Virology
SC Virology
GA 346JD
UT WOS:000088866500049
PM 10933723
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Baudoux, P
   Carrat, C
   Besnardeau, L
   Charley, B
   Laude, H
AF Baudoux, P
   Carrat, C
   Besnardeau, L
   Charley, B
   Laude, H
TI Coronavirus pseudoparticles formed with recombinant M and E proteins
   induce alpha interferon synthesis by leukocytes
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS VIRUS; MOUSE SPLEEN-CELLS;
   MEMBRANE-PROTEIN; BOVINE CORONAVIRUS; ENVELOPE PROTEIN; VIRION ENVELOPE;
   MATRIX PROTEIN; GLYCOPROTEIN-M; GOLGI-COMPLEX; IFN-ALPHA
AB Transmissible gastroenteritis virus (TGEV), an enteric coronavirus of swine, is a potent inducer of alpha interferon (IFN-alpha) both in vivo and in vitro. Incubation of peripheral blood mononuclear cells with noninfectious viral material such as inactivated virions or fixed, infected cells leads to early and strong IFN-alpha synthesis. Previous studies have shown that antibodies against the virus membrane glycoprotein M blocked the IFN induction and that two viruses with a mutated protein exhibited a decreased interferogenic activity, thus arguing for a direct involvement of hi protein in this phenomenon. In this study, the IFN-alpha-inducing activity of recombinant M protein expressed in the absence or presence of other TGEV structural proteins was examined, Fixed cells coexpressing M I together with at least the minor structural protein E were found to induce IFN-alpha almost as efficiently as TGEV-infected cells. Pseudoparticles resembling authentic virions were released in the culture medium of cells coexpressing M and E proteins. The interferogenic activity of purified pseudoparticles was shown to be comparable to that of TGEV virions, thus establishing that neither ribonucleoprotein nor spikes are required for IFN induction. The replacement of the externally exposed, N-terminal domain of M with that of bovine coronavirus (BCV) led to the production of chimeric particles with no major change in interferogenicity, although the structures of the TGEV and BCV ectodomains markedly differ. Moreover, BCV pseudoparticles also exhibited interferogenic activity. Together these observations suggest that the ability of coronavirus particles to induce IFN-alpha is more likely to involve a specific, multimeric structure than a definite sequence motif.
C1 INRA, Unite Virol Immunol Mol, F-78350 Jouy En Josas, France.
RP Laude, H (reprint author), INRA, Unite Virol Immunol Mol, F-78350 Jouy En Josas, France.
EM laude@biotec.jouy.inra.fr
CR ABRAHAM S, 1990, VIROLOGY, V177, P488, DOI 10.1016/0042-6822(90)90513-Q
   ANKEL H, 1994, VIROLOGY, V205, P34, DOI 10.1006/viro.1994.1617
   Baudoux P, 1995, Adv Exp Med Biol, V380, P305
   BAUDOUX P, 1996, THESIS I NAT AGR PAR
   BAUDOUX P, IN PRESS ADV EXP MED
   BOSS ECW, 1996, VIROLOGY, V218, P52
   CAPOBIANCHI MR, 1992, AIDS RES HUM RETROV, V8, P575, DOI 10.1089/aid.1992.8.575
   CHARLEY B, 1991, SCAND J IMMUNOL, V33, P435, DOI 10.1111/j.1365-3083.1991.tb01792.x
   CHARLEY B, 1988, J VIROL, V62, P8, DOI 10.1128/JVI.62.1.8-11.1988
   DEARCE HD, 1992, VET IMMUNOL IMMUNOP, V30, P319, DOI 10.1016/0165-2427(92)90102-V
   DELMAS B, 1991, VIRUS RES, V20, P107, DOI 10.1016/0168-1702(91)90103-3
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   ELEOUET JF, 1995, VIROLOGY, V206, P817, DOI 10.1006/viro.1995.1004
   Enjuanes L., 1995, The coronaviridae., P337
   FITZGERALDBOCARSLY P, 1993, PHARMACOL THERAPEUT, V60, P39, DOI 10.1016/0163-7258(93)90021-5
   FRANCIS ML, 1993, J IMMUNOL, V151, P2208
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   GODET M, 1992, VIROLOGY, V188, P666, DOI 10.1016/0042-6822(92)90521-P
   GODET M, 1991, VIROLOGY, V185, P732, DOI 10.1016/0042-6822(91)90544-L
   ITO Y, 1994, J GEN VIROL, V75, P567, DOI 10.1099/0022-1317-75-3-567
   ITO Y, 1994, ARCH VIROL, V138, P187, DOI 10.1007/BF01379125
   JESTIN V, 1991, ANN RECH VET, V22, P365
   Kim KMH, 1997, J VIROL, V71, P3922, DOI 10.1128/JVI.71.5.3922-3931.1997
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   LABONNARDIERE C, 1981, INFECT IMMUN, V32, P28, DOI 10.1128/IAI.32.1.28-31.1981
   LAL MMC, 1997, ADV VIRUS RES, V48, P1
   LAPPS W, 1987, VIROLOGY, V157, P47, DOI 10.1016/0042-6822(87)90312-6
   LAUDE H, 1986, J GEN VIROL, V67, P119, DOI 10.1099/0022-1317-67-1-119
   LAUDE H, 1987, J GEN VIROL, V68, P1687, DOI 10.1099/0022-1317-68-6-1687
   LAUDE H, 1992, J VIROL, V66, P743, DOI 10.1128/JVI.66.2.743-749.1992
   LEBON P, 1982, VIROLOGY, V119, P504, DOI 10.1016/0042-6822(82)90109-X
   LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S
   LOCKER JK, 1995, J BIOL CHEM, V270, P8815, DOI 10.1074/jbc.270.15.8815
   LOCKER JK, 1992, J BIOL CHEM, V267, P14094
   NOWACKI W, 1993, RES IMMUNOL, V144, P111, DOI 10.1016/0923-2494(93)80066-8
   RASSCHAERT D, 1987, BIOCHIMIE, V69, P591, DOI 10.1016/0300-9084(87)90178-7
   Riffault S, 1997, VET RES, V28, P105
   Riffault S, 1997, J GEN VIROL, V78, P2483, DOI 10.1099/0022-1317-78-10-2483
   RISCO C, 1995, J VIROL, V69, P5269, DOI 10.1128/JVI.69.9.5269-5277.1995
   ROGELGAILLARD C, 1993, FISH SHELLFISH IMMUN, V3, P383, DOI 10.1006/fsim.1993.1037
   Rottier P.J.M., 1995, CORONAVIRIDAE, P115
   ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022
   SANDBERG K, 1991, SCAND J IMMUNOL, V34, P565, DOI 10.1111/j.1365-3083.1991.tb01580.x
   SAVOYSKY E, 1990, RES VIROLOGY, V141, P411, DOI 10.1016/0923-2516(90)90042-H
   SPLICHAL I, 1994, IMMUNOL LETT, V43, P203, DOI 10.1016/0165-2478(94)90224-0
   Svensson H, 1996, SCAND J IMMUNOL, V44, P164, DOI 10.1046/j.1365-3083.1996.d01-289.x
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   VENNEMA H, UNPUB
   WOLOSZYN N, 1990, NUCLEIC ACIDS RES, V18, P1303, DOI 10.1093/nar/18.5.1303
   YU X, 1994, VIROLOGY, V202, P1018, DOI 10.1006/viro.1994.1430
   Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173
NR 52
TC 122
Z9 140
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 1998
VL 72
IS 11
BP 8636
EP 8643
DI 10.1128/JVI.72.11.8636-8643.1998
PG 8
WC Virology
SC Virology
GA 127WN
UT WOS:000076373700022
PM 9765403
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU JARVIS, TC
   KIRKEGAARD, K
AF JARVIS, TC
   KIRKEGAARD, K
TI POLIOVIRUS RNA RECOMBINATION - MECHANISTIC STUDIES IN THE ABSENCE OF
   SELECTION
SO EMBO JOURNAL
LA English
DT Article
DE COPY-CHOICE; QUANTITATIVE PCR; RNA RECOMBINATION; RNA VIRUS; TEMPLATE
   SWITCHING
ID POLYMERASE CHAIN-REACTION; VIRUS; DNA; REPLICATION; SEQUENCE; GENOMES;
   CORONAVIRUSES; TRANSCRIPTS; EXPRESSION; EVOLUTION
AB Direct and quantitative detection of recombinant RNA molecules by polymerase chain reaction (PCR) provides a novel method for studying recombination in RNA viruses without selection for viable progeny. The parental poliovirus strains used in this study contained polymorphic marker loci approximately 600 bases apart; both exhibited wild-type growth characteristics. We established conditions under which the amount of PCR product was linearly proportional to the amount of input template, and the reproducibility was high. Recombinant progeny were predominantly homologous and arose at frequencies up to 2 x 10(-3). Recombination events increased in frequency throughout replication, indicating that there is no viral RNA sequestration or inhibition of recombination late in infection as proposed in earlier genetic studies. Previous studies have demonstrated that poliovirus recombination occurs by a copy-choice mechanism in which the viral polymerase switches templates during negative-strand synthesis. Varying the relative amount of input parental virus markedly altered reciprocal recombination frequencies. This, in conjunction with the kinetics data, indicated that acceptor template concentration is a determinant of template switching frequency. Since positive strands greatly outnumber negative strands throughout poliovirus infection, this would explain the bias toward recombination during negative-strand synthesis.
C1 UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA.
   UNIV COLORADO, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-25166]
CR AHLQUIST P, 1987, ADV VIRUS RES, V32, P215, DOI 10.1016/S0065-3527(08)60478-9
   ALLISON R, 1990, P NATL ACAD SCI USA, V87, P1820, DOI 10.1073/pnas.87.5.1820
   ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J
   BANNER LR, 1991, VIROLOGY, V185, P441, DOI 10.1016/0042-6822(91)90795-D
   BERGER SL, 1987, METHOD ENZYMOL, V152, P49
   BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8
   BIENZ K, 1980, VIROLOGY, V100, P390, DOI 10.1016/0042-6822(80)90530-9
   BISHOP JM, 1969, J MOL BIOL, V46, P235, DOI 10.1016/0022-2836(69)90419-7
   BUJARSKI JJ, 1986, NATURE, V321, P528, DOI 10.1038/321528a0
   CASCONE PJ, 1990, EMBO J, V9, P1709, DOI 10.1002/j.1460-2075.1990.tb08294.x
   COMPTON SR, 1990, J VIROL, V64, P4067, DOI 10.1128/JVI.64.9.4067-4075.1990
   COOPER PD, 1968, VIROLOGY, V35, P584, DOI 10.1016/0042-6822(68)90287-0
   Cooper PD, 1977, COMPREHENSIVE VIROLO, V9, P133
   FROHMAN MA, 1990, PCR PROTOCOLS GUIDE, P228
   GAUSS P, 1987, MOL GEN GENET, V206, P24, DOI 10.1007/BF00326532
   GUINEA R, 1990, EMBO J, V9, P2011, DOI 10.1002/j.1460-2075.1990.tb08329.x
   HAHN CS, 1988, P NATL ACAD SCI USA, V85, P5997, DOI 10.1073/pnas.85.16.5997
   HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255
   Horiuchi K., 1975, RNA PHAGES, P29
   JARVIS TC, 1991, TRENDS GENET, V7, P186, DOI 10.1016/0168-9525(91)90434-R
   KEESE P, 1985, P NATL ACAD SCI USA, V82, P4582, DOI 10.1073/pnas.82.14.4582
   KING AMQ, 1988, NUCLEIC ACIDS RES, V16, P11705, DOI 10.1093/nar/16.24.11705
   KING AMQ, 1987, TRENDS GENET, V3, P60, DOI 10.1016/0168-9525(87)90173-9
   KING AMQ, 1988, RNA GENETICS, V2, P149
   KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8
   KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0
   KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999
   LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985
   LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992
   LEDINKO N, 1963, VIROLOGY, V20, P107, DOI 10.1016/0042-6822(63)90145-4
   LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   MANIATIS T, 1982, MOL CLONING
   MCCAHON D, 1981, J GEN VIROL, V53, P333, DOI 10.1099/0022-1317-53-2-333
   MINDICH L, 1992, J VIROL, V66, P2605, DOI 10.1128/JVI.66.5.2605-2610.1992
   NOVAK JE, 1991, J VIROL, V65, P3384, DOI 10.1128/JVI.65.6.3384-3387.1991
   PALASINGAM K, 1992, J VIROL, V66, P2435, DOI 10.1128/JVI.66.4.2435-2442.1992
   RACANIELLO VR, 1981, P NATL ACAD SCI-BIOL, V78, P4887, DOI 10.1073/pnas.78.8.4887
   RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391
   RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624
   RICHARDS OC, 1984, J MOL BIOL, V173, P325, DOI 10.1016/0022-2836(84)90124-4
   ROTT ME, 1991, VIROLOGY, V185, P468, DOI 10.1016/0042-6822(91)90801-H
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SAIKI RK, 1989, POLYMERASE CHAIN REA, P25
   SARNOW P, 1989, J VIROL, V63, P467, DOI 10.1128/JVI.63.1.467-470.1989
   TOLSKAYA EA, 1987, VIROLOGY, V161, P54, DOI 10.1016/0042-6822(87)90170-X
   VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330
   WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717
   ZHANG CX, 1991, VIROLOGY, V184, P791, DOI 10.1016/0042-6822(91)90454-J
   Zimmer A, 1991, Methods Mol Biol, V7, P411, DOI 10.1385/0-89603-178-0:411
NR 50
TC 122
Z9 126
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD AUG
PY 1992
VL 11
IS 8
BP 3135
EP 3145
DI 10.1002/j.1460-2075.1992.tb05386.x
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA JE537
UT WOS:A1992JE53700043
PM 1379178
DA 2020-04-03
ER

PT J
AU SCHULTZE, B
   GROSS, HJ
   BROSSMER, R
   HERRLER, G
AF SCHULTZE, B
   GROSS, HJ
   BROSSMER, R
   HERRLER, G
TI THE S-PROTEIN OF BOVINE CORONAVIRUS IS A HEMAGGLUTININ RECOGNIZING
   9-O-ACETYLATED SIALIC-ACID AS A RECEPTOR DETERMINANT
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID INFLUENZA-C-VIRUS; N-ACETYL-9-O-ACETYLNEURAMINIC ACID; DESTROYING
   ENZYME; GLYCOPROTEIN; ERYTHROCYTES; BINDING; IDENTIFICATION;
   ACETYLESTERASE; ESTERASE
AB The S protein of bovine coronavirus (BCV) has been isolated from the viral membrane and purified by gradient centrifugation.  Purified S protein was identified as a viral hemagglutinin.  Inactivation of the cellular receptors by sialate 9-O-acetylesterase and generation of receptors by sialylation of erythrocytes with N-acetyl-9-O-acetylneuraminic acid (Neu5,9Ac2) indicate that S protein recognizes 9-O-acetylated sialic acid as a receptor determinant as has been shown previously for intact virions.  The second glycoprotein of BCV, HE, which has been thought previously to be responsible for the hemagglutinating activity of BCV, is a less efficient hemagglutinin; it agglutinates mouse and rat erythrocytes, but in contrast to S protein, it is unable to agglutinate chicken erythrocytes, which contain a lower level of Neu5,9Ac2 on their surface.  S protein is proposed to be responsible for the primary attachment of virus to cell surface receptors.  The potential of S protein as a probe for the detection of Neu5,9Ac2-containing glycoconjugates is demonstrated.
C1 UNIV MARBURG,INST VIROL,W-3550 MARBURG,GERMANY.
   UNIV HEIDELBERG,DEPT BIOCHEM 2,W-6900 HEIDELBERG,GERMANY.
CR CAVANAGH D, 1986, J GEN VIROL, V67, P1443, DOI 10.1099/0022-1317-67-7-1443
   CHERESH DA, 1984, J BIOL CHEM, V259, P7453
   COMPANS RW, 1970, VIROLOGY, V42, P880, DOI 10.1016/0042-6822(70)90337-5
   DEA S, 1989, ARCH VIROL, V106, P221, DOI 10.1007/BF01313955
   FORMANOWSKI F, 1988, VIRUS RES, V10, P177, DOI 10.1016/0168-1702(88)90014-7
   HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x
   HERRLER G, 1988, J GEN VIROL, V69, P839, DOI 10.1099/0022-1317-69-4-839
   HERRLER G, 1985, VIRUS RES, V2, P183, DOI 10.1016/0168-1702(85)90248-5
   HERRLER G, 1985, VIROLOGY, V141, P144, DOI 10.1016/0042-6822(85)90190-4
   HERRLER G, 1987, BIOL CHEM H-S, V368, P451, DOI 10.1515/bchm3.1987.368.1.451
   HIERHOLZER JC, 1972, VIROLOGY, V48, P516, DOI 10.1016/0042-6822(72)90062-1
   KING B, 1985, VIRUS RES, V2, P53, DOI 10.1016/0168-1702(85)90059-0
   KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X
   LAVER WG, 1969, VIROLOGY, V38, P105, DOI 10.1016/0042-6822(69)90132-9
   LAVER WG, 1984, VIROLOGY, V137, P314, DOI 10.1016/0042-6822(84)90223-X
   MARKWELL MAK, 1986, MICROBIOL LECTINS AG, P21
   PARKER MD, 1989, J GEN VIROL, V70, P155, DOI 10.1099/0022-1317-70-1-155
   PAULSON JC, 1987, METHOD ENZYMOL, V138, P162
   ROGERS GN, 1986, J BIOL CHEM, V261, P5947
   SCHULTZE B, 1991, VIROLOGY, V180, P221, DOI 10.1016/0042-6822(91)90026-8
   SCHULTZE B, 1990, VIRUS RES, V16, P185, DOI 10.1016/0168-1702(90)90022-4
   SHUKLA AK, 1982, H-S Z PHYSIOL CHEM, V363, P255, DOI 10.1515/bchm2.1982.363.1.255
   STYK B., 1955, FOLIA BIOL [PRAGUE], V1, P207
   VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526
   VLASAK R, 1988, J VIROL, V62, P4686, DOI 10.1128/JVI.62.12.4686-4690.1988
   VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4
NR 26
TC 122
Z9 124
U1 1
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 1991
VL 65
IS 11
BP 6232
EP 6237
DI 10.1128/JVI.65.11.6232-6237.1991
PG 6
WC Virology
SC Virology
GA GL296
UT WOS:A1991GL29600067
PM 1920630
OA Bronze
DA 2020-04-03
ER

PT J
AU KEENAN, KP
   JERVIS, HR
   MARCHWICKI, RH
   BINN, LN
AF KEENAN, KP
   JERVIS, HR
   MARCHWICKI, RH
   BINN, LN
TI INTESTINAL INFECTION OF NEONATAL DOGS WITH CANINE CORONAVIRUS 1-71 -
   STUDIES BY VIROLOGIC, HISTOLOGIC, HISTOCHEMICAL, AND IMMUNOFLUORESCENT
   TECHNIQUES
SO AMERICAN JOURNAL OF VETERINARY RESEARCH
LA English
DT Article
C1 WALTER REED ARMY INST RES,DIV VET MED,WASHINGTON,DC 20012.
   WALTER REED ARMY INST RES,DIV PATHOL,WASHINGTON,DC 20012.
CR BARKA T, 1963, HISTOCHEMISTRY THEOR, P242
   BARKA T, 1963, HISTOCHEMISTRY THEOR, P296
   Becker W B, 1967, J Virol, V1, P1019
   BINN LN, 1967, P SOC EXP BIOL MED, V126, P140, DOI 10.3181/00379727-126-32386
   BINN LN, 1975, 78TH P ANN M US AN H, P359
   BRADBURNE AF, 1971, PROG MED VIROL, V13, P373
   BURSTONE MS, 1961, J HISTOCHEM CYTOCHEM, V9, P146, DOI 10.1177/9.2.146
   CLARK SL, 1959, J BIOPHYS BIOCHEM CY, V5, P41, DOI 10.1083/jcb.5.1.41
   EWING WH, 1970, DIAGNOSTIC PROCEDURE, P227
   HOOPER BE, 1969, CAN J COMPARAT MED, V33, P29
   Kammeraad A, 1942, J MORPHOL, V70, P323, DOI 10.1002/jmor.1050700209
   KAPIKIAN AZ, 1969, DIAGNOSTIC PROCEDURE, P931
   KENT TH, 1966, AM J PATHOL, V48, P667
   LIU C, 1969, DIAGNOSTIC PROCEDURE, P179
   MEBUS CA, 1973, AM J VET RES, V34, P145
   MEBUS CA, 1973, VET PATHOL, V10, P45, DOI 10.1177/030098587301000105
   MENGELING WL, 1972, AM J VET RES, V33, P297
   MOON HW, 1972, VET PATHOL, V9, P3, DOI 10.1177/030098587200900102
   MOON HW, 1971, P SOC EXP BIOL MED, V137, P151, DOI 10.3181/00379727-137-35533
   PARKER JC, 1970, ARCH GES VIRUSFORSCH, V31, P293, DOI 10.1007/BF01253764
   PENSAERT M, 1970, ARCH GES VIRUSFORSCH, V31, P321, DOI 10.1007/BF01253767
   SHEAHAN DG, 1970, AM J PATHOL, V60, P1
   SPICER SS, 1965, J HISTOCHEM CYTOCHEM, V13, P211, DOI 10.1177/13.3.211
   Tajima M, 1970, Arch Gesamte Virusforsch, V29, P105, DOI 10.1007/BF01253886
   WACHSTEIN M, 1956, J HISTOCHEM CYTOCHEM, V4, P592, DOI 10.1177/4.6.592
   WOODE GN, 1975, VET REC, V96, P85, DOI 10.1136/vr.96.4.85
NR 26
TC 122
Z9 122
U1 0
U2 1
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360
SN 0002-9645
J9 AM J VET RES
JI Am. J. Vet. Res.
PY 1976
VL 37
IS 3
BP 247
EP 256
PG 10
WC Veterinary Sciences
SC Veterinary Sciences
GA BH142
UT WOS:A1976BH14200001
PM 1259219
DA 2020-04-03
ER

PT J
AU Lau, SKP
   Li, KSM
   Tsang, AKL
   Lam, CSF
   Ahmed, S
   Chen, HL
   Chan, KH
   Woo, PCY
   Yuen, KY
AF Lau, Susanna K. P.
   Li, Kenneth S. M.
   Tsang, Alan K. L.
   Lam, Carol S. F.
   Ahmed, Shakeel
   Chen, Honglin
   Chan, Kwok-Hung
   Woo, Patrick C. Y.
   Yuen, Kwok-Yung
TI Genetic Characterization of Betacoronavirus Lineage C Viruses in Bats
   Reveals Marked Sequence Divergence in the Spike Protein of Pipistrellus
   Bat Coronavirus HKU5 in Japanese Pipistrelle: Implications for the
   Origin of the Novel Middle East Respiratory Syndrome Coronavirus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID RECEPTOR-BINDING DOMAIN; COMPLETE GENOME; FUNCTIONAL RECEPTOR; AVIAN
   CORONAVIRUSES; DIFFERENT GENOTYPES; MAXIMUM-LIKELIHOOD;
   MOLECULAR-BIOLOGY; CRYSTAL-STRUCTURE; AMINOPEPTIDASE-N; MAJOR RECEPTOR
AB While the novel Middle East respiratory syndrome coronavirus (MERS-CoV) is closely related to Tylonycteris bat CoV HKU4 (Ty-BatCoV HKU4) and Pipistrellus bat CoV HKU5 (Pi-BatCoV HKU5) in bats from Hong Kong, and other potential lineage C betacoronaviruses in bats from Africa, Europe, and America, its animal origin remains obscure. To better understand the role of bats in its origin, we examined the molecular epidemiology and evolution of lineage C betacoronaviruses among bats. Ty-BatCoV HKU4 and Pi-BatCoV HKU5 were detected in 29% and 25% of alimentary samples from lesser bamboo bat (Tylonycteris pachypus) and Japanese pipistrelle (Pipistrellus abramus), respectively. Sequencing of their RNA polymerase (RdRp), spike (S), and nucleocapsid (N) genes revealed that MERS-CoV is more closely related to Pi-BatCoV HKU5 in RdRp (92.1% to 92.3% amino acid [aa] identity) but is more closely related to Ty-BatCoV HKU4 in S (66.8% to 67.4% aa identity) and N (71.9% to 72.3% aa identity). Although both viruses were under purifying selection, the S of Pi-BatCoV HKU5 displayed marked sequence polymorphisms and more positively selected sites than that of Ty-BatCoV HKU4, suggesting that Pi-BatCoV HKU5 may generate variants to occupy new ecological niches along with its host in diverse habitats. Molecular clock analysis showed that they diverged from a common ancestor with MERS-CoV at least several centuries ago. Although MERS-CoV may have diverged from potential lineage C betacoronaviruses in European bats more recently, these bat viruses were unlikely to be the direct ancestor of MERS-CoV. Intensive surveillance for lineage C betaCoVs in Pipistrellus and related bats with diverse habitats and other animals in the Middle East may fill the evolutionary gap.
C1 [Lau, Susanna K. P.; Woo, Patrick C. Y.; Yuen, Kwok-Yung] Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Lau, Susanna K. P.; Woo, Patrick C. Y.; Yuen, Kwok-Yung] Univ Hong Kong, Res Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China.
   [Lau, Susanna K. P.; Woo, Patrick C. Y.; Yuen, Kwok-Yung] Univ Hong Kong, Carol Yu Ctr Infect, Hong Kong, Hong Kong, Peoples R China.
   [Lau, Susanna K. P.; Li, Kenneth S. M.; Tsang, Alan K. L.; Lam, Carol S. F.; Ahmed, Shakeel; Chen, Honglin; Chan, Kwok-Hung; Woo, Patrick C. Y.; Yuen, Kwok-Yung] Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
EM pcywoo@hkucc.hku.hk; kyyuen@hkucc.hku.hk
RI Woo, Patrick Chiu Yat/AAJ-6112-2020; Chen, Honglin/C-4224-2009; Lau,
   Susanna Kar Pui/AAJ-6848-2020
OI Woo, Patrick Chiu Yat/0000-0001-9401-1832; Chen,
   Honglin/0000-0001-5108-8338; Lau, Susanna Kar Pui/0000-0002-1383-7374;
   Yuen, Kwok-yung/0000-0002-2083-1552
FU Research Grant Council Grant, University Grant Council; The University
   of Hong KongUniversity of Hong Kong; HKSAR Research Fund for the Control
   of Infectious Diseases of the Food and Health Bureau; Shaw Foundation;
   Providence Foundation Limited; Consultancy Service for Enhancing
   Laboratory Surveillance of Emerging Infectious Disease for the HKSAR
   Department of Health
FX We are grateful for the generous support of Carol Yu, Richard Yu, Hui
   Hoy, and Hui Ming in the genomic sequencing platform. This work was
   partly supported by the Research Grant Council Grant, University Grant
   Council; Strategic Research Theme Fund and University Development Fund,
   The University of Hong Kong; HKSAR Research Fund for the Control of
   Infectious Diseases of the Food and Health Bureau; Shaw Foundation;
   Providence Foundation Limited in memory of the late Lui Hac Minh; a
   donation from Eunice Lam; and the Consultancy Service for Enhancing
   Laboratory Surveillance of Emerging Infectious Disease for the HKSAR
   Department of Health.
CR AlBarrak AM, 2012, SAUDI MED J, V33, P1265
   Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Anthony SJ, 2013, J GEN VIROL, V94, P1028, DOI 10.1099/vir.0.049759-0
   Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37
   Baker SC, 2013, J VIROL
   Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   Buchholz U., 2013, Eurosurveillance, V18, P20406
   Chan JFW, 2013, J INFECT DIS, V207, P1743, DOI 10.1093/infdis/jit123
   Chan RWY, 2013, J VIROL, V87, P6604, DOI 10.1128/JVI.00009-13
   Chan WE, 2006, J VIROL, V80, P3225, DOI 10.1128/JVI.80.7.3225-3237.2006
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   de Groot RJ, 2011, VIRUS TAXONOMY, P806
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   Dominguez SR, 2007, EMERG INFECT DIS, V13, P1295, DOI 10.3201/eid1309.070491
   Dong BQ, 2007, J VIROL, V81, P6920, DOI 10.1128/JVI.00299-07
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Gloza-Rausch F, 2008, EMERG INFECT DIS, V14, P626, DOI 10.3201/eid1404.071439
   GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Hasoksuz M, 2007, J VIROL, V81, P4981, DOI 10.1128/JVI.02361-06
   Herrewegh AAPM, 1998, J VIROL, V72, P4508, DOI 10.1128/JVI.72.5.4508-4514.1998
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Hofmann H, 2006, J VIROL, V80, P8639, DOI 10.1128/JVI.00560-06
   Jiang SB, 2013, J INFECTION, V66, P464, DOI 10.1016/j.jinf.2012.12.003
   Johara MY, 2001, EMERG INFECT DIS, V7, P439
   Kindler E, 2013, MBIO, V4, DOI 10.1128/mBio.00611-12
   Krempl C, 1995, Adv Exp Med Biol, V380, P371
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2007, VIROLOGY, V367, P428, DOI 10.1016/j.virol.2007.06.009
   Lau SKP, 2012, J VIROL, V86, P11906, DOI 10.1128/JVI.01305-12
   Lau SKP, 2012, J VIROL, V86, P5481, DOI 10.1128/JVI.06927-11
   Lau SKP, 2011, J VIROL, V85, P11325, DOI 10.1128/JVI.05512-11
   Lau SKP, 2010, J VIROL, V84, P11385, DOI 10.1128/JVI.01121-10
   Lau SKP, 2010, J VIROL, V84, P2808, DOI 10.1128/JVI.02219-09
   Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Mihindukulasuriya KA, 2008, J VIROL, V82, P5084, DOI 10.1128/JVI.02722-07
   Muller MA, 2012, MBIO, V3, DOI 10.1128/mBio.00515-12
   Munster VJ, 2013, NEW ENGL J MED, V368, P1560, DOI 10.1056/NEJMc1215691
   Murrell B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002764
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peng GQ, 2011, P NATL ACAD SCI USA, V108, P10696, DOI 10.1073/pnas.1104306108
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pond SLK, 2005, BIOINFORMATICS, V21, P2531, DOI 10.1093/bioinformatics/bti320
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Pyrc K, 2006, J MOL BIOL, V364, P964, DOI 10.1016/j.jmb.2006.09.074
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   SCHULTZE B, 1992, J GEN VIROL, V73, P901, DOI 10.1099/0022-1317-73-4-901
   Shek CT, 2006, FIELD GUIDE TERRESTR, P108
   Smits SL, 2005, J BIOL CHEM, V280, P6933, DOI 10.1074/jbc.M409683200
   Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175
   Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Tang XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06
   Teeling EC, 2005, SCIENCE, V307, P580, DOI 10.1126/science.1105113
   Tong SX, 2012, P NATL ACAD SCI USA, V109, P4269, DOI 10.1073/pnas.1116200109
   Tong SX, 2009, EMERG INFECT DIS, V15, P482, DOI 10.3201/eid1503.081013
   Trigg J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023519
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vijgen L, 2005, J VIROL, V79, P1595, DOI 10.1128/JVI.79.3.1595-1604.2005
   VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526
   Vlasova AN, 2011, J GEN VIROL, V92, P1369, DOI 10.1099/vir.0.025353-0
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Woo PCY, 2006, J VIROL, V80, P7136, DOI 10.1128/JVI.00509-06
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.45
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   Woo PCY, 2009, J VIROL, V83, P908, DOI 10.1128/JVI.01977-08
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   World Health Organization, 2013, GLOB AL RESP NOV COR
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zeng QH, 2008, P NATL ACAD SCI USA, V105, P9065, DOI 10.1073/pnas.0800502105
   Zhou T, 2004, J VIROL, V78, P7217, DOI 10.1128/JVI.78.13.7217-7226.2004
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
   Zielecki F, 2013, J VIROL, V87, P5300, DOI 10.1128/JVI.03496-12
NR 91
TC 121
Z9 124
U1 0
U2 37
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD AUG
PY 2013
VL 87
IS 15
BP 8638
EP 8650
DI 10.1128/JVI.01055-13
PG 13
WC Virology
SC Virology
GA 180JO
UT WOS:000321590200033
PM 23720729
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Greninger, AL
   Chen, EC
   Sittler, T
   Scheinerman, A
   Roubinian, N
   Yu, GX
   Kim, E
   Pillai, DR
   Guyard, C
   Mazzulli, T
   Isa, P
   Arias, CF
   Hackett, J
   Schochetman, G
   Miller, S
   Tang, P
   Chiu, CY
AF Greninger, Alexander L.
   Chen, Eunice C.
   Sittler, Taylor
   Scheinerman, Alex
   Roubinian, Nareg
   Yu, Guixia
   Kim, Edward
   Pillai, Dylan R.
   Guyard, Cyril
   Mazzulli, Tony
   Isa, Pavel
   Arias, Carlos F.
   Hackett, John, Jr.
   Schochetman, Gerald
   Miller, Steve
   Tang, Patrick
   Chiu, Charles Y.
TI A Metagenomic Analysis of Pandemic Influenza A (2009 H1N1) Infection in
   Patients from North America
SO PLOS ONE
LA English
DT Article
ID FLUCHIP DIAGNOSTIC MICROARRAY; RESPIRATORY-TRACT INFECTIONS; VIRUS;
   IDENTIFICATION; CORONAVIRUS; HUMANS
AB Although metagenomics has been previously employed for pathogen discovery, its cost and complexity have prevented its use as a practical front-line diagnostic for unknown infectious diseases. Here we demonstrate the utility of two metagenomics-based strategies, a pan-viral microarray (Virochip) and deep sequencing, for the identification and characterization of 2009 pandemic H1N1 influenza A virus. Using nasopharyngeal swabs collected during the earliest stages of the pandemic in Mexico, Canada, and the United States (n = 17), the Virochip was able to detect a novel virus most closely related to swine influenza viruses without a priori information. Deep sequencing yielded reads corresponding to 2009 H1N1 influenza in each sample ( percentage of aligned sequences corresponding to 2009 H1N1 ranging from 0.0011% to 10.9%), with up to 97% coverage of the influenza genome in one sample. Detection of 2009 H1N1 by deep sequencing was possible even at titers near the limits of detection for specific RT-PCR, and the percentage of sequence reads was linearly correlated with virus titer. Deep sequencing also provided insights into the upper respiratory microbiota and host gene expression in response to 2009 H1N1 infection. An unbiased analysis combining sequence data from all 17 outbreak samples revealed that 90% of the 2009 H1N1 genome could be assembled de novo without the use of any reference sequence, including assembly of several near full-length genomic segments. These results indicate that a streamlined metagenomics detection strategy can potentially replace the multiple conventional diagnostic tests required to investigate an outbreak of a novel pathogen, and provide a blueprint for comprehensive diagnosis of unexplained acute illnesses or outbreaks in clinical and public health settings.
C1 [Greninger, Alexander L.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.
   [Chen, Eunice C.; Sittler, Taylor; Scheinerman, Alex; Yu, Guixia; Miller, Steve; Chiu, Charles Y.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Chen, Eunice C.; Sittler, Taylor; Scheinerman, Alex; Yu, Guixia; Miller, Steve; Chiu, Charles Y.] Univ Calif San Francisco, UCSF Abbott Viral Diagnost & Discovery Ctr, San Francisco, CA 94143 USA.
   [Roubinian, Nareg; Chiu, Charles Y.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Kim, Edward; Tang, Patrick] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.
   [Kim, Edward; Tang, Patrick] British Columbia Ctr Dis Control, Vancouver, BC, Canada.
   [Pillai, Dylan R.; Guyard, Cyril; Mazzulli, Tony] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Pillai, Dylan R.; Guyard, Cyril] Ontario Agcy Hlth Protect & Promot, Toronto, ON, Canada.
   [Mazzulli, Tony] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
   [Isa, Pavel; Arias, Carlos F.] Univ Nacl Autonoma Mexico, Inst Biotechnol, Cuernavaca, Morelos, Mexico.
   [Hackett, John, Jr.; Schochetman, Gerald] Abbott Diagnost, Abbott Pk, IL USA.
RP Greninger, AL (reprint author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.
EM charles.chiu@ucsf.edu
RI Arias, Carlos/O-4036-2019
OI Arias, Carlos/0000-0003-3130-4501; Greninger,
   Alexander/0000-0002-7443-0527; Tripp, Ralph/0000-0002-2924-9956; Chiu,
   Charles/0000-0003-2915-2094; , cyril/0000-0002-2721-0097; Tang,
   Patrick/0000-0003-1583-5484
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [AI074913];
   Kleine-Levin Syndrome Foundation; Abbott Diagnostics, Inc.Abbott
   Laboratories; Amazon, Inc.
FX C.Y.C. is supported by National Institutes of Health (NIH) K08 grant
   AI074913, a grant from the Kleine-Levin Syndrome Foundation, and a viral
   discovery award from Abbott Diagnostics, Inc. The authors also
   acknowledge an Amazon Web Services (AWS) grant to T. S., A. G., and
   C.Y.C. from Amazon, Inc., for high-performance computation on the
   Elastic Compute Cloud (EC2) platform. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Arnulf I, 2008, ANN NEUROL, V63, P482, DOI 10.1002/ana.21333
   Briese T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000455
   Chiu CY, 2008, P NATL ACAD SCI USA, V105, P14124, DOI 10.1073/pnas.0805968105
   Chiu CY, 2008, J PEDIATR-US, V153, P76, DOI 10.1016/j.jpeds.2007.12.035
   Chiu CY, 2006, CLIN INFECT DIS, V43, pE71, DOI 10.1086/507896
   Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810
   DEYDE VM, 2009, ANTIMICROB AGENTS CH
   Dohm JC, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn425
   Drummond AJ, 2009, GENEIOUS V4 7
   Eid J, 2009, SCIENCE, V323, P133, DOI 10.1126/science.1162986
   Faix DJ, 2009, NEW ENGL J MED, V361, P728, DOI 10.1056/NEJMc0904264
   Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586
   Finkbeiner SR, 2009, J VIROL, V83, P10836, DOI 10.1128/JVI.00998-09
   Fischer N, 2010, EMERG INFECT DIS, V16, P1000, DOI 10.3201/eid1606.100066
   Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062
   Ganev PN, 2010, LITHOSPHERE-US, V2, P33, DOI 10.1130/L51.1
   Greninger AL, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-82
   *GROUP NHW, 2009, GENOME RES, V19, P2317
   HALE BG, 2010, J VIROL
   Kistler A, 2007, J INFECT DIS, V196, P817, DOI 10.1086/520816
   Kistler AL, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-88
   Kuroda M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010256
   Lee CWH, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq089
   LI L, 2010, J VIROL
   Li LL, 2010, J VIROL, V84, P1674, DOI 10.1128/JVI.02109-09
   Lin BC, 2006, GENOME RES, V16, P527, DOI 10.1101/gr.4337206
   Lombardi VC, 2009, SCIENCE, V326, P585, DOI 10.1126/science.1179052
   Louie JK, 2010, NEW ENGL J MED, V362, P27, DOI 10.1056/NEJMoa0910444
   Lu Q, 2009, J CLIN MICROBIOL, V47, P3060, DOI 10.1128/JCM.01243-09
   Martinez DA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000906
   Mehlmann M, 2006, J CLIN MICROBIOL, V44, P2857, DOI 10.1128/JCM.00135-06
   Mi HY, 2009, METHODS MOL BIOL, V563, P123, DOI 10.1007/978-1-60761-175-2_7
   Nakamura S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004219
   Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201
   Palacios G, 2008, NEW ENGL J MED, V358, P991, DOI 10.1056/NEJMoa073785
   Palacios G, 2007, EMERG INFECT DIS, V13, P73, DOI 10.3201/eid1301.060837
   Palacios G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008540
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Shinde V, 2009, NEW ENGL J MED, V360, P2616, DOI 10.1056/NEJMoa0903812
   Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182
   Sorber K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003495
   Stewart FJ, 2010, ISME J, V4, P896, DOI 10.1038/ismej.2010.18
   Tang P, 2010, FUTURE MICROBIOL, V5, P177, DOI [10.2217/fmb.09.120, 10.2217/FMB.09.120]
   Thompson B, 2002, PORTAL-LIBR ACAD, V2, P3, DOI 10.1353/pla.2002.0022
   Townsend MB, 2006, J CLIN MICROBIOL, V44, P2863, DOI 10.1128/JCM.00134-06
   Treanor J, 2004, NEW ENGL J MED, V350, P218, DOI 10.1056/NEJMp038238
   Urisman A, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r78
   Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025
   Victoria JG, 2009, J VIROL, V83, P4642, DOI 10.1128/JVI.02301-08
   Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699
   Wang D, 2003, PLOS BIOL, V1, P257, DOI 10.1371/journal.pbio.0000002
   Wang Z, 2006, EMERG INFECT DIS, V12, P638, DOI 10.3201/eid1204.051441
   Willner D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007370
   Zhang HW, 2006, INT J MULTISCALE COM, V4, P3, DOI 10.1615/IntJMultCompEng.v4.i1.20
NR 55
TC 121
Z9 132
U1 1
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 18
PY 2010
VL 5
IS 10
AR e13381
DI 10.1371/journal.pone.0013381
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 665ON
UT WOS:000283045300008
PM 20976137
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Haijema, BJ
   Volders, H
   Rottier, PJM
AF Haijema, BJ
   Volders, H
   Rottier, PJM
TI Live, attenuated coronavirus vaccines through the directed deletion of
   group-specific genes provide protection against feline infectious
   peritonitis
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ANTIBODY-DEPENDENT ENHANCEMENT; CANINE CORONAVIRUS; FIPV VACCINE;
   ATTEMPTED IMMUNIZATION; INDEPENDENT EVALUATION; MEDIATED ENHANCEMENT;
   MONOCLONAL-ANTIBODY; VIRUS-REPLICATION; SPIKE PROTEIN; CATS
AB Feline infectious peritonitis (FIP) is a fatal immunity-mediated disease caused by mutants of a ubiquitous coronavirus. Since previous attempts to protect cats under laboratory and field conditions have been largely unsuccessful, we used our recently developed system of reverse genetics (B. J. Haijema, H. Volders, and P. J. M. Rottier, J. Virol. 77:4528-4538, 2003) for the development of a modified live FIP vaccine. With this objective, we deleted the group-specific gene cluster open reading frame 3abc or 7ab and obtained deletion mutant viruses that not only multiplied well in cell culture but also showed an attenuated phenotype in the cat. At doses at which the wild-type virus would be fatal, the mutants with gene deletions did not cause any clinical symptoms. They still induced an immune response, however, as judged from the high levels of virus-neutralizing antibodies. The FIP virus (FIPV) mutant lacking the 3abc cluster and, to a lesser extent, the mutant missing the 7ab cluster, protected cats against a lethal homologous challenge; no protection was obtained with the mutant devoid of both gene clusters. Our studies show that the deletion of group-specific genes from the coronavirus genome results in live attenuated candidate vaccines against FIPV. More generally, our approach may allow the development of vaccines against infections with other pathogenic coronaviruses, including that causing severe acute respiratory syndrome in humans.
C1 Univ Utrecht, Fac Vet Med, Dept Immunol & Infect Dis, Inst Virol, NL-3584 CL Utrecht, Netherlands.
RP Rottier, PJM (reprint author), Univ Utrecht, Fac Vet Med, Inst Virol, POB 80-165, NL-3508 TD Utrecht, Netherlands.
EM P.Rottier@vet.uu.nl
CR ADDIE DD, 1992, VET REC, V130, P133, DOI 10.1136/vr.130.7.133
   BARLOUGH JE, 1984, LAB ANIM SCI, V34, P592
   BARLOUGH JE, 1985, AVIAN DIS, V29, P613
   Cavanagh D., 1995, CORONAVIRIDAE, P73
   CORAPI WV, 1992, J VIROL, V66, P6695, DOI 10.1128/JVI.66.11.6695-6705.1992
   Curtis KM, 2002, J VIROL, V76, P1422, DOI 10.1128/JVI.76.3.1422-1434.2002
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   Fehr D, 1997, VACCINE, V15, P1101, DOI 10.1016/S0264-410X(97)00006-6
   GERBER JD, 1990, VACCINE, V8, P536, DOI 10.1016/0264-410X(90)90004-6
   GERBER JD, 1995, FELINE PRACT, V23, P62
   Glansbeek HL, 2002, J GEN VIROL, V83, P1, DOI 10.1099/0022-1317-83-1-1
   Groot R. J. de, 1995, The coronaviridae., P293
   Haijema BJ, 2003, J VIROL, V77, P4528, DOI 10.1128/JVI.77.8.4528-4538.2003
   Herrewegh AAPM, 1997, VIROLOGY, V234, P349, DOI 10.1006/viro.1997.8663
   Herrewegh AAPM, 1998, J VIROL, V72, P4508, DOI 10.1128/JVI.72.5.4508-4514.1998
   HERREWEGH AAPM, 1995, VIROLOGY, V212, P622, DOI 10.1006/viro.1995.1520
   Hohdatsu T, 1998, J VET MED SCI, V60, P49, DOI 10.1292/jvms.60.49
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   LOEFFLER DG, 1978, FELINE PRACT, V8, P43
   MCARDLE F, 1995, FELINE PRACT, V23, P67
   MCKEIRNAN AJ, 1981, FELINE PRACT, V11, P16
   Motokawa K, 1996, MICROBIOL IMMUNOL, V40, P425, DOI 10.1111/j.1348-0421.1996.tb01089.x
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   OCHIAI H, 1992, J MED VIROL, V36, P217, DOI 10.1002/jmv.1890360312
   OLSEN CW, 1992, J VIROL, V66, P956, DOI 10.1128/JVI.66.2.956-965.1992
   Ontiveros E, 2001, VIROLOGY, V289, P230, DOI 10.1006/viro.2001.1167
   Ortego J, 2003, VIROLOGY, V308, P13, DOI 10.1016/S0042-6822(02)00096-X
   Pedersen N C, 1987, Adv Exp Med Biol, V218, P529
   PEDERSEN NC, 1976, AM J VET RES, V37, P1449
   PEDERSEN NC, 1983, AM J VET RES, V44, P229
   PEDERSEN NC, 1985, COMP CONT EDUC PRACT, V7, P1001
   PEDERSEN NC, 1984, AM J VET RES, V45, P2580
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   PEIRIS JSM, 1979, NATURE, V282, P509, DOI 10.1038/282509a0
   PORTERFIELD JS, 1986, ADV VIRUS RES, V31, P335, DOI 10.1016/S0065-3527(08)60268-7
   SCOTT FW, 1995, FELINE PRACT, V23, P74
   SIDDELL SG, 1995, CORONAVIRIDAE, P1
   Sola I, 2003, J VIROL, V77, P4357, DOI 10.1128/JVI.77.7.4357-4369.2003
   STODDART CA, 1988, RES VET SCI, V45, P383, DOI 10.1016/S0034-5288(18)30970-6
   TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   Vennema H, 1998, VIROLOGY, V243, P150, DOI 10.1006/viro.1998.9045
   VENNEMA H, 1991, VIROLOGY, V181, P327, DOI 10.1016/0042-6822(91)90499-2
   WEISS RC, 1981, COMP IMMUNOL MICROB, V4, P175, DOI 10.1016/0147-9571(81)90003-5
   WOODS RD, 1979, VET MICROBIOL, V4, P11, DOI 10.1016/0378-1135(79)90025-7
NR 46
TC 121
Z9 137
U1 0
U2 14
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD APR
PY 2004
VL 78
IS 8
BP 3863
EP 3871
DI 10.1128/JVI.78.8.3863-3871.2004
PG 9
WC Virology
SC Virology
GA 809MU
UT WOS:000220641600008
PM 15047802
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Vijaykrishna, D
   Smith, GJD
   Zhang, JX
   Peiris, JSM
   Chen, H
   Guan, Y
AF Vijaykrishna, D.
   Smith, G. J. D.
   Zhang, J. X.
   Peiris, J. S. M.
   Chen, H.
   Guan, Y.
TI Evolutionary insights into the ecology of coronaviruses
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID RESPIRATORY-SYNDROME CORONAVIRUS; SARS-CORONAVIRUS; GENETIC ALGORITHM;
   GENOME SEQUENCE; PALM CIVET; VIRUS; RESERVOIRS; BATS; CHINA; PNEUMONIA
AB Although many novel members of the Coronaviridae have recently been recognized in different species, the ecology of coronaviruses has not been established. Our study indicates that bats harbor a much wider diversity of coronaviruses than any other animal species. Dating of different coronavirus lineages suggests that bat coronaviruses are older than those recognized in other animals and that the human severe acute respiratory syndrome (SARS) coronavirus was directly derived from viruses from wild animals in wet markets of southern China. Furthermore, the most closely related bat and SARS coronaviruses diverged in 1986, an estimated divergence time of 17 years prior to the outbreak, suggesting that there may have been transmission via an unknown intermediate host. Analysis of lineage-specific selection pressure also indicated that only SARS coronaviruses in civets and humans were under significant positive selection, also demonstrating a recent interspecies transmission. Analysis of population dynamics revealed that coronavirus populations in bats have constant population growth, while viruses from all other hosts show epidemic-like increases in population. These results indicate that diverse coronaviruses are endemic in different bat species, with repeated introductions to other animals and occasional establishment in other species. Our findings suggest that bats are likely the natural hosts for all presently known coronavirus lineages and that all coronaviruses recognized in other species were derived from viruses residing in bats. Further surveillance of bat and other animal populations is needed to fully describe the ecology and evolution of this virus family.
C1 Univ Hong Kong, State Key Lab Emerging Infect Dis, Dept Microbiol, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
RP Guan, Y (reprint author), Univ Hong Kong, State Key Lab Emerging Infect Dis, Dept Microbiol, Li Ka Shing Fac Med, Bldg 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.
EM yguan@hku.hk
RI Chen, Honglin/C-4224-2009; Dhanasekaran, Vijaykrishna/D-1011-2010;
   Vijaykrishna, Dhanasekaran/AAG-2077-2020; Chen, Guanhua/D-3056-2009;
   Zhang, Jinxia/C-4470-2009; Peiris, Joseph Sriyal Malik/C-4380-2009
OI Chen, Honglin/0000-0001-5108-8338; Dhanasekaran,
   Vijaykrishna/0000-0003-3293-6279; Vijaykrishna,
   Dhanasekaran/0000-0003-3293-6279; Peiris, Joseph Sriyal
   Malik/0000-0001-8217-5995; Smith, Gavin JD/0000-0001-5031-468X; Guan,
   Yi/0000-0001-6057-9243
CR Arbogast BS, 2002, ANNU REV ECOL SYST, V33, P707, DOI 10.1146/annurev.ecolsys.33.010802.150500
   AVISE JC, 1987, ANNU REV ECOL SYST, V18, P489, DOI 10.1146/annurev.ecolsys.18.1.489
   BAKER JAMES K., 1962, CONDOR, V64, P500, DOI 10.2307/1365473
   Bininda-Emonds ORP, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-156
   Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432
   DALPLANE JP, 1941, RHODE ISLAND AGR EXP, V284, P4
   DOYLE LP, 1946, J AM VET MED ASSOC, V108, P257
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Haydon DT, 2002, EMERG INFECT DIS, V8, P1468
   He RT, 2004, BIOCHEM BIOPH RES CO, V316, P476, DOI 10.1016/j.bbrc.2004.02.074
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Keele BF, 2006, SCIENCE, V313, P523, DOI 10.1126/science.1126531
   Pond SLK, 2006, MOL BIOL EVOL, V23, P1891, DOI 10.1093/molbev/msl051
   Lai M.M.C., 2001, FIELDS VIROLOGY, P1163
   Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   MANAKER RA, 1961, JNCI-J NATL CANCER I, V27, P29
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MCKEIRNAN AJ, 1981, FELINE PRACT, V11, P16
   PENSAERT MB, 1974, ARCH GES VIRUSFORSCH, V44, P35, DOI 10.1007/BF01242179
   PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606
   Pond SLK, 2005, MOL BIOL EVOL, V22, P478, DOI 10.1093/molbev/msi031
   Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079
   Shackelton LA, 2005, P NATL ACAD SCI USA, V102, P379, DOI 10.1073/pnas.0406765102
   Shimodaira H, 1999, MOL BIOL EVOL, V16, P1114, DOI 10.1093/oxfordjournals.molbev.a026201
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Storz J, 2000, J CLIN MICROBIOL, V38, P3291, DOI 10.1128/JCM.38.9.3291-3298.2000
   Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393
   Swofford DL, 2001, PAUP PHYLOGENETIC AN
   Tang XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Tu CC, 2004, EMERG INFECT DIS, V10, P2244, DOI 10.3201/eid1012.040520
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vijgen L, 2005, J VIROL, V79, P1595, DOI 10.1128/JVI.79.3.1595-1604.2005
   Vijgen L, 2006, J VIROL, V80, P7270, DOI 10.1128/JVI.02675-05
   Wang M, 2005, EMERG INFECT DIS, V11, P1860, DOI 10.3201/eid1112.041293
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   Xu RH, 2004, EMERG INFECT DIS, V10, P1030, DOI 10.3201/eid1006.030852
   Zeng FY, 2003, EXP BIOL MED, V228, P866, DOI 10.1177/15353702-0322807-13
NR 47
TC 120
Z9 124
U1 1
U2 22
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD APR
PY 2007
VL 81
IS 8
BP 4012
EP 4020
DI 10.1128/JVI.02605-06
PG 9
WC Virology
SC Virology
GA 157BF
UT WOS:000245692900033
PM 17267506
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Kan, B
   Wang, M
   Jing, HQ
   Xu, HF
   Jiang, XG
   Yan, MY
   Liang, WL
   Zheng, H
   Wan, KL
   Liu, QY
   Cui, BY
   Xu, YM
   Zhang, EM
   Wang, HX
   Ye, JR
   Li, GH
   Li, MH
   Cui, ZG
   Qi, XB
   Chen, K
   Du, L
   Gao, K
   Zhao, YT
   Zou, XZ
   Feng, YJ
   Gao, YF
   Hai, R
   Yu, DZ
   Guan, Y
   Xu, JG
AF Kan, B
   Wang, M
   Jing, HQ
   Xu, HF
   Jiang, XG
   Yan, MY
   Liang, WL
   Zheng, H
   Wan, KL
   Liu, QY
   Cui, BY
   Xu, YM
   Zhang, EM
   Wang, HX
   Ye, JR
   Li, GH
   Li, MH
   Cui, ZG
   Qi, XB
   Chen, K
   Du, L
   Gao, K
   Zhao, YT
   Zou, XZ
   Feng, YJ
   Gao, YF
   Hai, R
   Yu, DZ
   Guan, Y
   Xu, JG
TI Molecular evolution analysis and geographic investigation of severe
   acute respiratory syndrome coronavirus-like virus in palm civets at an
   animal market and on farms
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SARS-CORONAVIRUS; GENOME SEQUENCE; EPIDEMIOLOGY; PNEUMONIA; INFECTION;
   OUTBREAK; RECEPTOR
AB Massive numbers of palm civets were culled to remove sources for the reemergence of severe acute respiratory syndrome (SARS) in Guangdong Province, China, in January 2004, following SARS coronavirus detection in market animals. The virus was identified in all 91 palm civets and 15 raccoon dogs of animal market origin sampled prior to culling, but not in 1,107 palm civets later sampled at 25 farms, spread over 12 provinces, which were claimed to be the source of traded animals. Twenty-seven novel signature variation residues (SNVs) were identified on the spike gene and were analyzed for their phylogenetic relationships, based on 17 sequences obtained from animals in our study and from other published studies. Analysis indicated that the virus in palm civets at the live-animal market had evolved to infect humans. The evolutionary starting point was a prototype group consisting of three viral sequences of animal origin. Initially, seven SNV sites caused six amino acid changes, at positions 147, 228, 240, 479, 821, and 1080 of the spike protein, to generate low-pathogenicity viruses. One of these was linked to the first SARS patient in the 2003-2004 period. A further 14 SNVs caused 11 amino acid residue changes, at positions 360, 462, 472, 480, 487, 609, 613, 665, 743, 765, and 1163. The resulting high-pathogenicity groups were responsible for infections during the so-called early-phase epidemic of 2003. Finally, the remaining six SNVs caused four amino acid changes, at positions 227, 244, 344, and 778, which resulted in the group of viruses responsible for the global epidemic.
C1 Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, Beijing 102206, Peoples R China.
   Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing 102206, Peoples R China.
   Guangzhou Ctr Dis Control & Prevent, Guangzhou 510080, Guangdong, Peoples R China.
   Univ Hong Kong, Hong Kong Special Adm Reg, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
RP Xu, JG (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, POB 5, Beijing 102206, Peoples R China.
EM xujg@public.bta.net.cn
RI Wang, Hongxia/G-6655-2018
OI Guan, Yi/0000-0001-6057-9243
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI051915, U19 AI51915]
CR Antia R, 2003, NATURE, V426, P658, DOI 10.1038/nature02104
   Bi Shengli, 2003, Genomics Proteomics & Bioinformatics, V1, P180
   Chim SSC, 2003, LANCET, V362, P1807, DOI 10.1016/S0140-6736(03)14901-X
   Guan Y, 2004, LANCET, V363, P99, DOI 10.1016/S0140-6736(03)15259-2
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Herrmann LM, 2004, VIRUS RES, V102, P215, DOI 10.1016/j.virusres.2004.02.001
   Kliger Y, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-20
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Li LJ, 2003, CHINESE MED J-PEKING, V116, P1288
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Liang GD, 2004, EMERG INFECT DIS, V10, P1774, DOI 10.3201/eid1010.040445
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Ng EKO, 2003, CLIN CHEM, V49, P1976, DOI 10.1373/clinchem.2003.024125
   Normile D, 2004, SCIENCE, V303, P292, DOI 10.1126/science.303.5656.292
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Qin E'de, 2003, Genomics Proteomics & Bioinformatics, V1, P101
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Sui JH, 2005, J VIROL, V79, P5900, DOI 10.1128/JVI.79.10.5900-5906.2005
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Tsui SKW, 2003, NEW ENGL J MED, V349, P187, DOI 10.1056/NEJM200307103490216
   Tu CC, 2004, EMERG INFECT DIS, V10, P2244, DOI 10.3201/eid1012.040520
   Webster RG, 2004, LANCET, V363, P234, DOI 10.1016/S0140-6736(03)15329-9
   Wu DL, 2005, J VIROL, V79, P2620, DOI 10.1128/JVI.79.4.2620-2625.2005
   Wu XW, 2003, CHINESE MED J-PEKING, V116, P988
   Yeh SH, 2004, P NATL ACAD SCI USA, V101, P2542, DOI 10.1073/pnas.0307904100
   Zeng FY, 2003, EXP BIOL MED, V228, P866, DOI 10.1177/15353702-0322807-13
NR 32
TC 120
Z9 139
U1 2
U2 27
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2005
VL 79
IS 18
BP 11892
EP 11900
DI 10.1128/JVI.79.18.11892-11900.2005
PG 9
WC Virology
SC Virology
GA 961AI
UT WOS:000231633900034
PM 16140765
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU He, YX
   Zhou, YS
   Liu, SW
   Kou, ZH
   Li, WH
   Farzan, M
   Jiang, SB
AF He, YX
   Zhou, YS
   Liu, SW
   Kou, ZH
   Li, WH
   Farzan, M
   Jiang, SB
TI Receptor-binding domain of SARS-CoV spike protein induces highly potent
   neutralizing antibodies: implication for developing subunit vaccine
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE SARS-CoV; spike protein; receptor-binding domain; neutralizing antibody;
   vaccine
ID ACUTE RESPIRATORY SYNDROME; IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTIOUS
   PERITONITIS VIRUS; ANGIOTENSIN-CONVERTING ENZYME-2; HUMAN
   MONOCLONAL-ANTIBODY; SYNDROME CORONAVIRUS; DEPENDENT ENHANCEMENT;
   FUNCTIONAL-CHARACTERIZATION; ENHANCING ANTIBODIES; FUSION PROTEIN
AB The spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (CoV), a type I transmembrane envelope glycoprotein. consists of S1 and S2 domains responsible for virus binding and fusion, respectively. The S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. Here we show that a recombinant fusion protein (designated RBD-Fc) containing 193-amino acid RBD (residues 318-510) and a human IgG1 Fc fragment can induce highly potent antibody responses in the immunized rabbits. The antibodies recognized RBD on SI domain and completely inhibited SARS-CoV infection at a serum dilution of 1:10,240. Rabbit antisera effectively blocked binding of SI, which contains RBD, to ACE2. This suggests that RBD can induce highly potent neutralizing antibody responses and has potential to be developed as an effective and safe subunit vaccine for prevention of SARS. (C) 2004 Elsevier Inc. All rights reserved.
C1 New York Blood Ctr, Lindsley F Kimball Res Inst, Viral Immunol Lab, New York, NY 10021 USA.
   Beijing Inst Microbiol & Epidemiol, Dept Biol Mol, Beijing 100071, Peoples R China.
   Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Partners AIDS Res Ctr, Boston, MA 02115 USA.
RP Jiang, SB (reprint author), New York Blood Ctr, Lindsley F Kimball Res Inst, Viral Immunol Lab, New York, NY 10021 USA.
EM sjiang@nybloodcenter.org
RI Jiang, Shibo/L-4500-2014
OI Farzan, Michael/0000-0002-2990-5319; Li, Wenhui/0000-0003-1305-7404
CR Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X
   Cavanagh D., 1995, CORONAVIRIDAE, P73
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   CORAPI WV, 1992, J VIROL, V66, P6695, DOI 10.1128/JVI.66.11.6695-6705.1992
   Dimitrov DS, 2003, CELL, V115, P652, DOI 10.1016/S0092-8674(03)00976-0
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Enserink M, 2004, SCIENCE, V304, P1097, DOI 10.1126/science.304.5674.1097
   Fleck F, 2004, B WORLD HEALTH ORGAN, V82, P152
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Geisbert TW, 2002, VIROLOGY, V293, P15, DOI 10.1006/viro.2001.1279
   GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Ho TY, 2004, BIOCHEM BIOPH RES CO, V313, P938, DOI 10.1016/j.bbrc.2003.11.180
   Holmes KV, 2003, SCIENCE, V300, P1377, DOI 10.1126/science.1086418
   Holmes KV, 2003, NEW ENGL J MED, V348, P1948, DOI 10.1056/NEJMp030078
   JIANG S, 1991, J EXP MED, V174, P1557, DOI 10.1084/jem.174.6.1557
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0
   Kessler JA, 1997, AIDS RES HUM RETROV, V13, P575, DOI 10.1089/aid.1997.13.575
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Marshall E, 2004, SCIENCE, V303, P944, DOI 10.1126/science.303.5660.944
   Nie YC, 2004, J INFECT DIS, V190, P1119, DOI 10.1086/423286
   Oba Y, 2003, NEW ENGL J MED, V348, P2034
   OLSEN CW, 1993, J GEN VIROL, V74, P745, DOI 10.1099/0022-1317-74-4-745
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Phillips JJ, 2002, VIROLOGY, V301, P109, DOI 10.1006/viro.2002.1551
   Prabakaran P, 2004, BIOCHEM BIOPH RES CO, V314, P235, DOI 10.1016/j.bbrc.2003.12.081
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SMITH AL, 1991, J INFECT DIS, V163, P879, DOI 10.1093/infdis/163.4.879
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Takada A, 2003, REV MED VIROL, V13, P387, DOI 10.1002/rmv.405
   Takada A, 2001, J VIROL, V75, P2324, DOI 10.1128/JVI.75.5.2324-2330.2001
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   Tripet B, 2004, J BIOL CHEM, V279, P20836, DOI 10.1074/jbc.M400759200
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   Wang HJ, 2003, NEW ENGL J MED, V349, P507, DOI 10.1056/NEJM200307313490519
   Wang PG, 2004, BIOCHEM BIOPH RES CO, V315, P439, DOI 10.1016/j.bbrc.2004.01.076
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   WONG SK, 2003, J BIOL CHEM, V279, P3197
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   XU Y, 2004, J BIOL CHEM APR, V27
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zhang H, 2004, J VIROL, V78, P6938, DOI 10.1128/JVI.78.13.6938-6945.2004
   Zheng BJ, 2004, EMERG INFECT DIS, V10, P176, DOI 10.3201/eid1002.030533
NR 58
TC 120
Z9 132
U1 10
U2 22
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 12
PY 2004
VL 324
IS 2
BP 773
EP 781
DI 10.1016/j.bbrc.2004.09.106
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 866SR
UT WOS:000224794000044
PM 15474494
OA Bronze
DA 2020-04-03
ER

PT J
AU Wurm, T
   Chen, HY
   Hodgson, T
   Britton, P
   Brooks, G
   Hiscox, JA
AF Wurm, T
   Chen, HY
   Hodgson, T
   Britton, P
   Brooks, G
   Hiscox, JA
TI Localization to the nucleolus is a common feature of coronavirus
   nucleoproteins, and the protein may disrupt host cell division
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; RNA-BINDING DOMAIN; INFECTIOUS-BRONCHITIS VIRUS;
   CYCLIN-DEPENDENT KINASES; NUCLEOCAPSID PROTEIN; MOLECULAR-BIOLOGY;
   REPLICATION; SEQUENCE; REGION; GENES
AB The subcellular localization of transmissible gastroenteritis virus (TGEV) and mouse hepatitis virus (MHV) (group I and group II coronaviruses, respectively) nucleoproteins (N proteins) were examined by confocal microscopy. The proteins were shown to localize either to the cytoplasm alone or to the cytoplasm and a structure in the nucleus. This feature was confirmed to be the nucleolus by using specific antibodies to nucleolin, a major component of the nucleolus, and by confocal microscopy to image sections through a cell expressing N protein. These findings are consistent with our previous report for infectious bronchitis virus (group III coronavirus) (J. A. Hiscox et al., J. Virol. 75:506-512, 2001), indicating that nucleolar localization of the N protein is a common feature of the coronavirus family and is possibly of functional significance. Nucleolar localization signals were identified in the domain III region of the N protein from all three coronavirus groups, and this suggested that transport of N protein to the nucleus might be an active process. In addition, our results suggest that the N protein might function to disrupt cell division. Thus, we observed that approximately 30%. of cells transfected with the N protein appeared to be undergoing cell division. The most likely explanation for this is that the N protein induced a cell cycle delay or arrest, most likely in the G(2)/M phase. In a fraction of transfected cells expressing coronavirus N proteins, we observed multinucleate cells and dividing cells with nucleoli (which are only present during interphase). These findings are consistent with the possible inhibition of cytokinesis in these cells.
C1 Univ Reading, Sch Anim & Microbial Sci, Virol Grp, Reading RG6 6AJ, Berks, England.
   Univ Reading, Sch Anim & Microbial Sci, Cardiovasc Cell Cycle Control Grp, Reading RG6 6AJ, Berks, England.
   Inst Anim Hlth, Compton Lab, Div Mol Biol, Newbury RG20 7NN, Berks, England.
RP Hiscox, JA (reprint author), Univ Reading, Sch Anim & Microbial Sci, Virol Grp, POB 228, Reading RG6 6AJ, Berks, England.
OI Hiscox, Julian/0000-0002-6582-0275
CR ALBERTS B, 1994, MOL BIOL CELL, P381
   ALBO C, 1995, J VIROL, V69, P3799, DOI 10.1128/JVI.69.6.3799-3806.1995
   ALONSO JMM, 1992, VIROLOGY, V188, P168, DOI 10.1016/0042-6822(92)90746-C
   ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931
   Ausubel FM, 1987, CURRENT PROTOCOLS MO
   BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   BOURSNELL MEG, 1985, J GEN VIROL, V66, P573, DOI 10.1099/0022-1317-66-3-573
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   Brooks G, 1997, J MOL CELL CARDIOL, V29, P2261, DOI 10.1006/jmcc.1997.0471
   Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   CHANG RY, 1996, [No title captured], V70, P2210
   Chen DY, 2001, J CELL BIOL, V153, P169, DOI 10.1083/jcb.153.1.169
   Cologna R, 2000, VIROLOGY, V277, P235, DOI 10.1006/viro.2000.0611
   COMPTON SR, 1987, J VIROL, V61, P1814, DOI 10.1128/JVI.61.6.1814-1820.1987
   DAVIES HA, 1981, J GEN VIROL, V53, P67, DOI 10.1099/0022-1317-53-1-67
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   DUNDR M, 1995, J CELL SCI, V108, P2811
   Escors D, 2001, J VIROL, V75, P1312, DOI 10.1128/JVI.75.3.1312-1324.2001
   EVANS MR, 1980, VIROLOGY, V105, P582, DOI 10.1016/0042-6822(80)90058-6
   Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179
   Ginisty H, 1999, J CELL SCI, V112, P761
   Hiscox JA, 2001, J VIROL, V75, P506, DOI 10.1128/JVI.75.1.506-512.2001
   Hrimech M, 2000, EMBO J, V19, P3956, DOI 10.1093/emboj/19.15.3956
   KOBAYASHI M, 1994, J VIROL, V68, P8433, DOI 10.1128/JVI.68.12.8433-8436.1994
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547
   LAPPS W, 1987, VIROLOGY, V157, P47, DOI 10.1016/0042-6822(87)90312-6
   Laude H, 1995, CORONAVIRIDAE, P141, DOI 10.1007/978-1-4899-1531-3_7
   Li HP, 1997, P NATL ACAD SCI USA, V94, P9544, DOI 10.1073/pnas.94.18.9544
   Li JM, 1999, EUR HEART J, V20, P406, DOI 10.1053/euhj.1998.1308
   Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000
   Liu JL, 2000, J CELL SCI, V113, P1543
   Liu JL, 1997, J VIROL, V71, P3188, DOI 10.1128/JVI.71.4.3188-3196.1997
   Lutz P, 1996, J VIROL, V70, P3449, DOI 10.1128/JVI.70.6.3449-3460.1996
   MASTERS PS, 1992, ARCH VIROL, V125, P141, DOI 10.1007/BF01309634
   Matthews DA, 2001, J VIROL, V75, P1031, DOI 10.1128/JVI.75.2.1031-1038.2001
   MATTHEWS DA, 1998, J GEN VIROL, V79, P1031
   Molenkamp R, 2000, J GEN VIROL, V81, P2491, DOI 10.1099/0022-1317-81-10-2491
   Naniche D, 1999, J VIROL, V73, P1894, DOI 10.1128/JVI.73.3.1894-1901.1999
   Nelson GW, 2000, J GEN VIROL, V81, P181, DOI 10.1099/0022-1317-81-1-181
   NELSON GW, 1993, J GEN VIROL, V74, P1975, DOI 10.1099/0022-1317-74-9-1975
   NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L
   Op De Beeck A, 1997, Prog Cell Cycle Res, V3, P1
   PARKER MM, 1990, VIROLOGY, V179, P463, DOI 10.1016/0042-6822(90)90316-J
   PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1
   Platani M, 2000, J CELL BIOL, V151, P1561, DOI 10.1083/jcb.151.7.1561
   Poggioli GJ, 2000, J VIROL, V74, P9562, DOI 10.1128/JVI.74.20.9562-9570.2000
   PUVIONDUTILLEUL F, 1993, EUR J CELL BIOL, V61, P168
   Pyper JM, 1998, J VIROL, V72, P7697, DOI 10.1128/JVI.72.9.7697-7702.1998
   RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995
   RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5
   Risco C, 1996, J VIROL, V70, P4773, DOI 10.1128/JVI.70.7.4773-4777.1996
   Rowland RR, 1999, VIRUS RES, V64, P1, DOI 10.1016/S0168-1702(99)00048-9
   Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X
   Sambrook J., 1989, MOL CLONING LAB MANU
   Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4
   SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799
   SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990
   Snaar S, 2000, J CELL BIOL, V151, P653, DOI 10.1083/jcb.151.3.653
   Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961
   Stevens MP, 1998, J VIROL, V72, P5307, DOI 10.1128/JVI.72.6.5307-5312.1998
   STOHLMAN SA, 1988, J VIROL, V62, P4288, DOI 10.1128/JVI.62.11.4288-4295.1988
   TAHARA SM, 1994, VIROLOGY, V202, P621, DOI 10.1006/viro.1994.1383
   Waggoner S, 1998, J VIROL, V72, P6699, DOI 10.1128/JVI.72.8.6699-6709.1998
   Wang F, 2000, BIOCHEM BIOPH RES CO, V273, P479, DOI 10.1006/bbrc.2000.2970
   WILHELMSEN KC, 1981, VIROLOGY, V110, P225, DOI 10.1016/0042-6822(81)90027-1
   Zhou ML, 1996, VIROLOGY, V217, P191, DOI 10.1006/viro.1996.0106
NR 68
TC 120
Z9 142
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD OCT
PY 2001
VL 75
IS 19
BP 9345
EP 9356
DI 10.1128/JVI.75.19.9345-9356.2001
PG 12
WC Virology
SC Virology
GA 470XX
UT WOS:000170898600048
PM 11533198
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Duval, D
   Giger, U
AF Duval, D
   Giger, U
TI Vaccine-associated immune-mediated hemolytic anemia in the dog
SO JOURNAL OF VETERINARY INTERNAL MEDICINE
LA English
DT Article
ID THROMBOCYTOPENIA; PERTUSSIS; RUBELLA; CATS; MEDICINE; ALUMINUM; PURPURA;
   MEASLES
AB Vaccination has been incriminated as a trigger of immunemediated hemolytic anemia (IMHA) in dogs and in people, but evidence to support this association is lacking. In a controlled retrospective study, idiopathic IMHA was identified in 58 dogs over a 27-month period. When compared with a randomly selected control group of 70 dogs (presented for reasons other than IMHA) over the same period, the distribution of cases versus time since vaccination was different (P < .05), fifteen of the dogs (26%) had been vaccinated within 1 month (mean, 13 days; median, 14 days; range, 1 to 27 days) of developing IMHA (P < .0001), whereas in the control group no marked increase in frequency of presentation was seen in the first month after vaccination. The dogs with IMHA were divided into 2 groups based on time since vaccination: the vaccine IMHA group included dogs vaccinated within 1 month of developing IMHA; the nonvaccine IMHA group included dogs that developed IMHA more than 1 month after vaccination. The recently vaccinated dogs with IMHA (vaccine IMHA group) had significantly lower platelet counts (P < .05) and a trend towards increased prevalence of intravascular hemolysis and autoagglutination when compared with the nonvaccine IMHA group. Similar mortality rates were seen in the vaccine IMHA group (60%) and the nonvaccine IMHA group (44%), with the majority of fatalities (> 75%) occurring in the first 3 weeks after presentation. Persistent autoagglutination was a negative prognostic indicator for survival in both groups (P < .05). Presence of icterus and hyperbilirubinemia were negative prognostic indicators for survival in the nonvaccine IMHA group (P < .0001 and P < .01, respectively) but not in the vaccine IMHA group. In the recently vaccinated dogs, combination vaccines from various manufacturers against canine distemper, adenovirus type 2, leptospirosis, parainfluenza, and parvovirus (DHLPP) were involved in each case. Vaccines against rabies virus, Bordetella spp, coronavirus, and Lyme Borrelia were administered concomitantly to some dogs. This study provides the first clinical evidence for a temporal relationship of vaccine associated IMHA in the dog.
C1 UNIV PENN,SCH VET MED,DEPT CLIN STUDIES,PHILADELPHIA,PA 19104.
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL02355]
CR ATKINSON JP, 1977, ANN INTERN MED, V87, P213
   AXTHELM MK, 1987, AM J VET RES, V48, P1269
   AZEEMUDDIN S, 1987, CLIN PEDIATR, V26, P318
   CITRON ML, 1982, JAMA-J AM MED ASSOC, V248, P1178
   DODDS WJ, 1988, J AM VET MED ASSOC, V193, P1157
   DODDS WJ, 1983, ADV VET SCI COMP MED, V27, P163
   DODDS WJ, 1983, MOD VET PRACT    MAY, P375
   FELLER W, 1950, INTRO PROBABILITY TH, P54
   FINE PE, 1995, COMBINED VACCINES SI, P300
   FISCHBACH M, 1978, J IMMUNOL, V120, P1856
   Greene C.E, 1990, INFECT DIS DOG CAT, P21
   HANEBERG B, 1978, ACTA PAEDIATR SCAND, V67, P345, DOI 10.1111/j.1651-2227.1978.tb16332.x
   HENDRICK MJ, 1994, J AM VET MED ASSOC, V205, P1425
   HENDRICK MJ, 1991, J AM VET MED ASSOC, V198, P304
   HENDRICK MJ, 1992, CANCER RES, V52, P5391
   HOWSON CP, 1992, JAMA-J AM MED ASSOC, V267, P392, DOI 10.1001/jama.267.3.392
   JACKSON ML, 1985, CAN VET J, V26, P245
   JACOBS RM, 1984, J AM VET MED ASSOC, V185, P66
   KASS PH, 1993, J AM VET MED ASSOC, V203, P396
   KELTON JG, 1981, JAMA-J AM MED ASSOC, V245, P369, DOI 10.1001/jama.245.4.369
   KLAG AR, 1993, J AM VET MED ASSOC, V202, P783
   MCANULTY JF, 1985, J AM VET MED ASSOC, V186, P1217
   NEIDERUD J, 1983, ACTA PAEDIATR SCAND, V72, P613, DOI 10.1111/j.1651-2227.1983.tb09780.x
   OLIVARES M, 1989, PEDIATRICS, V84, P851
   PACKMAN CH, 1990, HEMATOLOGY, P666
   PATTERSON R, 1982, JAMA-J AM MED ASSOC, V248, P2637, DOI 10.1001/jama.248.20.2637
   PINEAU A, 1992, TOXICOLOGY, V73, P117, DOI 10.1016/0300-483X(92)90175-E
   PINEAU S, 1980, CAN VET J, V21, P82
   Schalm O. W., 1975, Canine Practice, V2, P37
   SMITH CA, 1995, J AM VET MED ASSOC, V207, P421
   STOCKHAM SL, 1980, J AM ANIM HOSP ASSOC, V16, P927
   STRAW B, 1978, VET MED SMALL AN JUN, P725
   SWITZER JW, 1981, VET CLIN N AM-SMALL, V11, P405, DOI 10.1016/S0195-5616(81)50036-2
   TIZARD I, 1987, VET IMMUNOLOGY INTRO, P381
   Werner LL, 1980, COMP CONT ED, V11, P96
NR 35
TC 120
Z9 121
U1 3
U2 28
PU AMER COLL VETERINARY INTERNAL MEDICINE
PI LAKEWOOD
PA 7175 W JEFFERSON AVE, STE 2125, LAKEWOOD, CO 80235 USA
SN 0891-6640
J9 J VET INTERN MED
JI J. Vet. Intern. Med.
PD SEP-OCT
PY 1996
VL 10
IS 5
BP 290
EP 295
DI 10.1111/j.1939-1676.1996.tb02064.x
PG 6
WC Veterinary Sciences
SC Veterinary Sciences
GA VG705
UT WOS:A1996VG70500002
PM 8884713
DA 2020-04-03
ER

PT J
AU OLSEN, CW
   CORAPI, WV
   NGICHABE, CK
   BAINES, JD
   SCOTT, FW
AF OLSEN, CW
   CORAPI, WV
   NGICHABE, CK
   BAINES, JD
   SCOTT, FW
TI MONOCLONAL-ANTIBODIES TO THE SPIKE PROTEIN OF FELINE INFECTIOUS
   PERITONITIS VIRUS MEDIATE ANTIBODY-DEPENDENT ENHANCEMENT OF INFECTION OF
   FELINE MACROPHAGES
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID YELLOW-FEVER VIRUS; CELL-LINE P388D1; VACCINIA VIRUS; FC RECEPTOR; HIV
   INFECTION; CORONAVIRUS; RECOMBINANT; INFLUENZA; PATHOGENESIS;
   REPLICATION
AB Antibody-dependent enhancement of virus infection is a process whereby virus-antibody complexes initiate infection of cells via Fc receptor-mediated endocytosis.  We sought to investigate antibody-dependent enhancement of feline infectious peritonitis virus infection of primary feline peritoneal macrophages in vitro.  Enhancement of infection was assessed, after indirect immunofluorescent-antibody labelling of infected cells, by determing the ratio between the number of cells infected in the presence and absence of virus-specific antibody.  Infection enhancement was initially demonstrated by using heat-inactivated, virus-specific feline antiserum.  Functional compatibility between murine immunoglobulin molecules and feline Fc receptors was demonstrated by using murine anti-sheep erythrocyte serum and an antibody-coated sheep erythrocyte phagocytosis assay.  Thirty-seven murine monoclonal antibodies specific for the nucleocapsid, membrane, or spike proteins of feline infectious peritonitis virus or transmissible gastroenteritis virus were assayed for their ability to enhance the infectivity of feline infectious peritonitis virus.  Infection enhancement was mediated by a subset of spike protein-specific monoclonal antibodies.  A distinct correlation was seen between the ability of a monoclonal antibody to cause virus neutralization in a routine cell culture neutralization assay and its ability to mediate infection enhancement of macrophages.  Infection enhancement was shown to be Fc receptor mediated by blockade of antibody-Fc receptor interaction using staphylococcal protein A.  Our results are consistent with the hypothesis that antibody-dependent enhancement of feline infectious peritonitis virus infectivity is mediated by antibody directed against specific sites on the spike protein.
C1 CORNELL UNIV,NEW YORK STATE COLL VET MED,CORNELL FELINE HLTH CTR,ITHACA,NY 14853.
RP OLSEN, CW (reprint author), CORNELL UNIV,NEW YORK STATE COLL VET MED,DEPT MICROBIOL IMMUNOL & PARASITOL,ITHACA,NY 14853, USA.
CR BAINES JD, 1988, THESIS CORNELL U ITH
   BARLOUGH JE, 1990, INFECT DIS, P300
   CORAPI WV, 1990, AM J VET RES, V51, P1388
   FISCUS SA, 1987, J VIROL, V61, P2607, DOI 10.1128/JVI.61.8.2607-2613.1987
   GIMENEZ HB, 1989, J GEN VIROL, V70, P89, DOI 10.1099/0022-1317-70-1-89
   GOLLINS SW, 1986, NATURE, V321, P244, DOI 10.1038/321244a0
   GOLLINS SW, 1984, J GEN VIROL, V65, P1261, DOI 10.1099/0022-1317-65-8-1261
   HALSTEAD SB, 1984, J IMMUNOL, V132, P1529
   HENCHAL EA, 1985, AM J TROP MED HYG, V34, P162, DOI 10.4269/ajtmh.1985.34.162
   HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647
   HOMSY J, 1990, J VIROL, V64, P1437, DOI 10.1128/JVI.64.4.1437-1440.1990
   HOTTA H, 1984, P SOC EXP BIOL MED, V175, P320, DOI 10.3181/00379727-175-41802
   JACOBSEGEELS HEL, 1980, J IMMUNOL, V125, P1606
   JACOBSEGEELS HEL, 1982, AM J VET RES, V43, P666
   JOLLY PE, 1989, J VIROL, V63, P1811, DOI 10.1128/JVI.63.4.1811-1813.1989
   KING AA, 1984, J GEN VIROL, V65, P1091, DOI 10.1099/0022-1317-65-6-1091
   KRILOV LR, 1989, J INFECT DIS, V160, P777, DOI 10.1093/infdis/160.5.777
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   MACKETT M, 1982, P NATL ACAD SCI-BIOL, V79, P7415, DOI 10.1073/pnas.79.23.7415
   MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984
   MACKETT M, 1985, DNA CLONING PRACTICA, V2, P191
   MORENS DM, 1990, J GEN VIROL, V71, P2909, DOI 10.1099/0022-1317-71-12-2909
   MORENS DM, 1987, J GEN VIROL, V68, P91, DOI 10.1099/0022-1317-68-1-91
   MORENS DM, 1987, J MED VIROL, V22, P169, DOI 10.1002/jmv.1890220208
   NGICHABE CK, UNPUB
   OCHIAI H, 1990, J MED VIROL, V30, P258, DOI 10.1002/jmv.1890300406
   OCHIAI H, 1988, J VIROL, V62, P20, DOI 10.1128/JVI.62.1.20-26.1988
   Olsen C. W., 1991, Feline Health Topics for Veterinarians, V6, P1
   OLSEN CW, 1991, FELINE HLTH TOPICS, V6, P8
   PANICALI D, 1983, P NATL ACAD SCI-BIOL, V80, P5364, DOI 10.1073/pnas.80.17.5364
   PEDERSEN NC, 1983, FELINE PRACT, V13, P5
   PEDERSEN NC, 1980, AM J VET RES, V41, P868
   PEIRIS JSM, 1981, NATURE, V289, P189, DOI 10.1038/289189a0
   PORTERFIELD JS, 1986, ADV VIRUS RES, V31, P335, DOI 10.1016/S0065-3527(08)60268-7
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   ROBINSON WE, 1990, P NATL ACAD SCI USA, V87, P3185, DOI 10.1073/pnas.87.8.3185
   SCHLESINGER JJ, 1981, J IMMUNOL, V127, P659
   SCHLESINGER JJ, 1983, J GEN VIROL, V64, P1255, DOI 10.1099/0022-1317-64-6-1255
   SCHLESINGER JJ, 1981, J MED VIROL, V8, P103, DOI 10.1002/jmv.1890080304
   SCOTT FW, 1986, CURRENT VET THERAPY, V9, P1059
   SMITH GL, 1983, P NATL ACAD SCI-BIOL, V80, P7155, DOI 10.1073/pnas.80.23.7155
   STODDART CA, 1989, J VIROL, V63, P436, DOI 10.1128/JVI.63.1.436-440.1989
   STODDART CA, 1988, J LEUKOCYTE BIOL, V44, P319
   STODDART CA, 1989, THESIS CORNELL U ITH
   TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065
   VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   WEISS RC, 1981, AM J VET RES, V42, P2036
   WEISS RC, 1981, AM J VET RES, V42, P382
   WEISS RC, 1981, COMP IMMUNOL MICROB, V4, P175, DOI 10.1016/0147-9571(81)90003-5
NR 50
TC 120
Z9 126
U1 1
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD FEB
PY 1992
VL 66
IS 2
BP 956
EP 965
DI 10.1128/JVI.66.2.956-965.1992
PG 10
WC Virology
SC Virology
GA GY965
UT WOS:A1992GY96500039
PM 1309922
OA Bronze
DA 2020-04-03
ER

PT J
AU VLASAK, R
   LUYTJES, W
   LEIDER, J
   SPAAN, W
   PALESE, P
AF VLASAK, R
   LUYTJES, W
   LEIDER, J
   SPAAN, W
   PALESE, P
TI THE E3-PROTEIN OF BOVINE CORONAVIRUS IS A RECEPTOR-DESTROYING ENZYME
   WITH ACETYLESTERASE ACTIVITY
SO JOURNAL OF VIROLOGY
LA English
DT Article
C1 CUNY MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029.
   STATE UNIV UTRECHT,DEPT INFECT DIS & IMMUNOL,DIV VIROL,UTRECHT,NETHERLANDS.
OI Palese, Peter/0000-0002-0337-5823
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-11823, AI18998]; NIGMS NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS) [GM07280]
CR AIR GM, 1983, GENETICS INFLUENZA V, P281
   BENDER ML, 1965, ANNU REV BIOCHEM, V34, P49, DOI 10.1146/annurev.bi.34.070165.000405
   BRAND C, 1980, VIROLOGY, V107, P424, DOI 10.1016/0042-6822(80)90309-8
   Bucher D, 1975, INFLUENZA VIRUSES IN, P83
   Cohen JA, 1967, METHOD ENZYMOL, V11, P686
   DEREGT D, 1987, J GEN VIROL, V68, P2863, DOI 10.1099/0022-1317-68-11-2863
   DEREGT D, 1987, VIROLOGY, V161, P410, DOI 10.1016/0042-6822(87)90134-6
   FORMANOWSKI F, 1988, VIRUS RES, V10, P177, DOI 10.1016/0168-1702(88)90014-7
   GOTTSCHALK A, 1957, BIOCHIM BIOPHYS ACTA, V23, P645, DOI 10.1016/0006-3002(57)90389-X
   HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x
   HERRLER G, 1988, J GEN VIROL, V69, P839, DOI 10.1099/0022-1317-69-4-839
   HOGUE BG, 1984, J VIROL, V51, P384, DOI 10.1128/JVI.51.2.384-388.1984
   HOMMA M, 1973, J VIROL, V12, P1457, DOI 10.1128/JVI.12.6.1457-1465.1973
   KING B, 1985, VIRUS RES, V2, P53, DOI 10.1016/0168-1702(85)90059-0
   KING B, 1982, J VIROL, V42, P700, DOI 10.1128/JVI.42.2.700-707.1982
   LAI MM, 1986, RNA GENETICS, V1, P115
   Lamb R, 1983, GENETICS INFLUENZA V, P21
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663
   NAGAI Y, 1977, VIROLOGY, V77, P125, DOI 10.1016/0042-6822(77)90412-3
   OHUCHI M, 1982, J VIROL, V42, P1076, DOI 10.1128/JVI.42.3.1076-1079.1982
   PALESE P, 1974, VIROLOGY, V61, P397, DOI 10.1016/0042-6822(74)90276-1
   PALESE P, 1974, VIROLOGY, V57, P227, DOI 10.1016/0042-6822(74)90123-8
   PARVIN JD, 1986, J VIROL, V59, P377, DOI 10.1128/JVI.59.2.377-383.1986
   ROGERS GN, 1986, J BIOL CHEM, V261, P5947
   SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1
   SCHEID A, 1974, VIROLOGY, V62, P125, DOI 10.1016/0042-6822(74)90308-0
   SCHEID A, 1972, VIROLOGY, V50, P640, DOI 10.1016/0042-6822(72)90418-7
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985
   TALBOT PJ, 1984, VIROLOGY, V132, P250, DOI 10.1016/0042-6822(84)90032-1
   VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526
   VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4
   WEGE H, 1979, J GEN VIROL, V42, P37, DOI 10.1099/0022-1317-42-1-37
   WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.biochem.56.1.365
NR 36
TC 120
Z9 120
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD DEC
PY 1988
VL 62
IS 12
BP 4686
EP 4690
DI 10.1128/JVI.62.12.4686-4690.1988
PG 5
WC Virology
SC Virology
GA Q9909
UT WOS:A1988Q990900031
PM 3184275
OA Bronze
DA 2020-04-03
ER

PT J
AU Hemida, MG
   Chu, DKW
   Poon, LLM
   Perera, RAPM
   Alhammadi, MA
   Ng, HY
   Siu, LY
   Guan, Y
   Alnaeem, A
   Peiris, M
AF Hemida, Maged G.
   Chu, Daniel K. W.
   Poon, Leo L. M.
   Perera, Ranawaka A. P. M.
   Alhammadi, Mohammad A.
   Hoi-yee Ng
   Siu, Lewis Y.
   Guan, Yi
   Alnaeem, Abdelmohsen
   Peiris, Malik
TI MERS Coronavirus in Dromedary Camel Herd, Saudi Arabia
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID ANTIBODIES; INFECTION; LIVESTOCK
AB A prospective study of a dromedary camel herd during the 2013-14 calving season showed Middle East respiratory syndrome coronavirus infection of calves and adults. Virus was isolated from the nose and feces but more frequently from the nose. Preexisting neutralizing antibody did not appear to protect against infection.
C1 [Hemida, Maged G.; Alhammadi, Mohammad A.; Alnaeem, Abdelmohsen] King Faisal Univ, Al Hufuf, Saudi Arabia.
   [Hemida, Maged G.] Kafrelsheikh Univ, Kafr Al Sheikh, Egypt.
   [Chu, Daniel K. W.; Poon, Leo L. M.; Perera, Ranawaka A. P. M.; Hoi-yee Ng; Siu, Lewis Y.; Guan, Yi; Peiris, Malik] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
RP Peiris, M (reprint author), Univ Hong Kong, Sch Publ Hlth, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.
EM aaalnaeem@kfu.edu.sa; malik@hku.hk
RI Poon, Leo/C-4382-2009; Perera, Ranawaka A.P.M/N-8263-2015; Peiris,
   Joseph Sriyal Malik/C-4380-2009; Hemida, Maged/L-9888-2016
OI Poon, Leo/0000-0002-9101-7953; Perera, Ranawaka
   A.P.M/0000-0003-3936-1535; Peiris, Joseph Sriyal
   Malik/0000-0001-8217-5995; Guan, Yi/0000-0001-6057-9243; Hemida,
   Maged/0000-0002-5986-7237; Chu, Daniel Ka Wing/0000-0002-9219-8979
FU King Faisal University Deanship of Scientific Research [143011];
   National Institute of Allergy and Infectious Diseases, National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [HHSN266200700005C]; European
   CommunityEuropean Community (EC) [223498]
FX We thank the King Faisal University Deanship of Scientific Research for
   their support (grant no. 143011). This research was funded by a research
   contract from the National Institute of Allergy and Infectious Diseases,
   National Institutes of Health (contract no. HHSN266200700005C), and a
   grant from the European Community Seventh Framework Program
   (FP7/2007-2013) under project European Management Platform for Emerging
   and Re-emerging Disease entities (grant agreement no. 223498) (EMPERIE).
CR Addie DD, 2000, VET REC, V146, P419, DOI 10.1136/vr.146.15.419
   Alagaili AN, 2014, MBIO, V5, DOI 10.1128/mBio.00884-14
   Chu DKW, 2014, EMERG INFECT DIS
   Cotten M, 2014, MBIO, V5, DOI 10.1128/mBio.01062-13
   Hemida MG, 2013, EUROSURVEILLANCE, V18, P21, DOI 10.2807/1560-7917.ES2013.18.50.20659
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Reusken CB, 2013, EUROSURVEILLANCE, V18, P14, DOI 10.2807/1560-7917.ES2013.18.50.20662
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   The WHO MERSCoV Research Group, 2013, PLOS CURR, V5
   WHO, MIDDL E RESP SYNDR C
NR 13
TC 119
Z9 124
U1 1
U2 21
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUL
PY 2014
VL 20
IS 7
BP 1231
EP 1234
DI 10.3201/eid2007.140571
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AK4JB
UT WOS:000338389900023
PM 24964193
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Lau, SKP
   Woo, PCY
   Tse, H
   Fu, CTY
   Au, WK
   Chen, XC
   Tsoi, HW
   Tsang, THF
   Chan, JSY
   Tsang, DNC
   Li, KSM
   Tse, CWS
   Ng, TK
   Tsang, OTY
   Zheng, BJ
   Tam, S
   Chan, KH
   Zhou, BP
   Yuen, KY
AF Lau, Susanna K. P.
   Woo, Patrick C. Y.
   Tse, Herman
   Fu, Clara T. Y.
   Au, Wing-Ka
   Chen, Xin-Chun
   Tsoi, Hoi-Wah
   Tsang, Thomas H. F.
   Chan, Joanna S. Y.
   Tsang, Dominic N. C.
   Li, Kenneth S. M.
   Tse, Cindy W. S.
   Ng, Tak-Keung
   Tsang, Owen T. Y.
   Zheng, Bo-Jian
   Tam, Sidney
   Chan, Kwok-Hung
   Zhou, Boping
   Yuen, Kwok-Yung
TI Identification of novel porcine and bovine parvoviruses closely related
   to human parvovirus 4
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID CHINESE HORSESHOE BATS; HUMAN BOCAVIRUS; MOLECULAR EPIDEMIOLOGY; GENETIC
   DIVERSITY; HUMAN CORONAVIRUS; COMPLETE GENOME; HUMAN PLASMA; SEQUENCE;
   VIRUS; PARV4
AB Human parvovirus 4 (PARV4), a recently discovered parvovirus found exclusively in human plasma and liver tissue, was considered phylogenetically distinct from other parvoviruses. Here, we report the discovery of two novel parvoviruses closely related to PARV4, porcine hokovirus (PHoV) and bovine hokovirus (BHoV), from porcine and bovine samples in Hong Kong. Their nearly full-length sequences were also analysed. PARV4-like viruses were detected by PCR among 44.4% (148/ 333) of porcine samples (including lymph nodes, liver, serum, nasopharyngeal and faecal samples), 13 % (4/32) of bovine spleen samples and 2 % (7/362) of human serum samples that were sent for human immunodeficiency virus and hepatitis C virus antibody tests. Three distinct parvoviruses were identified, including two novel parvoviruses, PHoV and BHoV, from porcine and bovine samples and PARV4 from humans, respectively. Analysis of genome sequences from seven PHoV strains, from three BHoV strains and from one PARV4 strain showed that the two animal parvoviruses were most similar to PARV4 with 61.5-63 % nt identities and, together with PARV4 (HHoV), formed a distinct cluster within the family Parvoviridae. The three parvoviruses also differed from other parvoviruses by their relatively large predicted VP1 protein and the presence of a small unique conserved putative protein. Based on these results, we propose a separate genus, Hokovirus, to describe these three parvoviruses. The co-cletection of porcine reproductive and respiratory syndrome virus, the agent associated with the recent 'high fever' disease outbreaks in pigs in China, from our porcine samples warrants further investigation.
C1 [Lau, Susanna K. P.; Woo, Patrick C. Y.; Tse, Herman; Zheng, Bo-Jian; Chan, Kwok-Hung; Yuen, Kwok-Yung] Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Lau, Susanna K. P.; Woo, Patrick C. Y.; Tse, Herman; Zheng, Bo-Jian; Chan, Kwok-Hung; Yuen, Kwok-Yung] Univ Hong Kong, Res Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China.
   [Lau, Susanna K. P.; Woo, Patrick C. Y.; Tse, Herman; Fu, Clara T. Y.; Tsoi, Hoi-Wah; Chan, Joanna S. Y.; Li, Kenneth S. M.; Zheng, Bo-Jian; Chan, Kwok-Hung; Yuen, Kwok-Yung] Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   [Tsang, Thomas H. F.] Ctr Hlth Protect, Dept Hlth, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Xin-Chun; Zhou, Boping] Shenzhen E Lake Hosp, Shenzhen, Peoples R China.
   [Tsang, Dominic N. C.] Queen Elizabeth Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Tse, Cindy W. S.] Kwong Wah Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Ng, Tak-Keung] Princess Margaret Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Tsang, Owen T. Y.] Princess Margaret Hosp, Dept Med & Geriatr, Hong Kong, Hong Kong, Peoples R China.
   [Tam, Sidney] Queen Mary Hosp, Dept Clin Biochem, Hong Kong, Hong Kong, Peoples R China.
   [Au, Wing-Ka] Food & Environm Hyg Dept, Hong Kong, Hong Kong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
EM kyyuen@hkucc.hku.hk
RI Woo, Patrick/C-4449-2009; Yuen, Kwok Yung/C-4465-2009; Tse,
   Herman/C-4425-2009; Lau, Susanna/C-4321-2009; Lau, Susanna Kar
   Pui/AAJ-6848-2020; Tsoi, Hoi Wah/C-4428-2009
OI Lau, Susanna Kar Pui/0000-0002-1383-7374; Yuen,
   Kwok-yung/0000-0002-2083-1552
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Allander T, 2001, P NATL ACAD SCI USA, V98, P11609, DOI 10.1073/pnas.211424698
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Fryer JF, 2007, J GEN VIROL, V88, P2162, DOI 10.1099/vir.0.82620-0
   Fryer JF, 2007, TRANSFUSION, V47, P1054, DOI 10.1111/j.1537-2995.2007.01235.x
   Fryer JF, 2006, EMERG INFECT DIS, V12, P151, DOI 10.3201/eid1201.050916
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hijikata M, 2001, JPN J INFECT DIS, V54, P244
   Hokynar K, 2002, VIROLOGY, V302, P224, DOI 10.1006/viro.2002.1673
   Johara MY, 2001, EMERG INFECT DIS, V7, P439
   Jones MS, 2005, J VIROL, V79, P8230, DOI 10.1128/JVI.79.13.8230-8236.2005
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   LaMonte AC, 2004, J INFECT DIS, V189, P847, DOI 10.1086/381899
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2007, VIROLOGY, V367, P428, DOI 10.1016/j.virol.2007.06.009
   Lau SKP, 2007, J INFECT DIS, V196, P986, DOI 10.1086/521310
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Lukashov VV, 2001, J VIROL, V75, P2729, DOI 10.1128/JVI.75.6.2729-2740.2001
   Manning A, 2007, J INFECT DIS, V195, P1345, DOI 10.1086/513280
   Nguyen QT, 1999, J CLIN MICROBIOL, V37, P2483, DOI 10.1128/JCM.37.8.2483-2487.1999
   Nguyen QT, 2002, VIROLOGY, V301, P374, DOI 10.1006/viro.2002.1585
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Servant A, 2002, J VIROL, V76, P9124, DOI 10.1128/JVI.76.18.9124-9134.2002
   Shackelton LA, 2005, P NATL ACAD SCI USA, V102, P379, DOI 10.1073/pnas.0406765102
   SHADE RO, 1986, J VIROL, V58, P921, DOI 10.1128/JVI.58.3.921-936.1986
   Simmonds P, 2007, EMERG INFECT DIS, V13, P1386, DOI 10.3201/eid1309.070428
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Soucie JM, 2000, TRANSFUSION, V40, P708, DOI 10.1046/j.1537-2995.2000.40060708.x
   SPAHN GJ, 1966, CORNELL VET, V56, P377
   Stoffel W., 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tang XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06
   Tian KG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000526
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Van Regenmortel M.H.V., 2000, VIRUS TAXONOMY CLASS
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Yu HJ, 2006, EMERG INFECT DIS, V12, P914, DOI 10.3201/eid1206.051194
NR 38
TC 119
Z9 133
U1 1
U2 12
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD AUG
PY 2008
VL 89
BP 1840
EP 1848
DI 10.1099/vir.0.2008/000380-0
PN 8
PG 9
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 335PF
UT WOS:000258301800006
PM 18632954
OA Bronze
DA 2020-04-03
ER

PT J
AU Lu, XY
   Chittaganpitch, M
   Olsen, SJ
   Mackay, IM
   Sloots, TP
   Fry, AM
   Erdman, DD
AF Lu, Xiaoyan
   Chittaganpitch, Malinee
   Olsen, Sonja J.
   Mackay, Ian M.
   Sloots, Theo P.
   Fry, Alicia M.
   Erdman, Dean D.
TI Real-time PCR assays for detection of bocavirus in human specimens
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID CHILDREN; CORONAVIRUS
AB The recently discovered human bocavirus (HBoV) is the first member of the family Parpoviridae, genus Bocavirus, to be potentially associated with human disease. Several studies have identified HBoV in respiratory specimens from children with acute respiratory disease, but the full spectrum of clinical disease and the epidemiology of HBoV infection remain unclear. The availability of rapid and reliable molecular diagnostics would therefore aid future studies of this novel virus. To address this, we developed two sensitive and specific real-time TaqMan PCR assays that target the HBoV NS1 and NP-1 genes. Both assays could reproducibly detect 10 copies of a recombinant DNA plasmid containing a partial region of the HBoV genome, with a dynamic range of 8 log units (10(1) to 10(8) copies). Eight blinded clinical specimen extracts positive for HBoV by an independent PCR assay were positive by both real-time assays. Among 1,178 NP swabs collected from hospitalized pneumonia patients in Sa Kaeo Province, Thailand, 53 (4.5%) were reproducibly positive for HBoV by one or both targets. Our data confirm the possible association of HBoV infection with pneumonia and demonstrate the utility of these real-time PCR assays for HBoV detection.
C1 Ctr Dis Control & Prevent, Resp & Gastroenteritis Viruses Branch, Div Viral Dis, Atlanta, GA 30333 USA.
   Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Atlanta, GA 30333 USA.
   Thailand Minist Publ Hlth, Natl Inst Hlth, Nonthaburi, Thailand.
   Thai MOPH US CDC Collaborat, Int Emerging Infect Program, Nonthaburi, Thailand.
   Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Qpid Lab, Brisbane, Qld, Australia.
   Univ Queensland, Clin Med Virol Ctr, St Lucia, Qld 4067, Australia.
RP Erdman, DD (reprint author), Ctr Dis Control & Prevent, Resp & Gastroenteritis Viruses Branch, Div Viral Dis, 1600 Clifton Rd NE,Mailstop G04, Atlanta, GA 30333 USA.
EM dde1@cdc.gov
RI Sloots, Theo P/E-6118-2011; Mackay, Ian M./B-2537-2010
OI Mackay, Ian M./0000-0003-3598-2350
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Bastien N, 2006, EMERG INFECT DIS, V12, P848, DOI 10.3201/eid1205.051424
   Bustin S.A., 2004, A Z QUANTITATIVE PCR
   Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500
   Emery SL, 2004, EMERG INFECT DIS, V10, P311, DOI 10.3201/eid1002.030759
   Foulongne V, 2006, EMERG INFECT DIS, V12, P862, DOI 10.3201/eid1205.051523
   Ma XM, 2006, J CLIN MICROBIOL, V44, P1132, DOI 10.1128/JCM.44.3.1132-1134.2006
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   TATTERSALL P, 2005, VIRUS TAXONOMY, P353
NR 9
TC 119
Z9 133
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD SEP
PY 2006
VL 44
IS 9
BP 3231
EP 3235
DI 10.1128/JCM.00889-06
PG 5
WC Microbiology
SC Microbiology
GA 086YB
UT WOS:000240708000026
PM 16954253
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU van Gageldonk-Lafeber, AB
   Heijnen, MLA
   Bartelds, AIM
   Peters, MF
   van der Plas, SM
   Wilbrink, B
AF van Gageldonk-Lafeber, AB
   Heijnen, MLA
   Bartelds, AIM
   Peters, MF
   van der Plas, SM
   Wilbrink, B
TI A case-control study of acute respiratory tract infection in general
   practice patients in the Netherlands
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID POLYMERASE CHAIN-REACTION; ELDERLY-PEOPLE; INFLUENZA; POPULATION;
   SYMPTOMS; CHILDREN; PCR; IDENTIFICATION; CONSULTATION; DIAGNOSIS
AB Background. Acute respiratory tract infections (ARTIs) are responsible for considerable morbidity in the community, but little is known about the presence of respiratory pathogens in asymptomatic individuals. We hypothesized that asymptomatic persons could have a subclinical infection and thus act as a source of transmission.
   Methods. During the period of 2000-2003, all patients with ARTI who visited their sentinel general practitioner had their data reported to estimate the incidence of ARTI in Dutch general practices. A random selection of these patients (case patients) and an equal number of asymptomatic persons visiting for other complaints (control subjects) were included in a case-control study. Nose and throat swabs of participants were tested for a broad range of pathogens.
   Results. The overall incidence of ARTI was 545 cases per 10,000 person-years, suggesting that, in the Dutch population, an estimated 900,000 persons annually consult their general practitioner for respiratory complaints. Rhinovirus was most common in case patients (24%), followed by influenza virus type A (11%) and coronavirus (7%). Viruses were detected in 58% of the case patients, beta-hemolytic streptococci group A were detected in 11%, and mixed infections were detected in 3%. Pathogens were detected in similar to 30% of control subjects, particularly in the youngest age groups.
   Conclusion. This study confirms that most ARTIs are viral and supports the reserved policy of prescribing antibiotics. In both case and control subjects, rhinovirus was the most common pathogen. Of bacterial infections, only group A beta-hemolytic streptococci were more common in case patients than in control subjects. Furthermore, we demonstrated that asymptomatic persons might be a neglected source of transmission.
C1 Natl Inst Publ Hlth & Environm, Diagnost Lab & Infect Dis & Perinatal Screening, NL-3720 BA Bilthoven, Netherlands.
   Natl Inst Publ Hlth & Environm, Dept Infect Dis Epidemiol, NL-3720 BA Bilthoven, Netherlands.
   Netherlands Inst Hlth Serv Res, Utrecht, Netherlands.
   Reg Lab Publ Hlth, Tilburg, Netherlands.
RP Wilbrink, B (reprint author), Natl Inst Publ Hlth & Environm, Diagnost Lab & Infect Dis & Perinatal Screening, POB 1, NL-3720 BA Bilthoven, Netherlands.
EM berry.wilbrink@rivm.nl
CR Andeweg AC, 1999, J CLIN MICROBIOL, V37, P524, DOI 10.1128/JCM.37.3.524-530.1999
   BARTELDS AIM, 1989, DUTCH SENTINEL PRACT
   Bruijnzeels MA, 1998, BRIT J GEN PRACT, V48, P880
   Butler CC, 2004, BRIT J GEN PRACT, V54, P536
   Carrat F, 1999, CLIN INFECT DIS, V28, P283, DOI 10.1086/515117
   CLAAS ECJ, 1992, J VIROL METHODS, V39, P1, DOI 10.1016/0166-0934(92)90120-3
   CUBIE HA, 1992, J MED VIROL, V38, P283, DOI 10.1002/jmv.1890380410
   de Wit MAS, 2001, EMERG INFECT DIS, V7, P82, DOI 10.3201/eid0701.010113
   Dorigo-Zetsma JW, 1999, J CLIN MICROBIOL, V37, P14, DOI 10.1128/JCM.37.1.14-17.1999
   *EUR INFL SURV SCH, 2002, ANN REP 2001 2002 IN
   Fleming D M, 2002, Commun Dis Public Health, V5, P7
   Fleming DM, 2000, EPIDEMIOL INFECT, V124, P245, DOI 10.1017/S0950268899003660
   Fleming DM, 1999, EUR J EPIDEMIOL, V15, P467, DOI 10.1023/A:1007525402861
   Fouchier RAM, 2000, J CLIN MICROBIOL, V38, P4096, DOI 10.1128/JCM.38.11.4096-4101.2000
   Graat JM, 2003, J CLIN EPIDEMIOL, V56, P1218, DOI 10.1016/S0895-4356(03)00171-9
   Gwaltney JM, 2002, AM J MED, V112, p13S
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993
   Kuyvenhoven MM, 2003, J ANTIMICROB CHEMOTH, V52, P675, DOI 10.1093/jac/dkg412
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70
   Monto AS, 2002, AM J MED, V112, p4S
   MONTO AS, 1995, AM J MED S6B, V99, P24
   MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052
   Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060
   NICHOLSON KG, 2000, TXB INFLUENZA
   Paget W J, 2002, Euro Surveill, V7, P147
   Reina J, 2004, An Pediatr (Barc), V61, P137
   Simpson C R, 2000, Health Bull (Edinb), V58, P489
   TANNOCK GA, 1993, FAM PRACT, V10, P378, DOI 10.1093/fampra/10.4.378
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   VANDERPLAS SM, 2004, INFECTIEZIEKTEN B, V3, P88
   WAT D, 2004, EUR J INTERN MED, V15, P79
NR 33
TC 119
Z9 123
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG 15
PY 2005
VL 41
IS 4
BP 490
EP 497
DI 10.1086/431982
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 946ZE
UT WOS:000230611000011
PM 16028157
OA Bronze
DA 2020-04-03
ER

PT J
AU Leung, GM
   Hedley, AJ
   Ho, LM
   Chau, P
   Wong, IOL
   Thach, TQ
   Ghani, AC
   Donnelly, CA
   Fraser, C
   Riley, S
   Ferguson, NM
   Anderson, RM
   Tsang, T
   Leung, PY
   Wong, V
   Chan, JCK
   Tsui, E
   Lo, SV
   Lam, TH
AF Leung, GM
   Hedley, AJ
   Ho, LM
   Chau, P
   Wong, IOL
   Thach, TQ
   Ghani, AC
   Donnelly, CA
   Fraser, C
   Riley, S
   Ferguson, NM
   Anderson, RM
   Tsang, T
   Leung, PY
   Wong, V
   Chan, JCK
   Tsui, E
   Lo, SV
   Lam, TH
TI The epidemiology of severe acute respiratory syndrome in the 2003 Hong
   Kong epidemic: An analysis of all 1755 patients
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID TRANSMISSION DYNAMICS; CORONAVIRUS INFECTION; SARS CORONAVIRUS;
   LABORATORY TESTS; OUTBREAK; TORONTO; CHILDREN; IMPACT; AGENT; CHINA
AB Background: As yet, no one has written a comprehensive epidemiologic account of a severe acute respiratory syndrome (SARS) outbreak from an affected country.
   Objective: To provide a comprehensive epidemiologic account of a SARS outbreak from an affected territory.
   Design: Epidemiologic analysis.
   Setting: The 2003 Hong Kong SARS outbreak.
   Participants: All 1755 cases and 302 deaths.
   Measurements: Sociodemographic characteristics; infection clusters by time, occupation, setting, and workplace; and geospatial relationships were determined. The mean and variance in the time from infection to onset (incubation period) were estimated in a small group of patients with known exposure. The mean and variance in time from onset to admission, from admission to discharge, or from admission to death were calculated. Logistic regression was used to identify important predictors of case fatality.
   Results: 49.3% of patients were infected in clinics, hospitals, or elderly or nursing homes, and the Amoy Gardens cluster accounted for 18.8% of cases. The ratio of women to men among infected individuals was 5:4. Health care workers accounted for 23.1% of all reported cases. The estimated mean incubation period was 4.6 days (95% CI, 3.8 to 5.8 days). Mean time from symptom onset to hospitalization varied between 2 and 8 days, decreasing over the course of the epidemic. Mean time from onset to death was 23.7 days (CI, 22.0 to 25.3 days), and mean time from onset to discharge was 26.5 days (CI, 25.8 to 27.2 days). Increasing age, male sex, atypical presenting symptoms, presence of comorbid conditions, and high lactate dehydrogenase level on admission were associated with a greater risk for death.
   Limitations: Estimates of the incubation period relied on statistical assumptions because few patients had known exposure times. Temporal changes in case management as the epidemic progressed, unavailable treatment information, and several potentially important factors that could not be thoroughly analyzed because of the limited sample size complicate interpretation of factors related to case fatality.
   Conclusions: This analysis of the complete data on the 2003 SARS epidemic in Hong Kong has revealed key epidemiologic features of the epidemic as it evolved.
C1 Univ Hong Kong, Dept Community Med, Hong Kong, Hong Kong, Peoples R China.
RP Lam, TH (reprint author), Univ Hong Kong, Dept Community Med, 21 Sassoon Rd,Fac Med Bldg,Pokfulam, Hong Kong, Hong Kong, Peoples R China.
EM commed@hkucc.hku.hk
RI Hedley, Anthony J/A-9113-2013; Leung, Gabriel/C-4336-2009; Ferguson,
   Neil/B-8578-2008; Fraser, Christophe/A-8109-2008; Hedley,
   Anthony/C-4305-2009; Riley, Steven/C-4384-2009; Ghani, Azra/B-8560-2009;
   Lam, Tai Hing/C-4317-2009
OI Ferguson, Neil/0000-0002-1154-8093; Fraser,
   Christophe/0000-0003-2399-9657; Donnelly, Christl/0000-0002-0195-2463;
   Leung, Gabriel/0000-0002-2503-6283; Ghani, Azra/0000-0002-0007-4910;
   Riley, Steven/0000-0001-7904-4804; Anderson, Roy/0000-0002-9528-3175;
   Lam, Tai Hing/0000-0002-2033-9971
CR [Anonymous], 2003, SARS HONG KONG EXP A
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   *CDCP, 2004, PUBL HLTH GUID COMM
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Fouchier RAM, 2004, CAN MED ASSOC J, V170, P63
   Fraser C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/pnas.0307506101
   Gomez G, 2004, STAT PAP, V45, P139, DOI 10.1007/BF02777221
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hon KLE, 2003, LANCET, V361, P1701, DOI 10.1016/S0140-6736(03)13364-8
   HONAKER J, 2004, AMELIA PROGRAM MISSI
   Hsieh YH, 2004, EMERG INFECT DIS, V10, P201, DOI 10.3201/eid1002.030515
   King G, 2001, AM POLIT SCI REV, V95, P49, DOI 10.1017/S0003055401000235
   LAI PC, 2004, IN PRESS ENV HLTH PE
   Lam TH, 2003, INT J EPIDEMIOL, V32, P178, DOI 10.1093/ije/dyg067
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Leung GM, 2004, EMERG INFECT DIS, V10, P1653, DOI 10.3201/eid1009.040155
   Leung GM, 2004, ANN INTERN MED, V141, P333, DOI 10.7326/0003-4819-141-5-200409070-00106
   Leung GM, 2003, J EPIDEMIOL COMMUN H, V57, P857, DOI 10.1136/jech.57.11.857
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Naylor CD, 2004, JAMA-J AM MED ASSOC, V291, P2483, DOI 10.1001/jama.291.20.2483
   Ng PC, 2004, PEDIATRICS, V113, pE7, DOI 10.1542/peds.113.1.e7
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Poon LLM, 2003, J CLIN VIROL, V28, P233, DOI 10.1016/j.jcv.2003.08.004
   Rainer TH, 2004, ANN INTERN MED, V140, P614, DOI 10.7326/0003-4819-140-8-200404200-00008
   Rainer TH, 2003, BRIT MED J, V326, P1354, DOI 10.1136/bmj.326.7403.1354
   Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478
   Rubin DB, 1987, MULTIPLE IMPUTATION
   Stuart A, 1994, KENDALLS ADV THEORY
   Tai D Y, 2003, Ann Acad Med Singapore, V32, pS34
   Tang P, 2004, CAN MED ASSOC J, V170, P47
   Wand M.P., 1995, KERNEL SMOOTHING
   *WHO, 2002, SUMM PROB SARS CAS O
   *WHO, 2003, US LAB METH SARS DIA
   Wong Wing-Wai, 2003, J Chin Med Assoc, V66, P323
   World Health Organization, 2003, CONS DOC EP SEV AC R
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 36
TC 119
Z9 120
U1 6
U2 19
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD NOV 2
PY 2004
VL 141
IS 9
BP 662
EP 673
DI 10.7326/0003-4819-141-9-200411020-00006
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 867JT
UT WOS:000224839600002
PM 15520422
OA Bronze
DA 2020-04-03
ER

PT J
AU Loeb, M
   McGeer, A
   Henry, B
   Ofner, M
   Rose, D
   Hlywka, T
   Levie, J
   McQueen, J
   Smith, S
   Moss, L
   Smith, A
   Green, K
   Walter, SD
AF Loeb, M
   McGeer, A
   Henry, B
   Ofner, M
   Rose, D
   Hlywka, T
   Levie, J
   McQueen, J
   Smith, S
   Moss, L
   Smith, A
   Green, K
   Walter, SD
TI SARS among critical care nurses, Toronto
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; IDENTIFICATION; CORONAVIRUS; CANADA
AB To determine factors that predispose or protect healthcare workers from severe acute respiratory syndrome (SARS), we conducted a retrospective cohort study among 43 nurses who worked in two Toronto critical care units with SARS patients. Eight of 32 nurses who entered a SARS patient's room were infected. The probability of SARS infection was 6% per shift worked. Assisting during intubation, suctioning before intubation, and manipulating the oxygen mask were high-risk activities. Consistently wearing a mask (either surgical or particulate respirator type N95) while caring for a SARS patient was protective for the nurses, and consistent use of the N95 mask was more protective than not wearing a mask. Risk was reduced by consistent use of a surgical mask, but not significantly. Risk was lower with consistent use of a N95 mask than with consistent use of a surgical mask. We conclude that activities related to intubation increase SARS risk and use of a mask (particularly a N95 mask) is protective.
C1 McMaster Univ, Hamilton, ON, Canada.
   Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
   Toronto Publ Hlth, Toronto, ON, Canada.
   Hlth Canada, Ottawa, ON K1A 0L2, Canada.
   Scarborough Grace Hosp, Scarborough, ON, Canada.
RP Loeb, M (reprint author), Henderson Gen Hosp, Hamilton, ON L8V 1C3, Canada.
EM loebm@mcmaster.ca
RI McGeer, Allison/AAB-6885-2020; mcgeer, allison/H-7747-2014
OI McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137
CR Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P433
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   *HLTH CAN, SEV AC RESP SYNDR CA
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Scales DC, 2003, EMERG INFECT DIS, V9, P1205, DOI 10.3201/eid0910.030525
   Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6
   Varia M, 2003, CAN MED ASSOC J, V169, P285
   *WHO, CUM NUMB PROB REP CA
   World Health Organization, CAS DEF SURV SEV AC
NR 12
TC 119
Z9 122
U1 1
U2 5
PU CENTER DISEASE CONTROL
PI ATLANTA
PA ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD FEB
PY 2004
VL 10
IS 2
BP 251
EP 255
DI 10.3201/eid1002.030838
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 772XH
UT WOS:000188867700017
PM 15030692
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Holmes, KV
AF Holmes, KV
TI SARS coronavirus: a new challenge for prevention and therapy
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; HUMAN ENTERIC CORONAVIRUSES; SPIKE PROTEIN;
   REPLICATION; COMPLEXES
C1 Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA.
RP Holmes, KV (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Campus Box B-175,4200 E 9th Ave, Denver, CO 80262 USA.
CR [Anonymous], 2003, WKLY EPIDEMIOL REC, V78, P97
   Ballesteros ML, 1997, VIROLOGY, V227, P378, DOI 10.1006/viro.1996.8344
   BATTAGLIA M, 1987, J INFECT DIS, V155, P140, DOI 10.1093/infdis/155.1.140
   BRADBURNE AF, 1971, PROG MED VIROL, V13, P373
   Chan-Yeung M, 2003, BRIT MED J, V326, P850, DOI 10.1136/bmj.326.7394.850
   Chilvers MA, 2001, EUR RESPIR J, V18, P965, DOI 10.1183/09031936.01.00093001
   de Arriba ML, 2002, VET IMMUNOL IMMUNOP, V85, P85, DOI 10.1016/S0165-2427(01)00417-2
   Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999
   DROSTEN C, 2003, IN PRESS N ENGL J ME
   FIELDS BN, 1996, FUNDAMENTAL VIROLOGY, P544
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   GERBERDING JL, IN PRESS N ENGL J ME
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Herrewegh AAPM, 1997, VIROLOGY, V234, P349, DOI 10.1006/viro.1997.8663
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   Kapikian A Z, 1975, Dev Biol Stand, V28, P42
   KSIAZEK TG, IN PRESS N ENGL J ME
   Lai M.M.C., 2001, FIELDS VIROLOGY, P1163
   LEE N, 2003, IN PRESS N ENGL J ME
   Lewicki DN, 2002, J BIOL CHEM, V277, P19727, DOI 10.1074/jbc.M201837200
   MACNAUGHTON MR, 1981, ARCH VIROL, V70, P301, DOI 10.1007/BF01320245
   MARRA MA, 2003, SCIENCE
   Matsuyama S, 2002, J VIROL, V76, P11819, DOI 10.1128/JVI.76.23.11819-11826.2002
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   POUTANEN SM, 2003, IN PRESS N ENGL J ME
   RESTA S, 1985, SCIENCE, V229, P978, DOI 10.1126/science.2992091
   ROTA PA, 2003, SCIENCE
   Sawicki DL, 2001, J GEN VIROL, V82, P385, DOI 10.1099/0022-1317-82-2-385
   Sethna PB, 1997, J VIROL, V71, P7744, DOI 10.1128/JVI.71.10.7744-7749.1997
   TSANG KW, 2003, IN PRESS N ENGL J ME
   *WHO, 2003, SEV AC RESP SYNDR SA
   Zelus BD, 2003, J VIROL, V77, P830, DOI 10.1128/JVI.77.2.830-840.2003
   Ziebuhr J, 1999, J VIROL, V73, P177, DOI 10.1128/JVI.73.1.177-185.1999
   2003, MMWR MORB MORTAL WKL, V52, P255
NR 35
TC 119
Z9 134
U1 1
U2 8
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN
PY 2003
VL 111
IS 11
BP 1605
EP 1609
DI 10.1172/JCI200318819
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 686GQ
UT WOS:000183313400001
PM 12782660
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU van Elden, LJR
   van Kraaij, MGJ
   Nijhuis, M
   Hendriksen, KAW
   Dekker, AW
   Rozenberg-Arska, M
   van Loon, AM
AF van Elden, LJR
   van Kraaij, MGJ
   Nijhuis, M
   Hendriksen, KAW
   Dekker, AW
   Rozenberg-Arska, M
   van Loon, AM
TI Polymerase chain reaction is more sensitive than viral culture and
   antigen testing for the detection of respiratory viruses in adults with
   hematological cancer and pneumonia
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID MARROW TRANSPLANT RECIPIENTS; TRANSCRIPTION-PCR ASSAY; SYNCYTIAL VIRUS;
   IMMUNOCOMPROMISED PATIENTS; REVERSE-TRANSCRIPTION; PARAINFLUENZA VIRUS;
   CLINICAL-SAMPLES; INFLUENZA-A; INFECTIONS; SPECIMENS
AB We retrospectively analyzed the value of polymerase chain reaction (PCR) for the detection of respiratory viral infections in 43 patients with hematological cancer whose bronchoalveolar lavage (BAL) samples had been stored. In addition, 17 nose-throat (NT) swabs and 29 blood samples had been obtained. PCR was performed to detect parainfluenza viruses 1-3, respiratory syncytial virus, rhinovirus, influenza viruses A and B, enteroviruses, and coronaviruses. Viral cultures or antigen testing of BAL samples revealed 9 respiratory viruses in 8 patients. By use of PCR, 8 more respiratory viruses were detected in another 7 patients, increasing the rate of identification from 19% to 35% (P<.0005). Available NT swabs yielded the same results with PCR as did BAL samples. We conclude that PCR is more sensitive than viral culture or antigen or serologic testing for detection of respiratory viruses in patients with hematological malignancies, and that it offers the possibility for early, more rapid diagnosis.
C1 Univ Med Ctr Utrecht, Dept Virol, Eijkman Winkler Inst Microbiol Infect Dis & Infla, NL-3508 GA Utrecht, Netherlands.
   Univ Med Ctr Untrecht, Dept Hematol, Utrecht, Netherlands.
RP van Loon, AM (reprint author), Univ Med Ctr Utrecht, Dept Virol, Eijkman Winkler Inst Microbiol Infect Dis & Infla, POB 85500, NL-3508 GA Utrecht, Netherlands.
EM a.m.vanloon@lab.azu.nl
OI Van Elden, Leontine/0000-0002-3878-8927
CR Andeweg AC, 1999, J CLIN MICROBIOL, V37, P524, DOI 10.1128/JCM.37.3.524-530.1999
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990
   Bowden Raleigh A., 1997, American Journal of Medicine, V102, P27, DOI 10.1016/S0002-9343(97)00007-7
   DOLLER G, 1992, J CLIN MICROBIOL, V30, P866
   Echavarria M, 2000, J CLIN MICROBIOL, V38, P2982, DOI 10.1128/JCM.38.8.2982-2984.2000
   Echevarria JE, 1998, J CLIN MICROBIOL, V36, P1388
   ENGLUND JA, 1988, ANN INTERN MED, V109, P203, DOI 10.7326/0003-4819-109-3-203
   Folz RJ, 1999, CHEST, V115, P901, DOI 10.1378/chest.115.3.901
   Ghosh S, 2000, BONE MARROW TRANSPL, V25, P751, DOI 10.1038/sj.bmt.1702228
   Ghosh S, 1999, CLIN INFECT DIS, V29, P528, DOI 10.1086/598627
   Gonzalez Y, 1999, BONE MARROW TRANSPL, V23, P511, DOI 10.1038/sj.bmt.1701605
   Gonzalez Y, 1999, HAEMATOLOGICA, V84, P820
   Gubareva LV, 1998, J INFECT DIS, V178, P1257, DOI 10.1086/314440
   Lewis VA, 1996, CLIN INFECT DIS, V23, P1033, DOI 10.1093/clinids/23.5.1033
   LJUNGMAN P, 1993, CLIN INFECT DIS, V17, P244, DOI 10.1093/clinids/17.2.244
   LJUNGMAN P, 1989, BONE MARROW TRANSPL, V4, P35
   Ljungman Per, 1997, American Journal of Medicine, V102, P44, DOI 10.1016/S0002-9343(97)00010-7
   MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052
   Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1
   NIJHUIS M, 1995, BIOTECHNIQUES, V19, P178
   NIJHUIS M, 1995, BIOTECHNIQUES, V19, P182
   Osiowy C, 1998, J CLIN MICROBIOL, V36, P3149, DOI 10.1128/JCM.36.11.3149-3154.1998
   Papadopoulos NG, 1999, J VIROL METHODS, V80, P179, DOI 10.1016/S0166-0934(99)00045-2
   Rabella N, 1999, CLIN INFECT DIS, V28, P1043, DOI 10.1086/514738
   Schiff GM, 2000, J INFECT DIS, V181, P20, DOI 10.1086/315176
   Schmid ML, 1998, BRIT MED J, V316, P275, DOI 10.1136/bmj.316.7127.275
   Silagy C, 1998, LANCET, V352, P1877
   Sparrelid E, 1997, BONE MARROW TRANSPL, V19, P905, DOI 10.1038/sj.bmt.1700752
   van Elden LJR, 2001, J CLIN MICROBIOL, V39, P196, DOI 10.1128/JCM.39.1.196-200.2001
   Verdonck LF, 1997, CLIN INFECT DIS, V24, P901, DOI 10.1093/clinids/24.5.901
   Wendt C H, 1995, Semin Respir Infect, V10, P224
   WENDT CH, 1992, NEW ENGL J MED, V326, P921, DOI 10.1056/NEJM199204023261404
   WHIMBEY E, 1995, CLIN INFECT DIS, V21, P376, DOI 10.1093/clinids/21.2.376
   WHIMBEY E, 1994, BONE MARROW TRANSPL, V13, P437
   Whimbey E, 1996, CLIN INFECT DIS, V22, P778, DOI 10.1093/clinids/22.5.778
   Whimbey Estella, 1997, American Journal of Medicine, V102, P10, DOI 10.1016/S0002-9343(97)80004-6
NR 36
TC 119
Z9 121
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JAN 15
PY 2002
VL 34
IS 2
BP 177
EP 183
DI 10.1086/338238
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 502BC
UT WOS:000172722900012
PM 11740705
OA Bronze
DA 2020-04-03
ER

PT J
AU Beauchemin, N
   Kunath, T
   Robitaille, J
   Chow, B
   Turbide, C
   Daniels, E
   Veillette, A
AF Beauchemin, N
   Kunath, T
   Robitaille, J
   Chow, B
   Turbide, C
   Daniels, E
   Veillette, A
TI Association of biliary glycoprotein with protein tyrosine phosphatase
   SHP-1 in malignant colon epithelial cells
SO ONCOGENE
LA English
DT Article
DE biliary glycoprotein; Bgp; C-CAM; colon carcinoma; SHP-1; PTP1C; HCP
ID ANTIGEN-RELATED GENE; CARCINOEMBRYONIC ANTIGEN; ADHESION MOLECULE;
   ECTO-ATPASE; C-CAM; PHOSPHOTYROSINE PHOSPHATASE; COLORECTAL CARCINOMAS;
   ENDOGENOUS SUBSTRATE; MONOCLONAL-ANTIBODY; MURINE CORONAVIRUS
AB Biliary glycoprotein (Bgp) is a member of the immunoglobulin superfamily and the carcinoembryonic antigen family. Previous studies have shown that Bgp functions as an intercellular adhesion molecule and a canalicular bile salt transporter. Moreover, we and others demonstrated that Bgp can inhibit colonic and prostatic tumor cell growth in vivo, through a mechanism which depends on sequences present in its cytoplasmic domain. In this study, we have examined the possibility that the cytoplasmic domain of Bgp can interact with signal transduction molecules. We showed that tyrosine phosphorylated Bgp, expressed in mouse colon carcinoma CT51 cells, could reversibly associate with protein tyrosine phosphatase SHP-1. Mutation of either of two tyrosine residues present in the cytoplasmic domain of Bgp abrogated SHP-1 binding, suggesting that this association was mediated by both tyrosine residues. Similarly, we noted that either of the two SH2 domains of SHP-1 could bind tyrosine phosphorylated Bgp in vitro. It is therefore conceivable that some of the functions of Bgp are mediated through its ability to induce intracellular protein tyrosine dephosphorylation.
C1 MCGILL UNIV,CTR CANC,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA.
   MCGILL UNIV,CTR CANC,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA.
   MCGILL UNIV,CTR CANC,DEPT ANAT & CELL BIOL,MONTREAL,PQ H3G 1Y6,CANADA.
RP Beauchemin, N (reprint author), MCGILL UNIV,CTR CANC,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA.
OI Kunath, Tilo/0000-0002-8805-7356
CR Adachi M, 1996, CELL, V85, P15
   BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267
   BRUMMER J, 1995, ONCOGENE, V11, P1649
   Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3
   COUTELIER JP, 1994, EUR J IMMUNOL, V24, P1383, DOI 10.1002/eji.1830240622
   DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523
   Daniels E, 1996, DEV DYNAM, V206, P272, DOI 10.1002/(SICI)1097-0177(199607)206:3<272::AID-AJA5>3.0.CO;2-F
   DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087
   DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088
   FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073
   GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z
   HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959
   HIXSON DC, 1985, CANCER RES, V45, P3742
   HSIEH JT, 1994, J BIOL CHEM, V269, P3711
   HSIEH JT, 1995, CANCER RES, V55, P190
   KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8
   Kunath T, 1995, ONCOGENE, V11, P2375
   KUPRINA NI, 1990, HISTOCHEMISTRY, V94, P179, DOI 10.1007/BF02440185
   LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239
   LIN SH, 1989, J BIOL CHEM, V264, P14408
   MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256
   MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396
   MCCUAIG K, 1993, GENE, V127, P173, DOI 10.1016/0378-1119(93)90716-G
   MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165
   MILLER AD, 1989, BIOTECHNIQUES, V7, P980
   NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009
   NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.0104f.x
   NEDELLEC P, 1994, J VIROL, V68, P4525
   NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744
   O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306
   OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505
   OCKLIND C, 1982, J BIOL CHEM, V257, P6788
   PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077
   Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141
   PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123
   RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0
   ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527
   ROSENBERG M, 1993, CANCER RES, V53, P4938
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083
   SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539
   SKUBITZ KM, 1995, J IMMUNOL, V155, P5382
   SMITH AL, 1991, J INFECT DIS, V163, P879, DOI 10.1093/infdis/163.4.879
   SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.ge.19.120185.002231
   THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510
   TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124
   UCHIDA T, 1994, J BIOL CHEM, V269, P12220
   VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217
   WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4
   YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577
   YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350
NR 53
TC 119
Z9 119
U1 0
U2 2
PU STOCKTON PRESS
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD FEB 20
PY 1997
VL 14
IS 7
BP 783
EP 790
DI 10.1038/sj.onc.1200888
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA WJ112
UT WOS:A1997WJ11200004
PM 9047385
OA Bronze
DA 2020-04-03
ER

PT J
AU Wang, LY
   Byrum, B
   Zhang, Y
AF Wang, Leyi
   Byrum, Beverly
   Zhang, Yan
TI Detection and Genetic Characterization of Deltacoronavirus in Pigs,
   Ohio, USA, 2014
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID VIRUS
AB In Ohio, United States, in early 2014, a deltacoronavirus was detected in feces and intestine samples from pigs with diarrhea! disease. The complete genome sequence and phylogenetic analysis of the virus confirmed that the virus is closely related to a porcine deltacoronavirus (porcine coronavirus HKU15) reported in Hong Kong in 2012.
C1 [Wang, Leyi; Byrum, Beverly; Zhang, Yan] Ohio Dept Agr, Reynoldsburg, OH 43068 USA.
RP Zhang, Y (reprint author), Ohio Dept Agr, Anim Dis Diagnost Lab, 8995 East Main St,Bldg 6, Reynoldsburg, OH 43068 USA.
EM yzhang@agri.ohio.gov
RI Wang, Leyi/G-9448-2014; Wang, Leyi/AAB-4248-2019
OI Wang, Leyi/0000-0001-5813-9505; Wang, Leyi/0000-0001-5813-9505
CR Chan JFW, 2013, TRENDS MICROBIOL, V21, P544, DOI 10.1016/j.tim.2013.05.005
   Huang YW, 2013, MBIO, V4, DOI 10.1128/mBio.00737-13
   Schwegmann-Wessels C, 2006, DEUT TIERARZTL WOCH, V113, P157
   Song D, 2012, VIRUS GENES, V44, P167, DOI 10.1007/s11262-012-0713-1
   Wang LY, 2014, EMERG INFECT DIS, V20, P917, DOI 10.3201/eid2005.140195
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
NR 7
TC 118
Z9 147
U1 0
U2 23
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUL
PY 2014
VL 20
IS 7
BP 1227
EP 1230
DI 10.3201/eid2007.140296
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AK4JB
UT WOS:000338389900022
PM 24964136
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Hijawi, B
   Abdallat, M
   Sayaydeh, A
   Alqasrawi, S
   Haddadin, A
   Jaarour, N
   Alsheikh, S
   Alsanouri, T
AF Hijawi, B.
   Abdallat, M.
   Sayaydeh, A.
   Alqasrawi, S.
   Haddadin, A.
   Jaarour, N.
   Alsheikh, S.
   Alsanouri, T.
TI Novel coronavirus infections in Jordan, April 2012: epidemiological
   findings from a retrospective investigation
SO EASTERN MEDITERRANEAN HEALTH JOURNAL
LA English
DT Article
AB In April 2012, an outbreak of acute respiratory illness occurred in a public hospital in Zarqa city, in Jordan; 8 health care workers were among the 11 people affected, 1 of who later died. The cause of the outbreak was unknown at the time and an epidemiological investigation including laboratory testing carried out immediately after the outbreak was inconclusive. Following the discovery of novel coronavirus infection (nCoV) in the Arabian peninsula in September 2012, stored respiratory and serum samples of patients from this outbreak were retested and the diagnosis of nCoV was confirmed in 2 deceased patients. This paper describes the epidemiological findings of retrospective investigation carried out in November 2012 and highlights the likelihood of nosocomial transmission of nCoV infection in a health-care setting. A total of 2 laboratory-confirmed and 11 probable cases were identified from this outbreak of whom 10 were HCWs and 2 were family members of cases.
EM sultanmabdalla@yahoo.com
FU Jordan Ministry of Health; World Health Organization Regional Office for
   the Eastern Mediterranean; World Health Organization Jordan country
   office; United States Naval Medical Research Unit-3 in Cairo; Centers
   for Disease Control and Prevention, Atlanta, GeorgiaUnited States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA
FX The Jordan Ministry of Health expresses it is appreciation and thanks to
   the World Health Organization Regional Office for the Eastern
   Mediterranean, the World Health Organization Jordan country office, the
   United States Naval Medical Research Unit-3 in Cairo and the Centers for
   Disease Control and Prevention, Atlanta, Georgia for their assistance
   and support.
CR AlBarrak AM, 2012, SAUDI MED J, V33, P1265
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Buchholz U, 2013, EUROSURVEILLANCE, V18, P6
   Health Protection Agency (HPA) UK NCoV Investigation team, 2013, EUROSURVEILLANCE, V18
   Severe respiratory disease of unknown origin-Jordan-outbreak in ICU, 2012, SEV RESP DIS UNKN OR
   Severe respiratory illness associated with a novel coronavirus-Saudi Arabia and Qatar, 2012, MORBIDITY MORTALITY, V61, P820
   World Health Organization, 2013, INT SURV REC HUM INF
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   2012, NOV COR INF UPD
NR 9
TC 118
Z9 124
U1 4
U2 11
PU WHO EASTERN MEDITERRANEAN REGIONAL OFFICE
PI NASR CITY, CAIRO
PA P. O. BOX 7608, NASR CITY, CAIRO, EGYPT
SN 1020-3397
EI 1687-1634
J9 E MEDITERR HEALTH J
JI East Mediterr. Health J.
PY 2013
VL 19
SU 1
BP S12
EP S18
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 163QZ
UT WOS:000320353300004
PM 23888790
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Wootton, SC
   Kim, DS
   Kondoh, Y
   Chen, E
   Lee, JS
   Song, JW
   Huh, JW
   Taniguchi, H
   Chiu, C
   Boushey, H
   Lancaster, LH
   Wolters, PJ
   DeRisi, J
   Ganem, D
   Collard, HR
AF Wootton, Sharon Chao
   Kim, Dong Soon
   Kondoh, Yasuhiro
   Chen, Eunice
   Lee, Joyce S.
   Song, Jin Woo
   Huh, Jin Won
   Taniguchi, Hiroyuki
   Chiu, Charles
   Boushey, Homer
   Lancaster, Lisa H.
   Wolters, Paul J.
   DeRisi, Joseph
   Ganem, Don
   Collard, Harold R.
TI Viral Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE acute lung injury; virus; infection; pulmonary fibrosis; etiology
ID TT VIRUS; PIRFENIDONE; PROFILES; PCR
AB Rationale: Idiopathic pulmonary fibrosis is a progressive, uniformly fatal interstitial lung disease. An acute exacerbation of idiopathic pulmonary fibrosis isanepisode of acute respiratory worsening without an identifiable etiology. Occult viral infection has been proposed as a possible cause of acute exacerbation.
   Objectives: To use unbiased genomics-based discovery methods to define the role of viruses in acute exacerbation of idiopathic pulmonary fibrosis.
   Methods: Bronchoalveolar lavage and serum from patients with acute exacerbation of idiopathic pulmonary fibrosis, stable disease, and acute lung injury were tested for viral nucleic acid using multiplex polymerase chain reaction, pan-viral microarray, and highthroughput cDNA sequencing.
   Measurements and Main Results: Four of forty-three patients with acute exacerbation of idiopathic pulmonary fibrosis had evidence of common respiratory viral infection (parainfluenza [n = 1], rhinovirus [n = 2], coronavirus [n = 1]); no viruses were detected in the bronchoalveolar lavage from stable patients. Pan-viral microarrays revealed additional evidence of viral infection (herpes simplex virus [n = 1], Epstein-Barr virus [n = 2], and torque teno virus [TTV] [n = 12]) in patients with acute exacerbation. TTV infection was significantly more common in patients with acute exacerbation than stable controls (P = 0.0003), but present in a similar percentage of acute lung injury controls. Deep sequencing of a subset of acute exacerbation cases confirmed the presence of TTV but did not identify additional viruses.
   Conclusions: Viral infection was not detected in most cases of acute exacerbation of idiopathic pulmonary fibrosis. TTV was present in a significant minority of cases, and cases of acute lung injury; the clinical significance of this finding remains to be determined.
C1 [Wootton, Sharon Chao] Univ Calif Berkeley, UC San Francisco UC Berkeley Joint Grad Grp Bioen, Berkeley, CA 94720 USA.
   [Wootton, Sharon Chao; DeRisi, Joseph] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem, San Francisco, CA USA.
   [Kim, Dong Soon; Song, Jin Woo; Huh, Jin Won] Univ Ulsan, Coll Med, Asan Med Ctr, Div Pulm & Crit Care Med,Dept Med, Seoul, South Korea.
   [Kondoh, Yasuhiro; Taniguchi, Hiroyuki] Tosei Gen Hosp, Dept Resp Med & Allergy, Seto, Japan.
   [Chen, Eunice; Chiu, Charles] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Lee, Joyce S.; Chiu, Charles; Boushey, Homer; Wolters, Paul J.; Ganem, Don; Collard, Harold R.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Lancaster, Lisa H.] Vanderbilt Univ, Dept Med, Nashville, TN USA.
   [Wootton, Sharon Chao; DeRisi, Joseph] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Med, San Francisco, CA USA.
RP Kim, DS (reprint author), Univ Ulsan, Dept Pulm & Crit Care, Asan Med Ctr, Seoul, South Korea.
EM dskim@amc.seoul.kr
OI Chiu, Charles/0000-0003-2915-2094
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL 086516]; HHMIHoward Hughes Medical Institute;
   Packard FoundationThe David & Lucile Packard Foundation; Doris Duke
   Charitable Research FoundationDoris Duke Charitable Foundation (DDCF);
   Abbott DiagnosticsAbbott Laboratories; GlaxoSmithKlineGlaxoSmithKline;
   McGraw-Hill Co.; Blackwell Publishing Ltd; Taylor Francis; Intermune;
   Actelion; Johnson JohnsonJohnson & Johnson USA; GileadGilead Sciences;
   Boehringer-IngelheimBoehringer Ingelheim; FibroGen; GenentechRoche
   HoldingGenentech; Arresto; CHEST Foundation/ASP
FX Supported by NHLBI HL 086516, HHMI, Packard Foundation, and Doris Duke
   Charitable Research Foundation.; S.C.W. does not have a financial
   relationship with a commercial entity that has an interest in the
   subject of this manuscript. D.S.K. does not have a financial
   relationship with a commercial entity that has an interest in the
   subject of this manuscript. Y.K. does not have a financial relationship
   with a commercial entity that has an interest in the subject of this
   manuscript. E.C. received funding for the Chui Lab from Abbott
   Diagnostics. J.S.L. does not have a financial relationship with a
   commercial entity that has an interest in the subject of this
   manuscript. J.W.S. does not have a financial relationship with a
   commercial entity that has an interest in the subject of this
   manuscript. J.W.H. does not have a financial relationship with a
   commercial entity that has an interest in the subject of this
   manuscript. H.T. does not have a financial relationship with a
   commercial entity that has an interest in the subject of this
   manuscript. C.C. received research support from Abbott Diagnostics. H.B.
   is a Board Member of the Health Effects Institute and was a consultant
   for Pharmaxis Ltd., KALOBIOS Pharmaceuticals, Inc., Merck Sharp & Dohme,
   and Genentech. He is employed by the University of California, San
   Francisco, and received grant support from GlaxoSmithKline. He receives
   royalties from McGraw-Hill Co., Blackwell Publishing Ltd, and Taylor &
   Francis. L.H.L. was on the Advisory Board for Intermune and Actelion.
   She received grant support from Intermune, Actelion, Johnson & Johnson,
   and Gilead. P.J.W. does not have a financial relationship with a
   commercial entity that has an interest in the subject of this
   manuscript. J.D. does not have a financial relationship with a
   commercial entity that has an interest in the subject of this
   manuscript. D.G. does not have a financial relationship with a
   commercial entity that has an interest in the subject of this
   manuscript. H.R.C.'s institution received consultancy fees from
   Boehringer-Ingelheim, FibroGen, Genentech, Gilead, Actelion, and
   Arresto. He received institutional grant support from the CHEST
   Foundation/ASP and received payment for the development of educational
   presentations from the France Foundation.
CR *AM THOR SOC, 2002, AM J RESP CRIT CARE, V165, P277, DOI DOI 10.1164/AJRCCM.165.2.ATS01
   *AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00
   AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U
   Azuma A, 2005, AM J RESP CRIT CARE, V171, P1040, DOI 10.1164/rccm.200404-571OC
   Bando M, 2001, RESP MED, V95, P935, DOI 10.1053/rmed.2001.1151
   Bernard GR, 2005, AM J RESP CRIT CARE, V172, P798, DOI 10.1164/rccm.200504-663OE
   Collard HR, 2007, AM J RESP CRIT CARE, V176, P636, DOI 10.1164/rccm.200703-463PP
   Collard HR, 2010, AM J PHYSIOL-LUNG C, V299, pL3, DOI 10.1152/ajplung.90637.2008
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Finkbeiner SR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000011
   Friaza V, 2010, J MICROBIOL METH, V82, P98, DOI 10.1016/j.mimet.2010.03.026
   Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234
   Handa A, 2000, TRANSFUSION, V40, P245, DOI 10.1046/j.1537-2995.2000.40020245.x
   Hino S, 2007, REV MED VIROL, V17, P45, DOI 10.1002/rmv.524
   Huie TJ, 2010, RESPIROLOGY, V15, P909, DOI 10.1111/j.1440-1843.2010.01774.x
   Kazufumi IT, 2003, VIRUS GENES, V26, P165, DOI 10.1023/A:1023487413912
   Kim Dong Soon, 2006, Proc Am Thorac Soc, V3, P285, DOI 10.1513/pats.200601-005TK
   Kim DS, 2006, EUR RESPIR J, V27, P143, DOI 10.1183/09031936.06.00114004
   Konishi K, 2009, AM J RESP CRIT CARE, V180, P167, DOI 10.1164/rccm.200810-1596OC
   Kubo H, 2005, CHEST, V128, P1475, DOI 10.1378/chest.128.3.1475
   Lam WY, 2007, J CLIN MICROBIOL, V45, P3631, DOI 10.1128/JCM.00280-07
   Maggi F, 2003, J VIROL, V77, P2418, DOI 10.1128/JVI.77.4.2418-2425.2003
   Mariscal LF, 2002, VIROLOGY, V301, P121, DOI 10.1006/viro.2002.1545
   Mushahwar IK, 1999, P NATL ACAD SCI USA, V96, P3177, DOI 10.1073/pnas.96.6.3177
   Okamoto H, 1999, VIROLOGY, V259, P428, DOI 10.1006/viro.1999.9770
   Okamura A, 1999, J MED VIROL, V58, P174, DOI 10.1002/(SICI)1096-9071(199906)58:2&lt;174::AID-JMV12&gt;3.0.CO;2-X
   Song JW, 2011, EUR RESPIR J, V37, P356, DOI 10.1183/09031936.00159709
   Taniguchi H, 2010, EUR RESPIR J, V35, P821, DOI 10.1183/09031936.00005209
   Urisman A, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r78
   Vannella KM, 2008, FIBROGENESIS TISSUE, V1, DOI 10.1186/1755-1536-1-2
   Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
NR 32
TC 118
Z9 124
U1 2
U2 16
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JUN 15
PY 2011
VL 183
IS 12
BP 1698
EP 1702
DI 10.1164/rccm.201010-1752OC
PG 5
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 786KC
UT WOS:000292305600022
PM 21471095
OA Green Published
DA 2020-04-03
ER

PT J
AU Eckerle, LD
   Becker, MM
   Halpin, RA
   Li, K
   Venter, E
   Lu, XT
   Scherbakova, S
   Graham, RL
   Baric, RS
   Stockwell, TB
   Spiro, DJ
   Denison, MR
AF Eckerle, Lance D.
   Becker, Michelle M.
   Halpin, Rebecca A.
   Li, Kelvin
   Venter, Eli
   Lu, Xiaotao
   Scherbakova, Sana
   Graham, Rachel L.
   Baric, Ralph S.
   Stockwell, Timothy B.
   Spiro, David J.
   Denison, Mark R.
TI Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus Replication Is
   Revealed by Complete Genome Sequencing
SO PLOS PATHOGENS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; DEPENDENT RNA-POLYMERASE; MURINE
   HEPATITIS-VIRUS; MOLECULAR EVOLUTION; LETHAL MUTAGENESIS; INFECTIOUS
   CDNA; MUTATION; RIBAVIRIN; FIDELITY; PROTEIN
AB Most RNA viruses lack the mechanisms to recognize and correct mutations that arise during genome replication, resulting in quasispecies diversity that is required for pathogenesis and adaptation. However, it is not known how viruses encoding large viral RNA genomes such as the Coronaviridae (26 to 32 kb) balance the requirements for genome stability and quasispecies diversity. Further, the limits of replication infidelity during replication of large RNA genomes and how decreased fidelity impacts virus fitness over time are not known. Our previous work demonstrated that genetic inactivation of the coronavirus exoribonuclease (ExoN) in nonstructural protein 14 (nsp14) of murine hepatitis virus results in a 15-fold decrease in replication fidelity. However, it is not known whether nsp14-ExoN is required for replication fidelity of all coronaviruses, nor the impact of decreased fidelity on genome diversity and fitness during replication and passage. We report here the engineering and recovery of nsp14-ExoN mutant viruses of severe acute respiratory syndrome coronavirus (SARS-CoV) that have stable growth defects and demonstrate a 21-fold increase in mutation frequency during replication in culture. Analysis of complete genome sequences from SARS-ExoN mutant viral clones revealed unique mutation sets in every genome examined from the same round of replication and a total of 100 unique mutations across the genome. Using novel bioinformatic tools and deep sequencing across the full-length genome following 10 population passages in vitro, we demonstrate retention of ExoN mutations and continued increased diversity and mutational load compared to wild-type SARS-CoV. The results define a novel genetic and bioinformatics model for introduction and identification of multi-allelic mutations in replication competent viruses that will be powerful tools for testing the effects of decreased fidelity and increased quasispecies diversity on viral replication, pathogenesis, and evolution.
C1 [Eckerle, Lance D.; Becker, Michelle M.; Lu, Xiaotao; Denison, Mark R.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
   [Eckerle, Lance D.; Becker, Michelle M.; Lu, Xiaotao; Denison, Mark R.] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN USA.
   [Eckerle, Lance D.; Becker, Michelle M.; Lu, Xiaotao; Denison, Mark R.] Vanderbilt Univ, Med Ctr, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN USA.
   [Halpin, Rebecca A.; Li, Kelvin; Venter, Eli; Scherbakova, Sana; Stockwell, Timothy B.; Spiro, David J.] J Craig Venter Inst, Rockville, MD USA.
   [Graham, Rachel L.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
   [Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA.
RP Eckerle, LD (reprint author), Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
EM mark.denison@vanderbilt.edu
RI Denison, Mark/O-7258-2018
OI Denison, Mark/0000-0003-2655-0900; Stockwell,
   Timothy/0000-0002-3595-4539
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [T32-AI049824, R01-AI026603, P01-AI059443, F32-AI080148, U54-AI057157];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [N01-AI-30071, HHSN272200900007C];
   Public Health ServiceUnited States Public Health Service [CA68485]
FX This work was supported by Public Health Service awards from the
   National Institute of Allergy and Infectious Diseases T32-AI049824
   (LDE); R01AI026603 (MRD); P01-AI059443 (RSB and RLG); F32-AI080148
   (RLG); U54-AI057157 (MMB); and NIH contract N01-AI-30071 and
   HHSN272200900007C (DJS). Additional support was provided by Public
   Health Service award CA68485 to the Vanderbilt University DNA Sequencing
   Shared Resource of the Vanderbilt-Ingram Cancer Center. The funding
   organizations had no role in study design, data collection or analysis,
   or preparation of the manuscript.
CR Almazan F, 2006, J VIROL, V80, P10900, DOI 10.1128/JVI.00385-06
   Arias A, 2001, J GEN VIROL, V82, P1049, DOI 10.1099/0022-1317-82-5-1049
   Arnold JJ, 2005, J BIOL CHEM, V280, P25706, DOI 10.1074/jbc.M503444200
   Becker MM, 2008, P NATL ACAD SCI USA, V105, P19944, DOI 10.1073/pnas.0808116105
   Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517
   Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004
   Brockway SM, 2003, J VIROL, V77, P10515, DOI 10.1128/JVI.77.19.10515-10527.2003
   Bull JJ, 2007, J VIROL, V81, P2930, DOI 10.1128/JVI.01624-06
   Bull JJ, 2005, PLOS COMPUT BIOL, V1, P450, DOI 10.1371/journal.pcbi.0010061
   Chen P, 2007, J BIOCHEM MOL BIOL, V40, P649
   Chen Y, 2009, P NATL ACAD SCI USA, V106, P3484, DOI 10.1073/pnas.0808790106
   Chung DH, 2007, J VIROL, V81, P11722, DOI 10.1128/JVI.00874-07
   Crotty S, 2000, NAT MED, V6, P1375
   Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598
   Cuevas JM, 2009, GENETICS, V183, P747, DOI 10.1534/genetics.109.106005
   DOMINGO E, 1978, CELL, V13, P735, DOI 10.1016/0092-8674(78)90223-4
   DOPAZO J, 1988, P NATL ACAD SCI USA, V85, P6811, DOI 10.1073/pnas.85.18.6811
   Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910
   DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160
   Eckerle LD, 2007, J VIROL, V81, P12135, DOI 10.1128/JVI.01296-07
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Graham RL, 2005, J VIROL, V79, P13399, DOI 10.1128/JVI.79.21.13399-13411.2005
   Harismendy O, 2009, BIOTECHNIQUES, V46, P229, DOI 10.2144/000113082
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   HOLLAND JJ, 1990, J VIROL, V64, P3960, DOI 10.1128/JVI.64.8.3960-3962.1990
   HOLLAND JJ, 1991, J VIROL, V65, P2960, DOI 10.1128/JVI.65.6.2960-2967.1991
   Imbert I, 2006, EMBO J, V25, P4933, DOI 10.1038/sj.emboj.7601368
   Jerzak GVS, 2007, VIROLOGY, V360, P469, DOI 10.1016/j.virol.2006.10.029
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Li K, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-191
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110
   Novella IS, 2004, J VIROL, V78, P9837, DOI 10.1128/JVI.78.18.9837-9841.2004
   Perales C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000658
   Pfeiffer JK, 2003, P NATL ACAD SCI USA, V100, P7289, DOI 10.1073/pnas.1232294100
   Pfeiffer JK, 2005, PLOS PATHOG, V1, P102, DOI 10.1371/journal.ppat.0010011
   Poon LLM, 2005, J MED VIROL, V76, P435, DOI 10.1002/jmv.20379
   QI J, 2009, BIOINFORMATICS
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Sawicki S G, 1995, Adv Exp Med Biol, V380, P499
   Sawicki SG, 2005, CURR TOP MICROBIOL, V287, P31, DOI 10.1007/3-540-26765-4_2
   Scott J, 2008, J BACTERIOL, V190, P6290, DOI 10.1128/JB.01569-07
   SILLITOE I, 2003, BIOINFORMATICS GENES, P81
   Sims AC, 2006, ADV EXP MED BIOL, V581, P535
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Tsibris AMN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005683
   Vabret A, 2006, J GEN VIROL, V87, P3349, DOI 10.1099/vir.0.82065-0
   van Hemert MJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000054
   Vignuzzi M, 2006, NATURE, V439, P344, DOI 10.1038/nature04388
   Vignuzzi M, 2005, VIRUS RES, V107, P173, DOI 10.1016/j.virusres.2004.11.007
   Vignuzzi M, 2008, NAT MED, V14, P154, DOI 10.1038/nm1726
   Vo NV, 2003, BIOCHEMISTRY-US, V42, P10462, DOI 10.1021/bi0344681
   von Brunn A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000459
   von Wagner M, 2003, J VIRAL HEPATITIS, V10, P413
   Wang CL, 2007, GENOME RES, V17, P1195, DOI 10.1101/gr.6468307
   Weese D, 2009, GENOME RES, V19, P1646, DOI 10.1101/gr.088823.108
   Yeh SH, 2004, P NATL ACAD SCI USA, V101, P2542, DOI 10.1073/pnas.0307904100
   Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Yount B, 2006, P NATL ACAD SCI USA, V103, P12546, DOI 10.1073/pnas.0605438103
   Zuniga S, 2004, J VIROL, V78, P980, DOI 10.1128/JVI.78.2.980-994.2004
NR 61
TC 118
Z9 119
U1 3
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAY
PY 2010
VL 6
IS 5
AR e1000896
DI 10.1371/journal.ppat.1000896
PG 15
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 610TL
UT WOS:000278759900016
PM 20463816
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Gagnon, CA
   Tremblay, D
   Tijssen, P
   Venne, MH
   Houde, A
   Elahi, SM
AF Gagnon, Carl A.
   Tremblay, Donald
   Tijssen, Peter
   Venne, Marie-Helene
   Houde, Alain
   Elahi, Seyyed Mehdy
TI The emergence of porcine circovirus 2b genotype (PCV-2b) in swine in
   Canada
SO CANADIAN VETERINARY JOURNAL-REVUE VETERINAIRE CANADIENNE
LA English
DT Article
ID MULTISYSTEMIC WASTING SYNDROME; HEPATITIS-E VIRUS; RESPIRATORY SYNDROME
   VIRUS; DIFFERENT GEOGRAPHIC REGIONS; EXPERIMENTAL REPRODUCTION;
   GENETIC-CHARACTERIZATION; EXPERIMENTAL-INFECTION; MOLECULAR
   CHARACTERIZATION; PCV2 REPLICATION; INFLUENZA-VIRUS
AB Since late 2004, the swine industry in the province of Quebec has experienced a significant increase in death rate related to postweaning multisystemic wasting syndrome (PMWS). To explain this phenomenon, 2 hypotheses were formulated: 1) the presence of a 2nd pathogen could be exacerbating the porcine circovirus 2 (PCV-2) infection, or 2) a new and more virulent PCV-2 strain could be infecting swine. In 2005, 13 PMWS cases were submitted to the Quebec provincial diagnostic laboratory and PCV-2 was the only virus that could be found consistently by PCR in all 13 samples. The PCR detection results obtained for other viruses revealed the following: 61.5% were positive for porcine reproductive and respiratory syndrome virus, 30.8% for swine influenza virus, 15.4% for porcine parvovirus, 69.2% for swine torque teno virus (swTTV), 38.5% for swine hepatitis E virus (swHEV) and 84.6% for Mycoplasma hyorhinis; transmissible gastroenteritis virus and porcine respiratory coronavirus (TGEV/PRCV) was not detected. Sequences of the entire genome revealed that these PCV-2 strains belonged to a genotype (named PCV-2b) that has never been reported in Canada. Further sequence analyses on 83 other Canadian PCV-2 positive cases submitted to the provincial diagnostic laboratory during years 2005 and 2006 showed that 79.5% of the viral sequences obtained clustered in the PCV-2b genotype. The appearance of the PCV-2b genotype in Canada may explain the death rate increase related to PMWS, but this relationship has to be confirmed.
C1 Univ Montreal, Fac Med Vet, GREMIP, St Hyacinthe, PQ J2S 7C6, Canada.
   Univ Montreal, Fac Med Vet, Serv Diagnost, St Hyacinthe, PQ J2S 7C6, Canada.
   Univ Quebec, Inst Armand Frappier, INRS, Laval, PQ H7V 1B7, Canada.
   Agr & Agri Food Canada, St Hyacinthe, PQ J2S 8E3, Canada.
RP Gagnon, CA (reprint author), Univ Montreal, Fac Med Vet, GREMIP, 3200 Rue Sicotte, St Hyacinthe, PQ J2S 7C6, Canada.
EM carl.a.gagnon@umontreal.ca
RI Gagnon, Carl A/A-9239-2015
OI Gagnon, Carl A./0000-0003-4528-541X
CR Allan GM, 1999, J COMP PATHOL, V121, P1, DOI 10.1053/jcpa.1998.0295
   Allan GM, 1998, J VET DIAGN INVEST, V10, P3, DOI 10.1177/104063879801000102
   Allan GM, 2000, ARCH VIROL, V145, P2421, DOI 10.1007/s007050070031
   *AM TYP CULT COLL, CRL1746 AM TYP CULT
   CARMAN S, 2006, AHL NEWSLETTER, V10
   Carman S, 2006, CAN VET J, V47, P761
   Chae C, 2004, VET J, V168, P41, DOI 10.1016/j.tvjl.2003.09.018
   Chae C, 2005, VET J, V169, P326, DOI 10.1016/j.tvjl.2004.01.012
   Cheung AK, 2003, VIROLOGY, V310, P41, DOI 10.1016/S0042-6822(03)00096-5
   Cheung AK, 2003, VIROLOGY, V305, P168, DOI 10.1006/viro.2002.1733
   Clavijo A, 2002, CAN J VET RES, V66, P117
   de Boisseson C, 2004, J GEN VIROL, V85, P293, DOI 10.1099/vir.0.19536-0
   DELAY J, 2005, AHL NEWSLETTER, V9
   Ellis J, 1998, CAN VET J, V39, P44
   Fenaux M, 2004, J VIROL, V78, P13440, DOI 10.1128/JVI.78.24.13440-13446.2004
   Fenaux M, 2000, J CLIN MICROBIOL, V38, P2494, DOI 10.1128/JCM.38.7.2494-2503.2000
   Halbur PG, 1996, J VET DIAGN INVEST, V8, P11, DOI 10.1177/104063879600800103
   Hamel AL, 1998, J VIROL, V72, P5262, DOI 10.1128/JVI.72.6.5262-5267.1998
   HARDING JC, 1997, SWINE HEALTH PROD, P201
   Harding JCS, 2004, VET MICROBIOL, V98, P131, DOI 10.1016/j.vetmic.2003.10.013
   Hotzel H, 1996, VET MICROBIOL, V49, P31, DOI 10.1016/0378-1135(95)00176-X
   Huang FF, 2002, J CLIN MICROBIOL, V40, P1326, DOI 10.1128/JCM.40.4.1326-1332.2002
   Kasorndorkbua C, 2003, CAN J VET RES, V67, P303
   Kim L, 2000, J VET DIAGN INVEST, V12, P385, DOI 10.1177/104063870001200418
   Kobisch Marylene, 2003, Methods Mol Biol, V216, P247
   Krakowka S, 2000, VET PATHOL, V37, P254, DOI 10.1354/vp.37-3-254
   Larochelle R, 2002, VIRUS RES, V90, P101, DOI 10.1016/S0168-1702(02)00141-7
   Lin JH, 2006, VET MICROBIOL, V115, P111, DOI 10.1016/j.vetmic.2006.02.004
   Liu J, 2005, J VIROL, V79, P8262, DOI 10.1128/JVI.79.13.8262-8274.2005
   Liu J, 2006, J VIROL, V80, P5065, DOI 10.1128/JVI.80.10.5065-5073.2006
   MA ICM, 2005, P 86 ANN M C RES WOR, P35
   Mankertz A, 2001, VIROLOGY, V279, P429, DOI 10.1006/viro.2000.0730
   Matsuda H, 2003, J INFECT DIS, V188, P944, DOI 10.1086/378074
   McKeown NE, 2004, VET MICROBIOL, V104, P113, DOI 10.1016/j.vetmic.2004.08.013
   Meehan BM, 1998, J GEN VIROL, V79, P2171, DOI 10.1099/0022-1317-79-9-2171
   Meng XJ, 1998, ARCH VIROL, V143, P1405, DOI 10.1007/s007050050384
   Meng XJ, 1999, J MED VIROL, V59, P297, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;297::AID-JMV6&gt;3.0.CO;2-3
   Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860
   MENG XJ, 1995, J GEN VIROL, V76, P3181, DOI 10.1099/0022-1317-76-12-3181
   MOORE C, 2006, RAPPORT ENQUETE INTE
   Nawagitgul P, 2000, J GEN VIROL, V81, P2281, DOI 10.1099/0022-1317-81-9-2281
   Opriessnig T, 2004, VET PATHOL, V41, P624, DOI 10.1354/vp.41-6-624
   Ouardani M, 1999, J CLIN MICROBIOL, V37, P3917, DOI 10.1128/JCM.37.12.3917-3924.1999
   Pogranichniy RM, 2002, J VET DIAGN INVEST, V14, P449, DOI 10.1177/104063870201400601
   Racine S, 2004, CLIN DIAGN LAB IMMUN, V11, P736, DOI 10.1128/CDLI.11.4.736-741.2004
   Rovira A, 2002, J VIROL, V76, P3232, DOI 10.1128/JVI.76.7.3232-3239.2002
   Sasseville AMJ, 2002, J GEN VIROL, V83, P2411, DOI 10.1099/0022-1317-83-10-2411
   Spackman E, 2002, J CLIN MICROBIOL, V40, P3256, DOI 10.1128/JCM.40.9.3256-3260.2002
   TISCHER I, 1982, NATURE, V295, P64, DOI 10.1038/295064a0
   Wellenberg GJ, 2004, RES VET SCI, V77, P177, DOI 10.1016/j.rvsc.2004.03.007
   Yazaki Y, 2003, J GEN VIROL, V84, P2351, DOI 10.1099/vir.0.19242-0
NR 51
TC 118
Z9 136
U1 0
U2 9
PU CANADIAN VET MED ASSOC
PI OTTAWA
PA 339 BOOTH ST ATTN: KIMBERLY ALLEN-MCGILL, OTTAWA, ONTARIO K1R 7K1,
   CANADA
SN 0008-5286
J9 CAN VET J
JI Can. Vet. J.-Rev. Vet. Can.
PD AUG
PY 2007
VL 48
IS 8
BP 811
EP 819
PG 9
WC Veterinary Sciences
SC Veterinary Sciences
GA 200PU
UT WOS:000248776100004
PM 17824323
DA 2020-04-03
ER

PT J
AU Ding, YQ
   He, L
   Zhang, QL
   Huang, ZX
   Che, XY
   Hou, JL
   Wang, HJ
   Shen, H
   Qiu, LW
   Li, ZG
   Geng, J
   Cai, JJ
   Han, HX
   Li, X
   Kang, W
   Weng, DS
   Liang, P
   Jiang, SB
AF Ding, YQ
   He, L
   Zhang, QL
   Huang, ZX
   Che, XY
   Hou, JL
   Wang, HJ
   Shen, H
   Qiu, LW
   Li, ZG
   Geng, J
   Cai, JJ
   Han, HX
   Li, X
   Kang, W
   Weng, DS
   Liang, P
   Jiang, SB
TI Organ distribution of severe acute respiratory syndrome (SARS)
   associated coronavirus (SARS-CoV) in SARS patients: implications for
   pathogenesis and virus transmission pathways
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE SARS; SARS-CoV; distribution; detection; pathogenesis; transmission
ID AMINOPEPTIDASE-N; RECEPTOR; IDENTIFICATION; PROTEIN; CHINA; INHIBITORS;
   EXPRESSION
AB We previously identified the major pathological changes in the respiratory and immune systems of patients who died of severe acute respiratory syndrome (SARS) but gained little information on the organ distribution of SARS-associated coronavirus (SARS-CoV). In the present study, we used a murine monoclonal antibody specific for SARS-CoV nucleoprotein, and probes specific for a SARS-CoV RNA polymerase gene fragment, for immunohistochemistry and in situ hybridization, respectively, to detect SARS-CoV systematically in tissues from patients who died of SARS. SARS-CoV was found in lung, trachea/bronchus, stomach, small intestine, distal convoluted renal tubule, sweat gland, parathyroid, pituitary, pancreas, adrenal gland, liver and cerebrum, but was not detected in oesophagus, spleen, lymph node, bone marrow, heart, aorta, cerebellum, thyroid, testis, ovary, uterus or muscle. These results suggest that, in addition to the respiratory system, the gastrointestinal tract and other organs with detectable SARS-CoV may also be targets of SARS-CoV infection. The pathological changes in these organs may be caused directly by the cytopathic effect mediated by local replication of the SARS-CoV; or indirectly as a result of systemic responses to respiratory failure or the harmful immune response induced by viral infection. In addition to viral spread through a respiratory route, SARS-CoV in the intestinal tract, kidney and sweat glands may be excreted via faeces, urine and sweat, thereby leading to virus transmission. This study provides important information for understanding the pathogenesis of SARS-CoV infection and sheds light on possible virus transmission pathways. This data will be useful for designing new strategies for prevention and treatment of SARS. Copyright (C) 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley Sons, Ltd.
C1 New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Viral Immunol, New York, NY 10021 USA.
   First Mil Med Univ, Nan Fang Hosp, Dept Pathol, Guangzhou, Peoples R China.
   First Mil Med Univ, Nan Fang Hosp, Dept Infect Dis, Guangzhou, Peoples R China.
   First Mil Med Univ, Zhujiang Hosp, Ctr Lab, Guangzhou, Peoples R China.
RP Ding, YQ (reprint author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Viral Immunol, 310 E 67th St, New York, NY 10021 USA.
EM dyq@fimmu.com; sjiang@nybloodcenter.org
RI KANG, Wei/C-5451-2016; Jiang, Shibo/L-4500-2014
OI KANG, Wei/0000-0002-4651-677X; 
CR Che Xiao-yan, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P640
   Che Xiao-yan, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P637
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   Dimitrov DS, 2003, CELL, V115, P652, DOI 10.1016/S0092-8674(03)00976-0
   DING Y, 2003, ZHONGHUA BING LI XUE, V32, P1965
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Enserink M, 2003, SCIENCE, V301, P1824
   Enserink M, 2003, SCIENCE, V301, P299, DOI 10.1126/science.301.5631.299
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   Kontoyiannis DP, 2003, LANCET, V361, P1558, DOI 10.1016/S0140-6736(03)13186-8
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Lounsbury KM, 2002, AM J PATHOL, V160, P1991, DOI 10.1016/S0002-9440(10)61149-2
   MACFIE N, CHINA CONFIRMS SARS
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Rados Carol, 2003, FDA Consum, V37, P14
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Wang HJ, 2003, NEW ENGL J MED, V349, P507, DOI 10.1056/NEJM200307313490519
   *WHO, CONS SOC EP SEV AC R
   *WHO, 2002, SUMM PROB SARS CAS O
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Yang Jie, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P424
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
NR 31
TC 118
Z9 130
U1 13
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JUN
PY 2004
VL 203
IS 2
BP 622
EP 630
DI 10.1002/path.1560
PG 9
WC Oncology; Pathology
SC Oncology; Pathology
GA 823SP
UT WOS:000221633700003
PM 15141376
OA Bronze
DA 2020-04-03
ER

PT S
AU Buddaert, W
   Van Reeth, K
   Pensaert, M
AF Buddaert, W
   Van Reeth, K
   Pensaert, M
BE Enjuanes, L
   Siddell, SG
   Spaan, W
TI In vivo and in vitro interferon (IFN) studies with the porcine
   reproductive and respiratory syndrome virus (PRRSV)
SO CORONAVIRUSES AND ARTERIVIRUSES
SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY
LA English
DT Article; Proceedings Paper
CT VIIth International Symposium on Coronaviruses and Arteriviruses
CY MAY 10-15, 1997
CL SEGOVIA, SPAIN
SP Int Comm Taxon Viruses, Ctr Nacl Biotecnol, Coronavirus Lab, Madrid
ID BLOOD MONONUCLEAR-CELLS; ALVEOLAR MACROPHAGES; ALPHA; PIGS; REPLICATION;
   INDUCTION; DISEASE
AB Some of the interactions between the porcine reproductive and respiratory syndrome virus (PRRSV) and the porcine interferon-alpha (IFN-alpha) system were studied. In a first experiment, it was shown that pretreatment of primary porcine alveolar macrophages (AMs) with recombinant porcine (rPo) IFN-alpha 1 resulted in significant reductions of PRRSV yield and numbers of antigen expressing cells. In a second experiment, sensitivity of PRRSV to IFN-alpha was confirmed in vivo. In pigs inoculated with porcine respiratory coronavirus (PRCV)-a potent inducer of endogenous IFN-alpha in the lungs of pigs-followed 2 days later by PRRSV-lung PRRSV titers were 1.7 to 2.9 log(10) TCID50 reduced compared to those in singly PRRSV inoculated pigs. It was concluded therefore that PRRSV has a fairly good sensitivity to the antiviral effects of IFN-alpha. A third experiment documented that in vivo PRRSV infection generally does not affect PRCV-induced IFN-alpha production in the lungs of pigs. In addition, it was shown that the IFN-inducing capacity of PRRSV is at least 159 times lower than that of PRCV. This finding suggests that cells other than AMs may be responsible for IFN production in the lungs of pigs.
C1 State Univ Ghent, Fac Med Vet, Lab Vet Virol, B-9820 Merelbeke, Belgium.
RP Buddaert, W (reprint author), State Univ Ghent, Fac Med Vet, Lab Vet Virol, Salisburylaan 133, B-9820 Merelbeke, Belgium.
CR ALBINA E, 1997, UNPUB J GEN VIROL
   ARTURSSON K, 1989, VET IMMUNOL IMMUNOP, V23, P345, DOI 10.1016/0165-2427(89)90146-3
   BABIUK LA, 1985, J GEN VIROL, V66, P2383, DOI 10.1099/0022-1317-66-11-2383
   CHARLEY B, 1990, RES IMMUNOL, V141, P141, DOI 10.1016/0923-2494(90)90133-J
   Duan X, 1997, VET MICROBIOL, V56, P9, DOI 10.1016/S0378-1135(96)01347-8
   ESPARZA I, 1988, J GEN VIROL, V69, P2973, DOI 10.1099/0022-1317-69-12-2973
   HOLLAND SP, 1991, AM J VET RES, V52, P1779
   IGLESIAS G, 1992, COMP IMMUNOL MICROB, V15, P249, DOI 10.1016/0147-9571(92)90004-B
   LEFEVRE F, 1990, J GEN VIROL, V71, P1057, DOI 10.1099/0022-1317-71-5-1057
   Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996
   SAKSELA E, 1984, PROG MED VIROL, V30, P78
   VANREETH K, 1994, AM J VET RES, V55, P1275
   VANREETH K, 1996, P 17 C INT PIG VET S, P137
   VANREETH K, 1995, P 3 C EUR SOC VET VI, P197
   WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296
NR 15
TC 118
Z9 130
U1 0
U2 8
PU PLENUM PRESS DIV PLENUM PUBLISHING CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0065-2598
BN 0-306-45910-8
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 1998
VL 440
BP 461
EP 467
PG 7
WC Immunology; Medicine, Research & Experimental; Microbiology; Virology
SC Immunology; Research & Experimental Medicine; Microbiology; Virology
GA BL64J
UT WOS:000076154700059
PM 9782316
DA 2020-04-03
ER

PT J
AU ARMSTRONG, J
   NIEMANN, H
   SMEEKENS, S
   ROTTIER, P
   WARREN, G
AF ARMSTRONG, J
   NIEMANN, H
   SMEEKENS, S
   ROTTIER, P
   WARREN, G
TI SEQUENCE AND TOPOLOGY OF A MODEL INTRACELLULAR MEMBRANE-PROTEIN,
   E1-GLYCOPROTEIN, FROM A CORONAVIRUS
SO NATURE
LA English
DT Article
C1 UNIV GIESSEN,FACHBEREICH HUMANMED,INST VIROL,D-6300 GIESSEN,FED REP GER.
   STATE UNIV UTRECHT,FAC VET,INST VIROL,3509 TD UTRECHT,NETHERLANDS.
RP ARMSTRONG, J (reprint author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,D-6900 HEIDELBERG,FED REP GER.
RI Smeekens, Sjef C/B-6683-2011
OI Smeekens, Sjef C/0000-0001-6631-9426
CR ARMSTRONG J, 1983, NUCLEIC ACIDS RES, V11, P883, DOI 10.1093/nar/11.3.883
   ARMSTRONG J, MOL BIOL PATHOGENESI
   BERGMANN JE, 1981, P NATL ACAD SCI-BIOL, V78, P1746, DOI 10.1073/pnas.78.3.1746
   BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835
   CHELEY S, 1981, VIROLOGY, V112, P596, DOI 10.1016/0042-6822(81)90305-6
   DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645
   DUBOISDALCQ ME, 1982, VIROLOGY, V119, P317, DOI 10.1016/0042-6822(82)90092-7
   DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453
   FURTHMAYR H, 1978, NATURE, V271, P519, DOI 10.1038/271519a0
   GAROFF H, 1983, J CELL BIOL, V97, P652, DOI 10.1083/jcb.97.3.652
   GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159
   GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   HOUSMAN D, 1970, NATURE, V227, P913, DOI 10.1038/227913a0
   JACOBS L, 1981, J VIROL, V39, P401, DOI 10.1128/JVI.39.2.401-406.1981
   LAI MMC, 1983, J VIROL, V46, P1027, DOI 10.1128/JVI.46.3.1027-1033.1983
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1982, J VIROL, V41, P557, DOI 10.1128/JVI.41.2.557-565.1982
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   LEIBOWITZ JL, 1982, J VIROL, V43, P905, DOI 10.1128/JVI.43.3.905-913.1982
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6
   NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x
   NIEMANN H, 1984, EMBO J, V3, P665, DOI 10.1002/j.1460-2075.1984.tb01864.x
   NIEMANN H, 1981, J MOL BIOL, V153, P993, DOI 10.1016/0022-2836(81)90463-0
   NIEMANN H, MOL BIOL PATHOGENESI
   QUINN P, 1983, J CELL BIOL, V96, P851, DOI 10.1083/jcb.96.3.851
   ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7
   ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223
   ROTTIER P, P NATN ACAD SCI US
   ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981
   SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5
   SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761
   SIEKEVITZ P, 1960, J BIOPHYS BIOCHEM CY, V7, P619, DOI 10.1083/jcb.7.4.619
   SKINNER MA, 1983, NUCLEIC ACIDS RES, V11, P5045, DOI 10.1093/nar/11.15.5045
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   SPAAN WJM, 1982, J VIROL, V42, P432, DOI 10.1128/JVI.42.2.432-439.1982
   STURMAN LS, 1977, VIROLOGY, V77, P650, DOI 10.1016/0042-6822(77)90489-5
   STURMAN LS, 1977, VIROLOGY, V77, P637, DOI 10.1016/0042-6822(77)90488-3
   TOOZE J, EUR J CELL BIOL
   VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17
NR 41
TC 118
Z9 121
U1 0
U2 0
PU MACMILLAN MAGAZINES LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW
SN 0028-0836
J9 NATURE
JI Nature
PY 1984
VL 308
IS 5961
BP 751
EP 752
DI 10.1038/308751a0
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA SM960
UT WOS:A1984SM96000058
PM 6325918
OA Bronze
DA 2020-04-03
ER

PT J
AU Jung, K
   Wang, QH
   Scheuer, KA
   Lu, ZY
   Zhang, Y
   Saif, LJ
AF Jung, Kwonil
   Wang, Qiuhong
   Scheuer, Kelly A.
   Lu, Zhongyan
   Zhang, Yan
   Saif, Linda J.
TI Pathology of US Porcine Epidemic Diarrhea Virus Strain PC21A in
   Gnotobiotic Pigs
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS VIRUS; RESPIRATORY CORONAVIRUS;
   UNITED-STATES; PIGLETS; SWINE; PREVALENCE; INFECTION; ENTERITIS
AB To understand the progression of porcine epidemic diarrhea virus infection, we inoculated gnotobiotic pigs with a newly emerged US strain, PC21A, of the virus. At 24-48 hours postinoculation, the pigs exhibited severe diarrhea and vomiting, fecal shedding, viremia, and severe atrophic enteritis. These findings confirm that strain PC21A is highly enteropathogenic.
C1 [Jung, Kwonil; Wang, Qiuhong; Scheuer, Kelly A.; Lu, Zhongyan; Saif, Linda J.] Ohio State Univ, Wooster, OH 44691 USA.
   [Zhang, Yan] Ohio Dept Agr, Reynoldsburg, OH USA.
RP Wang, QH (reprint author), Ohio State Univ, Dept Vet Prevent Med, Ohio Agr Res & Dev Ctr, Food Anim Hlth Res Program, 1680 Madison Ave, Wooster, OH 44691 USA.
EM wang.655@osu.edu
RI Saif, Linda/E-4005-2011
FU National Pork Board [13-222]
FX Salaries and research support were provided by state and federal funds
   appropriated to the Ohio Agricultural Research and Development Center,
   The Ohio State University. This work was supported in part by a grant
   from the National Pork Board (no. 13-222 to Q.W. and L.J.S.).
CR Amimo JO, 2013, J CLIN MICROBIOL, V51, P1142, DOI 10.1128/JCM.03193-12
   Chu DKW, 2008, J VIROL, V82, P9107, DOI 10.1128/JVI.00857-08
   Cima Greg, 2013, J Am Vet Med Assoc, V243, P469
   COUSSEMENT W, 1982, VET PATHOL, V19, P46, DOI 10.1177/030098588201900108
   DEBOUCK P, 1981, VET MICROBIOL, V6, P157, DOI 10.1016/0378-1135(81)90007-9
   Jung K, 2006, VET J, V171, P445, DOI 10.1016/j.tvjl.2005.02.016
   Jung K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041619
   Jung K, 2009, J GEN VIROL, V90, P2713, DOI 10.1099/vir.0.014001-0
   Kim L, 2000, J VET DIAGN INVEST, V12, P385, DOI 10.1177/104063870001200418
   Kim O, 2000, VET PATHOL, V37, P62, DOI 10.1354/vp.37-1-62
   Kim SH, 2007, J VIROL METHODS, V146, P172, DOI 10.1016/j.jviromet.2007.06.021
   Sisay Z, 2013, ARCH VIROL, V158, P1583, DOI 10.1007/s00705-013-1619-5
   Stevenson GW, 2013, J VET DIAGN INVEST, V25, P649, DOI 10.1177/1040638713501675
   SUEYOSHI M, 1995, J COMP PATHOL, V113, P59, DOI 10.1016/S0021-9975(05)80069-6
   Wang QH, 2011, EMERG INFECT DIS, V17, P1103, DOI [10.3201/eid1706.101756, 10.3201/eid/1706.101756]
NR 15
TC 117
Z9 126
U1 0
U2 22
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD APR
PY 2014
VL 20
IS 4
BP 662
EP 665
DI 10.3201/eid2004.131685
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AD8GO
UT WOS:000333504700018
PM 24795932
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Smith, I
   Wang, LF
AF Smith, Ina
   Wang, Lin-Fa
TI Bats and their virome: an important source of emerging viruses capable
   of infecting humans
SO CURRENT OPINION IN VIROLOGY
LA English
DT Article
ID EBOLA HEMORRHAGIC-FEVER; ACUTE RESPIRATORY SYNDROME; TO-PERSON
   TRANSMISSION; PUBLIC-HEALTH MEASURES; NIPAH-VIRUS; HENDRA VIRUS;
   RISK-FACTORS; FRUIT BATS; DISEASE EMERGENCE; FLYING-FOXES
AB Bats are being increasingly recognized as an important reservoir of zoonotic viruses of different families, including SARS coronavirus, Nipah virus, Hendra virus and Ebola virus. Several recent studies hypothesized that bats, an ancient group of flying mammals, are the major reservoir of several important RNA virus families from which other mammalian viruses of livestock and humans were derived. Although this hypothesis needs further investigation, the premise that bats carry a large number of viruses is commonly accepted. The question of whether bats have unique biological features making them ideal reservoir hosts has been the subject of several recent reviews. In this review, we will focus on the public health implications of bat derived zoonotic viral disease outbreaks, examine the drivers and risk factors of past disease outbreaks and outline research directions for better control of future disease events.
C1 [Smith, Ina; Wang, Lin-Fa] CSIRO Australian Anim Hlth Lab, Geelong, Vic 3220, Australia.
   [Wang, Lin-Fa] Duke NUS Grad Med Sch, Program Emerging Infect Dis, Singapore 169857, Singapore.
RP Wang, LF (reprint author), CSIRO Australian Anim Hlth Lab, Geelong, Vic 3220, Australia.
EM linfa.wang@csiro.au
RI Smith, Ina/H-7225-2013
OI Wang, Lin-Fa/0000-0003-2752-0535
CR Adjemian J, 2011, J INFECT DIS, V204, pS796, DOI 10.1093/infdis/jir312
   Aljofan M, 2009, VIRUS RES, V142, P92, DOI 10.1016/j.virusres.2009.01.014
   Amman BR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002877
   [Anonymous], 1978, Bull World Health Organ, V56, P271
   Arankalle VA, 2011, EMERG INFECT DIS, V17, P907, DOI 10.3201/eid1705.100968
   Bausch DG, 2007, J INFECT DIS, V196, pS142, DOI 10.1086/520545
   Bausch DG, 2003, EMERG INFECT DIS, V9, P1531, DOI 10.3201/eid0912.030355
   Beer B, 1999, NATURWISSENSCHAFTEN, V86, P8, DOI 10.1007/s001140050562
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Blum LS, 2009, AM J TROP MED HYG, V80, P96, DOI 10.4269/ajtmh.2009.80.96
   Brown C, 2004, REV SCI TECH OIE, V23, P435, DOI 10.20506/rst.23.2.1495
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Chua K B, 2010, Malays J Pathol, V32, P69
   Chua KB, 2007, P NATL ACAD SCI USA, V104, P11424, DOI 10.1073/pnas.0701372104
   Chua KB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025434
   Chua Kaw Bing, 2002, Malays J Pathol, V24, P15
   Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432
   Chua KB, 2003, MICROBES INFECT, V5, P487, DOI 10.1016/S1286-4579(03)00067-4
   Chua KB, 2003, J CLIN VIROL, V26, P265, DOI 10.1016/S1386-6532(02)00268-8
   Chua KB, 2002, MICROBES INFECT, V4, P145, DOI 10.1016/S1286-4579(01)01522-2
   Chua KB, 2001, J INFECTION, V42, P40, DOI 10.1053/jinf.2000.0782
   Corman V M, 2012, EUROSURVEILLANCE, V17, p[1, 1]
   Daniels P, 2001, MICROBES INFECT, V3, P289, DOI 10.1016/S1286-4579(01)01382-X
   Daszak P., 2006, Disease ecology: community structure and pathogen dynamics, P186
   Daszak P, 2001, ACTA TROP, V78, P103, DOI 10.1016/S0001-706X(00)00179-0
   Deng IM, 1978, B WORLD HEALTH ORGAN, V56, P247
   Donaldson EF, 2010, J VIROL, V84, P13004, DOI 10.1128/JVI.01255-10
   Dowell SF, 1999, J INFECT DIS, V179, pS87, DOI 10.1086/514284
   Epstein JH, 2008, EMERG INFECT DIS, V14, P1309, DOI 10.3201/eid1408.071492
   Field H, 2004, ARCH VIROL, P113
   Field H, 2001, MICROBES INFECT, V3, P307, DOI 10.1016/S1286-4579(01)01384-3
   Field HE, 2007, CURR TOP MICROBIOL, V315, P133
   Field HE, 2009, ZOONOSES PUBLIC HLTH, V56, P278, DOI 10.1111/j.1863-2378.2008.01218.x
   Field H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028678
   Francesconi P, 2003, EMERG INFECT DIS, V9, P1430, DOI 10.3201/eid0911.030339
   Ge XY, 2012, J VIROL, V86, P4620, DOI 10.1128/JVI.06671-11
   Gonzalez JP, 2007, CURR TOP MICROBIOL, V315, P363
   Groen G. Van Der, 1978, Ebola virus haemorrhagic fever. Proceedings of an international colloquium on Ebola virus infection and other haemorrhagic fevers held in Antwerp, Belgium, 6-8 December, 1977., P255
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Gurley ES, 2007, EMERG INFECT DIS, V13, P1031, DOI 10.3201/eid1307.061128
   Guyatt KJ, 2003, J GEN VIROL, V84, P485, DOI 10.1099/vir.0.18652-0
   Homaira N, 2010, EPIDEMIOL INFECT, V138, P1630, DOI 10.1017/S0950268810000695
   Johara MY, 2001, EMERG INFECT DIS, V7, P439
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496
   Khan SU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042689
   KNOBLER S, 2004, LEARNING SARS PREPAR
   Lam WK, 2003, RESPIROLOGY, V8, pS2, DOI 10.1046/j.1440-1843.2003.00516.x
   Lee J.-W., 2004, LEARNING SARS PREPAR
   Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a
   Leroy EM, 2009, VECTOR-BORNE ZOONOT, V9, P723, DOI 10.1089/vbz.2008.0167
   Li LL, 2010, J VIROL, V84, P6955, DOI 10.1128/JVI.00501-10
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Lim PL, 2004, NEW ENGL J MED, V350, P1740, DOI 10.1056/NEJMoa032565
   Luby SP, 2006, EMERG INFECT DIS, V12, P1888
   Luby SP, 2009, CLIN INFECT DIS, V49, P1743, DOI 10.1086/647951
   Mahalingam S, 2012, LANCET INFECT DIS, V3099, P1
   Marsh GA, 2011, J INFECT DIS, V204, pS804, DOI 10.1093/infdis/jir300
   Marsh GA, 2010, EMERG INFECT DIS, V16, P1767, DOI 10.3201/eid1611.100501
   Mathews F, 2009, ADV PARASIT, V68, P185, DOI 10.1016/S0065-308X(08)00608-8
   McFarlane R, 2012, ECOHEALTH, V9, P24, DOI 10.1007/s10393-012-0763-9
   Mendez DH, 2012, EMERG INFECT DIS, V18, P83, DOI 10.3201/eid1801.111006
   Morse SS, 2004, REV SCI TECH OIE, V23, P443, DOI 10.20506/rst.23.2.1494
   MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348
   MURRAY K, 1995, EMERG INFECT DIS, V1, P31, DOI 10.3201/eid0101.950107
   Nahar N, 2012, HLTH PROMOT INT
   Nahar N, 2010, ECOHEALTH, V7, P196, DOI 10.1007/s10393-010-0320-3
   Nowak R.M, 1994, WALKERS BATS WORLD
   Paton NI, 1999, LANCET, V354, P1253, DOI 10.1016/S0140-6736(99)04379-2
   Philbey AW, 1998, EMERG INFECT DIS, V4, P269, DOI 10.3201/eid0402.980214
   Plowright RK, 2008, P R SOC B, V275, P861, DOI 10.1098/rspb.2007.1260
   Plowright RK, 2011, P ROY SOC B-BIOL SCI, V278, P3703, DOI 10.1098/rspb.2011.0522
   Promed, 2012, NOV COR SAUD AR 15 N
   Promed, 2012, NOV COR SAUD AR HUM
   Pulliam JRC, 2012, J R SOC INTERFACE, V9, P89, DOI 10.1098/rsif.2011.0223
   Rahman MA, 2012, VECTOR-BORNE ZOONOT, V12, P65, DOI 10.1089/vbz.2011.0656
   SELVEY LA, 1995, MED J AUSTRALIA, V162, P642, DOI 10.5694/j.1326-5377.1995.tb126050.x
   Smith I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025275
   Streicker DG, 2012, P ROY SOC B-BIOL SCI, V279, P3384, DOI 10.1098/rspb.2012.0538
   Streicker DG, 2010, SCIENCE, V329, P676, DOI 10.1126/science.1188836
   Svoboda T, 2004, NEW ENGL J MED, V350, P2352, DOI 10.1056/NEJMoa032111
   Taniguchi S, 2011, EMERG INFECT DIS, V17, P1559, DOI 10.3201/eid1708.101693
   Taylor LH, 2001, PHILOS T R SOC B, V356, P983, DOI 10.1098/rstb.2001.0888
   Timen A, 2009, EMERG INFECT DIS, V15, P1171, DOI [10.3201/eid1508.090051, 10.3201/eid1508.090015]
   Tsang T, 2003, RESPIROLOGY, V8, pS46, DOI 10.1046/j.1440-1843.2003.00524.x
   Wang LF, 2011, CURR OPIN VIROL, V1, P649, DOI 10.1016/j.coviro.2011.10.013
   Webster RG, 2004, LANCET, V363, P234, DOI 10.1016/S0140-6736(03)15329-9
   WESTBURY HA, 1995, AUST VET J, V72, P278, DOI 10.1111/j.1751-0813.1995.tb03549.x
   *WHO, 2009, EB REST PIGS HUM PHI
   WHO, 2003, WORLD HLTH REP 2003
   *WHO, 2003, SEV AC RESP SYNDR SA
   *WHO, 2003, SUMM TABL SARS CAS C
   Wilkinson GS, 2002, AGING CELL, V1, P124, DOI 10.1046/j.1474-9728.2002.00020.x
   Wolfe ND, 2005, EMERG INFECT DIS, V11, P1822, DOI 10.3201/eid1112.040789
   Wong S, 2007, REV MED VIROL, V17, P67, DOI 10.1002/rmv.520
   Wood JLN, 2012, PHILOS T R SOC B, V367, P2881, DOI 10.1098/rstb.2012.0228
   World Health Organization, 2004, SARS LESS NEW DIS, P71
   World Health Organization Regional Office for South East Asia, 2009, NIP VIR INF
   World Health Organization Regional Office for South East Asia, 2012, NIP VIR OUTBR WHO S
   Yadav PD, 2012, AM J TROP MED HYG, V87, P576, DOI 10.4269/ajtmh.2012.11-0416
   Young PL, 1996, EMERG INFECT DIS, V2, P239, DOI 10.3201/eid0203.960315
   Zaki AM, 2012, N ENGL J MED
NR 102
TC 117
Z9 117
U1 2
U2 138
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1879-6257
J9 CURR OPIN VIROL
JI Curr. Opin. Virol.
PD FEB
PY 2013
VL 3
IS 1
BP 84
EP 91
DI 10.1016/j.coviro.2012.11.006
PG 8
WC Virology
SC Virology
GA 101FE
UT WOS:000315759800014
PM 23265969
DA 2020-04-03
ER

PT J
AU Woo, PCY
   Lau, SKP
   Lam, CSF
   Lai, KKY
   Huang, Y
   Lee, P
   Luk, GSM
   Dyrting, KC
   Chan, KH
   Yuen, KY
AF Woo, Patrick C. Y.
   Lau, Susanna K. P.
   Lam, Carol S. F.
   Lai, Kenneth K. Y.
   Huang, Yi
   Lee, Paul
   Luk, Geraldine S. M.
   Dyrting, Kitman C.
   Chan, Kwok-Hung
   Yuen, Kwok-Yung
TI Comparative Analysis of Complete Genome Sequences of Three Avian
   Coronaviruses Reveals a Novel Group 3c Coronavirus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; CHINESE HORSESHOE BATS; SARS-CORONAVIRUS;
   TURKEY CORONAVIRUS; MOLECULAR-BIOLOGY; PROTEIN FAMILIES; SOUTHERN CHINA;
   HONG-KONG; IDENTIFICATION; HKU1
AB In this territory-wide molecular epidemiology study of coronaviruses (CoVs) in Hong Kong involving 1,541 dead wild birds, three novel CoVs were identified in three different bird families (bulbul CoV HKU11 [BuCoV HKU11], thrush CoV HKU12 [ThCoV HKU12], and munia CoV HKU13 [MuCoV HKU13]). Four complete genomes of the three novel CoVs were sequenced. Their genomes (26,396 to 26,552 bases) represent the smallest known CoV genomes. In phylogenetic trees constructed using chymotrypsin-like protease (3CL(pro)), RNA-dependent RNA polymerase (Pol), helicase, spike, and nucleocapsid proteins, BuCoV HKU11, ThCoV HKU12, and MuCoV HKU13 formed a cluster distantly related to infectious bronchitis virus and turkey CoV (group 3a CoVs). For helicase, spike, and nucleocapsid, they were also clustered with a CoV recently discovered in Asian leopard cats, for which the complete genome sequence was not available. The 3CLpro, Pol, helicase, and nucleocapsid of the three CoVs possessed higher amino acid identities to those of group 3a CoVs than to those of group 1 and group 2 CoVs. Unique genomic features distinguishing them from other group 3 CoVs include a distinct transcription regulatory sequence and coding potential for small open reading frames. Based on these results, we propose a novel CoV subgroup, group 3c, to describe this distinct subgroup of CoVs under the group 3 CoVs. Avian CoVs are genetically more diverse than previously thought and may be closely related to some newly identified mammalian CoVs. Further studies would be important to delineate whether the Asian leopard cat CoV was a result of interspecies jumping from birds, a situation analogous to that of bat and civet severe acute respiratory syndrome CoVs.
C1 [Woo, Patrick C. Y.; Lau, Susanna K. P.; Yuen, Kwok-Yung] Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Woo, Patrick C. Y.; Lau, Susanna K. P.; Yuen, Kwok-Yung] Univ Hong Kong, Res Ctr Infect & Immunol, Hong Kong, Hong Kong, Peoples R China.
   [Woo, Patrick C. Y.; Lau, Susanna K. P.; Yuen, Kwok-Yung] Univ Hong Kong, Carol Yu Ctr Infect, Hong Kong, Hong Kong, Peoples R China.
   [Woo, Patrick C. Y.; Lau, Susanna K. P.; Lam, Carol S. F.; Lai, Kenneth K. Y.; Huang, Yi; Lee, Paul; Chan, Kwok-Hung; Yuen, Kwok-Yung] Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.
   [Luk, Geraldine S. M.; Dyrting, Kitman C.] Agr Fisheries & Conservat Dept, Hong Kong, Hong Kong, Peoples R China.
RP Yuen, KY (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, State Key Lab Emerging Infect Dis, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.
EM hkumicro@hkucc.hku.hk
OI Yuen, Kwok-yung/0000-0002-2083-1552
FU University Development Fund; The University of Hong KongUniversity of
   Hong Kong; The Tung Wah Group of Hospitals Fund; HKSAR Research Fund for
   the Control of Infectious Diseases of the Health, Welfare, and Food
   Bureau; Shaw Foundation
FX We thank York Y. N. Chow, Secretary of Health, Welfare, and Food, HKSAR,
   The Peoples' Republic of China; and Virology and Biotechnology
   Laboratory staff of the Tai Lung Veterinary Laboratory of the
   Agriculture, Fisheries, and Conservation Department of the HKSAR.; The
   views expressed in this paper are those of the authors only and may not
   represent the opinion of the Agriculture, Fisheries, and Conservation
   Department of the government of the HKSAR.; We are grateful for the
   generous support of Hui Hoy and Hui Ming in the genomic sequencing
   platform. This work is partly supported by a Research Grant Council
   grant; a University Development Fund and Outstanding Young Researcher
   Award from The University of Hong Kong; The Tung Wah Group of Hospitals
   Fund for Research in Infectious Diseases; the HKSAR Research Fund for
   the Control of Infectious Diseases of the Health, Welfare, and Food
   Bureau; and the Shaw Foundation.
CR Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37
   Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Cao J, 2008, VIRUS RES, V136, P43, DOI 10.1016/j.virusres.2008.04.015
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Chu DKW, 2008, J GEN VIROL, V89, P1282, DOI 10.1099/vir.0.83605-0
   Circella E, 2007, AVIAN PATHOL, V36, P251, DOI 10.1080/03079450701344738
   Dominguez SR, 2007, EMERG INFECT DIS, V13, P1295, DOI 10.3201/eid1309.070491
   Dong BQ, 2007, J VIROL, V81, P6920, DOI 10.1128/JVI.00299-07
   Ellis TM, 2004, AVIAN PATHOL, V33, P492, DOI 10.1080/03079450400003601
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Gloza-Rausch F, 2008, EMERG INFECT DIS, V14, P626, DOI 10.3201/eid1404.071439
   Gomaa MH, 2008, VIRUS RES, V135, P237, DOI 10.1016/j.virusres.2008.03.020
   Gough RE, 2006, AVIAN PATHOL, V35, P122, DOI 10.1080/03079450600597733
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hasoksuz M, 2007, J VIROL, V81, P4981, DOI 10.1128/JVI.02361-06
   Herrewegh AAPM, 1998, J VIROL, V72, P4508, DOI 10.1128/JVI.72.5.4508-4514.1998
   Huang Y, 2008, NUCLEIC ACIDS RES, V36, pD504, DOI 10.1093/nar/gkm754
   Jonassen CM, 2005, J GEN VIROL, V86, P1597, DOI 10.1099/vir.0.80927-0
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2007, VIROLOGY, V367, P428, DOI 10.1016/j.virol.2007.06.009
   Lau SKP, 2006, J CLIN MICROBIOL, V44, P2063, DOI 10.1128/JCM.02614-05
   Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Liu SW, 2005, J GEN VIROL, V86, P719, DOI 10.1099/vir.0.80546-0
   Mardani K, 2008, J VIROL, V82, P2013, DOI 10.1128/JVI.01694-07
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mihindukulasuriya KA, 2008, J VIROL, V82, P5084, DOI 10.1128/JVI.02722-07
   NUTTALL PA, 1982, ARCH VIROL, V73, P1, DOI 10.1007/BF01341722
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Robertson MP, 2005, PLOS BIOL, V3, P86, DOI 10.1371/journal.pbio.0030005
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175
   Stavrinides J, 2004, J VIROL, V78, P76, DOI 10.1128/JVI.78.1.76-82.2004
   Stoffel W., 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143
   Tang XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Woo PCY, 2006, CURR OPIN INFECT DIS, V19, P401, DOI 10.1097/01.qco.0000244043.08264.fc
   Woo PCY, 2006, J VIROL, V80, P7136, DOI 10.1128/JVI.00509-06
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Woo PCY, 2005, MICROBIOL IMMUNOL, V49, P899, DOI 10.1111/j.1348-0421.2005.tb03681.x
   Woo PCY, 2005, J INFECT DIS, V192, P1898, DOI 10.1086/497151
   Woo PCY, 2004, LANCET, V363, P841, DOI 10.1016/S0140-6736(04)15729-2
   Zhang JQ, 2007, VIROLOGY, V369, P92, DOI 10.1016/j.virol.2007.06.035
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
NR 50
TC 117
Z9 122
U1 1
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JAN 15
PY 2009
VL 83
IS 2
BP 908
EP 917
DI 10.1128/JVI.01977-08
PG 10
WC Virology
SC Virology
GA 388UO
UT WOS:000262045000038
PM 18971277
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Kaletsky, RL
   Simmons, G
   Bates, P
AF Kaletsky, Rachel L.
   Simmons, Graham
   Bates, Paul
TI Proteolysis of the Ebola virus glycoproteins enhances virus binding and
   infectivity
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CATHEPSIN-L; MEMBRANE-FUSION; ENDOSOMAL PROTEOLYSIS; SARS CORONAVIRUS;
   ENTRY; PROTEIN; RECEPTOR; IDENTIFICATION; VECTORS; SUBUNIT
AB Cellular cathepsins are required for Ebola virus infection and are believed to proteolytically process the Ebola virus glycoprotein (GP) during entry. However, the significance of cathepsin cleavage during infection remains unclear. Here we demonstrate a role for cathepsin L (CatL) cleavage of Ebola virus GP in the generation of a stable 18-kDa GP1 viral intermediate that exhibits increased binding to and infectivity for susceptible cell targets. Cell binding to a lymphocyte line was increased when CatL-proteolysed pseudovirions were used, but lymphocytes remained resistant to Ebola virus GP-mediated infection. Genetic removal of the highly glycosylated mucin domain in Ebola virus GP resulted in cell binding similar to that observed with CatL-treated full-length GP, and no overall enhancement of binding or infectivity was observed when mucin-deleted virions were treated with CatL. These results suggest that cathepsin cleavage of Ebola virus GP facilitates an interaction with a cellular receptor(s) and that removal of the mucin domain may facilitate receptor binding. The influence of CatL in Ebola virus GP receptor binding should be useful in future studies characterizing the mechanism of Ebola virus entry.
C1 [Kaletsky, Rachel L.; Simmons, Graham; Bates, Paul] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
RP Bates, P (reprint author), Univ Penn, Sch Med, Dept Microbiol, 225 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.
EM pbates@mail.med.upenn.edu
RI Bates, Paul/F-8823-2011; Simmons, Graham/G-3523-2012
OI Simmons, Graham/0000-0002-9615-7023; Kaletsky,
   Rachel/0000-0002-7176-9154; Bates, Paul/0000-0002-3918-5976
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [T32 AI007324, U54 AI057168, R01 AI043455,
   R01 AI43455, T32 AI07324]; NIGMS NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [T32 GM007229,
   T32 GM07229]
CR Barnard RJO, 2006, VIROLOGY, V344, P25, DOI 10.1016/j.virol.2005.09.021
   Chan SY, 2000, J VIROL, V74, P4933, DOI 10.1128/JVI.74.10.4933-4937.2000
   Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656
   CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016
   Geisbert TW, 1995, VIRUS RES, V39, P129, DOI 10.1016/0168-1702(95)00080-1
   Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200
   Kuhn JH, 2006, J BIOL CHEM, V281, P15951, DOI 10.1074/jbc.M601796200
   Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662
   Manicassamy B, 2005, J VIROL, V79, P4793, DOI 10.1128/JVI.79.8.4793-4805.2005
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Medina MF, 2003, MOL THER, V8, P777, DOI 10.1016/S1525-0016(03)00266-1
   Pager CT, 2006, VIROLOGY, V346, P251, DOI 10.1016/j.virol.2006.01.007
   Pager CT, 2005, J VIROL, V79, P12714, DOI 10.1128/JVI.79.20.12714-12720.2005
   Qiu ZZ, 2006, J VIROL, V80, P5768, DOI 10.1128/JVI.00442-06
   Schornberg K, 2006, J VIROL, V80, P4174, DOI 10.1128/JVI.80.8.4174-4178.2006
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Simmons G, 2002, J VIROL, V76, P2518, DOI 10.1128/JVI.76.5.2518-2528.2002
   SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628
   Takada A, 2004, J VIROL, V78, P2943, DOI 10.1128/JVI.78.6.2943-2947.2004
   Takada A, 1997, P NATL ACAD SCI USA, V94, P14764, DOI 10.1073/pnas.94.26.14764
   Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032
   Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wool-Lewis RJ, 1998, J VIROL, V72, P3155, DOI 10.1128/JVI.72.4.3155-3160.1998
   Yang ZY, 2000, NAT MED, V6, P886, DOI 10.1038/78654
NR 25
TC 117
Z9 120
U1 1
U2 19
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2007
VL 81
IS 24
BP 13378
EP 13384
DI 10.1128/JVI.01170-07
PG 7
WC Virology
SC Virology
GA 239XR
UT WOS:000251552100010
PM 17928356
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Esper, F
   Shapiro, ED
   Weibel, C
   Ferguson, D
   Landry, ML
   Kahn, JS
AF Esper, F
   Shapiro, ED
   Weibel, C
   Ferguson, D
   Landry, ML
   Kahn, JS
TI Association between a novel human coronavirus and Kawasaki disease
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; IDENTIFICATION; INFECTION; CHILDREN; TISSUES
AB Kawasaki disease is a systemic vasculitis of childhood; its etiology is unknown. We identified evidence of a novel human coronavirus, designated "New Haven coronavirus" (HCoV-NH), in respiratory secretions from a 6-month-old infant with classic Kawasaki disease. To further investigate the possible association between HCoV-NH infection and Kawasaki disease, we conducted a case-control study. Specimens of respiratory secretions from 8 (72.7%) of 11 children with Kawasaki disease and from 1 (4.5%) of 22 control subjects ( children without Kawasaki disease matched by age and the time the specimens were obtained) tested positive for HCoV-NH by reverse-transcriptase polymerase chain reaction (Mantel-Haenszel matched odds ratio, 16.0 [95% confidence interval, 3.4-74.4];) P = .0015). These data suggest that HCoV-NH infection is associated with Kawasaki disease.
C1 Yale Univ, Sch Med, Dept Pediat, Div Infect Dis, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Pediat, Div Gen Pediat, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA.
RP Kahn, JS (reprint author), Yale Univ, Sch Med, Dept Pediat, Div Infect Dis, POB 208064, New Haven, CT 06520 USA.
EM jeffrey.kahn@yale.edu
FU NCRR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [M01-RR06022]; NIAID NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [K24
   AI01703, T32 AI07210-20]
CR *AM AC PED, 2000, 2000 RED BOOK REP CO
   BELL DM, 1981, NEW ENGL J MED, V304, P1568, DOI 10.1056/NEJM198106253042603
   BURNS JC, 1986, NATURE, V323, P814, DOI 10.1038/323814a0
   Choi IH, 1997, J IMMUNOL, V159, P481
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Esper F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   GUSTAFSON TL, 1994, TRUE EPISTAT
   KIKUTA H, 1993, J PEDIATR-US, V123, P90, DOI 10.1016/S0022-3476(05)81546-X
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   MCINTOSH K, 1996, VIROLOGY, V1, P1095
   NIGRO G, 1994, LANCET, V343, P1260, DOI 10.1016/S0140-6736(94)92154-7
   Normann E, 1999, PEDIATR INFECT DIS J, V18, P72, DOI 10.1097/00006454-199901000-00020
   ROSENFELD EA, 1995, J PEDIATR-US, V126, P524, DOI 10.1016/S0022-3476(95)70344-6
   Rowley AH, 2004, J INFECT DIS, V190, P856, DOI 10.1086/422648
   Rowley AH, 1999, PEDIATR CLIN N AM, V46, P313, DOI 10.1016/S0031-3955(05)70120-6
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   YANAGAWA H, 1986, LANCET, V2, P1138
NR 18
TC 117
Z9 135
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB 15
PY 2005
VL 191
IS 4
BP 499
EP 502
DI 10.1086/428291
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 888ZM
UT WOS:000226413100003
PM 15655771
OA Bronze
DA 2020-04-03
ER

PT J
AU Chowell, G
   Fenimore, PW
   Castillo-Garsow, MA
   Castillo-Chavez, C
AF Chowell, G
   Fenimore, PW
   Castillo-Garsow, MA
   Castillo-Chavez, C
TI SARS outbreaks in Ontario, Hong Kong and Singapore: the role of
   diagnosis and isolation as a control mechanism
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
DE SARS; SEIJR; outbreak
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS
AB In this article we use global and regional data from the SARS epidemic in conjunction with a model of susceptible, exposed, infective, diagnosed, and recovered classes of people ("SEIJR") to extract average properties and rate constants for those populations. The model is fitted to data from the Ontario (Toronto) in Canada, Hong Kong in China and Singapore outbreaks and predictions are made based on various assumptions and observations, including the current effect of isolating individuals diagnosed with SARS. The epidemic dynamics for Hong Kong and Singapore appear to be different from the dynamics in Toronto, Ontario. Toronto shows a very rapid increase in the number of cases between March 31st and April 6th, followed by a significant slowing in the number of new cases. We explain this as the result of an increase in the diagnostic rate and in the effectiveness of patient isolation after March 26th. Our best estimates are consistent with SARS eventually being contained in Toronto, although the time of containment is sensitive to the parameters in our model. It is shown that despite the empirically modeled heterogeneity in transmission, SARS' average reproductive number is 1.2, a value quite similar to that computed for some strains of influenza (J. Math. Biol. 27 (1989) 233). Although it would not be surprising to see levels of SARS infection higher than 10% in some regions of the world (if unchecked), lack of data and the observed heterogeneity and sensitivity of parameters prevent us from predicting the long-term impact of SARS. The possibility that 10 or more percent of the world population at risk could eventually be infected with the virus in conjunction with a mortality rate of 3-7% or more, and indications of significant improvement in Toronto support the stringent measures that have been taken to isolate diagnosed cases. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Los Alamos Natl Lab, Ctr Nonlinear Studies, Los Alamos, NM 87545 USA.
   Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA.
   Univ Colima, Fac Ciencias, Colima 28045, Colima, Mexico.
   Univ Colima, Fac Letras, Colima 28045, Colima, Mexico.
RP Chowell, G (reprint author), Los Alamos Natl Lab, Ctr Nonlinear Studies, MS B258, Los Alamos, NM 87545 USA.
RI Chowell, Gerardo/A-4397-2008; Castillo-Chavez, Carlos/E-1412-2014;
   Chowell, Gerardo/F-5038-2012
OI Castillo-Chavez, Carlos/0000-0002-1046-3901; Chowell,
   Gerardo/0000-0003-2194-2251
CR Anderson RM, 1991, INFECT DIS HUMANS
   BRADSHER K, 2003, NY TIMES        0411
   BRADSHER K, 2003, NY TIMES        0408
   Brauer F., 2000, MATH MODELS POPULATI
   *C HLTH, 2003, SYMPT TREATM SARS
   *CAN MIN HLTH, 2003, SUMM SEV AC RESP SYN
   CASTILLOCHAVEZ C, 1989, J MATH BIOL, V27, P233, DOI 10.1007/BF00275810
   *CDC, 2003, INF CLOS CONT SARS P
   *CDC, 2003, FREQ ASK QUEST
   *CDC, 2003, IS QUAR
   Center for Disease Control, 2003, BAS INF SARS
   COOMER J, 2003, SUSPECTED SARS CASES
   DIEKMANN O, 2000, MATH EPIDEMIOLOGY IN
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gerberding JL, 2003, NEW ENGL J MED, V348, P2030, DOI 10.1056/NEJMe030067
   *INT SOC INF DIS, 2003, SARS WORLDWIDE  0416
   *INT SOC INF DIS, 2003, SARS WORLDWIDE  0325
   KALB C, 2003, NEWSWEEK        0428
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   MCNEILL DG, 2003, NY TIMES        0415
   MSNBC News Service, 2003, MSNBC NEWS SERVICE
   POMFRET J, 2003, WASHINGTON POST 0417
   POMFRET J, 2003, WASHINGTON POST 0409
   POMFRET J, 2003, WASHINGTON POST 0425
   SCHOEN JW, 2003, MSNBC NEWS SERV 0402
   SLOAN R, 2003, MSNBC NEWS SERV 0403
   STEIN R, 2003, WASHINGTON POST 0402
   STEIN R, 2003, WASHINGTON POST 0417
   *WHO, 2003, CUM NUMB REP PROB CA
   2003, MSNBC NEWS SERV 0415
   2003, FIRE CHIEF MAGA 0409
   2003, MSNBC NEWS SERV 0409
   2003, MINISTERS MAY REV SA
NR 33
TC 117
Z9 127
U1 5
U2 22
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-5193
J9 J THEOR BIOL
JI J. Theor. Biol.
PD SEP 7
PY 2003
VL 224
IS 1
BP 1
EP 8
DI 10.1016/S0022-5193(03)00228-5
PG 8
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 713GM
UT WOS:000184849200001
PM 12900200
DA 2020-04-03
ER

PT J
AU Hiscox, JA
   Wurm, T
   Wilson, L
   Britton, P
   Cavanagh, D
   Brooks, G
AF Hiscox, JA
   Wurm, T
   Wilson, L
   Britton, P
   Cavanagh, D
   Brooks, G
TI The coronavirus infectious bronchitis virus nucleoprotein localizes to
   the nucleolus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; RNA-BINDING DOMAIN; NUCLEOCAPSID PROTEIN;
   TRANSLATIONAL CONTROL; VIRAL REPLICATION; CORE PROTEIN; N-PROTEIN;
   SEQUENCE; GENES; IDENTIFICATION
AB The coronavirus nucleoprotein (N) has been reported to be involved in various aspects of virus replication. We examined by confocal microscopy the subcellular localization of the avian infectious bronchitis virus N protein both in the absence and in the context of an infected cell and found that N protein localizes both to the cytoplasmic and nucleolar compartments.
C1 Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.
   AFRC, Inst Anim Hlth, Compton Lab, Div Mol Biol, Newbury RG20 7NN, Berks, England.
RP Hiscox, JA (reprint author), Univ Reading, Sch Anim & Microbial Sci, POB 228, Reading RG6 6AJ, Berks, England.
EM j.a.hiscox@reading.ac.uk
OI Hiscox, Julian/0000-0002-6582-0275
CR ALBERTS B, 1994, MOL BIOL CELL, P381
   BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   BOURSNELL MEG, 1985, J GEN VIROL, V66, P573, DOI 10.1099/0022-1317-66-3-573
   Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   Chang RY, 1996, J VIROL, V70, P2201, DOI 10.1128/JVI.70.4.2201-2207.1996
   COMPTON SR, 1987, J VIROL, V61, P1814, DOI 10.1128/JVI.61.6.1814-1820.1987
   DAVIES HA, 1981, J GEN VIROL, V53, P67, DOI 10.1099/0022-1317-53-1-67
   HILTON A, 1986, J GEN VIROL, V67, P923, DOI 10.1099/0022-1317-67-5-923
   HISCOX JA, 1995, J VIROL, V69, P6219, DOI 10.1128/JVI.69.10.6219-6227.1995
   HISCOX JA, 1995, VIRUS RES, V36, P119, DOI 10.1016/0168-1702(94)00108-O
   Hiscox JA, 1997, J VIROL, V71, P7974, DOI 10.1128/JVI.71.10.7974-7977.1997
   KECK JG, 1988, VIRUS RES, V9, P343, DOI 10.1016/0168-1702(88)90093-7
   KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LAPPS W, 1987, VIROLOGY, V157, P47, DOI 10.1016/0042-6822(87)90312-6
   Laude H, 1995, CORONAVIRIDAE, P141, DOI 10.1007/978-1-4899-1531-3_7
   MASTERS PS, 1992, ARCH VIROL, V125, P141, DOI 10.1007/BF01309634
   MOCKETT APA, 1985, J VIROL METHODS, V12, P271, DOI 10.1016/0166-0934(85)90138-7
   Molenkamp R, 2000, J GEN VIROL, V81, P2491, DOI 10.1099/0022-1317-81-10-2491
   Nelson GW, 2000, J GEN VIROL, V81, P181, DOI 10.1099/0022-1317-81-1-181
   NELSON GW, 1993, J GEN VIROL, V74, P1975, DOI 10.1099/0022-1317-74-9-1975
   PARKER MM, 1990, VIROLOGY, V179, P463, DOI 10.1016/0042-6822(90)90316-J
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Risco C, 1996, J VIROL, V70, P4773, DOI 10.1128/JVI.70.7.4773-4777.1996
   Rowland RR, 1999, VIRUS RES, V64, P1, DOI 10.1016/S0168-1702(99)00048-9
   Sapats SI, 1996, VIROLOGY, V226, P412, DOI 10.1006/viro.1996.0670
   Sethna PB, 1997, J VIROL, V71, P7744, DOI 10.1128/JVI.71.10.7744-7749.1997
   Shi ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999
   SIDDELL S, 1982, ADV EXP MED BIOL, V142, P193
   STOHLMAN SA, 1988, J VIROL, V62, P4288, DOI 10.1128/JVI.62.11.4288-4295.1988
   SUTOU S, 1988, VIROLOGY, V165, P589, DOI 10.1016/0042-6822(88)90603-4
   TAHARA SM, 1994, VIROLOGY, V202, P621, DOI 10.1006/viro.1994.1383
   ULMANEN I, 1976, J VIROL, V20, P203, DOI 10.1128/JVI.20.1.203-210.1976
   van der Meer Y, 1999, J VIROL, V73, P7641, DOI 10.1128/JVI.73.9.7641-7657.1999
   WENGLER G, 1992, VIROLOGY, V191, P880, DOI 10.1016/0042-6822(92)90263-O
   WENGLER G, 1984, VIROLOGY, V134, P435, DOI 10.1016/0042-6822(84)90310-6
   WILHELMSEN KC, 1981, VIROLOGY, V110, P225, DOI 10.1016/0042-6822(81)90027-1
   WILLIAMS AK, 1992, VIRUS RES, V25, P213, DOI 10.1016/0168-1702(92)90135-V
   WILSON TMA, 1984, VIROLOGY, V137, P255, DOI 10.1016/0042-6822(84)90217-4
   Zhou ML, 1996, VIROLOGY, V217, P191, DOI 10.1006/viro.1996.0106
NR 41
TC 117
Z9 141
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JAN
PY 2001
VL 75
IS 1
BP 506
EP 512
DI 10.1128/JVI.75.1.506-512.2001
PG 7
WC Virology
SC Virology
GA 383BR
UT WOS:000165863000053
PM 11119619
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Walsh, EE
   Falsey, AR
   Hennessey, PA
AF Walsh, EE
   Falsey, AR
   Hennessey, PA
TI Respiratory syncytial and other virus infections in persons with chronic
   cardiopulmonary disease
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article; Proceedings Paper
CT 38th Interscience Conference on Antimicrobial Agents and Chemotherapy
CY SEP 24-28, 1998
CL SAN DIEGO, CALIFORNIA
ID CHRONIC-BRONCHITIS; ELDERLY PEOPLE; MYCOPLASMA-PNEUMONIAE;
   VIRAL-INFECTIONS; INFLUENZA; ADULTS; COMMUNITY; IMPACT; TRACT
AB Respiratory syncytial virus (RSV) has been increasingly recognized as an important cause of serious respiratory illness in some adult populations, including those with underlying cardiopulmonary diseases. However, the precise incidence and the clinical impact of RSV in this group are unknown. Therefore, the incidence and clinical impact of RSV infection in persons with chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) who reside in the community were prospectively evaluated over two consecutive winters in 134 persons. Eight RSV (incidence of 4.3 per 100 subject-winters), 13 influenza A (incidence of 7.0 per 100 subject-winters), seven rhinovirus, nine coronavirus, and two parainfluenza virus infections were identified. The clinical illnesses associated with RSV and influenza A virus were similar, causing both upper and lower respiratory signs and symptoms. The clinical impact was significant as three of eight RSV-infected subjects were hospitalized compared with six of 13 influenza A-infected persons and zero of seven rhinovirus-infected persons.
C1 Rochester Gen Hosp, Dept Med, Rochester, NY 14621 USA.
   Univ Rochester, Sch Med, Rochester, NY USA.
RP Walsh, EE (reprint author), Rochester Gen Hosp, Dept Med, 1435 Portland Ave, Rochester, NY 14621 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-45248]
CR AGIUS G, 1990, J MED VIROL, V30, P117, DOI 10.1002/jmv.1890300208
   BUSCHO RO, 1978, J INFECT DIS, V137, P377, DOI 10.1093/infdis/137.4.377
   CARILLI A, 1964, NEW ENGL J MED, V170, P123
   Chin MH, 1997, AM J PUBLIC HEALTH, V87, P643, DOI 10.2105/AJPH.87.4.643
   Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456
   Fagon J Y, 1996, Semin Respir Infect, V11, P109
   Falsey AR, 1998, J INFECT DIS, V177, P463, DOI 10.1086/517376
   FALSEY AR, 1995, J AM GERIATR SOC, V43, P30, DOI 10.1111/j.1532-5415.1995.tb06238.x
   Falsey AR, 1997, VACCINE, V15, P1130, DOI 10.1016/S0264-410X(97)00002-9
   FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389
   FALSEY AR, 1992, J AM GERIATR SOC, V40, P115, DOI 10.1111/j.1532-5415.1992.tb01929.x
   FLEMING DM, 1993, LANCET, V342, P1507, DOI 10.1016/S0140-6736(05)80082-0
   GUMP DW, 1976, AM REV RESPIR DIS, V113, P465
   Karron RA, 1997, J INFECT DIS, V176, P1428, DOI 10.1086/514138
   KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016
   LAMBERT HP, 1972, BMJ-BRIT MED J, V3, P323, DOI 10.1136/bmj.3.5822.323
   LAMY ME, 1973, CHEST, V63, P336, DOI 10.1378/chest.63.3.336
   LAWTON MP, 1971, J AM GERIATR SOC, V19, P465, DOI 10.1111/j.1532-5415.1971.tb01206.x
   Nicholson KG, 1996, EPIDEMIOL INFECT, V116, P51, DOI 10.1017/S0950268800058957
   Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060
   PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289, DOI 10.1093/oxfordjournals.aje.a121558
   SMITH CB, 1980, AM REV RESPIR DIS, V121, P225
   SOMMERVILLE RG, 1963, LANCET, V2, P1247
   WISELKA MJ, 1993, EPIDEMIOL INFECT, V111, P337, DOI 10.1017/S0950268800057046
   1990, MMWR, V39, P777
NR 25
TC 117
Z9 120
U1 0
U2 8
PU AMER LUNG ASSOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD SEP
PY 1999
VL 160
IS 3
BP 791
EP 795
DI 10.1164/ajrccm.160.3.9901004
PG 5
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 236ND
UT WOS:000082604700006
PM 10471598
DA 2020-04-03
ER

PT J
AU Gut, M
   Leutenegger, CM
   Huder, JB
   Pedersen, NC
   Lutz, H
AF Gut, M
   Leutenegger, CM
   Huder, JB
   Pedersen, NC
   Lutz, H
TI One-tube fluorogenic reverse transcription-polymerase chain reaction for
   the quantitation of feline coronaviruses
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE FCoV; viral RNA; quantitation; one-tube RT-PCR; TaqMan (TM); fluorogenic
   5 ' nuclease assay
ID INFECTIOUS PERITONITIS VIRUS; GENE-EXPRESSION; KITTENS; TISSUES; CATS;
   DNA; PCR; RNA
AB A one-tube reverse transcription-polymerase chain reaction (RT-PCR) for absolute feline coronavirus (FCoV) quantitation was developed. The assay is based on the 5' nuclease activity of the Thermus flavus (Tfl) polymerase and a fluorogenic probe which generates fluorescence when it is cleaved. The fluorogenic probe, also called TaqMan(TM) probe (Perkin Elmer, Foster City, USE), is an oligonucleotide designed to bind between the two PCR primers to the target cDNA and is labeled with a reporter and a quencher dye. In the intact probe, the quencher dye suppresses the fluorescence of the reporter dye by Forster-type energy transfer. During the polymerase extension steps the Tfl exonuclease activity cleaves the hybridised probe resulting in the generation of fluorescent emission of the reporter dye. The threshold cycle (C-T value) indicates the increase of reporter fluorescence and is directly related to the initial amount of target cDNA or RNA, respectively. Fluorescence is monitored in real time after each cycle by a Perkin-Elmer ABI Prism(R) 7700 Sequence Detector. After completion of amplification, the C-T values of the samples are calculated back to a standard curve, generated by amplification of diluted standard molecules. The one-tube RT-PCR described below allows precise quantitation, is highly sensitive, rapid (no separate reverse transcription step and no post-amplification steps): easy to handle, allows for a high sample throughput, shows a very good reproducibility, and can be executed with a low risk of contamination. The design of the primers-probe combination enables the detection of all known FCoV strains and is also useful for the detection of canine coronavirus, transmissible gastroenteritis virus and porcine respiratory coronavirus. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Univ Zurich, Dept Vet Internal Med, Clin Lab, CH-8057 Zurich, Switzerland.
   Univ Zurich, Swiss Natl Ctr Retroviruses, CH-8057 Zurich, Switzerland.
   Univ Calif Davis, Sch Vet Med, Ctr Compan Anim Hlth, Davis, CA USA.
RP Gut, M (reprint author), Univ Zurich, Dept Vet Internal Med, Clin Lab, Winterthurerstr 260, CH-8057 Zurich, Switzerland.
CR ADDIE DD, 1992, VET REC, V130, P133, DOI 10.1136/vr.130.7.133
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
   BRIDGEN A, 1993, J GEN VIROL, V74, P1795, DOI 10.1099/0022-1317-74-9-1795
   DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7
   Fehr D, 1997, VACCINE, V15, P1101, DOI 10.1016/S0264-410X(97)00006-6
   Foley JE, 1997, J AM VET MED ASSOC, V210, P1307
   FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105
   Gamble DA, 1997, J CLIN MICROBIOL, V35, P673, DOI 10.1128/JCM.35.3.673-675.1997
   HERREWEGH AAP, UNPUB
   HERREWEGH AAPM, 1995, J CLIN MICROBIOL, V33, P684, DOI 10.1128/JCM.33.3.684-689.1995
   KINOSHITA T, 1992, ANAL BIOCHEM, V206, P231, DOI 10.1016/0003-2697(92)90358-E
   LI XT, 1994, VET MICROBIOL, V42, P65, DOI 10.1016/0378-1135(94)90078-7
   LIVAK KJ, 1995, GUIDELINES DESIGNING
   NAGANO M, 1994, J BIOL CHEM, V269, P13337
   PEDERSEN NC, 1981, AM J VET RES, V42, P363
   PEDERSEN NC, 1995, FELINE PRACT, V23, P7
   SINGH M, UNPUB NOVEL INTERNAL
   VENNEMA H, 1995, FELINE PRACT, V23, P40
   WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717
NR 19
TC 117
Z9 119
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD JAN
PY 1999
VL 77
IS 1
BP 37
EP 46
DI 10.1016/S0166-0934(98)00129-3
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 164JQ
UT WOS:000078460800005
PM 10029323
OA Bronze
DA 2020-04-03
ER

PT J
AU GODET, M
   GROSCLAUDE, J
   DELMAS, B
   LAUDE, H
AF GODET, M
   GROSCLAUDE, J
   DELMAS, B
   LAUDE, H
TI MAJOR RECEPTOR-BINDING AND NEUTRALIZATION DETERMINANTS ARE LOCATED
   WITHIN THE SAME DOMAIN OF THE TRANSMISSIBLE GASTROENTERITIS VIRUS
   (CORONAVIRUS) SPIKE PROTEIN
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; PORCINE RESPIRATORY CORONAVIRUS; ANTIGENIC SITES;
   GLYCOPROTEIN-S; PEPLOMER GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; EXPRESSION
   VECTORS; SEQUENCE-ANALYSIS; AMINOPEPTIDASE-N; TGEV
AB The spike glycoprotein (S) of coronavirus, the major target for virus-neutralizing antibodies, is assumed to mediate the attachment of virions to the host cell. A 26-kilodalton fragment proteolytically cleaved from transmissible gastroenteritis virus (TGEV) S protein was previously shown to bear two adjacent antigenic sites, A and B, both defined by high-titer neutralizing antibodies. Recombinant baculoviruses expressing C-terminal truncations of the 26-kilodalton region were used to localize functionally important determinants in the S protein primary structure. Two overlapping 223- and 150-amino-acid-long products with serine 506 as a common N terminus expressed all of the site A and B epitopes and induced virus binding antibodies. Coexpression of one of these truncated protein S derivatives with aminopeptidase N (APN), a cell surface molecule acting as a receptor for TGEV. led to the formation of a complex which could be immunoprecipitated by anti-S antibodies. These data provide evidence that major neutralization-mediating and receptor-binding determinants reside together within a domain of the S protein which behaves like an independent module. In spite of their ability to prevent S-APN interaction, the neutralizing antibodies appeared to recognize a preformed complex, thus indicating that antibody- and receptor-binding determinants should be essentially distinct. Together these findings bring new insight into the molecular mechanism of TGEV neutralization.
C1 INRA, UNITE VIROL & IMMUNOL MOLEC, F-78852 JOUY EN JOSAS, FRANCE.
CR CAVANAGH D, 1994, ARCH VIROL, V135, P227, DOI 10.1007/BF01309782
   CORREA I, 1990, J GEN VIROL, V71, P271, DOI 10.1099/0022-1317-71-2-271
   DANIEL C, 1990, VIROLOGY, V174, P87, DOI 10.1016/0042-6822(90)90057-X
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   DEGROOT RJ, 1989, VIROLOGY, V171, P493, DOI 10.1016/0042-6822(89)90619-3
   DELMAS B, 1994, J VIROL, V68, P5216, DOI 10.1128/JVI.68.8.5216-5224.1994
   DELMAS B, 1990, J GEN VIROL, V71, P1313, DOI 10.1099/0022-1317-71-6-1313
   DELMAS B, 1993, ADV EXP MED BIOL, V342, P293
   DELMAS B, 1991, VIRUS RES, V20, P107, DOI 10.1016/0168-1702(91)90103-3
   DELMAS B, 1986, J GEN VIROL, V67, P1405, DOI 10.1099/0022-1317-67-7-1405
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   DIMMOCK NJ, 1987, TRENDS BIOCHEM SCI, V12, P70, DOI 10.1016/0968-0004(87)90034-X
   DUARTE M, 1994, J GEN VIROL, V75, P1195, DOI 10.1099/0022-1317-75-5-1195
   DUARTE M, 1993, ADV EXP MED BIOL, V342, P55
   DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716
   FAZAKERLEY JK, 1992, VIROLOGY, V187, P178, DOI 10.1016/0042-6822(92)90306-A
   Garwes D.J., 1978, VET MICROBIOL, V3, P179
   GEBAUER F, 1991, VIROLOGY, V183, P225, DOI 10.1016/0042-6822(91)90135-X
   GODET M, 1992, VIROLOGY, V188, P666, DOI 10.1016/0042-6822(92)90521-P
   GODET M, 1991, VIROLOGY, V185, P732, DOI 10.1016/0042-6822(91)90544-L
   JIMENEZ G, 1986, J VIROL, V60, P131
   KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   LAUDE H, 1986, J GEN VIROL, V67, P119, DOI 10.1099/0022-1317-67-1-119
   LAUDE H, 1993, VET RES, V24, P125
   LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526
   LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6
   MCNAMEE MG, 1989, BIOTECHNIQUES, V7, P466
   PARKER SE, 1989, VIROLOGY, V173, P664, DOI 10.1016/0042-6822(89)90579-5
   Pensaert M., 1993, VIRAL INFECT GASTROI, P627
   PULFORD DJ, 1991, VIROLOGY, V182, P765, DOI 10.1016/0042-6822(91)90617-K
   RASSCHAERT D, 1987, J GEN VIROL, V68, P1883, DOI 10.1099/0022-1317-68-7-1883
   RASSCHAERT D, 1990, J GEN VIROL, V71, P2599, DOI 10.1099/0022-1317-71-11-2599
   SANCHEZ CM, 1992, VIROLOGY, V190, P92, DOI 10.1016/0042-6822(92)91195-Z
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   Summers M.D., 1987, TEXAS AGR EXPT STATI
   SUNE C, 1990, VIROLOGY, V177, P559, DOI 10.1016/0042-6822(90)90521-R
   VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990
   WANG FI, 1992, VIROLOGY, V186, P742, DOI 10.1016/0042-6822(92)90041-M
   WEISMILLER DG, 1990, J VIROL, V64, P3051, DOI 10.1128/JVI.64.6.3051-3055.1990
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   YOKOMORI K, 1992, J VIROL, V66, P6194, DOI 10.1128/JVI.66.10.6194-6199.1992
NR 44
TC 117
Z9 128
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD DEC
PY 1994
VL 68
IS 12
BP 8008
EP 8016
DI 10.1128/JVI.68.12.8008-8016.1994
PG 9
WC Virology
SC Virology
GA PR432
UT WOS:A1994PR43200039
PM 7525985
OA Bronze
DA 2020-04-03
ER

PT J
AU DELMAS, B
   LAUDE, H
AF DELMAS, B
   LAUDE, H
TI ASSEMBLY OF CORONAVIRUS SPIKE PROTEIN INTO TRIMERS AND ITS ROLE IN
   EPITOPE EXPRESSION
SO JOURNAL OF VIROLOGY
LA English
DT Article
C1 INRA,VIROL & IMMUNOL MOLEC LAB,F-78350 JOUY EN JOSAS,FRANCE.
CR CAVANAGH D, 1983, J GEN VIROL, V64, P2577, DOI 10.1099/0022-1317-64-12-2577
   CLEGG JCS, 1975, NATURE, V254, P454, DOI 10.1038/254454a0
   COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179
   COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9
   DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   DELMAS B, 1990, J GEN VIROL, V71, P1313, DOI 10.1099/0022-1317-71-6-1313
   DELMAS B, 1986, J GEN VIROL, V67, P1405, DOI 10.1099/0022-1317-67-7-1405
   DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957
   DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89
   DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986
   ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.bi.56.070187.002433
   GALLAGHER TM, 1990, J VIROL, V64, P731, DOI 10.1128/JVI.64.2.731-741.1990
   GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0
   Harrison S. C., 1986, TOGAVIRIDAE FLAVIVIR, P21
   HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117
   KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631
   KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9
   LAUDE H, 1986, J GEN VIROL, V67, P119, DOI 10.1099/0022-1317-67-1-119
   MACHAMER CE, 1988, J BIOL CHEM, V263, P5955
   NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x
   RASSCHAERT D, 1987, J GEN VIROL, V68, P1883, DOI 10.1099/0022-1317-68-7-1883
   ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475
   VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990
   WILEY DC, 1977, VIROLOGY, V79, P446, DOI 10.1016/0042-6822(77)90371-3
   WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0
   YEWDELL JW, 1988, CELL, V52, P843, DOI 10.1016/0092-8674(88)90426-6
NR 29
TC 117
Z9 124
U1 1
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 1990
VL 64
IS 11
BP 5367
EP 5375
DI 10.1128/JVI.64.11.5367-5375.1990
PG 9
WC Virology
SC Virology
GA EE048
UT WOS:A1990EE04800018
PM 2170676
OA Bronze
DA 2020-04-03
ER

PT J
AU RASSCHAERT, D
   DUARTE, M
   LAUDE, H
AF RASSCHAERT, D
   DUARTE, M
   LAUDE, H
TI PORCINE RESPIRATORY CORONAVIRUS DIFFERS FROM TRANSMISSIBLE
   GASTROENTERITIS VIRUS BY A FEW GENOMIC DELETIONS
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
C1 INRA,CTR RECH,VIROL & IMMUNOL MOLEC LAB,DOMAINE VILVERT,F-78350 JOUY EN JOSAS,FRANCE.
CR BRITTON P, 1988, MOL MICROBIOL, V2, P497, DOI 10.1111/j.1365-2958.1988.tb00056.x
   BRITTON P, 1988, MOL MICROBIOL, V2, P89, DOI 10.1111/j.1365-2958.1988.tb00010.x
   BRITTON P, 1989, ARCH VIROL, V105, P165, DOI 10.1007/BF01311354
   BROWN I, 1986, VET REC, V119, P282, DOI 10.1136/vr.119.11.282
   CALLEBAUT P, 1988, J GEN VIROL, V69, P1725, DOI 10.1099/0022-1317-69-7-1725
   CAVANAGH D, 1990, VIROLOGY, V175, P306
   DALZIEL RG, 1986, J VIROL, V59, P463, DOI 10.1128/JVI.59.2.463-471.1986
   DELMAS B, 1990, J GEN VIROL, V71, P1313, DOI 10.1099/0022-1317-71-6-1313
   DELMAS B, 1986, J GEN VIROL, V67, P1405, DOI 10.1099/0022-1317-67-7-1405
   DURET C, 1988, RECL MED VET, V164, P221
   FLEMING JO, 1986, J VIROL, V58, P869, DOI 10.1128/JVI.58.3.869-875.1986
   GALLAGHER TM, 1990, J VIROL, V64, P731, DOI 10.1128/JVI.64.2.731-741.1990
   GARWES DJ, 1988, VET REC, V122, P86, DOI 10.1136/vr.122.4.86
   HAVE P, 1990, IN PRESS CORONAVIRUS
   JESTIN A, 1987, RECL MED VET, V163, P567
   KAPKE PA, 1988, VIRUS GENES, V2, P293
   Laude H., 1988, Journees de la Recherche Porcine en France, V20, P89
   LAUDE H, 1986, J GEN VIROL, V67, P119, DOI 10.1099/0022-1317-67-1-119
   LAUDE H, 1987, J GEN VIROL, V68, P1687, DOI 10.1099/0022-1317-68-6-1687
   LIM HM, 1988, GENE ANAL TECH, V5, P32, DOI 10.1016/0735-0651(88)90024-6
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   OTOOLE D, 1989, RES VET SCI, V47, P23, DOI 10.1016/S0034-5288(18)31226-8
   PENSAERT M, 1986, VET QUART, V8, P257, DOI 10.1080/01652176.1986.9694050
   PSARKER SE, 1989, VIROLOGY, V173, P664
   RASSCHAERT D, 1987, J GEN VIROL, V68, P1883, DOI 10.1099/0022-1317-68-7-1883
   RASSCHAERT D, 1987, BIOCHIMIE, V69, P591, DOI 10.1016/0300-9084(87)90178-7
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   Sambrook J., 1989, MOL CLONING LABORATO
   SCHMIDT I, 1987, J GEN VIROL, V68, P47, DOI 10.1099/0022-1317-68-1-47
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   VANNIEUWSTADT AP, 1989, VET REC, V124, P43, DOI 10.1136/vr.124.2.43
   WESLEY RD, 1989, VIRUS RES, V13, P87, DOI 10.1016/0168-1702(89)90008-7
   WESLEY RD, 1990, IN PRESS CORONAVIRUS
NR 33
TC 117
Z9 131
U1 0
U2 4
PU SOC GENERAL MICROBIOLOGY
PI READING
PA HARVEST HOUSE 62 LONDON ROAD, READING, BERKS, ENGLAND RG1 5AS
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD NOV
PY 1990
VL 71
BP 2599
EP 2607
DI 10.1099/0022-1317-71-11-2599
PN 11
PG 9
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA EH731
UT WOS:A1990EH73100013
PM 2174956
OA Bronze
DA 2020-04-03
ER

PT J
AU Lu, L
   Liu, Q
   Zhu, Y
   Chan, KH
   Qin, LL
   Li, Y
   Wang, Q
   Chan, JFW
   Du, LY
   Yu, F
   Ma, CQ
   Ye, S
   Yuen, KY
   Zhang, RG
   Jiang, SB
AF Lu, Lu
   Liu, Qi
   Zhu, Yun
   Chan, Kwok-Hung
   Qin, Lili
   Li, Yuan
   Wang, Qian
   Chan, Jasper Fuk-Woo
   Du, Lanying
   Yu, Fei
   Ma, Cuiqing
   Ye, Sheng
   Yuen, Kwok-Yung
   Zhang, Rongguang
   Jiang, Shibo
TI Structure-based discovery of Middle East respiratory syndrome
   coronavirus fusion inhibitor
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RECEPTOR-BINDING DOMAIN; SPIKE PROTEIN; CRYSTAL-STRUCTURE; MERS-COV;
   ENTRY INHIBITORS; 6-HELIX BUNDLE; CORE STRUCTURE; HIV-1 ENTRY; GP41;
   IDENTIFICATION
AB A novel human coronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV), has caused outbreaks of a SARS-like illness with high case fatality rate. The reports of its person-to-person transmission through close contacts have raised a global concern about its pandemic potential. Here we characterize the six-helix bundle fusion core structure of MERS-CoV spike protein S2 subunit by X-ray crystallography and biophysical analysis. We find that two peptides, HR1P and HR2P, spanning residues 998-1039 in HR1 and 1251-1286 in HR2 domains, respectively, can form a stable six-helix bundle fusion core structure, suggesting that MERS-CoV enters into the host cell mainly through membrane fusion mechanism. HR2P can effectively inhibit MERS-CoV replication and its spike protein-mediated cell-cell fusion. Introduction of hydrophilic residues into HR2P results in significant improvement of its stability, solubility and antiviral activity. Therefore, the HR2P analogues have good potential to be further developed into effective viral fusion inhibitors for treating MERS-CoV infection.
C1 [Lu, Lu; Liu, Qi; Li, Yuan; Wang, Qian; Jiang, Shibo] Fudan Univ, Key Lab Med Mol Virol, Minist Educ, Shanghai 200032, Peoples R China.
   [Lu, Lu; Liu, Qi; Li, Yuan; Wang, Qian; Jiang, Shibo] Fudan Univ, Minist Hlth, Shanghai Med Coll, Shanghai 200032, Peoples R China.
   [Lu, Lu; Liu, Qi; Li, Yuan; Wang, Qian; Jiang, Shibo] Fudan Univ, Inst Med Microbiol, Shanghai 200032, Peoples R China.
   [Liu, Qi; Qin, Lili; Ye, Sheng; Zhang, Rongguang] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
   [Chan, Kwok-Hung; Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung] Univ Hong Kong, Dept Microbiol, Carol Yu Ctr Infect, State Key Lab Emerging Infect Dis, Pokfulam, Hong Kong, Peoples R China.
   [Du, Lanying; Yu, Fei; Ma, Cuiqing; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
RP Yuen, KY (reprint author), Univ Hong Kong, Dept Microbiol, Carol Yu Ctr Infect, State Key Lab Emerging Infect Dis, Pokfulam, Hong Kong, Peoples R China.
EM kyyuen@hkucc.hku.hk; rzhang@sun5.ibp.ac.cn; shibojiang@fudan.edu.cn
RI Yu, Fei/K-4953-2019; Lu, Lu/K-7070-2014; Jiang, Shibo/L-4500-2014; Chan,
   Jasper F. W./D-8007-2013
OI Yu, Fei/0000-0001-6332-4326; Lu, Lu/0000-0002-2255-0391; Chan, Jasper F.
   W./0000-0001-6336-6657; Yuen, Kwok-yung/0000-0002-2083-1552
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81173098, 81102476]; 973 Program of ChinaNational
   Basic Research Program of China [2012CB519001, 2011CB911101]; Providence
   Foundation Limited
FX We are very grateful to the staff of the Structural Biology Core
   Facility in the Institute of Biophysics, Chinese Academy of Sciences,
   especially Ms Ya Wang and Mr Yi Han, for their technical assistance. We
   thank Professor Ron Fouchier for providing us the MERS-CoV isolate. This
   work was supported by grants from the National Natural Science
   Foundation of China (#81173098 to S.J. and #81102476 to L. L.), 973
   Program of China (#2012CB519001 to S.J. and #2011CB911101 to R.Z.), and
   the Providence Foundation Limited in memory of the late Mr Lui Hac Minh.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Borgo B, 2012, P NATL ACAD SCI USA, V109, P1494, DOI 10.1073/pnas.1115172109
   Buzon V, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000880
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan JFW, 2012, J INFECTION, V65, P477, DOI 10.1016/j.jinf.2012.10.002
   Chan JFW, 2013, TRENDS MICROBIOL, V21, P544, DOI 10.1016/j.tim.2013.05.005
   Chan JFW, 2013, J INFECT DIS, V207, P1743, DOI 10.1093/infdis/jit123
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Chen X, 2010, J BIOL CHEM, V285, P25506, DOI 10.1074/jbc.M110.101170
   Chen YQ, 2013, J VIROL, V87, P10777, DOI 10.1128/JVI.01756-13
   CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Deng YQ, 2006, STRUCTURE, V14, P889, DOI 10.1016/j.str.2006.03.007
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du LY, 2013, J VIROL, V87, P9939, DOI 10.1128/JVI.01048-13
   Duquerroy S, 2005, VIROLOGY, V335, P276, DOI 10.1016/j.virol.2005.02.022
   Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gallagher T, 2013, NATURE, V495, P176, DOI 10.1038/495176a
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   Hong LA, 2003, J VIROL METHODS, V107, P155, DOI 10.1016/S0166-0934(02)00213-6
   HUYGHUESDESPOINTES BMP, 1995, BIOCHEMISTRY-US, V34, P13267, DOI 10.1021/bi00041a001
   Ingallinella P, 2009, P NATL ACAD SCI USA, V106, P5801, DOI 10.1073/pnas.0901007106
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0
   Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004
   Jiang SB, 1995, PEPTIDE RES, V8, P345
   Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812
   Lau SKP, 2013, J VIROL, V87, P8638, DOI 10.1128/JVI.01055-13
   Liu C, 2006, BIOCHEM BIOPH RES CO, V345, P1108, DOI 10.1016/j.bbrc.2006.04.141
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M411141200
   Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lu L, 2013, MICROBES INFECT, V15, P625, DOI 10.1016/j.micinf.2013.06.003
   Lu L, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-104
   Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Ma GP, 2005, BIOCHEM BIOPH RES CO, V337, P1301, DOI 10.1016/j.bbrc.2005.09.189
   MCREE DE, 1999, PRACTICAL PROTEIN CR
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Mou H, 2013, J VIROL, V87, P9379, DOI 10.1128/JVI.01277-13
   Oishi S, 2008, J MED CHEM, V51, P388, DOI 10.1021/jm701109d
   Otaka A, 2002, ANGEW CHEM INT EDIT, V41, P2938, DOI 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Supekar VM, 2004, P NATL ACAD SCI USA, V101, P17958, DOI 10.1073/pnas.0406128102
   Tripet B, 2004, J BIOL CHEM, V279, P20836, DOI 10.1074/jbc.M400759200
   van B. S., 2012, MBIO, V3
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   WHO, NOV COR INF UPD MIDD
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Woo P. C., 2013, J VIROL, V81, P1574
   Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200
   Xu YH, 2004, J BIOL CHEM, V279, P30514, DOI 10.1074/jbc.M403760200
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhao GY, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-266
   Zheng Q, 2006, BIOCHEMISTRY-US, V45, P15205, DOI 10.1021/bi061686w
   Zhu JQ, 2004, BIOCHEM BIOPH RES CO, V319, P283, DOI 10.1016/j.bbrc.2004.04.141
NR 63
TC 116
Z9 131
U1 5
U2 57
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2014
VL 5
AR 3067
DI 10.1038/ncomms4067
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AA4RQ
UT WOS:000331084200009
PM 24473083
OA DOAJ Gold
DA 2020-04-03
ER

PT J
AU Donaldson, EF
   Haskew, AN
   Gates, JE
   Huynh, J
   Moore, CJ
   Frieman, MB
AF Donaldson, Eric F.
   Haskew, Aimee N.
   Gates, J. Edward
   Huynh, Jeremy
   Moore, Clea J.
   Frieman, Matthew B.
TI Metagenomic Analysis of the Viromes of Three North American Bat Species:
   Viral Diversity among Different Bat Species That Share a Common Habitat
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SARS-LIKE CORONAVIRUSES; CHINESE HORSESHOE BATS; WEST-NILE-VIRUS;
   SEQUENCE ALIGNMENT; GENETIC DIVERSITY; ESCHERICHIA-COLI; GENOME; ORIGIN;
   BACTERIOPHAGE; UNDERSTAND
AB Effective prediction of future viral zoonoses requires an in-depth understanding of the heterologous viral population in key animal species that will likely serve as reservoir hosts or intermediates during the next viral epidemic. The importance of bats as natural hosts for several important viral zoonoses, including Ebola, Marburg, Nipah, Hendra, and rabies viruses and severe acute respiratory syndrome-coronavirus (SARS-CoV), has been established; however, the large viral population diversity (virome) of bats has been partially determined for only a few of the similar to 1,200 bat species. To assess the virome of North American bats, we collected fecal, oral, urine, and tissue samples from individual bats captured at an abandoned railroad tunnel in Maryland that is cohabitated by 7 to 10 different bat species. Here, we present preliminary characterization of the virome of three common North American bat species, including big brown bats (Eptesicus fuscus), tricolored bats (Perimyotis subflavus), and little brown myotis (Myotis lucifugus). In samples derived from these bats, we identified viral sequences that were similar to at least three novel group 1 CoVs, large numbers of insect and plant virus sequences, and nearly full-length genomic sequences of two novel bacteriophages. These observations suggest that bats encounter and disseminate a large assortment of viruses capable of infecting many different animals, insects, and plants in nature.
C1 [Donaldson, Eric F.; Huynh, Jeremy] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Haskew, Aimee N.; Gates, J. Edward] Univ Maryland, Ctr Environm Sci, Appalachian Lab, Frostburg, MD 21532 USA.
   [Moore, Clea J.] Oakwood Univ, Dept Biol Sci, Huntsville, AL 35896 USA.
   [Frieman, Matthew B.] Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
RP Donaldson, EF (reprint author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
EM eric_donaldson@med.unc.edu
RI Gates, John/B-7397-2015
FU NIH, Southeastern Regional Center of Excellence for Emerging Infections
   and BiodefenseUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U54 AI057157]
FX This work was supported by NIH grant U54 AI057157 from the Southeastern
   Regional Center of Excellence for Emerging Infections and Biodefense.
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Allander T, 2001, P NATL ACAD SCI USA, V98, P11609, DOI 10.1073/pnas.211424698
   Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196
   Anderson NG, 2003, EMERG INFECT DIS, V9, P768
   Arias CF, 2009, ARCH MED RES, V40, P643, DOI 10.1016/j.arcmed.2009.10.007
   Becker MM, 2008, P NATL ACAD SCI USA, V105, P19944, DOI 10.1073/pnas.0808116105
   Benson DA, 2009, NUCLEIC ACIDS RES, V37, pD26, DOI 10.1093/nar/gkn723
   Brandao PE, 2008, BRAZ J INFECT DIS, V12, P466, DOI 10.1590/S1413-86702008000600003
   Breitbart M, 2005, BIOTECHNIQUES, V39, P729, DOI 10.2144/000112019
   BRUNT AA, 1996, PLANT VIRUSES ONLINE
   Bunde JM, 2006, J WILDLIFE DIS, V42, P455, DOI 10.7589/0090-3558-42.2.455
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Cann AJ, 2005, VIRUS GENES, V30, P151, DOI 10.1007/s11262-004-5624-3
   Carrington CVF, 2008, EMERG INFECT DIS, V14, P1890, DOI 10.3201/eid1412.080642
   CHINESE SME, 2004, SCIENCE, V303, P1666, DOI DOI 10.1126/SCIENCE.1092002
   Chu DKW, 2008, J GEN VIROL, V89, P1282, DOI 10.1099/vir.0.83605-0
   Chu DKW, 2006, J GEN VIROL, V87, P2461, DOI 10.1099/vir.0.82203-0
   Coetzee B, 2010, VIROLOGY, V400, P157, DOI 10.1016/j.virol.2010.01.023
   Davis W. H., 1969, BATS AM
   de Miranda JR, 2010, J INVERTEBR PATHOL, V103, pS48, DOI 10.1016/j.jip.2009.06.012
   Degnan PH, 2008, APPL ENVIRON MICROB, V74, P6782, DOI 10.1128/AEM.01285-08
   Degnan PH, 2008, MOL ECOL, V17, P916, DOI 10.1111/j.1365-294X.2007.03616.x
   Djikeng A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-5
   Djikeng A, 2009, FUTURE VIROL, V4, P47, DOI 10.2217/17460794.4.1.47
   Dominguez SR, 2007, EMERG INFECT DIS, V13, P1295, DOI 10.3201/eid1309.070491
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Finkbeiner SR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000011
   Frank DN, 2008, CURR OPIN GASTROEN, V24, P4, DOI 10.1097/MOG.0b013e3282f2b0e8
   Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062
   Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130
   Gaynor AM, 2007, PLOS PATHOG, V3, P595, DOI 10.1371/journal.ppat.0030064
   Gloza-Rausch F, 2008, EMERG INFECT DIS, V14, P626, DOI 10.3201/eid1404.071439
   Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259
   Greninger AL, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-82
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hatfull GF, 2010, J MOL BIOL, V397, P119, DOI 10.1016/j.jmb.2010.01.011
   Holmes EC, 2001, BIOL REV, V76, P239, DOI 10.1017/S1464793101005668
   Kottier S A, 1995, Adv Exp Med Biol, V380, P551
   Kristensen DM, 2010, TRENDS MICROBIOL, V18, P11, DOI 10.1016/j.tim.2009.11.003
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2007, VIROLOGY, V367, P428, DOI 10.1016/j.virol.2007.06.009
   Letarov A, 2009, J APPL MICROBIOL, V107, P1, DOI 10.1111/j.1365-2672.2009.04143.x
   Li LL, 2010, J VIROL, V84, P6955, DOI 10.1128/JVI.00501-10
   Li LL, 2009, J VIROL, V83, P12002, DOI 10.1128/JVI.01241-09
   Masters PS, 2005, CURR TOP MICROBIOL, V287, P133, DOI 10.1007/3-540-26765-4_5
   MENZEL MA, 2002, NE376 USDA FOR SERV, P376
   Misra V, 2009, J GEN VIROL, V90, P2015, DOI 10.1099/vir.0.010694-0
   Molnar V, 2008, ACTA VET HUNG, V56, P529, DOI 10.1556/AVet.56.2008.4.10
   Moran NA, 2005, P NATL ACAD SCI USA, V102, P16919, DOI 10.1073/pnas.0507029102
   Ng TFF, 2009, J VIROL, V83, P2500, DOI 10.1128/JVI.01946-08
   Peeters M, 2008, M S-MED SCI, V24, P621, DOI 10.1051/medsci/20082467621
   Pfefferle S, 2009, EMERG INFECT DIS, V15, P1377, DOI 10.3201/eid1509.090224
   Pilipski JD, 2004, J WILDLIFE DIS, V40, P335, DOI 10.7589/0090-3558-40.2.335
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Preidis GA, 2009, GASTROENTEROLOGY, V136, P2015, DOI 10.1053/j.gastro.2009.01.072
   Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842
   RACEY P, 2008, ECOLOGICAL BEHAV MET, P31
   RAESLY RL, 1987, AM MIDL NAT, V118, P15, DOI 10.2307/2425624
   Razafindratsimandresy R, 2009, J GEN VIROL, V90, P44, DOI 10.1099/vir.0.006825-0
   REICHARD JD, 2008, WING DAMAGE INDEX US
   Ren W, 2006, J GEN VIROL, V87, P3355, DOI 10.1099/vir.0.82220-0
   Rihtaric D, 2010, ARCH VIROL, V155, P507, DOI 10.1007/s00705-010-0612-5
   Rohwer F, 2002, J BACTERIOL, V184, P4529, DOI 10.1128/JB.184.16.4529-4535.2002
   Roossinck MJ, 2010, MOL ECOL, V19, P81, DOI 10.1111/j.1365-294X.2009.04470.x
   Sandstrom JP, 2001, MOL ECOL, V10, P217, DOI 10.1046/j.1365-294X.2001.01189.x
   Scholl D, 2005, J BACTERIOL, V187, P8499, DOI 10.1128/JB.187.24.8499-8503.2005
   Scholl D, 2005, APPL ENVIRON MICROB, V71, P4872, DOI 10.1128/AEM.71.8.4872-4874.2005
   Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182
   Snyder EE, 2007, NUCLEIC ACIDS RES, V35, pD401, DOI 10.1093/nar/gkl858
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Stockman LJ, 2008, EMERG INFECT DIS, V14, P999, DOI 10.3201/eid1406.070964
   Tajima S, 2005, VIROLOGY, V332, P38, DOI 10.1016/j.virol.2004.06.052
   Tandler B, 1996, J COMP PATHOL, V114, P1, DOI 10.1016/S0021-9975(96)80057-0
   Tang XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06
   Teeling EC, 2005, SCIENCE, V307, P580, DOI 10.1126/science.1105113
   Tudge C., 2000, VARIETY LIFE SURVEY
   Victoria JG, 2009, J VIROL, V83, P4642, DOI 10.1128/JVI.02301-08
   Victoria JG, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000163
   Vijgen L, 2005, J VIROL, V79, P1595, DOI 10.1128/JVI.79.3.1595-1604.2005
   VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971
   Watanabe S, 2010, EMERG INFECT DIS, V16, P986, DOI 10.3201/eid1606.091567
   Watanabe S, 2009, VIRUS GENES, V39, P90, DOI 10.1007/s11262-009-0368-8
   WHITAKER JO, 1993, BATS, V11, P23
   Wibbelt G, 2007, J GEN VIROL, V88, P2651, DOI 10.1099/vir.0.83045-0
   Willner D, 2009, ENVIRON MICROBIOL, V11, P1752, DOI 10.1111/j.1462-2920.2009.01901.x
   Wolfe ND, 2007, NATURE, V447, P279, DOI 10.1038/nature05775
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2009, EXP BIOL MED, V234, P1117, DOI 10.3181/0903-MR-94
   Woolhouse M, 2007, CRIT REV MICROBIOL, V33, P231, DOI 10.1080/10408410701647560
   Yuan JF, 2010, J GEN VIROL, V91, P1058, DOI 10.1099/vir.0.016378-0
   Zhang H, 1998, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V12, P226
NR 95
TC 116
Z9 124
U1 2
U2 57
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2010
VL 84
IS 24
BP 13004
EP 13018
DI 10.1128/JVI.01255-10
PG 15
WC Virology
SC Virology
GA 683IN
UT WOS:000284469600052
PM 20926577
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Daugherty, EL
   Perl, TM
   Needham, DM
   Rubinson, L
   Bilderback, A
   Rand, CS
AF Daugherty, Elizabeth L.
   Perl, Trish M.
   Needham, Dale M.
   Rubinson, Lewis
   Bilderback, Andrew
   Rand, Cynthia S.
TI The use of personal protective equipment for control of influenza among
   critical care clinicians: A survey study
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE personal protective equipment; survey; critical care; infection control
   and prevention
ID ACUTE RESPIRATORY SYNDROME; INFECTION-CONTROL; HAND HYGIENE; NOSOCOMIAL
   INFECTIONS; UNIVERSAL PRECAUTIONS; SARS CORONAVIRUS; SYNCYTIAL VIRUS;
   ADHERENCE; WORKERS; TRANSMISSION
AB Background. Intensive care units (ICUs) are potential high-risk areas for transmission of viruses causing febrile respiratory illness, such as influenza. Healthcare-associated influenza is prevented through healthcare worker (HCW) vaccination and effective use of U.S. Centers for Disease Control and Prevention recommended infection control practices, including use of personal protective equipment (PPE). Although effective PPE use may significantly reduce healthcare-associated influenza transmission, PPE adherence among ICU HCWs for preventing nosocomial influenza infection has not been evaluated.
   Objective: To characterize ICU HCW behavior, knowledge, and attitudes about recommended precautions for the prevention of healthcare-associated influenza infections.
   Design, Setting, and Participants A survey of 292 internal medicine house-staff, pulmonary/critical care fellows and faculty, nurses, and respiratory care professionals working in four ICUs in two hospitals in Baltimore, MD.
   Measurements and Main Results. Of those surveyed, 88% (n = 256) completed the survey. Only 63% of respondents were able to correctly identify adequate influenza PPE, and 62% reported high adherence (>80%) with PPE use for prevention of nosocomial influenza. In multivariable modeling, odds of high adherence varied by clinician type. Respondents who believed adherence was inconvenient had lower odds of high adherence (odds ratio 0.42, 95% confidence interval 0.22-0.82), and those reporting likelihood of being reprimanded for nonadherence were more likely to adhere (odds ratio 2.40, 95% confidence interval 1.25-4.62).
   Conclusions. ICU HCWs report suboptimal levels of influenza PPE adherence. This finding in a high-risk setting is particularly concerning, given that it likely overestimates actual behavior. Both suboptimal adherence levels and significant PPE knowledge gaps indicate that ICU HCWs may be at a substantial risk of developing and/or transmitting nosocomial respiratory viral infection. Improving respiratory virus infection control will likely require closing knowledge gaps and changing organizational factors that influence behavior. (Crit Care Med 2009; 37:1210-1216)
C1 [Rand, Cynthia S.] Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA.
   [Daugherty, Elizabeth L.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
   [Rubinson, Lewis] Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, Seattle, WA 98104 USA.
RP Daugherty, EL (reprint author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
EM edaughe2@jhmi.edu
FU Johns Hopkins Center for Innovative Medicine; Salisbury Family
   Foundation
FX Supported, in part, by the Johns Hopkins Center for Innovative Medicine,
   Mr. Charles Salisbury, and the Salisbury Family Foundation.
CR Berhe M, 2005, AM J INFECT CONTROL, V33, P55, DOI 10.1016/j.ajic.2004.07.011
   Booth TF, 2005, J INFECT DIS, V191, P1472, DOI 10.1086/429634
   Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458
   Chaovavanich Achara, 2004, Journal of the Medical Association of Thailand, V87, P1182
   Christian MD, 2004, EMERG INFECT DIS, V10, P287, DOI 10.3201/eid1002.030700
   DAUGHERTY EL, 2007, AM J RESP CRIT CARE, P175
   DeJoy DM, 1996, HEALTH EDUC QUART, V23, P159, DOI 10.1177/109019819602300203
   DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205
   Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795
   Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC
   Gershon RRM, 2000, AM J INFECT CONTROL, V28, P211, DOI 10.1067/mic.2000.105288
   Hamilton LC, 2006, STAT STATA UPDATED V
   HAMMOND JS, 1990, J TRAUMA, V30, P555, DOI 10.1097/00005373-199005000-00005
   HENRY K, 1992, ANN EMERG MED, V21, P941, DOI 10.1016/S0196-0644(05)82932-4
   Huang DT, 2007, CRIT CARE MED, V35, P165, DOI 10.1097/01.CCM.0000251505.76026.CF
   Karanfil LV, 1999, AM J INFECT CONTROL, V27, P91, DOI 10.1016/S0196-6553(99)70087-8
   KELEN GD, 1990, J ACQ IMMUN DEF SYND, V3, P987
   Kellerman SE, 2001, PEDIATR INFECT DIS J, V20, P566, DOI 10.1097/00006454-200106000-00004
   Loeb M, 2004, EMERG INFECT DIS, V10, P251, DOI 10.3201/eid1002.030838
   Low DE, 2003, NEW ENGL J MED, V349, P2381, DOI 10.1056/NEJMp038203
   Macartney KK, 2000, PEDIATRICS, V106, P520, DOI 10.1542/peds.106.3.520
   Moore D, 2005, AM J INFECT CONTROL, V33, P88, DOI 10.1016/j.ajic.2004.11.003
   Muller MP, 2006, CURR OPIN CRIT CARE, V12, P37, DOI 10.1097/01.ccx.0000198056.58083.a1
   O'Boyle CA, 2001, AM J INFECT CONTROL, V29, P352, DOI 10.1067/mic.2001.18405
   Ofner M., 2003, Morbidity and Mortality Weekly Report, V52, P433
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Pessoa-Silva CL, 2005, INFECT CONT HOSP EP, V26, P305, DOI 10.1086/502544
   Pittet D, 2004, ANN INTERN MED, V141, P1, DOI 10.7326/0003-4819-141-1-200407060-00008
   Rubinson L, 2003, JAMA-J AM MED ASSOC, V290, P2802, DOI 10.1001/jama.290.21.2802
   Sandrock C, 2008, CHEST, V133, P1221, DOI 10.1378/chest.07-0778
   *SARS COMM EX SUMM, SPRING FEAR, V1
   Sax H, 2007, INFECT CONT HOSP EP, V28, P1267, DOI 10.1086/521663
   Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6
   Shimokura G, 2006, AM J INFECT CONTROL, V34, P100, DOI 10.1016/j.ajic.2005.08.012
   Siegel JD, HEALTHCARE INFECT CO
   *STATACORP LP, 2005, INT STAT 9 2
   Tokars JI, 2001, INFECT CONT HOSP EP, V22, P449, DOI 10.1086/501933
   United States Department of Health and Human Services, 2005, HHS PAND INFL PLAN
   Warren DK, 2006, INFECT CONT HOSP EP, V27, P662, DOI 10.1086/506184
NR 39
TC 116
Z9 125
U1 4
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD APR
PY 2009
VL 37
IS 4
BP 1210
EP 1216
DI 10.1097/CCM.0b013e31819d67b5
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA 426HQ
UT WOS:000264699000004
PM 19242326
DA 2020-04-03
ER

PT J
AU Cameron, MJ
   Ran, L
   Xu, L
   Danesh, A
   Bermejo-Martin, JF
   Cameron, CM
   Muller, MP
   Gold, WL
   Richardson, SE
   Poutanen, SM
   Willey, BM
   DeVries, ME
   Fang, Y
   Seneviratne, C
   Bosinger, SE
   Persad, D
   Wilkinson, P
   Greller, LD
   Somogyi, R
   Humar, A
   Keshavjee, S
   Louie, M
   Loeb, MB
   Brunton, J
   McGeer, AJ
   Kelvin, DJ
AF Cameron, Mark J.
   Ran, Longsi
   Xu, Luoling
   Danesh, Ali
   Bermejo-Martin, Jesus F.
   Cameron, Cheryl M.
   Muller, Matthew P.
   Gold, Wayne L.
   Richardson, Susan E.
   Poutanen, Susan M.
   Willey, Barbara M.
   DeVries, Mark E.
   Fang, Yuan
   Seneviratne, Charit
   Bosinger, Steven E.
   Persad, Desmond
   Wilkinson, Peter
   Greller, Larry D.
   Somogyi, Roland
   Humar, Atul
   Keshavjee, Shaf
   Louie, Marie
   Loeb, Mark B.
   Brunton, James
   McGeer, Allison J.
   Kelvin, David J.
CA Canadian SARS Research Network
TI Interferon-mediated immunopathological events are associated with
   atypical innate and adaptive immune responses in patients with severe
   acute respiratory syndrome
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CRITICALLY-ILL PATIENTS; CORONAVIRUS SARS-COV; FUNCTIONAL RECEPTOR;
   PROGNOSTIC-FACTORS; EXPRESSION; GENES; GAMMA; LUNG; REPRODUCIBILITY;
   POLYMORPHISMS
AB It is not understood how immune inflammation influences the pathogenesis of severe acute respiratory syndrome (SARS). One area of strong controversy is the role of interferon (IFN) responses in the natural history of SARS. The fact that the majority of SARS patients recover after relatively moderate illness suggests that the prevailing notion of deficient type I IFN-mediated immunity, with hypercytokinemia driving a poor clinical course, is oversimplified. We used proteomic and genomic technology to systematically analyze host innate and adaptive immune responses of 40 clinically well-described patients with SARS during discrete phases of illness from the onset of symptoms to discharge or a fatal outcome. A novel signature of high IFN-alpha, IFN-gamma, and IFN-stimulated chemokine levels, plus robust antiviral IFN-stimulated gene (ISG) expression, accompanied early SARS sequelae. As acute illness progressed, SARS patients entered a crisis phase linked to oxygen saturation profiles. The majority of SARS patients resolved IFN responses at crisis and expressed adaptive immune genes. In contrast, patients with poor outcomes showed deviated ISG and immunoglobulin gene expression levels, persistent chemokine levels, and deficient anti-SARS spike antibody production. We contend that unregulated IFN responses during acute-phase SARS may culminate in a malfunction of the switch from innate immunity to adaptive immunity. The potential for the use of the gene signatures we describe in this study to better assess the immunopathology and clinical management of severe viral infections, such as SARS and avian influenza (H5N1), is therefore worth careful examination.
C1 Univ Toronto, Hlth Network, Div Expt Therapeut, MaRS Ctr, Toronto, ON M5G 1L7, Canada.
   Univ Valladolid, Valladolid, Spain.
   Toronto Med Labs, Toronto, ON, Canada.
   Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
   Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
   CHU Montreal, Hop St Luc, Montreal, PQ, Canada.
   Biosystemix, Sydenham, ON, Canada.
   Prov Lab Publ Hlth, Calgary, AB, Canada.
   McMaster Univ, Hamilton, ON, Canada.
RP Kelvin, DJ (reprint author), Univ Toronto, Hlth Network, Div Expt Therapeut, MaRS Ctr, 3-916 TMDT,101 Coll St, Toronto, ON M5G 1L7, Canada.
EM dkelvin@uhnres.utoronto.ca
RI Bermejo-Martin, Jesus Francisco/J-4574-2019; Cameron, Mark/O-6775-2019;
   McGeer, Allison/AAB-6885-2020; mcgeer, allison/H-7747-2014; Poutanen,
   Susan M./N-8066-2019; Poutanen, Susan M/F-9640-2012
OI Bermejo-Martin, Jesus Francisco/0000-0002-7998-6268; Cameron,
   Mark/0000-0003-4768-4094; McGeer, Allison/0000-0001-5647-6137; mcgeer,
   allison/0000-0001-5647-6137; Poutanen, Susan M./0000-0003-4747-2550;
   Poutanen, Susan M/0000-0003-4747-2550; Keshavjee,
   Shaf/0000-0003-4547-8094
CR Aubert M, 2003, INT REV IMMUNOL, V22, P361, DOI 10.1080/08830180305213
   Avendano M, 2003, CAN MED ASSOC J, V168, P1649
   Brierley MM, 2002, J INTERF CYTOK RES, V22, P835, DOI 10.1089/107999002760274845
   Brierley MM, 2005, J INTERF CYTOK RES, V25, P733, DOI 10.1089/jir.2005.25.733
   Castilletti C, 2005, VIROLOGY, V341, P163, DOI 10.1016/j.virol.2005.07.015
   Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770
   Chen Cheng-Yu, 2005, J Chin Med Assoc, V68, P4, DOI 10.1016/S1726-4901(09)70124-8
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Choi KW, 2003, ANN INTERN MED, V139, P715, DOI 10.7326/0003-4819-139-9-200311040-00005
   Cowling BJ, 2006, ARCH INTERN MED, V166, P1505, DOI 10.1001/archinte.166.14.1505
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Dutta N, 2006, CANCER-AM CANCER SOC, V106, P1685, DOI 10.1002/cncr.21784
   Farcas GA, 2005, J INFECT DIS, V191, P193, DOI 10.1086/426870
   Fowler RA, 2003, JAMA-J AM MED ASSOC, V290, P367, DOI 10.1001/jama.290.3.367
   Hamano E, 2005, BIOCHEM BIOPH RES CO, V329, P1234, DOI 10.1016/j.bbrc.2005.02.101
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Han T, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S2-S17
   He J, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-106
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Hwang DM, 2005, MODERN PATHOL, V18, P1, DOI 10.1038/modpathol.3800247
   Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kumar D, 2003, AM J TRANSPLANT, V3, P977, DOI 10.1034/j.1600-6143.2003.00197.x
   Lau YL, 2005, CURR OPIN IMMUNOL, V17, P404, DOI 10.1016/j.coi.2005.05.009
   Law HKW, 2005, BLOOD, V106, P2366, DOI 10.1182/blood-2004-10-4166
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lee YS, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-132
   Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lo AWI, 2006, J PATHOL, V208, P142, DOI 10.1002/path.1897
   Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665
   Mandavilli A, 2006, NATURE, V439, P382, DOI 10.1038/439382a
   Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Nie YC, 2004, J INFECT DIS, V190, P1119, DOI 10.1086/423286
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2
   Salto-Tellez M, 2005, CYTOKINE, V29, P92, DOI 10.1016/j.cyto.2004.09.002
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Shao L, 2002, CLIN DIAGN LAB IMMUN, V9, P739, DOI 10.1128/CDLI.9.4.739-746.2002
   Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239
   Smith PL, 2005, MOL IMMUNOL, V42, P869, DOI 10.1016/j.molimm.2004.11.008
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Strieter RM, 2003, CURR OPIN INFECT DIS, V16, P193, DOI 10.1097/00001432-200306000-00002
   Takaoka A, 2006, CELL MICROBIOL, V8, P907, DOI 10.1111/j.1462-5822.2006.00716.x
   Tang NLS, 2005, CLIN CHEM, V51, P2333, DOI 10.1373/clinchem.2005.054460
   Tsui PT, 2003, EMERG INFECT DIS, V9, P1064
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Wu CG, 2006, MOL MED, V12, P47, DOI 10.2119/2006-00020.Wu
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yu SY, 2005, WORLD J GASTROENTERO, V11, P5037, DOI 10.3748/wjg.v11.i32.5037
   Ziegler T, 2005, J VIROL, V79, P13800, DOI 10.1128/JVI.79.21.13800-13805.2005
   Zou ZS, 2004, CLIN INFECT DIS, V38, P483, DOI 10.1086/380973
NR 57
TC 116
Z9 122
U1 1
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD AUG
PY 2007
VL 81
IS 16
BP 8692
EP 8706
DI 10.1128/JVI.00527-07
PG 15
WC Virology
SC Virology
GA 198SZ
UT WOS:000248649100033
PM 17537853
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Beckham, JD
   Cadena, A
   Lin, JJ
   Piedra, PA
   Glezen, WP
   Greenberg, SB
   Atmar, RL
AF Beckham, JD
   Cadena, A
   Lin, JJ
   Piedra, PA
   Glezen, WP
   Greenberg, SB
   Atmar, RL
TI Respiratory viral infections in patients with chronic, obstructive
   pulmonary disease
SO JOURNAL OF INFECTION
LA English
DT Article
DE respiratory viral infection; influenza; respiratory syncytial virus;
   rhinovirus; parainfluenza virus; coronavirus; human metapneumovirus;
   chronic obstructive pulmonary disease; hospitalization; exacerbation
ID REVERSE TRANSCRIPTION-PCR; POLYMERASE-CHAIN-REACTION; SYNCYTIAL
   VIRUS-INFECTION; HUMAN METAPNEUMOVIRUS; RISK-FACTORS; EXACERBATIONS;
   INFLUENZA; DIAGNOSIS; ADENOVIRUSES; PREVALENCE
AB Objectives. The purpose of the present study was to apply reverse transcription- PCR (RT-PCR) assays to clinical specimens collected from patients with acute respiratory illness and chronic obstructive pulmonary disease (COPD).
   Methods. One hundred and ninety-four samples from two different study cohorts were analysed using RT-PCR assays for picornaviruses, coronaviruses 229E and OC43, influenza A and B viruses, respiratory syncytial. virus, parainfluenza types 1-3 viruses, and human metapneumovirus and a PCR assay for adenoviruses. The results were added to results obtained previously using cell culture and serologic methods.
   Results. RT-PCR assays identified an additional 35 respiratory virus- associated illnesses not identified previously by cell culture or serology (n=46). Picornaviruses and coronaviruses were the most common viral infections identified only by RT-PCR. Overall, 41.8% of the acute respiratory illnesses evaluated were associated with a respiratory virus infection, with picornaviruses, coronaviruses and influenza viruses being the most common infections recognized. No human metapneumovirus infections were identified by RT-IPCR assay.
   Conclusions. Respiratory viral infections are commonly associated with acute respiratory illness in COPD patients, and the use of RT-PCR assays significantly increases the ability to diagnose these infections. (c) 2004 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   Ben Taub Gen Hosp, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Med Serv, Houston, TX 77030 USA.
RP Atmar, RL (reprint author), Baylor Coll Med, Dept Med, 1 Baylor Plaza, Houston, TX 77030 USA.
EM ratmar@bcm.tmc.edu
RI Beckham, John/AAE-6694-2020
OI Beckham, John/0000-0001-9305-2683
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01-AI-15103]
CR ALLARD A, 1992, J MED VIROL, V37, P149, DOI 10.1002/jmv.1890370214
   Allard A, 2001, J CLIN MICROBIOL, V39, P498, DOI 10.1128/JCM.39.2.498-505.2001
   [Anonymous], 1987, AM REV RESPIR DIS, V136, P225
   ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196
   Arbour N, 2000, J VIROL, V74, P8913, DOI 10.1128/JVI.74.19.8913-8921.2000
   Arias Elizabeth, 2003, Natl Vital Stat Rep, V52, P1
   Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453
   Atmar RL, 1996, J CLIN MICROBIOL, V34, P2604, DOI 10.1128/JCM.34.10.2604-2606.1996
   Atmar RL, 1996, CLIN DIAGN VIROL, V7, P77, DOI 10.1016/S0928-0197(96)00254-1
   Bandi V, 2003, FEMS IMMUNOL MED MIC, V37, P69, DOI 10.1016/S0928-8244(03)00100-7
   Boivin G, 2002, J INFECT DIS, V186, P1330, DOI 10.1086/344319
   Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1
   Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137
   Fagon J Y, 1996, Semin Respir Infect, V11, P109
   Falsey AR, 2002, J INFECT DIS, V185, P1338, DOI 10.1086/339881
   Falsey AR, 2003, J INFECT DIS, V187, P785, DOI 10.1086/367901
   Fan J, 1996, J CLIN MICROBIOL, V34, P1914, DOI 10.1128/JCM.34.8.1914-1917.1996
   Garcia-Aymerich J, 2000, EUR RESPIR J, V16, P1037, DOI 10.1034/j.1399-3003.2000.16f03.x
   Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499
   Greenberg S B, 1999, Trans Am Clin Climatol Assoc, V110, P38
   Greenberg SB, 2000, AM J RESP CRIT CARE, V162, P167, DOI 10.1164/ajrccm.162.1.9911019
   Griffin MR, 2002, ARCH INTERN MED, V162, P1229, DOI 10.1001/archinte.162.11.1229
   Hamelin ME, 2004, CLIN INFECT DIS, V38, P983, DOI 10.1086/382536
   Hoyert D L, 2001, Natl Vital Stat Rep, V49, P1
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   KARRON RA, 1994, J CLIN MICROBIOL, V32, P484, DOI 10.1128/JCM.32.2.484-488.1994
   MURRAY RS, 1992, VIROLOGY, V188, P274, DOI 10.1016/0042-6822(92)90757-G
   POOLE PJ, 2003, COCHRANE DATABASE SY, V1
   Rohde G, 2003, THORAX, V58, P37, DOI 10.1136/thorax.58.1.37
   Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011
   Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032
   SMITH CB, 1976, J INFECT DIS, V134, P552, DOI 10.1093/infdis/134.6.552
   Tata LJ, 2003, THORAX, V58, P835, DOI 10.1136/thorax.58.10.835
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   van den Hoogen BG, 2003, J INFECT DIS, V188, P1571, DOI 10.1086/379200
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van Elden LJR, 2001, J CLIN MICROBIOL, V39, P196, DOI 10.1128/JCM.39.1.196-200.2001
   VANMILAAN AJ, 1994, J MED VIROL, V44, P80, DOI 10.1002/jmv.1890440115
   Walsh EE, 1999, AM J RESP CRIT CARE, V160, P791, DOI 10.1164/ajrccm.160.3.9901004
   Walsh EE, 2004, J INFECT DIS, V189, P233, DOI 10.1086/380907
   Walsh EE, 2001, J MED VIROL, V63, P259, DOI 10.1002/1096-9071(200103)63:3&lt;259::AID-JMV1010&gt;3.0.CO;2-X
   Wedzicha Jadwiga A, 2004, Proc Am Thorac Soc, V1, P115, DOI 10.1513/pats.2306030
   WISELKA MJ, 1993, EPIDEMIOL INFECT, V111, P337, DOI 10.1017/S0950268800057046
NR 44
TC 116
Z9 119
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD MAY
PY 2005
VL 50
IS 4
BP 322
EP 330
DI 10.1016/j.jinf.2004.07.011
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 925OJ
UT WOS:000229062100006
PM 15845430
DA 2020-04-03
ER

PT J
AU Booth, TF
   Kournikakis, B
   Bastien, N
   Ho, J
   Kobasa, D
   Stadnyk, L
   Li, Y
   Spence, M
   Paton, S
   Henry, B
   Mederski, B
   White, D
   Low, DE
   McGeer, A
   Simor, A
   Vearncombe, M
   Downey, J
   Jamieson, FB
   Tang, P
   Plummer, F
AF Booth, TF
   Kournikakis, B
   Bastien, N
   Ho, J
   Kobasa, D
   Stadnyk, L
   Li, Y
   Spence, M
   Paton, S
   Henry, B
   Mederski, B
   White, D
   Low, DE
   McGeer, A
   Simor, A
   Vearncombe, M
   Downey, J
   Jamieson, FB
   Tang, P
   Plummer, F
TI Detection of airborne severe acute respiratory syndrome (SARS)
   coronavirus and environmental contamination in SARS outbreak units
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HOSPITAL ROOMS; AIR SAMPLES; TRANSMISSION; VIRUS; SURVIVAL
AB Severe acute respiratory syndrome (SARS) is characterized by a risk of nosocomial transmission; however, the risk of airborne transmission of SARS is unknown. During the Toronto outbreaks of SARS, we investigated environmental contamination in SARS units, by employing novel air sampling and conventional surface swabbing. Two polymerase chain reaction (PCR)-positive air samples were obtained from a room occupied by a patient with SARS, indicating the presence of the virus in the air of the room. In addition, several PCR-positive swab samples were recovered from frequently touched surfaces in rooms occupied by patients with SARS (a bed table and a television remote control) and in a nurses' station used by staff (a medication refrigerator door). These data provide the first experimental confirmation of viral aerosol generation by a patient with SARS, indicating the possibility of airborne droplet transmission, which emphasizes the need for adequate respiratory protection, as well as for strict surface hygiene practices.
C1 Publ Hlth Agcy Canada, Canadian Sci Ctr Human & Anim Hlth, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada.
   Def Res & Dev Canada Suffield, Chem Biol Def Sect, Medicine Hat, AB, Canada.
   Publ Hlth Agcy Canada, Hlth Care Acquired Infect Div, Ottawa, ON, Canada.
   Toronto Publ Hlth, Toronto, ON, Canada.
   N York Gen Hosp, Toronto, ON, Canada.
   Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
   Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada.
   Toronto E Gen & Orthoped Hosp, Dept Med, Toronto, ON, Canada.
   Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   Ontario Minist Hlth & Long Term Care, Cent Publ Hlth Lab, Etobicoke, ON, Canada.
RP Booth, TF (reprint author), Publ Hlth Agcy Canada, Canadian Sci Ctr Human & Anim Hlth, Natl Microbiol Lab, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada.
EM tim_booth@hc-sc.gc.ca
RI Jamieson, Frances/B-2040-2013; Low, Donald/B-1726-2012; mcgeer,
   allison/H-7747-2014; McGeer, Allison/AAB-6885-2020
OI mcgeer, allison/0000-0001-5647-6137; McGeer,
   Allison/0000-0001-5647-6137; Tang, Patrick/0000-0003-1583-5484
CR Aintablian N, 1998, INFECT CONT HOSP EP, V19, P918
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Christian MD, 2004, EMERG INFECT DIS, V10, P287, DOI 10.3201/eid1002.030700
   Duan SM, 2003, BIOMED ENVIRON SCI, V16, P246
   Dull PM, 2002, EMERG INFECT DIS, V8, P1044, DOI 10.3201/eid0810.020356
   HO J, 2003, TR2001139 DRDC
   IJAZ MK, 1987, J VIROL METHODS, V18, P87, DOI 10.1016/0166-0934(87)90114-5
   IJAZ MK, 1985, J GEN VIROL, V66, P2743, DOI 10.1099/0022-1317-66-12-2743
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Myatt TA, 2004, AM J RESP CRIT CARE, V169, P1187, DOI 10.1164/rccm.200306-760OC
   Olsen SJ, 2003, NEW ENGL J MED, V349, P2416, DOI 10.1056/NEJMoa031349
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   *PUBL HLTH AG CAN, 2003, CLUST SEV AC RESP SY
   *PUBL HLTH AG CAN, 2003, INF CONTR GUID RESP
   *PUBL HLTH AG CAN, 2003, SARS ONT HLTH CAR WO
   Roy CJ, 2004, NEW ENGL J MED, V350, P1710, DOI 10.1056/NEJMp048051
   SAWYER MH, 1994, J INFECT DIS, V169, P91, DOI 10.1093/infdis/169.1.91
   Tang P, 2004, CAN MED ASSOC J, V170, P47
   World Health Organization, HOSP INF CONTR GUID
   Yu ITS, 2004, NEW ENGL J MED, V350, P1731, DOI 10.1056/NEJMoa032867
NR 20
TC 116
Z9 118
U1 8
U2 22
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 1
PY 2005
VL 191
IS 9
BP 1472
EP 1477
DI 10.1086/429634
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 913CS
UT WOS:000228128800014
PM 15809906
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Yang, ZY
   Werner, HC
   Kong, WP
   Leung, K
   Traggiai, E
   Lanzavecchia, A
   Nabel, GJ
AF Yang, ZY
   Werner, HC
   Kong, WP
   Leung, K
   Traggiai, E
   Lanzavecchia, A
   Nabel, GJ
TI Evasion of antibody neutralization in emerging severe acute respiratory
   syndrome coronaviruses
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE angiotensin-converting enzyme 2; enhancement; immunoglobulin G;
   pseudovirus
ID ANGIOTENSIN-CONVERTING ENZYME-2; SARS-CORONAVIRUS; PROTECTIVE IMMUNITY;
   SPIKE GLYCOPROTEIN; GENOME SEQUENCE; CELL-LINES; S-PROTEIN; RECEPTOR;
   VIRUS; ENTRY
AB Molecular characterization of the severe acute respiratory syndrome coronavirus has revealed genetic diversity among isolates. The spike (S) glycoprotein, the major target for vaccine and immune therapy, shows up to 17 substitutions in its 1,255-aa sequence; however, the biologic significance of these changes is unknown. Here, the functional effects of S mutations have been determined by analyzing their affinity for a viral receptor, human angiotensin-converting enzyme 2 (hACE-2), and their sensitivity to Ab neutralization with viral pseudotypes. Although minor differences among eight strains transmitted during human outbreaks in early 2003 were found, substantial functional changes were detected in S derived from a case in late 2003 from Guangdong province [S(GD03T0013)] and from two palm civets, S(SZ3) and S(SZ16). S(GD03T0013) depended less on the hACE-2 receptor and was markedly resistant to Ab inhibition. Unexpectedly, Abs that neutralized most human S glycoproteins enhanced entry mediated by the civet virus 5 glycoproteins. The mechanism of enhancement involved the interaction of Abs with conformational epitopes in the hACE-2-binding domain. Finally, improved immunogens and mAbs that minimize this complication have been defined. These data show that the entry of severe acute respiratory syndrome coronaviruses can be enhanced by Abs, and they underscore the need to address the evolving diversity of this newly emerged virus for vaccines and immune therapies.
C1 NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   Inst Biomed Res, CH-6500 Bellinzona, Switzerland.
RP Nabel, GJ (reprint author), NIAID, Vaccine Res Ctr, NIH, Bldg 40,Room 4502,MSC-3005,40 Convent Dr, Bethesda, MD 20892 USA.
EM gnabel@nih.gov
RI traggiai, elisabetta/A-2316-2009
CR Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.239.4839.476
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MURPHY BR, 1986, J CLIN MICROBIOL, V24, P197, DOI 10.1128/JCM.24.2.197-202.1986
   Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Ruan YJ, 2003, LANCET, V361, P1779, DOI 10.1016/S0140-6736(03)13414-9
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wool-Lewis RJ, 1998, J VIROL, V72, P3155, DOI 10.1128/JVI.72.4.3155-3160.1998
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
NR 25
TC 116
Z9 130
U1 1
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 18
PY 2005
VL 102
IS 3
BP 797
EP 801
DI 10.1073/pnas.0409065102
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 889IF
UT WOS:000226436000050
PM 15642942
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU STOHLMAN, SA
   BARIC, RS
   NELSON, GN
   SOE, LH
   WELTER, LM
   DEANS, RJ
AF STOHLMAN, SA
   BARIC, RS
   NELSON, GN
   SOE, LH
   WELTER, LM
   DEANS, RJ
TI SPECIFIC INTERACTION BETWEEN CORONAVIRUS LEADER RNA AND NUCLEOCAPSID
   PROTEIN
SO JOURNAL OF VIROLOGY
LA English
DT Article
C1 UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033.
   UNIV N CAROLINA,SCH PUBL HLTH,DEPT PARASITOL & LAB PRACTICE,CHAPEL HILL,NC 27514.
RP STOHLMAN, SA (reprint author), UNIV SO CALIF,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90033, USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 19244, AI 31386]; NINDS NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [NS 18146]
CR ANDERSON JE, 1985, NATURE, V316, P596, DOI 10.1038/316596a0
   ARMSTRONG J, 1983, NUCLEIC ACIDS RES, V11, P883, DOI 10.1093/nar/11.3.883
   ARNHEITER H, 1985, CELL, V41, P259, DOI 10.1016/0092-8674(85)90079-0
   BANERJEE AK, 1987, MICROBIOL REV, V51, P66, DOI 10.1128/MMBR.51.1.66-87.1987
   BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   BARIC RS, 1987, VIROLOGY, V156, P342, DOI 10.1016/0042-6822(87)90414-4
   BARIC RS, 1985, VIRUS RES, V3, P19, DOI 10.1016/0168-1702(85)90038-3
   BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1
   BRAYTON PR, 1982, J VIROL, V42, P847, DOI 10.1128/JVI.42.3.847-853.1982
   BRAYTON PR, 1984, VIROLOGY, V133, P197, DOI 10.1016/0042-6822(84)90439-2
   COMPTON SR, 1987, J VIROL, V61, P1814, DOI 10.1128/JVI.61.6.1814-1820.1987
   FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1
   FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X
   GILMORE W, 1987, P SOC EXP BIOL MED, V185, P177
   KURILLA MG, 1983, CELL, V34, P837, DOI 10.1016/0092-8674(83)90541-X
   LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   LAI MMC, 1982, J VIROL, V41, P557, DOI 10.1128/JVI.41.2.557-565.1982
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   MAKINO S, 1986, P NATL ACAD SCI USA, V83, P4204, DOI 10.1073/pnas.83.12.4204
   MAKINO S, 1985, J VIROL, V54, P329, DOI 10.1128/JVI.54.2.329-336.1985
   MANN R, 1985, J VIROL, V54, P401, DOI 10.1128/JVI.54.2.401-407.1985
   MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x
   RAJU R, 1987, J VIROL, V61, P667, DOI 10.1128/JVI.61.3.667-672.1987
   ROBBINS SG, 1986, VIROLOGY, V150, P402, DOI 10.1016/0042-6822(86)90305-3
   ROSEN CA, 1982, J VIROL, V44, P932, DOI 10.1128/JVI.44.3.932-938.1982
   SHIEH CK, 1987, VIROLOGY, V156, P321, DOI 10.1016/0042-6822(87)90412-0
   SKINNER MA, 1983, NUCLEIC ACIDS RES, V11, P5045, DOI 10.1093/nar/11.15.5045
   SOE LH, 1987, J VIROL, V61, P3968, DOI 10.1128/JVI.61.12.3968-3976.1987
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   STOHLMAN SA, 1983, VIROLOGY, V130, P527, DOI 10.1016/0042-6822(83)90106-X
   STOHLMAN SA, 1979, J VIROL, V32, P672, DOI 10.1128/JVI.32.2.672-675.1979
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
NR 35
TC 116
Z9 120
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 1988
VL 62
IS 11
BP 4288
EP 4295
DI 10.1128/JVI.62.11.4288-4295.1988
PG 8
WC Virology
SC Virology
GA Q4899
UT WOS:A1988Q489900047
PM 2845141
OA Bronze
DA 2020-04-03
ER

PT J
AU STURMAN, LS
   TAKEMOTO, KK
AF STURMAN, LS
   TAKEMOTO, KK
TI ENHANCED GROWTH OF A MURINE CORONAVIRUS IN TRANSFORMED MOUSE CELLS
SO INFECTION AND IMMUNITY
LA English
DT Article
CR AARONSON SA, 1970, VIROLOGY, V42, P9, DOI 10.1016/0042-6822(70)90233-3
   AARONSON SA, 1969, P NATL ACAD SCI USA, V64, P87, DOI 10.1073/pnas.64.1.87
   AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208
   AARONSON SA, 1971, SCIENCE, V174, P157, DOI 10.1126/science.174.4005.157
   BANG FB, 1960, P NATL ACAD SCI USA, V46, P1065, DOI 10.1073/pnas.46.8.1065
   BRADBURNE AF, 1969, ARCH GES VIRUSFORSCH, V28, P133, DOI 10.1007/BF01249379
   BRUCKOVA M, 1970, P SOC EXP BIOL MED, V135, P431
   CORIA MF, 1969, AVIAN DIS, V13, P540, DOI 10.2307/1588527
   Cunningham C H, 1970, Adv Vet Sci Comp Med, V14, P105
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   KAPIKIAN AZ, 1969, DIAGNOSTIC PROCEDURE, P931
   LUKERT PD, 1966, ARCH GES VIRUSFORSCH, V19, P265, DOI 10.1007/BF01241849
   LUKERT PD, 1965, AVIAN DIS, V9, P308, DOI 10.2307/1588016
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   PIAZZA M, 1969, EXPERIMENTAL VIRAL H
   SHIF I, 1970, J EXP MED, V131, P843, DOI 10.1084/jem.131.4.843
   STURMAN LS, 1966, J IMMUNOL, V97, P885
   TAKEMOTO KK, 1968, J NATL CANCER I, V41, P1401
   TYRRELL DAJ, 1965, BMJ-BRIT MED J, V1, P1467, DOI 10.1136/bmj.1.5448.1467
   1968, NATURE, V220, P650
NR 20
TC 116
Z9 116
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PY 1972
VL 6
IS 4
BP 501
EP &
DI 10.1128/IAI.6.4.501-507.1972
PG 0
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA N6185
UT WOS:A1972N618500012
PM 4564284
OA Bronze
DA 2020-04-03
ER

PT J
AU Gierer, S
   Bertram, S
   Kaup, F
   Wrensch, F
   Heurich, A
   Kramer-Kuhl, A
   Welsch, K
   Winkler, M
   Meyer, B
   Drosten, C
   Dittmer, U
   von Hahn, T
   Simmons, G
   Hofmann, H
   Pohlmann, S
AF Gierer, Stefanie
   Bertram, Stephanie
   Kaup, Franziska
   Wrensch, Florian
   Heurich, Adeline
   Kraemer-Kuehl, Annika
   Welsch, Kathrin
   Winkler, Michael
   Meyer, Benjamin
   Drosten, Christian
   Dittmer, Ulf
   von Hahn, Thomas
   Simmons, Graham
   Hofmann, Heike
   Poehlmann, Stefan
TI The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel
   Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is
   Targeted by Neutralizing Antibodies
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ACUTE-RESPIRATORY-SYNDROME; MEMBRANE-FUSION PROTEINS; EBOLA-VIRUS
   GLYCOPROTEIN; MOUSE HEPATITIS-VIRUS; EPITHELIAL-CELLS; INFECTION;
   INHIBITORS; SERINE; NL63; DETERMINANTS
AB The novel human coronavirus EMC (hCoV-EMC), which recently emerged in Saudi Arabia, is highly pathogenic and could pose a significant threat to public health. The elucidation of hCoV-EMC interactions with host cells is critical to our understanding of the pathogenesis of this virus and to the identification of targets for antiviral intervention. Here we investigated the viral and cellular determinants governing hCoV-EMC entry into host cells. We found that the spike protein of hCoV-EMC (EMC-S) is incorporated into lentiviral particles and mediates transduction of human cell lines derived from different organs, including the lungs, kidneys, and colon, as well as primary human macrophages. Expression of the known coronavirus receptors ACE2, CD13, and CEACAM1 did not facilitate EMC-S-driven transduction, suggesting that hCoV-EMC uses a novel receptor for entry. Directed protease expression and inhibition analyses revealed that TMPRSS2 and endosomal cathepsins activate EMC-S for virus-cell fusion and constitute potential targets for antiviral intervention. Finally, EMC-S-driven transduction was abrogated by serum from an hCoV-EMC-infected patient, indicating that EMC-S-specific neutralizing antibodies can be generated in patients. Collectively, our results indicate that hCoV-EMC uses a novel receptor for protease-activated entry into human cells and might be capable of extrapulmonary spread. In addition, they define TMPRSS2 and cathepsins B and L as potential targets for intervention and suggest that neutralizing antibodies contribute to the control of hCoV-EMC infection.
C1 [Gierer, Stefanie; Bertram, Stephanie; Kaup, Franziska; Wrensch, Florian; Heurich, Adeline; Kraemer-Kuehl, Annika; Welsch, Kathrin; Winkler, Michael; Hofmann, Heike; Poehlmann, Stefan] German Primate Ctr, Infect Biol Unit, Gottingen, Germany.
   [Meyer, Benjamin; Drosten, Christian] Univ Med Ctr, Inst Virol, Bonn, Germany.
   [Dittmer, Ulf] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, Essen, Germany.
   [von Hahn, Thomas] Hannover Med Sch, Inst Mol Biol, Hannover, Germany.
   [von Hahn, Thomas] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany.
   [Simmons, Graham] Blood Syst Res Inst, San Francisco, CA USA.
RP Pohlmann, S (reprint author), German Primate Ctr, Infect Biol Unit, Gottingen, Germany.
EM spoehlmann@dpz.eu
RI Mueller, Marcel/O-2425-2019; Simmons, Graham/G-3523-2012; Pohlmann,
   Stefan/H-2395-2011; Meyer, Bernhard/Q-9413-2016; Meyer,
   Benjamin/F-3285-2018
OI Mueller, Marcel/0000-0003-2242-5117; Simmons,
   Graham/0000-0002-9615-7023; Pohlmann, Stefan/0000-0001-6086-9136; Meyer,
   Benjamin/0000-0003-0601-3550; Wrensch, Florian/0000-0002-7258-5453
FU BMBF, SARS VerbundFederal Ministry of Education & Research (BMBF)
   [01KI1005C]; Leibniz Graduate School EIDIS [SFB 900]; Leibniz
   Foundation; National Institute of Allergy and Infectious DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI074986]
FX This work was supported by BMBF, SARS Verbund (grant 01KI1005C to S.G.,
   A.H., C.D., and S.P.), the Leibniz Graduate School EIDIS (F.W.), SFB 900
   (K.W.), the Leibniz Foundation, and grant R01AI074986 from the National
   Institute of Allergy and Infectious Diseases (G.S.).
CR Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Baric RS, 1999, J VIROL, V73, P638, DOI 10.1128/JVI.73.1.638-649.1999
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Bertram S, 2011, J VIROL, V85, P13363, DOI 10.1128/JVI.05300-11
   Bertram S, 2010, J VIROL, V84, P10016, DOI 10.1128/JVI.00239-10
   Bottcher E, 2006, J VIROL, V80, P9896, DOI 10.1128/JVI.01118-06
   BRADBURNE AF, 1967, BMJ-BRIT MED J, V3, P767, DOI 10.1136/bmj.3.5568.767
   Buchholz U., 2013, Eurosurveillance, V18, P20406
   Chan JFW, 2012, J INFECTION, V65, P477, DOI 10.1016/j.jinf.2012.10.002
   Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656
   Cinatl J, 2004, CELL MOL LIFE SCI, V61, P2100, DOI 10.1007/s00018-004-4222-9
   Evans MJ, 2007, NATURE, V446, P801, DOI 10.1038/nature05654
   Farcas GA, 2005, J INFECT DIS, V191, P193, DOI 10.1086/426870
   Gao F, 2003, AIDS RES HUM RETROV, V19, P817, DOI 10.1089/088922203769232610
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Glowacka I, 2010, J VIROL, V84, P1198, DOI 10.1128/JVI.01248-09
   GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   Hofmann H, 2006, J VIROL, V80, P8639, DOI 10.1128/JVI.00560-06
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   Huang JW, 2005, J FORMOS MED ASSOC, V104, P891
   Jiang SB, 2013, J INFECTION, V66, P464, DOI 10.1016/j.jinf.2012.12.003
   Jung H, 2008, ONCOGENE, V27, P2635, DOI 10.1038/sj.onc.1210914
   Karesh WB, 2012, LANCET, V380, P1936, DOI 10.1016/S0140-6736(12)61678-X
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Kawase M, 2009, J VIROL, V83, P712, DOI 10.1128/JVI.01933-08
   Kielian M, 2006, NAT REV MICROBIOL, V4, P67, DOI 10.1038/nrmicro1326
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Kwan ACP, 2005, J GASTROEN HEPATOL, V20, P606, DOI 10.1111/j.1440-1746.2005.03775.x
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   MCCLURE MO, 1988, EMBO J, V7, P513, DOI 10.1002/j.1460-2075.1988.tb02839.x
   MCCLURE MO, 1990, J GEN VIROL, V71, P767, DOI 10.1099/0022-1317-71-4-767
   Mcroy WC, 2008, J VIROL, V82, P1414, DOI 10.1128/JVI.01674-07
   Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004
   Muller MA, 2012, MBIO, V3, DOI 10.1128/mBio.00515-12
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Pyrc K, 2007, J VIROL, V81, P3051, DOI 10.1128/JVI.01466-06
   Reguera J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002859
   Shirogane Y, 2008, J VIROL, V82, P8942, DOI 10.1128/JVI.00676-08
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730
   SUPERTI F, 1987, J GEN VIROL, V68, P387, DOI 10.1099/0022-1317-68-2-387
   VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526
   Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762
   White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI [10.1080/10409230802058320, 10.1080/10409230802058320 ]
   WHO, 2012, BACKGR SUMM NOV COR
   *WHO, 2013, NOV COR INF UPD
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou YC, 2012, EXPERT REV ANTI-INFE, V10, P1129, DOI [10.1586/ERI.12.104, 10.1586/eri.12.104]
NR 61
TC 115
Z9 122
U1 1
U2 21
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 2013
VL 87
IS 10
BP 5502
EP 5511
DI 10.1128/JVI.00128-13
PG 10
WC Virology
SC Virology
GA 133QT
UT WOS:000318155000017
PM 23468491
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Midulla, F
   Scagnolari, C
   Bonci, E
   Pierangeli, A
   Antonelli, G
   De Angelis, D
   Berardi, R
   Moretti, C
AF Midulla, F.
   Scagnolari, C.
   Bonci, E.
   Pierangeli, A.
   Antonelli, G.
   De Angelis, D.
   Berardi, R.
   Moretti, C.
TI Respiratory syncytial virus, human bocavirus and rhinovirus
   bronchiolitis in infants
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID YOUNG-CHILDREN; HUMAN METAPNEUMOVIRUS; TRACT INFECTIONS; DISEASE;
   ASSOCIATION; ILLNESSES; SEVERITY; ASTHMA; TIME
AB Objective: To investigate the prevalence of 14 viruses in infants with bronchiolitis and to study demographic and clinical differences in those with respiratory syncytial virus (RSV), human bocavirus (hBoV) and rhinovirus (RV) infection.
   Methods: 182 infants aged <12 months hospitalised for bronchiolitis were enrolled. Infants underwent nasal washing for the detection of RSV, influenza virus A and B, human coronavirus OC43, 229E, NL-63, HUK1, adenovirus, RV, parainfluenza 1-3, human metapneumovirus and hBoV. Demographic, clinical and laboratory data were obtained from parents and from patient medical files. Main outcome measurements were age, breastfeeding history, family smoking habits, family history for asthma and atopy, blood eosinophil count, chest radiological findings, clinical severity score and number of days of hospitalisation.
   Results: A virus was detected in 57.2% of the 182 infants. The most frequently detected viruses were RSV (41.2%), hBoV (12.2%) and RV (8.8%). Infants with dual infections (RSV and hBoV) had a higher clinical severity score and more days of hospitalisation than infants with RSV, RV and hBoV bronchiolitis (mean +/- SD: 4.7+2.4 vs 4.3 +/- 2.4 vs 3.0 +/- 2.0 vs 2.9 +/- 1.7, p<0.05; and 6.0 +/- 3.2 vs 5.3 +/- 2.4 vs 4.0 +/- 1.6 vs 3.9 +/- 1.1 days; p<0.05). Infants with RV infection had higher blood eosinophil counts than infants with bronchiolitis from RSV and hBoV (307 +/- 436 vs 138 +/- 168 vs 89 +/- 19 n/mm(3); p<0.05).
   Conclusions: Although the major pathogen responsible for bronchiolitis remains RSV, the infection can also be caused by RV and hBoV. Demographic characteristics and clinical severity of the disease may depend on the number of viruses or on the specific virus detected.
C1 [Midulla, F.; Bonci, E.; De Angelis, D.; Berardi, R.; Moretti, C.] Univ Roma La Sapienza, Dept Pediat, I-00165 Rome, Italy.
   [Scagnolari, C.; Pierangeli, A.; Antonelli, G.] Univ Roma La Sapienza, Dept Expt Med, Virol Sect, I-00165 Rome, Italy.
RP Midulla, F (reprint author), Univ Roma La Sapienza, Dept Pediat, Viale Regina Elena 324, I-00165 Rome, Italy.
EM midulla@uniroma1.it
RI Pierangeli, Alessandra/A-6368-2008; Antonelli, Guido/K-7915-2016;
   SCAGNOLARI, CAROLINA/G-3837-2011
OI Pierangeli, Alessandra/0000-0003-0633-360X; SCAGNOLARI,
   CAROLINA/0000-0003-1044-1478; Bonci, Enea/0000-0003-3325-1124
FU Sapienza University (Fondi Progetto di Ricerca Universitaria)Sapienza
   University Rome
FX This work was supported in part by a grant to FM from Sapienza
   University (Fondi Progetto di Ricerca Universitaria).
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Alonso A, 2007, ACTA PAEDIATR, V96, P731, DOI 10.1111/j.1651-2227.2007.00266.x
   Bastien N, 2007, J CLIN MICROBIOL, V45, P610, DOI 10.1128/JCM.01044-06
   Canducci F, 2008, J MED VIROL, V80, P716, DOI 10.1002/jmv.21108
   Choi EH, 2006, CLIN INFECT DIS, V43, P585, DOI 10.1086/506350
   CLAVO C, 2008, PEDIATR INFECT DIS J, V2, P1
   Collins PL, 1996, FIELDS VIROLOGY, V1, P1205
   CURNUTTE JT, 1993, HEMATOLOGY INFANCY C, P904
   Ehlenfield DR, 2000, PEDIATRICS, V105, P79, DOI 10.1542/peds.105.1.79
   Garber BD, 2007, J FORENSIC PSYCHOL P, V7, P1, DOI 10.1300/J158v07n01_01
   Hall CB, 1999, J PEDIATR-US, V135, pS2
   Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC
   Jacques J, 2006, J CLIN VIROL, V35, P463, DOI 10.1016/j.jcv.2005.11.009
   Kesebir D, 2006, J INFECT DIS, V194, P1276, DOI 10.1086/508213
   Kleines M, 2007, J CLIN MICROBIOL, V45, P1032, DOI 10.1128/JCM.01884-06
   Korppi M, 2004, PEDIATR INFECT DIS J, V23, P995, DOI 10.1097/01.inf.0000143642.72480.53
   Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33
   Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024
   Maggi F, 2007, J CLIN VIROL, V38, P321, DOI 10.1016/j.jcv.2007.01.008
   Manoha C, 2007, J CLIN VIROL, V38, P221, DOI 10.1016/j.jcv.2006.12.005
   Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC
   Pierangeli A, 2007, J MED VIROL, V79, P463, DOI 10.1002/jmv.20832
   Pinto RA, 2006, PEDIATRICS, V117, pE878, DOI 10.1542/peds.2005-2119
   Semple MG, 2005, J INFECT DIS, V191, P382, DOI 10.1086/426457
   Terletskaia-Ladwig E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-20
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   Wainwright C, 2003, NEW ENGL J MED, V349, P27, DOI 10.1056/NEJMoa022226
   Wilson J, 2005, J INFECT DIS, V191, P1705, DOI 10.1086/429636
   Wolf DG, 2006, PEDIATR INFECT DIS J, V25, P320, DOI 10.1097/01.inf.0000207395.80657.cf
   Xepapadaki P, 2004, J CLIN VIROL, V30, P267, DOI 10.1016/j.jcv.2003.12.012
NR 30
TC 115
Z9 127
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
EI 1468-2044
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD JAN
PY 2010
VL 95
IS 1
BP 35
EP 41
DI 10.1136/adc.2008.153361
PG 7
WC Pediatrics
SC Pediatrics
GA 537XF
UT WOS:000273146900009
PM 19822538
DA 2020-04-03
ER

PT J
AU Falsey, AR
   Walsh, EE
AF Falsey, AR
   Walsh, EE
TI Viral pneumonia in older adults
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; TERM-CARE FACILITY; INFLUENZA VACCINATION;
   HUMAN METAPNEUMOVIRUS; ELDERLY-PEOPLE; RHINOVIRUS OUTBREAK;
   PARAINFLUENZA VIRUS; UNITED-STATES; INFECTION; COMMUNITY
AB Viruses account for a substantial portion of respiratory illnesses, including pneumonia, in the elderly population. Presently, influenza virus A H3N2 and respiratory syncytial virus are the most commonly identified viral pathogens in older adults with viral pneumonia. As diagnostic tests such as reverse-transcription polymerase chain reaction become more widely used, the relative importance of additional viruses ( such as parainfluenza, rhinoviruses, coronaviruses, and human metapneumovirus) will likely increase. Influenza virus should be considered as a cause of pneumonia during the winter months, especially during periods of peak activity. Patients with high-grade fever, myalgias, and cough should arouse the highest suspicion. Respiratory syncytial virus pneumonia should also be suspected during the winter in patients with coryza, wheezing, low-grade fever, and patchy infiltrates, especially if negative for influenza on rapid testing. Because clinical features and periods of activity for many viruses overlap, laboratory confirmation of influenza is recommended for cases involving seriously ill or institutionalized patients.
C1 Rochester Gen Hosp, Infect Dis Unit, Dept Med, Rochester, NY 14621 USA.
   Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA.
RP Falsey, AR (reprint author), Rochester Gen Hosp, Infect Dis Unit, Dept Med, 1425 Portland Ave, Rochester, NY 14621 USA.
EM ann.falsey@viahealth.org
CR *ACIP, 2005, [No title captured], V54, P1
   Boivin G, 2002, J INFECT DIS, V186, P1330, DOI 10.1086/344319
   *COMM DIS SURV CTR, 1983, BRIT MED J, V287, P1619
   Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456
   Effros RB, 2000, MECH AGEING DEV, V121, P161
   El-Sahly HM, 2000, CLIN INFECT DIS, V31, P96, DOI 10.1086/313937
   Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951
   Falsey AR, 2003, J INFECT DIS, V187, P785, DOI 10.1086/367901
   Falsey AR, 2000, CLIN MICROBIOL REV, V13, P371, DOI 10.1128/CMR.13.3.371-384.2000
   File TM, 2003, LANCET, V362, P1991, DOI 10.1016/S0140-6736(03)15021-0
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   FRANSEN H, 1969, Scandinavian Journal of Infectious Diseases, V1, P127, DOI 10.3109/inf.1969.1.issue-2.09
   GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661
   Govaert TME, 1998, FAM PRACT, V15, P16, DOI 10.1093/fampra/15.1.16
   Graat JM, 2003, J CLIN EPIDEMIOL, V56, P1218, DOI 10.1016/S0895-4356(03)00171-9
   Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507
   Hamelin ME, 2004, CLIN INFECT DIS, V38, P983, DOI 10.1086/382536
   Louie JK, 2005, CLIN INFECT DIS, V41, P262, DOI 10.1086/430915
   LOURIA DB, 1959, J CLIN INVEST, V38, P213, DOI 10.1172/JCI103789
   Marx A, 1999, CLIN INFECT DIS, V29, P134, DOI 10.1086/520142
   MCINTOSH K, 1970, AM J EPIDEMIOL, V91, P585, DOI 10.1093/oxfordjournals.aje.a121171
   MCINTOSH K, 2005, PRINCIPLES PRACTICE, P1990
   Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70
   Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028
   Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060
   Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513
   Simonsen L, 2005, ARCH INTERN MED, V165, P265, DOI 10.1001/archinte.165.3.265
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   WALD TG, 1995, ANN INTERN MED, V123, P588, DOI 10.7326/0003-4819-123-8-199510150-00004
   WALD TG, 1995, J AM GERIATR SOC, V43, P170, DOI 10.1111/j.1532-5415.1995.tb06384.x
   Walsh EE, 2002, J AM GERIATR SOC, V50, P1498, DOI 10.1046/j.1532-5415.2002.50404.x
   WEKSLER ME, 1995, INFECT DIS CLIN PRAC, V3, P464
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
NR 35
TC 115
Z9 121
U1 0
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD FEB 15
PY 2006
VL 42
IS 4
BP 518
EP 524
DI 10.1086/499955
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 004HO
UT WOS:000234742800013
PM 16421796
OA Bronze
DA 2020-04-03
ER

PT J
AU Gagea, MI
   Bateman, KG
   van Dreumel, T
   McEwen, BJ
   Carman, S
   Archambault, M
   Shanahan, RA
   Caswell, JL
AF Gagea, MI
   Bateman, KG
   van Dreumel, T
   McEwen, BJ
   Carman, S
   Archambault, M
   Shanahan, RA
   Caswell, JL
TI Diseases and pathogens associated with mortality in Ontario beef
   feedlots
SO JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION
LA English
DT Article
DE cilia-associated respiratory bacillus; Haemophilus somnus; Mannheima
   haemolytica; Mycoplasma bovis
ID BOVINE VIRAL DIARRHEA; RESPIRATORY SYNCYTIAL VIRUS; SHIPPING FEVER
   PNEUMONIA; MYCOPLASMA-BOVIS; HAEMOPHILUS-SOMNUS; WEIGHT-GAIN;
   PASTEURELLA-HAEMOLYTICA; PARAINFLUENZA-3 VIRUS; GNOTOBIOTIC CALVES;
   ALBERTA 1985-1988
AB This study determined the prevalence of diseases and pathogens associated with mortality or severe morbidity in 72 Ontario beef feedlots in calves that died or were euthanized within 60 days after arrival. Routine pathologic and microbiologic investigations, as well as immunohistochemical staining for detection of bovine viral diarrhea virus (BVDV) antigen, were performed on 99 calves that died or were euthanized within 60 days after arrival. Major disease conditions identified included fibrinosuppurative bronchopneumonia (49%), caseonecrotic bronchopneumonia or arthritis (or both) caused by Mycoplasma bovis (36%), viral respiratory disease (19%), BVDV-related diseases (21%), Histophilus somni myocarditis (8%), ruminal bloat (2%), and miscellaneous diseases (8%). Viral infections identified were BVDV (35%), bovine respiratory syncytial virus (9%), bovine herpesvirus-1 (6%), parainfluenza-3 virus (3%), and bovine coronavirus (2%). Bacteria isolated from the lungs included M. bovis (82%), Mycoplasma arginini (72%), Ureaplasma diversum (25%), Mannheimia haemolytica (27%), Pasteurella multocida (19%), H. somni (14%), and Arcanobacterium pyogenes (19%). Pneumonia was the most frequent cause of mortality of beef calves during the first 2 months after arrival in feedlots, representing 69% of total deaths. The prevalence of caseonecrotic bronchopneumonia caused by M. bovis was similar to that of fibrinosuppurative bronchopneumonia, and together, these diseases were the most common causes of pneumonia and death. M. bovis pneumonia and polyarthritis has emerged as an important cause of mortality in Ontario beef feedlots.
C1 Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.
   Univ Guelph, Ontario Vet Coll, Dept Populat Med, Guelph, ON N1G 2W1, Canada.
   Univ Guelph, Lab Serv Div, Hlth Anim Lab, Guelph, ON N1G 2W1, Canada.
RP Caswell, JL (reprint author), Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.
RI Caswell, Jeff/B-9279-2018
OI Caswell, Jeff/0000-0002-1991-3219
CR Adegboye DS, 1996, J AM VET MED ASSOC, V209, P647
   ADEGBOYE DS, 1995, J VET DIAGN INVEST, V7, P333, DOI 10.1177/104063879500700306
   ALLEN JW, 1992, CAN J VET RES, V56, P281
   ALLEN JW, 1992, CAN J VET RES, V56, P177
   BATEMAN KG, 1990, CAN VET J, V31, P689
   Carman S, 1998, J VET DIAGN INVEST, V10, P27, DOI 10.1177/104063879801000106
   CHO HJ, 1976, CAN J COMP MED, V40, P20
   CHURCH TL, 1981, CAN VET J, V22, P27
   Cornish TE, 2005, J VET DIAGN INVEST, V17, P110, DOI 10.1177/104063870501700203
   Edwards A., 1996, BOVINE PRACT, V30, P5
   Ellis JA, 1998, CAN J VET RES, V62, P161
   Fulton RW, 2000, CAN J VET RES, V64, P151
   Fulton RW, 2000, J VET DIAGN INVEST, V12, P33, DOI 10.1177/104063870001200106
   Fulton RW, 2002, CAN J VET RES, V66, P181
   Gagea MI, 2006, J VET DIAGN INVEST, V18, P29, DOI 10.1177/104063870601800105
   Gaun SK, 2002, APPL ENVIRON MICROB, V68, P2690, DOI 10.1128/AEM.68.6.2690-2698.2002
   Gilbert SA, 1999, J CLIN MICROBIOL, V37, P2020, DOI 10.1128/JCM.37.6.2020-2023.1999
   GOURLAY RN, 1989, VET REC, V124, P420, DOI 10.1136/vr.124.16.420
   GOURLAY RN, 1985, RES VET SCI, V38, P377, DOI 10.1016/S0034-5288(18)31813-7
   Griffin D, 1997, VET CLIN N AM-FOOD A, V13, P367, DOI 10.1016/S0749-0720(15)30302-9
   GRIFFIN D, 1994, P 27 ANN CONV AM ASS, P157
   Grooms DL, 2002, CLIN DIAGN LAB IMMUN, V9, P898, DOI 10.1128/CDLI.9.4.898-900.2002
   Haines DM, 2004, CAN VET J, V45, P231
   Haines DM, 2001, CAN VET J, V42, P857
   JACKSON JA, 1987, VET PATHOL, V24, P129, DOI 10.1177/030098588702400205
   JENSEN R, 1976, J AM VET MED ASSOC, V169, P497
   JENSEN R, 1976, J AM VET MED ASSOC, V169, P500
   Kapil S, 1996, J VET DIAGN INVEST, V8, P96, DOI 10.1177/104063879600800115
   Liebler-Tenorio EM, 2004, J VET DIAGN INVEST, V16, P388, DOI 10.1177/104063870401600504
   LINKNER H, 2000, MYCOPLASMAS RUMINANT, P67
   Loneragan GH, 2001, J AM VET MED ASSOC, V219, P1122, DOI 10.2460/javma.2001.219.1122
   MARTIN SW, 1981, CAN J COMP MED, V45, P103
   MARTIN SW, 1982, CAN J COMP MED, V46, P341
   Martin SW, 1998, CAN J VET RES, V62, P257
   MARTIN SW, 1980, CAN J COMP MED, V44, P1
   Martin SW, 1999, CAN VET J, V40, P560
   Njaa BL, 2000, J VET DIAGN INVEST, V12, P393, DOI 10.1177/104063870001200501
   POLLOCK CM, 2000, AABP P, V13, P152
   POTGIETER LND, 1988, VET PATHOL, V25, P124, DOI 10.1177/030098588802500204
   RIBBLE CS, 1995, CAN J VET RES, V59, P167
   RIBBLE CS, 1995, CAN VET J, V36, P753
   Rodriguez F, 1996, J COMP PATHOL, V115, P151, DOI 10.1016/S0021-9975(96)80037-5
   ROY MJ, 1992, LAB INVEST, V66, P437
   RYAN MJ, 1983, VET PATHOL, V20, P472, DOI 10.1177/030098588302000410
   Shahriar FM, 2002, CAN VET J, V43, P863
   Stoffregen B, 2000, VET MICROBIOL, V77, P157, DOI 10.1016/S0378-1135(00)00272-8
   Tegtmeier C, 1999, J VET MED B, V46, P693, DOI 10.1046/j.1439-0450.1999.00301.x
   TERLAAK EA, 1992, J VET MED B, V39, P553, DOI 10.1111/j.1439-0450.1992.tb01205.x
   TERLAAK EA, 1992, VET QUART, V14, P100, DOI 10.1080/01652176.1992.9694342
   THOMAS LH, 1986, VET PATHOL, V23, P571, DOI 10.1177/030098588602300505
   *USDA, 2000, N33612002123 USDA AP
   VANDONKERSGOED J, 1994, CAN VET J, V35, P573
   VOGEL GJ, 1994, COMP CONT EDUC PRACT, V16, P227
   WHITFORD HW, 1994, ISOLATION MYCOPLASMA, V1, P12
   Wittum TE, 1996, J AM VET MED ASSOC, V209, P814
   YATES WDG, 1982, CAN J COMP MED, V46, P225
   Youssef SA, 2004, VET PATHOL, V41, P649, DOI 10.1354/vp.41-6-649
NR 57
TC 115
Z9 127
U1 0
U2 28
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1040-6387
EI 1943-4936
J9 J VET DIAGN INVEST
JI J. Vet. Diagn. Invest.
PD JAN
PY 2006
VL 18
IS 1
BP 18
EP 28
DI 10.1177/104063870601800104
PG 11
WC Veterinary Sciences
SC Veterinary Sciences
GA 006CC
UT WOS:000234871700004
PM 16566254
OA Bronze
DA 2020-04-03
ER

PT J
AU Weingartl, H
   Czub, M
   Czub, S
   Neufeld, J
   Marszal, P
   Gren, J
   Smith, G
   Jones, S
   Proulx, R
   Deschambault, Y
   Grudeski, E
   Andonov, A
   He, RT
   Li, Y
   Copps, J
   Grolla, A
   Dick, D
   Berry, J
   Ganske, S
   Manning, L
   Cao, JX
AF Weingartl, H
   Czub, M
   Czub, S
   Neufeld, J
   Marszal, P
   Gren, J
   Smith, G
   Jones, S
   Proulx, R
   Deschambault, Y
   Grudeski, E
   Andonov, A
   He, RT
   Li, Y
   Copps, J
   Grolla, A
   Dick, D
   Berry, J
   Ganske, S
   Manning, L
   Cao, JX
TI Immunization with modified vaccinia virus Ankara-based recombinant
   vaccine against severe acute respiratory syndrome is associated with
   enhanced hepatitis in ferrets
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID FELINE INFECTIOUS PERITONITIS; SARS-ASSOCIATED CORONAVIRUS;
   MONOCLONAL-ANTIBODIES; EXPRESSION; MICE; CATS
AB Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) is a serious emerging human infectious disease. In this report, we immunized ferrets (Mustela putorius furo) with recombinant modified vaccinia virus Ankara (rMVA) expressing the SARS-CoV spike (S) protein. Immunized ferrets developed a more rapid and vigorous neutralizing antibody response than control animals after challenge with SARS-CoV; however, they also exhibited strong inflammatory responses in liver tissue. Inflammation in control animals exposed to SARS-CoV was relatively mild. Thus, our data suggest that vaccination with rMVA expressing SARS-CoV S protein is associated with enhanced hepatitis.
C1 Canadian Sci Ctr Human & Anim Hlth, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada.
   Canadian Sci Ctr Human & Anim Hlth, Natl Ctr Foreign Anim Dis, Winnipeg, MB R3E 3R2, Canada.
   Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3T 2N2, Canada.
RP Cao, JX (reprint author), Canadian Sci Ctr Human & Anim Hlth, Natl Microbiol Lab, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada.
EM jingxin_cao@hc-sc.gc.ca
RI Berry, Jody/C-3184-2013
CR Berry JD, 2004, J VIROL METHODS, V120, P87, DOI 10.1016/j.jviromet.2004.04.009
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07
   Chau TN, 2004, HEPATOLOGY, V39, P302, DOI 10.1002/hep.20111
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988
   FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1
   Gao WT, 2003, LANCET, V362, P1895, DOI 10.1016/S0140-6736(03)14962-8
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Marshall E, 2004, SCIENCE, V303, P944, DOI 10.1126/science.303.5660.944
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Moss B, 1996, P NATL ACAD SCI USA, V93, P11341, DOI 10.1073/pnas.93.21.11341
   OLSEN CW, 1993, VET MICROBIOL, V36, P1, DOI 10.1016/0378-1135(93)90126-R
   PEDERSEN NC, 1983, AM J VET RES, V44, P229
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   Weingartl HM, 2004, EMERG INFECT DIS, V10, P179, DOI 10.3201/eid1002.030677
   WEISS RC, 1981, COMP IMMUNOL MICROB, V4, P175, DOI 10.1016/0147-9571(81)90003-5
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
NR 20
TC 115
Z9 123
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2004
VL 78
IS 22
BP 12672
EP 12676
DI 10.1128/JVI.78.22.12672-12676.2004
PG 5
WC Virology
SC Virology
GA 866NY
UT WOS:000224781400060
PM 15507655
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Rao, BL
   Basu, A
   Wairagkar, NS
   Gore, MM
   Arankalle, VA
   Thakare, JP
   Jadi, RS
   Rao, KA
   Mishra, AC
AF Rao, BL
   Basu, A
   Wairagkar, NS
   Gore, MM
   Arankalle, VA
   Thakare, JP
   Jadi, RS
   Rao, KA
   Mishra, AC
TI A large outbreak of acute encephalitis with high fatality rate in
   children in Andhra Pradesh, India, in 2003, associated with Chandipura
   virus
SO LANCET
LA English
DT Article
ID FEBRILE ILLNESS; ASSAY; TRANSMISSION; ANIMALS; PCR
AB Background An outbreak of acute encephalitis of unknown origin with high case fatality (183 of 329 cases) was reported in children from Andhra Pradesh state in southern India during 2003. We investigated the causative agent.
   Methods Cell lines and peripheral blood lymphocyte co-cultures were used to isolate the causative agent from clinical samples. Identity of the agent was established by electron microscopy and serological and molecular assays.
   Findings Clinical samples tested negative for IgM antibodies to Japanese encephalitis, West Nile, dengue, and measles viruses, and for RNA of coronavirus, paramyxovirus, enterovirus, and influenza viruses. Virus was isolated from six patients with encephalitis and was identified as Chandipura virus by electron microscopy, complement fixation, and neutralisation tests. Chandipura virus RNA was detected in clinical samples from nine patients. Sequencing of five of these RNA samples showed 96.7-97.5% identity with the reference strain of 1965. Chandipura viral antigen and RNA were detected in brain tissue of a deceased child by immunofluorescent antibody test and PCR. Neutralising, IgG, and IgM antibodies to Chandipura virus were present in some patients' serum samples. Serum samples obtained after 4 days of illness were more frequently positive for IgM to Chandipura virus than were those obtained earlier (p<0.001). A similar trend was noted for neutralising antibodies.
   Interpretation Our findings suggest that this outbreak of acute encephalitis in Andhra Pradesh was associated with Chandipura virus, adding to the evidence suggesting that this virus should be considered as an important emerging pathogen.
C1 Natl Inst Virol, Pune 411001, Maharashtra, India.
   Karimnagar Dist Hosp, Karimnagar, Andhra Pradesh, India.
RP Mishra, AC (reprint author), Natl Inst Virol, 20A Dr Ambedkar Rd, Pune 411001, Maharashtra, India.
EM acm1750@rediffmail.com
CR BANERJEE K, 1984, VIRUS ECOLOGY, P109
   BHATT PN, 1967, INDIAN J MED RES, V55, P1295
   Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432
   DEMATTOS CA, 2001, FIELDS VIROLOGY, P1245
   DHANDA V, 1970, INDIAN J MED RES, V58, P179
   GORE MM, 1985, INDIAN J MED RES, V81, P343
   ILKAL MA, 1991, ACTA VIROL, V35, P27, DOI 10.1016/0166-0934(91)90082-B
   John T Jacob, 2003, Indian Pediatr, V40, P863
   KELKAR SD, 1976, INDIAN J MED RES, V64, P814
   KEMP GE, 1975, B WORLD HEALTH ORGAN, V52, P615
   Khan N, 1954, INDIAN J MED SCI, V8, P597
   KUMAR S, 2001, MEGA2 1 MOL EVOLUTIO
   NERURKAR LS, 1984, J CLIN MICROBIOL, V20, P109, DOI 10.1128/JCM.20.1.109-114.1984
   Poddar SK, 2002, J CLIN LAB ANAL, V16, P163, DOI 10.1002/jcla.10036
   RAO TR, 1967, INDIAN J MED RES, V55, P1306
   Read SJ, 1999, J CLIN MICROBIOL, V37, P1352, DOI 10.1128/JCM.37.5.1352-1355.1999
   RODRIGUE.FM, 1972, B WORLD HEALTH ORGAN, V46, P173
   RODRIGUES FM, 1984, INDIAN J MED RES S, P1
   RODRIGUES JJ, 1983, INDIAN J MED RES, V77, P303
   SEVER JL, 1962, J IMMUNOL, V88, P320
   Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9
   TESH RB, 1993, AM J TROP MED HYG, V32, P621
   Traore-Lamizana M, 2001, J MED ENTOMOL, V38, P480, DOI 10.1603/0022-2585-38.4.480
NR 23
TC 115
Z9 123
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD SEP 4
PY 2004
VL 364
IS 9437
BP 869
EP 874
DI 10.1016/S0140-6736(04)16982-1
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 851KY
UT WOS:000223685200033
PM 15351194
DA 2020-04-03
ER

PT J
AU Cowley, JA
   Dimmock, CM
   Spann, KM
   Walker, PJ
AF Cowley, JA
   Dimmock, CM
   Spann, KM
   Walker, PJ
TI Gill-associated virus of Penaeus monodon prawns: an invertebrate virus
   with ORF1a and ORF1b genes related to arteri- and coronaviruses
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID YELLOW-HEAD VIRUS; RIBOSOMAL FRAMESHIFTING SIGNAL; EPHEMERAL FEVER
   RHABDOVIRUS; MOUSE HEPATITIS-VIRUS; BERNE VIRUS; NUCLEOTIDE-SEQUENCE;
   RNA-POLYMERASE; MESSENGER-RNAS; REVERSE-TRANSCRIPTASE; GENOME
AB A 20089 nucleotide (nt) sequence was determined for the 5' end of the (+)-ssRNA genome of gill-associated virus (GAV), a yellow head-like virus infecting Penaeus monodon prawns. Clones were generated from a similar to 22 kb dsRNA purified from lymphoid organ total RNA of GAV-infected prawns. The region contains a single gene comprising two long overlapping open reading frames, ORF1a and ORF1b, of 4060 and 2646 amino acids, respectively. The ORFs are structurally related to the ORF1a and ORF1ab polyproteins of coronaviruses and arteriviruses. The 99 nt overlap between ORF1a and ORF1b contains a putative AAAUUUU 'slippery' sequence associated with -1 ribosomal frameshifting. A 131 nt stem-loop with the potential to form a complex pseudoknot resides 3 nt downstream of this sequence. Although different to the G/UUUAAAC frameshift sites and 'H-type' pseudoknots of nidoviruses, in vitro transcription/translation analysis demonstrated that the GAV element also facilitates read-through of the ORF1a/1b junction. As in coronaviruses, GAV ORF la encodes a 3C-like cysteine protease domain located between two hydrophobic regions. However, its sequence suggests some structural relationship to the chymotrypsin-like serine proteases of arteriviruses. ORF1b encodes homologues of the 'SDD' polymerase, which among (+)-RNA viruses is unique to nidoviruses, as well as metal-ion-binding and helicase domains. The presence of a dsRNA replicative intermediate and ORF1a and ORF1ab polyproteins translated by a - 1 frameshift suggests that GAV represents the first invertebrate member of the Order Nidovirales.
C1 CSIRO Trop Agr, Cooperat Res Ctr Aquaculture, Long Pocket Labs, Indooroopilly, Qld 4068, Australia.
RP Cowley, JA (reprint author), CSIRO Trop Agr, Cooperat Res Ctr Aquaculture, Long Pocket Labs, PMB 3, Indooroopilly, Qld 4068, Australia.
EM Jeff.Cowley@tag.csiro.au
RI Cowley, Jeff/H-7553-2013; Spann, Kirsten/B-4524-2013; Walker, Peter
   J/H-6059-2013
OI Spann, Kirsten/0000-0003-0567-8382; Walker, Peter J/0000-0003-1851-642X
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   BONILLA PJ, 1994, VIROLOGY, V198, P736, DOI 10.1006/viro.1994.1088
   BOONYARATPALIN S, 1993, FISH PATHOL, V28, P103, DOI 10.3147/jsfp.28.103
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   BRIERLEY I, 1992, J MOL BIOL, V227, P463, DOI 10.1016/0022-2836(92)90901-U
   BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885
   CARRINGTON JC, 1987, J VIROL, V61, P2540, DOI 10.1128/JVI.61.8.2540-2548.1987
   CHAN TYK, 1993, PHARMACOEPIDEM DR S, V2, P145
   Cowley JA, 1999, DIS AQUAT ORGAN, V36, P153, DOI 10.3354/dao036153
   COWLEY JA, 2000, IN PRESS DIS AQUATIC
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991
   DEVRIES AAF, 1990, NUCLEIC ACIDS RES, V18, P3241, DOI 10.1093/nar/18.11.3241
   Dumas J. B., 1991, Nucleic Acids Research, V19, P5227, DOI 10.1093/nar/19.19.5227
   ELEOUET JF, 1995, VIROLOGY, V206, P817, DOI 10.1006/viro.1995.1004
   Felsenstein J., 1993, PHYLIP PHYLOGENY INF
   FROUSSARD P, 1992, NUCLEIC ACIDS RES, V20, P2900, DOI 10.1093/nar/20.11.2900
   GODENY EK, 1993, VIROLOGY, V194, P585, DOI 10.1006/viro.1993.1298
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847
   HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419
   HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0
   JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1
   KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197
   KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   LIMSUWAN C, 1991, HDB CULTIVATION BLAC
   Loh PC, 1997, ADV VIRUS RES, V48, P263, DOI 10.1016/S0065-3527(08)60290-0
   Nadala ECB, 1997, DIS AQUAT ORGAN, V31, P141, DOI 10.3354/dao031141
   PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549
   PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806
   PLEIJ CWA, 1989, METHOD ENZYMOL, V180, P289
   Sambrook J., 1989, MOL CLONING LAB MANU
   SHIEH CK, 1987, VIROLOGY, V156, P321, DOI 10.1016/0042-6822(87)90412-0
   Snijder E. J., 1995, The coronaviridae., P239
   SNIJDER EJ, 1991, J GEN VIROL, V72, P1635, DOI 10.1099/0022-1317-72-7-1635
   SNIJDER EJ, 1990, J VIROL, V64, P331, DOI 10.1128/JVI.64.1.331-338.1990
   Snijder EJ, 1996, J BIOL CHEM, V271, P4864, DOI 10.1074/jbc.271.9.4864
   SNIJDER EJ, 1990, NUCLEIC ACIDS RES, V18, P4535, DOI 10.1093/nar/18.15.4535
   SONIGO P, 1986, CELL, V45, P375, DOI 10.1016/0092-8674(86)90323-5
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   Spann KM, 1997, DIS AQUAT ORGAN, V31, P169, DOI 10.3354/dao031169
   SPANN KM, 1995, DIS AQUAT ORGAN, V23, P127, DOI 10.3354/dao023127
   Tang KFJ, 1999, DIS AQUAT ORGAN, V35, P165, DOI 10.3354/dao035165
   ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   WALKER PJ, 1992, VIROLOGY, V191, P49, DOI 10.1016/0042-6822(92)90165-L
   WALKER PJ, 1994, J GEN VIROL, V75, P1889, DOI 10.1099/0022-1317-75-8-1889
   WEISS M, 1983, J GEN VIROL, V64, P1849, DOI 10.1099/0022-1317-64-9-1849
   WONGTEERASUPAYA C, 1995, DIS AQUAT ORGAN, V22, P45, DOI 10.3354/dao022045
   ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181
NR 56
TC 115
Z9 124
U1 0
U2 4
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD JUN
PY 2000
VL 81
BP 1473
EP 1484
DI 10.1099/0022-1317-81-6-1473
PN 6
PG 12
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 323AL
UT WOS:000087542300007
PM 10811931
OA Bronze
DA 2020-04-03
ER

PT J
AU MAKINO, S
   JOO, M
   MAKINO, JK
AF MAKINO, S
   JOO, M
   MAKINO, JK
TI A SYSTEM FOR STUDY OF CORONAVIRUS MESSENGER-RNA SYNTHESIS - A REGULATED,
   EXPRESSED SUBGENOMIC DEFECTIVE INTERFERING RNA RESULTS FROM INTERGENIC
   SITE INSERTION
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; LEADER-PRIMED TRANSCRIPTION; MURINE CORONAVIRUS;
   VIRAL RNAS; FUSION SITES; GENOMIC RNA; SEQUENCE; REPLICATION; PARTICLES;
   5'-END
AB A system that exploits defective interfering (DI) RNAs of mouse hepatitis virus (MHV) for deciphering the mechanisms of coronavirus mRNA transcription was developed.  A complete cDNA clone of MHV DI RNA containing an inserted intergenic region, derived from the area of genomic RNA between genes 6 and 7, was constructed.  After transfection of the in vitro-synthesized DI RNA into MHV-infected cells, replication of genomic DI RNA as well as transcription of the subgenomic DI RNA was observed.  S1 nuclease protection experiments, sequence analysis, and Northern (RNA) blotting analysis revealed that the subgenomic DI RNA contained the leader sequence at its 5' end and that the body of the subgenomic DI RNA started from the inserted intergenic sequence.  Two subgenomic DI RNAs were synthesized after inserting two intergenic sites into the MHV DI RNA.  Metabolic labeling of virus-specific protein in DI RNA replicating cells demonstrated that a protein was translated from the subgenomic DI RNA, which can therefore be considered a functional mRNA.  Transfection study of gel-purified genomic DI RNA and subgenomic DI RNA revealed that the introduction of genomic DI RNA, but not subgenomic DI RNA, into MHV-infected cells was required for synthesis of the subgenomic DI RNA.  A series of deletion mutations in the intergenic site demonstrated that the sequence flanking the consensus sequence of UCUAAAC affected the efficiency of subgenomic DI RNA transcription and that the consensus sequence was necessary but not sufficient for the synthesis of the subgenomic DI RNA.
RP MAKINO, S (reprint author), UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712, USA.
RI Makino, Shinji/E-8014-2015
OI Makino, Shinji/0000-0002-7831-1576
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI29984]
CR BAKER SC, 1990, EMBO J, V9, P4173, DOI 10.1002/j.1460-2075.1990.tb07641.x
   BARIC RS, 1985, VIRUS RES, V3, P19, DOI 10.1016/0168-1702(85)90038-3
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   FOSMIRE JA, UNPUB
   HIGUCHI R, 1990, PCR PROTOCOLS GUIDE, P177
   HIRANO N, 1974, ARCH GES VIRUSFORSCH, V44, P298, DOI 10.1007/BF01240618
   JEONG YH, UNPUB
   LAI MMC, 1983, J VIROL, V46, P1027, DOI 10.1128/JVI.46.3.1027-1033.1983
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978
   LAI MMC, 1984, P NATL ACAD SCI-BIOL, V81, P3626, DOI 10.1073/pnas.81.12.3626
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   MAKINO S, 1989, VIROLOGY, V169, P227, DOI 10.1016/0042-6822(89)90060-3
   MAKINO S, 1986, P NATL ACAD SCI USA, V83, P4204, DOI 10.1073/pnas.83.12.4204
   MAKINO S, 1988, J VIROL, V62, P3870, DOI 10.1128/JVI.62.10.3870-3873.1988
   MAKINO S, 1988, VIROLOGY, V163, P104, DOI 10.1016/0042-6822(88)90237-1
   MAKINO S, 1985, J VIROL, V54, P329, DOI 10.1128/JVI.54.2.329-336.1985
   MAKINO S, 1984, VIROLOGY, V139, P138, DOI 10.1016/0042-6822(84)90335-0
   MAKINO S, 1989, J VIROL, V63, P5285, DOI 10.1128/JVI.63.12.5285-5292.1989
   MAKINO S, 1988, VIROLOGY, V166, P550, DOI 10.1016/0042-6822(88)90526-0
   MAKINO S, 1990, J VIROL, V64, P6045, DOI 10.1128/JVI.64.12.6045-6053.1990
   MAKINO S, 1984, VIROLOGY, V133, P9, DOI 10.1016/0042-6822(84)90420-3
   MAKINO S, UNPUB
   MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835
   Sambrook J., 1989, MOL CLONING LABORATO
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   SETHNA PB, 1991, J VIROL, V65, P320, DOI 10.1128/JVI.65.1.320-325.1991
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   SHIEH CK, 1989, J VIROL, V63, P3729, DOI 10.1128/JVI.63.9.3729-3736.1989
   SHIEH CK, 1987, VIROLOGY, V156, P321, DOI 10.1016/0042-6822(87)90412-0
   SKINNER MA, 1983, NUCLEIC ACIDS RES, V11, P5045, DOI 10.1093/nar/11.15.5045
   SOE LH, 1987, J VIROL, V61, P3968, DOI 10.1128/JVI.61.12.3968-3976.1987
   SPAAN W, 1983, EMBO J, V2, P1939
   STOHLMAN SA, 1979, J VIROL, V32, P672, DOI 10.1128/JVI.32.2.672-675.1979
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   VANDERMOST RG, 1991, J VIROL, V65, P3219, DOI 10.1128/JVI.65.6.3219-3226.1991
   WEISS B, 1989, J VIROL, V63, P5310, DOI 10.1128/JVI.63.12.5310-5318.1989
   YOKOMORI K, 1989, VIROLOGY, V173, P683, DOI 10.1016/0042-6822(89)90581-3
   ZIMMERN D, 1978, P NATL ACAD SCI USA, V75, P4257, DOI 10.1073/pnas.75.9.4257
NR 42
TC 115
Z9 118
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 1991
VL 65
IS 11
BP 6031
EP 6041
DI 10.1128/JVI.65.11.6031-6041.1991
PG 11
WC Virology
SC Virology
GA GL296
UT WOS:A1991GL29600045
PM 1656085
OA Bronze
DA 2020-04-03
ER

PT J
AU Sabir, JSM
   Lam, TTY
   Ahmed, MMM
   Li, LF
   Shen, YY
   Abo-Aba, SEM
   Qureshi, MI
   Abu-Zeid, M
   Zhang, Y
   Khiyami, MA
   Alharbi, NS
   Hajrah, NH
   Sabir, MJ
   Mutwakil, MHZ
   Kabli, SA
   Alsulaimany, FAS
   Obaid, AY
   Zhou, BP
   Smith, DK
   Holmes, EC
   Zhu, HC
   Guan, Y
AF Sabir, Jamal S. M.
   Lam, Tommy T. -Y.
   Ahmed, Mohamed M. M.
   Li, Lifeng
   Shen, Yongyi
   Abo-Aba, Salah E. M.
   Qureshi, Muhammad I.
   Abu-Zeid, Mohamed
   Zhang, Yu
   Khiyami, Mohammad A.
   Alharbi, Njud S.
   Hajrah, Nahid H.
   Sabir, Meshaal J.
   Mutwakil, Mohammed H. Z.
   Kabli, Saleh A.
   Alsulaimany, Faten A. S.
   Obaid, Abdullah Y.
   Zhou, Boping
   Smith, David K.
   Holmes, Edward C.
   Zhu, Huachen
   Guan, Yi
TI Co-circulation of three camel coronavirus species and recombination of
   MERS-CoVs in Saudi Arabia
SO SCIENCE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE-EAST; DROMEDARY CAMELS;
   ANTIBODIES; IDENTIFICATION; LIVESTOCK; TRACT
AB Outbreaks of Middle East respiratory syndrome (MERS) raise questions about the prevalence and evolution of the MERS coronavirus (CoV) in its animal reservoir. Our surveillance in Saudi Arabia in 2014 and 2015 showed that viruses of the MERS-CoV species and a human CoV 229E-related lineage co-circulated at high prevalence, with frequent co-infections in the upper respiratory tract of dromedary camels. Including a betacoronavirus 1 species, we found that dromedary camels share three CoV species with humans. Several MERS-CoV lineages were present in camels, including a recombinant lineage that has been dominant since December 2014 and that subsequently led to the human outbreaks in 2015. Camels therefore serve as an important reservoir for the maintenance and diversification of the MERS-CoVs and are the source of human infections with this virus.
C1 [Sabir, Jamal S. M.; Ahmed, Mohamed M. M.; Abo-Aba, Salah E. M.; Qureshi, Muhammad I.; Abu-Zeid, Mohamed; Alharbi, Njud S.; Hajrah, Nahid H.; Sabir, Meshaal J.; Mutwakil, Mohammed H. Z.; Kabli, Saleh A.; Alsulaimany, Faten A. S.; Guan, Yi] King Abdulaziz Univ, Fac Sci, Dept Biol Sci, Biotechnol Res Grp, Jeddah 21589, Saudi Arabia.
   [Lam, Tommy T. -Y.; Zhang, Yu; Zhou, Boping; Zhu, Huachen; Guan, Yi] Univ Hong Kong, Shenzhen Peoples Hosp 3, State Key Lab Emerging Infect Dis, Shenzhen Branch, Shenzhen, Peoples R China.
   [Lam, Tommy T. -Y.; Li, Lifeng; Shen, Yongyi; Zhang, Yu; Zhu, Huachen; Guan, Yi] Shantou Univ, Univ Hong Kong, Joint Inst Virol, Shantou, Peoples R China.
   [Lam, Tommy T. -Y.; Li, Lifeng; Shen, Yongyi; Zhang, Yu; Smith, David K.; Zhu, Huachen; Guan, Yi] Univ Hong Kong, Sch Publ Hlth, Ctr Influenza Res, Hong Kong, Hong Kong, Peoples R China.
   [Lam, Tommy T. -Y.; Li, Lifeng; Shen, Yongyi; Zhang, Yu; Smith, David K.; Zhu, Huachen; Guan, Yi] Univ Hong Kong, Sch Publ Hlth, State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Holmes, Edward C.] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Charles Perkins Ctr, Sch Biol Sci, Sydney, NSW 2006, Australia.
   [Holmes, Edward C.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia.
   [Ahmed, Mohamed M. M.] City Sci Res & Technol Applicat, Genet Engn & Biotechnol Res Inst, Dept Nucle Acids Res, Alexandria, Egypt.
   [Abo-Aba, Salah E. M.; Abu-Zeid, Mohamed] Natl Res Ctr, Genet Engn & Biotechnol Div, Microbial Genet Dept, Giza, Egypt.
   [Khiyami, Mohammad A.] King Abdulaziz City Sci & Technol, Riyadh 11442, Saudi Arabia.
   [Obaid, Abdullah Y.] King Abdulaziz Univ, Fac Sci, Dept Chem, Jeddah 21589, Saudi Arabia.
RP Zhu, HC (reprint author), Univ Hong Kong, Shenzhen Peoples Hosp 3, State Key Lab Emerging Infect Dis, Shenzhen Branch, Shenzhen, Peoples R China.
EM zhuhch@hku.hk; yguan@hku.hk
RI Holmes, Edward/Y-2789-2019; Seleman, Mohamed/J-8211-2017; Ahmed,
   Mohamed/E-7818-2011; Zhu, Huachen/A-8252-2017; Sabir, Jamal S
   M/C-8102-2014; Lam, Tsan Yuk/D-4837-2012
OI Holmes, Edward/0000-0001-9596-3552; Seleman,
   Mohamed/0000-0003-2059-5796; Zhu, Huachen/0000-0003-2711-0501; Guan,
   Yi/0000-0001-6057-9243; Lam, Tsan Yuk/0000-0002-9769-1527
FU Deanship of Scientific Research of King Abdulaziz University [DSR
   46-130-35-HiCi]; Development Committee of Basic Sciences at King
   Abdulaziz University; Shenzhen Peacock Plan High-End Talents Program
   [KQTD201203]; Li Ka Shing Foundation; Theme-based Research Scheme
   [T11-705/14-N]; National Health and Medical Research Council of
   AustraliaNational Health and Medical Research Council of Australia
   [AF30]
FX We thank C.-H. Yip, C.-L. Cheung, Y. Chai, C. Ma, T. Gan, Z. Jin, Z. Ou,
   P. Huang, J. Zhou, and G. Yu for technical assistance and P. Kellam, A.
   Bin Saeed, M. Cotten, M. A. Barry, and A. M. Somily for making sequences
   available before their formal publication. This study was supported by
   the Deanship of Scientific Research (DSR 46-130-35-HiCi) of King
   Abdulaziz University; the Vice President for Educational Affairs A. O.
   Alyoubi under the umbrella of the Development Committee of Basic
   Sciences at King Abdulaziz University; the Shenzhen Peacock Plan
   High-End Talents Program (award KQTD201203); and the Li Ka Shing
   Foundation and Theme-based Research Scheme (award T11-705/14-N). E.C.H.
   is supported by an Australia Fellowship from the National Health and
   Medical Research Council of Australia (award AF30). All authors declare
   no competing financial interests. The sequences generated by this study
   were deposited in GenBank under accession numbers KT368824 to KT368916;
   additional data can be found in the supplementary materials.
CR Adney DR, 2014, EMERG INFECT DIS, V20, P1999, DOI 10.3201/eid2012.141280
   Alagaili AN, 2014, MBIO, V5, DOI 10.1128/mBio.00884-14
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Corman VM, 2014, EMERG INFECT DIS, V20, P1319, DOI 10.3201/eid2008.140596
   Corman VM, 2014, J VIROL, V88, P11297, DOI 10.1128/JVI.01498-14
   Crossley BM, 2012, VIRUSES-BASEL, V4, P3689, DOI 10.3390/v4123689
   Crossley BM, 2010, J VET DIAGN INVEST, V22, P94, DOI 10.1177/104063871002200118
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Farag Elmoubasher A. B. A., 2015, Infection Ecology & Epidemiology, V5, DOI 10.3402/iee.v5.28305
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hemida MG, 2013, EUROSURVEILLANCE, V18, P21, DOI 10.2807/1560-7917.ES2013.18.50.20659
   Khalafalla AI, 2015, EMERG INFECT DIS, V21, P1153, DOI 10.3201/eid2107.150070
   Kim Y. J., 2015, GENOME ANNOUNC, V3
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Muller MA, 2015, LANCET INFECT DIS, V15, P559, DOI 10.1016/S1473-3099(15)70090-3
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Wernery U, 2015, EMERG INFECT DIS, V21, P1019, DOI 10.3201/eid2106.150038
   Woo PCY, 2014, EMERG INFECT DIS, V20, P560, DOI 10.3201/eid2004.131769
   World Health Organization, 2015, MIDD E RESP SYNDR CO
   Xie Q, 2015, SCI CHINA LIFE SCI, V58, P818, DOI 10.1007/s11427-015-4903-7
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 23
TC 114
Z9 114
U1 15
U2 62
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JAN 1
PY 2016
VL 351
IS 6268
BP 81
EP 84
DI 10.1126/science.aac8608
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CZ8QM
UT WOS:000367364200047
PM 26678874
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Lei, Y
   Moore, CB
   Liesman, RM
   O'Connor, BP
   Bergstralh, DT
   Chen, ZJJ
   Pickles, RJ
   Ting, JPY
AF Lei, Yu
   Moore, Chris B.
   Liesman, Rachael M.
   O'Connor, Brian P.
   Bergstralh, Daniel T.
   Chen, Zhijian J.
   Pickles, Raymond J.
   Ting, Jenny P. -Y.
TI MAVS-Mediated Apoptosis and Its Inhibition by Viral Proteins
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; ANTIVIRAL SIGNALING PROTEIN;
   NF-KAPPA-B; ACTIVATION; IDENTIFICATION; MITOCHONDRIA; INFECTION;
   PATHWAYS; IPAF
AB Background: Host responses to viral infection include both immune activation and programmed cell death. The mitochondrial antiviral signaling adaptor, MAVS (IPS-1, VISA or Cardif) is critical for host defenses to viral infection by inducing type-1 interferons (IFN-I), however its role in virus-induced apoptotic responses has not been elucidated.
   Principal Findings: We show that MAVS causes apoptosis independent of its function in initiating IFN-I production. MAVS-induced cell death requires mitochondrial localization, is caspase dependent, and displays hallmarks of apoptosis. Furthermore, MAVS(-/-) fibroblasts are resistant to Sendai virus-induced apoptosis. A functional screen identifies the hepatitis C virus NS3/4A and the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) nonstructural protein (NSP15) as inhibitors of MAVS-induced apoptosis, possibly as a method of immune evasion.
   Significance:This study describes a novel role for MAVS in controlling viral infections through the induction of apoptosis, and identifies viral proteins which inhibit this host response.
C1 [Lei, Yu; Moore, Chris B.; O'Connor, Brian P.; Bergstralh, Daniel T.; Ting, Jenny P. -Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Lei, Yu] Univ N Carolina, Dept Oral Biol, Chapel Hill, NC 27599 USA.
   [Moore, Chris B.] Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA.
   [Liesman, Rachael M.; O'Connor, Brian P.; Pickles, Raymond J.; Ting, Jenny P. -Y.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Chen, Zhijian J.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dept Mol Biol, Dallas, TX 75390 USA.
RP Lei, Y (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
EM Jenny_Ting@med.unc.edu
RI Chen, Zhijian/C-6039-2012
OI Chen, Zhijian/0000-0002-8475-8251; Bergstralh, Dan/0000-0003-1689-3715;
   Lei, Yu/0000-0002-9868-9824
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID)
FX This work was supported by grants from NIAID for SERCEB and Human
   Immunology to J.P.-Y.T. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8
   Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139
   Chan-Yeung M, 2003, RESPIROLOGY, V8, P131, DOI 10.1046/j.1440-1843.2003.00453.x
   Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040
   Chen CY, 2007, J INFECT DIS, V196, P405, DOI 10.1086/519166
   Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   FREIMAN M, 2003, [No title captured], V133, P101
   Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019
   Griffin DE, 1997, ANNU REV MICROBIOL, V51, P565, DOI 10.1146/annurev.micro.51.1.565
   Hacker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193
   Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000
   Holm GH, 2007, J BIOL CHEM, V282, P21953, DOI 10.1074/jbc.M702112200
   Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560
   Iseni F, 2002, EMBO J, V21, P5141, DOI 10.1093/emboj/cdf513
   Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101
   Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047
   LAN YL, 2005, [No title captured], V17, P404
   Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102
   Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193
   Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859
   MOORE CB, 2006, [No title captured], V151, P573
   Moore CB, 2008, IMMUNITY, V28, P735, DOI 10.1016/j.immuni.2008.05.005
   Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200
   PEIRIS JS, 2001, [No title captured], V361, P1767
   Peters K, 2008, J VIROL, V82, P3500, DOI 10.1128/JVI.02536-07
   Potter JA, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-11
   Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200
   Reeves MB, 2007, SCIENCE, V316, P1345, DOI 10.1126/science.1142984
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sadasivam S, 2005, ONCOGENE, V24, P627, DOI 10.1038/sj.onc.1208201
   Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012
   Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001
   Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004
   Tan YX, 2007, J VIROL, V81, P6346, DOI 10.1128/JVI.00090-07
   TING JP, 2000, [No title captured], V20, P285
   van Deventer HW, 2008, AM J PATHOL, V173, P253, DOI 10.2353/ajpath.2008.070732
   Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014
   Yang Y, 2007, P NATL ACAD SCI USA, V104, P7253, DOI 10.1073/pnas.0611506104
   YE Z, 2008, [No title captured]
   Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087
   YONEYAMA M, 2005, [No title captured], V173, P2581
   ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367
   ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661
   Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2
NR 50
TC 114
Z9 118
U1 2
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 7
PY 2009
VL 4
IS 5
AR e5466
DI 10.1371/journal.pone.0005466
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 601NK
UT WOS:000278066700001
PM 19404494
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Neuvonen, M
   Ahola, T
AF Neuvonen, Maarit
   Ahola, Tero
TI Differential Activities of Cellular and Viral Macro Domain Proteins in
   Binding of ADP-Ribose Metabolites
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE ADP-ribose; poly(ADP-ribose); alphavirus; coronavirus; mitochondrial
   localization
ID GENE-EXPRESSION; CONSERVED DOMAIN; RNA REPLICATION; MESSENGER-RNA; CORE
   HISTONE; LRP16 GENE; POLY(ADP-RIBOSE); VIRUS; IDENTIFICATION;
   CORONAVIRUS
AB Macro domain is a highly conserved protein domain found in both eukaryotes and prokaryotes. Macro domains are also encoded by a set of positive-strand RNA viruses that replicate in the cytoplasm of animal cells, including coronaviruses and alphaviruses. The functions of the macro domain are poorly understood, but it has been suggested to be an ADP-ribose-binding module. We have here characterized three novel human macro domain proteins that were found to reside either in the cytoplasm and nucleus [macro domain protein 2 (MDO2) and ganglioside-induced differentiation-associated protein 2] or in mitochondria [macro domain protein 1 (MDO1)], and compared them with viral macro domains from Semliki Forest virus, hepatitis E virus, and severe acute respiratory syndrome coronavirus, and with a yeast macro protein, Poa1p. MDO2 specifically bound monomeric ADP-ribose with a high affinity (K-d=0.1.5 mu M), but did not bind poly(ADPribose) efficiently. MDO2 also hydrolyzed ADP-ribose-1" phosphate, resembling Poa1p in all these properties. Ganglioside-induced differentiation-associated protein 2 did not show affinity for ADP-ribose or its derivatives, but instead bound poly(A). MDO1 was generally active in these reactions, including poly(A) binding. Individual point mutations in MDO1. abolished monomeric ADP-ribose binding, but not poly(ADP-ribose) binding; in poly(ADP-ribose) binding assays, the monomer did not compete against polymer binding. The viral macro proteins bound poly(ADP-ribose) and poly(A), but had a low affinity for monomeric ADP-ribose. Thus, the viral proteins do not closely resemble any of the human proteins in their biochemical functions. The differential activity profiles of the human proteins implicate them in different cellular pathways, some of which may involve RNA rather than ADP-ribose derivatives. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Neuvonen, Maarit; Ahola, Tero] Univ Helsinki, Inst Biotechnol, Helsinki 00014, Finland.
RP Ahola, T (reprint author), Univ Helsinki, Inst Biotechnol, POB 56 Viikinkaari 9, Helsinki 00014, Finland.
EM tero.ahola@helsinki.fi
OI Neuvonen, Maarit/0000-0002-7209-3029
FU Sigrid Juselius FoundationSigrid Juselius Foundation; Academy of
   FinlandAcademy of Finland [211121]
FX We thank Dr. Tuula Nyman for help with mass spectrometry, Pia Salomaa
   for cloning and protein purification in the initial phase of the
   project, and Riikka Vayrynen for technical assistance. Financial support
   from the Sigrid Juselius Foundation and the Academy of Finland (grant
   211121) is gratefully acknowledged.
CR Agelopoulos M, 2006, EMBO J, V25, P4843, DOI 10.1038/sj.emboj.7601364
   Aguiar RCT, 2005, J BIOL CHEM, V280, P33756, DOI 10.1074/jbc.M505408200
   Aguiar RCT, 2000, BLOOD, V96, P4328, DOI 10.1182/blood.V96.13.4328.h8004328_4328_4334
   Ahel I, 2008, NATURE, V451, P81, DOI 10.1038/nature06420
   Allen MD, 2003, J MOL BIOL, V330, P503, DOI 10.1016/S0022-2836(03)00473-X
   Anantharaman V, 2002, NUCLEIC ACIDS RES, V30, P1427, DOI 10.1093/nar/30.7.1427
   Bick MJ, 2003, J VIROL, V77, P11555, DOI 10.1128/JVI.77.21.11555-11562.2003
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   Cipriani G, 2005, J BIOL CHEM, V280, P17227, DOI 10.1074/jbc.M414526200
   CLAROS MG, 1995, COMPUT APPL BIOSCI, V11, P441
   Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275
   Costanzi C, 2001, J BIOL CHEM, V276, P21776, DOI 10.1074/jbc.M010919200
   D'Angelo I, 2006, EMBO REP, V7, P174, DOI 10.1038/sj.embor.7400602
   Di Girolamo M, 2005, FEBS J, V272, P4565, DOI 10.1111/j.1742-4658.2005.04876.x
   Egloff MP, 2006, J VIROL, V80, P8493, DOI 10.1128/JVI.00713-06
   Flaus A, 2006, NUCLEIC ACIDS RES, V34, P2887, DOI 10.1093/nar/gkl295
   Goenka S, 2006, P NATL ACAD SCI USA, V103, P4210, DOI 10.1073/pnas.0506981103
   GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6
   Han WD, 2003, ENDOCR-RELAT CANCER, V10, P217, DOI 10.1677/erc.0.0100217
   Kaariainen L, 2002, PROG NUCLEIC ACID RE, V71, P187, DOI 10.1016/S0079-6603(02)71044-1
   Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664
   Kerns JA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040021
   KOONIN EV, 1992, P NATL ACAD SCI USA, V89, P8259, DOI 10.1073/pnas.89.17.8259
   Kujala P, 2001, J VIROL, V75, P3873, DOI 10.1128/JVI.75.8.3873-3884.2001
   Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956
   LAAKKONEN P, 1994, J VIROL, V68, P7418, DOI 10.1128/JVI.68.11.7418-7425.1994
   Liu H, 1999, J NEUROCHEM, V72, P1781, DOI 10.1046/j.1471-4159.1999.0721781.x
   Maas NMC, 2007, J MED GENET, V44, DOI 10.1136/jmg.2007.049510
   MacDonald MR, 2007, J VIROL, V81, P13509, DOI 10.1128/JVI.00402-07
   Magden J, 2001, J VIROL, V75, P6249, DOI 10.1128/JVI.75.14.6249-6255.2001
   Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839
   Malet H, 2006, ACTA CRYSTALLOGR F, V62, P405, DOI 10.1107/S1744309106009274
   Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153
   Meng YG, 2007, CELL RES, V17, P869, DOI 10.1038/cr.2007.79
   Meyer RG, 2007, EXP CELL RES, V313, P2920, DOI 10.1016/j.yexcr.2007.03.043
   MINAGA T, 1983, J BIOL CHEM, V258, P5726
   Otto H, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-139
   PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014
   PEHRSON JR, 1992, SCIENCE, V257, P1398
   Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837
   Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187
   Putics A, 2006, J GEN VIROL, V87, P651, DOI 10.1099/vir.0.81596-0
   Putics A, 2005, J VIROL, V79, P12721, DOI 10.1128/JVI.79.20.12721-12731.2005
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Salonen A, 2005, CURR TOP MICROBIOL, V285, P139
   Scovassi AI, 2004, FASEB J, V18, P1487, DOI 10.1096/fj.04-1841rev
   Shull NP, 2005, NUCLEIC ACIDS RES, V33, P650, DOI 10.1093/nar/gki211
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   UCHIDA T, 1990, JPN J EXP MED, V60, P13
   Virag L, 2005, CELL MOL LIFE SCI, V62, P719, DOI 10.1007/s00018-004-4502-4
   Zhao YL, 2005, J MOL ENDOCRINOL, V34, P77, DOI 10.1677/jme.1.01628
NR 51
TC 114
Z9 117
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD JAN 9
PY 2009
VL 385
IS 1
BP 212
EP 225
DI 10.1016/j.jmb.2008.10.045
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 400LT
UT WOS:000262870200021
PM 18983849
DA 2020-04-03
ER

PT J
AU Paizis, G
   Tikellis, C
   Cooper, ME
   Schembri, JM
   Lew, RA
   Smith, AI
   Shaw, T
   Warner, FJ
   Zuilli, A
   Burrell, LM
   Angus, PW
AF Paizis, G
   Tikellis, C
   Cooper, ME
   Schembri, JM
   Lew, RA
   Smith, AI
   Shaw, T
   Warner, FJ
   Zuilli, A
   Burrell, LM
   Angus, PW
TI Chronic liver injury in rats and humans upregulates the novel enzyme
   angiotensin converting enzyme 2
SO GUT
LA English
DT Article
ID RENIN-ANGIOTENSIN; VASCULAR-TONE; ACE2; CIRRHOSIS; RECEPTOR; SYSTEM;
   CARBOXYPEPTIDASE; EXPRESSION; CORONAVIRUS; HOMOLOG
AB Background: Angiotensin converting enzyme (ACE) 2 is a recently identified homologue of ACE that may counterregulate the actions of angiotensin (Ang) II by facilitating its breakdown to Ang 1-7. The renin-angiotensin system (RAS) has been implicated in the pathogenesis of cirrhosis but the role of ACE2 in liver disease is not known.
   Aims: This study examined the effects of liver injury on ACE2 expression and activity in experimental hepatic fibrosis and human cirrhosis, and the effects of Ang 1-7 on vascular tone in cirrhotic rat aorta.
   Methods: In sham operated and bile duct ligated (BDL) rats, quantitative reverse transcriptase-polymerase chain reaction was used to assess hepatic ACE2 mRNA, and western blotting and immunohistochemistry to quantify and localise ACE2 protein. ACE2 activity was quantified by quenched fluorescent substrate assay. Similar studies were performed in normal human liver and in hepatitis C cirrhosis.
   Results: ACE2 mRNA was detectable at low levels in rat liver and increased following BDL (363-fold; p<0.01). ACE2 protein increased after BDL (23.5-fold; p<0.05) as did ACE2 activity (fourfold; p<0.05). In human cirrhotic liver, gene (>30-fold), protein expression (97-fold), and activity of ACE2 (2.4 fold) were increased compared with controls (all p<0.01). In healthy livers, ACE2 was confined to endothelial cells, occasional bile ducts, and perivenular hepatocytes but in both BDL and human cirrhosis there was widespread parenchymal expression of ACE2 protein. Exposure of cultured human hepatocytes to hypoxia led to increased ACE2 expression. In preconstricted rat aorta, Ang 1-7 alone did not affect vascular tone but it significantly enhanced acetylcholine mediated vasodilatation in cirrhotic vessels.
   Conclusions: ACE2 expression is significantly increased in liver injury in both humans and rat, possibly in response to increasing hepatocellular hypoxia, and may modulate RAS activity in cirrhosis.
C1 Univ Melbourne, Dept Med, Austin Hlth, Heidelberg, Vic, Australia.
   Baker Heart Res Inst, Melbourne, Vic, Australia.
   Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia.
   Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia.
RP Angus, PW (reprint author), Austin Hlth, Dept Gastroenterol & Hepatol, Heidelberg, Vic 3084, Australia.
EM peter.angus@austin.org.au
RI Cooper, Mark/AAC-5326-2020; Lew, Rebecca A/C-5454-2008; Cooper, Mark
   E/E-8680-2010
OI Cooper, Mark E/0000-0002-5953-642X; Smith, Ian/0000-0002-4143-2892
CR Bataller R, 2003, GASTROENTEROLOGY, V125, P117, DOI 10.1016/S0016-5085(03)00695-4
   Brosnihan KB, 1996, HYPERTENSION, V27, P523, DOI 10.1161/01.HYP.27.3.523
   Burrell LM, 2005, EUR HEART J, V26, P369, DOI 10.1093/eurheartj/ehi114
   Burrell LM, 2004, TRENDS ENDOCRIN MET, V15, P166, DOI 10.1016/j.tem.2004.03.001
   Chau TN, 2004, HEPATOLOGY, V39, P302, DOI 10.1002/hep.20111
   Corpechot C, 2002, HEPATOLOGY, V35, P1010, DOI 10.1053/jhep.2002.32524
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Dales NA, 2002, J AM CHEM SOC, V124, P11852, DOI 10.1021/ja0277226
   Dimitrov DS, 2003, CELL, V115, P652, DOI 10.1016/S0092-8674(03)00976-0
   DONOGHUE M, 2000, CIRC RES, V87, P1
   Ferrario CM, 1997, HYPERTENSION, V30, P535, DOI 10.1161/01.HYP.30.3.535
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   Helmy A, 2000, GASTROENTEROLOGY, V118, P565, DOI 10.1016/S0016-5085(00)70263-0
   JOHNSTON CI, 1994, HYPERTENSION, V23, P258, DOI 10.1161/01.HYP.23.2.258
   Jonsson JR, 2001, GASTROENTEROLOGY, V121, P148, DOI 10.1053/gast.2001.25480
   KOUNTOURAS J, 1984, BRIT J EXP PATHOL, V65, P305
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Muthalif MM, 1998, J PHARMACOL EXP THER, V284, P388
   Newby DE, 1998, CARDIOVASC RES, V38, P221, DOI 10.1016/S0008-6363(98)00008-X
   Paizis G, 2002, GASTROENTEROLOGY, V123, P1667, DOI 10.1053/gast.2002.36561
   Paizis G, 2001, J HEPATOL, V35, P376, DOI 10.1016/S0168-8278(01)00146-5
   PORSTI I, 1994, BRIT J PHARMACOL, V111, P652
   Roks AJM, 1999, HYPERTENSION, V34, P296, DOI 10.1161/01.HYP.34.2.296
   Tikellis C, 2003, HYPERTENSION, V41, P392, DOI 10.1161/01.HYP.0000060689.38912.CB
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200
   Yagil Y, 2003, HYPERTENSION, V41, P871, DOI 10.1161/01.HYP.0000063886.71596.C8
   Zulli A, 2003, ARTERIOSCL THROM VAS, V23, P1358, DOI 10.1161/01.ATV.0000080686.39871.54
NR 28
TC 114
Z9 129
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD DEC
PY 2005
VL 54
IS 12
BP 1790
EP 1796
DI 10.1136/gut.2004.062398
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 983ND
UT WOS:000233238300024
PM 16166274
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Arden, KE
   Nissen, MD
   Sloots, TP
   Mackay, IM
AF Arden, KE
   Nissen, MD
   Sloots, TP
   Mackay, IM
TI New human coronavirus, HCoV-NL63, associated with severe lower
   respiratory tract disease in Australia
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE human coronavirus; emerging; respiratory; pediatric; disease
ID INFECTION; RHINOVIRUS; VIRUSES; PCR
AB A new human coronavirus, HCoV-NL63, was associated recently with bronchiolitis. The current study aimed to examine retrospectively stored specimens for the presence of HCoV-NL63 using nested RT-PCR assays targeting the 1a and 1b genes. The study population was composed of patients with acute respiratory disease warranting presentation to Queensland hospitals. HCoVNL63 was detected in the nasopharyngeal aspirates (NPA) of 16 of 840 specimens representing 766 patients (2%). HCoV-NL63 positive individuals were diagnosed most commonly with lower respiratory tract (LRT) disease (81%). The clinical diagnosis was commonly supported by an abnormal chest X-ray (56%) together with respiratory distress (50%), wheeze (44%), and r (a) over cap les (25%) on first presentation with HCoV-NL63 infection. All patients positive for HCoV-NL63 required admission to hospital. Among 38% of HCoV-NL63 positive specimens a second pathogen was detected. Sequencing of amplicon from gene 1b revealed more than 99% nucleotide homology with the viral type strains while sequencing amplicon from gene la permitted the grouping of viral strains. It was shown that HCoV-NL63 is associated with severe LRT disease in an Australian hospital setting during the cooler months of the year. We propose that HCoV-NL63 is a global and seasonal pathogen of both children and adults associated with severe LRT illness. (C) 2005Wiley-Liss,Ine.
C1 Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Clin Virol & Mol Microbiol Res Units, Brisbane, Qld 4029, Australia.
   Royal Childrens Hosp, Clin Med Virol Ctr, Brisbane, Qld 4029, Australia.
   Univ Queensland, Clin & Med Virol Ctr, Brisbane, Qld 4029, Australia.
   Royal Childrens Hosp, Dept Paediat & Child Hlth, Brisbane, Qld 4029, Australia.
RP Mackay, IM (reprint author), Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Clin Virol & Mol Microbiol Res Units, Herston Rd, Brisbane, Qld 4029, Australia.
EM ian.mackay@uq.edu.au
RI Sloots, Theo P/E-6118-2011; Arden, Katherine/D-7970-2017; Nissen,
   Michael D/M-6823-2013; Mackay, Ian M./B-2537-2010
OI Arden, Katherine/0000-0003-3195-124X; Nissen, Michael
   D/0000-0003-1686-3313; Mackay, Ian M./0000-0003-3598-2350
CR Falsey AR, 2002, J INFECT DIS, V185, P1338, DOI 10.1086/339881
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406
   Heikkinen T, 2003, LANCET, V361, P51, DOI 10.1016/S0140-6736(03)12162-9
   Kosters K, 2002, J CLIN MICROBIOL, V40, P1719, DOI 10.1128/JCM.40.5.1719-1722.2002
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102
   Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SELWYN BJ, 1990, REV INFECT DIS, V12, pS870
   Simons JN, 1996, J VIROL, V70, P6126, DOI 10.1128/JVI.70.9.6126-6135.1996
   Syrmis MW, 2004, J MOL DIAGN, V6, P125, DOI 10.1016/S1525-1578(10)60500-4
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   van Elden LJR, 2004, J INFECT DIS, V189, P652, DOI 10.1086/381207
   VILE RG, 1995, VIROLOGY, V214, P307, DOI 10.1006/viro.1995.9923
   Yeh EA, 2004, PEDIATRICS, V113, pE73, DOI 10.1542/peds.113.1.e73
NR 21
TC 114
Z9 122
U1 2
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD MAR
PY 2005
VL 75
IS 3
BP 455
EP 462
DI 10.1002/jmv.20288
PG 8
WC Virology
SC Virology
GA 893EA
UT WOS:000226700900014
PM 15648064
OA Bronze
DA 2020-04-03
ER

PT J
AU Moes, E
   Vijgen, L
   Keyaerts, E
   Zlateva, K
   Li, S
   Maes, P
   Pyrc, K
   Berkhout, B
   van der Hoek, L
   Van Ranst, M
AF Moes, E
   Vijgen, L
   Keyaerts, E
   Zlateva, K
   Li, S
   Maes, P
   Pyrc, K
   Berkhout, B
   van der Hoek, L
   Van Ranst, M
TI A novel pancoronavirus RT-PCR assay: frequent detection of human
   coronavirus NL63 in children hospitalized with respiratory tract
   infections in Belgium
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID SARS-CORONAVIRUS; VIRUS; IDENTIFICATION; DIAGNOSIS; CONSENSUS; SEQUENCE;
   DISEASE; GENOME; ADULTS; OC43
AB Background: Four human coronaviruses are currently known to infect the respiratory tract: human coronaviruses OC43 ( HCoV- OC43) and 229E ( HCoV- 229E), SARS associated coronavirus ( SARS- CoV) and the recently identified human coronavirus NL63 ( HCoV- NL63). In this study we explored the incidence of HCoV- NL63 infection in children diagnosed with respiratory tract infections in Belgium.
   Methods: Samples from children hospitalized with respiratory diseases during the winter seasons of 2003 and 2004 were evaluated for the presence of HCoV- NL63 using a optimized pancoronavirus RT- PCR assay.
   Results: Seven HCoV- NL63 positive samples were identified, six were collected during January/ February 2003 and one at the end of February 2004.
   Conclusions: Our results support the notation that HCoV- NL63 can cause serious respiratory symptoms in children. Sequence analysis of the S gene showed that our isolates could be classified into two subtypes corresponding to the two prototype HCoV- NL63 sequences isolated in The Netherlands in 1988 and 2003, indicating that these two subtypes may currently be cocirculating.
C1 Univ Leuven, Rega Inst Med Res, Lab Clin & Epidemiol Virol, Dept Microbiol & Immunol, Louvain, Belgium.
   Univ Amsterdam, Acad Med Ctr, Dept Human Virol, NL-1105 AZ Amsterdam, Netherlands.
RP Van Ranst, M (reprint author), Univ Leuven, Rega Inst Med Res, Lab Clin & Epidemiol Virol, Dept Microbiol & Immunol, Louvain, Belgium.
EM elien.moes@uz.kuleuven.ac.be; leen.vijgen@uz.kuleuven.ac.be;
   els.keyaerts@uz.kuleuven.ac.be; kalina.zlateva@uz.kuleuven.ac.be;
   sandra.li@uz.kuleuven.ac.be; piet.3.maes@uz.kuleuven.ac.be;
   k.a.pyrc@amc.uva.nl; b.berkhout@amc.uva.nl; c.m.vanderhoek@amc.uva.nl;
   marc.vanranst@uz.kuleuven.ac.be
RI Van Ranst, Marc/P-7522-2017; Maes, Piet/P-7782-2017; van der Hoek,
   Lia/Y-6412-2019; Keyaerts, Els/F-2305-2018
OI Van Ranst, Marc/0000-0002-1674-4157; Maes, Piet/0000-0002-4571-5232;
   Keyaerts, Els/0000-0002-1849-3240; Pyrc, Krzysztof/0000-0002-3867-7688
CR Almeida J D, 1967, J Gen Virol, V1, P175, DOI 10.1099/0022-1317-1-2-175
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101
   Gagneur A, 2002, J HOSP INFECT, V51, P59, DOI 10.1053/jhin.2002.1179
   Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   Guy JS, 2000, J CLIN MICROBIOL, V38, P4523, DOI 10.1128/JCM.38.12.4523-4526.2000
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   HENDLEY JO, 1972, AM REV RESPIR DIS, V105, P805
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   Lai M.M.C., 2001, FIELDS VIROLOGY, P1163
   LARSON HE, 1980, J MED VIROL, V5, P221, DOI 10.1002/jmv.1890050306
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   Nicholas KB, 1997, EMBNEW NEWS, V4, P14
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9
   Sun ZF, 2004, J CLIN MICROBIOL, V42, P2351, DOI 10.1128/JCM.42.5.2351-2352.2004
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   TYRRELL DAJ, 1965, BMJ-BRIT MED J, V1, P1467, DOI 10.1136/bmj.1.5448.1467
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   Vabret A, 2001, J VIROL METHODS, V97, P59, DOI 10.1016/S0166-0934(01)00343-3
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
NR 28
TC 114
Z9 130
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD FEB 1
PY 2005
VL 5
AR 6
DI 10.1186/1471-2334-5-6
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA 900DQ
UT WOS:000227196000001
PM 15686594
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Almazan, F
   Galan, C
   Enjuanes, L
AF Almazan, F
   Galan, C
   Enjuanes, L
TI The nucleoprotein is required for efficient coronavirus genome
   replication
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS; ACUTE RESPIRATORY SYNDROME;
   LENGTH INFECTIOUS CDNA; REVERSE GENETICS; RNA-SYNTHESIS; VIRUS GENOME;
   TRANSCRIPTION; EXPRESSION; SEQUENCE; IDENTIFICATION
AB The construction of a set of transmissible gastroenteritis coronavirus (TGEV)-derived replicons as bacterial artificial chromosomes is reported. These replicons were generated by sequential deletion of nonessential genes for virus replication, using a modified TGEV full-length cDNA clone containing unique restriction sites between each pair of consecutive genes. Efficient activity of TGEV replicons was associated with the presence of the nucleoprotein provided either in cis or in trans. TGEV replicons were functional in several cell lines, including the human cell line 293T, in which no or very low cytopathic effect was observed, and expressed high amounts of heterologous protein.
C1 CSIC, Dept Mol & Cell Biol, Ctr Nacl Biotecnol, E-28049 Madrid, Spain.
RP Enjuanes, L (reprint author), CSIC, Dept Mol & Cell Biol, Ctr Nacl Biotecnol, Campus Univ Autonoma, E-28049 Madrid, Spain.
EM L.Enjuanes@enb.uam.es
RI Almazan, Fernando/K-8781-2015; Enjuanes, Luis/F-7845-2016
OI Almazan, Fernando/0000-0002-5752-8469; Enjuanes,
   Luis/0000-0002-0854-0226
CR Agapov EV, 1998, P NATL ACAD SCI USA, V95, P12989, DOI 10.1073/pnas.95.22.12989
   Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   Alonso S, 2002, J VIROL, V76, P1293, DOI 10.1128/JVI.76.3.1293-1308.2002
   Casais R, 2001, J VIROL, V75, P12359, DOI 10.1128/JVI.75.24.12359-12369.2001
   DELMAS B, 1993, ADV EXP MED BIOL, V342, P293
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Enjuanes L, 2000, VIRUS TAXONOMY CLASS, P827
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Frolov I, 1996, P NATL ACAD SCI USA, V93, P11371, DOI 10.1073/pnas.93.21.11371
   Gonzalez JM, 2002, J VIROL, V76, P4655, DOI 10.1128/JVI.76.9.4655-4661.2002
   Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2
   Holmes KV, 2003, SCIENCE, V300, P1377, DOI 10.1126/science.1086418
   Izeta A, 1999, J VIROL, V73, P1535, DOI 10.1128/JVI.73.2.1535-1545.1999
   Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Masters PS, 1999, ADV VIRUS RES, V53, P245, DOI 10.1016/S0065-3527(08)60351-6
   Molenkamp R, 2000, J GEN VIROL, V81, P2491, DOI 10.1099/0022-1317-81-10-2491
   Ortego J, 2003, VIROLOGY, V308, P13, DOI 10.1016/S0042-6822(02)00096-X
   Ortego J, 2002, J VIROL, V76, P11518, DOI 10.1128/JVI.76.22.11518-11529.2002
   Penzes Z, 2001, VIRUS GENES, V23, P105, DOI 10.1023/A:1011147832586
   Repass JF, 1998, J VIROL, V72, P7926, DOI 10.1128/JVI.72.10.7926-7933.1998
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   Siddell S, 2001, ADV EXP MED BIOL, V494, P453
   Sola I, 2003, J VIROL, V77, P4357, DOI 10.1128/JVI.77.7.4357-4369.2003
   Stalcup RP, 1998, VIROLOGY, V241, P112, DOI 10.1006/viro.1997.8957
   Thiel V, 2003, J VIROL, V77, P9790, DOI 10.1128/JVI.77.18.9790-9798.2003
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   Thiel V, 2001, J VIROL, V75, P6676, DOI 10.1128/JVI.75.14.6676-6681.2001
   Tijms MA, 2001, P NATL ACAD SCI USA, V98, P1889, DOI 10.1073/pnas.041390398
   Williams GD, 1999, J VIROL, V73, P8349, DOI 10.1128/JVI.73.10.8349-8355.1999
   Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Yount B, 2002, J VIROL, V76, P11065, DOI 10.1128/JVI.76.21.11065-11078.2002
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Zuniga S, 2004, J VIROL, V78, P980, DOI 10.1128/JVI.78.2.980-994.2004
NR 39
TC 114
Z9 128
U1 1
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2004
VL 78
IS 22
BP 12683
EP 12688
DI 10.1128/JVI.78.22.12683-12688.2004
PG 6
WC Virology
SC Virology
GA 866NY
UT WOS:000224781400062
PM 15507657
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Summerfield, A
   Guzylack-Piriou, L
   Schaub, A
   Carrasco, CP
   Tache, V
   Charley, B
   McCullough, KC
AF Summerfield, A
   Guzylack-Piriou, L
   Schaub, A
   Carrasco, CP
   Tache, V
   Charley, B
   McCullough, KC
TI Porcine peripheral blood dendritic cells and natural
   interferon-producing cells
SO IMMUNOLOGY
LA English
DT Article
ID ALPHA-PRODUCING CELLS; MONOCLONAL-ANTIBODIES; CORONAVIRUS TGEV;
   GENE-EXPRESSION; MONOCYTIC CELLS; IMMUNE-SYSTEM; LYMPH-NODES; IFN-ALPHA;
   IN-VITRO; B-CELLS
AB Peripheral blood contains two major particular infrequent dendritic cells (DC) subsets linking the innate and specific immune system, the myeloid DC and plasmacytoid DC equivalent to the natural interferon-producing cells (NIPC). The functional characterization of these cells demands large volumes of blood, making a large animal model more appropriate and beneficial for certain studies. Here, two subsets of porcine blood mononuclear cells expressing swine workshop cluster 3 (SWC3, a SIRP family member), are described and compared to monocytes. The blood DC specialized in T-cell stimulation were major histocompatibility complex (MHC) class II+, CD80/86(+), CD1(+/-), CD4(-), and in contrast to monocytes CD14(-). A CD16(-) and a CD16(+) subset could be discriminated. Granulocyte-macrophage colony-stimulating factor and interleukin-3 were survival factors for this DC subset, and culture induced an up-regulation of MHC class II and CD80/86. The second subset described, are porcine NIPC, typically CD4(++), MHC class IIlow, CD80/86(low), CD1(-), CD8(-/low), CD16(-/low) and CD45RA(-/low). Porcine NIPC had high interleukin-3 binding capacity, and survived in response to this cytokine. Their unique function was strong interferon type I secretion after virus stimulation. Both subsets were endocytically active when freshly isolated, and down-regulated this activity after in vitro maturation. Taken together, the present report has delineated porcine blood DC and NIPC, permitting a more detailed understanding of innate immune defences, particularly in response to infections.
C1 Inst Virol & Immunoprophylaxis, CH-3147 Mittelhausern, Switzerland.
   INRA, Jouy En Josas, France.
RP Summerfield, A (reprint author), Inst Virol & Immunoprophylaxis, CH-3147 Mittelhausern, Switzerland.
EM artur.summerfield@ivi.admin.ch
RI Summerfield, Artur/H-6025-2019
OI Summerfield, Artur/0000-0001-8292-4634
CR Alvarez B, 2000, TISSUE ANTIGENS, V55, P342, DOI 10.1034/j.1399-0039.2000.550408.x
   Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736
   Balazs M, 2002, IMMUNITY, V17, P341, DOI 10.1016/S1074-7613(02)00389-8
   Barchet W, 2002, J EXP MED, V195, P507, DOI 10.1084/jem.20011666
   Basta S, 1999, J IMMUNOL, V162, P3961
   Baudoux P, 1998, J VIROL, V72, P8636, DOI 10.1128/JVI.72.11.8636-8643.1998
   Bautista EM, 2002, VET IMMUNOL IMMUNOP, V88, P131, DOI 10.1016/S0165-2427(02)00152-6
   BLECHA F, 1994, VET IMMUNOL IMMUNOP, V43, P269, DOI 10.1016/0165-2427(94)90147-3
   Carrasco CP, 2001, IMMUNOLOGY, V104, P175, DOI 10.1046/j.1365-2567.2001.01299.x
   Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360
   CHARLEY B, 1990, RES IMMUNOL, V141, P141, DOI 10.1016/0923-2494(90)90133-J
   CHARLEY B, 1991, SCAND J IMMUNOL, V33, P435, DOI 10.1111/j.1365-3083.1991.tb01792.x
   Comeau MR, 2002, J IMMUNOL, V169, P75, DOI 10.4049/jimmunol.169.1.75
   Dalod M, 2002, J EXP MED, V195, P517, DOI 10.1084/jem.20011672
   Dominguez J, 2001, VET IMMUNOL IMMUNOP, V80, P111, DOI 10.1016/S0165-2427(01)00286-0
   Feldman S, 2001, CLIN IMMUNOL, V101, P201, DOI 10.1006/clim.2001.5111
   FELDMAN SB, 1994, VIROLOGY, V204, P1, DOI 10.1006/viro.1994.1504
   FITZGERALDBOCARSLY P, 1993, PHARMACOL THERAPEUT, V60, P39, DOI 10.1016/0163-7258(93)90021-5
   Galibert L, 2001, SEMIN IMMUNOL, V13, P283, DOI 10.1006/smim.2001.0324
   Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101
   Haverson K, 2001, VET IMMUNOL IMMUNOP, V80, P25, DOI 10.1016/S0165-2427(01)00291-4
   Haverson K, 2000, IMMUNOLOGY, V101, P492, DOI 10.1046/j.1365-2567.2000.00128.x
   Hawley RJ, 1997, XENOTRANSPLANTATION, V4, P103, DOI 10.1111/j.1399-3089.1997.tb00172.x
   Hochrein H, 2002, HUM IMMUNOL, V63, P1103, DOI 10.1016/S0198-8859(02)00748-6
   Ito T, 1999, J IMMUNOL, V163, P1409
   Johansson B, 2000, J IMMUNOL, V164, P1847, DOI 10.4049/jimmunol.164.4.1847
   Kelsall BL, 2002, NAT IMMUNOL, V3, P699, DOI 10.1038/ni0802-699
   Knoetig SM, 2002, ANTIVIR RES, V53, P75, DOI 10.1016/S0166-3542(01)00193-0
   Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U
   MCCULLOUGH KC, 1993, IMMUNOL LETT, V37, P83, DOI 10.1016/0165-2478(93)90136-P
   McCullough KC, 1997, VET IMMUNOL IMMUNOP, V58, P265, DOI 10.1016/S0165-2427(97)00045-7
   Meissner P, 2001, BIOTECHNOL BIOENG, V75, P197, DOI 10.1002/bit.1179
   Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4
   Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171
   NOWACKI W, 1993, RES IMMUNOL, V144, P111, DOI 10.1016/0923-2494(93)80066-8
   O'Keeffe M, 2003, BLOOD, V101, P1453, DOI 10.1182/blood-2002-03-0974
   ODOHERTY U, 1993, J EXP MED, V178, P1067, DOI 10.1084/jem.178.3.1067
   PERRIN P, 1995, BIOLOGICALS, V23, P207, DOI 10.1006/biol.1995.0034
   Riffault S, 1996, J INTERF CYTOK RES, V16, P1007, DOI 10.1089/jir.1996.16.1007
   Riffault S, 1997, VET RES, V28, P77
   Riffault S, 1997, J GEN VIROL, V78, P2483, DOI 10.1099/0022-1317-78-10-2483
   Riffault S, 2001, VET RES, V32, P71, DOI 10.1051/vetres:2001111
   SAALMULLER A, 1988, RES VET SCI, V45, P311, DOI 10.1016/S0034-5288(18)30957-3
   Saalmuller A, 1996, IMMUNOL TODAY, V17, P352, DOI 10.1016/S0167-5699(96)90273-X
   Salmon H, 2000, SCAND J IMMUNOL, V52, P164
   Schakel K, 2002, IMMUNITY, V17, P289, DOI 10.1016/S1074-7613(02)00393-X
   Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835
   Sinkora J, 2002, VET IMMUNOL IMMUNOP, V87, P301, DOI 10.1016/S0165-2427(02)00056-9
   Sousa CRE, 2001, IMMUNITY, V14, P495
   Splichal I, 1997, RES IMMUNOL, V148, P247, DOI 10.1016/S0923-2494(97)80866-8
   Summerfield A, 1997, J LEUKOCYTE BIOL, V62, P176
   Svensson H, 1996, SCAND J IMMUNOL, V44, P164, DOI 10.1046/j.1365-3083.1996.d01-289.x
   Wykes M, 2000, IMMUNOLOGY, V100, P1, DOI 10.1046/j.1365-2567.2000.00044.x
   ZHOU LJ, 1995, BLOOD, V86, P3295, DOI 10.1182/blood.V86.9.3295.bloodjournal8693295
NR 54
TC 114
Z9 121
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
EI 1365-2567
J9 IMMUNOLOGY
JI Immunology
PD DEC
PY 2003
VL 110
IS 4
BP 440
EP 449
DI 10.1111/j.1365-2567.2003.01755.x
PG 10
WC Immunology
SC Immunology
GA 747GU
UT WOS:000186797500006
PM 14632641
OA Green Published
DA 2020-04-03
ER

PT J
AU Bos, ECW
   Luytjes, W
   VanderMeulen, H
   Koerten, HK
   Spaan, WJM
AF Bos, ECW
   Luytjes, W
   VanderMeulen, H
   Koerten, HK
   Spaan, WJM
TI The production of recombinant infectious DI-particles of a murine
   coronavirus in the absence of helper virus
SO VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS VIRUS-A59; SPIKE PROTEIN; PROTEOLYTIC CLEAVAGE; VIRAL
   GLYCOPROTEIN; E1 GLYCOPROTEIN; RNA-POLYMERASE; CELL-FUSION; 3' END;
   EXPRESSION; MEMBRANE
AB We have studied the production and release of infectious DI-particles in vaccinia-T7-polymerase recombinant virus-infected L cells that were transfected with five different plasmids expressing the synthetic DI RNA MIDI-HD and the four structural proteins (M, N, S, and E) of the murine coronavirus MHV-A59. The DI cDNA contains the hepatitis delta ribozyme sequences to generate in the transfected cells a defined 3' end. In EM studies of transfected cells virus-like particles (VLP) were observed in vesicles. Release of the particles into the medium was studied by immunoprecipitations of proteins released into the culture supernatant Particle release was independent of S or N, but required M and E. Coexpression of E and M was sufficient for particle release. Coexpression of the structural proteins and the MIDI-HD RNA resulted in the production and release of infectious DI-particles. Infectivity of the DI-particles was determined by adding helper virus MHV-A59 to the medium containing the VLPs and using this mixture to infect new L cells. Intracellular RNA of several subsequent undiluted passages was isolated to detect the MIDI-HD RNA. Passage of the MIDI-HD RNA was dependent on the expression of the structural proteins of MHV-A59 in the transfected cells. In the absence of either E or M, MIDI-HD RNA could not be passaged to fresh L cells. We have thus developed a system in which we can produce coronavirus-like particles and an assay to test their infectivity. (C) 1996 Academic Press, Inc.
C1 LEIDEN STATE UNIV,DEPT VIROL,2300 AH LEIDEN,NETHERLANDS.
   LEIDEN STATE UNIV,LAB ELECTRON MICROSCOPY,2300 AH LEIDEN,NETHERLANDS.
CR ALLISON SL, 1995, J VIROL, V69, P695, DOI 10.1128/JVI.69.2.695-700.1995
   ANDERSON R, 1993, VIROLOGY, V194, P224, DOI 10.1006/viro.1993.1253
   ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0
   BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   BOS ECW, 1995, VIROLOGY, V214, P463
   BREDENBEEK P, 1990, THESIS U UTRECHT
   CHANG RY, 1994, J VIROL, V68, P8223, DOI 10.1128/JVI.68.12.8223-8231.1994
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   DENBOON JA, 1995, J VIROL, V69, P4500, DOI 10.1128/JVI.69.7.4500-4505.1995
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   FOSMIRE JA, 1992, J VIROL, V66, P3522, DOI 10.1128/JVI.66.6.3522-3530.1992
   FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X
   GALLAGHER TM, 1992, VIROLOGY, V191, P517, DOI 10.1016/0042-6822(92)90223-C
   GOMBOLD JL, 1993, J VIROL, V67, P4504, DOI 10.1128/JVI.67.8.4504-4512.1993
   HOBMAN TC, 1994, VIROLOGY, V574, P585
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   HOLMES KV, 1987, POSITIVE STRAND RNA, P339
   JOKLIK WK, 1964, J MOL BIOL, V10, P452, DOI 10.1016/S0022-2836(64)80066-8
   KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S
   LOCKER JK, 1995, J BIOL CHEM, V270, P8815, DOI 10.1074/jbc.270.15.8815
   LOCKER JK, 1992, J BIOL CHEM, V267, P14094
   LOCKER JK, 1994, J CELL BIOL, V124, P55
   LOEWY A, 1995, J VIROL, V69, P469, DOI 10.1128/JVI.69.1.469-475.1995
   LOPEZ S, 1994, J VIROL, V68, P1316, DOI 10.1128/JVI.68.3.1316-1323.1994
   LUYTJES W, 1995, CORONAVIRIDAE, P33
   MAKINO S, 1989, J VIROL, V63, P5285, DOI 10.1128/JVI.63.12.5285-5292.1989
   MASTERS PS, 1994, J VIROL, V68, P328, DOI 10.1128/JVI.68.1.328-337.1994
   MEBATSION T, 1995, J VIROL, V69, P1444, DOI 10.1128/JVI.69.3.1444-1451.1995
   MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X
   NIEMANN H, 1981, J MOL BIOL, V533, P993
   OPSTELTEN DJE, 1993, J VIROL, V67, P7394, DOI 10.1128/JVI.67.12.7394-7401.1993
   OPSTELTEN DJE, 1994, ADV EXP MED BIOL, V342, P189
   OPSTELTEN DJE, 1995, IN PRESS ADV EXP MED
   PATTNAIK AK, 1992, CELL, V69, P1011, DOI 10.1016/0092-8674(92)90619-N
   PENG D, 1995, J VIROL, V69, P5475, DOI 10.1128/JVI.69.9.5475-5484.1995
   PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I
   QIU ZY, 1994, J VIROL, V68, P4086, DOI 10.1128/JVI.68.6.4086-4091.1994
   ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987
   ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981
   Sambrook J., 1989, MOL CLONING LAB MANU
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9
   STAUBER R, 1993, J GEN VIROL, V74, P183, DOI 10.1099/0022-1317-74-2-183
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   STURMAN LS, 1990, J VIROL, V64, P3042, DOI 10.1128/JVI.64.6.3042-3050.1990
   SUOMALAINEN M, 1992, J VIROL, V66, P4737, DOI 10.1128/JVI.66.8.4737-4747.1992
   TAGUCHI F, 1993, J VIROL, V67, P1195, DOI 10.1128/JVI.67.3.1195-1202.1993
   TOOZE J, 1987, J CELL BIOL, V105, P1215, DOI 10.1083/jcb.105.3.1215
   TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475
   TUNG FYT, 1992, VIROLOGY, V186, P676, DOI 10.1016/0042-6822(92)90034-M
   VANDERMOST RG, 1992, NUCLEIC ACIDS RES, V20, P3375, DOI 10.1093/nar/20.13.3375
   VANDERMOST RG, 1991, J VIROL, V65, P3219, DOI 10.1128/JVI.65.6.3219-3226.1991
   VENNEMA H, 1991, GENE, V108, P201, DOI 10.1016/0378-1119(91)90435-E
   VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990
   YU X, 1994, VIROLOGY, V202, P1018, DOI 10.1006/viro.1994.1430
NR 59
TC 114
Z9 120
U1 0
U2 0
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PD APR 1
PY 1996
VL 218
IS 1
BP 52
EP 60
DI 10.1006/viro.1996.0165
PG 9
WC Virology
SC Virology
GA UD495
UT WOS:A1996UD49500006
PM 8615041
OA Bronze
DA 2020-04-03
ER

PT J
AU LARSON, HE
   REED, SE
   TYRRELL, DAJ
AF LARSON, HE
   REED, SE
   TYRRELL, DAJ
TI ISOLATION OF RHINOVIRUSES AND CORONAVIRUSES FROM 38 COLDS IN ADULTS
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
C1 COMMON COLD UNIT,SALISBURY,WILTSHIRE,ENGLAND.
RP LARSON, HE (reprint author), CLIN RES CTR,MRC,WATFORD RD,HARROW HA1 3UJ,MIDDLESEX,ENGLAND.
CR BEARE AS, 1977, CHEMOPROPHYLAXIS VIR, V2, P27
   CAVALLARO JJ, 1970, J INFECT DIS, V122, P272, DOI 10.1093/infdis/122.4.272
   GARDNER SD, 1969, J HYG-CAMB, V67, P545, DOI 10.1017/S002217240004198X
   GRIST NR, 1974, DIAGNOSTIC METHODS C, P121
   GWALTNEY JM, 1974, YALE J BIOL MEDICINE, V48, P17
   HIGGINS PG, 1974, J HYG-CAMBRIDGE, V72, P425, DOI 10.1017/S0022172400023664
   HIGGINS PG, 1973, J MED MICROBIOL, V6, P177, DOI 10.1099/00222615-6-2-177
   JOOSTING AC, 1968, BRIT MED J, V4, P153, DOI 10.1136/bmj.4.5624.153
   McIntosh K., 1974, Current Topics in Microbiology and Immunology, V63, P85
   MCINTOSH K, 1970, AM J EPIDEMIOL, V91, P585, DOI 10.1093/oxfordjournals.aje.a121171
   STOTT EJ, 1968, ARCH GES VIRUSFORSCH, V23, P236, DOI 10.1007/BF01241896
   TYRRELL DA, 1966, LANCET, V1, P76
   TYRRELL DAJ, 1969, BMJ-BRIT MED J, V1, P471, DOI 10.1136/bmj.1.5642.471
   TYRRELL DAJ, 1967, BRIT J EXP PATHOL, V48, P217
   TYRRELL DAJ, 1965, COMMON COLDS RELATED, P45
NR 15
TC 114
Z9 117
U1 0
U2 4
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PY 1980
VL 5
IS 3
BP 221
EP 229
DI 10.1002/jmv.1890050306
PG 9
WC Virology
SC Virology
GA KC687
UT WOS:A1980KC68700005
PM 6262450
OA Bronze
DA 2020-04-03
ER

PT J
AU NAGASHIMA, K
   WEGE, H
   MEYERMANN, R
   MEULEN, VT
AF NAGASHIMA, K
   WEGE, H
   MEYERMANN, R
   MEULEN, VT
TI CORONA VIRUS-INDUCED SUB-ACUTE DEMYELINATING ENCEPHALOMYELITIS IN RATS -
   MORPHOLOGICAL ANALYSIS
SO ACTA NEUROPATHOLOGICA
LA English
DT Article
C1 UNIV WURZBURG,INST VIROL & IMMUNOBIOL,D-8700 WURZBURG,FED REP GER.
CR BAILEY OT, 1949, J EXP MED, V90, P195, DOI 10.1084/jem.90.3.195
   BLUMCKE S, 1966, ACTA NEUROPATHOL, V7, P44
   BUNGE RP, 1968, PHYSIOL REV, V48, P197
   FIELD EJ, 1966, AM J PATHOL, V49, P537
   FUJITA S, 1974, 7TH INT C NEUR BUD, P95
   Koestner A., 1974, Slow virus diseases,, P86
   LAMPERT P, 1967, ACTA NEUROPATHOL, V9, P99, DOI 10.1007/BF00691436
   LAMPERT PW, 1973, ACTA NEUROPATHOL, V24, P76, DOI 10.1007/BF00691421
   MORI S, 1970, J COMP NEUROL, V139, P1, DOI 10.1002/cne.901390102
   Nagashima K, 1978, Adv Exp Med Biol, V100, P395
   RAINE CS, 1976, J NEUROL SCI, V30, P13, DOI 10.1016/0022-510X(76)90251-3
   SKOFF RP, 1976, J COMP NEUROL, V169, P291, DOI 10.1002/cne.901690303
   SKOFF RP, 1976, NATURE, V264, P560, DOI 10.1038/264560a0
   VAUGHN JE, 1969, Z ZELLFORSCH MIK ANA, V94, P293, DOI 10.1007/BF00319179
   WAKSMAN BH, 1962, J NEUROPATH EXP NEUR, V21, P491, DOI 10.1097/00005072-196210000-00001
   WEINER LP, 1973, ARCH NEUROL-CHICAGO, V28, P293
   WISNIEWSKI H, 1972, LAB INVEST, V26, P589
   WISNIEWSKI HM, 1977, BRIT MED BULL, V33, P54
NR 18
TC 114
Z9 114
U1 3
U2 3
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0001-6322
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PY 1978
VL 44
IS 1
BP 63
EP 70
DI 10.1007/BF00691641
PG 8
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA FT837
UT WOS:A1978FT83700010
PM 212923
OA Green Accepted, Bronze
DA 2020-04-03
ER

PT J
AU Wang, QH
   Qi, JX
   Yuan, Y
   Xuan, YF
   Han, PC
   Wan, YH
   Ji, W
   Li, Y
   Wu, Y
   Wang, JW
   Iwamoto, A
   Woo, PCY
   Yuen, KY
   Yan, JH
   Lu, GW
   Gao, GF
AF Wang, Qihui
   Qi, Jianxun
   Yuan, Yuan
   Xuan, Yifang
   Han, Pengcheng
   Wan, Yuhua
   Ji, Wei
   Li, Yan
   Wu, Ying
   Wang, Jianwei
   Iwamoto, Aikichi
   Woo, Patrick C. Y.
   Yuen, Kwok-Yung
   Yan, Jinghua
   Lu, Guangwen
   Gao, George F.
TI Bat Origins of MERS-CoV Supported by Bat Coronavirus HKU4 Usage of Human
   Receptor CD26
SO CELL HOST & MICROBE
LA English
DT Article
ID RESPIRATORY-SYNDROME CORONAVIRUS; ANGIOTENSIN-CONVERTING ENZYME-2;
   SARS-LIKE CORONAVIRUS; PROTEIN FUSION CORE; MIDDLE-EAST;
   CRYSTAL-STRUCTURE; SPIKE PROTEIN; FUNCTIONAL RECEPTOR; AVIAN
   CORONAVIRUSES; DROMEDARY CAMELS
AB The recently reported Middle East respiratory syndrome coronavirus (MERS-CoV) is phylogenetically closely related to the bat coronaviruses (BatCoVs) HKU4 and HKU5. However, the evolutionary pathway of MERS-CoV is still unclear. A receptor binding domain (RBD) in the MERS-CoV envelope-embedded spike protein specifically engages human CD26 (hCD26) to initiate viral entry. The high sequence identity in the viral spike protein prompted us to investigate if HKU4 and HKU5 can recognize hCD26 for cell entry. We found that HKU4-RBD, but not HKU5-RBD, binds to hCD26, and pseudotyped viruses embedding HKU4 spike can infect cells via hCD26 recognition. The structure of the HKU4-RBD/hCD26 complex revealed a hCD26-binding mode similar overall to that observed for MERS-RBD. HKU4-RBD, however, is less adapted to hCD26 than MERS-RBD, explaining its lower affinity for receptor binding. Our findings support a bat origin for MERS-CoV and indicate the need for surveillance of HKU4-related viruses in bats.
C1 [Wang, Qihui; Qi, Jianxun; Yuan, Yuan; Wan, Yuhua; Li, Yan; Wu, Ying; Yan, Jinghua; Lu, Guangwen; Gao, George F.] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.
   [Yuan, Yuan; Gao, George F.] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China.
   [Xuan, Yifang; Gao, George F.] Chinese Acad Sci, Beijing Inst Life Sci, Beijing 100101, Peoples R China.
   [Han, Pengcheng] Chinese Acad Sci, Inst Zool, State Key Lab Reprod Biol, Beijing 100101, Peoples R China.
   [Wan, Yuhua] Anhui Univ, Sch Life Sci, Hefei 230039, Peoples R China.
   [Ji, Wei; Gao, George F.] Chinese Ctr Dis Control & Prevent China CDC, Natl Inst Viral Dis Control & Prevent, Beijing 102206, Peoples R China.
   [Wang, Jianwei] Chinese Acad Med Sci, Inst Pathogen Biol, MOH Key Lab Syst Biol Pathogens, Beijing 100730, Peoples R China.
   [Wang, Jianwei] Peking Union Med Coll, Beijing 100101, Peoples R China.
   [Iwamoto, Aikichi] Chinese Acad Sci, Inst Microbiol, China Japan Joint Lab Mol Microbiol & Mol Immunol, Beijing 100101, Peoples R China.
   [Iwamoto, Aikichi] Univ Tokyo, Res Hosp, Adv Clin Res Ctr, Dept Infect Dis & Appl Immunol,Div Infect Dis,Min, Tokyo 1088639, Japan.
   [Woo, Patrick C. Y.; Yuen, Kwok-Yung] Univ Hong Kong, State Key Lab Emerging Infect Dis, Pokfulam 999077, Hong Kong, Peoples R China.
   [Woo, Patrick C. Y.; Yuen, Kwok-Yung] Univ Hong Kong, Dept Microbiol, Pokfulam 999077, Hong Kong, Peoples R China.
   [Yuen, Kwok-Yung; Gao, George F.] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou 310003, Zhejiang, Peoples R China.
   [Gao, George F.] Chinese Ctr Dis Control & Prevent China CDC, Off Director Gen, Beijing 102206, Peoples R China.
RP Gao, GF (reprint author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.
EM gaof@im.ac.cn
RI Wang, Jianwei/W-5916-2019; Woo, Patrick Chiu Yat/AAJ-6112-2020
OI Woo, Patrick Chiu Yat/0000-0001-9401-1832; Yuen,
   Kwok-yung/0000-0002-2083-1552
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China [81290342]; China National Grand S&T Special
   Project [2014ZX10004-001-006]; Strategic Priority Research Program of
   the Chinese Academy of SciencesChinese Academy of Sciences
   [XDB08020100]; NSFC Innovative Research Group [81321063]
FX This work was supported by the National Natural Science Foundation of
   China (NSFC, Grant No. 81290342), the China National Grand S&T Special
   Project (No. 2014ZX10004-001-006), and the Strategic Priority Research
   Program of the Chinese Academy of Sciences (Grant No. XDB08020100). We
   thank the staff at the Shanghai Synchrotron Radiation Facility (SSRF)
   and Tong Zhao at the Institute of Microbiology, Chinese Academy of
   Sciences for support. G.F.G. is a leading principal investigator of the
   NSFC Innovative Research Group (Grant No. 81321063).
CR Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100
   FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985
   Gao GF, 2007, COMBATING THE THREAT OF PANDEMIC INFLUENZA: DRUG DISCOVERY APPROACHES, P226, DOI 10.1002/9780470179727.ch10
   Gao J, 2013, J VIROL, V87, P13134, DOI 10.1128/JVI.02433-13
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   Gorrell MD, 2001, SCAND J IMMUNOL, V54, P249, DOI 10.1046/j.1365-3083.2001.00984.x
   Gorse GJ, 2009, J INFECT DIS, V199, P847, DOI 10.1086/597122
   Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Jean A, 2013, PEDIATR INFECT DIS J, V32, P325, DOI 10.1097/INF.0b013e3182812787
   Jevsnik M, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-365
   King AMQ, 2012, VIRUS TAXONOMY
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lai M.M.C., 2007, FIELDS VIROLOGY, V1, P1305
   Lau SKP, 2013, J VIROL, V87, P8638, DOI 10.1128/JVI.01055-13
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lu GW, 2012, PROTEIN CELL, V3, P803, DOI 10.1007/s13238-012-2811-1
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004
   Peng GQ, 2011, P NATL ACAD SCI USA, V108, P10696, DOI 10.1073/pnas.1104306108
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reguera J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002859
   Ren W, 2008, J VIROL, V82, P1899, DOI 10.1128/JVI.01085-07
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028
   Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI 10.1093/molbev/mst197
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Weihofen WA, 2004, J BIOL CHEM, V279, P43330, DOI 10.1074/jbc.M405001200
   WHO, MIDDL E RESP SYNDR C
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Woo PCY, 2009, J VIROL, V83, P908, DOI 10.1128/JVI.01977-08
   World Health Organization, CUM NUMB REP PROB CA
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200
   Xu YH, 2004, J BIOL CHEM, V279, P30514, DOI 10.1074/jbc.M403760200
   Yang Y., 2014, P NATL ACAD IN PRESS
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 53
TC 113
Z9 115
U1 4
U2 51
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD SEP 10
PY 2014
VL 16
IS 3
BP 328
EP 337
DI 10.1016/j.chom.2014.08.009
PG 10
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA AP4OL
UT WOS:000342057000010
PM 25211075
OA Bronze
DA 2020-04-03
ER

PT S
AU Bailey, CC
   Zhong, GC
   Huang, IC
   Farzan, M
AF Bailey, Charles C.
   Zhong, Guocai
   Huang, I-Chueh
   Farzan, Michael
BE Enquist, LW
TI IFITM-Family Proteins: The Cell's First Line of Antiviral Defense
SO ANNUAL REVIEW OF VIROLOGY, VOL 1
SE Annual Review of Virology
LA English
DT Article; Book Chapter
DE IFITM3; restriction factor; interferon; dengue virus; Ebola virus;
   flavivirus; influenza A virus; SARS coronavirus; viral entry
ID INDUCED TRANSMEMBRANE PROTEIN-3; VESICULAR STOMATITIS-VIRUS; IMPERFECTA
   TYPE-V; WEST NILE VIRUS; SARS CORONAVIRUS; S-PALMITOYLATION;
   INFLUENZA-VIRUS; B-LYMPHOCYTES; GENE-PRODUCTS; DENGUE VIRUS
AB Animal cells use a wide variety of mechanisms to slow or prevent replication of viruses. These mechanisms are usually mediated by antiviral proteins whose expression and activities can be constitutive but are frequently amplified by interferon induction. Among these interferon-stimulated proteins, members of the IFITM (interferon-induced transmembrane) family are unique because they prevent infection before a virus can traverse the lipid bilayer of the cell. At least three human IFITMproteins-IFITM1, IFITM2, and IFITM3-have antiviral activities. These activities limit infection in cultured cells by many viruses, including dengue virus, Ebola virus, influenza A virus, severe acute respiratory syndrome coronavirus, and West Nile virus. Murine Ifitm3 controls influenza A virus infection in vivo, and polymor-phisms in human IFITM3 correlate with the severity of both seasonal and highly pathogenic avian influenza virus. Here we review the discovery and characterization of the IFITM proteins, describe the spectrum of their antiviral activities, and discuss potential mechanisms underlying these effects.
C1 [Bailey, Charles C.; Zhong, Guocai; Farzan, Michael] Scripps Res Inst, Dept Infect Dis, Jupiter, FL 33458 USA.
   [Huang, I-Chueh] Univ Calif Riverside, Coll Nat & Agr Sci, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA.
RP Bailey, CC (reprint author), Scripps Res Inst, Dept Infect Dis, Jupiter, FL 33458 USA.
EM cbailey@scripps.edu; gzhong@scripps.edu; ichueh.huang@ucr.edu;
   mfarzan@scripps.edu
OI Farzan, Michael/0000-0002-2990-5319
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [L40 AI091009, U54 AI057159, R01 AI100953,
   R00 AI093679]
CR Alber D, 1996, J INTERF CYTOK RES, V16, P375, DOI 10.1089/jir.1996.16.375
   Almen MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031961
   Amini-Bavil-Olyaee S, 2013, CELL HOST MICROBE, V13, P452, DOI 10.1016/j.chom.2013.03.006
   Anafu AA, 2013, J BIOL CHEM, V288, P17261, DOI 10.1074/jbc.M112.438515
   Bailey CC, 2013, J BIOL CHEM, V288, P32184, DOI 10.1074/jbc.M113.514356
   Bailey CC, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002909
   Bieniasz PD, 2004, NAT IMMUNOL, V5, P1109, DOI 10.1038/ni1125
   BRADBURY LE, 1992, J IMMUNOL, V149, P2841
   Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017
   Brem R, 2003, CELL MOL LIFE SCI, V60, P1235, DOI 10.1007/s00018-003-3016-9
   Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656
   Chandran K, 2002, J VIROL, V76, P9920, DOI 10.1128/JVI.76.19.9920-9933.2002
   Chandran K, 1998, J VIROL, V72, P467, DOI 10.1128/JVI.72.1.467-475.1998
   CHEN YX, 1984, J IMMUNOL, V133, P2496
   Cho TJ, 2012, AM J HUM GENET, V91, P343, DOI 10.1016/j.ajhg.2012.06.005
   Chutiwitoonchai N, 2013, MICROBES INFECT, V15, P280, DOI 10.1016/j.micinf.2012.12.003
   DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860
   Diamond MS, 2013, NAT REV IMMUNOL, V13, P46, DOI 10.1038/nri3344
   Duggal NK, 2012, NAT REV IMMUNOL, V12, P687, DOI 10.1038/nri3295
   Ebert DH, 2002, J BIOL CHEM, V277, P24609, DOI 10.1074/jbc.M201107200
   EVANS SS, 1990, BLOOD, V76, P2583
   Everitt AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080723
   Everitt AR, 2012, NATURE, V484, P519, DOI 10.1038/nature10921
   Feeley EM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002337
   Frey M, 1997, J IMMUNOL, V158, P5424
   FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8
   Hach JC, 2013, J VIROL, V87, P9923, DOI 10.1128/JVI.00621-13
   Hanagata N, 2011, J BONE MINER METAB, V29, P279, DOI 10.1007/s00774-010-0221-0
   Hickford D, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-155
   Huang IC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001258
   Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200
   Jia R, 2014, CELL MICROBIOL, V16, P1080, DOI 10.1111/cmi.12262
   Jia R, 2012, J VIROL, V86, P13697, DOI 10.1128/JVI.01828-12
   Jiang D, 2010, J VIROL, V84, P8332, DOI 10.1128/JVI.02199-09
   Johnson MC, 2006, VET IMMUNOL IMMUNOP, V110, P357, DOI 10.1016/j.vetimm.2005.12.007
   Lange U C, 2003, BMC Dev Biol, V3, P1, DOI 10.1186/1471-213X-3-1
   Lange UC, 2008, MOL CELL BIOL, V28, P4688, DOI 10.1128/MCB.00272-08
   Li K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003124
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lin TY, 2013, CELL REP, V5, P895, DOI 10.1016/j.celrep.2013.10.033
   Lu J, 2011, J VIROL, V85, P2126, DOI 10.1128/JVI.01531-10
   MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407
   Mills TC, 2014, J INFECT DIS, V209, P1028, DOI 10.1093/infdis/jit468
   Moffatt P, 2008, J BONE MINER RES, V23, P1497, DOI 10.1359/JBMR.080412
   Mudhasani R, 2013, J VIROL, V87, P8451, DOI 10.1128/JVI.03382-12
   Oldenburg J, 2007, VIROLOGY, V364, P132, DOI 10.1016/j.virol.2007.03.003
   Pasqual G, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002232
   Raychoudhuri A, 2011, J VIROL, V85, P12881, DOI 10.1128/JVI.05633-11
   REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840
   Rojek JM, 2008, J VIROL, V82, P7677, DOI 10.1128/JVI.00560-08
   Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927
   Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907
   Semler O, 2012, AM J HUM GENET, V91, P349, DOI 10.1016/j.ajhg.2012.06.011
   Shan Z, 2013, J BIOL CHEM, V288, P35093, DOI 10.1074/jbc.M113.511949
   Shapira SD, 2009, CELL, V139, P1255, DOI 10.1016/j.cell.2009.12.018
   Smith RA, 2006, GENES IMMUN, V7, P113, DOI 10.1038/sj.gene.6364278
   Smith SE, 2013, J VIROL, V87, P12957, DOI 10.1128/JVI.01443-13
   TAKAHASHI S, 1990, J IMMUNOL, V145, P2207
   Tanaka SS, 2002, MECH DEVELOP, V119, pS261, DOI 10.1016/S0925-4773(03)00126-6
   Tanaka SS, 2005, DEV CELL, V9, P745, DOI 10.1016/j.devcel.2005.10.010
   van der Schaar HM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000244
   Wakim LM, 2013, NAT IMMUNOL, V14, P238, DOI 10.1038/ni.2525
   Wakim LM, 2012, J IMMUNOL, V189, P3462, DOI 10.4049/jimmunol.1201305
   Wang ZF, 2014, P NATL ACAD SCI USA, V111, P769, DOI 10.1073/pnas.1321748111
   Weidner JM, 2010, J VIROL, V84, P12646, DOI 10.1128/JVI.01328-10
   Wilkins C, 2013, HEPATOLOGY, V57, P461, DOI 10.1002/hep.26066
   Xu Y, 2009, ACTA BIOCH BIOPH SIN, V41, P488, DOI 10.1093/abbs/gmp034
   Yount JS, 2012, J BIOL CHEM, V287, P19631, DOI 10.1074/jbc.M112.362095
   Yount JS, 2010, NAT CHEM BIOL, V6, P610, DOI [10.1038/NCHEMBIO.405, 10.1038/nchembio.405]
   Zhang LQ, 2002, J VIROL, V76, P5654, DOI 10.1128/JVI.76.11.5654-5666.2002
   Zhang YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2433
   Zhang Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049265
   Zhu HZ, 2003, J VIROL, V77, P5493, DOI 10.1128/JVI.77.9.5493-5498.2003
   Zucchi I, 2004, P NATL ACAD SCI USA, V101, P1880, DOI 10.1073/pnas.0307292101
NR 74
TC 113
Z9 121
U1 3
U2 24
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 2327-056X
J9 ANNU REV VIROL
PY 2014
VL 1
BP 261
EP 283
DI 10.1146/annurev-virology-031413-085537
PG 23
WC Virology
SC Virology
GA BC2CK
UT WOS:000350745100014
PM 25599080
OA Green Accepted
DA 2020-04-03
ER

PT J
AU Drexler, JF
   Gloza-Rausch, F
   Glende, J
   Corman, VM
   Muth, D
   Goettsche, M
   Seebens, A
   Niedrig, M
   Pfefferle, S
   Yordanov, S
   Zhelyazkov, L
   Hermanns, U
   Vallo, P
   Lukashev, A
   Muller, MA
   Deng, HK
   Herrler, G
   Drosten, C
AF Drexler, Jan Felix
   Gloza-Rausch, Florian
   Glende, Joerg
   Corman, Victor Max
   Muth, Doreen
   Goettsche, Matthias
   Seebens, Antje
   Niedrig, Matthias
   Pfefferle, Susanne
   Yordanov, Stoian
   Zhelyazkov, Lyubomir
   Hermanns, Uwe
   Vallo, Peter
   Lukashev, Alexander
   Mueller, Marcel Alexander
   Deng, Hongkui
   Herrler, Georg
   Drosten, Christian
TI Genomic Characterization of Severe Acute Respiratory Syndrome-Related
   Coronavirus in European Bats and Classification of Coronaviruses Based
   on Partial RNA-Dependent RNA Polymerase Gene Sequences
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CROSS-SPECIES TRANSMISSION; SARS-LIKE CORONAVIRUSES; RESERVOIR HOSTS;
   HORSESHOE BATS; VIRUS; IDENTIFICATION; PROTEIN; CHINA; INFECTIONS;
   PREVALENCE
AB Bats may host emerging viruses, including coronaviruses (CoV). We conducted an evaluation of CoV in rhinolophid and vespertilionid bat species common in Europe. Rhinolophids carried severe acute respiratory syndrome (SARS)-related CoV at high frequencies and concentrations (26% of animals are positive; up to 2.4 x 108 copies per gram of feces), as well as two Alphacoronavirus clades, one novel and one related to the HKU2 clade. All three clades present in Miniopterus bats in China (HKU7, HKU8, and 1A related) were also present in European Miniopterus bats. An additional novel Alphacoronavirus clade (bat CoV [BtCoV]/BNM98-30) was detected in Nyctalus leisleri. A CoV grouping criterion was developed by comparing amino acid identities across an 816-bp fragment of the RNA-dependent RNA polymerases (RdRp) of all accepted mammalian CoV species (RdRp-based grouping units [RGU]). Criteria for defining separate RGU in mammalian CoV were a > 4.8% amino acid distance for alphacoronaviruses and a > 6.3% distance for betacoronaviruses. All the abovementioned novel clades represented independent RGU. Strict associations between CoV RGU and host bat genera were confirmed for six independent RGU represented simultaneously in China and Europe. A SARSrelated virus (BtCoV/BM48-31/Bulgaria/2008) from a Rhinolophus blasii (Rhi bla) bat was fully sequenced. It is predicted that proteins 3b and 6 were highly divergent from those proteins in all known SARS-related CoV. Open reading frame 8 (ORF8) was surprisingly absent. Surface expression of spike and staining with sera of SARS survivors suggested low antigenic overlap with SARS CoV. However, the receptor binding domain of SARS CoV showed higher similarity with that of BtCoV/BM48-31/Bulgaria/2008 than with that of any Chinese bat-borne CoV. Critical spike domains 472 and 487 were identical and similar, respectively. This study underlines the importance of assessments of the zoonotic potential of widely distributed bat-borne CoV.
C1 [Drexler, Jan Felix; Gloza-Rausch, Florian; Corman, Victor Max; Muth, Doreen; Seebens, Antje; Pfefferle, Susanne; Mueller, Marcel Alexander; Drosten, Christian] Univ Bonn, Inst Virol, Med Ctr, D-53127 Bonn, Germany.
   [Gloza-Rausch, Florian; Seebens, Antje] Ctr Bat Protect & Informat, Bad Segeberg, Germany.
   [Glende, Joerg; Herrler, Georg] Univ Vet Med, Inst Virol, Hannover, Germany.
   [Goettsche, Matthias] Univ Kiel, Inst Zool, Dept Ecol, D-24098 Kiel, Germany.
   [Niedrig, Matthias] Robert Koch Inst, D-1000 Berlin, Germany.
   [Yordanov, Stoian; Zhelyazkov, Lyubomir] Forestry Board Directorate Strandja Nat Pk, Malko Tarnovo, Bulgaria.
   [Hermanns, Uwe] Bat Conservat & Res Grp Mecklenburg Vorpommern, Rostock, Germany.
   [Vallo, Peter] Acad Sci Czech Republ, Inst Vertebrate Biol, Vvi, Brno, Czech Republic.
   [Lukashev, Alexander] Chumakov Inst Poliomyelitis & Viral Encephalitide, Moscow, Russia.
   [Deng, Hongkui] Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China.
RP Drosten, C (reprint author), Univ Bonn, Inst Virol, Med Ctr, D-53127 Bonn, Germany.
EM drosten@virology-bonn.de
RI Lukashev, Alexander/G-2777-2013; ASCR, IVB/A-9883-2011; Corman, Victor
   Max/K-1319-2019; Mueller, Marcel/O-2425-2019; Drexler, Jan
   Felix/C-1004-2014; Vallo, Peter/F-9650-2014
OI Lukashev, Alexander/0000-0001-7365-0352; Corman, Victor
   Max/0000-0002-3605-0136; Mueller, Marcel/0000-0003-2242-5117; Drexler,
   Jan Felix/0000-0002-3509-0232
FU BONFOR; European UnionEuropean Union (EU) [223498]; EVA [228292]; German
   Federal Ministry of Education and Research (BMBF)Federal Ministry of
   Education & Research (BMBF)
FX Victor Corman received a scholarship from a BONFOR intramural grant at
   the University of Bonn. This study was funded by the European Union FP7
   projects EMPERIE (grant agreement 223498) and EVA (grant agreement
   228292) and the German Federal Ministry of Education and Research (BMBF)
   via the project Ecology and Pathogenesis of SARS, an Archetypical
   Zoonosis (project code 01KIO701).
CR Becker MM, 2008, P NATL ACAD SCI USA, V105, P19944, DOI 10.1073/pnas.0808116105
   Benda Petr, 2003, Acta Societatis Zoologicae Bohemicae, V67, P245
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Cavanagh D, 1997, ARCH VIROL, V142, P629
   CHINESE SME, 2004, SCIENCE, V303, P1666, DOI DOI 10.1126/SCIENCE.1092002
   Chu DKW, 2008, J GEN VIROL, V89, P1282, DOI 10.1099/vir.0.83605-0
   Csorba G, 2003, HORSESHOE BATS WORLD
   de Groot RJ, 2008, REVISION FAMILY CORO
   Luna LKD, 2007, J CLIN MICROBIOL, V45, P1049, DOI 10.1128/JCM.02426-06
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Dietz C, 2009, HDB BATS EUROPE NW A
   Dobson AP, 2005, SCIENCE, V310, P628, DOI 10.1126/science.1120872
   Drexler JF, 2009, PLOS MED, V6, P210, DOI 10.1371/journal.pmed.1000031
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Egloff MP, 2006, J VIROL, V80, P8493, DOI 10.1128/JVI.00713-06
   Eickmann M, 2003, SCIENCE, V302, P1504
   Forster JL, 2008, J VIROL METHODS, V149, P190, DOI 10.1016/j.jviromet.2007.12.020
   Gelman A, 1996, Stat Methods Med Res, V5, P339, DOI 10.1177/096228029600500402
   Gloza-Rausch F, 2008, EMERG INFECT DIS, V14, P626, DOI 10.3201/eid1404.071439
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Halpin K, 2000, J GEN VIROL, V81, P1927, DOI 10.1099/0022-1317-81-8-1927
   ISAACS D, 1983, ARCH DIS CHILD, V58, P500, DOI 10.1136/adc.58.7.500
   Johara MY, 2001, EMERG INFECT DIS, V7, P439
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   LARSON HE, 1980, J MED VIROL, V5, P221, DOI 10.1002/jmv.1890050306
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006
   Liang GD, 2004, EMERG INFECT DIS, V10, P1774, DOI 10.3201/eid1010.040445
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Nargi-Aizenman JL, 2002, VIROLOGY, V293, P164, DOI 10.1006/viro.2001.1253
   Nel LH, 2007, CRIT REV MICROBIOL, V33, P301, DOI 10.1080/10408410701647602
   Oostra M, 2007, J VIROL, V81, P13876, DOI 10.1128/JVI.01631-07
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Pfefferle S, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-131
   Pfefferle S, 2009, EMERG INFECT DIS, V15, P1377, DOI 10.3201/eid1509.090224
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Qu XX, 2005, J BIOL CHEM, V280, P29588, DOI 10.1074/jbc.M500662200
   Ren W, 2008, J VIROL, V82, P1899, DOI 10.1128/JVI.01085-07
   Ren W, 2006, J GEN VIROL, V87, P3355, DOI 10.1099/vir.0.82220-0
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Schwegmann-Wessels C, 2006, ADV EXP MED BIOL, V581, P271
   Sheahan T, 2008, J VIROL, V82, P8721, DOI 10.1128/JVI.00818-08
   Sheahan T, 2008, J VIROL, V82, P2274, DOI 10.1128/JVI.02041-07
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Swanepoel R, 2007, EMERG INFECT DIS, V13, P1847, DOI 10.3201/eid1312.071115
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tang XC, 2006, J VIROL, V80, P7481, DOI 10.1128/JVI.00697-06
   Uhlenhaut C, 2005, J VIROL METHODS, V128, P189, DOI 10.1016/j.jviromet.2005.05.002
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   Vabret A, 2008, J PAEDIATR CHILD H, V44, P176, DOI 10.1111/j.1440-1754.2007.01246.x
   Vallo P, 2008, ACTA CHIROPTEROL, V10, P193, DOI 10.3161/150811008X414782
   Vijaykrishna D, 2007, J VIROL, V81, P4012, DOI 10.1128/JVI.02605-06
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Xu YY, 2009, J VIROL, V83, P1083, DOI 10.1128/JVI.01862-08
   Zhou HX, 2010, J VIROL, V84, P3542, DOI 10.1128/JVI.02570-09
NR 64
TC 113
Z9 118
U1 1
U2 38
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2010
VL 84
IS 21
BP 11336
EP 11349
DI 10.1128/JVI.00650-10
PG 14
WC Virology
SC Virology
GA 660LE
UT WOS:000282643400038
PM 20686038
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Taylor, MP
   Kirkegaard, K
AF Taylor, Matthew P.
   Kirkegaard, Karla
TI Modification of cellular autophagy protein LC3 by poliovirus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID VIRAL REPLICATION COMPLEX; DOUBLE-MEMBRANE VESICLES;
   ENDOPLASMIC-RETICULUM; SARS-CORONAVIRUS; RNA REPLICATION; IN-VITRO;
   CELLS; VIRUS; YEAST; INHIBITION
AB Poliovirus infection remodels intracellular membranes, creating a large number of membranous vesicles on which viral RNA replication occurs. Poliovirus-induced vesicles display hallmarks of cellular autophagosomes, including delimiting double membranes surrounding the cytosolic lumen, acquisition of the endosomal marker LAMP-1, and recruitment of the 18-kDa host protein LC3. Autophagy results in the covalent lipidation of LC3, conferring the property of membrane association to this previously microtubule-associated protein and providing a biochemical marker for the induction of autophagy. Here, we report that a similar modification of LC3 occurs both during poliovirus infection and following expression of a single viral protein, a stable precursor termed 2BC. Therefore, one of the early steps in cellular autophagy, LC3 modification, can be genetically separated from the induction of double-membraned vesicles that contain the modified LC3, which requires both viral proteins 2BC and 3A. The existence of viral inducers that promote a distinct aspect of the formation of autophagosome-like membranes both facilitates the dissection of this cellular process and supports the hypothesis that this branch of the innate immune response is directly subverted by poliovirus.
C1 [Taylor, Matthew P.; Kirkegaard, Karla] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.
RP Kirkegaard, K (reprint author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, 299 Campus Dr, Stanford, CA 94305 USA.
EM karlak@stanford.edu
OI Taylor, Matthew/0000-0003-0199-7175
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI048756, AI048756]; NIGMS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [GM007276, T32 GM007276]
CR BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8
   Bilir A, 2001, PATHOBIOLOGY, V69, P120, DOI 10.1159/000048766
   Bursch W, 2000, J CELL SCI, V113, P1189
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Chang CP, 2007, HEPATOLOGY, V45, P286, DOI 10.1002/hep.21509
   Chen JB, 2003, J VIROL, V77, P2568, DOI 10.1128/JVI.77.4.2568-2577.2003
   CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329
   Cuconati A, 1998, J VIROL, V72, P1297, DOI 10.1128/JVI.72.2.1297-1307.1998
   DALES S, 1965, VIROLOGY, V26, P379, DOI 10.1016/0042-6822(65)90001-2
   Dodd DA, 2001, J VIROL, V75, P8158, DOI 10.1128/JVI.75.17.8158-8165.2001
   Doedens JR, 1997, J VIROL, V71, P9054, DOI 10.1128/JVI.71.12.9054-9064.1997
   DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x
   DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923
   Gutierrez MG, 2007, P NATL ACAD SCI USA, V104, P1829, DOI 10.1073/pnas.0601437104
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   GUINEA R, 1990, EMBO J, V9, P2011, DOI 10.1002/j.1460-2075.1990.tb08329.x
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8
   Kirkegaard K, 2005, AUTOPHAGY, V1, P182, DOI 10.4161/auto.1.3.2065
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x
   Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005
   Lyle JM, 2002, SCIENCE, V296, P2218, DOI 10.1126/science.1070585
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   MOSSER AG, 1972, VIROLOGY, V47, P30, DOI 10.1016/0042-6822(72)90235-8
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391
   Reggiori F, 2005, CURR OPIN CELL BIOL, V17, P415, DOI 10.1016/j.ceb.2005.06.007
   Salonen A, 2005, CURR TOP MICROBIOL, V285, P139
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996
   Snijder EJ, 2001, J GEN VIROL, V82, P985, DOI 10.1099/0022-1317-82-5-985
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Sou Y, 2006, J BIOL CHEM, V281, P3017, DOI 10.1074/jbc.M505888200
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000
   Swanson MS, 2006, J IMMUNOL, V177, P4945, DOI 10.4049/jimmunol.177.8.4945
   Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200
   Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040
   Wileman T, 2006, SCIENCE, V312, P875, DOI 10.1126/science.1126766
NR 52
TC 113
Z9 125
U1 1
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 2007
VL 81
IS 22
BP 12543
EP 12553
DI 10.1128/JVI.00755-07
PG 11
WC Virology
SC Virology
GA 275IP
UT WOS:000254065400045
PM 17804493
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Jiang, Y
   Xu, J
   Zhou, CZ
   Wu, ZG
   Zhong, SQ
   Liu, JH
   Luo, W
   Chen, T
   Qin, QH
   Deng, P
AF Jiang, Y
   Xu, J
   Zhou, CZ
   Wu, ZG
   Zhong, SQ
   Liu, JH
   Luo, W
   Chen, T
   Qin, QH
   Deng, P
TI Characterization of cytokine/chemokine profiles of severe acute
   respiratory syndrome
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE chemokine; coronavirus; cytokine; severe acute respiratory; syndrome
ID INTERFERON-INDUCIBLE PROTEIN-10; SARS-ASSOCIATED CORONAVIRUS; CXC
   CHEMOKINES IP-10; INFLUENZA-A; HUMAN MACROPHAGES; EPITHELIAL-CELLS; LUNG
   PATHOLOGY; T-CELLS; CYTOKINES; INFECTION
AB Rationale: There is currently no optimal treatment or effective drug for severe acute respiratory syndrome (SARS), because the immunopathologic mechanism is poorly understood. Objectives: To explore the immune mechanism underlying the pathogenesis of SARS, we studied the expression profile of cytokines/chemokines in the blood and the immunopathology of the lung and lymphoid tissues. Methods: Fourteen cytokines/chemokines in the blood of 23 patients with SARS were dynamically screened, using a bead-based multlassay system. Reverse transcription-polymerase chain reaction was performed to amplify mRNA. Histopathology of the lung and lymphoid tissues at autopsy was examined, using methods of immunohistochemistry and double immunofluorescence staining. Main Results: Interferon-inducible protein-10 (IP-10) was markedly elevated in the blood during the early stage of SARS, and remained at a high level until convalescence. Moreover, IP-10 was highly expressed in both lung and lymphoid tissues, where monocyte-macrophage infiltration and depletion of lymphocytes were observed. The levels of interleukin-6, interieukin-8, and monocyte chemoattractant protein-1 were concomitantly increased in the blood of the patients with superinfection, and the mRNAs for these cytokines were also increased in lung tissues. Conclusions: Induction of IP-10 is a critical event in the initiation of immune-mediated acute lung injury and lymphocyte apoptosis during the development of SARS. Superinfection after the immune injury is the main cause of death. The prompt elevation of interleukin-6, interieukin-8, and monocyte chemoattractant protein-1 is a sign of superinfection, indicating a high risk of death.
C1 So Med Univ, Dept Pathophysiol, Key Lab Funct Proteom Guangdong Province, Guangzhou 510515, Peoples R China.
   Guangzhou Inst Resp Dis, Guangzhou, Peoples R China.
   Hong Kong Univ Sci & Technol, Hong Kong, Hong Kong, Peoples R China.
RP Jiang, Y (reprint author), So Med Univ, Dept Pathophysiol, Key Lab Funct Proteom Guangdong Province, Guangzhou 510515, Peoples R China.
EM yjiang@fimmu.com; xufeili@vip.163.com
OI Wu, Zhenguo/0000-0003-3049-8324
CR Agostini C, 2000, AM J RESP CRIT CARE, V162, P1466, DOI 10.1164/ajrccm.162.4.2003130
   Arai K, 2002, CELL IMMUNOL, V219, P48, DOI 10.1016/S0008-8749(02)00584-1
   Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563
   Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491
   Cebulla CM, 1999, INTERVIROLOGY, V42, P325, DOI 10.1159/000053968
   Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7
   Christen U, 2004, J CLIN INVEST, V113, P74, DOI 10.1172/JCI200417005
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195
   Enserink M, 2004, SCIENCE, V303, P1273
   Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8
   Fry D E, 2000, Surg Infect (Larchmt), V1, P155, DOI 10.1089/109629600750018088
   Geppert A, 2002, CRIT CARE MED, V30, P1987, DOI 10.1097/00003246-200209000-00007
   Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Hoey J, 2003, CAN MED ASSOC J, V168, P1566
   Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI200318819, 10.1172/JCI18819]
   Holmes KV, 2003, NEW ENGL J MED, V348, P1948, DOI 10.1056/NEJMp030078
   Hsueh PR, 2003, EMERG INFECT DIS, V9, P1163
   Hutchinson KL, 2001, J MED VIROL, V65, P561, DOI 10.1002/jmv.2073
   Jones BM, 2004, CLIN EXP IMMUNOL, V135, P467, DOI 10.1111/j.1365-2249.2003.02391.x
   Julkunen I, 2000, VACCINE, V19, pS32, DOI 10.1016/S0264-410X(00)00275-9
   Kelley VR, 2003, SPRINGER SEMIN IMMUN, V24, P411, DOI 10.1007/s00281-003-0124-4
   Kieseier BC, 2002, BRAIN, V125, P823, DOI 10.1093/brain/awf070
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lane BR, 2003, VIROLOGY, V307, P122, DOI 10.1016/S0042-6822(02)00045-4
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu MT, 2001, J IMMUNOL, V167, P4091, DOI 10.4049/jimmunol.167.7.4091
   Liu MT, 2000, J IMMUNOL, V165, P2327, DOI 10.4049/jimmunol.165.5.2327
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mason DY, 2000, J PATHOL, V191, P452
   Matikainen S, 2000, VIROLOGY, V276, P138, DOI 10.1006/viro.2000.0542
   Ng PC, 2004, PEDIATRICS, V113, pE7, DOI 10.1542/peds.113.1.e7
   Ng PC, 2003, ARCH DIS CHILD, V88, P209
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   O'Donnell R, 2003, BRIT MED J, V327, P620, DOI 10.1136/bmj.327.7415.620-b
   Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001
   Openshaw PJM, 2004, CLIN EXP IMMUNOL, V136, P11, DOI 10.1111/j.1365-2249.2004.02448.x
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5
   Romagnani P, 2001, BLOOD, V97, P601, DOI 10.1182/blood.V97.3.601
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Sauty A, 1999, J IMMUNOL, V162, P3549
   Sgadari C, 1996, P NATL ACAD SCI USA, V93, P13791, DOI 10.1073/pnas.93.24.13791
   Stroher U, 2004, J INFECT DIS, V189, P1164, DOI 10.1086/382597
   Tsang KW, 2003, AM J RESP CRIT CARE, V168, P417, DOI 10.1164/rccm.2305012
   von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407
   Wetzel MA, 2002, VIROLOGY, V292, P6, DOI 10.1006/viro.2001.1249
   Williams BRG, 2003, SCIENCE, V300, P1100, DOI 10.1126/science.1085277
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   World Health Organization, CUM NUMB REP PROB CA
   Zhong NS, 2003, AM J RESP CRIT CARE, V168, P7, DOI 10.1164/rccm.200305-707OE
NR 58
TC 113
Z9 132
U1 3
U2 9
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD APR 15
PY 2005
VL 171
IS 8
BP 850
EP 857
DI 10.1164/rccm.200407-857OC
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 916VP
UT WOS:000228414800009
PM 15657466
DA 2020-04-03
ER

PT J
AU Fauci, AS
   Touchette, NA
   Folkers, GK
AF Fauci, AS
   Touchette, NA
   Folkers, GK
TI Emerging infectious diseases: a 10-year perspective from the National
   Institute of Allergy and Infectious Diseases
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; SMALLPOX VACCINE; GENOME SEQUENCE;
   SPIKE PROTEIN; EFFICACY; SARS; NEUTRALIZATION; TUBERCULOSIS; RESISTANCE;
   CHALLENGE
AB Although optimists once imagined that serious infectious disease threats would by now be conquered, newly emerging (e.g., severe acute respiratory syndrome [SARS]), reemerging (e.g., West Nile virus), and even deliberately disseminated infectious diseases (e.g., anthrax bioterrorism) continue to appear throughout the world. Over the past decade, the global effort to identify and characterize infectious agents, decipher the underlying pathways by which they cause disease, and develop preventive measures and treatments for many of the world's most dangerous pathogens has resulted in considerable progress. Intramural and extramural investigators supported by the National Institute of Allergy and Infectious Diseases (NIAID) have contributed substantially to this effort. This overview highlights selected NIAID-sponsored research advances over the past decade, with a focus on progress in combating HIV/AIDS, malaria, tuberculosis, influenza, SARS, West Nile virus, and potential bioterror agents. Many basic research discoveries have been translated into novel diagnostics, antiviral and antimicrobial compounds, and vaccines, often with extraordinary speed.
C1 NIAID, NIH, Bethesda, MD 20892 USA.
RP Touchette, NA (reprint author), NIAID, NIH, 9000 Rockville Pike,Bldg 31,Room 7A05, Bethesda, MD 20892 USA.
EM ntouchette@niaid.nih.gov
CR Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Borovsky D, 2003, J EXP BIOL, V206, P3869, DOI 10.1242/jeb.00602
   Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X
   Butcher PD, 2004, TUBERCULOSIS, V84, P131, DOI 10.1016/j.tube.2004.01.002
   *CDCP, INFL WEB PAG
   *CDCP, 2003, HIV AIDS SURV REP 20
   de la Salmoniere YOLG, 2004, J CLIN MICROBIOL, V42, P2913, DOI 10.1128/JCM.42.7.2913-2918.2004
   Earl PL, 2004, NATURE, V428, P182, DOI 10.1038/nature02331
   Fauci AS, 2001, CLIN INFECT DIS, V32, P675, DOI 10.1086/319235
   Fauci AS, 2003, NAT MED, V9, P839, DOI 10.1038/nm0703-839
   Fidock DA, 2004, NAT REV DRUG DISCOV, V3, P509, DOI 10.1038/nrd1416
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Graham BS, 2005, J INFECT DIS, V191, P647, DOI 10.1086/428406
   Hall RA, 2004, EXPERT OPIN BIOL TH, V4, P1295, DOI 10.1517/14712598.4.8.1295
   Harper Scott A, 2003, MMWR Recomm Rep, V52, P1
   Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882
   Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181
   Horwitz MA, 2003, INFECT IMMUN, V71, P1672, DOI 10.1128/IAI.71.4.1672-1679.2003
   Infectious Diseases Society of America, 2004, BAD BUGS NO DRUGS AN
   Institute of Medicine, 2003, MICR THREATS HLTH EM
   Jacobs-Lorena Marcelo, 2003, Journal of Vector Borne Diseases, V40, P73
   Jernigan DB, 2002, EMERG INFECT DIS, V8, P1019, DOI 10.3201/eid0810.020353
   Johnson DJ, 2004, MOL CELL, V15, P867, DOI 10.1016/j.molcel.2004.09.012
   Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916
   Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951
   Komar Nicholas, 2003, Adv Virus Res, V61, P185
   MAASSAB HF, 1969, B WORLD HEALTH ORGAN, V41, P589
   Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759
   *NAT CTR BIOT INF, 2005, ENTR GEN
   *NAT I ALL INF DIS, 2004, PRESS REL
   *NAT I ALL INF DIS, 2005, TUB ANC EN PRES THRE
   *NAT I ALL INF DIS, NIAID RES SEV AC RES
   *NAT I ALL INF DIS, 2005, NIAID BIOD RES
   Reed SG, 2003, TUBERCULOSIS, V83, P213, DOI 10.1016/S1472-9792(02)00080-X
   Shimoni Z, 2001, EMERG INFECT DIS, V7, P759
   Sidhu ABS, 2002, SCIENCE, V298, P210, DOI 10.1126/science.1074045
   Skeiky YAW, 2004, J IMMUNOL, V172, P7618, DOI 10.4049/jimmunol.172.12.7618
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876
   Titball RW, 2004, EXPERT OPIN BIOL TH, V4, P965, DOI 10.1517/14712598.4.6.965
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   (UNAIDS) Joint United Nations Program on HIV/AIDS, 2004, 2004 REP GLOB AIDS E
   Webby RJ, 2004, LANCET, V363, P1099, DOI 10.1016/S0140-6736(04)15892-3
   *WHO, 2005, INFL WEB PAG
   *WHO, 2004, PORTF MAL VACC CURR
   WHO, 2004, WORLD HLTH REP 2004
   Wyatt LS, 2004, P NATL ACAD SCI USA, V101, P4590, DOI 10.1073/pnas.0401165101
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
NR 49
TC 113
Z9 120
U1 1
U2 12
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD APR
PY 2005
VL 11
IS 4
BP 519
EP 525
DI 10.3201/eid1104.041167
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 910OH
UT WOS:000227940700001
PM 15829188
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Fischer, F
   Stegen, CF
   Masters, PS
   Samsonoff, WA
AF Fischer, F
   Stegen, CF
   Masters, PS
   Samsonoff, WA
TI Analysis of constructed E gene mutants of mouse hepatitis virus confirms
   a pivotal role for E protein in coronavirus assembly
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SYSTEMATIC MUTATIONAL ANALYSIS; TARGETED RNA RECOMBINATION; OPEN READING
   FRAME; SEMLIKI FOREST VIRUS; MURINE CORONAVIRUS; NUCLEOCAPSID PROTEIN;
   MEMBRANE-PROTEIN; BOVINE CORONAVIRUS; ENVELOPE PROTEIN; DELETION MUTANT
AB Expression studies have shown that the coronavirus small envelope protein E and the much more abundant membrane glycoprotein M are both necessary and sufficient for the assembly of virus-like particles in cells. As a step toward understanding the function of the mouse hepatitis virus (MHV) E protein, we carried out clustered charged to-alanine mutagenesis on the E gene and incorporated the resulting mutations into the MHV genome by targeted recombination. Of the four possible clustered charged-to-alanine E gene mutants, one was apparently lethal and one had a wild-type phenotype. The two other mutants were partially temperature sensitive, forming small plaques at the nonpermissive temperature. Revertant analyses of these two mutants demonstrated that the created mutations were responsible for the temperature-sensitive phenotype of each and provided support for possible interactions among E protein monomers. Both temperature-sensitive mutants were also found to be markedly thermolabile when grown at the permissive temperature, suggesting that there was a flaw in their assembly. Most significantly, when virions of one of the mutants were examined by electron microscopy, they were found to have strikingly aberrant morphology in comparison to the wild type: most mutant virions had pinched and elongated shapes that were rarely seen among wild-type virions. These results demonstrate an important, probably essential, role for the E protein in coronavirus morphogenesis.
C1 SUNY Albany, Dept Biomed Sci, Albany, NY USA.
   SUNY Albany, Dept Sci Biol, Albany, NY USA.
   New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA.
RP Masters, PS (reprint author), NYSDOH, David Axelrod Inst, Wadsworth Ctr, New Scotland Ave,POB 22002, Albany, NY 12201 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 39544, R01 AI039544]
CR ABRAHAM S, 1990, VIROLOGY, V177, P488, DOI 10.1016/0042-6822(90)90513-Q
   BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498
   BENNETT WF, 1991, J BIOL CHEM, V266, P5191
   Bos ECW, 1996, VIROLOGY, V218, P52, DOI 10.1006/viro.1996.0165
   BOURSNELL MEG, 1985, J GEN VIROL, V66, P2253, DOI 10.1099/0022-1317-66-10-2253
   BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242
   Brian DA, 1995, CORONAVIRIDAE, P165
   BUDZILOWICZ CJ, 1987, VIROLOGY, V157, P509, DOI 10.1016/0042-6822(87)90293-5
   de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998
   DECIMO D, 1993, ARCH VIROL, V130, P279, DOI 10.1007/BF01309660
   DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994
   FICHOT O, 1990, NUCLEIC ACIDS RES, V18, P6162, DOI 10.1093/nar/18.20.6162
   Fischer F, 1997, J VIROL, V71, P5148, DOI 10.1128/JVI.71.7.5148-5160.1997
   Fischer F, 1997, J VIROL, V71, P996, DOI 10.1128/JVI.71.2.996-1003.1997
   FOSMIRE JA, 1992, J VIROL, V66, P3522, DOI 10.1128/JVI.66.6.3522-3530.1992
   GODET M, 1992, VIROLOGY, V188, P666, DOI 10.1016/0042-6822(92)90521-P
   HASSETT DE, 1994, P NATL ACAD SCI USA, V91, P4554, DOI 10.1073/pnas.91.10.4554
   Horton R.M., 1991, DIRECTED MUTAGENESIS, P217
   Hsue B, 1997, J VIROL, V71, P7567, DOI 10.1128/JVI.71.10.7567-7578.1997
   IVANOVA L, 1995, VIROLOGY, V206, P1027, DOI 10.1006/viro.1995.1025
   KINGSMAN SM, 1980, VIROLOGY, V101, P458, DOI 10.1016/0042-6822(80)90459-6
   KOETZNER CA, 1992, J VIROL, V66, P1841, DOI 10.1128/JVI.66.4.1841-1848.1992
   LEIBOWITZ JL, 1988, VIROLOGY, V164, P156, DOI 10.1016/0042-6822(88)90631-9
   LILJESTROM P, 1991, J VIROL, V65, P4107
   LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S
   LIU DX, 1991, VIROLOGY, V184, P531, DOI 10.1016/0042-6822(91)90423-9
   LOEWY A, 1995, J VIROL, V69, P469, DOI 10.1128/JVI.69.1.469-475.1995
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   MASTERS PS, 1994, J VIROL, V68, P328, DOI 10.1128/JVI.68.1.328-337.1994
   PARKER MA, UNPUB
   PARKER MM, 1990, VIROLOGY, V179, P463, DOI 10.1016/0042-6822(90)90316-J
   PENG D, 1995, J VIROL, V69, P3449, DOI 10.1128/JVI.69.6.3449-3457.1995
   PENG D, 1995, J VIROL, V69, P5475, DOI 10.1128/JVI.69.9.5475-5484.1995
   REIJO RA, 1994, MOL BIOL CELL, V5, P29
   Sambrook J., 1989, MOL CLONING LAB MANU
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SCHWARZ B, 1990, J VIROL, V64, P4784, DOI 10.1128/JVI.64.10.4784-4791.1990
   SENANAYAKE SD, 1992, J VIROL, V66, P5277, DOI 10.1128/JVI.66.9.5277-5283.1992
   SIDDELL SG, 1995, CORONAVIRIDAE, P1
   SKINNER MA, 1985, J GEN VIROL, V66, P593, DOI 10.1099/0022-1317-66-3-593
   SKINNER MA, 1985, J GEN VIROL, V66, P581, DOI 10.1099/0022-1317-66-3-581
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   WEISS SR, 1993, ARCH VIROL, V129, P301, DOI 10.1007/BF01316905
   WERTMAN KF, 1992, GENETICS, V132, P337
   Xiang WK, 1995, RNA, V1, P892
   YOKOMORI K, 1991, J VIROL, V65, P5605, DOI 10.1128/JVI.65.10.5605-5608.1991
   YU X, 1994, VIROLOGY, V202, P1018, DOI 10.1006/viro.1994.1430
NR 47
TC 113
Z9 118
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD OCT
PY 1998
VL 72
IS 10
BP 7885
EP 7894
DI 10.1128/JVI.72.10.7885-7894.1998
PG 10
WC Virology
SC Virology
GA 118WN
UT WOS:000075864100020
PM 9733825
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Reusken, CB
   Ababneh, M
   Raj, VS
   Meyer, B
   Eljarah, A
   Abutarbush, S
   Godeke, GJ
   Bestebroer, TM
   Zutt, I
   Muller, MA
   Bosch, BJ
   Rottier, PJ
   Osterhaus, AD
   Drosten, C
   Haagmans, BL
   Koopmans, MP
AF Reusken, C. B.
   Ababneh, M.
   Raj, V. S.
   Meyer, B.
   Eljarah, A.
   Abutarbush, S.
   Godeke, G. J.
   Bestebroer, T. M.
   Zutt, I.
   Mueller, M. A.
   Bosch, B. J.
   Rottier, P. J.
   Osterhaus, A. D.
   Drosten, C.
   Haagmans, B. L.
   Koopmans, M. P.
TI Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in
   major livestock species in an affected region in Jordan, June to
   September 2013
SO EUROSURVEILLANCE
LA English
DT Article
AB Between June and September 2013, sera from 11 dromedary camels, 150 goats, 126 sheep and 91 cows were collected in Jordan, where the first human Middle-East respiratory syndrome (MERS) cluster appeared in 2012. All sera were tested for MERS-coronavirus (MERS-CoV) specific antibodies by protein microarray with confirmation by virus neutralisation. Neutralising antibodies were found in all camel sera while sera from goats and cattle tested negative. Although six sheep sera reacted with MERS-CoV antigen, neutralising antibodies were not detected.
C1 [Reusken, C. B.; Godeke, G. J.; Zutt, I.; Koopmans, M. P.] Natl Inst Publ Hlth & Environm, Div Virol, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands.
   [Reusken, C. B.; Raj, V. S.; Bestebroer, T. M.; Osterhaus, A. D.; Haagmans, B. L.; Koopmans, M. P.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
   [Ababneh, M.] Jordan Univ Sci & Technol, Fac Vet Med, Dept Vet Basic Med Sci, Irbid, Jordan.
   [Meyer, B.; Mueller, M. A.; Drosten, C.] Univ Bonn, Inst Virol, Med Ctr, Bonn, Germany.
   [Eljarah, A.; Abutarbush, S.] Jordan Univ Sci & Technol, Fac Vet Med, Dept Vet Clin Sci, Irbid, Jordan.
   [Bosch, B. J.; Rottier, P. J.] Univ Utrecht, Div Virol, Dept Infect Dis & Immunol, Fac Vet Med, Utrecht, Netherlands.
RP Reusken, CB (reprint author), Natl Inst Publ Hlth & Environm, Div Virol, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands.
EM chantal.reusken@rivm.nl
RI Mueller, Marcel/O-2425-2019; Raj, V Stalin/E-9670-2016; Meyer,
   Bernhard/Q-9413-2016; Meyer, Benjamin/F-3285-2018; Koopmans,
   Marion/Y-9170-2019
OI Mueller, Marcel/0000-0003-2242-5117; Raj, V Stalin/0000-0003-2250-8481;
   Meyer, Benjamin/0000-0003-0601-3550; Koopmans,
   Marion/0000-0002-5204-2312; Haagmans, Bart/0000-0001-6221-2015
FU European UnionEuropean Union (EU) [223498]; ANTIGONE [278976]
FX Janko van Beek is acknowledged for assistance with figure 2. BH, CD and
   AO were funded by the European Union FP7 project EMPERIE (contract
   number 223498). AO, CD and MK were funded by ANTIGONE (contract number
   278976).
CR Cotten M, 2013, LANCET
   Cotten M, 2013, EMERG INFECT DIS, V19, P736, DOI 10.3201/eid1905.130057
   Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3
   Hijawi B, 2013, E MEDITERR HEALTH J, V19, pS12
   Penttinen PM, 2013, EUROSURVEILLANCE, V18
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Reusken C, 2013, EUROSURVEILLANCE, V18, P2, DOI 10.2807/1560-7917.ES2013.18.14.20441
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Wernery U, 2001, J VET MED B, V48, P561, DOI 10.1046/j.1439-0450.2001.00478.x
   World Health Organization Global Alert and Response (GAR), GLOB AL RESP GAR MID
NR 10
TC 112
Z9 119
U1 1
U2 27
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD DEC 12
PY 2013
VL 18
IS 50
BP 14
EP 20
AR 20662
DI 10.2807/1560-7917.ES2013.18.50.20662
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 275ON
UT WOS:000328686800004
PM 24342516
OA DOAJ Gold
DA 2020-04-03
ER

PT J
AU Erles, K
   Toomey, C
   Brooks, HW
   Brownlie, J
AF Erles, K
   Toomey, C
   Brooks, HW
   Brownlie, J
TI Detection of a group 2 coronavirus in dogs with canine infectious
   respiratory disease
SO VIROLOGY
LA English
DT Article
DE coronavirus; canine respiratory disease; kennel cough
ID VIRUSES
AB An investigation into the causes of canine infectious respiratory disease was carried out in a large rehoming kennel. Tissue samples taken from the respiratory tract of diseased dogs were tested for the presence of coronaviruses using RT-PCR with conserved primers for the polymerase gene. Sequence analysis of four positive samples showed the presence of a coronavirus with high similarity to both bovine and human coronavirus (strain OC43) in their polymerase and spike genes, whereas there was a low similarity to comparable genes in the enteric canine coronavirus. This canine respiratory coronavirus (CRCV) was detected by RT-PCR in 32/119 tracheal and 20/119 lung samples, with the highest prevalence being detected in dogs with mild clinical symptoms. Serological analysis showed that the presence of antibodies against CRCV on the day of entry into the kennel decreased the risk of developing respiratory disease. (C) 2003 Elsevier Science (USA). All rights reserved.
C1 Univ London Royal Vet Coll, Dept Pathol & Infectious Dis, Hatfield AL9 7TA, Herts, England.
RP Erles, K (reprint author), Univ London Royal Vet Coll, Dept Pathol & Infectious Dis, Hawkshead Lane, Hatfield AL9 7TA, Herts, England.
EM kerles@rvc.ac.uk
CR Appel MJ, 1987, VIRUS INFECT CARNIVO, P201
   APPEL MJG, 1970, J AM VET MED ASSOC, V156, P1778
   BEMIS DA, 1977, J INFECT DIS, V135, P753, DOI 10.1093/infdis/135.5.753
   BEMIS DA, 1977, CORNELL VET, V67, P282
   BINN LN, 1967, P SOC EXP BIOL MED, V126, P140, DOI 10.3181/00379727-126-32386
   BINN LN, 1979, LAB ANIM SCI, V29, P48
   Chilvers MA, 2001, EUR RESPIR J, V18, P965, DOI 10.1183/09031936.01.00093001
   DITCHFIELD J., 1962, CANADIAN VET JOUR, V3, P238
   Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Ignjatovic J, 2000, REV SCI TECH OIE, V19, P493, DOI 10.20506/rst.19.2.1228
   KARPAS A, 1968, P SOC EXP BIOL MED, V127, P45, DOI 10.3181/00379727-127-32618
   Keil DJ, 1998, J AM VET MED ASSOC, V212, P200
   LOU TY, 1963, AM J HYG, V77, P293, DOI 10.1093/oxfordjournals.aje.a120320
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   PEARSON WR, 1990, METHOD ENZYMOL, V183, P63
   PENSAERT M, 1986, VET QUART, V8, P257, DOI 10.1080/01652176.1986.9694050
   RANDOLPH JF, 1993, AM J VET RES, V54, P387
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9
   Storz J, 2000, J AM VET MED ASSOC, V216, P1599, DOI 10.2460/javma.2000.216.1599
   TENNANT BJ, 1993, VET REC, V132, P7, DOI 10.1136/vr.132.1.7
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
NR 23
TC 112
Z9 119
U1 1
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUN 5
PY 2003
VL 310
IS 2
BP 216
EP 223
DI 10.1016/S0042-6822(03)00160-0
PG 8
WC Virology
SC Virology
GA 688YM
UT WOS:000183464900003
PM 12781709
OA Bronze
DA 2020-04-03
ER

PT J
AU KUSTERS, JG
   JAGER, EJ
   NIESTERS, HGM
   VANDERZEIJST, BAM
AF KUSTERS, JG
   JAGER, EJ
   NIESTERS, HGM
   VANDERZEIJST, BAM
TI SEQUENCE EVIDENCE FOR RNA RECOMBINATION IN FIELD ISOLATES OF AVIAN
   CORONAVIRUS INFECTIOUS-BRONCHITIS VIRUS
SO VACCINE
LA English
DT Article
C1 STATE UNIV UTRECHT,INST INFECT DIS & IMMUNOL,POB 80165,3508 TD UTRECHT,NETHERLANDS.
   STATE UNIV UTRECHT,INST MOLEC BIOL & MED BIOTECHNOL,3508 TD UTRECHT,NETHERLANDS.
RI Van der Zeijst, Bernard B.A./A-3847-2013; Van der Zeijst,
   Bernard/AAH-1415-2020; Niesters, Hubert/AAH-6808-2019
OI Van der Zeijst, Bernard B.A./0000-0001-9316-2161; Van der Zeijst,
   Bernard/0000-0001-9316-2161; Niesters, Hubert/0000-0002-1758-0430
CR BINNS MM, 1986, J GEN VIROL, V67, P2825, DOI 10.1099/0022-1317-67-12-2825
   BINNS MM, 1985, J GEN VIROL, V66, P719, DOI 10.1099/0022-1317-66-4-719
   CAVANAGH D, 1986, VIRUS RES, V4, P133, DOI 10.1016/0168-1702(86)90037-7
   CAVANAGH D, 1984, AVIAN PATHOL, V13, P573, DOI 10.1080/03079458408418556
   CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435
   CAVANAGH D, 1988, J GEN VIROL, V69, P621, DOI 10.1099/0022-1317-69-3-621
   COOK JKA, 1984, AVIAN PATHOL, V13, P733, DOI 10.1080/03079458408418570
   DAVELAAR FG, 1984, VET QUART, V6, P114, DOI 10.1080/01652176.1984.9693924
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   KECK JG, 1988, J VIROL, V62, P1810, DOI 10.1128/JVI.62.5.1810-1813.1988
   KOCH G, 1986, ISR J VET MED, V41, P89
   KUSTERS JG, 1987, J GEN VIROL, V68, P343, DOI 10.1099/0022-1317-68-2-343
   KUSTERS JG, 1989, VIROLOGY, V169, P217, DOI 10.1016/0042-6822(89)90058-5
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MOCKETT APA, 1984, J GEN VIROL, V65, P2281, DOI 10.1099/0022-1317-65-12-2281
   NIESTERS HGM, 1986, VIRUS RES, V5, P253, DOI 10.1016/0168-1702(86)90022-5
   QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581
   STERN DF, 1982, J VIROL, V44, P794, DOI 10.1128/JVI.44.3.794-803.1982
   SUTOU S, 1988, VIROLOGY, V165, P589, DOI 10.1016/0042-6822(88)90603-4
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
NR 21
TC 112
Z9 125
U1 0
U2 2
PU BUTTERWORTH-HEINEMANN LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB
SN 0264-410X
J9 VACCINE
JI Vaccine
PD DEC
PY 1990
VL 8
IS 6
BP 605
EP 608
DI 10.1016/0264-410X(90)90018-H
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA EM444
UT WOS:A1990EM44400018
PM 1708184
DA 2020-04-03
ER

PT J
AU Cowling, BJ
   Park, M
   Fang, VJ
   Wu, P
   Leung, GM
   Wu, JT
AF Cowling, B. J.
   Park, M.
   Fang, V. J.
   Wu, P.
   Leung, G. M.
   Wu, J. T.
TI Preliminary epidemiological assessment of MERS-CoV outbreak in South
   Korea, May to June 2015
SO EUROSURVEILLANCE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; HONG-KONG
AB South Korea is experiencing the largest outbreak of Middle East respiratory syndrome coronavirus infections outside the Arabian Peninsula, with 166 laboratory-confirmed cases, including 24 deaths up to 19 June 2015. We estimated that the mean incubation period was 6.7 days and the mean serial interval 12.6 days. We found it unlikely that infectiousness precedes symptom onset. Based on currently available data, we predict an overall case fatality risk of 21% (95% credible interval: 14-31).
C1 [Cowling, B. J.; Park, M.; Fang, V. J.; Wu, P.; Leung, G. M.; Wu, J. T.] Univ Hong Kong, Sch Publ Hlth, Collaborating Ctr Infect Dis Epidemiol & Control, WHO,Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
RP Cowling, BJ (reprint author), Univ Hong Kong, Sch Publ Hlth, Collaborating Ctr Infect Dis Epidemiol & Control, WHO,Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
EM joewu@hku.hk
RI Cowling, Benjamin John/C-4263-2009; Wu, Joseph Tsz Kei/C-4450-2009
OI Cowling, Benjamin John/0000-0002-6297-7154; Leung,
   Gabriel/0000-0002-2503-6283; Wu, Peng/0000-0003-1157-9401; Wu, Joseph
   Tsz Kei/0000-0002-3155-5987
FU Harvard Center for Communicable Disease Dynamics from the National
   Institute of General Medical Sciences [U54 GM088558]; Health and Medical
   Research Fund, Food and Health Bureau, Government of the Hong Kong
   Special Administrative Region [14131432, HKS-15-E05]
FX This research was supported by the Harvard Center for Communicable
   Disease Dynamics from the National Institute of General Medical Sciences
   (grant no. U54 GM088558), the Health and Medical Research Fund, Food and
   Health Bureau, Government of the Hong Kong Special Administrative Region
   (grant no. 14131432), and a commissioned grant from the Health and
   Medical Research Fund, Food and Health Bureau, Government of the Hong
   Kong Special Administrative Region (grant no. HKS-15-E05). The funding
   bodies had no role in study design, data collection and analysis,
   preparation of the manuscript, or the decision to publish.
CR Al-Tawfiq JA, 2014, CLIN INFECT DIS, V59, P160, DOI 10.1093/cid/ciu226
   [Anonymous], 2015, RAPID RISK ASSESSMEN
   [Anonymous], 2013, PLOS CURR, P5, DOI DOI 10.1371/CURRENTS.OUTBREAKS.0BF719E352E7478F8AD85FA30127DDB8
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Breban R, 2013, LANCET, V382, P694, DOI 10.1016/S0140-6736(13)61492-0
   Cauchemez S., 2013, Eurosurveillance, V18, P20503
   Cauchemez S, 2014, LANCET INFECT DIS, V14, P50, DOI 10.1016/S1473-3099(13)70304-9
   Chowell G, 2014, EPIDEMICS-NETH, V9, P40, DOI 10.1016/j.epidem.2014.09.011
   Cowling BJ, 2007, EPIDEMIOLOGY, V18, P253, DOI 10.1097/01.ede.0000254660.07942.fb
   Fisman DN, 2014, LANCET, V383, P189, DOI 10.1016/S0140-6736(13)62123-6
   Fisman DN, 2014, LANCET INFECT DIS, V14, P6, DOI 10.1016/S1473-3099(13)70283-4
   Garske T, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2840
   Ghani AC, 2005, AM J EPIDEMIOL, V162, P479, DOI 10.1093/aje/kwi230
   Jun K, 2015, THE WALL STREET JOUR
   Lau EHY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-50
   Leung GM, 2004, ANN INTERN MED, V141, P662, DOI 10.7326/0003-4819-141-9-200411020-00006
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Fisman David, 2014, PLoS Curr, V6, DOI [10.1371/currents.outbreaks.98d2f8f3382d84f390736cd5f5fe133c, 10.1371/currents.outbreaks.89c0d3783f36958d96ebbae97348d571]
   Oboho IK, 2015, NEW ENGL J MED, V372, P846, DOI 10.1056/NEJMoa1408636
   Ock Hyun-ju, 2015, THE KOREA HERALD
   Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003
   Samsung Medical Center (SMC), ABOUT SMC
   World Health Organization Regional Office for the Western Pacific (WHO/Western Pacific Region), 2015, MIDDLE EAST RESPIRAT
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zumla A, 2015, LANCET
NR 26
TC 111
Z9 114
U1 2
U2 32
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD JUN 25
PY 2015
VL 20
IS 25
BP 7
EP 13
AR 21163
DI 10.2807/1560-7917.ES2015.20.25.21163
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA CL9WH
UT WOS:000357328500002
PM 26132767
OA DOAJ Gold, Green Accepted
DA 2020-04-03
ER

PT J
AU van den Bergh, MR
   Biesbroek, G
   Rossen, JWA
   Piters, WAAD
   Bosch, AATM
   van Gils, EJM
   Wang, XH
   Boonacker, CWB
   Veenhoven, RH
   Bruin, JP
   Bogaert, D
   Sanders, EAM
AF van den Bergh, Menno R.
   Biesbroek, Giske
   Rossen, John W. A.
   Piters, Wouter A. A. de Steenhuijsen
   Bosch, Astrid A. T. M.
   van Gils, Elske J. M.
   Wang, Xinhui
   Boonacker, Chantal W. B.
   Veenhoven, Reinier H.
   Bruin, Jacob P.
   Bogaert, Debby
   Sanders, Elisabeth A. M.
TI Associations between Pathogens in the Upper Respiratory Tract of Young
   Children: Interplay between Viruses and Bacteria
SO PLOS ONE
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; RANDOMIZED CONTROLLED-TRIAL;
   STREPTOCOCCUS-PNEUMONIAE; STAPHYLOCOCCUS-AUREUS; HAEMOPHILUS-INFLUENZAE;
   SYNCYTIAL VIRUS; MICROBIOTA; COLONIZATION; COMMUNITY; CARRIAGE
AB Background: High rates of potentially pathogenic bacteria and respiratory viruses can be detected in the upper respiratory tract of healthy children. Investigating presence of and associations between these pathogens in healthy individuals is still a rather unexplored field of research, but may have implications for interpreting findings during disease.
   Methodology/Principal Findings: We selected 986 nasopharyngeal samples from 433 6- to 24-month-old healthy children that had participated in a randomized controlled trial. We determined the presence of 20 common respiratory viruses using real-time PCR. Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus were identified by conventional culture methods. Information on risk factors was obtained by questionnaires. We performed multivariate logistic regression analyses followed by partial correlation analysis to identify the overall pattern of associations. S. pneumoniae colonization was positively associated with the presence of H. influenzae (adjusted odds ratio 1.60, 95% confidence interval 1.18-2.16), M. catarrhalis (1.78, 1.29-2.47), human rhinoviruses (1.63, 1.19-2.22) and enteroviruses (1.97, 1.26-3.10), and negatively associated with S. aureus presence (0.59, 0.35-0.98). H. influenzae was positively associated with human rhinoviruses (1.63, 1.22-2.18) and respiratory syncytial viruses (2.78, 1.06-7.28). M. catarrhalis colonization was positively associated with coronaviruses (1.99, 1.01-3.93) and adenoviruses (3.69, 1.29-10.56), and negatively with S. aureus carriage (0.42, 0.25-0.69). We observed a strong positive association between S. aureus and influenza viruses (4.87, 1.59-14.89). In addition, human rhinoviruses and enteroviruses were positively correlated (2.40, 1.66-3.47), as were enteroviruses and human bocavirus, WU polyomavirus, parainfluenza viruses, and human parechovirus. A negative association was observed between human rhinoviruses and coronaviruses.
   Conclusions/Significance: Our data revealed high viral and bacterial prevalence rates and distinct bacterial-bacterial, viral-bacterial and viral-viral associations in healthy children, hinting towards the complexity and potential dynamics of microbial communities in the upper respiratory tract. This warrants careful consideration when associating microbial presence with specific respiratory diseases.
C1 [van den Bergh, Menno R.; Biesbroek, Giske; Piters, Wouter A. A. de Steenhuijsen; Bosch, Astrid A. T. M.; van Gils, Elske J. M.; Wang, Xinhui; Bogaert, Debby; Sanders, Elisabeth A. M.] Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, Wilhelmina Childrens Hosp, Utrecht, Netherlands.
   [van den Bergh, Menno R.; van Gils, Elske J. M.; Veenhoven, Reinier H.] Spaarne Hosp, Res Ctr, Linnaeus Inst, Hoofddorp, Netherlands.
   [Rossen, John W. A.] St Elizabeth Hosp, Lab Med Microbiol & Immunol, Tilburg, Netherlands.
   [Boonacker, Chantal W. B.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Bruin, Jacob P.] Reg Publ Hlth Lab, Haarlem, Netherlands.
RP Bogaert, D (reprint author), Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, Wilhelmina Childrens Hosp, Utrecht, Netherlands.
EM d.bogaert@umcutrecht.nl
RI Rossen, John W/G-7564-2011; de Steenhuijsen Piters, Wouter/AAI-9952-2020
OI Rossen, John W/0000-0002-7167-8623; de Steenhuijsen Piters,
   Wouter/0000-0002-1144-4067; Bogaert, Debby/0000-0003-2651-7000
FU Netherlands Organisation for Scientific Research through NWO-VENI
   [91610121]; ZonMWNetherlands Organization for Health Research and
   Development [91209010]; Dutch Ministry of Health; PfizerPfizer; Baxter;
   GlaxoSmithKlineGlaxoSmithKline
FX This work was supported by The Netherlands Organisation for Scientific
   Research through NWO-VENI Grant 91610121, ZonMW Grant 91209010 and the
   Dutch Ministry of Health. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.; DB declares to have received consulting fees from Pfizer.
   EAMS declares to have received unrestricted research support from Pfizer
   and Baxter, consulting fees from Pfizer and GlaxoSmithKline, lecturing
   fees from Pfizer, and grant support for vaccine studies from Pfizer and
   GlaxoSmithKline. RHV declares to have received research support from
   GlaxoSmithKline and Pfizer for vaccine studies and consulting fees from
   GlaxoSmithKline. None of the fees or grants listed here were received
   for the research described in this paper. For all other authors no
   conflicts of interest were declared. This does not alter the authors'
   adherence to all the PLOS ONE policies on sharing data and materials.
CR Avadhanula V, 2006, J VIROL, V80, P1629, DOI 10.1128/JVI.80.4.1629-1636.2006
   Biesbroek G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032942
   Blaser MJ, 2009, NAT REV MICROBIOL, V7, P887, DOI 10.1038/nrmicro2245
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Bogaert D, 2004, LANCET, V363, P1871, DOI 10.1016/S0140-6736(04)16357-5
   Bogaert D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017035
   Brogden KA, 2004, LANCET, V365, P253, DOI 10.1016/S0140-6736(05)70155-0
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324
   Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014
   Fredricks DN, 1996, CLIN MICROBIOL REV, V9, P18, DOI 10.1128/CMR.9.1.18
   Fuhrman JA, 2009, NATURE, V459, P193, DOI 10.1038/nature08058
   HUEBNER RJ, 1957, ANN NY ACAD SCI, V67, P430, DOI 10.1111/j.1749-6632.1957.tb46066.x
   Ishizuka S, 2003, J INFECT DIS, V188, P1928, DOI 10.1086/379833
   Iverson AR, 2011, J INFECT DIS, V203, P880, DOI 10.1093/infdis/jiq113
   Jacoby P, 2007, VACCINE, V25, P2458, DOI 10.1016/j.vaccine.2006.09.020
   Jansen AGSC, 2008, EPIDEMIOL INFECT, V136, P1448, DOI 10.1017/S0950268807000271
   Jansen RR, 2011, J CLIN MICROBIOL, V49, P2631, DOI 10.1128/JCM.02094-10
   Kane M, 2011, SCIENCE, V334, P245, DOI 10.1126/science.1210718
   Klugman KP, 2007, SCIENCE, V316, P49
   Koon K, 2010, EMERG INFECT DIS, V16, P1976, DOI 10.3201/eid1612.091697
   Kuss SK, 2011, SCIENCE, V334, P249, DOI 10.1126/science.1211057
   Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077
   Margolis E, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-59
   O'Brien Katherine L, 2003, Pediatr Infect Dis J, V22, pe1, DOI 10.1097/00006454-200302000-00010
   Peltola V, 2011, PEDIATR INFECT DIS J, V30, P456, DOI 10.1097/INF.0b013e318208ee82
   Pericone CD, 2000, INFECT IMMUN, V68, P3990, DOI 10.1128/IAI.68.7.3990-3997.2000
   Prokhorov A. V., 2001, ENCY MATH
   Regev-Yochay G, 2004, JAMA-J AM MED ASSOC, V292, P716, DOI 10.1001/jama.292.6.716
   Rivers TM, 1937, J BACTERIOL, V33, P1
   Selva L, 2009, P NATL ACAD SCI USA, V106, P1234, DOI 10.1073/pnas.0809600106
   Singeton RJ, 2010, J MED VIROL, V82, P1282, DOI 10.1002/jmv.21790
   van de Pol AC, 2006, CRIT CARE, V10, DOI 10.1186/cc4895
   van de Pol AC, 2007, J CLIN MICROBIOL, V45, P2260, DOI 10.1128/JCM.00848-07
   van de Pol AC, 2009, EMERG INFECT DIS, V15, P454, DOI 10.3201/eid1503.081203
   van Gils EJM, 2011, VACCINE, V29, P7595, DOI 10.1016/j.vaccine.2011.08.049
   van Gils EJM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020229
   van Gils EJM, 2009, JAMA-J AM MED ASSOC, V302, P159, DOI 10.1001/jama.2009.975
   Wiertsema SP, 2011, J MED VIROL, V83, P2008, DOI 10.1002/jmv.22221
   Willing BP, 2011, NAT REV MICROBIOL, V9, P233, DOI 10.1038/nrmicro2536
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 40
TC 111
Z9 112
U1 2
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2012
VL 7
IS 10
AR e47711
DI 10.1371/journal.pone.0047711
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AF
UT WOS:000311146900096
PM 23082199
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Pantin-Jackwood, MJ
   Day, JM
   Jackwood, MW
   Spackman, E
AF Pantin-Jackwood, Mary J.
   Day, J. Michael
   Jackwood, Mark W.
   Spackman, Erica
TI Enteric Viruses Detected by Molecular Methods in Commercial Chicken and
   Turkey Flocks in the United States Between 2005 and 2006
SO AVIAN DISEASES
LA English
DT Article
DE avian adenovirus; avian astrovirus; avian nephritis virus; avian
   rotavirus; avian reovirus; enteric virus; avian coronavirus;
   phylogenetic analysis
ID AVIAN NEPHRITIS VIRUS; INFECTIOUS-BRONCHITIS VIRUS; POLYMERASE
   CHAIN-REACTION; SMALL ROUND VIRUS; GROUP-A ROTAVIRUS; POULT ENTERITIS;
   MORTALITY SYNDROME; BROILER CHICKS; RT-PCR; ASTROVIRUSES
AB Intestinal samples collected from 43 commercial broiler and 33 commercial turkey flocks from all regions of the United States during 2005 and 2006 were examined for the presence of astrovirus, rotavirus, reovirus, and coronavirus by reverse transcription-polymerase chain reaction (PCR), and for the presence of groups 1 and 2 adenovirus by PCR. Phylogenetic analysis was performed to further characterize the viruses and to evaluate species association and geographic patterns. Astroviruses were identified in samples from 86% of the chicken flocks and from 100% of the turkey flocks. Both chicken astrovirus and avian nephritis virus (ANV) were identified in chicken samples, and often both viruses were detected in the same flock. Turkey astrovirus type-2 and turkey astrovirus type-1 were found in 100% and 15.4% of the turkey flocks, respectively. In addition, 12.5% of turkey flocks were positive for ANV. Rotaviruses were present in 46.5% of the chicken flocks tested and in 69.7% of the turkey flocks tested. Based upon the rotavirus NSP4 gene sequence, the chicken and turkey origin rotaviruses assorted in a species-specific manner. The turkey origin rotaviruses also assorted based upon geographical location. Reoviruses were identified in 62.8% and 45.5% of chicken and turkey flocks, respectively. Based on the reovirus S4 gene segment, the chicken and turkey origin viruses assorted separately, and they were distinct from all previously reported avian reoviruses. Coronaviruses were detected in the intestinal contents of chickens, but not turkeys. Adenoviruses were not detected in any chicken or turkeys flocks. Of the 76 total chicken and turkey flocks tested, only three chicken flocks were negative for all viruses targeted by this study. Most flocks were positive for two or more of the viruses, and overall no clear pattern of virus geographic distribution was evident. This study provides updated enteric virus prevalence data for the United States using molecular methods, and it reinforces that enteric viruses are widespread in poultry throughout the United States, although the clinical importance of most of these viruses remains unclear.
C1 [Pantin-Jackwood, Mary J.; Day, J. Michael; Spackman, Erica] USDA ARS, SE Poultry Res Lab, Athens, GA 30605 USA.
   [Jackwood, Mark W.] Univ Georgia, Dept Populat Hlth, Coll Vet Med, Athens, GA 30677 USA.
RP Spackman, E (reprint author), USDA ARS, SE Poultry Res Lab, 934 Coll Stn Rd, Athens, GA 30605 USA.
EM erica.spackman@ars.usda.gov
OI Pantin-Jackwood, Mary J./0000-0003-0414-213X; Spackman,
   Erica/0000-0002-4935-2360
FU USDA/ARS CRISUnited States Department of Agriculture (USDA)
   [6612-32000-020]
FX We gratefully acknowledge industry partners who made this work possible.
   We also thank Diane Smith, Scott Lee, Rebecca Hammer, Chris Stephens,
   Debbie Hilt, and the SAA sequencing facility for technical assistance
   with this work. The work was supported by USDA/ARS CRIS project
   6612-32000-020.
CR Barnes HJ, 2000, REV SCI TECH OIE, V19, P565, DOI 10.20506/rst.19.2.1234
   Barnes HJ, 2003, DIS POULTRY, P1171
   Baxendale W, 2004, AVIAN PATHOL, V33, P364, DOI 10.1080/0307945042000220426
   Benavente J, 2007, VIRUS RES, V123, P105, DOI 10.1016/j.virusres.2006.09.005
   Callison SA, 2006, J VIROL METHODS, V138, P60, DOI 10.1016/j.jviromet.2006.07.018
   Cattoli G, 2005, VET REC, V156, P220
   CAVANAGH D, 2003, DIS POULTRY, P101
   CONNOR TJ, 1987, AVIAN PATHOL, V16, P15, DOI 10.1080/03079458708436348
   COWEN B, 1978, AVIAN DIS, V22, P115, DOI 10.2307/1589514
   Day JM, 2007, AVIAN DIS, V51, P681, DOI 10.1637/0005-2086(2007)51[681:AMRTFT]2.0.CO;2
   Elschner M, 2005, J VET MED B, V52, P211, DOI 10.1111/j.1439-0450.2005.00848.x
   FRAZIER JA, 1990, AVIAN PATHOL, V19, P139, DOI 10.1080/03079459008418663
   GRIMES TM, 1977, AVIAN DIS, V21, P220, DOI 10.2307/1589342
   Guy JS, 1998, POULTRY SCI, V77, P1166, DOI 10.1093/ps/77.8.1166
   Heggen-Peay CL, 2002, AVIAN DIS, V46, P32, DOI 10.1637/0005-2086(2002)046[0032:IOARFP]2.0.CO;2
   Hess M, 1999, J VIROL METHODS, V81, P199, DOI 10.1016/S0166-0934(99)00067-1
   IMADA T, 1980, NATL I ANIM HEALTH Q, V20, P79
   Jackwood MW, 2003, AVIAN DIS, V47, P718, DOI 10.1637/6075
   Lee CW, 2003, J VET DIAGN INVEST, V15, P344, DOI 10.1177/104063870301500407
   Liu HJ, 2003, VIROLOGY, V314, P336, DOI 10.1016/S0042-6822(03)00415-X
   Mandoki M, 2006, AVIAN PATHOL, V35, P224, DOI 10.1080/03079450600711037
   Mandoki MR, 2006, ACTA VET HUNG, V54, P51, DOI 10.1556/AVet.54.2006.1.6
   MCNULTY MS, 1980, VET REC, V106, P561, DOI 10.1136/vr.106.26.561
   MCNULTY MS, 1979, ARCH VIROL, V61, P13, DOI 10.1007/BF01320587
   MCNULTY MS, 1980, AVIAN PATHOL, V9, P363, DOI 10.1080/03079458008418420
   MCNULTY MS, 1978, VET REC, V103, P319, DOI 10.1136/vr.103.14.319-a
   MCNULTY MS, 1984, ARCH VIROL, V81, P113, DOI 10.1007/BF01309301
   MCNULTY MS, 1989, AVIAN PATHOL, V18, P215, DOI 10.1080/03079458908418596
   McNulty MS, 2003, DIS POULTRY, P308
   NICHOLAS RAJ, 1988, VET REC, V123, P398, DOI 10.1136/vr.123.15.398
   Otto P, 2006, AVIAN DIS, V50, P411, DOI 10.1637/7511-020106R.1
   Pantin-Jackwood MJ, 2007, AVIAN DIS, V51, P674, DOI 10.1637/0005-2086(2007)51[674:PMOCTF]2.0.CO;2
   Pantin-Jackwood MJ, 2006, AVIAN DIS, V50, P397, DOI 10.1637/7512-020606R.1
   Pantin-Jackwood MJ, 2006, VIRUS GENES, V32, P187, DOI 10.1007/s11262-005-6875-3
   REYNOLDS DL, 1987, AVIAN DIS, V31, P272, DOI 10.2307/1590872
   REYNOLDS DL, 1987, AVIAN DIS, V31, P89, DOI 10.2307/1590779
   REYNOLDS DL, 1986, AVIAN DIS, V30, P728, DOI 10.2307/1590577
   Rosenberger J.K., 2003, DIS POULTRY, P283
   SAIF LJ, 1985, AVIAN DIS, V29, P798, DOI 10.2307/1590671
   SAIF YM, 1990, AVIAN DIS, V34, P762, DOI 10.2307/1591277
   Saif YM, 2003, DIS POULTRY, P213
   SCHNITZER TJ, 1985, VIROLOGY, V141, P167, DOI 10.1016/0042-6822(85)90194-1
   SHIRAI J, 1990, AVIAN DIS, V34, P295, DOI 10.2307/1591411
   SHIRAI J, 1992, AVIAN DIS, V36, P369, DOI 10.2307/1591515
   Spackman E, 2005, AVIAN DIS, V49, P86, DOI 10.1637/7265-082304R
   Suresh M, 1996, J VIROL, V70, P30, DOI 10.1128/JVI.70.1.30-36.1996
   Tang Y, 2005, AVIAN DIS, V49, P182, DOI 10.1637/7255-080504R
   THEIL KW, 1986, AVIAN DIS, V30, P829, DOI 10.2307/1590594
   THEIL KW, 1987, J CLIN MICROBIOL, V25, P333, DOI 10.1128/JCM.25.2.333-337.1987
   YASON CV, 1987, AM J VET RES, V48, P977
   Yu M, 2000, AVIAN DIS, V44, P297, DOI 10.2307/1592543
NR 51
TC 111
Z9 114
U1 0
U2 15
PU AMER ASSOC AVIAN PATHOLOGISTS
PI ATHENS
PA 953 COLLEGE STATION RD, ATHENS, GA 30602-4875 USA
SN 0005-2086
J9 AVIAN DIS
JI Avian Dis.
PD JUN
PY 2008
VL 52
IS 2
BP 235
EP 244
DI 10.1637/8174-111507-Reg.1
PG 10
WC Veterinary Sciences
SC Veterinary Sciences
GA 372NI
UT WOS:000260907900007
PM 18646452
DA 2020-04-03
ER

PT J
AU DeDiego, ML
   Alvarez, E
   Almazan, F
   Rejas, MT
   Lamirande, E
   Roberts, A
   Shieh, WJ
   Zaki, SR
   Subbarao, K
   Enjuanes, L
AF DeDiego, Marta L.
   Alvarez, Enrique
   Almazan, Fernando
   Rejas, Maria Teresa
   Lamirande, Elaine
   Roberts, Anjeanette
   Shieh, Wun-Ju
   Zaki, Sherif R.
   Subbarao, Kanta
   Enjuanes, Luis
TI A severe acute respiratory syndrome coronavirus that lacks the E gene is
   attenuated in vitro and in vivo
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID BRONCHITIS-VIRUS-E; VIRAL STRUCTURAL PROTEIN; GOLDEN SYRIAN-HAMSTERS;
   SARS-CORONAVIRUS; MEMBRANE-PROTEIN; ENVELOPE PROTEIN; RNA-SYNTHESIS; ION
   CHANNELS; CELL-LINES; REPLICATION
AB A deletion mutant of severe acute respiratory syndrome coronavirus (SARS-CoV) has been engineered by deleting the structural E gene in an infectious cDNA clone that was constructed as a bacterial artificial chromosome (BAC). The recombinant virus lacking the E gene (rSARS-CoV-Delta E) was rescued in Vero E6 cells. The recovered deletion mutant grew in Vero E6, Huh-7, and CaCo-2 cells to titers 20-, 200-, and 200-fold lower than the recombinant wild-type virus, respectively, indicating that although the E protein has an effect on growth, it is not essential for virus replication. No differences in virion stability under a wide range of pH and temperature were detected between the deletion mutant and recombinant wild-type viruses. Although both viruses showed the same morphology by electron microscopy, the process of morphogenesis seemed to be less efficient with the defective virus than with the recombinant wild-type one. The rSARS-CoV-AE virus replicated to titers 100- to 1,000-fold lower than the recombinant wild-type virus in the upper and lower respiratory tract of hamsters, and the lower viral load was accompanied by less inflammation in the lungs of hamsters infected with rSARS-CoV-Delta E virus than with the recombinant wild-type virus. Therefore, the SARS-CoV that lacks the E gene is attenuated in hamsters, might be a safer research tool, and may be a good candidate for the development of a live attenuated SARS-CoV vaccine.
C1 CSIC, Dept Mol & Cell Biol, Ctr Nacl Biotecnol, Madrid 28049, Spain.
   UAM, CSIC, Ctr Biol Mol, Fac Ciencias, Madrid 28049, Spain.
   NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.
RP Enjuanes, L (reprint author), CSIC, Dept Mol & Cell Biol, Ctr Nacl Biotecnol, Darwin 3,Campus Univ Autonoma, Madrid 28049, Spain.
EM L.Enjuanes@cnb.uam.es
RI De Diego, Marta Lopez/B-2307-2017; Almazan, Fernando/K-8781-2015;
   Enjuanes, Luis/F-7845-2016
OI De Diego, Marta Lopez/0000-0002-7888-7372; Almazan,
   Fernando/0000-0002-5752-8469; Enjuanes, Luis/0000-0002-0854-0226;
   Subbarao, Kanta/0000-0003-1713-3056; Alvarez Vazquez,
   Enrique/0000-0002-4889-175X
FU Intramural NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA
CR Almazan F, 2006, J VIROL, V80, P10900, DOI 10.1128/JVI.00385-06
   Arbely E, 2004, J MOL BIOL, V341, P769, DOI 10.1016/j.jmb.2004.06.044
   Baudoux P, 1998, J VIROL, V72, P8636, DOI 10.1128/JVI.72.11.8636-8643.1998
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   Chu CM, 2004, CAN MED ASSOC J, V171, P1349, DOI 10.1503/cmaj.1040398
   Corse E, 2000, J VIROL, V74, P4319, DOI 10.1128/JVI.74.9.4319-4326.2000
   Corse E, 2003, VIROLOGY, V312, P25, DOI 10.1016/S0042-6822(03)00175-2
   Corse E, 2002, J VIROL, V76, P1273, DOI 10.1128/JVI.76.3.1273-1284.2002
   Curtis KM, 2002, J VIROL, V76, P1422, DOI 10.1128/JVI.76.3.1422-1434.2002
   Darnell MER, 2004, J VIROL METHODS, V121, P85, DOI 10.1016/j.jviromet.2004.06.006
   de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fischer F, 1998, J VIROL, V72, P7885, DOI 10.1128/JVI.72.10.7885-7894.1998
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Gillim-Ross L, 2004, J CLIN MICROBIOL, V42, P3196, DOI 10.1128/JCM.42.7.3196-3206.2004
   GODET M, 1992, VIROLOGY, V188, P666, DOI 10.1016/0042-6822(92)90521-P
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   Haijema BJ, 2004, J VIROL, V78, P3863, DOI 10.1128/JVI.78.8.3863-3871.2004
   Hattermann K, 2005, ARCH VIROL, V150, P1023, DOI 10.1007/s00705-004-0461-1
   Ho Y, 2004, BIOCHEM BIOPH RES CO, V318, P833, DOI 10.1016/j.bbrc.2004.04.111
   Huang C, 2006, J VIROL, V80, P7287, DOI 10.1128/JVI.00414-06
   Huang Y, 2004, J VIROL, V78, P12557, DOI 10.1128/JVI.78.22.12557-12565.2004
   Hung IFN, 2004, EMERG INFECT DIS, V10, P1550, DOI 10.3201/eid1009.040058
   Ito N, 2005, J VIROL, V79, P3182, DOI 10.1128/JVI.79.5.3182-3186.2005
   Khattari Z, 2006, BIOPHYS J, V90, P2038, DOI 10.1529/biophysj.105.072892
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Kuo LL, 2003, J VIROL, V77, P4597, DOI 10.1128/JVI.77.8.4597-4608.2003
   Liao Y, 2004, BIOCHEM BIOPH RES CO, V325, P374, DOI 10.1016/j.bbrc.2004.10.050
   Liao Y, 2006, VIROLOGY, V349, P264, DOI 10.1016/j.virol.2006.01.028
   Madan V, 2005, FEBS LETT, V579, P3607, DOI 10.1016/j.febslet.2005.05.046
   Maeda J, 2001, VIROLOGY, V281, P163, DOI 10.1006/viro.2001.0818
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Masters PS, 2006, ADV EXP MED BIOL, V581, P163
   Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009
   Mossel EC, 2005, J VIROL, V79, P3846, DOI 10.1128/JVI.79.6.3846-3850.2005
   Ng ML, 2003, J GEN VIROL, V84, P3291, DOI 10.1099/vir.0.19505-0
   Ortego J, 2003, VIROLOGY, V308, P13, DOI 10.1016/S0042-6822(02)00096-X
   Ortego J, 2002, J VIROL, V76, P11518, DOI 10.1128/JVI.76.22.11518-11529.2002
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Raamsman MJB, 2000, J VIROL, V74, P2333, DOI 10.1128/JVI.74.5.2333-2342.2000
   Roberts A, 2006, J INFECT DIS, V193, P685, DOI 10.1086/500143
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Shen S, 2005, BIOCHEM BIOPH RES CO, V330, P286, DOI 10.1016/j.bbrc.2005.02.153
   Siddell SG, 1995, CORONAVIRIDAE
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Torres J, 2006, BIOPHYS J, V91, P938, DOI 10.1529/biophysj.105.080119
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Wilson L, 2004, VIROLOGY, V330, P322, DOI 10.1016/j.virol.2004.09.033
   Wilson L, 2006, VIROLOGY, V353, P294, DOI 10.1016/j.virol.2006.05.028
   Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005
   ZEBEDEE SL, 1985, J VIROL, V56, P502, DOI 10.1128/JVI.56.2.502-511.1985
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Zuniga S, 2004, J VIROL, V78, P980, DOI 10.1128/JVI.78.2.980-994.2004
NR 60
TC 111
Z9 115
U1 2
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD FEB
PY 2007
VL 81
IS 4
BP 1701
EP 1713
DI 10.1128/JVI.01467-06
PG 13
WC Virology
SC Virology
GA 136RI
UT WOS:000244241400017
PM 17108030
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Kuo, LL
   Masters, PS
AF Kuo, LL
   Masters, PS
TI The small envelope protein E is not essential for murine coronavirus
   replication
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; TRANSMISSIBLE GASTROENTERITIS CORONAVIRUS;
   TARGETED RNA RECOMBINATION; INTERNAL RIBOSOME ENTRY; MEMBRANE-PROTEIN;
   REVERSE GENETICS; VIRION ENVELOPE; INFECTED-CELLS; GOLGI-COMPLEX;
   PARTICLES
AB The importance of the small envelope (E) protein in the assembly of coronaviruses has been demonstrated in several studies. While its precise function is not clearly defined, E is a pivotal player in the morphogenesis of the virion envelope. Expression of the E protein alone results in its incorporation into vesicles that are released from cells, and the coexpression of the E protein with the membrane protein M leads to the assembly of coronavirus-like particles. We have previously generated E gene mutants of mouse hepatitis virus (MHV) that had marked defects in viral growth and produced virions that were aberrantly assembled in comparison to mild-type virions. We have now been able to obtain a viable MHV mutant in which the entire E gene, as well as the nonessential upstream genes 4 and 5a, has been deleted. This mutant (DeltaE) was obtained by a targeted RNA recombination method that makes use of a powerful host range-based selection system. The DeltaE mutant produces tiny plaques with an unusual morphology compared to plaques formed by wild-type MHV. Despite its low growth rate and low infectious titer, the DeltaE mutant is genetically stable, showing no detectable phenotypic changes after several passages. The properties of this mutant provide further support for the importance of E protein in MHV replication, but surprisingly, they also show that E protein is not essential.
C1 SUNY Albany, New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst, Albany, NY 12201 USA.
   SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA.
RP Masters, PS (reprint author), SUNY Albany, New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst, New Scotland Ave,POB 22002, Albany, NY 12201 USA.
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI039544, AI 39544]
CR Baudoux P, 1998, J VIROL, V72, P8636, DOI 10.1128/JVI.72.11.8636-8643.1998
   Bos ECW, 1996, VIROLOGY, V218, P52, DOI 10.1006/viro.1996.0165
   Corse E, 2000, J VIROL, V74, P4319, DOI 10.1128/JVI.74.9.4319-4326.2000
   Corse E, 2002, J VIROL, V76, P1273, DOI 10.1128/JVI.76.3.1273-1284.2002
   Curtis KM, 2002, J VIROL, V76, P1422, DOI 10.1128/JVI.76.3.1422-1434.2002
   DAVIDFERREIRA JF, 1965, J CELL BIOL, V24, P57, DOI 10.1083/jcb.24.1.57
   de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   de Vries AAF, 1997, SEMIN VIROL, V8, P33, DOI 10.1006/smvy.1997.0104
   Escors D, 2001, J VIROL, V75, P1312, DOI 10.1128/JVI.75.3.1312-1324.2001
   Fischer F, 1998, J VIROL, V72, P7885, DOI 10.1128/JVI.72.10.7885-7894.1998
   Fischer F, 1997, J VIROL, V71, P5148, DOI 10.1128/JVI.71.7.5148-5160.1997
   GODET M, 1992, VIROLOGY, V188, P666, DOI 10.1016/0042-6822(92)90521-P
   Jendrach M, 1999, ARCH VIROL, V144, P921, DOI 10.1007/s007050050556
   KOETZNER CA, 1992, J VIROL, V66, P1841, DOI 10.1128/JVI.66.4.1841-1848.1992
   KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55
   Kuo L, 2002, J VIROL, V76, P4987, DOI 10.1128/JVI.76.10.4987-4999.2002
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Laude H, 1995, CORONAVIRIDAE, P141, DOI 10.1007/978-1-4899-1531-3_7
   LIU DX, 1991, VIROLOGY, V185, P911, DOI 10.1016/0042-6822(91)90572-S
   Maeda J, 2001, VIROLOGY, V281, P163, DOI 10.1006/viro.2001.0818
   Maeda J, 1999, VIROLOGY, V263, P265, DOI 10.1006/viro.1999.9955
   MASTERS PS, 1994, J VIROL, V68, P328, DOI 10.1128/JVI.68.1.328-337.1994
   Masters PS, 1999, ADV VIRUS RES, V53, P245, DOI 10.1016/S0065-3527(08)60351-6
   Narayanan K, 2000, J VIROL, V74, P8127, DOI 10.1128/JVI.74.17.8127-8134.2000
   Narayanan K, 2001, J VIROL, V75, P9059, DOI 10.1128/JVI.75.19.9059-9067.2001
   Ontiveros E, 2001, VIROLOGY, V289, P230, DOI 10.1006/viro.2001.1167
   Ortego J, 2002, J VIROL, V76, P11518, DOI 10.1128/JVI.76.22.11518-11529.2002
   Raamsman MJB, 2000, J VIROL, V74, P2333, DOI 10.1128/JVI.74.5.2333-2342.2000
   Risco C, 1998, J VIROL, V72, P4022, DOI 10.1128/JVI.72.5.4022-4031.1998
   Risco C, 1996, J VIROL, V70, P4773, DOI 10.1128/JVI.70.7.4773-4777.1996
   Rottier P.J.M., 1995, CORONAVIRIDAE, P115
   Salanueva IJ, 1999, J VIROL, V73, P7952, DOI 10.1128/JVI.73.10.7952-7964.1999
   SAMBROOK J, 2001, MOL CLONING LAB MANU
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   Snijder EJ, 1999, J VIROL, V73, P6335, DOI 10.1128/JVI.73.8.6335-6345.1999
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   THIEL V, 1994, J GEN VIROL, V75, P3041, DOI 10.1099/0022-1317-75-11-3041
   TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475
   VANDERMOST RG, 1995, CORONAVIRIDAE, P11
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   WEISS SR, 1993, ARCH VIROL, V129, P301, DOI 10.1007/BF01316905
   YOKOMORI K, 1991, J VIROL, V65, P5605, DOI 10.1128/JVI.65.10.5605-5608.1991
   YU X, 1994, VIROLOGY, V202, P1018, DOI 10.1006/viro.1994.1430
NR 45
TC 111
Z9 122
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD APR
PY 2003
VL 77
IS 8
BP 4597
EP 4608
DI 10.1128/JVI.77.8.4597-4608.2003
PG 12
WC Virology
SC Virology
GA 662VU
UT WOS:000181970200013
PM 12663766
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Ballesteros, ML
   Sanchez, CM
   Enjuanes, L
AF Ballesteros, ML
   Sanchez, CM
   Enjuanes, L
TI Two amino acid changes at the N-terminus of transmissible
   gastroenteritis coronavirus spike protein result in the loss of enteric
   tropism
SO VIROLOGY
LA English
DT Article
ID PORCINE RESPIRATORY CORONAVIRUS; TEMPERATURE-SENSITIVE MUTANTS; MURINE
   CORONAVIRUSES; MAJOR RECEPTOR; VIRUS; NEUTRALIZATION; RNA;
   RECOMBINATION; GLYCOPROTEIN; ORGANIZATION
AB To study the molecular basis of TGEV tropism, a collection of recombinants between the PUR46-MAD strain of transmissible gastroenteritis coronavirus (TGEV) infecting the enteric and respiratory tracts and the PTV strain, which only infects the respiratory tract, was generated. The recombinant isolation frequency was about 10(-9) recombinants per nucleotide and was 3.7-fold higher at the 5'-end of the S gene than in other areas of the genome. Thirty recombinants were plaque purified and characterized phenotypically and genetically. All recombinant viruses had a single crossover and had inherited the 5'- and 3'-halves of their genome from the enteric and respiratory parents, respectively. Recombinant viruses were classified into three groups, named 1 to 3, according to the location of the crossover. Group 1 recombinants had the crossover in the S gene, while in Groups 2 and 3 the crossovers were located in ORF1b and ORF1a, respectively. The tropism of the recombinants was studied. Recombinants of Group 1 had enteric and respiratory tropism, while Group 2 recombinants infected the respiratory, but not the enteric, tract. Viruses of both groups differed by two nucleotide changes at positions 214 and 655. Both changes may be in principle responsible for the loss of enteric tropism but only the change in nucleotide 655 was specifically found in the respiratory isolates and most likely this single nucleotide change, which leads to a substitution in amino acid 219 of the S protein, was responsible for the loss of enteric tropism in the closely related PUR-46 isolates. The available data indicate that in order to infect enteric tract cells with TGEV, two different domains of the S protein, mapping between amino acids 522 and 744 and around amino acid 219, respectively, are involved. The first domain binds to porcine aminopeptidase N, the cellular receptor for TGEV. In the other domain maps a second factor of undefined nature but which may be the binding site for a coreceptor essential for the enteric tropism of TGEV. (C) 1997 Academic Press
C1 UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,DEPT MOL & CELL BIOL,E-28049 MADRID,SPAIN.
RI Enjuanes, Luis/F-7845-2016
OI Enjuanes, Luis/0000-0002-0854-0226
CR BERNARD S, 1995, J GEN VIROL, V76, P2235, DOI 10.1099/0022-1317-76-9-2235
   BRITTON P, 1991, VIRUS RES, V21, P181, DOI 10.1016/0168-1702(91)90032-Q
   BRITTON P, 1990, 8 INT C VIR BERL
   CALLEBAUT P, 1988, J GEN VIROL, V69, P1725, DOI 10.1099/0022-1317-69-7-1725
   CAVANAGH D, 1994, ARCH VIROL, V135, P227, DOI 10.1007/BF01309782
   CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435
   CORREA I, 1988, VIRUS RES, V10, P77, DOI 10.1016/0168-1702(88)90059-7
   COX E, 1990, RES VET SCI, V48, P165, DOI 10.1016/S0034-5288(18)30984-6
   DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   ELEOUET JF, 1995, VIROLOGY, V206, P817, DOI 10.1006/viro.1995.1004
   Enjuanes L., 1995, The coronaviridae., P337
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   FICHOT O, 1990, NUCLEIC ACIDS RES, V18, P6162, DOI 10.1093/nar/18.20.6162
   FU KS, 1994, J VIROL, V68, P7458, DOI 10.1128/JVI.68.11.7458-7466.1994
   GEBAUER F, 1991, VIROLOGY, V183, P225, DOI 10.1016/0042-6822(91)90135-X
   GODET M, 1994, J VIROL, V68, P8008, DOI 10.1128/JVI.68.12.8008-8016.1994
   HOLMES KV, 1989, CELL BIOL VIRUS ENTR, P85
   JIMENEZ G, 1986, J VIROL, V60, P131
   KAPKE PA, 1986, VIROLOGY, V151, P41, DOI 10.1016/0042-6822(86)90102-9
   KENNY AJ, 1982, PHYSIOL REV, V62, P91
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   LAUDE H, 1993, VET RES, V24, P125
   Lunney J.K., 1986, SWINE BIOMEDICAL RES, V3, P1821
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MCCLURKIN AW, 1966, CAN J COMP MED VET S, V30, P190
   MCKITTRICK SP, 1993, BIOTECHNIQUES, V15, P802
   Mendez A, 1996, VIROLOGY, V217, P495, DOI 10.1006/viro.1996.0144
   NOREN O, 1986, ENZYMES ENTEROCYTE P
   PENSAERT M, 1986, 9 INT PIG VET SOC C, P40
   RASSCHAERT D, 1987, BIOCHIMIE, V69, P591, DOI 10.1016/0300-9084(87)90178-7
   RASSCHAERT D, 1990, J GEN VIROL, V71, P2599, DOI 10.1099/0022-1317-71-11-2599
   ROBB JA, 1979, VIROLOGY, V94, P385, DOI 10.1016/0042-6822(79)90469-0
   SACHS DH, 1976, TRANSPLANTATION, V22, P559, DOI 10.1097/00007890-197612000-00004
   SAIF LJ, 1992, DIS SWINE, P382
   SANCHEZ CM, 1990, VIROLOGY, V174, P410, DOI 10.1016/0042-6822(90)90094-8
   SANCHEZ CM, 1992, VIROLOGY, V190, P92, DOI 10.1016/0042-6822(92)91195-Z
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SEMENZA G, 1986, ANN REV CELL BIOL, V2, P225
   SHEPLEY MP, 1994, J VIROL, V68, P1301, DOI 10.1128/JVI.68.3.1301-1308.1994
   Siddell SG, 1995, CORONAVIRIDAE
   STURMAN LS, 1983, ADV VIRUS RES, V28, P36
   SUNE C, 1990, VIROLOGY, V177, P559, DOI 10.1016/0042-6822(90)90521-R
   Suzuki H, 1996, J VIROL, V70, P2632, DOI 10.1128/JVI.70.4.2632-2636.1996
   TAKEUCHI Y, 1991, J VIROL, V65, P1710, DOI 10.1128/JVI.65.4.1710-1718.1991
   VAUGHN EM, 1994, J CLIN MICROBIOL, V32, P1809, DOI 10.1128/JCM.32.7.1809-1812.1994
   Wesley R D, 1990, J Vet Diagn Invest, V2, P312
   WESLEY RD, 1991, J VIROL, V65, P3369, DOI 10.1128/JVI.65.6.3369-3373.1991
   WESLEY RD, 1990, J VIROL, V64, P4761, DOI 10.1128/JVI.64.10.4761-4766.1990
   YOKOMORI K, 1993, VIROLOGY, V196, P45, DOI 10.1006/viro.1993.1453
NR 51
TC 111
Z9 138
U1 0
U2 8
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JAN 20
PY 1997
VL 227
IS 2
BP 378
EP 388
DI 10.1006/viro.1996.8344
PG 11
WC Virology
SC Virology
GA WD572
UT WOS:A1997WD57200012
PM 9018137
OA Bronze
DA 2020-04-03
ER

PT J
AU COMPTON, SR
   BARTHOLD, SW
   SMITH, AL
AF COMPTON, SR
   BARTHOLD, SW
   SMITH, AL
TI THE CELLULAR AND MOLECULAR PATHOGENESIS OF CORONAVIRUSES
SO LABORATORY ANIMAL SCIENCE
LA English
DT Article
ID MOUSE HEPATITIS-VIRUS; CENTRAL-NERVOUS-SYSTEM; OPEN READING FRAME;
   RIBOSOMAL FRAMESHIFTING SIGNAL; BOVINE ENTERIC CORONAVIRUSES;
   INFECTIOUS-BRONCHITIS VIRUS; LEADER-PRIMED TRANSCRIPTION; PUTATIVE
   POLYMERASE GENE; MINUS-STRAND RNAS; MURINE CORONAVIRUS
AB Coronaviruses cause a wide spectrum of diseases in humans and animals but generally fall into two classes, with respiratory or enteric tropisms. Mouse hepatitis virus (MHV) and rat coronaviruses are the viruses most frequently encountered in the laboratory animal setting. This review focuses primarily on the cellular and molecular aspects of MHV pathogenesis. The high mutation and recombination rates of coronaviruses lead to a diverse, ever-changing population of MHV strains. The spike (S) protein is the most variable coronavirus protein and is responsible for binding to cell surface receptors, inducing cell fusion and humoral and cellular immunity. Differences within the S protein of different MHV strains have been linked to their variable tropisms. Since immunity to MHV is strain-specific, seropositive mice can be reinfected with different strains of MHV. Natural infections with MHV are acute, with persistence occurring at the population level, not within an individual mouse, unless it is immunocompromised. Age, genotype, immunologic status of the mouse, and MHV strain influence the type and severity of disease caused by MHV. Interference with research by MHV has been reported primarily in the fields of immunology and tumor biology and may be a reflection of MHV's capacity to grow in several types of immune cells. While many methods are available to diagnose coronavirus infection, serologic tests, primarily ELISA and IFA, are the most commonly used. MHV is best managed on a preventive basis. Elimination of MHV from a population requires cessation of breeding and halting the introduction of naive mice into the population.
C1 YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510.
RP COMPTON, SR (reprint author), YALE UNIV,SCH MED,COMPARAT MED SECT,NEW HAVEN,CT 06510, USA.
FU NCRR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [RR04507, RR02039]
CR ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0
   BAKER SC, 1990, EMBO J, V9, P4173, DOI 10.1002/j.1460-2075.1990.tb07641.x
   BANG FB, 1960, P NATL ACAD SCI USA, V46, P1065, DOI 10.1073/pnas.46.8.1065
   BANNER LR, 1991, VIROLOGY, V185, P441, DOI 10.1016/0042-6822(91)90795-D
   BANNER LR, 1990, VIROLOGY, V175, P548, DOI 10.1016/0042-6822(90)90439-X
   BARIC RS, 1983, J VIROL, V48, P633, DOI 10.1128/JVI.48.3.633-640.1983
   BARIC RS, 1990, VIROLOGY, V177, P646, DOI 10.1016/0042-6822(90)90530-5
   BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988
   BARIC RS, 1985, VIRUS RES, V3, P19, DOI 10.1016/0168-1702(85)90038-3
   Barthold S. W., 1986, Viral and mycoplasmal infections of laboratory rodents. Effects on biomedical research., P571
   BARTHOLD SW, 1984, ARCH VIROL, V81, P103, DOI 10.1007/BF01309300
   BARTHOLD SW, 1985, LAB ANIM SCI, V35, P613
   BARTHOLD SW, 1982, LAB ANIM SCI, V32, P376
   BARTHOLD SW, 1990, LAB ANIM SCI, V40, P133
   BARTHOLD SW, 1988, ACTA NEUROPATHOL, V76, P502, DOI 10.1007/BF00686390
   BARTHOLD SW, 1989, ARCH VIROL, V107, P171, DOI 10.1007/BF01317914
   BARTHOLD SW, 1989, ARCH VIROL, V104, P187, DOI 10.1007/BF01315542
   BARTHOLD SW, 1986, ARCH VIROL, V91, P247, DOI 10.1007/BF01314284
   BARTHOLD SW, 1987, VIRUS RES, V7, P225, DOI 10.1016/0168-1702(87)90030-X
   BARTHOLD SW, 1987, LAB ANIM SCI, V37, P36
   BARTHOLD SW, 1992, ARCH VIROL, V122, P35, DOI 10.1007/BF01321116
   BHATT PN, 1972, J INFECT DIS, V126, P123, DOI 10.1093/infdis/126.2.123
   BIA FJ, 1980, JAMA-J AM MED ASSOC, V244, P367, DOI 10.1001/jama.244.4.367
   BOORMAN GA, 1982, AM J PATHOL, V106, P110
   BOURSNELL MEG, 1987, J GEN VIROL, V68, P57, DOI 10.1099/0022-1317-68-1-57
   BOYLE JF, 1987, J VIROL, V61, P185, DOI 10.1128/JVI.61.1.185-189.1987
   BRAUNSTEINER H, 1954, J EXP MED, V100, P665, DOI 10.1084/jem.100.6.665
   BRAYTON PR, 1981, J GEN VIROL, V56, P457, DOI 10.1099/0022-1317-56-2-457
   BREDENBEEK PJ, 1990, NUCLEIC ACIDS RES, V18, P1825, DOI 10.1093/nar/18.7.1825
   BRIERLEY I, 1991, J MOL BIOL, V220, P889, DOI 10.1016/0022-2836(91)90361-9
   BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   BROWN TDK, 1984, J GEN VIROL, V65, P1437, DOI 10.1099/0022-1317-65-8-1437
   BUDZILOWICZ CJ, 1985, J VIROL, V53, P834, DOI 10.1128/JVI.53.3.834-840.1985
   BUDZILOWICZ CJ, 1987, VIROLOGY, V157, P509, DOI 10.1016/0042-6822(87)90293-5
   CARRANO VA, 1984, LAB ANIM SCI, V34, P573
   CASEBOLT DB, 1987, CELL IMMUNOL, V109, P97, DOI 10.1016/0008-8749(87)90295-4
   CASEBOLT DB, 1992, J CLIN MICROBIOL, V30, P608, DOI 10.1128/JCM.30.3.608-612.1992
   CAVANAGH D, 1986, VIRUS RES, V4, P133, DOI 10.1016/0168-1702(86)90037-7
   CHELEY S, 1981, VIROLOGY, V112, P596, DOI 10.1016/0042-6822(81)90305-6
   COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2
   COOKMILLS JM, 1992, IMMUNOLOGY, V75, P542
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   DALZIEL RG, 1986, J VIROL, V59, P463, DOI 10.1128/JVI.59.2.463-471.1986
   DAYA M, 1989, J GEN VIROL, V70, P3335, DOI 10.1099/0022-1317-70-12-3335
   DEA S, 1990, J VIROL, V64, P3112, DOI 10.1128/JVI.64.6.3112-3118.1990
   DEGROOT RJ, 1987, J GEN VIROL, V68, P2639, DOI 10.1099/0022-1317-68-10-2639
   DEMPSEY WL, 1986, J LEUKOCYTE BIOL, V39, P559
   DENISON M, 1987, VIROLOGY, V157, P565, DOI 10.1016/0042-6822(87)90303-5
   DENISON MR, 1986, J VIROL, V60, P12, DOI 10.1128/JVI.60.1.12-18.1986
   DENISON MR, 1991, J VIROL, V65, P3076, DOI 10.1128/JVI.65.6.3076-3082.1991
   DESOUZA M, 1989, J CLIN MICROBIOL, V27, P185, DOI 10.1128/JCM.27.1.185-187.1989
   DESOUZA MS, 1991, LAB ANIM SCI, V41, P99
   DESOUZA MS, 1991, LAB ANIM SCI, V41, P112
   DINDZANS VJ, 1986, J IMMUNOL, V137, P2355
   DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991
   FAZAKERLEY JK, 1992, VIROLOGY, V187, P178, DOI 10.1016/0042-6822(92)90306-A
   FLEMING JO, 1989, VIROLOGY, V168, P162, DOI 10.1016/0042-6822(89)90415-7
   FLEMING JO, 1986, J VIROL, V58, P869, DOI 10.1128/JVI.58.3.869-875.1986
   FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1
   FOX JG, 1977, LAB ANIM SCI, V27, P173
   FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985
   FU KS, 1992, VIROLOGY, V189, P88, DOI 10.1016/0042-6822(92)90684-H
   GAERTNER DJ, 1991, ARCH VIROL, V118, P57, DOI 10.1007/BF01311303
   GALLAGHER TM, 1991, J VIROL, V65, P1916, DOI 10.1128/JVI.65.4.1916-1928.1991
   GALLAGHER TM, 1990, J VIROL, V64, P731, DOI 10.1128/JVI.64.2.731-741.1990
   GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0
   HIERHOLZER JC, 1979, INFECT IMMUN, V24, P508, DOI 10.1128/IAI.24.2.508-522.1979
   HOFMANN MA, 1990, J VIROL, V64, P4108, DOI 10.1128/JVI.64.9.4108-4114.1990
   HOFMANN MA, 1991, J VIROL, V65, P6331, DOI 10.1128/JVI.65.11.6331-6333.1991
   HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255
   HOLMES, 1990, VIROLOGY, P841
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   HOMBERGER FR, 1991, J CLIN MICROBIOL, V29, P2789, DOI 10.1128/JCM.29.12.2789-2793.1991
   HOMBERGER FR, 1992, LAB ANIM SCI, V42, P347
   HOMBERGER FR, 1992, ARCH VIROL, V122, P133, DOI 10.1007/BF01321123
   HOMBERGER FR, 1992, IN PRESS ARCH VIROL
   KECK JG, 1988, J VIROL, V62, P1989, DOI 10.1128/JVI.62.6.1989-1998.1988
   KECK JG, 1988, J VIROL, V62, P1810, DOI 10.1128/JVI.62.5.1810-1813.1988
   KECK JG, 1987, VIROLOGY, V156, P331, DOI 10.1016/0042-6822(87)90413-2
   KING B, 1985, VIRUS RES, V2, P53, DOI 10.1016/0168-1702(85)90059-0
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   KNOBLER RL, 1981, J EXP MED, V153, P832, DOI 10.1084/jem.153.4.832
   KUNITA S, 1992, LAB ANIM SCI, V42, P593
   KYUWA S, 1988, J VIROL, V62, P3506, DOI 10.1128/JVI.62.9.3506-3508.1988
   LAI MMC, 1983, J VIROL, V46, P1027, DOI 10.1128/JVI.46.3.1027-1033.1983
   LAI MMC, 1981, J VIROL, V39, P823, DOI 10.1128/JVI.39.3.823-834.1981
   LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985
   LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511
   LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992
   LAI MMC, 1982, J VIROL, V41, P557, DOI 10.1128/JVI.41.2.557-565.1982
   LAI MMC, 1982, J VIROL, V44, P487, DOI 10.1128/JVI.44.2.487-492.1982
   LAMONICA N, 1991, VIROLOGY, V182, P883
   LAMONTAGNE L, 1989, J IMMUNOL, V142, P4458
   LECOMTE J, 1987, ARCH VIROL, V97, P123, DOI 10.1007/BF01310740
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   LEIBOWITZ JL, 1981, VIROLOGY, V114, P39, DOI 10.1016/0042-6822(81)90250-6
   LEIBOWITZ JL, 1988, VIROLOGY, V164, P156, DOI 10.1016/0042-6822(88)90631-9
   LEVY GA, 1981, J EXP MED, V154, P1150, DOI 10.1084/jem.154.4.1150
   LUYTJES W, 1988, VIROLOGY, V166, P415, DOI 10.1016/0042-6822(88)90512-0
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MANAKER RA, 1961, JNCI-J NATL CANCER I, V27, P29
   MASTERS PS, 1992, ARCH VIROL, V125, P141, DOI 10.1007/BF01309634
   MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9
   MIZZEN L, 1983, VIROLOGY, V128, P407, DOI 10.1016/0042-6822(83)90266-0
   MORRIS VL, 1989, VIROLOGY, V169, P127, DOI 10.1016/0042-6822(89)90048-2
   NAKANAGA K, 1986, J VIROL, V59, P168, DOI 10.1128/JVI.59.1.168-171.1986
   PACHUK CJ, 1989, VIROLOGY, V171, P141, DOI 10.1016/0042-6822(89)90520-5
   PARKER JC, 1970, ARCH GES VIRUSFORSCH, V31, P293, DOI 10.1007/BF01253764
   PARKER SE, 1989, VIROLOGY, V173, P664, DOI 10.1016/0042-6822(89)90579-5
   PFLEIDERER M, 1991, J GEN VIROL, V72, P1309, DOI 10.1099/0022-1317-72-6-1309
   RASSCHAERT D, 1987, J GEN VIROL, V68, P1883, DOI 10.1099/0022-1317-68-7-1883
   ROBBINS SG, 1986, VIROLOGY, V150, P402, DOI 10.1016/0042-6822(86)90305-3
   ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421
   ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987
   ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022
   SABESIN SM, 1972, AM J GASTROENTEROL, V58, P259
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   SCHAAD MC, 1990, VIROLOGY, V177, P634, DOI 10.1016/0042-6822(90)90529-Z
   SCHMIDT I, 1987, J GEN VIROL, V68, P47, DOI 10.1099/0022-1317-68-1-47
   SCHULTZE B, 1991, VIROLOGY, V180, P221, DOI 10.1016/0042-6822(91)90026-8
   SETHNA PB, 1991, J VIROL, V65, P320, DOI 10.1128/JVI.65.1.320-325.1991
   SETHNA PB, 1989, P NATL ACAD SCI USA, V86, P5626, DOI 10.1073/pnas.86.14.5626
   SHIEH CK, 1989, J VIROL, V63, P3729, DOI 10.1128/JVI.63.9.3729-3736.1989
   SHIEH CK, 1987, VIROLOGY, V156, P321, DOI 10.1016/0042-6822(87)90412-0
   SIDDELL S, 1982, CURR TOP MICROBIOL, V99, P131
   SKINNER MA, 1985, J GEN VIROL, V66, P581, DOI 10.1099/0022-1317-66-3-581
   SMITH AL, 1991, LAB ANIM SCI, V41, P106
   SMITH AL, 1991, ARCH VIROL, V121, P89, DOI 10.1007/BF01316746
   SMITH AL, 1983, AM J TROP MED HYG, V32, P1172, DOI 10.4269/ajtmh.1983.32.1172
   SMITH AL, 1983, LAB ANIM SCI, V33, P157
   SMITH AL, 1986, J VIROL METHODS, V14, P335, DOI 10.1016/0166-0934(86)90035-2
   SMITH AL, 1992, ARCH VIROL, V125, P39, DOI 10.1007/BF01309627
   SMITH AL, 1991, J INFECT DIS, V163, P879, DOI 10.1093/infdis/163.4.879
   SMITH MS, 1984, J IMMUNOL, V133, P428
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   SPAAN W, 1983, EMBO J, V2, P1839, DOI 10.1002/j.1460-2075.1983.tb01667.x
   SPAAN WJM, 1982, J VIROL, V42, P432, DOI 10.1128/JVI.42.2.432-439.1982
   STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2
   STOHLMAN SA, 1978, ARCH VIROL, V57, P53, DOI 10.1007/BF01315637
   STOHLMAN SA, 1979, VIROLOGY, V98, P448, DOI 10.1016/0042-6822(79)90567-1
   STOHLMAN SA, 1979, J VIROL, V32, P672, DOI 10.1128/JVI.32.2.672-675.1979
   STOHLMAN SA, 1988, J VIROL, V62, P4288, DOI 10.1128/JVI.62.11.4288-4295.1988
   STOHLMAN SA, 1980, J IMMUNOL, V124, P1733
   STOHLMAN SA, 1978, IMMUNOGENETICS, V6, P277, DOI 10.1007/BF01563919
   STOHLMAN SA, 1992, VIROLOGY, V189, P217
   STORZ J, 1981, INFECT IMMUN, V31, P1214, DOI 10.1128/IAI.31.3.1214-1222.1981
   STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6
   STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985
   STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980
   SUGIYAMA K, 1980, ARCH VIROL, V66, P95, DOI 10.1007/BF01314978
   SUSSMAN MA, 1989, J VIROL, V63, P3051, DOI 10.1128/JVI.63.7.3051-3056.1989
   TAGUCHI F, 1985, J VIROL, V54, P429, DOI 10.1128/JVI.54.2.429-435.1985
   TAGUCHI F, 1986, VIROLOGY, V155, P267, DOI 10.1016/0042-6822(86)90187-X
   TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   TOOZE J, 1985, EUR J CELL BIOL, V37, P203
   TRAAVIK T, 1977, ARCH VIROL, V55, P25, DOI 10.1007/BF01314476
   VERBEEK A, 1991, ARCH VIROL, V121, P199, DOI 10.1007/BF01316754
   VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526
   VLASAK R, 1988, J VIROL, V62, P4686, DOI 10.1128/JVI.62.12.4686-4690.1988
   WANG FI, 1992, VIROLOGY, V186, P742, DOI 10.1016/0042-6822(92)90041-M
   WEGE H, 1982, CURR TOP MICROBIOL, V99, P165
   WEGE H, 1988, J GEN VIROL, V69, P87, DOI 10.1099/0022-1317-69-1-87
   WEGE H, 1984, J GEN VIROL, V65, P1931, DOI 10.1099/0022-1317-65-11-1931
   WEIR EC, 1987, LAB ANIM SCI, V37, P455
   WELSH RM, 1986, J IMMUNOL, V136, P1364
   WILLIAMS RK, 1990, J VIROL, V64, P3817, DOI 10.1128/JVI.64.8.3817-3823.1990
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   WILLIAMSON JSP, 1990, J VIROL, V64, P4589, DOI 10.1128/JVI.64.9.4589-4592.1990
   YAMAGUCHI K, 1991, J NEUROIMMUNOL, V32, P1, DOI 10.1016/0165-5728(91)90065-F
   YOKOMORI K, 1991, VIROLOGY, V183, P647, DOI 10.1016/0042-6822(91)90994-M
   YOKOMORI K, 1992, J VIROL, V66, P2865, DOI 10.1128/JVI.66.5.2865-2874.1992
   YOKOMORI K, 1989, VIROLOGY, V173, P683, DOI 10.1016/0042-6822(89)90581-3
   YOSHIKURA H, 1981, VIROLOGY, V113, P503, DOI 10.1016/0042-6822(81)90178-1
   ZHANG XM, 1992, VIROLOGY, V186, P318, DOI 10.1016/0042-6822(92)90089-8
   1991, LAB ANIM SCI, V41, P199
NR 179
TC 111
Z9 111
U1 0
U2 5
PU AMER ASSOC LABORATORY ANIMAL SCIENCE
PI CORDOVA
PA 70 TIMBERCREEK DR, SUITE 5, CORDOVA, TN 38018
SN 0023-6764
J9 LAB ANIM SCI
JI Lab. Anim. Sci.
PD FEB
PY 1993
VL 43
IS 1
BP 15
EP 28
PG 14
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA KP472
UT WOS:A1993KP47200004
PM 8384676
DA 2020-04-03
ER

PT J
AU MEYERS, G
   TAUTZ, N
   STARK, R
   BROWNLIE, J
   DUBOVI, EJ
   COLLETT, MS
   THIEL, HJ
AF MEYERS, G
   TAUTZ, N
   STARK, R
   BROWNLIE, J
   DUBOVI, EJ
   COLLETT, MS
   THIEL, HJ
TI REARRANGEMENT OF VIRAL SEQUENCES IN CYTOPATHOGENIC PESTIVIRUSES
SO VIROLOGY
LA English
DT Article
ID HOG-CHOLERA VIRUS; DIARRHEA VIRUS; RNA RECOMBINATION; MURINE
   CORONAVIRUSES; NUCLEOTIDE-SEQUENCE; PUTATIVE HELICASES;
   MOLECULAR-CLONING; MUCOSAL DISEASE; GENE-EXPRESSION; UBIQUITIN
C1 FED RES CTR VIRUS DIS ANIM, POB 1149, W-7400 TUBINGEN, GERMANY.
   CORNELL UNIV, NEW YORK STATE COLL VET MED, ITHACA, NY 14853 USA.
   AFRC, INST ANIM HLTH, NEWBURY RG16 0NN, BERKS, ENGLAND.
   MEDIMMUNE INC, GAITHERSBURG, MD 20878 USA.
RI Tautz, Norbert/D-4252-2011
CR BAKER JC, 1987, J AM VET MED ASSOC, V190, P1449
   BANNER LR, 1991, VIROLOGY, V185, P441, DOI 10.1016/0042-6822(91)90795-D
   BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7
   BOLIN SR, 1985, AM J VET RES, V46, P573
   BROWNLIE J, 1984, VET REC, V114, P535, DOI 10.1136/vr.114.22.535
   COLLETT MS, 1988, J GEN VIROL, V69, P2637, DOI 10.1099/0022-1317-69-10-2637
   COLLETT MS, 1988, VIROLOGY, V165, P191, DOI 10.1016/0042-6822(88)90672-1
   COLLETT MS, 1988, VIROLOGY, V165, P200, DOI 10.1016/0042-6822(88)90673-3
   COLLETT MS, 1991, ARCH VIROL, P19
   CORAPI WV, 1988, J VIROL, V62, P2823, DOI 10.1128/JVI.62.8.2823-2827.1988
   DEMOERLOOZE L, 1990, VIROLOGY, V177, P812, DOI 10.1016/0042-6822(90)90555-6
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387
   DONIS RO, 1987, AM J VET RES, V48, P1549
   DONIS RO, 1987, J GEN VIROL, V68, P1597, DOI 10.1099/0022-1317-68-6-1597
   FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2
   FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713
   GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889
   GREISERWILKE I, 1992, J GEN VIROL, V73, P47, DOI 10.1099/0022-1317-73-1-47
   GUTEKUNST DE, 1963, CAN J COMP MED VET S, V27, P121
   Harlow E., 1988, ANTIBODIES LABORATOR
   HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156
   JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953
   Kessler S W, 1981, Methods Enzymol, V73, P442
   KHATCHIKIAN D, 1989, NATURE, V340, P156, DOI 10.1038/340156a0
   King A. M. Q., 1987, The molecular biology of the positive strand RNA viruses, P129
   KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8
   LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985
   LAZZARINI RA, 1981, CELL, V26, P145, DOI 10.1016/0092-8674(81)90298-1
   MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986
   MANIATIS T, 1989, MOL CLONING
   MEYERS G, 1989, VIROLOGY, V171, P555, DOI 10.1016/0042-6822(89)90625-9
   MEYERS G, 1991, VIROLOGY, V180, P602, DOI 10.1016/0042-6822(91)90074-L
   MEYERS G, 1989, NATURE, V341, P491, DOI 10.1038/341491a0
   MEYERS G, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P25
   OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x
   POCOCK DH, 1987, ARCH VIROL, V94, P43, DOI 10.1007/BF01313724
   PURCHIO AF, 1984, J VIROL, V50, P666, DOI 10.1128/JVI.50.2.666-669.1984
   RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245
   REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0
   RENARD A, 1987, Patent No. 86870095
   RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3
   RUMENAPF T, 1991, J VIROL, V65, P589
   RUMENAPF T, 1989, VIROLOGY, V171, P18, DOI 10.1016/0042-6822(89)90506-0
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986
   THIEL HJ, 1991, J VIROL, V65, P4705, DOI 10.1128/JVI.65.9.4705-4712.1991
   WENGLER G, 1991, CLASSIFICATION NOMEN
   WISKERCHEN M, 1991, VIROLOGY, V184, P341, DOI 10.1016/0042-6822(91)90850-B
   WISKERCHEN M, 1991, J VIROL, V65, P4508, DOI 10.1128/JVI.65.8.4508-4514.1991
NR 50
TC 111
Z9 116
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD NOV
PY 1992
VL 191
IS 1
BP 368
EP 386
DI 10.1016/0042-6822(92)90199-Y
PG 19
WC Virology
SC Virology
GA JT446
UT WOS:A1992JT44600040
PM 1329326
DA 2020-04-03
ER

PT J
AU Wang, LS
   Shi, W
   Joyce, MG
   Modjarrad, K
   Zhang, Y
   Leung, K
   Lees, CR
   Zhou, TQ
   Yassine, HM
   Kanekiyo, M
   Yang, ZY
   Chen, XJ
   Becker, MM
   Freeman, M
   Vogel, L
   Johnson, JC
   Olinger, G
   Todd, JP
   Bagci, U
   Solomon, J
   Mollura, DJ
   Hensley, L
   Jahrling, P
   Denison, MR
   Rao, SS
   Subbarao, K
   Kwong, PD
   Mascola, JR
   Kong, WP
   Graham, BS
AF Wang, Lingshu
   Shi, Wei
   Joyce, M. Gordon
   Modjarrad, Kayvon
   Zhang, Yi
   Leung, Kwanyee
   Lees, Christopher R.
   Zhou, Tongqing
   Yassine, Hadi M.
   Kanekiyo, Masaru
   Yang, Zhi-yong
   Chen, Xuejun
   Becker, Michelle M.
   Freeman, Megan
   Vogel, Leatrice
   Johnson, Joshua C.
   Olinger, Gene
   Todd, John P.
   Bagci, Ulas
   Solomon, Jeffrey
   Mollura, Daniel J.
   Hensley, Lisa
   Jahrling, Peter
   Denison, Mark R.
   Rao, Srinivas S.
   Subbarao, Kanta
   Kwong, Peter D.
   Mascola, John R.
   Kong, Wing-Pui
   Graham, Barney S.
TI Evaluation of candidate vaccine approaches for MERS-CoV
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; RECEPTOR-BINDING DOMAIN;
   IMMUNE-RESPONSES; SPIKE PROTEIN; NEUTRALIZING ANTIBODIES; SAUDI-ARABIA;
   GLYCOPROTEIN; MICE; IMMUNOGENICITY; IMMUNIZATION
AB The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) as a cause of severe respiratory disease highlights the need for effective approaches to CoV vaccine development. Efforts focused solely on the receptor-binding domain (RBD) of the viral Spike (S) glycoprotein may not optimize neutralizing antibody (NAb) responses. Here we show that immunogens based on full-length S DNA and S1 subunit protein elicit robust serumneutralizing activity against several MERS-CoV strains in mice and non-human primates. Serological analysis and isolation of murine monoclonal antibodies revealed that immunization elicits NAbs to RBD and, non-RBD portions of S1 and S2 subunit. Multiple neutralization mechanisms were demonstrated by solving the atomic structure of a NAb-RBD complex, through sequencing of neutralization escape viruses and by constructing MERS-CoV S variants for serological assays. Immunization of rhesus macaques confers protection against MERS-CoV-induced radiographic pneumonia, as assessed using computerized tomography, supporting this strategy as a promising approach for MERS-CoV vaccine development.
C1 [Wang, Lingshu; Shi, Wei; Joyce, M. Gordon; Modjarrad, Kayvon; Zhang, Yi; Leung, Kwanyee; Lees, Christopher R.; Zhou, Tongqing; Yassine, Hadi M.; Kanekiyo, Masaru; Yang, Zhi-yong; Chen, Xuejun; Todd, John P.; Rao, Srinivas S.; Kwong, Peter D.; Mascola, John R.; Kong, Wing-Pui; Graham, Barney S.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Modjarrad, Kayvon] US Mil HIV Res Program, Walter Reed Army Inst Res, Silver Spring, MD 20910 USA.
   [Modjarrad, Kayvon] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA.
   [Yang, Zhi-yong] Sanofi Aventis, Cambridge, MA 02139 USA.
   [Becker, Michelle M.; Freeman, Megan; Denison, Mark R.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
   [Vogel, Leatrice; Subbarao, Kanta] NIAID, Emerging Resp Viruses Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   [Johnson, Joshua C.; Olinger, Gene; Hensley, Lisa; Jahrling, Peter] NIAID, Integrated Res Facil, NIH, Frederick, MD 21702 USA.
   [Bagci, Ulas; Solomon, Jeffrey; Mollura, Daniel J.] NIH, Ctr Infect Dis Imaging, Dept Radiol & Imaging Sci, Bethesda, MD 20892 USA.
   [Bagci, Ulas] Univ Cent Florida, CRCV, Orlando, FL 32816 USA.
   [Denison, Mark R.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA.
RP Kong, WP (reprint author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM wkong@niaid.nih.gov; bgraham@nih.gov
RI Graham, Barney S./AAC-5898-2019; freeman, megan culler/AAF-3626-2020;
   Kanekiyo, Masaru/Y-9820-2018; Denison, Mark/O-7258-2018; Zhou,
   Tongqing/Z-1145-2019; Kanekiyo, Masaru/K-5361-2019; Zhou,
   Tongqing/A-6880-2010
OI Graham, Barney S./0000-0001-8112-0853; Kanekiyo,
   Masaru/0000-0001-5767-1532; Denison, Mark/0000-0003-2655-0900; Zhou,
   Tongqing/0000-0002-3935-4637; Kanekiyo, Masaru/0000-0001-5767-1532;
   Zhou, Tongqing/0000-0002-3935-4637; Olinger, Gene/0000-0001-7338-0292;
   Subbarao, Kanta/0000-0003-1713-3056; Johnson,
   Joshua/0000-0002-5677-3841; Bagci, Ulas/0000-0001-7379-6829
FU Intramural Research Program of the Vaccine Research Center, National
   Institute of Allergy and Infectious Diseases, NIH; US Department of
   Energy, Basic Energy Sciences, Office of ScienceUnited States Department
   of Energy (DOE) [W-31-109-Eng-38];  [RO1-AI-108197]
FX We thank members of the Viral Pathogenesis and Virology Laboratories as
   well as the Structural Biology and Structural Bioinformatics Sections at
   the Vaccine Research Center for insightful comments and helpful
   discussions. We also thank Brenda Hartman and Jonathon Stuckey for their
   assistance in preparing the figures. The data presented in this
   manuscript are tabulated in the main paper and the Supplementary
   Materials. Atomic coordinates and structure factors of the reported
   crystal structures have been deposited in the Protein Data Bank under
   accession codes 4ZPT, 4ZPV and 4ZPW. This work was supported by the
   Intramural Research Program of the Vaccine Research Center, National
   Institute of Allergy and Infectious Diseases, NIH. Use of sector 22
   (SER-CAT) at the Advanced Photon Source was supported by the US
   Department of Energy, Basic Energy Sciences, Office of Science, under
   contract number W-31-109-Eng-38. M.R.D, and M.M.B. were supported by
   RO1-AI-108197. Research was conducted in compliance with the Animal
   Welfare Act and other federal statutes and regulations relating to
   animals and experiments involving animals and adheres to principles
   stated in the Guide for the Care and Use of Laboratory Animals, NRC
   Publication, 2011 edition.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Barouch DH, 2005, J VIROL, V79, P8828, DOI 10.1128/JVI.79.14.8828-8834.2005
   Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427
   Breban R, 2013, LANCET, V382, P694, DOI 10.1016/S0140-6736(13)61492-0
   Briese T, 2014, MBIO, V5, DOI 10.1128/mBio.01146-14
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Cargnelutti DE, 2013, NEW MICROBIOL, V36, P145
   Catanzaro AT, 2007, VACCINE, V25, P4085, DOI 10.1016/j.vaccine.2007.02.050
   Cauchemez S, 2014, LANCET INFECT DIS, V14, P50, DOI 10.1016/S1473-3099(13)70304-9
   Caulfield MJ, 2002, J VIROL, V76, P10038, DOI 10.1128/JVI.76.19.10038-10043.2002
   CAVANAGH D, 1983, J GEN VIROL, V64, P2577, DOI 10.1099/0022-1317-64-12-2577
   Chaitra MG, 2007, VACCINE, V25, P7168, DOI 10.1016/j.vaccine.2007.07.026
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Coleman CM, 2014, VACCINE, V32, P3169, DOI 10.1016/j.vaccine.2014.04.016
   DAVIS HL, 1995, HUM GENE THER, V6, P1447, DOI 10.1089/hum.1995.6.11-1447
   de Wit E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069127
   Du LY, 2014, J VIROL, V88, P7045, DOI 10.1128/JVI.00433-14
   Du LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081587
   ECDC, 2014, EP UPD MIDDL E RESP
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   FAN ZC, 1992, J MOL BIOL, V228, P188, DOI 10.1016/0022-2836(92)90500-J
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Jiang LW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008140
   Khurana S, 2013, J INFECT DIS, V208, P413, DOI 10.1093/infdis/jit178
   Kong WP, 2005, J VIROL, V79, P13915, DOI 10.1128/JVI.79.22.13915-13923.2005
   Ledgerwood JE, 2013, J INFECT DIS, V208, P418, DOI 10.1093/infdis/jit180
   Ledgerwood JE, 2011, LANCET INFECT DIS, V11, P916, DOI 10.1016/S1473-3099(11)70240-7
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Ma CQ, 2014, VACCINE, V32, P2100, DOI 10.1016/j.vaccine.2014.02.004
   Mansoor A, 2014, IEEE T MED IMAGING, V33, P2293, DOI 10.1109/TMI.2014.2337057
   Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Mou H, 2013, J VIROL, V87, P9379, DOI 10.1128/JVI.01277-13
   Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382
   Ohnuma K, 2013, J VIROL, V87, P13892, DOI 10.1128/JVI.02448-13
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pak JE, 2009, J MOL BIOL, V388, P815, DOI 10.1016/j.jmb.2009.03.042
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Shedlock DJ, 2000, J LEUKOCYTE BIOL, V68, P793
   STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0
   Sui JH, 2014, J VIROL, V88, P13769, DOI 10.1128/JVI.02232-14
   Tang XC, 2014, P NATL ACAD SCI USA, V111, pE2018, DOI 10.1073/pnas.1402074111
   World Health Organization, 2014, MIDDL E RESP SYNDR C
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
   Ying TL, 2014, J VIROL, V88, P7796, DOI 10.1128/JVI.00912-14
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 54
TC 110
Z9 117
U1 3
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL
PY 2015
VL 6
AR 7712
DI 10.1038/ncomms8712
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO0RA
UT WOS:000358858500018
PM 26218507
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Frieman, M
   Ratia, K
   Johnston, RE
   Mesecar, AD
   Baric, RS
AF Frieman, Matthew
   Ratia, Kiira
   Johnston, Robert E.
   Mesecar, Andrew D.
   Baric, Ralph S.
TI Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease
   Ubiquitin-Like Domain and Catalytic Domain Regulate Antagonism of IRF3
   and NF-kappa B Signaling
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID EQUINE ENCEPHALITIS-VIRUS; MURINE HEPATITIS-VIRUS; I INTERFERON;
   EBOLA-VIRUS; V-PROTEIN; EXPRESSION; INDUCTION; IDENTIFICATION;
   ALPHA/BETA; RESPONSES
AB The outcome of a viral infection is regulated in part by the complex coordination of viral and host interactions that compete for the control and optimization of virus replication. Severe acute respiratory syndrome coronavirus (SARS-CoV) intimately engages and regulates the host innate immune responses during infection. Using a novel interferon (IFN) antagonism screen, we show that the SARS-CoV proteome contains several replicase, structural, and accessory proteins that antagonize the IFN pathway. In this study, we focus on the SARS-CoV papain-like protease (PLP), which engages and antagonizes the IFN induction and NF-kappa B signaling pathways. PLP blocks these pathways by affecting activation of the important signaling proteins in each pathway, IRF3 and NF-kappa B. We also show that the ubiquitin-like domain of PLP is necessary for pathway antagonism but not sufficient by itself to block these pathways regardless of the enzymatic activity of the protease. The potential mechanism of PLP antagonism and its role in pathogenesis are discussed.
C1 [Frieman, Matthew; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Ratia, Kiira; Mesecar, Andrew D.] Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA.
   [Ratia, Kiira; Mesecar, Andrew D.] Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA.
   [Johnston, Robert E.] Univ N Carolina, Carolina Vaccine Inst, Chapel Hill, NC 27599 USA.
   [Johnston, Robert E.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
RP Baric, RS (reprint author), Univ N Carolina, Dept Epidemiol, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
EM rbaric@email.unc.edu
OI Mesecar, Andrew/0000-0002-1241-2577
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P01AI060915, P01AI059443, F32AI066542]
FX We are grateful for the support of NIH grant P01AI060915 to A. D. M.,
   NIH grant P01AI059443 to R. S. B., and NIH grant F32AI066542 to M. B.
   F.; We also thank Martha Collier for production of VRPs, John Hiscott
   for phospho-specific IRF3 antibodies, Luis Enjuanes and Jose Luis Nieto
   for SARS-CoV anti-E antibody, and Susan Baker for the V5-PLP plasmid and
   helpful discussions.
CR Aguilar PV, 2008, J VIROL, V82, P4920, DOI 10.1128/JVI.02514-07
   Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6
   Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101
   Balasuriya UBR, 2000, J VIROL, V74, P10623, DOI 10.1128/JVI.74.22.10623-10630.2000
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Barretto N, 2006, ADV EXP MED BIOL, V581, P37
   Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297
   Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770
   Cornell CT, 2006, J VIROL, V80, P6637, DOI 10.1128/JVI.02572-05
   Cruz CD, 2006, J VIROL, V80, P5644, DOI 10.1128/JVI.02400-05
   Davis NL, 2000, J VIROL, V74, P371, DOI 10.1128/JVI.74.1.371-378.2000
   De Lang A, 2007, PLOS PATHOG, V3, P1129, DOI 10.1371/journal.ppat.0030112
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Dowell SF, 2004, LANCET INFECT DIS, V4, P704, DOI 10.1016/S1473-3099(04)01177-6
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Eckerle LD, 2007, J VIROL, V81, P12135, DOI 10.1128/JVI.01296-07
   Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493
   Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508
   Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004
   Graham RL, 2005, J VIROL, V79, P13399, DOI 10.1128/JVI.79.21.13399-13411.2005
   Han Yun, 2003, J Tradit Chin Med, V23, P214
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Hengel H, 2005, TRENDS IMMUNOL, V26, P396, DOI 10.1016/j.it.2005.05.004
   Hiscott J, 2003, ANN NY ACAD SCI, V1010, P237, DOI 10.1196/annals.1299.042
   Ikeda F, 2007, EMBO J, V26, P3451, DOI 10.1038/sj.emboj.7601773
   Kash JC, 2006, J VIROL, V80, P3009, DOI 10.1128/JVI.80.6.3009-3020.2006
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7
   May MJ, 2004, J BIOL CHEM, V279, P45528, DOI 10.1074/jbc.M408579200
   McWhirter SM, 2005, CELL, V122, P645, DOI 10.1016/j.cell.2005.08.026
   Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Parisien JP, 2001, VIROLOGY, V283, P230, DOI 10.1006/viro.2001.0856
   Park MS, 2003, J VIROL, V77, P1501, DOI 10.1128/JVI.77.2.1501-1511.2003
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Pushko P, 1997, VIROLOGY, V239, P389, DOI 10.1006/viro.1997.8878
   QIAN XY, 1994, J VIROL, V68, P2433, DOI 10.1128/JVI.68.4.2433-2441.1994
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Reid SP, 2006, J VIROL, V80, P5156, DOI 10.1128/JVI.02349-05
   Rivas C, 1998, VIROLOGY, V243, P406, DOI 10.1006/viro.1998.9072
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Schijns VECJ, 1996, J IMMUNOL, V157, P815
   Schoneboom BA, 2000, J INTERF CYTOK RES, V20, P205, DOI 10.1089/107999000312621
   Shabman RS, 2007, J VIROL, V81, P237, DOI 10.1128/JVI.01590-06
   SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4
   Terzic J, 2007, BIOCHEM SOC T, V35, P942, DOI 10.1042/BST0350942
   Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843
   Warfield KL, 2003, P NATL ACAD SCI USA, V100, P15889, DOI 10.1073/pnas.2237038100
   Wathelet MG, 2007, J VIROL, V81, P11620, DOI 10.1128/JVI.00702-07
   Webster RG, 2004, LANCET, V363, P234, DOI 10.1016/S0140-6736(03)15329-9
   Xiang Y, 2002, J VIROL, V76, P5251, DOI 10.1128/JVI.76.10.5251-5259.2002
   Ye Y, 2007, J VIROL, V81, P2554, DOI 10.1128/JVI.01634-06
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Zheng DH, 2008, CELL RES, V18, P1105, DOI 10.1038/cr.2008.294
   Zhou ZP, 2005, EUR J IMMUNOL, V35, P1918, DOI 10.1002/eji.200525971
NR 59
TC 110
Z9 119
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUL
PY 2009
VL 83
IS 13
BP 6689
EP 6705
DI 10.1128/JVI.02220-08
PG 17
WC Virology
SC Virology
GA 462LM
UT WOS:000267354100036
PM 19369340
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Zhao, ZJ
   Thackrayl, LB
   Miller, BC
   Lynnl, LM
   Becker, MM
   Ward, E
   Mizushima, NN
   Denison, MR
   Virgin, HW
AF Zhao, Zijiang
   Thackrayl, Larissa B.
   Miller, Brian C.
   Lynnl, Leresa M.
   Becker, Michelle M.
   Ward, Eric
   Mizushima, Noboru N.
   Denison, Mark R.
   Virgin, Herbert W., IV
TI Coronavirus replication does not require the autophagy gene ATG5
SO AUTOPHAGY
LA English
DT Article
DE autophagy; coronavirus; macrophage; fibroblast; murine hepatitis virus
ID VIRUS STRAIN A59; CELL-SURVIVAL; EMBRYONIC-DEVELOPMENT; MACROPHAGES;
   PROTEIN; BECLIN-1; MICE; TUMORIGENESIS; EXPRESSION; INFECTION
AB Macroautophagy (herein autophagy) is a cellular process, requiring ATG5, by which cells deliver double membrane-bound packets containing cytoplasm or cytoplasmic organelles to the lysosome. This process has been reported in some cases to be antiviral, while in other cases it has been reported to be required for efficient viral replication or release. A role for autophagy in RNA virus replication has been an attractive hypothesis because of the association of RNA virus replication with complex membrane rearrangements in the cytoplasm that can generate opposed double membranes. In this study we demonstrate that ATG5 is not required for murine hepatitis virus (MHV) replication in either bone marrow derived macrophages (BMM phi) lacking ATG5 by virtue of Crerecombinase mediated gene deletion or primary low passage murine ATG5(-/-) embryonic fibroblasts (pMEFs). We conclude that neither ATG5 nor an intact autophagic pathway are required for MHV replication or release.
C1 Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   Tokyo Med & Dent Univ, Dept Physiol & Cell Biol, Tokyo, Japan.
   Japan Sci & Technol Agcy, Solut Oriented Res Sci & Technol, Kawaguchi, Japan.
   Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA.
RP Virgin, HW (reprint author), Washington Univ, Dept Pathol & Immunol, Sch Med, 660 S Eudid Ave,Box 8118, St Louis, MO 63110 USA.
EM virgin@wustl.edu
RI Denison, Mark/O-7258-2018; Mizushima, Noboru/C-3635-2009
OI Denison, Mark/0000-0003-2655-0900; Mizushima,
   Noboru/0000-0002-6258-6444; Miller, Brian/0000-0001-5931-4184
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI50083, AI59443, U54 AI057160]
CR BRADY G, 1995, CURR BIOL, V5, P909, DOI 10.1016/S0960-9822(95)00181-3
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Faust N, 2000, BLOOD, V96, P719
   GAGNETEN S, 1995, J VIROL, V69, P889, DOI 10.1128/JVI.69.2.889-895.1995
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Heise MT, 1998, VIROLOGY, V241, P331, DOI 10.1006/viro.1997.8969
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu Y, 2005, CELL, V121, P567, DOI 10.1016/j.cell.2005.03.007
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Nicholls JM, 2006, PLOS MED, V3, P222, DOI 10.1371/journal.pmed.0030027
   Ohsumi Y, 2004, SEMIN CELL DEV BIOL, V15, P231, DOI 10.1016/j.semcdb.2003.12.004
   Orvedahl A, 2007, CELL HOST MICROBE, V1, P23, DOI 10.1016/j.chom.2006.12.001
   Otto GP, 2004, J BIOL CHEM, V279, P15621, DOI 10.1074/jbc.M311139200
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200
   Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002
   Rottier PJM, 2005, J VIROL, V79, P14122, DOI 10.1128/JVI.79.22.14122-14130.2005
   Schickli JH, 1997, J VIROL, V71, P9499, DOI 10.1128/JVI.71.12.9499-9507.1997
   SCHINDLER L, 1983, IMMUNOL LETT, V7, P107, DOI 10.1016/0165-2478(83)90042-1
   Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299
   Talloczy Z, 2006, AUTOPHAGY, V2, P24, DOI 10.4161/auto.2176
   VIRGIN HW, 2007, FIELDS VIROLOGY, V1, P327
   Wijburg OLC, 1997, IMMUNOLOGY, V92, P252, DOI 10.1046/j.1365-2567.1997.00340.x
   Wijburg OLC, 1996, IMMUNOLOGY, V87, P34
   Ye JX, 2007, AM J PATHOL, V170, P538, DOI 10.2353/ajpath.2007.060469
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang HY, 2006, AUTOPHAGY, V2, P91, DOI 10.4161/auto.2.2.2297
NR 44
TC 110
Z9 113
U1 0
U2 3
PU LANDES BIOSCIENCE
PI GEORGETOWN
PA 810 SOUTH CHURCH STREET, GEORGETOWN, TX 78626 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD NOV-DEC
PY 2007
VL 3
IS 6
BP 581
EP 585
DI 10.4161/auto.4782
PG 5
WC Cell Biology
SC Cell Biology
GA 229IR
UT WOS:000250797000007
PM 17700057
OA Bronze, Green Published, Green Accepted
DA 2020-04-03
ER

PT J
AU Zust, R
   Cervantes-Barragan, L
   Kuri, T
   Blakqori, G
   Weber, F
   Ludewig, B
   Thiel, V
AF Zuest, Roland
   Cervantes-Barragan, Luisa
   Kuri, Thomas
   Blakqori, Gjon
   Weber, Friedemann
   Ludewig, Burkhard
   Thiel, Volker
TI Coronavirus non-structural protein 1 is a major pathogenicity factor:
   Implications for the rational design of coronavirus vaccines
SO PLOS PATHOGENS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; MOUSE HEPATITIS-VIRUS;
   SARS-CORONAVIRUS; IN-VITRO; REVERSE GENETICS; DENDRITIC CELLS;
   INFECTION; REPLICATION; GENOME; VACCINATION
AB Attenuated viral vaccines can be generated by targeting essential pathogenicity factors. We report here the rational design of an attenuated recombinant coronavirus vaccine based on a deletion in the coding sequence of the nonstructural protein 1 (nsp1). In cell culture, nsp1 of mouse hepatitis virus (MHV), like its SARS-coronavirus homolog, strongly reduced cellular gene expression. The effect of nsp1 on MHV replication in vitro and in vivo was analyzed using a recombinant MHV encoding a deletion in the nsp1-coding sequence. The recombinant MHV nsp1 mutant grew normally in tissue culture, but was severely attenuated in vivo. Replication and spread of the nsp1 mutant virus was restored almost to wild-type levels in type I interferon (IFN) receptor-deficient mice, indicating that nsp1 interferes efficiently with the type I IFN system. Importantly, replication of nsp1 mutant virus in professional antigen-presenting cells such as conventional dendritic cells and macrophages, and induction of type I IFN in plasmacytoid dendritic cells, was not impaired. Furthermore, even low doses of nsp1 mutant MHV elicited potent cytotoxic T cell responses and protected mice against homologous and heterologous virus challenge. Taken together, the presented attenuation strategy provides a paradigm for the development of highly efficient coronavirus vaccines.
C1 Kantonal Hosp, Res Dept, St Gallen, Switzerland.
   Hosp Especialidades Ctr Med La Raza, Ctr Med Nacl Siglo XXI, Inst Mexicano Seguro Social, Unit Invest Med Immunochem, Mexico City, DF, Mexico.
   Univ Freiburg, Dept Virol, Freiburg, Germany.
RP Thiel, V (reprint author), Univ St Andrews, Ctr Biomol Sci, Sch Biol, N Haugh, St Andrews, Fife, Scotland.
EM volker.thiel@kssg.ch
RI Thiel, Volker/AAI-2391-2019; Weber, Friedemann/AAB-3425-2019
OI Weber, Friedemann/0000-0001-9737-337X; Thiel, Volker/0000-0002-5783-0887
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [5 R21 AI062246, R21 AI062246]
CR Almeida MS, 2007, J VIROL, V81, P3151, DOI 10.1128/JVI.01939-06
   BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U
   Brockway SM, 2005, VIROLOGY, V340, P209, DOI 10.1016/j.virol.2005.06.035
   Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Coley SE, 2005, J VIROL, V79, P3097, DOI 10.1128/JVI.79.5.3097-3106.2005
   Curtis KM, 2002, J VIROL, V76, P1422, DOI 10.1128/JVI.76.3.1422-1434.2002
   De Groot-Mijnes JDF, 2005, J VIROL, V79, P1036, DOI 10.1128/JVI.79.2.1036-1044.2005
   de Haan CAM, 2002, VIROLOGY, V296, P177, DOI 10.1006/viro.2002.1412
   Enjuanes L, 2005, CURR TOP MICROBIOL, V287, P161, DOI 10.1007/3-540-26765-4_6
   Eriksson KK, 2006, ADV EXP MED BIOL, V581, P203
   Falsey AR, 1997, J AM GERIATR SOC, V45, P706, DOI 10.1111/j.1532-5415.1997.tb01474.x
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Freigang S, 2005, TRENDS IMMUNOL, V26, P13, DOI 10.1016/j.it.2004.11.013
   Graham RL, 2005, J VIROL, V79, P13399, DOI 10.1128/JVI.79.21.13399-13411.2005
   Haijema BJ, 2004, J VIROL, V78, P3863, DOI 10.1128/JVI.78.8.3863-3871.2004
   Haller O, 2006, VIROLOGY, V344, P119, DOI 10.1016/j.virol.2005.09.024
   Hertzig T, 2004, J GEN VIROL, V85, P1717, DOI 10.1099/vir.0.80044-0
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Lamb LS, 2005, BIOL BLOOD MARROW TR, V11, P62, DOI 10.1016/j.bbmt.2004.12.186
   Lassnig C, 2005, P NATL ACAD SCI USA, V102, P8275, DOI 10.1073/pnas.0408589102
   Law HKW, 2005, BLOOD, V106, P2366, DOI 10.1182/blood-2004-10-4166
   Lefeuvre Anabelle, 2004, Curr Infect Dis Rep, V6, P96, DOI 10.1007/s11908-996-0005-9
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Moore ZS, 2006, LANCET, V367, P425, DOI 10.1016/S0140-6736(06)68143-9
   MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221
   Oehen S, 2000, IMMUNOLOGY, V99, P163, DOI 10.1046/j.1365-2567.2000.00950.x
   Ortego J, 2003, VIROLOGY, V308, P13, DOI 10.1016/S0042-6822(02)00096-X
   Ortego J, 2002, J VIROL, V76, P11518, DOI 10.1128/JVI.76.22.11518-11529.2002
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998
   Plotkin SA, 2005, NAT MED, V11, pS5, DOI 10.1038/nm1209
   Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019
   Putics A, 2005, J VIROL, V79, P12721, DOI 10.1128/JVI.79.20.12721-12731.2005
   Racaniello VR, 2006, VIROLOGY, V344, P9, DOI 10.1016/j.virol.2005.09.015
   Richt JA, 2006, J VIROL, V80, P11009, DOI 10.1128/JVI.00787-06
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Sperry SM, 2005, J VIROL, V79, P3391, DOI 10.1128/JVI.79.6.3391-3400.2005
   Talon J, 2000, P NATL ACAD SCI USA, V97, P4309, DOI 10.1073/pnas.070525997
   Thiel V, 2003, J VIROL, V77, P9790, DOI 10.1128/JVI.77.18.9790-9798.2003
   Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273
   Tseng CTK, 2007, J VIROL, V81, P1162, DOI 10.1128/JVI.01702-06
   Turner BC, 2004, J VIROL, V78, P5486, DOI 10.1128/JVI.78.10.5486-5490.2004
   van der Hoek L, 2006, FEMS MICROBIOL REV, V30, P760, DOI 10.1111/j.1574-6976.2006.00032.x
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Ye Y, 2007, J VIROL, V81, P2554, DOI 10.1128/JVI.01634-06
   Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087
   Zhou HX, 2006, J VIROL, V80, P2506, DOI 10.1128/JVI.80.5.2506-2514.2006
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 55
TC 110
Z9 112
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD AUG
PY 2007
VL 3
IS 8
BP 1062
EP 1072
AR e109
DI 10.1371/journal.ppat.0030109
PG 11
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 214WF
UT WOS:000249768200005
PM 17696607
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Paton, DJ
   Christiansen, KH
   Alenius, S
   Cranwell, MP
   Pritchard, GC
   Drew, TW
AF Paton, DJ
   Christiansen, KH
   Alenius, S
   Cranwell, MP
   Pritchard, GC
   Drew, TW
TI Prevalence of antibodies to bovine virus diarrhoea virus and other
   viruses in bulk tank milk in England and Wales
SO VETERINARY RECORD
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; INFECTION; DISEASE
AB Bulk tank milk samples from 1070 dairy herds in England and Wales were tested by ELISA for antibodies to bovine virus diarrhoea virus (BVDV). A subset of 341 herds was tested by ELISA for antibodies to bovine herpesvirus 1 (BHV-1), bovine respiratory syncytial virus (BRSV) and bovine coronavirus (BCV), None of the herds had less than 40 dairy cows and none had been vaccinated against BVDV. The prevalence of BVDV antibody-positive herds in the national population was estimated at 95 per cent and approximately 65 per cent of the herds had a high level of bulk tank antibody suggestive of recent infection with BVDV, Dairy herds in East Anglia and the south-east of England had a significantly lower risk of being BVDV antibody-positive than herds in the rest of England and Wales. However, these regional differences tended to diminish with increasing herd size. Around 69 per cent of the herds were BHV-1 antibody-positive and all the herds were antibody positive to BRSV and BCV. Comparison with earlier serological surveys revealed that there had been little change in the prevalence and distribution of BVDV antibody-positive herds in England and Wales over the last 20 years, but that there had been an increase in the prevalence of BHV-1 antibody-positive herds.
C1 Cent Vet Lab, Vet Labs Agcy, Addlestone KT15 3NB, Surrey, England.
   Natl Vet Inst, S-75007 Uppsala, Sweden.
   Vet Invest Ctr, Vet Labs Agcy, Exeter, Devon, England.
   Vet Invest Ctr, Vet Labs Agcy, Bury St Edmunds IP33 2RX, Suffolk, England.
RP Paton, DJ (reprint author), Cent Vet Lab, Vet Labs Agcy, Addlestone KT15 3NB, Surrey, England.
RI Drew, Trevor W/C-5200-2011; cranwell, michael/C-9684-2011
CR ALENIUS S, 1991, ACTA VET SCAND, V32, P163
   ALENIUS S, 1996, P 3 ESVV C PEST LEL
   BITSCH V, 1995, VET CLIN N AM-FOOD A, V11, P627, DOI 10.1016/S0749-0720(15)30471-0
   BROWNLIE J, 1995, VET REC, V137, P58, DOI 10.1136/vr.137.3.58
   Dean AG, 1990, EPI INFO VERSION 5 W
   DUFFELL SJ, 1985, VET REC, V117, P240, DOI 10.1136/vr.117.10.240
   EDWARDS S, 1988, VET REC, V123, P614
   Edwards S, 1990, Rev Sci Tech, V9, P115
   EDWARDS S, 1987, VET REC, V120, P71, DOI 10.1136/vr.120.3.71
   Elvander M, 1996, VET REC, V138, P101, DOI 10.1136/vr.138.5.101
   ELVANDER M, 1995, J VET DIAGN INVEST, V7, P177, DOI 10.1177/104063879500700202
   ESPUNA E, 1988, MED VET, V5, P499
   Frankena K, 1997, VET REC, V140, P90, DOI 10.1136/vr.140.4.90
   HARKNESS JW, 1978, RES VET SCI, V24, P98, DOI 10.1016/S0034-5288(18)33106-0
   Hartman A, 1997, VET REC, V140, P484, DOI 10.1136/vr.140.18.484
   HOGG AA, 1992, P BRIT CATT VET ASS, P347
   HOUE H, 1991, PREV VET MED, V11, P9, DOI 10.1016/S0167-5877(05)80040-6
   HOUE H, 1995, VET CLIN N AM-FOOD A, V11, P521, DOI 10.1016/S0749-0720(15)30465-5
   LEVY PS, 1980, SAMPLING HLTH PROFES, P37
   LINDBERG A, 1995, P SOC VET EP PREV ME, P132
   *MAFF, 1996, AGR HORT CENS ENGL W
   MCCULLOUGH SJ, 1987, IRISH VET J, V41, P342
   NISKANEN R, 1993, VET REC, V133, P341, DOI 10.1136/vr.133.14.341
   NISKANEN R, 1991, ARCH VIROL         S, V3, P245
   PRITCHARD GC, 1992, P SOC VET EP PREV ME, P168
   *STAT EP RES CORP, 1993, EGR REF MAN REV 4
   VANWUIJCKHUISE L, 1993, P 6 M DUTCH SOC VET, P7
   VERHOEFF J, 1984, VET REC, V114, P288, DOI 10.1136/vr.114.12.288
   *VET LAB AG, 1996, VET INV SURV REP 199, P34
   Waage S., 1994, Proceedings 18th World Buiatrics Congress: 26th Congress of the Italian Association of Buiatrics, Bologna, Italy, August 29-September 2, 1994. Volume 1., P773
NR 30
TC 110
Z9 112
U1 1
U2 11
PU BRITISH VETERINARY ASSOC
PI LONDON
PA 7 MANSFIELD ST, LONDON, ENGLAND W1M 0AT
SN 0042-4900
J9 VET REC
JI Vet. Rec.
PD APR 11
PY 1998
VL 142
IS 15
BP 385
EP 391
DI 10.1136/vr.142.15.385
PG 9
WC Veterinary Sciences
SC Veterinary Sciences
GA ZK306
UT WOS:000073306000012
PM 9586130
DA 2020-04-03
ER

PT J
AU Haagmans, BL
   van den Brand, JMA
   Raj, VS
   Volz, A
   Wohlsein, P
   Smits, SL
   Schipper, D
   Bestebroer, TM
   Okba, N
   Fux, R
   Bensaid, A
   Foz, DS
   Kuiken, T
   Baumgartner, W
   Segales, J
   Sutter, G
   Osterhaus, ADME
AF Haagmans, Bart L.
   van den Brand, Judith M. A.
   Raj, V. Stalin
   Volz, Asisa
   Wohlsein, Peter
   Smits, Saskia L.
   Schipper, Debby
   Bestebroer, Theo M.
   Okba, Nisreen
   Fux, Robert
   Bensaid, Albert
   Foz, David Solanes
   Kuiken, Thijs
   Baumgaertner, Wolfgang
   Segales, Joaquim
   Sutter, Gerd
   Osterhaus, Albert D. M. E.
TI An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV
   infection in dromedary camels
SO SCIENCE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; RECEPTOR-BINDING DOMAIN; SAUDI-ARABIA;
   SPIKE PROTEIN; MOUSE MODEL; ANTIBODIES; TRACT; REPLICATION; EXPOSURE;
   EFFICACY
AB Middle East respiratory syndrome coronavirus (MERS-CoV) infections have led to an ongoing outbreak in humans, which was fueled by multiple zoonotic MERS-CoV introductions from dromedary camels. In addition to the implementation of hygiene measures to limit further camel-to-human and human-to-human transmissions, vaccine-mediated reduction of MERS-CoV spread from the animal reservoir may be envisaged. Here we show that a modified vaccinia virus Ankara (MVA) vaccine expressing the MERS-CoV spike protein confers mucosal immunity in dromedary camels. Compared with results for control animals, we observed a significant reduction of excreted infectious virus and viral RNA transcripts in vaccinated animals upon MERS-CoV challenge. Protection correlated with the presence of serum neutralizing antibodies to MERS-CoV. Induction of MVA-specific antibodies that cross-neutralize camelpox virus would also provide protection against camelpox.
C1 [Haagmans, Bart L.; van den Brand, Judith M. A.; Raj, V. Stalin; Smits, Saskia L.; Schipper, Debby; Bestebroer, Theo M.; Okba, Nisreen; Kuiken, Thijs; Osterhaus, Albert D. M. E.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
   [Volz, Asisa; Fux, Robert; Sutter, Gerd] Univ Munich, Inst Infect Dis & Zoonoses, German Ctr Infect Res DZIF, Munich, Germany.
   [Wohlsein, Peter; Baumgaertner, Wolfgang] Univ Vet Med, Dept Pathol, Hannover, Germany.
   [Bensaid, Albert; Foz, David Solanes; Segales, Joaquim] Univ Autonoma Barcelona, IRTA, CReSA, Bellaterra 08193, Spain.
   [Segales, Joaquim] Univ Autonoma Barcelona, Fac Vet, Dept Sanitat & Anat Anim, Bellaterra 08193, Spain.
   [Osterhaus, Albert D. M. E.] Artemis One Hlth, Utrecht, Netherlands.
   [Osterhaus, Albert D. M. E.] Univ Vet Med, Res Ctr Emerging Infect & Zoonoses RIZ, Hannover, Germany.
RP Haagmans, BL (reprint author), Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
EM b.haagmans@erasmusmc.nl; gerd.sutter@lmu.de;
   albert.osterhaus@tiho-hannover.de
RI Raj, V Stalin/E-9670-2016; Bensaid, Albert/K-1960-2017; Okba, Nisreen
   MA/K-9984-2017; Segales, Joaquim/AAB-4815-2020; Segales,
   Joaquim/A-4933-2011
OI Raj, V Stalin/0000-0003-2250-8481; Bensaid, Albert/0000-0001-6493-3756;
   Okba, Nisreen MA/0000-0002-2394-1079; Segales,
   Joaquim/0000-0002-1539-7261; Segales, Joaquim/0000-0002-1539-7261;
   Haagmans, Bart/0000-0001-6221-2015; Kuiken, Thijs/0000-0001-5501-9049;
   Sutter, Gerd/0000-0001-6143-082X
FU Nederlandse Organisatie voor Wetenschappelijk OnderzoekNetherlands
   Organization for Scientific Research (NWO) [91213066];
   Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the
   Ministry of Science and Culture of Lower Saxony, Germany; Zoonotic
   Anticipation and Preparedness Initiative (ZAPI project) [Innovative
   Medicines Initiative (IMI) grant] [115760]; IMI; European
   CommissionEuropean Commission Joint Research Centre
FX We thank F. van der Panne for figure preparation and P. van Run, S.
   Jany, X. Abad, I. Cordon, M. Jesus Navas, M. Mora, and all animal
   caretakers from the CReSA biosecurity level 3 laboratories and animal
   facilities for technical assistance. This study was funded by
   Nederlandse Organisatie voor Wetenschappelijk Onderzoek (grant 91213066)
   and was supported in part by the Niedersachsen-Research Network on
   Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of
   Lower Saxony, Germany. Animal model development was performed as part of
   the Zoonotic Anticipation and Preparedness Initiative (ZAPI project)
   [Innovative Medicines Initiative (IMI) grant 115760], with assistance
   and financial support from IMI and the European Commission and
   contributions from the EFPIA partners. B.L.H., V.S.R., T.M.B., G.S., and
   A.D.M.E.O. have applied for patents on MERS-CoV. A.D.M.E.O. is chief
   scientific officer of Viroclinics Biosciences. A.D.M.E.O and T.K. hold
   certificates of shares in Viroclinics Biosciences. Nucleotide sequence
   data are available in GenBank under accession numbers KT966879 and
   KT966880.
CR Adney DR, 2014, EMERG INFECT DIS, V20, P1999, DOI 10.3201/eid2012.141280
   Alagaili AN, 2014, MBIO, V5, DOI 10.1128/mBio.00884-14
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Chan RWY, 2014, LANCET RESP MED, V2, P813, DOI 10.1016/S2213-2600(14)70158-4
   de Wit E, 2013, P NATL ACAD SCI USA, V110, P16598, DOI 10.1073/pnas.1310744110
   Du LY, 2013, J VIROL, V87, P9939, DOI 10.1128/JVI.01048-13
   Duraffour S, 2011, ANTIVIR RES, V92, P167, DOI 10.1016/j.antiviral.2011.09.003
   Haagmans BL, 2015, J VIROL, V89, P6131, DOI 10.1128/JVI.00661-15
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   HAFEZ SM, 1992, VACCINE, V10, P533, DOI 10.1016/0264-410X(92)90353-L
   Hemida MG, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.23.20828
   Hemida MG, 2014, EMERG INFECT DIS, V20, P1231, DOI 10.3201/eid2007.140571
   Khalafalla AI, 2015, EMERG INFECT DIS, V21, P1153, DOI 10.3201/eid2107.150070
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Mou H, 2013, J VIROL, V87, P9379, DOI 10.1128/JVI.01277-13
   Muller MA, 2015, LANCET INFECT DIS, V15, P559, DOI 10.1016/S1473-3099(15)70090-3
   Muller MA, 2014, EMERG INFECT DIS, V20, P2093, DOI 10.3201/eid2012.141026
   Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462
   Pascal KE, 2015, P NATL ACAD SCI USA, V112, P8738, DOI 10.1073/pnas.1510830112
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reusken CBEM, 2015, EMERG INFECT DIS, V21, P1422, DOI 10.3201/eid2108.150481
   Reusken CBEM, 2014, EMERG INFECT DIS, V20, P1370, DOI 10.3201/eid2008.140590
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Song F, 2013, J VIROL, V87, P11950, DOI 10.1128/JVI.01672-13
   Stittelaar KJ, 2000, J VIROL, V74, P4236, DOI 10.1128/JVI.74.9.4236-4243.2000
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   VENNEMA H, 1990, J VIROL, V64, P1407, DOI 10.1128/JVI.64.3.1407-1409.1990
   Volz A, 2015, J VIROL, V89, P8651, DOI 10.1128/JVI.00614-15
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhao JC, 2015, J VIROL, V89, P6117, DOI 10.1128/JVI.00446-15
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 32
TC 109
Z9 110
U1 8
U2 37
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JAN 1
PY 2016
VL 351
IS 6268
BP 77
EP 81
DI 10.1126/science.aad1283
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CZ8QM
UT WOS:000367364200046
PM 26678878
OA Bronze
HC Y
HP N
DA 2020-04-03
ER

PT J
AU Corman, VM
   Jores, J
   Meyer, B
   Younan, M
   Liljander, A
   Said, MY
   Gluecks, I
   Lattwein, E
   Bosch, BJ
   Drexler, JF
   Bornstein, S
   Drosten, C
   Muller, MA
AF Corman, Victor M.
   Jores, Joerg
   Meyer, Benjamin
   Younan, Mario
   Liljander, Anne
   Said, Mohammed Y.
   Gluecks, Ilona
   Lattwein, Erik
   Bosch, Berend-Jan
   Drexler, Jan Felix
   Bornstein, Set
   Drosten, Christian
   Mueller, Marcel A.
TI Antibodies against MERS Coronavirus in Dromedary Camels, Kenya,
   1992-2013
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; BAT; VIRUSES
AB Dromedary camels are a putative source for human infections with Middle East respiratory syndrome coronavirus. We showed that camels sampled in different regions in Kenya during 1992-2013 have antibodies against this virus. High densities of camel populations correlated with increased seropositivity and might be a factor in predicting long-term virus maintenance.
C1 [Corman, Victor M.; Meyer, Benjamin; Drexler, Jan Felix; Drosten, Christian; Mueller, Marcel A.] Univ Bonn, Med Ctr, D-53105 Bonn, Germany.
   [Jores, Joerg; Liljander, Anne; Said, Mohammed Y.] Int Livestock Res Inst, Nairobi, Kenya.
   [Younan, Mario] Vet Sans Frontieres Germany, Nairobi, Kenya.
   [Gluecks, Ilona] Vet Sans Frontieres Suisse, Nairobi, Kenya.
   [Lattwein, Erik] EUROIMMUN AG, Lubeck, Germany.
   [Bosch, Berend-Jan] Univ Utrecht, Utrecht, Netherlands.
   [Bornstein, Set] Natl Vet Inst, S-75007 Uppsala, Sweden.
RP Drosten, C (reprint author), Univ Bonn, Med Ctr, Inst Virol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM drosten@virology-bonn.de
RI Meyer, Bernhard/Q-9413-2016; Mueller, Marcel/O-2425-2019; Corman, Victor
   Max/K-1319-2019; Meyer, Benjamin/F-3285-2018; said, mohammed/E-4932-2019
OI Mueller, Marcel/0000-0003-2242-5117; Corman, Victor
   Max/0000-0002-3605-0136; Meyer, Benjamin/0000-0003-0601-3550; said,
   mohammed/0000-0001-9278-3193; Drexler, Jan Felix/0000-0002-3509-0232;
   Jores, Joerg/0000-0003-3790-5746
FU European CommissionEuropean Commission Joint Research Centre [223498,
   278976]; German Research Foundation (DFG)German Research Foundation
   (DFG) [DR772/3-1]; Consultative Group for International Agricultural
   Research Program on Agriculture for Nutrition and Health; Centrum of
   International Migration
FX This study was supported by the European Commission (FP7-EMPERIE no.
   223498 and FP7-ANTIGONE no. 278976) and the German Research Foundation
   (DFG grant DR772/3-1 to C.D.) and the Consultative Group for
   International Agricultural Research Program on Agriculture for Nutrition
   and Health. A.L. was supported by the Centrum of International
   Migration. C.D. received infrastructural support from the German Center
   for Infection Research.
CR Aklilu Y, 2009, LIVESTOCK EXPORTS HO
   Alagaili AN, 2014, MBIO, V5, DOI 10.1128/mBio.00884-14
   Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Chu DKW, 2014, EMERG INFECT DIS, V20, P1049, DOI 10.3201/eid2006.140299
   Drexler JF, 2011, EMERG INFECT DIS, V17, P449, DOI 10.3201/eid1703.100526
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Mahmoud HA, 2010, CAMEL MARKETING NO K
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Ottichilo Wilber K., 2000, Conservation Biology Series (Dordrecht), V12, P203
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Reusken CBEM, 2010, VECTOR-BORNE ZOONOT, V10, P785, DOI 10.1089/vbz.2009.0173
   World Health Organization, 2014, MIDDL E RESP SYNDR C
NR 15
TC 109
Z9 115
U1 1
U2 20
PU CENTERS  DISEASE CONTROL & PREVENTION
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD AUG
PY 2014
VL 20
IS 8
BP 1319
EP 1322
DI 10.3201/eid2008.140596
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AM4ZF
UT WOS:000339864000007
PM 25075637
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Ying, TL
   Du, LY
   Ju, TW
   Prabakaran, P
   Lau, CCY
   Lu, L
   Liu, Q
   Wang, LL
   Feng, Y
   Wang, YP
   Zheng, BJ
   Yuen, KY
   Jiang, SB
   Dimitrov, DS
AF Ying, Tianlei
   Du, Lanying
   Ju, Tina W.
   Prabakaran, Ponraj
   Lau, Candy C. Y.
   Lu, Lu
   Liu, Qi
   Wang, Lili
   Feng, Yang
   Wang, Yanping
   Zheng, Bo-Jian
   Yuen, Kwok-Yung
   Jiang, Shibo
   Dimitrov, Dimiter S.
TI Exceptionally Potent Neutralization of Middle East Respiratory Syndrome
   Coronavirus by Human Monoclonal Antibodies
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID RECEPTOR-BINDING DOMAIN; MERS-COV; SAUDI-ARABIA; THERAPEUTICS; VIRUSES;
   IDENTIFICATION; PROTEIN; HENDRA; NIPAH; HIV-1
AB The recently discovered Middle East respiratory syndrome coronavirus (MERS-CoV) continues to infect humans, with high mortality. Specific, highly effective therapeutics and vaccines against the MERS-CoV are urgently needed to save human lives and address the pandemic concerns. We identified three human monoclonal antibodies (MAbs), m336, m337, and m338, targeting the receptor (CD26/DPP4) binding domain (RBD) of the MERS-CoV spike glycoprotein from a very large naive-antibody library (containing similar to 10(11) antibodies). They bound with high affinity: equilibrium dissociation constants for the three MAbs were equal to 4.2, 9.3, and 15 nM, respectively, as measured by Biacore for Fabs binding to RBD. The avidity for IgG1 m336, m337, and m338 was even higher: 99, 820, and 560 pM, respectively. The antibodies bound to overlapping epitopes that overlap the receptor binding site on the RBD as suggested by competition experiments and further supported by site-directed mutagenesis of the RBD and a docking model of the m336-RBD complex. The highest-affinity MAb, m336, neutralized both pseudotyped and live MERS-CoV with exceptional potency, 50% neutralization at 0.005 and 0.07 mu g/ml, respectively, likely by competing with DPP4 for binding to the S glycoprotein. The exceptionally high neutralization activity of these antibodies and especially m336 suggests that they have great potential for prophylaxis and therapy of MERS-CoV infection in humans and as a tool for development of vaccine immunogens. The rapid identification (within several weeks) of potent MAbs suggests a possibility to use the new large antibody library and related methodology for a quick response to the public threat resulting from emerging coronaviruses.
   IMPORTANCE
   A novel human coronavirus, the Middle East respiratory syndrome coronavirus (MERS-CoV), was found to infect humans with a high mortality rate in 2012, just 1 decade after the appearance of the first highly pathogenic coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV). There are no effective therapeutics available. It is highly desirable to find an approach for rapidly developing potent therapeutics against MERS-CoV, which not only can be implemented for MERS treatment but also can help to develop a platform strategy to combat future emerging coronaviruses. We report here the identification of human monoclonal antibodies (MAbs) from a large nonimmune antibody library that target MERS-CoV. One of the antibodies, m336, neutralized the virus with exceptional potency. It therefore may have great potential as a candidate therapeutic and as a reagent to facilitate the development of vaccines against MERS-CoV.
C1 [Ying, Tianlei; Ju, Tina W.; Prabakaran, Ponraj; Feng, Yang; Wang, Yanping; Dimitrov, Dimiter S.] NCI, Prot Interact Grp, Expt Immunol Lab, Canc & Inflammat Program,Ctr Canc Res,NIH, Frederick, MD 21701 USA.
   [Du, Lanying; Wang, Lili; Jiang, Shibo] New York Blood Ctr, Lindsley Kimball Res Inst, New York, NY 10021 USA.
   [Prabakaran, Ponraj; Zheng, Bo-Jian; Yuen, Kwok-Yung] Leidos Biomed Res Inc, Basic Sci Program, Frederick Natl Lab, Frederick, MD USA.
   [Lau, Candy C. Y.] Univ Hong Kong, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China.
   [Lu, Lu; Liu, Qi; Jiang, Shibo] Fudan Univ, Key Lab Med Mol Virol, Minist Educ, Shanghai Med Coll, Shanghai 200433, Peoples R China.
   [Lu, Lu; Liu, Qi; Jiang, Shibo] Fudan Univ, Key Lab Med Mol Virol, Minist Hlth, Shanghai Med Coll, Shanghai 200433, Peoples R China.
   [Lu, Lu; Liu, Qi; Jiang, Shibo] Fudan Univ, Inst Med Microbiol, Shanghai 200433, Peoples R China.
RP Ying, TL (reprint author), NCI, Prot Interact Grp, Expt Immunol Lab, Canc & Inflammat Program,Ctr Canc Res,NIH, Frederick, MD 21701 USA.
EM yingt@mail.nih.gov; dimiter.dimitrov@nih.gov
RI 应, 天雷/P-5396-2019; Lu, Lu/K-7070-2014; Jiang, Shibo/L-4500-2014; Ponraj,
   Prabakaran/D-6325-2011
OI 应, 天雷/0000-0002-9597-2843; Lu, Lu/0000-0002-2255-0391; Ponraj,
   Prabakaran/0000-0002-4049-4813; Yuen, Kwok-yung/0000-0002-2083-1552
FU NIH, National Cancer Institute, Center for Cancer ResearchUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI); NIH, National Cancer
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [N01-CO-12400, HHSN261200800001E]
FX This work was supported by the Intramural Research Program of the NIH,
   National Cancer Institute, Center for Cancer Research, and by Federal
   funds from the NIH, National Cancer Institute, under contract no.
   N01-CO-12400 and HHSN261200800001E.
CR Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Bossart KN, 2008, VIROLOGY, V372, P357, DOI 10.1016/j.virol.2007.11.011
   Bossart KN, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002901
   Bossart KN, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000642
   Carter PJ, 2006, NAT REV IMMUNOL, V6, P343, DOI 10.1038/nri1837
   Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974
   Chan CH, 2001, BLOOD, V97, P1023, DOI 10.1182/blood.V97.4.1023
   Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Devitt E, 2013, NAT MED, V19, P952, DOI 10.1038/nm0813-952
   Dimitrov Dimiter S, 2012, Methods Mol Biol, V899, P1, DOI 10.1007/978-1-61779-921-1_1
   Du LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081587
   Du LY, 2013, J VIROL, V87, P9939, DOI 10.1128/JVI.01048-13
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Kwong PD, 2012, IMMUNITY, V37, P412, DOI 10.1016/j.immuni.2012.08.012
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Marasco WA, 2007, NAT BIOTECHNOL, V25, DOI 10.1038/nbt1363
   Marcatili P, 2008, BIOINFORMATICS, V24, P1953, DOI 10.1093/bioinformatics/btn341
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Ohshima N, 2011, J VIROL, V85, P11048, DOI 10.1128/JVI.05397-11
   Prabakaran Ponraj, 2012, Front Microbiol, V3, P277, DOI 10.3389/fmicb.2012.00277
   Prabakaran P, 2009, EXPERT OPIN BIOL TH, V9, P355, DOI [10.1517/14712590902763755, 10.1517/14712590902763755 ]
   Schrama D, 2006, NAT REV DRUG DISCOV, V5, P147, DOI 10.1038/nrd1957
   Scott LJ, 1999, DRUGS, V58, P305, DOI 10.2165/00003495-199958020-00009
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
   Zhu Zhongyu, 2013, Virologica Sinica, V28, P71, DOI 10.1007/s12250-013-3313-x
   Zhu ZY, 2006, J VIROL, V80, P891, DOI 10.1128/JVI.80.2.891-899.2006
NR 32
TC 109
Z9 121
U1 6
U2 37
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUL
PY 2014
VL 88
IS 14
BP 7796
EP 7805
DI 10.1128/JVI.00912-14
PG 10
WC Virology
SC Virology
GA AK5CT
UT WOS:000338442600012
PM 24789777
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Al-Tawfiq, JA
   Momattin, H
   Dib, J
   Memish, ZA
AF Al-Tawfiq, Jaffar A.
   Momattin, Hisham
   Dib, Jean
   Memish, Ziad A.
TI Ribavirin and interferon therapy in patients infected with the Middle
   East respiratory syndrome coronavirus: an observational study
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE MERS-CoV; Interferon; Ribavirin; Pegylated interferon
ID FAMILY CLUSTER; SYNDROME SARS; SAUDI-ARABIA; MERS-COV; OUTBREAK;
   PNEUMONIA; SINGAPORE
AB Background: The Middle East respiratory syndrome coronavirus (MERS-CoV) has been reported to have a high case-fatality rate. Currently, there is no specific therapy or vaccine with proven effectiveness for MERS-CoV infections.
   Methods: A combination of ribavirin and interferon therapy was used for the treatment of five MERS-CoV-positive patients. We reviewed the therapeutic schedule and the outcome of these patients.
   Results: All patients were critically ill with acute respiratory distress syndrome treated with adjunctive corticosteroids and were on mechanical ventilation at the time of initiation of therapy. The median time from admission to therapy with ribavirin and interferon was 19 (range 10-22) days. None of the patients responded to the supportive or therapeutic interventions and all died of their illness.
   Conclusions: While ribavirin and interferon may be effective in some patients, our practical experience suggests that critically ill patients with multiple comorbidities who are diagnosed late in the course of their illness may not benefit from combination antiviral therapy as preclinical data suggest. There is clearly an urgent need for a novel effective antiviral therapy for this emerging global threat. (C) 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. All rights reserved.
C1 [Al-Tawfiq, Jaffar A.] Saudi Aramco Med Serv Org, Internal Med, Dhahran Hlth Ctr, Dhahran 31311, Saudi Arabia.
   [Al-Tawfiq, Jaffar A.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [Momattin, Hisham; Dib, Jean] Saudi Aramco Med Serv Org, Pharm Serv Div, Dhahran 31311, Saudi Arabia.
   [Memish, Ziad A.] Minist Hlth, WHO Collaborating Ctr Mass Gathering Med, Riyadh, Saudi Arabia.
   [Memish, Ziad A.] Al Faisal Univ, Riyadh, Saudi Arabia.
RP Al-Tawfiq, JA (reprint author), Saudi Aramco Med Serv Org, Internal Med, Dhahran Hlth Ctr, POB 76,Room A-428-2,Bldg 61, Dhahran 31311, Saudi Arabia.
EM jaffar.tawfiq@aramco.com
CR Adisasmito W, 2010, J INFECT DIS, V202, P1154, DOI 10.1086/656316
   [Anonymous], 2009, PROD INF REBETOL R O
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Chan JF, 2013, J INFECT
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Hsu LY, 2003, EMERG INFECT DIS, V9, P713
   Leong HN, 2004, TROP MED INT HEALTH, V9, P923, DOI 10.1111/j.1365-3156.2004.01281.x
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Momattin H, 2013, INT J INFECT DIS, V17, pE792, DOI 10.1016/j.ijid.2013.07.002
   Omrani AS, 2013, INT J INFECT DIS, V17, pE668, DOI 10.1016/j.ijid.2013.07.001
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Penttinen PM, 2013, EUROSURVEILLANCE, V18, P11, DOI 10.2807/1560-7917.ES2013.18.39.20596
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   World Health Organization, 2013, MIDDL E RESP SYNDR C
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
NR 22
TC 109
Z9 115
U1 3
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAR
PY 2014
VL 20
BP 42
EP 46
DI 10.1016/j.ijid.2013.12.003
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA AD9DO
UT WOS:000333565100008
PM 24406736
OA DOAJ Gold
DA 2020-04-03
ER

PT J
AU Hemida, MG
   Perera, RA
   Wang, P
   Alhammadi, MA
   Siu, LY
   Li, M
   Poon, LL
   Saif, L
   Alnaeem, A
   Peiris, M
AF Hemida, M. G.
   Perera, R. A.
   Wang, P.
   Alhammadi, M. A.
   Siu, L. Y.
   Li, M.
   Poon, L. L.
   Saif, L.
   Alnaeem, A.
   Peiris, M.
TI Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in
   domestic livestock in Saudi Arabia, 2010 to 2013
SO EUROSURVEILLANCE
LA English
DT Article
AB In Saudi Arabia, including regions of Riyadh and Al Ahsa, pseudoparticle neutralisation (ppNT) and microneutralisation (MNT) tests detected no antibodies to Middle East Respiratory Syndrome coronavirus (MERS-CoV) in sheep (n= 100), goats (n= 45), cattle (n= 50) and chickens (n= 240). Dromedary camels however, had a high prevalence of MERS-CoV antibodies. Bovine coronavirus (BCoV) infected sera from cattle had no cross-reactivity in MERS-CoV ppNT or MNT, while many dromedary camels' sera reacted to both BCoV and MERS-CoV. Some nevertheless displayed specific serologic reaction profiles to MERS-CoV.
C1 [Hemida, M. G.; Perera, R. A.] King Faisal Univ, Coll Vet Med, Dept Microbiol & Parasitol, Al Hasa, Saudi Arabia.
   [Hemida, M. G.] Kaferelsheik Univ, Fac Vet Med, Dept Virol, Kafr Al Sheikh, Egypt.
   [Hemida, M. G.; Poon, L. L.; Peiris, M.] Univ Hong Kong, Influenza Res Ctr, Hong Kong, Hong Kong, Peoples R China.
   [Perera, R. A.; Siu, L. Y.; Li, M.; Poon, L. L.] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China.
   [Wang, P.; Siu, L. Y.; Li, M.] Univ Hong Kong, HKU Pasteur Pole, Hong Kong, Hong Kong, Peoples R China.
   [Wang, P.] Chinese Acad Sci, Key Lab Prot & Peptide Pharmaceut, Joint Lab Struct Virol & Immunol, Univ Tokyo, Beijing, Peoples R China.
   [Saif, L.] Ohio State Univ, OARDC, Dept Vet Prevent Med, Food Anim Hlth Res Program, Wooster, OH USA.
   [Alnaeem, A.] King Faisal Univ, Coll Vet Med, Dept Clin Studies, Al Hasa, Saudi Arabia.
RP Hemida, MG (reprint author), King Faisal Univ, Coll Vet Med, Dept Microbiol & Parasitol, Al Hasa, Saudi Arabia.
EM mhemida@kfu.edu.sa; mahenp@hku.hk; pgwang@hkucc.hku.hk;
   malhammadi@kfu.edu.sa; lmy288@hku.hk; llmpoon@hku.hk; saif.2@osu.edu;
   aaalnaeem@kfu.edu; malik@hku.hk
RI Perera, Ranawaka A.P.M/N-8263-2015; Saif, Linda/E-4005-2011; Hemida,
   Maged/L-9888-2016; Poon, Leo/C-4382-2009
OI Perera, Ranawaka A.P.M/0000-0003-3936-1535; Hemida,
   Maged/0000-0002-5986-7237; Poon, Leo/0000-0002-9101-7953; Wang,
   Peigang/0000-0001-6045-2007
FU Deanship of Scientific Research at King Faisal University; European
   CommunityEuropean Community (EC) [223498]; National Institute of Allergy
   and Infectious Diseases (NIAID)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [HHSN266200700005C]
FX This study was supported by a grant from the Deanship of Scientific
   Research at King Faisal University. Work at the University of Hong Kong
   was supported by grants from the European Community Seventh Framework
   Program (FP7/2007-2013) under project European management Platform for
   Emerging and Re-emerging Disease entities (Grant agreement No. 223498)
   (EMPERIE) and a research contract from the National Institute of Allergy
   and Infectious Diseases (NIAID) contract HHSN266200700005C
CR Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Flajnik MF, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001120
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   The WHO MERS-CoV Research Group, 2013, PLOS CURR, V5
   WHO, MIDDL E RESP SYNDR C
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 10
TC 109
Z9 116
U1 1
U2 26
PU EUR CENTRE DIS PREVENTION & CONTROL
PI STOCKHOLM
PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN
SN 1560-7917
J9 EUROSURVEILLANCE
JI Eurosurveillance
PD DEC 12
PY 2013
VL 18
IS 50
BP 21
EP 27
AR 20659
DI 10.2807/1560-7917.ES2013.18.50.20659
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 275ON
UT WOS:000328686800005
PM 24342517
OA DOAJ Gold
DA 2020-04-03
ER

PT J
AU Ge, XY
   Li, Y
   Yang, XL
   Zhang, HJ
   Zhou, P
   Zhang, YZ
   Shi, ZL
AF Ge, Xingyi
   Li, Yan
   Yang, Xinglou
   Zhang, Huajun
   Zhou, Peng
   Zhang, Yunzhi
   Shi, Zhengli
TI Metagenomic Analysis of Viruses from Bat Fecal Samples Reveals Many
   Novel Viruses in Insectivorous Bats in China
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SARS-LIKE CORONAVIRUSES; GENETIC DIVERSITY; EXPERIMENTAL-INFECTION;
   VIRAL METAGENOMICS; SEQUENCE ALIGNMENT; HORSESHOE BATS; PTEROPID BATS;
   NIPAH VIRUS; RESERVOIR; ASTROVIRUSES
AB Increasing data indicate that bats harbor diverse viruses, some of which cause severe human diseases. In this study, sequence-independent amplification and high-throughput sequencing (Solexa) were applied to the metagenomic analysis of viruses in bat fecal samples collected from 6 locations in China. A total of 8,746,417 reads with a length of 306,124,595 bp were obtained. Among these reads, 13,541 (0.15%) had similarity to phage sequences and 9,170 (0.1%) had similarity to eukaryotic virus sequences. A total of 129 assembled contigs (>100 nucleotides) were constructed and compared with GenBank: 32 contigs were related to phages, and 97 were related to eukaryotic viruses. The most frequent reads and contigs related to eukaryotic viruses were homologous to densoviruses, dicistroviruses, coronaviruses, parvoviruses, and tobamoviruses, a range that includes viruses from invertebrates, vertebrates, and plants. Most of the contigs had low identities to known viral genomic or protein sequences, suggesting that a large number of novel and genetically diverse insect viruses as well as putative mammalian viruses are transmitted by bats in China. This study provides the first preliminary understanding of the virome of some bat populations in China, which may guide the discovery and isolation of novel viruses in the future.
C1 [Ge, Xingyi; Li, Yan; Yang, Xinglou; Zhang, Huajun; Zhou, Peng; Shi, Zhengli] Chinese Acad Sci, State Key Lab Virol, Wuhan Inst Virol, Wuhan, Peoples R China.
   [Zhang, Yunzhi] Yunnan Inst Endem Dis Control & Prevent, Dali, Peoples R China.
RP Shi, ZL (reprint author), Chinese Acad Sci, State Key Lab Virol, Wuhan Inst Virol, Wuhan, Peoples R China.
EM shi.zlshi@wh.iov.cn
RI Shi, Zhengli/A-1013-2013; Zhou, Peng/I-8578-2015
OI Shi, Zhengli/0000-0001-8089-163X; Zhou, Peng/0000-0003-1938-8255; Yang,
   Xing-Lou/0000-0002-5317-8983
FU State Key Program for Basic ResearchState Key Development Program for
   Basic Research of China [2011CB504701]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [30970137]
FX This work was jointly funded by the State Key Program for Basic Research
   Grant (2011CB504701) and the National Natural Science Foundation of
   China (30970137).
CR Almeida MF, 2005, EPIDEMIOL INFECT, V133, P523, DOI 10.1017/S0950268804003656
   Bench SR, 2007, APPL ENVIRON MICROB, V73, P7629, DOI 10.1128/AEM.00938-07
   Blinkova O, 2009, J VIROL, V83, P4631, DOI 10.1128/JVI.02085-08
   Breitbart M, 2003, J BACTERIOL, V185, P6220, DOI 10.1128/JB.185.20.6220-6223.2003
   Breitbart M, 2002, P NATL ACAD SCI USA, V99, P14250, DOI 10.1073/pnas.202488399
   Breitbart M, 2008, RES MICROBIOL, V159, P367, DOI 10.1016/j.resmic.2008.04.006
   Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06
   Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282
   Cheng WX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013583
   Chu DKW, 2008, J VIROL, V82, P9107, DOI 10.1128/JVI.00857-08
   Delwart EL, 2007, REV MED VIROL, V17, P115, DOI 10.1002/rmv.532
   Djikeng A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007264
   Donaldson EF, 2010, J VIROL, V84, P13004, DOI 10.1128/JVI.01255-10
   Drexler JF, 2010, J VIROL, V84, P11336, DOI 10.1128/JVI.00650-10
   Ge XY, 2011, J GEN VIROL, V92, P2646, DOI 10.1099/vir.0.034108-0
   Halpin K, 2000, J GEN VIROL, V81, P1927, DOI 10.1099/0022-1317-81-8-1927
   Hughes GJ, 2006, ARCH VIROL, V151, P2021, DOI 10.1007/s00705-005-0785-0
   Johara MY, 2001, EMERG INFECT DIS, V7, P439
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Lau SKP, 2011, J VIROL, V85, P8819, DOI 10.1128/JVI.02364-10
   Lau SKP, 2010, J VIROL, V84, P11385, DOI 10.1128/JVI.01121-10
   Lau SKP, 2010, J VIROL, V84, P2808, DOI 10.1128/JVI.02219-09
   Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a
   Li LL, 2010, J VIROL, V84, P6955, DOI 10.1128/JVI.00501-10
   Li LL, 2010, J VIROL, V84, P1674, DOI 10.1128/JVI.02109-09
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li Y, 2010, J GEN VIROL, V91, P2601, DOI 10.1099/vir.0.020032-0
   Li Y, 2010, J VIROL, V84, P3889, DOI 10.1128/JVI.02497-09
   Luby SP, 2009, EMERG INFECT DIS, V15, P1229, DOI 10.3201/eid1508.081237
   Middleton DJ, 2007, J COMP PATHOL, V136, P266, DOI 10.1016/j.jcpa.2007.03.002
   Nakashima N, 2009, VIRUS RES, V139, P137, DOI 10.1016/j.virusres.2008.06.006
   Ng TFF, 2009, J VIROL, V83, P2500, DOI 10.1128/JVI.01946-08
   Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042
   Poon LLM, 2005, J VIROL, V79, P2001, DOI 10.1128/JVI.79.4.2001-2009.2005
   Ren W, 2006, J GEN VIROL, V87, P3355, DOI 10.1099/vir.0.82220-0
   Rosario K, 2009, J GEN VIROL, V90, P2418, DOI 10.1099/vir.0.012955-0
   Schoenfeld T, 2008, APPL ENVIRON MICROB, V74, P4164, DOI 10.1128/AEM.02598-07
   Shi ZL, 2010, PROTEIN CELL, V1, P109, DOI 10.1007/s13238-010-0029-7
   Sullivan MB, 2008, ENVIRON MICROBIOL, V10, P2810, DOI 10.1111/j.1462-2920.2008.01702.x
   Tjornehoj K, 2006, J COMP PATHOL, V134, P190, DOI 10.1016/j.jcpa.2005.10.005
   Towner JS, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000536
   Victoria JG, 2009, J VIROL, V83, P4642, DOI 10.1128/JVI.02301-08
   Victoria JG, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000163
   Wang F, 2010, VIRUS GENES, V41, P305, DOI 10.1007/s11262-010-0506-3
   Williamson SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001456
   Woo PCY, 2007, J VIROL, V81, P1574, DOI 10.1128/JVI.02182-06
   Yuan JF, 2010, J GEN VIROL, V91, P1058, DOI 10.1099/vir.0.016378-0
   Zhu HC, 2009, J GEN VIROL, V90, P883, DOI 10.1099/vir.0.007732-0
NR 49
TC 109
Z9 123
U1 1
U2 36
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD APR
PY 2012
VL 86
IS 8
BP 4620
EP 4630
DI 10.1128/JVI.06671-11
PG 11
WC Virology
SC Virology
GA 917NU
UT WOS:000302185400056
PM 22345464
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Bahir, I
   Fromer, M
   Prat, Y
   Linial, M
AF Bahir, Iris
   Fromer, Menachem
   Prat, Yosef
   Linial, Michal
TI Viral adaptation to host: a proteome-based analysis of codon usage and
   amino acid preferences
SO MOLECULAR SYSTEMS BIOLOGY
LA English
DT Article
DE capsid; codon usage; host tropism; protein classification; UniProt
   database; viral proteome
ID SYNONYMOUS CODON; NUCLEOTIDE COMPOSITION; ESCHERICHIA-COLI; GENOME
   EVOLUTION; GENE-EXPRESSION; RNA VIRUSES; BIAS; KNOWLEDGEBASE;
   GLYCOPROTEIN; CORONAVIRUS
AB Viruses differ markedly in their specificity toward host organisms. Here, we test the level of general sequence adaptation that viruses display toward their hosts. We compiled a representative data set of viruses that infect hosts ranging from bacteria to humans. We consider their respective amino acid and codon usages and compare them among the viruses and their hosts. We show that bacteria-infecting viruses are strongly adapted to their specific hosts, but that they differ from other unrelated bacterial hosts. Viruses that infect humans, but not those that infect other mammals or aves, show a strong resemblance to most mammalian and avian hosts, in terms of both amino acid and codon preferences. In groups of viruses that infect humans or other mammals, the highest observed level of adaptation of viral proteins to host codon usages is for those proteins that appear abundantly in the virion. In contrast, proteins that are known to participate in host-specific recognition do not necessarily adapt to their respective hosts. The implication for the potential of viral infectivity is discussed. Molecular Systems Biology 5: 311; published online 13 October 2009; doi:10.1038/msb.2009.71
C1 [Bahir, Iris; Linial, Michal] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.
   [Fromer, Menachem; Prat, Yosef] Hebrew Univ Jerusalem, Sch Engn & Comp Sci, IL-91904 Jerusalem, Israel.
   [Linial, Michal] Hebrew Univ Jerusalem, Sudarsky Ctr Computat Biol, IL-91904 Jerusalem, Israel.
RP Linial, M (reprint author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Edmond J Safra Campus Givat Ram, IL-91904 Jerusalem, Israel.
EM michall@cc.huji.ac.il
RI Fromer, Menachem/G-2116-2012
OI Fromer, Menachem/0000-0003-3749-4342
FU EUEuropean Union (EU); Israel Science Foundation (ISF)Israel Science
   Foundation
FX We thank Nati Linial for valuable suggestions and a critical view
   throughout the research. We thank the ProtoNet research group for
   comments and discussions. YP and MF are fellows of the SCCB, the
   Sudarsky Center for Computational Biology. This research is partially
   supported by EU Prospects FR7 and a grant from the Israel Science
   Foundation (ISF).
CR Akashi H, 2001, CURR OPIN GENET DEV, V11, P660, DOI 10.1016/S0959-437X(00)00250-1
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131
   BARRAI I, 1990, NUCLEIC ACIDS RES, V18, P3021, DOI 10.1093/nar/18.10.3021
   Barrai I, 2008, INTERVIROLOGY, V51, P101, DOI 10.1159/000134267
   Barrett JW, 2006, VIRUS GENES, V33, P15, DOI 10.1007/s11262-005-0035-7
   Berkhout B, 2002, AIDS RES HUM RETROV, V18, P133, DOI 10.1089/08892220252779674
   BERNARDI G, 1986, J MOL EVOL, V24, P1, DOI 10.1007/BF02099946
   BONHOEFFER S, 1994, P NATL ACAD SCI USA, V91, P8062, DOI 10.1073/pnas.91.17.8062
   Boutet Emmanuel, 2007, V406, P89
   BRONSON EC, 1994, J MOL EVOL, V38, P506, DOI 10.1007/BF00178851
   Brower-Sinning R, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-2-r18
   Campitelli L, 1997, VIROLOGY, V232, P310, DOI 10.1006/viro.1997.8514
   Carbone A, 2008, J MOL EVOL, V66, P210, DOI 10.1007/s00239-008-9068-6
   Coleman JR, 2008, SCIENCE, V320, P1784, DOI 10.1126/science.1155761
   Costantini M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-146
   Crill WD, 2000, GENETICS, V154, P27
   dos Reis M, 2009, MOL BIOL EVOL, V26, P451, DOI 10.1093/molbev/msn272
   DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171
   Duret L, 2000, TRENDS GENET, V16, P287, DOI 10.1016/S0168-9525(00)02041-2
   Duret L, 2002, CURR OPIN GENET DEV, V12, P640, DOI 10.1016/S0959-437X(02)00353-2
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Garrigues HJ, 2008, J VIROL, V82, P1570, DOI 10.1128/JVI.01673-07
   Gu WJ, 2004, VIRUS RES, V101, P155, DOI 10.1016/j.virusres.2004.01.006
   HOLMES EC, 1992, P NATL ACAD SCI USA, V89, P4835, DOI 10.1073/pnas.89.11.4835
   Jenkins GM, 2003, VIRUS RES, V92, P1, DOI 10.1016/S0168-1702(02)00309-X
   Kawashima Y, 2009, NATURE, V458, P641, DOI 10.1038/nature07746
   Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670
   Koonin EV, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-29
   Kudla G, 2009, SCIENCE, V324, P255, DOI 10.1126/science.1170160
   Lucks JB, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000001
   McFadden G, 2005, NAT REV MICROBIOL, V3, P201, DOI 10.1038/nrmicro1099
   MELNICK JL, 1972, PROG MED VIROL, V14, P321
   Mueller S, 2006, J VIROL, V80, P9687, DOI 10.1128/JVI.00738-06
   Rambaut A, 2004, NAT REV GENET, V5, P52, DOI 10.1038/nrg1246
   Roossinck MJ, 1997, ANNU REV PHYTOPATHOL, V35, P191, DOI 10.1146/annurev.phyto.35.1.191
   Sau K, 2006, BIOSYSTEMS, V85, P107, DOI 10.1016/j.biosystems.2005.12.004
   Sawyer SL, 2005, P NATL ACAD SCI USA, V102, P2832, DOI 10.1073/pnas.0409853102
   Semon M, 2006, MOL BIOL EVOL, V23, P523, DOI 10.1093/molbev/msj053
   Shackelton LA, 2008, J THEOR BIOL, V254, P128, DOI 10.1016/j.jtbi.2008.05.024
   Shackelton LA, 2006, J MOL EVOL, V62, P551, DOI 10.1007/s00239-005-0221-1
   SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207
   TRUYEN U, 1995, J VIROL, V69, P4702, DOI 10.1128/JVI.69.8.4702-4710.1995
   Van Etten JL, 1999, ANNU REV MICROBIOL, V53, P447, DOI 10.1146/annurev.micro.53.1.447
   van Hemert FJ, 2007, VIROLOGY, V361, P447, DOI 10.1016/j.virol.2006.11.021
   Zhao KN, 2003, VIRUS RES, V98, P95, DOI 10.1016/j.virusres.2003.08.019
NR 45
TC 109
Z9 118
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-4292
J9 MOL SYST BIOL
JI Mol. Syst. Biol.
PD OCT
PY 2009
VL 5
AR 311
DI 10.1038/msb.2009.71
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 513UJ
UT WOS:000271349000004
PM 19888206
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Bonzel, L
   Tenenbaum, T
   Schroten, H
   Schildgen, O
   Schweitzer-Krantz, S
   Adams, O
AF Bonzel, Linda
   Tenenbaum, Tobias
   Schroten, Horst
   Schildgen, Oliver
   Schweitzer-Krantz, Susanne
   Adams, Ortwin
TI Frequent detection of viral coinfection in children hospitalized with
   acute respiratory tract infection using a real-time polymerase chain
   reaction
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE respiratory viruses; viral coinfection; real-time PCR
ID HUMAN BOCAVIRUS; HUMAN METAPNEUMOVIRUS; VIRUS-INFECTIONS;
   SYNCYTIAL-VIRUS; PCR ASSAYS; CORONAVIRUSES; DIAGNOSIS; DNA
AB Background: Respiratory viruses are the main cause of acute respiratory tract infection (ARI) in children. Real-time polymerase chain reaction (PCR) technology is highly practicable for the rapid detection of viral pathogens. The simultaneous detection of a broad spectrum of viruses enables the diagnosis and evaluation of viral coinfection in ARI.
   Methods: A 1-step real-time PCR was developed for the detection of 12 respiratory viruses (10 RNA and 2 DNA viruses) in clinical samples. Clinical samples from 254 children admitted to the Departments of Pediatrics with ARI during a 10-month period were tested.
   Results: Respiratory syncytial virus (RSV) was the most frequently detected pathogen in 112 samples (44.1%), followed by human bocavirus (hBoV) in 49 (19.3%), and rhinovirus in 17 samples (6.7%). Viral coinfection was detected in 41 (16.1%) samples with RSV and hBoV being the most dominating combination (27 cases, 10.6%). Viral coinfection was found in 10 cases (17%) of children with bronchitis (n = 58) and in 7 cases (23%) of bronchiolitis (n = 30). In patients with pneumonia (n = 51), 17 cases (33%) were positive for 2 or more viral pathogens.
   Conclusions: Simultaneous testing of respiratory viruses by real-time PCR is a suitable tool for the detection of viral coinfections. In children hospitalized because of respiratory infection viral coinfection is frequently detected with RSV and hBoV being a common combination.
C1 [Bonzel, Linda; Adams, Ortwin] Univ Dusseldorf, Inst Virol, D-40225 Dusseldorf, Germany.
   [Tenenbaum, Tobias; Schroten, Horst] Univ Dusseldorf, Dept Gen Pediat, D-40225 Dusseldorf, Germany.
   [Schildgen, Oliver] Univ Bonn, Inst Med Microbiol Immunol & Parasitol, Dept Virol, D-5300 Bonn, Germany.
   [Schweitzer-Krantz, Susanne] Evangel Krankenhaus Dusseldorf, Childrens Hosp, Dusseldorf, Germany.
RP Adams, O (reprint author), Univ Dusseldorf, Inst Virol, Geb 22-21,Univ Str 1, D-40225 Dusseldorf, Germany.
EM ortwin.adams@uni-duesseldorf.de
RI Schildgen, Oliver/D-5327-2014
OI Schildgen, Oliver/0000-0003-4297-9627
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196
   Arden KE, 2006, J MED VIROL, V78, P1232, DOI 10.1002/jmv.20689
   Arnold JC, 2006, CLIN INFECT DIS, V43, P283, DOI 10.1086/505399
   Bastien N, 2003, J CLIN MICROBIOL, V41, P4642, DOI 10.1128/JCM.41.10.4642-4646.2003
   Bellau-Pujol S, 2005, J VIROL METHODS, V126, P53, DOI 10.1016/j.jviromet.2005.01.020
   Brouard J, 2000, ARCH PEDIATRIE, V7, p531S, DOI 10.1016/S0929-693X(00)80180-3
   Choi EH, 2006, CLIN INFECT DIS, V43, P585, DOI 10.1086/506350
   Coiras MT, 2004, J MED VIROL, V72, P484, DOI 10.1002/jmv.20008
   Falsey AR, 2006, J CLIN VIROL, V35, P46, DOI 10.1016/j.jcv.2005.04.004
   Falsey AR, 2006, CLIN INFECT DIS, V42, P518, DOI 10.1086/499955
   FALSEY AR, 2005, DRUG AGING, V22, P577, DOI DOI 10.2165/00002512-200522070-00004
   Foulongne V, 2006, EMERG INFECT DIS, V12, P1251, DOI 10.3201/eid1708.060213.
   Freymuth F, 2006, J MED VIROL, V78, P1498, DOI 10.1002/jmv.20725
   Gunson RN, 2005, J CLIN VIROL, V33, P341, DOI 10.1016/j.jcv.2004.11.025
   Heim A, 2003, J MED VIROL, V70, P228, DOI 10.1002/jmv.10382
   Kim YJ, 2007, SEMIN RESP CRIT CARE, V28, P222, DOI 10.1055/s-2007-976494
   Legg JP, 2005, PEDIATR INFECT DIS J, V24, P611, DOI 10.1097/01.inf.0000168747.94999.aa
   Ma XM, 2006, J CLIN MICROBIOL, V44, P1132, DOI 10.1128/JCM.44.3.1132-1134.2006
   Manoha C, 2007, J CLIN VIROL, V38, P221, DOI 10.1016/j.jcv.2006.12.005
   Pierangeli A, 2007, J MED VIROL, V79, P463, DOI 10.1002/jmv.20832
   Pyrc K, 2007, EXPERT REV ANTI-INFE, V5, P245, DOI 10.1586/14787210.5.2.245
   Pyrc K, 2007, J VIROL, V81, P3051, DOI 10.1128/JVI.01466-06
   Scheltinga SA, 2005, J CLIN VIROL, V33, P306, DOI 10.1016/j.jcv.2004.08.021
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Templeton KE, 2004, J CLIN MICROBIOL, V42, P1564, DOI 10.1128/JCM.42.4.1564-1569.2004
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   Walsh EE, 1999, AM J RESP CRIT CARE, V160, P791, DOI 10.1164/ajrccm.160.3.9901004
   Weigl JAI, 2005, KLIN PADIATR, V217, P259, DOI 10.1055/s-2004-820352
   Weissbrich B, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-109
NR 30
TC 109
Z9 117
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUL
PY 2008
VL 27
IS 7
BP 589
EP 594
DI 10.1097/INF.0b013e3181694fb9
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 319PR
UT WOS:000257176600002
PM 18520973
DA 2020-04-03
ER

PT J
AU Roberts, A
   Paddock, C
   Vogel, L
   Butter, E
   Zaki, S
   Subbarao, K
AF Roberts, A
   Paddock, C
   Vogel, L
   Butter, E
   Zaki, S
   Subbarao, K
TI Aged BALB/c mice as a model for increased severity of severe acute
   respiratory syndrome in elderly humans
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CORONAVIRUS SPIKE PROTEIN; LUNG PATHOLOGY; AFRICAN-GREEN; SARS;
   INFECTION; IMMUNOSENESCENCE; NEUTRALIZATION; REPLICATION; OUTBREAK;
   IMMUNITY
AB Advanced age has repeatedly been identified as an independent correlate of adverse outcome and a predictor of mortality in cases of severe acute respiratory syndrome (SARS). SARS-associated mortality may exceed 50% for persons aged 60 years or older. Heightened susceptibility of the elderly to severe SARS and the ability of SARS coronavirus to replicate in mice led us to examine whether aged mice might be susceptible to disease. We report here that viral replication in aged mice was associated with clinical illness and pneumonia, demonstrating an age-related susceptibility to SARS disease in animals that parallels the human experience.
C1 NIAID, LID, NIH, Bethesda, MD 20892 USA.
   Ctr Dis Control & Prevent, Infect Dis Pathol Act, Atlanta, GA USA.
RP Roberts, A (reprint author), NIAID, LID, NIH, 50 South Dr,Room 6351,MSC 8007, Bethesda, MD 20892 USA.
EM ajroberts@niaid.nih.gov
OI Subbarao, Kanta/0000-0003-1713-3056
CR Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Booth CM, 2003, JAMA-J AM MED ASSOC, V290, P334
   Bruunsgaard H, 2001, CURR OPIN HEMATOL, V8, P131, DOI 10.1097/00062752-200105000-00001
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X
   Chan JWM, 2003, THORAX, V58, P686, DOI 10.1136/thorax.58.8.686
   Chan MSM, 2004, AM J ROENTGENOL, V182, P49, DOI 10.2214/ajr.182.1.1820049
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8
   Ginaldi L, 2001, MICROBES INFECT, V3, P851, DOI 10.1016/S1286-4579(01)01443-5
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70
   Muller NL, 2004, AM J ROENTGENOL, V182, P39, DOI 10.2214/ajr.182.1.1820039
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   PAWELEC G, 1995, IMMUNOL TODAY, V16, P420, DOI 10.1016/0167-5699(95)80017-4
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Plowden J, 2004, AGING CELL, V3, P161, DOI 10.1111/j.1474-9728.2004.00102.x
   Renshaw M, 2002, J IMMUNOL, V169, P4697, DOI 10.4049/jimmunol.169.9.4697
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   SHIEH WJ, IN PRESS HUM PATHOL
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Tsui PT, 2003, EMERG INFECT DIS, V9, P1064
   Weingartl HM, 2004, EMERG INFECT DIS, V10, P179, DOI 10.3201/eid1002.030677
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zhang YX, 2002, EXP BIOL MED, V227, P133
NR 36
TC 109
Z9 116
U1 2
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 2005
VL 79
IS 9
BP 5833
EP 5838
DI 10.1128/JVI.79.9.5833-5838.2005
PG 6
WC Virology
SC Virology
GA 917CH
UT WOS:000228433100060
PM 15827197
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Bastien, N
   Anderson, K
   Hart, L
   Van Caeseele, P
   Brandt, K
   Milley, D
   Hatchette, T
   Weiss, EC
   Li, Y
AF Bastien, N
   Anderson, K
   Hart, L
   Van Caeseele, P
   Brandt, K
   Milley, D
   Hatchette, T
   Weiss, EC
   Li, Y
TI Human coronavirus NL63 infection in Canada
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID VIRUS-INFECTIONS; HOSPITALIZATIONS; PNEUMONIA
AB The isolation of human coronavirus NL63 (HCoV-NL63) in The Netherlands raised questions about its contribution to respiratory illness. In this study, a total of 525 respiratory specimens, collected in Canada primarily during the winter months of 2001-2002, were tested for HCoV-NL63; 19 tested positive for HCoV-NL63, demonstrating virus activity during January-March 2002. Patients with HCoV-NL63 were 1 month-100 years old ( median age, 37 years). The main clinical presentations were fever (15/19), sore throat (5/19), and cough (9/19), and 4 patients were hospitalized. These results provide evidence for the worldwide distribution of HCoV-NL63.
C1 Canadian Sci Ctr Human & Anim Hlth, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada.
   Cadham Prov Lab, Winnipeg, MB, Canada.
   Saskatchewan Hlth, Prov Lab, Regina, SK, Canada.
   Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada.
   Manitoba Hlth, Brandon, MB, Canada.
RP Li, Y (reprint author), Canadian Sci Ctr Human & Anim Hlth, Natl Microbiol Lab, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada.
EM yan_li@phac-aspc.gc.ca
CR COLLINS PL, 2001, FIELDS VIROLOGY, V1, P1443
   *ED BOARD RESP DIS, 2001, RESP DIS CAN
   El-Sahly HM, 2000, CLIN INFECT DIS, V31, P96, DOI 10.1086/313937
   Falsey AR, 2002, J INFECT DIS, V185, P1338, DOI 10.1086/339881
   Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499
   HOLMES KV, 2001, FIELDS VIROLOGY, V1, P1187
   Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   Muller-Pebody B, 2002, EPIDEMIOL INFECT, V129, P99, DOI 10.1017/S095026880200729X
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   *WHO DEP COMM DIS, 2003, SUM PROB SARS CAS ON
NR 13
TC 109
Z9 120
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB 15
PY 2005
VL 191
IS 4
BP 503
EP 506
DI 10.1086/426869
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 888ZM
UT WOS:000226413100004
PM 15655772
OA Bronze
DA 2020-04-03
ER

PT J
AU Wilson, L
   Mckinlay, C
   Gage, P
   Ewart, G
AF Wilson, L
   Mckinlay, C
   Gage, P
   Ewart, G
TI SARS coronavirus E protein forms cation-selective ion channels
SO VIROLOGY
LA English
DT Article
DE Severe Acute Respiratory Syndrome (SARS); coronavirus; budding; E
   protein; ion channel; conductance; Vpu; hydrophobic; monovalent cation;
   mouse hepatitis virus (MHV)
ID VIRUS TYPE-1 VPU; HEPATITIS-C-VIRUS; GOLGI-COMPLEX; TRANSMEMBRANE
   DOMAIN; MURINE CORONAVIRUS; MEMBRANE-PROTEIN; P7 PROTEIN; M2 PROTEIN;
   HIV-1 GAG; RELEASE
AB Severe Acute Respiratory Syndrome (SARS) is caused by a novel coronavirus (SARS-CoV). Coronaviruses including SARS-CoV encode an envelope (E) protein, a small, hydrophobic membrane protein. We report that, in planar lipid bilayers, synthetic peptides corresponding to the SARS-CoV E protein forms ion channels that are more permeable to monovalent cations than to monovalent anions. Affinity-purified polyclonal antibodies recognizing the N-terminal 19 residues of SARS-CoV E protein were used to establish the specificity of channel forination by inhibiting the ion currents generated in the presence of the E protein peptides. (C) 2004 Elsevier Inc. All rights reserved.
C1 Australian Natl Univ, Biotron Ltd, Canberra, ACT 2601, Australia.
   Australian Natl Univ, Sch Med, Canberra, ACT 2601, Australia.
   Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.
RP Wilson, L (reprint author), Australian Natl Univ, Biotron Ltd, LPO Box A315, Canberra, ACT 2601, Australia.
EM lwilson@biotron.com.au
CR Arbely E, 2004, J MOL BIOL, V341, P769, DOI 10.1016/j.jmb.2004.06.044
   Baudoux P, 1998, J VIROL, V72, P8636, DOI 10.1128/JVI.72.11.8636-8643.1998
   Becker CFW, 2004, J BIOL CHEM, V279, P17483, DOI 10.1074/jbc.M313212200
   Bos ECW, 1996, VIROLOGY, V218, P52, DOI 10.1006/viro.1996.0165
   Callahan MA, 1998, J VIROL, V72, P5189, DOI 10.1128/JVI.72.6.5189-5197.1998
   Corse E, 2000, J VIROL, V74, P4319, DOI 10.1128/JVI.74.9.4319-4326.2000
   Deora A, 2000, VIROLOGY, V269, P305, DOI 10.1006/viro.1999.0094
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   DUFF KC, 1994, VIROLOGY, V202, P287, DOI 10.1006/viro.1994.1345
   DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q
   Ewart GD, 1996, J VIROL, V70, P7108, DOI 10.1128/JVI.70.10.7108-7115.1996
   Fischer F, 1998, J VIROL, V72, P7885, DOI 10.1128/JVI.72.10.7885-7894.1998
   Fischer WB, 2002, BBA-BIOMEMBRANES, V1561, P27, DOI 10.1016/S0304-4157(01)00009-0
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   GERAGHTY RJ, 1994, J MED PRIMATOL, V23, P146, DOI 10.1111/j.1600-0684.1994.tb00115.x
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   Gonzalez ME, 2003, FEBS LETT, V552, P28, DOI 10.1016/S0014-5793(03)00780-4
   Gonzalez ME, 2001, VIROLOGY, V279, P201, DOI 10.1006/viro.2000.0708
   GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381
   GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195
   Griffin SDC, 2003, FEBS LETT, V535, P34, DOI 10.1016/S0014-5793(02)03851-6
   Handley MA, 2001, VIROLOGY, V291, P198, DOI 10.1006/viro.2001.1166
   Ho Y, 2004, BIOCHEM BIOPH RES CO, V318, P833, DOI 10.1016/j.bbrc.2004.04.111
   Hsu K, 2004, MOL CELL, V14, P259, DOI 10.1016/S1097-2765(04)00183-2
   KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuo LL, 2003, J VIROL, V77, P4597, DOI 10.1128/JVI.77.8.4597-4608.2003
   LU YA, 1991, MOL IMMUNOL, V28, P623
   Maeda J, 1999, VIROLOGY, V263, P265, DOI 10.1006/viro.1999.9955
   MALDARELLI F, 1993, J VIROL, V67, P5056, DOI 10.1128/JVI.67.8.5056-5061.1993
   Marassi FM, 1999, P NATL ACAD SCI USA, V96, P14336, DOI 10.1073/pnas.96.25.14336
   Melton JV, 2002, J BIOL CHEM, V277, P46923, DOI 10.1074/jbc.M207847200
   Montal M, 2003, FEBS LETT, V552, P47, DOI 10.1016/S0014-5793(03)00849-4
   Mould JA, 2000, J BIOL CHEM, V275, P31038, DOI 10.1074/jbc.M003663200
   Mould JA, 2003, DEV CELL, V5, P175, DOI 10.1016/S1534-5807(03)00190-4
   Ortego J, 2002, J VIROL, V76, P11518, DOI 10.1128/JVI.76.22.11518-11529.2002
   Pavlovic D, 2003, P NATL ACAD SCI USA, V100, P6104, DOI 10.1073/pnas.1031527100
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111
   PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I
   Premkumar A, 2004, FEBS LETT, V557, P99, DOI 10.1016/S0014-5793(03)01453-4
   Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733
   Schubert U, 1996, FEBS LETT, V398, P12, DOI 10.1016/S0014-5793(96)01146-5
   Schubert U, 1996, J VIROL, V70, P809, DOI 10.1128/JVI.70.2.809-819.1996
   Shen X, 2003, ACTA PHARMACOL SIN, V24, P505
   SIDDELL SG, 1995, CORONAVIRIDAE, P1
   SIDDELL SG, 1995, CORONAVIRIDAE, P181
   Sunstrom NA, 1996, J MEMBRANE BIOL, V150, P127, DOI 10.1007/s002329900037
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   *WHO, 2003, WKLY EPIDEMIOL REC, V78, P310
   YAO XJ, 1992, J VIROL, V66, P5119, DOI 10.1128/JVI.66.8.5119-5126.1992
NR 55
TC 109
Z9 114
U1 1
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD DEC 5
PY 2004
VL 330
IS 1
BP 322
EP 331
DI 10.1016/j.virol.2004.09.033
PG 10
WC Virology
SC Virology
GA 872GL
UT WOS:000225195600030
PM 15527857
OA Bronze
DA 2020-04-03
ER

PT J
AU Jennings, LC
   Anderson, TP
   Werno, AM
   Beynon, KA
   Murdoch, DR
AF Jennings, LC
   Anderson, TP
   Werno, AM
   Beynon, KA
   Murdoch, DR
TI Viral etiology of acute respiratory tract infections in children
   presenting to hospital - Role of polymerase chain reaction and
   demonstration of multiple infections
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE acute respiratory tract infections; children; polymerase chain reaction;
   multiple infections; respiratory syncytial virus
ID SYNCYTIAL VIRUS; RT-PCR; HUMAN METAPNEUMOVIRUS; INFLUENZA-VIRUS;
   RHINOVIRUS; DISEASE; COMMUNITY; ADULTS; ADENOVIRUS; DIAGNOSIS
AB Background: Viral lower respiratory tract infections are a leading cause of hospitalization for young children.
   Methods: We used polymerase chain reaction (PCR) and conventional methods of cell culture and antigen detection to establish the viral etiology of acute respiratory tract infections in 75 hospitalized children.
   Results: One or more viral pathogens were detected in 65 (87%) children, with respiratory syncytial virus being the most commonly identified virus (36 children). Other viruses identified included influenza virus types A and B, parainfluenzavirus type 3, adenovirus, enterovirus, rhinovirus, coronavirus and human metapneumovirus. PCR increased the diagnostic yield significantly compared with antigen detection and culture, with 39 (21%) diagnoses identified by this method. Multiple infections were identified in 20 (27%) children.
   Conclusions: PCR-based methodologies offer increased sensitivity for the detection of most respiratory viruses in young children. The inclusion of PCR into diagnostic testing strategies is needed to broaden our understanding of the natural ecology of respiratory viruses and the significance of multiple infections.
C1 Univ Otago, Canterbury Hlth Labs, Microbiol Unit, Christchurch, New Zealand.
   Univ Otago, Christchurch Sch Med & Hlth Sci, Dept Pathol, Christchurch, New Zealand.
RP Jennings, LC (reprint author), Univ Otago, Canterbury Hlth Labs, Microbiol Unit, Christchurch, New Zealand.
RI Murdoch, David/A-2012-2009
CR Alexander R, 2001, J VIROL METHODS, V97, P77, DOI 10.1016/S0166-0934(01)00344-5
   Collins CL, 2002, J INFECTION, V45, P10, DOI 10.1053/jinf.2001.1016
   Corne JM, 1999, J VIROL METHODS, V82, P9, DOI 10.1016/S0166-0934(99)00073-7
   Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137
   Echavarria M, 1998, J CLIN MICROBIOL, V36, P3323, DOI 10.1128/JCM.36.11.3323-3326.1998
   Freymuth F, 1997, CLIN DIAGN VIROL, V8, P31, DOI 10.1016/S0928-0197(97)00060-3
   Gilbert LL, 1996, J CLIN MICROBIOL, V34, P140, DOI 10.1128/JCM.34.1.140-143.1996
   GLEZEN WP, 1971, J PEDIATR-US, V78, P397, DOI 10.1016/S0022-3476(71)80218-4
   HENRICKSON KJ, 1998, SEMIN PEDIAT INFECT, V9, P217
   HUANG QS, 2002, LABLINK, V10, P11
   HUNT D, 2002, NZ PUBLIC HLTH R APR, P1
   IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204
   JENNINGS LC, 1978, J HYG-CAMBRIDGE, V81, P49, DOI 10.1017/S0022172400053766
   JENNINGS LC, 1985, NEW ZEAL MED J, V98, P582
   JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993
   Kehl SC, 2001, J CLIN MICROBIOL, V39, P1696, DOI 10.1128/JCM.39.5.1696-1701.2001
   LEVEN M, 1997, CLIN MICROBIOL REV, V10, P242
   MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779
   MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052
   NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982
   Nissen MD, 2002, MED J AUSTRALIA, V176, P188, DOI 10.5694/j.1326-5377.2002.tb04354.x
   Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC
   Papadopoulos NG, 1999, J VIROL METHODS, V80, P179, DOI 10.1016/S0166-0934(99)00045-2
   RAY CG, 1993, PEDIATR INFECT DIS J, V12, P15, DOI 10.1097/00006454-199301000-00005
   SCHMIDT HJ, 1991, PEDIATR INFECT DIS J, V10, P700, DOI 10.1097/00006454-199109000-00015
   SENO M, 1991, AM J CLIN PATHOL, V95, P765, DOI 10.1093/ajcp/95.6.765
   Stockton J, 2002, EMERG INFECT DIS, V8, P897, DOI 10.3201/eid0809.020084
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   van Elden LJR, 2001, J CLIN MICROBIOL, V39, P196, DOI 10.1128/JCM.39.1.196-200.2001
   van Elden LJR, 2002, CLIN INFECT DIS, V34, P177, DOI 10.1086/338238
   WANER JL, 1994, CLIN MICROBIOL REV, V7, P143, DOI 10.1128/CMR.7.2.143-151.1994
   Werno AM, 2004, J PAEDIATR CHILD H, V40, P549, DOI 10.1111/j.1440-1754.2004.00461.x
NR 32
TC 109
Z9 117
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2004
VL 23
IS 11
BP 1003
EP 1007
DI 10.1097/01.inf.0000143648.04673.6c
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 872HD
UT WOS:000225197400005
PM 15545854
DA 2020-04-03
ER

PT J
AU Goldsmith, CS
   Tatti, KM
   Ksiazek, TG
   Rollin, PE
   Comer, JA
   Lee, WW
   Rota, PA
   Bankamp, B
   Bellini, WJ
   Zaki, SR
AF Goldsmith, CS
   Tatti, KM
   Ksiazek, TG
   Rollin, PE
   Comer, JA
   Lee, WW
   Rota, PA
   Bankamp, B
   Bellini, WJ
   Zaki, SR
TI Ultrastructural characterization of SARS coronavirus
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; DOUBLE-MEMBRANE VESICLES; MOUSE
   HEPATITIS-VIRUS; HEMORRHAGIC-FEVER; NIPAH VIRUS; REPLICATION; ZAIRE;
   CELLS; PATHOLOGY; INFECTION
AB Severe acute respiratory syndrome (SARS) was first described during a 2002-2003 global outbreak of severe pneumonia associated with human deaths and person-to-person disease transmission. The etiologic agent was initially identified as a coronavirus by thin-section electron microscopic examination of a virus isolate. Virions were spherical, 78 nm in mean diameter, and composed of a helical nucleocapsid within an envelope with surface projections. We show that infection with the SARS-associated coronavirus resulted in distinct ultrastructural features: double-membrane vesicles, nucleocapsid inclusions, and large granular areas of cytoplasm. These three structures and the coronavirus particles were shown to be positive for viral proteins and RNA by using ultrastructural immunogold and in situ hybridization assays. In addition, ultrastructural examination of a bronchiolar lavage specimen from a SARS patient showed numerous coronavirus-infected cells with features similar to those in infected culture cells. Electron microscopic studies were critical in identifying the etiologic agent of the SARS outbreak and in guiding subsequent laboratory and epidemiologic investigations.
C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
RP Goldsmith, CS (reprint author), Ctr Dis Control & Prevent, Mailstop G30,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM cgoldsmith@cdc.gov
RI Tatti, Kathleen M/H-5912-2012
OI Tatti, Kathleen M/0000-0001-9414-7887
CR Bankamp B, 2002, J VIROL, V76, P7073, DOI 10.1128/JVI.76.14.7073-7081.2002
   Becker W B, 1967, J Virol, V1, P1019
   BOWEN ETW, 1977, LANCET, V1, P571
   *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P226
   *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P241
   *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P248
   Centers for Disease Control and Prevention, 2003, MMWR-MORBID MORTAL W, V52, P537
   Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432
   DAVIDFERREIRA JF, 1965, J CELL BIOL, V24, P57, DOI 10.1083/jcb.24.1.57
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   DUBOISDALCQ M, 1984, ASSEMBLY ENVELOPED R, P100
   DUBOISDALCQ ME, 1982, VIROLOGY, V119, P317, DOI 10.1016/0042-6822(82)90092-7
   Emery SL, 2004, EMERG INFECT DIS, V10, P311, DOI 10.3201/eid1002.030759
   Enjuanes L, 2000, VIRUS TAXONOMY CLASS, P827
   Folz RJ, 1999, CHEST, V115, P901, DOI 10.1378/chest.115.3.901
   GHADIALLY F, 1997, ULTRASTRUCTURAL PATH
   Goldsmith CS, 2003, VIRUS RES, V92, P89, DOI 10.1016/S0168-1702(02)00323-4
   Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002
   HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X
   Holmes KV, 2001, FIELDS VIROLOGY, P1187
   JOHNSON KM, 1977, LANCET, V1, P569
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   OSHIRO LS, 1971, J GEN VIROL, V12, P161, DOI 10.1099/0022-1317-12-2-161
   PATTYN S, 1977, LANCET, V1, P573
   Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   SCHIDLOVSKY G, 1978, J NATL CANCER I, V61, P91, DOI 10.1093/jnci/61.1.91
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Stohr K, 2003, LANCET, V361, P1730, DOI 10.1016/S0140-6736(03)13376-4
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   WHO, 2003, SUMM PROB SARS CAS O
   World Health Organization (WHO), 2003, SEV AC RESP SYNDR MU
NR 40
TC 109
Z9 114
U1 0
U2 2
PU CENTER DISEASE CONTROL
PI ATLANTA
PA ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD FEB
PY 2004
VL 10
IS 2
BP 320
EP 326
DI 10.3201/eid1002.030913
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 772XH
UT WOS:000188867700030
PM 15030705
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU VanReeth, K
   Nauwynck, H
   Pensaert, M
AF VanReeth, K
   Nauwynck, H
   Pensaert, M
TI Dual infections of feeder pigs with porcine reproductive and respiratory
   syndrome virus followed by porcine respiratory coronavirus or swine
   influenza virus: A clinical and virological study
SO VETERINARY MICROBIOLOGY
LA English
DT Article
DE porcine reproductive and respiratory syndrome virus; porcine respiratory
   coronavirus; swine influenza virus; dual infections; pigs
ID TRANSMISSIBLE GASTROENTERITIS
AB Dual infections of pigs with porcine reproductive and respiratory syndrome virus (PRRSV) followed by a second common respiratory virus, either porcine respiratory coronavirus (PRCV) or swine influenza virus (SIV), were studied. The aim was to determine if dual infections, as compared to single virus infections, result in enhanced clinical manifestations. It was also examined if PRRSV replication affects replication of PRCV or SIV in the respiratory tract. Groups of conventional 10 week old pigs were inoculated with PRRSV-only (3 pigs), PRCV-only (4 pigs) or SIV-only (4 pigs). Dual inoculations with PRRSV-PRCV (4 pigs) and PRRSV-SIV (3 groups of 3, 4 and 5 pigs) were performed at a 3 day interval. A group of uninoculated control pigs (8 pigs) was included. The infection with PRRSV-only induced a transient fever (40.2 degrees C) at 2 DPI, but no respiratory signs. The PRCV-only infection remained subclinical. The SIV-only infection resulted in a one day fever (40.1 degrees C) with moderate tachypnoea and dyspnoea. Mean weight gain in the virus-inoculated groups was retarded compared with the control group.
   The PRRSV-PRCV infection induced a 9 day lasting fever (peak 40.9 degrees C) with tachypnoea, dyspnoea and productive coughing. The PRRSV-SIV infection resulted in fever and respiratory signs in all 3 groups. Clinical signs, however, were more pronounced in group 1 than in groups 2 and 3. Pigs of group 1 showed fever during 10 days (peak 41.4 degrees C), tachypnoea, marked dyspnoea with abdominal breathing, and a productive cough. Pigs of groups 2 and 3 had fever for 5 and 3 days (peaks 40.6 and 40.3 degrees C) respectively and mild respiratory disorders. Mean weight gain during 14 DPI of the 2nd virus was 5.9 kg in the PRRSV-PRCV group and 4.0, 6.8 and 6.7 ki: in PRRSV-SIV groups 1, 2 and 3 respectively. Mean weight gain during the corresponding period in the PRRSV-only group was 8.6 kg. It was concluded that dual infections with viruses causes more severe disease and growth retardation than single PRRSV infection.
   PRCV excretion curves were similar in single and dual virus inoculated groups. Excretion of SIV was delayed by 2 days in the dual inoculated pigs. Thus, replication of the second virus is not (PRCV) or only slightly (SIV) affected by a prior infection with PRRSV.
RP VanReeth, K (reprint author), STATE UNIV GHENT,FAC VET MED,LAB VET VIROL,SALISBURYLAAN 133,B-9820 MERELBEKE,BELGIUM.
OI Nauwynck, Hans/0000-0001-5470-0713
CR ALBINA E, 1992, VET REC, V130, P58, DOI 10.1136/vr.130.3.58
   BOETNER A, 1993, AIR3CT920939 PRRS CO
   COX E, 1990, RES VET SCI, V48, P165, DOI 10.1016/S0034-5288(18)30984-6
   DURAN JP, 1992, AM ASS SEINE PRACTIT, P16
   DURAN JP, 1992, VET MICROBIOL, V33, P203
   Edwards S, 1992, AM ASS SWINE PRACTIT, V4, P32
   FELD NC, 1992, VET MICROBIOL, V30, P35, DOI 10.1016/0378-1135(92)90092-8
   GROSCHUP MH, 1993, J VET MED B, V40, P681, DOI 10.1111/j.1439-0450.1993.tb00192.x
   HAESEBROUCK F, 1986, VET MICROBIOL, V11, P239, DOI 10.1016/0378-1135(86)90026-X
   HOUBEN S, 1995, J VET MED B, V42, P209, DOI 10.1111/j.1439-0450.1995.tb00704.x
   OHLINGER VF, 1991, TIERARZTL UMSCHAU, V46, P703
   PALMER DF, 1975, US DHEW IMMUNOLOGY S, V6
   POL JMA, 1991, VET QUART, V13, P137, DOI 10.1080/01652176.1991.9694298
   RAMOS J, 1992, AM ASS SWINE PRACTIT, P25
   VANREETH K, 1994, VET REC, V135, P594
   VANREETH K, 1994, AM J VET RES, V55, P1275
   VANREETH K, 1992, P 12 C INT PIG VET S, P152
   VANREETH K, 1994, P 3 C EUR SOC VET VI, P197
   VOETS MT, 1980, VET QUART, V2, P211, DOI 10.1080/01652176.1980.9693783
   VYNCKIER A, 1993, VLAAMS DIERGEN TIJDS, V62, P118
   WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296
   ZHOU Y, 1992, AM ASS SWINE PRACT N, P32
NR 22
TC 109
Z9 113
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1135
J9 VET MICROBIOL
JI Vet. Microbiol.
PD FEB
PY 1996
VL 48
IS 3-4
BP 325
EP 335
DI 10.1016/0378-1135(95)00145-X
PG 11
WC Microbiology; Veterinary Sciences
SC Microbiology; Veterinary Sciences
GA UB831
UT WOS:A1996UB83100013
PM 9054128
DA 2020-04-03
ER

PT J
AU SANCHEZ, CM
   GEBAUER, F
   SUNE, C
   MENDEZ, A
   DOPAZO, J
   ENJUANES, L
AF SANCHEZ, CM
   GEBAUER, F
   SUNE, C
   MENDEZ, A
   DOPAZO, J
   ENJUANES, L
TI GENETIC EVOLUTION AND TROPISM OF TRANSMISSIBLE GASTROENTERITIS
   CORONAVIRUSES
SO VIROLOGY
LA English
DT Article
ID PORCINE RESPIRATORY CORONAVIRUS; ANTIGENIC SITES; NUCLEOTIDE-SEQUENCE;
   MOSAIC-VIRUS; GLYCOPROTEIN; REPLICATION; SWINE; DIFFERENTIATION;
   RECOMBINATION; PROTEINS
C1 UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,CANTO BLANCO,E-28049 MADRID,SPAIN.
   UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,E-28049 MADRID,SPAIN.
   INST NACL INVEST AGR,DEPT SANIDAD ANIM,E-28012 MADRID,SPAIN.
RI Sune, Carlos/AAA-8198-2019; Mendez, Ana/F-9729-2016; Enjuanes,
   Luis/F-7845-2016; Gebauer, Fatima/E-7725-2015; Dopazo,
   Joaquin/A-9270-2014
OI Sune, Carlos/0000-0002-7991-0458; Mendez, Ana/0000-0001-6393-1644;
   Gebauer, Fatima/0000-0001-7563-0013; Dopazo,
   Joaquin/0000-0003-3318-120X; Enjuanes, Luis/0000-0002-0854-0226
CR ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5
   BANNER LR, 1991, VIROLOGY, V185, P441, DOI 10.1016/0042-6822(91)90795-D
   BECK E, 1987, J VIROL, V61, P1621, DOI 10.1128/JVI.61.5.1621-1629.1987
   BOHL EH, 1972, INFECT IMMUN, V6, P289, DOI 10.1128/IAI.6.3.289-301.1972
   BRITTON P, 1990, VIRUS RES, V18, P71, DOI 10.1016/0168-1702(90)90090-X
   BRITTON P, 1990, 7TH INT C VIR, pP6
   BROWN I, 1986, VET REC, V119, P282, DOI 10.1136/vr.119.11.282
   BUJARSKI JJ, 1991, J VIROL, V65, P4153, DOI 10.1128/JVI.65.8.4153-4159.1991
   CALLEBAUT P, 1988, J GEN VIROL, V69, P1725, DOI 10.1099/0022-1317-69-7-1725
   CARRILLO C, 1990, VIRUS RES, V15, P45, DOI 10.1016/0168-1702(90)90012-Z
   CASCONE PJ, 1990, EMBO J, V9, P1709, DOI 10.1002/j.1460-2075.1990.tb08294.x
   CORREA I, 1990, J GEN VIROL, V71, P271, DOI 10.1099/0022-1317-71-2-271
   COX E, 1990, RES VET SCI, V48, P165, DOI 10.1016/S0034-5288(18)30984-6
   COX E, 1990, VET MICROBIOL, V23, P237, DOI 10.1016/0378-1135(90)90154-N
   DEGROOT RJ, 1987, J MOL BIOL, V196, P963, DOI 10.1016/0022-2836(87)90422-0
   DELMAS B, 1990, J GEN VIROL, V71, P1313, DOI 10.1099/0022-1317-71-6-1313
   Domingo E., 1988, RNA GENETICS, VIII, P3
   DOYLE LP, 1946, J AM VET MED ASSOC, V108, P257
   DURET C, 1988, RECL MED VET, V164, P221
   Efron B., 1982, JACKKNIFE BOOTSTRAP
   ENJUANES L, 1992, CORONAVIRUSES
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   FELSENSTEIN J, 1990, PHYLIP MANUAL VERSIO
   FICHOT O, 1990, NUCLEIC ACIDS RES, V18, P6162, DOI 10.1093/nar/18.20.6162
   FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279
   FURUUCHI S, 1976, AM J VET RES, V37, P1401
   Garwes D.J., 1978, VET MICROBIOL, V3, P179
   GARWES DJ, 1988, VET REC, V122, P86, DOI 10.1136/vr.122.4.86
   GEBAUER F, 1991, VIROLOGY, V183, P225, DOI 10.1016/0042-6822(91)90135-X
   JACOBS L, 1987, VIRUS RES, V8, P363, DOI 10.1016/0168-1702(87)90008-6
   JUKES T H, 1969, P21
   Kimura M, 1983, NEUTRAL THEORY MOL E
   KING AMQ, 1988, RNA GENETICS, V2, P149
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992
   LEVINE AJ, 1984, CONCEPTS VIRAL PATHO, P130
   MCCLURKIN AW, 1966, CAN J COMP MED VET S, V30, P190
   MONROE SS, 1983, P NATL ACAD SCI-BIOL, V80, P3279, DOI 10.1073/pnas.80.11.3279
   PENSAERT M, 1986, VET QUART, V8, P257, DOI 10.1080/01652176.1986.9694050
   RAFFO AJ, 1991, VIROLOGY, V184, P277, DOI 10.1016/0042-6822(91)90844-2
   RASSCHAERT D, 1987, J GEN VIROL, V68, P1883, DOI 10.1099/0022-1317-68-7-1883
   RASSCHAERT D, 1990, J GEN VIROL, V71, P2599, DOI 10.1099/0022-1317-71-11-2599
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   SANCHEZ CM, 1990, VIROLOGY, V174, P410, DOI 10.1016/0042-6822(90)90094-8
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SIDDELL S, 1982, CURR TOP MICROBIOL, V99, P131
   Sokal R. R., 1981, BIOMETRY
   SOURDIS J, 1988, MOL BIOL EVOL, V5, P298
   SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939
   SUNE C, 1990, VIROLOGY, V177, P559, DOI 10.1016/0042-6822(90)90521-R
   UNDERDAHL NR, 1974, AM J VET RES, V35, P1209
   Wesley R D, 1990, J Vet Diagn Invest, V2, P312
   WESLEY RD, 1991, J VIROL, V65, P3369, DOI 10.1128/JVI.65.6.3369-3373.1991
   WESLEY RD, 1990, ADV EXP MED BIOL, V276, P301
   WESLEY RD, 1990, J VIROL, V64, P4761, DOI 10.1128/JVI.64.10.4761-4766.1990
NR 55
TC 109
Z9 121
U1 2
U2 8
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0042-6822
J9 VIROLOGY
JI Virology
PD SEP
PY 1992
VL 190
IS 1
BP 92
EP 105
DI 10.1016/0042-6822(92)91195-Z
PG 14
WC Virology
SC Virology
GA JL549
UT WOS:A1992JL54900010
PM 1326823
DA 2020-04-03
ER

PT J
AU Pascal, KE
   Coleman, CM
   Mujica, AO
   Kamat, V
   Badithe, A
   Fairhurst, J
   Hunt, C
   Strein, J
   Berrebi, A
   Sisk, JM
   Matthews, KL
   Babb, R
   Chen, G
   Lai, KMV
   Huang, TT
   Olson, W
   Yancopoulos, GD
   Stahl, N
   Frieman, MB
   Kyratsous, CA
AF Pascal, Kristen E.
   Coleman, Christopher M.
   Mujica, Alejandro O.
   Kamat, Vishal
   Badithe, Ashok
   Fairhurst, Jeanette
   Hunt, Charleen
   Strein, John
   Berrebi, Alexander
   Sisk, Jeanne M.
   Matthews, Krystal L.
   Babb, Robert
   Chen, Gang
   Lai, Ka-Man V.
   Huang, Tammy T.
   Olson, William
   Yancopoulos, George D.
   Stahl, Neil
   Frieman, Matthew B.
   Kyratsous, Christos A.
TI Pre- and postexposure efficacy of fully human antibodies against Spike
   protein in a novel humanized mouse model of MERS-CoV infection
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE MERS-CoV; Spike; DPP4; neutralizing antibody; mouse model
ID RESPIRATORY SYNDROME CORONAVIRUS; DIPEPTIDYL PEPTIDASE 4; NEUTRALIZING
   ANTIBODIES; IMMUNOGLOBULIN GENES; FUNCTIONAL RECEPTOR; SAUDI-ARABIA;
   MICE; REPLICATION; GENERATION; VIRUS
AB Traditional approaches to antimicrobial drug development are poorly suited to combatting the emergence of novel pathogens. Additionally, the lack of small animal models for these infections hinders the in vivo testing of potential therapeutics. Here we demonstrate the use of the VelocImmune technology (a mouse that expresses human antibody-variable heavy chains and. light chains) alongside the VelociGene technology (which allows for rapid engineering of the mouse genome) to quickly develop and evaluate antibodies against an emerging viral disease. Specifically, we show the rapid generation of fully human neutralizing antibodies against the recently emerged Middle East Respiratory Syndrome coronavirus (MERS-CoV) and development of a humanized mouse model for MERS-CoV infection, which was used to demonstrate the therapeutic efficacy of the isolated antibodies. The VelocImmune and VelociGene technologies are powerful platforms that can be used to rapidly respond to emerging epidemics.
C1 [Pascal, Kristen E.; Mujica, Alejandro O.; Kamat, Vishal; Badithe, Ashok; Fairhurst, Jeanette; Hunt, Charleen; Strein, John; Babb, Robert; Chen, Gang; Lai, Ka-Man V.; Huang, Tammy T.; Olson, William; Yancopoulos, George D.; Stahl, Neil; Kyratsous, Christos A.] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
   [Coleman, Christopher M.; Sisk, Jeanne M.; Matthews, Krystal L.; Frieman, Matthew B.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
   [Berrebi, Alexander] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA.
RP Yancopoulos, GD (reprint author), Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
EM george@regeneron.com; christos.kyratsous@regeneron.com
OI Coleman, Christopher/0000-0002-7306-8407; Pascal,
   Kristen/0000-0003-4826-4606
FU Regeneron Pharmaceuticals, Inc.
FX K.E.P., A.O.M., V.K., A.B., J.F., C.H., J.S., R.B., G.C., K.-M.V.L.,
   T.T.H., W.O., G.D.Y., N.S., and C.A.K. are employees of Regeneron
   Pharmaceuticals, Inc. The work was funded by Regeneron Pharmaceuticals,
   Inc.
CR Adedeji AO, 2014, ANTIMICROB AGENTS CH, V58, P4894, DOI 10.1128/AAC.02994-14
   Agrawal AS, 2015, J VIROL, V89, P3659, DOI 10.1128/JVI.03427-14
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Cockrell AS, 2014, J VIROL, V88, P5195, DOI 10.1128/JVI.03764-13
   Coleman CM, 2014, VACCINE, V32, P3169, DOI 10.1016/j.vaccine.2014.04.016
   Coleman CM, 2014, J GEN VIROL, V95, P408, DOI 10.1099/vir.0.060640-0
   Coleman CM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003595
   Cotten M, 2014, MBIO, V5, DOI 10.1128/mBio.01062-13
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Du LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081587
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Eckerle LD, 2007, J VIROL, V81, P12135, DOI 10.1128/JVI.01296-07
   Falzarano D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004250
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   GOOD RA, 1991, CANCER, V68, P1415, DOI 10.1002/1097-0142(19910915)68:6+<1415::AID-CNCR2820681402>3.0.CO;2-0
   Hildebrandt M, 2000, CLIN SCI, V99, P93, DOI 10.1042/CS19990368
   Jiang LW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008140
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Macdonald LE, 2014, P NATL ACAD SCI USA, V111, P5147, DOI 10.1073/pnas.1323896111
   Malpica JM, 2002, GENETICS, V162, P1505
   Marasco WA, 2007, NAT BIOTECHNOL, V25, DOI 10.1038/nbt1363
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Murphy AJ, 2014, P NATL ACAD SCI USA, V111, P5153, DOI 10.1073/pnas.1324022111
   Page C, 2012, J VIROL, V86, P13334, DOI 10.1128/JVI.01689-12
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Perlman S, 2013, NEW ENGL J MED, V369, P466, DOI 10.1056/NEJMe1308724
   Poueymirou WT, 2007, NAT BIOTECHNOL, V25, P91, DOI 10.1038/nbt1263
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003760
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Tang XC, 2014, P NATL ACAD SCI USA, V111, pE2018, DOI 10.1073/pnas.1402074111
   Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wang XW, 2000, J IMMUNOL METHODS, V244, P217, DOI 10.1016/S0022-1759(00)00260-X
   Ying TL, 2014, J VIROL, V88, P7796, DOI 10.1128/JVI.00912-14
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
NR 42
TC 108
Z9 116
U1 4
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 14
PY 2015
VL 112
IS 28
BP 8738
EP 8743
DI 10.1073/pnas.1510830112
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CM7MU
UT WOS:000357878700063
PM 26124093
OA Green Published, Bronze
DA 2020-04-03
ER

PT J
AU Omrani, AS
   Saad, MM
   Baig, K
   Bahloul, A
   Abdul-Matin, M
   Alaidaroos, AY
   Almakhlafi, GA
   Albarrak, MM
   Memish, ZA
   Albarrak, AM
AF Omrani, Ali S.
   Saad, Mustafa M.
   Baig, Kamran
   Bahloul, Abdelkarim
   Abdul-Matin, Mohammed
   Alaidaroos, Amal Y.
   Almakhlafi, Ghaleb A.
   Albarrak, Mohammed M.
   Memish, Ziad A.
   Albarrak, Ali M.
TI Ribavirin and interferon alfa-2a for severe Middle East respiratory
   syndrome coronavirus infection: a retrospective cohort study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID SAUDI-ARABIA; MERS-COV; REPLICATION; THERAPY; LESSONS; ASSAYS; SARS;
   BETA
AB Background Middle East respiratory syndrome coronavirus (MERS-CoV) infection is associated with high mortality and has no approved antiviral therapy. We aimed to compare ribavirin and interferon alfa-2a treatment for patients with severe MERS-CoV infection with a supportive therapy only.
   Methods In this retrospective cohort study, we included adults (aged >= 16 years) with laboratory-confirmed MERS-CoV infection and pneumonia needing ventilation support, diagnosed between Oct 23, 2012, and May 1, 2014, at the Prince Sultan Military Medical City (Riyadh, Saudi Arabia). All patients received appropriate supportive care and regular clinical and laboratory monitoring, but patients diagnosed after Sept 16, 2013, were also given oral ribavirin (dose based on calculated creatinine clearance, for 8-10 days) and subcutaneous pegylated interferon alfa-2a (180 mu g per week for 2 weeks). The primary endpoint was 14-day and 28-day survival from the date of MERS-CoV infection diagnosis. We used chi(2) and Fischer's exact test to analyse categorical variables and the t test to analyse continuous variables.
   Findings We analysed 20 patients who received ribavirin and interferon (treatment group; initiated a median of 3 days [range 0-8] after diagnosis) and 24 who did not (comparator group). Baseline clinical and laboratory characteristics were similar between groups, apart from baseline absolute neutrophil count, which was significantly lower in the comparator group (5.88x10(9)/L [SD 3.95] vs 9.88x10(9)/L [6.63]; p=0.023). 14 (70%) of 20 patients in the treatment group had survived after 14 days, compared with seven (29%) of 24 in the comparator group (p=0.004). After 28 days, six (30%) of 20 and four (17%) of 24, respectively, had survived (p=0.54). Adverse effects were similar between groups, apart from reduction in haemoglobin, which was significantly greater in the treatment group than in the comparator group (4.32 g/L [SD 2.47] vs 2.14 g/L [1.90]; p=0.002).
   Interpretation In patients with severe MERS-CoV infection, ribavirin and interferon alfa-2a therapy is associated with significantly improved survival at 14 days, but not at 28 days. Further assessment in appropriately designed randomised trials is recommended.
C1 [Omrani, Ali S.; Saad, Mustafa M.; Bahloul, Abdelkarim; Alaidaroos, Amal Y.; Albarrak, Mohammed M.] Prince Sultan Mil Med City, Div Infect Dis, Riyadh, Saudi Arabia.
   [Baig, Kamran; Alaidaroos, Amal Y.] Prince Sultan Mil Med City, Dept Infect Prevent & Control, Riyadh, Saudi Arabia.
   [Abdul-Matin, Mohammed] Prince Sultan Mil Med City, Dept Med, Riyadh, Saudi Arabia.
   [Almakhlafi, Ghaleb A.; Albarrak, Mohammed M.] Prince Sultan Mil Med City, Dept Crit Care, Riyadh, Saudi Arabia.
   [Memish, Ziad A.] Al Faisal Univ, Riyadh 11514, Saudi Arabia.
   [Memish, Ziad A.] Minist Hlth, Riyadh, Saudi Arabia.
RP Memish, ZA (reprint author), Al Faisal Univ, POB 54146, Riyadh 11514, Saudi Arabia.
EM zmemish@yahoo.com
OI Baig, Kamran/0000-0002-5174-1007; Omrani, Ali/0000-0001-5309-6358
FU GileadGilead Sciences; PfizerPfizer; MSD; ViiV;
   GlaxoSmithKlineGlaxoSmithKline; Sanofi-AventisSanofi-Aventis; Biopharma;
   Bristol-Myers SquibbBristol-Myers Squibb; Janssen-CilagJohnson & Johnson
   USAJanssen Biotech Inc; Edwards Lifesciences
FX ASO has received consultancy fees from Gilead, Pfizer, MSD, and ViiV;
   payment for lectures from Pfizer, MSD, GlaxoSmithKline, and
   Sanofi-Aventis; and sponsorship to attend international meetings and
   conferences from MSD, Pfizer, Biopharma, Bristol-Myers Squibb, and
   Janssen-Cilag. All has received travel funding to attend an
   international meeting from Pfizer. GAA has received travel funding to
   attend an international meeting from Edwards Lifesciences. All other
   authors declare no competing interests.
CR Al-Tawfiq JA, 2014, CLIN INFECT DIS, V59, P160, DOI 10.1093/cid/ciu226
   Al-Tawfiq JA, 2014, INT J INFECT DIS, V20, P42, DOI 10.1016/j.ijid.2013.12.003
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Corman VM, 2012, EUROSURVEILLANCE, V17, P2
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI 10.1007/s00134-012-2769-8
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   European Centre for Disease Prevention and Control, 2014, SEV RESP DIS ASS MID
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   ISARIC International Severe Acute Respiratory & Emerging Infection Consortium, 2013, CLIN DEC MAK TOOL TR
   Khalid M, RIBAVIRIN INTERFERON
   Knowles SR, 2003, CLIN INFECT DIS, V37, P1139, DOI 10.1086/378304
   McCloskey B, 2013, LANCET INFECT DIS, V13, P384, DOI 10.1016/S1473-3099(13)70082-3
   Momattin H, 2013, INT J INFECT DIS, V17, pE792, DOI 10.1016/j.ijid.2013.07.002
   Omrani AS, 2013, INT J INFECT DIS, V17, pE668, DOI 10.1016/j.ijid.2013.07.001
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076
   US Centers for Disease Control and Prevention National Healthcare Safety Network, 2014, SURV DEF SPEC TYP IN
   WHO, 2013, CLIN MAN SEV AC RESP
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 26
TC 108
Z9 123
U1 7
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD NOV
PY 2014
VL 14
IS 11
BP 1090
EP 1095
DI 10.1016/S1473-3099(14)70920-X
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA AR7EZ
UT WOS:000343743700034
PM 25278221
OA Bronze
DA 2020-04-03
ER

PT J
AU Woo, PCY
   Lau, SKP
   Teng, JLL
   Tsang, AKL
   Joseph, M
   Wong, EYM
   Tang, Y
   Sivakumar, S
   Xie, J
   Bai, R
   Wernery, R
   Wernery, U
   Yuen, KY
AF Woo, Patrick C. Y.
   Lau, Susanna K. P.
   Teng, Jade L. L.
   Tsang, Alan K. L.
   Joseph, Marina
   Wong, Emily Y. M.
   Tang, Ying
   Sivakumar, Saritha
   Xie, Jun
   Bai, Ru
   Wernery, Renate
   Wernery, Ulrich
   Yuen, Kwok-Yung
TI New Hepatitis E Virus Genotype in Camels, the Middle East
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID GAMMACORONAVIRUS; BETACORONAVIRUS; CORONAVIRUS; DISCOVERY; REVEALS
AB In a molecular epidemiology study of hepatitis E virus (HEV) in dromedaries in Dubai, United Arab Emirates, HEV was detected in fecal samples from 3 camels. Complete genome sequencing of 2 strains showed >20% overall nucleotide difference to known HEVs. Comparative genomic and phylogenetic analyses revealed a previously unrecognized HEV genotype.
C1 [Woo, Patrick C. Y.; Lau, Susanna K. P.; Yuen, Kwok-Yung] State Key Lab Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Woo, Patrick C. Y.; Lau, Susanna K. P.; Teng, Jade L. L.; Tsang, Alan K. L.; Wong, Emily Y. M.; Tang, Ying; Xie, Jun; Bai, Ru; Yuen, Kwok-Yung] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
   [Joseph, Marina; Sivakumar, Saritha; Wernery, Renate; Wernery, Ulrich] Cent Vet Res Lab, Dubai, U Arab Emirates.
RP Woo, PCY (reprint author), Univ Hong Kong, Dept Microbiol, State Key Lab Emerging Infect Dis, Queen Mary Hosp, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.
EM pcywoo@hkucc.hku.hk
RI Woo, Patrick Chiu Yat/AAJ-6112-2020; Lau, Susanna Kar Pui/AAJ-6848-2020
OI Woo, Patrick Chiu Yat/0000-0001-9401-1832; Lau, Susanna Kar
   Pui/0000-0002-1383-7374; Yuen, Kwok-yung/0000-0002-2083-1552
FU Hong Kong Special Administrative Region Health and Medical Research
   Fund; University of Hong KongUniversity of Hong Kong; Research Grant
   Council Grant, University Grant Council; Consultancy Service for
   Enhancing Laboratory Surveillance of Emerging Infectious Disease for the
   Hong Kong Special Administrative Region Department of Health
FX This work was partly supported by the Hong Kong Special Administrative
   Region Health and Medical Research Fund; Seed Funding for Theme-Based
   Research Scheme, and Strategic Research Theme Fund, The University of
   Hong Kong; Theme-based Research Scheme, Research Grant Council Grant,
   University Grant Council; and Consultancy Service for Enhancing
   Laboratory Surveillance of Emerging Infectious Disease for the Hong Kong
   Special Administrative Region Department of Health.
CR Abro Ali Hassan, 2009, J Pak Med Assoc, V59, P92
   Graff J, 2006, J VIROL, V80, P5919, DOI 10.1128/JVI.00046-06
   Huang YW, 2007, J VIROL, V81, P3018, DOI 10.1128/JVI.02259-06
   Johne R, 2010, EMERG INFECT DIS, V16, P1452, DOI 10.3201/eid1609.100444
   Krog JS, 2013, EMERG INFECT DIS, V19, P2028, DOI 10.3201/eid1912.130614
   Matsuda H, 2003, J INFECT DIS, V188, P944, DOI 10.1086/378074
   Purdy MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035974
   Raj VS, 2012, EMERG INFECT DIS, V18, P1369, DOI 10.3201/eid1808.111659
   Smith DB, 2013, J VIROL, V87, P4161, DOI 10.1128/JVI.02762-12
   Takahashi M, 2011, J GEN VIROL, V92, P902, DOI 10.1099/vir.0.029470-0
   Woo PCY, 2006, J VIROL, V80, P7136, DOI 10.1128/JVI.00509-06
   Woo PCY, 2014, EMERG INFECT DIS, V20, P560, DOI 10.3201/eid2004.131769
   Woo PCY, 2014, J VIROL, V88, P1318, DOI 10.1128/JVI.02351-13
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Woo PCY, 2012, J VIROL, V86, P2797, DOI 10.1128/JVI.05481-11
NR 15
TC 108
Z9 109
U1 1
U2 10
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUN
PY 2014
VL 20
IS 6
BP 1044
EP 1048
DI 10.3201/eid2006.140140
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AI0SZ
UT WOS:000336561600022
PM 24856611
OA DOAJ Gold, Green Published
DA 2020-04-03
ER

PT J
AU Tang, XC
   Agnihothram, SS
   Jiao, YJ
   Stanhope, J
   Graham, RL
   Peterson, EC
   Avnir, Y
   Tallarico, ASC
   Sheehan, J
   Zhu, Q
   Baric, RS
   Marasco, WA
AF Tang, Xian-Chun
   Agnihothram, Sudhakar S.
   Jiao, Yongjun
   Stanhope, Jeremy
   Graham, Rachel L.
   Peterson, Eric C.
   Avnir, Yuval
   Tallarico, Aimee St. Clair
   Sheehan, Jared
   Zhu, Quan
   Baric, Ralph S.
   Marasco, Wayne A.
TI Identification of human neutralizing antibodies against MERS-CoV and
   their role in virus adaptive evolution
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE IGHV1-69; biodefense; emerging pathogen; zoonosis; humoral immunity
ID RESPIRATORY SYNDROME CORONAVIRUS; HUMAN MONOCLONAL-ANTIBODIES;
   RECEPTOR-BINDING DOMAIN; MIDDLE-EAST; SPIKE PROTEIN; POTENT
   NEUTRALIZATION; SARS-CORONAVIRUS; DROMEDARY CAMELS; STRUCTURAL BASIS;
   IN-VITRO
AB The newly emerging Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes a Severe Acute Respiratory Syndrome-like disease with similar to 43% mortality. Given the recent detection of virus in dromedary camels, zoonotic transfer of MERS-CoV to humans is suspected. In addition, little is known about the role of human neutralizing Ab (nAb) pressure as a driving force in MERS-CoV adaptive evolution. Here, we used a well-characterized nonimmune human Ab-phage library and a panning strategy with proteoliposomes and cells to identify seven human nAbs against the receptor-binding domain (RBD) of the MERS-CoV Spike protein. These nAbs bind to three different epitopes in the RBD and human dipeptidyl peptidase 4 (hDPP4) interface with subnanomolar/nanomolar binding affinities and block the binding of MERS-CoV Spike protein with its hDPP4 receptor. Escape mutant assays identified five amino acid residues that are critical for neutralization escape. Despite the close proximity of the three epitopes on the RBD interface, escape from one epitope did not have a major impact on neutralization with Abs directed to a different epitope. Importantly, the majority of escape mutations had negative impacts on hDPP4 receptor binding and viral fitness. To our knowledge, these results provide the first report on human nAbs against MERS-CoV that may contribute to MERS-CoV clearance and evolution. Moreover, in the absence of a licensed vaccine or antiviral for MERS, this panel of nAbs offers the possibility of developing human mAb-based immunotherapy, especially for health-care workers.
C1 [Tang, Xian-Chun; Jiao, Yongjun; Stanhope, Jeremy; Peterson, Eric C.; Avnir, Yuval; Tallarico, Aimee St. Clair; Sheehan, Jared; Zhu, Quan; Marasco, Wayne A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
   [Agnihothram, Sudhakar S.; Graham, Rachel L.; Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
RP Marasco, WA (reprint author), Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
EM rbaric@ad.unc.edu; wayne_marasco@dfci.harvard.edu
FU Defense Advanced Research Projects AgencyUnited States Department of
   DefenseDefense Advanced Research Projects Agency (DARPA)
   [W911NF-10-0226]; National Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [R01AI085524]
FX We thank Drs. Zhen Zhang and De-Kuan Chang for helpful discussions and
   Dr. Maria Zambon and Dr. Robin Gopal at Public Health England for
   providing the MERS-CoV England-1 strain. This work was supported by
   Defense Advanced Research Projects Agency Grant W911NF-10-0226 (to W. A.
   M.) and National Institutes of Health Grant R01AI085524 (to W. A. M. and
   R.B.).
CR Agnihothram S, 2014, J INFECT DIS, V209, P995, DOI 10.1093/infdis/jit609
   Alagaili A. N., 2014, MBIO, V5
   Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Anthony SJ, 2013, J GEN VIROL, V94, P1028, DOI 10.1099/vir.0.049759-0
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Bakker ABH, 2008, VACCINE, V26, P5922, DOI 10.1016/j.vaccine.2008.08.050
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Boyd SD, 2010, J IMMUNOL, V184, P6986, DOI 10.4049/jimmunol.1000445
   Breban R, 2013, LANCET, V382, P694, DOI 10.1016/S0140-6736(13)61492-0
   Chan CH, 2001, BLOOD, V97, P1023, DOI 10.1182/blood.V97.4.1023
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Corti D, 2013, ANNU REV IMMUNOL, V31, P705, DOI 10.1146/annurev-immunol-032712-095916
   Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669
   Cotten M, 2014, MBIO, V5, DOI 10.1128/mBio.01062-13
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Cotten M, 2013, EMERG INFECT DIS, V19, P736, DOI 10.3201/eid1905.130057
   Dimitrov DS, 2010, MABS-AUSTIN, V2, P347, DOI 10.4161/mabs.2.3.11779
   Du LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081587
   Eckerle I, 2014, EMERG INFECT DIS, V20, P276, DOI 10.3201/eid2002.131182
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Farci P, 2010, P NATL ACAD SCI USA, V107, P8766, DOI [10.1073/pnas.1003854107, 10.1073/pnas.1003833107]
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   Gould LH, 2005, J VIROL, V79, P14606, DOI 10.1128/JVI.79.23.14606-14613.2005
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   Huang CC, 2004, P NATL ACAD SCI USA, V101, P2706, DOI 10.1073/pnas.0308527100
   Kashyap AK, 2008, P NATL ACAD SCI USA, V105, P5986, DOI 10.1073/pnas.0801367105
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Marasco WA, 2007, NAT BIOTECHNOL, V25, DOI 10.1038/nbt1363
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Meyer B, 2014, EMERG INFECT DIS, V20, P552, DOI 10.3201/eid2004.131746
   Mirzabekov T, 2000, NAT BIOTECHNOL, V18, P649, DOI 10.1038/76501
   Mou H, 2013, J VIROL, V87, P9379, DOI 10.1128/JVI.01277-13
   Muller MA, 2012, MBIO, V3, DOI 10.1128/mBio.00515-12
   Perera RA, 2013, EUROSURVEILLANCE, V18, P8, DOI 10.2807/1560-7917.ES2013.18.36.20574
   Public Health England ISARIC, 2013, TREATM MERS COV DEC
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rani M, 2012, J VIROL, V86, P9113, DOI 10.1128/JVI.00233-12
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Song F, 2013, J VIROL, V87, P11950, DOI 10.1128/JVI.01672-13
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566
   Sui JH, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000197
   Tahir M, 2013, EUROSURVEILLANCE, V18, P4
   Taube R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003181
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Throsby M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003942
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Watson CT, 2012, GENES IMMUN, V13, P363, DOI 10.1038/gene.2012.12
   Woo PCY, 2006, VIROLOGY, V351, P180, DOI 10.1016/j.virol.2006.02.041
   Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890
   Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532
   Xu C, 2007, J IMMUNOL, V179, P2408, DOI 10.4049/jimmunol.179.4.2408
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 60
TC 108
Z9 118
U1 2
U2 31
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 13
PY 2014
VL 111
IS 19
BP E2018
EP E2026
DI 10.1073/pnas.1402074111
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AH0GS
UT WOS:000335798000015
PM 24778221
OA Bronze, Green Published
DA 2020-04-03
ER

PT J
AU Hamming, OJ
   Terczynska-Dyla, E
   Vieyres, G
   Dijkman, R
   Jorgensen, SE
   Akhtar, H
   Siupka, P
   Pietschmann, T
   Thiel, V
   Hartmann, R
AF Hamming, Ole J.
   Terczynska-Dyla, Ewa
   Vieyres, Gabrielle
   Dijkman, Ronald
   Jorgensen, Sanne E.
   Akhtar, Hashaam
   Siupka, Piotr
   Pietschmann, Thomas
   Thiel, Volker
   Hartmann, Rune
TI Interferon lambda 4 signals via the IFN lambda receptor to regulate
   antiviral activity against HCV and coronaviruses
SO EMBO JOURNAL
LA English
DT Article
DE coronavirus; genetics; hepatitis C virus; interferon lambda; interferon
   therapy
ID GENETIC-VARIATION; IL28B; CLEARANCE; CELLS; REPLICATION; ACTIVATION;
   EXPRESSION; PROTECTION; VIRUSES; MODEL
AB The IFNL4 gene is a recently discovered type III interferon, which in a significant fraction of the human population harbours a frameshift mutation abolishing the IFN lambda 4 ORF. The expression of IFN lambda 4 is correlated with both poor spontaneous clearance of hepatitis C virus (HCV) and poor response to treatment with type I interferon. Here, we show that the IFNL4 gene encodes an active type III interferon, named IFN lambda 4, which signals through the IFN lambda R1 and IL-10R2 receptor chains. Recombinant IFN lambda 4 is antiviral against both HCV and coronaviruses at levels comparable to IFN lambda 3. However, the secretion of IFN lambda 4 is impaired compared to that of IFN lambda 3, and this impairment is not due to a weak signal peptide, which was previously believed. We found that IFN lambda 4 gets N-linked glycosylated and that this glycosylation is required for secretion. Nevertheless, this glycosylation is not required for activity. Together, these findings result in the paradox that IFN lambda 4 is strongly antiviral but a disadvantage during HCV infection.
C1 [Hamming, Ole J.; Terczynska-Dyla, Ewa; Jorgensen, Sanne E.; Akhtar, Hashaam; Siupka, Piotr; Hartmann, Rune] Aarhus Univ, Dept Mol Biol & Genet, DK-8000 Aarhus, Denmark.
   [Vieyres, Gabrielle; Pietschmann, Thomas] TWINCORE Ctr Expt & Clin, Inst Expt Virol, Hannover, Germany.
   [Dijkman, Ronald; Thiel, Volker] Kantonal Hosp, Inst Immunobiol, St Gallen, Switzerland.
   [Thiel, Volker] Univ Zurich, Vetsuisse Fac, Zurich, Switzerland.
RP Hartmann, R (reprint author), Aarhus Univ, Dept Mol Biol & Genet, Gustav Wieds Vej 10, DK-8000 Aarhus, Denmark.
EM rh@mb.au.dk
RI Pietschmann, Thomas/E-9241-2015; Thiel, Volker/AAI-2391-2019
OI Pietschmann, Thomas/0000-0001-5138-6239; Hartmann,
   Rune/0000-0003-1159-066X; Dijkman, Ronald/0000-0003-0320-2743; Thiel,
   Volker/0000-0002-5783-0887
FU Danish Cancer SocietyDanish Cancer Society [R20-A927]; Danish Council
   for Independent Research, Medical Research [11-107588]; Swiss National
   Science FoundationSwiss National Science Foundation (SNSF)
   [31003A_132898]; 3R Research Foundation Switzerland [128-11]; Deutsche
   Forschungsgemeinschaft (Priority Programme (SPP)) [1596]
FX We wish to thank Dr Sergei Kotenko for the kind gift of the IFN lambda
   R1 and IFN lambda 3 expression plasmids, Dr Georg Kochs for the Mx-Luc
   reporter plasmid and Dr Gilles Uze for the gift of HL-116 cells
   expressing the IFNlR1. We are also in debt to Lisbeth Heilesen and Dr
   Hans Henrik Gad for critical reading of the manuscript. This work was
   funded by the Danish Cancer Society (grant: R20-A927; RH), and the
   Danish Council for Independent Research, Medical Research (grant
   11-107588; RH); the Swiss National Science Foundation (project
   31003A_132898; VT), the 3R Research Foundation Switzerland (project
   128-11; VT and RD), and the Deutsche Forschungsgemeinschaft (Priority
   Programme (SPP) 1596; VT).
CR Ank N, 2006, J VIROL, V80, P4501, DOI 10.1128/JVI.80.9.4501-4509.2006
   Bibert S, 2013, J EXP MED, V210, P1109, DOI 10.1084/jem.20130012
   Bitzegeio J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000978
   Booth D, 2013, NAT GENET, V45, P119, DOI 10.1038/ng.2537
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   DeLano WL, 2008, PYMOL MOL GRAPHICS S
   Dellgren C, 2009, GENES IMMUN, V10, P125, DOI 10.1038/gene.2008.87
   Dickensheets H, 2013, J LEUKOCYTE BIOL, V93, P377, DOI 10.1189/jlb.0812395
   Dijkman R, 2009, J VIROL, V83, P7739, DOI 10.1128/JVI.00614-09
   Doyle SE, 2006, HEPATOLOGY, V44, P896, DOI 10.1002/hep.21312
   Dumoutier L, 2003, BIOCHEM J, V370, P391, DOI 10.1042/BJ20021935
   Fox BA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004933
   Gad HH, 2009, J BIOL CHEM, V284, P20869, DOI 10.1074/jbc.M109.002923
   Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
   Gentzsch J, 2011, ANTIVIR RES, V89, P136, DOI 10.1016/j.antiviral.2010.12.005
   Haid S, 2010, J VIROL, V84, P964, DOI 10.1128/JVI.01504-09
   Jorns C, 2006, J MED VIROL, V78, P74, DOI 10.1002/jmv.20506
   Kim SU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069166
   Kindler E, 2013, MBIO, V4, DOI 10.1128/mBio.00611-12
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lasfar A, 2006, CANCER RES, V66, P4468, DOI 10.1158/0008-5472.CAN-05-3653
   Logsdon NJ, 2012, P NATL ACAD SCI USA, V109, P12704, DOI 10.1073/pnas.1117551109
   Lupberger J, 2013, HEPATOLOGY, V58, P1225, DOI [10.1002/hep.26443, 10.1002/hep.26404]
   Meager A, 2005, CYTOKINE, V31, P109, DOI 10.1016/j.cyto.2005.04.003
   Melchjorsen J, 2009, J INTERF CYTOK RES, V29, P199, DOI 10.1089/jir.2008.0050
   Mennechet FJD, 2006, BLOOD, V107, P4417, DOI 10.1182/blood-2005-10-4129
   Miknis ZJ, 2010, J MOL BIOL, V404, P650, DOI 10.1016/j.jmb.2010.09.068
   Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10
   Narbus CM, 2011, J VIROL, V85, P12087, DOI 10.1128/JVI.05843-11
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pietschmann T, 2006, P NATL ACAD SCI USA, V103, P7408, DOI 10.1073/pnas.0504877103
   Pott J, 2011, P NATL ACAD SCI USA, V108, P7944, DOI 10.1073/pnas.1100552108
   Prokunina-Olsson L, 2013, NAT GENET, V45, P164, DOI 10.1038/ng.2521
   Ramos EL, 2010, J INTERF CYTOK RES, V30, P591, DOI 10.1089/jir.2010.0066
   Ray Katrina, 2013, Nat Rev Gastroenterol Hepatol, V10, P63, DOI 10.1038/nrgastro.2013.7
   Reiss S, 2011, CELL HOST MICROBE, V9, P32, DOI 10.1016/j.chom.2010.12.002
   Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   Uze G, 2007, BIOCHIMIE, V89, P729, DOI 10.1016/j.biochi.2007.01.008
   van den Worm SHE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032857
   Vieyres G, 2013, METHODS, V59, P233, DOI 10.1016/j.ymeth.2012.09.005
   Wang Y, 2013, J VIRAL HEPATITIS, V20, P385, DOI 10.1111/jvh.12040
   Zhou ZL, 2007, J VIROL, V81, P7749, DOI 10.1128/JVI.02438-06
NR 44
TC 108
Z9 111
U1 1
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD NOV 27
PY 2013
VL 32
IS 23
BP 3055
EP 3065
DI 10.1038/emboj.2013.232
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 262JQ
UT WOS:000327731300007
PM 24169568
OA Green Published
DA 2020-04-03
ER

PT J
AU Malet, H
   Coutard, B
   Jamal, S
   Dutartre, H
   Papageorgiou, N
   Neuvonen, M
   Ahola, T
   Forrester, N
   Gould, EA
   Lafitte, D
   Ferron, F
   Lescar, J
   Gorbalenya, AE
   de Lamballerie, X
   Canard, B
AF Malet, Helene
   Coutard, Bruno
   Jamal, Said
   Dutartre, Helene
   Papageorgiou, Nicolas
   Neuvonen, Maarit
   Ahola, Tero
   Forrester, Naomi
   Gould, Ernest A.
   Lafitte, Daniel
   Ferron, Francois
   Lescar, Julien
   Gorbalenya, Alexander E.
   de Lamballerie, Xavier
   Canard, Bruno
TI The Crystal Structures of Chikungunya and Venezuelan Equine Encephalitis
   Virus nsP3 Macro Domains Define a Conserved Adenosine Binding Pocket
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; ADP-RIBOSE-BINDING; SINDBIS-VIRUS;
   NONSTRUCTURAL PROTEIN; PHOSPHORYLATION; REPLICATION; IDENTIFICATION;
   EXPRESSION; COMPLEXES; GENES
AB Macro domains (also called "X domains") constitute a protein module family present in all kingdoms of life, including viruses of the Coronaviridae and Togaviridae families. Crystal structures of the macro domain from the Chikungunya virus (an "Old World" alphavirus) and the Venezuelan equine encephalitis virus (a "New World" alphavirus) were determined at resolutions of 1.65 and 2.30 angstrom, respectively. These domains are active as adenosine di-phosphoribose 1 ''-phosphate phosphatases. Both the Chikungunya and the Venezuelan equine encephalitis virus macro domains are ADP-ribose binding modules, as revealed by structural and functional analysis. A single aspartic acid conserved through all macro domains is responsible for the specific binding of the adenine base. Sequence-unspecific binding to long, negatively charged polymers such as poly(ADP-ribose), DNA, and RNA is observed and attributed to positively charged patches outside of the active site pocket, as judged by mutagenesis and binding studies. The crystal structure of the Chikungunya virus macro domain with an RNA trimer shows a binding mode utilizing the same adenine-binding pocket as ADP-ribose, but avoiding the ADP-ribose 1 ''-phosphate phosphatase active site. This leaves the AMP binding site as the sole common feature in all macro domains.
C1 [Malet, Helene; Coutard, Bruno; Jamal, Said; Dutartre, Helene; Papageorgiou, Nicolas; Ferron, Francois; Lescar, Julien; Canard, Bruno] CNRS, F-13288 Marseille, France.
   [Malet, Helene; Coutard, Bruno; Jamal, Said; Dutartre, Helene; Papageorgiou, Nicolas; Ferron, Francois; Lescar, Julien; Canard, Bruno] Univ Aix Marseille 1, F-13288 Marseille, France.
   [Malet, Helene; Coutard, Bruno; Jamal, Said; Dutartre, Helene; Papageorgiou, Nicolas; Ferron, Francois; Lescar, Julien; Canard, Bruno] Univ Aix Marseille 2, UMR 6098, ESIL Case 925, F-13288 Marseille, France.
   [Neuvonen, Maarit; Ahola, Tero] Univ Helsinki, Inst Biotechnol, Helsinki 00014, Finland.
   [Forrester, Naomi; Gould, Ernest A.] CEH Oxford, Oxford OX1 3SR, England.
   [Lafitte, Daniel] Aix Marseille Univ, Fac Pharm, INSERM, UMR CRO2 911, F-13285 Marseille 05, France.
   [Gorbalenya, Alexander E.] Leiden Univ, Med Ctr, Dept Med Microbiol, Leiden, Netherlands.
   [de Lamballerie, Xavier] Univ Mediterranee, Inst Rech & Dev, UMR190, Fac Med Marseille, F-130052 Marseille 05, France.
RP Canard, B (reprint author), CNRS, F-13288 Marseille, France.
EM bruno.canard@afmb.univ-mrs.fr
RI Dutartre, Helene/H-8837-2016; Dutartre, Helene/L-7463-2019; Gorbalenya,
   Alexander E/J-4818-2012
OI Dutartre, Helene/0000-0002-2682-4302; Dutartre,
   Helene/0000-0002-2682-4302; Gorbalenya, Alexander E/0000-0002-4967-7341;
   lafitte, daniel/0000-0001-9921-7522; Ferron,
   Francois/0000-0002-8351-4992; Neuvonen, Maarit/0000-0002-7209-3029;
   MALET, Helene/0000-0002-2834-7386; Canard, Bruno/0000-0003-4924-1991
FU European Union 6th FrameworkEuropean Union (EU) [LSHG-CT-2004-511960];
   Agence Nationale de la RechercheFrench National Research Agency (ANR);
   Natural Environment Research CouncilNERC Natural Environment Research
   Council [CEH010021]
FX We thank Violaine Lantez, Karen Dalle, and Nade` ge Brisbarre for
   technical support, as well as the European and SOLEIL Synchrotron
   Radiation Facility staffs for help with crystallographic data
   collection. A. E. G. thanks Dmitriy Samborsky and Alexander Kravchenko
   for administrating the Viralis software.; This work was supported in
   part by the VIZIER integrated project (LSHG-CT-2004-511960) of the
   European Union 6th Framework, the Direction Generale de l'Armement, and
   the Agence Nationale de la Recherche (CHIKVIRULENCE grant).
CR AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507
   Allen MD, 2003, J MOL BIOL, V330, P503, DOI 10.1016/S0022-2836(03)00473-X
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   Berrow NS, 2006, ACTA CRYSTALLOGR D, V62, P1218, DOI 10.1107/S0907444906031337
   Chakravarthy S, 2005, MOL CELL BIOL, V25, P7616, DOI 10.1128/MCB.25.17.7616-7624.2005
   Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592
   de Lamballerie X, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-33
   Dolinsky TJ, 2007, NUCLEIC ACIDS RES, V35, pW522, DOI 10.1093/nar/gkm276
   Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0
   Egloff MP, 2006, J VIROL, V80, P8493, DOI 10.1128/JVI.00713-06
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Ericsson UB, 2006, ANAL BIOCHEM, V357, P289, DOI 10.1016/j.ab.2006.07.027
   Eriksson KK, 2008, J VIROL, V82, P12325, DOI 10.1128/JVI.02082-08
   Geerlof A, 2006, ACTA CRYSTALLOGR D, V62, P1125, DOI 10.1107/S0907444906030307
   GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6
   KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588
   Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664
   KENNEDY AC, 1980, J RHEUMATOL, V7, P231
   Kumaran D, 2005, PROTEIN SCI, V14, P719, DOI 10.1110/ps.041132005
   Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956
   Ladurner AG, 2003, MOL CELL, V12, P1, DOI 10.1016/S1097-2765(03)00284-3
   LASTARZA MW, 1994, VIROLOGY, V202, P224, DOI 10.1006/viro.1994.1338
   Leslie AGW, 1992, JOINT CCP4 ESF EACMB, V26
   Letunic I, 2006, NUCLEIC ACIDS RES, V34, pD257, DOI 10.1093/nar/gkj079
   LI GP, 1990, VIROLOGY, V179, P416, DOI 10.1016/0042-6822(90)90310-N
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Malet H, 2006, ACTA CRYSTALLOGR F, V62, P405, DOI 10.1107/S1744309106009274
   Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153
   McCoy AJ, 2007, ACTA CRYSTALLOGR D, V63, P32, DOI 10.1107/S0907444906045975
   MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159
   Nargi-Aizenman JL, 2002, VIROLOGY, V293, P164, DOI 10.1006/viro.2001.1253
   Neuvonen M, 2009, J MOL BIOL, V385, P212, DOI 10.1016/j.jmb.2008.10.045
   Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1177/108705710100600609
   Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837
   PERANEN J, 1990, J VIROL, V64, P1888
   Piotrowski Y, 2009, PROTEIN SCI, V18, P6, DOI 10.1002/pro.15
   Powers AM, 2001, J VIROL, V75, P10118, DOI 10.1128/JVI.75.21.10118-10131.2001
   Putics A, 2005, J VIROL, V79, P12721, DOI 10.1128/JVI.79.20.12721-12731.2005
   RIKKONEN M, 1994, J VIROL, V68, P5804, DOI 10.1128/JVI.68.9.5804-5810.1994
   Rivas F, 1997, J INFECT DIS, V175, P828, DOI 10.1086/513978
   Roversi P, 2000, ACTA CRYSTALLOGR D, V56, P1316, DOI 10.1107/S0907444900008490
   Rubach JK, 2009, VIROLOGY, V384, P201, DOI 10.1016/j.virol.2008.10.030
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678
   Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   STRAUSS EG, 1992, VIROLOGY, V191, P932, DOI 10.1016/0042-6822(92)90268-T
   Tuittila MT, 2000, J VIROL, V74, P4579, DOI 10.1128/JVI.74.10.4579-4589.2000
   Vihinen H, 2001, J BIOL CHEM, V276, P5745, DOI 10.1074/jbc.M006077200
   Vihinen H, 2000, J BIOL CHEM, V275, P27775
   WANG YF, 1994, J VIROL, V68, P6466, DOI 10.1128/JVI.68.10.6466-6475.1994
   WEAVER SC, 2005, VIRUS TAXONOMY, P999
   WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587
NR 53
TC 108
Z9 109
U1 0
U2 16
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUL
PY 2009
VL 83
IS 13
BP 6534
EP 6545
DI 10.1128/JVI.00189-09
PG 12
WC Virology
SC Virology
GA 462LM
UT WOS:000267354100021
PM 19386706
OA Green Published, Bronze, Green Accepted
DA 2020-04-03
ER

EF